{"title": "PDF", "author": "PDF", "url": "https://www.tk.de/resource/blob/2043446/bfb1f2dcadf688c355c0a64114544d34/studienband-langfassung-innovationsreport-2015-data.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "\u00a0\nInnovationsreport \u00a02015\u00a0\n(Langfassung) \u00a0\n\u00a0\n\u00a0\n\u00a0\nAuswertungsergebnisse von Routinedaten der \nTechniker Krankenkasse aus den Jahren 2012 und 2013 \u00a0\n\u00a0\n\u00a0\nSOCIUM \u2013 Universit\u00e4t Bremen \u00a0\n \nDaniela Boeschen, D\u00f6rte Fuchs, Judith G\u00fcnther, Gerd Glaeske \n \n \n  \nUnter Mitarbeit von Angela Fritsch, Frieda H\u00f6fel und Sarah Volz\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n \nErstellt mit freundlicher Unterst\u00fctz ung der Techniker Krankenkasse (TK) \n\u00a0 \n2\u00a0 \n \nInnovationsreport 2015 \u00a0  \n \n \n \n \n  \n \n \n \n  \n \n \n \n  \n \n \n \n \n \n  \n \n \n \n  \n \n \n \n \n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\nAnschrift\u00a0der\u00a0Verfasser: \u00a0Universit\u00e4t \u00a0Bremen,\u00a0SOCIUM,\u00a0Unicom\u2010Geb\u00e4ude, \u00a0Mary\u2010Somerville \u2010Str.\u00a05,\u00a0\n28359\u00a0Bremen\u00a0\n\u00a0\u00a0\nAus\u00a0Gr\u00fcnden\u00a0der\u00a0besseren\u00a0Lesbarkeit \u00a0wurde\u00a0an\u00a0manchen \u00a0Stellen\u00a0auf\u00a0die\u00a0Nennung\u00a0beider\u00a0ge\u2010\nschlechtsspezifischer \u00a0Formen\u00a0verzichtet. \u00a0Im\u00a0Allgemeinen \u00a0ist\u00a0aber\u00a0das\u00a0jeweils\u00a0andere\u00a0Geschlecht \u00a0\nebenfalls\u00a0gemeint\n. \n3\u00a0\n \nInnovationsreport 2015 \u00a0 Inhaltsverzeichnis \u00a0\nVorwort\u00a0zum\u00a0Innovationsreport \u00a02015.............................................................................................. \u00a05\u00a0\nZweites\u00a0Vorwort\u00a0zum\u00a0Innovationsreport \u00a02015\u00a0................................................................................. \u00a07\u00a0\n1\u00a0Einleitung \u00a0............................................................................................................................... ..\u00a011\u00a0\n2\u00a0Ziele\u00a0und\u00a0Methodik \u00a0.................................................................................................................. \u00a015\u00a0\n2.1\u00a0 Zielsetzung \u00a0............................................................................................................................15 \u00a0\n2.2\u00a0 Methodik \u00a0zur\u00a0Bewertung \u00a0der\u00a0neuen\u00a0Arzneimittel \u00a0...............................................................15 \u00a0\n2.3\u00a0 Methodik \u00a0der\u00a0Routinedaten \u2010Analyse\u00a0...................................................................................18 \u00a0\n3\u00a0Neue\u00a0Arzneimittel \u00a0des\u00a0Jahres\u00a02012\u00a0\u2013\u00a0\u00dcbersicht \u00a0........................................................................ \u00a021\u00a0\n4\u00a0Wirkstoffportr\u00e4ts \u00a0mit\u00a0Versorgungsanalysen \u00a0............................................................................. \u00a030\u00a0\n4.1\u00a0 Aclidiniumbromid \u00a0.................................................................................................................30 \u00a0\n4.2\u00a0 Aflibercept \u00a0............................................................................................................................34 \u00a0\n4.3\u00a0 Axitinib\u00a0............................................................................................................................... ...39\u00a0\n4.4\u00a0 Azilsartanmedoxomil \u00a0............................................................................................................43 \u00a0\n4.5\u00a0 Brentuximabvedotin \u00a0.............................................................................................................47 \u00a0\n4.6\u00a0 Ceftarolinfosamil \u00a0..................................................................................................................51 \u00a0\n4.7\u00a0 Crizotinib \u00a0..............................................................................................................................5 3\u00a0\n4.8\u00a0 Dapagliflozin \u00a0.........................................................................................................................57 \u00a0\n4.9\u00a0 Decitabin \u00a0..............................................................................................................................6 1\u00a0\n4.10\u00a0Ivacaftor\u00a0............................................................................................................................... 65\u00a0\n4.11\u00a0Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0.............................................................................................69 \u00a0\n4.12\u00a0Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0.............................................................................................73 \u00a0\n4.13\u00a0Pasireotid \u00a0..............................................................................................................................7 7\u00a0\n4.14\u00a0Perampanel \u00a0..........................................................................................................................82 \u00a0\n4.15\u00a0Pixantron \u00a0..............................................................................................................................8 6\u00a0\n4.16\u00a0Rilpivirin\u00a0............................................................................................................................... .90\u00a0\n4.17\u00a0Ruxolitinib \u00a0.............................................................................................................................94 \u00a0\n4.18\u00a0Tegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0Oteracil\u00a0..............................................................................................98 \u00a0\n4.19\u00a0Vandetanib \u00a0........................................................................................................................ \u00a0102\u00a0\n4.20\u00a0Vemurafenib \u00a0...................................................................................................................... \u00a0106\u00a0\n5\u00a0R\u00fcckblick: \u00a0Arzneimittel \u00a0aus\u00a0dem\u00a0Innovationsreport \u00a02014\u00a0(Neue\u00a0Wirkstoffe \u00a0des\u00a0Jahres\u00a02011)\u00a0.\u00a0110\u00a0\n6\u00a0Diskussion \u00a0.............................................................................................................................. \u00a0115\u00a0\n7\u00a0Neue\u00a0Arzneimittel \u00a0zur\u00a0Behandlung \u00a0von\u00a0Multipler \u00a0Sklerose\u00a0..................................................... \u00a0120\u00a0\n7.1\u00a0 Die\u00a0Marktentwicklung \u00a0von\u00a0Fingolimod \u00a0(Gilenya\u00ae) \u00a0............................................................ \u00a0120\u00a0\n7.2\u00a0 Lange\u00a0vor\u00a0Fingolimod: \u00a0Der\u00a0Wirkstoff \u00a0Azathioprin \u00a0............................................................. \u00a0127\u00a0\n8\u00a0Arzneimittel \u00a0zur\u00a0Behandlung \u00a0onkologischer \u00a0Erkrankungen \u00a0in\u00a0Deutschland \u00a0\u2013\u00a0Besteht\u00a0eine\u00a0\nKorrelation \u00a0zwischen \u00a0stetig\u00a0wachsenden \u00a0Ums\u00e4tzen \u00a0und\u00a0Nutzen?\u00a0................................................ \u00a0134\u00a0\n8.1\u00a0 Nutzen\u00fcberlegungen \u00a0am\u00a0Beispiel\u00a0Vemurafenib \u00a0............................................................... \u00a0136\u00a0\n8.2\u00a0 Die\u00a0Kosten\u00a0der\u00a0Behandlung \u00a0............................................................................................... \u00a0137\u00a0 \n4\u00a0 \n \nInnovationsreport 2015 \u00a08.3\u00a0 Hohe\u00a0Preise\u00a0bei\u00a0geringem \u00a0Nutzen?\u00a0................................................................................... \u00a0138\u00a0\n8.4\u00a0 Notwendige \u00a0Ver\u00e4nderungen \u00a0in\u00a0der\u00a0Zukunft\u00a0..................................................................... \u00a0140\u00a0\n9\u00a0Die\u00a0Hormontherapie \u00a0in\u00a0und\u00a0nach\u00a0den\u00a0Wechseljahren \u00a0............................................................. \u00a0144\u00a0\n9.1\u00a0 Verordnungscharakteristika \u00a0der\u00a0Hormontherapie \u00a0in\u00a0und\u00a0nach\u00a0den\u00a0Wechseljahren \u00a0in\u00a0der\u00a0TK146\u00a0\n9.1.1\u00a0Verordnungspr\u00e4valenzen \u00a0der\u00a0Hormontherapie \u00a0......................................................... \u00a0147\u00a0\n9.1.2\u00a0Regionale \u00a0Unterschiede \u00a0.............................................................................................. \u00a0148\u00a0\n9.1.3\u00a0Kosten\u00a0der\u00a0Hormontherapie \u00a0....................................................................................... \u00a0151\u00a0\n9.1.4\u00a0Verordnung \u00a0nach\u00a0Wirkstoffgruppen \u00a0........................................................................... \u00a0151\u00a0\n10\u00a0Keypoints \u00a0............................................................................................................................... \u00a0155\u00a0\n11\u00a0Anhang:\u00a0Hintergrundinformationen \u00a0zu\u00a0den\u00a0Wirkstoffen \u00a0......................................................... \u00a0158\u00a0\n11.1\u00a0Aclidiniumbromid \u00a0.............................................................................................................. \u00a0158\u00a0\n11.2\u00a0Aflibercept \u00a0......................................................................................................................... \u00a0163\u00a0\n11.3\u00a0Axitinib\u00a0............................................................................................................................... \u00a0172\u00a0\n11.4\u00a0Azilsartanmedoxomil \u00a0......................................................................................................... \u00a0176\u00a0\n11.5\u00a0Brentuximabvedotin \u00a0.......................................................................................................... \u00a0179\u00a0\n11.6\u00a0Ceftarolinfosamil \u00a0............................................................................................................... \u00a0183\u00a0\n11.7\u00a0Crizotinib \u00a0........................................................................................................................... \u00a0187\u00a0\n11.8\u00a0Dapagliflozin \u00a0...................................................................................................................... \u00a0190\u00a0\n11.9\u00a0Decitabin \u00a0........................................................................................................................... \u00a0194\u00a0\n11.10\u00a0Ivacaftor\u00a0............................................................................................................................ \u00a0198\u00a0\n11.11\u00a0Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0.......................................................................................... \u00a0203\u00a0\n11.12\u00a0Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0.......................................................................................... \u00a0207\u00a0\n11.13\u00a0Pasireotid \u00a0........................................................................................................................... \u00a0211\u00a0\n11.14\u00a0Perampanel \u00a0....................................................................................................................... \u00a0216\u00a0\n11.15\u00a0Pixantron \u00a0........................................................................................................................... \u00a0220\u00a0\n11.16\u00a0Rilpivirin\u00a0............................................................................................................................. \u00a0224\u00a0\n11.17\u00a0Ruxolitinib \u00a0.......................................................................................................................... \u00a0230\u00a0\n11.18\u00a0Tegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0Oteracil\u00a0........................................................................................... \u00a0235\u00a0\n11.19\u00a0Vandetanib \u00a0........................................................................................................................ \u00a0239\u00a0\n11.20\u00a0Vemurafenib \u00a0...................................................................................................................... \u00a0243\u00a0\nLiteraturverzeichnis \u00a0..................................................................................................................... \u00a0246\u00a0\nAbk\u00fcrzungsverzeichnis \u00a0................................................................................................................ \u00a0269\u00a0\nAbbildungsverzeichnis \u00a0................................................................................................................. \u00a0271\u00a0\nTabellenverzeichnis \u00a0..................................................................................................................... \u00a0273\u00a0\n\u00a0\u00a0 \n5\u00a0\n \nInnovationsreport 2015 \u00a0 Vorwort\u00a0zum\u00a0Innovationsreport \u00a02015\u00a0\nDr.\u00a0Jens\u00a0Baas,\u00a0Vorsitzender \u00a0des\u00a0Vorstands \u00a0der\u00a0Techniker \u00a0Krankenkasse \u00a0\nDer\u00a0Innovationsreport \u00a0wird\u00a0in\u00a0diesem\u00a0Jahr\u00a0bereits\u00a0zum\u00a0dritten\u00a0Mal\u00a0in\u00a0Folge\u00a0von\u00a0der\u00a0Techniker \u00a0\nKrankenkasse \u00a0herausgeben. \u00a0Erstellt\u00a0vom\u00a0SOCIUM,\u00a0Forschungszentrum \u00a0Ungleichheit \u00a0und\u00a0Sozialpolitik \u00a0\nan\u00a0der\u00a0Universit\u00e4t \u00a0Bremen,\u00a0beinhaltet \u00a0er\u00a0\u2013\u00a0wie\u00a0in\u00a0den\u00a0Vorjahren \u00a0auch\u00a0\u2013\u00a0unter\u00a0anderem\u00a0eine\u00a0\nstrukturierte \u00a0\u00dcbersicht \u00a0\u00fcber\u00a0Bewertungen \u00a0von\u00a0neuen\u00a0Arzneimitteln, \u00a0so\u00a0genannte \u00a0Arzneimittel \u2010\nInnovationen. \u00a0\nDer\u00a0Innovationsreport \u00a02015\u00a0bewertet \u00a0die\u00a019\u00a0neuen\u00a0Wirkstoffe \u00a0bzw.\u00a0Wirkstoffkombinationen \u00a0des\u00a0\nJahres\u00a02012.\u00a0Vier\u00a0dieser\u00a0Arzneistoffe \u00a0sind\u00a0zur\u00a0Therapie\u00a0von\u00a0Volkskrankheiten \u00a0indiziert.\u00a0Damit\u00a0wird\u00a0der\u00a0\nReport\u00a0immer\u00a0mehr\u00a0auch\u00a0f\u00fcr\u00a0Haus\u00e4rzte \u00a0zu\u00a0einer\u00a0relevanten \u00a0Informationsquelle. \u00a0Denn\u00a0die\u00a0Arznei\u2010\nmitteltherapie \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0findet\u00a0nicht\u00a0nur\u00a0in\u00a0den\u00a0Facharztpraxen \u00a0und\u00a0im\u00a0station\u00e4ren \u00a0\nBereich\u00a0statt.\u00a0Insoweit\u00a0ist\u00a0es\u00a0wichtig,\u00a0allen\u00a0Arztgruppen \u00a0einen\u00a0\u00dcberblick \u00a0\u00fcber\u00a0die\u00a0Bewertung \u00a0der\u00a0\nneuen\u00a0Pr\u00e4parate \u00a0zu\u00a0geben.\u00a0\nEine\u00a0aktuelle\u00a0Befragung \u00a0vom\u00a0Meinungsforschungsinstitut \u00a0DocCheck \u00a0im\u00a0Auftrag\u00a0der\u00a0TK\u00a0hat\u00a0in\u00a0diesem\u00a0\nZusammenhang \u00a0interessante \u00a0Ergebnisse \u00a0gebracht. \u00a0Befragt\u00a0wurden\u00a0\u00c4rzte,\u00a0wie\u00a0sie\u00a0ihre\u00a0Verordnungs \u2010\nentscheidung \u00a0im\u00a0Hinblick\u00a0auf\u00a0neue\u00a0Arzneimittel \u00a0treffen.\u00a0Dabei\u00a0werden\u00a0Leitlinien\u00a0als\u00a0dritth\u00e4ufigste \u00a0\nQuelle\u00a0zur\u00a0Verordnungsentscheidung \u00a0genannt\u00a0(von\u00a030\u00a0Prozent\u00a0der\u00a0Befragten), \u00a0die\u00a0Ergebnisse \u00a0der\u00a0fr\u00fc\u2010\nhen\u00a0Nutzenbewertung \u00a0nannten\u00a0jedoch\u00a0nur\u00a015\u00a0Prozent\u00a0der\u00a0befragten \u00a0\u00c4rzte\u00a0als\u00a0Quelle.\u00a0Das\u00a0bedeutet, \u00a0\ndass\u00a0die\u00a0Verordner \u00a0den\u00a0Leitlinien\u00a0offenbar\u00a0mehr\u00a0Beachtung \u00a0schenken \u00a0als\u00a0dem\u00a0G\u2010BA.\u00a0\nStellt\u00a0man\u00a0jedoch\u00a0die\u00a0Gesamtbewertungen \u00a0(\"Gesamtampel\") \u00a0der\u00a0einzelnen \u00a0Arzneistoffe \u00a0der\u00a0\nInnovationsreporte \u00a02013,\u00a02014\u00a0und\u00a02015\u00a0dem\u00a0\u2013\u00a0oftmals\u00a0raschen\u00a0\u2013\u00a0Eingang\u00a0in\u00a0die\u00a0Leitlinien\u00a0\ngegen\u00fcber, \u00a0so\u00a0zeigt\u00a0sich,\u00a0dass\u00a0von\u00a062\u00a0in\u00a0den\u00a0Reporten \u00a0bewerteten \u00a0Wirkstoffen \u00a039\u00a0den\u00a0Eingang\u00a0in\u00a0die\u00a0\nLeitlinien\u00a0gefunden \u00a0haben,\u00a0jedoch\u00a034\u00a0eine\u00a0\u201erote\u00a0Gesamtampel\u201c \u00a0von\u00a0den\u00a0Autoren\u00a0des\u00a0SOCIUM\u00a0\nzugesprochen \u00a0bekamen. \u00a0\u00a0\nEs\u00a0ist\u00a0aus\u00a0unserer\u00a0Sicht\u00a0also\u00a0notwendig, \u00a0dass\u00a0die\u00a0Bewertungsergebnisse \u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung \u00a0\nauch\u00a0fest\u00a0in\u00a0den\u00a0Leitlinien\u2010Prozessen \u00a0verankert \u00a0werden.\u00a0Zus\u00e4tzlich \u00a0m\u00fcssen\u00a0\u00c4rzte\u00a0anhand\u00a0gezielter\u00a0\nArzneimittelinformationen \u00a0zeitnah\u00a0und\u00a0praxisorientiert \u00a0\u00fcber\u00a0die\u00a0Bewertungsergebnisse \u00a0informiert \u00a0\nwerden.\u00a0Diesem\u00a0Ziel\u00a0dient\u00a0der\u00a0vorliegende \u00a0Innovationsreport \u00a02015.\u00a0\nDurch\u00a0die\u00a0Nutzung\u00a0von\u00a0Routinedaten \u00a0der\u00a0TK\u00a0kann\u00a0der\u00a0Report\u00a0weitere\u00a0interessante \u00a0Erkenntnisse \u00a0zur\u00a0\nVersorgungsrealit\u00e4t \u00a0mit\u00a0neuen\u00a0Arzneistoffen \u00a0liefern.\u00a0So\u00a0zeigen\u00a0sich\u00a0erneut\u00a0hohe\u00a0Verordnungszahlen \u00a0\nf\u00fcr\u00a0neue\u00a0Arzneimittel \u00a0insgesamt \u00a0\u2013\u00a0auch\u00a0f\u00fcr\u00a0Pr\u00e4parate \u00a0ohne\u00a0Zusatznutzen \u00a0\u2013\u00a0und\u00a0deutliche \u00a0regionale \u00a0\nUnterschiede \u00a0in\u00a0der\u00a0Verordnungspr\u00e4valenz \u00a0der\u00a0neuen\u00a0Arzneimittel. \u00a0Solche\u00a0Unterschiede \u00a0sind\u00a0auch\u00a0in\u00a0\nanderen\u00a0medizinischen \u00a0Bereichen \u00a0erkennbar, \u00a0z.B.\u00a0bei\u00a0der\u00a0H\u00e4ufigkeit \u00a0der\u00a0Durchf\u00fchrung \u00a0bestimmter \u00a0\nOperationen. \u00a0In\u00a0den\u00a0meisten\u00a0F\u00e4llen\u00a0sind\u00a0diese\u00a0unterschiedlichen \u00a0Pr\u00e4valenzen \u00a0fachlich\u00a0aber\u00a0nicht\u00a0zu\u00a0\nbegr\u00fcnden. \u00a0Es\u00a0sollten\u00a0daher\u00a0Wege\u00a0gefunden \u00a0werden,\u00a0diese\u00a0Unterschiede \u00a0\u2013\u00a0und\u00a0damit\u00a0Ineffizienzen \u00a0\nund\u00a0mitunter\u00a0falsche\u00a0Behandlungen \u00a0\u2013\u00a0abzubauen. \u00a0Die\u00a0Transparenz, \u00a0die\u00a0der\u00a0Innovationsreport \u00a0an\u00a0\ndieser\u00a0Stelle\u00a0bietet,\u00a0kann\u00a0dabei\u00a0helfen.\u00a0\nDer\u00a0Report\u00a0verfolgt\u00a0dar\u00fcber\u00a0hinaus\u00a0im\u00a0Rahmen\u00a0der\u00a0Nachbeobachtung \u00a0der\u00a0neuen\u00a0Arzneimittel \u00a0des\u00a0\nJahres\u00a02011\u00a0die\u00a0aktuelle\u00a0Marktentwicklung \u00a0von\u00a0Fingolimod \u00a0(Gilenya\u00ae) \u00a0bis\u00a0in\u00a0das\u00a0Jahr\u00a02014.\u00a0Dies\u00a0ist\u00a0\ndeshalb\u00a0aufschlussreich, \u00a0da\u00a0es\u00a0verschiedene \u00a0Bewertungsverfahren \u00a0gab\u00a0und\u00a0trotz\u00a0lediglich\u00a0geringem \u00a0\nZusatznutzen \u00a0f\u00fcr\u00a0eine\u00a0kleine\u00a0Subgruppe \u00a0hohe\u00a0Verordnungszahlen \u00a0festzustellen \u00a0waren.\u00a0Das\u00a0Einspar\u2010 \n6\u00a0 \n \nInnovationsreport 2015 \u00a0potential\u00a0f\u00fcr\u00a0die\u00a0GKV\u00a0liegt\u00a0in\u00a0Millionenh\u00f6he, \u00a0wenn\u00a0das\u00a0Pr\u00e4parat\u00a0nur\u00a0f\u00fcr\u00a0die\u00a0Patienten \u00a0eingesetzt \u00a0wird,\u00a0\nf\u00fcr\u00a0die\u00a0auch\u00a0ein\u00a0Zusatznutzen \u00a0festgestellt \u00a0wurde.\u00a0In\u00a0einem\u00a0weiteren\u00a0Sonderkapitel \u00a0widmet\u00a0sich\u00a0der\u00a0\nInnovationsreport \u00a02015\u00a0den\u00a0allgemeinen \u00a0Herausforderungen \u00a0im\u00a0AMNOG\u2010Prozess\u00a0in\u00a0Bezug\u00a0auf\u00a0die\u00a0\nsensible\u00a0Diagnose\u00a0\u201eKrebs\"\u00a0und\u00a0die\u00a0angemessene \u00a0Preisfindung \u00a0in\u00a0diesem\u00a0Bereich.\u00a0Am\u00a0Beispiel\u00a0der\u00a0\nonkologischen \u00a0Pr\u00e4parate \u00a0Vemurafenib \u00a0(Zelboraf\u00ae) \u00a0und\u00a0Dabrafenib \u00a0(Tafinlar\u00ae) \u00a0werden\u00a0zus\u00e4tzlich \u00a0\nkonkrete\u00a0Schwierigkeiten \u00a0im\u00a0Hinblick\u00a0auf\u00a0die\u00a0zweckm\u00e4\u00dfige \u00a0Vergleichstherapie \u00a0aufgezeigt. \u00a0Hier\u00a0\nbeschreiben \u00a0die\u00a0Wissenschaftler \u00a0notwendige \u00a0Ver\u00e4nderungsbedarfe. \u00a0\nInsgesamt \u00a0zeigt\u00a0sich,\u00a0dass\u00a0das\u00a0AMNOG\u00a0zwar\u00a0Einsparungen \u00a0generiert, \u00a0diese\u00a0aber\u00a0lediglich\u00a0eine\u00a0\u201ehom\u00f6\u2010\nopathische \u00a0Entlastung\" \u00a0f\u00fcr\u00a0die\u00a0GKV\u00a0bedeuten. \u00a0Deshalb\u00a0sollte\u00a0\u00fcber\u00a0weitere\u00a0Anpassungen \u00a0im\u00a0Preis\u2010\nfindungsprozess \u00a0nachgedacht \u00a0werden.\u00a0\nDie\u00a0Steigerung \u00a0der\u00a0Versorgungsqualit\u00e4t \u00a0in\u00a0der\u00a0GKV\u00a0ist\u00a0in\u00a0aller\u00a0Munde.\u00a0Tats\u00e4chliche \u00a0Schritte,\u00a0um\u00a0das\u00a0\nZiel\u00a0zu\u00a0erreichen, \u00a0Qualit\u00e4tstransparenz \u00a0und\u00a0auch\u00a0eine\u00a0Anbindung \u00a0von\u00a0Qualit\u00e4tsergebnissen \u00a0an\u00a0die\u00a0\nVerg\u00fctung, \u00a0erweisen\u00a0sich\u00a0aber\u00a0als\u00a0langwierig \u00a0und\u00a0schwierig. \u00a0Der\u00a0Innovationsreport \u00a0kann\u00a0\u2013\u00a0zumindest \u00a0\nim\u00a0Arzneimittelbereich \u00a0\u2013\u00a0schon\u00a0heute\u00a0ein\u00a0Beitrag\u00a0sein,\u00a0zu\u00a0mehr\u00a0Versorgungsqualit\u00e4t \u00a0und\u00a0zu\u00a0einer\u00a0\nh\u00f6heren\u00a0Arzneimitteltherapiesicherheit \u00a0beizusteuern. \u00a0\n   \n7\u00a0\n \nInnovationsreport 2015 \u00a0 Zweites\u00a0Vorwort\u00a0zum\u00a0Innovationsreport \u00a02015\u00a0\nProf.\u00a0Dr.\u00a0Petra\u00a0Th\u00fcrmann \u00a0und\u00a0Prof.\u00a0Dr.\u00a0Wolf\u2010Dieter\u00a0Ludwig\u00a0\nAuch\u00a0die\u00a0Bilanz\u00a0im\u00a0Innovationsreport \u00a02015,\u00a0der\u00a0die\u00a019\u00a0neuen\u00a0Wirkstoffe \u00a0aus\u00a0dem\u00a0Jahr\u00a02012\u00a0bewertet, \u00a0\nist\u00a0ern\u00fcchternd. \u00a0Bei\u00a0etwa\u00a0der\u00a0H\u00e4lfte\u00a0der\u00a0Wirkstoffe \u00a0bzw.\u00a0einer\u00a0Wirkstoffkombination \u00a0findet\u00a0sich\u00a0eine\u00a0\n\u201erote\u00a0Ampel\u201c,\u00a0da\u00a0medikament\u00f6se \u00a0Alternativen \u00a0bereits\u00a0auf\u00a0dem\u00a0Markt\u00a0zur\u00a0Verf\u00fcgung \u00a0stehen\u00a0und\u00a0ein\u00a0\n\u00fcberzeugender, \u00a0f\u00fcr\u00a0die\u00a0Patienten \u00a0relevanter \u00a0therapeutischer \u00a0Fortschritt \u00a0weder\u00a0durch\u00a0die\u00a0Bewertung \u00a0\nim\u00a0Innovationsreport \u00a0noch\u00a0anhand\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung \u00a0im\u00a0Rahmen\u00a0des\u00a0AMNOG\u00a0erkennbar \u00a0\nist.\u00a0\nDieser\u00a0Innovationsreport \u00a0verdeutlicht \u00a0dar\u00fcber\u00a0hinaus,\u00a0dass\u00a0auch\u00a0im\u00a0Jahr\u00a02012\u00a0die\u00a0Auswirkungen \u00a0der\u00a0\nProduktivit\u00e4ts \u2010\u00a0und\u00a0Innovationskrise \u00a0in\u00a0der\u00a0pharmazeutischen \u00a0Industrie\u00a0noch\u00a0nicht\u00a0\u00fcberwunden \u00a0wa\u2010\nren.\u00a0Die\u00a0pharmazeutischen \u00a0Unternehmer \u00a0positionieren \u00a0sich\u00a0zunehmend \u00a0in\u00a0lukrativen \u00a0Therapie\u2010\ngebieten\u00a0mit\u00a0unver\u00e4ndert \u00a0gro\u00dfem\u00a0Bedarf\u00a0an\u00a0echten\u00a0Innovationen, \u00a0wie\u00a0beispielsweise \u00a0der\u00a0Onkologie, \u00a0\noder\u00a0aber\u00a0konzentrieren \u00a0sich\u00a0auf\u00a0die\u00a0Entwicklung \u00a0von\u00a0Arzneimitteln \u00a0gegen\u00a0seltene\u00a0Leiden\u00a0\u2013\u00a0f\u00fcnf\u00a0von\u00a0\ninsgesamt \u00a019\u00a0neu\u00a0zugelassenen \u00a0Wirkstoffen \u00a0sind\u00a0Orphan\u00a0Drugs .\u00a0Neun\u00a0der\u00a0insgesamt \u00a019\u00a0Wirkstoffe, \u00a0\nsomit\u00a0fast\u00a050\u00a0Prozent,\u00a0wurden\u00a0f\u00fcr\u00a0onkologische \u00a0Indikationen \u00a0zugelassen, \u00a0aber\u00a0nur\u00a0eines\u00a0dieser\u00a0\nOnkologika \u00a0erhielt\u00a0im\u00a0Gesamt\u2010Score\u00a0des\u00a0Innovationsreports \u00a02015\u00a0eine\u00a0\u201egr\u00fcne\u00a0Ampel\u201c,\u00a0der\u00a0Wirkstoff \u00a0\nVemurafenib. \u00a0Dieser\u00a0weist\u00a0als\u00a0einziger\u00a0neuer\u00a0Wirkstoff \u00a0einen\u00a0\u00fcberzeugenden \u00a0(Zusatz\u2010)Nutzen\u00a0auf.\u00a0\nDer\u00a0Trend,\u00a0dass\u00a0gerade\u00a0in\u00a0der\u00a0Onkologie \u00a0neue\u00a0Wirkstoffe \u00a0als\u00a0Orphan\u00a0Drugs\u00a0und\u00a0nach\u00a0beschleunigten \u00a0\nZulassungsverfahren \u00a0(von\u00a0der\u00a0Europ\u00e4ischen \u00a0Arzneimittel \u2010Agentur\u00a0h\u00e4ufig\u00a0im\u00a0Rahmen\u00a0der\u00a0\nsogenannten \u00a0\u201econditional \u00a0marketing \u00a0authorisation\u201c \u00a0und/oder \u00a0des\u00a0\u201eaccelerated \u00a0assessment\u201c) \u00a0\nzugelassen \u00a0werden,\u00a0ist\u00a0unverkennbar. \u00a0Diese\u00a0beschleunigten \u00a0Zulassungsverfahren \u00a0\u2013\u00a0vergleichbar \u00a0mit\u00a0\nder\u00a0in\u00a0den\u00a0USA\u00a02012\u00a0neu\u00a0eingef\u00fchrten, \u00a0bisher\u00a0\u00fcberwiegend \u00a0f\u00fcr\u00a0onkologische \u00a0Wirkstoffe \u00a0vergebenen \u00a0\n\u201ebreakthrough \u2010therapy\u00a0designation\u201c \u00a0\u2013\u00a0wird\u00a0zu\u00a0Recht\u00a0zunehmend \u00a0kritisiert.\u00a0Im\u00a0Rahmen\u00a0dieser\u00a0\nZulassungsverfahren \u00a0werden\u00a0dadurch\u00a0die\u00a0Anforderungen \u00a0an\u00a0die\u00a0Erkenntnisse \u00a0zu\u00a0Wirksamkeit \u00a0bzw.\u00a0\nSchaden\u00a0bei\u00a0Zulassung \u00a0weiter\u00a0verringert \u00a0und\u00a0angesichts \u00a0von\u00a0Bezeichnungen \u00a0wie\u00a0\nDurchbruchinnovation \u00a0bei\u00a0Patienten \u00a0sowie\u00a0\u00c4rzten\u00a0Erwartungen \u00a0an\u00a0einen\u00a0gro\u00dfen\u00a0therapeutischen \u00a0\nFortschritt \u00a0geweckt\u00a0\u2013\u00a0leider\u00a0meist\u00a0zu\u00a0Unrecht.\u00a0\u00a0\nEin\u00a0weiteres\u00a0Problem,\u00a0die\u00a0Kostenexplosion \u00a0in\u00a0der\u00a0medikament\u00f6sen \u00a0Therapie\u00a0onkologischer \u00a0Erkrank\u2010\nungen,\u00a0zuletzt\u00a0auch\u00a0bei\u00a0neu\u00a0zugelassenen \u00a0Wirkstoffen \u00a0zur\u00a0Behandlung \u00a0der\u00a0Hepatitis\u00a0C\u00a0zu\u00a0beobachten, \u00a0\nist\u00a0un\u00fcbersehbar \u00a0und\u00a0erfordert\u00a0Ma\u00dfnahmen \u00a0von\u00a0Seiten\u00a0der\u00a0Gesundheitspolitik. \u00a0Die\u00a0in\u00a0den\u00a0letzten\u00a0\nJahren\u00a0teilweise\u00a0rasant\u00a0gestiegenen \u00a0Preise\u00a0f\u00fcr\u00a0neue\u00a0onkologische \u00a0Wirkstoffe \u00a0werden\u00a0in\u00a0den\u00a0USA,\u00a0\ninzwischen \u00a0aber\u00a0auch\u00a0in\u00a0Europa\u00a0sehr\u00a0kritisch\u00a0kommentiert. \u00a0Aktuelle\u00a0Untersuchungen \u00a0von\u00a0\nWissenschaftlern \u00a0aus\u00a0dem\u00a0National\u00a0Cancer\u00a0Institute\u00a0in\u00a0den\u00a0USA\u00a0liefern\u00a0weitere\u00a0Belege\u00a0f\u00fcr\u00a0das\u00a0un\u2010\nseri\u00f6se\u00a0Vorgehen \u00a0der\u00a0pharmazeutischen \u00a0Unternehmer \u00a0bei\u00a0der\u00a0Preissetzung \u00a0f\u00fcr\u00a0neue\u00a0onkologische \u00a0\nArzneimittel. \u00a0So\u00a0findet\u00a0sich\u00a0bei\u00a0den\u00a0von\u00a02009\u00a0bis\u00a02013\u00a0von\u00a0der\u00a0Food\u00a0and\u00a0Drug\u00a0Administration \u00a0(FDA)\u00a0\nzugelassenen \u00a0onkologischen \u00a0Arzneimittel \u00a0keine\u00a0Korrelation \u00a0zwischen\u00a0der\u00a0H\u00f6he\u00a0der\u00a0vom\u00a0pharma\u2010\nzeutischen \u00a0Unternehmer \u00a0verlangten \u00a0Preise\u00a0und\u00a0des\u00a0Innovationsgrades \u00a0\u2013\u00a0d.\u00a0h.\u00a0neuartiges \u00a0Wirkprinzip \u00a0\noder\u00a0Nachfolgepr\u00e4parat \u00a0(\u201enext\u2010in\u2010class\u201c)\u00a0\u2013\u00a0oder\u00a0dem\u00a0bei\u00a0Zulassung \u00a0belegten\u00a0klinischen \u00a0Nutzen.\u00a0Diese\u00a0\nAnalysen\u00a0widerlegen \u00a0auch\u00a0die\u00a0vom\u00a0pharmazeutischen \u00a0Unternehmer \u00a0h\u00e4ufig\u00a0genannten \u00a0Gr\u00fcnde\u00a0f\u00fcr\u00a0die\u00a0\nsehr\u00a0hohen\u00a0Kosten\u00a0neuer\u00a0onkologischer \u00a0Arzneimittel \u00a0\u2013\u00a0Ausgaben \u00a0f\u00fcr\u00a0Forschung \u00a0und\u00a0Entwicklung \u00a0\u2013\u00a0\nund\u00a0verdeutlichen \u00a0eindrucksvoll, \u00a0dass\u00a0die\u00a0aktuelle\u00a0Preisgestaltung \u00a0nicht\u00a0rational\u00a0erfolgt,\u00a0sondern\u00a0in\u00a0\nerster\u00a0Linie\u00a0widerspiegelt, \u00a0was\u00a0der\u00a0Markt\u00a0bereit\u00a0ist\u00a0zu\u00a0zahlen.\u00a0Die\u00a0vermutlich \u00a0unbeabsichtigten, \u00a0aber\u00a0\nsehr\u00a0negativen \u00a0Auswirkungen \u00a0der\u00a0inzwischen \u00a0meist\u00a0exorbitanten \u00a0Preise\u00a0f\u00fcr\u00a0onkologische \u00a0Wirkstoffe, \u00a0\nsind\u00a0offensichtlich: \u00a0Die\u00a0Entwicklung \u00a0einer\u00a0Vielzahl\u00a0lukrativer, \u00a0\u00e4hnlicher \u00a0Wirkstoffe \u00a0mit\u00a0marginalem \u00a0 \n8\u00a0 \n \nInnovationsreport 2015 \u00a0Nutzen\u00a0\u2013\u00a0heute\u00a0auch\u00a0als\u00a0Me\u2010too\u2010Mentalit\u00e4t \u00a0bezeichnet \u00a0\u2013\u00a0behindert \u00a0die\u00a0Entwicklung \u00a0echter,\u00a0patien\u2010\ntenrelevanter \u00a0Innovationen \u00a0und\u00a0f\u00f6rdert\u00a0sicher\u00a0nicht\u00a0die\u00a0Kreativit\u00e4t \u00a0in\u00a0der\u00a0klinischen \u00a0Forschung. \u00a0Es\u00a0ist\u00a0\ndeshalb\u00a0Aufgabe\u00a0von\u00a0\u00c4rzten,\u00a0Krankenkassen \u00a0und\u00a0Gesundheitspolitikern, \u00a0aber\u00a0auch\u00a0der\u00a0Gesellschaft \u00a0\ninsgesamt, \u00a0dar\u00fcber\u00a0nachzudenken, \u00a0wie\u00a0dieser\u00a0Profitmaximierung \u00a0der\u00a0pharmazeutischen \u00a0Unter\u2010\nnehmer\u00a0zu\u00a0Lasten\u00a0unseres\u00a0solidarisch \u00a0finanzierten \u00a0Gesundheitssystems, \u00a0aber\u00a0auch\u00a0individueller \u00a0Pa\u2010\ntienten\u00a0wirksam\u00a0begegnet \u00a0werden\u00a0kann.\u00a0Bedenkt\u00a0man\u00a0die\u00a0Tatsache, \u00a0dass\u00a0die\u00a0Cystic\u00a0Fibrosis\u00a0\nFoundation \u00a0mit\u00a075\u00a0Mio.\u00a0US\u2010$\u00a0zur\u00a0klinischen \u00a0Forschung \u00a0zu\u00a0Ivacaftor\u00a0beigetragen \u00a0und\u00a0ihr\u00a0Netzwerk \u00a0den\u00a0\nPatienten \u00a0zur\u00a0Verf\u00fcgung \u00a0gestellt\u00a0hat,\u00a0so\u00a0erscheinen \u00a0j\u00e4hrliche\u00a0Behandlungskosten \u00a0von\u00a0etwa\u00a0280.000\u00a0\u20ac\u00a0\nunverst\u00e4ndlich \u00a0und\u00a0ma\u00dflos.\u00a0Hier\u00a0hat\u00a0sich\u00a0offenbar\u00a0eine\u00a0Messlatte \u00a0hinsichtlich \u00a0des\u00a0Kostenbereichs \u00a0von\u00a0\nArzneimitteln \u00a0f\u00fcr\u00a0wirklich\u00a0seltene,\u00a0meist\u00a0heredit\u00e4re \u00a0Erkrankungen \u00a0entwickelt, \u00a0an\u00a0dem\u00a0sich\u00a0interes\u2010\nsanterweise \u00a0alle\u00a0Orphan\u00a0Drugs\u00a0orientieren, \u00a0wie\u00a0beispielsweise \u00a0Imiglucerase \u00a0(Morbus\u00a0Gaucher)\u00a0oder\u00a0\nIdursulfase \u00a0(Mukopolysaccharidose \u00a0Typ\u00a0II,\u00a0Hunter\u00a0Syndrom). \u00a0Diese\u00a0werden\u00a0von\u00a0einigen\u00a0Europ\u00e4ischen \u00a0\nGesundheitssystemen \u00a0noch\u00a0nicht\u00a0oder\u00a0nicht\u00a0mehr\u00a0erstattet, \u00a0wobei\u00a0teilweise\u00a0Hilfsfonds \u00a0diese\u00a0Leistung\u00a0\n\u00fcbernehmen. \u00a0\nZu\u00a0einem\u00a0berechtigten \u00a0Aufschrei \u00a0kam\u00a0es\u00a0international, \u00a0als\u00a0die\u00a0Kosten\u00a0f\u00fcr\u00a0Sofosbuvir \u00a0bekannt\u00a0wurden,\u00a0\nund\u00a0man\u00a0von\u00a0der\u00a0\u201e1.000\u2010$\u2010Pill\u201c\u00a0sprach.\u00a0Sofosbuvir \u00a0kann\u00a0bei\u00a0verschiedenen \u00a0Genotypen \u00a0von\u00a0Hepatitis\u00a0\nC\u00a0eingesetzt \u00a0werden,\u00a0daran\u00a0sind\u00a0etwa\u00a0300.000\u00a0Menschen \u00a0in\u00a0Deutschland \u00a0erkrankt.\u00a0Wie\u00a0viele\u00a0davon\u00a0\nnun\u00a0mit\u00a0Sofosbuvir \u00a0behandelt \u00a0werden,\u00a0wird\u00a0man\u00a0erst\u00a0anhand\u00a0von\u00a0Analysen\u00a0in\u00a0den\u00a0kommenden \u00a0\nJahren\u00a0sehen.\u00a0Weltweit\u00a0leben\u00a0vor\u00a0allem\u00a0in\u00a0Schwellen \u2010\u00a0und\u00a0Entwicklungsl\u00e4ndern \u00a0Millionen \u00a0von\u00a0\npotentiellen \u00a0Patienten. \u00a0Selbstverst\u00e4ndlich \u00a0ist\u00a0es\u00a0ein\u00a0therapeutischer \u00a0Durchbruch, \u00a0wenn\u00a0mit\u00a0Hilfe\u00a0\nneuer,\u00a0bei\u00a0Hepatitis\u00a0C\u00a0besser\u00a0wirksamer \u00a0Arzneimittel \u00a0\u00fcber\u00a090\u00a0Prozent\u00a0der\u00a0Patienten \u00a0geheilt\u00a0und\u00a0\nLeberzellkarzinome \u00a0sowie\u00a0Transplantationen \u00a0vermieden \u00a0werden\u00a0k\u00f6nnen.\u00a0Die\u00a0reinen\u00a0\nHerstellungskosten \u00a0wurden\u00a0mit\u00a0136\u00a0US\u2010$\u00a0(f\u00fcr\u00a0eine\u00a0komplette \u00a0zw\u00f6lfw\u00f6chige \u00a0Therapie) \u00a0berechnet, \u00a0was\u00a0\nSchwellen \u2010\u00a0und\u00a0Entwicklungsl\u00e4nder \u00a0erm\u00f6glicht, \u00a0dieses\u00a0Medikament \u00a0\u00fcber\u00a0spezielle\u00a0Vertr\u00e4ge\u00a0und\u00a0mit\u00a0\ninternationaler \u00a0Unterst\u00fctzung \u00a0(in\u00a0Analogie\u00a0zu\u00a0HIV\u2010Medikamenten) \u00a0ihrer\u00a0Bev\u00f6lkerung \u00a0zur\u00a0Verf\u00fcgung \u00a0\nzu\u00a0stellen.\u00a0Das\u00a0wird\u00a0jedoch\u00a0keineswegs \u00a0zu\u00a0angemessenen \u00a0Preisen\u00a0in\u00a0Europa\u00a0und\u00a0den\u00a0USA\u00a0f\u00fchren,\u00a0so\u00a0\nlange\u00a0hier\u00a0noch\u00a0eine\u00a0\u201ewillingness \u00a0to\u00a0pay\u201c\u00a0f\u00fcr\u00a0H\u00f6chstpreise \u00a0besteht.\u00a0\u00a0\nAuch\u00a0die\u00a0Rahmenbedingungen \u00a0f\u00fcr\u00a0die\u00a0Entwicklung \u00a0der\u00a0Orphan\u00a0Drugs\u00a0\u2013\u00a0von\u00a0pharmazeutischen \u00a0\nUnternehmern \u00a0seit\u00a0Jahren\u00a0bereits,\u00a0ebenso\u00a0wie\u00a0die\u00a0Onkologie, \u00a0als\u00a0neues,\u00a0sehr\u00a0lukratives \u00a0Gesch\u00e4ftsfeld \u00a0\nerkannt\u00a0\u2013\u00a0sollte\u00a0von\u00a0Seiten\u00a0der\u00a0regulatorischen \u00a0Beh\u00f6rden \u00a0und\u00a0der\u00a0Gesundheitspolitik \u00a0einer\u00a0kritischen \u00a0\nAnalyse\u00a0unterzogen \u00a0werden.\u00a0Orphan\u00a0Drugs\u00a0zeigen\u00a0in\u00a0den\u00a0letzten\u00a0Jahren\u00a0ein\u00a0stabiles\u00a0\nUmsatzwachstum, \u00a0mit\u00a0Wachstumsraten \u00a0von\u00a0etwa\u00a07,5\u00a0Prozent\u00a0und\u00a0inzwischen \u00a0einem\u00a0globalen\u00a0\nUmsatz\u00a0von\u00a0mehr\u00a0als\u00a0100\u00a0Mrd.\u00a0US\u2010Dollar\u00a0pro\u00a0Jahr\u00a0\u2013\u00a0dies\u00a0entspricht \u00a0einem\u00a0Anteil\u00a0von\u00a0etwa\u00a015\u00a0Prozent\u00a0\nam\u00a0weltweiten \u00a0Umsatz\u00a0von\u00a0Arzneimitteln. \u00a0Dies\u00a0ist\u00a0leider\u00a0kaum\u00a0auf\u00a0die\u00a0Entwicklung \u00a0von\u00a0Orphan\u00a0Drugs\u00a0\nf\u00fcr\u00a0Patienten \u00a0mit\u00a0sehr\u00a0seltenen\u00a0angeborenen \u00a0Erkrankungen, \u00a0wie\u00a0der\u00a0Mukoviszidose \u00a0oder\u00a0\nMukopolysaccharidose, \u00a0zur\u00fcckzuf\u00fchren, \u00a0sondern\u00a0eher\u00a0auf\u00a0eine\u00a0\u201eOrphanisierung\u201c \u00a0sogenannter \u00a0\nVolkskrankheiten \u00a0im\u00a0Rahmen\u00a0der\u00a0individualisierten \u00a0Arzneimitteltherapie \u00a0\u2013\u00a0insbesondere \u00a0bei\u00a0\nKrebserkrankungen, \u00a0bei\u00a0denen\u00a0es\u00a0zunehmend \u00a0gelingt,\u00a0kleine\u00a0Untergruppen \u00a0bei\u00a0eher\u00a0h\u00e4ufigen\u00a0\nTumorerkrankungen \u00a0anhand\u00a0von\u00a0Biomarkern \u00a0zu\u00a0unterscheiden. \u00a0Orphan\u00a0Drugs\u00a0werden\u00a0in\u00a0\nZulassungsstudien, \u00a0etwa\u00a0bei\u00a0onkologischen \u00a0und\u00a0neurologischen \u00a0Erkrankungen, \u00a0weniger\u00a0gr\u00fcndlich \u00a0\ngepr\u00fcft\u00a0als\u00a0andere\u00a0Arzneimittel. \u00a0Dies\u00a0liegt\u00a0u.a.\u00a0an\u00a0der\u00a0kleinen\u00a0Zahl\u00a0von\u00a0untersuchten \u00a0Patienten, \u00a0dem\u00a0\nmitunter\u00a0nicht\u2010randomisierten \u00a0Design\u00a0der\u00a0klinischen \u00a0Studien\u00a0mit\u00a0meist\u00a0Surrogatendpunkten \u00a0und\u00a0der\u00a0\nsehr\u00a0kurzen\u00a0Nachbeobachtung. \u00a0Auch\u00a0hier\u00a0gilt\u00a0es,\u00a0in\u00a0Zukunft\u00a0die\u00a0Anforderungen \u00a0an\u00a0die\u00a0Zulassung \u00a0von\u00a0\nOrphan\u00a0Drugs\u00a0zu\u00a0erh\u00f6hen\u00a0und\u00a0dabei\u00a0mehr\u00a0Wert\u00a0zu\u00a0legen\u00a0auf\u00a0wissenschaftliche \u00a0Erkenntnisse \u00a0zu\u00a0 \n9\u00a0\n \nInnovationsreport 2015 \u00a0patientenrelevanten \u00a0Endpunkten \u00a0sowie\u00a0auf\u00a0Vergleichsstudien \u00a0mit\u00a0therapeutischen \u00a0Alternativen, \u00a0die\u00a0\nauch\u00a0bei\u00a0Orphan\u00a0Drugs\u00a0mitunter\u00a0zur\u00a0Verf\u00fcgung \u00a0stehen.\u00a0\u00a0 \n10\u00a0 \n \nInnovationsreport 2015 \u00a0\u00a0\u00a0 \n11\u00a0\n \nInnovationsreport 2015 \u00a0 1 Einleitung \u00a0\u00a0\nGerd\u00a0Glaeske\u00a0\nDer\u00a0Innovationsreport \u00a0erscheint \u00a0nun\u00a0zum\u00a0dritten\u00a0Mal.\u00a0Er\u00a0schlie\u00dft\u00a0die\u00a0neuen\u00a0Arzneimittel \u00a0des\u00a0Jahres\u00a0\n2012\u00a0ein\u00a0und\u00a0analysiert \u00a0die\u00a0Marktentwicklung \u00a0dieser\u00a0neuen\u00a0Arzneimittel \u00a0in\u00a0den\u00a0Jahren\u00a02012\u00a0und\u00a0\n2013\u00a0auf\u00a0der\u00a0Basis\u00a0von\u00a0Verordnungsdaten \u00a0der\u00a0Techniker \u00a0Krankenkasse \u00a0(TK).\u00a0Dabei\u00a0werden\u00a0sowohl\u00a0die\u00a0\nverordneten \u00a0Mengen\u00a0als\u00a0auch\u00a0die\u00a0Ausgaben \u00a0betrachtet \u00a0und\u00a0in\u00a0Bezug\u00a0zum\u00a0Nutzen\u00a0dieser\u00a0Arzneimittel \u00a0\nin\u00a0der\u00a0jeweiligen \u00a0Indikation \u00a0gesetzt.\u00a0\u00dcber\u00a0die\u00a0Ergebnisse \u00a0der\u00a0Zulassung \u00a0und\u00a0der\u00a0AMNOG\u2010\nFr\u00fchbewertung \u00a0hinaus\u00a0werden\u00a0in\u00a0die\u00a0Nutzenbewertung \u00a0des\u00a0Innovationsreportes \u00a0auch\u00a0Publikationen \u00a0\neinbezogen, \u00a0die\u00a0nach\u00a0dem\u00a0Markteintritt \u00a0der\u00a0jeweiligen \u00a0Mittel\u00a0ver\u00f6ffentlicht \u00a0wurden.\u00a0Aufgenommen \u00a0\nwerden\u00a0auch\u00a0ver\u00f6ffentlichte \u00a0Hinweise\u00a0zum\u00a0Thema\u00a0\u201eArzneimitteltherapiesicherheit\u201c, \u00a0die\u00a0wegen\u00a0der\u00a0\nbegrenzten \u00a0Aussagen \u00a0von\u00a0Zulassungsstudien \u00a0erst\u00a0im\u00a0Rahmen\u00a0der\u00a0\u201ereal\u2010life\u201c\u2010Versorgung \u00a0auff\u00e4llig\u00a0\nwerden,\u00a0weil\u00a0dort\u00a0unselektierte \u00a0gr\u00f6\u00dfere\u00a0Patientengruppen \u00a0gegen\u00fcber \u00a0den\u00a0Patienten \u00a0in\u00a0\nZulassungsstudien \u00a0mit\u00a0den\u00a0neu\u00a0zugelassenen \u00a0Mitteln\u00a0behandelt \u00a0werden.\u00a0Einfl\u00fcsse\u00a0von\u00a0Komorbidit\u00e4t, \u00a0\nPolypharmazie, \u00a0Alter\u00a0und\u00a0Geschlecht, \u00a0aber\u00a0auch\u00a0die\u00a0Kenntnisse \u00a0von\u00a0\u00c4rzten\u00a0oder\u00a0die\u00a0Adh\u00e4renz \u00a0der\u00a0\nPatienten \u00a0k\u00f6nnen\u00a0in\u00a0diesem\u00a0realen\u00a0Versorgungsumfeld \u00a0erstmals\u00a0erkennbar \u00a0werden.\u00a0Die\u00a0gr\u00f6\u00dfere\u00a0\nPatientenanzahl \u00a0dieser\u00a0Studien\u00a0gegen\u00fcber \u00a0der\u00a0Gr\u00f6\u00dfe\u00a0der\u00a0Patientenpopulation \u00a0in\u00a0Zulassungsstudien \u00a0\nkann\u00a0auch\u00a0zur\u00a0Aufdeckung \u00a0von\u00a0seltenen\u00a0unerw\u00fcnschten \u00a0Ereignissen \u00a0und\u00a0Wirkungen \u00a0f\u00fchren,\u00a0die\u00a0\nbisher\u00a0nicht\u00a0erkannt\u00a0werden\u00a0konnten.\u00a0Dies\u00a0f\u00fchrt\u00a0in\u00a0vielen\u00a0F\u00e4llen\u00a0zu\u00a0einer\u00a0differenzierteren \u00a0Bewertung \u00a0\nder\u00a0Nutzen\u2010Schaden\u2010Relation\u00a0als\u00a0dies\u00a0auf\u00a0Basis\u00a0von\u00a0Zulassungsstudien \u00a0mit\u00a0geringen\u00a0Patientenzahlen \u00a0\n\u00fcber\u00a0einen\u00a0\u00fcberschaubaren \u00a0Zeitraum\u00a0m\u00f6glich\u00a0ist.\u00a0Sichtbares \u00a0Zeichen\u00a0einer\u00a0erg\u00e4nzten \u00a0Nutzen\u2010\nSchaden\u2010Relation\u00a0sind\u00a0z.B.\u00a0Rote\u2010Hand\u2010Briefe,\u00a0die\u00a0vom\u00a0jeweiligen \u00a0pharmazeutischen \u00a0Unternehmer \u00a0\n(pU)\u00a0an\u00a0\u00c4rzte\u00a0verschickt \u00a0werden\u00a0m\u00fcssen,\u00a0um\u00a0auf\u00a0neu\u00a0erkannte\u00a0Risiken\u00a0aufmerksam \u00a0zu\u00a0machen.\u00a0\nEbenso\u00a0kann\u00a0es\u00a0auch\u00a0zu\u00a0neuen\u00a0Erkenntnissen \u00a0\u00fcber\u00a0die\u00a0Effektivit\u00e4t \u00a0neuer\u00a0Arzneimittel \u00a0kommen. \u00a0Diese\u00a0\nstellt\u00a0sich\u00a0in\u00a0den\u00a0vom\u00a0pU\u00a0geplanten \u00a0und\u00a0durchgef\u00fchrten \u00a0klinischen \u00a0Studien,\u00a0die\u00a0in\u00a0erster\u00a0Linie\u00a0zur\u00a0\nMarktzulassung \u00a0f\u00fchren\u00a0sollen,\u00a0oftmals\u00a0positiver\u00a0dar\u00a0als\u00a0in\u00a0der\u00a0Patientenversorgung. \u00a0Die\u00a0\nEffektivit\u00e4tsverluste \u00a0bei\u00a0der\u00a0Arzneimittelanwendung \u00a0sind\u00a0in\u00a0diesem\u00a0Zusammenhang \u00a0un\u00fcbersehbar. \u00a0\nSie\u00a0k\u00f6nnen\u00a0sowohl\u00a0durch\u00a0die\u00a0Rahmenbedingungen \u00a0des\u00a0Systems\u00a0(z.B.\u00a0begrenzte \u00a0finanzielle \u00a0\nRessourcen), \u00a0durch\u00a0die\u00a0Strukturqualit\u00e4t \u00a0der\u00a0Behandler \u00a0(eingeschr\u00e4nkte \u00a0Erfahrungen \u00a0im\u00a0Umgang\u00a0mit\u00a0\nden\u00a0neuen\u00a0Arzneimitteln) \u00a0als\u00a0auch\u00a0durch\u00a0Adh\u00e4renzprobleme \u00a0auf\u00a0Seiten\u00a0der\u00a0Patienten \u00a0bedingt\u00a0sein.\u00a0\nAll\u00a0diese\u00a0Einschr\u00e4nkungen \u00a0haben\u00a0in\u00a0klinischen \u00a0Zulassungsstudien \u00a0wegen\u00a0der\u00a0geplanten \u00a0Anwendung, \u00a0\nder\u00a0ausgew\u00e4hlten \u00a0Patientenpopulation \u00a0und\u00a0des\u00a0strikten\u00a0Monitorings \u00a0der\u00a0beteiligten \u00a0fachkundigen \u00a0\n\u00c4rzte\u00a0kaum\u00a0Bedeutung, \u00a0weil\u00a0die\u00a0Studiendurchf\u00fchrung \u00a0so\u00a0kontrolliert \u00a0vorgenommen \u00a0wird,\u00a0dass\u00a0ein\u00a0\nMarktzutritt \u00a0nicht\u00a0gef\u00e4hrdet \u00a0ist.\u00a0Im\u00a0Mittelpunkt \u00a0solcher\u00a0Zulassungsstudien \u00a0steht\u00a0der\u00a0im\u00a0\nArzneimittelgesetz \u00a0(AMG)\u00a0geforderte \u00a0Nachweis \u00a0von\u00a0Wirksamkeit, \u00a0Unbedenklichkeit \u00a0und\u00a0\npharmazeutischer \u00a0Qualit\u00e4t,\u00a0w\u00e4hrend\u00a0der\u00a0Patientennutzen \u00a0im\u00a0\u00a7\u00a035b\u00a0des\u00a05.\u00a0Sozialgesetzbuches \u00a0(SGB\u00a0V)\u00a0\ndefiniert\u00a0ist\u00a0als\u00a0Verringerung \u00a0der\u00a0Mortalit\u00e4t, \u00a0der\u00a0Morbidit\u00e4tslast \u00a0und\u00a0der\u00a0unerw\u00fcnschten \u00a0Wirkungen \u00a0\nsowie\u00a0der\u00a0Verbesserung \u00a0der\u00a0Lebensqualit\u00e4t .\u00a0Die\u00a0Anforderungen \u00a0des\u00a0AMG\u00a0und\u00a0des\u00a0SGB\u00a0V\u00a0sind\u00a0\nbez\u00fcglich \u00a0der\u00a0Patientenorientierung \u00a0keineswegs \u00a0kongruent, \u00a0die\u00a0\u00dcbertragbarkeit \u00a0der\u00a0in\u00a0\nZulassungsstudien \u00a0gefundenen \u00a0Effektivit\u00e4t \u00a0auf\u00a0die\u00a0Patientenversorgung \u00a0nach\u00a0der\u00a0Zulassung \u00a0ist\u00a0daher\u00a0\nin\u00a0vielen\u00a0Indikationen \u00a0berechtigterweise \u00a0von\u00a0Zweifeln\u00a0begleitet. \u00a0Dies\u00a0gilt\u00a0vor\u00a0allem\u00a0f\u00fcr\u00a0die\u00a0\nAnwendung \u00a0von\u00a0Arzneimitteln \u00a0bei\u00a0der\u00a0Behandlung \u00a0von\u00a0Krebserkrankungen, \u00a0Rheumatoider \u00a0Arthritis,\u00a0\nMultipler \u00a0Sklerose,\u00a0Psoriasis\u00a0oder\u00a0Hepatitis\u00a0C\u00a0\u2013\u00a0allesamt\u00a0Indikationen, \u00a0bei\u00a0denen\u00a0neue\u00a0zumeist\u00a0\ngentechnologisch \u00a0oder\u00a0biologisch \u00a0hergestellte \u00a0Arzneimittel \u00a0einen\u00a0therapeutischen \u00a0Fortschritt \u00a0f\u00fcr\u00a0die\u00a0\nPatienten \u00a0versprechen. \u00a0Langzeiterfahrungen \u00a0\u00fcber\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0fehlen\u00a0hier\u00a0aber\u00a0h\u00e4ufig.\u00a0Aus\u00a0\ndiesem\u00a0Grunde\u00a0erscheint \u00a0es\u00a0unerl\u00e4sslich \u00a0f\u00fcr\u00a0viele\u00a0neue\u00a0Arzneimittel, \u00a0insbesondere \u00a0f\u00fcr\u00a0solche\u00a0aus\u00a0den\u00a0 \n12\u00a0 \n \nInnovationsreport 2015 \u00a0genannten \u00a0Indikationsbereichen, \u00a0nach\u00a0der\u00a0AMNOG\u2010Fr\u00fchbewertung \u00a0eine\u00a0Sp\u00e4tbewertung \u00a0nach\u00a0drei\u00a0\n(bis\u00a0f\u00fcnf)\u00a0Jahren\u00a0vorzusehen, \u00a0um\u00a0den\u00a0Patientennutzen, \u00a0wie\u00a0er\u00a0im\u00a0\u00a7\u00a035b\u00a0des\u00a0SGB\u00a0V\u00a0definiert\u00a0ist,\u00a0besser\u00a0\nbestimmen \u00a0zu\u00a0k\u00f6nnen.\u00a0\nIm\u00a0Folgenden \u00a0werden\u00a0daher\u00a0die\u00a0Indikationsbereiche \u00a0der\u00a0im\u00a0Jahre\u00a02012\u00a0neu\u00a0auf\u00a0den\u00a0Markt\u00a0\ngekommenen \u00a0Arzneimittel \u00a0nach\u00a0Verordnungen, \u00a0Ausgaben \u00a0und\u00a0Anzahl\u00a0der\u00a0behandelten \u00a0Versicherten \u00a0\ndargestellt. \u00a0Auff\u00e4llig\u00a0dabei\u00a0sind\u00a0die\u00a0Unterschiede \u00a0in\u00a0den\u00a0Ausgaben \u00a0je\u00a0nach\u00a0Indikationsgebiet. \u00a0\n\u201eSpitzenreiter\u201c \u00a0bei\u00a0den\u00a0Ausgaben \u00a0der\u00a0TK\u00a0sind\u00a0bei\u00a0den\u00a0neuen\u00a0Arzneimitteln \u00a0des\u00a0Jahres\u00a02012\u00a0im\u00a0f\u00fcr\u00a0den\u00a0\nReport\u00a0angesetzten \u00a0Untersuchungszeitraum \u00a02012\u00a0und\u00a02013\u00a0die\u00a0Arzneimittel \u00a0zur\u00a0Behandlung \u00a0\n\u201eB\u00f6sartiger \u00a0Neubildungen\u201c, \u00a0also\u00a0Wirkstoffe \u00a0zur\u00a0Therapie\u00a0onkologischer \u00a0Erkrankungen. \u00a0Die\u00a0Kosten\u00a0f\u00fcr\u00a0\nsolche\u00a0Mittel\u00a0werden\u00a0nur\u00a0zur\u00fcckhaltend \u00a0diskutiert \u00a0oder\u00a0gar\u00a0kritisiert,\u00a0da\u00a0f\u00fcr\u00a0Patienten \u00a0mit\u00a0\nKrebserkrankungen \u00a0alle\u00a0therapeutischen \u00a0M\u00f6glichkeiten \u00a0ausgesch\u00f6pft \u00a0werden\u00a0sollen.\u00a0Kostenaspekte \u00a0\nd\u00fcrfen\u00a0nach\u00a0Meinung\u00a0vieler\u00a0keine\u00a0Rolle\u00a0spielen,\u00a0wenn\u00a0es\u00a0um\u00a0die\u00a0Lebensverl\u00e4ngerung \u00a0eines\u00a0\nKrebspatienten \u00a0geht,\u00a0selbst\u00a0wenn\u00a0es\u00a0sich\u00a0hierbei\u00a0nur\u00a0um\u00a0wenige\u00a0Monate\u00a0handelt.\u00a0Insofern\u00a0kann\u00a0es\u00a0\nauch\u00a0nicht\u00a0unbedingt \u00a0erstaunen, \u00a0dass\u00a0gerade\u00a0die\u00a0Forschung \u00a0und\u00a0Vermarktung \u00a0neuer\u00a0und\u00a0meist\u00a0teurer\u00a0\nOnkologika \u00a0f\u00fcr\u00a0viele\u00a0pU\u00a0ganz\u00a0oben\u00a0auf\u00a0der\u00a0Priorit\u00e4tenliste \u00a0stehen.\u00a0Da\u00a0die\u00a0Preisfindung \u00a0f\u00fcr\u00a0solche\u00a0\nonkologisch \u00a0eingesetzten \u00a0Arzneimittel \u00a0aber\u00a0ein\u00a0un\u00fcberschaubares \u00a0Problem\u00a0f\u00fcr\u00a0die\u00a0gesetzliche \u00a0\nKrankenversicherung \u00a0(GKV)\u00a0darstellt,\u00a0ist\u00a0diesem\u00a0Thema\u00a0ein\u00a0eigenes\u00a0Kapitel\u00a0gewidmet \u00a0(siehe\u00a0Kapitel\u00a0\n8).\u00a0\nTabelle\u00a01\u00a0fasst\u00a0die\u00a0Indikationen \u00a0zusammen, \u00a0in\u00a0denen\u00a0die\u00a0hier\u00a0zur\u00a0Betrachtung \u00a0stehenden \u00a0neuen\u00a0\nArzneimittel \u00a0des\u00a0Jahres\u00a02012\u00a0auf\u00a0den\u00a0Markt\u00a0gebracht\u00a0wurden.\u00a0Dabei\u00a0entfallen\u00a0allein\u00a0neun\u00a0der\u00a019\u00a0\nWirkstoffe \u00a0bzw.\u00a0Wirkstoffkombinationen \u00a0auf\u00a0den\u00a0onkologischen \u00a0Bereich,\u00a0zu\u00a0erkennen \u00a0an\u00a0der\u00a0L\u2010\nCodierung \u00a0im\u00a0ATC\u2010Code.\u00a0\nBetrachtet \u00a0man\u00a0die\u00a0Verordnungs \u2010\u00a0und\u00a0Ausgabenentwicklung, \u00a0dann\u00a0f\u00e4llt\u00a0auf,\u00a0dass\u00a0eine\u00a0(relativ)\u00a0\ngeringe\u00a0Anzahl\u00a0Verordnungen \u00a0auf\u00a0Onkologika \u00a0entf\u00e4llt\u00a0(17,9\u00a0Prozent\u00a0aller\u00a0Verordnungen \u00a0neuer\u00a0\nArzneimittel \u00a0im\u00a0Jahr\u00a02012\u00a0und\u00a012,7\u00a0Prozent\u00a0im\u00a0Jahr\u00a02013),\u00a0diese\u00a0aber\u00a081\u00a0Prozent\u00a0im\u00a0Jahr\u00a02012\u00a0und\u00a0\n64,5\u00a0Prozent\u00a0im\u00a0Jahr\u00a02013\u00a0der\u00a0Ausgaben \u00a0f\u00fcr\u00a0die\u00a0GKV\u00a0verursachen \u00a0(siehe\u00a0Tabelle\u00a02).\u00a0\nDie\u00a0Verordnungen \u00a0von\u00a0Arzneimitteln \u00a0zur\u00a0Behandlung \u00a0von\u00a0Krankheiten \u00a0des\u00a0Herz\u2010Kreislaufsystems \u00a0\nsowie\u00a0die\u00a0Verordnungen \u00a0\u00fcber\u00a0Hormonpr\u00e4parate \u00a0sind\u00a0im\u00a0Jahr\u00a02013\u00a0f\u00fchrend\u00a0in\u00a0der\u00a0\nVerordnungsmenge. \u00a0Bei\u00a0den\u00a0Ausgabenanteilen \u00a0liegen\u00a0die\u00a0Arzneimittel \u00a0zur\u00a0Behandlung \u00a0von\u00a0\n\u201eB\u00f6sartigen \u00a0Neubildungen\u201c \u00a0und\u00a0\u201eSonstigen \u00a0Neubildungen\u201c \u00a0aber\u00a0deutlich\u00a0an\u00a0der\u00a0Spitze.\u00a0Es\u00a0geh\u00f6rt\u00a0\ndaher\u00a0zu\u00a0den\u00a0dringendsten \u00a0Aufgaben \u00a0der\u00a0GKV,\u00a0Rahmenbedingungen \u00a0f\u00fcr\u00a0die\u00a0Einf\u00fchrung \u00a0und\u00a0die\u00a0\nNutzenbewertung \u00a0sowie\u00a0Kriterien\u00a0f\u00fcr\u00a0die\u00a0Preisfestsetzung \u00a0(Erstattungsbetr\u00e4ge) \u00a0und\u00a0f\u00fcr\u00a0\nPreisverhandlungen \u00a0weiterzuentwickeln \u00a0(z.B.\u00a0mit\u00a0der\u00a0obligatorischen \u00a0Durchf\u00fchrung \u00a0von\u00a0\nVersorgungsstudien \u00a0und\u00a0einer\u00a0anschlie\u00dfenden \u00a0\u201eSp\u00e4tbewertung\u201c \u00a0nach\u00a0drei\u00a0bis\u00a0f\u00fcnf\u00a0Jahren),\u00a0die\u00a0den\u00a0\nErfordernissen \u00a0dieses\u00a0Marktsegmentes \u00a0gerecht\u00a0werden.\u00a0Geschieht \u00a0dies\u00a0nicht\u00a0rechtzeitig, \u00a0k\u00f6nnte\u00a0auf\u00a0\nDauer\u00a0die\u00a0Finanzierbarkeit \u00a0dieser\u00a0f\u00fcr\u00a0viele\u00a0Patienten \u00a0besonders \u00a0wichtigen \u00a0Arzneimittelgruppe \u00a0\ngef\u00e4hrdet \u00a0sein.\u00a0Vorschl\u00e4ge \u00a0f\u00fcr\u00a0m\u00f6gliche\u00a0Strategien \u00a0werden\u00a0im\u00a0Kapitel\u00a08\u00a0zur\u00a0Diskussion \u00a0gestellt.\u00a0\n \u00a0 \n13\u00a0\n \nInnovationsreport 2015 \u00a0Wirkstof f\u00a0 Indikation \u00a0 International \u00a0Classification \u00a0of\u00a0\nDiseases\u00a0(ICD)\u00a0ATC\u2010Code\nAclidiniumbromid \u00a0 Chronisch \u00a0obstruktive \u00a0Lungenkrankheit Krankheiten \u00a0des\u00a0\nAtmungssystems \u00a0R03BB05\nAflibercept \u00a0 Neovaskul\u00e4re \u00a0altersabh\u00e4ngige \u00a0\nMakuladegeneration \u00a0Krankheiten \u00a0des\u00a0Auges\u00a0und\u00a0der\u00a0\nAugenanhangsgebilde \u00a0S01LA05\nAxitinib\u00a0 Zweitlinien \u2010Therapie des\u00a0\nfortgeschrittenen \u00a0Nierenzellkarzinoms \u00a0B\u00f6sartige \u00a0Neubildungen \u00a0 L01XE17\nAzilsartanmedoxomil \u00a0Essentielle \u00a0Hypertonie Krankheiten \u00a0des\u00a0\nKreislaufsystems \u00a0C09CA09\nBrentuximabvedotin \u00a0\n(O)\u00a0Rezidiviertes \u00a0oder\u00a0refrakt\u00e4res \u00a0CD30+\u00a0\nHodgkin\u2010Lymphom \u00a0B\u00f6sartige \u00a0Neubildungen \u00a0 L01XC12\nCeftarolinfosamil \u00a0 Haut\u2010\u00a0und\u00a0Weichteilgewebeinfektion, \u00a0\nambulant \u00a0erworbene \u00a0Pneumonie \u00a0Krankheiten \u00a0des\u00a0\nAtmungssystems \u00a0(hier\u00a0nur\u00a0eine\u00a0\nNennung) \u00a0J01DI02\nCrizotinib \u00a0 ALK\u2010positives, \u00a0fortgeschrittenes \u00a0nicht\u2010\nkleinzelliges \u00a0Lungenkarzinom \u00a0B\u00f6sartige \u00a0Neubildungen \u00a0 L01XE16\nDapagliflozin \u00a0 Typ\u20102\u2010Diabetes\u00a0mellitus\u00a0zur\u00a0\nVerbesserung \u00a0der\u00a0Blutzuckerkontrolle \u00a0Endokrine, \u00a0Ern\u00e4hrungs \u2010\u00a0und\u00a0\nStoffwechselkrankheiten \u00a0A10BX09\nDecitabin \u00a0(O)\u00a0 Akute\u00a0myeloische \u00a0Leuk\u00e4mie B\u00f6sartige \u00a0Neubildungen \u00a0 L01BC08\nIvacaftor\u00a0(O)\u00a0 Zystische\u00a0Fibrose\u00a0(Mukoviszidose) \u00a0mit\u00a0\nG551D\u2010Mutation \u00a0Endokrine, \u00a0Ern\u00e4hrungs \u2010\u00a0und\u00a0\nStoffwechselkrankheiten \u00a0R07AX02\nNomegestrolacetat \u00a0+\u00a0\nEstradiol\u00a0Orale\u00a0Kontrazeption Kontrazeptive \u00a0Ma\u00dfnahmen \u00a0 G03AA14\nNomegestrolacetat \u00a0+\u00a0\nEstradiol\u00a0Hormontherapie \u00a0bei\u00a0postmenopausalen \u00a0\nFrauen\u00a0Klimakterische \u00a0St\u00f6rungen \u00a0 G03FB12\nPasireotid \u00a0(O)\u00a0 Nicht\u2010operabler \u00a0Morbus\u00a0Cushing Endokrine, \u00a0Ern\u00e4hrungs \u2010\u00a0und\u00a0\nStoffwechselkrankheiten \u00a0H01CB05\nPerampanel \u00a0 Zusatztherapie \u00a0fokaler\u00a0Anf\u00e4lle Krankheiten \u00a0des\u00a0\nNervensystems \u00a0N03AX22\nPixantron \u00a0 Rezidivierte \u00a0oder\u00a0therapierefrakt\u00e4re \u00a0\naggressive \u00a0Non\u2010Hodgkin\u2010B\u2010Zell\u2010\nLymphome \u00a0B\u00f6sartige \u00a0Neubildungen \u00a0 L01DB11\nRilpivirin\u00a0 Antiretrovirale \u00a0Kombinationstherapie \u00a0\nder\u00a0HIV\u20101\u2010Infektion\u00a0Bestimmte \u00a0infekti\u00f6se \u00a0und\u00a0\nparasit\u00e4re \u00a0Krankheiten \u00a0J05AG05\nRuxolitinib \u00a0(O)\u00a0 Splenomegalie \u00a0oder\u00a0Symptome \u00a0bei\u00a0\nMyelofibrose \u00a0Sonstige\u00a0Neubildungen \u00a0\nunsicheren \u00a0oder\u00a0unbekannten \u00a0\nVerhaltens \u00a0des\u00a0lymphatischen, \u00a0\nblutbildenden \u00a0und\u00a0verwandten \u00a0\nGewebes\u00a0L01XE18\nTegafur\u00a0+\u00a0Gimeracil+ \u00a0\nOteracil\u00a0\u00a0\n(fixe\u00a0Kombination) \u00a0Fortgeschrittenes \u00a0Magenkarzinom \u00a0in\u00a0\nKombination \u00a0mit\u00a0Cisplatin\u00a0B\u00f6sartige \u00a0Neubildungen \u00a0 L01BC73\nVandetanib \u00a0 Aggressives \u00a0medull\u00e4res \u00a0\nSchilddr\u00fcsenkarzinom \u00a0B\u00f6sartige \u00a0Neubildungen \u00a0 L01XE12\nVemurafenib \u00a0 BRAF\u2010V600\u2010positives\u00a0metastasiertes\nMelanom \u00a0B\u00f6sartige \u00a0Neubildungen \u00a0 L01XE15\nTabelle\u00a01:\u00a0Indikationen \u00a0der\u00a0neuen\u00a0Arzneimittel \u00a0des\u00a0Jahres\u00a02012\u00a0\u00a0 \n14\u00a0 \n \nInnovationsreport 2015 \u00a0Rang\u00a0\nnach\u00a0\nAusgaben \u00a0\nder\u00a0TK\u00a0\n2013\u00a0ICD\u00a0Anzahl\u00a0\nbehandelte \u00a0\nVersicherte \u00a0\n2012\u00a0Anzahl\u00a0\nbehandelte \u00a0\nVersicherte \u00a0\n2013\u00a0Anzahl\u00a0\nder\u00a0VO*\u00a0\n2012\u00a0\u00a0\n(in\u00a0%)\u00a0Anzahl\u00a0\nder\u00a0VO*\u00a0\n2013\u00a0\u00a0\n(in\u00a0%)\u00a0Ausgaben \u00a0\nder\u00a0TK\u00a02012\u00a0\nin\u00a0Euro\u00a0\u00a0\n(in\u00a0%)\u00a0Ausgaben \u00a0der\u00a0\nTK\u00a02013\u00a0in\u00a0\nEuro\u00a0\n(in\u00a0%)\u00a0\n1\u00a0 B\u00f6sartige \u00a0Neubildungen \u00a0121\u00a0 346\u00a01.268\u00a0\n(14,2%)\u00a03.602\u00a0\n(8,8%)\u00a03.957.564,30 \u00a0\n(60,1%)\u00a0\u00a011.509.695,03 \u00a0\n(41,9%)\u00a0\u00a0\n2\u00a0Sonstige\u00a0Neubildungen \u00a0\nunsicheren \u00a0oder\u00a0\nunbekannten \u00a0Verhaltens \u00a0\ndes\u00a0lymphatischen, \u00a0\nblutbildenden \u00a0und\u00a0\nverwandten \u00a0Gewebes\u00a0102\u00a0 214\u00a0332\u00a0\n(3,7%)\u00a01.597\u00a0\n(3,9%)\u00a01.375.699,08 \u00a0\n(20,9%)\u00a0\u00a06.201.958,07 \u00a0\n(22,6%)\u00a0\u00a0\n3\u00a0Endokrine, \u00a0Ern\u00e4hrungs \u2010\u00a0\nund\u00a0Stoffwechsel \u2010\nkrankheiten \u00a078\u00a0 2.951\u00a0178\u00a0\n(2,0%)\u00a08.168\u00a0\n(19,9%)\u00a0657.013,88 \u00a0\n(10,0%)\u00a0\u00a03.675.992,09 \u00a0\n(13,4%)\u00a0\u00a0\n4\u00a0Krankheiten \u00a0des\u00a0Auges\u00a0\nund\u00a0der\u00a0\nAugenanhangsgebilde \u00a0\u00a0 1.179\u00a0\u00a02.859\u00a0\n(7,0%)\u00a0\u00a03.195.178,85 \u00a0\n(11,6%)\u00a0\u00a0\n5\u00a0Krankheiten \u00a0des\u00a0\nAtmungssystems \u00a0721\u00a0 5.206\u00a0843\u00a0\n(9,4%)\u00a011.348\u00a0\n(27,7%)\u00a079.654,99 \u00a0\n(1,2%)\u00a0\u00a01.231.229,72 \u00a0\n(4,5%)\u00a0\u00a0\n6\u00a0Krankheiten \u00a0des\u00a0\nNervensystems \u00a094\u00a0 321\u00a0444\u00a0\n(5,0%)\u00a02.851\u00a0\n(6,9%)\u00a0116.121,34 \u00a0\n(1,8%)\u00a0\u00a01.027.458,75 \u00a0\n(3,7%)\u00a0\u00a0\n7\u00a0Krankheiten \u00a0des\u00a0\nKreislaufsystems \u00a01.236\u00a0 1.245\u00a03.257\u00a0\n(36,4\u00a0%)\u00a04.033\u00a0\n(9,8%)\u00a0262.058,62 \u00a0\n(4,0%)\u00a0\u00a0357.911,25 \u00a0\n(1,3%)\u00a0\u00a0\n8\u00a0Hormone, \u00a0systemische \u00a0\nohne\u00a0Sexualhormone \u00a01.373\u00a0 2.734\u00a02.525\u00a0\n(28,2%)\u00a06.430\u00a0\n(15,7%)\u00a083.871,70 \u00a0\n(1,3%)\u00a0\u00a0220.079,30 \u00a0\n(0,8%)\u00a0\u00a0\n9\u00a0Bestimmte \u00a0infekti\u00f6se \u00a0und\u00a0\nparasit\u00e4re \u00a0Krankheiten \u00a034\u00a0 34\u00a0106\u00a0\n(1,2%)\u00a0147\u00a0\n(0,4%)\u00a049.101,62 \u00a0\n(0,7%)\u00a0\u00a067.414,10 \u00a0\n(0,2%)\u00a0\u00a0\n1\u20109\u00a0 Gesamt\u00a0 3.759\u00a0 14.230\u00a08.953\u00a0\n(100,0%)\u00a041.035\u00a0\n(100,0%)\u00a06.581.085,53 \u00a0\n(100,0%)\u00a0\u00a027.486.917,16 \u00a0\n(100,0%)\u00a0\n*In\u00a0Anzahl\u00a0Packungen. \u00a0Generell:\u00a0Die\u00a0Prozentangaben \u00a0beziehen\u00a0sich\u00a0auf\u00a0die\u00a0Grundgesamtheit \u00a0der\u00a0neuen\u00a0Arzneimittel \u00a02012.\u00a0\nTabelle\u00a02:\u00a0Quantitative \u00a0Charakteristika \u00a0der\u00a0Anteile\u00a0von\u00a0neuen\u00a0Arzneimitteln \u00a0des\u00a0Jahres\u00a02012\u00a0in\u00a0den\u00a0Jahren\u00a0\n2012\u00a0und\u00a02013\u00a0auf\u00a0Basis\u00a0der\u00a0TK\u2010Routinedaten \u00a0\n \u00a0 \n15\u00a0\n \nInnovationsreport 2015 \u00a0 2 Ziele\u00a0und\u00a0Methodik \u00a0\u00a0\nDaniela\u00a0Boeschen \u00a0\n2.1 Zielsetzung \u00a0\nDie\u00a0Ziele\u00a0des\u00a0vorliegenden \u00a0Innovationsreports \u00a0sind\u00a0zum\u00a0einen,\u00a0neue\u00a0Arzneimittel \u00a0anhand\u00a0der\u00a0aktu\u2010\nellen\u00a0Studienlage \u00a0nach\u00a0den\u00a0Kriterien\u00a0der\u00a0Evidenz\u2010basierten \u00a0Medizin\u00a0zu\u00a0bewerten, \u00a0und\u00a0zum\u00a0anderen,\u00a0\nauf\u00a0der\u00a0Basis\u00a0von\u00a0Daten\u00a0der\u00a0Techniker \u00a0Krankenkasse \u00a0(TK)\u00a0Verordnungscharakteristika \u00a0dieser\u00a0Arznei\u2010\nmittel\u00a0nach\u00a0der\u00a0Markteinf\u00fchrung \u00a0darzustellen. \u00a0Es\u00a0sollen\u00a0also\u00a0die\u00a0Evidenz\u00a0zu\u00a0und\u00a0die\u00a0Versorgung \u00a0mit\u00a0\nArzneimittelneuheiten \u00a0abgebildet \u00a0werden,\u00a0um\u00a0Erkenntnisse \u00a0dar\u00fcber\u00a0zu\u00a0gewinnen, \u00a0wie\u00a0die\u00a0neuen\u00a0\nMittel\u00a0verordnet \u00a0werden\u00a0und\u00a0wie\u00a0sie\u00a0sich\u00a0im\u00a0Arzneimittelmarkt \u00a0behaupten. \u00a0Im\u00a0diesj\u00e4hrigen \u00a0\nInnovationsreport \u00a0stehen\u00a0schwerpunktm\u00e4\u00dfig \u00a0die\u00a0neuen\u00a0Wirkstoffe \u00a0des\u00a0Jahres\u00a02012\u00a0im\u00a0Fokus.\u00a0Zu\u00a0\nihrer\u00a0Bewertung \u00a0werden\u00a0auch\u00a0Studien\u00a0ber\u00fccksichtigt, \u00a0deren\u00a0Ergebnisse \u00a0erst\u00a0nach\u00a0Markteinf\u00fchrung \u00a0\nder\u00a0jeweiligen \u00a0Wirkstoffe \u00a0publiziert \u00a0worden\u00a0sind.\u00a0Ebenso\u00a0finden\u00a0neue\u00a0Erkenntnisse \u00a0zu\u00a0\nSicherheitsrisiken \u00a0Beachtung, \u00a0die\u00a0zum\u00a0Zeitpunkt \u00a0der\u00a0Zulassung \u00a0und\u00a0zum\u00a0Zeitpunkt \u00a0der\u00a0AMNOG\u2010\nNutzenbewertung \u00a0noch\u00a0nicht\u00a0bekannt\u00a0gewesen\u00a0sind.\u00a0Unsere\u00a0Bewertungen \u00a0werden\u00a0durch\u00a0\nAuswertungen \u00a0von\u00a0Routinedaten \u00a0der\u00a0Techniker \u00a0Krankenkasse \u00a0der\u00a0Jahre\u00a02012\u00a0und\u00a02013\u00a0erg\u00e4nzt,\u00a0um\u00a0\nEinsichten \u00a0in\u00a0das\u00a0Versorgungsgeschehen \u00a0zu\u00a0gewinnen. \u00a0Im\u00a0R\u00fcckblick \u00a0auf\u00a0die\u00a0im\u00a0Innovationsreport \u00a0\n2014\u00a0behandelten \u00a0Arzneimittel \u00a0(neue\u00a0Wirkstoffe \u00a0des\u00a0Jahres\u00a02011)\u00a0wird\u00a0auch\u00a0gezeigt,\u00a0wie\u00a0diese\u00a0sich\u00a0\nim\u00a0Markt\u00a0weiterentwickelt \u00a0haben\u00a0und\u00a0ob\u00a0neue\u00a0Risiken\u00a0aufgetreten \u00a0sind,\u00a0mit\u00a0denen\u00a0die\u00a0\nTherapiesicherheit \u00a0gef\u00e4hrdet \u00a0sein\u00a0kann.\u00a0\u00a0\nIm\u00a0Anschluss \u00a0an\u00a0die\u00a0Wirkstoffportr\u00e4ts \u00a0mit\u00a0ihren\u00a0Versorgungsanalysen \u00a0widmen\u00a0wir\u00a0uns\u00a0den\u00a0\nSonderkapiteln. \u00a0Im\u00a0ersten\u00a0Sonderkapitel \u00a0soll\u00a0im\u00a0Zuge\u00a0der\u00a0Nachbeobachtung \u00a0der\u00a0Wirkstoffe \u00a0aus\u00a02011\u00a0\n(Innovationsreport \u00a02014)\u00a0die\u00a0Verordnungsausweitung \u00a0von\u00a0Fingolimod \u00a0beleuchtet \u00a0werden.\u00a0Aufgrund \u00a0\ndes\u00a0hohen\u00a0Anteils\u00a0onkologischer \u00a0Wirkstoffe \u00a0an\u00a0der\u00a0Gesamtzahl \u00a0der\u00a02012\u00a0zugelassenen \u00a0Pr\u00e4parate \u00a0\nbefasst\u00a0sich\u00a0das\u00a0zweite\u00a0Sonderkapitel \u00a0mit\u00a0den\u00a0Besonderheiten \u00a0des\u00a0onkologischen \u00a0Marktes.\u00a0Der\u00a0\nSchwerpunkt \u00a0liegt\u00a0dabei\u00a0auf\u00a0der\u00a0gerechten \u00a0bzw.\u00a0gerechtfertigten \u00a0Preisbildung. \u00a0Im\u00a0Jahr\u00a02012\u00a0wurde\u00a0\nau\u00dferdem \u00a0ein\u00a0neues\u00a0Gestagen \u00a0(Nomegestrolacetat) \u00a0in\u00a0Kombination \u00a0mit\u00a0Estradiol\u00a0sowohl\u00a0zur\u00a0oralen\u00a0\nKontrazeption \u00a0als\u00a0auch\u00a0zur\u00a0Hormontherapie \u00a0(HT)\u00a0zugelassen. \u00a0Aus\u00a0diesem\u00a0Anlass\u00a0soll\u00a0das\u00a0Thema\u00a0HT\u00a0im\u00a0\ndritten\u00a0Sonderkapitel \u00a0n\u00e4her\u00a0er\u00f6rtert\u00a0werden.\u00a0\u00a0\n\u00a0\n2.2 Methodik \u00a0zur\u00a0Bewertung \u00a0der\u00a0neuen\u00a0Arzneimittel \u00a0\nF\u00fcr\u00a0den\u00a0vorliegenden \u00a0Report\u00a0wurden\u00a0Medikamente \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0ber\u00fccksichtigt, \u00a0die\u00a0im\u00a0Jahr\u00a0\n2012\u00a0erstmals\u00a0in\u00a0den\u00a0deutschen \u00a0Arzneimittelmarkt \u00a0eingef\u00fchrt \u00a0wurden\u00a0(Tabelle\u00a03),\u00a0der\u00a0Wirkstoff \u00a0\nVemurafenib \u00a0wurde\u00a0bereits\u00a0im\u00a0\u201eInnovationsreport \u00a02014\u201c\u00a0vorab\u00a0bewertet. \u00a0Generell\u00a0wurden\u00a0neue\u00a0\nArzneimittel \u00a0mit\u00a0bereits\u00a0in\u00a0anderen\u00a0zugelassenen \u00a0Pr\u00e4paraten \u00a0verf\u00fcgbaren \u00a0Wirkstoffen \u00a0(z.B.\u00a0Generika) \u00a0\noder\u00a0neue\u00a0Kombinationen \u00a0aus\u00a0bereits\u00a0bekannten \u00a0Wirkstoffen \u00a0nicht\u00a0ber\u00fccksichtigt. \u00a0Hierzu\u00a0z\u00e4hlt\u00a0auch\u00a0\nder\u00a0Wirkstoff \u00a0Tianeptin \u00a0(Tianeurax\u00ae), \u00a0ein\u00a0atypisches \u00a0trizyklisches \u00a0Antidepressivum, \u00a0das\u00a0in\u00a0Frankreich \u00a0\n1988\u00a0und\u00a0in\u00a0\u00d6sterreich \u00a01999\u00a0unter\u00a0dem\u00a0Handelsnamen \u00a0Stablon\u00ae\u00a0eingef\u00fchrt \u00a0und\u00a0seit\u00a0dem\u00a0Jahr\u00a02012\u00a0\nin\u00a0Deutschland \u00a0erstmalig \u00a0als\u00a0Generikum \u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0der\u00a0Depression \u00a0zugelassen \u00a0wurde.\u00a0Da\u00a0f\u00fcr\u00a0\nTianeptin \u00a0kein\u00a0Patentschutz \u00a0besteht,\u00a0gilt\u00a0es\u00a0gem\u00e4\u00df\u00a0der\u00a0Arzneimittel \u2010Nutzenbewertungsverordnung \u00a0\nnicht\u00a0als\u00a0neues\u00a0Arzneimittel \u00a0und\u00a0unterliegt \u00a0damit\u00a0nicht\u00a0der\u00a0Nutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V.\u00a0\nNeben\u00a0Tianeptin \u00a0erhielten\u00a0zwei\u00a0weitere\u00a0Wirkstoffe \u00a0(Influenza \u2010Impfstoff, \u00a0Meningokokkenkonjugat \u2010 \n16\u00a0 \n \nInnovationsreport 2015 \u00a0Impfstoff) \u00a0eine\u00a0nationale \u00a0Zulassung \u00a0durch\u00a0das\u00a0Bundesinstitut \u00a0f\u00fcr\u00a0Arzneimittel \u00a0und\u00a0Medizinprodukte \u00a0\n(BfArM)\u00a0bzw.\u00a0durch\u00a0das\u00a0Paul\u2010Ehrlich\u2010Institut\u00a0(PEI).\u00a0Alle\u00a0weiteren\u00a0neuen\u00a0Arzneimittel \u00a0wurden\u00a0EU\u2010weit\u00a0\nzentral\u00a0zugelassen. \u00a0Schon\u00a0die\u00a0Innovationsreporte \u00a0aus\u00a0den\u00a0Jahren\u00a02013\u00a0und\u00a02014\u00a0zeigten,\u00a0dass\u00a0\nnationale \u00a0Zulassungen \u00a0bei\u00a0Einf\u00fchrungen \u00a0auf\u00a0den\u00a0deutschen \u00a0Arzneimittelmarkt \u00a0kaum\u00a0noch\u00a0ins\u00a0\nGewicht\u00a0fallen.\u00a0\u00a0\nDie\u00a0Bewertung \u00a0der\u00a0Studienlage \u00a0basierte\u00a0zum\u00a0einen\u00a0auf\u00a0den\u00a0Ergebnissen \u00a0der\u00a0Zulassungsstudien \u00a0sowie\u00a0\ndem\u00a0Beurteilungsbericht \u00a0der\u00a0verantwortlichen \u00a0Zulassungsbeh\u00f6rde \u00a0und\u00a0zum\u00a0anderen\u00a0auf\u00a0Literatur\u2010\nrecherchen, \u00a0welche\u00a0die\u00a0Autoren\u00a0Boeschen \u00a0(DB),\u00a0Fuchs\u00a0(DF)\u00a0und\u00a0G\u00fcnther\u00a0(JG)\u00a0unabh\u00e4ngig \u00a0\nvoneinander \u00a0durchf\u00fchrten. \u00a0Haupts\u00e4chlich \u00a0wurde\u00a0in\u00a0der\u00a0Literaturdatenbank \u00a0MEDLINE \u00a0\u00fcber\u00a0PubMed\u00a0\nrecherchiert. \u00a0Hierbei\u00a0wurden\u00a0im\u00a0Wesentlichen \u00a0kontrollierte \u00a0und\u00a0bzw.\u00a0oder\u00a0versorgungsrelevante \u00a0\nStudien\u00a0eingeschlossen. \u00a0Zus\u00e4tzlich \u00a0wurden\u00a0Standardwerke \u00a0der\u00a0wissenschaftlichen \u00a0Literatur\u00a0und\u00a0\nSekund\u00e4rliteratur \u00a0wie\u00a0das\u00a0arznei\u2010telegramm \u00a0genutzt.\u00a0Die\u00a0anschlie\u00dfende \u00a0Beurteilung \u00a0zur\u00a0Evidenz\u00a0\nnahmen\u00a0DB,\u00a0DF\u00a0und\u00a0JG\u00a0dann\u00a0im\u00a0Konsensverfahren \u00a0vor.\u00a0F\u00fcr\u00a0die\u00a0Leitlinienempfehlungen \u00a0zu\u00a0den\u00a0\neinzelnen \u00a0Arzneimitteln \u00a0und\u00a0ihren\u00a0jeweiligen \u00a0Indikationsgebieten \u00a0wurden\u00a0Leitlinien\u00a0genutzt,\u00a0die\u00a0im\u00a0\nRegister\u00a0der\u00a0Arbeitsgemeinschaft \u00a0der\u00a0Wissenschaftlichen \u00a0Medizinischen \u00a0Fachgesellschaften \u00a0e.V.\u00a0\n(AWMF)\u00a0eingetragen \u00a0sind.\u00a0Sollte\u00a0zu\u00a0den\u00a0bestimmten \u00a0Indikationsgebieten \u00a0keine\u00a0AWMF\u2010Leitlinie\u00a0zu\u00a0\nfinden\u00a0gewesen\u00a0sein,\u00a0wurde\u00a0nach\u00a0anderen\u00a0nationalen \u00a0oder\u00a0internationalen \u00a0Handlungsempfehlungen \u00a0\ngesucht.\u00a0Bei\u00a0den\u00a0einzelnen \u00a0Wirkstoffen \u00a0wurden\u00a0verschiedene \u00a0Punkte\u00a0separat\u00a0bewertet: \u00a0die\u00a0\nVerf\u00fcgbarkeit \u00a0bestehender \u00a0medikament\u00f6ser \u00a0Therapien, \u00a0der\u00a0patientenorientierte \u00a0(Zusatz\u2010)Nutzen\u00a0\nund\u00a0die\u00a0Kosten\u00a0des\u00a0neuen\u00a0Arzneimittels \u00a0im\u00a0Vergleich \u00a0zu\u00a0bisher\u00a0verf\u00fcgbaren \u00a0Arzneimitteln. \u00a0Waren\u00a0bis\u00a0\ndato\u00a0keine\u00a0medikament\u00f6sen \u00a0Therapien \u00a0f\u00fcr\u00a0die\u00a0jeweilige\u00a0Erkrankung \u00a0verf\u00fcgbar, \u00a0wurde\u00a0der\u00a0Nutzen\u00a0\n(therapeutische \u00a0Wirksamkeit) \u00a0des\u00a0neuen\u00a0Arzneimittels \u00a0bewertet. \u00a0F\u00fcr\u00a0jeden\u00a0der\u00a0drei\u00a0genannten \u00a0\nPunkte\u00a0wurde\u00a0ein\u00a0Ampelschema \u00a0genutzt,\u00a0wobei\u00a0die\u00a0Farben\u00a0das\u00a0Folgende\u00a0bedeuten: \u00a0\nVerf\u00fcgbare \u00a0Therapien \u00a0\n\uf0b7 Rot:\u00a0Das\u00a0neue\u00a0Arzneimittel \u00a0stellt\u00a0eine\u00a0weitere\u00a0Therapieoption \u00a0f\u00fcr\u00a0das\u00a0zugelassene \u00a0Anwen\u2010\ndungsgebiet \u00a0dar,\u00a0es\u00a0gibt\u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0der\u00a0jeweiligen \u00a0Erkrankung(en) \u00a0bereits\u00a0zugelas\u2010\nsene\u00a0Arzneimittel \u00a0auf\u00a0dem\u00a0deutschen \u00a0Markt.\u00a0\n\uf0b7 Gelb :\u00a0Das\u00a0neue\u00a0Arzneimittel \u00a0stellt\u00a0eine\u00a0Subgruppen \u2010Novit\u00e4t\u00a0dar,\u00a0da\u00a0f\u00fcr\u00a0eine\u00a0bestimmte \u00a0\nUntergruppe \u00a0der\u00a0Erkrankten \u00a0keine\u00a0Therapiem\u00f6glichkeit \u00a0vorhanden \u00a0ist,\u00a0z.B.\u00a0weil\u00a0bei\u00a0bisher\u00a0\nzugelassenen \u00a0Arzneimitteln \u00a0Resistenzen \u00a0vorliegen. \u00a0\n\uf0b7 Gr\u00fcn :\u00a0Das\u00a0neue\u00a0Arzneimittel \u00a0bietet\u00a0erstmals\u00a0die\u00a0M\u00f6glichkeit, \u00a0die\u00a0Erkrankung, \u00a0f\u00fcr\u00a0die\u00a0es\u00a0\nzugelassen \u00a0ist,\u00a0medikament\u00f6s \u00a0zu\u00a0behandeln. \u00a0\n(Zusatz\u2010)Nutzen\u00a0\n\uf0b7 Rot:\u00a0Das\u00a0neue\u00a0Arzneimittel \u00a0bietet\u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0gegen\u00fcber \u00a0den\u00a0bisher\u00a0verf\u00fcgbaren \u00a0\nArzneimitteln \u00a0keine\u00a0patientenrelevante \u00a0Verbesserung \u00a0oder\u00a0weist\u00a0sogar\u00a0eine\u00a0schlechtere \u00a0\nNutzen\u2010Schaden\u2010Relation\u00a0auf\u00a0als\u00a0bisher\u00a0verf\u00fcgbare \u00a0Arzneimittel \u00a0(z.B.\u00a0mehr\u00a0Nebenwir \u2010\nkungen).\u00a0\n\uf0b7 Gelb :\u00a0Das\u00a0neue\u00a0Arzneimittel \u00a0bietet\u00a0Verbesserungen \u00a0in\u00a0Bezug\u00a0auf\u00a0die\u00a0therapeutische \u00a0Wirk\u2010\nsamkeit\u00a0oder\u00a0die\u00a0Vertr\u00e4glichkeit \u00a0bzw.\u00a0Therapiesicherheit, \u00a0wobei\u00a0die\u00a0Evidenz\u00a0nicht\u00a0eindeutig \u00a0\nist\u00a0(z.B.\u00a0heterogene \u00a0Studienergebnisse) \u00a0oder\u00a0die\u00a0beobachteten \u00a0Verbesserungen \u00a0eher\u00a0gering\u00a0\nausfallen. \u00a0 \n17\u00a0\n \nInnovationsreport 2015 \u00a0\uf0b7 Gr\u00fcn :\u00a0Das\u00a0neue\u00a0Arzneimittel \u00a0bietet\u00a0f\u00fcr\u00a0die\u00a0zugelassene \u00a0Behandlung \u00a0der\u00a0spezifischen \u00a0\nErkrankung \u00a0eine\u00a0Verbesserung \u00a0gegen\u00fcber \u00a0den\u00a0bisher\u00a0verf\u00fcgbaren \u00a0Arzneimitteln \u00a0bez\u00fcglich \u00a0\nklinisch\u00a0relevanter \u00a0Endpunkte. \u00a0Der\u00a0erforderliche \u00a0Zusatzeffekt \u00a0wird\u00a0hier\u00a0in\u00a0Abh\u00e4ngigkeit \u00a0von\u00a0\nder\u00a0jeweiligen \u00a0Indikation \u00a0festgelegt, \u00a0so\u00a0dass\u00a0z.B.\u00a0auch\u00a0kleinere\u00a0(aber\u00a0patientenrelevante) \u00a0\nVerbesserungen \u00a0bei\u00a0seltenen\u00a0Erkrankungen, \u00a0f\u00fcr\u00a0die\u00a0es\u00a0noch\u00a0keine\u00a0Therapie\u00a0gibt,\u00a0an\u00a0Gewicht\u00a0\ngewinnen. \u00a0Auch\u00a0wenn\u00a0es\u00a0eindeutige \u00a0Belege\u00a0daf\u00fcr\u00a0gibt,\u00a0dass\u00a0die\u00a0Nutzen\u2010Schaden\u2010Bilanz\u00a0\ngegen\u00fcber \u00a0bisherigen \u00a0Therapien \u00a0z.B.\u00a0aufgrund\u00a0einer\u00a0Verminderung \u00a0schwerer\u00a0unerw\u00fcnschter \u00a0\nWirkungen \u00a0reduziert\u00a0ist,\u00a0wurde\u00a0mit\u00a0\u201egr\u00fcn\u201c\u00a0bewertet. \u00a0\nKosten\u00a0\n\uf0b7 Rot:\u00a0Das\u00a0neue\u00a0Arzneimittel \u00a0ist\u00a0in\u00a0Bezug\u00a0auf\u00a0einen\u00a0vergleichbaren \u00a0Anwendungszeitraum \u00a0teurer\u00a0\nals\u00a0andere,\u00a0bisher\u00a0f\u00fcr\u00a0das\u00a0jeweilige\u00a0Anwendungsgebiet \u00a0zugelassene \u00a0Arzneimittel \u00a0(zweck\u2010\nm\u00e4\u00dfige\u00a0Vergleichstherapie). \u00a0Bei\u00a0mehreren \u00a0Indikationen \u00a0ist\u00a0prim\u00e4r\u00a0die\u00a0Indikation \u00a0f\u00fcr\u00a0die\u00a0\nBewertung \u00a0relevant,\u00a0bei\u00a0welcher\u00a0aufgrund\u00a0epidemiologischer \u00a0Daten\u00a0die\u00a0meisten\u00a0Anwender \u00a0\nzu\u00a0erwarten \u00a0sind.\u00a0\n\uf0b7 Gelb :\u00a0Das\u00a0neue\u00a0Arzneimittel \u00a0kostet\u00a0in\u00a0Bezug\u00a0auf\u00a0einen\u00a0vergleichbaren \u00a0Anwendungszeitraum \u00a0\nungef\u00e4hr\u00a0gleich\u00a0viel\u00a0wie\u00a0bisher\u00a0f\u00fcr\u00a0das\u00a0jeweilige\u00a0Anwendungsgebiet \u00a0zugelassene \u00a0Arzneimittel \u00a0\n(zweckm\u00e4\u00dfige \u00a0Vergleichstherapie). \u00a0Oder\u00a0einige\u00a0wichtige\u00a0Arzneimittelgruppen \u00a0sind\u00a0g\u00fcnstiger, \u00a0\nw\u00e4hrend\u00a0andere\u00a0relevante \u00a0Alternativen \u00a0teurer\u00a0sind\u00a0als\u00a0das\u00a0neue\u00a0Arzneimittel. \u00a0Bei\u00a0mehreren \u00a0\nIndikationen \u00a0ist\u00a0prim\u00e4r\u00a0die\u00a0Indikation \u00a0f\u00fcr\u00a0die\u00a0Bewertung \u00a0relevant,\u00a0bei\u00a0welcher\u00a0aufgrund\u00a0\nepidemiologischer \u00a0Daten\u00a0die\u00a0meisten\u00a0Anwender \u00a0zu\u00a0erwarten \u00a0sind.\u00a0\u00a0\n\uf0b7 Gr\u00fcn :\u00a0Das\u00a0neue\u00a0Arzneimittel \u00a0ist\u00a0in\u00a0Bezug\u00a0auf\u00a0einen\u00a0vergleichbaren \u00a0Anwendungszeitraum \u00a0\ng\u00fcnstiger \u00a0als\u00a0bisher\u00a0f\u00fcr\u00a0das\u00a0jeweilige\u00a0Anwendungsgebiet \u00a0zugelassene \u00a0Arzneimittel \u00a0(zweck\u2010\nm\u00e4\u00dfige\u00a0Vergleichstherapie). \u00a0Bei\u00a0mehreren \u00a0Indikationen \u00a0ist\u00a0prim\u00e4r\u00a0die\u00a0Indikation \u00a0f\u00fcr\u00a0die\u00a0Be\u2010\nwertung\u00a0relevant,\u00a0bei\u00a0welcher\u00a0aufgrund\u00a0epidemiologischer \u00a0Daten\u00a0die\u00a0meisten\u00a0Anwender \u00a0zu\u00a0\nerwarten\u00a0sind.\u00a0\n\uf0b7 Wei\u00df :\u00a0Ein\u00a0aktueller\u00a0Kostenvergleich \u00a0mit\u00a0Arzneimitteln, \u00a0die\u00a0sich\u00a0bereits\u00a0l\u00e4nger\u00a0auf\u00a0dem\u00a0Markt\u00a0\nbefinden, \u00a0ist\u00a0entweder \u00a0aufgrund\u00a0einer\u00a0fehlenden \u00a0Markteinf\u00fchrung \u00a0bzw.\u00a0einer\u00a0Markt\u2010\nr\u00fccknahme \u00a0des\u00a0neuen\u00a0Arzneimittels \u00a0oder\u00a0aufgrund\u00a0des\u00a0Fehlens\u00a0einer\u00a0zweckm\u00e4\u00dfigen \u00a0medi\u2010\nkament\u00f6sen \u00a0Vergleichstherapie \u00a0nicht\u00a0m\u00f6glich.\u00a0\nWenn\u00a0die\u00a0Ampel\u00a0bei\u00a0den\u00a0\u201everf\u00fcgbaren \u00a0Therapien\u201c \u00a0rot\u00a0gekennzeichnet \u00a0ist,\u00a0ist\u00a0dies\u00a0nicht\u00a0automatisch \u00a0\nnegativ\u00a0zu\u00a0sehen.\u00a0Sofern\u00a0diese\u00a0neue\u00a0Substanz\u00a0einen\u00a0therapeutischen \u00a0Fortschritt \u00a0mit\u00a0sich\u00a0bringt,\u00a0also\u00a0\neine\u00a0gr\u00fcne\u00a0Ampel\u00a0beim\u00a0\u201e(Zusatz\u2010)Nutzen\u201c\u00a0zu\u00a0sehen\u00a0ist,\u00a0kann\u00a0immer\u00a0noch\u00a0eine\u00a0relevante \u00a0therapeu\u2010\ntische\u00a0Innovation \u00a0vorliegen. \u00a0Die\u00a0Verf\u00fcgbarkeit \u00a0bestehender \u00a0Therapien \u00a0orientiert \u00a0sich\u00a0hier\u00a0an\u00a0der\u00a0\nSituation\u00a0zum\u00a0Zeitpunkt \u00a0des\u00a0Redaktionsschlusses, \u00a0der\u00a0(Zusatz\u2010)Nutzen\u00a0wird\u00a0auf\u00a0Basis\u00a0der\u00a0aktuellen \u00a0\nLiteratur\u00a0(Redaktionsschluss: \u00a015.06.2015) \u00a0bestimmt, \u00a0ebenso\u00a0werden\u00a0die\u00a0Kosten\u00a0auf\u00a0Basis\u00a0aktueller\u00a0\nPreisst\u00e4nde \u00a0(Lauer\u2010Taxe,\u00a0Stand:\u00a015.06.2015) \u00a0beurteilt. \u00a0Sollte\u00a0das\u00a0neue\u00a0Arzneimittel \u00a0f\u00fcr\u00a0mehrere\u00a0\nAnwendungsgebiete \u00a0zugelassen \u00a0sein,\u00a0wurde\u00a0unsere\u00a0Bewertung \u00a0durch\u00a0die\u00a0Haupt\u2010\u00a0bzw.\u00a0Erstindikation \u00a0\ngeleitet,\u00a0sofern\u00a0diese\u00a0identifizierbar \u00a0war.\u00a0\nIm\u00a0Rahmen\u00a0von\u00a0Arzneimittelstudien \u00a0m\u00f6glicherweise \u00a0auftretende \u00a0unerw\u00fcnschte \u00a0Ereignisse \u00a0bzw.\u00a0\nNebenwirkungen \u00a0wurden\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a03\u00a0Abs.\u00a06,\u00a07\u00a0und\u00a08\u00a0der\u00a0\u201eVerordnung \u00a0\u00fcber\u00a0die\u00a0Anwendung \u00a0der\u00a0Guten\u00a0\nKlinischen \u00a0Praxis\u00a0bei\u00a0der\u00a0Durchf\u00fchrung \u00a0von\u00a0klinischen \u00a0Pr\u00fcfungen \u00a0mit\u00a0Arzneimitteln \u00a0zur\u00a0Anwendung \u00a0\nam\u00a0Menschen\u201c \u00a0(GCP\u2010Verordnung) \u00a0wie\u00a0folgt\u00a0definiert\u00a0und\u00a0so\u00a0auch\u00a0in\u00a0den\u00a0Bewertungen \u00a0dieses\u00a0Reports\u00a0\nbehandelt: \u00a0\u00a0 \u00a0 \n18\u00a0 \n \nInnovationsreport 2015 \u00a0\uf0b7 Unerw\u00fcnschtes \u00a0Ereignis\u00a0ist\u00a0jedes\u00a0nachteilige \u00a0Vorkommnis, \u00a0das\u00a0einer\u00a0betroffenen \u00a0Person\u00a0\nwiderf\u00e4hrt, \u00a0der\u00a0ein\u00a0Pr\u00fcfpr\u00e4parat \u00a0verabreicht \u00a0wurde\u00a0und\u00a0das\u00a0nicht\u00a0notwendigerweise \u00a0in\u00a0ur\u2010\ns\u00e4chlichem \u00a0Zusammenhang \u00a0mit\u00a0dieser\u00a0Behandlung \u00a0steht.\u00a0\n\uf0b7 Nebenwirkung \u00a0ist\u00a0jede\u00a0nachteilige \u00a0und\u00a0unbeabsichtigte \u00a0Reaktion\u00a0auf\u00a0ein\u00a0Pr\u00fcfpr\u00e4parat, \u00a0\nunabh\u00e4ngig \u00a0von\u00a0dessen\u00a0Dosierung. \u00a0\n\uf0b7 Schwerwiegendes \u00a0unerw\u00fcnschtes \u00a0Ereignis\u00a0oder\u00a0schwerwiegende \u00a0Nebenwirkung \u00a0ist\u00a0jedes\u00a0\nunerw\u00fcnschte \u00a0Ereignis\u00a0oder\u00a0jede\u00a0Nebenwirkung, \u00a0das\u00a0oder\u00a0die\u00a0t\u00f6dlich\u00a0oder\u00a0lebensbedrohend \u00a0\nist,\u00a0eine\u00a0station\u00e4re \u00a0Behandlung \u00a0oder\u00a0deren\u00a0Verl\u00e4ngerung \u00a0erforderlich \u00a0macht\u00a0oder\u00a0zu\u00a0\nbleibender \u00a0oder\u00a0schwerwiegender \u00a0Behinderung \u00a0oder\u00a0Invalidit\u00e4t \u00a0f\u00fchrt\u00a0oder\u00a0eine\u00a0kongenitale \u00a0\nAnomalie \u00a0oder\u00a0einen\u00a0Geburtsfehler \u00a0zur\u00a0Folge\u00a0hat\u00a0(Bundesministerium \u00a0der\u00a0Justiz\u00a0und\u00a0f\u00fcr\u00a0\nVerbraucherschutz, \u00a02012).\u00a0\nDie\u00a0im\u00a0Rahmen\u00a0der\u00a0Wirkstoffportr\u00e4ts \u00a0angegebenen \u00a0Therapiekosten \u00a0wurden\u00a0f\u00fcr\u00a0die\u00a0Packungsgr\u00f6\u00dfe \u00a0\nberechnet, \u00a0deren\u00a0Verordnung \u00a0f\u00fcr\u00a0die\u00a0angegebene \u00a0Behandlungsdauer \u00a0am\u00a0preisg\u00fcnstigsten \u00a0war.\u00a0Die\u00a0\nBerechnung \u00a0erfolgte\u00a0auf\u00a0Basis\u00a0der\u00a0Brutto\u2010Apothekenverkaufspreise \u00a0zum\u00a0Preisstand \u00a015.06.2015 \u00a0\n(Lauer\u2010Taxe).\u00a0Reimporte \u00a0sowie\u00a0m\u00f6gliche\u00a0Rabatte\u00a0(pU,\u00a0Apotheke) \u00a0wurden\u00a0nicht\u00a0ber\u00fccksichtigt, \u00a0so\u00a0dass\u00a0\ndie\u00a0Preise\u00a0nur\u00a0als\u00a0Richtwert \u00a0betrachtet \u00a0werden\u00a0k\u00f6nnen.\u00a0Sofern\u00a0das\u00a0jeweilige\u00a0Arzneimittel \u00a0f\u00fcr\u00a0mehrere\u00a0\nIndikationsgebiete \u00a0zugelassen \u00a0ist,\u00a0wurden\u00a0die\u00a0Therapiekosten \u00a0separat\u00a0f\u00fcr\u00a0jedes\u00a0Indikationsgebiet \u00a0\nberechnet. \u00a0Die\u00a0Dosierungen \u00a0wurden\u00a0den\u00a0Fachinformationen \u00a0der\u00a0pU\u00a0entnommen. \u00a0Gab\u00a0es\u00a0\nunterschiedliche \u00a0Dosierungsempfehlungen \u00a0(z.B.\u00a0Initialdosis, \u00a0Erhaltungsdosis, \u00a0Komedikation) \u00a0wurde\u00a0\ndie\u00a0DDD\u00a0zur\u00a0Dosisberechnung \u00a0hinzugezogen. \u00a0Abweichungen \u00a0finden\u00a0explizit\u00a0Erw\u00e4hnung \u00a0bei\u00a0den\u00a0\njeweiligen \u00a0Wirkstoffportr\u00e4ts. \u00a0Bezog\u00a0sich\u00a0die\u00a0Wirkstoffmenge \u00a0auf\u00a0das\u00a0K\u00f6rpergewicht \u00a0(KG)\u00a0oder\u00a0die\u00a0\nK\u00f6rperoberfl\u00e4che, \u00a0wurden\u00a0als\u00a0Standard\u00a072\u00a0kg\u00a0K\u00f6rpergewicht \u00a0bzw.\u00a01,73\u00a0m2\u00a0als\u00a0durchschnittliche \u00a0\nK\u00f6rperoberfl\u00e4che \u00a0(KOF)\u00a0angenommen. \u00a0Sind\u00a0die\u00a0neuen\u00a0Wirkstoffe \u00a0als\u00a0Tabletten, \u00a0Filmtabletten \u00a0oder\u00a0\n(Hart\u2010)Kapseln\u00a0zugelassen, \u00a0so\u00a0wurde\u00a0die\u00a0f\u00fcr\u00a0die\u00a0Therapiedauer \u00a0ben\u00f6tigte \u00a0St\u00fcckzahl \u00a0zugrunde \u00a0gelegt,\u00a0\ngleiches\u00a0galt\u00a0f\u00fcr\u00a0Ampullen \u00a0bzw.\u00a0Fertigspritzen \u00a0mit\u00a0Injektionsl\u00f6sungen. \u00a0Bei\u00a0Injektions \u2010\u00a0und\u00a0\nInfusionsl\u00f6sungen \u00a0in\u00a0Mehrdosenbeh\u00e4ltnissen \u00a0wurden\u00a0bei\u00a0der\u00a0Berechnung \u00a0ganze\u00a0Flaschen\u00a0bzw.\u00a0\nAmpullen \u00a0ber\u00fccksichtigt. \u00a0\nIm\u00a0Hinblick\u00a0auf\u00a0die\u00a0Vergleichstherapie \u00a0orientierten \u00a0wir\u00a0uns\u00a0an\u00a0den\u00a0Arzneimitteln, \u00a0die\u00a0auch\u00a0vom\u00a0G\u2010BA\u00a0\nals\u00a0zweckm\u00e4\u00dfige \u00a0Vergleichstherapeutika \u00a0festgelegt \u00a0worden\u00a0waren,\u00a0sofern\u00a0diese\u00a0zum\u00a0Zeitpunkt \u00a0\nunserer\u00a0Bewertung \u00a0noch\u00a0als\u00a0solche\u00a0einzustufen \u00a0waren,\u00a0gegebenenfalls \u00a0fanden\u00a0Anpassungen \u00a0statt.\u00a0\nHilfsmittel \u00a0f\u00fcr\u00a0Injektionen \u00a0oder\u00a0sonstige\u00a0Kosten\u00a0im\u00a0Zusammenhang \u00a0mit\u00a0der\u00a0Arzneimittelanwendung \u00a0\nfanden\u00a0keine\u00a0Ber\u00fccksichtigung. \u00a0\u00a0\n\u00a0\n2.3 Methodik \u00a0der\u00a0Routinedaten \u2010Analyse\u00a0\nF\u00fcr\u00a0die\u00a0Analyse\u00a0zur\u00a0Versorgung \u00a0mit\u00a0innovativen \u00a0Arzneimitteln \u00a0wurden\u00a0Arzneimitteldaten \u00a0aus\u00a0der\u00a0\nambulanten \u00a0Versorgung \u00a0von\u00a08,1\u00a0Mio.\u00a0Versicherten \u00a0(im\u00a0Jahr\u00a02012)\u00a0und\u00a08,5\u00a0Mio.\u00a0Versicherten \u00a0(im\u00a0Jahr\u00a0\n2013)\u00a0der\u00a0TK\u00a0aus\u00a0den\u00a0o.g.\u00a0Jahren\u00a0genutzt.\u00a0Die\u00a0zur\u00a0Erstellung \u00a0des\u00a0Reports\u00a0ben\u00f6tigten \u00a0Daten\u00a0wurden\u00a0\nbereits\u00a0im\u00a0Haus\u00a0der\u00a0TK\u00a0selektiert \u00a0und\u00a0anonymisiert \u00a0an\u00a0die\u00a0Universit\u00e4t \u00a0Bremen\u00a0weitergeleitet. \u00a0Die\u00a0\nAnonymisierung \u00a0s\u00e4mtlicher \u00a0Daten\u00a0erfolgte\u00a0unter\u00a0Verwendung \u00a0einer\u00a0Fallnummer, \u00a0die\u00a0es\u00a0erm\u00f6glichte, \u00a0\nanonymisierte \u00a0Datens\u00e4tze \u00a0miteinander \u00a0zu\u00a0verkn\u00fcpfen, \u00a0ohne\u00a0dass\u00a0die\u00a0Identit\u00e4t\u00a0der\u00a0Versicherten \u00a0\nfestgestellt \u00a0werden\u00a0kann.\u00a0Es\u00a0wurden\u00a0f\u00fcr\u00a0die\u00a0allgemeinen \u00a0Auswertungen \u00a0nur\u00a0Daten\u00a0ber\u00fccksichtigt, \u00a0bei\u00a0\ndenen\u00a0auch\u00a0Angaben\u00a0zu\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0der\u00a0Versicherten \u00a0vorlagen. \u00a0Nach\u00a0unserer\u00a0Methodik \u00a0\nentsprach \u00a0eine\u00a0\u00e4rztliche\u00a0Verordnung \u00a0analog\u00a0zum\u00a0Arzneiverordnungs \u2010Report\u00a0(Schwabe \u00a0&\u00a0Paffrath,\u00a0 \n19\u00a0\n \nInnovationsreport 2015 \u00a02011)\u00a0genau\u00a0einer\u00a0Arzneimittelpackung, \u00a0d.h.\u00a0zwei\u00a0auf\u00a0einem\u00a0Rezeptblatt \u00a0verordnete \u00a0Packungen \u00a0\nz\u00e4hlten\u00a0als\u00a0zwei\u00a0Verordnungen. \u00a0Bei\u00a0den\u00a0Verordnungsanalysen \u00a0wurden\u00a0neben\u00a0Fertigarzneimitteln \u00a0\nauch\u00a0Rezepturen \u00a0mit\u00a0den\u00a0neuen\u00a0Wirkstoffen \u00a0ber\u00fccksichtigt. \u00a0Hier\u00a0flossen\u00a0die\u00a0Abrechnungsdaten \u00a0ein,\u00a0\ndie\u00a0auf\u00a0dem\u00a0Rezept\u00a0vermerkt\u00a0waren\u00a0(Brutto\u2010Apothekenabgabepreis). \u00a0\nBei\u00a0der\u00a0Untersuchung \u00a0der\u00a0Arzneimittelverordnungsdaten \u00a0wurde\u00a0die\u00a0von\u00a0der\u00a0WHO\u00a0seit\u00a01981\u00a0\nempfohlene \u00a0ATC\u2010Codierung \u00a0genutzt.\u00a0Es\u00a0handelt\u00a0sich\u00a0hierbei\u00a0um\u00a0ein\u00a0Klassifikationssystem \u00a0(Anatomical \u00a0\nTherapeutic \u00a0Chemical ),\u00a0bei\u00a0dem\u00a0die\u00a0jeweiligen \u00a0Wirkstoffe \u00a0entsprechend \u00a0dem\u00a0Organ\u00a0oder\u00a0\nOrgansystem, \u00a0auf\u00a0das\u00a0sie\u00a0einwirken, \u00a0sowie\u00a0nach\u00a0ihren\u00a0chemischen, \u00a0pharmakologischen \u00a0und\u00a0thera\u2010\npeutischen \u00a0Eigenschaften \u00a0in\u00a0verschiedene \u00a0Gruppen\u00a0aufgeteilt \u00a0werden\u00a0(WHO,\u00a02004).\u00a0Das\u00a0wissen\u2010\nschaftliche \u00a0Institut\u00a0der\u00a0Ortskrankenkassen \u00a0(WIdO)\u00a0f\u00fchrt\u00a0eine\u00a0ATC\u2010Datenbank, \u00a0die\u00a0den\u00a0deutschen \u00a0\nVerh\u00e4ltnissen \u00a0nach\u00a0WHO\u2010Richtlinien \u00a0angepasst \u00a0wurde.\u00a0Die\u00a0Arzneimittel \u00a0werden\u00a0nach\u00a0dem\u00a0ATC\u2010\nSystem\u00a0in\u00a014\u00a0Hauptgruppen \u00a0(Ebene\u00a01)\u00a0gegliedert, \u00a0mit\u00a0zwei\u00a0therapeutisch \u2010pharmakologischen \u00a0\nUntergruppen \u00a0(Ebene\u00a02\u00a0und\u00a03).\u00a0Eine\u00a0anatomisch \u2010therapeutisch \u2010chemische \u00a0Untergruppe \u00a0bildet\u00a0die\u00a04.\u00a0\nEbene,\u00a0w\u00e4hrend\u00a0die\u00a05.\u00a0Ebene\u00a0den\u00a0chemischen \u00a0Wirkstoff \u00a0benennt.\u00a0\nSeit\u00a0dem\u00a0Inkrafttreten \u00a0des\u00a0GKV\u2010Modernisierungsgesetzes \u00a0(GMG)\u00a0zum\u00a01.1.2004\u00a0sind\u00a0die\u00a0\nKassen\u00e4rztlichen \u00a0Vereinigungen \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a0295\u00a0SGB\u00a0V\u00a0zur\u00a0Weitergabe \u00a0ambulanter \u00a0Daten\u00a0an\u00a0die\u00a0GKV\u00a0\nverpflichtet. \u00a0So\u00a0muss\u00a0f\u00fcr\u00a0jeden\u00a0Patienten \u00a0der\u00a0Behandlungsanlass, \u00a0das\u00a0Datum\u00a0der\u00a0Leistungserbringung \u00a0\nund\u00a0die\u00a0Art\u00a0der\u00a0Leistungserbringung \u00a0genannt\u00a0werden,\u00a0wenn\u00a0die\u00a0Leistungen \u00a0abgerechnet \u00a0werden\u00a0\nsollen.\u00a0Die\u00a0von\u00a0der\u00a0WHO\u00a0entwickelte \u00a0internationale \u00a0Klassifikation \u00a0der\u00a0Krankheiten \u00a0International \u00a0\nClassification \u00a0of\u00a0Diseases\u00a0(ICD)\u00a0stellt\u00a0die\u00a0Grundlage \u00a0der\u00a0gesetzlich \u00a0vorgeschriebenen \u00a0Diagnose\u2010\nverschl\u00fcsselung \u00a0im\u00a0ambulanten \u00a0und\u00a0station\u00e4ren \u00a0Sektor\u00a0dar.\u00a0In\u00a0Deutschland \u00a0wird\u00a0die\u00a0Diagnose\u00a0als\u00a0\nBehandlungsanlass \u00a0nach\u00a0der\u00a0internationalen \u00a0Klassifikation \u00a0von\u00a0Krankheiten \u00a0in\u00a0der\u00a0deutschen \u00a0Fassung\u00a0\n(ICD\u2010GM;\u00a0german\u00a0modification )\u00a0verschl\u00fcsselt \u00a0und\u00a0\u00fcbermittelt. \u00a0Eine\u00a0Hierarchisierung \u00a0nach\u00a0Haupt\u2010\u00a0und\u00a0\nNebendiagnosen \u00a0je\u00a0Behandlungsfall \u00a0ist\u00a0derzeit\u00a0nicht\u00a0m\u00f6glich,\u00a0weswegen \u00a0ein\u00a0einzelner\u00a0Arztbesuch, \u00a0\neine\u00a0Arzneimittelverordnung \u00a0bzw.\u00a0eine\u00a0therapeutische \u00a0Ma\u00dfnahme \u00a0nicht\u00a0eindeutig \u00a0einer\u00a0Diagnose\u00a0\nzugeteilt\u00a0werden\u00a0kann.\u00a0Werden\u00a0Diagnosen \u00a0in\u00a0mehreren \u00a0Quartalen \u00a0bzw.\u00a0von\u00a0unterschiedlichen \u00a0\u00c4rzten\u00a0\nwiederholt, \u00a0kann\u00a0dies\u00a0als\u00a0Ma\u00dfnahme \u00a0betrachtet \u00a0werden,\u00a0m\u00f6glichst \u00a0nur\u00a0tats\u00e4chlich \u00a0Erkrankte \u00a0\nauszuw\u00e4hlen \u00a0(Windt,\u00a02010).\u00a0\u00a0\nZur\u00a0Messung\u00a0der\u00a0Verordnungsvolumina \u00a0verwendeten \u00a0wir\u00a0definierte \u00a0Tagesdosen \u00a0(DDD).\u00a0Es\u00a0handelt\u00a0\nsich\u00a0um\u00a0eine\u00a0rein\u00a0rechnerische, \u00a0international \u00a0gebr\u00e4uchliche \u00a0Messgr\u00f6\u00dfe, \u00a0die\u00a0nicht\u00a0notwendigerweise \u00a0\ndie\u00a0empfohlene \u00a0Dosierung \u00a0oder\u00a0die\u00a0tats\u00e4chlich \u00a0angewendeten \u00a0Dosierungen \u00a0(PDD\u00a0\u2013\u00a0Prescribed \u00a0Daily\u00a0\nDose )\u00a0eines\u00a0Arzneimittels \u00a0wiedergibt \u00a0(Pfannkuche \u00a0et\u00a0al.,\u00a02009).\u00a0F\u00fcr\u00a0jeden\u00a0Wirkstoff \u00a0legt\u00a0die\u00a0WHO\u00a0eine\u00a0\nDosierung \u00a0fest,\u00a0die\u00a0f\u00fcr\u00a0dessen\u00a0Hauptindikation \u00a0der\u00a0mittleren \u00a0t\u00e4glichen\u00a0Erhaltungsdosis \u00a0f\u00fcr\u00a0Erwach\u2010\nsene\u00a0entspricht \u00a0(Fricke\u00a0&\u00a0G\u00fcnther,\u00a02001).\u00a0Eine\u00a0\u00dcbersetzung \u00a0und\u00a0Anpassung \u00a0an\u00a0den\u00a0deutschen \u00a0Markt\u00a0\nwird\u00a0j\u00e4hrlich\u00a0vom\u00a0WIdO\u00a0erstellt\u00a0und\u00a0wurde\u00a02004\u00a0vom\u00a0damaligen \u00a0Bundesministerium \u00a0f\u00fcr\u00a0Gesundheit \u00a0\nund\u00a0Soziale\u00a0Sicherung \u00a0als\u00a0amtlich\u00a0erkl\u00e4rt\u00a0(Fricke\u00a0&\u00a0Zawinell,\u00a02009).\u00a0Diese\u00a0j\u00e4hrlich\u00a0aktualisierte \u00a0Liste\u00a0ist\u00a0\nunter\u00a0http://www.dimdi.de/static/de/klassi/atcddd/ \u00a0verf\u00fcgbar. \u00a0Hierbei\u00a0wurden\u00a0je\u00a0nach\u00a0Untersu\u2010\nchungsjahr \u00a0jeweils\u00a0die\u00a0zuletzt\u00a0ge\u00e4nderten \u00a0Fassungen \u00a0der\u00a0entsprechenden \u00a0Jahre\u00a0genutzt.\u00a0\n   \n20\u00a0 \n \nInnovationsreport 2015 \u00a0Wirkstof f\u00a0 ATC\u2010Code\nAclidiniumbromid \u00a0\u00a0 R03BB05\u00a0\nAflibercept \u00a0 S01LA05\u00a0\nAxitinib\u00a0 L01XE17\u00a0\nAzilsartanmedoxomil \u00a0 C09CA09\u00a0\nBrentuximabvedotin \u00a0 L01XC12\u00a0\nCeftarolinfosamil \u00a0 J01DI02\u00a0\nCrizotinib \u00a0\u00a0 L01XE16\u00a0\nDapagliflozin \u00a0 A10BX09\u00a0\nDecitabin \u00a0 L01BC08\u00a0\nIvacaftor\u00a0 R07AX02\u00a0\nNomegestrolacetat \u00a0+\u00a0Estradiol\u00a0 G03AA14 \u00a0\nNomegestrolacetat \u00a0+\u00a0Estradiol\u00a0 G03FB12\u00a0\nPasireotid \u00a0 H01CB05\u00a0\nPerampanel \u00a0 N03AX22 \u00a0\nPixantron \u00a0 L01DB11\u00a0\nRilpivirin\u00a0 J05AG05\u00a0\nRuxolitinib \u00a0 L01XE18\u00a0\nTegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0Oteracil\u00a0 L01BC73\u00a0\nVandetanib \u00a0 L01XE12\u00a0\nVemurafenib \u00a0 L01XE15\u00a0\nTabelle\u00a03:\u00a0Im\u00a0Report\u00a0bewertete \u00a0neue\u00a0Wirkstoffe \u00a0des\u00a0Jahres\u00a02012\u00a0und\u00a0die\u00a0entsprechenden \u00a0ATC\u2010Codes\u00a0\n   \n21\u00a0\n \nInnovationsreport 2015 \u00a0 3 Neue\u00a0Arzneimittel \u00a0des\u00a0Jahres\u00a02012\u00a0\u2013\u00a0\u00dcbersicht \u00a0\nDaniela\u00a0Boeschen \u00a0\nIm\u00a0Jahr\u00a02012\u00a0wurden\u00a022\u00a0neue\u00a0Wirkstoffe \u00a0bzw.\u00a0Wirkstoffkombinationen \u00a0eingef\u00fchrt \u00a0(Influenza \u2010\nImpfstoff, \u00a0Meningokokkenkonjugat \u2010Impfstoff \u00a0und\u00a0Tianeptin \u00a0im\u00a0Folgenden \u00a0nicht\u00a0ber\u00fccksichtigt). \u00a0\nDamit\u00a0war\u00a0das\u00a0Niveau\u00a0vergleichbar \u00a0mit\u00a0dem\u00a0Jahr\u00a02011,\u00a0aber\u00a0niedriger\u00a0als\u00a0in\u00a0den\u00a0Jahren\u00a02006\u20102010\u00a0\n(jeweils\u00a0zwischen\u00a027\u00a0und\u00a036\u00a0neue\u00a0Wirkstoffe) \u00a0(Abbildung \u00a01).\u00a0\u00a0\n\u00a0\n\u00a0\nAbbildung \u00a01:\u00a0Markteinf\u00fchrung \u00a0von\u00a0Arzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0mit\u00a0der\u00a0Anzahl\u00a0innovativer \u00a0und\u00a0\nverbesserter \u00a0Wirkstoffe \u00a0im\u00a0Zeitraum \u00a01995\u20102012\u00a0(eigene\u00a0Darstellung \u00a0nach\u00a0Schwabe\u00a0&\u00a0Paffrath,\u00a02013)\u00a0\n\u00a0\nBasierend \u00a0auf\u00a0der\u00a0Klassifikation \u00a0nach\u00a0Fricke\u00a0&\u00a0Klaus\u00a0zur\u00a0Bewertung \u00a0des\u00a0Innovationsgrades \u00a0vergaben \u00a0\ndie\u00a0Autoren\u00a0des\u00a0Arzneiverordnungs \u2010Reports\u00a0(Schwabe \u00a0&\u00a0Paffrath,\u00a02013)\u00a0achtmal\u00a0ein\u00a0\u201eA\u201c\u00a0f\u00fcr\u00a0\ninnovative \u00a0Substanzen: \u00a0Brentuximabvedotin \u00a0(zur\u00a0Behandlung \u00a0von\u00a0Patienten \u00a0mit\u00a0rezidiviertem \u00a0oder\u00a0\nrefrakt\u00e4rem \u00a0CD30+\u00a0Hodgkin\u2010Lymphom \u00a0(HL)\u00a0und\u00a0zur\u00a0Therapie\u00a0von\u00a0erwachsenen \u00a0Patienten \u00a0mit\u00a0\nrezidiviertem \u00a0oder\u00a0refrakt\u00e4rem \u00a0systemischem \u00a0anaplastischem \u00a0gro\u00dfzelligem \u00a0Lymphom \u00a0(sALCL)),\u00a0\nDapagliflozin \u00a0(zur\u00a0Behandlung \u00a0des\u00a0Diabetes\u00a0mellitus\u00a0Typ\u00a02\u00a0bei\u00a0Erwachsenen), \u00a0Ivacaftor\u00a0(zur\u00a0\nBehandlung \u00a0der\u00a0zystischen \u00a0Fibrose\u00a0bei\u00a0Patienten \u00a0ab\u00a0sechs\u00a0Jahren\u00a0mit\u00a0einer\u00a0G551D\u2010Mutation \u00a0im\u00a0Cystic\u00a0\nFibrosis\u00a0Transmembrane \u00a0Conductance \u00a0Regulator \u00a0(CFTR)\u2010Gen),\u00a0Pasireotid \u00a0(zur\u00a0Therapie\u00a0von\u00a0Patienten \u00a0\nmit\u00a0Morbus\u00a0Cushing\u00a0bzw.\u00a0Akromegalie), \u00a0Perampanel \u00a0(als\u00a0Zusatztherapie \u00a0fokaler\u00a0Anf\u00e4lle\u00a0mit\u00a0oder\u00a0\nohne\u00a0sekund\u00e4re \u00a0Generalisierung \u00a0bei\u00a0Epilepsie\u2010Patienten \u00a0ab\u00a0zw\u00f6lf\u00a0Jahren),\u00a0Ruxolitinib \u00a0(zur\u00a0\nBehandlung \u00a0chronisch \u00a0myeloproliferativer \u00a0Erkrankungen \u00a0wie\u00a0der\u00a0prim\u00e4ren \u00a0Myelofibrose), \u00a0\nVandetanib \u00a0(zur\u00a0Therapie\u00a0des\u00a0aggressiven \u00a0und\u00a0symptomatischen \u00a0medull\u00e4ren \u00a0Schilddr\u00fcsenkarzinoms \u00a0\nbei\u00a0Patienten \u00a0mit\u00a0nicht\u2010resezierbarer, \u00a0lokal\u00a0fortgeschrittener \u00a0oder\u00a0metastasierter \u00a0Erkrankung) \u00a0und\u00a0\nVemurafenib \u00a0(als\u00a0Monotherapie \u00a0zur\u00a0Behandlung \u00a0von\u00a0erwachsenen \u00a0Patienten \u00a0mit\u00a0BRAF\u2010V600\u00a0\nMutation \u2010positivem \u00a0nicht\u2010resezierbarem \u00a0oder\u00a0metastasiertem \u00a0Melanom). \u00a0Nach\u00a0dieser\u00a0Klassifizierung \u00a0\n \n22\u00a0 \n \nInnovationsreport 2015 \u00a0wurde\u00a0im\u00a0Vergleich \u00a0zum\u00a0Jahr\u00a02011\u00a0(14\u2010mal\u00a0\u201eA\u201c)\u00a0seltener\u00a0ein\u00a0hoher\u00a0Innovationsgrad \u00a0erreicht.\u00a0\nW\u00e4hrend \u00a0es\u00a0sich\u00a0bei\u00a0der\u00a0Einstufung \u00a0\u201eA\u201c\u00a0des\u00a0Innovationsgrades \u00a0im\u00a0Vorjahr\u00a0sechsmal\u00a0um\u00a0eine\u00a0\nDoppelbewertung \u00a0wie\u00a0A/C\u00a0(\u201eInnovative \u00a0Struktur\u00a0bzw.\u00a0neuartiges \u00a0Wirkprinzip \u00a0mit\u00a0therapeutischer \u00a0\nRelevanz/Analogpr\u00e4parat \u00a0mit\u00a0keinen\u00a0oder\u00a0nur\u00a0marginalen \u00a0Unterschieden \u00a0zu\u00a0bereits\u00a0eingef\u00fchrten \u00a0\nPr\u00e4paraten\u201c) \u00a0oder\u00a0A/D\u00a0(\u201eInnovative \u00a0Struktur\u00a0bzw.\u00a0neuartiges \u00a0Wirkprinzip \u00a0mit\u00a0therapeutischer \u00a0\nRelevanz/Nicht \u00a0ausreichend \u00a0gesichertes \u00a0Wirkprinzip \u00a0oder\u00a0unklarer\u00a0therapeutischer \u00a0Stellenwert\u201c) \u00a0\nhandelte, \u00a0wurden\u00a0f\u00fcr\u00a0das\u00a0Jahr\u00a02012\u00a0nur\u00a0zwei\u00a0Wirkstoffe \u00a0(Dapagliflozin \u00a0und\u00a0Perampanel) \u00a0doppelt\u00a0\nbewertet \u00a0(jeweils\u00a0mit\u00a0A/C)\u00a0(siehe\u00a0Tabelle\u00a04).\u00a0\nDie\u00a0Pharmazeutische \u00a0Zeitung\u00a0(PZ)\u00a0kam\u00a0in\u00a0ihrer\u00a0Bewertung \u00a0der\u00a0in\u00a0diesem\u00a0Report\u00a0zu\u00a0untersuchenden \u00a0\n19\u00a0Wirkstoffe \u00a0bzw.\u00a0Wirkstoffkombinationen \u00a0zu\u00a0vergleichbaren \u00a0Ergebnissen. \u00a0Sieben\u00a0der\u00a0Substanzen \u00a0\nwurden\u00a0von\u00a0den\u00a0Autoren\u00a0vorl\u00e4ufig\u00a0als\u00a0\u201eSprunginnovation\u201c \u00a0(Brentuximabvedotin, \u00a0Crizotinib \u00a0(zur\u00a0\nBiomarker \u2010stratifizierten \u00a0Behandlung \u00a0von\u00a0Erwachsenen \u00a0mit\u00a0vorbehandeltem, \u00a0ALK\u2010positivem, \u00a0\nfortgeschrittenem, \u00a0nicht\u2010kleinzelligem \u00a0Bronchialkarzinom), \u00a0Dapagliflozin, \u00a0Ivacaftor, \u00a0Pasireotid, \u00a0\nRuxolitinib \u00a0und\u00a0Vemurafenib), \u00a0drei\u00a0als\u00a0\u201eSchrittinnovation\u201c \u00a0(Aflibercept \u00a0(hier\u00a0zur\u00a0Behandlung \u00a0der\u00a0\nneovaskul\u00e4ren \u00a0feuchten, \u00a0altersbedingten \u00a0Makuladegeneration), \u00a0Perampanel \u00a0und\u00a0Vandetanib) \u00a0und\u00a0\ndie\u00a0H\u00e4lfte\u00a0der\u00a0Wirkstoffe \u00a0bzw.\u00a0Wirkstoffkombinationen \u00a0als\u00a0\u201eAnalogpr\u00e4parate\u201c \u00a0bewertet. \u00a0Bei\u00a0dieser\u00a0\nEinordnung \u00a0spielte\u00a0ebenfalls\u00a0eine\u00a0Rolle,\u00a0ob\u00a0ein\u00a0v\u00f6llig\u00a0neuer\u00a0Wirkmechanismus \u00a0vorliegt.\u00a0Anders\u00a0f\u00e4llt\u00a0\ndas\u00a0Ergebnis\u00a0aus,\u00a0wenn\u00a0man\u00a0die\u00a0ausschlie\u00dflich \u00a0auf\u00a0einer\u00a0Nutzen\u2010Schaden\u2010Relation\u00a0und\u00a0dem\u00a0daraus\u00a0\nfolgenden \u00a0therapeutischen \u00a0Stellenwert \u00a0basierenden \u00a0Bewertungen \u00a0des\u00a0arznei\u2010telegramms \u00a0(a\u2010t)\u00a0bzw.\u00a0\ndes\u00a0Arzneimittelkursbuches \u00a0(aus\u00a0dem\u00a0gleichen\u00a0Verlag)\u00a0zu\u00a0Rate\u00a0zieht:\u00a0Hier\u00a0wurde\u00a0bei\u00a0den\u00a0neuen\u00a0\nArzneimitteln \u00a0des\u00a0Jahres\u00a02012\u00a0nur\u00a0Vemurafenib \u00a0als\u00a0\u201eMittel\u00a0der\u00a0Wahl\u201c\u00a0bezeichnet. \u00a0Nach\u00a0Auffassung \u00a0\nder\u00a0Autoren\u00a0befand\u00a0sich\u00a0unter\u00a0den\u00a0neuen\u00a0Wirkstoffen \u00a0bzw.\u00a0Wirkstoffkombinationen \u00a0kein\u00a0\u201eMittel\u00a0der\u00a0\nReserve\u201c. \u00a0Das\u00a0Antihypertonikum \u00a0Azilsartanmedoxomil, \u00a0die\u00a0Wirkstoffkombination \u00a0Nomegestrolacetat \u00a0\n+\u00a0Estradiol, \u00a0sowohl\u00a0als\u00a0orales\u00a0Kontrazeptivum \u00a0als\u00a0auch\u00a0zur\u00a0Hormontherapie \u00a0f\u00fcr\u00a0postmenopausale \u00a0\nFrauen,\u00a0sowie\u00a0Perampanel \u00a0werden\u00a0hingegen\u00a0als\u00a0\u201eVariante \u00a0ohne\u00a0besonderen \u00a0Stellenwert\u201c \u00a0bezeichnet. \u00a0\nDapagliflozin \u00a0\u2013\u00a0immerhin \u00a0von\u00a0den\u00a0Autoren\u00a0der\u00a0PZ\u00a0als\u00a0Sprunginnovation \u00a0eingeordnet \u00a0\u2013\u00a0wird\u00a0vom\u00a0a\u2010t\u00a0\nals\u00a0\u201eweiteres \u00a0Antidiabetikum \u00a0und\u00a0Additivum\u201c \u00a0gesehen\u00a0und\u00a0erh\u00e4lt\u00a0aus\u00a0diesem\u00a0Grund\u00a0die\u00a0weniger\u00a0\nrespektable \u00a0Bewertung \u00a0als\u00a0\u201eumstrittenes \u00a0Therapieprinzip\u201c. \u00a0Nur\u00a0zw\u00f6lf\u00a0der\u00a019\u00a0Wirkstoffe \u00a0wurden\u00a0einer\u00a0\nBewertung \u00a0unterzogen. \u00a0Im\u00a0Jahr\u00a02011\u00a0startete\u00a0nach\u00a0den\u00a0Vorgaben \u00a0des\u00a0\nArzneimittelmarktneuordnungsgesetzes \u00a0(AMNOG) \u00a0die\u00a0fr\u00fche\u00a0Nutzenbewertung \u00a0durch\u00a0den\u00a0\nGemeinsamen \u00a0Bundesausschuss \u00a0(G\u2010BA)\u00a0bei\u00a0neu\u00a0in\u00a0den\u00a0Markt\u00a0eingef\u00fchrten \u00a0Arzneimitteln \u00a0mit\u00a0neuen\u00a0\nWirkstoffen, \u00a0neuen\u00a0Wirkstoffkombinationen \u00a0sowie\u00a0bei\u00a0Indikationserweiterungen. \u00a0Seitdem\u00a0gibt\u00a0es\u00a0in\u00a0\nDeutschland \u00a0erstmals\u00a0eine\u00a0Kopplung \u00a0von\u00a0ermitteltem \u00a0(Zusatz\u2010)Nutzen\u00a0und\u00a0dem\u00a0Erstattungsbetrag \u00a0\nder\u00a0GKV,\u00a0der\u00a0im\u00a0Anschluss \u00a0an\u00a0den\u00a0Beschluss \u00a0zum\u00a0Zusatznutzen \u00a0zwischen\u00a0pU\u00a0und\u00a0GKV\u2010Spitzenverband \u00a0\nausgehandelt \u00a0wird.\u00a0Bei\u00a0den\u00a0neuen\u00a0Arzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0oder\u00a0\nWirkstoffkombinationen \u00a0des\u00a0Jahres\u00a02012,\u00a0die\u00a0in\u00a0diesem\u00a0Innovationsreport \u00a0thematisiert \u00a0werden,\u00a0\nkonstatierte \u00a0der\u00a0G\u2010BA\u00a0dreimal\u00a0die\u00a0zweitbeste \u00a0Bewertung \u00a0(\u201ebetr\u00e4chtlicher \u00a0Zusatznutzen\u201c), \u00a0zumindest \u00a0\nf\u00fcr\u00a0einen\u00a0Teil\u00a0der\u00a0zugelassenen \u00a0Anwendungsgebiete. \u00a0Dies\u00a0war\u00a0der\u00a0Fall\u00a0bei\u00a0Crizotinib, \u00a0bei\u00a0dem\u00a0Orphan\u00a0\nDrug\u00a0Ivacaftor\u00a0sowie\u00a0bei\u00a0Vemurafenib. \u00a0F\u00fcr\u00a0Ivacaftor\u00a0sah\u00a0der\u00a0G\u2010BA\u00a0diesen\u00a0Beleg\u00a0allerdings \u00a0nur\u00a0f\u00fcr\u00a0\nJugendliche \u00a0(ab\u00a012\u00a0Jahre)\u00a0und\u00a0erwachsene \u00a0Patienten. \u00a0Einschr\u00e4nkend \u00a0kommt\u00a0hinzu,\u00a0dass\u00a0es\u00a0sich\u00a0bei\u00a0\nCrizotinib \u00a0lediglich\u00a0um\u00a0einen\u00a0Anhaltspunkt \u00a0und\u00a0bei\u00a0Vemurafenib \u00a0nur\u00a0um\u00a0einen\u00a0Hinweis\u00a0auf\u00a0einen\u00a0\nZusatznutzen \u00a0handelte. \u00a0Bei\u00a0weiteren\u00a0sieben\u00a0der\u00a0insgesamt \u00a019\u00a0neuen\u00a0Wirkstoffe \u00a0sah\u00a0der\u00a0G\u2010BA\u00a0Belege,\u00a0\nHinweise\u00a0oder\u00a0Anhaltspunkte \u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0Zusatznutzen: \u00a0Axitinib\u00a0zur\u00a0Zweitlinienbehandlung \u00a0\ndes\u00a0fortgeschrittenen \u00a0Nierenzellkarzinoms, \u00a0Decitabin \u00a0zur\u00a0Behandlung \u00a0von\u00a0Patienten \u00a0ab\u00a0einem\u00a0Alter\u00a0\nvon\u00a065\u00a0Jahren\u00a0mit\u00a0neu\u00a0diagnostizierter \u00a0de\u00a0novo\u00a0oder\u00a0sekund\u00e4rer \u00a0akuter\u00a0myeloischer \u00a0Leuk\u00e4mie \u00a0(AML),\u00a0\nf\u00fcr\u00a0die\u00a0eine\u00a0Standard\u2010Induktionschemotherapie \u00a0nicht\u00a0in\u00a0Frage\u00a0kommt,\u00a0Ivacaftor\u00a0bei\u00a0Kindern\u00a0zwischen\u00a0 \n23\u00a0\n \nInnovationsreport 2015 \u00a0sechs\u00a0bis\u00a0elf\u00a0Jahren,\u00a0Pasireotid, \u00a0Rilpivirin\u00a0f\u00fcr\u00a0die\u00a0antiretrovirale \u00a0Kombinationsbehandlung \u00a0von\u00a0HIV\u20101\u2010\nInfektionen \u00a0bei\u00a0antiretroviral \u00a0nicht\u2010vorbehandelten \u00a0Erwachsenen \u00a0mit\u00a0einer\u00a0Viruslast\u00a0von\u00a0maximal\u00a0\n100.000\u00a0RNA\u2010Kopien/ml \u00a0sowie\u00a0Ruxolitinib \u00a0und\u00a0Vandetanib. \u00a0Vier\u00a0dieser\u00a0Wirkstoffe \u00a0waren\u00a0Orphan\u00a0\nDrugs\u00a0(Tabelle\u00a04).\u00a0Das\u00a0MRSA\u2010wirksame \u00a0Staphylococcen \u2010Cephalosporin \u00a0Ceftarolinfosamil \u00a0wurde\u00a0\nwegen\u00a0Geringf\u00fcgigkeit \u00a0nach\u00a0\u00a7\u00a035a\u00a0Abs.\u00a01a\u00a0SGB\u00a0V\u00a0freigestellt. \u00a0Die\u00a0hormonellen \u00a0\nKombinationspr\u00e4parate \u00a0bestehend \u00a0aus\u00a0Nomegestrolacetat \u00a0plus\u00a0Estradiol, \u00a0die\u00a0entweder \u00a0als\u00a0orales\u00a0\nKontrazeptivum \u00a0oder\u00a0zur\u00a0Hormontherapie \u00a0bei\u00a0postmenopausalen \u00a0Frauen\u00a0eingesetzt \u00a0werden,\u00a0sind\u00a0als\u00a0\nMittel\u00a0zur\u00a0Pr\u00e4vention \u00a0von\u00a0Krankheiten \u00a0nicht\u00a0generell\u00a0erstattungsf\u00e4hig \u00a0und\u00a0wurden\u00a0daher\u00a0nicht\u00a0in\u00a0die\u00a0\nNutzenbewertung \u00a0des\u00a0G\u2010BA\u00a0einbezogen. \u00a0Insgesamt \u00a0erhielten\u00a0von\u00a0den\u00a0neuen\u00a0Arzneimitteln \u00a0des\u00a0Jahres\u00a0\n2012\u00a0mit\u00a0Brentuximabvedotin, \u00a0Decitabin, \u00a0Ivacaftor, \u00a0Pasireotid \u00a0sowie\u00a0Ruxolitinib \u00a0f\u00fcnf\u00a0Wirkstoffe \u00a0den\u00a0\nOrphan\u00a0Drug\u2010Status.\u00a0Orphan\u00a0Drugs\u00a0(\u201eArzneimittel \u2010Waisen\u201c)\u00a0sind\u00a0Arzneimittel \u00a0zur\u00a0Behandlung \u00a0\nseltener\u00a0Krankheiten. \u00a0In\u00a0der\u00a0Europ\u00e4ischen \u00a0Union\u00a0gilt\u00a0eine\u00a0Krankheit \u00a0als\u00a0selten,\u00a0wenn\u00a0weniger\u00a0als\u00a0f\u00fcnf\u00a0\nvon\u00a010.000\u00a0Menschen \u00a0an\u00a0ihr\u00a0leiden.\u00a0Im\u00a0Jahr\u00a0zuvor\u00a0waren\u00a0es\u00a0mit\u00a0Pirfenidon \u00a0zur\u00a0Behandlung \u00a0der\u00a0\nidiopathischen \u00a0Lungenfibrose \u00a0und\u00a0Tafamidis \u00a0zur\u00a0Behandlung \u00a0einer\u00a0Transthyretin \u2010Amyloidose \u00a0nur\u00a0\nzwei\u00a0Wirkstoffe \u00a0mit\u00a0diesem\u00a0Status.\u00a0Bei\u00a0Orphan\u00a0Drugs\u00a0gilt\u00a0gem\u00e4\u00df\u00a0rechtlicher \u00a0Rahmenbedingungen \u00a0der\u00a0\nZusatznutzen \u00a0als\u00a0belegt\u00a0und\u00a0der\u00a0G\u2010BA\u00a0bewertet \u00a0lediglich\u00a0das\u00a0Ausma\u00df\u00a0desselben. \u00a0Die\u00a0Erg\u00e4nzung \u00a0der\u00a0\nNutzenbewertung \u00a0wird\u00a0erst\u00a0dann\u00a0verpflichtend, \u00a0wenn\u00a0der\u00a0Umsatz\u00a0des\u00a0entsprechenden \u00a0Arzneimittels \u00a0\nin\u00a0einem\u00a0Jahr\u00a0die\u00a0Schwelle\u00a0von\u00a050\u00a0Mio.\u00a0Euro\u00a0\u00fcbersteigt. \u00a0Unter\u00a0den\u00a0neuen\u00a0Arzneimitteln \u00a0des\u00a0Jahres\u00a0\n2012\u00a0befinden\u00a0sich\u00a0zwei\u00a0gentechnisch \u00a0bzw.\u00a0biotechnologisch \u00a0hergestellte \u00a0Wirkstoffe \u00a0(\u201eBiologicals \u201c):\u00a0\nAflibercept \u00a0sowie\u00a0der\u00a0Chemotoxin \u2010gekoppelte \u00a0CD30\u2010Antik\u00f6rper \u00a0Brentuximabvedotin. \u00a0 \n24\u00a0 \n \nInnovationsreport 2015 \u00a0Wirkstof f\u00a0 Indikation \u00a0 AMNOG\u2010NBW\nZusatznutzen \u00a0Fricke/\nKlaus\u00a0a\u2010t/AKB\u2010\nBewertung \u00a0PZ\u2010Bewertung\nAclidinium \u2010\nbromid\u00a0COPD\u00a0 Nicht\u00a0belegt1\u00a0 C\u00a0 Variante\u00a0 Analogpr\u00e4parat* \u00a0\nAflibercept \u00a0 AMD\u00a0 Nicht\u00a0belegt2B\u00a0 Variante\u00a0 Schrittinnovation* \u00a0\nAxitinib\u00a0 Nierenzell \u2010\nkarzinom \u00a0Nicht\u00a0belegt3\u00a0\nGeringH,4\u00a0C\u00a0 \u2013\u00a0 Analogpr\u00e4parat* \u00a0\nAzilsartan \u2010\u00a0\nmedoxomil \u00a0Essentielle \u00a0\nHypertonie \u00a0Nicht\u00a0belegt\u00a0 C\u00a0 Variante\u00a0 Analogpr\u00e4parat* \u00a0\nBrentuximab \u2010\nvedotin\u00a0(O)\u00a0CD30+\u00a0Hodgkin\u2010\nLymphom \u00a0Nicht\u00a0quantifizierbarB,5\u00a0 A\u00a0 \u2013\u00a0 Sprunginnovation* \u00a0\nCeftarolinfosamil \u00a0Haut\u2010\u00a0und\u00a0\nWeichteilgewe \u2010\nbeinfektion, \u00a0\nambulant \u00a0\nerworbene \u00a0\nPneumonie \u00a0Wegen\u00a0Geringf\u00fcgigkeit \u00a0\nnach\u00a0\u00a7\u00a035a\u00a0Abs.\u00a01a\u00a0\u00a0\nSGB\u00a0V\u00a0\u201eAndere\u00a0Beta\u2010\nLactam\u2010Antibiotika\u201c \u00a0\nfreigestellt \u00a0\u00a0\n\u00a0C\u00a0 \u2013\u00a0 Analogpr\u00e4parat \u00a0\nCrizotinib \u00a0 Lungenkarzinom \u00a0\u00a0 Betr\u00e4chtlichA,6\u00a0\nNicht\u00a0belegt7\u00a0B\u00a0 \u2013\u00a0 Sprunginnovation* \u00a0\nDapagliflozin \u00a0 Diabetes\u00a0Typ\u00a02\u00a0 Nicht\u00a0belegt8\u00a0 A/C\u00a0 Umstrittenes \u00a0\nTherapie\u2010\nprinzip\u00a0Sprunginnovation* \u00a0\nDecitabin \u00a0(O)\u00a0 AML\u00a0 GeringB\u00a0 C\u00a0 \u2013\u00a0 Analogpr\u00e4parat* \u00a0\nIvacaftor\u00a0(O)\u00a0 Zystische\u00a0Fibrose\u00a0\n(Mukoviszidose) \u00a0GeringB,9\nBetr\u00e4chtlichB,10\u00a0A\u00a0 \u2013\u00a0 Sprunginnovation* \u00a0\nNomegestrol \u2010\nacetat\u00a0+\u00a0Estradiol\u00a0Orale\u00a0\nKontrazeption \u00a0Keine\u00a0Nutzenbewertung, \u00a0\nda\u00a0es\u00a0sich\u00a0um\u00a0ein\u00a0nicht\u00a0\ngenerell\u00a0erstat\u2010\ntungsf\u00e4higes \u00a0Arznei\u2010\nmittel\u00a0handelt\u00a0C\u00a0 Variante\u00a0 Analogpr\u00e4parat* \u00a0\nNomegestrol \u2010\nacetat\u00a0+\u00a0Estradiol\u00a0Hormontherapie \u00a0\nbei\u00a0postmeno \u2010\npausalen\u00a0Frauen\u00a0Keine\u00a0Nutzenbewertung, \u00a0\nda\u00a0es\u00a0sich\u00a0um\u00a0ein\u00a0nicht\u00a0\ngenerell\u00a0erstat\u2010\ntungsf\u00e4higes \u00a0Arznei\u2010\nmittel\u00a0handelt\u00a0C\u00a0 Variante\u00a0 keine\u00a0Bewertung \u00a0\nPasireotid \u00a0(O)\u00a0 Morbus\u00a0Cushing\u00a0 GeringB,11\u00a0 A\u00a0 \u2013\u00a0 Sprunginnovation* \u00a0\nPerampanel \u00a0 Epilepsie\u00a0 Nicht\u00a0belegt\u00a0 A/C\u00a0 Variante\u00a0 Schrittinnovation* \u00a0\nPixantron \u00a0 Non\u2010Hodgkin\u2010B\u2010\nZell\u2010Lymphome \u00a0Nicht\u00a0belegt12\u00a0 C\u00a0 \u2013\u00a0 Analogpr\u00e4parat* \u00a0\nRilpivirin\u00a0 HIV\u00a0 GeringB\u00a0 C\u00a0 \u2013\u00a0 Analogpr\u00e4parat* \u00a0\nRuxolitinib \u00a0(O)\u00a0 Splenomegalie \u00a0\noder\u00a0Symptome \u00a0\nbei\u00a0Myelofibrose \u00a0GeringB\u00a0 A\u00a0 \u2013\u00a0 Sprunginnovation* \u00a0\nTegafur\u00a0+\u00a0\nGimeracil \u00a0+\u00a0\nOteracil\u00a0Magenkarzinom \u00a0\u00a0 Nicht\u00a0belegt\u00a0 B\u00a0 \u2013\u00a0 keine\u00a0Bewertung \u00a0\nVandetanib \u00a0 Schilddr\u00fcsen \u2010\nkarzinom \u00a0GeringA,13\u00a0 A\u00a0 \u2013\u00a0 Schrittinnovation* \u00a0\nVemurafenib \u00a0 Melanom \u00a0 Betr\u00e4chtlichH\u00a0 A\u00a0 Mittel\u00a0der\u00a0\nWahl\u00a0Sprunginnovation* \u00a0\nTabelle\u00a04:\u00a0\u00dcbersicht \u00a0der\u00a0neuen\u00a0Wirkstoffe/Wirkstoffkombinationen \u00a0des\u00a0Jahres\u00a02012\u00a0und\u00a0deren\u00a0Bewertungen \u00a0\nin\u00a0Standardwerken \u00a0\nNBW\u00a0=\u00a0Nutzenbewertung, \u00a0a\u2010t\u00a0=\u00a0arznei\u2010telegramm, \u00a0AKB\u00a0=\u00a0Arzneimittelkursbuch, \u00a0PZ\u00a0=\u00a0Pharmazeutische \u00a0Zeitung,\u00a0*)\u00a0Vorl\u00e4ufige \u00a0Bewertung, \u00a0Abk\u00fcrzungen \u00a0bei\u00a0\nAMNOG\u2010NBW:\u00a0B\u00a0=\u00a0Beleg\u00a0f\u00fcr\u00a0Zusatznutzen \u00a0mit\u00a0dem\u00a0Ausma\u00df\u2026, \u00a0H\u00a0=\u00a0Hinweis\u00a0auf\u00a0Zusatznutzen \u00a0mit\u00a0dem\u00a0Ausma\u00df\u2026, \u00a0A\u00a0=\u00a0Anhaltspunkt \u00a0f\u00fcr\u00a0Zusatznutzen \u00a0mit\u00a0dem\u00a0\nAusma\u00df\u2026, \u00a01)\u00a0Bei\u00a0Patienten \u00a0ab\u00a0Therapiestufe \u00a0II\u00a0sowie\u00a0bei\u00a0Patienten \u00a0ab\u00a0Therapiestufe \u00a0III/IV\u00a0mit\u00a0mehr\u00a0als\u00a0zwei\u00a0Exazerbationen. \u00a02)\u00a0Zur\u00a0Behandlung \u00a0von\u00a0\nErwachsenen \u00a0mit\u00a0neovaskul\u00e4rer \u00a0(feuchter) \u00a0altersbedingter \u00a0Makuladegeneration. \u00a03)\u00a0Nach\u00a0vorangegangener \u00a0Therapie\u00a0mit\u00a0Sunitinib. \u00a04)\u00a0Nach\u00a0vorangegangener \u00a0\nTherapie\u00a0mit\u00a0einem\u00a0Zytokin.\u00a05)\u00a0Nach\u00a0einer\u00a0autologen \u00a0Stammzelltransplantation \u00a0bzw.\u00a0nach\u00a0mindestens \u00a0zwei\u00a0vorangegangenen \u00a0Therapien, \u00a0wenn\u00a0eine\u00a0autologe\u00a0\nStammzelltransplantation/Kombinationschemotherapie \u00a0nicht\u00a0als\u00a0Behandlungsoption \u00a0in\u00a0Frage\u00a0kommt\u00a0bzw.\u00a0zur\u00a0Behandlung \u00a0rezidivierter/refrakt\u00e4rer \u00a0\nsystemischer \u00a0anaplastischer \u00a0gro\u00dfzelliger \u00a0Lymphome. \u00a06)\u00a0Patienten, \u00a0bei\u00a0denen\u00a0eine\u00a0Chemotherapie \u00a0angezeigt \u00a0ist.\u00a07)\u00a0Patienten, \u00a0bei\u00a0denen\u00a0eine\u00a0Chemotherapie \u00a0\nnicht\u00a0angezeigt \u00a0ist.\u00a08)\u00a0Sowohl\u00a0als\u00a0Monotherapie \u00a0wie\u00a0auch\u00a0als\u00a0Add\u2010on\u2010Kombinationstherapie \u00a0f\u00fcr\u00a0alle\u00a0aufgef\u00fchrten \u00a0Indikationsgebiete. \u00a09)\u00a0Bei\u00a0Kindern\u00a0zwischen\u00a06\u00a0\nbis\u00a011\u00a0Jahre.\u00a010)\u00a0Bei\u00a0Jugendlichen \u00a0(ab\u00a012\u00a0Jahre)\u00a0und\u00a0Erwachsenen. \u00a011)\u00a0Bei\u00a0erwachsenen \u00a0Patienten \u00a0mit\u00a0Morbus\u00a0Cushing,\u00a0f\u00fcr\u00a0die\u00a0ein\u00a0chirurgischer \u00a0Eingriff\u00a0keine\u00a0\nOption\u00a0ist\u00a0oder\u00a0bei\u00a0denen\u00a0ein\u00a0chirurgischer \u00a0Eingriff\u00a0fehlgeschlagen \u00a0ist.\u00a012)\u00a0Bei\u00a0Anwendung \u00a0als\u00a0F\u00fcnft\u2010\u00a0und\u00a0Mehrlinientherapie \u00a0bei\u00a0Patienten, \u00a0die\u00a0refrakt\u00e4r\u00a0gegen\u00a0\ndie\u00a0vorausgegangene \u00a0Therapie\u00a0waren.\u00a013)\u00a0Gegen\u00fcber \u00a0Best\u00a0Supportive \u00a0Care.\u00a0\u00a0 \u00a0 \n25\u00a0\n \nInnovationsreport 2015 \u00a0\nRang\u00a0Wirkstoff \u00a0\n(Handelsname) \u00a0Techniker \u00a0Krankenkasse GKV\u00a0gesamt\u00a0\nUmsatz\u00a0\n2013\u00a0\n[in\u00a0Tsd.\u00a0\u20ac]\u00a0Umsatz\u2010\n\u00e4nd.\u00a0zum\u00a0\nVorjahr\u00a0Verordnete\nPackg.\u00a02013\n[in\u00a0Tsd.]Umsatz\u00a02013\u00a0\u00a0\n[in\u00a0Tsd.\u00a0\u20ac]\u00a0Absatz\u00a02013\n[in\u00a0Tsd.]\n1\u00a0Ruxolitinib \u00a0\n(Jakavi\u00ae\u00a0(O))\u00a06.202,0\u00a0 +351% 1,6 57.301,2\u00a0 14,8\n2\u00a0Vemurafenib \u00a0\n(Zelboraf\u00ae) \u00a05.131,3\u00a0 +65% 1,8 44.743,6\u00a0 15,5\n3\u00a0Aflibercept \u00a0\u00a0\n(Eylea\u00ae)\u00a03.195,2\u00a0\u2010 * 2,9 15.840,2\u00a0 13,9\n4\u00a0Ivacaftor\u00a0\u00a0\n(Kalydeco\u00ae \u00a0(O))\u00a01.887,3\u00a0 +363% 0,1 30.171,9\u00a0 1,2\n5\u00a0Axitinib\u00a0\u00a0\n(Inlyta\u00ae)\u00a01.841,2\u00a0 +1.125% 0,4 19.760,2\u00a0 4,6\n6\u00a0Crizotinib \u00a0\u00a0\n(Xalkori\u00ae) \u00a01.353,4\u00a0 +1.140% 0,2 9.372,3\u00a0 1,3\n7\u00a0Dapagliflozin \u00a0\u00a0\n(Forxiga\u00ae) \u00a01.352,0\u00a0+15.878% 7,9 16.763,2\u00a0 99,7\n8\u00a0Aclidiniumbromid \u00a0\u00a0\n(Bretaris\u00ae \u00a0Genuair\u00ae, \u00a0\nEklira\u00ae\u00a0Genuair\u00ae) \u00a01.231,2\u00a0 +4.456% 11,3 19.359,2\u00a0 180,5\n9\u00a0Decitabin \u00a0\u00a0\n(Dacogen\u00ae \u00a0(O))\u00a01.214,6\u00a0 +1.737% 0,6 9.774,7\u00a0 5,0\n10\u00a0Brentuximabvedotin \u00a0\n(Adcetris\u00ae \u00a0(O))\u00a01.184,5\u00a0 +1.167% 0,2 6.239,6\u00a0 1,3\n11\u00a0Perampanel \u00a0\u00a0\n(Fycompa\u00ae) \u00a01.027,5\u00a0 +785% 2,9 10.423,7\u00a0 26,9\n12\u00a0Vandetanib \u00a0\u00a0\n(Caprelsa\u00ae) \u00a0607,4\u00a0 +43% 0,1 3.451,6\u00a0 0,7\n13\u00a0Pasireotid \u00a0\u00a0\n(Signifor\u00ae \u00a0(O))\u00a0436,6\u00a0 +82% 0,2 2.187,3\u00a0 0,9\n14\u00a0Azilsartanmedoxomil\n(Edarbi\u00ae)\u00a0357,9\u00a0 +37% 4,0 4.352,2\u00a0 48,2\n15\u00a0Nomegestrolacetat \u00a0+\u00a0\u00a0\nEstradiol\u00a0\n(Zoely\u00ae)\u00a0198,2\u00a0 +136% 5,9 1.486,8\u00a0 44,2\n16\u00a0Pixantron \u00a0\u00a0\n(Pixuvri\u00ae) \u00a0156,9\u00a0 \u2010* 0,2 605,6\u00a0 0,6\n17\u00a0Rilpivirin\u00a0\u00a0\n(Edurant\u00ae) \u00a067,4\u00a0 +37% 0,1 556,2\u00a0 1,2\n18\u00a0Nomegestrolacetat \u00a0+\u00a0\u00a0\nEstradiol\u00a0\n(Naemis\u00ae) \u00a021,8\u00a0 \u2010* 0,5 169,3\u00a0 4,2\n19\u00a0Tegafur,\u00a0Gimeracil \u00a0\n(Teysuno\u00ae) \u00a020,3\u00a0 +1.199% 0,1 231,1\u00a0 0,7\n1\u201019\u00a0Gesamt\u00a0 27.486,7\u00a0 +\u00a0317\u00a0% 41,0 252.789,9 \u00a0 465,4\nBezogen\u00a0auf\u00a0die\u00a0neuen\u00a0Arzneimittel \u00a0aus\u00a0dem\u00a0Jahr\u00a02012\u00a0ausgenommen \u00a0Ceftarolinfosamil \u00a0f\u00fcr\u00a0den\u00a0gesamten \u00a0GKV\u2010Markt;\u00a0\nZeitpunkt \u00a0der\u00a0Markteinf\u00fchrung \u00a0im\u00a0Vorjahr\u00a0beeinflusst \u00a0die\u00a0prozentuale \u00a0\u00c4nderung; \u00a0Daten\u00a0nach\u00a0IMS\u00a0Health\u00a0(2013)\u00a0*)\u00a0keine\u00a0\nAngabe\u00a0;\u00a0\u201eO\"\u00a0=\u00a0Orphan\u00a0Drug\u00a0\nTabelle\u00a05:\u00a0Top\u2010Liste\u00a0der\u00a0neuen\u00a0Arzneimittel \u00a0des\u00a0Jahres\u00a02012\u00a0\u2013\u00a0nach\u00a0Umsatz\u00a0im\u00a0Jahr\u00a02013\u00a0(TK\u00a0und\u00a0gesamter \u00a0\nApothekenmarkt \u00a0Deutschlands) \u00a0\n   \n26\u00a0 \n \nInnovationsreport 2015 \u00a0\nRang\u00a0Wirkstoff \u00a0Techniker \u00a0Krankenkasse GKV\u00a0gesamt\u00a0\nVer\u2010\u00a0\nordnete\u00a0\nPackg.\u00a0\n2013\u00a0\n[in\u00a0Tsd.]\u00a0Packg.\u00a0\n\u00c4nderung \u00a0zum\u00a0\nVorjahrUmsatz\u00a0\n2013\n[in\u00a0Tsd.\u00a0\u20ac]Absatz\u00a02013\u00a0\n[in\u00a0Tsd.]\u00a0Umsatz\u00a02013\u00a0\n[in\u00a0Tsd.\u00a0\u20ac]\n1\u00a0Aclidiniumbromid \u00a0\n(Bretaris\u00ae \u00a0Genuair\u00ae, \u00a0\nEklira\u00ae\u00a0Genuair\u00ae) \u00a011,3\u00a0 1.246% 1.231,2 180,5\u00a0 19.359,2\n2\u00a0Dapagliflozin \u00a0\u00a0\n(Forxiga\u00ae) \u00a07,9\u00a0 12.080% 1.352,0 99,7\u00a0 16.763,2\n3\u00a0Nomegestrolacetat \u00a0+\u00a0\nEstradiol\u00a0\n(Zoely\u00ae)\u00a05,9\u00a0 133% 198,2 44,2\u00a0 1.486,8\n4\u00a0Azilsartanmedoxomil \u00a0\n(Edarbi\u00ae)\u00a04,0\u00a0 24% 357,9 48,2\u00a0 4.352,2\n5\u00a0Aflibercept \u00a0\u00a0\n(Eylea\u00ae)\u00a02,9\u00a0 \u2010* 3.195,2 13,9\u00a0 15.840,2\n6\u00a0Perampanel \u00a0\n(Fycompa\u00ae) \u00a02,9\u00a0 542% 1.027,5 26,9\u00a0 10.423,7\n7\u00a0Vemurafenib \u00a0\u00a0\n(Zelboraf\u00ae) \u00a01,8\u00a0 65% 5.131,3 15,5\u00a0 44.743,6\n8\u00a0Ruxolitinib \u00a0\u00a0\n(Jakavi\u00ae\u00a0(O))\u00a01,6\u00a0 381% 6.202,0 14,8\u00a0 57.301,2\n9\u00a0Decitabin \u00a0\u00a0\n(Dacogen\u00ae \u00a0(O))\u00a00,6\u00a0 1.736% 1.214,6 5,0\u00a0 9.774,7\n10\u00a0Nomegestrolacetat \u00a0+\u00a0\nEstradiol\u00a0\n(Naemis\u00ae) \u00a00,5\u00a0 \u2010* 21,8 4,2\u00a0 169,3\n11\u00a0Axitinib\u00a0\n(Inlyta\u00ae)\u00a00,4\u00a0 1.218% 1.841,2 4,6\u00a0 19.760,2\n12\u00a0Brentuximabvedotin \u00a0\n(Adcetris\u00ae \u00a0(O))\u00a00,2\u00a0 1.167% 1.184,5 1,3\u00a0 6.239,6\n13\u00a0Crizotinib \u00a0\u00a0\n(Xalkori\u00ae) \u00a00,2\u00a0 1.140% 1.353,4 1,3\u00a0 9.372,3\n14\u00a0Pasireotid \u00a0\u00a0\n(Signifor\u00ae \u00a0(O))\u00a00,2\u00a0 82% 436,6 0,9\u00a0 2.187,3\n15\u00a0Pixantron \u00a0\u00a0\n(Pixuvri\u00ae) \u00a00,2\u00a0 \u2010* 156,9 0,6\u00a0 605,6\n16\u00a0Rilpivirin\u00a0\n(Edurant\u00ae) \u00a00,1\u00a0 39% 67,4 1,2\u00a0 556,2\n17\u00a0Vandetanib \u00a0\u00a0\n(Caprelsa\u00ae) \u00a00,1\u00a0 47% 607,4 0,7\u00a0 3.451,6\n18\u00a0Ivacaftor\u00a0\n(Kalydeco\u00ae \u00a0(O))\u00a00,1\u00a0 363% 1.887,3 1,2\u00a0 30.171,9\n19\u00a0Tegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0\nOteracil\u00a0\n(Teysuno\u00ae) \u00a00,1\u00a0 675% 20,3 0,7\u00a0 231,1\n1\u201019\u00a0\u00a0\nGesamt\u00a0\n\u00a041,0\u00a0 358% 27.486,7 465,4\u00a0 252.789,9\nBezogen\u00a0auf\u00a0die\u00a0neuen\u00a0Arzneimittel \u00a0aus\u00a0dem\u00a0Jahr\u00a02012\u00a0ausgenommen \u00a0Ceftarolinfosamil \u00a0f\u00fcr\u00a0den\u00a0gesamten \u00a0GKV\u2010Markt;\u00a0\nZeitpunkt \u00a0der\u00a0Markteinf\u00fchrung \u00a0im\u00a0Vorjahr\u00a0beeinflusst \u00a0die\u00a0prozentuale \u00a0\u00c4nderung; \u00a0Daten\u00a0nach\u00a0IMS\u00a0Health\u00a0(2013)\u00a0*)\u00a0keine\u00a0\nAngabe\u00a0;\u00a0\u201eO\"\u00a0=\u00a0Orphan\u00a0Drug\u00a0\nTabelle\u00a06:\u00a0Top\u2010Liste\u00a0der\u00a0neuen\u00a0Arzneimittel \u00a0des\u00a0Jahres\u00a02012\u00a0\u2013\u00a0nach\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0im\u00a0Jahr\u00a0\n2013\u00a0(TK\u00a0und\u00a0gesamter \u00a0Apothekenmarkt \u00a0Deutschlands) \u00a0\u00a0 \n27\u00a0\n \nInnovationsreport 2015 \u00a0Der\u00a0Umsatz\u00a0der\u00a0neuen\u00a0Arzneimittel \u00a0des\u00a0Jahres\u00a02012\u00a0lag\u00a0in\u00a0der\u00a0untersuchten \u00a0Population \u00a0der\u00a0TK\u2010\nVersicherten \u00a0bei\u00a027,5\u00a0Mio.\u00a0Euro\u00a0(gemessen \u00a0f\u00fcr\u00a0das\u00a0Jahr\u00a02013).\u00a0Verglichen \u00a0mit\u00a0den\u00a0neuen\u00a0\nArzneimitteln \u00a0im\u00a0Jahr\u00a02011\u00a0handelt\u00a0es\u00a0sich\u00a0dabei\u00a0um\u00a0verh\u00e4ltnism\u00e4\u00dfig \u00a0geringe\u00a0Kosten,\u00a0trotz\u00a0\nvergleichbarer \u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0(n\u00a0=\u00a041,0\u00a0Tsd.\u00a0vs.\u00a0n\u00a0=\u00a049,2\u00a0Tsd.\u00a0f\u00fcr\u00a0das\u00a0Jahr\u00a02012)\u00a0der\u00a0\nneuen\u00a0Arzneimittel, \u00a0die\u00a0seinerzeit \u00a0einen\u00a0Umsatz\u00a0von\u00a074,0\u00a0Mio.\u00a0Euro\u00a0generierten. \u00a0Lag\u00a0der\u00a0\ndurchschnittliche \u00a0Preis\u00a0pro\u00a0Packung\u00a0damals\u00a0bei\u00a0rund\u00a01.504\u00a0Euro\u00a0(Windt\u00a0et\u00a0al.,\u00a02014),\u00a0so\u00a0waren\u00a0es\u00a0nun\u00a0\ndurchschnittlich \u00a0670\u00a0Euro.\u00a0Das\u00a0umsatzst\u00e4rkste \u00a0Arzneimittel \u00a0im\u00a0Jahr\u00a02013\u00a0ist\u00a0das\u00a0Orphan\u00a0Drug\u00a0\nRuxolitinib, \u00a0das\u00a0unter\u00a0anderem\u00a0zur\u00a0Therapie\u00a0der\u00a0seltenen\u00a0Leuk\u00e4mie \u2010Form\u00a0Myelofibrose \u00a0eingesetzt \u00a0\nwird\u00a0und\u00a0214\u00a0TK\u2010Versicherten \u00a0verordnet \u00a0wurde\u00a0(Tabelle\u00a07).\u00a0Der\u00a0Tyrosinkinaseinhibitor \u00a0Vemurafenib \u00a0\nzur\u00a0Therapie\u00a0des\u00a0BRAF\u2010V600\u2010positiven\u00a0metastasierten \u00a0Melanoms \u00a0sowie\u00a0Aflibercept \u00a0als\u00a0ein\u00a0weiterer\u00a0\nHemmstoff \u00a0des\u00a0vaskul\u00e4ren \u00a0endothelialen \u00a0Wachstumsfaktors, \u00a0unter\u00a0anderem\u00a0verordnet \u00a0zur\u00a0\nBehandlung \u00a0der\u00a0altersabh\u00e4ngigen \u00a0Makuladegeneration, \u00a0folgen\u00a0auf\u00a0Rang\u00a02\u00a0bzw.\u00a03\u00a0nach\u00a0Umsatz\u00a0bei\u00a0\nden\u00a0neuen\u00a0Arzneimitteln \u00a0(Tabelle\u00a05).\u00a0Das\u00a0im\u00a0Jahr\u00a02013\u00a0am\u00a0h\u00e4ufigsten \u00a0verordnete \u00a0neue\u00a0Arzneimittel \u00a0\ndes\u00a0Jahres\u00a02012\u00a0war\u00a0mit\u00a011,3\u00a0Tsd.\u00a0verschriebenen \u00a0Packungen \u00a0Aclidiniumbromid, \u00a0als\u00a0therapeutische \u00a0\nOption\u00a0bei\u00a0der\u00a0chronisch \u00a0obstruktiven \u00a0Lungenkrankheit. \u00a0Auf\u00a0Platz\u00a02\u00a0nach\u00a0Verordnungen \u00a0rangiert\u00a0das\u00a0\nAntidiabetikum \u00a0Dapagliflozin \u00a0\u2013\u00a0trotz\u00a0negativer \u00a0Nutzenbewertung \u00a0durch\u00a0den\u00a0G\u2010BA\u00a0im\u00a0Juni\u00a02013\u00a0\n(Tabelle\u00a06).\u00a0\nEtwa\u00a00,2\u00a0Prozent\u00a0(n\u00a0=\u00a014.202)\u00a0der\u00a0TK\u2010Versicherten \u00a0erhielten\u00a0im\u00a0Jahr\u00a02013\u00a0ein\u00a0Arzneimittel, \u00a0das\u00a0im\u00a0\nLaufe\u00a0des\u00a0Vorjahres \u00a0in\u00a0den\u00a0Markt\u00a0eingef\u00fchrt \u00a0wurde\u00a0(Tabelle\u00a07).\u00a0Die\u00a0neuen\u00a0Arzneimittel \u00a0aus\u00a0dem\u00a0Jahr\u00a0\n2011\u00a0bekamen \u00a0nur\u00a0halb\u00a0so\u00a0viele\u00a0Versicherte \u00a0verordnet \u00a0(Windt\u00a0et\u00a0al.,\u00a02014).\u00a0Auf\u00a0Bundeslandebene \u00a0\nzeigten\u00a0sich\u00a0hinsichtlich \u00a0der\u00a0Verordnungspr\u00e4valenz \u00a0bei\u00a0den\u00a0Neueinf\u00fchrungen \u00a0wie\u00a0auch\u00a0schon\u00a0in\u00a0den\u00a0\nJahren\u00a0zuvor\u00a0regionale \u00a0Differenzen: \u00a0Die\u00a0Bundesl\u00e4nder \u00a0mit\u00a0einer\u00a0h\u00f6heren\u00a0H\u00e4ufigkeit \u00a0von\u00a0\nVerschreibungen \u00a0neuer\u00a0Arzneimittel \u00a0bilden\u00a0eine\u00a0Achse\u00a0vom\u00a0Nordosten \u00a0(Mecklenburg \u2010Vorpommern) \u00a0\nzum\u00a0s\u00fcdlichen \u00a0Westen\u00a0(Saarland), \u00a0w\u00e4hrend\u00a0der\u00a0Nordwesten \u00a0die\u00a0niedrigste \u00a0Verordnungspr\u00e4valenz \u00a0\naufweist\u00a0(Abbildung \u00a02).\u00a0Die\u00a0dargestellten \u00a0Zahlen\u00a0geben\u00a0die\u00a0Verordnungsanteile \u00a0der\u00a0TK\u2010Versicherten \u00a0\n(je\u00a0Tausend\u00a0Versicherte) \u00a0im\u00a0Vergleich \u00a0zu\u00a0allen\u00a0TK\u2010Versicherten \u00a0des\u00a0jeweiligen \u00a0Bundeslandes \u00a0wieder.\u00a0\nDie\u00a0Gr\u00fcnde\u00a0f\u00fcr\u00a0solche\u00a0Differenzen \u00a0sind\u00a0im\u00a0Einzelnen \u00a0nicht\u00a0klar,\u00a0aus\u00a0fr\u00fcheren\u00a0Untersuchungen \u00a0sind\u00a0\ninsbesondere \u00a0Ost\u2010West\u2010Unterschiede \u00a0mit\u00a0kostenintensiver \u00a0Verordnung \u00a0in\u00a0den\u00a0ehemals\u00a0Neuen\u00a0\nBundesl\u00e4ndern \u00a0bekannt\u00a0(H\u00e4ussler \u00a0et\u00a0al.,\u00a02013).\u00a0\u00a0\nBei\u00a0f\u00fcnf\u00a0Wirkstoffen \u00a0lag\u00a0die\u00a0Verordnungspr\u00e4valenz \u00a0bei\u00a0\u00fcber\u00a010\u00a0je\u00a0100.000\u00a0Versicherte, \u00a0und\u00a0zwar\u00a0beim\u00a0\nCOPD\u2010Medikament \u00a0Aclidiniumbromid, \u00a0bei\u00a0Aflibercept \u00a0(u.a.\u00a0zur\u00a0Therapie\u00a0der\u00a0altersabh\u00e4ngigen \u00a0\nMakuladegeneration), \u00a0bei\u00a0dem\u00a0Antihypertonikum \u00a0Azilsartanmedoxomil, \u00a0bei\u00a0dem\u00a0oralen\u00a0Antidia\u2010\nbetikum\u00a0Dapagliflozin \u00a0sowie\u00a0bei\u00a0der\u00a0fixen\u00a0Wirkstoffkombination \u00a0Nomegestrolacetat \u00a0plus\u00a0Estradiol\u00a0als\u00a0\norales\u00a0Kontrazeptivum. \u00a0Im\u00a0August\u00a02013\u00a0erhielt\u00a0der\u00a0Wirkstoff \u00a0Aflibercept \u00a0die\u00a0Zulassungsweiterung \u00a0f\u00fcr\u00a0\ndie\u00a0Behandlung \u00a0einer\u00a0Visusbeeintr\u00e4chtigung \u00a0aufgrund\u00a0eines\u00a0Makula\u00f6dems \u00a0infolge\u00a0eines\u00a0retinalen\u00a0\nVenenverschlusses \u00a0oder\u00a0Zentralvenenverschlusses. \u00a0Diese\u00a0Zulassungserweiterung \u00a0wirkte\u00a0sich\u00a0\nvermutlich \u00a0auf\u00a0den\u00a0Umsatz\u00a0bzw.\u00a0die\u00a0Verordnungspr\u00e4valenz \u00a0aus.\u00a0\u00a0\nIm\u00a0Mittel\u00a0waren\u00a0TK\u2010Versicherte \u00a0mit\u00a0der\u00a0Verordnung \u00a0eines\u00a0neuen\u00a0Arzneimittels \u00a055,3\u00a0Jahre\u00a0alt\u00a0\n(Vorjahresinnovation: \u00a056,7\u00a0Jahre)\u00a0und\u00a0bei\u00a0einem\u00a0Anteil\u00a0von\u00a052,2\u00a0Prozent\u00a0eher\u00a0weiblich,\u00a0bedingt\u00a0durch\u00a0\ndie\u00a0beiden\u00a0Hormonpr\u00e4parate \u00a0Zoely\u00ae\u00a0und\u00a0Naemis\u00ae\u00a0(Nomegestrolacetat \u00a0+\u00a0Estradiol), \u00a0die\u00a0ausschlie\u00dflich \u00a0\nan\u00a0Frauen\u00a0verordnet \u00a0wurden.\u00a0\u00a0 \u00a0 \n28\u00a0 \n \nInnovationsreport 2015 \u00a0\n\u00a0\nAbbildung \u00a02:\u00a0Verordnungspr\u00e4valenz \u00a0der\u00a0neuen\u00a0Wirkstoffe \u00a0in\u00a0Promille\u00a0nach\u00a0Bundesl\u00e4ndern \u00a0(nur\u00a0Verord\u2010\nnungen\u00a0im\u00a0Jahr\u00a02013)\u00a0bezogen\u00a0auf\u00a0die\u00a0Versicherten \u00a0der\u00a0TK\u00a0\n\u00a0\n \u00a0\n \n29\u00a0\n \nInnovationsreport 2015 \u00a0 Wirkstoff \u00a0 Anz.\u00a0Versicherte \u00a0Pr\u00e4valenz \u00a0je\u00a0\n100.000\u00a0Vers.\u00a0Alter\nMittelwert \u00a0Anteil\u00a0weiblich\u00a0\nAclidiniumbromid \u00a0 5.206\u00a0 61,5\u00a0 64,5\u00a0 42,40%\u00a0\nAflibercept \u00a0 1.179\u00a0 13,9\u00a0 75,3\u00a0 48,30%\u00a0\nAxitinib\u00a0 84\u00a0 1\u00a0 67,4\u00a0 15,50%\u00a0\nAzilsartanmedoxomil \u00a0 1.245\u00a0 14,7\u00a0 62,1\u00a0 41,60%\u00a0\nBrentuximabvedotin \u00a0(O)\u00a0 18\u00a0 0,2\u00a0 52,8\u00a0 22,20%\u00a0\nCrizotinib \u00a0 30\u00a0 0,4\u00a0 57,6\u00a0 56,70%\u00a0\nDapagliflozin \u00a0 2.926\u00a0 34,6\u00a0 59,8\u00a0 35,30%\u00a0\nDecitabin \u00a0(O)\u00a0 50\u00a0 0,6\u00a0 74,9\u00a0 30,00%\u00a0\nIvacaftor\u00a0(O)\u00a0 8\u00a0 0,1\u00a0 23,5\u00a0 37,50%\u00a0\nNomegestrolacetat \u00a0+\u00a0\u00a0\nEstradiol\u00a0\n(orale\u00a0Kontrazeption) \u00a02.423\u00a0 28,6\u00a0 18,7\u00a0 99,90%\u00a0\nNomegestrolacetat \u00a0+\u00a0\u00a0\nEstradiol\u00a0\n(Hormontherapie) \u00a0312\u00a0 3,7\u00a0 48,8\u00a0\u00a0 100,00%\u00a0\nPasireotid \u00a0(O)\u00a0 17\u00a0 0,2\u00a0 50,9\u00a0 76,50%\u00a0\nPerampanel \u00a0 321\u00a0 3,8\u00a0 35,2\u00a0 49,50%\u00a0\nPixantron \u00a0 9\u00a0 0,1\u00a0 63,4\u00a0 44,40%\u00a0\nRilpivirin\u00a0 34\u00a0 0,4\u00a0 46,7\u00a0 11,80%\u00a0\nRuxolitinib \u00a0(O)\u00a0 214\u00a0 2,5\u00a0 66,7\u00a0 36,00%\u00a0\nTegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0\nOteracil\u00a019\u00a0 0,2\u00a0 62,8\u00a0 47,40%\u00a0\nVandetanib \u00a0 16\u00a0 0,2\u00a0 57,2\u00a0 18,80%\u00a0\nVemurafenib \u00a0 120\u00a0 1,4\u00a0 58,6\u00a0 45,00%\u00a0\nGesamt\u00a0 14.231*\u00a0 168\u00a0 55,3\u00a0 52,20%\u00a0\u00a0\n*)\u00a0Doppelz\u00e4hlung \u00a0von\u00a0Versicherten \u00a0mit\u00a0Verordnung \u00a0in\u00a02013\u00a0(Einfachz\u00e4hlung: \u00a0n=\u00a014.202\u00a0in\u00a02013)\u00a0\nTabelle\u00a07:\u00a0Anzahl,\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0der\u00a0Versicherten \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0der\u00a0neuen\u00a0\nWirkstoffe \u00a0(Daten\u00a0aus\u00a0dem\u00a0Jahr\u00a02013)\u00a0\u00a0 \n30\u00a0 \n \nInnovationsreport 2015 \u00a0 4 Wirkstoffportr\u00e4ts \u00a0mit\u00a0Versorgungsanalysen \u00a0\nDaniela\u00a0Boeschen, \u00a0D\u00f6rte\u00a0Fuchs,\u00a0Judith\u00a0G\u00fcnther\u00a0\n4.1 Aclidiniumbromid \u00a0\nHandelsname: \u00a0Bretaris\u00ae\u00a0Genuair\u00ae, \u00a0Eklira\u00ae\u00a0Genuair\u00ae\u00a0u.a.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Hersteller: \u00a0Berlin\u2010Chemie/Menarini \u00a0u.a.\u00a0\nIndikation: \u00a0COPD\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Markteinf\u00fchrung: \u00a0Oktober\u00a02012\u00a0\nATC\u2010Code:\u00a0R03BB05\u00a0 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DDD:\u00a00,644\u00a0mg\u00a0\nDarreichungsform: \u00a0Pulver\u00a0zur\u00a0Inhalation \u00a0\nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0158\u00a0\nBewertung \u00a0\nAclidiniumbromid \u00a0ist\u00a0neben\u00a0Tiotropiumbromid \u00a0ein\u00a0weiterer\u00a0Vertreter \u00a0der\u00a0langwirkenden \u00a0Muscarin \u2010\nRezeptorantagonisten \u00a0und\u00a0als\u00a0Pulverinhalat \u00a0zugelassen \u00a0zur\u00a0symptomatischen \u00a0bronchodilatatorischen \u00a0\nDauertherapie \u00a0der\u00a0COPD.\u00a0Als\u00a0Monotherapeutikum \u00a0wie\u00a0auch\u00a0als\u00a0fixe\u00a0Kombination \u00a0mit\u00a0Formoterol \u00a0\nwird\u00a0der\u00a0Wirkstoff \u00a0sowohl\u00a0von\u00a0Berlin\u2010Chemie/Menarini \u00a0als\u00a0Monopr\u00e4parat \u00a0Bretaris\u00ae\u00a0Genuair\u00ae\u00a0und\u00a0\nFixkombination \u00a0Brimica\u00ae\u00a0Genuair\u00ae\u00a0als\u00a0auch\u00a0von\u00a0AstraZeneca \u00a0als\u00a0Monopr\u00e4parat \u00a0Eklira\u00ae\u00a0Genuair\u00ae\u00a0und\u00a0\nFixkombination \u00a0Duaklir\u00ae\u00a0Genuair\u00ae\u00a0vertrieben. \u00a0Da\u00a0die\u00a0einmal\u00a0t\u00e4gliche\u00a0Dosierung \u00a0keine\u00a0klinisch\u00a0\nrelevante \u00a0Wirkung\u00a0zeigte,\u00a0muss\u00a0Aclidiniumbromid \u00a0\u2013\u00a0im\u00a0Gegensatz \u00a0zu\u00a0dem\u00a0chemisch \u00a0\u00e4hnlichen \u00a0\nTiotropiumbromid \u00a0\u2013\u00a0zweimal\u00a0t\u00e4glich\u00a0inhaliert\u00a0werden.\u00a0\u00a0\nPrim\u00e4rer\u00a0Endpunkt \u00a0der\u00a0zulassungsrelevanten \u00a0ATTAIN\u2010Studie\u00a0war\u00a0die\u00a0\u00c4nderung \u00a0der\u00a0morgens\u00a0vor\u00a0der\u00a0\nAnwendung \u00a0gemessenen \u00a0FEV1\u00a0nach\u00a024\u00a0Wochen\u00a0gegen\u00fcber \u00a0dem\u00a0Ausgangswert. \u00a0Die\u00a0Differenz\u00a0von\u00a0\n128\u00a0ml\u00a0(2\u00a0x\u00a0t\u00e4glich\u00a0400\u00a0\u00b5g\u00a0Aclidiniumbromid \u00a0vs.\u00a0Placebo)\u00a0wurde\u00a0als\u00a0signifikant \u00a0eingestuft. \u00a0Dieses\u00a0\nErgebnis\u00a0wurde\u00a0von\u00a0einer\u00a0weiteren\u00a0Studie\u00a0(ACCORD) \u00a0best\u00e4tigt. \u00a0Hier\u00a0verringerte \u00a0Aclidiniumbromid \u00a0\nau\u00dferdem \u00a0fr\u00fchmorgendliche \u00a0Symptome \u00a0der\u00a0Kurzatmigkeit \u00a0in\u00a0der\u00a0ersten\u00a0Stunde\u00a0nach\u00a0dem\u00a0Aufstehen. \u00a0\nAuch\u00a0waren\u00a0n\u00e4chtliche \u00a0Symptome \u00a0wie\u00a0Dyspnoe, \u00a0Husten,\u00a0Auswurf\u00a0oder\u00a0Keuchen\u00a0signifikant \u00a0seltener.\u00a0\nMittlerweile \u00a0liegen\u00a0klinische\u00a0Studien\u00a0vor,\u00a0die\u00a0die\u00a0Wirkung\u00a0von\u00a0Aclidiniumbromid \u00a0auf\u00a0die\u00a0\nLungenfunktion \u00a0im\u00a0Vergleich \u00a0zu\u00a0Placebo\u00a0und\u00a0Tiotropiumbromid \u00a0gepr\u00fcft\u00a0haben.\u00a0Im\u00a0Direktvergleich \u00a0\nmit\u00a0Tiotropiumbromid \u00a0(18\u00a0\u00b5g\u00a0einmal\u00a0t\u00e4glich)\u00a0waren\u00a0die\u00a0bronchodilatatorischen \u00a0Effekte\u00a0der\u00a0beiden\u00a0\nWirkstoffe \u00a0\u00e4hnlich\u00a0gut.\u00a0Die\u00a0n\u00e4chtliche \u00a0Lungenfunktion \u00a0konnte\u00a0unter\u00a0Aclidiniumbromid \u00a0nur\u00a0numerisch \u00a0\nverbessert \u00a0werden.\u00a0Studien\u00a0mit\u00a0einer\u00a0gr\u00f6\u00dferen\u00a0Patientenzahl \u00a0sowie\u00a0l\u00e4ngerer\u00a0Dauer\u00a0werden\u00a0ben\u00f6tigt,\u00a0\num\u00a0diesen\u00a0Effekt\u00a0gegebenenfalls \u00a0auch\u00a0statistisch \u00a0zu\u00a0erh\u00e4rten. \u00a0\nH\u00e4ufigste \u00a0Nebenwirkungen \u00a0unter\u00a0Aclidiniumbromid \u00a0sind\u00a0\u2013\u00a0neben\u00a0den\u00a0typischen \u00a0anticholinergen \u00a0\nNebenwirkungen \u00a0wie\u00a0trockener \u00a0Mund,\u00a0verschwommenes \u00a0Sehen\u00a0und\u00a0Harnverhalten \u00a0\u2013\u00a0Kopf\u2010\nschmerzen, \u00a0Nasopharyngitis \u00a0und\u00a0Durchf\u00e4lle. \u00a0Patienten \u00a0mit\u00a0akuten\u00a0oder\u00a0schweren \u00a0Herzerkrankungen, \u00a0\nwie\u00a0beispielsweise \u00a0instabile\u00a0Angina\u00a0pectoris\u00a0oder\u00a0Myokardinfarkt \u00a0in\u00a0der\u00a0Anamnese, \u00a0wird\u00a0geraten,\u00a0\nAclidiniumbromid \u00a0nur\u00a0mit\u00a0Vorsicht\u00a0anzuwenden, \u00a0da\u00a0keine\u00a0Erfahrungen \u00a0f\u00fcr\u00a0dieses\u00a0Patientenkollektiv \u00a0\nvorliegen \u00a0und\u00a0der\u00a0anticholinerge \u00a0Wirkmechanismus \u00a0negative\u00a0Auswirkungen \u00a0auf\u00a0diese\u00a0Erkrankungen \u00a0\nhaben\u00a0kann.\u00a0\u00a0\nIm\u00a0Vergleich \u00a0zu\u00a0anderen\u00a0inhalativen \u00a0Bronchodilatatoren \u00a0konstatierte \u00a0der\u00a0G\u2010BA\u00a0in\u00a0seinem\u00a0Beschluss \u00a0\nvom\u00a021.03.2013 \u00a0f\u00fcr\u00a0den\u00a0Wirkstoff \u00a0Aclidiniumbromid \u00a0keinen\u00a0Zusatznutzen \u00a0gegen\u00fcber \u00a0langwirkenden \u00a0\n\u03b2\u20102\u2010Sympathomimetika \u00a0oder\u00a0dem\u00a0langwirkenden \u00a0Anticholinergikum \u00a0Tiotropiumbromid. \u00a0In\u00a0seinem\u00a0\nDossier\u00a0legte\u00a0der\u00a0pU\u00a0keine\u00a0belastbaren \u00a0Ergebnisse \u00a0vor.\u00a0So\u00a0fehlten\u00a0f\u00fcr\u00a0den\u00a0direkten\u00a0Vergleich \u00a0Studien\u00a0 \n31\u00a0\n \nInnovationsreport 2015 \u00a0mit\u00a0einer\u00a0ausreichenden \u00a0Studiendauer, \u00a0der\u00a0indirekte\u00a0Vergleich \u00a0lie\u00df\u00a0hingegen\u00a0keine\u00a0valide\u00a0Bewertung \u00a0\ndes\u00a0Zusatznutzens \u00a0aufgrund\u00a0mangelhafter \u00a0Qualit\u00e4t\u00a0zu.\u00a0\n\u00a0\nVerf\u00fcgbare \u00a0Therapien \u00a0\n\u00a0(Zusatz\u2010)Nutzen\n\u00a0Kosten\n\u00a0\n Weiterer\u00a0langwirkender \u00a0\nMuscarin \u2010Rezeptorantagonist \u00a0\nzur\u00a0bronchodilatatorischen \u00a0\nDauertherapie \u00a0der\u00a0COPD\u00a0\u00a0 Nach\u00a0derzeitiger \u00a0Studienlage \u00a0kein\u00a0\nZusatznutzen \u00a0gegen\u00fcber \u00a0bereits\u00a0\nbestehenden \u00a0Therapien \u00a0ersichtlich \u00a0In\u00a0den\u00a0meisten\u00a0F\u00e4llen\u00a0deutlich\u00a0\nteurer\u00a0als\u00a0Vergleichstherapie \u00a0\n(Ausnahme: \u00a0im\u00a0Vergleich \u00a0zu\u00a0\nTiotropiumbromid \u00a0g\u00fcnstiger) \u00a0\n \u00a0 \u00a0\u00a0 \u00a0\n\u00a0\n   \nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien: \u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen:\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien\u00a0\nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0\nC\u00a0 Variante\u00a0ohne\u00a0besonderen \u00a0Stellenwert \u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nDie\u00a0Verordnungszahlen \u00a0des\u00a0langwirkenden \u00a0Muscarin \u2010Rezeptorantagonisten \u00a0Aclidiniumbromid \u00a0\n(Bretaris\u00ae \u00a0Genuair\u00ae, \u00a0Eklira\u00ae\u00a0Genuair\u00ae) \u00a0stiegen\u00a0bei\u00a0der\u00a0TK\u00a0nach\u00a0der\u00a0Markteinf\u00fchrung \u00a0konstant\u00a0an\u00a0und\u00a0\nerreichten \u00a0im\u00a0Oktober\u00a02013\u00a0mit\u00a0ca.\u00a01.300\u00a0Packungen \u00a0ihren\u00a0H\u00f6hepunkt \u00a0(Abbildung \u00a03).\u00a0Das\u00a0ver\u00e4nderte \u00a0\nVerordnungsverhalten \u00a0hinsichtlich \u00a0der\u00a0Packungsgr\u00f6\u00dfen \u00a0l\u00e4sst\u00a0sich\u00a0mit\u00a0einer\u00a0\u00c4nderung \u00a0der\u00a0\nNormgr\u00f6\u00dfen \u00a0zum\u00a001.07.2013 \u00a0erkl\u00e4ren.\u00a0Der\u00a0Erkrankung \u00a0COPD\u00a0entsprechend \u00a0waren\u00a0es\u00a0Versicherte \u00a0\nzwischen\u00a050\u00a0und\u00a080\u00a0Jahren,\u00a0die\u00a0dieses\u00a0Atemwegsmedikament \u00a0erhielten. \u00a0Zum\u00a0gr\u00f6\u00dften\u00a0Teil\u00a0handelte\u00a0\nes\u00a0sich\u00a0dabei\u00a0um\u00a0M\u00e4nner\u00a0(Abbildung \u00a04).\u00a0Das\u00a0Umsatzmaximum \u00a0pro\u00a0Monat\u00a0lag\u00a0bei\u00a0ca.\u00a0140.000\u00a0Euro\u00a0\n(Abbildung \u00a05).\u00a0\n\u00a0\u00a0\n \n32\u00a0\n \n \nInnovationsreport 2015 \u00a0\n\u00a0\nAbbildung \u00a03:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Aclidiniumbromid \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u2010\n2013)\u00a0\n\u00a0\n\u00a0\nAbbildung \u00a04:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Aclidiniumbromid \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0\n(2013)\u00a0\u00a0\n \n33\u00a0\n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a05:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Aclidiniumbromid \u00a0nach\u00a0Monaten \u00a0\n(2012\u20102013)\u00a0\n \u00a0\n \n34\u00a0 \n \nInnovationsreport 2015 \u00a0 4.2 Aflibercept \u00a0\nHandelsname: \u00a0Eylea\u00ae       Hersteller: \u00a0Bayer \nIndikation: \u00a0AMD,\u00a0Makula\u00f6dem \u00a0 \u00a0\u00a0\u00a0 Markteinf\u00fchrung: \u00a0Dezember \u00a02012 \nATC\u2010Code:\u00a0S01LA05\u00a0     DDD:\u00a00,018\u00a0DE \nDarreichungsform: \u00a0Injektionsl\u00f6sung  \nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0163\u00a0\nBewertung \u00a0\nMit\u00a0Aflibercept \u00a0ist\u00a0ein\u00a0weiterer\u00a0Hemmstoff \u00a0des\u00a0vaskul\u00e4ren \u00a0endothelialen \u00a0Wachstumsfaktors \u00a0(VEGF)\u00a0in\u00a0\nder\u00a0Ophthalmologie \u00a0verf\u00fcgbar \u00a0und\u00a0nach\u00a0seiner\u00a0Markteinf\u00fchrung \u00a0mittlerweile \u00a0zugelassen \u00a0zur\u00a0\nBehandlung \u00a0der\u00a0neovaskul\u00e4ren \u00a0(feuchten) \u00a0altersbedingten \u00a0Makuladegeneration, \u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0\neiner\u00a0Visusbeeintr\u00e4chtigung \u00a0aufgrund\u00a0eines\u00a0Makula\u00f6dems \u00a0infolge\u00a0eines\u00a0retinalen\u00a0Venenverschlusses \u00a0\nbzw.\u00a0infolge\u00a0eines\u00a0Zentralvenenverschlusses \u00a0sowie\u00a0zur\u00a0Therapie\u00a0einer\u00a0Visusbeeintr\u00e4chtigung \u00a0\naufgrund\u00a0eines\u00a0diabetischen \u00a0Makula\u00f6dems. \u00a0Aflibercept \u00a0wird\u00a0als\u00a0intravitreale \u00a0Injektion\u00a0angewendet, \u00a0\ndas\u00a0Behandlungsintervall \u00a0richtet\u00a0sich\u00a0nach\u00a0der\u00a0jeweiligen \u00a0Erkrankung. \u00a0\nAufgrund \u00a0der\u00a0Indikationserweiterungen \u00a0kurz\u00a0nach\u00a0Markteinf\u00fchrung \u00a0von\u00a0Aflibercept \u00a0liegen\u00a0\nmittlerweile \u00a0mehrere\u00a0kontrollierte \u00a0klinische\u00a0Studien\u00a0f\u00fcr\u00a0verschiedene \u00a0Indikationsgebiete \u00a0vor,\u00a0die\u00a0die\u00a0\nWirksamkeit \u00a0und\u00a0Sicherheit \u00a0des\u00a0neuen\u00a0VEGF\u2010Hemmmers \u00a0untersuchten. \u00a0\u00a0\nZulassungsrelevant \u00a0f\u00fcr\u00a0die\u00a0Indikation \u00a0der\u00a0AMD\u00a0waren\u00a0zwei\u00a0aktiv\u00a0kontrollierte \u00a0klinische\u00a0Phase\u2010III\u2010\nStudien\u00a0(VIEW\u00a01\u00a0und\u00a0VIEW\u00a02).\u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0war\u00a0die\u00a0Nicht\u2010Unterlegenheit \u00a0des\u00a0Aflibercept \u2010\nRegimes\u00a0im\u00a0Vergleich \u00a0zu\u00a0Ranibizumab \u00a0gemessen \u00a0am\u00a0Anteil\u00a0der\u00a0Patienten \u00a0mit\u00a0erhaltener \u00a0Sehsch\u00e4rfe \u00a0\n(weniger\u00a0als\u00a015\u00a0EDTRS\u2010Buchstaben, \u00a0Early\u00a0Treatment \u00a0Diabetic\u00a0Retinopathy \u00a0Study\u00a0Lesetafel ,\u00a0im\u00a0\nVergleich \u00a0zum\u00a0Ausgangswert). \u00a0Sowohl\u00a0in\u00a0VIEW\u00a01\u00a0als\u00a0auch\u00a0in\u00a0VIEW\u00a02\u00a0entsprachen \u00a0alle\u00a0drei\u00a0\nDosierungsregime \u00a0von\u00a0Aflibercept \u00a0klinisch\u00a0der\u00a0Wirksamkeit \u00a0von\u00a0Ranibizumab \u00a0(95,1\u201096,3\u00a0Prozent\u00a0vs.\u00a0\n94,4\u00a0Prozent).\u00a0Aus\u00a0den\u00a0Zulassungsstudien \u00a0geht\u00a0allerdings \u00a0nicht\u00a0eindeutig \u00a0hervor,\u00a0welches\u00a0das\u00a0\ng\u00fcnstigere \u00a0Therapieschema \u00a0von\u00a0Aflibercept \u00a0f\u00fcr\u00a0Patienten \u00a0darstellt.\u00a0Die\u00a0Gabe\u00a0des\u00a0Wirkstoffes \u00a0nur\u00a0alle\u00a0\nzwei\u00a0Monate\u00a0hat\u00a0letztendlich \u00a0den\u00a0Vorteil\u00a0der\u00a0selteneren \u00a0Injektion. \u00a0Auch\u00a0wurde\u00a0Ranibizumab \u00a0in\u00a0den\u00a0\nbeiden\u00a0Studien\u00a0nicht\u00a0gem\u00e4\u00df\u00a0seiner\u00a0Zulassung \u00a0\u2013\u00a0n\u00e4mlich\u00a0bedarfsadaptiert \u00a0\u2013\u00a0eingesetzt. \u00a0Die\u00a0\nzweimonatliche \u00a0Gabe\u00a0von\u00a0Aflibercept \u00a0ist\u00a0zwar\u00a0genauso\u00a0wirksam\u00a0wie\u00a0die\u00a0monatliche \u00a0Gabe\u00a0von\u00a0\nRanibizumab, \u00a0dennoch\u00a0besteht\u00a0die\u00a0M\u00f6glichkeit \u00a0einer\u00a0k\u00fcrzeren\u00a0Therapiedauer \u00a0durch\u00a0Anwendung \u00a0des\u00a0\nletztgenannten \u00a0VEGF\u2010Hemmers. \u00a0Der\u00a0vermeintliche \u00a0Vorteil\u00a0Aflibercepts \u00a0gegen\u00fcber \u00a0Ranibizumab \u00a0kann\u00a0\nsomit\u00a0nicht\u00a0als\u00a0therapeutisch \u00a0relevanter \u00a0Vorteil\u00a0angebracht \u00a0werden,\u00a0da\u00a0Ranibizumab \u00a0aufgrund\u00a0der\u00a0\nFestlegungen \u00a0im\u00a0Studienprotokoll \u00a0h\u00e4ufiger\u00a0als\u00a0im\u00a0klinischen \u00a0Alltag\u00a0und\u00a0laut\u00a0Zulassung \u00a0\u00fcblich\u00a0injiziert\u00a0\nwurde.\u00a0\u00a0\nWirksamkeit \u00a0und\u00a0Sicherheit \u00a0von\u00a0Aflibercept \u00a0zur\u00a0Therapie\u00a0eines\u00a0Makula\u00f6dems \u00a0infolge\u00a0eines\u00a0retinalen\u00a0\nZentralverschlusses \u00a0wurden\u00a0in\u00a0zwei\u00a0doppelblinden \u00a0kontrollierten \u00a0Studien\u00a0aufgezeigt. \u00a0Prim\u00e4rer\u00a0\nEndpunkt \u00a0in\u00a0der\u00a0COPERNICUS \u2010Studie\u00a0war\u00a0der\u00a0Anteil\u00a0an\u00a0Patienten \u00a0mit\u00a0einer\u00a0Verbesserung \u00a0der\u00a0\nSehsch\u00e4rfe \u00a0um\u00a0\u2265 \u00a015\u00a0Buchstaben \u00a0nach\u00a024\u00a0Wochen.\u00a0Sekund\u00e4re \u00a0Endpunkte \u00a0waren\u00a0Morbidit\u00e4t, \u00a0\ngesundheitsbezogene \u00a0Lebensqualit\u00e4t \u00a0und\u00a0unerw\u00fcnschte \u00a0Ereignisse. \u00a0Ein\u00a0vergleichbares \u00a0Studiendesign \u00a0\nwies\u00a0auch\u00a0die\u00a0GALILEO\u2010Studie\u00a0auf,\u00a0die\u00a0die\u00a0Ergebnisse \u00a0der\u00a0COPERNICUS \u2010Studie\u00a0best\u00e4tigte. \u00a0Zwar\u00a0erwies\u00a0\nsich\u00a0die\u00a0Verbesserung \u00a0der\u00a0Sehsch\u00e4rfe \u00a0in\u00a0beiden\u00a0Studien\u00a0als\u00a0signifikant \u00a0im\u00a0Vergleich \u00a0zur\u00a0\nScheinmedikation, \u00a0aber\u00a0auch\u00a0in\u00a0diesen\u00a0Studien\u00a0wurde\u00a0Aflibercept \u00a0nicht\u00a0zulassungsgem\u00e4\u00df \u00a0eingesetzt. \u00a0\u00a0 \n35\u00a0\n \nInnovationsreport 2015 \u00a0Im\u00a0Gegensatz \u00a0zur\u00a0Anwendung \u00a0laut\u00a0Fachinformation \u00a0sahen\u00a0die\u00a0Behandlungsregime \u00a0der\u00a0ersten\u00a0\nBehandlungsphase \u00a0der\u00a0beiden\u00a0Studien\u00a0sechs\u00a0intravitreale \u00a0Injektionen \u00a0mit\u00a0der\u00a0jeweiligen \u00a0\nStudienmedikation \u00a0bis\u00a0einschlie\u00dflich \u00a0Woche\u00a020\u00a0als\u00a0fest\u00a0eingeplant \u00a0vor.\u00a0In\u00a0dieser\u00a0Studienphase \u00a0wurde\u00a0\neine\u00a0Weiterbehandlung \u00a0nicht\u00a0vom\u00a0Therapieverlauf \u00a0des\u00a0individuellen \u00a0Patienten \u00a0abh\u00e4ngig\u00a0gemacht. \u00a0\nErgebnisse \u00a0von\u00a0Post\u2010hoc\u2010Analysen\u00a0zeigten\u00a0jedoch,\u00a0dass\u00a0sowohl\u00a0in\u00a0Einzel\u2010\u00a0als\u00a0auch\u00a0in\u00a0gepoolten \u00a0\nAnalysen\u00a0zu\u00a0den\u00a0beiden\u00a0Zulassungsstudien \u00a0die\u00a0Therapieantwort \u00a0(Response )\u00a0bereits\u00a0um\u00a0den\u00a0dritten\u00a0\nMonat\u00a0herum\u00a0ein\u00a0Plateau\u00a0erreicht.\u00a0\u00a0\nBei\u00a0den\u00a0f\u00fcr\u00a0die\u00a0Zulassung \u00a0zur\u00a0Behandlung \u00a0der\u00a0Visusbeeintr\u00e4chtigung \u00a0infolge\u00a0eines\u00a0diabetischen \u00a0\nMakula\u00f6dems \u00a0entscheidenden \u00a0Studien\u00a0VISTA\u00a0und\u00a0VIVID\u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0einen\u00a0Head\u2010to\u2010Head\u2010\nVergleich \u00a0zwischen\u00a0Aflibercept \u00a0oder\u00a0einer\u00a0Laserfotokoagulation. \u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0der\u00a0Studien\u00a0war\u00a0\ndie\u00a0Ver\u00e4nderung \u00a0der\u00a0bestkorrigierten \u00a0Sehsch\u00e4rfe \u00a0nach\u00a0einem\u00a0Jahr\u00a0(52\u00a0Wochen). \u00a0In\u00a0beiden\u00a0Studien\u00a0\nerwies\u00a0sich\u00a0die\u00a0intravitreale \u00a0Injektion\u00a0mit\u00a0Aflibercept \u00a0(beide\u00a0Dosisregime) \u00a0nach\u00a052\u00a0Wochen\u00a0als\u00a0\n\u00fcberlegen \u00a0bei\u00a0den\u00a0Wirksamkeitsendpunkten \u00a0gegen\u00fcber \u00a0der\u00a0Lasertherapie. \u00a0Bei\u00a0den\u00a0135\u00a0Teilnehmern \u00a0\nin\u00a0der\u00a0VIVID\u2010Studie,\u00a0die\u00a0je\u00a0eine\u00a0Aflibercept \u2010Injektion\u00a0alle\u00a0acht\u00a0Wochen\u00a0nach\u00a0einer\u00a0initialen\u00a0\nBehandlung \u00a0mit\u00a0f\u00fcnf\u00a0monatlichen \u00a0Dosen\u00a0erhalten\u00a0hatten,\u00a0wurde\u00a0nach\u00a0einem\u00a0Jahr\u00a0ein\u00a0\ndurchschnittlicher \u00a0Gewinn\u00a0von\u00a010,7\u00a0Buchstaben \u00a0beobachtet. \u00a0Die\u00a0132\u00a0Patienten \u00a0in\u00a0der\u00a0\nVergleichsgruppe \u00a0mit\u00a0Lasertherapie \u00a0hatten\u00a0dagegen\u00a0lediglich\u00a0eine\u00a0durchschnittliche \u00a0Ver\u00e4nderung \u00a0bei\u00a0\nder\u00a0bestkorrigierten \u00a0Sehsch\u00e4rfe \u00a0von\u00a01,2\u00a0Buchstaben \u00a0erreicht.\u00a0Auch\u00a0konnte\u00a0ungef\u00e4hr\u00a0ein\u00a0Drittel\u00a0der\u00a0\nPatienten \u00a0in\u00a0der\u00a0VIVID\u2010Studie\u00a0unter\u00a0der\u00a0Therapie\u00a0mit\u00a0Aflibercept \u00a02\u00a0mg\u00a0alle\u00a0zwei\u00a0Monate\u00a0einen\u00a0\nGewinn\u00a0von\u00a015\u00a0Buchstaben \u00a0verbuchen. \u00a0Dagegen\u00a0waren\u00a0es\u00a0unter\u00a0der\u00a0Laser\u2010Behandlung \u00a0nur\u00a09,1\u00a0\nProzent\u00a0der\u00a0Patienten. \u00a0In\u00a0der\u00a0VISTA\u2010Studie\u00a0erzielten\u00a0die\u00a0Patienten \u00a0mit\u00a0allen\u00a0drei\u00a0Therapieregimen \u00a0\n(Aflibercept \u00a0bzw.\u00a0Laserkoagulation) \u00a0vergleichbare \u00a0Ergebnisse \u00a0wie\u00a0in\u00a0der\u00a0VIVID\u2010Studie.\u00a0\nSchwerwiegende \u00a0Nebenwirkungen, \u00a0die\u00a0mit\u00a0dem\u00a0Injektionsverfahren \u00a0in\u00a0Zusammenhang \u00a0standen,\u00a0\ntraten\u00a0nach\u00a0Angabe\u00a0des\u00a0pU\u00a0bei\u00a0weniger\u00a0als\u00a01\u00a0von\u00a02.200\u00a0IVT\u2010Injektionen \u00a0auf.\u00a0Zu\u00a0diesen\u00a0z\u00e4hlten\u00a0\nErblindung, \u00a0Endophthalmitis, \u00a0Netzhautabl\u00f6sung, \u00a0traumatischer \u00a0Katarakt,\u00a0Glask\u00f6rperblutung, \u00a0\nGlask\u00f6rperabhebung \u00a0und\u00a0erh\u00f6hter\u00a0Augeninnendruck. \u00a0Arterielle \u00a0thromboembolische \u00a0Ereignisse \u00a0sind\u00a0\nebenfalls\u00a0Nebenwirkungen, \u00a0die\u00a0eventuell \u00a0mit\u00a0der\u00a0systemischen \u00a0VEGF\u2010Hemmung \u00a0in\u00a0Verbindung \u00a0\nstehen,\u00a0wodurch\u00a0das\u00a0theoretische \u00a0Risiko\u00a0arterieller \u00a0thromboembolischer \u00a0Ereignisse \u00a0nach\u00a0IVT\u2010\nInjektion\u00a0von\u00a0VEGF\u2010Hemmern \u00a0besteht.\u00a0Da\u00a0es\u00a0sich\u00a0bei\u00a0Aflibercept \u00a0um\u00a0ein\u00a0rekombinantes \u00a0\nFusionsprotein \u00a0aus\u00a0extrazellul\u00e4ren \u00a0Anteilen\u00a0der\u00a0VEGF\u2010Rezeptoren \u00a0und\u00a0dem\u00a0Fc\u2010Fragment \u00a0von\u00a0\nhumanem \u00a0IgG1\u00a0handelt,\u00a0besitzt\u00a0das\u00a0Arzneimittel \u00a0auch\u00a0immunogene \u00a0Eigenschaften. \u00a0Schmerzen, \u00a0\nPhotophobie \u00a0oder\u00a0R\u00f6tung\u00a0k\u00f6nnen\u00a0als\u00a0klinische\u00a0Anzeichen \u00a0einer\u00a0\u00dcberempfindlichkeit \u00a0auftreten. \u00a0\u00a0\nIn\u00a0seiner\u00a0fr\u00fchen\u00a0Nutzenbewertung \u00a0konstatierte \u00a0der\u00a0G\u2010BA\u00a0f\u00fcr\u00a0die\u00a0Indikationen \u00a0\u201eAltersabh\u00e4ngige \u00a0\nMakuladegeneration\u201c \u00a0sowie\u00a0\u201eVisusbeeintr\u00e4chtigung \u00a0infolge\u00a0eines\u00a0diabetischen \u00a0Makula\u00f6dems\u201c \u00a0\nkeinen\u00a0Zusatznutzen \u00a0von\u00a0Aflibercept \u00a0gegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0Ranibizumab. \u00a0\nAuch\u00a0in\u00a0Bezug\u00a0auf\u00a0die\u00a0Anwendung \u00a0von\u00a0Aflibercept \u00a0bei\u00a0Erwachsenen \u00a0zur\u00a0Behandlung \u00a0einer\u00a0\n\u201eVisusbeeintr\u00e4chtigung \u00a0 aufgrund\u00a0 eines\u00a0 Makula\u00f6dems \u00a0 infolge\u00a0 eines\u00a0 retinalen\u00a0\nZentralvenenverschlusses \u00a0(ZVV)\u201c\u00a0urteilte\u00a0der\u00a0G\u2010BA\u00a0in\u00a0seinem\u00a0zweiten\u00a0Beschluss \u00a0f\u00fcr\u00a0diesen\u00a0Wirkstoff, \u00a0\ndass\u00a0ein\u00a0Zusatznutzen \u00a0gegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0Dexamethason \u00a0\n(intravitreales \u00a0Implantat) \u00a0oder\u00a0Ranibizumab \u00a0nicht\u00a0belegt\u00a0sei.\u00a0\n \u00a0 \n36\u00a0\n \n \nInnovationsreport 2015 \u00a0Verf\u00fcgbare \u00a0Therapien  \n\u00a0(Zusatz\u2010)Nutzen\n\u00a0Kosten\n\u00a0\n Weiterer\u00a0VEGF\u2010Inhibitor \u00a0 Keine\u00a0Verbesserung \u00a0hinsichtlich \u00a0\nbestehender \u00a0Therapien   \n  \n\u00a0\n\u00a0\u00a0  Im\u00a0Median\u00a0zwar\u00a0g\u00fcnstiger \u00a0als\u00a0\nbestehende \u00a0Therapie, \u00a0bei\u00a0\nFortbestehen \u00a0eines\u00a0stabilen\u00a0\nVerlaufsbefundes \u00a0nach\u00a0drei\u00a0\nInjektionen \u00a0allerdings \u00a0teurer\u00a0\nals\u00a0Ranibizumab \u00a0\n  \n\u00a0\n\u00a0\u00a0   \nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien: \u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen:\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien  \nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0\nB\u00a0(AMD)\u00a0 Variante\u00a0ohne\u00a0besonderen \u00a0Stellenwert \u00a0(AMD)\u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nDie\u00a0Verordnungszahlen \u00a0vom\u00a0VEGF\u2010Inhibitor\u00a0Aflibercept \u00a0(Eylea\u00ae)\u00a0stiegen\u00a0nach\u00a0der\u00a0Markteinf\u00fchrung \u00a0\nEnde\u00a02012\u00a0im\u00a0Oktober\u00a0des\u00a0darauffolgenden \u00a0Jahres\u00a0exponentiell \u00a0an\u00a0\u2013\u00a0vermutlich \u00a0infolge\u00a0der\u00a0\nZulassungserweiterung \u00a0auf\u00a0die\u00a0Indikation \u00a0\u201eVisusbeeintr\u00e4chtigung \u00a0aufgrund\u00a0eines\u00a0Makula\u00f6dems \u00a0\ninfolge\u00a0eines\u00a0retinalen\u00a0Venenverschlusses \u00a0oder\u00a0Zentralvenenverschluss\u201c \u00a0am\u00a026.\u00a0August\u00a02013\u00a0\n(Abbildung \u00a06).\u00a0Den\u00a0Indikationsgebieten \u00a0entsprechend \u00a0waren\u00a0die\u00a0Versicherten \u00a0mit\u00a0mindestens \u00a0einer\u00a0\nVerordnung \u00a0zum\u00a0gr\u00f6\u00dften\u00a0Teil\u00a0Erwachsene \u00a0zwischen\u00a070\u00a0und\u00a080\u00a0Jahren\u00a0(Abbildung \u00a07).\u00a0Aflibercept \u00a0\nerreichte\u00a0sein\u00a0Umsatzmaximum \u00a0im\u00a0Dezember \u00a02013,\u00a0dieser\u00a0lag\u00a0bei\u00a0ca.\u00a0850.000\u00a0Euro\u00a0(Abbildung \u00a08).\u00a0\u00a0\n \u00a0\n \n37\u00a0\n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a06:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Aflibercept \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0\n\u00a0\n \nAbbildung \u00a07:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Aflibercept \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0\n \u00a0\n \n38\u00a0\n \n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a08:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Aflibercept \u00a0nach\u00a0Monaten \u00a0(2012\u2010\n2013)\u00a0\n \u00a0\n \n39\u00a0\n \nInnovationsreport 2015 \u00a0 4.3 Axitinib\u00a0\nHandelsname: \u00a0Inlyta\u00ae\u00a0\u00a0\u00a0\u00a0\u00a0 Hersteller: \u00a0Pfizer\u00a0\nIndikation: \u00a0Nierenzellkarzinom \u00a0\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung: \u00a0Oktober\u00a02012\u00a0\nATC\u2010Code:\u00a0L01XE17\u00a0\u00a0\u00a0\u00a0\u00a0 DDD:\u00a010\u00a0mg\u00a0\nDarreichungsform: \u00a0Filmtablette \u00a0\nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0172\u00a0\nBewertung \u00a0\nAxitinib\u00a0ist\u00a0der\u00a0vierte\u00a0Vertreter \u00a0der\u00a0Tyrosinkinaseinhibitoren \u00a0zur\u00a0Zweitlinienbehandlung \u00a0des\u00a0\nfortgeschrittenen \u00a0Nierenzellkarzinoms. \u00a0Der\u00a0Wirkstoff \u00a0wird\u00a0oral\u00a0eingenommen. \u00a0\nPrim\u00e4rer\u00a0Endpunkt \u00a0der\u00a0Zulassungsstudie \u00a0(AXIS\u00a01032)\u00a0war\u00a0das\u00a0progressionsfreie \u00a0\u00dcberleben, \u00a0welches\u00a0\nin\u00a0der\u00a0Gesamtpopulation \u00a0um\u00a0zwei\u00a0Monate\u00a0(Median)\u00a0im\u00a0Vergleich \u00a0zu\u00a0Sorafenib \u00a0signifikant \u00a0verl\u00e4ngert \u00a0\nwerden\u00a0konnte,\u00a0wobei\u00a0dieser\u00a0Wert\u00a0in\u00a0den\u00a0Subgruppen \u00a0je\u00a0nach\u00a0Vorbehandlung \u00a0unterschiedlich \u00a0\nausfiel.\u00a0\u00a0\nBei\u00a0vier\u00a0Prozent\u00a0der\u00a0mit\u00a0Axitinib\u00a0und\u00a0bei\u00a0acht\u00a0Prozent\u00a0der\u00a0mit\u00a0Sorafenib \u00a0behandelten \u00a0Patienten \u00a0\nwurde\u00a0die\u00a0Therapie\u00a0wegen\u00a0toxischer\u00a0Nebenwirkungen \u00a0abgebrochen. \u00a0Die\u00a0h\u00e4ufigsten \u00a0Nebenwirkungen \u00a0\nvon\u00a0Axitinib\u00a0waren\u00a0Diarrhoe, \u00a0Hypertonie \u00a0und\u00a0Fatigue,\u00a0die\u00a0von\u00a0Sorafenib \u00a0Diarrhoe, \u00a0PPE\u00a0(Hand\u2010Fu\u00df\u2010\nSyndrom) \u00a0und\u00a0Alopezie.\u00a0In\u00a0der\u00a0Schweiz\u00a0warnte\u00a0Pfizer\u00a0in\u00a0Abstimmung \u00a0mit\u00a0der\u00a0dortigen\u00a0\nGesundheitsbeh\u00f6rde \u00a0vor\u00a0weiteren\u00a0Risiken:\u00a0Im\u00a0Zusammenhang \u00a0mit\u00a0der\u00a0Gabe\u00a0des\u00a0selektiven \u00a0\nTyrosinkinaseinhibitors \u00a0seien\u00a0kardiopulmonale \u00a0Ereignisse, \u00a0in\u00a0einigen\u00a0F\u00e4llen\u00a0mit\u00a0t\u00f6dlichem \u00a0Ausgang,\u00a0\naufgetreten \u00a0\u2013\u00a0unabh\u00e4ngig \u00a0von\u00a0einer\u00a0Herzerkrankung \u00a0in\u00a0der\u00a0Vorgeschichte. \u00a0\nDie\u00a0Nutzenbewertung \u00a0des\u00a0G\u2010BA\u00a0erfolgte\u00a0separat\u00a0f\u00fcr\u00a0zwei\u00a0Gruppen\u00a0von\u00a0Patienten \u00a0mit\u00a0\nfortgeschrittenem \u00a0Nierenzellkarzinom. \u00a0F\u00fcr\u00a0Patienten \u00a0nach\u00a0Versagen \u00a0einer\u00a0vorausgegangenen \u00a0\nTherapie\u00a0mit\u00a0einem\u00a0Zytokin\u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0einen\u00a0Hinweis\u00a0auf\u00a0einen\u00a0geringen\u00a0Zusatznutzen \u00a0von\u00a0\nAxitinib\u00a0gegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0Sorafenib. \u00a0In\u00a0der\u00a0Gruppe\u00a0mit\u00a0\nvorausgegangener \u00a0Behandlung \u00a0mit\u00a0dem\u00a0Tyrosinkinaseinhibitor \u00a0Sunitinib\u00a0sieht\u00a0er\u00a0hingegen\u00a0einen\u00a0\nZusatznutzen \u00a0gegen\u00fcber \u00a0der\u00a0gew\u00e4hlten \u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0Everolimus \u00a0als\u00a0nicht\u00a0\nbelegt\u00a0an,\u00a0da\u00a0direkte\u00a0Vergleichsstudien \u00a0nicht\u00a0vorliegen. \u00a0Der\u00a0Beschluss \u00a0ist\u00a0zun\u00e4chst\u00a0auf\u00a0vier\u00a0Jahre\u00a0(bis\u00a0\nM\u00e4rz\u00a02017)\u00a0befristet.\u00a0Grund\u00a0daf\u00fcr\u00a0ist,\u00a0dass\u00a0der\u00a0Zusatznutzen \u00a0von\u00a0Axitinib\u00a0f\u00fcr\u00a0erwachsene \u00a0Patienten \u00a0\nnach\u00a0Versagen \u00a0von\u00a0vorangegangener \u00a0Therapie\u00a0mit\u00a0Sunitinib\u00a0oder\u00a0einem\u00a0Zytokin\u00a0begrenzt\u00a0ist\u00a0und\u00a0nur\u00a0\nunzureichend \u00a0Daten\u00a0vorliegen \u00a0f\u00fcr\u00a0Patienten \u00a0mit\u00a0nicht\u2010klarzelligem \u00a0Nierenzellkarzinom \u00a0und\u00a0f\u00fcr\u00a0\nPatienten \u00a0mit\u00a0lokal\u00a0fortgeschrittenem \u00a0Nierenzellkarzinom \u00a0ohne\u00a0(Fern\u2010)Metastasen. \u00a0Da\u00a0Zytokine\u00a0\nbereits\u00a0heute\u00a0nur\u00a0noch\u00a0selten\u00a0als\u00a0Erstlinien \u2010Therapie\u00a0beim\u00a0fortgeschrittenen \u00a0Nierenzellkarzinom \u00a0\neingesetzt \u00a0werden,\u00a0kann\u00a0auch\u00a0in\u00a0Zukunft\u00a0mit\u00a0einer\u00a0weiteren\u00a0Abnahme \u00a0ihrer\u00a0therapeutischen \u00a0\nRelevanz\u00a0in\u00a0der\u00a0Erstlinienbehandlung \u00a0gerechnet \u00a0werden.\u00a0\n \u00a0 \n40\u00a0\n \n \nInnovationsreport 2015 \u00a0Verf\u00fcgbare \u00a0Therapien  \n\u00a0(Zusatz\u2010)Nutzen\n\u00a0Kosten\u00a0\n\u00a0\n Weiterer\u00a0Tyrosinkinase \u2010\ninhibitor\u00a0zur\u00a0\nZweitlinienbehandlung \u00a0des\u00a0\nfortgeschrittenen \u00a0\nNierenzellkarzinoms  \u00a0  \u00a0\n   Nach\u00a0Vorbehandlung \u00a0m\u00f6glicherweise \u00a0\nbesser\u00a0vertr\u00e4glich \u00a0als\u00a0Standardtherapie, \u00a0\nkein\u00a0Vorteil\u00a0im\u00a0Gesamt\u00fcberleben. \u00a0In\u00a0\nEinzelf\u00e4llen \u00a0schwere\u00a0Nebenwirkungen \u00a0\nm\u00f6glich   \n    \n  G\u00fcnstiger \u00a0als\u00a0Vergleichsthe \u2010\nrapien\u00a0\nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien: \u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen:\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien  \nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0\nC\u00a0 Keine\u00a0Bewertung \u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nDie\u00a0Verordnungszahlen \u00a0des\u00a0Tyrosinkinaseinhibitors \u00a0Axitinib\u00a0(Inlyta\u00ae)\u00a0erreichten \u00a0neun\u00a0Monate\u00a0nach\u00a0\nseiner\u00a0Markteinf\u00fchrung \u00a0ihr\u00a0Maximum \u00a0(55\u00a0Packungen) \u00a0und\u00a0sanken\u00a0schlie\u00dflich \u00a0im\u00a0Dezember \u00a02013\u00a0auf\u00a0\nein\u00a0Niveau\u00a0von\u00a0etwa\u00a040\u00a0Packungen \u00a0pro\u00a0Monat\u00a0(Abbildung \u00a09).\u00a0Das\u00a0hatte\u00a0auf\u00a0die\u00a0Umsatzzahlen \u00a0\nallerdings \u00a0keinen\u00a0erheblichen \u00a0Einfluss\u00a0(Abbildung \u00a011).\u00a0Die\u00a084\u00a0Versicherten \u00a0mit\u00a0Verordnungen \u00a0im\u00a0Jahr\u00a0\n2013\u00a0waren\u00a0mit\u00a0knapp\u00a090\u00a0Prozent\u00a0m\u00e4nnliche \u00a0Erwachsene \u00a0zwischen\u00a050\u00a0und\u00a080\u00a0Jahren\u00a0(Abbildung \u00a010).\u00a0\n\u00a0\u00a0\n \n41\u00a0\n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a09:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Axitinib\u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0\n\u00a0\n \nAbbildung \u00a010:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Axitinib\u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0\n\u00a0\u00a0\n \n42\u00a0\n \n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a011:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Axitinib\u00a0nach\u00a0Monaten \u00a0(2012\u20102013)\n \n43\u00a0\n \nInnovationsreport 2015 \u00a0 4.4 Azilsartanmedoxomil \u00a0\n\u00a0\u00a0\u00a0Handelsname: \u00a0Edarbi\u00ae\u00a0 \u00a0\u00a0\u00a0 Hersteller: \u00a0Takeda\u00a0\nIndikation: \u00a0Essentielle \u00a0Hypertonie \u00a0\u00a0 \u00a0 Markteinf\u00fchrung: \u00a0Januar\u00a02012\u00a0\nATC\u2010Code:\u00a0C09CA09\u00a0 \u00a0\u00a0\u00a0\u00a0 DDD:\u00a040\u00a0mg\u00a0\nDarreichungsform: \u00a0Tablette\u00a0\nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0176\u00a0\nBewertung \u00a0\nAzilsartanmedoxomil \u00a0ist\u00a0der\u00a0nunmehr\u00a0achte\u00a0in\u00a0Deutschland \u00a0zugelassene \u00a0Vertreter \u00a0aus\u00a0der\u00a0Gruppe\u00a0\nder\u00a0Angiotensin \u2010II\u2010Antagonisten. \u00a0Das\u00a0Mittel\u00a0kann\u00a0zur\u00a0Behandlung \u00a0Erwachsener \u00a0mit\u00a0essentieller \u00a0\nHypertonie \u00a0eingesetzt \u00a0werden.\u00a0Der\u00a0Wirkstoff \u00a0steht\u00a0dem\u00a0Markt\u00a0in\u00a0fester\u00a0Zubereitungsform \u00a0zum\u00a0\nEinnehmen \u00a0(Tablette) \u00a0zur\u00a0Verf\u00fcgung. \u00a0\nAzilsartanmedoxomil \u00a0ist\u00a0ein\u00a0Prodrug,\u00a0das\u00a0durch\u00a0hepatische \u00a0und\u00a0enterale\u00a0Esterasen \u00a0im\u00a0menschlichen \u00a0\nOrganismus \u00a0erst\u00a0in\u00a0den\u00a0aktiven\u00a0Metaboliten \u00a0Azilsartan \u00a0\u00fcberf\u00fchrt \u00a0werden\u00a0muss.\u00a0Der\u00a0Wirkstoff \u00a0wurde\u00a0\nin\u00a0verschiedenen \u00a0randomisiert \u00a0kontrollierten \u00a0Studien\u00a0an\u00a0Patienten \u00a0mit\u00a0essentieller \u00a0Hypertonie \u00a0\nuntersucht. \u00a0Vergleichsbehandlungen \u00a0waren\u00a0Placebo\u00a0und\u00a0aktive\u00a0Kontrollen \u00a0wie\u00a0Candesartan, \u00a0\nOlmesartan \u00a0und\u00a0Valsartan. \u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0war\u00a0in\u00a0allen\u00a0F\u00e4llen\u00a0die\u00a0Senkung\u00a0des\u00a0(je\u00a0nach\u00a0\nStudienfrage \u00a0systolischen \u00a0oder\u00a0diastolischen) \u00a0Blutdrucks. \u00a0In\u00a0den\u00a0klinischen \u00a0Studien\u00a0konnte\u00a0eine\u00a0etwas\u00a0\nst\u00e4rkere\u00a0blutdrucksenkende \u00a0Wirkung\u00a0im\u00a0Vergleich \u00a0zu\u00a0den\u00a0anderen\u00a0Sartanen\u00a0wie\u00a0auch\u00a0im\u00a0Vergleich \u00a0zu\u00a0\nACE\u2010Hemmern \u00a0(Ramipril) \u00a0gezeigt\u00a0werden.\u00a0Anhand\u00a0patientenrelevanter \u00a0Endpunkte \u00a0wie\u00a0\nkardiovaskul\u00e4re \u00a0Sterblichkeit, \u00a0Herzinfarkt \u00a0und\u00a0Schlaganfall \u00a0sind\u00a0f\u00fcr\u00a0Azilsartanmedoxomil \u00a0gegen\u00fcber \u00a0\ndiesen\u00a0Komparatoren \u00a0aber\u00a0weder\u00a0\u00c4quivalenz \u00a0bzw.\u00a0Nicht\u2010Unter\u2010\u00a0noch\u00a0\u00dcberlegenheit \u00a0gezeigt.\u00a0\u00a0\nAls\u00a0unerw\u00fcnschte \u00a0Wirkung\u00a0trat\u00a0in\u00a0den\u00a0kontrollierten \u00a0Untersuchungen \u00a0am\u00a0h\u00e4ufigsten \u00a0Schwindel \u00a0auf.\u00a0\nAuch\u00a0Kopfschmerzen \u00a0und\u00a0\u00c4nderungen \u00a0der\u00a0Lipidspiegel \u00a0wurden\u00a0verzeichnet. \u00a0Gesamtinzidenz \u00a0\nunerw\u00fcnschter \u00a0Wirkungen \u00a0und\u00a0Auspr\u00e4gung \u00a0waren\u00a0innerhalb \u00a0klinischer \u00a0Studien\u00a0aber\u00a0mit\u00a0denen\u00a0der\u00a0\nKontroll\u2010Gruppen\u00a0\u2013\u00a0einschlie\u00dflich \u00a0der\u00a0Placebo\u2010Gruppe\u00a0\u2013\u00a0vergleichbar. \u00a0Auch\u00a0wurde\u00a0die\u00a0Studien\u2010\nbehandlung \u00a0in\u00a0den\u00a0Verum\u2010Gruppen\u00a0nicht\u00a0h\u00e4ufiger\u00a0als\u00a0in\u00a0der\u00a0Placebo\u2010Gruppe\u00a0wegen\u00a0unerw\u00fcnschter \u00a0\nWirkungen \u00a0vorzeitig\u00a0beendet.\u00a0\u00a0\nTrotz\u00a0Aufforderung \u00a0durch\u00a0den\u00a0G\u2010BA\u00a0hat\u00a0der\u00a0pU\u00a0darauf\u00a0verzichtet, \u00a0die\u00a0f\u00fcr\u00a0eine\u00a0fr\u00fche\u00a0\nNutzenbewertung \u00a0erforderlichen \u00a0Unterlagen \u00a0in\u00a0Form\u00a0eines\u00a0Nutzendossiers \u00a0fristgerecht \u00a0einzureichen. \u00a0\nDie\u00a0Verfahrensordnung \u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung \u00a0sieht\u00a0in\u00a0diesem\u00a0Fall\u00a0vor,\u00a0dass\u00a0der\u00a0Zusatznutzen \u00a0\ndes\u00a0entsprechenden \u00a0Fertigarzneimittels \u00a0als\u00a0nicht\u00a0belegt\u00a0angesehen \u00a0werden\u00a0muss\u00a0und\u00a0das\u00a0Mittel\u00a0\nsomit\u00a0in\u00a0die\u00a0Festbetragsgruppe \u00a0eingereiht \u00a0wird.\u00a0Als\u00a0Begr\u00fcndung \u00a0wird\u00a0auch\u00a0darauf\u00a0hingewiesen, \u00a0dass\u00a0\nf\u00fcr\u00a0Azilsartanmedoxomil \u00a0gegen\u00fcber \u00a0den\u00a0verwandten \u00a0Substanzen \u00a0derselben \u00a0Wirkstoffgruppe \u00a0eine\u00a0\n\u00dcberlegenheit \u00a0anhand\u00a0patientenrelevanter \u00a0Endpunkte \u00a0weder\u00a0verl\u00e4sslich \u00a0signifikant \u00a0noch\u00a0klinisch\u00a0\nrelevant\u00a0nachgewiesen \u00a0wurde.\u00a0\u00a0\n \u00a0 \n44\u00a0\n \n \nInnovationsreport 2015 \u00a0Verf\u00fcgbare \u00a0Therapien  \n\u00a0(Zusatz\u2010)Nutzen Kosten\n Weitere\u00a0blutdrucksenkende \u00a0\nTherapieoption \u00a0bei\u00a0essentieller \u00a0\nHypertonie  \u00a0 Keine\u00a0therapeutisch \u00a0relevanten \u00a0\nVorteile.\u00a0Es\u00a0fehlen\u00a0Studien\u00a0zu\u00a0\npatientenrelevanten \u00a0Endpunkten  Teurer\u00a0als\u00a0die\u00a0vom\u00a0G\u2010BA\u00a0\nvorgegebene \u00a0Vergleichs \u2010\ntherapie,\u00a0aber\u00a0im\u00a0Bereich\u00a0der\u00a0\nAT1\u2010Blocker\u00a0liegend\u00a0\n \u00a0   \n \n \n  \n \n     \nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien: \u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen:\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien  \nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0\nC\u00a0 Variante\u00a0ohne\u00a0besonderen \u00a0Stellenwert \u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nInsgesamt \u00a0erhielten\u00a0im\u00a0Jahr\u00a02013\u00a01.245\u00a0erwachsene \u00a0TK\u2010Versicherte \u00a0mindestens \u00a0eine\u00a0Verordnung \u00a0des\u00a0\nAngiotensin \u2010Rezeptorantagonisten \u00a0Azilsartanmedoxomil \u00a0(Edarbi\u00ae), \u00a0es\u00a0handelt\u00a0sich\u00a0um\u00a0mehrheitlich \u00a0\nm\u00e4nnliche \u00a0Versicherte \u00a0zwischen\u00a050\u00a0und\u00a080\u00a0Jahren\u00a0(Abbildung \u00a013).\u00a0Ab\u00a0dem\u00a0Zeitpunkt \u00a0der\u00a0\nMarkteinf\u00fchrung \u00a0stiegen\u00a0die\u00a0Verordnungszahlen \u00a0schnell\u00a0an\u00a0und\u00a0pendelten \u00a0ab\u00a0Oktober\u00a02012\u00a0zwischen\u00a0\n320\u00a0und\u00a0360\u00a0Packungen \u00a0pro\u00a0Monat\u00a0(Ausrei\u00dfer: \u00a0Januar\u00a02013\u00a0als\u00a0verordnungsst\u00e4rkster \u00a0Monat\u00a0mit\u00a0\nknapp\u00a0450\u00a0Packungen, \u00a0was\u00a0mit\u00a0dem\u00a0Beginn\u00a0eines\u00a0neuen\u00a0Quartals\u00a0zusammenh\u00e4ngen \u00a0kann)\u00a0\n(Abbildung \u00a012).\u00a0\u00c4hnlich\u00a0verhielten \u00a0sich\u00a0die\u00a0Monatszahlen \u00a0bei\u00a0den\u00a0DDD\u00a0und\u00a0Bruttoums\u00e4tzen \u00a0\n(Abbildung \u00a014).\u00a0\n \u00a0\n \n45\u00a0\n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a012:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Azilsartanmedoxomil \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0\n(2012\u20102013)\u00a0\n\u00a0\n \nAbbildung \u00a013:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Azilsartanmedoxomil \u00a0nach\u00a0Alter\u00a0und\u00a0Ge\u2010\nschlecht\u00a0(2013)\u00a0\n\u00a0\n \n46\u00a0\n \n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a014:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Azilsartanmedoxomil \u00a0nach\u00a0Monaten \u00a0\n(2012\u20102013)\u00a0\n\u00a0 \u00a0\n \n47\u00a0\n \nInnovationsreport 2015 \u00a0 4.5 Brentuximabvedotin \u00a0\nHandelsname: \u00a0Adcetris\u00ae \u00a0 \u00a0\u00a0\u00a0 Hersteller: \u00a0Takeda\u00a0\nIndikation: \u00a0CD30+\u00a0Hodgkin\u2010Lymphom \u00a0\u00a0u.a.\u00a0\u00a0 Markteinf\u00fchrung: \u00a0Dezember \u00a02012\u00a0\nATC\u2010Code:\u00a0L01XC12\u00a0 \u00a0\u00a0\u00a0\u00a0 DDD:\u00a06\u00a0mg\u00a0\nDarreichungsform: \u00a0Pulver\u00a0zur\u00a0Herstellung \u00a0einer\u00a0Infusionsl\u00f6sung \u00a0\nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0179 \nBewertung \u00a0\nBrentuximabvedotin \u00a0ist\u00a0ein\u00a0Konjugat\u00a0(sog.\u00a0Antibody\u2010drug\u00a0conjugate ,\u00a0ADC)\u00a0aus\u00a0einem\u00a0monoklonalen \u00a0\nAntik\u00f6rper \u00a0und\u00a0einem\u00a0Zytostatikum \u00a0(Monomethylauristatin \u00a0E),\u00a0das\u00a0zur\u00a0Behandlung \u00a0von\u00a0Patienten \u00a0mit\u00a0\nrezidiviertem \u00a0oder\u00a0refrakt\u00e4rem \u00a0CD30+\u00a0Hodgkin\u2010Lymphom \u00a0(HL)\u00a0und\u00a0zur\u00a0Therapie\u00a0von\u00a0erwachsenen \u00a0\nPatienten \u00a0mit\u00a0rezidiviertem \u00a0oder\u00a0refrakt\u00e4rem \u00a0systemischem \u00a0anaplastischem \u00a0gro\u00dfzelligem \u00a0Lymphom \u00a0\n(sALCL)\u00a0als\u00a0Orphan\u00a0Drug\u00a0zugelassen \u00a0wurde.\u00a0Bis\u00a0dato\u00a0gab\u00a0es\u00a0in\u00a0Deutschland \u00a0keine\u00a0speziell\u00a0f\u00fcr\u00a0diese\u00a0\nIndikationen \u00a0zugelassenen \u00a0Medikamente. \u00a0So\u00a0war\u00a0bislang\u00a0beispielsweise \u00a0bei\u00a0den\u00a0meisten\u00a0Patienten \u00a0\nmit\u00a0Hodgkin\u2010Lymphom \u00a0und\u00a0Rezidiv\u00a0nach\u00a0der\u00a0Initialtherapie \u00a0eine\u00a0erneute\u00a0Polychemotherapie \u00a0gefolgt\u00a0\nvon\u00a0einer\u00a0Hochdosis \u2010Chemotherapie \u00a0mit\u00a0anschlie\u00dfender \u00a0autologer \u00a0Blutstammzelltransplantation \u00a0\n(ASCT)\u00a0die\u00a0Therapie\u00a0der\u00a0Wahl.\u00a0Sowohl\u00a0f\u00fcr\u00a0Patienten, \u00a0f\u00fcr\u00a0die\u00a0eine\u00a0Hochdosis \u2010Chemotherapie \u00a0nicht\u00a0\ngeeignet\u00a0ist,\u00a0als\u00a0auch\u00a0f\u00fcr\u00a0solche\u00a0mit\u00a0erneutem \u00a0Rezidiv\u00a0nach\u00a0ASCT\u00a0gibt\u00a0es\u00a0keine\u00a0Standardtherapie. \u00a0\u00a0\nWirksamkeit \u00a0und\u00a0Sicherheit \u00a0von\u00a0Brentuximabvedotin \u00a0als\u00a0Monotherapie \u00a0wurden\u00a0im\u00a0Wesentlichen \u00a0in\u00a0\nzwei\u00a0Phase\u2010II\u2010Studien\u00a0an\u00a0Patienten \u00a0mit\u00a0rezidiviertem \u00a0oder\u00a0refrakt\u00e4rem \u00a0HL\u00a0oder\u00a0sALCL\u00a0untersucht. \u00a0In\u00a0\nden\u00a0beiden\u00a0Studien\u00a0f\u00fchrte\u00a0der\u00a0Wirkstoff \u00a0bei\u00a034\u00a0Prozent\u00a0(HL)\u00a0bzw.\u00a059\u00a0Prozent\u00a0(sALCL)\u00a0der\u00a0Patienten \u00a0zu\u00a0\neiner\u00a0kompletten \u00a0Remission. \u00a0\u00a0\nAls\u00a0h\u00e4ufigste \u00a0Nebenwirkungen \u00a0der\u00a0Schweregrade \u00a03\u00a0und\u00a04\u00a0traten\u00a0Neutropenie, \u00a0Thrombozytopenie \u00a0\nund\u00a0periphere \u00a0sensorische \u00a0Neuropathie \u00a0auf.\u00a0\nBrentuximabvedotin \u00a0ist\u00a0ein\u00a0Orphan\u00a0Drug ,\u00a0f\u00fcr\u00a0das\u00a0der\u00a0medizinische \u00a0Zusatznutzen \u00a0durch\u00a0die\u00a0Zulassung \u00a0\nals\u00a0belegt\u00a0gilt.\u00a0Das\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens \u00a0wird\u00a0vom\u00a0G\u2010BA\u00a0auf\u00a0der\u00a0Grundlage \u00a0der\u00a0Zulassung \u00a0und\u00a0\nder\u00a0ihr\u00a0zugrunde \u00a0liegenden \u00a0Studien\u00a0bestimmt. \u00a0Eine\u00a0zweckm\u00e4\u00dfige \u00a0Vergleichstherapie \u00a0wird\u00a0zur\u00a0\nBewertung \u00a0nicht\u00a0herangezogen. \u00a0Die\u00a0beiden\u00a0Zulassungsstudien \u00a0f\u00fcr\u00a0Brentuximabvedotin \u00a0sind\u00a0offene,\u00a0\neinarmige \u00a0Phase\u2010II\u2010Studien,\u00a0deren\u00a0Ergebnisse \u00a0ein\u00a0hohes\u00a0Verzerrungspotential \u00a0aufweisen. \u00a0Gleiches\u00a0gilt\u00a0\nf\u00fcr\u00a0die\u00a0aggregierte \u00a0Fallserie\u00a0von\u00a0ASCT\u2010naiven\u00a0Patienten. \u00a0Aus\u00a0diesem\u00a0Grund\u00a0bewertete \u00a0der\u00a0G\u2010BA\u00a0das\u00a0\nAusma\u00df\u00a0des\u00a0Zusatznutzens \u00a0als\u00a0nicht\u00a0quantifizierbar \u00a0und\u00a0zwar\u00a0bei\u00a0allen\u00a0drei\u00a0Indikationen: \u00a01)\u00a0\nBehandlung \u00a0von\u00a0erwachsenen \u00a0Patienten \u00a0mit\u00a0rezidiviertem \u00a0oder\u00a0refrakt\u00e4rem \u00a0CD30+\u00a0HL\u00a0nach\u00a0ASCT\u00a0\noder\u00a02)\u00a0Behandlung \u00a0von\u00a0erwachsenen \u00a0Patienten \u00a0mit\u00a0rezidiviertem \u00a0oder\u00a0refrakt\u00e4rem \u00a0CD30+\u00a0HL\u00a0nach\u00a0\nmindestens \u00a0zwei\u00a0vorangegangenen \u00a0Therapien, \u00a0wenn\u00a0eine\u00a0ASCT\u00a0oder\u00a0eine\u00a0\nKombinationschemotherapie \u00a0nicht\u00a0als\u00a0Behandlungsoption \u00a0in\u00a0Frage\u00a0kommt\u00a0oder\u00a03)\u00a0Behandlung \u00a0von\u00a0\nerwachsenen \u00a0Patienten \u00a0mit\u00a0rezidiviertem \u00a0oder\u00a0refrakt\u00e4rem \u00a0sALCL.\u00a0\u00a0 \n48\u00a0\n \n \nInnovationsreport 2015 \u00a0Verf\u00fcgbare \u00a0Therapien \u00a0\n\u00a0(Zusatz\u2010)Nutzen\n\u00a0Kosten\n\u00a0\n  \u00a0  Erstes\u00a0zugelassenes \u00a0\nArzneimittel \u00a0f\u00fcr\u00a0diese\u00a0\nIndikation. \u00a0Ein\u00a0Kostenvergleich \u00a0\nist\u00a0somit\u00a0nicht\u00a0m\u00f6glich\u00a0\n   Verbesserung \u00a0des\u00a0\nGesamt\u00fcberlebens \u00a0m\u00f6glich,\u00a0aber\u00a0\ndurch\u00a0vorliegende \u00a0Studiendaten \u00a0\nnicht\u00a0belegt.\u00a0Schwerwiegende \u00a0\nNebenwirkungen \u00a0m\u00f6glich   \n Neues\u00a0zielgerichtetes \u00a0\nTherapieprinzip \u00a0zur\u00a0\nBehandlung \u00a0von\u00a0Patienten \u00a0mit\u00a0\nrezidiviertem \u00a0oder\u00a0refrakt\u00e4rem \u00a0\nCD30+\u00a0Hodgkin\u2010Lymphom  \u00a0   \nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien :\u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen :\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten :\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien \u00a0\nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0\nA\u00a0 Keine\u00a0Bewertung \u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nDas\u00a0Orphan\u00a0Drug\u00a0Brentuximabvedotin \u00a0(Adcetris\u00ae) \u00a0wurde\u00a0im\u00a0Jahr\u00a02013\u00a0als\u00a0Rezeptur\u00a0abgerechnet. \u00a0\nDabei\u00a0schwanken \u00a0die\u00a0Verordnungszahlen \u00a0zwischen\u00a010\u00a0und\u00a030\u00a0Packungen \u00a0(Abbildung \u00a015).\u00a0Von\u00a0den\u00a0TK\u2010\nVersicherten \u00a0erhielten\u00a014\u00a0m\u00e4nnliche \u00a0Versicherte \u00a0mindestens \u00a0eine\u00a0Verordnung \u00a0im\u00a0Vergleich \u00a0zu\u00a0vier\u00a0\nweiblichen \u00a0Versicherten \u00a0(Abbildung \u00a016).\u00a0Im\u00a0Jahr\u00a02013\u00a0generierten \u00a0die\u00a0Verordnungen \u00a0bei\u00a0der\u00a0TK\u00a0einen\u00a0\nmonatlichen \u00a0Umsatz\u00a0zwischen\u00a060.000\u00a0und\u00a0140.000\u00a0Euro\u00a0(Abbildung \u00a017).\u00a0\n\u00a0\u00a0\n \n49\u00a0\n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a015:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Brentuximabvedotin \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u2010\n2013)\u00a0\n\u00a0\n \nAbbildung \u00a016:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Brentuximabvedotin \u00a0nach\u00a0Alter\u00a0und\u00a0Ge\u2010\nschlecht\u00a0(2013)\u00a0\u00a0\n \n50\u00a0\n \n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a017:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Brentuximabvedotin \u00a0nach\u00a0Monaten \u00a0\n(2012\u20102013)\u00a0\n\u00a0 \u00a0\n \n51\u00a0\n \nInnovationsreport 2015 \u00a0 4.6 Ceftarolinfosamil \u00a0\nHandelsname: \u00a0Zinforo\u00ae\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0 \u00a0 Hersteller: \u00a0AstraZeneca \u00a0\nIndikation: \u00a0Haut\u2010\u00a0und\u00a0Weichgewebeinfektion, \u00a0Pneumonie \u00a0\u00a0 \u00a0 Markteinf\u00fchrung: \u00a0Oktober\u00a02012\u00a0\nATC\u2010Code:\u00a0J01DI02\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 DDD:\u00a01,2\u00a0g\u00a0\nDarreichungsform: \u00a0Pulver\u00a0zur\u00a0Herstellung \u00a0eine\u00a0Infusionsl\u00f6sung \u00a0\nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0183\u00a0\nBewertung \u00a0\nCeftarolinfosamil \u00a0ist\u00a0ein\u00a0MRSA\u2010wirksames \u00a0Staphylococcen \u2010Cephalosporin \u00a0mit\u00a0guter\u00a0Wirksamkeit \u00a0im\u00a0\ngrampositiven \u00a0und\u00a0mit\u00a0geringerer \u00a0Aktivit\u00e4t\u00a0im\u00a0gramnegativen \u00a0Bereich.\u00a0Das\u00a0parenteral \u00a0zu\u00a0\nverabreichende \u00a0Cephalosporin \u00a0kann\u00a0bei\u00a0komplizierten \u00a0Haut\u2010\u00a0und\u00a0Weichgewebeinfektionen \u00a0sowie\u00a0bei\u00a0\nambulant \u00a0erworbenen \u00a0Pneumonien \u00a0eingesetzt \u00a0werden.\u00a0\u00a0\nCeftarolinfosamil \u00a0wurde\u00a0vor\u00a0der\u00a0Zulassung \u00a0durch\u00a0ein\u00a0klinisches \u00a0Studienprogramm \u00a0bestehend \u00a0aus\u00a0vier\u00a0\nPhase\u2010III\u2010Studien\u00a0an\u00a0Patienten \u00a0mit\u00a0komplizierten \u00a0Haut\u2010\u00a0und\u00a0Weichgewebeinfektionen \u00a0sowie\u00a0an\u00a0\nPatienten \u00a0mit\u00a0ambulant \u00a0erworbenen \u00a0Pneumonien \u00a0auf\u00a0Wirksamkeit \u00a0und\u00a0Vertr\u00e4glichkeit \u00a0gepr\u00fcft.\u00a0\nGegen\u00fcber \u00a0einer\u00a0Kombinationstherapie \u00a0aus\u00a0Vancomycin \u00a0plus\u00a0Aztreonam \u00a0(jeweils\u00a01\u00a0g\u00a0i.v.\u00a0alle\u00a0zw\u00f6lf\u00a0\nStunden)\u00a0war\u00a0Ceftarolinfosamil \u00a0(600\u00a0mg\u00a0i.v.\u00a0alle\u00a0zw\u00f6lf\u00a0Stunden)\u00a0bei\u00a0Patienten \u00a0mit\u00a0komplizierten \u00a0Haut\u2010\u00a0\nund\u00a0Weichgewebeinfektionen \u00a0sowohl\u00a0im\u00a0gesamten \u00a0Studienkollektiv \u00a0wie\u00a0auch\u00a0bei\u00a0Patienten \u00a0mit\u00a0\nMRSA\u2010Infektionen \u00a0bzgl.\u00a0klinischer \u00a0Heilungsrate \u00a0nicht\u00a0unterlegen. \u00a0Nach\u00a0Intention\u2010to\u2010treat\u2010Analyse\u00a0\nkann\u00a0nach\u00a0einer\u00a0Behandlungsdauer \u00a0von\u00a0f\u00fcnf\u00a0bis\u00a014\u00a0Tagen\u00a0bei\u00a0dieser\u00a0Indikation \u00a0mit\u00a0Heilungsraten \u00a0von\u00a0\n85,9\u00a0Prozent\u00a0unter\u00a0Ceftarolinfosamil \u00a0im\u00a0Vergleich \u00a0zu\u00a085,5\u00a0Prozent\u00a0unter\u00a0Kontrollbehandlung \u00a0\ngerechnet \u00a0werden.\u00a0Werden\u00a0nur\u00a0Patienten \u00a0ausgewertet, \u00a0f\u00fcr\u00a0die\u00a0vollst\u00e4ndige \u00a0Daten\u00a0zur\u00a0\nEndpunkterhebung \u00a0vorhanden \u00a0waren,\u00a0liegen\u00a0die\u00a0Heilungsraten \u00a0bei\u00a091,6\u00a0Prozent\u00a0vs.\u00a092,7\u00a0Prozent.\u00a0Bei\u00a0\nMRSA\u2010Patienten \u00a0lagen\u00a0die\u00a0Heilungsraten \u00a0bei\u00a093,4\u00a0Prozent\u00a0unter\u00a0Ceftarolinfosamil \u00a0vs.\u00a094,3\u00a0Prozent\u00a0\nunter\u00a0Kontrollbehandlung. \u00a0\u00a0\nZwei\u00a0Untersuchungen \u00a0an\u00a0Patienten \u00a0mit\u00a0ambulant \u00a0erworbener \u00a0Pneumonie \u00a0wurden\u00a0im\u00a0Vergleich \u00a0zu\u00a0\nCeftriaxon \u00a0durchgef\u00fchrt. \u00a0Eingeschlossen \u00a0waren\u00a0Patienten \u00a0mit\u00a0ambulant \u00a0erworbener \u00a0Pneumonie, \u00a0die\u00a0\ndeswegen \u00a0ein\u00a0Krankenhaus \u00a0aufsuchten, \u00a0aber\u00a0nicht\u00a0intensivmedizinisch \u00a0versorgt\u00a0werden\u00a0mussten.\u00a0In\u00a0\nden\u00a0Einzelstudien \u00a0ergibt\u00a0sich\u00a0f\u00fcr\u00a0Ceftarolinfosamil \u00a0eine\u00a0Nicht\u2010Unterlegenheit \u00a0gegen\u00fcber \u00a0Ceftriaxon. \u00a0\nIn\u00a0der\u00a0zusammengefassten \u00a0Datenanalyse \u00a0werden\u00a0im\u00a0modifizierten \u00a0ITT\u2010Kollektiv\u00a0unter\u00a0\nCeftarolinfosamil \u00a0Heilungsraten \u00a0von\u00a082,6\u00a0Prozent\u00a0vs.\u00a076,6\u00a0Prozent\u00a0unter\u00a0Ceftriaxon \u00a0gesehen.\u00a0Die\u00a0\nRatendifferenz \u00a0zwischen\u00a0den\u00a0Behandlungsgruppen \u00a0lag\u00a0bei\u00a0sechs\u00a0Prozent,\u00a0allerdings \u00a0mit\u00a0einem\u00a0\nbreiten\u00a0Konfidenzintervall \u00a0(CI\u00a095\u00a0Prozent:\u00a01,4\u00a0Prozent\u00a0bis\u00a010,7\u00a0Prozent),\u00a0und\u00a0k\u00f6nnte\u00a0mit\u00a0einer\u00a0\nbesseren\u00a0Wirksamkeit \u00a0von\u00a0Ceftarolinfosamil \u00a0auf\u00a0multiresistenten \u00a0Streptococcus \u00a0pneumoniae \u00a0in\u00a0Zu\u2010\nsammenhang \u00a0stehen.\u00a0Ceftarolinfosamil \u00a0ist\u00a0gegen\u00a0eine\u00a0Vielzahl\u00a0resistenter \u00a0grampositiver \u00a0Kokken\u00a0\neinschlie\u00dflich \u00a0Methicillin \u2010resistentem \u00a0Staphylococcus \u00a0aureus\u00a0(MRSA),\u00a0Methicillin \u2010resistentem \u00a0\nStaphylococcus \u00a0epidermis \u00a0(MRSE)\u00a0und\u00a0Penicillin\u2010resistenter \u00a0Pneumokokken \u00a0sowie\u00a0gegen\u00a0viele\u00a0\nAmpicillin \u2010empfindliche \u00a0Enterokokken \u00a0(mit\u00a0Ausnahme \u00a0von\u00a0Vancomycin \u2010resistentem \u00a0Enterokokkus \u00a0\nfaecium)\u00a0wirksam.\u00a0Au\u00dferdem \u00a0zeigt\u00a0es\u00a0eine\u00a0gute\u00a0Wirksamkeit \u00a0gegen\u00a0Haemophilus \u00a0influenzae, \u00a0\nNeisseria\u00a0gonorrhoeae \u00a0und\u00a0Moraxella \u00a0catarrhalis. \u00a0Nicht\u00a0wirksam\u00a0ist\u00a0Ceftarolinfosamil \u00a0bei\u00a0Infektionen \u00a0\nmit\u00a0Legionellen, \u00a0Mycoplasma \u2010Arten,\u00a0Proteus\u2010Subspezies \u00a0und\u00a0Pseudomonas \u00a0aeruginosa. \u00a0Aufgrund \u00a0der\u00a0\nunzureichenden \u00a0Wirksamkeit \u00a0im\u00a0gramnegativen \u00a0Bereich\u00a0ist\u00a0ein\u00a0gezielter\u00a0Einsatz\u00a0von\u00a0Ceftarolinfosamil \u00a0\nnur\u00a0bei\u00a0Infektionen \u00a0mit\u00a0grampositiven \u00a0Kokken\u00a0zu\u00a0empfehlen, \u00a0da\u00a0bereits\u00a0Ceftarolinfosamil \u2010resistente \u00a0\nMRSA\u2010St\u00e4mme\u00a0isoliert\u00a0werden\u00a0konnten.\u00a0Bei\u00a0ungezieltem \u00a0Einsatz\u00a0des\u00a0Mittels\u00a0drohen\u00a0aufgrund\u00a0des\u00a0 \n52\u00a0\n \n \nInnovationsreport 2015 \u00a0erh\u00f6hten \u00a0Selektionsdrucks \u00a0vermehrt \u00a0Infektionen \u00a0mit\u00a0diesen\u00a0Erregern. \u00a0Da\u00a0Ceftarolinfosamil \u00a0eine\u00a0gute\u00a0\nMRSA\u2010Wirksamkeit \u00a0aufweist,\u00a0werden\u00a0f\u00fcr\u00a0seinen\u00a0Einsatz\u00a0bei\u00a0komplizierten \u00a0Haut\u2010\u00a0und\u00a0Weich\u2010\ngewebeinfektionen \u00a0Vorteile\u00a0gesehen.\u00a0Sein\u00a0Stellenwert \u00a0bei\u00a0der\u00a0Behandlung \u00a0ambulant \u00a0erworbener \u00a0\nPneumonien \u00a0ist\u00a0dagegen\u00a0unklar.\u00a0Es\u00a0fehlen\u00a0hinreichende \u00a0Belege\u00a0f\u00fcr\u00a0die\u00a0Effektivit\u00e4t \u00a0von\u00a0\nCeftarolinfosamil \u00a0bei\u00a0Risikopatienten \u00a0f\u00fcr\u00a0MRSA\u2010verursachte \u00a0Pneumonien, \u00a0da\u00a0hierf\u00fcr\u00a0noch\u00a0keine\u00a0\nStudie\u00a0vorgelegt \u00a0wurde.\u00a0\u00a0\nDas\u00a0Vertr\u00e4glichkeitsprofil \u00a0von\u00a0Ceftarolinfosamil \u00a0entspricht \u00a0nach\u00a0den\u00a0derzeit\u00a0vorliegenden \u00a0\nUntersuchungsdaten \u00a0dem\u00a0der\u00a0Wirkstoffgruppen. \u00a0Am\u00a0h\u00e4ufigsten \u00a0treten\u00a0gastrointestinale \u00a0\nBeschwerden \u00a0wie\u00a0\u00dcbelkeit\u00a0und\u00a0Durchfall\u00a0(ca.\u00a0drei\u00a0Prozent)\u00a0auf,\u00a0gefolgt\u00a0von\u00a0Kopfschmerzen \u00a0und\u00a0\nHautreaktionen \u00a0wie\u00a0Juckreiz\u00a0(ca.\u00a0zwei\u00a0Prozent).\u00a0\nDa\u00a0das\u00a0Mittel\u00a0seine\u00a0Anwendung \u00a0vor\u00a0allem\u00a0im\u00a0Krankenhaus \u00a0findet,\u00a0wurde\u00a0wegen\u00a0Geringf\u00fcgigkeit \u00a0der\u00a0\nzu\u00a0erwartenden \u00a0Ausgaben \u00a0der\u00a0pU\u00a0durch\u00a0den\u00a0G\u2010BA\u00a0von\u00a0der\u00a0Verpflichtung \u00a0freigestellt, \u00a0geeignete \u00a0\nUnterlagen \u00a0f\u00fcr\u00a0eine\u00a0fr\u00fche\u00a0Nutzenbewertung \u00a0vorzulegen. \u00a0\n\u00a0\nVerf\u00fcgbare \u00a0Therapien \u00a0\n\u00a0(Zusatz\u2010)Nutzen\n\u00a0Kosten\u00a0\n\u00a0\n   Keine\u00a0therapeutisch \u00a0relevanten \u00a0Vorteile\u00a0\ngegen\u00fcber \u00a0verf\u00fcgbaren \u00a0Therapieoptionen. \u00a0\nAufgrund \u00a0guter\u00a0Wirksamkeit \u00a0im\u00a0\ngrampositiven \u00a0Bereich\u00a0(einschlie\u00dflich \u00a0MRSA)\u00a0\nund\u00a0l\u00fcckenhafter \u00a0Wirksamkeit \u00a0im\u00a0\ngramnegativen \u00a0Bereich\u00a0wird\u00a0ein\u00a0gezielter\u00a0\nEinsatz\u00a0empfohlen, \u00a0um\u00a0Resistenz \u2010\nentwicklungen \u00a0zu\u00a0vermeiden  Der\u00a0Wirkstoff \u00a0wird\u00a0nur\u00a0an\u00a0\nKrankenhausversorgenden \u00a0\nApotheken \u00a0ausgeliefert. \u00a0Aus\u00a0\ndiesem\u00a0Grund\u00a0erfolgt\u00a0keine\u00a0\nKostenberechnung \u00a0\n Zum\u00a0Zeitpunkt \u00a0der\u00a0Zulassung \u00a0\nerstes\u00a0MRSA\u2010wirksames \u00a0\nStaphylococcen \u2010\nCephalosporin  \u00a0\u00a0 \u00a0\n   \u00a0\n  \u00a0\nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien :\u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen :\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten :\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien \u00a0\nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0\nC\u00a0 Keine\u00a0Bewertung \u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nDer\u00a0Wirkstoff \u00a0wurde\u00a0im\u00a0untersuchten \u00a0Zeitraum\u00a0im\u00a0ambulanten \u00a0Bereich\u00a0nicht\u00a0f\u00fcr\u00a0Versicherte \u00a0der\u00a0TK\u00a0\nverordnet. \u00a0\n \u00a0\n \n53\u00a0\n \nInnovationsreport 2015 \u00a0 4.7 Crizotinib \u00a0\nHandelsname: \u00a0Xalkori\u00ae\u00a0\u00a0\u00a0\u00a0 Hersteller: \u00a0Pfizer\u00a0\nIndikation: \u00a0Lungenkarzinom \u00a0 \u00a0 \u00a0\u00a0\u00a0 Markteinf\u00fchrung: \u00a0November \u00a02012\u00a0\nATC\u2010Code:\u00a0L01XE16\u00a0 \u00a0\u00a0\u00a0\u00a0 DDD:\u00a00,5\u00a0g\u00a0\nDarreichungsform: \u00a0Hartkapsel \u00a0\nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0187 \nBewertung \u00a0\nCrizotinib \u00a0ist\u00a0ein\u00a0oral\u00a0einzunehmender \u00a0Tyrosinkinaseinhibitor \u00a0der\u00a0Anaplastische \u2010Lymphom \u2010Kinase\u00a0\n(ALK).\u00a0Es\u00a0handelt\u00a0sich\u00a0um\u00a0ein\u00a0neuartiges \u00a0Wirkprinzip, \u00a0mit\u00a0dessen\u00a0Hilfe\u00a0eine\u00a0Biomarker \u2010stratifizierte \u00a0\nBehandlung \u00a0von\u00a0Erwachsenen \u00a0mit\u00a0vorbehandeltem, \u00a0ALK\u2010positivem, \u00a0fortgeschrittenem \u00a0nicht\u2010\nkleinzelligem \u00a0Bronchialkarzinom \u00a0(NSCLC)\u00a0m\u00f6glich\u00a0wird.\u00a0Crizotinib \u00a0hat\u00a0aufgrund\u00a0der\u00a0hohen\u00a0\nAnsprechraten \u00a0in\u00a0den\u00a0Phase\u2010I\u2010Studien\u00a0eine\u00a0beschleunigte \u00a0Zulassung \u00a0mit\u00a0Auflagen\u00a0(Conditional \u00a0\nMarketing \u00a0Authorization )\u00a0erhalten.\u00a0\u00a0\nDer\u00a0Zulassung \u00a0von\u00a0Crizotinib \u00a0lagen\u00a0die\u00a0zu\u00a0diesem\u00a0Zeitpunkt \u00a0noch\u00a0nicht\u00a0abgeschlossenen \u00a0Studien\u00a0\nzugrunde. \u00a0In\u00a0der\u00a0f\u00fcr\u00a0die\u00a0Zulassung \u00a0relevanten \u00a0Phase\u2010I\u2010Studie\u00a0an\u00a0ALK\u2010positiven, \u00a0rezidivierten \u00a0und\u00a0\nvorbehandelten \u00a0Patienten \u00a0lag\u00a0die\u00a0Ansprechrate \u00a0bei\u00a060\u00a0Prozent,\u00a0das\u00a0progressionsfreie \u00a0\u00dcberleben \u00a0be\u2010\ntrug\u00a09,2\u00a0Monate.\u00a0Diese\u00a0im\u00a0Vergleich \u00a0zur\u00a0Zweitlinienbehandlung \u00a0mit\u00a0konventioneller \u00a0Chemotherapie \u00a0\nhohe\u00a0Ansprechrate \u00a0wurde\u00a0in\u00a0einer\u00a0weiteren\u00a0einarmigen \u00a0Phase\u2010II\u2010Studie\u00a0best\u00e4tigt\u00a0und\u00a0f\u00fchrte\u00a0zur\u00a0\nbeschleunigten, \u00a0bedingten \u00a0Zulassung \u00a0bei\u00a0der\u00a0FDA\u00a0im\u00a0August\u00a02011.\u00a0In\u00a0die\u00a0offene,\u00a0kontrollierte, \u00a0\nrandomisierte \u00a0Phase\u2010III\u2010Studie\u00a0PROFILE\u00a01007\u00a0wurden\u00a0318\u00a0Patienten \u00a0mit\u00a0fortgeschrittenem \u00a0ALK\u2010\npositiven\u00a0NSCLC\u00a0nach\u00a0Vorbehandlung \u00a0mit\u00a0einer\u00a0Platin\u2010haltigen\u00a0Chemotherapie \u00a0eingeschlossen. \u00a0Sie\u00a0\nerhielten\u00a0entweder \u00a0zweimal\u00a0t\u00e4glich\u00a0250\u00a0mg\u00a0Crizotinib \u00a0oder\u00a0eine\u00a0Zweitlinien \u2010Chemotherapie \u00a0mit\u00a0\nPemetrexed \u00a0oder\u00a0Docetaxel. \u00a0Prim\u00e4rer\u00a0Studienendpunkt \u00a0war\u00a0das\u00a0progressionsfreie \u00a0\u00dcberleben, \u00a0\nwelches\u00a0im\u00a0Crizotinib \u2010Arm\u00a0bei\u00a07,7\u00a0Monaten\u00a0und\u00a0im\u00a0Chemotherapie \u2010Arm\u00a0bei\u00a0drei\u00a0Monaten\u00a0lag.\u00a0Das\u00a0\nobjektive \u00a0Ansprechen \u00a0auf\u00a0Crizotinib \u00a0betrug\u00a065,3\u00a0Prozent\u00a0vs.\u00a019,5\u00a0Prozent\u00a0auf\u00a0die\u00a0Chemotherapie. \u00a0Das\u00a0\nGesamt\u00fcberleben \u00a0war\u00a0in\u00a0beiden\u00a0Armen\u00a0vergleichbar \u00a0hoch,\u00a0da\u00a0nach\u00a0einer\u00a0Interimsanalyse \u00a0ein\u00a0\nCrossover \u00a0m\u00f6glich\u00a0war\u00a0und\u00a0die\u00a0meisten\u00a0Patienten \u00a0aus\u00a0der\u00a0Chemotherapie \u2010Gruppe\u00a0im\u00a0Rezidiv\u00a0\nCrizotinib \u00a0erhielten. \u00a0\nIn\u00a0den\u00a0bis\u00a0dato\u00a0vorliegenden \u00a0Studien\u00a0traten\u00a0unter\u00a0Behandlung \u00a0mit\u00a0Crizotinib \u00a0F\u00e4lle\u00a0von\u00a0schwerer, \u00a0\nlebensbedrohlicher \u00a0oder\u00a0t\u00f6dlicher\u00a0Pneumonitis \u00a0auf.\u00a0Crizotinib \u00a0verl\u00e4ngert \u00a0au\u00dferdem \u00a0das\u00a0QT\u2010Intervall\u00a0\nund\u00a0kann\u00a0Bradykardien \u00a0ausl\u00f6sen, \u00a0was\u00a0bei\u00a0einer\u00a0Kombination \u00a0mit\u00a0anderen,\u00a0Bradykardie \u2010ausl\u00f6senden \u00a0\nArzneimitteln \u00a0(z.B.\u00a0Verapamil, \u00a0Diltiazem, \u00a0Clonidin)\u00a0beachtet\u00a0werden\u00a0sollte.\u00a0Um\u00a0die\u00a0Therapiesicherheit \u00a0\nnicht\u00a0zu\u00a0gef\u00e4hrden, \u00a0sollte\u00a0die\u00a0gleichzeitige \u00a0Anwendung \u00a0von\u00a0Crizotinib \u00a0mit\u00a0starken\u00a0CYP3A4\u2010Inhibitoren \u00a0\nbzw.\u00a0\u2010Induktoren \u00a0und\u00a0CYP3A4\u2010Substraten \u00a0mit\u00a0enger\u00a0therapeutischer \u00a0Breite\u00a0grunds\u00e4tzlich \u00a0vermieden \u00a0\nwerden.\u00a0Gleiches\u00a0gilt\u00a0f\u00fcr\u00a0Grapefruit \u00a0oder\u00a0Grapefruitsaft, \u00a0der\u00a0ebenfalls\u00a0die\u00a0Crizotinib \u2010\nPlasmakonzentration \u00a0erh\u00f6hen\u00a0kann.\u00a0\nF\u00fcr\u00a0Patienten \u00a0mit\u00a0vorbehandeltem, \u00a0fortgeschrittenem \u00a0ALK\u2010positiven\u00a0NSCLC,\u00a0bei\u00a0denen\u00a0eine\u00a0\nChemotherapie \u00a0angezeigt \u00a0ist,\u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0einen\u00a0Anhaltspunkt \u00a0f\u00fcr\u00a0einen\u00a0betr\u00e4chtlichen \u00a0\nZusatznutzen \u00a0von\u00a0Crizotinib \u00a0gegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie, \u00a0bestehend \u00a0aus\u00a0\nDocetaxel \u00a0oder\u00a0Pemetrexed, \u00a0aufgrund\u00a0einer\u00a0deutlichen \u00a0Verbesserung \u00a0der\u00a0Lebensqualit\u00e4t \u00a0und\u00a0einer\u00a0\ndeutlichen \u00a0Verringerung \u00a0von\u00a0Symptomen \u00a0wie\u00a0Atemnot, \u00a0Schmerz\u00a0und\u00a0Husten.\u00a0F\u00fcr\u00a0Patienten \u00a0ohne\u00a0\nIndikation \u00a0f\u00fcr\u00a0eine\u00a0Chemotherapie \u00a0ist\u00a0aufgrund\u00a0fehlender \u00a0Daten\u00a0ein\u00a0Zusatznutzen \u00a0gegen\u00fcber \u00a0Best\u00a0\nSupportive \u00a0Care\u00a0nicht\u00a0belegt.\u00a0\u00a0 \u00a0 \n54\u00a0\n \n \nInnovationsreport 2015 \u00a0Verf\u00fcgbare \u00a0Therapien \u00a0\n\u00a0(Zusatz\u2010)Nutzen\n\u00a0Kosten\n\u00a0\n  \n\u00a0\n\u00a0\u00a0  Teurer\u00a0als\u00a0alternative \u00a0\nTherapieoption \u00a0(Docetaxel) \u00a0\n   M\u00f6gliche \u00a0Lebensqualit\u00e4ts \u2010\nverbesserung \u00a0bei\u00a0bestimmten \u00a0\nPatienten   \n Erster\u00a0Tyrosinkinaseinhibitor \u00a0\nder\u00a0anaplastischen \u00a0Lymphom \u2010\nkinase,\u00a0wodurch\u00a0eine\u00a0\nBiomarker \u2010stratifizierte \u00a0\nLungenkrebsbehandlung \u00a0\nerm\u00f6glicht \u00a0wird \u00a0    \nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien :\u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen :\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten :\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien \u00a0\nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0\nB\u00a0 Keine\u00a0Bewertung \u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nCrizotinib \u00a0(Xalkori\u00ae) \u00a0wurde\u00a0seit\u00a0der\u00a0Markteinf\u00fchrung \u00a0in\u00a0jedem\u00a0Monat\u00a0verordnet \u00a0(Abbildung \u00a018),\u00a0eine\u00a0\nZunahme \u00a0der\u00a0monatlichen \u00a0Verschreibungen \u00a0und\u00a0Bruttoums\u00e4tze \u00a0bis\u00a0Juli\u00a02013\u00a0mit\u00a0einem\u00a0vorl\u00e4ufigen \u00a0\nMaximum \u00a0in\u00a0diesem\u00a0Monat\u00a0(Abbildung \u00a018,\u00a0Abbildung \u00a020)\u00a0ist\u00a0deutlich\u00a0zu\u00a0erkennen. \u00a0Die\u00a0Versicherten \u00a0\nmit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0waren\u00a0zum\u00a0gr\u00f6\u00dften\u00a0Teil\u00a0Frauen\u00a0zwischen\u00a040\u00a0und\u00a070\u00a0Jahren\u00a0\n(Abbildung \u00a019).\u00a0Dies\u00a0l\u00e4sst\u00a0sich\u00a0m\u00f6glicherweise \u00a0dadurch\u00a0erkl\u00e4ren,\u00a0dass\u00a0Patienten \u00a0mit\u00a0ALK\u2010positivem \u00a0\nNSCLC\u00a0insgesamt \u00a0j\u00fcnger\u00a0sind\u00a0als\u00a0die\u00a0anderen\u00a0Subgruppen \u00a0des\u00a0NSCLC\u00a0und\u00a0mehr\u00a0Nichtraucher \u00a0oder\u00a0\n\u201eleichte\u201c\u00a0Raucher\u00a0aufweisen. \u00a0\n \u00a0\n \n55\u00a0\n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a018:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Crizotinib \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0\n\u00a0\n \nAbbildung \u00a019:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Crizotinib \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0\n\u00a0\u00a0\n \n56\u00a0\n \n \nInnovationsreport 2015 \u00a0\n\u00a0\nAbbildung \u00a020:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Crizotinib \u00a0nach\u00a0Monaten \u00a0(2012\u2010\n2013)\u00a0\u00a0\n \n57\u00a0\n \nInnovationsreport 2015 \u00a0 4.8 Dapagliflozin \u00a0\nHandelsname: \u00a0Forxiga\u00ae     Hersteller: \u00a0AstraZeneca  \nIndikation: \u00a0Diabetes\u00a0mellitus\u00a0Typ\u00a02\u00a0\u00a0 \u00a0 Markteinf\u00fchrung: \u00a0Dezember \u00a02012 \nATC\u2010Code:\u00a0A10BX09      DDD:\u00a010\u00a0mg \nDarreichungsform: \u00a0Filmtablette  \nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0190\u00a0\nBewertung \u00a0\nDapagliflozin \u00a0wurde\u00a02012\u00a0als\u00a0erster\u00a0Vertreter \u00a0einer\u00a0neuen\u00a0Wirkstoffgruppe \u00a0in\u00a0den\u00a0Handel\u00a0gebracht. \u00a0\nDas\u00a0Mittel\u00a0wirkt\u00a0als\u00a0Natrium\u2010Glucose\u2010Cotransporter \u20102\u2010Hemmer\u00a0und\u00a0sorgt\u00a0daf\u00fcr,\u00a0dass\u00a0in\u00a0der\u00a0Niere\u00a0\n\u00fcber\u00a0die\u00a0Hemmung \u00a0des\u00a0Cotransporters \u00a0weniger\u00a0Glucose\u00a0und\u00a0weniger\u00a0Natrium\u00a0aus\u00a0dem\u00a0Prim\u00e4rharn \u00a0\nr\u00fcckresorbiert \u00a0werden.\u00a0Das\u00a0oral\u00a0einzunehmende \u00a0Mittel\u00a0ist\u00a0zur\u00a0Behandlung \u00a0von\u00a0Diabetes\u00a0mellitus\u00a0Typ\u00a0\n2\u00a0bei\u00a0Erwachsenen \u00a0zugelassen, \u00a0wenn\u00a0Metformin \u00a0nicht\u00a0vertragen \u00a0wird\u00a0oder\u00a0alleine\u00a0nicht\u00a0ausreichend \u00a0\nwirksam\u00a0ist.\u00a0\u00a0\nZum\u00a0Zeitpunkt \u00a0der\u00a0Zulassung \u00a0wurden\u00a0verschiedene \u00a0Sicherheitssignale \u00a0eingehend \u00a0betrachtet. \u00a0Dazu\u00a0\ngeh\u00f6rten\u00a0u.a.\u00a0verschiedene \u00a0Krebserkrankungen, \u00a0Knochenfrakturen, \u00a0schwere\u00a0Harnweg\u2010\u00a0bzw.\u00a0\nGenitalinfektionen. \u00a0Die\u00a0vom\u00a0pU\u00a0bereit\u00a0gestellten \u00a0Informationen \u00a0reichten\u00a0der\u00a0Europ\u00e4ischen \u00a0\nZulassungsbeh\u00f6rde \u00a0aus,\u00a0um\u00a0die\u00a0Sicherheitsbedenken \u00a0zu\u00a0zerstreuen \u00a0und\u00a0das\u00a0Mittel\u00a0Ende\u00a02012\u00a0\neuropaweit \u00a0zuzulassen. \u00a0Die\u00a0amerikanische \u00a0Zulassungsbeh\u00f6rde \u00a0hingegen\u00a0stimmte\u00a0einer\u00a0Zulassung \u00a0erst\u00a0\nAnfang\u00a02014\u00a0zu\u00a0und\u00a0fordert\u00a0weitere\u00a0Untersuchungen \u00a0zur\u00a0kardiovaskul\u00e4ren \u00a0Sicherheit \u00a0bei\u00a0\nRisikopatienten, \u00a0Studien\u00a0zur\u00a0besseren\u00a0Absch\u00e4tzung \u00a0des\u00a0Risikos\u00a0f\u00fcr\u00a0die\u00a0Entwicklung \u00a0eines\u00a0\nBlasenkarzinoms \u00a0(randomisierte, \u00a0klinische\u00a0Studien\u00a0und\u00a0tierexperimentelle \u00a0Untersuchungen) \u00a0sowie\u00a0\nein\u00a0Pharmakovigilanzprogramm \u00a0zur\u00a0Dokumentation \u00a0von\u00a0Leberfunktionsst\u00f6rungen \u00a0und\u00a0den\u00a0Erfah\u2010\nrungen\u00a0in\u00a0Schwangerschaft \u00a0und\u00a0Stillzeit.\u00a0\nF\u00fcr\u00a0die\u00a0Zulassung \u00a0wurden\u00a0Daten\u00a0von\u00a0insgesamt \u00a0elf\u00a0randomisierten \u00a0kontrollierten \u00a0doppelblinden \u00a0\nPhase\u2010III\u2010Studien\u00a0mit\u00a0in\u00a0Summe\u00a05.700\u00a0Patienten \u00a0ausgewertet. \u00a0Dapagliflozin \u00a0f\u00fchrte\u00a0in\u00a0Placebo\u2010\nkontrollierten \u00a0Studien\u00a0zu\u00a0einer\u00a0m\u00e4\u00dfigen\u00a0Senkung\u00a0des\u00a0HB1Ac\u2010Wertes\u00a0von\u00a00,55\u00a0bis\u00a00,8\u00a0Prozent\u00a0und\u00a0\nzeigte\u00a0in\u00a0direkt\u00a0vergleichenden \u00a0Studien\u00a0hierin\u00a0eine\u00a0Nicht\u2010Unterlegenheit \u00a0gegen\u00fcber \u00a0\nSulfonylharnstoffen \u00a0(Glipizid,\u00a0in\u00a0Deutschland \u00a0au\u00dfer\u00a0Handel)\u00a0und\u00a0Metformin. \u00a0Dar\u00fcber\u00a0hinaus\u00a0liegen\u00a0\nplacebokontrollierte \u00a0Untersuchungen \u00a0mit\u00a0Dapagliflozin \u00a0als\u00a0Add\u2010on\u2010Medikation \u00a0zu\u00a0Metformin, \u00a0\nSulfonylharnstoffen, \u00a0Pioglitazon, \u00a0Sitagliptin \u00a0und\u00a0Insulin\u00a0vor.\u00a0\u00a0\nUnter\u00a0Dapagliflozin \u00a0werden\u00a0vermehrt \u00a0urogentiale \u00a0Infektionen \u00a0wie\u00a0Harnweginfektionen, \u00a0Vulvo\u2010\nvaginitis\u00a0und\u00a0Balanitis\u00a0beobachtet, \u00a0da\u00a0es\u00a0zu\u00a0einer\u00a0Glukoseanreicherung \u00a0im\u00a0Harn\u00a0kommt.\u00a0Diese\u00a0\nNebenwirkungen \u00a0treten\u00a0bei\u00a0einem\u00a0bis\u00a0zehn\u00a0von\u00a0100\u00a0Behandelten \u00a0auf.\u00a0Als\u00a0potentielle \u00a0\nUnvertr\u00e4glichkeiten \u00a0in\u00a0der\u00a0Langzeitbehandlung \u00a0m\u00fcssen\u00a0Auswirkungen \u00a0auf\u00a0die\u00a0Nieren\u2010\u00a0und\u00a0\nLeberfunktion \u00a0und\u00a0den\u00a0Knochenstoffwechsel \u00a0und\u00a0verschiedene \u00a0Krebserkrankungen \u00a0(Blase,\u00a0Prostata\u00a0\nund\u00a0Brust)\u00a0weiter\u00a0unter\u00a0Beobachtung \u00a0bleiben.\u00a0\nDapagliflozin \u00a0wurde\u00a0im\u00a0Jahr\u00a02013\u00a0bzgl.\u00a0seines\u00a0Zusatznutzens \u00a0in\u00a0der\u00a0antidiabetischen \u00a0Therapie\u00a0\nbewertet. \u00a0Da\u00a0der\u00a0pU\u00a0keine\u00a0geeigneten \u00a0Daten\u00a0zur\u00a0Beurteilung \u00a0der\u00a0Vor\u2010\u00a0und\u00a0Nachteile \u00a0von\u00a0\nDapagliflozin \u00a0vorlegen\u00a0konnte,\u00a0wurde\u00a0durch\u00a0das\u00a0IQWiG\u00a0f\u00fcr\u00a0keines\u00a0der\u00a0genannten \u00a0\nAnwendungsgebiete \u00a0ein\u00a0Zusatznutzen \u00a0festgestellt. \u00a0Dieser\u00a0Ansicht\u00a0folgte\u00a0der\u00a0G\u2010BA\u00a0in\u00a0seiner\u00a0\nBeschlussfassung \u00a0vom\u00a06.\u00a0Juni\u00a02013\u00a0und\u00a0stellte\u00a0fest,\u00a0dass\u00a0weder\u00a0f\u00fcr\u00a0die\u00a0Monotherapie \u00a0mit\u00a0 \n58\u00a0\n \n \nInnovationsreport 2015 \u00a0Dapagliflozin, \u00a0noch\u00a0f\u00fcr\u00a0die\u00a0Kombinationstherapie \u00a0von\u00a0Dapagliflozin \u00a0mit\u00a0Metformin, \u00a0mit\u00a0einem\u00a0\nSulfonylharnstoff \u00a0oder\u00a0mit\u00a0Insulin\u00a0ein\u00a0Zusatznutzen \u00a0belegt\u00a0ist.\u00a0\u00a0\nZeitweilig \u00a0setzte\u00a0der\u00a0pU\u00a0im\u00a0Anschluss \u00a0an\u00a0die\u00a0beh\u00f6rdliche \u00a0Stellungnahme \u00a0die\u00a0Produkte\u00a0au\u00dfer\u00a0Vertrieb.\u00a0\nErst\u00a0nach\u00a0einer\u00a0Einigung\u00a0in\u00a0den\u00a0Preisverhandlungen \u00a0waren\u00a0die\u00a0Mittel\u00a0wieder\u00a0im\u00a0deutschen \u00a0\nArzneimittelmarkt \u00a0verf\u00fcgbar. \u00a0\u00a0\n\u00a0\nVerf\u00fcgbare \u00a0Therapien \u00a0\n\u00a0(Zusatz\u2010)Nutzen\u00a0\n\u00a0Kosten\u00a0\n\u00a0\n  \u00a0 Keine\u00a0therapeutisch \u00a0relevanten \u00a0\nVorteile\u00a0gegen\u00fcber \u00a0verf\u00fcgbaren \u00a0\nTherapieoptionen. \u00a0Es\u00a0fehlen\u00a0\nStudien\u00a0zu\u00a0patientenrelevanten \u00a0\nEndpunkten  Teurer\u00a0als\u00a0alternative \u00a0\nTherapieoptionen \u00a0\n Erster\u00a0Vertreter \u00a0einer\u00a0neuen\u00a0\nWirkstoffgruppe, \u00a0aber\u00a0lediglich\u00a0\nweitere\u00a0Therapieoption  \u00a0  \n\u00a0\n\u00a0\n    \n   \nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien :\u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen :\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten :\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien \u00a0\nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0 AMB\u2010Bewertung \u00a0\nA/C\u00a0 Umstrittenes \u00a0Therapieprinzip \u00a0 Keine\u00a0Empfehlung \u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nDie\u00a0Verordnungszahlen \u00a0des\u00a0SGLT2\u2010Inhibitors \u00a0Dapagliflozin \u00a0(Forxiga\u00ae) \u00a0erreichten \u00a0schon\u00a0drei\u00a0Monate\u00a0\nnach\u00a0seiner\u00a0Markteinf\u00fchrung \u00a0ein\u00a0Niveau\u00a0von\u00a0knapp\u00a0400\u00a0Packungen \u00a0(Abbildung \u00a021).\u00a0Nachdem \u00a0der\u00a0\nGemeinsame \u00a0Bundesausschuss \u00a0in\u00a0seinem\u00a0Beschluss \u00a0(Juni\u00a02013)\u00a0zur\u00a0fr\u00fchen\u00a0Nutzenbewertung \u00a0keinen\u00a0\nZusatznutzen \u00a0im\u00a0Verh\u00e4ltnis \u00a0zur\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0feststellen \u00a0konnte,\u00a0scheinen\u00a0sich\u00a0\ndie\u00a0monatlichen \u00a0Verordnungszahlen \u00a0und\u00a0Bruttoums\u00e4tze \u00a0auf\u00a0dem\u00a0bis\u00a0Juni\u00a02013\u00a0erreichten \u00a0Niveau\u00a0zu\u00a0\nstabilisieren \u00a0(Abbildung \u00a023).\u00a0Die\u00a0Umsatzzahlen \u00a0lagen\u00a0im\u00a0letzten\u00a0Quartal\u00a02013\u00a0zwischen\u00a0140.000\u00a0und\u00a0\n150.000\u00a0Euro.\u00a0Die\u00a0meisten\u00a0Versicherten \u00a0mit\u00a0Forxiga\u00ae\u2010Verordnung \u00a0waren\u00a0zwischen\u00a050\u00a0und\u00a070\u00a0Jahre\u00a0\nalt\u00a0und\u00a0zu\u00a0einem\u00a0gr\u00f6\u00dferen \u00a0Teil\u00a0m\u00e4nnlich\u00a0(Abbildung \u00a022).\u00a0\u00a0\n\u00a0\u00a0\n \n59\u00a0\n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a021:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Dapagliflozin \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0\n\u00a0\n \nAbbildung \u00a022:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Dapagliflozin \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0\n(2013)\u00a0\n\u00a0\u00a0\n \n60\u00a0\n \n \nInnovationsreport 2015 \u00a0\n\u00a0\nAbbildung \u00a023:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Dapagliflozin \u00a0nach\u00a0Monaten \u00a0(2012\u2010\n2013)\u00a0 \u00a0\n \n61\u00a0\n \nInnovationsreport 2015 \u00a0 4.9 Decitabin \u00a0\nHandelsname: \u00a0Dacogen\u00ae     Hersteller: \u00a0Janssen\u00a0Cilag \nIndikation: \u00a0Akute\u00a0myeloische \u00a0Leuk\u00e4mie   Markteinf\u00fchrung: \u00a0November \u00a02012 \nATC\u2010Code:\u00a0L01BC08\u00a0    DDD:\u00a06,43\u00a0mg \nDarreichungsform: \u00a0Pulver\u00a0zur\u00a0Herstellung \u00a0einer\u00a0Infusionsl\u00f6sung  \nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0194\u00a0\nBewertung \u00a0\nDecitabin \u00a0ist\u00a0ein\u00a0Cytidin\u2010Desoxynucleosid \u2010Analogon \u00a0mit\u00a0dualem\u00a0Wirkungsmechanismus. \u00a0Nach\u00a0\nintrazellul\u00e4rer \u00a0Umwandlung \u00a0zum\u00a0Triphosphat \u00a0wird\u00a0es\u00a0als\u00a0Antimetabolit \u00a0in\u00a0die\u00a0DNA\u00a0eingebaut \u00a0und\u00a0\nst\u00f6rt\u00a0so\u00a0als\u00a0klassisches \u00a0Zytostatikum \u00a0die\u00a0Zellproliferation. \u00a0Zudem\u00a0hemmt\u00a0es\u00a0die\u00a0DNA\u2010\nMethyltransferase, \u00a0ein\u00a0Enzym,\u00a0welches\u00a0die\u00a0Promoterregion \u00a0von\u00a0Tumorsuppressorgenen \u00a0methyliert \u00a0\nund\u00a0das\u00a0Ablesen\u00a0dieser\u00a0Gene\u00a0hemmt.\u00a0Nach\u00a0Azacitidin \u00a0ist\u00a0Decitabin \u00a0der\u00a0zweite\u00a0Methyltransferase \u2010\nHemmer, \u00a0der\u00a0zur\u00a0Behandlung \u00a0von\u00a0Patienten \u00a0ab\u00a0einem\u00a0Alter\u00a0von\u00a065\u00a0Jahren\u00a0mit\u00a0neu\u00a0diagnostizierter \u00a0de\u00a0\nnovo\u00a0oder\u00a0sekund\u00e4rer \u00a0akuter\u00a0myeloischer \u00a0Leuk\u00e4mie \u00a0(AML)\u00a0zugelassen \u00a0wurde,\u00a0f\u00fcr\u00a0die\u00a0eine\u00a0Standard\u2010\nInduktionschemotherapie \u00a0nicht\u00a0in\u00a0Frage\u00a0kommt.\u00a0Da\u00a0die\u00a0AML\u00a0als\u00a0seltene\u00a0Erkrankung \u00a0gilt,\u00a0wurde\u00a0\nDecitabin \u00a02006\u00a0von\u00a0der\u00a0EMA\u00a0als\u00a0Orphan\u00a0Drug\u00a0ausgewiesen. \u00a0\u00a0\nAufgrund \u00a0geringer\u00a0Toleranz\u00a0gegen\u00fcber \u00a0intensiver \u00a0Induktionschemotherapie \u00a0sowie\u00a0Post\u2010Remissions \u2010\nChemotherapien \u00a0sind\u00a0die\u00a0Behandlungsm\u00f6glichkeiten \u00a0f\u00fcr\u00a0AML\u2010Patienten, \u00a0die\u00a065\u00a0Jahre\u00a0und\u00a0\u00e4lter\u00a0sind,\u00a0\nbegrenzt. \u00a0So\u00a0erfolgte\u00a0die\u00a0Bewertung \u00a0durch\u00a0die\u00a0EMA\u00a0von\u00a0Decitabin \u00a0zum\u00a0Zeitpunkt \u00a0der\u00a0Zulassung \u00a0\nhaupts\u00e4chlich \u00a0auf\u00a0Grundlage \u00a0einer\u00a0nicht\u2010verblindeten \u00a0randomisierten \u00a0kontrollierten \u00a0Studie\u00a0an\u00a0485\u00a0\nPatienten. \u00a0Untersucht \u00a0wurden\u00a0die\u00a0Effekte\u00a0von\u00a0Decitabin \u00a0im\u00a0Vergleich \u00a0BSC\u00a0bzw.\u00a0niedrig\u00a0dosiertem \u00a0\nCytarabin. \u00a0Zum\u00a0prim\u00e4ren \u00a0Erhebungszeitpunkt \u00a0konnte\u00a0gegen\u00fcber \u00a0der\u00a0Kontrollgruppe \u00a0f\u00fcr\u00a0Decitabin \u00a0\neine\u00a0numerische, \u00a0aber\u00a0statistisch \u00a0nicht\u00a0signifikante \u00a0Verl\u00e4ngerung \u00a0der\u00a0Gesamt\u00fcberlebenszeit \u00a0um\u00a02,7\u00a0\nMonate\u00a0beobachtet \u00a0werden.\u00a0Erst\u00a0in\u00a0der\u00a0ungeplanten \u00a0Analyse\u00a0nach\u00a0einem\u00a0Jahr\u00a0wurde\u00a0f\u00fcr\u00a0die\u00a0\nDifferenz\u00a0in\u00a0der\u00a0Gesamt\u00fcberlebenszeit \u00a0statistische \u00a0Signifikanz \u00a0erreicht.\u00a0\u00a0\nAls\u00a0sehr\u00a0h\u00e4ufige\u00a0Nebenwirkungen \u00a0traten\u00a0vor\u00a0allem\u00a0Myelosuppression \u00a0und\u00a0damit\u00a0verbunden \u00a0\nThrombozytopenie, \u00a0Neutropenie \u00a0mit\u00a0und\u00a0ohne\u00a0Fieber\u00a0und\u00a0An\u00e4mie\u00a0sowie\u00a0Pneumonie \u00a0auf.\u00a0Das\u00a0\nSicherheitsprofil \u00a0von\u00a0Decitabin \u00a0\u00e4hnelt\u00a0dem\u00a0von\u00a0niedrig\u00a0dosiertem \u00a0Cytarabin, \u00a0allerdings \u00a0traten\u00a0\nInfektionen \u00a0und\u00a0Neutropenie \u00a0unter\u00a0dem\u00a0neueren\u00a0Wirkstoff \u00a0h\u00e4ufiger\u00a0auf.\u00a0\nF\u00fcr\u00a0Decitabin \u00a0als\u00a0Orphan\u2010Arzneimittel \u00a0gilt\u00a0der\u00a0Zusatznutzen \u00a0durch\u00a0die\u00a0Zulassung \u00a0als\u00a0belegt.\u00a0Trotz\u00a0der\u00a0\nSchwere\u00a0der\u00a0Erkrankung \u00a0AML\u00a0und\u00a0der\u00a0wenigen\u00a0Therapieoptionen \u00a0f\u00fcr\u00a0\u00e4ltere\u00a0Patienten \u00a0konstatiert \u00a0der\u00a0\nG\u2010BA\u00a0nur\u00a0einen\u00a0geringen\u00a0Zusatznutzen \u00a0f\u00fcr\u00a0Decitabin. \u00a0\n \u00a0 \n62\u00a0\n \n \nInnovationsreport 2015 \u00a0Verf\u00fcgbare \u00a0Therapien  \n\u00a0(Zusatz\u2010)Nutzen\n\u00a0Kosten\n\u00a0\n Zweiter\u00a0Methyltransferase \u2010\nHemmer\u00a0zur\u00a0Behandlung \u00a0einer\u00a0\nneu\u00a0diagnostizierten \u00a0de\u00a0novo\u00a0\noder\u00a0sekund\u00e4ren \u00a0akuten\u00a0AML \u00a0 Keine\u00a0sichere\u00a0Aussage\u00a0zum\u00a0\nGesamt\u00fcberleben \u00a0m\u00f6glich.\u00a0\nHinweise\u00a0auf\u00a0die\u00a0Unterlegenheit \u00a0\nvon\u00a0Decitabin \u00a0gegen\u00fcber \u00a0Azacitidin \u00a0\nbzw.\u00a0niedrig\u00a0dosiertem \u00a0Cytarabin \u00a0\nbei\u00a0Patienten \u00a0mit\u00a0Myelo\u2010\ndysplastischem \u00a0Syndrom\u00a0(MDS)  Teurer\u00a0als\u00a0alternative \u00a0Thera\u2010\npieoption \u00a0\n  \u00a0  \n\u00a0\n\u00a0 \n    \n\u00a0\n\u00a0\nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien :\u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen :\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten :\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien \u00a0\nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0\nC\u00a0 Keine\u00a0Bewertung \u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nVom\u00a0Orphan\u00a0Drug\u00a0Decitabin \u00a0(Dacogen\u00ae) \u00a0finden\u00a0sich\u00a0in\u00a0den\u00a0Routinedaten \u00a0zun\u00e4chst\u00a0ausschlie\u00dflich \u00a0\nRezepturabrechnungen, \u00a0sp\u00e4ter\u00a0erfolgen\u00a0\u00fcberraschenderweise \u00a0Verordnungen \u00a0der\u00a0N1\u2010Packungen \u00a0\n(Abbildung \u00a024).\u00a0Trotz\u00a0niedriger\u00a0Verordnungszahlen \u00a0schwankten \u00a0die\u00a0Ums\u00e4tze\u00a0aufgrund\u00a0des\u00a0hohen\u00a0\nArzneimittelverkaufspreises \u00a0im\u00a0Jahr\u00a02013\u00a0grob\u00a0zwischen\u00a040.000\u00a0und\u00a0160.000\u00a0Euro\u00a0je\u00a0Monat\u00a0\n(Abbildung \u00a026).\u00a0Die\u00a0meisten\u00a0Versicherten \u00a0waren\u00a0m\u00e4nnlich\u00a0und\u00a0zwischen\u00a070\u00a0und\u00a080\u00a0Jahre\u00a0alt,\u00a0und\u00a0\nobwohl\u00a0das\u00a0Medikament \u00a0f\u00fcr\u00a0erwachsene \u00a0Patienten \u00a0ab\u00a0einem\u00a0Alter\u00a0von\u00a065\u00a0Jahren\u00a0zugelassen \u00a0wurde,\u00a0\nzeigten\u00a0die\u00a0Auswertungen \u00a0auch\u00a0Verordnungen \u00a0in\u00a0j\u00fcngeren\u00a0Altersgruppen \u00a0(Abbildung \u00a025).\u00a0\u00a0\n \u00a0\n \n63\u00a0\n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a024:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Decitabin \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0\n\u00a0\n \nAbbildung \u00a025:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Decitabin \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0\n \u00a0\n \n64\u00a0\n \n \nInnovationsreport 2015 \u00a0\n\u00a0\nAbbildung \u00a026:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Decitabin \u00a0nach\u00a0Monaten \u00a0(2012\u2010\n2013)\u00a0\u00a0\n \n65\u00a0\n \nInnovationsreport 2015 \u00a0 4.10 Ivacaftor\u00a0\nHandelsname: \u00a0Kalydeco\u00ae     Hersteller: \u00a0Vertex  \nIndikation: \u00a0Zystische\u00a0Fibrose\u00a0(Mukoviszidose) \u00a0 Markteinf\u00fchrung: \u00a0August\u00a02012 \nATC\u2010Code:\u00a0R07AX02\u00a0    DDD:\u00a00,3\u00a0g \nDarreichungsform: \u00a0Filmtablette  \nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0198 \nBewertung \u00a0\nIvacaftor\u00a0ist\u00a0zugelassen \u00a0zur\u00a0Behandlung \u00a0der\u00a0zystischen \u00a0Fibrose\u00a0bei\u00a0Patienten \u00a0ab\u00a0sechs\u00a0Jahren\u00a0mit\u00a0\neiner\u00a0G551D\u2010Mutation \u00a0im\u00a0Cystic\u00a0Fibrosis\u00a0Transmembrane \u00a0Conductance \u00a0Regulator \u00a0(CFTR)\u2010Gen.\u00a0Der\u00a0\nWirkstoff \u00a0kann\u00a0als\u00a0erstes\u00a0kausal\u00a0wirkendes \u00a0Arzneimittel \u00a0bei\u00a0Mukoviszidose \u2010Patienten \u00a0mit\u00a0\nnachgewiesenen \u00a0Gating\u2010Mutationen \u00a0der\u00a0Klasse\u00a0III\u00a0therapeutisch \u00a0eingesetzt \u00a0werden.\u00a0Ivacaftor\u00a0ist\u00a0als\u00a0\nOrphan\u00a0Drug\u00a0zugelassen. \u00a0\u00a0\nIvacaftor\u00a0wurde\u00a0f\u00fcr\u00a0die\u00a0zugelassene \u00a0Indikation \u00a0in\u00a0zwei\u00a0doppelblinden, \u00a0randomisiserten, \u00a0Placebo\u2010\nkontrollierten \u00a0Studien\u00a0der\u00a0Phase\u00a0III\u00a0an\u00a0relativ\u00a0kleinen\u00a0Patientenkollektiven \u00a0\u00fcber\u00a048\u00a0\nBehandlungswochen \u00a0untersucht. \u00a0Als\u00a0Surrogat\u00a0f\u00fcr\u00a0patientenrelevante \u00a0Endpunkte \u00a0wurde\u00a0in\u00a0den\u00a0\nUntersuchungen \u00a0die\u00a0Lungenfunktion \u00a0(gemessen \u00a0als\u00a0forcierte\u00a0Einsekundenkapazit\u00e4t \u00a0(FEV1%))\u00a0\nverbessert. \u00a0Au\u00dferdem \u00a0ergab\u00a0sich\u00a0eine\u00a0im\u00a0Vergleich \u00a0zu\u00a0Placebo\u00a0deutlichere \u00a0(m\u00f6glicherweise \u00a0\nprognosverbessernde) \u00a0Gewichtszunahme \u00a0bei\u00a0den\u00a0mit\u00a0Ivacaftor\u00a0behandelten \u00a0Personen. \u00a0Bei\u00a0Patienten \u00a0\n\u00fcber\u00a0zw\u00f6lf\u00a0Jahren\u00a0und\u00a0Erwachsenen \u00a0konnten\u00a0durch\u00a0die\u00a0Behandlung \u00a0zudem\u00a0die\u00a0Rate\u00a0an\u00a0\nExazerbationen \u00a0reduziert\u00a0und\u00a0die\u00a0Lebensqualit\u00e4t \u00a0verbessert \u00a0werden.\u00a0Eine\u00a0aktuelle\u00a0systematische \u00a0\n\u00dcbersicht \u00a0best\u00e4tigt\u00a0f\u00fcr\u00a0Ivacaftor\u00a0im\u00a0Vergleich \u00a0zu\u00a0Placebo\u00a0sowohl\u00a0f\u00fcr\u00a0Kinder\u00a0als\u00a0auch\u00a0f\u00fcr\u00a0Erwachsene \u00a0\nmit\u00a0Gating\u2010Mutationen \u00a0der\u00a0Klasse\u00a0III\u00a0eine\u00a0Verbesserung \u00a0der\u00a0Lungenfunktion \u00a0und\u00a0f\u00fcr\u00a0\u00e4ltere\u00a0Kinder\u00a0und\u00a0\nErwachsene \u00a0eine\u00a0Verringerung \u00a0der\u00a0Exazerbationsrate \u00a0oder\u00a0von\u00a0Krankenhauseinweisungen \u00a0und\u00a0der\u00a0\nNotwendigkeit \u00a0einer\u00a0intraven\u00f6sen \u00a0Antibiotikagabe. \u00a0Ivacaftor\u00a0ist\u00a0dagegen\u00a0bei\u00a0Patienten \u00a0mit\u00a0Gating\u2010\nMutationen \u00a0der\u00a0Klasse\u00a0II\u00a0nach\u00a0den\u00a0bisher\u00a0verf\u00fcgbaren \u00a0Daten\u00a0nicht\u00a0therapeutisch \u00a0wirksam.\u00a0\u00a0\nIn\u00a0beiden\u00a0Studien\u00a0traten\u00a0Nebenwirkungen \u00a0in\u00a0den\u00a0Behandlungsgruppen \u00a0h\u00e4ufig\u00a0auf,\u00a0insbesondere \u00a0\nKopfschmerzen, \u00a0obere\u00a0Atemwegserkrankungen, \u00a0Durchfall\u00a0und\u00a0Schwindel. \u00a0Schwere\u00a0unerw\u00fcnschte \u00a0\nWirkungen \u00a0wurden\u00a0aber\u00a0unter\u00a0Placebo\u00a0h\u00e4ufiger\u00a0beobachtet, \u00a0auch\u00a0wurde\u00a0die\u00a0Studienbehandlung \u00a0\nunter\u00a0Placebo\u00a0h\u00e4ufiger\u00a0wegen\u00a0unerw\u00fcnschter \u00a0Wirkungen \u00a0abgebrochen. \u00a0Diese\u00a0Unterschiede \u00a0sind\u00a0aber\u00a0\nnicht\u00a0statistisch \u00a0signifikant. \u00a0Da\u00a0der\u00a0Wirkstoff \u00a0\u00fcber\u00a0das\u00a0Cytochrom \u00a0P\u00a0450\u2010Enzymsystem, \u00a0insbesondere \u00a0\n\u00fcber\u00a0CYP3A4\u00a0bzw.\u00a0CYP3A5,\u00a0metabolisiert \u00a0wird,\u00a0sind\u00a0beim\u00a0therapeutischen \u00a0Einsatz\u00a0zahlreiche \u00a0\nInteraktionen \u00a0mit\u00a0starken\u00a0Inhibitoren \u00a0bzw.\u00a0Induktoren \u00a0dieser\u00a0Isoenzyme \u00a0zu\u00a0beachten. \u00a0\nDas\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens \u00a0von\u00a0Ivacaftor\u00a0wurde\u00a0durch\u00a0den\u00a0G\u2010BA\u00a0nach\u00a0\u00a7\u00a035a\u00a0Absatz\u00a01\u00a0Satz\u00a010\u00a0\ni.V.m.\u00a05.\u00a0Kapitel\u00a0\u00a7\u00a012\u00a0Nr.\u00a01\u00a0Satz\u00a02\u00a0VerfO\u00a0auf\u00a0Grundlage \u00a0der\u00a0Zulassungsstudien \u00a0bewertet. \u00a0Auf\u00a0Basis\u00a0von\u00a0\nzwei\u00a0randomisiert \u2010kontrollierten \u00a0Phase\u2010III\u2010Studien\u00a0wird\u00a0dem\u00a0Mittel\u00a0\u2013\u00a0subgruppenspezifisch \u00a0\u2013\u00a0ein\u00a0\nZusatznutzen \u00a0bei\u00a0Patienten \u00a0mit\u00a0einer\u00a0G551D\u2010Mutation \u00a0im\u00a0CFTR\u2010Gen\u00a0attestiert: \u00a0F\u00fcr\u00a0Kinder\u00a0zwischen\u00a0\nsechs\u00a0und\u00a0elf\u00a0Jahren\u00a0besitzt\u00a0Ivacaftor\u00a0danach\u00a0aufgrund\u00a0der\u00a0Verbesserung \u00a0der\u00a0Lungenfunktion \u00a0und\u00a0\ngegebenenfalls \u00a0auch\u00a0einer\u00a0Gewichtszunahme \u00a0einen\u00a0geringen\u00a0Zusatznutzen .\u00a0Aussagen \u00a0zu\u00a0klinisch\u00a0\nrelevanten \u00a0Endpunkten \u00a0wie\u00a0Verringerung \u00a0von\u00a0Exazerbationen \u00a0oder\u00a0zur\u00a0Verbesserung \u00a0der\u00a0\nLebensqualit\u00e4t \u00a0k\u00f6nnen\u00a0f\u00fcr\u00a0dieses\u00a0Patientenkollektiv \u00a0nicht\u00a0gemacht\u00a0werden.\u00a0F\u00fcr\u00a0Jugendliche \u00a0(ab\u00a0zw\u00f6lf\u00a0\nJahre)\u00a0und\u00a0Erwachsene \u00a0wird\u00a0dagegen\u00a0ein\u00a0betr\u00e4chtlicher \u00a0Zusatznutzen \u00a0gesehen:\u00a0Ivacaftor\u00a0f\u00fchrt\u00a0bei\u00a0\ndiesem\u00a0Kollektiv\u00a0zu\u00a0einer\u00a0Verbesserung \u00a0der\u00a0Lungenfunktion \u00a0(FEV1%)\u00a0und\u00a0einer\u00a0Gewichtszunahme, \u00a0\nzeigt\u00a0aber\u00a0auch\u00a0eine\u00a0Verringerung \u00a0der\u00a0Exazerbationsrate. \u00a0\u00a0 \n66\u00a0\n \n \nInnovationsreport 2015 \u00a0Im\u00a0Februar\u00a02015\u00a0wurde\u00a0f\u00fcr\u00a0die\u00a0Erweiterung \u00a0der\u00a0Zulassungsgebiete \u00a0auf\u00a0Mukoviszidose \u2010Patienten \u00a0mit\u00a0\nGating\u2010Mutationen \u00a0G1244E,\u00a0G1349D,\u00a0G178R,\u00a0G551S,\u00a0S1251N,\u00a0S1255P,\u00a0S549N\u00a0und\u00a0S549R\u00a0ebenfalls\u00a0\nein\u00a0geringer\u00a0Zusatznutzen \u00a0festgestellt. \u00a0In\u00a0den\u00a0vorhandenen \u00a0Studien\u00a0waren\u00a0nur\u00a0wenige\u00a0Patienten \u00a0mit\u00a0\nNon\u2010G551D\u2010Mutationen \u00a0vertreten. \u00a0Die\u00a0Daten\u00a0zeigen\u00a0f\u00fcr\u00a0Patienten \u00a0mit\u00a0milder\u00a0bis\u00a0moderater \u00a0\nLungenerkrankung \u00a0eine\u00a0signifikante \u00a0Verbesserung \u00a0der\u00a0Lungenfunktion \u00a0(FEV1%)\u00a0sowie\u00a0eine\u00a0leichte\u00a0\nVerbesserung \u00a0des\u00a0BMI\u00a0und\u00a0lassen\u00a0eine\u00a0Verbesserung \u00a0der\u00a0Lebensqualit\u00e4t \u00a0erkennen. \u00a0Valide\u00a0Aussagen \u00a0\nzur\u00a0Verminderung \u00a0von\u00a0Exazerbationen \u00a0des\u00a0Krankheitsbildes \u00a0lassen\u00a0sich\u00a0dagegen\u00a0nicht\u00a0ableiten.\u00a0\u00a0\n\u00a0\nVerf\u00fcgbare \u00a0Therapien \u00a0\n\u00a0(Zusatz\u2010)Nutzen\n\u00a0Kosten\n\u00a0\n  \u00a0\n \n  F\u00fcr\u00a0das\u00a0zugelassene \u00a0\nPatientenkollektiv \u00a0einzige\u00a0\nkausal\u00a0wirkende \u00a0\nTherapieoption. \u00a0Aus\u00a0diesem\u00a0\nGrund\u00a0findet\u00a0kein\u00a0\nKostenvergleich \u00a0statt\u00a0\n F\u00fcr\u00a0das\u00a0zugelassene \u00a0Patienten \u2010\nkollektiv\u00a0einzige\u00a0kausal\u00a0wirken\u2010\nde\u00a0Therapieoption. \u00a0Allerdings \u00a0\nprofitiert\u00a0nur\u00a0ein\u00a0relativ\u00a0kleiner\u00a0\nAnteil\u00a0der\u00a0Mukoviszidose \u2010\nPatienten \u00a0von\u00a0dem\u00a0Wirkstoff   Keine\u00a0Daten\u00a0zur\u00a0Mortalit\u00e4t. \u00a0Bei\u00a0\nKindern\u00a0ab\u00a06\u00a0Jahren,\u00a0Jugendlichen \u00a0\nund\u00a0Erwachsenen \u00a0Verbesserungen \u00a0\nder\u00a0Lungenfunktion; \u00a0bei\u00a0Kindern\u00a0\nund\u00a0Jugendlichen \u00a0ab\u00a012\u00a0Jahren\u00a0\nsowie\u00a0Erwachsenen \u00a0Reduktion \u00a0von\u00a0\nExazerbationen. \u00a0Allerdings \u00a0fehlen\u00a0\nDaten\u00a0zur\u00a0Langzeitvertr\u00e4glichkeit   \n \n \u00a0   \n \n \nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien :\u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen :\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten :\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien \u00a0\nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0\nA\u00a0 Keine\u00a0Bewertung \u00a0\u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nDas\u00a0Orphan\u2010Arzneimittel \u00a0Ivacaftor\u00a0(Kalydeco\u00ae) \u00a0wurde\u00a0im\u00a0untersuchten \u00a0Zeitraum\u00a0lediglich\u00a0an\u00a0acht\u00a0TK\u2010\nVersicherte \u00a0(\u00fcberwiegend \u00a0m\u00e4nnliche \u00a0Kinder\u00a0und\u00a0Jugendliche) \u00a0verabreicht \u00a0(Abbildung \u00a028).\u00a0\nDementsprechend \u00a0waren\u00a0auch\u00a0die\u00a0Verordnungszahlen \u00a0\u00fcberschaubar \u00a0(Abbildung \u00a027).\u00a0Dennoch\u00a0\nerzielte\u00a0das\u00a0erste\u00a0Arzneimittel \u00a0zur\u00a0Behandlung \u00a0der\u00a0zystischen \u00a0Fibrose\u00a0(Mukoviszidose) \u00a0mit\u00a0einer\u00a0\nG551D\u2010Mutation \u00a0im\u00a0Gen\u00a0des\u00a0Cystic\u00a0Fibrosis\u00a0Transmembrane \u00a0Conductance \u00a0Regulator \u00a0(CFTR)\u00a0aufgrund\u00a0\ndes\u00a0relativen\u00a0hohen\u00a0Preises\u00a0(Apothekenverkaufspreis \u00a0N2\u00a025.504,69 \u00a0Euro,\u00a0Lauer\u2010Taxe\u00a0Stand:\u00a0\nNovember \u00a02013)\u00a0im\u00a0November \u00a02013\u00a0einen\u00a0Umsatz\u00a0von\u00a0gut\u00a0280.000\u00a0Euro\u00a0(Abbildung \u00a029).\u00a0\u00a0\n \u00a0\n \n67\u00a0\n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a027:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Ivacaftor\u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0\n\u00a0\n \nAbbildung \u00a028:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Ivacaftor\u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0\n \u00a0\n \n68\u00a0\n \n \nInnovationsreport 2015 \u00a0\n\u00a0\nAbbildung \u00a029:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Ivacaftor\u00a0nach\u00a0Monaten \u00a0(2012\u2010\n2013)\u00a0\n \u00a0\n \n69\u00a0\n \nInnovationsreport 2015 \u00a0 4.11 Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0\nHandelsname: \u00a0Zoely\u00ae      Hersteller: \u00a0MSD \nIndikation: \u00a0Orale\u00a0Kontrazeption \u00a0\u00a0 \u00a0 Markteinf\u00fchrung: \u00a0Januar\u00a02012 \nATC\u2010Code:\u00a0G03AA14      DDD:\u00a01\u00a0Zykluspackung \u00a0mit\u00a028\u00a0Tabletten  \nDarreichungsform: \u00a0Filmtablette  \nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0203\u00a0\nBewertung \u00a0\nIn\u00a0Zoely\u00ae\u00a0wurden\u00a0erstmals\u00a0in\u00a0einem\u00a0Einphasen \u2010Pr\u00e4parat\u00a0zur\u00a0Kontrazeption \u00a0das\u00a0nat\u00fcrlich\u00a0vor\u2010\nkommende \u00a0Estradiol\u00a0und\u00a0das\u00a0neuartige \u00a0Gestagen \u00a0Nomegestrolacetat \u00a0fix\u00a0kombiniert. \u00a0Als\u00a0Estrogen\u2010\nkomponente \u00a0wirkt\u00a0Estradiol\u00a0vergleichsweise \u00a0schwach.\u00a0Nomegestrol \u00a0ist\u00a0ein\u00a0relativ\u00a0selektiv\u00a0wirkender \u00a0\nProgesteron \u2010Agonist,\u00a0ohne\u00a0relevante \u00a0Wirkungen \u00a0am\u00a0Estrogen\u2010Rezeptor\u00a0und\u00a0leicht\u00a0antagonistischen \u00a0\nEigenschaften \u00a0am\u00a0Androgen \u2010Rezeptor. \u00a0Die\u00a0Zykluspackung \u00a0beinhaltet \u00a024\u00a0wirkstoffhaltige \u00a0Tabletten. \u00a0\nAn\u00a0den\u00a0verbleibenden \u00a0vier\u00a0Tagen\u00a0eines\u00a0Zyklus\u00a0werden\u00a0wirkstofffreie \u00a0Tabletten \u00a0eingenommen. \u00a0\u00a0\nDie\u00a0kontrazeptive \u00a0Wirksamkeit \u00a0von\u00a0Zoely\u00ae\u00a0unterscheidet \u00a0sich\u00a0nach\u00a0den\u00a0bisher\u00a0vorliegenden \u00a0\nErkenntnissen \u00a0nicht\u00a0im\u00a0Vergleich \u00a0zu\u00a0anderen\u00a0\u2013\u00a0\u00fcblicherweise \u00a0\u00fcber\u00a021\u00a0Tage\u00a0eingenommenen \u00a0\u2013\u00a0Ein\u2010\nphasen\u2010Pr\u00e4paraten1.\u00a0Direkte\u00a0Vergleichsstudien \u00a0liegen\u00a0allerdings \u00a0nur\u00a0f\u00fcr\u00a0Drospirenon/Ethinylestradiol \u2010\nEinphasen \u2010Pr\u00e4parate \u00a0vor,\u00a0Vergleichsuntersuchungen \u00a0gegen\u00fcber \u00a0der\u00a0Standardkombination \u00a0Levonor\u2010\ngestrel/Ethinylestradiol \u00a0in\u00a0niedriger\u00a0Dosierung \u00a0fehlen.\u00a0In\u00a0den\u00a0publizierten \u00a0klinischen \u00a0Untersuchungen \u00a0\nzeigte\u00a0Zoely\u00ae\u00a0ein\u00a0den\u00a0\u00fcblichen\u00a0hormonellen \u00a0Kombinationskontrazeptiva \u00a0vergleichbares \u00a0Neben\u2010\nwirkungsprofil. \u00a0Allerdings \u00a0hat\u00a0die\u00a0neue\u00a0Estradiol\u2010Nomegestrol \u2010Kombination \u00a0deutliche \u00a0Auswirkungen \u00a0\nauf\u00a0das\u00a0Blutungsmuster \u00a0der\u00a0Anwenderinnen: \u00a0Bereits\u00a0in\u00a0den\u00a0ersten\u00a0Einnahmemonaten \u00a0kann\u00a0die\u00a0\nAbbruchblutung \u00a0ausbleiben, \u00a0ohne\u00a0dass\u00a0eine\u00a0Schwangerschaft \u00a0vorliegt.\u00a0Nach\u00a0den\u00a0ersten\u00a0drei\u00a0\nEinnahmemonaten \u00a0sind\u00a0davon\u00a0f\u00fcnf\u00a0von\u00a0100\u00a0Frauen\u00a0betroffen. \u00a0Innerhalb \u00a0des\u00a0ersten\u00a0Behand\u2010\nlungsjahres \u00a0liegt\u00a0die\u00a0Amenorrhoerate \u00a0zwischen\u00a018\u00a0und\u00a032\u00a0von\u00a0100\u00a0Frauen.\u00a0Das\u00a0erschwert \u00a0die\u00a0\nEinsch\u00e4tzung \u00a0des\u00a0Konzeptionsschutzes \u00a0durch\u00a0die\u00a0Anwenderinnen. \u00a0\u00a0\nTrotz\u00a0der\u00a0nat\u00fcrlich\u00a0vorkommenden \u00a0Estrogenkomponente \u00a0gelten\u00a0f\u00fcr\u00a0Zoely\u00ae\u00a0die\u00a0gleichen\u00a0\nGegenanzeigen \u00a0und\u00a0Warnhinweise \u00a0wie\u00a0auch\u00a0f\u00fcr\u00a0Ethinylestradiol \u2010haltige\u00a0Kombinationskontrazeptiva, \u00a0\nda\u00a0spezifische \u00a0Untersuchungen \u00a0oder\u00a0Erfahrungswerte \u00a0f\u00fcr\u00a0die\u00a0neue\u00a0Kombination \u00a0bislang\u00a0fehlen.\u00a0So\u00a0\nl\u00e4sst\u00a0sich\u00a0auch\u00a0das\u00a0Thromboembolierisiko \u00a0von\u00a0Zoely\u00ae\u00a0nicht\u00a0sicher\u00a0einsch\u00e4tzen. \u00a0Das\u00a0enthaltene \u00a0\nschwach\u00a0wirkende \u00a0Estradiol\u00a0l\u00e4sst\u00a0einerseits \u00a0gegen\u00fcber \u00a0Ethinylestradiol \u00a0niedrigere \u00a0Thromboseraten \u00a0\nerwarten, \u00a0andererseits \u00a0ist\u00a0dem\u00a0Mittel\u00a0mit\u00a0Nomegestrol \u00a0ein\u00a0wenig\u00a0erprobtes \u00a0Gestagen \u00a0zugesetzt, \u00a0f\u00fcr\u00a0\ndas\u00a0noch\u00a0keine\u00a0Vergleichsdaten \u00a0zu\u00a0anderen\u00a0Gestagenkomponenten \u00a0vorliegen. \u00a0Im\u00a0Vergleich \u00a0zu\u00a0\nDrospirenon/Ethinylestradiol \u00a0scheint\u00a0lediglich\u00a0Akne\u00a0h\u00e4ufiger\u00a0aufzutreten \u00a0(15,4\u00a0Prozent\u00a0unter\u00a0Zoely\u00ae\u00a0\nvs.\u00a07,9\u00a0Prozent\u00a0unter\u00a0Vergleich). \u00a0Insgesamt \u00a0werden\u00a0unter\u00a0Zoely\u00ae\u00a0h\u00e4ufiger\u00a0Nebenwirkungen \u00a0beklagt\u00a0\n(ca.\u00a075\u00a0Prozent\u00a0unter\u00a0Zoely\u00ae\u00a0vs.\u00a069\u00a0Prozent\u00a0unter\u00a0Vergleich). \u00a0\nNach\u00a0der\u00a0Richtlinie \u00a0des\u00a0G\u2010BA\u00a0der\u00a0Krankenkassen \u00a0und\u00a0\u00c4rzte\u00a0zur\u00a0Empf\u00e4ngnisregelung \u00a0und\u00a0zum\u00a0\nSchwangerschaftsabbruch \u00a0fallen\u00a0die\u00a0Kosten\u00a0f\u00fcr\u00a0Mittel\u00a0zur\u00a0Empf\u00e4ngnisverh\u00fctung \u00a0nicht\u00a0unter\u00a0die\u00a0\n                                        \n1\u00a0Die\u00a0kontrazeptive \u00a0Wirksamkeit \u00a0von\u00a0Verh\u00fctungsmitteln \u00a0wird\u00a0mit\u00a0Hilfe\u00a0des\u00a0Pearl\u00a0Index\u00a0beziffert.\u00a0Dieser\u00a0gibt\u00a0die\u00a0Anzahl\u00a0an\u00a0Schwangerschaf \u2010\nten\u00a0pro\u00a0100\u00a0Frauenjahre \u00a0an.\u00a0Bei\u00a0Frauen,\u00a0die\u00a0nicht\u00a0verh\u00fcten, \u00a0liegt\u00a0der\u00a0Pearl\u00a0Index\u00a0bei\u00a060\u00a0bis\u00a080\u00a0Schwangerschaften \u00a0pro\u00a0100\u00a0Frauenjahre. \u00a0Der\u00a0\nPearl\u00a0Index\u00a0nach\u00a0Sterilisation \u00a0einer\u00a0Frau\u00a0liegt\u00a0im\u00a0Vergleich \u00a0dazu\u00a0bei\u00a00,2\u00a0bis\u00a00,3\u00a0Schwangerschaften \u00a0pro\u00a0100\u00a0Frauenjahre. \u00a0Bei\u00a0der\u00a0Pille\u00a0wird\u00a0\nder\u00a0Pearl\u00a0Index\u00a0\u2013\u00a0vorausgesetzt \u00a0sie\u00a0wird\u00a0regelm\u00e4\u00dfig \u00a0und\u00a0entsprechend \u00a0der\u00a0Einnahmeempfehlungen \u00a0angewendet \u00a0\u2013\u00a0mit\u00a00,1\u00a0bis\u00a00,9\u00a0angege\u2010\nben\u00a0(Pro\u00a0Familia,\u00a02013).\u00a0\u00a0\n\u00a0 \n70\u00a0\n \n \nInnovationsreport 2015 \u00a0Leistungspflicht \u00a0der\u00a0GKV.\u00a0Ausgenommen \u00a0hiervon\u00a0sind\u00a0verordnungspflichtige \u00a0Kontrazeptiva \u00a0bei\u00a0\nFrauen\u00a0bis\u00a0zum\u00a0vollendeten \u00a020.\u00a0Lebensjahr, \u00a0d.h.\u00a0bis\u00a0einen\u00a0Tag\u00a0vor\u00a0ihrem\u00a020.\u00a0Geburtstag. \u00a0Da\u00a0Zoely\u00ae\u00a0als\u00a0\nKontrazeptivum \u00a0nur\u00a0in\u00a0bestimmten \u00a0F\u00e4llen\u00a0der\u00a0Erstattungspflicht \u00a0der\u00a0GKV\u00a0unterliegt, \u00a0wurde\u00a0keine\u00a0\nNutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a735a\u00a0SGBV\u00a0durchgef\u00fchrt. \u00a0\u00a0\n\u00a0\nVerf\u00fcgbare \u00a0Therapien \u00a0\n\u00a0(Zusatz\u2010)Nutzen\n\u00a0Kosten\n\u00a0\n Neue\u00a0Fixkombination, \u00a0aber\u00a0nur\u00a0\nweitere\u00a0Therapieoption \u00a0\u00a0 Keine\u00a0relevante \u00a0Verbesserung \u00a0\ngegen\u00fcber \u00a0vorhandenen, \u00a0gut\u00a0\nerprobten \u00a0Therapieoptionen \u00a0mit\u00a0\nUnsicherheiten \u00a0bzgl.\u00a0\nVertr\u00e4glichkeit  Da\u00a0Zoely\u00ae\u00a0als\u00a0Kontrazeptivum \u00a0\nnur\u00a0in\u00a0bestimmten \u00a0F\u00e4llen\u00a0der\u00a0\nErstattungspflicht \u00a0der\u00a0GKV\u00a0\nunterliegt, \u00a0findet\u00a0kein\u00a0\nKostenvergleich \u00a0statt\u00a0\n  \u00a0  \n\u00a0\n\u00a0\n  \u00a0  \n   \nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien :\u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen :\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten :\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien \u00a0\nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0\nC\u00a0 Variante\u00a0ohne\u00a0besonderen \u00a0Stellenwert \u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nDas\u00a0orale\u00a0Kontrazeptivum \u00a0Zoely\u00ae\u00a0ist\u00a0neben\u00a0dem\u00a0COPD\u2010Medikament \u00a0Aclidiniumbromid \u00a0eines\u00a0der\u00a0\nverordnungsst\u00e4rksten \u00a0Arzneimittel, \u00a0die\u00a0in\u00a0diesem\u00a0Report\u00a0betrachtet \u00a0wurden\u00a0(Pr\u00e4valenz \u00a0je\u00a0100.000\u00a0\nVersicherte: \u00a028,6\u00a0im\u00a0Untersuchungszeitraum). \u00a0So\u00a0stiegen\u00a0die\u00a0Verordnungszahlen \u00a0nach\u00a0der\u00a0\nMarkteinf\u00fchrung \u00a0im\u00a0Januar\u00a0konstant\u00a0an\u00a0und\u00a0folgten\u00a0einem\u00a0Drei\u2010Monats\u2010Zyklus\u00a0(Abbildung \u00a030),\u00a0der\u00a0\nsich\u00a0auch\u00a0am\u00a0Umsatz\u00a0bemerkbar \u00a0machte.\u00a0Im\u00a0Jahr\u00a02013\u00a0erreichte\u00a0das\u00a0Pr\u00e4parat\u00a0monatliche \u00a0\nUmsatzzahlen \u00a0von\u00a0ca.\u00a020.000\u00a0Euro\u00a0(Abbildung \u00a032).\u00a0Zoely\u00ae\u00a0wurde\u00a0der\u00a0Indikation \u00a0entsprechend \u00a0\nausschlie\u00dflich \u00a0Frauen\u00a0verordnet, \u00a0wobei\u00a0die\u00a0Altersgruppe \u00a0der\u00a00\u2010\u00a0bis\u00a029\u2010J\u00e4hrigen\u00a0mit\u00a0ca.\u00a096\u00a0Prozent\u00a0\ndominierte \u00a0(Abbildung \u00a031).\u00a0Hormonelle \u00a0Kontrazeptiva \u00a0sind\u00a0laut\u00a0Richtlinie\u00a0zur\u00a0Empf\u00e4ngnisregelung \u00a0\nund\u00a0zum\u00a0Schwangerschaftsabbruch \u00a0zu\u00a0Lasten\u00a0der\u00a0gesetzlichen \u00a0Krankenversicherung \u00a0nur\u00a0bis\u00a0zum\u00a0\nvollendeten \u00a020.\u00a0Lebensjahr \u00a0verordnungsf\u00e4hig. \u00a0Das\u00a020.\u00a0Lebensjahr \u00a0endet\u00a0einen\u00a0Tag\u00a0vor\u00a0dem\u00a020.\u00a0\nGeburtstag. \u00a0Dennoch\u00a0wurden\u00a0im\u00a0Jahr\u00a02013\u00a0ca.\u00a0vier\u00a0Prozent\u00a0der\u00a0Verordnungen \u00a0zu\u00a0Zoely\u00ae\u00a0auch\u00a0in\u00a0\nh\u00f6herem\u00a0Lebensalter \u00a0veranlasst. \u00a0\u00a0\n\u00a0\u00a0\n \n71\u00a0\n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a030:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0(orales\u00a0Kontrazeptivum) \u00a0je\u00a0\nMonat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0\n\u00a0\n \nAbbildung \u00a031:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0(orales\u00a0Kont\u2010\nrazeptivum) \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0\n\u00a0\u00a0\n \n72\u00a0\n \n \nInnovationsreport 2015 \u00a0\n\u00a0\nAbbildung \u00a032:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0(ora\u2010\nles\u00a0Kontrazeptivum) \u00a0nach\u00a0Monaten \u00a0(2012\u20102013)\u00a0\n \u00a0\n \n73\u00a0\n \nInnovationsreport 2015 \u00a0 4.12 Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0\nHandelsname: \u00a0Naemis\u00ae    Hersteller: \u00a0Teva \nIndikation: \u00a0Hormontherapie \u00a0\u00a0  Markteinf\u00fchrung: \u00a0November \u00a02012 \nATC\u2010Code:\u00a0G03FB12\u00a0   DDD:\u00a01\u00a0Zykluspackung \u00a0mit\u00a024\u00a0Tabletten \u00a0\u00a0\nDarreichungsform: \u00a0Tablette  \nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0207\u00a0\nBewertung \u00a0\nNaemis\u00ae\u00a0ist\u00a0ein\u00a0klassisches \u00a0Sequenzpr\u00e4parat \u00a0zur\u00a0Hormontherapie \u00a0in\u00a0der\u00a0Postmenopause, \u00a0wenn\u00a0\naufgrund\u00a0der\u00a0\u00c4nderungen \u00a0im\u00a0Hormonhaushalt \u00a0typische\u00a0Beschwerden \u00a0wie\u00a0Hitzewallungen, \u00a0\nSchwei\u00dfausbr\u00fcche \u00a0und\u00a0vaginale\u00a0Trockenheit \u00a0auftreten \u00a0und\u00a0nicht\u00a0toleriert\u00a0werden.\u00a0Das\u00a0Mittel\u00a0enth\u00e4lt\u00a0\nals\u00a0Estrogen\u2010Komponente \u00a0das\u00a0in\u00a0dieser\u00a0Indikation \u00a0\u00fcbliche\u00a0Estradiol, \u00a0als\u00a0Gestagen \u2010Komponente \u00a0ist\u00a0\nNomegestrol, \u00a0ein\u00a0neuartiges \u00a0Gestagen \u00a0der\u00a0vierten\u00a0Generation, \u00a0zugesetzt. \u00a0Es\u00a0besitzt\u00a0bereits\u00a0seit\u00a0\nSeptember \u00a02003\u00a0eine\u00a0nationale \u00a0Zulassung, \u00a0wurde\u00a0aber\u00a0erst\u00a0im\u00a0November \u00a02012,\u00a0also\u00a0sogar\u00a0noch\u00a0nach\u00a0\nder\u00a0Zulassung \u00a0des\u00a0ebenfalls\u00a0Nomegestrol \u2010enthaltenen \u00a0Kontrazeptivums \u00a0Zoely\u00ae,\u00a0im\u00a0deutschen \u00a0Markt\u00a0\neingef\u00fchrt. \u00a0\nKlinische\u00a0Untersuchungen \u00a0mit\u00a0Nomegestrol \u00a0wurden\u00a0bereits\u00a0in\u00a0den\u00a01980er\u00a0Jahren\u00a0durchgef\u00fchrt, \u00a0\nallerdings \u00a0nur\u00a0in\u00a0geringer\u00a0Zahl\u00a0zum\u00a0zugelassenen \u00a0Indikationsgebiet. \u00a0Der\u00a0sequentielle \u00a0Einsatz\u00a0von\u00a0\nEstradiol\u00a0und\u00a0Nomegestrol \u00a0f\u00fchrt\u00a0den\u00a0vorhandenen \u00a0klinischen \u00a0Studien\u00a0zufolge\u00a0zu\u00a0einer\u00a0Linderung \u00a0\npostmenopausaler \u00a0Beschwerden \u00a0gemessen \u00a0am\u00a0Kuppermann \u2010Score1\u00a0und\u00a0zu\u00a0regelm\u00e4\u00dfigen \u00a0\nAbbruchblutungen \u00a0bei\u00a093\u201096\u00a0Prozent\u00a0der\u00a0Anwenderinnen. \u00a0Nomegestrol \u00a0ist\u00a0im\u00a0Vergleich \u00a0zu\u00a0anderen\u00a0\nin\u00a0dieser\u00a0Indikation \u00a0\u00fcblicherweise \u00a0eingesetzten \u00a0Gestagenen \u00a0wie\u00a0Norethisteron, \u00a0Levonorgestrel \u00a0oder\u00a0\nMedroxyprogesteronacetat \u00a0aber\u00a0noch\u00a0wenig\u00a0erprobt.\u00a0So\u00a0fehlen\u00a0insbesondere \u00a0im\u00a0Hinblick\u00a0auf\u00a0sein\u00a0\nthromboembolisches \u00a0Risikopotential \u00a0verwertbare \u00a0Vergleichsdaten \u00a0zu\u00a0den\u00a0genannten \u00a0\nStandardgestagenen. \u00a0\nNaemis\u00ae\u00a0wurde\u00a0im\u00a0Jahr\u00a02012\u00a0als\u00a0zweites\u00a0Mittel\u00a0mit\u00a0der\u00a0Kombination \u00a0Estradiol\u00a0und\u00a0Nomegestrol \u00a0\n(allerdings \u00a0mit\u00a0unterschiedlicher \u00a0Dosierung \u00a0der\u00a0Einzelwirkstoffe \u00a0in\u00a0der\u00a0jeweiligen \u00a0Applikationsform \u00a0\nund\u00a0anderslautender \u00a0Indikation) \u00a0in\u00a0den\u00a0deutschen \u00a0Arzneimittelmarkt \u00a0eingef\u00fchrt. \u00a0Eine\u00a0fr\u00fche\u00a0\nNutzenbewertung \u00a0f\u00fcr\u00a0dieses\u00a0Mittel\u00a0wurde\u00a0nicht\u00a0vorgenommen. \u00a0\u00a0\n \u00a0\n                                        \n1\u00a0Bei\u00a0dem\u00a0Kupperman \u2010Score\u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0einen\u00a0numerischen \u00a0Index,\u00a0der\u00a0elf\u00a0klimakterische \u00a0Beschwerden \u00a0(Hitzewallungen, \u00a0Par\u00e4sthe\u2010\nsien,\u00a0Schlaflosigkeit, \u00a0Nervosit\u00e4t, \u00a0Melancholie, \u00a0Schwindel, \u00a0Schw\u00e4che, \u00a0Gelenkschmerzen \u00a0oder\u00a0Muskelschmerzen, \u00a0Kopfschmerzen, \u00a0Herzklop\u2010\nfen\u00a0und\u00a0Ameisenlaufen) \u00a0beinhaltet. \u00a0Jedes\u00a0Symptom \u00a0ist\u00a0von\u00a00\u00a0bis\u00a03\u00a0nach\u00a0Schweregrad \u00a0und\u00a0Symptome \u00a0(0\u00a0=\u00a0keine\u00a0Symptome \u00a0und\u00a03\u00a0=\u00a0\nschwerste) \u00a0gewichtet. \u00a0Die\u00a0maximale \u00a0Punktzahl \u00a0betr\u00e4gt\u00a051\u00a0Punkte.\u00a0\n\u00a0 \n74\u00a0\n \n \nInnovationsreport 2015 \u00a0Verf\u00fcgbare \u00a0Therapien  \n\u00a0(Zusatz\u2010)Nutzen\n\u00a0Kosten\n\u00a0\n Neue\u00a0Fixkombination, \u00a0aber\u00a0\nlediglich\u00a0weitere\u00a0Therapie\u2010\noption  \u00a0 Keine\u00a0relevante \u00a0Verbesserung \u00a0\ngegen\u00fcber \u00a0vorhandenen, \u00a0gut\u00a0\nerprobten \u00a0Therapieoptionen; \u00a0\nUnsicherheiten \u00a0bzgl.\u00a0\nVertr\u00e4glichkeit  Da\u00a0Naemis\u00ae\u00a0als\u00a0Hormontherapie\nnur\u00a0in\u00a0bestimmten \u00a0F\u00e4llen\u00a0der\u00a0\nErstattungspflicht \u00a0der\u00a0GKV\u00a0\nunterliegt, \u00a0findet\u00a0kein\u00a0\nKostenvergleich \u00a0statt\u00a0\n  \u00a0  \n\u00a0\n\u00a0 \n  \u00a0  \n\u00a0\n\u00a0 \nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien :\u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen :\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten :\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien  \nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0\nC\u00a0 Variante\u00a0ohne\u00a0besonderen \u00a0Stellenwert \u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nObwohl\u00a0schon\u00a0seit\u00a0November \u00a02012\u00a0auf\u00a0dem\u00a0deutschen \u00a0Arzneimittelmarkt \u00a0erh\u00e4ltlich, \u00a0sind\u00a0erst\u00a0im\u00a0\nM\u00e4rz\u00a02013\u00a0die\u00a0ersten\u00a0Verordnungen \u00a0in\u00a0den\u00a0ambulanten \u00a0Routinedaten \u00a0der\u00a0TK\u00a0ersichtlich. \u00a0Im\u00a0\nGegensatz \u00a0zur\u00a0Wirkstoffkombination, \u00a0die\u00a0als\u00a0orales\u00a0Kontrazeptivum \u00a0im\u00a0Handel\u00a0ist,\u00a0lag\u00a0das\u00a0\nVerordnungsmaximum \u00a0von\u00a0Naemis\u00ae\u00a0nur\u00a0bei\u00a0knapp\u00a070\u00a0Packungen \u00a0im\u00a0Monat\u00a0(Abbildung \u00a033),\u00a0was\u00a0sich\u00a0\nletztendlich \u00a0auch\u00a0in\u00a0den\u00a0niedrigen \u00a0Umsatzzahlen \u00a0pro\u00a0Monat\u00a0widerspiegelte \u00a0(Abbildung \u00a035).\u00a0\nEntsprechend \u00a0der\u00a0Zulassung \u00a0\u2013\u00a0Hormontherapie \u00a0bei\u00a0postmenopausalen \u00a0Frauen\u00a0\u2013\u00a0fand\u00a0eine\u00a0\nVerordnung \u00a0ausschlie\u00dflich \u00a0bei\u00a0weiblichen \u00a0TK\u2010Versicherten \u00a0statt\u00a0und\u00a0betraf\u00a0mit\u00a092\u00a0Prozent\u00a0der\u00a0\nVersicherten \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0die\u00a0Altersgruppe \u00a0der\u00a040\u2010\u00a0bis\u00a059\u2010J\u00e4hrigen\u00a0(Abbildung \u00a0\n34).\u00a0\u00a0\n \u00a0\n \n75\u00a0\n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a033:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0(Hormontherapie) \u00a0je\u00a0Monat\u00a0\nnach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0\n\u00a0\n \nAbbildung \u00a034:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0(Hormonthe \u2010\nrapie)\u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0\n\u00a0\n \n76\u00a0\n \n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a035:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0\n(Hormontherapie) \u00a0nach\u00a0Monaten \u00a0(2012\u20102013)\u00a0\n\u00a0\u00a0\n \n77\u00a0\n \nInnovationsreport 2015 \u00a0 4.13 Pasireotid \u00a0\n\u00a0\u00a0\u00a0Handelsname: \u00a0Signifor\u00ae     Hersteller: \u00a0Novartis\u00a0Pharma  \nIndikation: \u00a0Morbus\u00a0Cushing\u00a0\u00a0   Zulassung: \u00a0Juni\u00a02012 \nATC\u2010Code:\u00a0H01CB05\u00a0    DDD:\u00a01,2\u00a0mg\u00a0\nDarreichungsform: \u00a0Injektionsl\u00f6sung \u00a0\nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0211\u00a0\nBewertung \u00a0\nPasireotid \u00a0ist\u00a0ein\u00a0Orphan\u00a0Drug\u00a0aus\u00a0der\u00a0Gruppe\u00a0der\u00a0Somatostatin \u2010Analoga,\u00a0welches\u00a0f\u00fcr\u00a0die\u00a0\nBehandlung \u00a0von\u00a0erwachsenen \u00a0Patienten \u00a0mit\u00a0Morbus\u00a0Cushing\u00a0indiziert\u00a0ist,\u00a0f\u00fcr\u00a0die\u00a0ein\u00a0chirurgischer \u00a0\nEingriff\u00a0keine\u00a0Option\u00a0ist\u00a0oder\u00a0bei\u00a0denen\u00a0ein\u00a0chirurgischer \u00a0Eingriff\u00a0fehlgeschlagen \u00a0ist.\u00a0Die\u00a0empfohlene \u00a0\nAnfangsdosierung \u00a0betr\u00e4gt\u00a00,6\u00a0mg\u00a0als\u00a0subkutane \u00a0Injektion\u00a0zweimal\u00a0t\u00e4glich.\u00a0Zwei\u00a0Monate\u00a0nach\u00a0Beginn\u00a0\nder\u00a0Behandlung \u00a0sollte\u00a0bei\u00a0den\u00a0Patienten \u00a0der\u00a0klinische\u00a0Nutzen\u00a0beurteilt\u00a0werden.\u00a0Patienten \u00a0mit\u00a0einer\u00a0\nsignifikanten \u00a0Abnahme \u00a0des\u00a0freien\u00a0Cortisols\u00a0im\u00a0Urin\u00a0sollten\u00a0so\u00a0lange\u00a0behandelt \u00a0werden,\u00a0wie\u00a0der\u00a0\nNutzen\u00a0anh\u00e4lt.\u00a0Bis\u00a0zur\u00a0Markteinf\u00fchrung \u00a0von\u00a0Signifor\u00ae\u00a0bestand\u00a0die\u00a0erfolgreiche \u00a0Therapie\u00a0des\u00a0Morbus\u00a0\nCushing\u00a0aus\u00a0der\u00a0chirurgischen \u00a0Entfernung \u00a0des\u00a0Tumors\u00a0oder\u00a0der\u00a0Nebennieren. \u00a0Die\u00a0bis\u00a0dato\u00a0\nunternommenen \u00a0Behandlungsversuche \u00a0mit\u00a0Ketoconazol, \u00a0Cabergolin \u00a0oder\u00a0Mifepriston \u00a0erfolgten\u00a0\nausschlie\u00dflich \u00a0Off\u2010Label .\u00a0\nEnde\u00a02014\u00a0erteilte\u00a0die\u00a0Europ\u00e4ische \u00a0Kommission \u00a0f\u00fcr\u00a0Signifor\u00ae\u00a0auch\u00a0die\u00a0Zulassung \u00a0zur\u00a0Behandlung \u00a0von\u00a0\nerwachsenen \u00a0Patienten \u00a0mit\u00a0Akromegalie, \u00a0f\u00fcr\u00a0die\u00a0ein\u00a0chirurgischer \u00a0Eingriff\u00a0keine\u00a0Option\u00a0ist\u00a0oder\u00a0nicht\u00a0\nkurativ\u00a0erfolgreich \u00a0war,\u00a0und\u00a0die\u00a0unter\u00a0der\u00a0Behandlung \u00a0mit\u00a0einem\u00a0anderen\u00a0Somatostatin \u2010Analogon, \u00a0\nbeispielsweise \u00a0Lanreotid \u00a0oder\u00a0Octreotid, \u00a0unzureichend \u00a0kontrolliert \u00a0sind.\u00a0Hier\u00a0betr\u00e4gt\u00a0die\u00a0empfohlene \u00a0\nAnfangsdosierung \u00a040\u00a0mg\u00a0Pasireotid \u00a0alle\u00a0vier\u00a0Wochen.\u00a0Bei\u00a0Patienten, \u00a0bei\u00a0denen\u00a0nach\u00a0dreimonatiger \u00a0\nBehandlung \u00a0mit\u00a0Signifor\u00ae\u00a0mit\u00a040\u00a0mg\u00a0GH\u00a0und\u00a0IGF\u20101\u2010Plasmaspiegel \u00a0nicht\u00a0vollst\u00e4ndig \u00a0kontrolliert \u00a0sind,\u00a0\nkann\u00a0die\u00a0Dosis\u00a0auf\u00a0maximal\u00a060\u00a0mg\u00a0erh\u00f6ht\u00a0werden.\u00a0\nDie\u00a0Wirkung\u00a0des\u00a0Somatostatin \u2010Analogons \u00a0beruht\u00a0auf\u00a0einer\u00a0Hemmung \u00a0der\u00a0Hormonfreisetzung \u00a0durch\u00a0\nAdrenocorticotropes \u2010Hormon(ACTH) \u2010produzierende \u00a0Hypophysenadenome, \u00a0wodurch\u00a0der\u00a0Cortisol\u2010\nSpiegel\u00a0gesenkt\u00a0und\u00a0klinische\u00a0Symptome \u00a0der\u00a0Krankheit \u00a0vermindert \u00a0werden.\u00a0Zulassungsrelevante \u00a0\nDaten\u00a0lieferte\u00a0eine\u00a0randomisierte \u00a0Doppelblindstudie \u00a0mit\u00a0insgesamt \u00a0162\u00a0Morbus\u00a0Cushing\u2010Patienten, \u00a0\nbei\u00a0denen\u00a0entweder \u00a0ein\u00a0rezidivierender \u00a0oder\u00a0nicht\u2010operabler \u00a0Morbus\u00a0Cushing\u00a0diagnostiziert \u00a0worden\u00a0\nwar.\u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0dieser\u00a0Studie\u00a0war\u00a0der\u00a0Anteil\u00a0der\u00a0Patienten, \u00a0die\u00a0nach\u00a0sechsmonatiger \u00a0\nTherapie\u00a0einen\u00a0normalisierten \u00a0Cortisol\u2010Spiegel\u00a0im\u00a0Urin\u00a0aufwiesen. \u00a0Die\u00a0Behandlung \u00a0wurde\u00a0im\u00a0\nAnschluss \u00a0als\u00a0open\u2010label\u00a0f\u00fcr\u00a0die\u00a0n\u00e4chsten\u00a0sechs\u00a0Monate\u00a0weitergef\u00fchrt. \u00a012\u00a0der\u00a082\u00a0Patienten \u00a0(15\u00a0\nProzent)\u00a0aus\u00a0dem\u00a0Behandlungsarm \u00a0mit\u00a0600\u00a0\u00b5g\u00a0Pasireotid \u00a0und\u00a021\u00a0der\u00a080\u00a0Patienten \u00a0(26\u00a0Prozent)\u00a0aus\u00a0\ndem\u00a0Behandlungsarm \u00a0mit\u00a0900\u00a0\u00b5g\u00a0Pasireotid \u00a0erreichten \u00a0den\u00a0prim\u00e4ren \u00a0Endpunkt. \u00a0Die\u00a0mediane\u00a0urin\u00e4re\u00a0\nCortisolausscheidung \u00a0hatte\u00a0bereits\u00a0nach\u00a0einer\u00a0zweimonatigen \u00a0Behandlung \u00a0um\u00a0die\u00a0H\u00e4lfte\u00a0\nabgenommen. \u00a0Das\u00a0Niveau\u00a0konnte\u00a0in\u00a0beiden\u00a0Behandlungsarmen \u00a0bis\u00a0zum\u00a0Studienende \u00a0nach\u00a0zw\u00f6lf\u00a0\nMonaten\u00a0gehalten\u00a0werden.\u00a0\nIn\u00a0der\u00a0Studie\u00a0kam\u00a0es\u00a0bei\u00a0der\u00a0H\u00e4lfte\u00a0der\u00a0Patienten \u00a0zu\u00a0Nebenwirkungen \u00a03.\u00a0oder\u00a04.\u00a0Grades.\u00a0Unter\u00a0dem\u00a0\nneuen\u00a0Wirkstoff \u00a0wurden\u00a0h\u00e4ufiger\u00a0Hyperglyk\u00e4mien \u00a0diagnostiziert, \u00a0weswegen \u00a0der\u00a0Blutzucker \u00a0bei\u00a0den\u00a0\nbehandelten \u00a0Patienten \u00a0regelm\u00e4\u00dfig \u00a0kontrolliert \u00a0werden\u00a0sollte.\u00a0Auch\u00a0wird\u00a0eine\u00a0klinische\u00a0\u00dcberwachung \u00a0\nder\u00a0Herzfrequenz \u00a0vor\u00a0allem\u00a0zu\u00a0Behandlungsbeginn \u00a0bei\u00a0den\u00a0Patienten \u00a0empfohlen, \u00a0die\u00a0Pasireotid \u00a0\nzusammen \u00a0mit\u00a0Bradykardie \u2010ausl\u00f6senden \u00a0Arzneimitteln \u00a0bekommen \u00a0(Betablocker, \u00a0Anticholinergika, \u00a0 \n78\u00a0 \n \nInnovationsreport 2015 \u00a0Calciumkanalblocker, \u00a0Antiarrhythmika). \u00a0Gleiches\u00a0gilt\u00a0f\u00fcr\u00a0Patienten, \u00a0die\u00a0zus\u00e4tzlich \u00a0Arzneimittel \u00a0\nerhalten,\u00a0die\u00a0das\u00a0QT\u2010Intervall\u00a0verl\u00e4ngern. \u00a0\u00a0\nDie\u00a0Zulassung \u00a0des\u00a0Wirkstoffes \u00a0zur\u00a0Behandlung \u00a0der\u00a0Akromegalie \u00a0beruht\u00a0auf\u00a0einer\u00a0Pivotalstudie. \u00a0In\u00a0\ndieser\u00a0klinischen \u00a0Untersuchung \u00a0wurden\u00a0die\u00a0Patienten \u00a0auf\u00a0zwei\u00a0Pasireotid \u2010Interventionsgruppen \u00a0\n(doppelblind, \u00a040\u00a0oder\u00a060\u00a0mg)\u00a0und\u00a0eine\u00a0Kontrollgruppe, \u00a0in\u00a0der\u00a0die\u00a0bisherige\u00a0Behandlung \u00a0mit\u00a0einem\u00a0\nSomatostatin \u2010Analogon \u00a0fortgesetzt \u00a0wurde,\u00a0aufgeteilt. \u00a0Insgesamt \u00a0betrug\u00a0die\u00a0Behandlungsdauer \u00a024\u00a0\nWochen.\u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0dieser\u00a0Studie\u00a0war\u00a0der\u00a0Anteil\u00a0der\u00a0Patienten \u00a0mit\u00a0biochemischer \u00a0Kontrolle\u00a0\n\u2013\u00a0definiert\u00a0als\u00a0ein\u00a0Wachstumshormon \u2010(GH)Wert \u00a0<\u00a02,5\u00a0\u03bcg/l\u00a0und\u00a0Normalisierung \u00a0des\u00a0f\u00fcr\u00a0Geschlecht \u00a0\nund\u00a0Alter\u00a0adjustierten \u00a0Insulin\u2010\u00e4hnlichen \u00a0Wachstumsfaktor \u00a0(IGF)\u20101\u2010Wertes\u00a0im\u00a0Serum\u00a0nach\u00a024\u00a0Wochen.\u00a0\nDen\u00a0prim\u00e4ren \u00a0Endpunkt \u00a0erreichten \u00a015\u00a0Prozent\u00a0aus\u00a0der\u00a040\u00a0mg\u2010Verum\u2010Gruppe\u00a0und\u00a020\u00a0Prozent\u00a0aus\u00a0der\u00a0\n60\u00a0mg\u2010Verum\u2010Gruppe\u00a0(vs.\u00a0null\u00a0Prozent\u00a0aus\u00a0der\u00a0aktiven\u00a0Kontrollgruppe). \u00a0Auch\u00a0hinsichtlich \u00a0der\u00a0\nVer\u00e4nderung \u00a0der\u00a0Kopfschmerzsymptomatik \u00a0gab\u00a0es\u00a0einen\u00a0statistisch \u00a0signifikanten \u00a0Effekt\u00a0zugunsten \u00a0\nder\u00a0Interventionsgruppen. \u00a0Bei\u00a0den\u00a0anderen\u00a0Akromegalie \u2010Symptomen \u00a0wie\u00a0beispielsweise \u00a0Fatigue,\u00a0\nPar\u00e4sthesie, \u00a0Osteoarthralgie \u00a0oder\u00a0Ringgr\u00f6\u00dfe \u00a0gab\u00a0es\u00a0allerdings \u00a0keinen\u00a0signifikanten \u00a0Unterschied \u00a0im\u00a0\nVergleich \u00a0zur\u00a0aktiven\u00a0Kontrollgruppe. \u00a0\u00a0\nF\u00fcr\u00a0Morbus\u00a0Cushing\u2010Patienten, \u00a0bei\u00a0denen\u00a0die\u00a0Behandlung \u00a0mit\u00a0Pasireotid \u00a0angezeigt \u00a0ist,\u00a0da\u00a0ein\u00a0\nchirurgischer \u00a0Eingriff\u00a0keine\u00a0Option\u00a0darstellt\u00a0oder\u00a0bei\u00a0denen\u00a0ein\u00a0chirurgischer \u00a0Eingriff\u00a0fehlgeschlagen \u00a0\nist,\u00a0konstatierte \u00a0der\u00a0G\u2010BA\u00a0in\u00a0seinem\u00a0Beschluss \u00a0vom\u00a06.\u00a0Dezember \u00a02012\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0\nZusatznutzens \u00a0als\u00a0gering.\u00a0Begr\u00fcndet \u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0seine\u00a0Entscheidung \u00a0darin,\u00a0dass\u00a0derzeit\u00a0noch\u00a0\nkeine\u00a0Aussage\u00a0zum\u00a0Endpunkt \u00a0Gesamt\u00fcberleben \u00a0getroffen \u00a0werden\u00a0kann.\u00a0Eine\u00a0dauerhafte \u00a0Senkung\u00a0des\u00a0\npathologisch \u00a0erh\u00f6hten \u00a0Serum\u2010Cortisolspiegels \u00a0sei\u00a0nach\u00a0Auffassung \u00a0des\u00a0G\u2010BA\u00a0zwar\u00a0patientenrelevant, \u00a0\naufgrund\u00a0der\u00a0begrenzten \u00a0Studiendauer \u00a0liegen\u00a0jedoch\u00a0keine\u00a0Daten\u00a0vor,\u00a0die\u00a0eine\u00a0Nachhaltigkeit \u00a0des\u00a0\nEffektes\u00a0zeigen\u00a0und\u00a0eine\u00a0Bewertung \u00a0von\u00a0Pasireotid \u00a0f\u00fcr\u00a0die\u00a0Langzeitanwendung \u00a0zulassen.\u00a0Ferner\u00a0f\u00fchrt\u00a0\nder\u00a0G\u2010BA\u00a0an,\u00a0dass\u00a0ein\u00a0hoher\u00a0Anteil\u00a0an\u00a0Patienten \u00a0nicht\u00a0oder\u00a0nicht\u00a0ausreichend \u00a0auf\u00a0die\u00a0Therapie\u00a0mit\u00a0\nPasireotid \u00a0anspricht \u00a0(Non\u2010Responder ).\u00a0So\u00a0war\u00a0neben\u00a0dem\u00a0Auftreten \u00a0unerw\u00fcnschter \u00a0Ereignisse \u00a0ein\u00a0\nunbefriedigendes \u00a0Therapieansprechen \u00a0der\u00a0h\u00e4ufigste \u00a0Grund\u00a0f\u00fcr\u00a0einen\u00a0Studienabbruch \u00a0gem\u00e4\u00df\u00a0\nIntention\u2010To\u2010Treat\u2010Prinzip.\u00a0\nZu\u00a0der\u00a0gleichen\u00a0Bewertung \u00a0kam\u00a0der\u00a0Ausschuss \u00a0bei\u00a0dem\u00a0Indikationsgebiet \u00a0\u201eAkromegalie\u201c. \u00a0Auch\u00a0hier\u00a0\nkonstatierte \u00a0der\u00a0G\u2010BA\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens \u00a0als\u00a0gering\u00a0f\u00fcr\u00a0Patienten, \u00a0bei\u00a0denen\u00a0eine\u00a0\nchirurgische \u00a0Behandlung \u00a0nicht\u00a0erfolgreich \u00a0war\u00a0oder\u00a0nicht\u00a0in\u00a0Frage\u00a0kommt,\u00a0und\u00a0die\u00a0auf\u00a0eine\u00a0\nBehandlung \u00a0mit\u00a0einem\u00a0anderen\u00a0Somatostatin \u2010Analogon \u00a0nicht\u00a0ausreichend \u00a0angesprochen \u00a0haben.\u00a0In\u00a0\nder\u00a0Gesamtbetrachtung \u00a0der\u00a0Ergebnisse \u00a0zur\u00a0Morbidit\u00e4t, \u00a0zur\u00a0Lebensqualit\u00e4t \u00a0und\u00a0zu\u00a0den\u00a0\nNebenwirkungen \u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0keine\u00a0nachhaltige \u00a0bisher\u00a0nicht\u00a0erreichte\u00a0deutliche \u00a0Verbesserung \u00a0des\u00a0\ntherapierelevanten \u00a0Nutzens,\u00a0insbesondere \u00a0keine\u00a0Abschw\u00e4chung \u00a0schwerwiegender \u00a0Symptome \u00a0oder\u00a0\neine\u00a0f\u00fcr\u00a0die\u00a0Patientinnen \u00a0und\u00a0Patienten \u00a0sp\u00fcrbare\u00a0Linderung \u00a0der\u00a0Erkrankung. \u00a0Au\u00dferdem \u00a0m\u00fcssen\u00a0die\u00a0\npositiven\u00a0Effekte\u00a0bei\u00a0der\u00a0biochemischen \u00a0Kontrolle\u00a0und\u00a0der\u00a0Verbesserung \u00a0der\u00a0Kopfschmerzen \u00a0\nabgewogen \u00a0werden\u00a0gegen\u00fcber \u00a0den\u00a0negativen \u00a0Effekten\u00a0der\u00a0erh\u00f6hten \u00a0Nebenwirkungen. \u00a0\n\u00a0\n\u00a0 \u00a0 \n79\u00a0\n \nInnovationsreport 2015 \u00a0Verf\u00fcgbare \u00a0Therapien  \n\u00a0(Zusatz\u2010)Nutzen\n\u00a0Kosten\n\u00a0\n  \u00a0  \n\u00a0\n\u00a0Erstes\u00a0Somatostatin \u2010Analogon \u00a0\nzur\u00a0medikament\u00f6sen \u00a0\nBehandlung \u00a0des\u00a0Morbus\u00a0\nCushing,\u00a0weswegen \u00a0kein\u00a0\nKostenvergleich \u00a0durchgef\u00fchrt \u00a0\nwird\u00a0\n  \u00a0 Senkt\u00a0den\u00a0pathologisch \u00a0erh\u00f6hten \u00a0\nCortisol\u2010Plasmaspiegel \u00a0und\u00a0die\u00a0\ndamit\u00a0verbundenen \u00a0Krankheits \u2010\nbeschwerden. \u00a0Keine\u00a0Daten\u00a0zum\u00a0\nGesamt\u00fcberleben \u00a0und\u00a0zur\u00a0\nLangzeitvertr\u00e4glichkeit \u00a0vorhanden   \n Erstes\u00a0Somatostatin \u2010Analogon \u00a0\nzur\u00a0medikament\u00f6sen \u00a0\nBehandlung \u00a0des\u00a0Morbus\u00a0\nCushing,\u00a0wenn\u00a0ein\u00a0\nchirurgischer \u00a0Eingriff\u00a0keine\u00a0\nOption\u00a0ist\u00a0oder\u00a0fehlgeschlagen \u00a0\nist \u00a0    \nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien :\u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen :\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten :\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien \u00a0\nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0\nA\u00a0 Keine\u00a0Bewertung \u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nIm\u00a0Beobachtungszeitraum \u00a0erhielten\u00a0insgesamt \u00a018\u00a0TK\u2010Versicherte \u00a0(in\u00a0der\u00a0Mehrzahl \u00a0weibliche \u00a0\nPatienten \u00a0zwischen\u00a040\u00a0und\u00a060\u00a0Jahre)\u00a0mindestens \u00a0eine\u00a0Verordnung \u00a0des\u00a0Orphan\u00a0Drug\u00a0Pasireotid \u00a0\n(Abbildung \u00a037).\u00a0Mit\u00a0\u00fcberschaubaren \u00a0Verordnungszahlen \u00a0(Abbildung \u00a036)\u00a0konnten\u00a0Ums\u00e4tze\u00a0von\u00a0bis\u00a0zu\u00a0\n60.000\u00a0Euro\u00a0im\u00a0Monat\u00a0generiert \u00a0werden\u00a0(Abbildung \u00a038).\u00a0\u00a0\n \u00a0\n \n80\u00a0\n \n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a036:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Pasireotid \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0\n\u00a0\n \nAbbildung \u00a037:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Pasireotid \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0\n \u00a0\n \n81\u00a0\n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a038:Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Pasireotid \u00a0nach\u00a0Monaten \u00a0(2012\u2010\n2013)\u00a0\n\u00a0\n\u00a0\u00a0\n \n82\u00a0 \n \nInnovationsreport 2015 \u00a0 4.14 Perampanel \u00a0\nHandelsname: \u00a0Fycompa\u00ae     Hersteller: \u00a0Eisai \nIndikation: \u00a0Epilepsie\u00a0(Zusatztherapie \u00a0fokale\u00a0Anf\u00e4lle)\u00a0Markteinf\u00fchrung: \u00a0September \u00a02012 \nATC\u2010Code:\u00a0N03AX22      DDD:\u00a08\u00a0mg \nDarreichungsform: \u00a0Filmtablette  \nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0216\u00a0\nBewertung \u00a0\nPerampanel, \u00a0zur\u00a0pharmakotherapeutischen \u00a0Gruppe\u00a0der\u00a0Antiepileptika \u00a0geh\u00f6rend, \u00a0ist\u00a0der\u00a0erste\u00a0\nVertreter \u00a0der\u00a0selektiven, \u00a0nicht\u2010kompetitiven \u00a0AMPA\u2010Rezeptorantagonisten. \u00a0Im\u00a0Juli\u00a02012\u00a0erfolgte\u00a0die\u00a0\neuropaweite \u00a0Zulassung \u00a0von\u00a0Perampanel \u00a0als\u00a0Zusatztherapie \u00a0fokaler\u00a0Anf\u00e4lle\u00a0mit\u00a0oder\u00a0ohne\u00a0sekund\u00e4re \u00a0\nGeneralisierung \u00a0bei\u00a0Epilepsie\u2010Patienten \u00a0ab\u00a0zw\u00f6lf\u00a0Jahren.\u00a0In\u00a0Abh\u00e4ngigkeit \u00a0vom\u00a0individuellen \u00a0\nAnsprechen \u00a0muss\u00a0der\u00a0Wirkstoff \u00a0bis\u00a0zur\u00a0gew\u00fcnschten \u00a0Erhaltungsdosis \u00a0auftitriert \u00a0werden.\u00a0Die\u00a0\nEinnahme \u00a0erfolgt\u00a0einmal\u00a0t\u00e4glich\u00a0abends\u00a0vor\u00a0dem\u00a0Schlafengehen. \u00a0\nIn\u00a0den\u00a0drei\u00a0Pivotalstudien, \u00a0in\u00a0denen\u00a0Perampanel \u00a0als\u00a0zus\u00e4tzliche \u00a0Gabe\u00a0zu\u00a0anderen\u00a0Antiepileptika \u00a0\nverabreicht \u00a0wurde,\u00a0wurde\u00a0als\u00a0prim\u00e4rer\u00a0Endpunkt \u00a0die\u00a0Verringerung \u00a0der\u00a0Anfallsh\u00e4ufigkeit \u00a0um\u00a0\nmindestens \u00a050\u00a0Prozent\u00a0untersucht. \u00a0Unabh\u00e4ngig \u00a0von\u00a0der\u00a0jeweiligen \u00a0Perampanel \u2010Dosis\u00a0(8\u00a0oder\u00a012\u00a0mg)\u00a0\nkonnte\u00a0dies\u00a0bei\u00a0mehr\u00a0als\u00a030\u00a0Prozent\u00a0der\u00a0Studienteilnehmer \u00a0erreicht\u00a0werden.\u00a0Damit\u00a0ist\u00a0der\u00a0AMPA\u2010\nRezeptorantagonist \u00a0in\u00a0seiner\u00a0Wirksamkeit \u00a0und\u00a0Vertr\u00e4glichkeit \u00a0vergleichbar \u00a0mit\u00a0anderen\u00a0\nAntikonvulsiva, \u00a0die\u00a0f\u00fcr\u00a0die\u00a0Add\u2010on\u2010Therapie\u00a0eingesetzt \u00a0werden.\u00a0\u00a0\nH\u00e4ufigste \u00a0Nebenwirkungen \u00a0in\u00a0den\u00a0klinischen \u00a0Studien\u00a0waren\u00a0neben\u00a0Schwindel \u00a0und\u00a0Somnolenz \u00a0auch\u00a0\nver\u00e4ndertes \u00a0Essverhalten \u00a0(erh\u00f6hter \u00a0oder\u00a0verminderter \u00a0Appetit),\u00a0Verwirrtheit, \u00a0Angst,\u00a0Aggressivit\u00e4t \u00a0\nund\u00a0Reizbarkeit. \u00a0\u00a0\nDer\u00a0Wirkstoff \u00a0durchlief\u00a0insgesamt \u00a0zweimal\u00a0die\u00a0fr\u00fche\u00a0Nutzenbewertung. \u00a0In\u00a0seinem\u00a0ersten\u00a0Beschluss \u00a0\nvom\u00a07.\u00a0M\u00e4rz\u00a02013\u00a0konstatierte \u00a0der\u00a0G\u2010BA\u00a0dem\u00a0neuen\u00a0Wirkstoff \u00a0einen\u00a0nicht\u00a0belegten\u00a0Zusatznutzen \u00a0im\u00a0\nVerh\u00e4ltnis \u00a0zur\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0(Lamotrigin \u00a0oder\u00a0Topiramat, \u00a0wenn\u00a0Lamotrigin \u00a0als\u00a0\nBasismedikation \u00a0gegeben\u00a0wurde).\u00a0Als\u00a0Konsequenz \u00a0nahm\u00a0der\u00a0pU\u00a0das\u00a0Arzneimittel \u00a0nach\u00a0nur\u00a0neun\u00a0\nMonaten\u00a0Marktzugeh\u00f6rigkeit \u00a0wieder\u00a0aus\u00a0dem\u00a0Handel\u00a0und\u00a0auf\u00a0seinen\u00a0Antrag\u00a0wurde\u00a0eine\u00a0erneute\u00a0\nNutzenbewertung \u00a0zu\u00a0dem\u00a0Wirkstoff \u00a0Perampanel \u00a0veranlasst. \u00a0Auch\u00a0in\u00a0der\u00a0zweiten\u00a0Nutzenbewertung \u00a0\nvom\u00a06.\u00a0November \u00a02014\u00a0fiel\u00a0das\u00a0Urteil\u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0zu\u00a0Ungunsten \u00a0des\u00a0\nneuen\u00a0Wirkstoffes \u00a0aus,\u00a0trotz\u00a0neuer,\u00a0umfassender \u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0mit\u00a0insgesamt \u00a0\nzehn\u00a0\u2013\u00a0sowohl\u00a0patentierten \u00a0als\u00a0auch\u00a0generischen \u00a0\u2013\u00a0Wirkstoffen. \u00a0\u00a0\nGerade\u00a0f\u00fcr\u00a0die\u00a0Personen, \u00a0die\u00a0mit\u00a0den\u00a0bisher\u00a0verf\u00fcgbaren \u00a0Therapien \u00a0nicht\u00a0optimal\u00a0anfallsfrei \u00a0\neingestellt \u00a0werden\u00a0konnten,\u00a0er\u00f6ffnet\u00a0sich\u00a0durch\u00a0die\u00a0Markteinf\u00fchrung \u00a0neuer\u00a0Antiepileptika \u00a0eine\u00a0\nweitere\u00a0Therapieoption. \u00a0Mit\u00a0Perampanel \u00a0wurde\u00a0im\u00a0Jahr\u00a02013\u00a0erneut\u00a0ein\u00a0Antiepileptikum \u00a0vom\u00a0Markt\u00a0\ngenommen, \u00a0so\u00a0dass\u00a0Patienten, \u00a0die\u00a0m\u00f6glicherweise \u00a0zum\u00a0ersten\u00a0Mal\u00a0eine\u00a0f\u00fcr\u00a0sie\u00a0individuell \u00a0optimale\u00a0\nBehandlung \u00a0erfahren, \u00a0erneut\u00a0vor\u00a0dem\u00a0Problem\u00a0stehen.\u00a0So\u00a0sollten\u00a0medizinische \u00a0Fachgesellschaften \u00a0\nst\u00e4rker\u00a0eingebunden \u00a0werden,\u00a0wenn\u00a0es\u00a0um\u00a0die\u00a0Bewertung \u00a0und\u00a0Entscheidungsfindung \u00a0\u00fcber\u00a0den\u00a0\nZusatznutzen \u00a0neuer\u00a0(Add\u2010on\u2010)Medikamente \u00a0zur\u00a0Epilepsiebehandlung \u00a0geht.\u00a0\n\u00a0 \u00a0 \n83\u00a0\n \nInnovationsreport 2015 \u00a0Verf\u00fcgbare \u00a0Therapien  \n\u00a0(Zusatz\u2010)Nutzen\n\u00a0Kosten\n\u00a0\n  \n\u00a0\n\u00a0\u00a0 Wirksamkeit \u00a0und\u00a0Vertr\u00e4glichkeit \u00a0\nliegen\u00a0in\u00a0einem\u00a0\u00e4hnlichen \u00a0\nBereich\u00a0wie\u00a0f\u00fcr\u00a0andere\u00a0neue\u00a0\nAntiepileptika  Kostenanalyse \u00a0ist\u00a0derzeit\u00a0nicht\u00a0\nm\u00f6glich\u00a0(Marktr\u00fccknahme \u00a0\nMitte\u00a02013)\u00a0\n Weitere\u00a0Therapieoption, \u00a0\nallerdings \u00a0erster\u00a0Vertreter \u00a0seiner  \nWirkstoffklasse \u00a0\u00a0   \n  \n\u00a0\n\u00a0\u00a0    \nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien :\u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen :\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten :\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien \u00a0\nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0\nA/C\u00a0 Variante\u00a0ohne\u00a0besonderen \u00a0Stellenwert \u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nDie\u00a0Verordnungszahlen \u00a0von\u00a0Perampanel \u00a0(Fycompa\u00ae) \u00a0stiegen\u00a0nach\u00a0seiner\u00a0Markteinf\u00fchrung \u00a0im\u00a0\nSeptember \u00a02012\u00a0rasch\u00a0an,\u00a0erreichten \u00a0ihr\u00a0Maximum \u00a0im\u00a0April\u00a02013\u00a0mit\u00a0ca.\u00a0300\u00a0Packungen \u00a0(ohne\u00a0\nNormgr\u00f6\u00dfen \u2010Angabe)\u00a0und\u00a0sanken\u00a0in\u00a0den\u00a0darauffolgenden \u00a0Monaten\u00a0leicht\u00a0ab\u00a0(Abbildung \u00a039).\u00a0Sie\u00a0\nverteilten \u00a0sich\u00a0zu\u00a0nahezu\u00a0gleichen\u00a0Teilen\u00a0auf\u00a0M\u00e4nner\u00a0und\u00a0Frauen\u00a0(Abbildung \u00a040).\u00a0Der\u00a0h\u00f6chste\u00a0Umsatz\u00a0\nmit\u00a0mehr\u00a0als\u00a0100.000\u00a0Euro\u00a0wurde\u00a0indes\u00a0im\u00a0Juli\u00a0erreicht\u00a0(Abbildung \u00a041).\u00a0Der\u00a0pU\u00a0hatte\u00a0in\u00a0seiner\u00a0\nPressemitteilung \u00a0eine\u00a0l\u00fcckenlose \u00a0Versorgung \u00a0der\u00a0bis\u00a0dato\u00a0mit\u00a0diesem\u00a0Antiepileptikum \u00a0eingestellten \u00a0\nPatienten \u00a0zugesagt. \u00a0\n \u00a0\n \n84\u00a0\n \n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a039:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Perampanel \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0\u00a0\n\u00a0\n \nAbbildung \u00a040:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Perampanel \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0\n(2013)\u00a0\u00a0\n \n85\u00a0\n \nInnovationsreport 2015 \u00a0\n\u00a0\nAbbildung \u00a041:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Perampanel \u00a0nach\u00a0Monaten \u00a0(2012\u2010\n2013)\u00a0\n\u00a0\u00a0\n \n86\u00a0 \n \nInnovationsreport 2015 \u00a0 4.15 Pixantron \u00a0\nHandelsname: \u00a0Pixuvri\u00ae     Hersteller: \u00a0CTI\u00a0Life\u00a0Sciences\u00a0Ltd. \nIndikation: \u00a0Non\u2010Hodgkin\u2010B\u2010Zell\u2010Lymphome \u00a0  Markteinf\u00fchrung: \u00a0Dezember \u00a02012 \nATC\u2010Code:\u00a0L01DB11      DDD:\u00a09,64\u00a0mg \nDarreichungsform: \u00a0Pulver\u00a0zur\u00a0Herstellung \u00a0einer\u00a0Infusionsl\u00f6sung  \nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0220\u00a0\nBewertung \u00a0\nPixantron \u00a0ist\u00a0eine\u00a0zytotoxische \u00a0DNA\u2010interkalierende \u00a0Substanz\u00a0aus\u00a0der\u00a0Gruppe\u00a0der\u00a0\nAnthracyclinderivate, \u00a0deren\u00a0chemische \u00a0Struktur\u00a0sich\u00a0von\u00a0Mitoxantron \u00a0ableitet.\u00a0Sie\u00a0soll\u00a0die\u00a0durch\u00a0\nAnthracycline \u00a0ausgel\u00f6ste \u00a0Kardiotoxizit\u00e4t \u00a0vermindern. \u00a0Pixoxantron \u00a0ist\u00a0zugelassen \u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0\nvon\u00a0erwachsenen \u00a0Patienten \u00a0mit\u00a0mehrfach \u00a0rezidivierten \u00a0oder\u00a0therapierefrakt\u00e4ren \u00a0aggressiven \u00a0B\u2010Zell\u00a0\nNon\u2010Hodgkin\u2010Lymphomen \u00a0(NHL).\u00a0Die\u00a0Anwendung \u00a0erfolgt\u00a0als\u00a0intraven\u00f6se \u00a0Infusion\u00a0unter\u00a0Verwendung \u00a0\neines\u00a0In\u2010Line\u2010Filters\u00a0\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von\u00a0mindestens \u00a060\u00a0Minuten. \u00a0\nIn\u00a0der\u00a0f\u00fcr\u00a0die\u00a0Zulassung \u00a0relevanten \u00a0offenen,\u00a0randomisierten \u00a0kontrollierten \u00a0Studie\u00a0erhielten\u00a0die\u00a0\nPatienten \u00a0mit\u00a0aggressiven \u00a0B\u2010NHL,\u00a0die\u00a0nach\u00a02\u00a0oder\u00a0mehr\u00a0vorangegangenen \u00a0Chemotherapien \u00a0\nrezidivierten, \u00a0entweder \u00a0sechs\u00a0Zyklen\u00a0Pixantron \u00a0oder\u00a0ein\u00a0anderes\u00a0vom\u00a0behandelnden \u00a0Arzt\u00a0\nausgew\u00e4hltes \u00a0Zytostatikum \u00a0\u2013\u00a0jeweils\u00a0als\u00a0Monotherapie. \u00a0Mit\u00a0Pixantron \u00a0erreichten \u00a020\u00a0Prozent\u00a0der\u00a0\nPatienten \u00a0eine\u00a0komplette \u00a0Remission \u00a0im\u00a0Vergleich \u00a0zu\u00a05,7\u00a0Prozent\u00a0im\u00a0aktiven\u00a0Kontroll\u2010Arm.\u00a0Das\u00a0\nmediane\u00a0progressionsfreie \u00a0\u00dcberleben \u00a0verl\u00e4ngerte \u00a0sich\u00a0durch\u00a0Pixantron \u00a0signifikant \u00a0um\u00a02,7\u00a0Monate.\u00a0\nEine\u00a0genaue\u00a0Bewertung \u00a0des\u00a0Nutzen\u2010Schaden\u2010Verh\u00e4ltnisses \u00a0dieses\u00a0neuartigen \u00a0Zytotstatikums \u00a0ist\u00a0aus\u00a0\nSicht\u00a0der\u00a0EMA\u00a0jedoch\u00a0erst\u00a0nach\u00a0Vorlage\u00a0der\u00a0zus\u00e4tzlich \u00a0angeforderten \u00a0Daten\u00a0\u00fcber\u00a0Patienten \u00a0mit\u00a0einer\u00a0\nvorangehenden \u00a0Behandlung \u00a0mit\u00a0Rituximab \u00a0m\u00f6glich.\u00a0Diese\u00a0Daten\u00a0sind\u00a0notwendig, \u00a0da\u00a0in\u00a0der\u00a0Erstlinien \u2010\nTherapie\u00a0das\u00a0Rituximab \u2010CHOP\u00a0(Cyclophosphamid, \u00a0Doxorubicin, \u00a0Vincristin, \u00a0Prednison) \u2010Protokoll\u00a0den\u00a0\nGoldstandard \u00a0stellt.\u00a0Zudem\u00a0weist\u00a0die\u00a0f\u00fcr\u00a0die\u00a0Zulassung \u00a0vorlegte\u00a0Studie\u00a0weitere\u00a0relevante \u00a0M\u00e4ngel\u00a0auf,\u00a0\ndie\u00a0ihre\u00a0Aussagekraft \u00a0stark\u00a0einschr\u00e4nken. \u00a0Bei\u00a0Rezidiven \u00a0werden\u00a0Patienten, \u00a0die\u00a0aufgrund\u00a0ihrer\u00a0\nKomorbidit\u00e4t \u00a0oder\u00a0ihres\u00a0Alters\u00a0f\u00fcr\u00a0eine\u00a0autologe\u00a0Blutstammzelltransplantation \u00a0(ASCT)\u00a0nicht\u00a0geeignet\u00a0\nsind,\u00a0mit\u00a0Regimen\u00a0behandelt, \u00a0in\u00a0denen\u00a0Rituximab \u00a0mit\u00a0anderen\u00a0Zytostatika \u00a0als\u00a0in\u00a0CHOP\u00a0kombiniert \u00a0\nwird,\u00a0z.B.\u00a0mit\u00a0Cisplatin\u00a0und\u00a0Cytarabin \u00a0in\u00a0R\u2010DHAP\u00a0oder\u00a0mit\u00a0Ifosfamid, \u00a0Carboplatin \u00a0und\u00a0Etoposid\u00a0in\u00a0R\u2010\nICE.\u00a0Im\u00a0Falle\u00a0eines\u00a0erneuten \u00a0Rezidivs\u00a0k\u00f6nnen\u00a0allerdings \u00a0h\u00e4ufig\u00a0die\u00a0in\u00a0der\u00a0Erst\u2010\u00a0und\u00a0Zweitlinie \u00a0\nverwendeten \u00a0Zytostatika \u00a0nicht\u00a0mehr\u00a0verwendet \u00a0werden,\u00a0z.B.\u00a0Anthrazykline \u00a0bei\u00a0Erreichen \u00a0der\u00a0\nkumulativen \u00a0H\u00f6chstdosis. \u00a0Aus\u00a0diesem\u00a0Grund\u00a0wurde\u00a0die\u00a0Zulassung \u00a0des\u00a0neuen\u00a0Wirkstoffes \u00a0auch\u00a0mit\u00a0\nder\u00a0Auflage\u00a0verkn\u00fcpft, \u00a0dass\u00a0bis\u00a0Juni\u00a02015\u00a0eine\u00a0randomisierte, \u00a0kontrollierte \u00a0Phase\u2010III\u2010Studie\u00a0mit\u00a0\nPixantron \u2010Rituximab \u00a0versus\u00a0Gemcitabin \u2010Rituximab \u00a0bei\u00a0Patienten \u00a0mit\u00a0aggressivem \u00a0B\u2010Zell\u2010Non\u2010\nHodgkin\u2010Lymphom \u00a0durchgef\u00fchrt \u00a0wird,\u00a0bei\u00a0denen\u00a0die\u00a0Erstlinien \u2010Therapie\u00a0mit\u00a0R\u2010CHOP\u00a0versagt\u00a0hat\u00a0und\u00a0\neine\u00a0ASCT\u00a0(Zweitlinie) \u00a0nicht\u00a0durchgef\u00fchrt \u00a0werden\u00a0kann,\u00a0oder\u00a0bei\u00a0denen\u00a0eine\u00a0ASCT\u00a0versagt\u00a0hat\u00a0(Dritt\u2010\u00a0\noder\u00a0Viertlinie). \u00a0\nDie\u00a0h\u00e4ufigsten \u00a0Nebenwirkungen \u00a0unter\u00a0Pixantron \u00a0waren\u00a0febrile\u00a0und\u00a0nicht\u2010febrile\u00a0Neutropenien \u00a0sowie\u00a0\nThrombozytopenien. \u00a0\nDer\u00a0G\u2010BA\u00a0wertet\u00a0den\u00a0Zusatznutzen \u00a0von\u00a0Pixantron \u00a0gegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0\n(patientenindividuelle \u00a0Therapie\u00a0u.a.\u00a0mit\u00a0Bleomycin, \u00a0Cyclophosphamid, \u00a0Etoposid\u00a0etc.)\u00a0als\u00a0nicht\u00a0belegt.\u00a0\u00a0\n \u00a0 \n87\u00a0\n \nInnovationsreport 2015 \u00a0Verf\u00fcgbare \u00a0Therapien  \n\u00a0(Zusatz\u2010)Nutzen\n\u00a0Kosten\n\u00a0\n Weitere\u00a0Therapieoption \u00a0 Stellenwert \u00a0gegen\u00fcber \u00a0den\u00a0\nvorhandenen \u00a0Therapieoptionen \u00a0\nwegen\u00a0fehlender \u00a0Daten\u00a0derzeit\u00a0\nnicht\u00a0feststellbar. \u00a0Keine\u00a0\nsignifikante \u00a0Verl\u00e4ngerung \u00a0des\u00a0\nGesamt\u00fcberlebens \u00a0Teurer\u00a0als\u00a0vergleichende \u00a0\nTherapieoptionen \u00a0\n \u00a0\n   \n  \n\u00a0\n\u00a0\u00a0   \nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien :\u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen :\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten :\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien \u00a0\nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0\nC\u00a0 Keine\u00a0Bewertung \u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nNach\u00a0seiner\u00a0Markteinf\u00fchrung \u00a0im\u00a0Dezember \u00a02012\u00a0finden\u00a0sich\u00a0in\u00a0den\u00a0Routinedaten \u00a0der\u00a0TK\u00a0erstmals\u00a0im\u00a0\nFebruar\u00a02013\u00a0Verordnungsdaten \u00a0zu\u00a0Pixantron \u00a0(Pixuvri\u00ae) \u00a0und\u00a0zwar\u00a0in\u00a0erster\u00a0Linie\u00a0als\u00a0Rezeptur\u00a0\nabgerechnet \u00a0(Abbildung \u00a042).\u00a0Trotz\u00a0geringer\u00a0Verordnungszahlen \u00a0bei\u00a0einer\u00a0\u00fcberschaubaren \u00a0\nVersichertenzahl \u00a0(im\u00a0Beobachtungszeitraum \u00a0erhielten\u00a0nur\u00a0insgesamt \u00a0neun\u00a0TK\u2010Versicherte \u00a0diesen\u00a0\nWirkstoff) \u00a0(Abbildung \u00a043),\u00a0lagen\u00a0die\u00a0monatlichen \u00a0Bruttoums\u00e4tze \u00a0in\u00a0der\u00a0Spitze\u00a0bei\u00a0knapp\u00a020.000\u00a0Euro\u00a0\n(Abbildung \u00a044).\u00a0\u00a0\n \u00a0\n \n88\u00a0\n \n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a042:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Pixantron \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0\n\u00a0\n \nAbbildung \u00a043:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Pixantron \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0\n \u00a0\n \n89\u00a0\n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a044:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Pixantron \u00a0nach\u00a0Monaten \u00a0(2012\u2010\n2013)\u00a0\u00a0\n \n90\u00a0 \n \nInnovationsreport 2015 \u00a0 4.16 Rilpivirin\u00a0\nHandelsname: \u00a0Edurant\u00ae\u00a0 \u00a0\u00a0\u00a0 Hersteller: \u00a0Janssen\u00a0Cilag\u00a0\nIndikation: \u00a0Humanes \u00a0Immundefizienz \u2010Virus\u00a0Typ\u00a01\u00a0Markteinf\u00fchrung: \u00a0Januar\u00a02012\u00a0\u00a0\nATC\u2010Code:\u00a0J05AG05\u00a0 \u00a0\u00a0\u00a0\u00a0 DDD:\u00a025\u00a0mg\u00a0\nDarreichungsform: \u00a0Filmtablette \u00a0\nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0224 \nBewertung \u00a0\nNach\u00a0Delavirdin, \u00a0Efavirenz, \u00a0Nevirapin \u00a0und\u00a0Etravirin\u00a0ist\u00a0Rilpivirin\u00a0der\u00a0f\u00fcnfte\u00a0Vertreter \u00a0der\u00a0nicht\u2010\nnukleosidischen \u00a0Reverse\u2010Transkriptase \u2010Inhibitoren \u00a0(NNRTI),\u00a0zugelassen \u00a0f\u00fcr\u00a0die\u00a0antiretrovirale \u00a0\nKombinationsbehandlung \u00a0von\u00a0HIV\u20101\u2010Infektionen \u00a0bei\u00a0antiretroviral \u00a0nicht\u00a0vorbehandelten \u00a0\nErwachsenen \u00a0mit\u00a0einer\u00a0Viruslast\u00a0von\u00a0maximal\u00a0100.000\u00a0RNA\u2010Kopien/ml. \u00a0Gilead\u00a0Sciences\u00a0bietet\u00a0den\u00a0\nWirkstoff \u00a0auch\u00a0in\u00a0fixer\u00a0Kombination \u00a0mit\u00a0Emtricitabin \u00a0und\u00a0Tenofovir \u00a0unter\u00a0dem\u00a0Handelsnamen \u00a0\nEviplera\u00ae \u00a0an,\u00a0welche\u00a0im\u00a0Gegensatz \u00a0zum\u00a0Monotherapeutikum \u00a0sowohl\u00a0f\u00fcr\u00a0antiretroviral \u2010therapienaive \u00a0\nwie\u00a0auch\u00a0f\u00fcr\u00a0antiretroviral \u2010therapieerfahrene \u00a0Patienten \u00a0zugelassen \u00a0ist.\u00a0Neben\u00a0Atripla\u00ae\u00a0\n(Kombinationspr\u00e4parat \u00a0bestehend \u00a0aus\u00a0Efavirenz, \u00a0Emtricitabin \u00a0+\u00a0Tenofovir) \u00a0steht\u00a0damit\u00a0ein\u00a0weiteres\u00a0\nSingle\u2010Dose\u2010Regime\u00a0zur\u00a0Verf\u00fcgung. \u00a0Da\u00a0in\u00a0klinischen \u00a0Studien\u00a0Patienten \u00a0mit\u00a0einer\u00a0Ausgangsviruslast \u00a0\nvon\u00a0mehr\u00a0als\u00a0100.000\u00a0Viruskopien/ml \u00a0bei\u00a0virologischem \u00a0Versagen \u00a0auch\u00a0eine\u00a0h\u00f6here\u00a0Rate\u00a0\nbehandlungsbedingter \u00a0Resistenzen \u00a0gegen\u00a0NNRTI\u00a0aufwiesen, \u00a0wurde\u00a0die\u00a0Indikation \u00a0von\u00a0Rilpivirin\u00a0auf\u00a0\ndie\u00a0Behandlung \u00a0von\u00a0HIV\u2010Patienten \u00a0mit\u00a0einer\u00a0Viruslast\u00a0von\u00a0maximal\u00a0100.000\u00a0RNA\u2010Kopien/ml \u00a0\nbeschr\u00e4nkt. \u00a0\nRilpivirin\u00a0wies\u00a0hinsichtlich \u00a0des\u00a0prim\u00e4ren \u00a0Endpunktes \u00a0in\u00a0den\u00a0beiden\u00a0klinischen \u00a0Studien\u00a0\u2013\u00a0Anzahl\u00a0der\u00a0\nPatienten \u00a0mit\u00a0einer\u00a0Viruslast\u00a0unter\u00a050\u00a0Kopien/ml \u00a0nach\u00a048\u00a0Wochen\u00a0\u2013\u00a0eine\u00a0Nicht\u2010Unterlegenheit \u00a0\ngegen\u00fcber \u00a0Efavirenz\u00a0auf,\u00a0verbunden \u00a0mit\u00a0einem\u00a0g\u00fcnstigeren \u00a0Nebenwirkungsprofil. \u00a0Der\u00a0besseren\u00a0\nVertr\u00e4glichkeit \u00a0steht\u00a0allerdings \u00a0auch\u00a0eine\u00a0h\u00f6here\u00a0virologische \u00a0Versagerrate \u00a0(Non\u2010Response )\u00a0als\u00a0unter\u00a0\nEfavirenz\u00a0gegen\u00fcber \u00a0(7\u00a0Prozent\u00a0(24\u00a0von\u00a0340)\u00a0vs.\u00a05\u00a0Prozent\u00a0(18\u00a0von\u00a0338)).\u00a0bzw.\u00a013\u00a0Prozent\u00a0(45\u00a0von\u00a0\n346)\u00a0vs.\u00a06\u00a0Prozent\u00a0(21\u00a0von\u00a0344)).\u00a0\u00a0\nDas\u00a0Nebenwirkungsprofil \u00a0fiel\u00a0f\u00fcr\u00a0die\u00a0Rilpivirin\u2010Gruppe\u00a0deutlich\u00a0g\u00fcnstiger \u00a0aus,\u00a0besonders \u00a0hinsichtlich \u00a0\nder\u00a0neurologischen \u00a0Nebenwirkungen \u00a0Schlaflosigkeit, \u00a0Depression \u00a0und\u00a0M\u00fcdigkeit, \u00a0die\u00a0h\u00e4ufig\u00a0zum\u00a0\nAbbruch\u00a0der\u00a0Standardtherapie \u00a0f\u00fchren.\u00a0\u00a0\nDer\u00a0G\u2010BA\u00a0sah\u00a0f\u00fcr\u00a0den\u00a0Wirkstoff \u00a0Rilpivirin\u00a0gegen\u00fcber \u00a0Efavirenz, \u00a0jeweils\u00a0in\u00a0freier\u00a0Kombination \u00a0mit\u00a0\nTenofovir \u00a0plus\u00a0Emtricitabin \u00a0oder\u00a0Abacavir\u00a0plus\u00a0Lamivudin, \u00a0bei\u00a0nicht\u00a0vorbehandelten \u00a0Patienten \u00a0einen\u00a0\nBeleg\u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0Zusatznutzen .\u00a0Bei\u00a0der\u00a0Bewertung \u00a0der\u00a0Fix\u2010Kombination, \u00a0bestehend \u00a0aus\u00a0\nRilpivirin\u00a0plus\u00a0Emtricitabin \u00a0plus\u00a0Tenofovir, \u00a0kam\u00a0der\u00a0G\u2010BA\u00a0bei\u00a0der\u00a0Gesamtschau \u00a0der\u00a0Ergebnisse \u00a0zu\u00a0\neinem\u00a0\u00e4hnlichen \u00a0Urteil\u00a0und\u00a0konstatierte \u00a0gegen\u00fcber \u00a0Efavirenz\u00a0plus\u00a0Emtricitabin \u00a0plus\u00a0Tenofovir \u00a0\nebenfalls\u00a0einen\u00a0Beleg\u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0Zusatznutzen \u00a0(G\u2010BA,\u00a02012a).\u00a0Im\u00a0Jahr\u00a02014\u00a0durchlief\u00a0die\u00a0\nFixkombination \u00a0eine\u00a0erneute\u00a0Nutzenbewertung \u00a0f\u00fcr\u00a0die\u00a0Erweiterung \u00a0des\u00a0Indikationsgebiets \u00a0um\u00a0\nantiretroviral \u00a0vorbehandelte \u00a0Patienten \u00a0ohne\u00a0HIV\u20101\u00a0Mutationen, \u00a0die\u00a0bekannterma\u00dfen \u00a0mit\u00a0Resistenzen \u00a0\nassoziiert \u00a0sind.\u00a0F\u00fcr\u00a0diese\u00a0Indikation \u00a0sah\u00a0der\u00a0G\u2010BA\u00a0den\u00a0Zusatznutzen \u00a0gegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0\nVergleichstherapie \u00a0(individuelle \u00a0antiretrovirale \u00a0Therapie) \u00a0als\u00a0nicht\u00a0belegt\u00a0an.\u00a0\u00a0 \u00a0 \n91\u00a0\n \nInnovationsreport 2015 \u00a0Verf\u00fcgbare \u00a0Therapien \u00a0\n\u00a0(Zusatz\u2010)Nutzen\n\u00a0Kosten\n\u00a0\n Weitere\u00a0Therapieoption\n\u00a0\n\u00a0\u00a0   \n\u00a0\n   Bei\u00a0nicht\u00a0vorbehandelten \u00a0HIV\u2010\nPatienten \u00a0kein\u00a0signifikanter \u00a0Vorteil\u00a0\nim\u00a0Vergleich \u00a0beim\u00a0virologischen \u00a0\nAnsprechen. \u00a0Aber\u00a0geringf\u00fcgig \u00a0\nbessere\u00a0neurologische \u00a0Vertr\u00e4g\u2010\nlichkeit  Kosten\u00a0vergleichbar \u00a0mit\u00a0alter\u2010\nnativer\u00a0Therapieoption \u00a0\n \n \n  \n \n     \nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien :\u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen :\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten :\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien \u00a0\nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0 AMB\u2010Bewertung \u00a0\nC\u00a0 Keine\u00a0Bewertung \u00a0 Weitere\u00a0Therapieoption \u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nW\u00e4hrend \u00a0direkt\u00a0nach\u00a0Markteinf\u00fchrung \u00a0nur\u00a0die\u00a0N1\u2010Packungsgr\u00f6\u00dfe \u00a0von\u00a0Rilpivirin\u00a0(Edurant\u00ae) \u00a0verordnet \u00a0\nwurde,\u00a0fanden\u00a0sich\u00a0im\u00a0letzten\u00a0Quartal\u00a02013\u00a0fast\u00a0ausschlie\u00dflich \u00a0N2\u2010Packungen \u00a0in\u00a0den\u00a0\nVerordnungsdaten, \u00a0was\u00a0durch\u00a0eine\u00a0\u00c4nderung \u00a0in\u00a0der\u00a0Normgr\u00f6\u00dfe \u00a0(von\u00a0N1\u00a0auf\u00a0N2)\u00a0im\u00a0September \u00a02013\u00a0\nzu\u00a0erkl\u00e4ren\u00a0ist\u00a0(Abbildung \u00a045).\u00a0Nach\u00a0Ver\u00f6ffentlichung \u00a0des\u00a0G\u2010BA\u2010Beschlusses \u00a0am\u00a005.\u00a0Juli\u00a02012,\u00a0in\u00a0\nwelchem\u00a0dem\u00a0Nicht\u2010Nukleosid \u2010Reverse\u2010Transkriptaseinhibitor \u00a0ein\u00a0Beleg\u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0\nZusatznutzen \u00a0konstatiert \u00a0wurde,\u00a0gingen\u00a0die\u00a0Verordnungszahlen \u00a0weiter\u00a0nach\u00a0oben\u00a0und\u00a0erzielten\u00a0einen\u00a0\nmonatlichen \u00a0Bruttoumsatz \u00a0von\u00a0bis\u00a0zu\u00a010.000\u00a0\u20ac\u00a0(Abbildung \u00a047).\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0\nVerordnung \u00a0waren\u00a0zu\u00a088\u00a0Prozent\u00a0m\u00e4nnlichen \u00a0Geschlechts \u00a0und\u00a0\u00fcberwiegend \u00a0Patienten \u00a0im\u00a0mittleren \u00a0\nAlter\u00a0(Abbildung \u00a046).\u00a0\u00a0\n \u00a0\n \n92\u00a0\n \n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a045:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Rilpivirin\u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0\n\u00a0\n \nAbbildung \u00a046:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Rilpivirin\u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0\n \u00a0\n \n93\u00a0\n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a047:Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Rilpivirin\u00a0nach\u00a0Monaten \u00a0(2012\u20102013)\n \n94\u00a0 \n \nInnovationsreport 2015 \u00a0 4.17 Ruxolitinib \u00a0\nHandelsname: \u00a0Jakavi\u00ae\u00a0\u00a0\u00a0\u00a0\u00a0 Hersteller: \u00a0Novartis\u00a0Pharma\u00a0\nIndikation: \u00a0Symptome \u00a0der\u00a0Myelofibrose \u00a0u.a.\u00a0\u00a0 \u00a0 Markteinf\u00fchrung: \u00a0September \u00a02012\u00a0\nATC\u2010Code:\u00a0L01XE18\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0 DDD:\u00a030\u00a0mg\u00a0\nDarreichungsform: \u00a0Tablette\u00a0\nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0230\u00a0\nBewertung \u00a0\nRuxolitinib \u00a0ist\u00a0ein\u00a0oral\u00a0einzunehmender, \u00a0selektiver \u00a0Hemmer\u00a0der\u00a0Janus\u2010assoziierten \u00a0Kinasen\u00a0(JAK)\u00a01\u00a0\nund\u00a02.\u00a0Die\u00a0JAK\u00a0leiten\u00a0Signale\u00a0von\u00a0Zytokinen \u00a0und\u00a0Wachstumsfaktoren \u00a0weiter,\u00a0die\u00a0f\u00fcr\u00a0die\u00a0H\u00e4matopoese \u00a0\nund\u00a0die\u00a0Immunfunktion \u00a0wichtig\u00a0sind.\u00a0Die\u00a0Dysregulation \u00a0der\u00a0JAK\u2010Signalwege \u00a0ist\u00a0charakteristisch \u00a0f\u00fcr\u00a0die\u00a0\nMyelofibrose. \u00a0Mit\u00a0dem\u00a0JAK\u2010Inhibitor\u00a0Ruxolitinib \u00a0wurde\u00a0erstmals\u00a0eine\u00a0effektive\u00a0medikament\u00f6se \u00a0\nTherapie\u00a0zur\u00a0Behandlung \u00a0chronisch \u00a0myeloproliferativer \u00a0Erkrankungen \u00a0wie\u00a0der\u00a0prim\u00e4ren \u00a0Myelofibrose \u00a0\nals\u00a0Orphan\u00a0Drug\u00a0zugelassen. \u00a0Mittlerweile \u00a0steht\u00a0der\u00a0Wirkstoff \u00a0auch\u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0von\u00a0\nErwachsenen \u00a0mit\u00a0Polycythaemia \u00a0vera\u00a0zur\u00a0Verf\u00fcgung, \u00a0die\u00a0resistent\u00a0oder\u00a0intolerant \u00a0gegen\u00fcber \u00a0\nHydroxycarbamid \u00a0sind.\u00a0\u00a0\nDie\u00a0Myelofibrose \u00a0ist\u00a0eine\u00a0b\u00f6sartige \u00a0h\u00e4matologische \u00a0Erkrankung, \u00a0f\u00fcr\u00a0deren\u00a0Pathogenese \u00a0erworbene \u00a0\nMutationen \u00a0in\u00a0der\u00a0h\u00e4matopoetischen \u00a0Stammzelle \u00a0mit\u00a0St\u00f6rungen \u00a0der\u00a0Signaltransduktion, \u00a0klonaler\u00a0\nMyeloproliferation \u00a0und\u00a0abnormer \u00a0Zytokinexpression \u00a0verantwortlich \u00a0gemacht\u00a0werden.\u00a0Sie\u00a0kann\u00a0\nprim\u00e4r\u00a0(prim\u00e4re\u00a0Myelofibrose, \u00a0PMF)\u00a0oder\u00a0sekund\u00e4r, \u00a0z.B.\u00a0infolge\u00a0einer\u00a0Polycythaemia \u00a0vera\u00a0oder\u00a0\nEssentiellen \u00a0Thrombozyth\u00e4mie \u00a0(Post\u2010PV\u2010MF,\u00a0Post\u2010ET\u2010MF)\u00a0auftreten. \u00a0Sie\u00a0geht\u00a0mit\u00a0fortschreitender \u00a0\nFibrosierung \u00a0des\u00a0Knochenmarks \u00a0einher\u00a0und\u00a0beruht\u00a0auf\u00a0einer\u00a0Fehlfunktion \u00a0h\u00e4matopoetischer \u00a0\nStammzellen. \u00a0So\u00a0ist\u00a0die\u00a0allogene\u00a0Stammzelltransplantation \u00a0\u2013\u00a0entweder \u00a0mit\u00a0einem\u00a0Familien\u2010\u00a0oder\u00a0\neinem\u00a0Fremdspender \u00a0durchgef\u00fchrt \u00a0\u2013\u00a0nach\u00a0wie\u00a0vor\u00a0die\u00a0einzige\u00a0Therapie\u00a0mit\u00a0kurativem \u00a0Charakter, \u00a0die\u00a0\njedoch\u00a0mit\u00a0einer\u00a0nicht\u00a0unerheblichen \u00a0Morbidit\u00e4t \u00a0und\u00a0Mortalit\u00e4t \u00a0belastet\u00a0ist.\u00a0\nF\u00fcr\u00a0die\u00a0Zulassung \u00a0wurden\u00a0zwei\u00a0randomisierte \u00a0Phase\u2010III\u2010Studien\u00a0eingereicht: \u00a0eine\u00a0doppelblinde \u00a0\nplacebokontrollierte \u00a0Studie\u00a0(COMFORT \u2010I)\u00a0und\u00a0eine\u00a0offene\u00a0Studie\u00a0gegen\u00a0die\u00a0beste\u00a0verf\u00fcgbare \u00a0\nTherapie\u00a0(COMFORT \u2010II).\u00a0In\u00a0die\u00a0Studien\u00a0aufgenommen \u00a0wurden\u00a0Patienten \u00a0mit\u00a0PMF\u00a0oder\u00a0Post\u2010PV/ET\u2010\nMF.\u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0war\u00a0die\u00a0Verringerung \u00a0der\u00a0Milzgr\u00f6\u00dfe \u00a0um\u00a0mindestens \u00a035\u00a0Prozent\u00a0im\u00a0Vergleich \u00a0\nzum\u00a0Ausgangswert. \u00a0In\u00a0den\u00a0klinischen \u00a0Studien\u00a0reduzierte \u00a0Ruxolitinib \u00a0die\u00a0Milzgr\u00f6\u00dfe \u00a0signifikant \u00a0bei\u00a0ca.\u00a0\neinem\u00a0Drittel\u00a0der\u00a0Patienten \u00a0und\u00a0verminderte \u00a0symptomatische \u00a0Ver\u00e4nderungen \u00a0der\u00a0Krankheit \u00a0wie\u00a0\nbeispielsweise \u00a0M\u00fcdigkeit, \u00a0Schw\u00e4che, \u00a0Bauchschmerzen, \u00a0Kachexie, \u00a0Gewichtsverlust, \u00a0Juckreiz,\u00a0\nn\u00e4chtliche \u00a0Schwei\u00dfausbr\u00fcche \u00a0und\u00a0Knochenschmerzen. \u00a0Eine\u00a0statistisch \u00a0signifikante \u00a0Verl\u00e4ngerung \u00a0des\u00a0\nGesamt\u00fcberlebens \u00a0unter\u00a0dem\u00a0Wirkstoff \u00a0wurde\u00a0in\u00a0beiden\u00a0Studien\u00a0nicht\u00a0nachgewiesen. \u00a0Auch\u00a0traten\u00a0\nnach\u00a0dem\u00a0Absetzten \u00a0der\u00a0Medikation \u00a0die\u00a0Symptome \u00a0der\u00a0Myelofibrose \u00a0wieder\u00a0auf.\u00a0\u00a0\nDer\u00a0positiven\u00a0Wirkung\u00a0stand\u00a0das\u00a0erh\u00f6hte\u00a0Risiko\u00a0schwerer\u00a0h\u00e4matologischer \u00a0Nebenwirkungen \u00a0\n(An\u00e4mie,\u00a0Thrombozytopenie \u00a0und\u00a0Neutropenie) \u00a0sowie\u00a0ein\u00a0erh\u00f6htes\u00a0Infektionsrisiko \u00a0(Herpes\u00a0zoster,\u00a0\nHarnwegsinfektionen) \u00a0entgegen. \u00a0Weitere\u00a0Nebenwirkungen \u00a0sind\u00a0Blutungen \u00a0und\u00a0der\u00a0Anstieg\u00a0von\u00a0\nTransaminasen. \u00a0\u00a0\n \u00a0 \n95\u00a0\n \nInnovationsreport 2015 \u00a0In\u00a0der\u00a0ersten\u00a0Nutzenbewertung \u00a0im\u00a0M\u00e4rz\u00a02013\u00a0ergab\u00a0die\u00a0Quantifizierung \u00a0des\u00a0Zusatznutzens \u00a0durch\u00a0den\u00a0\nG\u2010BA\u00a0einen\u00a0geringen\u00a0Zusatznutzen \u00a0f\u00fcr\u00a0Ruloxitinib. \u00a0In\u00a0seiner\u00a0zweiten\u00a0Nutzenbewertung \u00a0im\u00a0November \u00a0\n2014\u00a0\u2013\u00a0der\u00a0Umsatz\u00a0des\u00a0Medikaments \u00a0hatte\u00a0die\u00a0im\u00a0AMNOG\u00a0festgelegte \u00a0Umsatzgrenze \u00a0von\u00a050\u00a0Mio.\u00a0\nEuro\u00a0\u00fcberschritten, \u00a0so\u00a0dass\u00a0ein\u00a0erneutes\u00a0Verfahren \u00a0eingeleitet \u00a0werden\u00a0musste\u00a0\u2013\u00a0stellte\u00a0der\u00a0G\u2010BA\u00a0fest,\u00a0\ndass\u00a0die\u00a0vorliegenden \u00a0Daten\u00a0f\u00fcr\u00a0Ruxolitinib \u00a0einen\u00a0Anhaltspunkt \u00a0f\u00fcr\u00a0einen\u00a0betr\u00e4chtlichen \u00a0\nZusatznutzen \u00a0gegen\u00fcber \u00a0Best\u00a0Supportive \u00a0Care\u00a0geben.\u00a0\n\u00a0\nVerf\u00fcgbare \u00a0Therapien \u00a0\n\u00a0(Zusatz\u2010)Nutzen\n\u00a0Kosten\n\u00a0\n  \n\u00a0\n\u00a0\u00a0  Erstes\u00a0Arzneimittel \u00a0f\u00fcr\u00a0die\u00a0\nBehandlung \u00a0verschiedener \u00a0\nFormen\u00a0der\u00a0Myelofibrose. \u00a0Aus\u00a0\ndiesem\u00a0Grund\u00a0wird\u00a0kein\u00a0\nKostenvergleich \u00a0angestellt \u00a0\n  \u00a0 F\u00fcr\u00a0Patienten \u00a0mit\u00a0Myelofibrose: \u00a0\nVerringerung \u00a0der\u00a0Milzgr\u00f6\u00dfe \u00a0und\u00a0\nVerbesserung \u00a0der\u00a0\nAllgemeinsymptome   \n \n \n Erstes\u00a0Arzneimittel \u00a0f\u00fcr\u00a0die\u00a0\nBehandlung \u00a0verschiedener \u00a0Formen\u00a0\nder\u00a0Myelofibrose  \u00a0    \nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien :\u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen :\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten :\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien \u00a0\nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0 AMB\u2010Bewertung \u00a0\nA\u00a0 Keine\u00a0Bewertung \u00a0Beschr\u00e4nkung \u00a0auf\u00a0Patien\u2010\nten\u00a0mit\u00a0einer\u00a0fortge\u2010\nschrittenen \u00a0PMF\u00a0oder\u00a0\nPost\u2010PV/ET\u2010MF\u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nInsgesamt \u00a0214\u00a0TK\u2010Versicherte \u00a0(davon\u00a064\u00a0Prozent\u00a0M\u00e4nner,\u00a0\u00fcberwiegend \u00a0in\u00a0der\u00a0Altersgruppe \u00a0der\u00a070\u2010\u00a0\nbis\u00a080\u2010J\u00e4hrigen)\u00a0erhielten\u00a0im\u00a0Beobachtungszeitraum \u00a0mindestens \u00a0eine\u00a0Verordnung \u00a0mit\u00a0dem\u00a0Wirkstoff \u00a0\nRuxolitinib \u00a0(Abbildung \u00a049).\u00a0Nach\u00a0der\u00a0Markteinf\u00fchrung \u00a0stiegen\u00a0die\u00a0Verordnungszahlen \u00a0relativ\u00a0\nkonstant\u00a0an\u00a0(Abbildung \u00a048).\u00a0Im\u00a0umsatzst\u00e4rksten \u00a0Monat\u00a0(Dezember \u00a02013)\u00a0wurden\u00a0mit\u00a0Jakavi\u00ae\u00a0gut\u00a0\n650.000\u00a0Euro\u00a0erzielt\u00a0(Abbildung \u00a050).\u00a0\u00a0\n \n96\u00a0\n \n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a048:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Ruxolitinib \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0\n\u00a0\n \nAbbildung \u00a049:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Ruxolitinib \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\n \n97\u00a0\n \nInnovationsreport 2015 \u00a0\n\u00a0\nAbbildung \u00a050:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Ruxolitinib \u00a0nach\u00a0Monaten \u00a0(2012\u2010\n2013)\u00a0\u00a0\n \n98\u00a0 \n \nInnovationsreport 2015 \u00a0 4.18 Tegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0Oteracil\u00a0\nHandelsname: \u00a0Teysuno\u00ae \u00a0\u00a0\u00a0\u00a0 Hersteller: \u00a0Nordic\u00a0Pharma\u00a0\nIndikation: \u00a0Magenkarzinom \u00a0\u00a0 \u00a0 \u00a0 \u00a0 Markteinf\u00fchrung: \u00a0Juli\u00a02012\u00a0\nATC\u2010Code:\u00a0L01BC73\u00a0 \u00a0\u00a0\u00a0\u00a0 DDD:\u00a067,5\u00a0mg\u00a0bezogen\u00a0auf\u00a0Tegafur\u00a0\nDarreichungsform: \u00a0Hartkapsel \u00a0\nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0235\u00a0\nBewertung \u00a0\nDas\u00a0oral\u00a0einsetzbare \u00a0Kombinationspr\u00e4parat \u00a0Teysuno\u00ae, \u00a0bestehend \u00a0aus\u00a0den\u00a0Wirkstoffen \u00a0Tegafur,\u00a0\nGimeracil \u00a0und\u00a0Oteracil,\u00a0wurde\u00a0zur\u00a0Behandlung \u00a0von\u00a0erwachsenen \u00a0Patienten \u00a0mit\u00a0fortgeschrittenem \u00a0\nMagenkarzinom \u00a0in\u00a0Kombination \u00a0mit\u00a0Cisplatin\u00a0zugelassen. \u00a0Tegafur\u00a0ist\u00a0wie\u00a0der\u00a0Wirkstoff \u00a0Capecitabin \u00a0\nein\u00a0Prodrug\u00a0von\u00a05\u2010Fluorouracil \u00a0und\u00a0wird\u00a0schon\u00a0l\u00e4nger\u00a0in\u00a0der\u00a0Onkologie \u00a0eingesetzt. \u00a0Die\u00a0beiden\u00a0\nanderen\u00a0Wirkstoffe \u00a0sollen\u00a0dabei\u00a0f\u00fcr\u00a0eine\u00a0bessere\u00a0Wirksamkeit \u00a0und\u00a0gastrointestinale \u00a0Vertr\u00e4glichkeit \u00a0\u2013\u00a0\nvor\u00a0allem\u00a0durch\u00a0Verminderung \u00a0von\u00a0Diarrh\u00f6en \u00a0\u2013\u00a0der\u00a0zytostatischen \u00a0Behandlung \u00a0sorgen.\u00a0Beide\u00a0\nSubstanzen \u00a0sind\u00a0spezifische \u00a0Hemmstoffe \u00a0von\u00a0Enzymen: \u00a0Gimeracil \u00a0hemmt\u00a0die\u00a0\nDihydropyrimidindehydrogenase \u00a0und\u00a0verlangsamt \u00a0so\u00a0den\u00a0Abbau\u00a0von\u00a05\u2010FU\u00a0im\u00a0K\u00f6rper.\u00a0Oteracil\u00a0hemmt\u00a0\ndie\u00a0Orotatphosphoribosyltransferase \u00a0und\u00a0senkt\u00a0damit\u00a0die\u00a0Aktivit\u00e4t\u00a0von\u00a05\u2010FU\u00a0in\u00a0der\u00a0Magen\u2010Darm\u2010\nMukosa.\u00a0\nF\u00fcr\u00a0die\u00a0europ\u00e4ische \u00a0Zulassung \u00a0relevante \u00a0Daten\u00a0lieferte\u00a0die\u00a0FLAGS\u2010Studie.\u00a0In\u00a0dieser\u00a0offenen,\u00a0\nrandomisierten \u00a0und\u00a0aktiv\u2010kontrollierten \u00a0Phase\u2010III\u2010Studie\u00a0wurden\u00a0Wirksamkeit \u00a0und\u00a0Sicherheit \u00a0von\u00a0\nTeysuno\u00ae \u00a0im\u00a0Vergleich \u00a0zu\u00a05\u2010FU,\u00a0jeweils\u00a0in\u00a0Kombination \u00a0mit\u00a0Cisplatin,\u00a0untersucht. \u00a0Patienten, \u00a0die\u00a0in\u00a0\ndiese\u00a0Studie\u00a0aufgenommen \u00a0wurden,\u00a0wiesen\u00a0ein\u00a0fortgeschrittenes \u00a0Magen\u2010\u00a0oder\u00a0gastro\u00f6sophageales \u00a0\nAdenokarzinom \u00a0auf\u00a0und\u00a0waren\u00a0in\u00a0diesen\u00a0Indikationen \u00a0noch\u00a0nicht\u00a0mit\u00a0einer\u00a0Chemotherapie \u00a0behandelt \u00a0\nworden.\u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0dieser\u00a0Studie\u00a0war\u00a0die\u00a0\u00dcberlegenheit \u00a0im\u00a0Gesamt\u00fcberleben \u00a0der\u00a0\nDreifachkombination \u00a0+\u00a0Cisplatin\u00a0im\u00a0Vergleich \u00a0zu\u00a05\u2010FU\u00a0+\u00a0Cisplatin.\u00a0Das\u00a0\u00dcberleben \u00a0wurde\u00a0definiert\u00a0als\u00a0\ndie\u00a0Zeit\u00a0vom\u00a0Tag\u00a0der\u00a0Randomisierung \u00a0bis\u00a0zum\u00a0Todestag. \u00a0\u00a0\nBei\u00a0vergleichbarer \u00a0Wirksamkeit \u00a0in\u00a0Bezug\u00a0auf\u00a0das\u00a0mediane\u00a0Gesamt\u00fcberleben \u00a0(8,6\u00a0Monate\u00a0in\u00a0der\u00a0\nVerum\u2010Gruppe\u00a0vs.\u00a07,9\u00a0Monate\u00a0im\u00a0Kontroll\u2010Arm)\u00a0zeigten\u00a0sich\u00a0signifikante \u00a0Sicherheitsvorteile \u00a0unter\u00a0der\u00a0\nDreifachkombination \u00a0+\u00a0Cisplatin\u00a0gegen\u00fcber \u00a05\u2010FU\u00a0+\u00a0Cisplatin\u00a0(Neutropenie \u00a032,3\u00a0Prozent\u00a0vs.\u00a063,3\u00a0\nProzent,\u00a0Stomatitis \u00a01,3\u00a0Prozent\u00a0vs.\u00a013,6\u00a0Prozent,\u00a0Hypokali\u00e4mie \u00a03,6\u00a0Prozent\u00a0vs.\u00a010,8\u00a0Prozent,\u00a0\ntherapiebedingte \u00a0Todesf\u00e4lle \u00a02,5\u00a0Prozent\u00a0vs.\u00a04,9\u00a0Prozent).\u00a0\u00a0\nWeil\u00a0der\u00a0pU\u00a0keine\u00a0vollst\u00e4ndigen \u00a0Angaben\u00a0zum\u00a0medizinischen \u00a0Zusatznutzen \u00a0aufzeigen \u00a0konnte,\u00a0ist\u00a0\ngem\u00e4\u00df\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0f\u00fcr\u00a0Teysuno\u00ae \u00a0ein\u00a0Zusatznutzen \u00a0im\u00a0Verh\u00e4ltnis \u00a0\nzur\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0(Zweifachkombination \u00a0von\u00a0Cisplatin\u00a0mit\u00a05\u2010Fluorouracil \u00a0oder\u00a0\nCapecitabin) \u00a0nicht\u00a0belegt .\u00a0\n \u00a0 \n99\u00a0\n \nInnovationsreport 2015 \u00a0Verf\u00fcgbare \u00a0Therapien  \n\u00a0(Zusatz\u2010)Nutzen\n\u00a0Kosten\n\u00a0\n Weitere\u00a0Therapieoption\n\u00a0\n\u00a0\u00a0  \n\u00a0Teurer\u00a0als\u00a0vergleichbare \u00a0The\u2010\nrapiealternativen \u00a0\n  \n \n  Kein\u00a0Vorteil\u00a0im\u00a0Gesamt\u2010\n\u00fcberleben, \u00a0aber\u00a0bessere\u00a0\nVertr\u00e4glichkeit \u00a0im\u00a0Vergleich \u00a0zur\u00a0\nintraven\u00f6sen \u00a0Infusionstherapie   \n\u00a0\n  \n \n     \n \nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien :\u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen :\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten :\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien \u00a0\nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0\nB\u00a0 Keine\u00a0Bewertung \u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nDie\u00a0fixe\u00a0Kombination \u00a0aus\u00a0Tegafur,\u00a0Gimeracil \u00a0und\u00a0Oteracil\u00a0(Teysuno\u00ae) \u00a0wurde\u00a0im\u00a0Jahr\u00a02013\u00a0nur\u00a0\ninsgesamt \u00a019\u00a0TK\u2010Versicherte \u00a0verordnet \u00a0(Abbildung \u00a052).\u00a0Dementsprechend \u00a0\u00fcberschaubar \u00a0waren\u00a0die\u00a0\nVerordnungszahlen \u00a0(Abbildung \u00a051).\u00a0Die\u00a0erzielten\u00a0Monatsums\u00e4tze \u00a0lagen\u00a0zwischen\u00a01.000\u00a0und\u00a03.000\u00a0\nEuro\u00a0(Abbildung \u00a053).\u00a0\n \u00a0\n \n100\u00a0\n \n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a051:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Tegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0Oteracil\u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6 \u2010\n\u00dfen\u00a0(2012\u20102013)\u00a0\n\u00a0\n \nAbbildung \u00a052:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Tegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0Oteracil\u00a0nach\u00a0Alter\u00a0und\u00a0\nGeschlecht \u00a0(2013)\u00a0\u00a0\n \n101\u00a0\n \nInnovationsreport 2015 \u00a0\n\u00a0\nAbbildung \u00a053:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Tegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0Oteracil\u00a0nach\u00a0\nMonaten \u00a0(2012\u20102013)\u00a0\u00a0\n \n102\u00a0 \n \nInnovationsreport 2015 \u00a0 4.19 Vandetanib \u00a0\nHandelsname: \u00a0Caprelsa\u00ae \u00a0 \u00a0\u00a0\u00a0 Hersteller: \u00a0AstraZeneca \u00a0\nIndikation: \u00a0Schilddr\u00fcsenkarzinom \u00a0\u00a0\u00a0 Markteinf\u00fchrung: \u00a0M\u00e4rz\u00a02012\u00a0\u00a0\nATC\u2010Code:\u00a0L01XE12\u00a0 \u00a0\u00a0\u00a0\u00a0 DDD:\u00a00,3\u00a0g\u00a0\nDarreichungsform: \u00a0Filmtablette \u00a0\nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0239\u00a0\nBewertung \u00a0\nVandetanib \u00a0ist\u00a0ein\u00a0Multi\u2010Tyrosinkinase \u2010Hemmer, \u00a0der\u00a0den\u00a0vaskul\u00e4ren \u00a0endothelialen \u00a0(VEGFR\u20102)\u00a0sowie\u00a0\nden\u00a0epidermalen \u00a0Wachstumsfaktor \u2010Rezeptor\u00a0(EGFR)\u00a0und\u00a0das\u00a0RET\u2010Protoonkogen \u00a0mit\u00a0\nTyrosinkinaseaktivit\u00e4t \u00a0hemmt.\u00a0Dadurch\u00a0reduziert\u00a0der\u00a0Wirkstoff \u00a0die\u00a0Blutversorgung \u00a0der\u00a0malignen \u00a0\nZellen\u00a0und\u00a0verz\u00f6gert \u00a0das\u00a0Wachstum \u00a0des\u00a0Karzinoms. \u00a0Vandetanib \u00a0wurde\u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0des\u00a0\naggressiven \u00a0und\u00a0symptomatischen \u00a0medull\u00e4ren \u00a0Schilddr\u00fcsenkarzinoms \u00a0bei\u00a0Patienten \u00a0mit\u00a0nicht\u2010rese\u2010\nzierbarer, \u00a0lokal\u00a0fortgeschrittener \u00a0oder\u00a0metastasierter \u00a0Erkrankung \u00a0zugelassen. \u00a0Somit\u00a0stellt\u00a0der\u00a0\nWirkstoff \u00a0die\u00a0erste\u00a0zugelassene \u00a0Arzneimitteltherapie \u00a0in\u00a0dieser\u00a0Indikation \u00a0dar.\u00a0Aufgrund \u00a0der\u00a0unklaren\u00a0\nNutzen\u2010Schaden\u2010Bilanz\u00a0wird\u00a0in\u00a0der\u00a0Fachinformation \u00a0ausdr\u00fccklich \u00a0darauf\u00a0hingewiesen, \u00a0dass\u00a0die\u00a0\nBehandlung \u00a0mit\u00a0Vandetanib \u00a0auf\u00a0Patienten \u00a0mit\u00a0einem\u00a0symptomatisch \u2010aggressiven \u00a0Verlauf\u00a0der\u00a0\nErkrankung \u00a0beschr\u00e4nkt \u00a0ist.\u00a0Auch\u00a0wird\u00a0ein\u00a0Test\u00a0auf\u00a0RET\u2010Mutation \u00a0empfohlen. \u00a0Wegen\u00a0der\u00a0h\u00e4ufigen\u00a0und\u00a0\nz.T.\u00a0schwerwiegenden \u00a0Nebenwirkungen \u00a0wurde\u00a0Vandetanib \u00a0von\u00a0der\u00a0EMA\u00a0unter\u00a0Auflagen\u00a0und\u00a0nur\u00a0f\u00fcr\u00a0\nPatienten \u00a0mit\u00a0symptomatischem \u00a0und\u00a0gleichzeitig \u00a0aggressivem \u00a0Verlauf\u00a0der\u00a0Erkrankung \u00a0zugelassen. \u00a0\nVandetanib \u00a0wird\u00a0einmal\u00a0t\u00e4glich\u00a0als\u00a0Tablette\u00a0in\u00a0einer\u00a0Dosis\u00a0von\u00a0300\u00a0mg\u00a0eingenommen. \u00a0\nRelevante \u00a0Daten\u00a0f\u00fcr\u00a0die\u00a0Zulassung \u00a0lieferte\u00a0eine\u00a0placebokontrollierte, \u00a0doppelblinde \u00a0Phase\u2010III\u2010Studie\u00a0(n\u00a0\n=\u00a0331).\u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0war\u00a0das\u00a0progressionsfreie \u00a0\u00dcberleben. \u00a0Zu\u00a0den\u00a0sekund\u00e4ren \u00a0Endpunkten \u00a0\ngeh\u00f6rte\u00a0das\u00a0Gesamt\u00fcberleben \u00a0sowie\u00a0die\u00a0Zeit\u00a0bis\u00a0zur\u00a0Schmerzverschlimmerung. \u00a0Der\u00a0mediane\u00a0\nBeobachtungszeitraum \u00a0betrug\u00a024\u00a0Monate.\u00a0W\u00e4hrend \u00a0die\u00a0Patienten \u00a0unter\u00a0Placebo\u00a0im\u00a0Median\u00a019,3\u00a0\nMonate\u00a0ohne\u00a0Progression \u00a0der\u00a0Erkrankung \u00a0lebten,\u00a0konnte\u00a0das\u00a0progressionsfreie \u00a0\u00dcberleben \u00a0im\u00a0Verum\u2010\nArm\u00a0noch\u00a0nicht\u00a0berechnet \u00a0werden\u00a0(aufgetretene \u00a0Ereignissen \u00a0waren\u00a0zum\u00a0Zeitpunkt \u00a0der\u00a0Auswertung \u00a0\nnoch\u00a0nicht\u00a0ausreichend) \u00a0und\u00a0wurde\u00a0deshalb\u00a0auf\u00a030,5\u00a0Monate\u00a0gesch\u00e4tzt. \u00a0In\u00a0Bezug\u00a0auf\u00a0das\u00a0\nGesamt\u00fcberleben \u00a0ergab\u00a0sich\u00a0in\u00a0der\u00a0zulassungsrelevanten \u00a0klinischen \u00a0Studie\u00a0jedoch\u00a0kein\u00a0signifikanter \u00a0\nUnterschied \u00a0zwischen\u00a0den\u00a0Behandlungsgruppen. \u00a0\u00a0\nIn\u00a0erster\u00a0Linie\u00a0betreffen \u00a0die\u00a0Nebenwirkungen \u00a0Herzrhythmusst\u00f6rungen \u00a0infolge\u00a0einer\u00a0erheblichen \u00a0und\u00a0\nkonzentrationsabh\u00e4ngigen \u00a0Verl\u00e4ngerung \u00a0der\u00a0QTc\u2010Zeit.\u00a0Erstmalige \u00a0QTc\u2010Verl\u00e4ngerungen \u00a0traten\u00a0\ntypischerweise \u00a0in\u00a0den\u00a0ersten\u00a0drei\u00a0Monaten\u00a0der\u00a0Behandlung \u00a0auf,\u00a0aber\u00a0auch\u00a0danach.\u00a0Torsade\u2010de\u2010\npointes\u00a0Tachykardien \u00a0und\u00a0pl\u00f6tzliche \u00a0Todesf\u00e4lle \u00a0unter\u00a0Vandetanib \u00a0sind\u00a0beschrieben. \u00a0Die\u00a0lange\u00a0\nHalbwertszeit \u00a0von\u00a0Vandetanib \u00a0(19\u00a0Tage)\u00a0macht\u00a0die\u00a0Verl\u00e4ngerung \u00a0der\u00a0QTc\u2010Zeit\u00a0besonders \u00a0\nproblematisch. \u00a0Aus\u00a0Sicherheitsgr\u00fcnden \u00a0muss\u00a0den\u00a0Patienten \u00a0mit\u00a0der\u00a0Verschreibung \u00a0von\u00a0Caprelsa\u00ae \u00a0ein\u00a0\nPatientenpass \u00a0ausgeh\u00e4ndigt \u00a0werden,\u00a0der\u00a0\u00fcber\u00a0die\u00a0Vorsichtsma\u00dfnahmen \u00a0und\u00a0\u00fcber\u00a0Symptome \u00a0\ninformiert, \u00a0die\u00a0eine\u00a0fr\u00fchzeitige \u00a0Erkennung \u00a0bedeutsamer \u00a0Nebenwirkungen \u00a0erm\u00f6glichen. \u00a0Zudem\u00a0ist\u00a0in\u00a0\nseltenen\u00a0F\u00e4llen\u00a0unter\u00a0Vandetanib \u00a0ein\u00a0posteriores \u00a0reversibles \u00a0Enzephalopathiesyndrom \u00a0beschrieben, \u00a0\ndas\u00a0sich\u00a0bei\u00a0den\u00a0Betroffenen \u00a0durch\u00a0Krampfanf\u00e4lle, \u00a0Kopfschmerzen \u00a0und\u00a0Verwirrtheit \u00a0bemerkbar \u00a0\nmacht.\u00a0\nIm\u00a0ersten\u00a0Beschluss \u00a0zur\u00a0fr\u00fchen\u00a0Nutzenbewertung \u00a0sah\u00a0der\u00a0G\u2010BA\u00a0zun\u00e4chst\u00a0keinen\u00a0Zusatznutzen \u00a0f\u00fcr\u00a0\nVandetanib, \u00a0da\u00a0das\u00a0Dossier\u00a0als\u00a0inhaltlich\u00a0unvollst\u00e4ndig \u00a0angesehen \u00a0wurde.\u00a0Nachdem \u00a0der\u00a0pU\u00a0ein\u00a0\n\u00fcberarbeitetes \u00a0Dossier\u00a0mit\u00a0der\u00a0Auswertung \u00a0von\u00a0Daten\u00a0f\u00fcr\u00a0die\u00a0gem\u00e4\u00df\u00a0Zulassung \u00a0behandelten \u00a0 \n103\u00a0\n \nInnovationsreport 2015 \u00a0Patienten \u00a0vorlegte,\u00a0erfolgte\u00a0im\u00a0Fr\u00fchjahr\u00a02013\u00a0eine\u00a0erneute\u00a0Nutzenbewertung \u00a0mit\u00a0dem\u00a0Ergebnis\u00a0des\u00a0\nnicht\u00a0belegten\u00a0Zusatznutzens .\u00a0Im\u00a0Stellungnahmeverfahren \u00a0beim\u00a0G\u2010BA\u00a0reichte\u00a0der\u00a0pU\u00a0nochmals \u00a0\nzus\u00e4tzliche \u00a0Studiendaten, \u00a0diesmal\u00a0zu\u00a0den\u00a0Nebenwirkungen \u00a0und\u00a0zur\u00a0Auspr\u00e4gung \u00a0der\u00a0Schmerzen \u00a0nach,\u00a0\naufgrund\u00a0derer\u00a0das\u00a0IQWIG\u00a0im\u00a0August\u00a02013\u00a0in\u00a0einem\u00a0Addendum \u00a0Vandetanib \u00a0einen\u00a0Anhaltspunkt \u00a0f\u00fcr\u00a0\neinen\u00a0geringen\u00a0Zusatznutzen \u00a0f\u00fcr\u00a0unter\u00a065\u2010J\u00e4hrige\u00a0im\u00a0Hinblick\u00a0auf\u00a0eine\u00a0verz\u00f6gerte \u00a0\nSchmerzprogression \u00a0bescheinigt. \u00a0Der\u00a0G\u2010BA\u00a0stellte\u00a0in\u00a0seinem\u00a0anschlie\u00dfenden \u00a0Beschluss \u00a0vom\u00a0Septem\u2010\nber\u00a02013\u00a0f\u00fcr\u00a0Vandetanib \u00a0ebenfalls\u00a0einen\u00a0Anhaltspunkt \u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0Zusatznutzen \u00a0fest,\u00a0\nallerdings \u00a0ohne\u00a0altersspezifische \u00a0Einschr\u00e4nkungen. \u00a0\n\u00a0\nVerf\u00fcgbare \u00a0Therapien \u00a0\n\u00a0(Zusatz\u2010)Nutzen\n\u00a0Kosten\n\u00a0\n Weitere\u00a0Therapieoption \u00a0\n(neben\u00a0Cabozantinib, \u00a0Erteilung\u00a0\nder\u00a0Zulassung: \u00a0M\u00e4rz\u00a02014) \u00a0   Kein\u00a0direkter\u00a0Kostenvergleich, \u00a0\nda\u00a0Therapieoption \u00a0aus\u00a0BSC\u00a0\nbesteht\u00a0und\u00a0diese\u00a0sowie\u00a0ihre\u00a0\ndaraus\u00a0resultierenden \u00a0Kosten\u00a0\npatientenindividuell \u00a0\nunterschiedlich \u00a0ausfallen\u00a0\nk\u00f6nnen\u00a0\n  \u00a0 Signifikante \u00a0Verl\u00e4ngerung \u00a0des\u00a0\nprogressionsfreien \u00a0\u00dcberlebens, \u00a0\nin\u00a0Bezug\u00a0auf\u00a0das\u00a0Gesamt\u2010\n\u00fcberleben \u00a0kein\u00a0signifikanter \u00a0\nUnterschied. \u00a0Schwere\u00a0\nNebenwirkungen \u00a0m\u00f6glich.\u00a0\nUnklares\u00a0Nutzen\u2010Schaden\u2010\nVerh\u00e4ltnis \u00a0f\u00fcr\u00a0Patienten \u00a0ohne\u00a0\nMutation   \n \n \n \n \u00a0\n \n \n    \nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien :\u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen :\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten :\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien \u00a0\nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0 AMB\u2010Bewertung \u00a0\nA\u00a0 Keine\u00a0Bewertung \u00a0Therapieoption, \u00a0allerdings \u00a0\nnur\u00a0bei\u00a0schneller\u00a0Progres\u2010\nsion\u00a0der\u00a0Erkrankung \u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nDer\u00a0Tyrosinkinaseinhibitor \u00a0Vandetanib \u00a0(Caprelsa\u00ae) \u00a0erreichte\u00a0nach\u00a0seinem\u00a0Marktzugang \u00a0im\u00a0M\u00e4rz\u00a02012\u00a0\nschon\u00a0nach\u00a0drei\u00a0Monaten \u00a0ein\u00a0relativ\u00a0gleichm\u00e4\u00dfiges \u00a0Verordnungsplateau \u00a0mit\u00a0kleineren \u00a0Ausrei\u00dfern \u00a0\nsowohl\u00a0nach\u00a0oben\u00a0als\u00a0auch\u00a0nach\u00a0unten\u00a0(Abbildung \u00a054),\u00a0die\u00a0sich\u00a0auch\u00a0in\u00a0den\u00a0DDD\u00a0widerspiegelten \u00a0\n(Abbildung \u00a056).\u00a0Trotz\u00a0der\u00a0relativ\u00a0geringen\u00a0Anzahl\u00a0an\u00a0Verordnungen, \u00a0wurde\u00a0aufgrund\u00a0des\u00a0hohen\u00a0\nPreises\u00a0ein\u00a0gutes\u00a0Jahr\u00a0nach\u00a0seiner\u00a0Markteinf\u00fchrung \u00a0die\u00a0Umsatzschwelle \u00a0von\u00a070.000\u00a0Euro\u00a0erreicht\u00a0\n(Abbildung \u00a056).\u00a0Im\u00a0untersuchten \u00a0Zeitraum\u00a0bekamen \u00a0nur\u00a016\u00a0TK\u2010Versicherte \u00a0Vandetanib \u00a0verordnet, \u00a0\ndavon\u00a0zu\u00a080\u00a0Prozent\u00a0m\u00e4nnliche \u00a0Patienten \u00a0(Abbildung \u00a055).\u00a0\u00a0 \u00a0\n \n104\u00a0\n \n \nInnovationsreport 2015 \u00a0\u00a0\n \nAbbildung \u00a054:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Vandetanib \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0\n\u00a0\n \nAbbildung \u00a055:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Vandetanib \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0\n(2013)\u00a0\u00a0\n \n105\u00a0\n \nInnovationsreport 2015 \u00a0\n\u00a0\nAbbildung \u00a056:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Vandetanib \u00a0nach\u00a0Monaten \u00a0(2012\u2010\n2013)\u00a0\n\u00a0\n \u00a0\n \n106\u00a0 \n \nInnovationsreport 2015 \u00a0 4.20 Vemurafenib \u00a0\nHandelsname: \u00a0Zelboraf\u00ae \u00a0\u00a0\u00a0\u00a0 Hersteller: \u00a0Roche\u00a0\nIndikation: \u00a0Melanom \u00a0(metastasiert, \u00a0nicht\u00a0operabel) \u00a0Markteinf\u00fchrung: \u00a0M\u00e4rz\u00a02012\u00a0\u00a0\nATC\u2010Code:\u00a0L01XE15\u00a0 \u00a0\u00a0\u00a0\u00a0 DDD:\u00a01.920\u00a0mg\u00a0\nDarreichungsform: \u00a0Filmtablette \u00a0\nHintergrundinformationen: \u00a0siehe\u00a0Seite\u00a0243\u00a0\nBewertung \u00a0\nVemurafenib \u00a0ist\u00a0ein\u00a0oral\u00a0zu\u00a0verabreichender \u00a0Hemmer\u00a0der\u00a0BRAF\u2010Serin\u2010Threonin\u2010Kinase,\u00a0die\u00a0als\u00a0\nwichtiger \u00a0Bestandteil \u00a0des\u00a0RAS\u2010RAF\u2010Signalwegs \u00a0die\u00a0normale\u00a0Zellteilung \u00a0stimuliert. \u00a0V600\u2010Mutationen \u00a0\nim\u00a0Gen,\u00a0das\u00a0die\u00a0BRAF\u2010Serin\u2010Threonin\u2010Kinase\u00a0kodiert,\u00a0f\u00fchren\u00a0zu\u00a0verst\u00e4rkter \u00a0Zellproliferation \u00a0und\u00a0\nverhindern \u00a0den\u00a0programmierten \u00a0Zelltod\u00a0(Apoptose). \u00a0Der\u00a0Wirkstoff \u00a0ist\u00a0zugelassen \u00a0als\u00a0Monotherapie \u00a0\nzur\u00a0Behandlung \u00a0von\u00a0erwachsenen \u00a0Patienten \u00a0mit\u00a0BRAF\u2010V600\u00a0Mutation \u2010positivem \u00a0nicht\u2010resezierbarem \u00a0\noder\u00a0metastasiertem \u00a0Melanom. \u00a0Vor\u00a0dem\u00a0Einsatz\u00a0muss\u00a0durch\u00a0einen\u00a0validierten \u00a0Test\u00a0nachgewiesen \u00a0\nwerden,\u00a0ob\u00a0im\u00a0Tumorgewebe \u00a0ein\u00a0bestimmter \u00a0diagnostischer \u00a0Marker\u00a0(BRAF\u2010V600\u2010Mutation) \u00a0\nvorhanden \u00a0ist.\u00a0Dies\u00a0ist\u00a0bei\u00a0etwa\u00a0der\u00a0H\u00e4lfte\u00a0der\u00a0in\u00a0Frage\u00a0kommenden \u00a0Patienten \u00a0der\u00a0Fall.\u00a0Nur\u00a0bei\u00a0einem\u00a0\npositiven\u00a0Testergebnis \u00a0kann\u00a0von\u00a0einer\u00a0Wirkung\u00a0f\u00fcr\u00a0Vemurafenib \u00a0ausgegangen \u00a0werden.\u00a0\u00a0\nZulassungsrelevant \u00a0war\u00a0eine\u00a0offene,\u00a0randomisierte \u00a0Phase\u2010III\u2010Studie\u00a0mit\u00a0675\u00a0therapienaiven \u00a0Patienten \u00a0\nund\u00a0vorliegendem \u00a0BRAF\u2010V600E\u2010Mutation \u2010positivem, \u00a0nicht\u2010resezierbarem \u00a0oder\u00a0metastasierten \u00a0\nMelanom, \u00a0die\u00a0entweder \u00a0Vemurafenib \u00a0960\u00a0mg\u00a0zweimal\u00a0t\u00e4glich\u00a0oder\u00a0alle\u00a0drei\u00a0Wochen\u00a01.000\u00a0mg/m2\u00a0\nDacarbazin \u00a0erhielten. \u00a0Bei\u00a0der\u00a0zuvor\u00a0festgelegten \u00a0Interimsanalyse \u00a0wurden\u00a0signifikante \u00a0\nVerbesserungen \u00a0in\u00a0den\u00a0beiden\u00a0co\u2010prim\u00e4ren \u00a0Endpunkten \u00a0Gesamt\u00fcberleben \u00a0und\u00a0progressionsfreies \u00a0\n\u00dcberleben \u00a0beobachtet. \u00a0So\u00a0lag\u00a0nach\u00a0sechs\u00a0Monaten \u00a0das\u00a0Gesamt\u00fcberleben \u00a0in\u00a0der\u00a0Vemurafenib \u2010\nGruppe\u00a0bei\u00a084\u00a0Prozent\u00a0und\u00a0in\u00a0der\u00a0Dacarbazin \u2010Gruppe\u00a0bei\u00a064\u00a0Prozent,\u00a0das\u00a0progressionsfreie \u00a0\n\u00dcberleben \u00a0wurde\u00a0durchschnittlich \u00a0von\u00a01,6\u00a0auf\u00a05,3\u00a0Monate\u00a0verl\u00e4ngert. \u00a0\u00a0\nH\u00e4ufigste \u00a0Nebenwirkungen \u00a0waren\u00a0Gelenkschmerzen, \u00a0Hautausschlag, \u00a0M\u00fcdigkeit, \u00a0Haarausfall, \u00a0\nPlattenepithelkarzinom, \u00a0Lichtempfindlichkeit, \u00a0\u00dcbelkeit\u00a0und\u00a0Durchfall. \u00a0Bei\u00a038\u00a0Prozent\u00a0der\u00a0Patienten \u00a0\nerfolgte\u00a0eine\u00a0Dosisanpassung \u00a0aufgrund\u00a0toxischer\u00a0Effekte.\u00a0Ein\u00a0Rote\u2010Hand\u2010Brief\u00a0vom\u00a030.08.2013 \u00a0\nmachte\u00a0darauf\u00a0aufmerksam, \u00a0dass\u00a0Krebserkrankungen, \u00a0die\u00a0in\u00a0Verbindung \u00a0mit\u00a0einer\u00a0RAS(Rat\u00a0sarcoma) \u2010\nMutation \u00a0stehen,\u00a0fortschreiten \u00a0k\u00f6nnen.\u00a0Zudem\u00a0ist\u00a0das\u00a0Auftreten \u00a0eines\u00a0DRESS\u2010Symptoms \u00a0m\u00f6glich\u00a0\n(Arzneimittelausschlag \u00a0mit\u00a0Eosinophilie \u00a0und\u00a0systemischen \u00a0Symptomen). \u00a0Weitere\u00a0Pharmakovigilanz \u2010\nDaten\u00a0im\u00a0Hinblick\u00a0auf\u00a0eine\u00a0m\u00f6gliche\u00a0Nieren\u2010\u00a0oder\u00a0Pankreastoxizit\u00e4t \u00a0sowie\u00a0ein\u00a0erh\u00f6htes\u00a0Risiko\u00a0f\u00fcr\u00a0\nweitere\u00a0extrakutane \u00a0Krebserkrankungen \u00a0sind\u00a0erforderlich. \u00a0\u00a0\nVemurafenib \u00a0wurde\u00a0im\u00a0Rahmen\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung \u00a0durch\u00a0den\u00a0Gemeinsamen \u00a0\nBundesausschuss \u00a0mit\u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0Dacarbazin \u00a0verglichen. \u00a0In\u00a0der\u00a0\nGesamtschau \u00a0der\u00a0Vor\u2010\u00a0und\u00a0Nachteile \u00a0konnte\u00a0ein\u00a0Hinweis\u00a0auf\u00a0einen\u00a0betr\u00e4chtlichen \u00a0Zusatznutzen \u00a0von\u00a0\nVemurafenib \u00a0gegen\u00fcber \u00a0Dacarbazin \u00a0festgestellt \u00a0werden.\u00a0Die\u00a0Bewertung \u00a0erfolgte\u00a0im\u00a0Wesentlichen \u00a0auf\u00a0\nBasis\u00a0von\u00a0Daten\u00a0einer\u00a0randomisierten \u00a0kontrollierten \u00a0Studie\u00a0mit\u00a0Enrichment \u00a0Design1.\u00a0In\u00a0Bezug\u00a0auf\u00a0das\u00a0\nGesamt\u00fcberleben \u00a0zeigte\u00a0sich\u00a0in\u00a0den\u00a0Daten\u00a0ein\u00a0signifikanter \u00a0Vorteil\u00a0f\u00fcr\u00a0Vemurafenib, \u00a0das\u00a0mediane\u00a0\n                                        \n1\u00a0Beim\u00a0Enrichment \u00a0Design\u00a0findet\u00a0zun\u00e4chst\u00a0eine\u00a0Biomarker \u2010Messung\u00a0statt\u00a0und\u00a0nur\u00a0die\u00a0Biomarker \u2010positiven\u00a0Patienten, \u00a0von\u00a0denen\u00a0man\u00a0\nannimmt, \u00a0dass\u00a0ausschlie\u00dflich \u00a0sie\u00a0profitieren, \u00a0werden\u00a0dann\u00a0n\u00e4her\u00a0untersucht \u00a0und\u00a0anschlie\u00dfend \u00a0randomisiert \u00a0entweder \u00a0der\u00a0Interventions \u2010\u00a0\noder\u00a0der\u00a0Kontrollgruppe \u00a0zugeteilt. \u00a0Hierbei\u00a0hat\u00a0die\u00a0neue\u00a0Therapie\u00a0in\u00a0der\u00a0Regel\u00a0einen\u00a0direkten\u00a0Biomarker \u2010Bezug,\u00a0w\u00e4hrend\u00a0die\u00a0Kontrollgruppe \u00a0\neine\u00a0bisherige\u00a0Standardtherapie \u00a0erh\u00e4lt.\u00a0Siehe\u00a0auch\u00a0\u201eInnovationsreport \u00a02014\u201c,\u00a0in\u00a0dem\u00a0sowohl\u00a0Vemurafenib \u00a0und\u00a0der\u00a0BRAF\u2010V600\u2010Test\u00a0als\u00a0\nauch\u00a0das\u00a0Design\u00a0der\u00a0Biomarker \u2010Studien\u00a0ausf\u00fchrlich \u00a0beschrieben \u00a0wurden.\u00a0 \n107\u00a0\n \nInnovationsreport 2015 \u00a0Gesamt\u00fcberleben \u00a0verl\u00e4ngerte \u00a0sich\u00a0gegen\u00fcber \u00a0Dacarbazin \u00a0von\u00a09,6\u00a0auf\u00a013,2\u00a0Monate.\u00a0F\u00fcr\u00a0die\u00a0\nEndpunkte \u00a0Morbidit\u00e4t \u00a0und\u00a0Lebensqualit\u00e4t \u00a0konnten\u00a0hingegen\u00a0keine\u00a0relevanten \u00a0Vorteile\u00a0gefunden \u00a0\nwerden.\u00a0Die\u00a0Neubewertung \u00a0nach\u00a0Fristablauf \u00a0(Beschlussfassung \u00a0vom\u00a06.\u00a0M\u00e4rz\u00a02014)\u00a0best\u00e4tigte \u00a0erneut\u00a0\nden\u00a0Hinweis\u00a0auf\u00a0einen\u00a0betr\u00e4chtlichen \u00a0Zusatznutzen \u00a0von\u00a0Vemurafenib \u00a0gegen\u00fcber \u00a0Dacarbazin \u00a0\n(Lebensverl\u00e4ngerung \u00a0um\u00a0vier\u00a0Monate). \u00a0\n\u00a0\nVerf\u00fcgbare \u00a0Therapien \u00a0\n\u00a0(Zusatz\u2010)Nutzen\n\u00a0Kosten\n\u00a0\n  \u00a0   Teurer\u00a0als\u00a0Therapiealternative\n\u00a0\n\u00a0\n Melanom \u2010Therapie\u00a0bei\u00a0\nVorliegen \u00a0einer\u00a0spezifischen \u00a0\nMutation  \u00a0    \n \n \n  \n \n  Verl\u00e4ngerung \u00a0des\u00a0Gesamt\u2010\n\u00fcberlebens, \u00a0problematische \u00a0\nNebenwirkungen \u00a0m\u00f6glich   \nErl\u00e4uterung \u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare \u00a0Therapien :\u00a0rot\u00a0=\u00a0weitere\u00a0Therapieoption, \u00a0gelb\u00a0=\u00a0Subgruppen \u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010)Nutzen :\u00a0\nrot\u00a0=\u00a0keine\u00a0Verbesserung \u00a0oder\u00a0schlechte \u00a0Nutzen/Schaden \u2010Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen, \u00a0gr\u00fcn\u00a0=\u00a0Verbesserung \u00a0harter\u00a0\nEndpunkte; \u00a0Kosten :\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende \u00a0Therapien, \u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils, \u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger \u00a0als\u00a0bestehende \u00a0\nTherapien \u00a0\nWie\u00a0bewerten \u00a0andere?\u00a0\nBewertung \u00a0nach\u00a0Fricke/Klaus \u00a0 a\u2010t\u2010Bewertung \u00a0 AMB\u2010Bewertung \u00a0\nA\u00a0 Mittel\u00a0der\u00a0Wahl\u00a0Erweiterung \u00a0der\u00a0therapeu\u2010\ntischen\u00a0M\u00f6glichkeiten, \u00a0\nallerdings \u00a0kein\u00a0\ntherapeutischer \u00a0\nDurchbruch \u00a0\n\u00a0\nVersorgungsanalyse \u00a0\nDie\u00a0Verordnungszahlen \u00a0des\u00a0ersten\u00a0selektiven \u00a0BRAF\u2010Inhibitors \u00a0stiegen\u00a0nach\u00a0der\u00a0positiven\u00a0fr\u00fchen\u00a0\nNutzenbewertung \u00a0im\u00a0September \u00a02012,\u00a0in\u00a0der\u00a0der\u00a0G\u2010BA\u00a0in\u00a0der\u00a0Gesamtschau \u00a0der\u00a0Vor\u2010\u00a0und\u00a0Nachteile \u00a0\neinen\u00a0Hinweis\u00a0auf\u00a0einen\u00a0betr\u00e4chtlichen \u00a0Zusatznutzen \u00a0gegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0\nVergleichstherapie \u00a0(Dacarbazin) \u00a0feststellen \u00a0konnte,\u00a0weiter\u00a0an\u00a0und\u00a0erreichten \u00a0in\u00a0der\u00a0Spitze\u00a0knapp\u00a0180\u00a0\nPackungen \u00a0im\u00a0Monat\u00a0(Abbildung \u00a057).\u00a0In\u00a0den\u00a0letzten\u00a0vier\u00a0Monaten\u00a0des\u00a0Beobachtungszeitraumes \u00a0\nsanken\u00a0die\u00a0Zahlen\u00a0wieder.\u00a0Es\u00a0wird\u00a0nur\u00a0ein\u00a0relativ\u00a0kleiner\u00a0Anteil\u00a0an\u00a0Patienten \u00a0mit\u00a0dem\u00a0neuen\u00a0\nMedikament \u00a0behandelt, \u00a0so\u00a0dass\u00a0\u2013\u00a0ausgehend \u00a0von\u00a0den\u00a0Verordnungszahlen \u00a0\u2013\u00a0der\u00a0Verbrauch \u00a0pro\u00a0\nPatient\u00a0recht\u00a0hoch\u00a0liegt\u00a0(Abbildung \u00a058,\u00a0Abbildung \u00a059).\u00a0Die\u00a0durchschnittlich \u00a01.000\u00a0verordneten \u00a0\nTagesdosen \u00a0(DDD)\u00a0verursachten \u00a0sehr\u00a0hohe\u00a0Ausgaben \u00a0bzw.\u00a0Umsatzwerte \u00a0zwischen\u00a0400.000\u00a0und\u00a0\n500.000\u00a0Euro\u00a0(Abbildung \u00a059).\u00a0W\u00e4hrend \u00a0in\u00a0j\u00fcngeren\u00a0Jahren\u00a0eher\u00a0Frauen\u00a0eine\u00a0Vemurafenib \u2010\nVerordnung \u00a0erhalten,\u00a0sind\u00a0im\u00a0hohen\u00a0Alter\u00a0die\u00a0so\u00a0behandelten \u00a0Patienten \u00a0vorwiegend \u00a0m\u00e4nnlich\u00a0\n(Abbildung \u00a058).\u00a0\u00a0 \u00a0\n \n108\u00a0\n \n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a057:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Vemurafenib \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0\n\u00a0\n \nAbbildung \u00a058:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Vemurafenib \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0\n(2013)\u00a0\u00a0\n \n109\u00a0\n \nInnovationsreport 2015 \u00a0\n\u00a0\nAbbildung \u00a059:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Vemurafenib \u00a0nach\u00a0Monaten \u00a0(2012\u2010\n2013)\u00a0\n  \n \n110\u00a0 \n \nInnovationsreport 2015 \u00a0 5 R\u00fcckblick: \u00a0Arzneimittel \u00a0aus\u00a0dem\u00a0Innovationsreport \u00a02014\u00a0(Neue\u00a0Wirkstoffe \u00a0\ndes\u00a0Jahres\u00a02011)\u00a0\nDaniela\u00a0Boeschen \u00a0\nIm\u00a0Innovationsreport \u00a02014\u00a0wurden\u00a0die\u00a0zwanzig\u00a0neuen\u00a0Arzneimittel \u00a0des\u00a0Jahres\u00a02011\u00a0behandelt, \u00a0\nzuz\u00fcglich\u00a0Vemurafenib \u00a0im\u00a0Sonderkapitel \u00a0\u201eStratifizierende \u00a0Medizin:\u00a0Potentiale \u00a0und\u00a0Grenzen\u201d. \u00a0\nAbirateron \u00a0und\u00a0Ticagrelor \u00a0erwiesen\u00a0sich\u00a0vom\u00a0Nutzen\u00a0her\u00a0insgesamt \u00a0als\u00a0beste\u00a0Arzneimittel. \u00a0Der\u00a0\nAndrogen \u2010Biosynthese \u2010Hemmstoff \u00a0Abirateron \u00a0wurde\u00a0im\u00a0September \u00a02011\u00a0zugelassen \u00a0zur\u00a0Behandlung \u00a0\ndes\u00a0metastasierten, \u00a0kastrationsresistenten \u00a0Prostatakarzinoms \u00a0bei\u00a0erwachsenen \u00a0M\u00e4nnern \u00a0und\u00a0stellt\u00a0\nsowohl\u00a0f\u00fcr\u00a0Patienten, \u00a0bei\u00a0denen\u00a0eine\u00a0Chemotherapie \u00a0noch\u00a0nicht\u00a0klinisch\u00a0indiziert\u00a0ist,\u00a0als\u00a0auch\u00a0f\u00fcr\u00a0\nsolche,\u00a0f\u00fcr\u00a0die\u00a0nach\u00a0einer\u00a0ersten\u00a0Docetaxel \u2010Behandlung \u00a0eine\u00a0weitere\u00a0nicht\u00a0in\u00a0Frage\u00a0kommt,\u00a0eine\u00a0\nm\u00f6gliche\u00a0Therapieoption \u00a0dar.\u00a0Unter\u00a0Abirateron \u00a0konnten\u00a0harte\u00a0Endpunkte \u00a0wie\u00a0die\u00a0Lebenserwartung \u00a0\noder\u00a0die\u00a0Krankheitsfolgen \u00a0deutlich\u00a0verbessert \u00a0werden.\u00a0Die\u00a0Vorteile\u00a0des\u00a0Thrombozytenaggregations \u2010\nhemmers \u00a0Ticagrelor \u00a0sind\u00a0insbesondere \u00a0bei\u00a0instabiler \u00a0Angina\u00a0pectoris\u00a0oder\u00a0Myokardinfarkt \u00a0ohne\u00a0ST\u2010\nStrecken\u2010Hebung\u00a0belegt.\u00a0Mit\u00a0dem\u00a0Immunsuppressivum \u00a0Pirfenidon, \u00a0zugelassen \u00a0zur\u00a0Behandlung \u00a0von\u00a0\nleichter\u00a0bis\u00a0mittelschwerer \u00a0idiopathischer \u00a0pulmonaler \u00a0Fibrose,\u00a0und\u00a0Tafamidis \u00a0zur\u00a0Verz\u00f6gerung \u00a0der\u00a0\nNervensch\u00e4digung \u00a0im\u00a0Fr\u00fchstadium \u00a0bei\u00a0erwachsenen \u00a0Patienten \u00a0mit\u00a0Transthyretin \u2010Amyloidose, \u00a0\nschnitten \u00a0zwei\u00a0Orphan\u00a0Drugs\u00a0zwar\u00a0hinsichtlich \u00a0der\u00a0Therapieverf\u00fcgbarkeit \u00a0sehr\u00a0gut\u00a0ab\u00a0\u2013\u00a0was\u00a0auch\u00a0bei\u00a0\ndiesem\u00a0Status\u00a0nicht\u00a0anders\u00a0zu\u00a0erwarten\u00a0ist\u00a0\u2013\u00a0allerdings \u00a0mit\u00a0noch\u00a0unklarem \u00a0Nutzen\u00a0f\u00fcr\u00a0die\u00a0Patienten. \u00a0\nInsgesamt \u00a0elf\u00a0Wirkstoffe \u00a0aus\u00a0dem\u00a0Jahr\u00a02011\u00a0zeigten\u00a0Hinweise\u00a0f\u00fcr\u00a0eine\u00a0Verbesserung \u00a0der\u00a0Nutzen\u2010\nSchaden\u2010Relation\u00a0gegen\u00fcber \u00a0bislang\u00a0verf\u00fcgbaren \u00a0Therapien \u00a0(bezogen\u00a0auf\u00a0patientenrelevante \u00a0\nEndpunkte \u00a0oder\u00a0Lebensqualit\u00e4t). \u00a0F\u00fcr\u00a0mehrere\u00a0neue\u00a0Arzneimittel \u00a0wurden\u00a0Gesundheitsrisiken \u00a0erst\u00a0\nnach\u00a0Markteinf\u00fchrung \u00a0bekannt.\u00a0So\u00a0ver\u00f6ffentlichten \u00a0die\u00a0pU\u00a0beispielsweise \u00a0f\u00fcr\u00a0die\u00a0Wirkstoffe \u00a0\nBoceprevir \u00a0(Victrelis\u00ae) \u00a0und\u00a0Telaprevir \u00a0(Incivo\u00ae)\u00a0zur\u00a0Therapie\u00a0der\u00a0chronischen \u00a0Hepatitis\u00a0C\u00a0\nentsprechende \u00a0Sicherheitshinweise \u00a0in\u00a0Form\u00a0von\u00a0Rote\u2010Hand\u2010Briefen\u00a0(MSD,\u00a02012;\u00a0Janssen\u00a0Cilag,\u00a02013).\u00a0\nAuch\u00a0das\u00a0Immunsuppressivum \u00a0Belatacept \u00a0(Nulojix\u00ae), \u00a0welches\u00a0in\u00a0Kombination \u00a0mit\u00a0Corticoiden \u00a0und\u00a0\nMycophenols\u00e4ure \u00a0zur\u00a0Prophylaxe \u00a0einer\u00a0Transplantatabsto\u00dfung \u00a0bei\u00a0den\u00a0Patienten \u00a0indiziert\u00a0ist,\u00a0die\u00a0\neine\u00a0neue\u00a0Niere\u00a0erhalten\u00a0haben,\u00a0wurde\u00a0in\u00a0einem\u00a0Informationsbrief \u00a0vermehrt \u00a0von\u00a0Transplantat \u2010\nAbsto\u00dfungsreaktionen \u00a0berichtet\u00a0(BMS,\u00a02013).\u00a0\nUmsatz\u00a0und\u00a0Verordnungsmengen \u00a0dieser\u00a0Arzneimittel \u00a0stiegen\u00a0im\u00a0Jahr\u00a02013\u00a0gegen\u00fcber \u00a0dem\u00a0Vorjahr\u00a0\num\u00a034\u00a0Prozent\u00a0(Tabelle\u00a08)\u00a0bzw.\u00a064\u00a0Prozent\u00a0(Tabelle\u00a09).\u00a0Zu\u00a0einer\u00a0knappen\u00a0Verdopplung \u00a0des\u00a0Umsatzes \u00a0\nkam\u00a0es\u00a0bei\u00a0dem\u00a0Androgen \u2010Biosynthese \u2010Hemmstoff \u00a0Abirateron \u00a0(+\u00a094\u00a0Prozent)\u00a0und\u00a0dem\u00a0\nThrombozytenaggregationshemmer \u00a0Ticagrelor \u00a0(+\u00a089\u00a0Prozent)\u00a0(Tabelle\u00a08).\u00a0Der\u00a0Umsatz\u00a0des\u00a0\nImmunsuppressivums \u00a0Belatacept \u00a0konnte\u00a0um\u00a0das\u00a01,5fache\u00a0gesteigert \u00a0werden\u00a0(+\u00a0161\u00a0Prozent).\u00a0\nApixaban \u00a0(Eliquis\u00ae), \u00a0u.a.\u00a0indiziert\u00a0zur\u00a0Prophylaxe \u00a0von\u00a0Thrombose \u00a0und\u00a0Schlaganfall, \u00a0konnte\u00a0seine\u00a0\nUmsatz\u2010\u00a0und\u00a0Verordnungszahlen \u00a0hingegen\u00a0um\u00a0das\u00a050\u2010\u00a0(+\u00a05.000\u00a0Prozent)\u00a0bzw.\u00a040fache\u00a0(3.963\u00a0\nProzent)\u00a0steigern\u00a0(Tabelle\u00a08,\u00a0Tabelle\u00a09,\u00a0Abbildung \u00a060).\u00a0Im\u00a0Jahr\u00a02013\u00a0f\u00fchrt\u00a0die\u00a0Top\u2010Liste\u00a0nach\u00a0Umsatz\u00a0\nAbirateron \u00a0(Zytiga\u00ae)\u00a0an,\u00a0bei\u00a0den\u00a0Verordnungen \u00a0ist\u00a0es\u00a0Ticagrelor \u00a0(Brilique\u00ae) \u00a0(Tabelle\u00a08,\u00a0Tabelle\u00a09,\u00a0\nAbbildung \u00a063).\u00a0Den\u00a0gr\u00f6\u00dften\u00a0R\u00fcckgang \u00a0der\u00a0noch\u00a0im\u00a0Markt\u00a0befindlichen \u00a0Arzneimittel \u00a0verzeichneten \u00a0die\u00a0\nantiviralen \u00a0Wirkstoffe \u00a0Boceprevir \u00a0und\u00a0Telaprevir, \u00a0hier\u00a0sanken\u00a0die\u00a0Umsatzzahlen \u00a0um\u00a033\u00a0Prozent\u00a0bzw.\u00a0\n58\u00a0Prozent\u00a0und\u00a0die\u00a0Verordnungszahlen \u00a0um\u00a024\u00a0Prozent\u00a0bzw.\u00a056\u00a0Prozent\u00a0(Abbildung \u00a061,\u00a0Abbildung \u00a062).\u00a0\nIm\u00a0April\u00a02013\u00a0informierte \u00a0Janssen\u00a0Cilag\u00a0in\u00a0einem\u00a0Rote\u2010Hand\u2010Brief\u00a0\u00fcber\u00a0das\u00a0Auftreten \u00a0schwerer \u00a0\nHautreaktionen \u00a0in\u00a0Verbindung \u00a0mit\u00a0einer\u00a0Telaprevir \u2010Therapie, \u00a0was\u00a0die\u00a0ohnehin\u00a0schon\u00a0sinkenden \u00a0\nVerordnungszahlen \u00a0weiter\u00a0abfallen\u00a0lie\u00df.\u00a0Trotz\u00a0R\u00fcckgang \u00a0der\u00a0Telaprevir \u2010Verordnungen \u00a0befindet\u00a0sich\u00a0\nder\u00a0Wirkstoff \u00a0auf\u00a0dem\u00a0vierten\u00a0Platz\u00a0der\u00a0Top\u2010Liste\u00a0nach\u00a0Umsatz\u00a0(Tabelle\u00a08).\u00a0Auch\u00a0bei\u00a0Cabazitaxel, \u00a0in\u00a0 \n111\u00a0\n \nInnovationsreport 2015 \u00a0Kombination \u00a0mit\u00a0Prednison \u00a0oder\u00a0Prednisolon \u00a0zugelassen \u00a0zur\u00a0Behandlung \u00a0von\u00a0Patienten \u00a0mit\u00a0\nmetastasiertem \u00a0hormonrefrakt\u00e4rem \u00a0Prostatakarzinom, \u00a0die\u00a0mit\u00a0einem\u00a0Docetaxel \u2010basierten \u00a0\nTherapieschema \u00a0vorbehandelt \u00a0sind,\u00a0gab\u00a0es\u00a0einen\u00a0R\u00fcckgang \u00a0der\u00a0Verordnungszahlen \u00a0um\u00a019\u00a0Prozent.\u00a0\nRang\u00a0\u00a0\n2013\u00a0Rang\u00a0\u00a0\n2012\u00a0Wirkstof f\n(Handelsname) \u00a0Umsatz\u00a02013\n[in\u00a0Tsd.\u00a0\u20ac]Umsatz\u00e4nd. \u00a0zum\nVorjahr\u00a0[%]Anzahl\u00a0Versicherte \u00a0\nmit\u00a0VO\u00a02013\n1\u00a0 2\u00a0Abirateron\n(Zytiga\u00ae)\u00a032.098,4 +\u00a094% 1.073\n2\u00a0 1\u00a0Fingolimod\n(Gileya\u00ae)\u00a028.444,9 +\u00a066% 1.328\n3\u00a0 4\u00a0Fampridin\n(Fampyra\u00ae) \u00a010.012,5 +\u00a028% 2.340\n4\u00a0 3\u00a0Telaprevir\n(Incivo\u00ae)\u00a05.305,6 \u2010\u00a058% 177\n5\u00a0 5\u00a0Ipilimumab \u00a0\n(Yervoy\u00ae) \u00a04.875,8 +\u00a010% 82\n6\u00a0 9\u00a0Ticagrelor\n(Brilique\u00ae) \u00a03.794,1 +\u00a089% 6.187\n7\u00a0 8\u00a0Pirfenidon\n(Esbriet\u00ae) \u00a02.674,1 +\u00a019% 127\n8\u00a0 6\u00a0Boceprevir\n(Victrlis\u00ae) \u00a02.498,7 \u2010\u00a033% 130\n9\u00a0 7\u00a0Cabazitaxel \u00a0\n(Jevtana\u00ae) \u00a02.443,1 \u2010\u00a020% 123\n10\u00a0 12\u00a0Tafamidis\n(Vyndaquel\u00ae) \u00a01.555,0 +\u00a073% 9\n11\u00a0 10\u00a0Eribulin\u00a0\n(Halaven\u00ae) \u00a01.553,5 +\u00a04% 182\n12\u00a0 18\u00a0Apixaban\n(Eliquis\u00ae)\u00a01.300,8 +\u00a05.000% 2.799\n13\u00a0 11\u00a0Nabiximols\n(Sativex\u00ae) \u00a01.158,6 +\u00a022% 617\n14\u00a0 13\u00a0Belimumab \u00a0\n(Benlysta\u00ae) \u00a0544,1 +\u00a013% 65\n15\u00a0 17\u00a0Belatacept\n(Nulojix\u00ae) \u00a0100,0 +\u00a0161% 8\n16\u00a0 16\u00a0Dexamfetamin \u00a0\n(Attentin\u00ae) \u00a096,3 +\u00a077% 233\n17\u00a0 19\u00a0Pitavastatin \u00a0\n(Livazo\u00ae)\u00a00,0 \u2010\u00a075% 1\n18\u00a0 15\u00a0Collagenase \u00a0\n(Xiapex\u00ae) \u00a00,0 Keine\u00a0VO 0\n19\u00a0 14\u00a0Retigabin\n(Trobalt\u00ae) \u00a00,0 Keine\u00a0VO 0\n1\u201019\u00a0 1\u201019\u00a0Gesamt\u00a0 98.455,7 +\u00a034% 15.481*\n*)\u00a0Doppelz\u00e4hlung \u00a0von\u00a0Versicherten \u00a0(n=\u00a015.018)\u00a0\nTabelle\u00a08:\u00a0Umsatzzahlen \u00a0der\u00a0Arzneimittel \u00a0des\u00a0letzten\u00a0Innovationsreportes \u00a0im\u00a0Jahr\u00a02013\u00a0und\u00a0\u00c4nderungen \u00a0zum\u00a0\nVorjahr\u00a0(TK\u2010Daten)\u00a0\u00a0 \n112\u00a0 \n \nInnovationsreport 2015 \u00a0Rang\u00a0\u00a0\n2013\u00a0Rang\u00a0\u00a0\n2012\u00a0Wirkstof f\n(Handelsname) \u00a0Verordnete \u00a0\nPackungen \u00a0\n2013\n[in\u00a0Tsd.\u00a0\u20ac]Verordnungs\u00e4nd.\nzum\nVorjahr\u00a0[%]Anzahl\u00a0Versicherte \u00a0\nmit\u00a0VO\u00a02013\n1\u00a0 2\u00a0Ticagrelor \u00a0\n(Brilique\u00ae) \u00a023,6 +\u00a086% 6.187\n2\u00a0 1\u00a0Fampridin\n(Fampyra\u00ae) \u00a019,6 +\u00a023% 2.340\n3\u00a0 3\u00a0Fingolimod\n(Gilenya\u00ae) \u00a012,2 +\u00a066% 1.328\n4\u00a0 15\u00a0Apixaban \u00a0\n(Eliquis\u00ae)\u00a08,8 +\u00a03.963% 2.799\n5\u00a0 4\u00a0Abirateron \u00a0\u00a0\n(Zytiga\u00ae)\u00a05,9 +\u00a095% 1.073\n6\u00a0 5\u00a0Eribulin\u00a0\n(Halaven\u00ae) \u00a02,2 +\u00a010% 182\n7\u00a0 6\u00a0Nabiximols\n(Sativex\u00ae) \u00a01,9 +\u00a022% 617\n8\u00a0 10\u00a0Dexamfetamin \u00a0\u00a0\n(Attentin\u00ae) \u00a01,4 +\u00a071% 233\n9\u00a0 11\u00a0Belimumab \u00a0\n(Benlysta\u00ae) \u00a01,2 +\u00a063% 65\n10\u00a0 9\u00a0Pirfenidon\n(Esbriet\u00ae) \u00a00,9 +\u00a010% 127\n11\u00a0 8\u00a0Boceprevir\n(Victrelis\u00ae) \u00a00,7 \u2010\u00a024% 130\n12\u00a0 7\u00a0Telaprevir \u00a0\n(Incivo\u00ae)\u00a00,6 \u2010\u00a056% 177\n13\u00a0 12\u00a0Cabazitaxel \u00a0\u00a0\n(Jevtana\u00ae) \u00a00,5 \u2010\u00a019% 123\n14\u00a0 14\u00a0Ipilimumab \u00a0\u00a0\n(Yervoy\u00ae) \u00a00,4 +\u00a014% 82\n15\u00a0 17\u00a0Tafamidis\n(Vyndaqel\u00ae) \u00a00,1 +\u00a073% 9\n16\u00a0 18\u00a0Belatacept\n(Nulojix\u00ae) \u00a00,1 +\u00a0171% 8\n17\u00a0 19\u00a0Pitavastatin \u00a0\n(Livazo\u00ae)\u00a00,0 \u2010\u00a083% 1\n18\u00a0 13\u00a0Retigabin \u00a0\n(Trobalt\u00ae) \u00a00,0 Keine\u00a0VO 0\n19\u00a0 16\u00a0Collagenase \u00a0\n(Xiapex\u00ae) \u00a00,0 Keine\u00a0VO\u00a0 0\n1\u201019\u00a0 1\u201019\u00a0Gesamt\u00a0 80,2 +\u00a064% 15.481*\n*)\u00a0Doppelz\u00e4hlung \u00a0von\u00a0Versicherten \u00a0(n=\u00a015.018)\u00a0\nTabelle\u00a09:\u00a0Verordnungszahlen \u00a0der\u00a0Arzneimittel \u00a0des\u00a0letzten\u00a0Innovationsreportes \u00a0im\u00a0Jahr\u00a02013\u00a0und\u00a0\n\u00c4nderungen \u00a0zum\u00a0Vorjahr\u00a0(TK\u2010Daten)\u00a0\n   \n113\u00a0\n \nInnovationsreport 2015 \u00a0\n \nAbbildung \u00a060:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Apixaban \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0\n\u00a0\n \nAbbildung \u00a061:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Boceprevir \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0\n \u00a0\n \n114\u00a0\n \n \nInnovationsreport 2015 \u00a0\n\u00a0\nAbbildung \u00a062:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Telaprevir \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0\n\u00a0\n\u00a0\nAbbildung \u00a063:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Ticagrelor \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0\n \u00a0\n \n115\u00a0\n \nInnovationsreport 2015 \u00a0 6 Diskussion \u00a0\nDaniela\u00a0Boeschen \u00a0\nTabelle\u00a010\u00a0fasst\u00a0die\u00a0im\u00a0Innovationsreport \u00a02015\u00a0getroffenen \u00a0Bewertungen \u00a0nach\u00a0dem\u00a0im\u00a0Report\u00a0\ngenutzten \u00a0Ampelschema \u00a0zusammen. \u00a0\u00a0\n\u00a0\nTabelle\u00a010:\u00a0Zusammenfassung \u00a0der\u00a0Wirkstoffbewertungen \u00a0(neue\u00a0Wirkstoffe \u00a0des\u00a0Jahres\u00a02012)\u00a0nach\u00a0dem\u00a0im\u00a0\nReport\u00a0genutzten \u00a0Ampelschema \u00a0\u00a0\n \n116\u00a0 \n \nInnovationsreport 2015 \u00a0Die\u00a0hier\u00a0vorgestellten \u00a0und\u00a0auf\u00a0der\u00a0Basis\u00a0einer\u00a0Literaturrecherche \u00a0vorgenommenen \u00a0Bewertungen \u00a0\nverdeutlichen, \u00a0dass\u00a0neue\u00a0Arzneimittel \u00a0h\u00e4ufig\u00a0nicht\u00a0mit\u00a0einem\u00a0erkennbaren \u00a0therapeutischen \u00a0\nFortschritt \u00a0verbunden \u00a0sind\u00a0und\u00a0daher\u00a0keine\u00a0wirklichen \u00a0therapeutischen \u00a0Innovationen \u00a0darstellen, \u00a0\nsondern\u00a0in\u00a0vielen\u00a0F\u00e4llen\u00a0lediglich\u00a0als\u00a0\u201ekommerzielle \u00a0bzw.\u00a0\u00f6konomische\u201c \u00a0Innovationen \u00a0angesprochen \u00a0\nwerden\u00a0m\u00fcssen,\u00a0deren\u00a0Einsatz\u00a0die\u00a0Therapie\u00a0verteuert, \u00a0ohne\u00a0einen\u00a0patientenrelevanten \u00a0Zusatznutzen \u00a0\nanzubieten. \u00a0\u00a0\nTabelle\u00a011\u00a0(alle\u00a0Wirkstoffe \u00a0aus\u00a0dem\u00a0Jahr\u00a02012\u00a0ohne\u00a0Orphan\u00a0Drugs )\u00a0und\u00a0Tabelle\u00a012\u00a0(ausschlie\u00dflich \u00a0\nOrphan\u00a0Drugs )\u00a0geben\u00a0die\u00a0Gesamt\u2010Scores\u00a0der\u00a0Innovationsbewertungen \u00a0wieder.\u00a0Arzneimittel \u00a0f\u00fcr\u00a0\nseltene\u00a0Leiden\u00a0spielen\u00a0in\u00a0der\u00a0AMNOG\u2010Nutzenbewertung \u00a0eine\u00a0gesonderte \u00a0Rolle,\u00a0die\u00a0Differenzierung \u00a0\nder\u00a0Gesamt\u2010Scores\u00a0ber\u00fccksichtigt \u00a0ihre\u00a0\u201eSonderstellung\u201c \u00a0und\u00a0tr\u00e4gt\u00a0zu\u00a0einem\u00a0besseren\u00a0Bewertungs \u2010\nverst\u00e4ndnis \u00a0bei.\u00a0\nBei\u00a0den\u00a0neuen\u00a0Wirkstoffen \u00a0aus\u00a0dem\u00a0Jahr\u00a02012\u00a0(ohne\u00a0Orphan\u00a0Drugs )\u00a0zeigte\u00a0die\u00a0Nutzen\u2010Ampel\u00a0\nlediglich\u00a0einmal\u00a0\u201egr\u00fcn\u201c,\u00a0und\u00a0zwar\u00a0bei\u00a0dem\u00a0Wirkstoff \u00a0Vemurafenib \u00a0(Zelboraf\u00ae) \u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0von\u00a0\nerwachsenen \u00a0Patienten, \u00a0die\u00a0an\u00a0einem\u00a0schwarzen \u00a0Hautkrebs \u00a0(malignes \u00a0Melanom) \u00a0erkrankt\u00a0sind\u00a0und\u00a0\nderen\u00a0Melanom \u00a0nicht\u00a0mehr\u00a0durch\u00a0eine\u00a0Operation \u00a0entfernbar \u00a0ist\u00a0oder\u00a0bei\u00a0denen\u00a0sich\u00a0bereits\u00a0\nMetastasen \u00a0gebildet\u00a0haben.\u00a0Auch\u00a0wurde\u00a0die\u00a0\u201erote\u00a0Nutzenampel\u201c \u00a0bei\u00a0knapp\u00a0der\u00a0H\u00e4lfte\u00a0der\u00a0neuen\u00a0\nWirkstoffe \u00a0bzw.\u00a0Wirkstoffkombinationen \u00a0vergeben \u00a0(im\u00a0Vorjahres \u2010Innovationsreport \u00a0wurde\u00a0diese\u00a0bei\u00a0\nlediglich\u00a0sieben\u00a0von\u00a020\u00a0Wirkstoffen \u00a0gesehen). \u00a0Im\u00a0Gesamt\u2010Score\u00a0(Tabelle\u00a011)\u00a0schnitt\u00a0in\u00a0diesem\u00a0\nInnovationsreport \u00a0nur\u00a0ein\u00a0Wirkstoff, \u00a0Vemurafenib, \u00a0mit\u00a0insgesamt \u00a0\u201egr\u00fcn\u201c\u00a0ab.\u00a0Mit\u00a0Brentuxi\u2010\nmabvedotin, \u00a0Ivacaftor, \u00a0Pasireotid \u00a0und\u00a0Ruxolitinib \u00a0befanden \u00a0sich\u00a0die\u00a0vier\u00a0Orphan\u00a0Drugs\u00a0hingegen\u00a0nur\u00a0\nim\u00a0gelben\u00a0Bereich\u00a0(Tabelle\u00a012).\u00a0H\u00e4ufig\u00a0zeigte\u00a0die\u00a0Ampel\u00a0beim\u00a0Nutzen\u00a0\u201egelb\u201c,\u00a0weil\u00a0\u2013\u00a0wie\u00a0bereits\u00a0in\u00a0den\u00a0\nJahren\u00a0zuvor\u00a0\u2013\u00a0Hinweise\u00a0auf\u00a0Vorteile\u00a0vorlagen, \u00a0aber\u00a0m\u00f6glicherweise \u00a0doch\u00a0gute\u00a0Belege\u00a0f\u00fcr\u00a0einen\u00a0\npatientenrelevanten \u00a0Nutzen\u00a0fehlten,\u00a0oder\u00a0weil\u00a0starke\u00a0unerw\u00fcnschte \u00a0Wirkungen \u00a0die\u00a0positiven\u00a0Effekte\u00a0\nzum\u00a0Teil\u00a0aufhoben. \u00a0Aufgrund \u00a0der\u00a0negativ\u00a0ausgefallenen \u00a0Nutzenbewertung \u00a0wurde\u00a0mit\u00a0Perampanel \u00a0\nnur\u00a0ein\u00a0Wirkstoff \u00a0des\u00a0\u201eArzneimitteljahrgangs \u00a02012\u201c\u00a0vom\u00a0Markt\u00a0genommen. \u00a0Mit\u00a012\u00a0der\u00a020\u00a0Pr\u00e4parate \u00a0\nfindet\u00a0die\u00a0Mehrheit \u00a0der\u00a0betrachteten \u00a0neuen\u00a0Arzneimittel \u00a0innerhalb \u00a0von\u00a0etwa\u00a0zwei\u00a0bis\u00a0drei\u00a0Jahren\u00a0\nnach\u00a0der\u00a0Markteinf\u00fchrung \u00a0Eingang\u00a0in\u00a0\u00e4rztliche\u00a0Therapie\u2010Leitlinien\u00a0(Tabelle\u00a010).\u00a0Betrachtet \u00a0man\u00a0die\u00a0\nBesonderheiten \u00a0nach\u00a0Markteinf\u00fchrung \u00a0dieser\u00a0neuen\u00a0Arzneimittel \u00a0aus\u00a0dem\u00a0Jahr\u00a02012,\u00a0so\u00a0f\u00e4llt\u00a0auf,\u00a0\ndass\u00a0es\u00a0im\u00a0Zusammenhang \u00a0mit\u00a0der\u00a0Anwendung \u00a0in\u00a0der\u00a0realen\u00a0Versorgung \u00a0weniger\u00a0Publikationen \u00a0zu\u00a0\nNegativmeldungen \u00a0oder\u00a0Sicherheitshinweisen \u00a0gab.\u00a0W\u00e4hrend \u00a0im\u00a0Vorjahres \u2010Innovationsreport \u00a0noch\u00a0\nvon\u00a0acht\u00a0Meldungen \u00a0die\u00a0Rede\u00a0war,\u00a0sind\u00a0in\u00a0diesem\u00a0Jahr\u00a0nur\u00a0drei\u00a0Wirkstoffe \u00a0(Axitinib,\u00a0Pixantron \u00a0und\u00a0\nVemurafenib) \u00a0betroffen. \u00a0F\u00fcr\u00a0den\u00a0Wirkstoff \u00a0Vemurafenib \u00a0wurde\u00a0ein\u00a0Rote\u2010Hand\u2010Brief\u00a0ver\u00f6ffentlicht, \u00a0\nmit\u00a0denen\u00a0der\u00a0pU\u00a0heilberufliche \u00a0Fachkreise \u00a0\u00fcber\u00a0neu\u00a0erkannte\u00a0Arzneimittelrisiken \u00a0informierte, \u00a0die\u00a0\nzum\u00a0Zeitpunkt \u00a0der\u00a0Zulassung \u00a0noch\u00a0nicht\u00a0(oder\u00a0nicht\u00a0in\u00a0dem\u00a0Ma\u00dfe)\u00a0bekannt\u00a0waren.\u00a0Bei\u00a0zwei\u00a0weiteren\u00a0\nWirkstoffen \u00a0(Axitinib\u00a0und\u00a0Pixantron) \u00a0wurden\u00a0Informationsbriefe \u00a0zu\u00a0m\u00f6glichen \u00a0\nSicherheitsma\u00dfnahmen \u00a0bzw.\u00a0Dosierungsfehlern \u00a0versendet. \u00a0\nDer\u00a0Blick\u00a0auf\u00a0die\u00a0Kostenspalte \u00a0der\u00a0Tabelle\u00a011\u00a0zeigt,\u00a0dass\u00a0nach\u00a0wie\u00a0vor\u00a0und\u00a0trotz\u00a0ausgehandelter \u00a0\nErstattungsbetr\u00e4ge \u00a0viele\u00a0neue\u00a0Arzneimittel \u00a0zum\u00a0Teil\u00a0noch\u00a0deutlich\u00a0teurer\u00a0sind\u00a0als\u00a0die\u00a0\u00e4lteren\u00a0\nVergleichsarzneimittel. \u00a0So\u00a0lag\u00a0der\u00a0Umsatz\u00a0der\u00a0neuen\u00a0Arzneimittel \u00a0des\u00a0Jahres\u00a02012\u00a0in\u00a0der\u00a0\nuntersuchten \u00a0Population \u00a0der\u00a0TK\u2010Versicherten \u00a0bei\u00a027,5\u00a0Mio.\u00a0Euro\u00a0(gemessen \u00a0f\u00fcr\u00a0das\u00a0Jahr\u00a02013).\u00a0\nVerglichen \u00a0mit\u00a0den\u00a0neuen\u00a0Arzneimitteln \u00a0des\u00a0Jahres\u00a02011\u00a0handelt\u00a0es\u00a0sich\u00a0dabei\u00a0um\u00a0verh\u00e4ltnism\u00e4\u00dfig \u00a0\ngeringe\u00a0Kosten,\u00a0trotz\u00a0vergleichbarer \u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0(n\u00a0=\u00a041,0\u00a0Tsd.\u00a0In\u00a02013\u00a0vs.\u00a0n\u00a0=\u00a049,2\u00a0\nTsd.\u00a0in\u00a02012)\u00a0der\u00a0neuen\u00a0Arzneimittel. \u00a0Das\u00a0umsatzst\u00e4rkste \u00a0Arzneimittel \u00a0im\u00a0Jahr\u00a02013\u00a0war\u00a0das\u00a0Orphan\u00a0\nDrug\u00a0Ruxolitinib, \u00a0das\u00a0unter\u00a0anderem\u00a0zur\u00a0Therapie\u00a0der\u00a0seltenen\u00a0Leuk\u00e4mie \u2010Form\u00a0Myelofibrose \u00a0 \n117\u00a0\n \nInnovationsreport 2015 \u00a0eingesetzt \u00a0wird.\u00a0Das\u00a0im\u00a0Jahr\u00a02013\u00a0am\u00a0h\u00e4ufigsten \u00a0verordnete \u00a0neue\u00a0Arzneimittel \u00a0des\u00a0Jahres\u00a02012\u00a0war\u00a0\nmit\u00a011,3\u00a0Tsd.\u00a0verschriebenen \u00a0Packungen \u00a0Aclidiniumbromid, \u00a0als\u00a0therapeutische \u00a0Option\u00a0bei\u00a0der\u00a0\nchronisch \u00a0obstruktiven \u00a0Lungenkrankheit. \u00a0Auf\u00a0Platz\u00a02\u00a0nach\u00a0Verordnungen \u00a0rangiert\u00a0das\u00a0Antidiabetikum \u00a0\nDapagliflozin \u00a0\u2013\u00a0trotz\u00a0negativer \u00a0Nutzenbewertung \u00a0durch\u00a0den\u00a0G\u2010BA\u00a0im\u00a0Juni\u00a02013.\u00a0\n\u00a0\nVerf\u00fcgbare \u00a0\nTherapien \u00a0\u00a0(Zusatz\u2010)Nutzen Kosten Gesamt\u2010Score\u00a0\nAclidiniumbromid \u00a0\u00a0\nAflibercept \u00a0\nAxitinib\u00a0\nAzilsartanmedoxomil \u00a0\u00a0\nNomegestrolacetat \u00a0+\u00a0\nEstradiol\u00a0(Zoely\u00ae)\u00a0\u00a0\nNomegestrolacetat \u00a0+\u00a0\nEstradiol\u00a0(Naemis\u00ae) \u00a0\u00a0\nPixantron \u00a0\u00a0\nRilpivirin\u00a0\u00a0\nTegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0\nOteracil\u00a0\u00a0\nVandetanib \u00a0\u00a0Aclidiniumbromid \u00a0\u00a0\nAflibercept \u00a0\nAzilsartanmedoxomil \u00a0\u00a0\nCeftarolinfosamil \u00a0\u00a0\nDapagliflozin \u00a0\u00a0\nNomegestrolacetat \u00a0+\u00a0\nEstradiol\u00a0(Zoely\u00ae)\u00a0\u00a0\nNomegestrolacetat \u00a0+\u00a0\nEstradiol\u00a0(Naemis\u00ae) \u00a0\nPerampanel \u00a0\u00a0\nPixantron \u00a0\u00a0\u00a0Aclidiniumbromid \u00a0\u00a0\nAzilsartanmedoxomil \u00a0\u00a0\nCrizotinib \u00a0\nDapagliflozin \u00a0\u00a0\nPixantron \u00a0\u00a0\nTegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0\nOteracil\u00a0\u00a0\nVemurafenib \u00a0\u00a0 Tegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0\u00a0\nOteracil\u00a0(2\u00a0P.)\u00a0\nVandetanib \u00a0(2\u00a0P)\u00a0\nAflibercept \u00a0(1\u00a0P.)\u00a0\nCeftarolinfosamil \u00a0(1\u00a0P.)\u00a0\nDapagliflozin \u00a0(1\u00a0P.)\u00a0\nPerampanel \u00a0(1\u00a0P.)\u00a0\nAclidiniumbromid \u00a0(0\u00a0P.)\u00a0\nAzilsartanmedoxomil \u00a0\u00a0\n(0\u00a0P.)\u00a0\nNomegestrolacetat \u00a0+\u00a0\nEstradiol\u00a0(Zoely\u00ae)\u00a0(0\u00a0P.)\u00a0\nNomegestrolacetat \u00a0+\u00a0\nEstradiol\u00a0(Naemis\u00ae) \u00a0(0\u00a0P.)\u00a0\nPixantron \u00a0(0\u00a0P.)\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0  \u00a0\nCeftarolinfosamil \u00a0\u00a0\nDapagliflozin \u00a0\u00a0\nPerampanel \u00a0\u00a0\nVemurafenib \u00a0\u00a0Axitinib\u00a0\nCrizotinib \u00a0\nRilpivirin\u00a0\u00a0\nTegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0\nOteracil\u00a0\u00a0\nVandetanib \u00a0\n\u00a0\u00a0Aflibercept \u00a0\u00a0\nRilpivirin\u00a0\u00a0 Axitinib\u00a0(4\u00a0P.)\u00a0\nCrizotinib \u00a0(4\u00a0P.)\u00a0\nRilpivirin\u00a0(3\u00a0P.)\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0  \u00a0\nCrizotinib \u00a0\u00a0\n\u00a0\u00a0Vemurafenib \u00a0\u00a0 \u00a0Axitinib\u00a0\u00a0  Vemurafenib \u00a0(5\u00a0P.)\u00a0\nTabelle\u00a011:\u00a0Gesamt\u2010Score\u00a0Innovationsbewertung \u00a0\nScore\u2010Erl\u00e4uterung :\u00a0Bei\u00a0den\u00a0Wirkstoffportr\u00e4ts \u00a0wurden\u00a0die\u00a0einzelnen \u00a0Punkte\u00a0der\u00a0Innovationsbewertung \u00a0separat\u00a0betrachtet, \u00a0der\u00a0\npatientenrelevante \u00a0Zusatznutzen \u00a0erhielt\u00a0das\u00a0gr\u00f6\u00dfte\u00a0Gewicht.\u00a0Die\u00a0Vergabe\u00a0der\u00a0Punkte\u00a0wurde\u00a0wie\u00a0folgt\u00a0vorgenommen: \u00a0Verf\u00fcgbare \u00a0\nTherapien: \u00a0rote\u00a0Ampel\u00a0=\u00a00\u00a0Punkte,\u00a0gelbe\u00a0Ampel\u00a0=\u00a01\u00a0Punkt,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a02\u00a0Punkte;\u00a0(Zusatz\u2010)Nutzen :\u00a0rote\u00a0Ampel\u00a0=\u00a00\u00a0Punkte,\u00a0gelbe\u00a0Ampel\u00a0=\u00a0\n2\u00a0Punkte,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a04\u00a0Punkte;\u00a0Kosten :\u00a0rote\u00a0Ampel\u00a0=\u00a00\u00a0Punkte,\u00a0gelbe\u00a0Ampel\u00a0=\u00a01\u00a0Punkt,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a02\u00a0Punkte;\u00a0Gesamt :\u00a0rote\u00a0Ampel\u00a0=\u00a0\nh\u00f6chstens \u00a02\u00a0Punkte,\u00a0gelbe\u00a0Ampel\u00a0=\u00a03\u00a0oder\u00a04\u00a0Punkte,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a05\u00a0Punkte\u00a0und\u00a0mehr.\u00a0\u00a0 \u00a0 \n118\u00a0 \n \nInnovationsreport 2015 \u00a0Verf\u00fcgbare \u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen Gesamt\u2010Score\u00a0\nDecitabin \u00a0\n\u00a0\u00a0Decitabin \u00a0\u00a0\n\u00a0 Decitabin \u00a0(0\u00a0P.)\u00a0\n\u00a0 \u00a0 \u00a0 \u00a0  \u00a0\nIvacaftor\u00a0\n\u00a0\u00a0Brentuximabvedotin \u00a0\nIvacaftor\u00a0\nPasireotid \u00a0\u00a0\nRuxolitinib \u00a0\n\u00a0 Brentuximabvedotin \u00a0(4\u00a0P.)\u00a0\nPasireotid \u00a0(4\u00a0P.)\u00a0\nRuxolitinib \u00a0(4\u00a0P.)\u00a0\nIvacaftor\u00a0(3\u00a0P.)\u00a0\n\u00a0\n\u00a0 \u00a0 \u00a0 \u00a0  \u00a0\nBrentuximabvedotin \u00a0\nPasireotid \u00a0\nRuxolitinib \u00a0\u00a0\n\u00a0\u00a0\u00a0  \u00a0\nTabelle\u00a012:\u00a0Gesamt\u2010Score\u00a0Innovationsbewertung \u00a0Orphan\u00a0Drugs\u00a0\nScore\u2010Erl\u00e4uterung :\u00a0Bei\u00a0den\u00a0Wirkstoffportr\u00e4ts \u00a0wurden\u00a0die\u00a0einzelnen \u00a0Punkte\u00a0der\u00a0Innovationsbewertung \u00a0separat\u00a0betrachtet, \u00a0der\u00a0\npatientenrelevante \u00a0Zusatznutzen \u00a0erhielt\u00a0das\u00a0gr\u00f6\u00dfte\u00a0Gewicht.\u00a0Die\u00a0Vergabe\u00a0der\u00a0Punkte\u00a0wurde\u00a0wie\u00a0folgt\u00a0vorgenommen: \u00a0Verf\u00fcgbare \u00a0\nTherapien: \u00a0rote\u00a0Ampel\u00a0=\u00a00\u00a0Punkte,\u00a0gelbe\u00a0Ampel\u00a0=\u00a01\u00a0Punkt,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a02\u00a0Punkte;\u00a0(Zusatz\u2010)Nutzen :\u00a0rote\u00a0Ampel\u00a0=\u00a00\u00a0Punkte,\u00a0gelbe\u00a0Ampel\u00a0=\u00a0\n2\u00a0Punkte,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a04\u00a0Punkte\u00a0Gesamt :\u00a0rote\u00a0Ampel\u00a0=\u00a0h\u00f6chstens \u00a02\u00a0Punkte,\u00a0gelbe\u00a0Ampel\u00a0=\u00a03\u00a0oder\u00a04\u00a0Punkte,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a05\u00a0Punkte\u00a0und\u00a0\nmehr.\u00a0\u00a0\n\u00a0\nEtwa\u00a00,2\u00a0Prozent\u00a0(n\u00a0=\u00a014.202)\u00a0der\u00a0TK\u2010Versicherten \u00a0erhielten\u00a0im\u00a0Jahr\u00a02013\u00a0ein\u00a0Arzneimittel, \u00a0das\u00a0im\u00a0\nLaufe\u00a0des\u00a0Vorjahres \u00a0in\u00a0den\u00a0Markt\u00a0eingef\u00fchrt \u00a0wurde.\u00a0Ber\u00fccksichtigt \u00a0man\u00a0bei\u00a0der\u00a0Erstellung \u00a0einer\u00a0Karte\u00a0\nder\u00a0Innovations \u2010Verordnungspr\u00e4valenz \u00a0nach\u00a0Bundesl\u00e4ndern \u00a0nur\u00a0diejenigen \u00a0Arzneimittel, \u00a0denen\u00a0im\u00a0\nvorliegenden \u00a0Report\u00a0ein\u00a0fehlender \u00a0Zusatznutzen \u00a0konstatiert \u00a0wurde,\u00a0ergeben\u00a0sich\u00a0regionale \u00a0\nUnterschiede \u00a0(Abbildung \u00a064).\u00a0Die\u00a0Zahlen\u00a0zeigen\u00a0die\u00a0Verordnungsanteile \u00a0der\u00a0TK\u2010Versicherten \u00a0(je\u00a0\nTausend\u00a0Versicherte) \u00a0im\u00a0Vergleich \u00a0zu\u00a0allen\u00a0TK\u2010Versicherten \u00a0des\u00a0jeweiligen \u00a0Bundeslandes. \u00a0Die\u00a0nach\u00a0\nSachsen\u00a0(2,64\u00a0Promille)\u00a0gr\u00f6\u00dften\u00a0Verordnungsanteile \u00a0bei\u00a0Arzneimitteln \u00a0mit\u00a0einer\u00a0\u201eroten\u00a0Nutzen\u2010\nAmpel\u201c\u00a0finden\u00a0sich\u00a0neben\u00a0Sachsen\u2010Anhalt\u00a0(2,62\u00a0Promille)\u00a0auch\u00a0in\u00a0Th\u00fcringen \u00a0(1,87\u00a0Promille). \u00a0Bremen\u00a0\nweist\u00a0mit\u00a00,77\u00a0Promille\u00a0die\u00a0niedrigste \u00a0Verordnungspr\u00e4valenz \u00a0auf.\u00a0\nDie\u00a0wirkstoffbezogenen \u00a0Versorgungsanalysen \u00a0zeigten,\u00a0dass\u00a0die\u00a0Verordnungszahlen \u00a0nach\u00a0der\u00a0\nMarkteinf\u00fchrung \u00a0h\u00e4ufig\u00a0in\u00a0den\u00a0ersten\u00a0sechs\u00a0bis\u00a0zw\u00f6lf\u00a0Monaten\u00a0ansteigen, \u00a0woraufhin \u00a0\nunterschiedliche \u00a0Entwicklungen \u00a0folgen:\u00a0So\u00a0stiegen\u00a0die\u00a0Verordnungszahlen \u00a0vom\u00a0VEGF\u2010Inhibitor\u00a0\nAflibercept \u00a0(Eylea\u00ae)\u00a0nach\u00a0der\u00a0Markteinf\u00fchrung \u00a0Ende\u00a02012\u00a0im\u00a0Oktober\u00a0des\u00a0darauffolgenden \u00a0Jahres\u00a0\nexponentiell \u00a0an,\u00a0was\u00a0m\u00f6glicherweise \u00a0mit\u00a0der\u00a0Zulassungserweiterung \u00a0auf\u00a0die\u00a0Indikation \u00a0\n\u201eVisusbeeintr\u00e4chtigung \u00a0aufgrund\u00a0eines\u00a0Makula\u00f6dems \u00a0infolge\u00a0eines\u00a0retinalen\u00a0Venenverschlusses \u00a0oder\u00a0\nZentralvenenverschluss\u201c \u00a0in\u00a0Zusammenhang \u00a0gebracht\u00a0werden\u00a0kann.\u00a0Der\u00a0Tyrosinkinaseinhibitor \u00a0\nVandetanib \u00a0(Caprelsa\u00ae) \u00a0erreichte\u00a0hingegen\u00a0nach\u00a0seinem\u00a0Marktzugang \u00a0im\u00a0M\u00e4rz\u00a02012\u00a0schon\u00a0nach\u00a0drei\u00a0\nMonaten\u00a0ein\u00a0relativ\u00a0gleichm\u00e4\u00dfiges \u00a0Verordnungsplateau. \u00a0\u00a0 \n119\u00a0\n \nInnovationsreport 2015 \u00a0\n\u00a0\nAbbildung \u00a064:\u00a0Verordnungspr\u00e4valenz \u00a0der\u00a0neuen\u00a0Wirkstoffe \u00a0aus\u00a0dem\u00a0Jahr\u00a02012\u00a0ohne\u00a0Zusatznutzen \u00a0(\u201erote\u00a0\nAmpel\u201c)\u00a0f\u00fcr\u00a0TK\u2010Versicherte \u00a0in\u00a0Promille\u00a0nach\u00a0Bundesl\u00e4ndern \u00a0(nur\u00a0Verordnungen \u00a0im\u00a0Jahr\u00a02013)\u00a0\n \u00a0\n \n120\u00a0 \n \nInnovationsreport 2015 \u00a0 7 Neue\u00a0Arzneimittel \u00a0zur\u00a0Behandlung \u00a0von\u00a0Multipler \u00a0Sklerose\u00a0\nGerd\u00a0Glaeske\u00a0\n7.1 Die\u00a0Marktentwicklung \u00a0von\u00a0Fingolimod \u00a0(Gilenya\u00ae) \u00a0\nAm\u00a029.\u00a0M\u00e4rz\u00a02012\u00a0wurde\u00a0das\u00a0Ergebnis\u00a0der\u00a0Nutzenbewertung \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0f\u00fcr\u00a0das\u00a0Pr\u00e4parat\u00a0\nGilenya\u00ae\u00a0mit\u00a0dem\u00a0Wirkstoff \u00a0Fingolimod \u00a0auf\u00a0den\u00a0Internetseiten \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0\npubliziert \u00a0(G\u2010BA,\u00a02012j).\u00a0Das\u00a0Mittel\u00a0war\u00a0zun\u00e4chst\u00a0zugelassen \u00a0zur\u00a0krankheitsmodifizierenden \u00a0\nMonotherapie \u00a0von\u00a0hochaktiver \u00a0schubf\u00f6rmig \u2010remittierend \u00a0verlaufender \u00a0Multipler \u00a0Sklerose\u00a0(MS)\u00a0bei\u00a0\nerwachsenen \u00a0Patienten, \u00a0bei\u00a0denen\u00a0trotz\u00a0der\u00a0Behandlung \u00a0mit\u00a0einem\u00a0Beta\u2010Interferon \u00a0(IFN\u2010\u03b2)\u00a0weiterhin \u00a0\neine\u00a0hohe\u00a0Krankheitsaktivit\u00e4t \u00a0besteht\u00a0und\u00a0bei\u00a0Patienten, \u00a0die\u00a0unter\u00a0einer\u00a0rasch\u00a0fortschreitenden \u00a0\nschweren \u00a0schubf\u00f6rmig \u2010remittierend \u00a0verlaufenden \u00a0Multiplen \u00a0Sklerose,\u00a0definiert\u00a0durch\u00a0zwei\u00a0oder\u00a0\nmehr\u00a0Sch\u00fcbe\u00a0mit\u00a0Behinderungsprogression \u00a0pro\u00a0Jahr,\u00a0leiden.\u00a0Im\u00a0Verfahren \u00a0zur\u00a0Nutzenbewertung \u00a0hat\u00a0\nder\u00a0Gemeinsame \u00a0Bundesausschuss \u00a0in\u00a0seiner\u00a0Sitzung\u00a0folgende\u00a0Ergebnisse \u00a0verabschiedet: \u00a0\n\uf0b7 Im\u00a0Vergleich \u00a0mit\u00a0dem\u00a0Mittel\u00a0Glatirameracetat \u00a0wird\u00a0bei\u00a0Patienten \u00a0mit\u00a0hochaktiver \u00a0\nschubf\u00f6rmig \u00a0remittierender \u00a0Multipler \u00a0Sklerose\u00a0(RRMS),\u00a0die\u00a0nicht\u00a0auf\u00a0IFN\u2010\u03b2\u00a0angesprochen \u00a0\nhaben,\u00a0kein\u00a0Zusatznutzen \u00a0gesehen.\u00a0\n\uf0b7 Im\u00a0Vergleich \u00a0mit\u00a0IFN\u2010\u03b2\u00a0f\u00fcr\u00a0Patienten \u00a0mit\u00a0hochaktiver \u00a0RRMS,\u00a0die\u00a0vorher\u00a0noch\u00a0keine\u00a0INF\u2010\u03b2\u2010\nBehandlung \u00a0bekommen \u00a0haben,\u00a0wird\u00a0kein\u00a0Zusatznutzen \u00a0gegen\u00fcber \u00a0IFN\u2010\u03b2\u00a0(1a\u00a0oder\u00a01b)\u00a0\ngesehen.\u00a0\n\uf0b7 Bei\u00a0Patienten \u00a0mit\u00a0einer\u00a0rasch\u00a0fortschreitenden \u00a0schweren \u00a0RRMS\u00a0wird\u00a0gegen\u00fcber \u00a0der\u00a0\nBehandlung \u00a0mit\u00a0IFN\u2010\u03b2\u00a01a\u00a0ein\u00a0Anhaltspunkt \u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0Zusatznutzen \u00a0festgestellt. \u00a0\nWegen\u00a0der\u00a0Befristung \u00a0der\u00a0ersten\u00a0Bewertung \u00a0bis\u00a0zum\u00a029.\u00a0M\u00e4rz\u00a02015\u00a0musste\u00a0der\u00a0pU\u00a0bis\u00a0zum\u00a0Juli\u00a02015\u00a0\neinen\u00a0Zusatzbericht \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0zur\u00a0neuerlichen \u00a0Beratung\u00a0\u00fcber\u00a0den\u00a0Zusatznutzen \u00a0von\u00a0\nFingolimod \u00a0einreichen \u00a0(siehe\u00a0\u00a7\u00a035a,\u00a03).\u00a0Das\u00a0erneute\u00a0Verfahren \u00a0nach\u00a0der\u00a0Befristung \u00a0wurde\u00a0zum\u00a01.\u00a0\nApril\u00a02015\u00a0begonnen. \u00a0Mittlerweile \u00a0liegt\u00a0die\u00a0Nutzenbewertung \u00a0vom\u00a0IQWiG\u00a0vor\u00a0(IQWiG,\u00a02015a):\u00a0\n\uf0b7 Im\u00a0Vergleich \u00a0mit\u00a0dem\u00a0Mittel\u00a0Glatirameracetat \u00a0oder\u00a0IFN\u2010\u03b2\u00a01a\u00a0oder\u00a01b\u00a0wird\u00a0bei\u00a0Patienten \u00a0mit\u00a0\nhochaktiver \u00a0RRMS\u00a0(vollst\u00e4ndige \u00a0Vorbehandlung \u00a0mit\u00a0IFN\u2010\u03b2)\u00a0kein\u00a0Zusatznutzen \u00a0gesehen.\u00a0\n\uf0b7 Im\u00a0Vergleich \u00a0zur\u00a0Fortf\u00fchrung \u00a0der\u00a0krankheitsmodifizierenden \u00a0Therapie\u00a0mit\u00a0IFN\u2010\u03b2\u00a0mit\u00a0einer\u00a0\ngem\u00e4\u00df\u00a0Zulassung \u00a0optimierten \u00a0Dosierung \u00a0bis\u00a0zu\u00a0einem\u00a0angemessenen \u00a0Zyklus,\u00a0der\u00a0\nnormalerweise \u00a0mindestens \u00a0ein\u00a0Jahr\u00a0andauert, \u00a0wird\u00a0bei\u00a0Patienten \u00a0mit\u00a0hochaktiver \u00a0RRMS\u00a0\n(keine\u00a0vollst\u00e4ndige \u00a0Vorbehandlung \u00a0mit\u00a0IFN\u2010\u03b2)\u00a0ein\u00a0Hinweis\u00a0auf\u00a0einen\u00a0betr\u00e4chtlichen \u00a0\nZusatznutzen \u00a0gesehen.\u00a0\n\uf0b7 Im\u00a0Vergleich \u00a0mit\u00a0dem\u00a0Mittel\u00a0Glatirameracetat \u00a0oder\u00a0IFN\u2010\u03b2\u00a01a\u00a0oder\u00a01b\u00a0wird\u00a0bei\u00a0weiblichen \u00a0\nPatienten \u00a0mit\u00a0rasch\u00a0fortschreitender \u00a0schwerer \u00a0RRMS\u00a0ein\u00a0Hinweis\u00a0auf\u00a0einen\u00a0betr\u00e4chtlichen \u00a0\nZusatznutzen \u00a0gesehen,\u00a0bei\u00a0Patienten \u00a0m\u00e4nnlichen \u00a0Geschlechts \u00a0hingegen\u00a0ein\u00a0Hinweis\u00a0auf\u00a0einen\u00a0\ngeringen\u00a0Zusatznutzen. \u00a0\nWegen\u00a0einer\u00a0Zulassungserweiterung \u00a0am\u00a023.\u00a0Mai\u00a02014\u00a0fasste\u00a0der\u00a0G\u2010BA\u00a0am\u00a018.\u00a0Dezember \u00a02014\u00a0erneut\u00a0\neinen\u00a0Beschluss \u00a0\u00fcber\u00a0den\u00a0Zusatznutzen \u00a0von\u00a0Fingolimod. \u00a0Die\u00a0Zulassungserweiterung \u00a0bezog\u00a0sich\u00a0auf\u00a0\nPatienten \u00a0mit\u00a0hoher\u00a0Krankheitsaktivit\u00e4t \u00a0trotz\u00a0der\u00a0Behandlung \u00a0mit\u00a0mindestens \u00a0einer\u00a0\nkrankheitsmodifizierenden \u00a0Therapie. \u00a0In\u00a0der\u00a0Zulassung \u00a0des\u00a0neuen\u00a0Anwendungsgebietes \u00a0f\u00fcr\u00a0Gilenya\u00ae\u00a0\nist\u00a0die\u00a0Beschr\u00e4nkung \u00a0der\u00a0Vorbehandlung \u00a0der\u00a0Patienten \u00a0mit\u00a0IFN\u2010\u00df\u00a0ersetzt\u00a0durch\u00a0mindestens \u00a0eine\u00a0\nkrankheitsmodifizierende \u00a0Therapie\u00a0f\u00fcr\u00a0die\u00a0schubf\u00f6rmig \u2010remittierend \u00a0verlaufende \u00a0Multiple\u00a0Sklerose .\u00a0 \n121\u00a0\n \nInnovationsreport 2015 \u00a0Auch\u00a0diese\u00a0Indikationserweiterung \u00a0erhielt\u00a0im\u00a0Vergleich \u00a0zur\u00a0Therapie\u00a0mit\u00a0Glatirameracetat \u00a0oder\u00a0IFN\u2010\u03b2\u2010\n1a\u00a0und\u00a0\u20101b\u00a0die\u00a0Bewertung: \u00a0Ein\u00a0Zusatznutzen \u00a0ist\u00a0nicht\u00a0belegt .\u00a0\nInsgesamt \u00a0war\u00a0das\u00a0Ergebnis\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung \u00a0f\u00fcr\u00a0Novartis\u00a0ohne\u00a0Frage\u00a0ern\u00fcchternd. \u00a0\nHinzu\u00a0kamen\u00a0Sicherheitswarnungen \u00a0wegen\u00a0unerw\u00fcnschter \u00a0Wirkungen \u00a0am\u00a0Herzen\u00a0(siehe\u00a0auch\u00a0der\u00a0\nRote\u2010Hand\u2010Brief\u00a0zu\u00a0Gilenya\u00ae\u00a0vom\u00a026.\u00a0Januar\u00a02012),\u00a0die\u00a0dazu\u00a0f\u00fchrten,\u00a0dass\u00a0in\u00a0der\u00a0Beschlussfassung \u00a0\ndes\u00a0G\u2010BA\u00a0auch\u00a0kardiologische \u00a0Kontrolluntersuchungen \u00a0als\u00a0zus\u00e4tzlich \u00a0notwendige \u00a0GKV\u2010Leistungen \u00a0\naufgef\u00fchrt \u00a0wurden.\u00a0Nach\u00a0wie\u00a0vor\u00a0gilt\u00a0die\u00a0Langzeitvertr\u00e4glichkeit \u00a0des\u00a0Immunsuppressivums \u00a0als\u00a0nicht\u00a0\nausreichend \u00a0untersucht, \u00a0es\u00a0sind\u00a0Einzelfallmeldungen \u00a0\u00fcber\u00a0pl\u00f6tzliche \u00a0Todesf\u00e4lle \u00a0nach\u00a0der\u00a0Einnahme \u00a0\nvon\u00a0Fingolimod \u00a0bekannt\u00a0geworden. \u00a0Patienten \u00a0mit\u00a0kardiovaskul\u00e4ren \u00a0Risiken\u00a0und\u00a0solche,\u00a0die\u00a0andere\u00a0\nArzneimittel \u00a0mit\u00a0Wirkung\u00a0auf\u00a0die\u00a0Herzreizleitung \u00a0einnehmen, \u00a0sollten\u00a0dieses\u00a0Mittel\u00a0daher\u00a0nicht\u00a0\nverordnet \u00a0bekommen. \u00a0Fingolimod \u00a0wirkt\u00a0im\u00a0Tierversuch \u00a0teratogen, \u00a0im\u00a0Gegensatz \u00a0zu\u00a0beispielsweise \u00a0\nInterferon \u00a0und\u00a0Azathioprin \u00a0bestehen \u00a0aber\u00a0noch\u00a0keine\u00a0Erfahrungen \u00a0bei\u00a0Schwangeren \u00a0\n(www.embryotox.de ).\u00a0Frauen,\u00a0die\u00a0mit\u00a0diesem\u00a0MS\u2010Mittel\u00a0behandelt \u00a0werden,\u00a0m\u00fcssen\u00a0daher\u00a0\nzuverl\u00e4ssig \u00a0und\u00a0wirksam\u00a0verh\u00fcten, \u00a0f\u00fcr\u00a0M\u00e4nner\u00a0gibt\u00a0es\u00a0hingegen\u00a0keine\u00a0Einschr\u00e4nkungen. \u00a0\u00a0\nTrotz\u00a0all\u00a0dieser\u00a0Bedenken \u00a0und\u00a0Einschr\u00e4nkungen \u00a0sind\u00a0die\u00a0Verordnungsmengen \u00a0von\u00a0Gilenya\u00ae\u00a0seit\u00a0\nseinem\u00a0Markteintritt \u00a0deutlich\u00a0angestiegen. \u00a0\nIm\u00a0Dossier\u00a0des\u00a0pU\u00a0zur\u00a0Nutzenbewertung \u00a0war\u00a0die\u00a0Zielpopulation \u00a0f\u00fcr\u00a0Fingolimod \u00a0in\u00a0der\u00a0GKV\u00a0mit\u00a09.734\u00a0\nPatienten \u00a0angegeben \u00a0worden,\u00a0der\u00a0G\u2010BA\u00a0sah\u00a0Anhaltspunkte \u00a0f\u00fcr\u00a0einen\u00a0Zusatznutzen \u00a0jedoch\u00a0nur\u00a0f\u00fcr\u00a0die\u00a0\nGruppe\u00a0von\u00a0Patienten \u00a0mit\u00a0einer\u00a0rasch\u00a0fortschreitenden \u00a0schweren \u00a0RRMS.\u00a0In\u00a0der\u00a0Bekanntmachung \u00a0im\u00a0\nBundesanzeiger \u00a0(G\u2010BA,\u00a02012j)\u00a0war\u00a0diese\u00a0Gruppe\u00a0auf\u00a01.500\u00a0Personen \u00a0gesch\u00e4tzt \u00a0worden\u00a0und\u00a0damit\u00a0auf\u00a0\netwa\u00a0ein\u00a0Prozent\u00a0der\u00a0gesch\u00e4tzten \u00a0Gesamtpopulation \u00a0von\u00a0MS\u2010Patienten, \u00a0die\u00a0f\u00fcr\u00a0Deutschland \u00a0mit\u00a0\n120.000\u00a0bis\u00a0140.000\u00a0Erkrankten \u00a0angegeben \u00a0wird.\u00a0Allein\u00a0in\u00a0der\u00a0TK\u00a0werden\u00a0seit\u00a0dem\u00a0Jahr\u00a02012\u00a0j\u00e4hrlich\u00a0\nann\u00e4hernd \u00a01.500\u00a0Versicherte \u00a0mit\u00a0Fingolimod \u00a0behandelt, \u00a0im\u00a0Jahre\u00a02013\u00a0wurden\u00a01.331\u00a0Patienten \u00a0\ndamit\u00a0therapiert, \u00a0in\u00a0den\u00a0ersten\u00a0zwei\u00a0Quartalen \u00a0des\u00a0Jahres\u00a02014\u00a0waren\u00a0es\u00a01.370\u00a0(siehe\u00a0Tabelle\u00a013).\u00a0\nDamit\u00a0werden\u00a0im\u00a0ersten\u00a0Halbjahr\u00a02014\u00a0insgesamt \u00a011,3\u00a0Prozent\u00a0aller\u00a0arzneimittel \u2010behandelten \u00a012.096\u00a0\nbei\u00a0der\u00a0TK\u00a0versicherten \u00a0MS\u2010Patienten \u00a0mit\u00a0Fingolimod \u00a0behandelt. \u00a0Bezogen\u00a0auf\u00a0die\u00a0Sch\u00e4tzungen \u00a0im\u00a0\nDossier\u00a0und\u00a0in\u00a0der\u00a0Bekanntmachung \u00a0im\u00a0Bundesanzeiger \u00a0vom\u00a04.\u00a0Mai\u00a02012\u00a0kann\u00a0eine\u00a0Fehlversorgung \u00a0\nbei\u00a0Versicherten \u00a0der\u00a0TK\u00a0angenommen \u00a0werden.\u00a0\nMit\u00a0diesen\u00a0Verordnungsmengen \u00a0korrelieren \u00a0auch\u00a0die\u00a0Ausgaben \u00a0der\u00a0TK\u00a0f\u00fcr\u00a0dieses\u00a0MS\u2010Mittel.\u00a0Die\u00a0\nJahrestherapiekosten \u00a0pro\u00a0Patient\u00a0werden\u00a0in\u00a0der\u00a0Bekanntmachung \u00a0des\u00a0Bundesanzeigers \u00a0mit\u00a0\n26.432,71 \u00a0Euro\u00a0f\u00fcr\u00a0die\u00a0Grundgesamtheit \u00a0der\u00a0Zielpopulation \u00a0angegeben \u00a0\u2013\u00a0einschlie\u00dflich \u00a0der\u00a0Kosten\u00a0\nder\u00a0zus\u00e4tzlich \u00a0notwendigen \u00a0GKV\u2010Leistungen, \u00a0wie\u00a0beispielsweise \u00a0ophthalmologische \u00a0und\u00a0\nkardiologische \u00a0Kontrolluntersuchungen, \u00a0Tests\u00a0auf\u00a0Antik\u00f6rper \u00a0gegen\u00a0das\u00a0Varicella\u2010Zoster\u2010Virus\u00a0(VZV)\u00a0\n(bei\u00a0nicht\u00a0anamnestisch \u00a0bekannter \u00a0Windpockenerkrankung \u00a0bzw.\u00a0ohne\u00a0Impfung\u00a0gegen\u00a0das\u00a0VZV)\u00a0sowie\u00a0\nImpfungen \u00a0gegen\u00a0das\u00a0VZV.\u00a0Die\u00a0entsprechenden \u00a0Kosten\u00a0f\u00fcr\u00a0die\u00a0zweckm\u00e4\u00dfige \u00a0Vergleichstherapie \u00a0mit\u00a0\nInterferon \u00a0betragen\u00a0insgesamt \u00a0rund\u00a018.390\u00a0Euro.\u00a0Eine\u00a0weder\u00a0notwendige \u00a0noch\u00a0geeignete \u00a0Therapie\u00a0\nmit\u00a0Fingolimod \u00a0f\u00fcr\u00a0die\u00a0Mehrheit \u00a0der\u00a0MS\u2010Patienten \u00a0erh\u00f6ht\u00a0daher\u00a0deutlich\u00a0die\u00a0Ausgabenbelastungen \u00a0\nbei\u00a0den\u00a0Krankenkassen \u00a0f\u00fcr\u00a0die\u00a0MS\u2010Behandlung. \u00a0Die\u00a0Gesamtmenge \u00a0der\u00a0Verordnungen \u00a0von\u00a0Fingolimod \u00a0\nzu\u00a0Lasten\u00a0der\u00a0GKV\u00a0von\u00a02,2\u00a0Mio.\u00a0Tagesdosen \u00a0im\u00a0Jahr\u00a02013\u00a0mit\u00a0Nettokosten \u00a0von\u00a064,02\u00a0Euro\u00a0pro\u00a0DDD\u00a0\nverursachen \u00a023.433\u00a0Euro\u00a0Nettokosten \u00a0und\u00a0damit\u00a0ann\u00e4hernd \u00a0den\u00a0vom\u00a0G\u2010BA\u00a0genannten \u00a0Jahresbetrag. \u00a0\nMit\u00a0der\u00a0empfohlenen \u00a0t\u00e4glichen\u00a0Anwendung \u00a0w\u00fcrden\u00a0mit\u00a0den\u00a02,2\u00a0Mio.\u00a0DDD\u00a0etwa\u00a06.030\u00a0Patienten \u00a0mit\u00a0\nFingolimod \u00a0zu\u00a0Lasten\u00a0der\u00a0GKV\u00a0behandelt \u00a0werden.\u00a0Der\u00a0pU\u00a0hatte\u00a0in\u00a0seinem\u00a0Dossier\u00a0die\u00a0in\u00a0Frage\u00a0\nkommende \u00a0Population \u00a0sogar\u00a0auf\u00a0etwa\u00a09.500\u00a0Patienten \u00a0(nach\u00a0der\u00a0Indikationserweiterung) \u00a0gesch\u00e4tzt. \u00a0\nIn\u00a0der\u00a0GKV\u00a0werden\u00a0derartig\u00a0viele\u00a0Patienten \u00a0jedoch\u00a0offensichtlich \u00a0nicht\u00a0mit\u00a0Fingolimod \u00a0behandelt. \u00a0 \n122\u00a0 \n \nInnovationsreport 2015 \u00a0Wenn\u00a0in\u00a0der\u00a0GKV\u00a0statt\u00a0der\u00a0gesch\u00e4tzten \u00a06.030\u00a0mit\u00a02,2\u00a0Mio.\u00a0DDD\u00a0behandelten \u00a0MS\u2010Patienten \u00a0die\u00a0vom\u00a0\nG\u2010BA\u00a0als\u00a0zweckm\u00e4\u00dfig \u00a0deklarierte \u00a0Therapie\u00a0(IFN)\u00a0f\u00fcr\u00a04.500\u00a0Patienten \u00a0gew\u00e4hlt\u00a0werden\u00a0w\u00fcrde,\u00a0w\u00e4re\u00a0das\u00a0\nEinsparpotential \u00a0betr\u00e4chtlich. \u00a0F\u00fcr\u00a0die\u00a0Fingolimod \u2010Therapie\u00a0m\u00fcssten\u00a0nur\u00a035,1\u00a0Mio.\u00a0Euro\u00a0f\u00fcr\u00a0die\u00a0\nTherapie\u00a0der\u00a01.500\u00a0Patienten, \u00a0bei\u00a0denen\u00a0es\u00a0potentiell \u00a0Anhaltspunkte \u00a0f\u00fcr\u00a0einen\u00a0Zusatznutzen \u00a0gibt,\u00a0und\u00a0\netwa\u00a082,7\u00a0Mio.\u00a0Euro\u00a0f\u00fcr\u00a0die\u00a0IFN\u2010\u03b2\u2010Therapie\u00a0ausgegeben \u00a0werden.\u00a0Aus\u00a0der\u00a0Vermeidung \u00a0dieser\u00a0\nFehlversorgung \u00a0w\u00fcrde\u00a0ein\u00a0Einsparpotential \u00a0von\u00a022,8\u00a0Mio.\u00a0Euro\u00a0resultieren \u00a0(immerhin \u00a0knapp\u00a017\u00a0\nProzent,\u00a0berechnet \u00a0auf\u00a0die\u00a0Fingolimod \u2010Ausgaben). \u00a0\u00a0\n\u00a0\nJahr\u00a0 Wirkstoff** \u00a0Bruttoausgaben \u00a0\nin\u00a0Mio.\u00a0Euro\u00a0Anzahl\u00a0\nPackungen \u00a0Anzahl\u00a0TK\u2010\nVersicherte \u00a0\nmit\u00a0MS\u00a0Prozentsatz \u00a0\nAnzahl\u00a0TK\u2010\nVersicherte \u00a0\nmit\u00a0MS\u00a0\ngesamt\u00a0Prozentsatz \u00a0\nAnzahl\u00a0an\u00a0\nBruttoausgaben\ngesamt\u00a0\n2012\u00a0Fingolimod \u00a0 16,83\u00a0 7.240\u00a0 831\u00a0 7,3%\u00a0 9,11%\u00a0\nGabe\u00a0von\u00a0\nweiteren\u00a0AM*\nkein\u00a0\nFingolimod \u00a0167,84\u00a0 79.748\u00a0 10.498\u00a0 92,7%\u00a0 90,89%\u00a0\nGesamt\u00a0 184,67\u00a0 86.988\u00a0 11.329\u00a0 100,0%\u00a0 100,0%\u00a0\n2013\u00a0Fingolimod \u00a0 28,31\u00a0 12.179\u00a0 1.331\u00a0 10,4%\u00a0 13,01%\u00a0\nGabe\u00a0von\u00a0\nweiteren\u00a0AM*\nkein\u00a0\nFingolimod \u00a0189,28\u00a0 86.667\u00a0 11.490\u00a0 89,6%\u00a0 86,99%\u00a0\nGesamt\u00a0 217,59\u00a0 98.846\u00a0 12.821\u00a0 100,0%\u00a0 100,0%\u00a0\n2014\u00a0\n(1.\u00a0und\u00a02.\u00a0\nQuartal)\u00a0Fingolimod \u00a0 14,91\u00a0 7.423\u00a0 1.371\u00a0 11,3%\u00a0 13,27%\u00a0\nGabe\u00a0von\u00a0\nweiteren\u00a0AM*\nkein\u00a0\nFingolimod \u00a097,43\u00a0 39.271\u00a0 10.725\u00a0 88,7%\u00a0 86,73%\u00a0\nGesamt\u00a0 112,34\u00a0 46.694\u00a0 12.096\u00a0 100,0%\u00a0 100,0%\u00a0\n*ber\u00fccksichtigte \u00a0ATC\u2010Codes:\u00a0L03AX13, \u00a0L04AA34, \u00a0L04AA23, \u00a0L03AB07, \u00a0L03AB08, \u00a0L04AA31, \u00a0L04AX01. \u00a0Datenbasis: \u00a0Apothekendaten \u00a0Januar\u00a0\n2012\u00a0bis\u00a0Juni\u00a02014;\u00a0Diagnosedaten \u00a0Januar\u00a02011\u00a0bis\u00a0Juni\u00a02014.\u00a0Kriterium: \u00a0Die\u00a0Diagnose\u00a0(ICD\u00a0G35)\u00a0muss\u00a0vor\u00a0der\u00a0Verordnung \u00a0erfolgt\u00a0sein.\u00a0Es\u00a0\nwerden\u00a0nur\u00a0Verordnungen \u00a0ber\u00fccksichtigt, \u00a0denen\u00a0eine\u00a0Diagnose\u00a0zugeordnet \u00a0werden\u00a0kann.\u00a0**Die\u00a0Wirkstoffe \u00a0PEG\u2010Interferon \u00a0und\u00a0\nDimethylfumarat \u00a0werden\u00a0bei\u00a0dieser\u00a0Auswertung \u00a0nicht\u00a0ber\u00fccksichtigt, \u00a0da\u00a0PEG\u2010Interferon \u00a0nicht\u00a0immer\u00a0einen\u00a0eigenen\u00a0ATC\u2010Code\u00a0hatte.\u00a0\nTabelle\u00a013:\u00a0\u00dcbersicht \u00a0der\u00a0Verordnungen \u00a0von\u00a0Fingolimod \u00a0und\u00a0weiterer\u00a0medikament\u00f6ser \u00a0Therapien \u00a0bei\u00a0TK\u2010\nVersicherten \u00a0mit\u00a0MS\u2010Erkrankung \u00a0(ICD\u00a0G35)\u00a0\n\u00a0\nTabelle\u00a013\u00a0zeigt\u00a0die\u00a0Ausgaben \u00a0f\u00fcr\u00a0die\u00a0Verordnungen \u00a0von\u00a0Fingolimod \u00a0sowie\u00a0die\u00a0Gesamtausgaben \u00a0f\u00fcr\u00a0\ndie\u00a0medikament\u00f6se \u00a0Behandlung \u00a0von\u00a0MS\u00a0bei\u00a0der\u00a0TK\u00a0in\u00a0den\u00a0Jahren\u00a02012,\u00a02013\u00a0und\u00a0den\u00a0ersten\u00a0beiden\u00a0\nQuartalen \u00a0des\u00a0Jahres\u00a02014.\u00a028,3\u00a0Mio.\u00a0Euro\u00a0werden\u00a0z.B.\u00a0im\u00a0Jahre\u00a02013\u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0von\u00a01.331\u00a0\nPatienten \u00a0mit\u00a0Fingolimod \u00a0ausgegeben \u00a0(10,4\u00a0Prozent\u00a0aller\u00a0arzneimittel \u2010behandelten \u00a0MS\u2010Patienten), \u00a0\ndas\u00a0sind\u00a013\u00a0Prozent\u00a0der\u00a0Gesamtausgaben \u00a0f\u00fcr\u00a0die\u00a0MS\u2010Behandlung \u00a0in\u00a0der\u00a0TK.\u00a0Im\u00a0Durchschnitt \u00a0entfallen\u00a0\nsomit\u00a0auf\u00a0jeden\u00a0Fingolimod \u2010Patienten \u00a021.270\u00a0Euro\u00a0im\u00a0Jahre\u00a02013,\u00a0w\u00e4hrend\u00a0bei\u00a0den\u00a0anderen\u00a0MS\u2010\nPatienten \u00a016.470\u00a0Euro\u00a0an\u00a0Arzneimittelkosten \u00a0anfallen,\u00a0also\u00a0pro\u00a0Patienten \u00a04.800\u00a0Euro\u00a0weniger.\u00a0Wenn\u00a0\nin\u00a0diesem\u00a0Zusammenhang \u00a0angenommen \u00a0werden\u00a0kann,\u00a0dass\u00a0bei\u00a0nur\u00a0etwa\u00a0einem\u00a0Prozent\u00a0der\u00a0\ngesamten \u00a0MS\u2010Population \u00a0bei\u00a0der\u00a0TK\u00a0mit\u00a0der\u00a0Fingolimod \u2010Behandlung \u00a0Anhaltspunkte \u00a0f\u00fcr\u00a0einen\u00a0\ngeringen\u00a0Zusatznutzen \u00a0vorhanden \u00a0sind,\u00a0bekommen \u00a0etwa\u00a0neun\u00a0Prozent\u00a0dieser\u00a0MS\u2010Kranken\u00a0nicht\u00a0 \n123\u00a0\n \nInnovationsreport 2015 \u00a0unbedingt \u00a0therapeutisch \u00a0notwendig \u00a0dieses\u00a0Arzneimittel. \u00a0Das\u00a0Einsparpotential \u00a0l\u00e4ge\u00a0daher\u00a0bei\u00a0etwa\u00a05\u00a0\nMio.\u00a0Euro\u00a0im\u00a0Jahre\u00a02013.\u00a0\nDie\u00a0Verordnungen \u00a0f\u00fcr\u00a0Fingolimod \u00a0betreffen \u00a0vor\u00a0allem\u00a0MS\u2010Patienten \u00a0in\u00a0j\u00fcngeren\u00a0bis\u00a0mittleren \u00a0\nAltersgruppen \u00a0(siehe\u00a0Abbildung \u00a065).\u00a0Nach\u00a0den\u00a0vorliegenden \u00a0epidemiologischen \u00a0Daten\u00a0tritt\u00a0die\u00a0\nMultiple\u00a0Sklerose\u00a0in\u00a0der\u00a0Zeit\u00a0zwischen\u00a0dem\u00a020.\u00a0und\u00a040.\u00a0Lebensjahr \u00a0erstmals\u00a0auf,\u00a0ein\u00a0auff\u00e4llig\u00a0hoher\u00a0\nAnteil\u00a0der\u00a0Neuerkrankungen \u00a0tritt\u00a0um\u00a0das\u00a030.\u00a0Lebensjahr \u00a0auf.\u00a0\u00a0\n\u00a0\n\u00a0\nAbbildung \u00a065:\u00a0Ausgaben \u00a0und\u00a0verordnete \u00a0Packungen \u00a0von\u00a0Fingolimod \u00a0nach\u00a0Alter\u00a0der\u00a0TK\u2010Versicherten \u00a0mit\u00a0einer\u00a0\nMS\u2010Diagnose \u00a0im\u00a0Jahr\u00a02013\u00a0\u00a0\n\u00a0\nBei\u00a0Frauen\u00a0tritt\u00a0die\u00a0chronisch \u2010entz\u00fcndliche \u00a0Erkrankung \u00a0etwa\u00a0doppelt\u00a0so\u00a0h\u00e4ufig\u00a0auf\u00a0wie\u00a0bei\u00a0M\u00e4nnern \u00a0\nund\u00a0ist\u00a0nicht\u00a0auf\u00a0die\u00a0h\u00f6here\u00a0Lebenserwartung \u00a0von\u00a0Frauen\u00a0zur\u00fcckzuf\u00fchren \u00a0(Hoffmann \u00a0et\u00a0al.,\u00a02009).\u00a0\nDie\u00a0Fingolimod \u2010Population \u00a0bei\u00a0der\u00a0TK\u00a0stimmt\u00a0mit\u00a0diesen\u00a0alters\u2010\u00a0und\u00a0geschlechtsspezifischen \u00a0epide\u2010\nmiologischen \u00a0Befunden \u00a0durchaus\u00a0\u00fcberein\u00a0(siehe\u00a0Abbildung \u00a066).\u00a0\nEntsprechend \u00a0den\u00a0epidemiologischen \u00a0Krankheitsmustern \u00a0verteilen\u00a0sich\u00a0auch\u00a0die\u00a0verordneten \u00a0Pa\u2010\nckungen:\u00a0Da\u00a0Frauen\u00a0eine\u00a0h\u00f6here\u00a0Pr\u00e4valenz \u00a0der\u00a0MS\u00a0aufweisen, \u00a0liegt\u00a0die\u00a0Anzahl\u00a0der\u00a0verordneten \u00a0Pa\u2010\nckungen\u00a0bei\u00a0ihnen\u00a0auch\u00a0deutlich\u00a0h\u00f6her\u00a0(siehe\u00a0Abbildung \u00a067).\u00a0\nIn\u00a0diesem\u00a0Zusammenhang \u00a0wird\u00a0deutlich,\u00a0wie\u00a0dringend\u00a0erforderlich \u00a0es\u00a0ist,\u00a0Patientinnen \u00a0und\u00a0\u00c4rzte\u00a0an\u00a0\ndas\u00a0teratogene \u00a0Potential\u00a0von\u00a0Fingolimod \u00a0zu\u00a0erinnern. \u00a0Schlie\u00dflich \u00a0zeigt\u00a0die\u00a0Verteilung \u00a0der\u00a0Patienten, \u00a0\ndass\u00a0h\u00e4ufig\u00a0Frauen\u00a0im\u00a0geb\u00e4rf\u00e4higen \u00a0Alter\u00a0dieses\u00a0Mittel\u00a0verordnet \u00a0bekommen \u00a0(siehe\u00a0Abbildung \u00a066,\u00a0\nAbbildung \u00a067).\u00a0\n \n124\u00a0\n \n \nInnovationsreport 2015 \u00a0\n\u00a0\nAbbildung \u00a066:\u00a0Verteilung \u00a0der\u00a0Patienten \u00a0mit\u00a0Fingolimod \u2010Verordnungen \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0im\u00a0Jahr\u00a0\n2013\u00a0\n\u00a0\n\u00a0\nAbbildung \u00a067:\u00a0Verordnete \u00a0Packungen \u00a0Fingolimod \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0im\u00a0Jahr\u00a02013\u00a0\n \u00a0\n \n125\u00a0\n \nInnovationsreport 2015 \u00a0Die\u00a0Verordnungen \u00a0von\u00a0Fingolimod \u00a0zu\u00a0Lasten\u00a0der\u00a0TK\u00a0f\u00fcr\u00a0die\u00a01.331\u00a0Patienten \u00a0haben\u00a0im\u00a0Jahre\u00a02013\u00a0vor\u00a0\nallem\u00a0neurologisch \u00a0t\u00e4tige\u00a0Fach\u00e4rzte \u00a0aus\u00a0dem\u00a0niedergelassenen \u00a0Bereich\u00a0und\u00a0aus\u00a0Fachambulanzen \u00a0\nvorgenommen. \u00a0Auf\u00a0ihre\u00a0Verordnungen \u00a0entfallen\u00a0daher\u00a0auch\u00a0die\u00a0h\u00f6chsten \u00a0Ausgaben \u00a0(siehe\u00a0Abbildung \u00a0\n68,\u00a0Abbildung \u00a069,\u00a0Abbildung \u00a070).\u00a0\u00a0\n\u00a0\n\u00a0\n*\u00a0beschreibt \u00a0Pseudonummern \u00a0wie\u00a0999999900, \u00a0bei\u00a0Institutsambulanzen, \u00a0Spezialzentren, \u00a0Bundeswehrzentren \u00a0\nAbbildung \u00a068:\u00a0Anzahl\u00a0der\u00a0mit\u00a0Fingolimod \u00a0behandelten \u00a0Versicherten \u00a0nach\u00a0Arztgruppen \u00a0in\u00a0den\u00a0Jahren\u00a02012\u00a0\nund\u00a02013\u00a0\n \u00a0\n \n126\u00a0\n \n \nInnovationsreport 2015 \u00a0\n\u00a0\n*\u00a0beschreibt \u00a0Pseudonummern \u00a0wie\u00a0999999900, \u00a0bei\u00a0Institutsambulanzen, \u00a0Spezialzentren, \u00a0Bundeswehrzentren \u00a0\nAbbildung \u00a069:\u00a0Verordnete \u00a0Packungen \u00a0von\u00a0Fingolimod \u00a0nach\u00a0Arztgruppen \u00a0in\u00a0den\u00a0Jahren\u00a02012\u00a0und\u00a02013\u00a0\n\u00a0\n\u00a0\n*\u00a0beschreibt \u00a0Pseudonummern \u00a0wie\u00a0999999900, \u00a0bei\u00a0Institutsambulanzen, \u00a0Spezialzentren, \u00a0Bundeswehrzentren \u00a0\nAbbildung \u00a070:\u00a0Umsatz\u00a0von\u00a0Fingolimod \u00a0nach\u00a0Arztgruppen \u00a0in\u00a0den\u00a0Jahren\u00a02012\u00a0und\u00a02013\u00a0\n \u00a0\n \n127\u00a0\n \nInnovationsreport 2015 \u00a0 7.2 Lange\u00a0vor\u00a0Fingolimod: \u00a0Der\u00a0Wirkstoff \u00a0Azathioprin \u00a0\nGanz\u00a0anders\u00a0liegen\u00a0die\u00a0Verh\u00e4ltnisse \u00a0bei\u00a0der\u00a0Verordnung \u00a0von\u00a0Azathioprin \u00a0zur\u00a0Behandlung \u00a0der\u00a0MS,\u00a0das\u00a0\nunter\u00a0dem\u00a0Handelsnamen \u00a0Imurek\u00ae\u00a0im\u00a0Jahre\u00a01965\u00a0erstmals\u00a0angeboten \u00a0wurde.\u00a0Vor\u00a0der\u00a0im\u00a0Jahr\u00a01995\u00a0\neingef\u00fchrten \u00a0Therapie\u00a0mit\u00a0IFN\u2010\u03b2\u00a0wurden\u00a0vor\u00a0allem\u00a0Glukokortikoidsteroide \u00a0und\u00a0Azathioprin \u00a0zur\u00a0\nBehandlung \u00a0der\u00a0MS\u00a0eingesetzt. \u00a0Seit\u00a0einigen\u00a0Jahren\u00a0wird\u00a0in\u00a0Publikationen \u00a0darauf\u00a0hingewiesen, \u00a0dass\u00a0\nAzathioprin \u00a0eine\u00a0\u00e4hnliche\u00a0Nutzen\u2010Schaden\u2010Relation\u00a0aufweist\u00a0wie\u00a0IFN\u2010\u03b2\u00a0(Casetta\u00a0et\u00a0al.,\u00a02009).\u00a0Es\u00a0\nfehlen\u00a0allerdings \u00a0methodisch \u00a0hochwertige \u00a0Studien,\u00a0vor\u00a0allem\u00a0direkte\u00a0Vergleichsstudien \u00a0gegen\u00a0\nGlatirameracetat \u00a0oder\u00a0IFN\u2010\u03b2\u00a0nach\u00a0den\u00a0heutigen\u00a0wissenschaftlichen \u00a0und\u00a0regulatorischen \u00a0Standards. \u00a0\nAzathioprin \u00a0wird\u00a0im\u00a0Zusammenhang \u00a0mit\u00a0einer\u00a0wirtschaftlichen \u00a0Verordnungsweise \u00a0in\u00a0den\u00a0\nTherapieempfehlungen \u00a0des\u00a0G\u2010BA\u00a0immer\u00a0noch\u00a0erw\u00e4hnt.\u00a0Die\u00a0Jahrestherapiekosten \u00a0liegen\u00a0f\u00fcr\u00a0dieses\u00a0\nImmunsuppressivum \u00a0nur\u00a0bei\u00a0rund\u00a01.600\u00a0Euro\u00a0(G\u2010BA,\u00a02015a).\u00a0Dort\u00a0hei\u00dft\u00a0es:\u00a0\u201eIn\u00a0einer\u00a0vergleichenden \u00a0\nDarstellung \u00a0wurde\u00a0gezeigt,\u00a0dass\u00a0f\u00fcr\u00a0das\u00a0Kriterium \u00a0Verminderung \u00a0der\u00a0Schubzahl \u00a0durch\u00a0Azathioprin \u00a0\nvergleichbare \u00a0Ergebnisse \u00a0erreicht\u00a0werden\u00a0k\u00f6nnen\u00a0wie\u00a0durch\u00a0neuere\u00a0Therapieprinzipien, \u00a0zu\u00a0denen\u00a0\nInterferon \u2010beta\u00a0und\u00a0Glatirameracetat \u00a0geh\u00f6ren.\u00a0Eine\u00a0signifikante \u00a0Verlangsamung \u00a0der\u00a0\nKrankheitsprogression \u00a0ist\u00a0f\u00fcr\u00a0Azathioprin \u00a0jedoch\u00a0nicht\u00a0belegt.\u00a0Die\u00a0Azathioprin \u2010Zielgruppe \u00a0sind\u00a0\nPatienten \u00a0mit\u00a0schubf\u00f6rmiger \u00a0Multipler \u00a0Sklerose,\u00a0wenn\u00a0eine\u00a0immunmodulatorische \u00a0Therapie\u00a0\nangezeigt \u00a0und\u00a0eine\u00a0Therapie\u00a0mit\u00a0IFN\u2010\u03b2\u00a0nicht\u00a0m\u00f6glich\u00a0ist\u00a0oder\u00a0unter\u00a0einer\u00a0bisherigen \u00a0Therapie\u00a0mit\u00a0\nAzathioprin \u00a0ein\u00a0stabiler\u00a0Verlauf\u00a0erreicht\u00a0wurde.\u00a0Der\u00a0Vorteil\u00a0einer\u00a0oralen\u00a0Anwendung \u00a0ist\u00a0gegeben.\u00a0Die\u00a0\nStartdosis \u00a0besteht\u00a0aus\u00a02,5\u00a0mg/kg\u00a0KG,\u00a0gegeben\u00a0in\u00a0zwei\u00a0oder\u00a0drei\u00a0Einzeldosen. \u00a0Die\u00a0weitere\u00a0\nTherapiesteuerung \u00a0erfolgt\u00a0nach\u00a0Vertr\u00e4glichkeit \u00a0und\u00a0insbesondere \u00a0den\u00a0h\u00e4matologischen \u00a0Kriterien. \u00a0Der\u00a0\nNutzen\u00a0einer\u00a0Kombinationstherapie \u00a0von\u00a0Azathioprin \u00a0mit\u00a0Interferon \u2010beta\u00a01\u00a0ist\u00a0nicht\u00a0belegt\u00a0und\u00a0\nGegenstand \u00a0der\u00a0klinischen \u00a0Forschung\u201c \u00a0(G\u2010BA,\u00a02015a).\u00a0\nDie\u00a0Deutsche \u00a0Gesellschaft \u00a0f\u00fcr\u00a0Neurologie \u00a0(DGN)\u00a0nennt\u00a0Azathioprin \u00a0in\u00a0ihrer\u00a02014\u00a0\u00fcberarbeiteten \u00a0\nLeitlinie\u00a0entsprechend \u00a0seiner\u00a0Zulassung \u00a0als\u00a0Mittel\u00a0der\u00a0Reserve,\u00a0wenn\u00a0eine\u00a0immunmodulatorische \u00a0\nTherapie\u00a0angezeigt \u00a0und\u00a0eine\u00a0Therapie\u00a0mit\u00a0IFN\u2010\u03b2\u00a0nicht\u00a0m\u00f6glich\u00a0ist\u00a0oder\u00a0wenn\u00a0unter\u00a0der\u00a0Therapie\u00a0mit\u00a0\nAzathioprin \u00a0ein\u00a0stabiler\u00a0Verlauf\u00a0erreicht\u00a0werden\u00a0kann\u00a0(Abbildung \u00a071).\u00a0\nBei\u00a0der\u00a0Behandlung \u00a0von\u00a0TK\u2010Versicherten \u00a0mit\u00a0MS\u00a0wird\u00a0Azathioprin \u00a0besonders \u00a0h\u00e4ufig\u00a0bei\u00a0\u00e4lteren\u00a0\nMenschen \u00a0ab\u00a0dem\u00a045.\u00a0Lebensjahr \u00a0eingesetzt \u00a0(Abbildung \u00a072).\u00a0Offensichtlich \u00a0handelt\u00a0es\u00a0sich\u00a0hierbei\u00a0\num\u00a0diejenigen \u00a0Patienten, \u00a0bei\u00a0denen\u00a0unter\u00a0Azathioprin \u00a0eine\u00a0stabile\u00a0Behandlungssituation \u00a0erreicht\u00a0\nwerden\u00a0konnte\u00a0und\u00a0die\u00a0daher\u00a0weiter\u00a0mit\u00a0diesem\u00a0Medikament \u00a0behandelt \u00a0werden.\u00a0\u00a0\n \u00a0 \n128\u00a0 \n \nInnovationsreport 2015 \u00a0\n\u00a0\nQuelle:\u00a0DGN\u00a0(2014)\u00a0\nCIS\u00a0=\u00a0Clinically\u00a0Isolated\u00a0Syndrome \u00a0(klinisch\u00a0isoliertes\u00a0Syndrom), \u00a0dabei\u00a0kann\u00a0es\u00a0sich\u00a0um\u00a0das\u00a0Anfangsstadium \u00a0der\u00a0MS\u00a0handeln.\u00a0Kennzeichnend \u00a0ist\u00a0die\u00a0\nBeschr\u00e4nkung \u00a0der\u00a0ersten\u00a0neurologischen \u00a0Erscheinungen \u00a0auf\u00a0ein\u00a0bestimmtes \u00a0Gebiet\u00a0(beispielsweise \u00a0auf\u00a0den\u00a0Sehnerv). \u00a0\u00a0\nSPMS\u00a0=\u00a0Sekund\u00e4r \u00a0progrediente \u00a0MS,\u00a0Verschlechterung \u00a0der\u00a0MS\u2010bedingten \u00a0Symptome \u00a0und\u00a0neurologischen \u00a0Ausfallerscheinungen. \u00a0Nachdem \u00a0anf\u00e4nglich \u00a0noch\u00a0\neinzelne\u00a0Sch\u00fcbe\u00a0auftreten \u00a0k\u00f6nnen,\u00a0nach\u00a0denen\u00a0sich\u00a0die\u00a0k\u00f6rperliche \u00a0Behinderung \u00a0etwas\u00a0zur\u00fcckbilden \u00a0kann,\u00a0kommt\u00a0es\u00a0im\u00a0weiteren\u00a0Verlauf\u00a0der\u00a0Erkrankung \u00a0zu\u00a0\neinem\u00a0dauerhaften \u00a0Fortschreiten \u00a0der\u00a0Erkrankung \u00a0ohne\u00a0Perioden\u00a0der\u00a0Remission. \u00a0\u00a0\nBei\u00a0Versagen \u00a0einer\u00a0verlaufsmodifizierenden \u00a0Therapie\u00a0bei\u00a0milder/moderater \u00a0Verlaufsform \u00a0einer\u00a0MS\u00a0werden\u00a0diese\u00a0Patienten \u00a0wie\u00a0eine\u00a0aktive\u00a0MS\u00a0behandelt. \u00a0\n1Substanzen \u00a0in\u00a0alphabetischer \u00a0Reihenfolge; \u00a0die\u00a0hier\u00a0gew\u00e4hlte\u00a0Darstellung \u00a0impliziert \u00a0KEINE\u00a0\u00dcberlegenheit \u00a0einer\u00a0Substanz\u00a0gegen\u00fcber \u00a0einer\u00a0anderen\u00a0innerhalb \u00a0\neiner\u00a0Indikationsgruppe \u00a0(dargestellt \u00a0innerhalb \u00a0eines\u00a0Kastens).\u00a02Zugelassen \u00a0wenn\u00a0IFN\u2010\u03b2\u00a0nicht\u00a0m\u00f6glich\u00a0oder\u00a0unter\u00a0Azathioprin \u2010Therapie\u00a0stabiler\u00a0Verlauf\u00a0erreicht.\u00a0\n3Einsatz\u00a0nur\u00a0postpartal \u00a0im\u00a0Einzelfall\u00a0gerechtfertigt, \u00a0insbesondere \u00a0vor\u00a0dem\u00a0Hintergrund \u00a0fehlender \u00a0Behandlungsalternativen. \u00a04Zugelassen \u00a0f\u00fcr\u00a0bedrohlich \u00a0\nverlaufende \u00a0Autoimmunerkrankungen, \u00a0somit\u00a0lediglich\u00a0nur\u00a0f\u00fcr\u00a0fulminante \u00a0F\u00e4lle\u00a0als\u00a0Ausweichtherapie \u00a0vorzusehen, \u00a0idealerweise \u00a0nur\u00a0an\u00a0ausgewiesenen \u00a0MS\u2010\nZentren.\u00a0\nAbbildung \u00a071:\u00a0Stufentherapie \u00a0der\u00a0Multiplen \u00a0Sklerose\u00a0\n \u00a0\n \n129\u00a0\n \nInnovationsreport 2015 \u00a0\n\u00a0\nAbbildung \u00a072:\u00a0Ausgaben \u00a0und\u00a0verordnete \u00a0Packungen \u00a0von\u00a0Azathioprin \u00a0nach\u00a0Alter\u00a0der\u00a0TK\u2010Versicherten \u00a0mit\u00a0ei\u2010\nner\u00a0MS\u2010Diagnose \u00a0im\u00a0Jahr\u00a02013\u00a0\n\u00a0\nDie\u00a0Anzahl\u00a0der\u00a0Versicherten, \u00a0die\u00a0mit\u00a0Azathioprin \u00a0behandelt \u00a0werden,\u00a0liegt\u00a0deutlich\u00a0niedriger\u00a0als\u00a0die\u00a0\nder\u00a0Fingolimod \u2010Patienten, \u00a0und\u00a0auch\u00a0hier,\u00a0wie\u00a0insgesamt \u00a0bei\u00a0MS,\u00a0sind\u00a0die\u00a0Frauen\u00a0in\u00a0der\u00a0\u00dcberzahl\u00a0\n(Tabelle\u00a014).\u00a0\n\u00a0\nWirkstoff \u00a0 Anzahl\u00a0Patienten \u00a02012\u00a0 Anzahl\u00a0Patienten \u00a02013\u00a0Anzahl\u00a0Patienten \u00a0\n1.\u00a0und\u00a02.\u00a0Quartal\u00a02014\u00a0\n\u00a0\nAzathioprin \u00a0\n\u00a0335\u00a0\u2640\u00a0+\u00a0157\u00a0\u2642\u00a0=\u00a0492\u00a0 332\u00a0\u2640 +\u00a0173\u00a0\u2642=\u00a0\u00a0\u00a0\u00a0505\u00a0 278\u00a0\u2640 +\u00a0140\u00a0\u2642\u00a0=\u00a0\u00a0\u00a0\u00a0418\u00a0\n\u00a0\nFingolimod \u00a0\n\u00a0595\u00a0\u2640+\u00a0236\u00a0\u2642\u00a0=\u00a0831\u00a0 936\u00a0\u2640 +\u00a0395\u00a0\u2642\u00a0=\u00a01.331\u00a0 959\u00a0\u2640 +\u00a0412\u00a0\u2642\u00a0=\u00a01.371\u00a0\nTabelle\u00a014:\u00a0Verteilung \u00a0und\u00a0Anzahl\u00a0der\u00a0MS\u2010Patientinnen \u00a0und\u00a0Patienten \u00a0auf\u00a0die\u00a0Wirkstoffe \u00a0Azathioprin \u00a0und\u00a0\nFingolimod \u00a0auf\u00a0Basis\u00a0von\u00a0TK\u2010Routinedaten \u00a0\n\u00a0\nEntsprechend \u00a0geschlechtsunterschiedlich \u00a0fallen\u00a0auch\u00a0die\u00a0verordneten \u00a0Packungsmengen \u00a0von\u00a0Azathi\u2010\noprin\u2010haltigen\u00a0Arzneimitteln \u00a0aus\u00a0(vorzugsweise \u00a0Imurek\u00ae,\u00a0weil\u00a0dieses\u00a0Mittel\u00a0f\u00fcr\u00a0die\u00a0Anwendung \u00a0bei\u00a0\nMS\u00a0zugelassen \u00a0ist)\u00a0(Abbildung \u00a073).\u00a0\n \u00a0\n \n130\u00a0\n \n \nInnovationsreport 2015 \u00a0\n\u00a0\nAbbildung \u00a073:\u00a0Verordnete \u00a0Packungen \u00a0von\u00a0Azathioprin \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0im\u00a0Jahr\u00a02013\u00a0\n\u00a0\nAn\u00a0der\u00a0Versorgung \u00a0von\u00a0MS\u2010Patienten, \u00a0die\u00a0mit\u00a0Azathioprin \u00a0behandelt \u00a0werden,\u00a0sind\u00a0weit\u00a0mehr\u00a0\nArztgruppen \u00a0beteiligt\u00a0als\u00a0bei\u00a0den\u00a0mit\u00a0Fingolimod \u00a0behandelten \u00a0MS\u2010Patienten. \u00a0Zwar\u00a0dominieren \u00a0auch\u00a0\nhier\u00a0die\u00a0Neurologen, \u00a0Azathioprin \u00a0wird\u00a0aber\u00a0an\u00a0weitaus\u00a0mehr\u00a0Patienten \u00a0von\u00a0Fach\u00e4rzten \u00a0f\u00fcr\u00a0\nAllgemeinmedizin \u00a0und\u00a0Innere\u00a0Medizin\u00a0verordnet. \u00a0Dies\u00a0hat\u00a0m\u00f6glicherweise \u00a0damit\u00a0zu\u00a0tun,\u00a0dass\u00a0\nAzathioprin \u00a0nicht\u00a0nur\u00a0bei\u00a0den\u00a0hochaktiven \u00a0Verlaufsformen, \u00a0sondern\u00a0auch\u00a0bei\u00a0milden\u00a0oder\u00a0moderaten \u00a0\nAuspr\u00e4gungen \u00a0der\u00a0MS\u00a0eingesetzt \u00a0werden\u00a0kann.\u00a0Au\u00dferdem \u00a0sind\u00a0hierunter \u00a0Patienten \u00a0zu\u00a0vermuten, \u00a0die\u00a0\nAzathioprin \u00a0schon\u00a0seit\u00a0Jahren\u00a0einnehmen \u00a0und\u00a0deren\u00a0Verordnungen \u00a0nicht\u00a0jedes\u00a0Mal\u00a0durch\u00a0einen\u00a0\nNeurologen \u00a0get\u00e4tigt\u00a0werden.\u00a0Hinzu\u00a0kommt\u00a0die\u00a0Tatsache\u00a0der\u00a0Budgeteinschr\u00e4nkungen \u00a0f\u00fcr\u00a0teure\u00a0\nImmunmodulatoren, \u00a0wohingegen \u00a0das\u00a0seit\u00a0langem\u00a0bekannte \u00a0Azathioprin \u00a0f\u00fcr\u00a0viele\u00a0Indikationen \u00a0\neingesetzt \u00a0wird\u00a0und\u00a0das\u00a0Budget\u00a0weniger\u00a0belastet\u00a0(Abbildung \u00a074).\u00a0\nNeurologen, \u00a0Fach\u00e4rzte \u00a0f\u00fcr\u00a0Allgemeinmedizin \u00a0und\u00a0Innere\u00a0Medizin\u00a0verordnen \u00a0insgesamt \u00a0die\u00a0meisten\u00a0\nPackungen \u00a0mit\u00a0Azathioprin \u2010haltigen\u00a0Arzneimitteln, \u00a0sowohl\u00a0im\u00a0Jahre\u00a02012\u00a0als\u00a0auch\u00a0im\u00a0Jahre\u00a02013.\u00a0Da\u00a0\ndie\u00a0Anzahl\u00a0der\u00a0TK\u2010versicherten \u00a0MS\u2010Patienten, \u00a0die\u00a0mit\u00a0Azathioprin \u00a0behandelt \u00a0wurden,\u00a0von\u00a0492\u00a0im\u00a0\nJahre\u00a02012\u00a0auf\u00a0505\u00a0im\u00a0Jahre\u00a02013\u00a0leicht\u00a0anstieg,\u00a0steigen\u00a0auch\u00a0die\u00a0verordneten \u00a0Mengen\u00a0und\u00a0die\u00a0\nentsprechenden \u00a0Ausgaben \u00a0leicht\u00a0an\u00a0(Abbildung \u00a075,\u00a0Abbildung \u00a076).\u00a0\u00a0\n \n131\u00a0\n \nInnovationsreport 2015 \u00a0\n\u00a0\nAbbildung \u00a074:\u00a0Anzahl\u00a0der\u00a0MS\u2010Patientinnen \u00a0und\u00a0Patienten \u00a0mit\u00a0Verordnung \u00a0von\u00a0Azathioprin \u00a0nach\u00a0Arztgruppen \u00a0\n\u00a0\n\u00a0\nAbbildung \u00a075:\u00a0Packungsverordnung \u00a0von\u00a0Azathioprin \u00a0nach\u00a0Arztgruppen \u00a0bei\u00a0der\u00a0Diagnose \u00a0MS\u00a0in\u00a0den\u00a0Jahren\u00a0\n2012\u00a0und\u00a02013\u00a0\u00a0 \u00a0\n \n132\u00a0\n \n \nInnovationsreport 2015 \u00a0\n\u00a0\nAbbildung \u00a076:\u00a0Ums\u00e4tze\u00a0von\u00a0Azathioprin \u00a0nach\u00a0Arztgruppen \u00a0in\u00a0den\u00a0Jahren\u00a02012\u00a0und\u00a02013\u00a0\n\u00a0\nAzathioprin \u00a0und\u00a0Fingolimod \u00a0sind\u00a0in\u00a0den\u00a0therapeutischen \u00a0M\u00f6glichkeiten \u00a0zur\u00a0Behandlung \u00a0von\u00a0MS\u00a0als\u00a0\nhistorische \u00a0Eckpunkte \u00a0anzusehen. \u00a0Bis\u00a0zum\u00a0Jahr\u00a01995\u00a0war\u00a0Azathioprin \u00a0zusammen \u00a0mit\u00a0\nGlukokortikoidsteroiden \u00a0der\u00a0gebr\u00e4uchliche \u00a0Wirkstoff, \u00a0danach\u00a0folgte\u00a0die\u00a0Zeit\u00a0der\u00a0Beta\u2010Interferone, \u00a0mit\u00a0\ndenen\u00a0ein\u00a0h\u00f6herer\u00a0Nutzen\u00a0f\u00fcr\u00a0die\u00a0MS\u2010Patienten \u00a0verbunden \u00a0war.\u00a0Das\u00a0gleiche\u00a0galt\u00a0f\u00fcr\u00a0Glatirameracetat \u00a0\n(Copaxone\u00ae), \u00a0das\u00a0erstmals\u00a02004\u00a0auf\u00a0dem\u00a0Markt\u00a0angeboten \u00a0wurde\u00a0und\u00a0nach\u00a0wie\u00a0vor\u00a0zu\u00a0den\u00a0meist\u00a0\nverordneten \u00a0Mitteln\u00a0zur\u00a0Behandlung \u00a0der\u00a0MS\u00a0geh\u00f6rt.\u00a0Natalizumab \u00a0(Tysabri\u00ae), \u00a0ein\u00a0monoklonaler \u00a0\nAntik\u00f6rper, \u00a0erweiterte \u00a0im\u00a0Jahre\u00a02006\u00a0das\u00a0Spektrum \u00a0der\u00a0MS\u2010Arzneimittel, \u00a0erhielt\u00a0aber\u00a0wegen\u00a0des\u00a0\nRisikos\u00a0der\u00a0Entwicklung \u00a0einer\u00a0progressiven \u00a0multifokalen \u00a0Leukenzephalopathie \u00a0(PML)\u00a0\u2013\u00a0einer\u00a0\nViruserkrankung, \u00a0die\u00a0t\u00f6dlich\u00a0enden\u00a0kann\u00a0\u2013\u00a0und\u00a0wegen\u00a0anderer\u00a0problematischer \u00a0Nebenwirkungen \u00a0\neine\u00a0relativ\u00a0enge\u00a0Indikation. \u00a0Das\u00a0Mittel\u00a0soll\u00a0nur\u00a0dann\u00a0eingesetzt \u00a0werden,\u00a0wenn\u00a0sich\u00a0nach\u00a0zw\u00f6lf\u00a0\nMonaten\u00a0einer\u00a0Behandlung \u00a0mit\u00a0IFN\u2010\u03b2\u00a0oder\u00a0Glatirameracetat \u00a0ein\u00a0unzureichendes \u00a0Therapieergebnis \u00a0\nzeigt.\u00a0Bei\u00a0bestimmten \u00a0Patienten \u00a0k\u00f6nnen\u00a0sich\u00a0mit\u00a0diesem\u00a0monoklonalen \u00a0Antik\u00f6rper \u00a0Vorteile\u00a0sowohl\u00a0in\u00a0\nder\u00a0Verringerung \u00a0der\u00a0Schubrate \u00a0als\u00a0auch\u00a0in\u00a0der\u00a0Lebensqualit\u00e4t \u00a0ohne\u00a0Schubrate \u00a0ergeben\u00a0\u2013\u00a0dies\u00a0gilt\u00a0\ninsbesondere \u00a0f\u00fcr\u00a0die\u00a0Eskalationstherapie. \u00a0IFN\u2010\u03b2\u00a0und\u00a0Glatirameracetat \u00a0bleiben\u00a0also\u00a0nach\u00a0wie\u00a0vor\u00a0die\u00a0\nzweckm\u00e4\u00dfige \u00a0Vergleichstherapie \u00a0f\u00fcr\u00a0alle\u00a0neuen\u00a0MS\u2010Mittel,\u00a0die\u00a0auf\u00a0den\u00a0Markt\u00a0kommen, \u00a0auch\u00a0z.B.\u00a0in\u00a0\nBezug\u00a0auf\u00a0das\u00a0Pr\u00e4parat\u00a0Tecfidera\u00ae \u00a0mit\u00a0dem\u00a0Wirkstoff \u00a0Dimethylfumarat. \u00a0Dies\u00a0wird\u00a0seit\u00a02014\u00a0auf\u00a0dem\u00a0\nMarkt\u00a0angeboten \u00a0und\u00a0erzielte\u00a0schon\u00a0im\u00a0ersten\u00a0Jahr\u00a0der\u00a0Vermarktung \u00a0au\u00dfergew\u00f6hnlich \u00a0hohe\u00a0\nUmsatzanteile. \u00a0\nDer\u00a0Wirkstoff \u00a0Fingolimod \u00a0(Gilenya\u00ae) \u00a0ist\u00a0nun\u00a0in\u00a0\u00e4hnlicher \u00a0Indikation \u00a0wie\u00a0Natalizumab \u00a0(Tysabri\u00ae) \u00a0seit\u00a0\n2011\u00a0auf\u00a0dem\u00a0Markt.\u00a0F\u00fcr\u00a0beide\u00a0Mittel\u00a0sind\u00a0aktuelle\u00a0Sicherheitshinweise \u00a0nach\u00a0der\u00a0Marktzulassung \u00a0\npubliziert \u00a0worden.\u00a0Bei\u00a0der\u00a0Einnahme \u00a0von\u00a0Fingolimod \u00a0wurde\u00a0neben\u00a0der\u00a0vor\u00fcbergehenden \u00a0Abnahme \u00a0\nder\u00a0Herzfrequenz \u00a0und\u00a0klinisch\u00a0relevanten \u00a0Herzrhythmusst\u00f6rungen \u00a0infolge\u00a0Verz\u00f6gerung \u00a0der\u00a0AV\u2010\n\u00dcberleitung \u00a0im\u00a0Jahr\u00a02015\u00a0auch\u00a0vor\u00a0in\u00a0Einzelf\u00e4llen \u00a0auftretender \u00a0PML\u00a0gewarnt.\u00a0\u00a0\n \n133\u00a0\n \nInnovationsreport 2015 \u00a0In\u00a0der\u00a0GKV\u00a0sind\u00a0im\u00a0Jahr\u00a02013\u00a0im\u00a0Zusammenhang \u00a0mit\u00a0der\u00a0Verordnung \u00a0bei\u00a0MS\u00a0f\u00fcr\u00a0die\u00a0in\u00a0Tabelle\u00a015\u00a0\ngenannten \u00a0Wirkstoffe \u00a0folgende\u00a0Mengen\u00a0und\u00a0Ausgaben \u00a0zustande\u00a0gekommen. \u00a0\u00a0\n\u00a0\nWirkstoffe \u00a0 DDD\u00a0in\u00a0Mio.\u00a0\u00c4nderung \u00a0in\u00a0Prozent\ngegen\u00fcber \u00a02012\u00a0DDD\u2010Nettokosten \u00a0in\u00a0Euro\u00a0\nIFN\u2010\u03b2\u00a0 13,8\u00a0 +0,3% 54,27\u00a0\nGlatirameracetat \u00a0 5,8\u00a0 +1,8% 45,94\u00a0\nNatalizumab \u00a0 1,8\u00a0 +6,8% 68,68\u00a0\nFingolimod \u00a0 2,2\u00a0 +60,5 % 64,02\u00a0\nQuelle:\u00a0Schwabe\u00a0&\u00a0Paffrath\u00a0(2014),\u00a0S.\u00a0795\u00a0\n*\u00a0Azathioprin \u00a0findet\u00a0aufgrund\u00a0unterschiedlicher \u00a0Indikationsstellungen \u00a0keine\u00a0Ber\u00fccksichtigung \u00a0in\u00a0dieser\u00a0Tabelle\u00a0\nTabelle\u00a015:\u00a0Verordnungen \u00a0und\u00a0Ums\u00e4tze\u00a0von\u00a0MS\u2010Arzneimitteln \u00a0in\u00a0der\u00a0GKV\u00a0im\u00a0Jahr\u00a02013\u00a0\u00a0\n\u00a0\nDass\u00a0daneben\u00a0auch\u00a0noch\u00a0andere\u00a0Arzneimittel \u00a0(z.B.\u00a0Glukokortikoidsteroide) \u00a0verordnet \u00a0werden\u00a0oder\u00a0\nviele\u00a0Patienten \u00a0auch\u00a0\u00fcber\u00a0l\u00e4ngere\u00a0Zeitr\u00e4ume \u00a0gar\u00a0keine\u00a0Arzneimittel \u00a0einnehmen, \u00a0muss\u00a0vermutet \u00a0wer\u2010\nden.\u00a0Tabelle\u00a015\u00a0zeigt\u00a0aber\u00a0nachdr\u00fccklich \u00a0die\u00a0Kostensteigerungen, \u00a0die\u00a0die\u00a0Behandlung \u00a0der\u00a0MS\u00a0inner\u2010\nhalb\u00a0eines\u00a0Jahres\u00a0erfahren\u00a0hat.\u00a0Die\u00a0Ausgaben \u00a0in\u00a0der\u00a0GKV\u00a0betragen\u00a0aktuell\u00a0deutlich\u00a0\u00fcber\u00a01,5\u00a0Mrd.\u00a0Eu\u2010\nro.\u00a0Ob\u00a0diese\u00a0Kostenzuw\u00e4chse \u00a0auch\u00a0zu\u00a0einem\u00a0entsprechenden \u00a0Zuwachs\u00a0im\u00a0Nutzen\u00a0gef\u00fchrt\u00a0und\u00a0welche\u00a0\nNebenwirkungen \u00a0zu\u00a0einer\u00a0zus\u00e4tzlichen \u00a0Belastung \u00a0von\u00a0MS\u2010\u00a0Patienten \u00a0gef\u00fchrt\u00a0haben,\u00a0sollte\u00a0genauer\u00a0\nuntersucht \u00a0werden.\u00a0\n\u00a0\u00a0 \n134\u00a0 \n \nInnovationsreport 2015 \u00a0 8 Arzneimittel \u00a0zur\u00a0Behandlung \u00a0onkologischer \u00a0Erkrankungen \u00a0in\u00a0Deutschland \u00a0\u2013\u00a0\nBesteht\u00a0eine\u00a0Korrelation \u00a0zwischen \u00a0stetig\u00a0wachsenden \u00a0Ums\u00e4tzen \u00a0und\u00a0Nutzen?\u00a0\nGerd\u00a0Glaeske\u00a0\nATC\u2010\nCode\u00a0Bezeichnung \u00a0Industrieumsatz \u00a0in\u00a0Tsd.\u00a0\u20ac\n(Anteil\u00a0in\u00a0Prozent\u00a0vom\u00a0\nGesamtumsatz \u00a0und\u00a0Ver\u00e4nderung \u00a0\nin\u00a0Prozent\u00a0gegen\u00fcber \u00a02013)\u00a0Packungsabsatz \u00a0in\u00a0Tsd.\u00a0\n(Anteil\u00a0in\u00a0Prozent\u00a0vom\u00a0\nGesamtabsatz \u00a0und\u00a0\nVer\u00e4nderung \u00a0in\u00a0Prozent\u00a0\ngegen\u00fcber \u00a02013)\u00a0\nL\u00a0 Antineoplastika \u00a0und\u00a0Immunmodulatoren \u00a05.942.190\n20,3%\u00a0(+\u00a05%)\u00a07.129\n0,5%\u00a0(\u2010\u00a01%)\u00a0\nL1\u00a0 Antineoplastika \u00a01.640.436\n5,6%\u00a0(+\u00a03%)\u00a01.957\n0,1%\u00a0(\u2010\u00a04%)\u00a0\nL2\u00a0 Cytostatische \u00a0Hormone \u00a0653.353\n2,2%\u00a0(+\u00a04%)\u00a01.912\n0,1%\u00a0(+\u00a02%)\u00a0\nL3\u00a0 Immunstimulantien \u00a01.088.465\n3,7%\u00a0(\u2010\u00a07%)\u00a0641\n0,0%\u00a0(\u2010\u00a017%)\u00a0\nL4\u00a0 Immunsuppressiva \u00a02.559.936\n8,8%\u00a0(+\u00a014%)\u00a02.620\n0,2%\u00a0(+\u00a03%)\u00a0\nN\u00a0 Nervensystem \u00a04.528.095 \u00a0\n15,5%\u00a0(+\u00a03%)\u00a0268.957\n17,8%\u00a0(0%)\u00a0\nA\u00a0 Verdauungstrakt \u00a0und\u00a0Stoffwechsel \u00a03.483.872\n11,9%\u00a0(+\u00a01%)\u00a0228.671\n15,1%\u00a0(0%)\u00a0\nJ\u00a0 Antiinfektiva, \u00a0systemisch \u00a02.893.878\n9,9%\u00a0(+\u00a023%)\u00a057.183\n3,8%\u00a0(\u2010\u00a07%)\u00a0\nC\u00a0 Cardiovaskul\u00e4res \u00a0System\u00a02.597.931 \u00a0\n8,9%\u00a0(\u2010\u00a06%)\u00a0206.313\n13,6%\u00a0(0%)\u00a0\nR\u00a0 Respirationssystem \u00a02.161.983\n7,4%\u00a0(\u2010\u00a03%)\u00a0264.509\n17,5%\u00a0(\u2010\u00a011%)\u00a0\nB\u00a0 Blut\u00a0und\u00a0blutbildende \u00a0Organe\u00a01.568.522\n5,4%\u00a0(+\u00a014%)\u00a048.795\n3,2%\u00a0(\u2010\u00a01%)\u00a0\nM\u00a0 Muskel\u2010\u00a0und\u00a0Skelettsystem \u00a01.152.635\n3,9%\u00a0(+\u00a06%)\u00a091.290\n6,0%\u00a0(\u2010\u00a01%)\u00a0\nG\u00a0 Urogenitalsystem \u00a0und\u00a0Sexualhormone \u00a01.114.921\n3,8%\u00a0(\u2010\u00a02%)\u00a061.837\u00a0\n4,1%\u00a0(0%)\u00a0\nS\u00a0 Sinnesorgane \u00a0830.854\n2,8%\u00a0(+\u00a010%)\u00a055.222\u00a0\n3,7%\u00a0(0%)\u00a0\nD\u00a0 Dermatologika \u00a0825.167\n2,8%\u00a0(+\u00a05%)\u00a0101.972\n6,7%\u00a0(\u2010\u00a01%)\u00a0\nT\u00a0 Diagnostika \u00a0655.294\n2,2%\u00a0(\u2010\u00a02%)\u00a032.358\n2,1%\u00a0(\u2010\u00a01%)\u00a0\nV\u00a0 Verschiedenes \u00a0643.799\n2,2%\u00a0(+\u00a06%)\u00a036.437\n2,4%\u00a0(+\u00a02%)\u00a0\nH\u00a0 Hormone, \u00a0systemisch \u00a0ohne\u00a0Sexualhormone \u00a0642.810\n2,2%\u00a0(+\u00a01%)\u00a042.993\n2,8%\u00a0(+\u00a03%)\u00a0\nK\u00a0 Infusionsl\u00f6sungen \u00a0145.443\n0,5%\u00a0(+\u00a08%)\u00a05.491\n0,4%\u00a0(\u2010\u00a02%)\u00a0\nP\u00a0 Parasitologie \u00a045.074\n0,2%\u00a0(+\u00a06%)\u00a03.072\n0,2%\u00a0(+\u00a012%)\u00a0\n\u00a0 Gesamt\u00a029.232.468 \u00a0\n100%\u00a0(+\u00a04%)\u00a01.512.228\n100%\u00a0(\u2010\u00a02%)\u00a0\nQuelle:\u00a0IMS\u00a0Health\u00a0(2014)\u00a0\nTabelle\u00a016:\u00a0Industrieums\u00e4tze \u00a0und\u00a0Packungsverk\u00e4ufe \u00a0in\u00a0der\u00a0ambulanten \u00a0Arzneimittelversorgung \u00a0in\u00a0\nDeutschland \u00a0im\u00a0Jahre\u00a02014\u00a0\u00a0 \n135\u00a0\n \nInnovationsreport 2015 \u00a0Die\u00a0Auflistung \u00a0von\u00a0Arzneimitteln \u00a0(Tabelle\u00a016)\u00a0zeigt\u00a0unverkennbar \u00a0die\u00a0f\u00fchrende \u00a0Rolle\u00a0von\u00a0Onkologika \u00a0\nals\u00a0umsatzst\u00e4rkste \u00a0Indikationsgruppe \u00a0des\u00a0GKV\u2010Arzneimittelmarktes. \u00a0Aufgeschl\u00fcsselt \u00a0nach\u00a0dem\u00a0ATC\u2010\nCode\u00a0zeigt\u00a0Tabelle\u00a016\u00a0die\u00a0Verteilung \u00a0der\u00a0Industrieums\u00e4tze \u00a0im\u00a0Jahre\u00a02014.\u00a0Insgesamt \u00a0entfielen\u00a0\ndemnach \u00a020\u00a0Prozent\u00a0aller\u00a0Ausgaben \u00a0in\u00a0der\u00a0Arzneimittelversorgung \u00a0auf\u00a0Arzneimittel, \u00a0die\u00a0f\u00fcr\u00a0die\u00a0\nBehandlung \u00a0von\u00a0onkologischen \u00a0Patienten \u00a0eingesetzt \u00a0werden.\u00a0Bereits\u00a02013\u00a0lagen\u00a0die\u00a0Bruttokosten \u00a0f\u00fcr\u00a0\nOnkologika \u00a0\u2013\u00a0Fertigarzneimittel \u00a0und\u00a0Rezepturarzneimittel \u00a0zusammengefasst \u00a0\u2013\u00a0bei\u00a04.406,9\u00a0Mio.\u00a0Euro\u00a0\n(ohne\u00a0Immunsuppressiva). \u00a0Monoklonale \u00a0Antik\u00f6rper \u00a0waren\u00a0dabei\u00a0die\u00a0umsatzst\u00e4rksten \u00a0Onkologika \u00a0\n(Schwabe \u00a0&\u00a0Paffrath,\u00a02014).\u00a0\nIm\u00a0Jahre\u00a02012\u00a0wurden\u00a023\u00a0Arzneimittel \u00a0neu\u00a0in\u00a0den\u00a0Markt\u00a0eingef\u00fchrt. \u00a0Davon\u00a0werden\u00a0neun\u00a0im\u00a0Bereich\u00a0\nonkologischer \u00a0Erkrankungen \u00a0eingesetzt \u00a0(Tabelle\u00a017).\u00a0Unter\u00a0den\u00a0neu\u00a0zugelassenen \u00a0Arzneimitteln \u00a0\nnehmen\u00a0Onkologika \u00a0schon\u00a0seit\u00a0Jahren\u00a0eine\u00a0f\u00fchrende \u00a0Rolle\u00a0ein.\u00a0So\u00a0wurden\u00a0etwa\u00a025\u201030\u00a0Prozent\u00a0der\u00a0in\u00a0\nden\u00a0vergangenen \u00a0Jahren\u00a0neu\u00a0zugelassenen \u00a0Arzneimittel \u00a0\u2013\u00a0oft\u00a0als\u00a0Orphan\u00a0Drugs\u00a0und\u00a0in\u00a0beschleunigten \u00a0\nVerfahren \u00a0\u2013\u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0solider\u00a0Tumoren\u00a0bzw.\u00a0h\u00e4matologischer \u00a0Neoplasien \u00a0entwickelt \u00a0\n(Ludwig,\u00a02015).\u00a0Derzeit\u00a0sind\u00a0gut\u00a0ein\u00a0Drittel\u00a0der\u00a0sich\u00a0in\u00a0Forschung \u00a0und\u00a0Entwicklung \u00a0befindenden \u00a0\nWirkstoffe \u00a0f\u00fcr\u00a0onkologische \u00a0Erkrankungen \u00a0vorgesehen, \u00a0so\u00a0dass\u00a0in\u00a0Deutschland \u00a0bis\u00a0zum\u00a0Jahr\u00a02016\u00a0die\u00a0\nZulassung \u00a0von\u00a020\u00a0neuen\u00a0onkologischen \u00a0Arzneimitteln \u00a0erwartet\u00a0wird\u00a0(Ludwig,\u00a02015).\u00a0\n\u00a0\nIndikation \u00a0 ICD\u00a0 Wirkstoff/Handelsname \u00a0\nZweitlinien \u2010Therapie\u00a0des\u00a0\nfortgeschrittenen \u00a0\nNierenzellkarzinoms \u00a0B\u00f6sartige \u00a0Neubildungen \u00a0Axitinib\u00a0\nInlyta\u00ae\u00a0\nRezidiviertes \u00a0oder\u00a0refrakt\u00e4res \u00a0\nCD30+\u00a0Hodgkin\u2010Lymphom \u00a0B\u00f6sartige \u00a0Neubildungen \u00a0Brentuximabvedotin \u00a0\nAdcetris\u00ae \u00a0\nALK\u2010positives, \u00a0fortgeschrittenes \u00a0\nnicht\u2010kleinzelliges \u00a0Lungenkarzinom \u00a0B\u00f6sartige \u00a0Neubildungen \u00a0Crizotinib \u00a0\nXalkori\u00ae\u00a0\nAkute\u00a0myeloische \u00a0Leuk\u00e4mie \u00a0 B\u00f6sartige \u00a0Neubildungen \u00a0Decitabin \u00a0\nDacogen\u00ae \u00a0\nRezidivierte \u00a0oder\u00a0therapierefrakt\u00e4re \u00a0\naggressive \u00a0Non\u2010Hodgkin\u2010B\u2010Zell\u2010\nLymphome \u00a0B\u00f6sartige \u00a0Neubildungen \u00a0Pixantron \u00a0\nPixuvri\u00ae\u00a0\nSplenomegalie \u00a0oder\u00a0Symptome \u00a0bei\u00a0\nMyelofibrose \u00a0Sonstige\u00a0Neubildungen \u00a0unsicheren \u00a0\noder\u00a0unbekannten \u00a0Verhaltens \u00a0des\u00a0\nlymphatischen, \u00a0blutbildenden \u00a0und\u00a0\nverwandten \u00a0Gewebes\u00a0Ruxolitinib \u00a0\nJakavi\u00ae\u00a0\nFortgeschrittenes \u00a0Magenkarzinom \u00a0\nin\u00a0Kombination \u00a0mit\u00a0Ciclosporin \u00a0B\u00f6sartige \u00a0Neubildungen \u00a0Tegafur+Gimeracil+Oreracil \u00a0\nTeysuno\u00ae \u00a0\nAggressives \u00a0medull\u00e4res \u00a0\nSchilddr\u00fcsenkarzinom \u00a0B\u00f6sartige \u00a0Neubildungen \u00a0Vandetanib \u00a0\nCaprelsa\u00ae \u00a0\nBRAF\u2010V600\u2010positives\u00a0metastasiertes \u00a0\nMelanom \u00a0B\u00f6sartige \u00a0Neubildungen \u00a0Vemurafenib \u00a0\u00a0\nZelboraf\u00ae \u00a0\nTabelle\u00a017:\u00a0Neu\u00a0zugelassene \u00a0Arzneimittel \u00a0zur\u00a0Behandlung \u00a0von\u00a0onkologischen \u00a0Erkrankungen \u00a0im\u00a0Jahr\u00a02012 \n136\u00a0 \n \nInnovationsreport 2015 \u00a0 8.1 Nutzen\u00fcberlegungen \u00a0am\u00a0Beispiel\u00a0Vemurafenib \u00a0\nAm\u00a0Beispiel\u00a0von\u00a0Vemurafenib \u00a0(Zelboraf\u00ae) \u00a0des\u00a0pU\u00a0Roche,\u00a0zugelassen \u00a0als\u00a0Monotherapie \u00a0zur\u00a0\nBehandlung \u00a0von\u00a0Erwachsenen \u00a0mit\u00a0BRAF\u2010V600\u2010Mutation \u2010positivem, \u00a0nicht\u2010resezierbarem \u00a0oder\u00a0\nmetastasiertem \u00a0Melanom, \u00a0soll\u00a0sowohl\u00a0die\u00a0Entwicklung \u00a0neuer\u00a0Behandlungsm\u00f6glichkeiten, \u00a0als\u00a0auch\u00a0\ndie\u00a0Kostenentwicklung \u00a0bei\u00a0den\u00a0Onkologika \u00a0n\u00e4her\u00a0dargestellt \u00a0werden.\u00a0\u00a0\nVemurafenib \u00a0ist\u00a0ein\u00a0oral\u00a0verf\u00fcgbarer, \u00a0selektiver \u00a0Inhibitor\u00a0der\u00a0BRAF\u2010Serin\u2010Threonin\u2010Kinase\u00a0und\u00a0z\u00e4hlt\u00a0\ndamit\u00a0zu\u00a0den\u00a0Kinaseinhibitoren, \u00a0die\u00a0im\u00a0K\u00f6rper\u00a0in\u00a0wichtige\u00a0Signal\u00fcbertragungswege \u00a0eingreifen. \u00a0Die\u00a0\nBRAF\u2010Serin\u2010Threonin\u2010Kinase\u00a0stimuliert \u00a0als\u00a0wichtiger \u00a0Bestandteil \u00a0des\u00a0RAS\u2010RAF\u2010Signalwegs \u00a0die\u00a0normale\u00a0\nZellteilung. \u00a0V600\u2010Mutationen \u00a0im\u00a0BRAF\u2010Serin\u2010Threonin\u2010Kinase\u00a0kodierenden \u00a0Gen\u00a0f\u00fchren\u00a0einerseits \u00a0zu\u00a0\nverst\u00e4rkter \u00a0Zellproliferation \u00a0und\u00a0andererseits \u00a0verhindern \u00a0sie\u00a0den\u00a0programmierten \u00a0Zelltod\u00a0(AMB,\u00a0\n2012).\u00a0Bei\u00a0ca.\u00a040\u201060\u00a0Prozent\u00a0der\u00a0malignen \u00a0Melanome \u00a0kommen\u00a0solche\u00a0BRAF\u2010Mutationen \u00a0vor\u00a0\n(Chapman \u00a0et\u00a0al.,\u00a02011).\u00a0\nMelanome \u00a0zeigen\u00a0sich\u00a0\u00fcberwiegend \u00a0auf\u00a0der\u00a0Haut\u00a0und\u00a0bilden\u00a0fr\u00fchzeitig \u00a0Metastasen. \u00a0Die\u00a0H\u00e4ufigkeit \u00a0\nvon\u00a0Melanomen \u00a0nimmt\u00a0aufgrund\u00a0der\u00a0steigenden \u00a0Sonnenexposition \u00a0erkennbar \u00a0zu.\u00a0So\u00a0lagen\u00a0im\u00a0Jahr\u00a0\n2008\u00a0die\u00a0Zahl\u00a0der\u00a0Neuerkrankungen \u00a0bei\u00a017.800\u00a0Personen \u00a0und\u00a0die\u00a0Zahl\u00a0der\u00a0Todesf\u00e4lle \u00a0bei\u00a02.500\u00a0(RKI\u00a0&\u00a0\nGEKID,\u00a02012).\u00a0Mittlerweile \u00a0ist\u00a0das\u00a0maligne\u00a0Melanom \u00a0auch\u00a0als\u00a0Berufskrankheit, \u00a0z.B.\u00a0bei\u00a0Dachdeckern, \u00a0\nanerkannt \u00a0worden.\u00a0\nWird\u00a0das\u00a0Melanom \u00a0in\u00a0einer\u00a0fr\u00fchen\u00a0Phase\u00a0diagnostiziert, \u00a0kann\u00a0in\u00a0den\u00a0meisten\u00a0F\u00e4llen\u00a0durch\u00a0eine\u00a0\nchirurgische \u00a0Intervention \u00a0die\u00a0Heilung\u00a0erreicht\u00a0werden,\u00a0weil\u00a0der\u00a0Tumor\u00a0in\u00a080\u201085\u00a0Prozent\u00a0zun\u00e4chst\u00a0\nlokalisiert \u00a0auftritt.\u00a0Ansonsten \u00a0standen\u00a0f\u00fcr\u00a0die\u00a0bisherige\u00a0Therapie\u00a0vor\u00a0allem\u00a0die\u00a0Zytostatika \u00a0Dacarbazin \u00a0\n(Therapiestandard, \u00a0auf\u00a0dem\u00a0Markt\u00a0seit\u00a01980)\u00a0und\u00a0Lomustin \u00a0(auf\u00a0dem\u00a0Markt\u00a0seit\u00a01998)\u00a0zur\u00a0Verf\u00fcgung. \u00a0\nF\u00fcr\u00a0beide\u00a0Wirkstoffe \u00a0konnte\u00a0allerdings \u00a0in\u00a0klinischen \u00a0Studien\u00a0nie\u00a0ein\u00a0\u00fcberzeugender \u00a0Nachweis \u00a0eines\u00a0\n\u00dcberlebensvorteils \u00a0f\u00fcr\u00a0Menschen, \u00a0die\u00a0an\u00a0dieser\u00a0aggressiven \u00a0Tumorerkrankung \u00a0litten,\u00a0gezeigt\u00a0werden.\u00a0\nIm\u00a0Jahr\u00a02011\u00a0wurde\u00a0das\u00a0Immuntherapeutikum \u00a0Ipilimumab \u00a0(Yervoy\u00ae) \u00a0eingef\u00fchrt, \u00a0mit\u00a0dem\u00a0im\u00a0\nVergleich \u00a0zu\u00a0den\u00a0bisher\u00a0\u00fcblichen\u00a0Therapien \u00a0eine\u00a0Verl\u00e4ngerung \u00a0des\u00a0Gesamt\u00fcberlebens \u00a0um\u00a0wenige\u00a0\nMonate\u00a0erreicht\u00a0werden\u00a0konnte\u00a0(Hodi\u00a0et\u00a0al.,\u00a02010).\u00a0\nEbenfalls\u00a0um\u00a0wenige\u00a0Monate\u00a0konnte\u00a0mit\u00a0Vemurafenib \u00a0in\u00a0klinischen \u00a0Studien\u00a0der\u00a0Phase\u00a0III\u00a0bei\u00a0der\u00a0\nBehandlung \u00a0von\u00a0therapienaiven \u00a0Patienten \u00a0mit\u00a0nicht\u2010resezierbarem \u00a0malignem \u00a0Melanom \u00a0eine\u00a0\nLebensverl\u00e4ngerung \u00a0gegen\u00fcber \u00a0der\u00a0Behandlung \u00a0mit\u00a0Dacarbazin \u00a0gezeigt\u00a0werden:\u00a0Die\u00a0Verl\u00e4ngerung \u00a0\ndes\u00a0Gesamt\u00fcberlebens \u00a0in\u00a0der\u00a0Erstlinientherapie \u00a0betrug\u00a03,6\u00a0Monate.\u00a0In\u00a0Bezug\u00a0auf\u00a0die\u00a0Variable\u00a0\nLebensqualit\u00e4t \u00a0unterschieden \u00a0sich\u00a0die\u00a0Behandlungsgruppen \u00a0nicht\u00a0(Robert\u00a0et\u00a0al.,\u00a02011a).\u00a0\nSeit\u00a0der\u00a0Zulassung \u00a0von\u00a0Vemurafenib \u00a0(Zelboraf\u00ae) \u00a0wird\u00a0der\u00a0patientenrelevante \u00a0Nutzen\u00a0allerdings \u00a0\nvermehrt \u00a0diskutiert, \u00a0weil\u00a0gravierende \u00a0unerw\u00fcnschte \u00a0Wirkungen \u00a0w\u00e4hrend\u00a0einer\u00a0Behandlung \u00a0auftreten \u00a0\nk\u00f6nnen.\u00a0Dazu\u00a0geh\u00f6ren\u00a0z.B.\u00a0Plattenepithelkarzinome \u00a0und\u00a0Lichtempfindlichkeitsreaktionen \u00a0(sehr\u00a0\nh\u00e4ufig),\u00a0Basalzellkarzinome \u00a0oder\u00a0L\u00e4hmungen \u00a0von\u00a0Gesichtsnerven \u00a0(h\u00e4ufig)\u00a0oder\u00a0Stevens\u2010Johnson\u2010\nSyndrom\u00a0und\u00a0periphere \u00a0Neuropathien \u00a0(gelegentlich) \u00a0(Akd\u00c4\u00a02012;\u00a0Prescrire\u00a0Int.,\u00a02012).\u00a0F\u00fcr\u00a0die\u00a0\nEntstehung \u00a0dieser\u00a0malignen \u00a0epithelialen \u00a0Tumoren\u00a0w\u00e4hrend\u00a0der\u00a0Behandlung \u00a0mit\u00a0einem\u00a0BRAF\u2010\nInhibitor\u00a0werden\u00a0Mutationen \u00a0im\u00a0HRAS\u2010Onkogen\u00a0und\u00a0eine\u00a0verst\u00e4rkte \u00a0Signaltransduktion \u00a0\u00fcber\u00a0eine\u00a0\nandere\u00a0Proteinkinase \u00a0(MAPK,\u00a0Mitogen\u2010Activated \u00a0Protein\u00a0Kinase )\u00a0verantwortlich \u00a0gemacht\u00a0(Robert\u00a0et\u00a0\nal.,\u00a02011b;\u00a0Weeraratna, \u00a02012).\u00a0\u00a0 \u00a0 \n137\u00a0\n \nInnovationsreport 2015 \u00a0Im\u00a0Beschluss \u00a0vom\u00a06.\u00a0September \u00a02012\u00a0attestierte \u00a0der\u00a0G\u2010BA\u00a0dem\u00a0Wirkstoff \u00a0Vemurafenib \u00a0trotz\u00a0der\u00a0\nHinweise\u00a0auf\u00a0solche\u00a0Nebenwirkungen \u00a0einen\u00a0Hinweis\u00a0f\u00fcr\u00a0einen\u00a0betr\u00e4chtlichen \u00a0Zusatznutzen. \u00a0Die\u00a0\nZielpopulation \u00a0wurde\u00a0mit\u00a01.400\u00a0Patienten \u00a0beziffert.\u00a0\nMit\u00a0Dabrafenib \u00a0(Tafinlar\u00ae) \u00a0kam\u00a0im\u00a0Oktober\u00a02013\u00a0ein\u00a0weiterer\u00a0Inhibitor\u00a0von\u00a0mutiertem \u00a0BRAF\u00a0in\u00a0der\u00a0\nVemurafenib \u2010Indikation \u00a0auf\u00a0den\u00a0Markt.\u00a0F\u00fcr\u00a0diesen\u00a0Wirkstoff \u00a0ver\u00f6ffentlichte \u00a0der\u00a0G\u2010BA\u00a0im\u00a0April\u00a02014\u00a0\neinen\u00a0Beschluss, \u00a0nach\u00a0dem\u00a0kein\u00a0Zusatznutzen \u00a0gegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0\nVemurafenib \u00a0belegt\u00a0ist.\u00a0Auch\u00a0die\u00a0Zeitschrift \u00a0Prescrire\u00a0Int.\u00a0urteilte\u00a0\u201eNothing\u00a0new\u201c\u00a0und\u00a0f\u00fchrte\u00a0aus,\u00a0dass\u00a0\nes\u00a0keinerlei\u00a0Vorteile\u00a0f\u00fcr\u00a0Patienten \u00a0g\u00e4be,\u00a0bei\u00a0denen\u00a0Vemurafenib \u00a0zuvor\u00a0keine\u00a0therapeutische \u00a0\nWirksamkeit \u00a0gezeigt\u00a0h\u00e4tte.\u00a0Zudem\u00a0seien\u00a0auch\u00a0die\u00a0meisten\u00a0Nebenwirkungen \u00a0f\u00fcr\u00a0beide\u00a0Wirkstoffe \u00a0\nvergleichbar \u00a0(Prescrire \u00a0Int.,\u00a02014a).\u00a0\n\u00a0\n8.2 Die\u00a0Kosten\u00a0der\u00a0Behandlung \u00a0\nDie\u00a0im\u00a0Jahr\u00a02012\u00a0f\u00fcr\u00a0Vemurafenib \u00a0publizierten \u00a0Jahrestherapiekosten \u00a0waren\u00a0betr\u00e4chtlich \u00a0und\u00a0wurden\u00a0\nmit\u00a0131.220\u00a0Euro\u00a0angegeben. \u00a0Die\u00a0Kosten\u00a0f\u00fcr\u00a0die\u00a0vom\u00a0G\u2010BA\u00a0festgelegte \u00a0zweckm\u00e4\u00dfige \u00a0\nVergleichstherapie \u00a0mit\u00a0dem\u00a0Wirkstoff \u00a0Dacarbazin \u00a0betrugen\u00a0im\u00a0ver\u00f6ffentlichten \u00a0Beschluss \u00a04.180\u00a0Euro\u00a0\n\u2013\u00a0dies\u00a0bedeutet\u00a0eine\u00a0Differenz\u00a0von\u00a0\u00fcber\u00a03.000\u00a0Prozent.\u00a0In\u00a0seinem\u00a0Beschluss \u00a0aus\u00a0dem\u00a0Jahr\u00a02014\u00a0zu\u00a0\nDabrafenib \u00a0publizierte \u00a0der\u00a0G\u2010BA\u00a0allerdings \u00a0bereits\u00a0deutlich\u00a0geringere \u00a0Jahrestherapiekosten, \u00a0da\u00a0in\u00a0der\u00a0\nZwischenzeit \u00a0ein\u00a0g\u00fcnstigerer \u00a0Erstattungsbetrag \u00a0ausgehandelt \u00a0werden\u00a0konnte:\u00a0F\u00fcr\u00a0Vemurafenib \u00a0\nwurden\u00a0Jahrestherapiekosten \u00a0von\u00a093.287\u00a0Euro\u00a0angegeben, \u00a0f\u00fcr\u00a0Dabrafenib \u00a0Jahrestherapiekosten \u00a0von\u00a0\n98.118\u00a0Euro.\u00a0Dies\u00a0ist\u00a0ein\u00a0gutes\u00a0Beispiel\u00a0daf\u00fcr,\u00a0dass\u00a0der\u00a0Preiswettbewerb \u00a0in\u00a0gleichen\u00a0\nIndikationsbereichen \u00a0mit\u00a0vergleichbaren \u00a0Arzneimitteln \u00a0nicht\u00a0immer\u00a0so\u00a0funktioniert, \u00a0wie\u00a0erhofft:\u00a0Man\u00a0\nh\u00e4tte\u00a0schlie\u00dflich \u00a0erwarten \u00a0k\u00f6nnen,\u00a0dass\u00a0f\u00fcr\u00a0ein\u00a0Me\u2010too\u2010Produkt\u00a0wie\u00a0Dabrafenib \u00a0ein\u00a0vergleichbarer \u00a0\nPreis\u00a0angeboten \u00a0werden\u00a0w\u00fcrde\u00a0wie\u00a0f\u00fcr\u00a0das\u00a0erstangebotene \u00a0Mittel\u00a0Vemurafenib. \u00a0Negative\u00a0\nKonsequenzen \u00a0der\u00a0Entwicklung \u00a0einer\u00a0Vielzahl\u00a0\u00e4hnlicher \u00a0(Me\u2010too)\u00a0und\u00a0sehr\u00a0teurer\u00a0Wirkstoffe \u00a0mit\u00a0\nh\u00e4ufig\u00a0nur\u00a0marginalem \u00a0Nutzen\u00a0in\u00a0der\u00a0Onkologie \u00a0sind\u00a0vor\u00a0allem,\u00a0dass\u00a0echte\u00a0patientenrelevante \u00a0\nInnovationen \u00a0nur\u00a0selten\u00a0entwickelt \u00a0werden\u00a0und\u00a0die\u00a0Kreativit\u00e4t \u00a0in\u00a0der\u00a0(pr\u00e4\u2010)klinischen \u00a0Forschung \u00a0\nabnimmt\u00a0(Fojo\u00a0et\u00a0al.,\u00a02014).\u00a0\nDie\u00a0Bewertungen \u00a0f\u00fcr\u00a0Zelboraf\u00ae \u00a0durch\u00a0das\u00a0IQWiG\u00a0und\u00a0das\u00a0britische\u00a0National\u00a0Institute\u00a0for\u00a0Health\u00a0and\u00a0\nCare\u00a0Excellence \u00a0(NICE)\u00a0fielen\u00a0im\u00a0Jahr\u00a02012\u00a0unterschiedlich \u00a0aus.\u00a0Zwar\u00a0haben\u00a0beide\u00a0Institutionen \u00a0die\u00a0\nBewertungen \u00a0von\u00a0Vemurafenib \u00a0auf\u00a0Basis\u00a0der\u00a0gleichen\u00a0BRIM3\u2010Publikation \u00a0vorgenommen \u00a0(siehe\u00a0\nChapman \u00a0et\u00a0al.,\u00a02011),\u00a0das\u00a0NICE\u00a0stellte\u00a0jedoch\u00a0den\u00a0\u201eWert\u201c\u00a0des\u00a0\u00dcberlebensgewinns \u00a0durchaus\u00a0in\u00a0Frage,\u00a0\nweil\u00a0viele\u00a0Patienten \u00a0im\u00a0Verlauf\u00a0der\u00a0Studie\u00a0die\u00a0antineoplastische \u00a0Medikation \u00a0gewechselt \u00a0h\u00e4tten.\u00a0\nWahrscheinlich \u00a0w\u00e4re\u00a0aber\u00a0ohne\u00a0einen\u00a0Wechsel\u00a0von\u00a0der\u00a0mit\u00a0Dacarbazin \u00a0behandelten \u00a0Kontrollgruppe \u00a0\nzur\u00a0Verum\u2010Gruppe\u00a0der\u00a0Vorteil\u00a0von\u00a0Vemurafenib \u00a0sogar\u00a0noch\u00a0h\u00f6her\u00a0ausgefallen. \u00a0Interessant \u00a0ist,\u00a0dass\u00a0\ndas\u00a0unabh\u00e4ngige \u00a0Arzneimittelbulletin \u00a0Prescrire\u00a0Int.,\u00a0das\u00a0sich\u00a0in\u00a0der\u00a0Regel\u00a0kritisch\u00a0mit\u00a0neuen\u00a0\nArzneimitteln \u00a0besch\u00e4ftigt, \u00a0seine\u00a0erste\u00a0Bewertung \u00a0aus\u00a0dem\u00a0Jahr\u00a02012\u00a0(\u201ejudgement \u00a0reserved\u201c) \u00a0im\u00a0Jahr\u00a0\n2014\u00a0revidiert\u00a0hat\u00a0und\u00a0trotz\u00a0der\u00a0auch\u00a0in\u00a0dieser\u00a0Zeitschrift \u00a0betonten, \u00a0teilweise\u00a0gravierenden \u00a0\nNebenwirkungen \u00a0Vemurafenib \u00a0jetzt\u00a0als\u00a0therapeutischen \u00a0Fortschritt \u00a0(\u201eoffers\u00a0an\u00a0advantage\u201c) \u00a0bewertet. \u00a0\nDie\u00a0Bewertung \u00a02014\u00a0wurde\u00a0mit\u00a0dem\u00a0Hinweis\u00a0erg\u00e4nzt,\u00a0dass\u00a0mit\u00a0diesem\u00a0neuen\u00a0Wirkstoff \u00a0aufgrund\u00a0der\u00a0\num\u00a0etwa\u00a0vier\u00a0Monate\u00a0verl\u00e4ngerten \u00a0Lebenszeit \u00a0gegen\u00fcber \u00a0der\u00a0Therapie\u00a0mit\u00a0Dacarbazin \u00a0ein\u00a0Vorteil\u00a0f\u00fcr\u00a0\nPatienten \u00a0mit\u00a0einem\u00a0BRAF\u2010V600\u00a0Mutation \u2010positivem, \u00a0nicht\u2010resezierbarem \u00a0oder\u00a0metastasiertem \u00a0\nMelanom \u00a0verbunden \u00a0sei.\u00a0\u00a0 \u00a0 \n138\u00a0 \n \nInnovationsreport 2015 \u00a0 8.3 Hohe\u00a0Preise\u00a0bei\u00a0geringem \u00a0Nutzen?\u00a0\nDie\u00a0rasant\u00a0steigenden \u00a0Kosten\u00a0f\u00fcr\u00a0onkologische \u00a0Wirkstoffe \u00a0durch\u00a0die\u00a0Anwendung \u00a0teilweise\u00a0\nbiotechnologisch \u00a0hergestellter \u00a0Arzneimittel \u00a0stellen\u00a0eine\u00a0Herausforderung \u00a0f\u00fcr\u00a0die\u00a0Finanzierung \u00a0durch\u00a0\ndie\u00a0gesetzlichen \u00a0Krankenkassen \u00a0dar.\u00a0Eine\u00a0Kombination \u00a0unterschiedlicher \u00a0Faktoren\u00a0f\u00fchrt\u00a0zum\u00a0Anstieg\u00a0\nder\u00a0Ausgaben: \u00a0Der\u00a0demografische \u00a0Wandel,\u00a0die\u00a0(auch\u00a0damit\u00a0einhergehende) \u00a0ansteigende \u00a0Pr\u00e4valenz \u00a0\nvon\u00a0Krebserkrankungen, \u00a0der\u00a0Anstieg\u00a0der\u00a0Anzahl\u00a0onkologischer \u00a0Arzneimittel \u00a0im\u00a0Markt\u00a0und\u00a0die\u00a0\nVerl\u00e4ngerung \u00a0der\u00a0Zeitspanne, \u00a0in\u00a0der\u00a0Patienten \u00a0erfolgreich \u00a0behandelt \u00a0werden\u00a0k\u00f6nnen.\u00a0Und\u00a0vor\u00a0allem\u00a0\nsind\u00a0es\u00a0die\u00a0Preise\u00a0f\u00fcr\u00a0die\u00a0neuen\u00a0onkologischen \u00a0\u2013\u00a0mitunter\u00a0zielgerichteten \u00a0(z.B.\u00a0Unterbrechung \u00a0von\u00a0\nSignalwegen \u00a0in\u00a0Tumorzellen) \u00a0und\u00a0zunehmend \u00a0h\u00e4ufig\u00a0mit\u00a0der\u00a0Untersuchung \u00a0(molekular)genetischer \u00a0\nBiomarker \u00a0(\u201ecompanion \u00a0diagnostics\u201c) \u00a0verkn\u00fcpften \u00a0Arzneimitteltherapien, \u00a0die\u00a0zu\u00a0den\u00a0erheblichen \u00a0\nAusgabensteigerungen \u00a0beitragen. \u00a0\u00a0\nIn\u00a0Deutschland \u00a0z\u00e4hlen\u00a0onkologische \u00a0Arzneimittel \u00a0schon\u00a0jetzt\u00a0mit\u00a04,4\u00a0Mrd.\u00a0Euro\u00a0zur\u00a0umsatzst\u00e4rksten \u00a0\nWirkstoffgruppe \u00a0im\u00a0Arzneimittelmarkt \u00a0der\u00a0gesetzlichen \u00a0Krankenversicherung, \u00a0station\u00e4r\u00a0verabreichte \u00a0\nonkologische \u00a0Arzneimittel \u00a0sind\u00a0dabei\u00a0nicht\u00a0mitgerechnet \u00a0(Ludwig\u00a0&\u00a0Schildmann, \u00a02015).\u00a0Aktuellen \u00a0\nSch\u00e4tzungen \u00a0zufolge\u00a0geht\u00a0man\u00a0f\u00fcr\u00a0das\u00a0Jahr\u00a02018\u00a0von\u00a0weltweit\u00a085\u2010115\u00a0Mrd.\u00a0US\u2010Dollar\u00a0Umsatz\u00a0von\u00a0\nonkologischen \u00a0Arzneimitteln \u00a0aus\u00a0bei\u00a0einem\u00a0j\u00e4hrlichen \u00a0Umsatzwachstum \u00a0von\u00a0sieben\u00a0bis\u00a0zehn\u00a0Prozent\u00a0\ngegen\u00fcber \u00a0dem\u00a0Jahr\u00a02014\u00a0(IMS,\u00a02014a).\u00a0\u00a0\nInnovationsgrad \u00a0bzw.\u00a0klinischer \u00a0Nutzen\u00a0stehen\u00a0jedoch\u00a0h\u00e4ufig\u00a0nicht\u00a0in\u00a0Korrelation \u00a0zu\u00a0den\u00a0Preisen,\u00a0die\u00a0\nder\u00a0pU\u00a0f\u00fcr\u00a0seine\u00a0Arzneimittel \u00a0veranschlagt. \u00a0Dies\u00a0wird\u00a0durch\u00a0eine\u00a0aktuelle\u00a0Analyse\u00a0von\u00a0\nWissenschaftlern \u00a0des\u00a0National\u00a0Cancer\u00a0Institute\u00a0in\u00a0den\u00a0USA\u00a0best\u00e4tigt\u00a0(Mailankody \u00a0&\u00a0Prasa,\u00a02015).\u00a0\nPreisgestaltungen \u00a0sind\u00a0letztendlich \u00a0auch\u00a0immer\u00a0eine\u00a0gesellschaftsrelevante \u00a0Frage.\u00a0Es\u00a0geht\u00a0oft\u00a0nicht\u00a0\nnur\u00a0um\u00a0das\u00a0evidenzbasierte \u00a0Nutzen\u2010Schaden\u2010Profil,\u00a0sondern\u00a0vielmehr\u00a0ebenso\u00a0um\u00a0den\u00a0\ngesellschaftlichen \u00a0\u201eWert\u201c\u00a0eines\u00a0Arzneimittels. \u00a0F\u00fcr\u00a0seine\u00a0Beurteilung \u00a0spielen\u00a0somit\u00a0nicht\u00a0nur\u00a0klinische\u00a0\nKontextfaktoren, \u00a0sondern\u00a0auch\u00a0die\u00a0Pr\u00e4ferenzen \u00a0und\u00a0Priorit\u00e4ten \u00a0einer\u00a0Gesellschaft \u00a0eine\u00a0\nentscheidende \u00a0Rolle\u00a0(Ludwig\u00a0&\u00a0Schildmann, \u00a02015).\u00a0So\u00a0ist\u00a0beispielsweise \u00a0mit\u00a0Vemurafenib \u00a0im\u00a0\nVergleich \u00a0zu\u00a0den\u00a0bisher\u00a0verf\u00fcgbaren \u00a0Therapieoptionen \u00a0bei\u00a0bestimmten \u00a0Formen\u00a0eines\u00a0malignen \u00a0\nMelanoms, \u00a0eine\u00a0rund\u00a0viermonatige \u00a0Verl\u00e4ngerung \u00a0des\u00a0Gesamt\u00fcberlebens \u00a0zu\u00a0erwarten. \u00a0Gegen\u00fcber \u00a0\nder\u00a0bisher\u00a0angewendeten \u00a0Behandlung \u00a0mit\u00a0Dacarbazin \u00a0mit\u00a0Jahrestherapiekosten \u00a0von\u00a0rund\u00a04.000\u00a0Euro\u00a0\nwird\u00a0nun\u00a0ein\u00a0Arzneimittel \u00a0mit\u00a0Jahrestherapiekosten \u00a0in\u00a0H\u00f6he\u00a0von\u00a0etwa\u00a0100.000\u00a0Euro\u00a0angewendet \u00a0\u2013\u00a0\neine\u00a0Heilung\u00a0ist\u00a0aber\u00a0auch\u00a0mit\u00a0diesem\u00a0Mittel\u00a0nicht\u00a0erreichbar. \u00a0Wirkstoffe \u00a0wie\u00a0Vemurafenib \u00a0und\u00a0\nDabrafenib \u00a0sind\u00a0sogenannte \u00a0\u201efirst\u2010in\u2010class\u201c\u00a0bzw.\u00a0\u201enext\u2010in\u2010class\u201c,\u00a0die\u00a0durch\u00a0ihr\u00a0Wirkprinzip \u00a0\nBehandlungsm\u00f6glichkeiten \u00a0f\u00fcr\u00a0die\u00a0Therapie\u00a0des\u00a0BRAF\u2010V600\u2010Mutation \u2010positiven\u00a0nicht\u2010resezierbaren \u00a0\noder\u00a0metastasierten \u00a0malignen \u00a0Melanoms \u00a0anbieten, \u00a0die\u00a0zuvor\u00a0so\u00a0nicht\u00a0vorhanden \u00a0waren.\u00a0F\u00fcr\u00a0die\u00a0in\u00a0\nFolge\u00a0derartiger \u00a0Entwicklungen \u00a0absehbaren \u00a0enormen\u00a0Kostensteigerungen \u00a0innerhalb \u00a0der\u00a0GKV\u00a0und\u00a0die\u00a0\ndamit\u00a0einhergehenden \u00a0zuk\u00fcnftigen \u00a0Finanzierungsprobleme \u00a0muss\u00a0nach\u00a0L\u00f6sungen \u00a0gesucht\u00a0werden,\u00a0die\u00a0\neine\u00a0wirtschaftliche \u00a0und\u00a0effiziente \u00a0Arzneimittelversorgung \u00a0(\u00a7\u00a012\u00a0SGB\u00a0V)\u00a0entsprechend \u00a0dem\u00a0aktuellen \u00a0\nStand\u00a0des\u00a0medizinischen \u00a0Wissens\u00a0gew\u00e4hrleisten, \u00a0den\u00a0medizinischen \u00a0Fortschritt \u00a0ber\u00fccksichtigen \u00a0(\u00a7\u00a02\u00a0\nSGB\u00a0V)\u00a0und\u00a0die\u00a0Humanit\u00e4t \u00a0in\u00a0der\u00a0Versorgung \u00a0wahren\u00a0(\u00a7\u00a070\u00a0SGB\u00a0V).\u00a0\nIm\u00a0Falle\u00a0der\u00a0BRAF\u2010Inhibitoren \u00a0zeigt\u00a0sich\u00a0eine\u00a0Schw\u00e4che \u00a0des\u00a0AMNOG\u2010Konzeptes, \u00a0die\u00a0sich\u00a0zugunsten \u00a0\ndes\u00a0Me\u2010too\u2010Arzneimittels \u00a0Dabrafenib \u00a0ausgewirkt \u00a0hat.\u00a0W\u00e4hrend \u00a0bei\u00a0Vemurafenib \u00a0noch\u00a0Dacarbazin, \u00a0\nein\u00a0Zytostatikum \u00a0aus\u00a0der\u00a0Gruppe\u00a0der\u00a0Alkylantien, \u00a0als\u00a0zweckm\u00e4\u00dfige \u00a0Vergleichstherapie \u00a0diente,\u00a0wurde\u00a0\nin\u00a0der\u00a0Fr\u00fchbewertung \u00a0von\u00a0Dabrafenib \u00a0das\u00a0schon\u00a0auf\u00a0dem\u00a0Markt\u00a0befindliche \u00a0und\u00a0bereits\u00a0im\u00a0AMNOG\u2010\nProzess\u00a0bewertete \u00a0Vemurafenib \u00a0festgelegt. \u00a0Da\u00a0es\u00a0keine\u00a0direkten\u00a0Vergleichsstudien \u00a0von\u00a0Dabrafenib \u00a0 \n139\u00a0\n \nInnovationsreport 2015 \u00a0und\u00a0Vemurafenib \u00a0gab,\u00a0legte\u00a0der\u00a0pU\u00a0einen\u00a0indirekten \u00a0Vergleich \u00a0der\u00a0Zulassungsstudien \u00a0von\u00a0Dabrafenib \u00a0\n(BREAK\u20103;\u00a0Hauschild \u00a0et\u00a0al.,\u00a02012)\u00a0und\u00a0Vemurafenib \u00a0(BRIM\u20103;\u00a0Chapman \u00a0et\u00a0al.,\u00a02011)\u00a0vor,\u00a0wobei\u00a0\nDacarbazin \u00a0als\u00a0Br\u00fcckenkomparator \u00a0diente.\u00a0Der\u00a0G\u2010BA\u00a0bewertete \u00a0diesen\u00a0Vergleich \u00a0als\u00a0nicht\u00a0\naussagekr\u00e4ftig, \u00a0da\u00a0in\u00a0der\u00a0BREAK\u20103\u2010Studie\u00a0die\u00a0Patienten \u00a0fr\u00fch\u00a0in\u00a0den\u00a0Dabrafenib \u2010Arm\u00a0wechseln \u00a0\nkonnten,\u00a0w\u00e4hrend\u00a0in\u00a0der\u00a0BRIM\u20103\u2010Studie\u00a0ein\u00a0Cross\u2010over\u00a0vor\u00a0dem\u00a0ersten\u00a0Datenschnitt \u00a0zw\u00f6lf\u00a0Monate\u00a0\nnach\u00a0Studienbeginn \u00a0nicht\u00a0m\u00f6glich\u00a0war.\u00a0Auch\u00a0wurden\u00a0die\u00a0Krankheitssymptome \u00a0in\u00a0beiden\u00a0Studien\u00a0mit\u00a0\nunterschiedlichen \u00a0Instrumenten \u00a0ausgewertet. \u00a0In\u00a0der\u00a0Gesamtschau \u00a0konstatierte \u00a0der\u00a0G\u2010BA\u00a0keinen\u00a0\nZusatznutzen \u00a0von\u00a0Dabrafenib \u00a0gegen\u00fcber \u00a0Vemurafenib \u00a0(G\u2010BA,\u00a02014g).\u00a0Dennoch\u00a0beanspruchte \u00a0der\u00a0pU\u00a0\nf\u00fcr\u00a0dieses\u00a0Mittel\u00a0eine\u00a0\u00e4hnliche\u00a0Preiskategorie \u00a0wie\u00a0f\u00fcr\u00a0Vemurafenib. \u00a0Das\u00a0f\u00fchrte\u00a0schlie\u00dflich \u00a0zu\u00a0dem\u00a0\nErgebnis,\u00a0dass\u00a0ein\u00a0Me\u2010too\u2010Produkt\u00a0ohne\u00a0Zusatznutzen \u00a0gegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0\nVergleichstherapie \u00a0den\u00a0gleichen\u00a0Preis\u00a0erzielen\u00a0konnte\u00a0wie\u00a0das\u00a0\u201eErstanbieter \u2010Produkt\u201c. \u00a0\u00a0\nDieser\u00a0Dabrafenib \u2010Beschluss \u00a0des\u00a0G\u2010BA\u00a0im\u00a0AMNOG\u2010Prozess\u00a0macht\u00a0eine\u00a0Reihe\u00a0von\u00a0Problemen \u00a0deutlich:\u00a0\n\uf0b7 Es\u00a0wurde\u00a0nicht\u00a0ausreichend \u00a0ber\u00fccksichtigt, \u00a0dass\u00a0Dabrafenib \u00a0in\u00a0einer\u00a0randomisierten, \u00a0aber\u00a0\nunverblindeten \u00a0Studie\u00a0in\u00a0Bezug\u00a0auf\u00a0die\u00a0Lebensverl\u00e4ngerung \u00a0nicht\u00a0effektiver \u00a0war\u00a0als\u00a0\nDacarbazin \u00a0(Prescrire \u00a0Int.,\u00a02014a).\u00a0Zwar\u00a0konnte\u00a0die\u00a0Verl\u00e4ngerung \u00a0des\u00a0\u00dcberlebens \u00a0durch\u00a0\nDabrafenib \u00a0in\u00a0der\u00a0BREAK\u20103\u2010Studie\u00a0aufgezeigt \u00a0werden,\u00a0allerdings \u00a0wurden\u00a0diese\u00a0Ergebnisse \u00a0aus\u00a0\nverschiedenen \u00a0Gr\u00fcnden\u00a0als\u00a0verzerrt\u00a0(vor\u00a0allem\u00a0wegen\u00a0des\u00a0fr\u00fchen\u00a0Cross\u2010over)\u00a0bewertet. \u00a0\nGegen\u00fcber \u00a0Dacarbazin, \u00a0das\u00a0damals\u00a0als\u00a0zweckm\u00e4\u00dfige \u00a0Vergleichstherapie \u00a0festgelegt \u00a0war,\u00a0kann\u00a0\nf\u00fcr\u00a0Dabrafenib \u00a0in\u00a0Bezug\u00a0auf\u00a0die\u00a0Gesamtsterblichkeit \u00a0kein\u00a0Zusatznutzen \u00a0festgestellt \u00a0werden\u00a0\n(G\u2010BA,\u00a02014g)\u00a0\u2013\u00a0dies\u00a0war\u00a0aber\u00a0f\u00fcr\u00a0Vemurafenib \u00a0gelungen\u00a0(G\u2010BA,\u00a02012i).\u00a0Auf\u00a0Grundlage \u00a0der\u00a0\nderzeit\u00a0vorliegenden \u00a0Daten\u00a0ist\u00a0somit\u00a0ungekl\u00e4rt, \u00a0ob\u00a0Dabrafenib \u00a0dem\u00a0urspr\u00fcnglichen \u00a0\nTherapiestandard \u00a0in\u00a0Bezug\u00a0auf\u00a0das\u00a0Gesamt\u00fcberleben \u00a0\u00fcberlegen \u00a0ist.\u00a0Ungekl\u00e4rt \u00a0ist\u00a0auch,\u00a0ob\u00a0\ndas\u00a0Mittel\u00a0dem\u00a0neuen\u00a0Therapiestandard \u00a0Vemurafenib \u00a0mindestens \u00a0ebenb\u00fcrtig \u00a0ist.\u00a0\n\uf0b7 Aus\u00a0nachvollziehbaren \u00a0Gr\u00fcnden\u00a0wurde\u00a0im\u00a0Verlauf\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung \u00a0von\u00a0\nDabrafenib \u00a0die\u00a0zweckm\u00e4\u00dfige \u00a0Vergleichstherapie \u00a0durch\u00a0den\u00a0G\u2010BA\u00a0angepasst \u00a0(IQWiG,\u00a02014a,\u00a0\nG\u2010BA,\u00a02014g).\u00a0Es\u00a0ist\u00a0dennoch\u00a0nur\u00a0schwer\u00a0nachzuvollziehen, \u00a0warum\u00a0bei\u00a0der\u00a0endg\u00fcltigen \u00a0\nBewertung \u00a0von\u00a0Dabrafenib \u00a0nicht\u00a0auch\u00a0die\u00a0Erkenntnisse \u00a0aus\u00a0dem\u00a0direkten\u00a0Vergleich \u00a0zu\u00a0\nDacarbazin \u00a0ber\u00fccksichtigt \u00a0wurden\u00a0und\u00a0auch\u00a0f\u00fcr\u00a0diese\u00a0Ebene\u00a0die\u00a0Bewertung \u00a0\u201ekein\u00a0\nZusatznutzen \u201c\u00a0getroffen \u00a0wurde.\u00a0\n\uf0b7 Es\u00a0fehlen\u00a0direkte\u00a0Vergleichsstudien \u00a0von\u00a0Vemurafenib \u00a0und\u00a0Dabrafenib. \u00a0Aus\u00a0den\u00a0bisher\u00a0\nvorliegenden \u00a0Studienergebnissen \u00a0ist\u00a0allerdings \u00a0zu\u00a0schlie\u00dfen, \u00a0dass\u00a0das\u00a0Spektrum \u00a0von\u00a0\nunerw\u00fcnschten \u00a0Wirkungen \u00a0beider\u00a0Wirkstoffe \u00a0vergleichbar \u00a0ausf\u00e4llt.\u00a0Gegen\u00fcber \u00a0Dacarbazin \u00a0ist\u00a0\nf\u00fcr\u00a0Dabrafenib \u00a0ein\u00a0gr\u00f6\u00dferer\u00a0Schaden\u00a0nicht\u00a0ausgeschlossen \u00a0(IQWiG,\u00a02013a,\u00a0\u00a0\nG\u2010BA,\u00a02014g).\u00a0\n\uf0b7 Der\u00a0Erstattungsbetrag \u00a0f\u00fcr\u00a0Dabrafenib \u00a0orientierte \u00a0sich\u00a0am\u00a0zun\u00e4chst\u00a0festgesetzten \u00a0\nErstattungsbetrag \u00a0f\u00fcr\u00a0Vemurafenib \u00a0und\u00a0lag\u00a0deutlich\u00a0niedriger. \u00a0Nachdem \u00a0der\u00a0Vemurafenib \u2010\nErstattungsbetrag \u00a0aber\u00a0im\u00a0Rahmen\u00a0von\u00a0Verhandlungen \u00a0abgesenkt \u00a0werden\u00a0konnte,\u00a0ergibt\u00a0sich\u00a0\ndie\u00a0inakzeptable \u00a0Situation, \u00a0dass\u00a0ein\u00a0Arzneimittel \u00a0ohne\u00a0Zusatznutzen \u00a0bez\u00fcglich \u00a0der\u00a0\nLebensverl\u00e4ngerung \u00a0gegen\u00fcber \u00a0dem\u00a0kosteng\u00fcnstigen \u00a0Dacarbazin \u00a0und\u00a0ohne\u00a0Zusatznutzen \u00a0\ngegen\u00fcber \u00a0dem\u00a0Wirkstoff \u00a0Vemurafenib, \u00a0das\u00a0einen\u00a0Zusatznutzen \u00a0in\u00a0der\u00a0Lebensverl\u00e4ngerung \u00a0\ngegen\u00fcber \u00a0Dacarbazin \u00a0zeigen\u00a0konnte,\u00a0sogar\u00a0mit\u00a0einem\u00a0h\u00f6heren\u00a0Erstattungsbetrag \u00a0zu\u00a0Lasten\u00a0\nder\u00a0GKV\u00a0angewendet \u00a0werden\u00a0kann.\u00a0\u00a0 \n140\u00a0 \n \nInnovationsreport 2015 \u00a0Insgesamt \u00a0wird\u00a0an\u00a0diesem\u00a0Beispiel\u00a0erkennbar, \u00a0dass\u00a0mit\u00a0den\u00a0derzeitigen \u00a0Regelungen \u00a0des\u00a0AMNOG\u2010\nProzesses \u00a0bei\u00a0der\u00a0Bewertung \u00a0von\u00a0Dabrafenib \u00a0ein\u00a0\u201eSystemversagen\u201c \u00a0zugunsten \u00a0des\u00a0pU\u00a0vorliegt\u00a0und\u00a0\ndringender \u00a0Regelungsbedarf \u00a0besteht,\u00a0um\u00a0derartige\u00a0F\u00e4lle\u00a0in\u00a0der\u00a0Zukunft\u00a0vermeiden \u00a0zu\u00a0k\u00f6nnen.\u00a0\n\u00a0\n8.4 Notwendige \u00a0Ver\u00e4nderungen \u00a0in\u00a0der\u00a0Zukunft\u00a0\nGrunds\u00e4tzlich \u00a0lassen\u00a0die\u00a0steigenden \u00a0Preise\u00a0und\u00a0Ausgaben \u00a0f\u00fcr\u00a0Arzneimittel \u00a0in\u00a0der\u00a0Onkologie, \u00a0aber\u00a0\nauch\u00a0in\u00a0anderen\u00a0Indikationen \u00a0wie\u00a0Rheumatoide \u00a0Arthritis,\u00a0Multiple\u00a0Sklerose,\u00a0Hepatitis\u00a0C\u00a0oder\u00a0\nPsoriasis, \u00a0Fragen\u00a0nach\u00a0einer\u00a0vertretbaren \u00a0Vereinbarung \u00a0eines\u00a0Erstattungsh\u00f6chstbetrages \u00a0in\u00a0der\u00a0GKV\u00a0\naufkommen. \u00a0Ver\u00e4nderungen \u00a0der\u00a0derzeitigen \u00a0Situation\u00a0scheinen\u00a0unerl\u00e4sslich. \u00a0\u00a0\nIn\u00a0Analogie\u00a0zum\u00a0GKV\u2010WSG,\u00a0in\u00a0dem\u00a0der\u00a0Gesetzgeber \u00a0mit\u00a0\u00a7\u00a031\u00a0Abs.\u00a02a\u00a0SGB\u00a0V\u00a0die\u00a0Festlegung \u00a0von\u00a0\nH\u00f6chstpreisen \u00a0f\u00fcr\u00a0Arzneimittel \u00a0eingef\u00fchrt \u00a0hat,\u00a0die\u00a0keiner\u00a0Festbetragsgruppe \u00a0zugeordnet \u00a0werden\u00a0\nk\u00f6nnen,\u00a0ist\u00a0f\u00fcr\u00a0den\u00a0Erstattungsbetrag \u00a0im\u00a0AMNOG\u2010Prozess\u00a0ebenfalls\u00a0eine\u00a0M\u00f6glichkeit \u00a0gegeben,\u00a0die\u00a0\nPreise\u00a0f\u00fcr\u00a0Arzneimittel \u00a0zu\u00a0begrenzen. \u00a0Der\u00a0Erstattungsbetrag \u00a0sollte\u00a0daher\u00a0nach\u00a0einer\u00a0tats\u00e4chlichen \u00a0\nKosten\u2010Nutzen\u2010Bewertung \u00a0durch\u00a0das\u00a0IQWiG\u00a0vorgeschlagen \u00a0und\u00a0vom\u00a0GKV\u2010Spitzenverband \u00a0mit\u00a0dem\u00a0\npU\u00a0verhandelt \u00a0werden.\u00a0\nDie\u00a0Einf\u00fchrung \u00a0von\u00a0derartigen \u00a0Erstattungsbetr\u00e4gen \u00a0sollte\u00a0darauf\u00a0abzielen,\u00a0die\u00a0Preise\u00a0neuer\u00a0und\u00a0\ninnovativer \u00a0Arzneimittel \u00a0an\u00a0ihren\u00a0tats\u00e4chlichen \u00a0therapeutischen \u00a0Innovationswert \u00a0anzupassen. \u00a0Von\u00a0\ndieser\u00a0Regelung \u00a0k\u00f6nnten\u00a0kosteneffektive \u00a0und\u00a0therapeutisch \u00a0alternativlose \u00a0Arzneimittel \u00a0\nausgenommen \u00a0werden.\u00a0Gleiches\u00a0gilt\u00a0f\u00fcr\u00a0Rabattvertr\u00e4ge, \u00a0die\u00a0nach\u00a0\u00a7\u00a0130a\u00a0(8)\u00a0SGB\u00a0V\u00a0auf\u00a0freiwilliger \u00a0\nBasis\u00a0zwischen\u00a0Krankenkassen \u00a0und\u00a0pU\u00a0abgeschlossen \u00a0werden.\u00a0Dies\u00a0bezieht\u00a0sich\u00a0sowohl\u00a0auf\u00a0\nRabattvertr\u00e4ge \u00a0f\u00fcr\u00a0Generika\u00a0als\u00a0auch\u00a0f\u00fcr\u00a0noch\u00a0patentgesch\u00fctzte \u00a0Arzneimittel. \u00a0\nMit\u00a0dem\u00a0AMNOG\u00a0wird\u00a0neben\u00a0der\u00a0Bewertung \u00a0des\u00a0Nutzens\u00a0auch\u00a0die\u00a0immer\u00a0wieder\u00a0geforderte \u00a0\nAufhebung \u00a0der\u00a0freien\u00a0Preisfestsetzung \u00a0durch\u00a0die\u00a0pU\u00a0umgesetzt. \u00a0Das\u00a0nun\u00a0eingef\u00fchrte \u00a0\nPreisfestsetzungsverfahren, \u00a0in\u00a0dem\u00a0die\u00a0pharmazeutische \u00a0Industrie\u00a0mit\u00a0dem\u00a0GKV\u2010Spitzenverband \u00a0\neinen\u00a0GKV\u2010Erstattungs(h\u00f6chst)betrag \u00a0aushandelt, \u00a0soll\u00a0die\u00a0Kosten\u00a0f\u00fcr\u00a0das\u00a0Gesundheitssystem \u00a0\nreduzieren \u00a0bzw.\u00a0die\u00a0Wirtschaftlichkeit \u00a0verbessern. \u00a0Dabei\u00a0muss\u00a0der\u00a0gesamte\u00a0Lebenszyklus \u00a0eines\u00a0\nArzneimittels \u00a0\u2013\u00a0angefangen \u00a0von\u00a0der\u00a0pr\u00e4klinischen \u00a0Forschung \u00a0bis\u00a0hin\u00a0zu\u00a0Post\u2010Zulassungsstudien \u00a0und\u00a0zu\u00a0\nDaten\u00a0aus\u00a0der\u00a0Versorgungsrealit\u00e4t \u00a0(Mengen, \u00a0Patientenpopulationen) \u00a0\u2013\u00a0ber\u00fccksichtigt \u00a0werden\u00a0\n(Ludwig\u00a0&\u00a0Schlidmann, \u00a02015).\u00a0Die\u00a0folgenden \u00a0Punkte\u00a0sollten\u00a0die\u00a0bereits\u00a0bestehenden \u00a0\nRahmenbedingungen \u00a0des\u00a0AMNOG\u00a0erg\u00e4nzen: \u00a0\n\uf0b7 Unerl\u00e4sslich \u00a0sind\u00a0erg\u00e4nzende \u00a0Regelungen \u00a0und\u00a0Verfahrensanforderungen \u00a0f\u00fcr\u00a0\n\u201eFolgebewertungen\u201c \u00a0(z.B.\u00a0aktualisierende \u00a0Bewertungen \u00a0im\u00a0Bezug\u00a0auf\u00a0erweiterte \u00a0Indikationen \u00a0\noder\u00a0neue\u00a0Patientenpopulationen) \u00a0von\u00a0solchen\u00a0Arzneimitteln, \u00a0f\u00fcr\u00a0die\u00a0in\u00a0der\u00a0AMNOG\u2010\nFr\u00fchbewertung \u00a0auf\u00a0Grund\u00a0der\u00a0vorliegenden \u00a0Studien\u00a0keine\u00a0ausreichend \u00a0sicheren\u00a0\nBeurteilungen \u00a0eines\u00a0patientenorientierten \u00a0Nutzens\u00a0nach\u00a0\u00a7\u00a035\u00a0b\u00a0SGB\u00a0V\u00a0m\u00f6glich\u00a0sind\u00a0\n(Verk\u00fcrzung \u00a0der\u00a0Krankheitsdauer, \u00a0die\u00a0Verl\u00e4ngerung \u00a0der\u00a0Lebensdauer, \u00a0die\u00a0Verringerung \u00a0der\u00a0\nNebenwirkungen \u00a0und\u00a0die\u00a0Verbesserung \u00a0der\u00a0Lebensqualit\u00e4t). \u00a0Dies\u00a0d\u00fcrfte\u00a0f\u00fcr\u00a0viele\u00a0der\u00a0zu\u00a0\nbewertenden \u00a0Arzneimittel \u00a0z.B.\u00a0aus\u00a0dem\u00a0Bereich\u00a0Onkologika, \u00a0der\u00a0Mittel\u00a0zur\u00a0Behandlung \u00a0von\u00a0\nMS,\u00a0Rheumatoider \u00a0Arthritis,\u00a0Psoriasis\u00a0u.v.a.m.\u00a0zutreffen. \u00a0W\u00e4hrend \u00a0Befristungen \u00a0der\u00a0\nBewertungsbeschl\u00fcsse \u00a0bereits\u00a0in\u00a0einigen\u00a0F\u00e4llen\u00a0vorgenommen \u00a0wurden\u00a0(z.B.\u00a0bei\u00a0Fingolimod), \u00a0\nwurde\u00a0von\u00a0dem\u00a0Instrument \u00a0der\u00a0Forderung \u00a0zur\u00a0Durchf\u00fchrung \u00a0erg\u00e4nzender \u00a0 \n141\u00a0\n \nInnovationsreport 2015 \u00a0versorgungsrelevanter \u00a0Studien\u00a0(siehe\u00a0\u00a7\u00a035\u00a0b\u00a0bzw.\u00a0\u00a7\u00a092\u00a0(2a)\u00a0SGB\u00a0V)\u00a0in\u00a0Abstimmung \u00a0mit\u00a0der\u00a0\nArzneimittelkommission \u00a0der\u00a0deutschen \u00a0\u00c4rzteschaft, \u00a0dem\u00a0Bundesinstitut \u00a0f\u00fcr\u00a0Arzneimittel \u00a0und\u00a0\nMedizinprodukte \u00a0oder\u00a0dem\u00a0Paul\u2010Ehrlich\u2010Institut\u00a0bisher\u00a0noch\u00a0kein\u00a0Gebrauch \u00a0gemacht, \u00a0obwohl\u00a0\ndies\u00a0in\u00a0vielen\u00a0F\u00e4llen\u00a0aus\u00a0Sicht\u00a0der\u00a0Patientenversorgung \u00a0dringend\u00a0erforderlich \u00a0w\u00e4re.\u00a0Diese\u00a0\nForderung \u00a0k\u00f6nnte\u00a0zudem\u00a0durch\u00a0das\u00a0IQWiG\u00a0unterst\u00fctzt \u00a0werden,\u00a0das\u00a0nach\u00a0\u00a7\u00a0139\u00a0a,\u00a0Abs.\u00a03,2\u00a0\nmit\u00a0der\u00a0Erstellung \u00a0von\u00a0wissenschaftlichen \u00a0Ausarbeitungen \u00a0zu\u00a0Fragen\u00a0der\u00a0Qualit\u00e4t\u00a0und\u00a0\nWirtschaftlichkeit \u00a0der\u00a0im\u00a0Rahmen\u00a0der\u00a0gesetzlichen \u00a0Krankenversicherung \u00a0erbrachten \u00a0\nLeistungen \u00a0unter\u00a0Ber\u00fccksichtigung \u00a0alters\u2010,\u00a0geschlechts \u2010\u00a0und\u00a0lebenslagenspezifischer \u00a0\nBesonderheiten \u00a0t\u00e4tig\u00a0werden\u00a0soll.\u00a0Solche\u00a0Daten\u00a0aus\u00a0pragmatischen \u00a0Studien\u00a0sollen\u00a0die\u00a0in\u00a0\nZulassungsstudien \u00a0gefundene \u00a0Wirksamkeit \u00a0(efficacy )\u00a0um\u00a0Daten\u00a0zum\u00a0patientenorientierten \u00a0\nNutzen\u00a0(efficacy\u00a0unter\u00a0realen\u00a0Versorgungsbedingungen \u00a0unter\u00a0Ber\u00fccksichtigung \u00a0von\u00a0patient\u2010\u00a0\nreported\u00a0outcomes \u00a0(PRO\u2019s)/ effectiveness )\u00a0erg\u00e4nzen\u00a0und\u00a0die\u00a0AMNOG\u2010Bewertungen \u00a0zugunsten \u00a0\nder\u00a0Patienten, \u00a0aber\u00a0auch\u00a0der\u00a0verordnenden \u00a0\u00c4rzte\u00a0\u201esicherer\u201c \u00a0machen.\u00a0\n\uf0b7 Basis\u00a0der\u00a0Preisverhandlung \u00a0soll\u00a0eine\u00a0Kosten\u2010Nutzen\u2010Bewertung \u00a0des\u00a0neuen\u00a0Arzneimittels \u00a0sein,\u00a0\nauch\u00a0unter\u00a0fr\u00fchzeitiger \u00a0Ber\u00fccksichtigung \u00a0von\u00a0direkten\u00a0und,\u00a0wenn\u00a0es\u00a0sinnvoll\u00a0erscheint, \u00a0\nindirekten \u00a0Krankheitskosten. \u00a0Da\u00a0die\u00a0pharmazeutischen \u00a0Unternehmen \u00a0ohne\u00a0Frage\u00a0auch\u00a0ihre\u00a0\nPreisgestaltung \u00a0an\u00a0diesen\u00a0Aspekten \u00a0orientieren \u00a0und\u00a0zu\u00a0legitimieren \u00a0versuchen, \u00a0sollte\u00a0auch\u00a0\ndie\u00a0GKV\u00a0die\u00a0Fakten\u00a0dieser\u00a0Kalkulationen \u00a0kennen.\u00a0Die\u00a0Methoden \u00a0der\u00a0Kosten\u2010Nutzen\u00a0\nBewertung \u00a0m\u00fcssen\u00a0dabei\u00a0wissenschaftlich \u00a0abgesichert \u00a0und\u00a0transparent \u00a0sein.\u00a0\nGesellschaftsethische \u00a0Implikationen \u00a0der\u00a0Kosten\u2010Nutzen\u2010Bewertung \u00a0m\u00fcssen\u00a0dabei\u00a0genauso\u00a0\nBer\u00fccksichtigung \u00a0finden\u00a0wie\u00a0patientenindividuelle \u00a0Fragestellungen. \u00a0So\u00a0sollten\u00a0auch\u00a0die\u00a0\nEmpfehlungen \u00a0der\u00a0American \u00a0Society\u00a0of\u00a0Oncology \u00a0f\u00fcr\u00a0patientenrelevante \u00a0Endpunkte \u00a0in\u00a0\nklinischen \u00a0Studien\u00a0beachtet\u00a0und\u00a0zum\u00a0Erkennen \u00a0von\u00a0ineffektiven \u00a0bzw.\u00a0nur\u00a0marginal\u00a0effektiven \u00a0\nArzneimitteln \u00a0herangezogen \u00a0werden\u00a0(Ellis\u00a0et\u00a0al.,\u00a02014).\u00a0Voraussetzung \u00a0hierf\u00fcr\u00a0ist,\u00a0dass\u00a0\nWerturteile \u00a0bei\u00a0der\u00a0Operationalisierung \u00a0des\u00a0Nutzens\u00a0onkologischer \u00a0Arzneimittel \u00a0transparent \u00a0\ngemacht\u00a0und\u00a0hinsichtlich \u00a0ihrer\u00a0ethischen \u00a0Begr\u00fcndbarkeit \u00a0analysiert \u00a0werden.\u00a0\n\uf0b7 Die\u00a0Preisfestsetzung \u00a0wird\u00a0regelm\u00e4\u00dfig \u00a0durch\u00a0Preis\u2010Volumen\u2010Abkommen \u00a0bzw.\u00a0\nmengenbezogene \u00a0Rabatte\u00a0erg\u00e4nzt,\u00a0um\u00a0zu\u00a0verhindern, \u00a0dass\u00a0bei\u00a0einem\u00a0gegebenen \u00a0Preis\u00a0der\u00a0\nUmsatz\u00a0\u00fcber\u00a0eine\u00a0Mengenausweitung \u00a0gesteigert \u00a0wird.\u00a0Daher\u00a0sollten\u00a0die\u00a0\u201eKann\u201c\u2010Regelungen \u00a0\nin\u00a0den\u00a0\u00a7\u00a0130\u00a0a,\u00a0Abs.\u00a08\u00a0und\u00a0\u00a7\u00a0130\u00a0c\u00a0durch\u00a0verpflichtende \u00a0Formulierungen \u00a0ersetzt\u00a0werden.\u00a0\nSolche\u00a0Rabattvertr\u00e4ge \u00a0k\u00f6nnen\u00a0das\u00a0Gesamtvolumen \u00a0kontrollieren \u00a0oder\u00a0aber\u00a0die\u00a0Tagesdosen \u00a0\npro\u00a0Patienten. \u00a0In\u00a0anderen\u00a0L\u00e4ndern\u00a0wurde\u00a0mit\u00a0dieser\u00a0Zusatzregelung \u00a0ein\u00a0guter\u00a0Erfolg\u00a0erzielt.\u00a0\n\uf0b7 Nicht\u00a0nur\u00a0der\u00a0Erstattungsbetrag, \u00a0sondern\u00a0auch\u00a0die\u00a0maximal\u00a0zu\u00a0erstattenden \u00a0\nJahrestherapiekosten \u00a0werden\u00a0zentral\u00a0festgelegt. \u00a0Mit\u00a0der\u00a0Festlegung \u00a0einer\u00a0H\u00f6chstgrenze \u00a0\ndieser\u00a0Ausgaben \u00a0soll\u00a0verhindert \u00a0werden,\u00a0dass\u00a0die\u00a0pharmazeutischen \u00a0Vertragspartner \u00a0\n\u201eMondpreise\u201c \u00a0fordern,\u00a0Dosierungen \u00a0und/oder \u00a0Behandlungsfrequenzen \u00a0ausweiten \u00a0und\u00a0\ndadurch\u00a0m\u00f6glicherweise \u00a0Zusatzbeitr\u00e4ge \u00a0bei\u00a0einzelnen \u00a0Kassen\u00a0f\u00e4llig\u00a0werden.\u00a0Dass\u00a0solche\u00a0\nAusgabensteigerungen \u00a0ausschlie\u00dflich \u00a0\u00fcber\u00a0einen\u00a0Zusatzbeitrag \u00a0kompensiert \u00a0werden\u00a0\nm\u00fcssten,\u00a0der\u00a0alleine\u00a0die\u00a0Versicherten \u00a0belastet,\u00a0widerspricht \u00a0dem\u00a0Grundsatz \u00a0der\u00a0GKV\u00a0einer\u00a0\neinkommensunabh\u00e4ngigen \u00a0Leistungspflicht \u00a0bei\u00a0einer\u00a0bedarfsgerechten \u00a0Versorgung. \u00a0\n\uf0b7 Jedes\u00a0Medikament, \u00a0das\u00a0keinen\u00a0Ausschlussgr\u00fcnden \u00a0in\u00a0der\u00a0GKV\u00a0unterliegt, \u00a0sollte\u00a0wie\u00a0bisher\u00a0ab\u00a0\nseiner\u00a0Zulassung \u00a0sofort\u00a0allen\u00a0Patienten \u00a0zur\u00a0Verf\u00fcgung \u00a0stehen.\u00a0Es\u00a0sollte\u00a0aber\u00a0bei\u00a0speziellen \u00a0\nArzneimitteln, \u00a0wie\u00a0z.B.\u00a0in\u00a0der\u00a0Onkologie, \u00a0bei\u00a0MS,\u00a0bei\u00a0rheumatoider \u00a0Arthritis\u00a0oder\u00a0bei\u00a0Hepatitis\u00a0\nC,\u00a0\u00fcber\u00a0einen\u00a0gewissen\u00a0Zeitraum\u00a0eine\u00a0Beschr\u00e4nkung \u00a0der\u00a0Patientenversorgung \u00a0auf\u00a0\nspezialisierte \u00a0Fach\u00e4rzte, \u00a0sowohl\u00a0in\u00a0Klinikambulanzen \u00a0oder\u00a0in\u00a0ambulanten \u00a0Praxen\u00a0(z.B.\u00a0nach\u00a0\nArt\u00a0der\u00a0Weiterbildung \u00a0oder\u00a0der\u00a0Behandlungserfahrungen) \u00a0stattfinden, \u00a0um\u00a0die\u00a0Verordnung \u00a0 \n142\u00a0 \n \nInnovationsreport 2015 \u00a0innovativer \u00a0Medikamente \u00a0unter\u00a0kontrollierten, \u00a0studien\u00e4hnlichen \u00a0Bedingungen \u00a0auf\u00a0der\u00a0Basis\u00a0\neiner\u00a0nachgewiesenen \u00a0Qualifikation \u00a0vorzunehmen. \u00a0Die\u00a0im\u00a0Innovationsfonds \u00a0finanzierte \u00a0\nVersorgungsforschung \u00a0(beispielsweise \u00a0Post\u2010Zulassungsstudien \u00a0in\u00a0Form\u00a0von\u00a0klinischen \u00a0\nRegistern) \u00a0k\u00f6nnte\u00a0in\u00a0diesem\u00a0Zusammenhang \u00a0begleitend \u00a0fundierte \u00a0Daten\u00a0f\u00fcr\u00a0eine\u00a0erweiterte \u00a0\nKosten\u2010Nutzen\u2010Bewertung \u00a0beisteuern. \u00a0\n\uf0b7 Der\u00a0Erstattungs(h\u00f6chst)betrag \u00a0wird\u00a0auf\u00a0nationaler \u00a0Ebene,\u00a0wie\u00a0oben\u00a0beschrieben, \u00a0verhandelt. \u00a0\nSollten\u00a0zum\u00a0Zeitpunkt \u00a0der\u00a0Zulassung \u00a0nicht\u00a0gen\u00fcgend \u00a0Daten\u00a0f\u00fcr\u00a0die\u00a0Kosten\u2010Nutzen\u2010Bewertung \u00a0\nvorliegen, \u00a0wird\u00a0ein\u00a0vorl\u00e4ufiger \u00a0Erstattungspreis \u00a0festgelegt \u00a0und\u00a0die\u00a0Befristung \u00a0(via\u00a0G\u2010BA\u2010\nRichtlinie) \u00a0mit\u00a0der\u00a0Auflage\u00a0verkn\u00fcpft, \u00a0in\u00a0einem\u00a0festzulegenden \u00a0Zeitraum\u00a0die\u00a0fehlenden \u00a0Daten\u00a0\nzu\u00a0generieren. \u00a0Die\u00a0Erstattungsf\u00e4higkeit \u00a0wird\u00a0zun\u00e4chst\u00a0auf\u00a0diesen\u00a0Zeitraum\u00a0begrenzt\u00a0\n(Verfahren \u00a0der\u00a0\u201evierten\u00a0H\u00fcrde\u201c).\u00a0\n\uf0b7 An\u00a0der\u00a0im\u00a0Rahmen\u00a0von\u00a0Post\u2010Zulassungsstudien \u00a0notwendigen \u00a0Dokumentation \u00a0m\u00fcssen\u00a0alle\u00a0\nVerordner \u00a0(und\u00a0Patienten) \u00a0teilnehmen. \u00a0Das\u00a0schlie\u00dft\u00a0die\u00a0Dokumentation \u00a0der\u00a0klinischen \u00a0Daten\u00a0\nein.\u00a0\u00a0\n\uf0b7 Bei\u00a0neuen\u00a0Arzneimitteln, \u00a0f\u00fcr\u00a0die\u00a0schon\u00a0im\u00a0Rahmen\u00a0von\u00a0Zulassungsstudien \u00a0ihr\u00a0\npatientenorientierter \u00a0Zusatznutzen \u00a0nachgewiesen \u00a0werden\u00a0konnte,\u00a0kann\u00a0von\u00a0der\u00a0\nPreisfestsetzung \u00a0\u00fcber\u00a0eine\u00a0begrenzte \u00a0Dauer\u00a0(s.o.)\u00a0von\u00a0zwei\u00a0(bis\u00a0drei)\u00a0Jahren\u00a0ab\u00a0Zulassung \u00a0\nabgesehen \u00a0werden.\u00a0Die\u00a0bisherigen \u00a0Erfahrungen \u00a0zeigen\u00a0allerdings, \u00a0dass\u00a0Erkenntnisse \u00a0\u00fcber\u00a0\neinen\u00a0patientenorientierten \u00a0Nutzen\u00a0nur\u00a0in\u00a0ausgesprochen \u00a0seltenen\u00a0F\u00e4llen\u00a0vorliegen \u00a0d\u00fcrften,\u00a0\nweil\u00a0die\u00a0Generierung \u00a0solcher\u00a0Daten\u00a0die\u00a0Zulassungsstudien \u00a0erheblich \u00a0verl\u00e4ngern \u00a0und\u00a0finanziell\u00a0\nbelastender \u00a0machen\u00a0w\u00fcrden.\u00a0Daher\u00a0wird\u00a0es\u00a0in\u00a0den\u00a0meisten\u00a0F\u00e4llen\u00a0dabei\u00a0bleiben,\u00a0dass\u00a0\nZulassungsstudien \u00a0in\u00a0der\u00a0Regel\u00a0kaum\u00a0R\u00fcckschl\u00fcsse \u00a0auf\u00a0einen\u00a0patientenorientierten \u00a0Nutzen,\u00a0\nwie\u00a0er\u00a0in\u00a0\u00a7\u00a035\u00a0b\u00a0des\u00a0SGB\u00a0V\u00a0definiert\u00a0ist,\u00a0zulassen\u00a0d\u00fcrften.\u00a0Gezeigt\u00a0werden\u00a0m\u00fcssten\u00a0nach\u00a0\u00a7\u00a035\u00a0\nb\u00a0die\u00a0Verk\u00fcrzung \u00a0der\u00a0Krankheitsdauer, \u00a0die\u00a0Verl\u00e4ngerung \u00a0der\u00a0Lebensdauer, \u00a0die\u00a0Verringerung \u00a0\nder\u00a0Nebenwirkungen \u00a0und\u00a0die\u00a0Verbesserung \u00a0der\u00a0Lebensqualit\u00e4t. \u00a0\n\uf0b7 Nach\u00a0Indikationserweiterungen \u00a0wird\u00a0der\u00a0Preis\u00a0mit\u00a0Blick\u00a0auf\u00a0den\u00a0Nutzen\u00a0f\u00fcr\u00a0die\u00a0Patienten, \u00a0auf\u00a0\ndie\u00a0Gr\u00f6\u00dfe\u00a0der\u00a0betroffenen \u00a0Bev\u00f6lkerungsgruppe \u00a0und\u00a0auf\u00a0die\u00a0Schwere\u00a0der\u00a0Erkrankung \u00a0\ngegebenenfalls \u00a0neu\u00a0festgesetzt. \u00a0\nDie\u00a0Folgen\u00a0solcher\u00a0Regelungen \u00a0sollten\u00a0nat\u00fcrlich\u00a0bedacht\u00a0werden.\u00a0Eine\u00a0Preisreduktion \u00a0in\u00a0Deutschland \u00a0\nk\u00f6nnte\u00a0dazu\u00a0f\u00fchren,\u00a0dass\u00a0Unternehmen \u00a0ihre\u00a0Arzneimittel \u00a0in\u00a0Deutschland \u00a0als\u00a0nach\u00a0wie\u00a0vor\u00a0wichtigem \u00a0\nReferenzpreisland \u00a0verz\u00f6gert \u00a0vermarkten, \u00a0damit\u00a0sich\u00a0die\u00a0hierzulande \u00a0erzielbaren \u00a0Preise\u00a0nicht\u00a0in\u00a0\nniedrigere \u00a0Preise\u00a0anderer\u00a0Staaten\u00a0\u201e\u00fcbersetzen\u201c. \u00a0Es\u00a0ist\u00a0allerdings \u00a0nicht\u00a0zu\u00a0erwarten, \u00a0dass\u00a0einer\u00a0der\u00a0\ngr\u00f6\u00dften\u00a0und\u00a0finanziell\u00a0am\u00a0besten\u00a0ausgestalteten \u00a0Pharmam\u00e4rkte \u00a0von\u00a0global\u00a0agierenden \u00a0pU\u00a0\nausgelassen \u00a0werden\u00a0kann.\u00a0\u00a0\nZudem\u00a0ergibt\u00a0sich\u00a0durchaus \u00a0ein\u00a0Vorteil\u00a0f\u00fcr\u00a0die\u00a0Unternehmen: \u00a0Sie\u00a0m\u00fcssen\u00a0keine\u00a0gesetzlichen \u00a0Eingriffe\u00a0\nw\u00e4hrend\u00a0der\u00a0Vertragsdauer \u00a0bef\u00fcrchten, \u00a0die\u00a0Auswirkungen \u00a0auf\u00a0ihre\u00a0Einnahmen \u00a0haben\u00a0k\u00f6nnten.\u00a0\nZugleich\u00a0erlauben\u00a0die\u00a0Vereinbarungen \u00a0\u00fcber\u00a0einen\u00a0Erstattungsbetrag \u00a0die\u00a0Planbarkeit \u00a0der\u00a0Ausgaben \u00a0\nder\u00a0GKV,\u00a0indem\u00a0die\u00a0\u00fcber\u00a0den\u00a0erwarteten \u00a0Ausgaben \u00a0liegenden \u00a0Kosten\u00a0von\u00a0den\u00a0pU\u00a0erstattet\u00a0werden.\u00a0\nRabattvertr\u00e4ge \u00a0nach\u00a0\u00a7\u00a0130a\u00a0SGB\u00a0V\u00a0k\u00f6nnten\u00a0ein\u00a0j\u00e4hrliches \u00a0Umsatzvolumen \u00a0oder\u00a0eine\u00a0Abstaffelung \u00a0von\u00a0\nMehrerl\u00f6sen \u00a0vorsehen \u00a0und\u00a0sind\u00a0somit\u00a0eine\u00a0Form\u00a0von\u00a0Preis\u2010Volumen\u2010Abkommen, \u00a0mit\u00a0dem\u00a0\nUnterschied, \u00a0dass\u00a0sie\u00a0nicht\u00a0explizit\u00a0in\u00a0ein\u00a0staatliches \u00a0Preis\u2010\u00a0und\u00a0Erstattungssystem \u00a0eingegliedert \u00a0sind.\u00a0\u00a0\nUm\u00a0auf\u00a0die\u00a0absehbare \u00a0Entwicklung \u00a0im\u00a0pharmazeutischen \u00a0Markt\u00a0vorbereitet \u00a0zu\u00a0sein,\u00a0ist\u00a0es\u00a0dringend\u00a0\nerforderlich, \u00a0dass\u00a0die\u00a0GKV\u00a0ein\u00a0weitergehendes \u00a0System\u00a0von\u00a0Kosten\u2010Nutzen\u2010Bewertungen \u00a0entwickelt, \u00a0\ndas\u00a0unter\u00a0Einbeziehung \u00a0von\u00a0Krankheitskosten \u00a0direkte\u00a0und\u00a0indirekte\u00a0Belastungen \u00a0in\u00a0die\u00a0Bewertung \u00a0 \n143\u00a0\n \nInnovationsreport 2015 \u00a0und\u00a0in\u00a0die\u00a0Festlegung \u00a0von\u00a0Erstattungsbetr\u00e4gen \u00a0einbezieht. \u00a0Die\u00a0\u201ereine\u201c\u00a0Vergleichsebene \u00a0\n\u201eArzneimittelpreise\u201c, \u00a0wie\u00a0sie\u00a0letztlich\u00a0auch\u00a0im\u00a0AMNOG,\u00a0wenn\u00a0auch\u00a0unter\u00a0Nutzung\u00a0einer\u00a0\nEffizienzgrenze, \u00a0vorgenommen \u00a0wird,\u00a0mag\u00a0in\u00a0der\u00a0Festbetragsregelung \u00a0die\u00a0zutreffende \u00a0Basis\u00a0f\u00fcr\u00a0das\u00a0\nAustarieren \u00a0eines\u00a0vertretbaren \u00a0Preisniveaus \u00a0sein,\u00a0ist\u00a0aber\u00a0unzureichend, \u00a0wenn\u00a0es\u00a0um\u00a0eine\u00a0wirklich\u00a0\nqualifizierte \u00a0Bewertung \u00a0von\u00a0Kosten\u00a0und\u00a0Nutzen\u00a0neuer\u00a0Arzneimittel \u00a0geht.\u00a0Die\u00a0internationalen \u00a0\nErfahrungen \u00a0sollten\u00a0daher\u00a0genutzt\u00a0werden,\u00a0um\u00a0auch\u00a0unser\u00a0Bewertungssystem \u00a0weiterzuentwickeln \u00a0\nund\u00a0Strategien \u00a0gegen\u00a0systemsprengende \u00a0Preise\u00a0neuer\u00a0Arzneimittel \u00a0zu\u00a0entwickeln \u00a0und\u00a0zu\u00a0\nimplementieren. \u00a0\u00a0 \n144\u00a0 \n \nInnovationsreport 2015 \u00a0 9 Die\u00a0Hormontherapie \u00a0in\u00a0und\u00a0nach\u00a0den\u00a0Wechseljahren \u00a0\nDaniela\u00a0Boeschen \u00a0\nFrauen\u00a0durchleben \u00a0im\u00a0Laufe\u00a0ihres\u00a0Lebens\u00a0verschiedene \u00a0Phasen,\u00a0die\u00a0von\u00a0k\u00f6rperlichen \u00a0Entwicklungen \u00a0\ngepr\u00e4gt\u00a0sind.\u00a0M\u00e4dchen \u00a0und\u00a0junge\u00a0Frauen\u00a0erleben\u00a0zwischen\u00a0dem\u00a012.\u00a0und\u00a016.\u00a0Lebensjahr \u00a0die\u00a0\nMenarche, \u00a0die\u00a0erste\u00a0Regelblutung. \u00a0Damit\u00a0beginnt\u00a0in\u00a0die\u00a0sogenannte \u00a0reproduktive \u00a0Phase,\u00a0in\u00a0der\u00a0vom\u00a0\nK\u00f6rper\u00a0befruchtungsf\u00e4hige \u00a0Eizellen\u00a0gebildet\u00a0werden.\u00a0Diese\u00a0Phase\u00a0endet\u00a0mit\u00a0der\u00a0Menopause, \u00a0dem\u00a0\nTag\u00a0der\u00a0letzten\u00a0Regelblutung. \u00a0Beide\u00a0Phasen\u00a0im\u00a0Leben\u00a0einer\u00a0Frau\u00a0sind\u00a0mit\u00a0Ver\u00e4nderungen \u00a0im\u00a0\nHormonspiegel \u00a0verbunden. \u00a0Nach\u00a0der\u00a0Menopause \u00a0stellen\u00a0die\u00a0weiblichen \u00a0Keimdr\u00fcsen \u00a0ihre\u00a0Funktion\u00a0\nlangsam\u00a0ein\u00a0\u2013\u00a0im\u00a05.\u00a0Lebensjahrzehnt \u00a0h\u00f6rt\u00a0sie\u00a0ganz\u00a0auf.\u00a0W\u00e4hrend \u00a0zu\u00a0Beginn\u00a0des\u00a0Klimakteriums \u00a0die\u00a0\nMenstruationsblutungen \u00a0unregelm\u00e4\u00dfiger \u00a0und\u00a0schw\u00e4cher \u00a0werden\u00a0und\u00a0Ovulationen \u00a0sowie\u00a0\nGelbk\u00f6rperbildungen \u00a0ausbleiben, \u00a0steigt\u00a0mit\u00a0dem\u00a0Abfall\u00a0der\u00a0Estrogen\u2010\u00a0und\u00a0Gestagenspiegel \u00a0f\u00fcr\u00a0einige\u00a0\nJahre\u00a0die\u00a0Gonadotropinaussch\u00fcttung \u00a0stark\u00a0an\u00a0(Mutschler \u00a0et\u00a0al.,\u00a02008).\u00a0Das\u00a0Erl\u00f6schen \u00a0der\u00a0Funktion\u00a0\nder\u00a0weiblichen \u00a0Keimdr\u00fcsen \u00a0ist\u00a0somit\u00a0ein\u00a0physiologischer \u00a0Prozess\u00a0und\u00a0entspricht \u00a0dem\u00a0nat\u00fcrlichen \u00a0\nVerlauf\u00a0im\u00a0Leben\u00a0einer\u00a0Frau.\u00a0Bei\u00a0ungef\u00e4hr\u00a0einem\u00a0Drittel\u00a0der\u00a0Frauen\u00a0treten\u00a0dabei\u00a0sogenannte \u00a0\nklimakterische \u00a0oder\u00a0postmenopausale \u00a0Beschwerden \u00a0auf,\u00a0die\u00a0h\u00e4ufig\u00a0vom\u00a0Arzt\u00a0behandelt \u00a0werden.\u00a0In\u00a0\nder\u00a0Fachliteratur \u00a0werden\u00a0u.a.\u00a0Hitzewallungen, \u00a0Schwei\u00dfausbr\u00fcche, \u00a0Schwindel \u00a0und\u00a0somatische \u00a0\nBeschwerden \u00a0wie\u00a0atrophische \u00a0Ver\u00e4nderungen \u00a0an\u00a0Genitalien \u00a0und\u00a0Br\u00fcsten\u00a0als\u00a0symptomatisch \u00a0\nbeschrieben, \u00a0die\u00a0in\u00a0erster\u00a0Linie\u00a0mit\u00a0dem\u00a0Abfall\u00a0der\u00a0Estrogensekretion \u00a0in\u00a0Zusammenhang \u00a0gebracht\u00a0\nwerden.\u00a0Dar\u00fcber\u00a0hinaus\u00a0werden\u00a0dem\u00a0klimakterischen \u00a0Syndrom\u00a0auch\u00a0psychonerv\u00f6se \u00a0Symptome \u00a0wie\u00a0\nSchlafst\u00f6rungen \u00a0und\u00a0Reizbarkeit \u00a0zugeordnet \u00a0(Braendle, \u00a02005;\u00a0Vitiello,\u00a02007).\u00a0Gerade\u00a0\nStimmungs\u00e4nderungen \u00a0bzw.\u00a0\u2013schwankungen \u00a0f\u00fchren\u00a0h\u00e4ufig\u00a0dazu,\u00a0dass\u00a0Frauen\u00a0im\u00a0Klimakterium \u00a0\n\u00e4rztlichen \u00a0Rat\u00a0suchen\u00a0und\u00a0sich\u00a0deshalb\u00a0auch\u00a0(medikament\u00f6s) \u00a0behandeln \u00a0lassen\u00a0wollen\u00a0(Parry,\u00a02008),\u00a0\nzumeist\u00a0mit\u00a0Hormonen. \u00a0Bis\u00a0heute\u00a0fehlen\u00a0aber\u00a0belastbare \u00a0Daten\u00a0aus\u00a0klinischen \u00a0Studien,\u00a0die\u00a0belegen,\u00a0\ndass\u00a0eine\u00a0Hormontherapie \u00a0in\u00a0der\u00a0Postmenopause \u00a0die\u00a0Lebensqualit\u00e4t \u00a0von\u00a0Frauen\u00a0steigert\u00a0\n(Marjoribanks \u00a0et\u00a0al.,\u00a02012).\u00a0\u00a0\nBei\u00a0einer\u00a0Hormontherapie \u00a0in\u00a0und\u00a0nach\u00a0den\u00a0Wechseljahren \u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0eine\u00a0medikament\u00f6se \u00a0\nestrogenhaltige \u00a0Therapie\u00a0f\u00fcr\u00a0Frauen\u00a0im\u00a0mittleren \u00a0Lebensalter, \u00a0die\u00a0helfen\u00a0soll,\u00a0belastende \u00a0\nvasomotorische \u00a0St\u00f6rungen \u00a0wie\u00a0Hitzewallungen, \u00a0psychische \u00a0Symptome \u00a0und\u00a0atrophische \u00a0\nVer\u00e4nderungen \u00a0im\u00a0Urogenitaltrakt \u00a0zu\u00a0verringern \u00a0oder\u00a0ganz\u00a0zu\u00a0vermeiden. \u00a0Bei\u00a0noch\u00a0vorhandenem \u00a0\nUterus\u00a0muss\u00a0aufgrund\u00a0des\u00a0Endometrium \u2010Karzinom \u2010Risikos\u00a0zus\u00e4tzlich \u00a0ein\u00a0Gestagen \u00a0in\u00a0kombinierter \u00a0\nTherapie\u00a0gegeben\u00a0werden.\u00a0\nNeben\u00a0der\u00a0Behandlung \u00a0dieser\u00a0(akuten)\u00a0Beschwerden \u00a0kann\u00a0die\u00a0Entscheidung \u00a0f\u00fcr\u00a0eine\u00a0hormonelle \u00a0\nGabe\u00a0auch\u00a0pr\u00e4ventiven \u00a0Charakter \u00a0haben.\u00a0So\u00a0wird\u00a0in\u00a0der\u00a0Fachliteratur \u00a0die\u00a0Einnahme \u00a0systemischer \u00a0\nHormonpr\u00e4parate \u00a0in\u00a0der\u00a0Postmenopause \u00a0als\u00a0Therapieoption \u00a0f\u00fcr\u00a0die\u00a0Osteoporosepr\u00e4vention \u00a0be\u2010\nschrieben, \u00a0Ergebnisse \u00a0systematischer \u00a0\u00dcbersichtsarbeiten \u00a0erh\u00e4rten\u00a0die\u00a0positive\u00a0Evidenzlage \u00a0in\u00a0diesem\u00a0\nEinsatzgebiet \u00a0(Marjoribanks \u00a0et\u00a0al.,\u00a02012,\u00a0Nelson,\u00a02002).\u00a0Positive\u00a0Auswirkungen \u00a0auf\u00a0koronare\u00a0\nErkrankungen \u00a0sind\u00a0hingegen\u00a0nicht\u00a0vorhanden \u00a0oder\u00a0allenfalls\u00a0gering\u00a0ausgepr\u00e4gt \u00a0(Boardman \u00a0et\u00a0al.,\u00a0\n2015),\u00a0auch\u00a0bietet\u00a0die\u00a0hormonelle \u00a0Einnahme \u00a0weder\u00a0Schutz\u00a0vor\u00a0dementiellen \u00a0Erkrankungen \u00a0im\u00a0Alter\u00a0\nnoch\u00a0vor\u00a0Inkontinenz \u00a0(Lethaby\u00a0et\u00a0al.,\u00a02008;\u00a0Marjoribanks \u00a0et\u00a0al.,\u00a02012).\u00a0Daf\u00fcr\u00a0steigt\u00a0mit\u00a0der\u00a0langfris\u2010\ntigen\u00a0Einnahme \u00a0weiblicher \u00a0Hormone \u00a0bei\u00a0einem\u00a0Durchschnittsalter \u00a0der\u00a0Anwenderinnen \u00a0von\u00a060\u00a0Jahren\u00a0\ndas\u00a0Risiko\u00a0f\u00fcr\u00a0Schlaganf\u00e4lle \u00a0und\u00a0ven\u00f6se\u00a0Thromboembolien \u00a0(Boardman \u00a0et\u00a0al.,\u00a02015)\u00a0sowie\u00a0das\u00a0Risiko\u00a0\nf\u00fcr\u00a0die\u00a0Entwicklung \u00a0eines\u00a0Mammakarzinoms \u00a0(Beral,\u00a02003;\u00a0Marjoribanks \u00a0et\u00a0al.,\u00a02012),\u00a0auch\u00a0noch\u00a0lange\u00a0\nnach\u00a0dem\u00a0Absetzen \u00a0der\u00a0Hormontherapie \u00a0(Chlebowski \u00a0et\u00a0al.,\u00a02010).\u00a0\u00a0 \n145\u00a0\n \nInnovationsreport 2015 \u00a0Mit\u00a0der\u00a0Ver\u00f6ffentlichung \u00a0der\u00a0Ergebnisse \u00a0zur\u00a0Women\u2019s \u00a0Health\u00a0Initiative\u00a0(WHI)\u00a0im\u00a0Jahr\u00a020021\u00a0und\u00a0\n20042\u00a0erreichte\u00a0die\u00a0Diskussion \u00a0um\u00a0das\u00a0Nutzen\u2010Risiko\u2010Potential\u00a0der\u00a0Hormontherapie \u00a0eine\u00a0neue\u00a0\nwissenschaftliche \u00a0Basis,\u00a0die\u00a0auch\u00a0zehn\u00a0Jahre\u00a0danach\u00a0die\u00a0z.T.\u00a0hochkontroversen \u00a0\nAuseinandersetzungen \u00a0bestimmt. \u00a0Nachdem \u00a0die\u00a0Studienergebnisse \u00a0dazu\u00a0f\u00fchrten,\u00a0dass\u00a0in\u00a0einigen\u00a0\nL\u00e4ndern\u00a0die\u00a0Sicherheit \u00a0und\u00a0der\u00a0Nutzen\u00a0einer\u00a0Hormontherapie \u00a0in\u00a0den\u00a0Wechseljahren \u00a0in\u00a0Frage\u00a0gestellt\u00a0\nwurde\u00a0(Beral\u00a0et\u00a0al.,\u00a02002),\u00a0gingen\u00a0u.a.\u00a0auch\u00a0in\u00a0Deutschland \u00a0die\u00a0Verordnungszahlen \u00a0zwischen\u00a01999\u00a0\nund\u00a02013\u00a0um\u00a076\u00a0Prozent\u00a0zur\u00fcck\u00a0(Schwabe \u00a0&\u00a0Paffrath,\u00a02014).\u00a0Dennoch\u00a0flammt\u00a0die\u00a0Diskussion \u00a0um\u00a0\nNutzen\u00a0und\u00a0Schaden\u00a0einer\u00a0Hormontherapie \u00a0immer\u00a0wieder\u00a0auf,\u00a0sei\u00a0es\u00a0wegen\u00a0angeblich \u00a0besserer\u00a0\nVertr\u00e4glichkeit \u00a0transdermaler \u00a0Zubereitungen \u00a0oder\u00a0wegen\u00a0fehlender \u00a0Studiendaten \u00a0f\u00fcr\u00a0peri\u2010\u00a0und\u00a0\npostmenopausaler \u00a0Frauen\u00a0im\u00a0Alter\u00a0zwischen\u00a045\u00a0und\u00a055\u00a0Jahren.\u00a0F\u00fcr\u00a0Pflasterzubereitungen \u00a0finden\u00a0sich\u00a0\nin\u00a0Beobachtungsstudien \u00a0Hinweise, \u00a0dass\u00a0die\u00a0Rate\u00a0von\u00a0Thrombosen, \u00a0Lungenembolien \u00a0und\u00a0\nSchlaganf\u00e4llen \u00a0geringer\u00a0ausf\u00e4llt\u00a0als\u00a0bei\u00a0oraler\u00a0Anwendung \u00a0(Canonico \u00a0et\u00a0al.,\u00a02008;\u00a0Renoux\u00a0et\u00a0al.,\u00a02010).\u00a0\nBeweisende \u00a0Studien\u00a0fehlen\u00a0aber.\u00a0Im\u00a0Jahr\u00a02012\u00a0wurde\u00a0zudem\u00a0eine\u00a0Studie\u00a0ver\u00f6ffentlicht, \u00a0in\u00a0der\u00a0ab\u00a0ca.\u00a0\n1990\u00a0peri\u2010\u00a0bzw.\u00a0postmenopausale \u00a0Frauen\u00a0im\u00a0Alter\u00a0von\u00a045\u00a0bis\u00a058\u00a0Jahren\u00a0randomisiert \u00a0entweder \u00a0mit\u00a0\neinem\u00a0kombinierten \u00a0Hormonpr\u00e4parat \u00a0behandelt \u00a0wurden\u00a0oder\u00a0keine\u00a0Therapie\u00a0erhielten\u00a0(Schierbeck \u00a0\net\u00a0al.,\u00a02012).\u00a0Im\u00a0Ergebnis\u00a0postulieren \u00a0die\u00a0Autoren\u00a0die\u00a0sogenannte \u00a0Timing\u2010Hypothese, \u00a0nach\u00a0der\u00a0bei\u00a0\neinem\u00a0fr\u00fchzeitigen \u00a0Einsatz\u00a0der\u00a0Hormontherapie \u00a0(unter\u00a060\u00a0Jahre)\u00a0bei\u00a0Frauen\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0\nHerzinfarkte \u00a0reduziert\u00a0werden\u00a0kann.\u00a0Die\u00a0Studie\u00a0weist\u00a0aber\u00a0massive\u00a0methodische \u00a0M\u00e4ngel\u00a0auf\u00a0\u2013\u00a0wie\u00a0\nbeispielsweise \u00a0die\u00a0nachtr\u00e4gliche \u00a0\u00c4nderung \u00a0des\u00a0prim\u00e4ren \u00a0Endpunktes \u00a0und\u00a0eine\u00a0geringe\u00a0Ereignisrate \u00a0\naufgrund\u00a0des\u00a0begrenzten \u00a0Studienkollektives \u00a0\u2013\u00a0und\u00a0kann\u00a0daher\u00a0nicht\u00a0als\u00a0Beleg\u00a0f\u00fcr\u00a0einen\u00a0pr\u00e4ventiven \u00a0\nkardiovaskul\u00e4ren \u00a0Nutzen\u00a0der\u00a0Hormontherapie \u00a0herangezogen \u00a0werden.\u00a0\nHormonpr\u00e4parate \u00a0werden\u00a0auch\u00a0derzeit\u00a0noch\u00a0von\u00a0zahlreichen \u00a0Frauen\u00a0eingenommen. \u00a0So\u00a0wurden\u00a0im\u00a0\nJahr\u00a02013\u00a0mehr\u00a0als\u00a0750.000\u00a0Frauen\u00a0in\u00a0Deutschland, \u00a0die\u00a0in\u00a0der\u00a0gesetzlichen \u00a0Krankenversicherung \u00a0\nversichert \u00a0sind,\u00a0mit\u00a0postmenopausalen \u00a0Hormonpr\u00e4paraten \u00a0dauerversorgt \u00a0(Schwabe \u00a0&\u00a0Paffrath,\u00a0\n2014).\u00a0Und\u00a0in\u00a0den\u00a0USA\u00a0und\u00a0Gro\u00dfbritannien \u00a0nehmen\u00a0nach\u00a0Angaben\u00a0der\u00a0Collaborative \u00a0Group\u00a0on\u00a0\nEpidemiological \u00a0Studies\u00a0of\u00a0Ovarian\u00a0Cancer\u00a0(2015)\u00a0allein\u00a0sechs\u00a0Millionen \u00a0Frauen\u00a0nach\u00a0den\u00a0\nWechseljahren \u00a0Hormonpr\u00e4parate \u00a0ein,\u00a0um\u00a0die\u00a0mit\u00a0dem\u00a0Klimakterium \u00a0verbundenen \u00a0Symptome \u00a0zu\u00a0\nlindern.\u00a0Die\u00a0im\u00a0Mai\u00a02015\u00a0publizierten \u00a0Ergebnisse \u00a0dieser\u00a0Arbeitsgruppe \u00a0geben\u00a0nun\u00a0erneut\u00a0Anlass,\u00a0den\u00a0\ndauerhaften \u00a0Einsatz\u00a0dieser\u00a0Wirkstoffe \u00a0und\u00a0Wirkstoffkombinationen \u00a0kritisch\u00a0zu\u00a0hinterfragen. \u00a0So\u00a0wird\u00a0\nden\u00a0Untersuchungen \u00a0zufolge\u00a0mit\u00a0der\u00a0Einnahme \u00a0einer\u00a0Hormontherapie \u00a0auch\u00a0der\u00a0Anstieg\u00a0der\u00a0\nOvarialkarzinome \u00a0in\u00a0Verbindung \u00a0gebracht\u00a0(Collaborative \u00a0Group\u00a0on\u00a0Epidemiological \u00a0Studies\u00a0of\u00a0Ovarian\u00a0\nCancer,\u00a02015):\u00a0Bei\u00a055\u00a0Prozent\u00a0der\u00a0Hormon\u2010Anwenderinnen \u00a0wurde\u00a0ein\u00a0Ovarialkarzinom \u00a0diagnostiziert, \u00a0\ndabei\u00a0stieg\u00a0das\u00a0Risiko\u00a0einer\u00a0solchen\u00a0Diagnose\u00a0bereits\u00a0bei\u00a0einer\u00a0Einnahmedauer \u00a0der\u00a0Hormonpr\u00e4parate \u00a0\nvon\u00a0weniger\u00a0als\u00a0f\u00fcnf\u00a0Jahren\u00a0signifikant \u00a0an.\u00a0Bei\u00a0einer\u00a0l\u00e4ngeren\u00a0Einnahmedauer \u00a0blieb\u00a0das\u00a0Risiko\u00a0erh\u00f6ht\u00a0\nund\u00a0sank\u00a0trotz\u00a0Absetzen \u00a0der\u00a0Pr\u00e4parate \u00a0nur\u00a0langsam\u00a0wieder\u00a0ab\u00a0(Collaborative \u00a0Group\u00a0on\u00a0\nEpidemiological \u00a0Studies\u00a0of\u00a0Ovarian\u00a0Cancer,\u00a02015).\u00a0\u00a0\nFestzuhalten \u00a0bleibt,\u00a0dass\u00a0eine\u00a0Hormontherapie \u00a0neben\u00a0dem\u00a0Nutzen\u00a0einer\u00a0Beschwerdebesserung \u00a0z.T.\u00a0\nschwerwiegende \u00a0Nebenwirkungen \u00a0haben\u00a0kann\u00a0\u2013\u00a0auch\u00a0und\u00a0insbesondere \u00a0bei\u00a0Daueranwendung. \u00a0\nFestzuhalten \u00a0bleibt\u00a0ebenso,\u00a0dass\u00a0nicht\u00a0jede\u00a0Frau\u00a0unter\u00a0Wechseljahrbeschwerden \u00a0leidet.\u00a0Gesch\u00e4tzt \u00a0\n                                        \n1\u00a0Die\u00a0WHI\u2010Studie\u00a0musste\u00a0vorzeitig\u00a0abgebrochen \u00a0werden,\u00a0weil\u00a0die\u00a0Gesundheitsrisiken \u00a0bei\u00a0der\u00a0Einnahme \u00a0einer\u00a0kombinierten \u00a0Estrogen\u2010\nGestagen \u2010Substitution \u00a0h\u00f6her\u00a0waren\u00a0als\u00a0der\u00a0Nutzen.\u00a0So\u00a0stieg\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0eine\u00a0koronare\u00a0Herzkrankheit \u00a0um\u00a029\u00a0Prozent,\u00a0f\u00fcr\u00a0Brustkrebs \u00a0um\u00a0\n26\u00a0Prozent,\u00a0f\u00fcr\u00a0Schlaganfall \u00a0um\u00a041\u00a0Prozent\u00a0und\u00a0f\u00fcr\u00a0Thrombosen \u00a0sogar\u00a0um\u00a0133\u00a0Prozent.\u00a0Demgegen\u00fcber \u00a0sank\u00a0u.a.\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0ein\u00a0kolorek\u2010\ntales\u00a0Karzinom \u00a0und\u00a0Oberschenkelhalsfrakturen. \u00a0Dennoch\u00a0\u00fcberwog\u00a0der\u00a0Schaden\u00a0den\u00a0Nutzen\u00a0(Rossouw \u00a0et\u00a0al.,\u00a02002).\u00a0\u00a0\n2\u00a0Auch\u00a0in\u00a0dieser\u00a0vorzeitig\u00a0abgebrochenen \u00a0Studie\u00a0zur\u00a0Hormontherapie, \u00a0in\u00a0der\u00a0die\u00a0Intervention \u00a0mit\u00a0einem\u00a0Estrogen\u2010Monopr\u00e4parat \u00a0erfolgte,\u00a0\nkonnte\u00a0kein\u00a0positives\u00a0Nutzen\u2010Risiko\u2010Verh\u00e4ltnis \u00a0(erh\u00f6htes \u00a0Schlaganfall \u2010\u00a0und\u00a0Thromboembolie \u2010Risiko)\u00a0aufgezeigt \u00a0werden\u00a0(Anderson \u00a0et\u00a0al.,\u00a0\n2004),\u00a0auch\u00a0wenn\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0H\u00fcftfrakturen \u00a0um\u00a039\u00a0Prozent\u00a0gesenkt\u00a0werden\u00a0konnte.\u00a0\u00a0 \n146\u00a0 \n \nInnovationsreport 2015 \u00a0wird,\u00a0dass\u00a0etwa\u00a0ein\u00a0Drittel\u00a0der\u00a0Frauen\u00a0mit\u00a0den\u00a0gravierenden \u00a0\u201eNebenwirkungen\u201c \u00a0dieser\u00a0Lebensphase \u00a0\nbelastet\u00a0ist.\u00a0Da\u00a0auch\u00a0nicht\u00a0jedes\u00a0Symptom \u00a0therapiert \u00a0werden\u00a0muss,\u00a0sollte\u00a0die\u00a0Gabe\u00a0von\u00a0Hormonen, \u00a0\ndie\u00a0in\u00a0der\u00a0Regel\u00a0\u00fcber\u00a0einen\u00a0l\u00e4ngeren\u00a0Zeitraum\u00a0erfolgt,\u00a0nur\u00a0nach\u00a0einer\u00a0sorgf\u00e4ltigen \u00a0individuellen \u00a0\nNutzen\u2010Risiko\u2010Aspekten \u00a0erfolgen\u00a0(DGGG,\u00a02010).\u00a0\nNach\u00a0Schwabe\u00a0&\u00a0Paffrath\u00a0ist\u00a0das\u00a0Gesamtverordnungsspektrum \u00a0an\u00a0Sexualhormonen \u00a0von\u00a0dem\u00a0weiter\u00a0\nandauernden \u00a0Verordnungsr\u00fcckgang \u00a0der\u00a0Estrogene \u00a0als\u00a0Folge\u00a0der\u00a0Therapieempfehlungen \u00a0zur\u00a0post\u2010\nmenopausalen \u00a0Hormontherapie \u00a0(siehe\u00a0Leitlinienempfehlungen, \u00a0Kapitel\u00a010.12 )\u00a0gepr\u00e4gt,\u00a0so\u00a0dass\u00a0Est\u2010\nrogene\u00a0im\u00a0Jahr\u00a02013\u00a0nur\u00a0noch\u00a0einen\u00a0Anteil\u00a0von\u00a030\u00a0Prozent\u00a0am\u00a0Verordnungsvolumen \u00a0der\u00a0Sexualhor \u2010\nmone\u00a0hatten\u00a0(Schwabe \u00a0&\u00a0Paffrath,\u00a02014).\u00a0Dieser\u00a0r\u00fcckl\u00e4ufige \u00a0Trend\u00a0ist\u00a0begr\u00fc\u00dfenswert, \u00a0dennoch\u00a0z\u00e4hlt\u00a0\ndie\u00a0Gruppe\u00a0der\u00a0Sexualhormone \u00a0nach\u00a0wie\u00a0vor\u00a0zu\u00a0den\u00a0zwanzig\u00a0verordnungsst\u00e4rksten \u00a0Arzneimittelgrup \u2010\npen\u00a0im\u00a0Jahr\u00a02013\u00a0(Schwabe \u00a0&\u00a0Paffrath,\u00a02014).\u00a0Inwieweit \u00a0der\u00a0r\u00fcckl\u00e4ufige \u00a0Trend\u00a0der\u00a0Hormontherapie \u00a0\nin\u00a0und\u00a0nach\u00a0den\u00a0Wechseljahren \u00a0auch\u00a0bei\u00a0den\u00a0in\u00a0der\u00a0TK\u00a0versicherten \u00a0Frauen\u00a0festgestellt \u00a0werden\u00a0kann,\u00a0\nsollen\u00a0die\u00a0nachfolgenden \u00a0Auswertungen \u00a0zeigen.\u00a0\u00a0\n\u00a0\n9.1 Verordnungscharakteristika \u00a0der\u00a0Hormontherapie \u00a0in\u00a0und\u00a0nach\u00a0den\u00a0\nWechseljahren \u00a0in\u00a0der\u00a0TK\u00a0\nF\u00fcr\u00a0die\u00a0vorliegende \u00a0Untersuchung \u00a0wurden\u00a0aus\u00a0den\u00a0Verordnungsdaten \u00a0der\u00a0TK\u00a0alle\u00a0f\u00fcr\u00a0die\u00a0peri\u2010\u00a0und\u00a0\npostmenopausale \u00a0Hormontherapie \u00a0relevanten \u00a0Pr\u00e4parate \u00a0ermittelt. \u00a0Die\u00a0zugelassene \u00a0Indikation \u00a0\u2013\u00a0kli\u2010\nmakterische \u00a0Beschwerden, \u00a0Hormontherapie \u00a0in\u00a0den\u00a0Wechseljahren \u00a0laut\u00a0entsprechender \u00a0Fach\u2010\ninformation \u00a0\u2013\u00a0wurde\u00a0nochmals \u00a0\u00fcberpr\u00fcft \u00a0und\u00a0die\u00a0Marktpr\u00e4senz \u00a0in\u00a0den\u00a0Jahren\u00a02011\u00a0bis\u00a02013\u00a0\nfestgestellt. \u00a0Die\u00a0Auswertung \u00a0aller\u00a0Verordnungen \u00a0hormonhaltiger \u00a0Mittel,\u00a0die\u00a0zur\u00a0Anwendung \u00a0im\u00a0\nKlimakterium \u00a0eingesetzt \u00a0werden\u00a0k\u00f6nnen,\u00a0erfolgte\u00a0auf\u00a0der\u00a0Basis\u00a0dieser\u00a0ausgew\u00e4hlten \u00a0Pr\u00e4parate \u00a0\n(Tabelle\u00a018).\u00a0\u00a0\n\u00a0\nWirkstof f\u00a0 ATC\u2010Code\nEstrogene \u00a0 G03C\nEstrogene \u00a0und\u00a0Gestagene, \u00a0kontinuierliche \u00a0Gesta\u2010\ngenabgabe \u00a0G03FA\u00a0\nEstrogene \u00a0und\u00a0Gestagene, \u00a0sequentielle \u00a0Gestagen \u2010\nabgabe\u00a0G03FB\nGestagene \u00a0 G03D\u00a0\nEstrogene \u00a0und\u00a0Androgene G03E\u00a0\nEstrogene \u00a0und\u00a0Antiandrogene \u00a0(nur\u00a0PZN\u00a006182976, \u00a0\n06182982 \u00a0,04650812, \u00a004650918, \u00a006339389, \u00a0\n00014367) \u00a0G03HB\u00a0\nTabelle\u00a018:\u00a0Untersuchte \u00a0Wirkstoffe \u00a0und\u00a0Wirkstoffgruppen \u00a0sowie\u00a0Pharmazentralnummern \u00a0(PZN)\u00a0zur\u00a0\nHormontherapie \u00a0\u00a0\n \u00a0 \n147\u00a0\n \nInnovationsreport 2015 \u00a0 9.1.1 Verordnungspr\u00e4valenzen \u00a0der\u00a0Hormontherapie \u00a0\nDie\u00a0vorliegenden \u00a0Auswertungen \u00a0zeigen,\u00a0dass\u00a0in\u00a0den\u00a0Jahren\u00a02011\u00a0bis\u00a02013\u00a0insgesamt \u00a0durchschnittlich \u00a0\n2\u00a0Mio.\u00a0Frauen\u00a0ab\u00a040\u00a0Jahren\u00a0mindestens \u00a0einen\u00a0Tag\u00a0bei\u00a0der\u00a0TK\u00a0versichert \u00a0waren\u00a0und\u00a0dass\u00a0von\u00a0diesen\u00a0\nca.\u00a0260.000\u2010270.000\u00a0pro\u00a0Jahr\u00a0mindestens \u00a0eine\u00a0Verordnung \u00a0mit\u00a0einem\u00a0Hormonpr\u00e4parat \u00a0bekommen \u00a0\nhaben\u00a0(12,5\u00a0Prozent).\u00a0\u00a0\nZur\u00a0besseren\u00a0Vergleichbarkeit \u00a0von\u00a0unterschiedlichen \u00a0Zeitr\u00e4umen \u00a0wurden\u00a0die\u00a0\nVerordnungspr\u00e4valenzen \u00a0nach\u00a0Alter\u00a0berechnet \u00a0(siehe\u00a0Tabelle\u00a019).\u00a0\nDer\u00a0Schwerpunkt \u00a0der\u00a0Verordnung \u00a0von\u00a0Hormonpr\u00e4paraten \u00a0liegt\u00a0im\u00a0Altersbereich \u00a0zwischen\u00a050\u00a0und\u00a070\u00a0\nJahren\u00a0(Tabelle\u00a019).\u00a0Betrachtet \u00a0man\u00a0den\u00a0Zeitverlauf, \u00a0wurde\u00a0im\u00a0Jahr\u00a02011\u00a0in\u00a0der\u00a0Altersgruppe \u00a0\nzwischen\u00a050\u00a0und\u00a070\u00a0Jahren\u00a0noch\u00a0jede\u00a0f\u00fcnfte\u00a0Frau\u00a0mit\u00a0Hormonen \u00a0behandelt. \u00a0Zwei\u00a0Jahre\u00a0sp\u00e4ter\u00a0ist\u00a0der\u00a0\nAnteil\u00a0der\u00a0Frauen,\u00a0die\u00a0mindestens \u00a0eine\u00a0Verordnung \u00a0mit\u00a0einem\u00a0Hormonpr\u00e4parat \u00a0aufweisen, \u00a0um\u00a0zwei\u00a0\nProzent\u00a0gesunken \u00a0(18,32\u00a0Prozent\u00a0im\u00a0Jahr\u00a02011\u00a0und\u00a016,42\u00a0Prozent\u00a0im\u00a0Jahr\u00a02013)\u00a0(Abbildung \u00a077).\u00a0\n\u00a0\n\u00a0 Prozentualer \u00a0Anteil\u00a0der\u00a0Hormon\u2010Anwenderinnen \u00a0an\u00a0den\u00a0weiblichen \u00a0TK\u2010\nVersicherten \u00a0in\u00a0der\u00a0jeweiligen \u00a0Altersgruppe \u00a0\nAlter\u00a0 2011 2012 2013\n40\u201044\u00a0 4,44 4,24 4,35\n45\u201049\u00a0 7,44 7,06 6,97\n50\u201054\u00a0 15,28 14,44 13,97\n55\u201059\u00a0 20,26 18,90 18,14\n60\u201064\u00a0 20,27 18,86 17,92\n65\u201069\u00a0 19,23 18,01 17,20\n70\u201074\u00a0 17,25 16,36 15,58\n75\u201079\u00a0 14,08 13,81 13,12\n80\u201084\u00a0 8,93 9,12 9,08\n85\u201089\u00a0 5,79 5,62 5,45\n90++\u00a0 3,28 3,48 3,28\nTabelle\u00a019:\u00a0Anteil\u00a0der\u00a0Hormon\u2010Anwenderinnen \u00a0unter\u00a0den\u00a0weiblichen \u00a0TK\u2010Versicherten \u00a0nach\u00a0Alter\u00a0in\u00a0den\u00a0\nJahren\u00a02011\u00a0bis\u00a02013\u00a0\n\u00a0\u00a0 \n148\u00a0\n \n \nInnovationsreport 2015 \u00a0\n\u00a0\n*\u00a0 Hormontherapie \u00a0 bei\u00a0 VO\u00a0 mit\u00a0 ATC\u00a0 G03C,\u00a0 G03D,\u00a0 G03E,\u00a0 G03FA,\u00a0 G03FB\u00a0 oder\u00a0\nPZN\u00a006182976, \u00a006182982, \u00a004650812, \u00a004650918, \u00a006339389, \u00a000014367 \u00a0\nVersicherte \u00a0werden\u00a0je\u00a0Jahr\u00a0einfach\u00a0gez\u00e4hlt\u00a0\nAbbildung \u00a077:\u00a0\u00dcbersicht \u00a0der\u00a0Anzahl\u00a0TK\u2010versicherter \u00a0Frauen\u00a0je\u00a0Alterscluster \u00a0mit\u00a0und\u00a0ohne\u00a0Hormontherapie* \u00a0in\u00a0\nden\u00a0Jahren\u00a02011\u00a0bis\u00a02013\u00a0\u00a0\n\u00a0\n9.1.2 Regionale \u00a0Unterschiede \u00a0\nDie\u00a0Auswertungen \u00a0zur\u00a0regionalen \u00a0Verteilung \u00a0wurden\u00a0anhand\u00a0von\u00a0Verordnungspr\u00e4valenzen \u00a0des\u00a0\nJahres\u00a02013\u00a0tabellarisch \u00a0auf\u00a0Ebene\u00a0des\u00a0jeweiligen \u00a0Bundeslandes \u00a0dargestellt. \u00a0\u00a0\nTabelle\u00a020\u00a0gibt\u00a0den\u00a0Anteil\u00a0der\u00a0weiblichen \u00a0TK\u2010Versicherten \u00a0ab\u00a040\u00a0Jahre\u00a0gemessen \u00a0an\u00a0der\u00a0\ndurchschnittlichen \u00a0weiblichen \u00a0BRD\u2010Bev\u00f6lkerung \u00a0ab\u00a040\u00a0Jahre\u00a0im\u00a0Jahr\u00a02013\u00a0wieder.\u00a0Die\u00a0gr\u00f6\u00dften\u00a0\nVerordnungsanteile \u00a0wurden\u00a0in\u00a0Hamburg \u00a0(17,62\u00a0Prozent)\u00a0und\u00a0Berlin\u00a0(16,75\u00a0Prozent)\u00a0identifiziert, \u00a0\nniedrige\u00a0Werte\u00a0fanden\u00a0sich\u00a0in\u00a0Sachsen\u2010Anhalt\u00a0(4,71\u00a0Prozent),\u00a0Th\u00fcringen \u00a0(4,36\u00a0Prozent)\u00a0und\u00a0Sachsen\u00a0\n(4,00\u00a0Prozent).\u00a0\u00a0\nGemessen \u00a0an\u00a0der\u00a0durchschnittlichen \u00a0weiblichen \u00a0Bev\u00f6lkerung \u00a0in\u00a0Deutschland \u00a0im\u00a0Jahr\u00a02013\u00a0versichert \u00a0\ndie\u00a0TK\u00a0einen\u00a0besonders \u00a0hohen\u00a0Anteil\u00a0von\u00a0Frauen\u00a0ab\u00a0dem\u00a040.\u00a0Lebensjahr \u00a0in\u00a0den\u00a0nordwestlichen \u00a0\nBundesl\u00e4ndern \u00a0(Tabelle\u00a021).\u00a0Der\u00a0h\u00f6chste\u00a0Verordnungsanteil \u00a0einer\u00a0Hormontherapie \u00a0f\u00fcr\u00a0die\u00a0weiblichen \u00a0\nTK\u2010Versicherten \u00a0liegt\u00a0im\u00a0Saarland\u00a0(14,41\u00a0Prozent),\u00a0gefolgt\u00a0von\u00a0Nordrhein \u2010Westfalen \u00a0(12,99\u00a0Prozent),\u00a0\nRheinland \u2010Pfalz\u00a0(12,76\u00a0Prozent),\u00a0Berlin\u00a0(12,74\u00a0Prozent),\u00a0Bremen\u00a0(12,73\u00a0Prozent)\u00a0und\u00a0Hamburg \u00a0(12,56\u00a0\nProzent).\u00a0Auff\u00e4llig\u00a0dabei\u00a0ist,\u00a0dass\u00a0in\u00a0allen\u00a0Bundesl\u00e4ndern \u00a0der\u00a0Anteil\u00a0an\u00a0Hormon\u2010Anwenderinnen \u00a0bei\u00a0\nden\u00a0weiblichen \u00a0TK\u2010Versicherten \u00a0r\u00fcckl\u00e4ufig \u00a0ist\u00a0(Tabelle\u00a021).\u00a0\u00a0\n \n149\u00a0\n \nInnovationsreport 2015 \u00a0Bundesland \u00a0 Weibliche \u00a0TK\u2010Versicherte \u00a0\nab\u00a040\u00a0JahreFrauen\u00a0ab\u00a040\u00a0Jahre\u00a0in\u00a0der\u00a0\nBRDAnteil\u00a0TK\u00a0an\u00a0BRD\nin\u00a0Prozent\nBaden\u2010W\u00fcrttemberg \u00a0 248.977 3.098.133 8,04\nBayern\u00a0 249.153 3.704.220 6,73\nBerlin\u00a0 160.489 958.291 16,75\nBrandenburg \u00a0 62.373 813.093 7,67\nBremen\u00a0 16.172 196.148 8,24\nHamburg \u00a0 85.178 483.287 17,62\nHessen\u00a0 193.664 1.797.588 10,77\nMecklenburg \u00a0 41.329 521.982 7,92\nNiedersachsen \u00a0 221.529 2.379.214 9,31\nNordrhein \u2010Westfalen \u00a0 564.346 5.329.849 10,59\nRheinland \u2010Pfalz\u00a0 103.397 1.224.165 8,45\nSaarland\u00a0 23.255 322.016 7,22\nSachsen\u00a0 52.898 1.320.807 4,00\nSachsen\u2010Anhalt\u00a0 35.962 763.617 4,71\nSchleswig \u2010Holstein\u00a0 104.231 880.938 11,83\nTh\u00fcringen \u00a0 31.086 712.481 4,36\nGesamt\u00a0 2.194.039 24.505.829 8,95\nTabelle\u00a020:\u00a0Anteil\u00a0der\u00a0weiblichen \u00a0TK\u2010Versicherten \u00a0ab\u00a040\u00a0Jahre\u00a0an\u00a0der\u00a0durchschnittlichen \u00a0weiblichen \u00a0\nBev\u00f6lkerung \u00a0ab\u00a040\u00a0Jahre\u00a0in\u00a0Deutschland \u00a0im\u00a0Jahr\u00a02013\u00a0\n\u00a0\nDie\u00a0Auswertung \u00a0zeigt\u00a0einen\u00a0Ost\u2010West\u2010Unterschied \u00a0in\u00a0dem\u00a0Anteil\u00a0der\u00a0Hormon\u2010Anwenderinnen \u00a0an\u00a0den\u00a0\nweiblichen \u00a0TK\u2010Versicherten \u00a0ab\u00a040\u00a0Jahren,\u00a0mit\u00a0niedrigeren \u00a0Werten\u00a0in\u00a0den\u00a0neuen\u00a0und\u00a0etwas\u00a0h\u00f6heren\u00a0\nWerten\u00a0in\u00a0den\u00a0alten\u00a0Bundesl\u00e4ndern. \u00a0\n\u00a0\u00a0 \n150\u00a0 \n \nInnovationsreport 2015 \u00a0\u00a0 Prozentualer \u00a0Anteil\u00a0der\u00a0Hormon\u2010Anwenderinnen \u00a0an\u00a0den\u00a0weiblichen \u00a0TK\u2010\nVersicherten \u00a0\u00fcber\u00a040\u00a0Jahre\u00a0\nBundesland \u00a0 2011 2012 2013\nBaden\u2010W\u00fcrttemberg \u00a0 12,74 12,23 11,92\nBayern\u00a0 12,77 12,15 11,88\nBerlin\u00a0 13,28 12,99 12,74\nBrandenburg \u00a0 11,57 11,10 10,92\nBremen\u00a0 13,63 12,96 12,73\nHamburg \u00a0 12,66 12,57 12,56\nHessen\u00a0 12,48 11,88 11,71\nMecklenburg \u00a0 11,83 11,01 10,64\nNiedersachsen \u00a0 12,86 12,08 11,80\nNordrhein \u2010Westfalen \u00a0 13,66 13,16 12,99\nRheinland \u2010Pfalz\u00a0 13,69 13,04 12,76\nSaarland\u00a0 15,25 14,60 14,41\nSachsen\u00a0 11,75 10,83 10,57\nSachsen\u2010Anhalt\u00a0 12,16 11,27 10,86\nSchleswig \u2010Holstein\u00a0 12,46 12,09 11,84\nTh\u00fcringen \u00a0 12,67 12,25 11,74\nGesamt\u00a0 12,99 12,44 12,21\nTabelle\u00a021:\u00a0Anteil\u00a0der\u00a0Hormon\u2010Anwenderinnen \u00a0der\u00a0weiblichen \u00a0TK\u2010Versicherten \u00a0\u00fcber\u00a040\u00a0Jahre\u00a0nach\u00a0\nBundesland \u00a0in\u00a0den\u00a0Jahren\u00a02011\u00a0bis\u00a02013\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0 \n151\u00a0\n \nInnovationsreport 2015 \u00a0 9.1.3 Kosten\u00a0der\u00a0Hormontherapie \u00a0\nBei\u00a0der\u00a0Anzahl\u00a0der\u00a0f\u00fcr\u00a0die\u00a0Hormontherapie \u00a0in\u00a0und\u00a0nach\u00a0den\u00a0Wechseljahren \u00a0verordneten \u00a0Packungen \u00a0\nl\u00e4sst\u00a0sich\u00a0f\u00fcr\u00a0das\u00a0Jahr\u00a02012\u00a0im\u00a0Vergleich \u00a0zu\u00a02011\u00a0zun\u00e4chst\u00a0ein\u00a0leichter\u00a0R\u00fcckgang \u00a0feststellen \u00a0(\u2010\u00a00,6\u00a0Pro\u2010\nzent),\u00a0im\u00a0Jahre\u00a02013\u00a0ist\u00a0dagegen\u00a0ein\u00a0erneuter\u00a0leichter\u00a0Anstieg\u00a0erkennbar, \u00a0der\u00a0den\u00a0R\u00fcckgang \u00a0in\u00a02012\u00a0\nkompensiert \u00a0und\u00a0dar\u00fcber\u00a0hinausgeht \u00a0(+\u00a02,9\u00a0Prozent)\u00a0(Tabelle\u00a022).\u00a0Die\u00a0Menge\u00a0der\u00a0definierten \u00a0\nTagesdosen \u00a0(DDD\u00a0=\u00a0defined\u00a0daily\u00a0doses )\u00a0sowie\u00a0die\u00a0Ausgaben \u00a0f\u00fcr\u00a0die\u00a0Hormontherapie \u00a0stiegen\u00a0\nhingegen\u00a0zwischen\u00a02011\u00a0und\u00a02013\u00a0kontinuierlich \u00a0leicht\u00a0an\u00a0(Tabelle\u00a022).\u00a0Im\u00a0Beobachtungszeitraum \u00a0\nwerden\u00a0insgesamt \u00a0gut\u00a01,87\u00a0Mio.\u00a0Packungen \u00a0Hormonpr\u00e4parate \u00a0zur\u00a0Anwendung \u00a0im\u00a0Klimakterium \u00a0\nverordnet. \u00a0\n\u00a0\n\u00a0 2011\u00a0\u00a0\n\u00a02012\u00a0 Differenz \u00a0in\u00a0\nProzent\u00a0\n2012\u00a0zu\u00a020112013\u00a0\u00a0\n\u00a0Differenz \u00a0in\u00a0\nProzent\u00a0\n2013\u00a0zu\u00a02012\nAnzahl\u00a0verordneter \u00a0\u00a0\nPackungen \u00a0620.729\u00a0 617.121 \u20100,6\u00a0% 635.003\u00a0 +2,9\u00a0%\u00a0\nVerordnete \u00a0DDD\u00a0 57.902.554 \u00a0 58.053.662 +0,3\u00a0% 59.920.476 \u00a0 +3,2\u00a0%\nBruttoausgaben \u00a0f\u00fcr\u00a0die\u00a0\u00a0\nHormontherapie \u00a017.484.795 \u00a0 17.527.441 +0,2\u00a0% 18.255.062 \u00a0 +4,2\u00a0%\nTabelle\u00a022:\u00a0Anzahl\u00a0der\u00a0verordneten \u00a0Packungen \u00a0und\u00a0DDD\u00a0(Estrogen \u00a0und\u00a0Gestagen) \u00a0sowie\u00a0Ausgaben \u00a0in\u00a0Euro\u00a0f\u00fcr\u00a0\ndie\u00a0Hormontherapie \u00a0in\u00a0den\u00a0Jahren\u00a02011\u00a0bis\u00a02013\u00a0auf\u00a0Basis\u00a0von\u00a0TK\u2010Routinedaten \u00a0\nDie\u00a0Ausgaben \u00a0pro\u00a0Hormon\u2010Anwenderin \u00a0liegen\u00a0im\u00a0Jahr\u00a02011\u00a0bei\u00a067,22\u00a0Euro,\u00a0im\u00a0Jahr\u00a02012\u00a0bei\u00a067,12\u00a0\nEuro\u00a0und\u00a0im\u00a0Jahr\u00a02013\u00a0bei\u00a068,02\u00a0Euro\u00a0pro\u00a0versicherte \u00a0Hormon\u2010Anwenderin. \u00a0\n\u00a0\n9.1.4 Verordnung \u00a0nach\u00a0Wirkstoffgruppen \u00a0\nDie\u00a0Auswertungen \u00a0hinsichtlich \u00a0der\u00a0einzelnen \u00a0Pr\u00e4parate \u00a0in\u00a0den\u00a0Wirkstoffgruppen \u00a0zeigen\u00a0\nunterschiedlich \u00a0hohe\u00a0Verordnungen. \u00a0Bei\u00a0der\u00a0Wirkstoffgruppe \u00a0der\u00a0estrogenhaltigen \u00a0Kombinationen \u00a0\nmit\u00a0sequentieller \u00a0Gestagenzugabe \u00a0wird\u00a0im\u00a0Jahr\u00a02013\u00a0f\u00fcr\u00a0weibliche \u00a0Versicherte \u00a0der\u00a0TK\u00a0am\u00a0h\u00e4ufigsten \u00a0\ndas\u00a0Pr\u00e4parat\u00a0Presomen \u00a0comp\u00ae\u00a0bzw.\u00a0conti\u00ae\u00a0verschrieben, \u00a0gefolgt\u00a0von\u00a0Femoston\u00ae \u00a0und\u00a0Mericomb\u00ae \u00a0\n(Tabelle\u00a023).\u00a0Die\u00a0Pr\u00e4parate \u00a0Cyclo\u00a0\u00d6strogynal\u00ae, \u00a0Gynamon\u00ae, \u00a0Estalis\u00ae\u00a0und\u00a0Osmil\u00ae\u00a0befinden\u00a0sich\u00a0\nmittlerweile \u00a0nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0(Stand\u00a0Lauer\u2010Taxe\u00a001.06.2015). \u00a0\u00a0\nIm\u00a0Hinblick\u00a0auf\u00a0die\u00a0Wirkstoffgruppe \u00a0der\u00a0estrogenhaltigen \u00a0Kombinationen \u00a0mit\u00a0kontinuierlicher \u00a0\nGestagenzugabe \u00a0sind\u00a0die\u00a0Pr\u00e4parate \u00a0Lafamme\u00ae, \u00a0Femoston \u00a0conti\u00ae\u00a0bzw.\u00a0mini\u00ae\u00a0und\u00a0Activelle\u00ae \u00a0unter\u00a0den\u00a0\nersten\u00a0drei\u00a0Fertigarzneimitteln. \u00a0Den\u00a0h\u00f6chsten \u00a0Verordnungsr\u00fcckgang \u00a0verzeichnet \u00a0Estragest\u00a0TTS\u00ae,\u00a0mit\u00a0\nder\u00a0fixen\u00a0Kombination \u00a0aus\u00a0Estradiol\u00a0und\u00a0Norethisteronacetat, \u00a0angewendet \u00a0als\u00a0transdermales \u00a0Pflaster\u00a0\n(Tabelle\u00a024),\u00a0begr\u00fcndet \u00a0in\u00a0der\u00a0Marktr\u00fccknahme \u00a0am\u00a001.06.2013. \u00a0\u00a0 \u00a0 \n152\u00a0 \n \nInnovationsreport 2015 \u00a0Pr\u00e4paratename \u00a0 DDD\u00a0in\u00a02011 DDD\u00a0in\u00a02012 Differenz \u00a0in\u00a0\nProzent\u00a0\n2012\u00a0zu\u00a02011DDD\u00a0in\u00a02013\u00a0Differenz \u00a0in\u00a0\nProzent\u00a0\n2013\u00a0zu\u00a02012\nPresomen \u00a0comp\u00ae/\u2010conti\u00ae\u00a0 1.328.600 1.205.736 \u20109,2\u00a0% 1.092.784 \u00a0\u20109,4\u00a0%\nFemoston\u00ae \u00a0 793.212 853.776 7,6\u00a0% 899.136\u00a0 5,3\u00a0%\nMericomb\u00ae \u00a0 497.672 482.748 \u20103,0\u00a0% 454.916\u00a0\u20105,8\u00a0%\nCyclo\u00a0Progynova \u00a0N\u00ae\u00a0 280.728 349.020 24,3\u00a0% 372.288\u00a0 6,7\u00a0%\nKlimonorm\u00ae \u00a0 189.896 200.452 5,6\u00a0% 205.268\u00a0 2,4\u00a0%\nFem\u00a07\u00a0Combi\u00ae\u00a0 111.213 142.405 28,0\u00a0% 180.568\u00a0 26,8\u00a0%\nSequidot\u00ae \u00a0 167.806 151.706 \u20109,6\u00a0% 163.438\u00a0 7,7\u00a0%\nNovofem\u00ae \u00a0 164.024 149.744 \u20108,7\u00a0% 137.172\u00a0\u2010 8,4\u00a0%\nTrisequens\u00ae \u00a0 123.480 114.436 \u20107,3\u00a0% 106.512\u00a0\u20106,9\u00a0%\n\u00d6stronara\u00ae \u00a0 73.668 66.556 \u20109,7\u00a0% 64.568\u00a0\u2010 3,0\u00a0%\nSisare\u00ae\u00a0 62.916 57.120 \u20109,2\u00a0% 51.408\u00a0\u201010,0\u00a0%\nNaemis\u00ae\u00a0 0 0 0,0\u00a0% 33.516\u00a0 0,0\u00a0%\nClimopax\u00a0cyclo\u00ae\u00a0 33.208 31.920 \u20103,9\u00a0% 27.888\u00a0\u201012,6\u00a0%\nCyclo\u00a0\u00d6strogynal\u00ae \u00a0 361.424 117.880 \u201067,\u00a04% 168\u00a0\u2010 99,9\u00a0%\nGynamon\u00ae \u00a0 84 0 0,0\u00a0% 0\u00a0 0,0\u00a0%\nEstalis\u00ae\u00a0 41.748 168 \u201099,6\u00a0% 0\u00a0 0,0\u00a0%\nOsmil\u00ae\u00a0 22.456 252 \u201098,9\u00a0% 0\u00a0 0,0\u00a0%\nGesamt\u00a0 4.252.136 3.923.918 \u20107,7% 3.789.630 \u00a0\u2010 3,4%\nTabelle\u00a023:\u00a0Die\u00a0verordnungsst\u00e4rksten \u00a0Pr\u00e4parate \u00a0in\u00a0der\u00a0Wirkstoffgruppe \u00a0der\u00a0estrogenhaltigen \u00a0Kombinationen \u00a0\nmit\u00a0sequentieller \u00a0Gestagenzugabe \u00a0in\u00a02011\u00a0bis\u00a02013,\u00a0absteigend \u00a0nach\u00a0verordneten \u00a0DDD\u00a0in\u00a02013\u00a0\n\u00a0\u00a0 \n153\u00a0\n \nInnovationsreport 2015 \u00a0Pr\u00e4paratename \u00a0 DDD\u00a0in\u00a02011 DDD\u00a0in\u00a02012 Differenz \u00a0in\u00a0\nProzent\n2012\u00a0zu\u00a02011DDD\u00a0in\u00a02013\u00a0Differenz \u00a0in\u00a0\nProzent\u00a0\n2013\u00a0zu\u00a02012\nLafamme\u00ae \u00a0 3.352.104 3.410.176 1,7\u00a0% 3.554.768 \u00a0 4,2\u00a0%\nFemoston \u00a0Conti\u00ae/\u2010mini\u00ae\u00a0 1.359.764 1.440.796 6,0\u00a0% 1.534.792 \u00a0 6,5\u00a0%\nActivelle\u00ae \u00a0 1.235.332 1.128.848 \u20108,6\u00a0% 1.065.484 \u00a0\u20105,6\u00a0%\nCliovelle\u00ae \u00a0 1.078.840 1.058.512 \u20101,9\u00a0% 1.058.652 \u00a0 0,0\u00a0%\nFem\u00a07\u00a0Conti\u00ae\u00a0 623.573 690.211 10,7\u00a0% 877.275\u00a0 27,1\u00a0%\nAngeliq\u00ae\u00a0 901.068 872.760 \u20103,1\u00a0% 840.952\u00a0\u2010 3,6\u00a0%\nEstragest\u00a0TTS\u00ae\u00a0 1.706.660 1.686.717 \u20101,2\u00a0% 659.400\u00a0\u201060,9\u00a0%\nWellnara\u00ae \u00a0 489.524 531.048 8,5\u00a0% 571.676\u00a0 7,7\u00a0%\nEstramon \u00a0comp\u00ae\u00a0 12.628 17.304 37,0\u00a0% 523.186\u00a0 2.923,5\u00a0%\nClionara\u00ae \u00a0 506.632 498.400 \u20101,6\u00a0% 506.968\u00a0 1,7\u00a0%\nMerigest\u00ae \u00a0 431.928 412.356 \u20104,5\u00a0% 348.810\u00a0\u201015,4\u00a0%\nClimopax\u00ae \u00a0 361.424 314.832 \u201012,9\u00a0% 280.168\u00a0\u2010 11,0\u00a0%\nIndivina\u00ae\u00a0 294.616 266.980 \u20109,4\u00a0% 245.056\u00a0\u20108,2\u00a0%\nClimodien\u00ae \u00a0 256.396 248.220 \u20103,2\u00a0% 232.316\u00a0\u2010 6,4\u00a0%\nKliogest\u00a0N\u00ae\u00a0 221.928 165.788 \u201025,3\u00a0% 144.256\u00a0\u201013,0\u00a0%\nGesamt\u00a0 12.832.417 12.742.949 \u20100,7% 12.443.759 \u00a0\u2010 2,3%\nTabelle\u00a024:\u00a0Die\u00a0verordnungsst\u00e4rksten \u00a0Pr\u00e4parate \u00a0in\u00a0der\u00a0Wirkstoffgruppe \u00a0der\u00a0estrogenhaltigen \u00a0Kombinationen \u00a0\nmit\u00a0kontinuierlicher \u00a0Gestagenzugabe \u00a0in\u00a02011\u00a0bis\u00a02013,\u00a0absteigend \u00a0nach\u00a0verordneten \u00a0DDD\u00a0in\u00a02013\u00a0\n\u00a0\nInsgesamt \u00a0kann\u00a0somit\u00a0auch\u00a0f\u00fcr\u00a0die\u00a0weiblichen \u00a0Versicherten \u00a0der\u00a0TK\u00a0zwischen\u00a02011\u00a0und\u00a02013\u00a0eine\u00a0\nAbnahme \u00a0der\u00a0Verordnungspr\u00e4valenz \u00a0weiblicher \u00a0Hormone \u00a0in\u00a0der\u00a0Postmenopause \u00a0gezeigt\u00a0werden.\u00a0Die\u00a0\nkritische\u00a0Auseinandersetzung \u00a0mit\u00a0dieser\u00a0Therapieform \u00a0sollte\u00a0aber\u00a0dennoch\u00a0\u2013\u00a0insbesondere \u00a0vor\u00a0dem\u00a0\nHintergrund \u00a0der\u00a0noch\u00a0immer\u00a0anhaltenden \u00a0Diskussionen \u00a0\u00fcber\u00a0das\u00a0F\u00fcr\u00a0und\u00a0Wider\u00a0verschiedener \u00a0\nTherapieoptionen \u00a0und\u00a0\u2010anpassungsm\u00f6glichkeiten \u00a0in\u00a0der\u00a0postmenopausalen \u00a0Hormonbehandlung \u00a0\u2013\u00a0\nnicht\u00a0beendet\u00a0werden.\u00a0\u00a0\nAus\u00a0Sicht\u00a0der\u00a0Versorgungsforschung \u00a0stellt\u00a0sich\u00a0vor\u00a0allem\u00a0die\u00a0Frage,\u00a0wie\u00a0den\u00a0Frauen\u00a0der\u00a0Weg\u00a0aus\u00a0einer\u00a0\nbestehenden \u00a0Hormontherapie \u00a0erleichtert \u00a0werden\u00a0kann.\u00a0Zu\u00a0bedenken \u00a0gilt,\u00a0dass\u00a0nach\u00a0Absetzen\u00a0der\u00a0\nHormontherapie \u00a0die\u00a0Wechseljahrbeschwerden \u00a0h\u00e4ufig\u00a0wiederkehren \u00a0bzw.\u00a0sich\u00a0bis\u00a0ins\u00a0hohe\u00a0\nLebensalter \u00a0verschieben \u00a0k\u00f6nnen\u00a0(Ness\u00a0et\u00a0al.,\u00a02006).\u00a0Untersuchungen \u00a0zeigen,\u00a0dass\u00a0insbesondere \u00a0\nvasomotorische \u00a0Beschwerden \u00a0nach\u00a0Beendigung \u00a0einer\u00a0Hormontherapie \u00a0wieder\u00a0auftreten \u00a0k\u00f6nnen\u00a0\u2013\u00a0\nunabh\u00e4ngig \u00a0davon,\u00a0ob\u00a0es\u00a0sich\u00a0dabei\u00a0um\u00a0ein\u00a0abruptes\u00a0Absetzen \u00a0oder\u00a0eine\u00a0ausschleichende \u00a0\nBehandlung \u00a0handelt\u00a0(Haimov\u2010Kochman \u00a0et\u00a0al.,\u00a02006;\u00a0Lindh\u2010Astrand\u00a0et\u00a0al.,\u00a02010).\u00a0Das\u00a0erneute\u00a0\nAuftreten \u00a0der\u00a0typischen \u00a0Wechseljahrbeschwerden \u00a0beim\u00a0Absetzversuch \u00a0kann\u00a0das\u00a0Therapieende \u00a0einer\u00a0\nHormonbehandlung \u00a0somit\u00a0erschweren \u00a0und\u00a0dazu\u00a0f\u00fchren,\u00a0die\u00a0Hormone \u00a0immer\u00a0weiter\u00a0anzuwenden. \u00a0\nDas\u00a0erkl\u00e4rt\u00a0die\u00a0relativ\u00a0hohen\u00a0Verordnungsanteile \u00a0bei\u00a0Frauen\u00a0jenseits\u00a0des\u00a060.\u00a0Lebensjahrs. \u00a0\u00a0 \n154\u00a0 \n \nInnovationsreport 2015 \u00a0Es\u00a0sollte\u00a0erreicht\u00a0werden,\u00a0dass\u00a0die\u00a0Anzahl\u00a0der\u00a0Hormon\u2010Anwenderinnen \u00a0weiter\u00a0abnimmt\u00a0und\u00a0dass\u00a0die\u00a0\ndamit\u00a0verbundenen \u00a0Langzeitrisiken \u00a0nicht\u00a0marginalisiert \u00a0werden.\u00a0Ein\u00a0genereller \u00a0Verzicht\u00a0auf\u00a0die\u00a0\nHormontherapie \u00a0kann\u00a0jedoch\u00a0sicherlich \u00a0nicht\u00a0erwartet\u00a0und\u00a0realisiert\u00a0werden.\u00a0Die\u00a0evidenzgest\u00fctzten \u00a0\nEmpfehlungen, \u00a0die\u00a0Hormontherapie \u00a0nur\u00a0nach\u00a0sorgf\u00e4ltiger, \u00a0individueller \u00a0Nutzen\u2010Risiko\u2010Abw\u00e4gung \u00a0und\u00a0\nallenfalls\u00a0kurzfristig \u00a0zur\u00a0Linderung \u00a0starker\u00a0Wechseljahrbeschwerden \u00a0einzusetzen, \u00a0sollten\u00a0auch\u00a0\nweiterhin \u00a0bei\u00a0der\u00a0Entscheidung \u00a0f\u00fcr\u00a0oder\u00a0gegen\u00a0eine\u00a0entsprechende \u00a0Behandlung \u00a0im\u00a0Vordergrund \u00a0\nstehen.\u00a0\u00a0\n \u00a0 \n155\u00a0\n \nInnovationsreport 2015 \u00a0 10 Keypoints \u00a0\u00a0\n\uf0b7 Der\u00a0Innovationsreport \u00a02015\u00a0bewertet\u00a0die\u00a019\u00a0neuen\u00a0Wirkstoffe \u00a0bzw.\u00a0Wirkstoffkombinationen \u00a0\ndes\u00a0Jahres\u00a02012.\u00a0Der\u00a0Wirkstoff \u00a0Nomegestrolacetat \u00a0wurde\u00a0(jeweils\u00a0als\u00a0Fixkombination \u00a0mit\u00a0\nEstradiol) \u00a0in\u00a0zwei\u00a0Indikationen \u00a0zugelassen, \u00a0sowohl\u00a0als\u00a0orales\u00a0Kontrazeptivum \u00a0als\u00a0auch\u00a0zur\u00a0\nHormontherapie \u00a0von\u00a0Wechseljahrbeschwerden, \u00a0so\u00a0dass\u00a0sich\u00a0insgesamt \u00a020\u00a0Bewertungen \u00a0im\u00a0\nReport\u00a0finden.\u00a0\n\uf0b7 Von\u00a0den\u00a020\u00a0bewerteten \u00a0Pr\u00e4paraten \u00a0bekam\u00a0nur\u00a0das\u00a0Krebsmittel \u00a0Zelboraf\u00ae \u00a0mit\u00a0dem\u00a0Wirkstoff \u00a0\nVemurafenib \u00a0eine\u00a0\u201egr\u00fcne\u00a0Gesamtampel\". \u00a0F\u00fcr\u00a0sieben\u00a0Pr\u00e4parate \u00a0zeigte\u00a0die\u00a0Ampel\u00a0\u201egelb\"\u00a0in\u00a0der\u00a0\nGesamtbewertung, \u00a0f\u00fcr\u00a0zw\u00f6lf\u00a0sogar\u00a0\u201erot\".\u00a0Der\u00a0zweite\u00a0\u201eAMNOG \u2010Jahrgang\" \u00a0brachte\u00a0somit\u00a0kaum\u00a0\nechte\u00a0therapeutische \u00a0Innovationen \u00a0hervor.\u00a0\n\uf0b7 Nach\u00a0dem\u00a0besseren\u00a0Abschneiden \u00a0der\u00a0neuen\u00a0Wirkstoffe \u00a0des\u00a0Jahres\u00a02011\u00a0gegen\u00fcber \u00a0dem\u00a0Jahr\u00a0\n2010\u00a0k\u00f6nnen\u00a0die\u00a0neuen\u00a0Arzneistoffe \u00a0des\u00a0Jahres\u00a02012\u00a0diesen\u00a0Trend\u00a0also\u00a0nicht\u00a0fortsetzen. \u00a0\nLediglich\u00a0einmal\u00a0zeigt\u00a0die\u00a0Ampel\u00a0\u201egr\u00fcn\",\u00a0im\u00a0Vorjahresreport \u00a0hingegen\u00a0dreimal.\u00a0\n\uf0b7 Obwohl\u00a0die\u00a0Bewertung \u00a0der\u00a0neuen\u00a0Wirkstoffe \u00a0des\u00a0Jahres\u00a02012\u00a0im\u00a0Vergleich \u00a0zum\u00a0vorherigen \u00a0\nJahrgang\u00a0deutlich\u00a0schlechter \u00a0ausfiel,\u00a0wurden\u00a0die\u00a0Pr\u00e4parate \u00a0nach\u00a0Markteinf\u00fchrung \u00a0beinahe\u00a0\ngenauso\u00a0h\u00e4ufig\u00a0verordnet \u00a0wie\u00a0die\u00a0neuen\u00a0Pr\u00e4parate \u00a0im\u00a0Vorjahr\u00a0(41\u00a0Tsd.\u00a0Packungen \u00a0vs.\u00a049\u00a0Tsd.\u00a0\nPackungen \u00a0zu\u00a0Lasten\u00a0der\u00a0TK\u00a0im\u00a0ersten\u00a0Jahr).\u00a0Der\u00a0Umsatz\u00a0fiel\u00a0dabei\u00a0geringer\u00a0aus\u00a0(27,5\u00a0Mio.\u00a0\nEuro\u00a0vs.\u00a074,0\u00a0Mio.\u00a0Euro).\u00a0\n\uf0b7 Erstaunlich \u00a0ist,\u00a0dass\u00a0mehr\u00a0als\u00a0die\u00a0H\u00e4lfte\u00a0der\u00a0neuen\u00a0Pr\u00e4parate, \u00a0n\u00e4mlich\u00a0zw\u00f6lf\u00a0von\u00a020,\u00a0innerhalb \u00a0\nvon\u00a0zwei\u00a0bis\u00a0drei\u00a0Jahren\u00a0nach\u00a0Marktzulassung \u00a0Eingang\u00a0in\u00a0Leitlinien\u00a0medizinischer \u00a0\nFachgesellschaften \u00a0findet\u00a0\u2013\u00a0und\u00a0dies\u00a0trotz\u00a0des\u00a0geringen\u00a0therapeutischen \u00a0Fortschritts \u00a0und\u00a0der\u00a0\nnegativen \u00a0Bewertungen. \u00a0\n\uf0b7 \u00c4rzte\u00a0nennen\u00a0Leitlinien\u00a0als\u00a0dritth\u00e4ufigste \u00a0Quelle\u00a0zur\u00a0Entscheidungsfindung, \u00a0ob\u00a0sie\u00a0ein\u00a0neues\u00a0\nArzneimittel \u00a0verordnen. \u00a0Die\u00a0Ergebnisse \u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung \u00a0werden\u00a0dagegen\u00a0\ndeutlich\u00a0seltener\u00a0als\u00a0Informationsquelle \u00a0angef\u00fchrt. \u00a0\u00c4rzte\u00a0vertrauen \u00a0den\u00a0Leitlinien\u00a0also\u00a0mehr\u00a0\nals\u00a0den\u00a0Ergebnissen \u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung. \u00a0Daher\u00a0ist\u00a0es\u00a0umso\u00a0folgenreicher, \u00a0wenn\u00a0in\u00a0\nLeitlinien\u00a0auch\u00a0Arzneimittel \u00a0genannt\u00a0werden,\u00a0die\u00a0weniger\u00a0\u00fcberzeugend \u00a0in\u00a0der\u00a0fr\u00fchen\u00a0\nNutzenbewertung \u00a0abgeschnitten \u00a0haben.\u00a0\u00a0\n\uf0b7 Die\u00a0Ergebnisse \u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung \u00a0wirken\u00a0sich\u00a0nicht\u00a0auf\u00a0das\u00a0\u00e4rztliche\u00a0Verordnungs \u2010\nverhalten \u00a0aus.\u00a0So\u00a0sah\u00a0der\u00a0G\u2010BA\u00a0z.B.\u00a0f\u00fcr\u00a0das\u00a0MS\u2010Therapeutikum \u00a0Fingolimod \u00a0bisher\u00a0einen\u00a0\nZusatznutzen \u00a0f\u00fcr\u00a0ca.\u00a01.500\u00a0Patienten \u00a0innerhalb \u00a0der\u00a0gesamten \u00a0GKV.\u00a0Diese\u00a0Fallzahl\u00a0wird\u00a0bereits\u00a0\nmit\u00a0TK\u2010Versicherten \u00a0nahezu\u00a0vollst\u00e4ndig \u00a0erreicht.\u00a0\n\uf0b7 Auff\u00e4llig\u00a0ist\u00a0weiterhin \u00a0die\u00a0hohe\u00a0Zahl\u00a0der\u00a0Neuzulassungen \u00a0in\u00a0Therapiegebieten, \u00a0die\u00a0vor\u00a0allem\u00a0\nf\u00fcr\u00a0die\u00a0pharmazeutischen \u00a0Unternehmer \u00a0\u00f6konomisch \u00a0lukrativ\u00a0sind.\u00a0Neun\u00a0der\u00a019\u00a0neuen\u00a0\nWirkstoffe, \u00a0also\u00a0beinahe\u00a050\u00a0Prozent,\u00a0werden\u00a0zur\u00a0Behandlung \u00a0von\u00a0Krebserkrankungen \u00a0\neingesetzt. \u00a0So\u00a0findet\u00a0Forschung \u00a0vornehmlich \u00a0nicht\u00a0nur\u00a0in\u00a0den\u00a0Bereichen \u00a0statt,\u00a0in\u00a0denen\u00a0sie\u00a0\naus\u00a0Sicht\u00a0der\u00a0Patienten \u00a0am\u00a0dringendsten \u00a0ben\u00f6tigt\u00a0wird,\u00a0sondern\u00a0in\u00a0Indikationsbereichen, \u00a0in\u00a0\ndenen\u00a0vergleichsweise \u00a0hohe\u00a0Preise\u00a0akzeptiert \u00a0werden.\u00a0\u00a0\n\uf0b7 Als\u00a0Trend\u00a0ist\u00a0unverkennbar, \u00a0dass\u00a0gerade\u00a0in\u00a0der\u00a0Onkologie \u00a0neue\u00a0Wirkstoffe \u00a0nach\u00a0\nbeschleunigten \u00a0Zulassungsverfahren \u00a0zugelassen \u00a0werden.\u00a0Diese\u00a0Verfahren \u00a0verringern \u00a0die\u00a0\nAnforderungen \u00a0an\u00a0die\u00a0Erkenntnisse \u00a0zu\u00a0Wirksamkeit \u00a0und\u00a0Schaden\u00a0bei\u00a0Zulassung \u00a0und\u00a0lassen\u00a0\nPatienten \u00a0und\u00a0\u00c4rzte\u00a0\u2013\u00a0leider\u00a0meist\u00a0zu\u00a0Unrecht\u00a0\u2013\u00a0einen\u00a0gro\u00dfen\u00a0therapeutischen \u00a0Fortschritt \u00a0\nerwarten. \u00a0\u00a0 \n156\u00a0 \n \nInnovationsreport 2015 \u00a0\uf0b7 Die\u00a0Produktivit\u00e4ts \u2010\u00a0und\u00a0Innovationskrise \u00a0in\u00a0der\u00a0pharmazeutischen \u00a0Industrie\u00a0ist\u00a0noch\u00a0\nkeineswegs \u00a0\u00fcberwunden. \u00a0Wenig(er) \u00a0ertragreich \u00a0erscheinende \u00a0Arzneimittelgruppen, \u00a0wie\u00a0z.B.\u00a0\nAntibiotika, \u00a0werden\u00a0kaum\u00a0beforscht, \u00a0obwohl\u00a0therapeutische \u00a0Innovationen \u00a0hier\u00a0zwingend \u00a0\nnotwendig \u00a0sind,\u00a0um\u00a0die\u00a0H\u00e4ufigkeit \u00a0von\u00a0Resistenzen \u00a0und\u00a0den\u00a0damit\u00a0alleine\u00a0in\u00a0Deutschland \u00a0\nverbundenen \u00a0rund\u00a015.000\u00a0Todesf\u00e4llen \u00a0zu\u00a0verringern. \u00a0\n\uf0b7 F\u00fcnf\u00a0der\u00a019\u00a0neuen\u00a0Wirkstoffe \u00a0wurden\u00a0als\u00a0Orphan\u00a0Drugs\u00a0zugelassen. \u00a0Die\u00a0vermehrte \u00a0Zulassung \u00a0\nvon\u00a0Orphan\u00a0Drugs\u00a0ist\u00a0aber\u00a0nicht\u00a0unbedingt \u00a0auf\u00a0die\u00a0Entwicklung \u00a0von\u00a0Arzneimitteln \u00a0gegen\u00a0sehr\u00a0\nseltene\u00a0angeborene \u00a0Erkrankungen \u00a0zur\u00fcckzuf\u00fchren, \u00a0sondern\u00a0eher\u00a0auf\u00a0eine\u00a0\u201eOrphanisierung\u201c \u00a0\nsogenannter \u00a0Volkskrankheiten. \u00a0Das\u00a0\u201eSlicing\u201c\u00a0von\u00a0Indikationen, \u00a0also\u00a0das\u00a0Zuschneiden \u00a0der\u00a0\nPatientengruppen \u00a0auf\u00a0das\u00a0Ma\u00df\u00a0von\u00a0seltenen\u00a0Krankheiten, \u00a0n\u00e4mlich\u00a0auf\u00a0maximal\u00a05\u00a0pro\u00a010.000\u00a0\nEinwohner \u00a0in\u00a0der\u00a0EU,\u00a0sichert\u00a0den\u00a0pharmazeutischen \u00a0Unternehmern \u00a0einen\u00a0relativ\u00a0raschen\u00a0\nDurchlauf \u00a0durch\u00a0das\u00a0AMNOG\u2010Verfahren \u00a0\u2013\u00a0der\u00a0Zusatznutzen \u00a0gilt\u00a0bei\u00a0solchen\u00a0Orphan\u00a0Drugs\u00a0\nvon\u00a0vornherein \u00a0als\u00a0gegeben.\u00a0\n\uf0b7 Vier\u00a0der\u00a020\u00a0neuen\u00a0Pr\u00e4parate \u00a0wurden\u00a0f\u00fcr\u00a0gro\u00dfe\u00a0Patientengruppen \u00a0entwickelt. \u00a0Sie\u00a0werden\u00a0zur\u00a0\nBehandlung \u00a0der\u00a0drei\u00a0Volkskrankheiten \u00a0COPD,\u00a0Hypertonie, \u00a0Diabetes\u00a0mellitus\u00a0Typ\u00a02\u00a0sowie\u00a0zur\u00a0\nHormontherapie \u00a0von\u00a0Wechseljahrbeschwerden \u00a0eingesetzt. \u00a0In\u00a0der\u00a0Bewertung \u00a0fielen\u00a0all\u00a0diese\u00a0\nPr\u00e4parate \u00a0durch.\u00a0\n\uf0b7 Trotz\u00a0der\u00a0seit\u00a0langem\u00a0gef\u00fchrten \u00a0Diskussion \u00a0um\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0einer\u00a0Hormontherapie \u00a0\nhat\u00a0in\u00a0dem\u00a0Zeitraum\u00a0von\u00a02011\u00a0bis\u00a02013\u00a0j\u00e4hrlich\u00a0jede\u00a0achte\u00a0weibliche \u00a0TK\u2010Versicherte \u00a0\u00fcber\u00a040\u00a0\nJahre\u00a0mindestens \u00a0eine\u00a0Verordnung \u00a0eines\u00a0Hormonpr\u00e4parates \u00a0zur\u00a0Behandlung \u00a0von\u00a0\nWechseljahrbeschwerden \u00a0bekommen. \u00a0Es\u00a0ist\u00a0vor\u00a0allem\u00a0die\u00a0Aufgabe\u00a0der\u00a0gyn\u00e4kologischen \u00a0\nFachgesellschaften, \u00a0einer\u00a0m\u00f6glicherweise \u00a0wieder\u00a0aufkeimenden \u00a0breiten\u00a0und\u00a0unkritischen \u00a0\nDauerverordnung \u00a0solcher\u00a0Hormontherapien \u00a0in\u00a0den\u00a0Wechseljahren \u00a0vorzubeugen. \u00a0Die\u00a0\nbekannten \u00a0Risiken\u00a0sind\u00a0auch\u00a0mit\u00a0neuen\u00a0Arzneimitteln \u00a0nicht\u00a0zu\u00a0umgehen: \u00a0H\u00e4ufigere \u00a0\nHerzinfarkte \u00a0und\u00a0Schlaganf\u00e4lle \u00a0sowie\u00a0ein\u00a0Anstieg\u00a0der\u00a0Brustkrebsraten \u00a0gegen\u00fcber \u00a0den\u00a0Frauen,\u00a0\ndie\u00a0keine\u00a0Hormontherapie \u00a0bekommen. \u00a0Daher\u00a0gilt\u00a0nach\u00a0wie\u00a0vor:\u00a0Solche\u00a0Mittel\u00a0sollen\u00a0nur\u00a0bei\u00a0\nstarken\u00a0Beschwerden \u00a0\u00fcber\u00a0m\u00f6glichst \u00a0kurze\u00a0Zeit\u00a0in\u00a0niedriger\u00a0Dosierung \u00a0gegeben\u00a0werden.\u00a0\n\uf0b7 Bei\u00a0Markteintritt \u00a0eines\u00a0neuen\u00a0Arzneimittels \u00a0ist\u00a0das\u00a0Wissen\u00a0zu\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\u2013\u00a0vor\u00a0\nallem\u00a0au\u00dferhalb \u00a0klinischer \u00a0Studien\u00a0\u2013\u00a0begrenzt. \u00a0Das\u00a0Beispiel\u00a0des\u00a0MS\u2010Mittels\u00a0Fingolimod \u00a0\nverdeutlicht \u00a0aufgrund\u00a0der\u00a0Identifikation \u00a0bisher\u00a0nicht\u00a0bekannter \u00a0gravierender \u00a0unerw\u00fcnschter \u00a0\nWirkungen, \u00a0wie\u00a0wichtig\u00a0im\u00a0Sinne\u00a0von\u00a0Patientenschutz \u00a0und\u00a0ad\u00e4quater \u00a0\u00c4rzteinformation \u00a0eine\u00a0\nkontinuierliche \u00a0(Neu)Bewertung \u00a0im\u00a0Rahmen\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung \u00a0ist.\u00a0\n\uf0b7 Es\u00a0wird\u00a0auch\u00a0auf\u00a0einen\u00a0\u201eSystemfehler\u201c \u00a0im\u00a0AMNOG\u00a0hingewiesen, \u00a0der\u00a0im\u00a0Rahmen\u00a0des\u00a0\nlernenden \u00a0Systems\u00a0behoben\u00a0werden\u00a0sollte:\u00a0Trotz\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung \u00a0k\u00f6nnen\u00a0\nArzneimittel \u00a0ohne\u00a0Zusatznutzen \u00a0einen\u00a0hohen\u00a0Preis\u00a0erzielen,\u00a0wenn\u00a0die\u00a0zweckm\u00e4\u00dfige \u00a0\nVergleichstherapie \u00a0ebenfalls\u00a0hochpreisig \u00a0ist.\u00a0Hier\u00a0sollten\u00a0ver\u00e4nderte \u00a0Entscheidungs \u2010\nbedingungen \u00a0eingef\u00fchrt \u00a0werden.\u00a0Das\u00a0Beispiel\u00a0Dabrafenib \u00a0zeigt,\u00a0dass\u00a0das\u00a0AMNOG\u00a0keinen\u00a0\nausreichenden \u00a0Schutz\u00a0vor\u00a0Me\u2010too\u2010Pr\u00e4paraten \u00a0bietet\u00a0und\u00a0dass\u00a0diese\u00a0ebenfalls\u00a0einen\u00a0hohen\u00a0\nPreis\u00a0erzielen\u00a0k\u00f6nnen.\u00a0\n\uf0b7 Das\u00a0Beispiel\u00a0Dabrafenib \u00a0zeigt\u00a0zudem,\u00a0dass\u00a0die\u00a0AMNOG\u2010Bewertung \u00a0\u201eein\u00a0Zusatznutzen \u00a0ist\u00a0\nnicht\u00a0belegt\"\u00a0keinesfalls \u00a0zwangsl\u00e4ufig \u00a0eine\u00a0therapeutische \u00a0Ebenb\u00fcrtigkeit \u00a0gegen\u00fcber \u00a0der\u00a0\nzweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0(hier:\u00a0Vemurafenib) \u00a0bedeutet. \u00a0\n\uf0b7 Nicht\u00a0alle\u00a0neuen\u00a0Wirkstoffe \u00a0des\u00a0Jahres\u00a02012\u00a0mussten\u00a0die\u00a0(vollst\u00e4ndige) \u00a0fr\u00fche\u00a0Nutzen\u2010\nbewertung \u00a0beim\u00a0G\u2010BA\u00a0durchlaufen. \u00a0Pr\u00e4parate \u00a0mit\u00a0einem\u00a0zu\u00a0erwartenden \u00a0geringen\u00a0Umsatz\u00a0\nk\u00f6nnen\u00a0von\u00a0der\u00a0Bewertung \u00a0freigestellt \u00a0werden.\u00a0Pr\u00e4parate, \u00a0die\u00a0nicht\u00a0generell\u00a0durch\u00a0die\u00a0GKV\u00a0 \n157\u00a0\n \nInnovationsreport 2015 \u00a0erstattungsf\u00e4hig \u00a0sind,\u00a0werden\u00a0ebenfalls\u00a0nicht\u00a0gepr\u00fcft.\u00a0Orphan\u00a0Drugs\u00a0durchlaufen \u00a0ein\u00a0\nvereinfachtes \u00a0Verfahren, \u00a0in\u00a0dem\u00a0der\u00a0Zusatznutzen \u00a0von\u00a0vorneherein \u00a0als\u00a0belegt\u00a0gilt\u00a0und\u00a0der\u00a0G\u2010\nBA\u00a0lediglich\u00a0\u00fcber\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens \u00a0entscheidet. \u00a0Die\u00a0Bewertungen \u00a0im\u00a0Inno\u2010\nvationsreport \u00a0zeigen\u00a0aber,\u00a0dass\u00a0grunds\u00e4tzlich \u00a0alle\u00a0neuen\u00a0Arzneimittel \u00a0bewertet \u00a0werden\u00a0soll\u2010\nten.\u00a0Entscheidend \u00a0ist\u00a0nicht\u00a0die\u00a0Frage,\u00a0ob\u00a0die\u00a0Pr\u00e4parate \u00a0von\u00a0der\u00a0GKV\u00a0erstattet\u00a0werden,\u00a0son\u2010\ndern\u00a0ob\u00a0sie\u00a0einen\u00a0Zusatznutzen \u00a0f\u00fcr\u00a0die\u00a0Patienten \u00a0haben.\u00a0Um\u00a0die\u00a0Versorgung \u00a0qualitativ \u00a0zu\u00a0ver\u2010\nbessern,\u00a0ben\u00f6tigen \u00a0die\u00a0verordnenden \u00a0\u00c4rzte\u00a0diese\u00a0Informationen \u00a0f\u00fcr\u00a0alle\u00a0neuen\u00a0Arzneimittel. \u00a0\nNur\u00a0so\u00a0k\u00f6nnen\u00a0die\u00a0Ergebnisse \u00a0des\u00a0AMNOG\u2010Verfahrens \u00a0zu\u00a0einer\u00a0praxistauglichen \u00a0Informa\u2010\ntionsquelle \u00a0f\u00fcr\u00a0die\u00a0\u00c4rzteschaft \u00a0werden.\u00a0\n \n \n \u00a0\n158\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a011 Anhang:\u00a0Hintergrundinformationen \u00a0zu\u00a0den\u00a0Wirkstoffen \u00a0\nDaniela\u00a0Boeschen, \u00a0D\u00f6rte\u00a0Fuchs,\u00a0Judith\u00a0G\u00fcnther\u00a0\n11.1 Aclidiniumbromid \u00a0\nHandelsname: \u00a0Bretaris\u00ae\u00a0Genuair\u00ae, \u00a0Eklira\u00ae\u00a0Genuair\u00ae\u00a0u.a.\u00a0\u00a0\u00a0\u00a0\u00a0Hersteller: \u00a0Berlin\u2010Chemie\u00a0/\u00a0Menarini\u00a0u.a.\u00a0\nIndikation: \u00a0COPD\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Markteinf\u00fchrung: \u00a0Oktober\u00a02012\u00a0\nATC\u2010Code:\u00a0R03BB05\u00a0 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DDD:\u00a00,644\u00a0mg\u00a0\nDarreichungsform: \u00a0Pulver\u00a0zur\u00a0Inhalation \u00a0\nBewertung: \u00a0siehe\u00a0Seite\u00a030\u00a0\u00a0\nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nNeben\u00a0Tiotropiumbromid \u00a0und\u00a0Glycopyrronium \u00a0ist\u00a0Aclidiniumbromid \u00a0ein\u00a0weiterer\u00a0Vertreter \u00a0der\u00a0\nlangwirkenden \u00a0Muscarin \u2010Rezeptorantagonisten \u00a0(LAMA\u00a0=\u00a0long\u00a0acting\u00a0muscarinic \u00a0antagonist(s ),\u00a0auch\u00a0\nlangwirksame \u00a0Anticholinergika) \u00a0zur\u00a0symptomatischen \u00a0bronchodilatatorischen \u00a0Dauertherapie \u00a0der\u00a0\nchronisch \u00a0obstruktiven \u00a0Lungenkrankheit. \u00a0\u00a0\nDer\u00a0kompetitive, \u00a0selektive\u00a0Antagonist \u00a0bewirkt\u00a0an\u00a0M3\u2010Rezeptoren \u00a0der\u00a0glatten\u00a0Bronchialmuskulatur \u00a0\neine\u00a0Bronchodilatation \u00a0und\u00a0verbessert \u00a0so\u00a0die\u00a0Lungenfunktion. \u00a0Nach\u00a0rascher\u00a0Resorption \u00a0in\u00a0der\u00a0Lunge\u00a0\nerreichen \u00a0COPD\u2010Patienten \u00a0in\u00a0der\u00a0Regel\u00a0innerhalb \u00a0von\u00a015\u00a0Minuten\u00a0die\u00a0maximale \u00a0\nPlasmakonzentration. \u00a0Da\u00a0Aclidiniumbromid \u00a0im\u00a0Plasma\u00a0rasch\u00a0zu\u00a0einem\u00a0inaktiven\u00a0Alkohol\u00a0und\u00a0einem\u00a0\nCarbons\u00e4uremetaboliten \u00a0hydrolysiert \u00a0wird,\u00a0ist\u00a0die\u00a0Rate\u00a0an\u00a0systemischen \u00a0anticholinergen \u00a0\nNebenwirkungen \u00a0gering\u00a0(EMA,\u00a02014a).\u00a0\n\u00a0Zulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nF\u00fcr\u00a0das\u00a0lang\u00a0wirksame \u00a0Anticholinergikum \u00a0erfolgte\u00a0die\u00a0Zulassung \u00a0im\u00a0Juli\u00a02012.\u00a0Die\u00a0Darreichungsform \u00a0\nist\u00a0ein\u00a0Trockenpulver \u2010Inhalator\u00a0zur\u00a0Mehrfachanwendung, \u00a0der\u00a0bereits\u00a0bef\u00fcllt\u00a0ausgeliefert \u00a0wird\u00a0und\u00a0\nzum\u00a0sofortigen \u00a0Gebrauch \u00a0geeignet\u00a0ist.\u00a0Urspr\u00fcnglich \u00a0wurde\u00a0eine\u00a0einmal\u00a0t\u00e4gliche\u00a0Dosierung \u00a0entwickelt, \u00a0\ndie\u00a0jedoch\u00a0in\u00a0zwei\u00a0Phase\u2010III\u2010Studien\n\u00a0keine\u00a0klinisch\u00a0relevante \u00a0Wirkung\u00a0zeigte,\u00a0so\u00a0dass\u00a0der\u00a0Wirkstoff \u00a0\nnun\u00a0zweimal\u00a0t\u00e4glich\u00a0inhaliert\u00a0werden\u00a0muss\u00a0(Almirall,\u00a02014).\u00a0In\u00a0der\u00a0Europ\u00e4ischen \u00a0Union\u00a0erfolgte\u00a0\ninzwischen \u00a0eine\u00a0Zulassung \u00a0f\u00fcr\u00a0die\u00a0Fixkombination \u00a0mit\u00a0Formoterol. \u00a0\u00a0\nDerzeit\u00a0sind\u00a0langwirkende \u00a0Muscarin \u2010Rezeptorantagonisten \u00a0nur\u00a0f\u00fcr\u00a0die\u00a0Therapie\u00a0der\u00a0COPD\u00a0zugelassen \u00a0\n(Stand\u00a0Dezember \u00a02014).\u00a0Aclidiniumbromid \u00a0eignet\u00a0sich\u00a0somit\u00a0weder\u00a0bei\u00a0einem\u00a0akuten\u00a0\nBronchospasmus \u2010Anfall\u00a0noch\u00a0sollte\u00a0es\u00a0zur\u00a0Therapie\u00a0des\u00a0Asthma\u00a0bronchiale \u00a0eingesetzt \u00a0werden\u00a0(EMA,\u00a0\n2014a).\u00a0\u00a0\n\u00a0\nInformationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nErst\u00a0wenn\u00a0es\u00a0im\u00a0weiteren\u00a0Verlauf\u00a0einer\u00a0chronischen \u00a0Bronchitis \u00a0zu\u00a0einer\u00a0zus\u00e4tzlichen \u00a0Einengung \u00a0der\u00a0\nAtemwege \u00a0kommt,\u00a0spricht\u00a0man\u00a0von\u00a0einer\u00a0chronisch \u00a0obstruktiven \u00a0Bronchitis, \u00a0welche\u00a0dann\u00a0als\u00a0COPD\u00a0\n(chronic\u00a0obstructive \u00a0pulmonary \u00a0disease )\u00a0bezeichnet \u00a0wird\u00a0(Mutschler \u00a0et\u00a0al.,\u00a02008).\u00a0Auch\u00a0nach\u00a0der\u00a0Gabe\u00a0 \n159\u00a0\n\u00a0\nHintergrundinformationen \u00a0von\u00a0Bronchodilatatoren \u00a0und\u00a0bzw.\u00a0oder\u00a0Corticosteroiden \u00a0ist\u00a0diese\u00a0chronische \u00a0Obstruktion \u00a0im\u00a0\nGegensatz \u00a0zum\u00a0Asthma\u00a0bronchiale \u00a0nicht\u00a0mehr\u00a0voll\u00a0reversibel. \u00a0Charakteristisch \u00a0f\u00fcr\u00a0die\u00a0COPD\u00a0ist\u00a0eine\u00a0\nFolge\u00a0pathophysiologischer \u00a0Ver\u00e4nderungen \u00a0in\u00a0der\u00a0Lunge,\u00a0die\u00a0zu\u00a0einer\u00a0andauernden \u00a0Reduzierung \u00a0des\u00a0\nAtemstroms \u00a0und\u00a0so\u00a0zu\u00a0einer\u00a0schnellen \u00a0Abnahme \u00a0der\u00a0Lungenfunktionsparameter \u00a0f\u00fchren.\u00a0Sowohl\u00a0die\u00a0\nchronische \u00a0Bronchitis \u00a0als\u00a0auch\u00a0das\u00a0Lungenemphysem \u00a0stellen\u00a0Verlaufsformen \u00a0der\u00a0COPD\u00a0dar.\u00a0COPD\u00a0ist\u00a0\nals\u00a0Sammelbegriff \u00a0zu\u00a0verstehen, \u00a0mit\u00a0dem\u00a0chronische \u00a0Lungenerkrankungen \u00a0beschrieben \u00a0werden,\u00a0bei\u00a0\ndenen\u00a0die\u00a0Atmung\u00a0infolge\u00a0einer\u00a0Sch\u00e4digung \u00a0der\u00a0Lunge\u00a0und\u00a0chronischer \u00a0Entz\u00fcndungsprozesse \u00a0\nhochgradig \u00a0beeintr\u00e4chtigt \u00a0ist.\u00a0Im\u00a0Allgemeinen \u00a0nehmen\u00a0die\u00a0entz\u00fcndlichen \u00a0und\u00a0strukturellen \u00a0\nVer\u00e4nderungen \u00a0mit\u00a0dem\u00a0Schweregrad \u00a0der\u00a0Erkrankung \u00a0zu\u00a0und\u00a0kommen\u00a0auch\u00a0bei\u00a0einem\u00a0erfolgreichen \u00a0\nVerzicht\u00a0auf\u00a0Tabakkonsum \u00a0\u2013\u00a0einer\u00a0der\u00a0wichtigsten \u00a0Ma\u00dfnahmen \u00a0\u2013\u00a0nicht\u00a0zum\u00a0Stillstand\u00a0(Hogg\u00a0et\u00a0al.,\u00a0\n2004).\u00a0Eine\u00a0Reihe\u00a0von\u00a0kardiopulmonalen \u00a0Krankheiten \u00a0wie\u00a0beispielsweise \u00a0Bronchiektasie, \u00a0\nBronchialkarzinom, \u00a0Lungentuberkulose, \u00a0Asthma\u00a0bronchiale, \u00a0aber\u00a0auch\u00a0Linksherzinsuffizienz, \u00a0k\u00f6nnen\u00a0\n\u00e4hnliche\u00a0Symptome \u00a0hervorrufen, \u00a0weswegen \u00a0die\u00a0Diagnose\u00a0COPD\u00a0stets\u00a0deren\u00a0Ausschluss \u00a0bedarf\u00a0\n(Mutschler \u00a0et\u00a0al.,\u00a02008).\u00a0Andererseits \u00a0handelt\u00a0es\u00a0sich\u00a0bei\u00a0der\u00a0COPD\u00a0um\u00a0eine\u00a0komplexe \u00a0\nSystemerkrankung, \u00a0die\u00a0nicht\u00a0nur\u00a0die\u00a0Atemwege \u00a0und\u00a0die\u00a0Lunge\u00a0betrifft.\u00a0So\u00a0weisen\u00a0COPD\u2010Patienten \u00a0\ndeutlich\u00a0erh\u00f6hte\u00a0Raten\u00a0an\u00a0Komorbidit\u00e4ten \u00a0auf,\u00a0die\u00a0mit\u00a0der\u00a0sytemischen \u00a0Komponente \u00a0der\u00a0COPD\u2010\nspezifischen \u00a0Entz\u00fcndung \u00a0in\u00a0Zusammenhang \u00a0gebracht\u00a0werden\u00a0(Fabbri\u00a0&\u00a0Rabe,\u00a02007).\u00a0\nHauptsymptome \u00a0einer\u00a0COPD\u00a0sind\u00a0neben\u00a0dem\u00a0Auswurf\u00a0von\u00a0z\u00e4hem\u00a0Schleim\u00a0und\u00a0chronischem \u00a0Husten\u00a0\nauch\u00a0die\u00a0Atemnot, \u00a0die\u00a0zu\u00a0Beginn\u00a0nur\u00a0unter\u00a0Belastung \u00a0auftritt.\u00a0Mittels\u00a0Spirometrie \u00a0wird\u00a0die\u00a0\nEinschr\u00e4nkung \u00a0der\u00a0Lungenfunktion \u00a0gemessen \u00a0und\u00a0damit\u00a0die\u00a0COPD\u00a0in\u00a0verschiedene \u00a0Schweregrade \u00a0\naufgeteilt, \u00a0wonach\u00a0sich\u00a0letztendlich \u00a0auch\u00a0ihre\u00a0Therapie\u00a0richtet\u00a0(Vogelmeier \u00a0et\u00a0al.,\u00a02007).\u00a0\u00a0\nDie\u00a0COPD\u00a0ist\u00a0nicht\u00a0nur\u00a0eine\u00a0der\u00a0h\u00e4ufigsten \u00a0Erkrankungen \u00a0weltweit, \u00a0sie\u00a0geh\u00f6rt\u00a0mittlerweile \u00a0auch\u00a0zu\u00a0\nden\u00a0f\u00fchrenden \u00a0Todesursachen. \u00a0Lag\u00a0sie\u00a01990\u00a0noch\u00a0an\u00a0sechster\u00a0Stelle\u00a0der\u00a0h\u00e4ufigsten \u00a0Todesursachen, \u00a0\nso\u00a0wird\u00a0sie\u00a0bis\u00a0zum\u00a0Jahr\u00a02020\u00a0auf\u00a0den\u00a0dritten\u00a0Platz\u00a0vorr\u00fccken \u00a0(NVL,\u00a02012).\u00a0Nach\u00a0Aussagen \u00a0des\u00a0Robert\u00a0\nKoch\u2010Instituts\u00a0ist\u00a0die\u00a0Pr\u00e4valenz \u00a0der\u00a0COPD\u00a0in\u00a0Deutschland \u00a0nicht\u00a0exakt\u00a0zu\u00a0beziffern, \u00a0da\u00a0sich\u00a0die\u00a0\nDefinition \u00a0der\u00a0Erkrankung \u00a0aus\u00a0der\u00a0Feststellung \u00a0einer\u00a0chronischen \u00a0Bronchitis \u00a0plus\u00a0einer\u00a0dauerhaften \u00a0\nVerengung \u00a0der\u00a0unteren\u00a0Atemwege \u00a0mit\u00a0und\u00a0ohne\u00a0Lungenemphysem \u00a0herleitet\u00a0(RKI,\u00a02014a).\u00a0\u00a0\n\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDa\u00a0die\u00a0einmal\u00a0t\u00e4gliche\u00a0Inhalation \u00a0von\u00a0Aclidiniumbromid \u00a0(1\u00a0x\u00a0t\u00e4glich\u00a0200\u00a0\u00b5g)\u00a0nicht\u00a0den\u00a0\nZulassungsanforderungen \u00a0einer\u00a0FEV1\u2010Verbesserung \u00a0gegen\u00fcber \u00a0dem\u00a0Ausgangswert \u00a0erf\u00fcllte\u00a0(Jones\u00a0et\u00a0\nal.,\u00a02011;\u00a0Cazzola\u00a0M\u00a0et\u00a0al.,\u00a02008;\u00a0Donohue, \u00a02005),\u00a0wurde\u00a0eine\u00a0weitere\u00a0placebokontrollierte \u00a0Studie\u00a0\ndurchgef\u00fchrt. \u00a0In\u00a0der\u00a0sogenannten \u00a0ATTAIN\u00a0(Aclidinium \u00a0To\u00a0Treat\u00a0Airway\u00a0obstruction \u00a0In\u00a0copd\u00a0patieNts )\u2010\nStudie\u00a0(Jones\u00a0et\u00a0al.,\u00a02012),\u00a0die\u00a0819\u00a0von\u00a0828\u00a0COPD\u2010Patienten \u00a0mit\u00a0stabiler\u00a0mittelgradiger \u00a0oder\u00a0schwerer \u00a0\nCOPD\u00a0abschlossen, \u00a0erhielten\u00a0die\u00a0Studienteilnehmer \u00a0nach\u00a0einer\u00a0zweiw\u00f6chigen \u00a0Run\u2010in\u2010Phase\u00a0entweder \u00a0\neine\u00a0zweimal\u00a0t\u00e4gliche\u00a0Gabe\u00a0von\u00a0200\u00a0bzw.\u00a0400\u00a0\u00b5g\u00a0Aclidiniumbromid \u00a0oder\u00a0Placebo.\u00a0Die\u00a0Beibehaltung \u00a0\nder\u00a0Komedikation \u00a0(inhalative \u00a0und\u00a0bzw.\u00a0oder\u00a0systemische \u00a0Glucocorticoide \u00a0entsprechend \u00a010\u00a0mg\u00a0\nPrednison, \u00a0retardiertes \u00a0Theophyllin, \u00a0Sauerstoff \u00a0<\u00a015\u00a0Stunden\u00a0t\u00e4glich\u00a0sowie\u00a0Salbutamol \u00a0bei\u00a0Bedarf)\u00a0\nwar\u00a0erlaubt.\u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0dieser\u00a0Studie\u00a0war\u00a0die\u00a0\u00c4nderung \u00a0der\u00a0morgens\u00a0vor\u00a0der\u00a0Anwendung \u00a0\ngemessenen \u00a0FEV1\u00a0nach\u00a024\u00a0Wochen\u00a0gegen\u00fcber \u00a0dem\u00a0Ausgangswert. \u00a0Die\u00a0Differenz\u00a0von\u00a0128\u00a0ml\u00a0(2\u00a0x\u00a0\nt\u00e4glich\u00a0400\u00a0\u00b5g\u00a0Aclidiniumbromid \u00a0vs.\u00a0Placebo)\u00a0wurde\u00a0als\u00a0signifikant \u00a0eingestuft. \u00a0Dieses\u00a0Ergebnis\u00a0wurde\u00a0\nvon\u00a0einer\u00a0weiteren\u00a0Studie\u00a0(ACCORD, \u00a0Kerwin\u00a0et\u00a0al.,\u00a02012)\u00a0best\u00e4tigt. \u00a0Hier\u00a0verringerte \u00a0Aclidiniumbromid \u00a0\nau\u00dferdem \u00a0fr\u00fchmorgendliche \u00a0Symptome \u00a0der\u00a0Kurzatmigkeit \u00a0in\u00a0der\u00a0ersten\u00a0Stunde\u00a0nach\u00a0dem\u00a0Aufstehen. \u00a0\nAuch\u00a0waren\u00a0n\u00e4chtliche \u00a0Symptome \u00a0wie\u00a0Dyspnoe, \u00a0Husten,\u00a0Auswurf\u00a0oder\u00a0Keuchen\u00a0signifikant \u00a0seltener.\u00a0\u00a0\n160\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Ni\u00a0et\u00a0al.\u00a0(2014)\u00a0kommen\u00a0in\u00a0ihrem\u00a0Cochrane \u00a0Review\u00a0zum\u00a0Schluss,\u00a0dass\u00a0Aclidiniumbromid \u00a0im\u00a0Vergleich \u00a0\nzu\u00a0Placebo\u00a0zwar\u00a0mit\u00a0einer\u00a0verbesserten \u00a0Lebensqualit\u00e4t \u00a0und\u00a0reduzierten \u00a0Krankenhausaufenthalten \u00a0\naufgrund\u00a0von\u00a0schweren \u00a0Exazerbationen \u00a0bei\u00a0Patienten \u00a0mit\u00a0mittelschwerer \u00a0bis\u00a0schwerer\u00a0COPD\u00a0stabil\u00a0\nist.\u00a0In\u00a0der\u00a0Gesamtschau \u00a0senkt\u00a0Aclidiniumbromid \u00a0jedoch\u00a0nicht\u00a0signifikant \u00a0die\u00a0Sterblichkeit, \u00a0\nschwerwiegende \u00a0unerw\u00fcnschte \u00a0Ereignisse \u00a0oder\u00a0Exazerbationen, \u00a0die\u00a0die\u00a0Gabe\u00a0von\u00a0oralen\u00a0Steroiden \u00a0\nund\u00a0bzw.\u00a0oder\u00a0Antibiotika \u00a0notwendig \u00a0machen.\u00a0Derzeit\u00a0sind\u00a0die\u00a0verf\u00fcgbaren \u00a0Daten\u00a0nicht\u00a0ausreichend \u00a0\nund\u00a0von\u00a0mangelhafter \u00a0Qualit\u00e4t,\u00a0um\u00a0einen\u00a0hinreichenden \u00a0und\u00a0qualit\u00e4tsgesicherten \u00a0Vergleich \u00a0zwischen\u00a0\nAclidiniumbromid \u00a0und\u00a0Tiotropiumbromid \u00a0herstellen \u00a0zu\u00a0k\u00f6nnen.\u00a0Auch\u00a0werden\u00a0aufgrund\u00a0der\u00a0\nderzeitigen \u00a0Datenlage \u00a0weitere\u00a0Studien\u00a0ben\u00f6tigt,\u00a0um\u00a0gesicherte \u00a0R\u00fcckschl\u00fcsse \u00a0hinsichtlich \u00a0der\u00a0\nWirksamkeit \u00a0und\u00a0Sicherheit \u00a0von\u00a0Aclidiniumbromid \u00a0im\u00a0Vergleich \u00a0zu\u00a0anderen\u00a0langwirkenden \u00a0Beta\u20102\u2010\nSympathomimetika \u00a0bzw.\u00a0zu\u00a0anderen\u00a0langwirkenden \u00a0Muscarin \u2010Rezeptorantagonisten \u00a0ziehen\u00a0zu\u00a0\nk\u00f6nnen\u00a0(Ni\u00a0et\u00a0al.,\u00a02014).\u00a0\u00a0\nInsgesamt \u00a0werden\u00a0langwirkenden \u00a0Muscarin \u2010Rezeptorantagonisten \u00a0in\u00a0ihrer\u00a0Wirksamkeit \u00a0\u2013\u00a0\nVermeidung \u00a0und\u00a0Verminderung \u00a0moderater \u00a0bis\u00a0schwerer\u00a0Exazerbationen \u00a0\u2013\u00a0als\u00a0gleichwertig \u00a0\nangesehen. \u00a0Aclidiniumbromid \u00a0wird\u00a0allerdings \u00a0mit\u00a0dem\u00a0geringsten \u00a0Risiko\u00a0von\u00a0schweren \u00a0\nExazerbationen \u00a0in\u00a0Verbindung \u00a0gebracht, \u00a0wenn\u00a0die\u00a0Behandlung \u00a0\u00fcber\u00a0mindestens \u00a0sechs\u00a0Monate\u00a0\nerfolgt\u00a0(Oba\u00a0&\u00a0Lone,\u00a02015).\u00a0Indes\u00a0werden\u00a0auch\u00a0hier\u00a0weitere\u00a0Studien\u00a0ben\u00f6tigt,\u00a0um\u00a0diese\u00a0Annahme \u00a0zu\u00a0\nerh\u00e4rten\u00a0(Oba\u00a0&\u00a0Lone,\u00a02015).\u00a0\nH\u00e4ufigste \u00a0Nebenwirkungen \u00a0unter\u00a0Aclidiniumbromid \u00a0sind\u00a0\u2013\u00a0neben\u00a0den\u00a0typischen \u00a0anticholinergen \u00a0\nNebenwirkungen \u00a0wie\u00a0trockener \u00a0Mund,\u00a0verschwommenes \u00a0Sehen\u00a0und\u00a0Harnverhalten \u00a0\u2013\u00a0\nKopfschmerzen, \u00a0Nasopharyngitis \u00a0und\u00a0Durchf\u00e4lle. \u00a0\u00a0\n\u00a0\nLeitlinienempfehlungen1\u00a0\nBis\u00a0heute\u00a0ist\u00a0keine\u00a0urs\u00e4chliche \u00a0Heilung\u00a0der\u00a0chronisch \u2010obstruktiven \u00a0Lungenerkrankung \u00a0m\u00f6glich.\u00a0Darum\u00a0\nwerden\u00a0in\u00a0Abh\u00e4ngigkeit \u00a0von\u00a0Alter\u00a0und\u00a0Komorbidit\u00e4ten \u00a0des\u00a0Patienten \u00a0folgende\u00a0Therapieziele \u00a0\nangestrebt \u00a0(NVL,\u00a02012):\u00a0Verminderung \u00a0der\u00a0Progression \u00a0der\u00a0Erkrankung, \u00a0Symptomlinderung, \u00a0\nSteigerung \u00a0der\u00a0k\u00f6rperlichen \u00a0Belastbarkeit, \u00a0Verbesserung \u00a0des\u00a0Gesamtstatus \u00a0und\u00a0der\u00a0Lebensqualit\u00e4t, \u00a0\nVorbeugung \u00a0und\u00a0Behandlung \u00a0von\u00a0Exazerbationen, \u00a0Vorbeugung \u00a0und\u00a0Behandlung \u00a0von\u00a0Komplikationen \u00a0\nsowie\u00a0Reduktion \u00a0der\u00a0Mortalit\u00e4t. \u00a0\nBasismedikamente \u00a0zur\u00a0Linderung \u00a0der\u00a0Beschwerden \u00a0der\u00a0COPD\u00a0sind\u00a0die\u00a0sogenannten \u00a0\nBronchodilatatoren \u00a0(Beta\u20102\u2010Sympathomimetika, \u00a0Anticholinergika). \u00a0Durch\u00a0Reduktion \u00a0der\u00a0bronchialen \u00a0\nMuskelspannung \u00a0f\u00fchren\u00a0sie\u00a0so\u00a0zu\u00a0einer\u00a0Erweiterung \u00a0der\u00a0Atemwege. \u00a0In\u00a0Abh\u00e4ngigkeit \u00a0des\u00a0Schwere\u2010\ngrades\u00a0werden\u00a0zu\u00a0den\u00a0rasch\u00a0wirkenden \u00a0inhalativen \u00a0Bronchodilatatoren \u00a0(beispielsweise \u00a0Fenoterol, \u00a0\nSalbutamol, \u00a0Terbutalin) \u00a0bei\u00a0Bedarf\u00a0auch\u00a0langwirkende \u00a0Bronchodilatatoren \u00a0wie\u00a0Formoterol \u00a0und\u00a0\nSalmeterol \u00a0zur\u00a0Dauertherapie \u00a0eingesetzt. \u00a0Die\u00a0Wahl\u00a0zwischen\u00a0Beta\u20102\u2010Sympathomimetika \u00a0und\u00a0\nAnticholinergika \u00a0h\u00e4ngt\u00a0dabei\u00a0vom\u00a0individuellen \u00a0Ansprechen \u00a0des\u00a0Patienten \u00a0und\u00a0der\u00a0unerw\u00fcnschten \u00a0\nWirkungen \u00a0ab\u00a0(NVL,\u00a02012).\u00a0Ein\u00a0weiterer\u00a0wenn\u00a0auch\u00a0schw\u00e4cherer \u00a0Bronchodilatator \u00a0ist\u00a0Theophyllin. \u00a0\nNeben\u00a0zahlreichen \u00a0Interaktionen \u00a0besitzt\u00a0er\u00a0eine\u00a0relativ\u00a0geringe\u00a0therapeutische \u00a0Breite.\u00a0So\u00a0kann\u00a0es\u00a0bei\u00a0\nzu\u00a0hoher\u00a0Dosierung \u00a0zu\u00a0Krampfanf\u00e4llen \u00a0kommen, \u00a0weswegen \u00a0die\u00a0Einnahme \u00a0des\u00a0Wirkstoffes \u00a0eine\u00a0\n                                        \n1\u00a0In\u00a0den\u00a0vorliegenden \u00a0Ausf\u00fchrungen \u00a0wird\u00a0im\u00a0Wesentlichen \u00a0nur\u00a0die\u00a0Therapie\u00a0der\u00a0stabilen\u00a0COPD\u00a0bei\u00a0Erwachsenen \u00a0behandelt. \u00a0Bei\u00a0akuten\u00a0\nExazerbationen \u00a0oder\u00a0Ma\u00dfnahmen \u00a0zur\u00a0COPD\u2010Pr\u00e4vention \u00a0sei\u00a0auf\u00a0die\u00a0entsprechende \u00a0Leitlinienliteratur \u00a0verwiesen. \u00a0 \n161\u00a0\n\u00a0\nHintergrundinformationen \u00a0regelm\u00e4\u00dfige \u00a0Kontrolle\u00a0des\u00a0Blutspiegels \u00a0erfordert. \u00a0Aus\u00a0diesem\u00a0Grund\u00a0kommt\u00a0Theophyllin \u00a0erst\u00a0nach\u00a0\nBeta\u20102\u2010Sympathomimetika \u00a0und\u00a0Anticholinergika \u00a0als\u00a0Bronchodilatator \u00a0der\u00a0dritten\u00a0Wahl\u00a0in\u00a0Frage.\u00a0\nInhalative \u00a0Corticosteroide \u00a0als\u00a0dauerhafte \u00a0Therapie\u00a0sollten\u00a0nur\u00a0dann\u00a0eingesetzt \u00a0werden,\u00a0wenn\u00a0es\u00a0\nunter\u00a0ihrer\u00a0Behandlung \u00a0zur\u00a0Besserung \u00a0von\u00a0Kenngr\u00f6\u00dfen \u00a0der\u00a0Lungenfunktion \u00a0und\u00a0bzw.\u00a0oder\u00a0der\u00a0\nSymptomatik \u00a0kommt\u00a0oder\u00a0aber\u00a0bei\u00a0h\u00e4ufigen\u00a0Exazerbationen \u00a0(NVL,\u00a02012).\u00a0\u00a0\nDie\u00a0neueren\u00a0langwirkenden \u00a0Anticholinergika \u00a0Aclidiniumbromid \u00a0und\u00a0Glycopyrronium \u00a0finden\u00a0aufgrund\u00a0\nihrer\u00a0Aktualit\u00e4t \u00a0keine\u00a0Erw\u00e4hnung \u00a0in\u00a0der\u00a0derzeit\u00a0g\u00fcltigen\u00a0Nationalen \u00a0Versorgungsleitlinie. \u00a0Die\u00a0Global\u00a0\nInitiative\u00a0for\u00a0Chronic\u00a0Obstructive \u00a0Lung\u00a0Disease\u00a0attestiert \u00a0allerdings \u00a0beiden\u00a0Wirkstoffen \u00a0eine\u00a0\u00e4hnliche\u00a0\nWirksamkeit \u00a0wie\u00a0Tiotropiumbromid \u00a0(GOLD,\u00a02015).\u00a0\n\u00a0\nNutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nUnter\u00a0Ber\u00fccksichtigung \u00a0des\u00a0Stufenschemas \u00a0der\u00a0Nationalen \u00a0Versorgungsleitlinie \u00a0COPD\u00a0(Version\u00a01.9,\u00a0\nJanuar\u00a02012)\u00a0ergab\u00a0die\u00a0fr\u00fche\u00a0Nutzenbewertung \u00a0von\u00a0Bretaris\u00ae\u00a0Genuair\u00ae\u00a0durch\u00a0den\u00a0Gemeinsamen \u00a0\nBundesausschuss \u00a0sowohl\u00a0f\u00fcr\u00a0die\u00a0Patienten \u00a0ab\u00a0Therapiestufe \u00a0II\u00a0als\u00a0auch\u00a0f\u00fcr\u00a0die\u00a0Patienten \u00a0ab\u00a0\nTherapiestufe \u00a0III/IV\u00a0mit\u00a0mehr\u00a0als\u00a0zwei\u00a0Exazerbationen: \u00a0Der\u00a0Zusatznutzen \u00a0f\u00fcr\u00a0Aclidiniumbromid \u00a0ist\u00a0\ngegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0nicht\u00a0belegt .\u00a0Als\u00a0zweckm\u00e4\u00dfige \u00a0Vergleichstherapie \u00a0\nwaren\u00a0f\u00fcr\u00a0Patienten \u00a0ab\u00a0Therapiestufe \u00a0II\u00a0langwirkende \u00a0Beta\u20102\u2010Sympathomimetika \u00a0(Formoterol, \u00a0\nSalmeterol) \u00a0bzw.\u00a0langwirkende \u00a0Anticholinergika \u00a0(Tiotropiumbromid) \u00a0und\u00a0zus\u00e4tzlich \u00a0f\u00fcr\u00a0Patienten \u00a0ab\u00a0\nTherapiestufe \u00a0III/IV\u00a0inhalative \u00a0Corticosteroide \u00a0festgelegt. \u00a0\nDer\u00a0G\u2010BA\u00a0begr\u00fcndet \u00a0seine\u00a0Entscheidung \u00a0u.a.\u00a0damit,\u00a0dass\u00a0die\u00a0Studiendauer \u00a0von\u00a0zwei\u00a0und\u00a0sechs\u00a0\nWochen\u00a0in\u00a0den\u00a0vom\u00a0pU\u00a0vorgelegten \u00a0Studien\u00a0nicht\u00a0ausreichend \u00a0lang\u00a0war,\u00a0um\u00a0einen\u00a0Zusatznutzen \u00a0f\u00fcr\u00a0\npatientenrelevante \u00a0Endpunkte \u00a0zu\u00a0belegen.\u00a0Schlie\u00dflich \u00a0handele\u00a0es\u00a0sich\u00a0bei\u00a0Aclidiniumbromid \u00a0um\u00a0ein\u00a0\ndauerhaft \u00a0einzusetzendes \u00a0Arzneimittel \u00a0(G\u2010BA,\u00a02013a).\u00a0Die\u00a0derzeitigen \u00a0Empfehlungen \u00a0der\u00a0\nEurop\u00e4ischen \u00a0Zulassungsbeh\u00f6rde \u00a0EMA\u00a0wie\u00a0auch\u00a0der\u00a0amerikanischen \u00a0Zulassungsbeh\u00f6rde \u00a0FDA\u00a0\nschlagen\u00a0im\u00a0Hinblick\u00a0auf\u00a0die\u00a0Arzneimittelentwicklung \u00a0f\u00fcr\u00a0die\u00a0Verbesserung \u00a0der\u00a0Lungenobstruktion \u00a0\neine\u00a0Behandlungsdauer \u00a0von\u00a0mindestens \u00a0drei\u00a0Monaten\u00a0vor,\u00a0hinsichtlich \u00a0der\u00a0Symptomverbesserung \u00a0\neine\u00a0Behandlungsdauer \u00a0von\u00a0mindestens \u00a0sechs\u00a0Monaten. \u00a0Auch\u00a0bei\u00a0Nachweis \u00a0kurzfristiger \u00a0Effekte\u00a0in\u00a0\nStudien\u00a0von\u00a0einer\u00a0Dauer\u00a0zwischen\u00a0zw\u00f6lf\u00a0bis\u00a024\u00a0Wochen\u00a0wird\u00a0der\u00a0Beleg\u00a0einer\u00a0nachhaltigen \u00a0\nWirksamkeit \u00a0in\u00a0Studien\u00a0von\u00a0mindestens \u00a0zw\u00f6lf\u00a0Monaten\u00a0angeraten \u00a0(G\u2010BA,\u00a02013a).\u00a0Zur\u00a0Untersuchung \u00a0\nvon\u00a0Effekten\u00a0auf\u00a0die\u00a0Exazerbationsrate \u00a0werden\u00a0ebenfalls\u00a0Studien\u00a0von\u00a0mindestens \u00a0einem\u00a0Jahr\u00a0\nempfohlen. \u00a0Zus\u00e4tzlich \u00a0zu\u00a0direkt\u00a0vergleichenden \u00a0Studien\u00a0reichte\u00a0der\u00a0pharmazeutische \u00a0Unternehmer \u00a0\neinen\u00a0indirekten \u00a0Vergleich \u00a0von\u00a0Aclidiniumbromid \u00a0und\u00a0Tiotropiumbromid \u00a0ein.\u00a0Aufgrund \u00a0mangelhafter \u00a0\nmethodischer \u00a0Qualit\u00e4t\u00a0und\u00a0Diskrepanzen \u00a0zwischen\u00a0den\u00a0aus\u00a0den\u00a0Originaldokumenten \u00a0und\u00a0den\u00a0im\u00a0\nModul\u00a04\u00a0des\u00a0Dossiers\u00a0aufbereiteten \u00a0Daten\u00a0konnte\u00a0auf\u00a0Grundlage \u00a0dieser\u00a0Analyse\u00a0aber\u00a0keine\u00a0valide\u00a0\nBewertung \u00a0des\u00a0Zusatznutzens \u00a0stattfinden \u00a0(G\u2010BA,\u00a02013a).\u00a0\n \u00a0\u00a0\n162\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Kosten\u00a0\nWirkstof f\u00a0 Behandlungsmodus Behandlungstage Jahrestherapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nAclidiniumbromid  2\u00a0x\u00a0t\u00e4glich\u00a0400\u00a0\u00b5g 360 499,12\u00a0\u20ac\nF\u00fcr\u00a0Patienten \u00a0ab\u00a0Therapiestufe \u00a0III/IV\u00a0mit\u00a0mehr\u00a0als\u00a0zwei\u00a0Exazerbationen \u00a0zus\u00e4tzlich  \nInhalative \u00a0Corticosteroide \u00a0\n(Beclometason)  2\u00a0x\u00a0t\u00e4glich\u00a00,2\u00a0mg 360 117,92\u00a0\u20ac\nInhalative \u00a0Corticosteroide \u00a0\n(Fluticason)  2\u00a0x\u00a0t\u00e4glich\u00a00,25\u00a0mg 360 269,16\u00a0\u20ac\nZweckm\u00e4\u00dfige \u00a0Vergleichstherapie  \u00a0\nTiotropiumbromid  1\u00a0x\u00a0t\u00e4glich\u00a018\u00a0\u00b5g 360 705,19\u00a0\u20ac\nOder/Und \u00a0langwirksame \u00a0Beta\u20102\u2010Sympathomimetika\nSalmeterol  2\u00a0x\u00a0t\u00e4glich\u00a025\u00a0\u00b5g 360 207,06\u00a0\u20ac\nFormoterol  1\u20102\u00a0x\u00a0t\u00e4glich\u00a012\u00a0\u00b5g 360 159,96\u2010319,92\u00a0\u20ac\nF\u00fcr\u00a0Patienten \u00a0ab\u00a0Therapiestufe \u00a0III/IV\u00a0mit\u00a0mehr\u00a0als\u00a0zwei\u00a0Exazerbationen \u00a0zus\u00e4tzlich  \nInhalative \u00a0Corticosteroide \u00a0\n(Beclometason)  2\u00a0x\u00a0t\u00e4glich\u00a00,2\u00a0mg 360 117,92\u00a0\u20ac\nInhalative \u00a0Corticosteroide \u00a0\n(Fluticason)  2\u00a0x\u00a0t\u00e4glich\u00a00,25\u00a0mg 360 269,16\u00a0\u20ac\nDarstellung \u00a0der\u00a0Behandlungsdauer \u00a0und\u00a0des\u00a0Verbrauchs \u00a0von\u00a0inhalativen \u00a0Corticosteroiden \u00a0exemplarisch \u00a0f\u00fcr\u00a0die\u00a0\nWirkstoffe \u00a0Beclometason \u00a0und\u00a0Fluticason \u00a0\nTabelle\u00a025:\u00a0Jahrestherapiekosten \u00a0von\u00a0Aclidiniumbromid \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0Kosten\u00a0\nzus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0\n \u00a0 \n163\u00a0\n\u00a0\nHintergrundinformationen \u00a011.2 Aflibercept \u00a0\u00a0\nHandelsname: \u00a0Eylea\u00ae       Hersteller: \u00a0Bayer \nIndikation: \u00a0AMD,\u00a0Makula\u00f6dem \u00a0 \u00a0\u00a0\u00a0 Markteinf\u00fchrung: \u00a0Dezember \u00a02012 \nATC\u2010Code:\u00a0S01LA05\u00a0     DDD:\u00a00,018\u00a0DE \nDarreichungsform: \u00a0Injektionsl\u00f6sung  \nBewertung: \u00a0siehe\u00a0Seite\u00a034\u00a0\nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nNach\u00a0Pegaptanib \u00a0(Macugen\u00ae) \u00a0und\u00a0Ranibizumab \u00a0(Lucentis\u00ae) \u00a0ist\u00a0mit\u00a0Aflibercept \u00a0(Eylea\u00ae)\u00a0ein\u00a0weiterer\u00a0\nHemmstoff \u00a0des\u00a0vaskul\u00e4ren \u00a0endothelialen \u00a0Wachstumsfaktors \u00a0(VEGF)\u00a0zugelassen \u00a0worden.\u00a0Das\u00a0\nrekombinante \u00a0Fusionsprotein \u00a0bindet\u00a0mit\u00a0sehr\u00a0hoher\u00a0Affinit\u00e4t\u00a0an\u00a0die\u00a0Wachstumsfaktoren \u00a0VEGF\u00a0\n(Vascular\u00a0Endothelial \u00a0Growth\u00a0Factor )\u2010A\u00a0und\u00a0PIGF\u00a0(Placental\u00a0Growth\u00a0Factor )\u00a0und\u00a0vermindert \u00a0so\u00a0die\u00a0\nAngiogenese. \u00a0Damit\u00a0ist\u00a0der\u00a0Wirkmechanismus \u00a0von\u00a0Eylea\u00ae\u00a0vergleichbar \u00a0mit\u00a0dem\u00a0von\u00a0Lucentis\u00ae \u00a0\n(Ranibizumab) \u00a0und\u00a0dem\u00a0nicht\u00a0f\u00fcr\u00a0die\u00a0neovaskul\u00e4re \u00a0(feuchte)\u00a0altersbedingte \u00a0Makuladegeneration \u00a0\n(AMD)\u00a0zugelassenen, \u00a0aber\u00a0von\u00a0vielen\u00a0\u00c4rzten\u00a0dennoch\u00a0off\u00a0label\u00a0eingesetzten \u00a0Avastin\u00ae\u00a0(Bevacizumab). \u00a0\n\u00a0Zulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nIm\u00a0November \u00a02012\u00a0erfolgte\u00a0die\u00a0Zulassung \u00a0f\u00fcr\u00a0Erwachsene \u00a0zur\u00a0\nBehandlung \u00a0der\u00a0AMD.\u00a0Im\u00a0August\u00a02013\u00a0\nerhielt\u00a0Eylea\u00ae\u00a0eine\u00a0Zulassungserweiterung \u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0einer\u00a0Visusbeeintr\u00e4chtigung \u00a0aufgrund\u00a0\neines\u00a0Makula\u00f6dems \u00a0infolge\u00a0eines\u00a0retinalen\u00a0Venenverschlusses \u00a0bzw.\u00a0infolge\u00a0eines\u00a0\nZentralvenenverschlusses. \u00a0Wiederum \u00a0ein\u00a0Jahr\u00a0sp\u00e4ter\u00a0(August\u00a02014)\u00a0wurde\u00a0die\u00a0Zulassung \u00a0auf\u00a0die\u00a0\nBehandlung \u00a0einer\u00a0Visusbeeintr\u00e4chtigung \u00a0aufgrund\u00a0eines\u00a0diabetischen \u00a0Makula\u00f6dems \u00a0erweitert. \u00a0\u00a0\nAflibercept \u00a0wird\u00a0als\u00a0intravitreale \u00a0Injektion\u00a0angewendet. \u00a0Die\u00a0empfohlene \u00a0Dosis\u00a0f\u00fcr\u00a0alle\u00a0drei\u00a0\nIndikationsgebiete \u00a0betr\u00e4gt\u00a02\u00a0mg,\u00a0das\u00a0Behandlungsintervall \u00a0richtet\u00a0sich\u00a0nach\u00a0der\u00a0jeweiligen \u00a0\nErkrankung \u00a0(Bayer,\u00a02015).\u00a0\n\u00a0\nInformationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nIm\u00a0Zentrum\u00a0der\u00a0Netzhaut\u00a0(Retina)\u00a0befindet\u00a0sich\u00a0ein\u00a0nur\u00a0wenige\u00a0Millimeter \u00a0durchmessender \u00a0\u201egelber\u00a0\nFleck\u201c,\u00a0die\u00a0sogenannte \u00a0Makula.\u00a0Als\u00a0Stelle\u00a0des\u00a0sch\u00e4rfsten \u00a0Sehens\u00a0im\u00a0Auge\u00a0ist\u00a0sie\u00a0zust\u00e4ndig \u00a0f\u00fcr\u00a0das\u00a0\nTagessehen, \u00a0das\u00a0Farbsehen \u00a0sowie\u00a0das\u00a0Aufl\u00f6sungsverm\u00f6gen. \u00a0Die\u00a0Funktionsf\u00e4higkeit \u00a0der\u00a0Makula\u00a0kann\u00a0\ndurch\u00a0verschiedene \u00a0Krankheiten \u00a0beeintr\u00e4chtigt \u00a0werden,\u00a0die\u00a0h\u00e4ufig\u00a0mit\u00a0fortschreitendem \u00a0Alter\u00a0\nauftreten. \u00a0Diese\u00a0Erkrankungen \u00a0m\u00fcssen\u00a0rechtzeitig \u00a0behandelt \u00a0werden,\u00a0um\u00a0dem\u00a0Sehverlust \u00a0\nentgegenzuwirken. \u00a0Zu\u00a0diesen\u00a0Erkrankungen \u00a0z\u00e4hlen\u00a0unter\u00a0anderem\u00a0die\u00a0AMD\u00a0sowie\u00a0das\u00a0Makula\u00f6dem. \u00a0\nUnter\u00a0einer\u00a0AMD\u00a0versteht\u00a0man\u00a0eine\u00a0altersbedingte \u00a0chronische \u00a0Erkrankung \u00a0des\u00a0Auges.\u00a0Man\u00a0\nunterscheidet \u00a0zwei\u00a0Formen\u00a0der\u00a0AMD:\u00a0die\u00a0\u201etrockene\u201c \u00a0und\u00a0die\u00a0seltener\u00a0vorkommende \u00a0\u2013\u00a0allerdings \u00a0\ndeutlich\u00a0aggressiver \u00a0verlaufende \u00a0\u2013\u00a0\u201efeuchte\u201c \u00a0oder\u00a0auch\u00a0\u201eneovaskul\u00e4re\u201c \u00a0AMD.\u00a0W\u00e4hrend \u00a0die\u00a0\n\u201etrockene\u201c \u00a0Form\u00a0durch\u00a0Degeneration \u00a0der\u00a0Netzhaut\u2010\u00a0und\u00a0Aderhautschicht \u00a0entsteht\u00a0und\u00a0ohne\u00a0\nExsudation \u00a0verl\u00e4uft,\u00a0geht\u00a0die\u00a0\u201efeuchte\u201c \u00a0AMD\u00a0neben\u00a0choroidalen \u00a0Gef\u00e4\u00dfneubildungen \u00a0mit\u00a0Exsudation \u00a0\nund\u00a0Blutaustritten \u00a0einher.\u00a0\u00a0\n164\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Durch\u00a0Ablagerung \u00a0von\u00a0Stoffwechselprodukten \u00a0sowie\u00a0letztendlich \u00a0ein\u00a0unkontrolliertes \u00a0\nGef\u00e4\u00dfwachstum1\u00a0unter\u00a0der\u00a0Makula\u00a0wird\u00a0allm\u00e4hlich \u00a0das\u00a0zentrale\u00a0Sehen\u00a0zerst\u00f6rt.\u00a0Dinge,\u00a0die\u00a0die\u00a0\nbetroffene \u00a0Person\u00a0fokussiert, \u00a0erscheinen \u00a0ihr\u00a0mit\u00a0der\u00a0Zeit\u00a0verschwommen, \u00a0unklar\u00a0und\u00a0weniger\u00a0\nkontrastreich. \u00a0Bei\u00a0den\u00a0Ursachen, \u00a0die\u00a0zur\u00a0Entwicklung \u00a0und\u00a0Progression \u00a0der\u00a0AMD\u00a0f\u00fchren,\u00a0besteht\u00a0\ngr\u00f6\u00dftenteils \u00a0noch\u00a0Ungewissheit. \u00a0Klar\u00a0ist,\u00a0dass\u00a0es\u00a0sich\u00a0bei\u00a0der\u00a0AMD\u00a0um\u00a0eine\u00a0multifaktoriell \u00a0bedingte, \u00a0\nkomplexe \u00a0Erkrankung \u00a0handelt,\u00a0bei\u00a0der\u00a0nicht\u00a0nur\u00a0das\u00a0Alter,\u00a0sondern\u00a0auch\u00a0verschiedene \u00a0\nUmweltfaktoren \u00a0und\u00a0eine\u00a0genetische \u00a0Pr\u00e4disposition \u00a0eine\u00a0Rolle\u00a0spielen\u00a0(Dietzel\u00a0et\u00a0al.,\u00a02010).\u00a0\u00a0\nDie\u00a0Pr\u00e4valenz \u00a0der\u00a0AMD\u00a0steigt\u00a0ab\u00a0dem\u00a070.\u00a0Lebensjahr \u00a0exponentiell \u00a0mit\u00a0dem\u00a0Alter\u00a0an.\u00a015\u00a0Prozent\u00a0der\u00a0\n65\u2010\u00a0bis\u00a074\u2010J\u00e4hrigen\u00a0sind\u00a0von\u00a0einem\u00a0AMD\u2010Fr\u00fchstadium \u00a0betroffen, \u00a0w\u00e4hrend\u00a0es\u00a0bei\u00a0den\u00a0\u00fcber\u00a085\u2010\nJ\u00e4hrigen\u00a0bereits\u00a030\u00a0Prozent\u00a0sind.\u00a0Die\u00a0Pr\u00e4valenz \u00a0der\u00a0AMD\u2010Sp\u00e4tformen \u00a0betr\u00e4gt\u00a0bei\u00a0den\u00a065\u2010\u00a0bis\u00a074\u2010\nJ\u00e4hrigen\u00a0ein\u00a0Prozent,\u00a0bei\u00a0den\u00a0\u00fcber\u00a085\u2010J\u00e4hrigen\u00a0hingegen\u00a013\u00a0Prozent\u00a0(van\u00a0Leeuwen\u00a0et\u00a0al.,\u00a02003).\u00a0\nDerzeit\u00a0sind\u00a0in\u00a0Deutschland \u00a0bis\u00a0zu\u00a04,5\u00a0Millionen \u00a0Menschen \u00a0von\u00a0einer\u00a0AMD\u00a0betroffen, \u00a0von\u00a0denen\u00a015\u00a0\nProzent\u00a0an\u00a0einer\u00a0potentiell \u00a0zur\u00a0Erblindung \u00a0f\u00fchrenden \u00a0Sp\u00e4tform \u00a0leiden.\u00a0Sch\u00e4tzungen \u00a0zufolge\u00a0werden\u00a0\nim\u00a0Jahr\u00a02020\u00a0bereits\u00a0mehr\u00a0als\u00a0eine\u00a0Millionen \u00a0Menschen \u00a0in\u00a0Deutschland \u00a0an\u00a0einem\u00a0Sp\u00e4tstadium \u00a0der\u00a0\nAMD\u00a0erkrankt\u00a0sein\u00a0(Schrader, \u00a02006).\u00a0\nEine\u00a0Wasseransammlung \u00a0in\u00a0der\u00a0Netzhaut\u00a0des\u00a0Auges\u00a0wird\u00a0als\u00a0Makula\u00f6dem \u00a0bezeichnet. \u00a0Ursache\u00a0daf\u00fcr\u00a0\nkann\u00a0entweder \u00a0ein\u00a0Verschluss \u00a0der\u00a0zentralen \u00a0Netzhautvene \u00a0des\u00a0Auges\u00a0sein\u00a0oder\u00a0aber\u00a0ein\u00a0Diabetes\u00a0\nmellitus\u00a0als\u00a0prim\u00e4re\u00a0Erkrankung. \u00a0Bei\u00a0dieser\u00a0Grunderkrankung \u00a0kann\u00a0es\u00a0durch\u00a0die\u00a0Sch\u00e4digung \u00a0kleiner\u00a0\nBlutgef\u00e4\u00dfe \u00a0und\u00a0der\u00a0daraus\u00a0resultierenden \u00a0durchl\u00e4ssigeren \u00a0Gef\u00e4\u00dfw\u00e4nde \u00a0zu\u00a0einem\u00a0Fl\u00fcssigkeitsaustritt \u00a0\nkommen. \u00a0Die\u00a0Fl\u00fcssigkeit \u00a0sammelt\u00a0sich\u00a0im\u00a0Gewebe\u00a0der\u00a0Netzhaut\u00a0und\u00a0f\u00fchrt\u00a0zu\u00a0einer\u00a0\u00d6dembildung, \u00a0in\u00a0\nderen\u00a0Folge\u00a0die\u00a0Versorgung \u00a0der\u00a0Netzhaut\u00a0mit\u00a0Sauerstoff \u00a0und\u00a0N\u00e4hrstoffen \u00a0leidet.\u00a0Um\u00a0der\u00a0\nMangelversorgung \u00a0entgegen \u00a0zu\u00a0wirken,\u00a0setzt\u00a0ein\u00a0Wachstum \u00a0neuer\u00a0Blutgef\u00e4\u00dfe \u00a0ein.\u00a0Das\u00a0diabetische \u00a0\nMakula\u00f6dem \u00a0geh\u00f6rt\u00a0zu\u00a0den\u00a0typischen \u00a0und\u00a0recht\u00a0h\u00e4ufigen\u00a0Folgeerkrankungen \u00a0des\u00a0Diabetes\u00a0mellitus,\u00a0\nda\u00a0erh\u00f6hte\u00a0Blutzuckerwerte \u00a0langfristig \u00a0Nerven\u00a0und\u00a0Blutgef\u00e4\u00dfe \u00a0sch\u00e4digen. \u00a0Zwar\u00a0entwickelt \u00a0nicht\u00a0jeder\u00a0\nDiabetiker \u00a0eine\u00a0diabetesbedingte \u00a0Sch\u00e4digung \u00a0der\u00a0Augen,\u00a0doch\u00a0je\u00a0l\u00e4nger\u00a0der\u00a0Diabetes\u00a0mellitus\u00a0\nbesteht,\u00a0desto\u00a0gr\u00f6\u00dfer\u00a0wird\u00a0das\u00a0Risiko,\u00a0an\u00a0einer\u00a0diabetischen \u00a0Retinopathie \u00a0zu\u00a0erkranken. \u00a0So\u00a0zeigen\u00a0ca.\u00a0\n30\u00a0Prozent\u00a0der\u00a0an\u00a0Diabetes\u00a0mellitus\u00a0erkrankten \u00a0Personen \u00a0Anzeichen \u00a0einer\u00a0Retinopathie \u00a0(42\u00a0Prozent\u00a0\nbei\u00a0Typ\u20101\u2010Diabetes\u00a0und\u00a028\u00a0Prozent\u00a0bei\u00a0Typ\u20102\u2010Diabetes\u00a0(DOG,\u00a02010)).\u00a0Bei\u00a0sechs\u00a0bis\u00a0zehn\u00a0Prozent\u00a0der\u00a0\nDiabetiker \u00a0tritt\u00a0ein\u00a0Makula\u00f6dem \u00a0auf,\u00a0das\u00a0bei\u00a0ca.\u00a0ein\u00a0bis\u00a0drei\u00a0Prozent\u00a0der\u00a0Betroffenen \u00a0urs\u00e4chlich \u00a0f\u00fcr\u00a0\neine\u00a0Sehbeeintr\u00e4chtigung \u00a0ist\u00a0(Chen\u00a0et\u00a0al.,\u00a02010).\u00a0\n\u00a0\u00a0\n                                        \n1\u00a0Durch\u00a0das\u00a0Wachstum \u00a0neuer\u00a0Gef\u00e4\u00dfe\u00a0(auch\u00a0als\u00a0Angiogenese \u00a0oder\u00a0Neovaskularisation \u00a0bezeichnet) \u00a0kommt\u00a0es\u00a0zu\u00a0Blut\u2010\u00a0und\u00a0\nFl\u00fcssigkeitsverlusten. \u00a0Der\u00a0Botenstoff \u00a0Vascular\u00a0Endothelial \u00a0Growth\u00a0Factor\u00a0(VEGF)\u00a0spielt\u00a0in\u00a0diesem\u00a0Krankheitsprozess \u00a0eine\u00a0entscheidende \u00a0\nRolle.\u00a0Er\u00a0steigert\u00a0die\u00a0physiologische \u00a0und\u00a0pathologische \u00a0Bildung\u00a0neuer\u00a0Gef\u00e4\u00dfe\u00a0sowie\u00a0die\u00a0vaskul\u00e4re \u00a0Permeabilit\u00e4t. \u00a0Die\u00a0Netzhaut \u00a0schwillt\u00a0an,\u00a0\nSinneszellen \u00a0werden\u00a0gesch\u00e4digt \u00a0und\u00a0in\u00a0der\u00a0Regel\u00a0kommt\u00a0es\u00a0zu\u00a0Blutungen \u00a0im\u00a0Bereich\u00a0der\u00a0Netzhaut \u00a0sowie\u00a0zu\u00a0Fettablagerungen. \u00a0Bildet\u00a0sich\u00a0\nschlie\u00dflich \u00a0eine\u00a0Narbe\u00a0im\u00a0Bereich\u00a0der\u00a0Makula\u00a0aus,\u00a0kann\u00a0die\u00a0Sehf\u00e4higkeit \u00a0dadurch\u00a0deutlich\u00a0beeintr\u00e4chtigt \u00a0werden.\u00a0 \n165\u00a0\n\u00a0\nHintergrundinformationen \u00a0Evidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nAufgrund \u00a0der\u00a0Indikationserweiterungen \u00a0von\u00a0Aflibercept \u00a0kurz\u00a0nach\u00a0Markteinf\u00fchrung \u00a0liegen\u00a0\nmittlerweile \u00a0mehrere\u00a0kontrollierte \u00a0klinische\u00a0Studien\u00a0f\u00fcr\u00a0verschiedene \u00a0Indikationsgebiete \u00a0vor,\u00a0die\u00a0die\u00a0\nWirksamkeit \u00a0und\u00a0Sicherheit \u00a0des\u00a0neuen\u00a0VEGF\u2010Hemmers \u00a0untersuchten. \u00a0\nAltersabh\u00e4ngige \u00a0Makuladegeneration: \u00a0Zulassungsrelevant \u00a0f\u00fcr\u00a0die\u00a0Indikation \u00a0AMD\u00a0waren\u00a0zwei\u00a0aktiv\u00a0\nkontrollierte \u00a0klinische\u00a0Phase\u2010III\u2010Studien\u00a0(VIEW\u00a01\u00a0und\u00a0VIEW\u00a02,\u00a0Heier\u00a0et\u00a0al.,\u00a02012).\u00a0In\u00a0die\u00a0Studien\u00a0\neingeschlossen \u00a0waren\u00a0insgesamt \u00a02.419\u00a0Patienten \u00a0mit\u00a0diagnostizierter \u00a0neovaskul\u00e4rer \u00a0altersabh\u00e4ngiger \u00a0\nMakuladegeneration \u00a0(Da\u00a0die\u00a0beiden\u00a0Studien\u00a0ein\u00a0fast\u00a0identisches \u00a0Studiendesign \u00a0aufwiesen, \u00a0wurden\u00a0\nsie\u00a0zusammen \u00a0publiziert). \u00a0Diese\u00a0erhielten\u00a0vier\u00a0intravitreale \u00a0Behandlungsoptionen \u00a0\u00fcber\u00a052\u00a0Wochen:\u00a0\nentweder \u00a0Aflibercept \u00a0(monatlich \u00a00,5\u00a0mg\u00a0bzw.\u00a02\u00a0mg\u00a0oder\u00a0alle\u00a0acht\u00a0Wochen\u00a02\u00a0mg)\u00a0oder\u00a0Ranibizumab \u00a0\n(monatlich \u00a00,5\u00a0mg).\u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0war\u00a0die\u00a0Nicht\u2010Unterlegenheit \u00a0des\u00a0Aflibercept \u2010Regimes\u00a0im\u00a0\nVergleich \u00a0zu\u00a0Ranibizumab \u00a0gemessen \u00a0am\u00a0Anteil\u00a0der\u00a0Patienten \u00a0mit\u00a0erhaltener \u00a0Sehsch\u00e4rfe \u00a0(weniger\u00a0als\u00a0\n15\u00a0EDTRS\u2010Buchstaben, \u00a0Early\u00a0Treatment \u00a0Diabetic\u00a0Retinopathy \u00a0Study\u00a0Lesetafel, \u00a0im\u00a0Vergleich \u00a0zum\u00a0\nAusgangswert). \u00a0Sowohl\u00a0in\u00a0VIEW\u00a01\u00a0als\u00a0auch\u00a0in\u00a0VIEW\u00a02\u00a0entsprachen \u00a0alle\u00a0drei\u00a0Dosierungsregime \u00a0von\u00a0\nAflibercept \u00a0klinisch\u00a0der\u00a0Wirksamkeit \u00a0von\u00a0Ranibizumab \u00a0(95,1\u201096,3\u00a0Prozent\u00a0vs.\u00a094,4\u00a0Prozent).\u00a0Okulare\u00a0\nund\u00a0systemische \u00a0Nebenwirkungen \u00a0waren\u00a0in\u00a0allen\u00a0Behandlungsgruppen \u00a0\u00e4hnlich.\u00a0\u00a0\nLaut\u00a0Fachinformation \u00a0(Bayer,\u00a02015)\u00a0wird\u00a0die\u00a0Behandlung \u00a0mit\u00a0Aflibercept \u00a0mit\u00a0drei\u00a0\naufeinanderfolgenden \u00a0monatlichen \u00a0Injektionen \u00a0initiiert,\u00a0gefolgt\u00a0von\u00a0einer\u00a0Injektion\u00a0alle\u00a0zwei\u00a0Wochen.\u00a0\nErst\u00a0nach\u00a0den\u00a0ersten\u00a0zw\u00f6lf\u00a0Monaten\u00a0der\u00a0Behandlung \u00a0kann\u00a0das\u00a0Behandlungsintervall \u00a0basierend \u00a0auf\u00a0\ndem\u00a0funktionellen \u00a0und\u00a0bzw.\u00a0oder\u00a0dem\u00a0morphologischen \u00a0Befund\u00a0verl\u00e4ngert \u00a0werden\u00a0(Bayer,\u00a02015).\u00a0\nAus\u00a0den\u00a0Zulassungsstudien \u00a0geht\u00a0nicht\u00a0eindeutig \u00a0hervor,\u00a0welches\u00a0hier\u00a0das\u00a0g\u00fcnstigere \u00a0Therapieschema \u00a0\nvon\u00a0Aflibercept \u00a0f\u00fcr\u00a0Patienten \u00a0darstellt.\u00a0Die\u00a0Gabe\u00a0des\u00a0Wirkstoffes \u00a0nur\u00a0alle\u00a0zwei\u00a0Monate\u00a0hat\u00a0\nletztendlich \u00a0den\u00a0Vorteil\u00a0der\u00a0selteneren \u00a0Injektion. \u00a0Die\u00a0Behandlung \u00a0mit\u00a0Ranibizumab \u00a0beginnt\u00a0mit\u00a0einer\u00a0\nInjektion\u00a0pro\u00a0Monat\u00a0bis\u00a0unter\u00a0kontinuierlicher \u00a0Behandlung \u00a0der\u00a0maximale \u00a0Visus\u00a0erreicht\u00a0ist\u00a0und\u00a0keine\u00a0\nAnzeichen \u00a0von\u00a0Krankheitsaktivit\u00e4t, \u00a0wie\u00a0etwa\u00a0eine\u00a0Ver\u00e4nderung \u00a0der\u00a0Sehsch\u00e4rfe \u00a0sowie\u00a0andere\u00a0\nKrankheitsanzeichen \u00a0und\u00a0\u2010symptome, \u00a0mehr\u00a0zu\u00a0erkennen \u00a0sind\u00a0(Novartis\u00a0Pharma,\u00a02014).\u00a0Somit\u00a0wurde\u00a0\nRanibizumab \u00a0in\u00a0den\u00a0beiden\u00a0Zulassungsstudien \u00a0nicht\u00a0gem\u00e4\u00df\u00a0seiner\u00a0Zulassung \u00a0\u2013\u00a0n\u00e4mlich\u00a0\nbedarfsadaptiert \u00a0\u2013\u00a0eingesetzt. \u00a0Die\u00a0zweimonatliche \u00a0Gabe\u00a0von\u00a0Aflibercept \u00a0ist\u00a0zwar\u00a0genauso\u00a0wirksam\u00a0\nwie\u00a0die\u00a0monatliche \u00a0Gabe\u00a0von\u00a0Ranibizumab, \u00a0dennoch\u00a0besteht\u00a0die\u00a0M\u00f6glichkeit \u00a0einer\u00a0k\u00fcrzeren\u00a0\nTherapiedauer \u00a0durch\u00a0Anwendung \u00a0des\u00a0letztgenannten \u00a0VEGF\u2010Hemmers. \u00a0Der\u00a0vermeintliche \u00a0Vorteil\u00a0\nAflibercepts \u00a0gegen\u00fcber \u00a0Ranibizumab \u00a0kann\u00a0somit\u00a0nicht\u00a0als\u00a0therapeutisch \u00a0relevanter \u00a0Vorteil\u00a0\nangebracht \u00a0werden,\u00a0da\u00a0Ranibizumab \u00a0aufgrund\u00a0der\u00a0Festlegungen \u00a0im\u00a0Studienprotokoll \u00a0h\u00e4ufiger\u00a0als\u00a0im\u00a0\nklinischen \u00a0Alltag\u00a0und\u00a0laut\u00a0Zulassung \u00a0\u00fcblich\u00a0injiziert\u00a0wurde.\u00a0\u00a0\nMakula\u00f6dem \u00a0infolge\u00a0eines\u00a0retinalen \u00a0Zentralvenenverschlusses: \u00a0Wirksamkeit \u00a0und\u00a0Sicherheit \u00a0von\u00a0\nAflibercept \u00a0zur\u00a0Therapie\u00a0eines\u00a0Makula\u00f6dems \u00a0infolge\u00a0eines\u00a0retinalen\u00a0Zentralverschlusses \u00a0wurde\u00a0in\u00a0\nzwei\u00a0doppelblinden \u00a0kontrollierten \u00a0Studien\u00a0aufgezeigt. \u00a0In\u00a0der\u00a0COPERNICUS \u2010Studie\u00a0(Boyer\u00a0et\u00a0al.,\u00a02012)\u00a0\nwurden\u00a0189\u00a0Patienten \u00a0nach\u00a0einem\u00a03:2\u00a0Schema\u00a0randomisiert: \u00a0Die\u00a0Verum\u2010Gruppe\u00a0erhielt\u00a0alle\u00a0vier\u00a0\nWochen\u00a0und\u00a0\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von\u00a0sechs\u00a0Monaten\u00a0eine\u00a0Aflibercept \u2010Injektion\u00a0(2\u00a0mg),\u00a0w\u00e4hrend\u00a0in\u00a0\nder\u00a0Kontrollgruppe \u00a0eine\u00a0monatliche \u00a0Scheininjektion \u00a0durchgef\u00fchrt \u00a0wurde.\u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0war\u00a0der\u00a0\nAnteil\u00a0an\u00a0Patienten \u00a0mit\u00a0einer\u00a0Verbesserung \u00a0der\u00a0Sehsch\u00e4rfe \u00a0um\u00a0\u2265\u00a015\u00a0Buchstaben \u00a0nach\u00a024\u00a0Wochen.\u00a0\nSekund\u00e4re \u00a0Endpunkte \u00a0waren\u00a0Morbidit\u00e4t, \u00a0gesundheitsbezogene \u00a0Lebensqualit\u00e4t \u00a0und\u00a0unerw\u00fcnschte \u00a0\nEreignisse. \u00a0Ein\u00a0vergleichbares \u00a0Studiendesign \u00a0wies\u00a0auch\u00a0die\u00a0GALILEO\u2010Studie\u00a0(Holz\u00a0et\u00a0al.,\u00a02013)\u00a0auf,\u00a0die\u00a0\ndie\u00a0Ergebnisse \u00a0der\u00a0COPERNICUS \u2010Studie\u00a0best\u00e4tigte. \u00a0\u00a0\n166\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Zwar\u00a0erwies\u00a0sich\u00a0die\u00a0Verbesserung \u00a0der\u00a0Sehsch\u00e4rfe \u00a0in\u00a0beiden\u00a0Studien\u00a0als\u00a0signifikant \u00a0im\u00a0Vergleich \u00a0zur\u00a0\nScheinmedikation, \u00a0jedoch\u00a0wurde\u00a0Aflibercept \u00a0nicht\u00a0gem\u00e4\u00df\u00a0seiner\u00a0Zulassung \u00a0eingesetzt. \u00a0Laut\u00a0\nFachinformation \u00a0von\u00a0Aflibercept \u00a0soll\u00a0auch\u00a0hier\u00a0die\u00a0Behandlung \u00a0nach\u00a0der\u00a0Initialinjektion \u00a0solange\u00a0\nmonatlich \u00a0fortgef\u00fchrt \u00a0werden,\u00a0bis\u00a0der\u00a0funktionelle \u00a0und\u00a0morphologische \u00a0Befund\u00a0bei\u00a0drei\u00a0aufeinander \u00a0\nfolgenden \u00a0monatlichen \u00a0Verlaufskontrollen \u00a0stabil\u00a0bleibt.\u00a0Bei\u00a0stabilem\u00a0Befund\u00a0kann\u00a0das\u00a0\nBehandlungsintervall \u00a0schrittweise \u00a0verl\u00e4ngert \u00a0werden.\u00a0Sollte\u00a0sich\u00a0hingegen\u00a0der\u00a0funktionelle \u00a0und\u00a0\nmorphologische \u00a0Befund\u00a0im\u00a0Verlauf\u00a0der\u00a0ersten\u00a0drei\u00a0Injektionen \u00a0nicht\u00a0verbessert \u00a0haben,\u00a0wird\u00a0nach\u00a0\nAngabe\u00a0des\u00a0pharmazeutischen \u00a0Unternehmers \u00a0die\u00a0Fortsetzung \u00a0der\u00a0Behandlung \u00a0nicht\u00a0empfohlen. \u00a0\u00a0\nIm\u00a0Gegensatz \u00a0zur\u00a0Anwendung \u00a0gem\u00e4\u00df\u00a0Fachinformation \u00a0sehen\u00a0die\u00a0Behandlungsregime \u00a0der\u00a0ersten\u00a0\nBehandlungsphase \u00a0in\u00a0den\u00a0beiden\u00a0Studien\u00a0sechs\u00a0intravitreale \u00a0Injektionen \u00a0mit\u00a0der\u00a0jeweiligen \u00a0\nStudienmedikation \u00a0bis\u00a0einschlie\u00dflich \u00a0Woche\u00a020\u00a0als\u00a0fest\u00a0eingeplant \u00a0vor.\u00a0In\u00a0dieser\u00a0Studienphase \u00a0wurde\u00a0\neine\u00a0Weiterbehandlung \u00a0nicht\u00a0vom\u00a0Therapieverlauf \u00a0des\u00a0individuellen \u00a0Patienten \u00a0abh\u00e4ngig\u00a0gemacht. \u00a0\nErgebnisse \u00a0von\u00a0Post\u2010hoc\u2010Analysen\u00a0zeigten\u00a0aber,\u00a0dass\u00a0sowohl\u00a0in\u00a0Einzel\u2010\u00a0als\u00a0auch\u00a0in\u00a0gepoolten \u00a0Analysen\u00a0\nzu\u00a0den\u00a0beiden\u00a0Zulassungsstudien \u00a0die\u00a0Therapieantwort \u00a0(Response )\u00a0bereits\u00a0um\u00a0den\u00a0dritten\u00a0Monat\u00a0\nherum\u00a0ein\u00a0Plateau\u00a0erreicht.\u00a0Von\u00a0einer\u00a0weiterf\u00fchrenden \u00a0monatlichen \u00a0Behandlung \u00a0mit\u00a0Aflibercept \u00a0\nprofitiert\u00a0haben\u00a0demnach \u00a0nur\u00a015\u00a0Prozent\u00a0der\u00a0Patienten \u00a0(IQWiG,\u00a02014b).\u00a0\nVisusbeeintr\u00e4chtigung \u00a0infolge\u00a0eines\u00a0diabetischen \u00a0Makula\u00f6dems: \u00a0Das\u00a0diabetische \u00a0Makula\u00f6dem \u00a0stellt\u00a0\neine\u00a0wesentliche \u00a0Komplikation \u00a0der\u00a0Retinopathie \u00a0bei\u00a0Diabetikern \u00a0dar.\u00a0Bei\u00a0den\u00a0f\u00fcr\u00a0die\u00a0Zulassung \u00a0zur\u00a0\nBehandlung \u00a0der\u00a0Visusbeeintr\u00e4chtigung \u00a0infolge\u00a0eines\u00a0diabetischen \u00a0Makula\u00f6dems \u00a0entscheidenden \u00a0\nStudien\u00a0VISTA\u00a0und\u00a0VIVID\u00a0(Korobelnik \u00a0et\u00a0al.,\u00a02014)\u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0einen\u00a0Head\u2010to\u2010Head\u2010Vergleich \u00a0\nzwischen\u00a0Aflibercept \u00a0und\u00a0einer\u00a0Laserfotokoagulation. \u00a0Eingeschlossen \u00a0wurden\u00a0872\u00a0Patienten \u00a0\n(Diabetes \u00a0mellitus\u00a0Typ\u00a01\u00a0oder\u00a02)\u00a0mit\u00a0Visusbeeintr\u00e4chtigung \u00a0aufgrund\u00a0eines\u00a0diabetischen \u00a0\nMakula\u00f6dems \u00a0mit\u00a0Beteiligung \u00a0der\u00a0Fovea\u00a0centralis.\u00a0Nach\u00a0Randomisierung \u00a0erhielten\u00a0die\u00a0\nStudienteilnehmer \u00a0entweder \u00a0eine\u00a0Behandlung \u00a0mit\u00a0Aflibercept \u00a02\u00a0mg\u00a0alle\u00a0vier\u00a0Wochen,\u00a0Aflibercept \u00a02\u00a0\nmg\u00a0nach\u00a0f\u00fcnf\u00a0initialen\u00a0Injektionen \u00a0alle\u00a0acht\u00a0Wochen\u00a0oder\u00a0Laserfotokoagulation \u00a0(F\u00fcr\u00a0den\u00a0Wirkstoff \u00a0\nund\u00a0diese\u00a0Indikation \u00a0zugelassen \u00a0wurde\u00a0die\u00a0Initialbehandlung \u00a0bestehend \u00a0aus\u00a0f\u00fcnf\u00a0\naufeinanderfolgenden \u00a0monatlichen \u00a0Injektionen, \u00a0gefolgt\u00a0von\u00a0einer\u00a0Injektion\u00a0alle\u00a0zwei\u00a0Monate). \u00a0F\u00fcr\u00a0\nalle\u00a0Patienten \u00a0war\u00a0ab\u00a0Woche\u00a024\u00a0neben\u00a0der\u00a0zugeteilten \u00a0Studienbehandlung \u00a0eine\u00a0aktive\u00a0\nZusatzbehandlung \u00a0m\u00f6glich,\u00a0f\u00fcr\u00a0die\u00a0bestimmte \u00a0Kriterien\u00a0zu\u00a0erf\u00fcllen\u00a0waren.\u00a0So\u00a0bestand\u00a0f\u00fcr\u00a0Patienten \u00a0\naus\u00a0dem\u00a0Interventionsarm \u00a0die\u00a0M\u00f6glichkeit, \u00a0eine\u00a0aktive\u00a0Laserfotokoagulation \u00a0zu\u00a0erhalten,\u00a0w\u00e4hrend\u00a0\nsich\u00a0Patienten \u00a0aus\u00a0dem\u00a0Kontroll\u2010Arm\u00a0f\u00fcr\u00a0eine\u00a0zus\u00e4tzliche \u00a0Aflibercept \u2010Injektion\u00a0entscheiden \u00a0konnten.\u00a0\nPrim\u00e4rer\u00a0Endpunkt \u00a0der\u00a0Studien\u00a0war\u00a0die\u00a0Ver\u00e4nderung \u00a0der\u00a0bestkorrigierten \u00a0Sehsch\u00e4rfe \u00a0nach\u00a0einem\u00a0\nJahr\u00a0(52\u00a0Wochen). \u00a0\nIn\u00a0beiden\u00a0Studien\u00a0erwies\u00a0sich\u00a0die\u00a0intravitreale \u00a0Injektion\u00a0mit\u00a0Aflibercept \u00a0(beide\u00a0Dosisregime) \u00a0nach\u00a052\u00a0\nWochen\u00a0als\u00a0\u00fcberlegen \u00a0bei\u00a0den\u00a0Wirksamkeitsendpunkten \u00a0gegen\u00fcber \u00a0der\u00a0Lasertherapie. \u00a0Bei\u00a0den\u00a0135\u00a0\nTeilnehmern, \u00a0die\u00a0je\u00a0eine\u00a0Aflibercept \u2010Injektion\u00a0alle\u00a0acht\u00a0Wochen\u00a0nach\u00a0einer\u00a0initialen\u00a0Behandlung \u00a0mit\u00a0\nf\u00fcnf\u00a0monatlichen \u00a0Dosen\u00a0erhalten\u00a0hatten,\u00a0wurde\u00a0nach\u00a0einem\u00a0Jahr\u00a0ein\u00a0durchschnittlicher \u00a0Gewinn\u00a0von\u00a0\n10,7\u00a0Buchstaben \u00a0beobachtet. \u00a0Die\u00a0132\u00a0Patienten \u00a0in\u00a0der\u00a0Vergleichsgruppe \u00a0mit\u00a0Lasertherapie \u00a0hatten\u00a0\ndagegen\u00a0lediglich\u00a0eine\u00a0durchschnittliche \u00a0Ver\u00e4nderung \u00a0bei\u00a0der\u00a0bestkorrigierten \u00a0Sehsch\u00e4rfe \u00a0von\u00a01,2\u00a0\nBuchstaben \u00a0erreicht.\u00a0Auch\u00a0konnte\u00a0ungef\u00e4hr\u00a0ein\u00a0Drittel\u00a0der\u00a0Patienten \u00a0in\u00a0der\u00a0VIVID\u2010Studie\u00a0unter\u00a0der\u00a0\nTherapie\u00a0mit\u00a0Aflibercept \u00a02\u00a0mg\u00a0alle\u00a0zwei\u00a0Monate\u00a0einen\u00a0Gewinn\u00a0von\u00a015\u00a0Buchstaben \u00a0verbuchen. \u00a0\nDagegen\u00a0waren\u00a0es\u00a0unter\u00a0der\u00a0Laser\u2010Behandlung \u00a0nur\u00a09,1\u00a0Prozent\u00a0der\u00a0Patienten. \u00a0In\u00a0der\u00a0VISTA\u2010Studie\u00a0\nerzielten\u00a0die\u00a0Patienten \u00a0mit\u00a0allen\u00a0drei\u00a0Therapieregimen \u00a0(Aflibercept \u00a0bzw.\u00a0Laserkoagulation) \u00a0\nvergleichbare \u00a0Ergebnisse \u00a0wie\u00a0in\u00a0der\u00a0VIVID\u2010Studie.\u00a0 \n167\u00a0\n\u00a0\nHintergrundinformationen \u00a0Das\u00a0Diabetic\u00a0Retinopathy \u00a0Clinical\u00a0Research\u00a0Network\u00a0hat\u00a0im\u00a0Rahmen\u00a0einer\u00a0randomisierten, \u00a0\nmultizentrischen \u00a0klinischen \u00a0Studie\u00a0erstmals\u00a0die\u00a0Wirksamkeit \u00a0und\u00a0Sicherheit \u00a0der\u00a0Wirkstoffe \u00a0\nAflibercept, \u00a0Bevacizumab \u00a0(off\u2010label )\u00a0und\u00a0Ranibizumab \u00a0verglichen. \u00a0In\u00a0dieser\u00a0Studie\u00a0wurden\u00a0insgesamt \u00a0\n660\u00a0Diabetes\u2010Patienten \u00a0mit\u00a0diagnostiziertem \u00a0DM\u00d6\u00a0therapiert. \u00a0Die\u00a0Behandlung \u00a0wurde\u00a0alle\u00a0vier\u00a0\nWochen\u00a0wiederholt, \u00a0als\u00a0prim\u00e4rer\u00a0Endpunkt \u00a0diente\u00a0die\u00a0mittlere\u00a0Ver\u00e4nderung \u00a0der\u00a0Sehst\u00e4rke \u00a0nach\u00a0\neinem\u00a0Jahr.\u00a0Bei\u00a0nur\u00a0moderat\u00a0verringerter \u00a0Sehleistung \u00a0wiesen\u00a0alle\u00a0drei\u00a0Wirkstoffe \u00a0eine\u00a0\u00e4hnliche\u00a0\nWirksamkeit \u00a0auf,\u00a0w\u00e4hrend\u00a0Studienteilnehmer \u00a0mit\u00a0st\u00e4rkeren \u00a0Einschr\u00e4nkungen \u00a0der\u00a0Sehst\u00e4rke \u00a0unter\u00a0\nder\u00a0Therapie\u00a0mit\u00a0Aflibercept \u00a0eine\u00a0signifikant \u00a0h\u00f6here\u00a0Verbesserung \u00a0der\u00a0Sehst\u00e4rke \u00a0erzielten\u00a0(The\u00a0\nDiabetic\u00a0Retinopathy \u00a0Clinical\u00a0Research\u00a0Network, \u00a02015).\u00a0Aus\u00a0diesem\u00a0Grund\u00a0sehen\u00a0die\u00a0Autoren\u00a0dieser\u00a0\nStudie\u00a0Aflibercept \u00a0als\u00a0erste\u00a0Wahl\u00a0bei\u00a0DM\u00d6\u2010Patienten \u00a0mit\u00a0bereits\u00a0fortgeschrittenem \u00a0Sehverlust \u00a0an.\u00a0\nSchwerwiegende \u00a0Nebenwirkungen, \u00a0die\u00a0mit\u00a0dem\u00a0Injektionsverfahren \u00a0in\u00a0Zusammenhang \u00a0standen,\u00a0\ntraten\u00a0nach\u00a0Angabe\u00a0des\u00a0pharmazeutischen \u00a0Unternehmers \u00a0bei\u00a0weniger\u00a0als\u00a01\u00a0von\u00a02.200\u00a0IVT\u2010\nInjektionen \u00a0auf\u00a0(Bayer,\u00a02014).\u00a0Zu\u00a0diesen\u00a0z\u00e4hlten\u00a0Erblindung, \u00a0Endophthalmitis, \u00a0Netzhautabl\u00f6sung, \u00a0\ntraumatischer \u00a0Katarakt,\u00a0Glask\u00f6rperblutung, \u00a0Katarakt,\u00a0Glask\u00f6rperabhebung \u00a0und\u00a0erh\u00f6hter\u00a0\nAugeninnendruck. \u00a0Arterielle \u00a0thromboembolische \u00a0Ereignisse \u00a0sind\u00a0ebenfalls\u00a0Nebenwirkungen, \u00a0die\u00a0\nm\u00f6glicherweise \u00a0mit\u00a0der\u00a0systemischen \u00a0VEGF\u2010Hemmung \u00a0in\u00a0Verbindung \u00a0stehen,\u00a0wof\u00fcr\u00a0ein\u00a0\ntheoretisches \u00a0Risiko\u00a0auch\u00a0bei\u00a0IVT\u2010Injektion\u00a0besteht.\u00a0\u00a0\n\u00a0\nLeitlinienempfehlungen \u00a0\nAltersabh\u00e4ngige \u00a0Makuladegeneration: \u00a0Mittlerweile \u00a0ist\u00a0es\u00a0State\u00a0of\u00a0the\u00a0Art,\u00a0das\u00a0krankhafte \u00a0\nGef\u00e4\u00dfwachstum \u00a0durch\u00a0die\u00a0Injektion\u00a0von\u00a0VEGF\u2010Hemmern \u00a0in\u00a0den\u00a0Glask\u00f6rper \u00a0einzud\u00e4mmen. \u00a0F\u00fcr\u00a0die\u00a0\nBehandlung \u00a0der\u00a0neovaskul\u00e4ren \u00a0AMD\u00a0besitzen\u00a0derzeit\u00a0Ranibizumab \u00a0und\u00a0Aflibercept \u00a0eine\u00a0Zulassung. \u00a0\nNach\u00a0Auffassung \u00a0der\u00a0DOG\u00a0(2014,\u00a0keine\u00a0systematisch \u00a0evidenzbasierte \u00a0Leitlinie)\u00a0sind\u00a0beide\u00a0in\u00a0ihrer\u00a0\nEffektivit\u00e4t \u00a0bez\u00fcglich \u00a0des\u00a0Visus\u00a0\u00fcber\u00a0einen\u00a0Beobachtungszeitraum \u00a0von\u00a0zwei\u00a0Jahren\u00a0basierend \u00a0auf\u00a0den\u00a0\nvorliegenden \u00a0Studien\u00a0als\u00a0gleichwertig \u00a0und\u00a0somit\u00a0gleicherma\u00dfen \u00a0als\u00a0Mittel\u00a0der\u00a0ersten\u00a0Wahl\u00a0\nanzusehen. \u00a0Auch\u00a0das\u00a0im\u00a0off\u2010label\u00a0use\u00a0eingesetzte \u00a0Bevacizumab \u00a0erscheint \u00a0bez\u00fcglich \u00a0der\u00a0Effektivit\u00e4t \u00a0\nund\u00a0des\u00a0Nebenwirkungsprofils \u00a0gleichwertig \u00a0(DOG,\u00a02014).\u00a0Die\u00a0Photodynamische \u00a0Therapie\u00a0(PDT)\u00a0wird\u00a0\nhingegen\u00a0allenfalls\u00a0bei\u00a0der\u00a0Sonderform \u00a0der\u00a0polypoidalen \u00a0chorioidalen \u00a0Vaskulopathie \u00a0(PCV)\u00a0erwogen\u00a0\n(DOG,\u00a02014).\u00a0\nMakula\u00f6dem \u00a0infolge\u00a0eines\u00a0retinalen \u00a0Zentralvenenverschlusses: \u00a0F\u00fcr\u00a0die\u00a0Therapie\u00a0des\u00a0Makula\u00f6dems \u00a0\ninfolge\u00a0eines\u00a0retinalen\u00a0Zentralvenenverschlusses \u00a0kommen\u00a0derzeit\u00a0Augeninjektionen \u00a0mit\u00a0VEGF\u2010\nHemmern \u00a0oder\u00a0Glucocorticoiden \u00a0in\u00a0Betracht. \u00a0Letztgenannte \u00a0gibt\u00a0es\u00a0auch\u00a0in\u00a0Form\u00a0eines\u00a0Implantats, \u00a0\nwelches\u00a0f\u00fcr\u00a0l\u00e4ngere\u00a0Zeit\u00a0im\u00a0Glask\u00f6rper \u00a0des\u00a0Auges\u00a0verbleibt. \u00a0Mit\u00a0Hilfe\u00a0intravitrealer \u00a0Injektionen \u00a0von\u00a0\nBevacizumab \u00a0(die\u00a0meisten\u00a0Daten\u00a0existieren \u00a0aus\u00a0Fallserien), \u00a0Ranibizumab \u00a0bzw.\u00a0Dexamethason \u00a0kann\u00a0\ndie\u00a0Visusprognose \u00a0in\u00a0relevantem \u00a0Ausma\u00df\u00a0verbessert \u00a0werden\u00a0(DOG,\u00a02010;\u00a0keine\u00a0systematisch \u00a0\nevidenzbasierte \u00a0Leitlinie). \u00a0Bez\u00fcglich \u00a0Wirksamkeit \u00a0und\u00a0Vertr\u00e4glichkeit \u00a0sind\u00a0die\u00a0VEGF\u2010Inhibitoren \u00a0\nallerdings \u00a0den\u00a0Glucocorticoidpr\u00e4paraten \u00a0\u00fcberlegen. \u00a0Der\u00a0Einsatz\u00a0des\u00a0Dexamethason \u2010Implantats \u00a0wird\u00a0\nvor\u00a0allem\u00a0bei\u00a0fehlendem \u00a0Ansprechen \u00a0auf\u00a0VEGF\u2010Inhibitoren \u00a0oder\u00a0bei\u00a0chronisch \u2010rezidivierendem \u00a0\nVerlauf\u00a0erwogen, \u00a0da\u00a0weniger\u00a0Injektionen \u00a0erforderlich \u00a0sind.\u00a0Aflibercept \u00a0war\u00a0zum\u00a0Zeitpunkt \u00a0der\u00a0DOG\u2010\nStellungnahme \u00a0noch\u00a0nicht\u00a0zugelassen \u00a0und\u00a0wird\u00a0dort\u00a0nur\u00a0kurz\u00a0erw\u00e4hnt.\u00a0Eine\u00a0Beurteilung \u00a0nach\u00a0den\u00a0\ndieser\u00a0Stellungnahme \u00a0zugrundeliegenden \u00a0Kriterien\u00a0war\u00a0daher\u00a0nicht\u00a0m\u00f6glich.\u00a0\u00a0\n168\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Visusbeeintr\u00e4chtigung \u00a0infolge\u00a0eines\u00a0diabetischen \u00a0Makula\u00f6dems: \u00a0Eine\u00a0Pharmakotherapie \u00a0kommt\u00a0\nnach\u00a0Angabe\u00a0der\u00a0DOG\u00a0(2013,\u00a0keine\u00a0systematisch \u00a0evidenzbasierte \u00a0Leitlinie)\u00a0bei\u00a0dem\u00a0diabetischen \u00a0\nMakula\u00f6dem \u00a0nur\u00a0mit\u00a0fovealer\u00a0Beteiligung \u00a0in\u00a0Frage.\u00a0Hier\u00a0besitzt\u00a0die\u00a0Anti\u2010VEGF\u2010Monotherapie \u00a0die\u00a0\nbeste\u00a0Wirksamkeit, \u00a0ein\u00a0Makula\u00f6dem \u00a0zur\u00fcckzubilden, \u00a0um\u00a0damit\u00a0eine\u00a0bestm\u00f6gliche \u00a0Visusentwicklung \u00a0\nzu\u00a0erm\u00f6glichen. \u00a0Eine\u00a0gute\u00a0Patienten \u2010Adh\u00e4renz \u00a0ist\u00a0dabei\u00a0unbedingt \u00a0notwendig. \u00a0Langzeiteffekte \u00a0auf\u00a0\nden\u00a0Visus\u00a0und\u00a0das\u00a0Sicherheitsprofil \u00a0der\u00a0Anti\u2010VEGF\u2010Therapie\u00a0k\u00f6nnen\u00a0bislang\u00a0noch\u00a0nicht\u00a0endg\u00fcltig \u00a0\nbeurteilt\u00a0werden\u00a0(DOG,\u00a02013).\u00a0Aufgrund \u00a0relativ\u00a0h\u00e4ufig\u00a0vorkommender \u00a0Nebenwirkungen \u00a0\n(Druckerh\u00f6hung \u00a0und\u00a0Katarakt\u2010Induktion \u00a0bzw.\u00a0\u2010Progression) \u00a0wird\u00a0die\u00a0intravitreale \u00a0Gabe\u00a0von\u00a0\nGlucocorticoiden \u00a0als\u00a0second\u2010line\u2010Therapie\u00a0betrachtet \u00a0(DOG,\u00a02013).\u00a0\n\u00a0\nNutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDurch\u00a0die\u00a0Indikationserweiterungen \u00a02013\u00a0und\u00a02014\u00a0liegen\u00a0mittlerweile \u00a0mehrere\u00a0Nutzenbewertungen \u00a0\ndes\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0vor.\u00a0\u00a0\nAltersabh\u00e4ngige \u00a0Makuladegeneration :\u00a0Der\u00a0G\u2010BA\u00a0bewertete \u00a0den\u00a0Zusatznutzen \u00a0von\u00a0Aflibercept \u00a0bei\u00a0\nAMD\u00a0im\u00a0Vergleich \u00a0zum\u00a0monoklonalen \u00a0Antik\u00f6rper \u00a0Ranibizumab \u00a0(Lucentis\u00ae). \u00a0Als\u00a0Grundlage \u00a0dienten\u00a0\ninsbesondere \u00a0die\u00a0Ergebnisse \u00a0der\u00a0zulassungsrelevanten \u00a0Studien\u00a0VIEW\u20101\u00a0und\u00a0VIEW\u20102\u00a0(Heier\u00a0et\u00a0al.,\u00a0\n2012).\u00a0Das\u00a0Pr\u00fcfungsgremium \u00a0bem\u00e4ngelte, \u00a0dass\u00a0die\u00a0Daten\u00a0f\u00fcr\u00a0einen\u00a0ad\u00e4quaten \u00a0Vergleich \u00a0nicht\u00a0\nausreichten, \u00a0da\u00a0die\u00a0Vergleichssubstanz \u00a0in\u00a0den\u00a0Studien\u00a0nicht\u00a0entsprechend \u00a0der\u00a0Zulassung \u00a0eingesetzt \u00a0\nworden\u00a0war.\u00a0So\u00a0kam\u00a0Ranibizumab \u00a0monatlich \u00a0zur\u00a0Anwendung, \u00a0unabh\u00e4ngig \u00a0davon,\u00a0ob\u00a0der\u00a0Visus\u00a0bei\u00a0\ndrei\u00a0aufeinanderfolgenden \u00a0monatlichen \u00a0Kontrollen \u00a0stabil\u00a0war.\u00a0Insgesamt \u00a0fehlten\u00a0dem\u00a0G\u2010BA\u00a0in\u00a0den\u00a0\nHerstellerunterlagen \u00a0Daten,\u00a0die\u00a0einen\u00a0Zusatznutzen \u00a0gegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0\nRanibizumab \u00a0hinreichend \u00a0belegen\u00a0konnten,\u00a0weshalb\u00a0die\u00a0Bewertung \u00a0im\u00a0Beschluss \u00a0lautete:\u00a0Kein\u00a0\nZusatznutzen \u00a0von\u00a0Aflibercept \u00a0gegen\u00fcber \u00a0Ranibizumab \u00a0(G\u2010BA,\u00a02013b).\u00a0\nMakula\u00f6dem \u00a0infolge\u00a0eines\u00a0retinalen \u00a0Zentralvenenverschlusses :\u00a0Im\u00a0Oktober\u00a0erfolgte\u00a0die\u00a0fr\u00fche\u00a0\nNutzenbewertung \u00a0von\u00a0Aflibercept \u00a0bei\u00a0der\u00a0Behandlung \u00a0von\u00a0Erwachsenen \u00a0mit\u00a0einer\u00a0Visus\u2010\nBeeintr\u00e4chtigung \u00a0aufgrund\u00a0eines\u00a0Makula\u00f6dems \u00a0infolge\u00a0eines\u00a0retinalen\u00a0Zentralvenenverschlusses \u00a0\n(ZVV).\u00a0Der\u00a0G\u2010BA\u00a0konstatierte \u00a0in\u00a0seinem\u00a0diesbez\u00fcglichen \u00a0Beschluss \u00a0vom\u00a020.\u00a0M\u00e4rz\u00a02014,\u00a0dass\u00a0der\u00a0\nZusatznutzen \u00a0von\u00a0Aflibercept \u00a0gegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0Dexamethason \u00a0\n(intravitreales \u00a0Implantat) \u00a0oder\u00a0Ranibizumab \u00a0nicht\u00a0belegt\u00a0ist.\u00a0F\u00fcr\u00a0die\u00a0zweckm\u00e4\u00dfige \u00a0Vergleichstherapie \u00a0\nDexamethason \u00a0(intravitreales \u00a0Implantat) \u00a0lagen\u00a0dem\u00a0G\u2010BA\u00a0von\u00a0Seiten\u00a0des\u00a0pharmazeutischen \u00a0\nUnternehmers \u00a0keine\u00a0Daten\u00a0vor.\u00a0F\u00fcr\u00a0den\u00a0Nachweis \u00a0eines\u00a0Zusatznutzens \u00a0gegen\u00fcber \u00a0Ranibizumab \u00a0legte\u00a0\nder\u00a0pharmazeutische \u00a0Unternehmer \u00a0hingegen\u00a0den\u00a0indirekten \u00a0Vergleich \u00a0der\u00a0beiden\u00a0Substanzen \u00a0\nbasierend \u00a0auf\u00a0drei\u00a0Studien\u00a0vor:\u00a0die\u00a0der\u00a0Zulassung \u00a0von\u00a0Aflibercept \u00a0zugrunde \u00a0liegenden \u00a0Studien\u00a0\nCOPERNICUS \u00a0und\u00a0GALILEO\u00a0sowie\u00a0die\u00a0der\u00a0Zulassung \u00a0von\u00a0Ranibizumab \u00a0zugrunde \u00a0liegende\u00a0Studie\u00a0\nCRUISE.\u00a0Die\u00a0beiden\u00a0Wirkstoffe \u00a0wurden\u00a0in\u00a0ihren\u00a0jeweiligen \u00a0Zulassungsstudien \u00a0gegen\u00a0Scheininjektion \u00a0\nverglichen, \u00a0wobei\u00a0der\u00a0pharmazeutische \u00a0Unternehmer \u00a0die\u00a0Kontrollintervention \u00a0als\u00a0\nBr\u00fcckenkomparator \u00a0nutzt.\u00a0\u00a0\nAus\u00a0Sicht\u00a0des\u00a0G\u2010BA\u00a0mangelte \u00a0es\u00a0jedoch\u00a0an\u00a0einer\u00a0evidenten \u00a0Datengrundlage \u00a0hinsichtlich \u00a0der\u00a0\nBewertung \u00a0des\u00a0Zusatznutzens \u00a0von\u00a0Aflibercept, \u00a0da\u00a0im\u00a0vom\u00a0pU\u00a0vorgelegten \u00a0Dossier\u00a0keine\u00a0Daten\u00a0f\u00fcr\u00a0\nAflibercept \u00a0bzw.\u00a0Ranibizumab \u00a0entsprechend \u00a0der\u00a0zugelassenen \u00a0Behandlungsschemata \u00a0vorlagen\u00a0und\u00a0\nsomit\u00a0die\u00a0eingeschlossenen \u00a0Studien\u00a0nicht\u00a0f\u00fcr\u00a0einen\u00a0ad\u00e4quaten \u00a0indirekten \u00a0Vergleich \u00a0zur\u00a0Beantwortung \u00a0\nder\u00a0Fragestellung \u00a0geeignet\u00a0waren\u00a0(G\u2010BA,\u00a02014a).\u00a0\u00a0 \n169\u00a0\n\u00a0\nHintergrundinformationen \u00a0Visusbeeintr\u00e4chtigung \u00a0infolge\u00a0eines\u00a0diabetischen \u00a0Makula\u00f6dems: \u00a0Im\u00a0Rahmen\u00a0der\u00a0\nZusatznutzenbewertung \u00a0f\u00fcr\u00a0den\u00a0Einsatz\u00a0beim\u00a0diabetischen \u00a0Makula\u00f6dem \u00a0wurde\u00a0Aflibercept \u00a0erneut\u00a0\nmit\u00a0Ranibizumab \u00a0verglichen. \u00a0Zum\u00a0Nachweis \u00a0des\u00a0Zusatznutzens \u00a0legte\u00a0der\u00a0pU\u00a0in\u00a0seinem\u00a0Dossier\u00a0einen\u00a0\nadjustierten \u00a0indirekten \u00a0Vergleich \u00a0vor,\u00a0in\u00a0dem\u00a0die\u00a0Aflibercept \u2010Studien\u00a0VISTA\u00a0und\u00a0VIVID\u00a0\u00fcber\u00a0den\u00a0\nBr\u00fcckenkomparator \u00a0Laserfotokoagulation \u00a0mit\u00a0den\u00a0Ranibizumab \u2010Studien\u00a0RESTORE\u00a0und\u00a0REVEAL\u00a0\nverglichen \u00a0wurden.\u00a0In\u00a0der\u00a0Gesamtschau \u00a0der\u00a0Ergebnisse \u00a0lagen\u00a0aus\u00a0Sicht\u00a0des\u00a0G\u2010BA\u00a0f\u00fcr\u00a0die\u00a0Endpunkte \u00a0\nder\u00a0Kategorien \u00a0\u201eMortalit\u00e4t\u201c, \u00a0\u201eLebensqualit\u00e4t\u201c, \u00a0\u201eGesundheitszustand\u201c \u00a0und\u00a0\u201eNebenwirkungen\u201c \u00a0keine\u00a0\nstatistisch \u00a0signifikanten \u00a0Unterschiede \u00a0vor.\u00a0Auch\u00a0f\u00fcr\u00a0den\u00a0Endpunkt \u00a0\u201eMorbidit\u00e4t\u201c \u00a0zeigten\u00a0sich\u00a0keine\u00a0\nkonsistenten, \u00a0klinisch\u00a0relevanten \u00a0Unterschiede \u00a0zwischen\u00a0Aflibercept \u00a0und\u00a0Ranibizumab. \u00a0Aus\u00a0diesen\u00a0\n\u00dcberlegungen \u00a0heraus\u00a0stellte\u00a0der\u00a0G\u2010BA\u00a0fest,\u00a0dass\u00a0ein\u00a0Zusatznutzen \u00a0von\u00a0Aflibercept \u00a0gegen\u00fcber \u00a0der\u00a0\nzweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0Ranibizumab \u00a0nicht\u00a0belegt\u00a0ist\u00a0(G\u2010BA,\u00a02015b).\u00a0\n\u00a0Kosten\u00a0\nWirkstof f\u00a0 Behandlungsmodus Behandlungstage (Jahres)Therapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nAflibercept  Drei\u00a0Injektionen \u00a0je\u00a04\u00a0mg\u00a0im\u00a0\nMonatsabstand. \u00a0Danach\u00a0alle\u00a0\nzwei\u00a0Monate.\u00a0\n\u00a07\n\u00a0\n\u00a07.712,39\u00a0\u20ac\n\u00a0\nVergleichstherapie  \u00a0\nRanibizumab  Monatliche \u00a0Injektionen \u00a0je\u00a02,3\u00a0\nmg,\u00a0bis\u00a0Visus\u00a0bei\u00a0drei\u00a0\nKontrollen \u00a0konstant. \u00a0\nWeiterbehandlung \u00a0bei\u00a0\nVisusverlust. \u00a012 3.788,88\u201015.155,52 \u00a0\u20ac\nPreise\u00a0berechnet \u00a0f\u00fcr\u00a0das\u00a0erste\u00a0Behandlungsjahr. \u00a0In\u00a0den\u00a0Folgejahren \u00a0k\u00f6nnen\u00a0die\u00a0Kosten\u00a0geringer\u00a0ausfallen. \u00a0 \nTabelle\u00a026:\u00a0Jahrestherapiekosten \u00a0(erstes\u00a0Jahr)\u00a0von\u00a0Aflibercept \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0\nKosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen). \u00a0Zugelassenes \u00a0Anwendungsgebiet: \u00a0AMD\u00a0\n \u00a0\u00a0\n170\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Wirkstof f Behandlungsmodus Behandlungstage (Jahres)Therapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nAflibercept  Monatliche \u00a0Injektionen \u00a0je\u00a02\u00a0\nmg\u00a0bis\u00a0funktioneller \u00a0und\u00a0\nmorphologischer \u00a0Befund\u00a0bei\u00a0\ndrei\u00a0Kontrollen \u00a0stabil,\u00a0\nWiederaufnahme \u00a0der\u00a0\nBehandlung \u00a0bei\u00a0\nVerschlechterung \u00a0des\u00a0\nBefundes \u00a0oder\u00a0Verl\u00e4ngerung \u00a0\ndes\u00a0Injektionsabstandes \u00a0in\u00a0\nAbh\u00e4ngigkeit \u00a0vom\u00a0\nKrankheitsverlauf. \u00a03\u201012 3.305,31\u201013.221,24 \u00a0\u20ac\nVergleichstherapie  \u00a0\nRanibizumab  Monatliche \u00a0Injektionen \u00a0je\u00a00,5\u00a0\nmg\u00a0bis\u00a0Visus\u00a0bei\u00a0drei\u00a0\nKontrollen \u00a0konstant. \u00a0Weiter\u2010\nbehandlung \u00a0bei\u00a0Visusverlust. \u00a03\u201012\n\u00a03.788,88\u201015.155,52 \u00a0\u20ac\nDexamethason \u00a0(Intravitreales \u00a0\nImplantat)  Im\u00a0ersten\u00a0Jahr1:\u00a0intravitreale \u00a0\nInjektionen \u00a0je\u00a00,7\u00a0mg,\u00a0\nWeiterbehandlung \u00a0bei\u00a0\nVisusverlust \u00a0(Abstand\u00a0\nmindestens \u00a0sechs\u00a0Monate).\u00a01\u20102\n\u00a01.395,41\u20102.790,82\u00a0\u20ac\nPreise\u00a0berechnet \u00a0f\u00fcr\u00a0das\u00a0erste\u00a0Jahr.\u00a0In\u00a0den\u00a0Folgejahren \u00a0k\u00f6nnen\u00a0die\u00a0Kosten\u00a0geringer\u00a0ausfallen\u00a0oder\u00a0bei\u00a0Fortbestehen \u00a0eines\u00a0stabilen\u00a0\nVerlaufsbefundes \u00a0ganz\u00a0entfallen. \u00a0 \n1Es\u00a0liegen\u00a0keine\u00a0Erfahrungswerte \u00a0zur\u00a0wiederholten \u00a0Verabreichung \u00a0von\u00a0mehr\u00a0als\u00a0zwei\u00a0Implantaten \u00a0bei\u00a0retinalem \u00a0Venenverschluss \u00a0vor\u00a0\n(Fachinformation \u00a0Ozurdex\u00ae; \u00a0Stand\u00a005.2013). \u00a0\u00a0\nTabelle\u00a027:\u00a0Jahrestherapiekosten \u00a0(erstes\u00a0Jahr)\u00a0von\u00a0Aflibercept \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0\nKosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen). \u00a0Zugelassenes \u00a0Anwendungsgebiet: \u00a0Makula\u00f6dem \u00a0infolge\u00a0eines\u00a0retinalen \u00a0\nZentralvenenverschlusses \u00a0\n \u00a0 \n171\u00a0\n\u00a0\nHintergrundinformationen \u00a0Wirkstof f Behandlungsmodus Behandlungstage (Jahres)Therapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nAflibercept  F\u00fcnf\u00a0Injektionen \u00a0je\u00a02\u00a0mg\u00a0\u00a0im\u00a0\nMonatsabstand, \u00a0danach\u00a0alle\u00a0\nzwei\u00a0Monate.\u00a08 8.814,16\u00a0\u20ac\nVergleichstherapie  \u00a0\nRanibizumab  Monatliche \u00a0Injektionen \u00a0je\u00a00,5\u00a0\nmg\u00a0bis\u00a0maximaler \u00a0Visus\u00a0\nerreicht\u00a0und/oder \u00a0keine\u00a0\nAnzeichen \u00a0von\u00a0Krankheits \u2010\naktivit\u00e4t;\u00a0Weiterbehandlung \u00a0\nauf\u00a0Basis\u00a0der\u00a0Krankheits \u2010\naktivit\u00e4t,\u00a0gemessen \u00a0anhand\u00a0der\u00a0\nSehsch\u00e4rfe \u00a0und/oder \u00a0\nmorphologischer \u00a0Kriterien.\u00a03\u201012 3.788,88\u201015.155,52 \u00a0\u20ac\nPreise\u00a0berechnet \u00a0f\u00fcr\u00a0das\u00a0erste\u00a0Jahr.\u00a0In\u00a0den\u00a0Folgejahren \u00a0k\u00f6nnen\u00a0die\u00a0Kosten\u00a0geringer\u00a0ausfallen\u00a0oder\u00a0bei\u00a0Fortbestehen \u00a0eines\u00a0stabilen\u00a0\nVerlaufsbefundes \u00a0ganz\u00a0entfallen. \u00a0 \nTabelle\u00a028:\u00a0Jahrestherapiekosten \u00a0(erstes\u00a0Jahr)\u00a0von\u00a0Aflibercept \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0\nKosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen). \u00a0Zugelassenes \u00a0Anwendungsgebiet: \u00a0Visusbeeintr\u00e4chtigung \u00a0infolge\u00a0eines\u00a0\ndiabetischen \u00a0Makula\u00f6dems \u00a0\n\u00a0\n\u00a0 \u00a0\u00a0\n172\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a011.3 Axitinib\u00a0\nHandelsname: \u00a0Inlyta\u00ae\u00a0\u00a0\u00a0\u00a0\u00a0 Hersteller: \u00a0Pfizer\u00a0\nIndikation: \u00a0Nierenzellkarzinom \u00a0\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung: \u00a0Oktober\u00a02012\u00a0\nATC\u2010Code:\u00a0L01XE17\u00a0\u00a0\u00a0\u00a0\u00a0 DDD:\u00a010\u00a0mg\u00a0\nDarreichungsform: \u00a0Filmtablette \u00a0\nBewertung: \u00a0siehe\u00a0Seite\u00a039 \nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nAxitinib\u00a0ist\u00a0ein\u00a0oraler\u00a0Tyrosinkinaseinhibitor \u00a0der\u00a0vaskul\u00e4ren \u00a0endothelialen \u00a0Wachstumsfaktor \u2010\nRezeptoren \u00a0VEGFR\u20101,\u00a0VEGFR\u20102\u00a0und\u00a0VEGFR\u20103.\u00a0\u00dcber\u00a0Bindung\u00a0an\u00a0diese\u00a0Rezeptoren \u00a0vermittelt \u00a0der\u00a0\nendotheliale \u00a0Wachstumsfaktor \u00a0VEGF\u00a0seine\u00a0stimulierenden \u00a0Effekte\u00a0auf\u00a0die\u00a0Proliferation \u00a0von\u00a0\nGef\u00e4\u00dfendothelzellen, \u00a0was\u00a0bei\u00a0Krebserkrankungen \u00a0Tumorwachstum \u00a0und\u00a0\u2010metastasierung \u00a0f\u00f6rdert.\u00a0\nEine\u00a0Hemmung \u00a0der\u00a0VEGF\u2010Rezeptoren \u00a0f\u00fchrt\u00a0zu\u00a0einer\u00a0Verz\u00f6gerung \u00a0des\u00a0Tumorwachstums, \u00a0zu\u00a0\nTumorregression \u00a0und\u00a0zur\u00a0Verringerung \u00a0der\u00a0Metastasierung. \u00a0Diese\u00a0Wirkungen \u00a0konnten\u00a0f\u00fcr\u00a0Axitinib\u00a0in\u00a0\nden\u00a0Zulassungsstudien \u00a0gezeigt\u00a0werden\u00a0(Pfizer,\u00a02014a;\u00a0EMA,\u00a02014b).\u00a0\n\u00a0Zulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nAxitinib\u00a0(Inlyta\u00ae)\u00a0wurde\u00a0nach\u00a0Sorafenib \u00a0(Nexavar\u00ae), \u00a0Sunitinib\u00a0(Sutent\u00ae) \u00a0und\u00a0Pazopanib \u00a0(Votrient\u00ae) \u00a0als\u00a0\nvierter\u00a0Tyrosinkinaseinhibitor \u00a0des\u00a0VEGFR\u00a0im\u00a0September \u00a02012\u00a0von\u00a0der\u00a0\nEMA\u00a0zugelassen. \u00a0Der\u00a0oral\u00a0\neinzunehmende \u00a0Wirkstoff \u00a0besitzt\u00a0eine\u00a0Zulassung \u00a0zur\u00a0Zweitlinien \u2010Therapie\u00a0des\u00a0fortgeschrittenen \u00a0\nNierenzellkarzinoms \u00a0(RCC,\u00a0renal\u00a0cell\u00a0cancer )\u00a0bei\u00a0erwachsenen \u00a0Patienten \u00a0nach\u00a0Versagen \u00a0von\u00a0\nvorangegangener \u00a0Behandlung \u00a0mit\u00a0Sunitinib\u00a0oder\u00a0einem\u00a0Zytokin\u00a0(Interleukin \u00a02\u00a0oder\u00a0Interferon \u2010\u03b1).\u00a0\n(Pfizer,\u00a02014a;\u00a0Schwabe\u00a0&\u00a0Paffrath,\u00a02013).\u00a0\n\u00a0Informationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nDas\u00a0Nierenzellkarzinom \u00a0macht\u00a0etwa\u00a0\n85\u00a0Prozent\u00a0der\u00a0Nierenkrebserkrankungen \u00a0im\u00a0Erwachsenenalter \u00a0\naus.\u00a0Die\u00a0Zahl\u00a0der\u00a0j\u00e4hrlichen \u00a0Neuerkrankungen \u00a0betr\u00e4gt\u00a0in\u00a0Deutschland \u00a0ungef\u00e4hr\u00a015.000,\u00a0davon\u00a0sind\u00a0ca.\u00a0\n1,5\u2010mal\u00a0mehr\u00a0M\u00e4nner\u00a0als\u00a0Frauen\u00a0betroffen. \u00a0Junge\u00a0Menschen \u00a0sind\u00a0sehr\u00a0selten\u00a0betroffen, \u00a0das\u00a0mittlere\u00a0\nErkrankungsalter \u00a0liegt\u00a0bei\u00a065\u201080\u00a0Jahren.\u00a0Rauchen, \u00a0Analgetikanephropathie \u00a0und\u00a0chronische \u00a0\nNiereninsuffizienz \u00a0erh\u00f6hen\u00a0das\u00a0Nierenkrebsrisiko \u00a0(RKI\u00a0&\u00a0ZfKD,\u00a02013a;\u00a0DGHO,\u00a02013a).\u00a0\u00a0\nEine\u00a0entscheidende \u00a0Rolle\u00a0f\u00fcr\u00a0die\u00a0Pathogenese \u00a0spielen\u00a0Mutationen \u00a0des\u00a0von\u2010Hippel\u2010Lindau\u00a0(VHL)\u2010Gens\u00a0\nmit\u00a0nachfolgendem \u00a0Funktionsverlust \u00a0des\u00a0VHL\u2010Proteins.\u00a0Dessen\u00a0Inaktivierung \u00a0f\u00fchrt\u00a0in\u00a0Tumorzellen \u00a0zu\u00a0\nerh\u00f6hten \u00a0Konzentrationen \u00a0des\u00a0vaskul\u00e4ren \u00a0endothelialen \u00a0Wachstumsfaktors \u00a0(VEGF)\u00a0und\u00a0des\u00a0Platelet\u2010\nderived\u00a0Growth\u00a0Factor\u00a0(PDGF)\u00a0und\u00a0damit\u00a0zu\u00a0einer\u00a0Beg\u00fcnstigung \u00a0von\u00a0Angiogenese \u00a0und\u00a0\nTumorwachstum \u00a0(Schwabe \u00a0&\u00a0Paffrath,\u00a02013;\u00a0Wick\u2010Urban,\u00a02008).\u00a0Nierenkrebs \u00a0macht\u00a0oft\u00a0lange\u00a0keine\u00a0\nBeschwerden \u00a0und\u00a0wird\u00a0h\u00e4ufig\u00a0zuf\u00e4llig\u00a0im\u00a0Rahmen\u00a0anderer\u00a0abdomineller \u00a0Diagnostik \u00a0entdeckt. \u00a0Selten\u00a0\nauftretende \u00a0Lokalsymptome \u00a0k\u00f6nnen\u00a0H\u00e4maturie, \u00a0Flankenschmerz, \u00a0eine\u00a0tastbare\u00a0abdominale \u00a0\nRaumforderung \u00a0oder\u00a0eine\u00a0neu\u00a0aufgetretene \u00a0Varikozele \u00a0sein,\u00a0mehr\u00a0als\u00a030\u00a0Prozent\u00a0der\u00a0Betroffenen \u00a0\ngehen\u00a0mit\u00a0unspezifischen \u00a0Krankheitszeichen \u00a0wie\u00a0M\u00fcdigkeit, \u00a0Gewichtsabnahme, \u00a0Anaemie, \u00a0\nBluthochdruck, \u00a0Fieber\u00a0oder\u00a0Neuropathie \u00a0zum\u00a0Arzt.\u00a0Im\u00a0fortgeschrittenen \u00a0Stadium\u00a0k\u00f6nnen\u00a0 \n173\u00a0\n\u00a0\nHintergrundinformationen \u00a0Metastasen \u2010bedingte\u00a0Symptome \u00a0wie\u00a0Knochenschmerzen, \u00a0Dyspnoe\u00a0und\u00a0neurologische \u00a0Ausf\u00e4lle\u00a0\nhinzukommen \u00a0(DGHO,\u00a02013a;\u00a0Wick\u2010Urban,\u00a02008).\u00a0\n\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDie\u00a0Zulassung \u00a0von\u00a0Axitinib\u00a0beruht\u00a0auf\u00a0der\u00a0randomisierten \u00a0Phase\u2010III\u2010Studie\u00a0AXIS\u00a01032.\u00a0Eingeschlossen \u00a0\nwurden\u00a0723\u00a0Patienten \u00a0mit\u00a0fortgeschrittenem \u00a0metastasiertem \u00a0Nierenzellkarzinom \u00a0mit\u00a0Progress\u00a0\nw\u00e4hrend\u00a0oder\u00a0nach\u00a0Erstlinien \u2010Therapie\u00a0mit\u00a0\u00fcberwiegend \u00a0Sunitinib\u00a0oder\u00a0einem\u00a0Zytokin.\u00a0Davon\u00a0\nerhielten\u00a0361\u00a0Patienten \u00a0Axitinib\u00a0(5\u00a0mg\u00a0zweimal\u00a0t\u00e4glich,\u00a0eine\u00a0Dosiserh\u00f6hung \u00a0auf\u00a07\u00a0mg\u00a0oder\u00a010\u00a0mg\u00a0\nzweimal\u00a0t\u00e4glich\u00a0war\u00a0erlaubt\u00a0f\u00fcr\u00a0Patienten \u00a0ohne\u00a0Bluthochdruck \u00a0und\u00a0ohne\u00a0schwerwiegende \u00a0\nNebenwirkungen) \u00a0und\u00a0362\u00a0Patienten \u00a0Sorafenib \u00a0(400\u00a0mg\u00a0zweimal\u00a0t\u00e4glich).\u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0war\u00a0das\u00a0\nprogressionsfreie \u00a0\u00dcberleben. \u00a0In\u00a0der\u00a0Gesamtpopulation \u00a0verl\u00e4ngerte \u00a0Axitinib\u00a0das\u00a0mediane\u00a0\nprogressionsfreie \u00a0\u00dcberleben \u00a0im\u00a0Vergleich \u00a0zu\u00a0Sorafenib \u00a0signifikant \u00a0von\u00a04,7\u00a0auf\u00a06,7\u00a0Monate,\u00a0wobei\u00a0\ndieser\u00a0Wert\u00a0in\u00a0den\u00a0Subgruppen \u00a0je\u00a0nach\u00a0Vorbehandlung \u00a0unterschiedlich \u00a0ausfiel.\u00a0Bei\u00a0vier\u00a0Prozent\u00a0der\u00a0\nmit\u00a0Axitinib\u00a0und\u00a0bei\u00a0acht\u00a0Prozent\u00a0der\u00a0mit\u00a0Sorafenib \u00a0behandelten \u00a0Patienten \u00a0wurde\u00a0die\u00a0Behandlung \u00a0\nwegen\u00a0toxischer\u00a0Nebenwirkungen \u00a0abgebrochen. \u00a0Die\u00a0h\u00e4ufigsten \u00a0Nebenwirkungen \u00a0von\u00a0Axitinib\u00a0waren\u00a0\nDiarrhoe, \u00a0Hypertonie \u00a0und\u00a0Fatigue,\u00a0die\u00a0von\u00a0Sorafenib \u00a0Diarrhoe, \u00a0PPE\u00a0(Hand\u2010Fu\u00df\u2010Syndrom) \u00a0und\u00a0\nAlopezie\u00a0(Rini\u00a0et\u00a0al.,\u00a02011).\u00a0\nIn\u00a0einer\u00a0weiteren\u00a0Phase\u2010III\u2010Studie\u00a0wurden\u00a0Wirksamkeit \u00a0und\u00a0Sicherheit \u00a0von\u00a0Axitinib\u00a0gegen\u00fcber \u00a0\nSorafenib \u00a0als\u00a0Zweitlinien \u2010Therapie\u00a0untersucht \u00a0(Motzer\u00a0et\u00a0al.,\u00a02013).\u00a0Auch\u00a0wenn\u00a0das\u00a0Gesamt\u00fcberleben \u00a0\nals\u00a0sekund\u00e4rer \u00a0Endpunkt \u00a0dieser\u00a0Studie\u00a0keine\u00a0Unterschiede \u00a0in\u00a0den\u00a0Behandlungsarmen \u00a0aufzeigte, \u00a0so\u00a0\nkonnte\u00a0doch\u00a0das\u00a0mediane\u00a0progressionsfreie \u00a0\u00dcberleben \u00a0unter\u00a0Axitinib\u00a0signifikant \u00a0verl\u00e4ngert \u00a0werden\u00a0\n(8,3\u00a0Monate\u00a0vs.\u00a05\u20107\u00a0Monate). \u00a0Eine\u00a0Studie\u00a0um\u00a0Rini\u00a0et\u00a0al.\u00a0(2013)\u00a0untersuchte \u00a0Axitinib\u00a0hingegen\u00a0als\u00a0\nm\u00f6gliche\u00a0Option\u00a0in\u00a0der\u00a0Erstlinien \u2010Therapie\u00a0unter\u00a0Ber\u00fccksichtigung \u00a0einer\u00a0individuellen \u00a0Dosistitration. \u00a0\nGrundannahme \u00a0dieser\u00a0Studie\u00a0war,\u00a0dass\u00a0die\u00a0Plasmaexposition \u00a0von\u00a0Axitinib\u00a0mit\u00a0der\u00a0Wirksamkeit \u00a0bei\u00a0\nmetastasiertem \u00a0Nierenzellkarzinom \u00a0korreliert. \u00a0Das\u00a0Ergebnis\u00a0dieser\u00a0Untersuchung \u00a0zeigte,\u00a0dass\u00a0der\u00a0\ngr\u00f6\u00dfere\u00a0Anteil\u00a0der\u00a0Patienten \u00a0in\u00a0der\u00a0Axitinib\u2010Titrations \u2010Gruppe\u00a0ein\u00a0objektives \u00a0Ansprechen \u00a0erzielte.\u00a0\nDies\u00a0wiederum \u00a0unterst\u00fctzt \u00a0das\u00a0Konzept\u00a0der\u00a0individuellen \u00a0Axitinib\u2010Dosistitration \u00a0bei\u00a0ausgew\u00e4hlten \u00a0\nPatienten \u00a0mit\u00a0metastasiertem \u00a0Nierenzellkarzinom. \u00a0\u00a0\n\u00a0\nLeitlinienempfehlungen \u00a0\nOperative \u00a0Entfernung \u00a0oder\u00a0Verkleinerung \u00a0von\u00a0Nierentumorgewebe \u00a0und\u00a0Metastasen \u00a0spielen\u00a0eine\u00a0\nwichtige\u00a0Rolle\u00a0in\u00a0der\u00a0Standardtherapie \u00a0des\u00a0Nierenzellkarzinoms. \u00a0Arzneimittel \u00a0sind\u00a0bislang\u00a0nur\u00a0f\u00fcr\u00a0\nPatienten \u00a0mit\u00a0metastasiertem \u00a0Nierenzellkarzinom \u00a0zugelassen. \u00a0Wegen\u00a0weitgehender \u00a0\nChemotherapieresistenz \u00a0waren\u00a0zur\u00a0systemischen \u00a0Behandlung \u00a0bis\u00a0vor\u00a0wenigen\u00a0Jahren\u00a0nur\u00a0die\u00a0\nZytokine\u00a0Interferon \u00a0\u03b1\u00a0und\u00a0Interleukin \u20102\u00a0verf\u00fcgbar. \u00a0Das\u00a0bessere\u00a0Verst\u00e4ndnis \u00a0der\u00a0Pathogenese \u00a0hat\u00a0die\u00a0\nEntwicklung \u00a0neuer\u00a0Arzneistoffe \u00a0aus\u00a0der\u00a0Gruppe\u00a0der\u00a0Tyrosinkinaseinhibitoren \u00a0(Sorafenib, \u00a0Sunitinib, \u00a0\nPazopanib, \u00a0Axitinib),\u00a0der\u00a0VEGF\u2010Inhibitoren \u00a0(Bevacizumab) \u00a0und\u00a0der\u00a0mTOR\u2010Inhibitoren \u00a0(Temsirolimus, \u00a0\nEverolimus) \u00a0erm\u00f6glicht \u00a0(Schwabe \u00a0&\u00a0Paffrath,\u00a02013).\u00a0\nDie\u00a0Leitlinie\u00a0der\u00a0DGHO\u00a0gibt\u00a0Therapieempfehlungen \u00a0in\u00a0Form\u00a0von\u00a0Algorithmen \u00a0f\u00fcr\u00a0die\u00a0medikament\u00f6se \u00a0\nErst\u2010\u00a0und\u00a0Zweitlinien \u2010Therapie, \u00a0nach\u00a0denen\u00a0die\u00a0verschiedenen \u00a0Wirkstoffe \u00a0je\u00a0nach\u00a0Prognose, \u00a0\nAllgemeinzustand, \u00a0Begleiterkrankungen \u00a0und\u00a0zu\u00a0erwartender \u00a0Nebenwirkungen \u00a0eingesetzt \u00a0werden.\u00a0\u00a0\n174\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Dabei\u00a0wird\u00a0deutlich,\u00a0dass\u00a0bei\u00a0den\u00a0meisten\u00a0Patienten \u00a0im\u00a0Krankheitsverlauf \u00a0eine\u00a0Sequenztherapie \u00a0mit\u00a0\nmehreren \u00a0Substanzen \u00a0unterschiedlicher \u00a0Wirkprofile \u00a0indiziert\u00a0ist.\u00a0Axitinib\u00a0ist\u00a0im\u00a0Algorithmus \u00a0f\u00fcr\u00a0die\u00a0\nZweitlinien \u2010Therapie\u00a0nach\u00a0Vorbehandlung \u00a0mit\u00a0Zytokinen \u00a0alternativ \u00a0zu\u00a0Pazopanib \u00a0oder\u00a0Sorafenib \u00a0und\u00a0\nnach\u00a0Vorbehandlung \u00a0mit\u00a0VEGFR\u2010Inhibitoren \u00a0alternativ \u00a0zu\u00a0Everolimus \u00a0oder\u00a0Sorafenib \u00a0aufgef\u00fchrt \u00a0\n(DGHO,\u00a02013a).\u00a0\n\u00a0\nNutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDie\u00a0Nutzenbewertung \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0wurde\u00a0f\u00fcr\u00a0zwei\u00a0unterschiedliche \u00a0\nGruppen\u00a0von\u00a0Patienten \u00a0mit\u00a0fortgeschrittenem \u00a0Nierenzellkarzinom \u00a0durchgef\u00fchrt. \u00a0\u00a0\nF\u00fcr\u00a0Patienten \u00a0nach\u00a0einem\u00a0Versagen \u00a0einer\u00a0vorausgegangenen \u00a0Therapie\u00a0mit\u00a0einem\u00a0Zytokin\u00a0sieht\u00a0der\u00a0\nGemeinsame \u00a0Bundesausschuss \u00a0einen\u00a0Hinweis\u00a0auf\u00a0einen\u00a0geringen\u00a0Zusatznutzen \u00a0von\u00a0Axitinib\u00a0\ngegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0Sorafenib \u00a0als\u00a0gegeben.\u00a0F\u00fcr\u00a0die\u00a0Bewertung \u00a0konnte\u00a0\neine\u00a0Teilpopulation \u00a0der\u00a0Zulassungsstudie \u00a0(AXIS)\u00a0herangezogen \u00a0werden.\u00a0Zwar\u00a0ergab\u00a0sich\u00a0bei\u00a0dem\u00a0\nEndpunkt \u00a0\u201eGesamt\u00fcberleben\u201c \u00a0kein\u00a0statistisch \u00a0signifikanter \u00a0Unterschied \u00a0zwischen\u00a0den\u00a0beiden\u00a0\nTherapiearmen, \u00a0f\u00fcr\u00a0den\u00a0\u201eHinweis\u00a0auf\u00a0einen\u00a0geringen\u00a0Zusatznutzen\u201c \u00a0ausschlaggebend \u00a0waren\u00a0in\u00a0\ndiesem\u00a0Fall\u00a0die\u00a0unterschiedlichen \u00a0Raten\u00a0an\u00a0unerw\u00fcnschten \u00a0Ereignissen. \u00a0Hinsichtlich \u00a0der\u00a0\nunerw\u00fcnschten \u00a0Ereignisse \u00a0\u201eHand\u2010Fu\u00df\u2010Syndrom\u201c, \u00a0\u201eAusschlag\u201c \u00a0und\u00a0\u201eAlopezie\u201c \u00a0zeigte\u00a0sich\u00a0ein\u00a0\nstatistisch \u00a0signifikanter \u00a0Vorteil\u00a0f\u00fcr\u00a0Axitinib.\u00a0Da\u00a0allerdings \u00a0f\u00fcr\u00a0die\u00a0unerw\u00fcnschten \u00a0Ereignisse \u00a0\u201eFatigue\u201c, \u00a0\n\u201eDysphonie\u201c \u00a0sowie\u00a0\u201e\u00dcbelkeit\u201c \u00a0die\u00a0Ergebnisse \u00a0zu\u00a0Gunsten\u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0\nausfielen, \u00a0kommt\u00a0der\u00a0G\u2010BA\u00a0in\u00a0der\u00a0Gesamtschau \u00a0zu\u00a0der\u00a0Auffassung, \u00a0dass\u00a0der\u00a0Zusatznutzen \u00a0von\u00a0Axitinib\u00a0\ngegen\u00fcber \u00a0Sorafenib \u00a0als\u00a0gering\u00a0einzusch\u00e4tzen \u00a0ist,\u00a0weswegen \u00a0die\u00a0Aussagesicherheit \u00a0in\u00a0die\u00a0Kategorie \u00a0\n\u201eHinweis\u201c \u00a0eingestuft \u00a0wurde.\u00a0\nIn\u00a0der\u00a0Gruppe\u00a0mit\u00a0vorausgegangener \u00a0Behandlung \u00a0mit\u00a0Sunitinib\u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0dagegen\u00a0einen\u00a0\nZusatznutzen \u00a0gegen\u00fcber \u00a0der\u00a0gew\u00e4hlten \u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0Everolimus \u00a0mangels\u00a0\nVorlage\u00a0direkter\u00a0Vergleichsstudien \u00a0als\u00a0nicht\u00a0belegt\u00a0an.\u00a0Der\u00a0hierf\u00fcr\u00a0durchgef\u00fchrte \u00a0nicht\u2010adjustierte \u00a0\nindirekte\u00a0Vergleich \u00a0wurde\u00a0f\u00fcr\u00a0die\u00a0Bewertung \u00a0als\u00a0methodisch \u00a0ungeeignet \u00a0abgelehnt \u00a0(G\u2010BA,\u00a02013c).\u00a0\nDer\u00a0G\u2010BA\u2010Beschluss \u00a0ist\u00a0zun\u00e4chst\u00a0auf\u00a0vier\u00a0Jahre\u00a0(bis\u00a0M\u00e4rz\u00a02017)\u00a0befristet.\u00a0Grund\u00a0daf\u00fcr\u00a0ist,\u00a0dass\u00a0der\u00a0\nZusatznutzen \u00a0von\u00a0Axitinib\u00a0auf\u00a0therapieerfahrene \u00a0Patienten \u00a0(Zytokin)\u00a0begrenzt\u00a0ist.\u00a0Da\u00a0bereits\u00a0heute\u00a0\neine\u00a0Zytokin\u2010Therapie\u00a0nur\u00a0noch\u00a0selten\u00a0als\u00a0Erstlinien \u2010Therapie\u00a0eingesetzt \u00a0wird,\u00a0kann\u00a0aufgrund\u00a0der\u00a0\nNeuentwicklung \u00a0auch\u00a0zuk\u00fcnftig \u00a0mit\u00a0einer\u00a0weiteren\u00a0Abnahme \u00a0der\u00a0therapeutischen \u00a0Relevanz\u00a0der\u00a0\nZytokine\u00a0in\u00a0der\u00a0Erstlinien \u2010Therapie\u00a0gerechnet \u00a0werden.\u00a0\n \u00a0 \n175\u00a0\n\u00a0\nHintergrundinformationen \u00a0Kosten\u00a0\nWirkstof f\u00a0 Behandlungsmodus Behandlungstage Jahrestherapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nAxitinib  2\u00a0x\u00a0t\u00e4glich\u00a05\u00a0mg 360 46.248,17 \u00a0\u20ac\nVergleichstherapie  \u00a0\nEverolimus  1\u00a0x\u00a0t\u00e4glich\u00a010\u00a0mg 360 56.206,56 \u00a0\u20ac\nSorafenib  2\u00a0x\u00a0t\u00e4glich\u00a0400\u00a0mg 360 62.669,83 \u00a0\u20ac\nTabelle\u00a029:\u00a0Jahrestherapiekosten \u00a0von\u00a0Axitinib\u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0Kosten\u00a0\nzus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0\n\u00a0\u00a0\u00a0\n176\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a011.4 Azilsartanmedoxomil \u00a0\n\u00a0\u00a0\u00a0Handelsname: \u00a0Edarbi\u00ae\u00a0 \u00a0\u00a0\u00a0 Hersteller: \u00a0Takeda\u00a0\nIndikation: \u00a0Essentielle \u00a0Hypertonie \u00a0\u00a0 \u00a0 Markteinf\u00fchrung: \u00a0Januar\u00a02012\u00a0\nATC\u2010Code:\u00a0C09CA09\u00a0 \u00a0\u00a0\u00a0\u00a0 DDD:\u00a040\u00a0mg\u00a0\nDarreichungsform: \u00a0Tablette\u00a0\nBewertung: \u00a0siehe\u00a0Seite\u00a043\u00a0\nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nAzilsartanmedoxomil \u00a0ist\u00a0ein\u00a0weiterer\u00a0Angiotensin \u2010II\u2010Antagonist. \u00a0Er\u00a0wirkt\u00a0als\u00a0Prodrug\u00a0und\u00a0wird\u00a0nach\u00a0\nResorption \u00a0im\u00a0Magen\u2010Darm\u2010Trakt\u00a0durch\u00a0enterale\u00a0sowie\u00a0hepatische \u00a0Esterasen \u00a0in\u00a0den\u00a0wirksamen \u00a0\nMetaboliten \u00a0Azilsartan \u00a0\u00fcberf\u00fchrt. \u00a0\u00a0\nAngiotensin \u00a0II\u00a0vermittelt \u00a0\u00fcber\u00a0die\u00a0spezifische \u00a0Bindung\u00a0an\u00a0AT1\u2010Rezeptoren \u00a0im\u00a0K\u00f6rper\u00a0unterschiedliche \u00a0\nVorg\u00e4nge: \u00a0An\u00a0den\u00a0glatten\u00a0Muskelzellen \u00a0bewirkt\u00a0es\u00a0eine\u00a0deutliche \u00a0Kontraktion. \u00a0Gleiche\u00a0Mengen\u2010\nanteile\u00a0von\u00a0Angiotensin \u00a0II\u00a0wirken\u00a010\u00a0bis\u00a040\u2010mal\u00a0st\u00e4rker\u00a0gef\u00e4\u00dfverengend \u00a0als\u00a0Noradrenalin. \u00a0Dies\u00a0f\u00fchrt\u00a0\nzu\u00a0einer\u00a0Erh\u00f6hung \u00a0des\u00a0peripheren \u00a0Gef\u00e4\u00dfwiderstandes \u00a0und\u00a0zur\u00a0Blutdrucksteigerung, \u00a0was\u00a0am\u00a0Herzen\u00a0\neine\u00a0Hypertrophie \u00a0und\u00a0Hyperplasie \u00a0der\u00a0Herzmuskelzellen \u00a0verursachen \u00a0kann.\u00a0Im\u00a0Gehirn\u00a0wird\u00a0durch\u00a0\nAngiotensin \u00a0II\u00a0die\u00a0Aussch\u00fcttung \u00a0von\u00a0Vasopressin \u00a0und\u00a0Antidiuretischem \u00a0Hormon\u00a0(ADH),\u00a0in\u00a0der\u00a0\nNebennierenrinde \u00a0die\u00a0von\u00a0Aldosteron \u00a0stimuliert. \u00a0Beides\u00a0kann\u00a0Fl\u00fcssigkeitsretention \u00a0und\u00a0\nBlutdrucksteigerung \u00a0bewirken. \u00a0Durch\u00a0die\u00a0Bindung\u00a0von\u00a0Azilsartan \u00a0an\u00a0den\u00a0AT1\u2010Rezeptor\u00a0werden\u00a0die\u00a0\nphysiologischen \u00a0Wirkungen \u00a0von\u00a0Angiotensin \u00a0II\u00a0unterbunden. \u00a0Dadurch\u00a0unterbleibt \u00a0zwar\u00a0auch\u00a0das\u00a0\nnegative\u00a0Feedback \u00a0von\u00a0Angiotensin \u00a0II\u00a0auf\u00a0die\u00a0Reninsekretion, \u00a0jedoch\u00a0reichen\u00a0der\u00a0Anstieg\u00a0der\u00a0Renin\u2010\nAktivit\u00e4t\u00a0im\u00a0Plasma\u00a0und\u00a0der\u00a0Angiotensin \u2010II\u2010Spiegel\u00a0im\u00a0Blut\u00a0nicht\u00a0aus,\u00a0um\u00a0die\u00a0blutdrucksenkende \u00a0\nWirkung\u00a0von\u00a0Azilsartan \u00a0aufzuheben \u00a0(F\u00f6rstermann \u00a0et\u00a0al.,\u00a02013).\u00a0\n\u00a0Zulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nEdarbi\u00ae\u00a0wurde\u00a0im\u00a0Dezember \u00a02011\u00a0zentral\u00a0durch\u00a0die\u00a0Europ\u00e4ische \u00a0Zulassungsbeh\u00f6rde \u00a0(EMA)\u00a0zur\u00a0\nBehandlung \u00a0der\u00a0essentiellen \u00a0Hypertonie \u00a0\nbei\u00a0Erwachsenen \u00a0zugelassen \u00a0(Takeda,\u00a02014a).\u00a0Der\u00a0Wirkstoff \u00a0\nsteht\u00a0dem\u00a0Markt\u00a0in\u00a0fester\u00a0Zubereitungsform \u00a0zum\u00a0Einnehmen \u00a0(Tablette) \u00a0in\u00a0drei\u00a0verschiedenen \u00a0\nEinzeldosen \u00a0(20,\u00a040\u00a0und\u00a080\u00a0mg)\u00a0zur\u00a0Verf\u00fcgung. \u00a0\u00a0\n\u00a0Informationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nArterielle \u00a0Hypertonie \u00a0ist\u00a0mit\u00a0einer\u00a0Pr\u00e4valenz \u00a0von\u00a030\u00a0bis\u00a045\u00a0Prozent\u00a0in\u00a0der\u00a0europ\u00e4ischen \u00a0\nAllgemeinbev\u00f6lkerung \u00a0ein\u00a0ma\u00dfgeblicher \u00a0Risikofaktor \u00a0f\u00fcr\u00a0die\u00a0kardiovaskul\u00e4re\n\u00a0Sterblichkeit \u00a0(ESC\u00a0\nPocket\u00a0Guidelines, \u00a0deutsch), \u00a0wobei\u00a0mit\u00a0steigendem \u00a0Alter\u00a0die\u00a0Anzahl\u00a0der\u00a0Erkrankten \u00a0deutlich\u00a0\nzunimmt. \u00a0Chronisch \u00a0erh\u00f6hte\u00a0Blutdruckwerte \u00a0f\u00fchren\u00a0zudem\u00a0zu\u00a0Organsch\u00e4den, \u00a0vor\u00a0allem\u00a0an\u00a0der\u00a0Niere.\u00a0\nAus\u00a0diesem\u00a0Grund\u00a0wird\u00a0eine\u00a0konsequente \u00a0Blutdrucksenkung \u00a0insbesondere \u00a0bei\u00a0fr\u00fchem\u00a0\nKrankheitsbeginn \u00a0empfohlen. \u00a0Studien\u00a0zufolge\u00a0geht\u00a0aber\u00a0auch\u00a0die\u00a0Dauerbehandlung \u00a0von\u00a0\nHochbetagten \u00a0mit\u00a0einer\u00a0Senkung\u00a0der\u00a0Sterblichkeit \u00a0einher,\u00a0so\u00a0dass\u00a0bei\u00a0guter\u00a0Vertr\u00e4glichkeit \u00a0ebenso\u00a0im\u00a0\nhohen\u00a0Alter\u00a0eine\u00a0blutdrucksenkende \u00a0Behandlung \u00a0zu\u00a0bef\u00fcrworten \u00a0ist\u00a0(Beckett\u00a0et\u00a0al.,\u00a02011;\u00a0Briasoulis \u00a0\net\u00a0al.,\u00a02013).\u00a0Die\u00a0europ\u00e4ischen \u00a0Leitlinienersteller \u00a0empfehlen \u00a0bei\u00a0\u00e4lteren\u00a0Menschen \u00a0eine\u00a0 \n177\u00a0\n\u00a0\nHintergrundinformationen \u00a0antihypertensive \u00a0Behandlung \u00a0ab\u00a0einem\u00a0systolischen \u00a0Blutdruck \u00a0von\u00a0\u00fcber\u00a0160\u00a0mg\u00a0(ESH/EHC, \u00a02013).\u00a0\nLaut\u00a0einem\u00a0Cochrane \u00a0Review\u00a0ergeben\u00a0sich\u00a0f\u00fcr\u00a0Wirkstoffe \u00a0mit\u00a0Einfluss\u00a0auf\u00a0das\u00a0Renin\u2010Angiotensin \u2010\nAldosteron \u2010System\u00a0im\u00a0Vergleich \u00a0zu\u00a0First\u2010Line\u2010Wirkstoffen \u00a0aus\u00a0anderen\u00a0Wirkstoffklassen \u00a0keine\u00a0\nrelevanten \u00a0Unterschiede \u00a0bzgl.\u00a0der\u00a0Verbesserung \u00a0patientenrelevanter \u00a0Endpunkte \u00a0wie\u00a0Mortalit\u00e4t \u00a0und\u00a0\nMorbidit\u00e4t \u00a0(Xue\u00a0et\u00a0al.,\u00a02015).\u00a0\n\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nAzilsartanmedoxomil \u00a0wurde\u00a0in\u00a0verschiedenen \u00a0randomisiert \u00a0kontrollierten \u00a0Studien\u00a0an\u00a0Patienten \u00a0mit\u00a0\nessentieller \u00a0Hypertonie \u00a0untersucht. \u00a0Vergleichsbehandlungen \u00a0waren\u00a0Placebo\u00a0und\u00a0aktive\u00a0Kontrollen \u00a0\nwie\u00a0Candesartan, \u00a0Olmesartan \u00a0und\u00a0Valsartan. \u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0war\u00a0in\u00a0allen\u00a0F\u00e4llen\u00a0die\u00a0Senkung\u00a0des\u00a0\n(je\u00a0nach\u00a0Studienfrage \u00a0systolischen \u00a0oder\u00a0diastolischen) \u00a0Blutdrucks. \u00a0In\u00a0den\u00a0klinischen \u00a0Studien\u00a0ergibt\u00a0\nsich\u00a0f\u00fcr\u00a0Azilsartanmedoxomil \u00a0gegen\u00fcber \u00a0Scheinbehandlung \u00a0eine\u00a0\u00fcberlegene \u00a0antihypertensive \u00a0\nWirksamkeit. \u00a0Den\u00a0verschiedenen \u00a0Verum\u2010Behandlungsoptionen \u00a0ist\u00a0Azilsartanmedoxomil \u00a0zumindest \u00a0\ngleichwertig, \u00a0in\u00a0Abh\u00e4ngigkeit \u00a0von\u00a0der\u00a0Dosierung \u00a0zeichnet\u00a0sich\u00a0allerdings \u00a0eine\u00a0geringf\u00fcgig \u00a0bessere\u00a024\u2010\nStunden\u2010Blutdruckkontrolle \u00a0f\u00fcr\u00a0Azilsartanmedoxomil \u00a0ab\u00a0(Takagi\u00a0et\u00a0al.,\u00a02014).\u00a0Ob\u00a0diese\u00a0Unterschiede \u00a0\nvon\u00a0klinischer \u00a0Bedeutung \u00a0sind,\u00a0bleibt\u00a0unklar,\u00a0da\u00a0valide\u00a0Studien\u00a0mit\u00a0patientenrelevanten \u00a0Endpunkten \u00a0\nwie\u00a0Sterblichkeit, \u00a0Herzinfarkt \u00a0und\u00a0Schlaganfallsrate \u00a0sowie\u00a0anderen\u00a0Endorgansch\u00e4den \u00a0fehlen.\u00a0\u00a0\nAls\u00a0unerw\u00fcnschte \u00a0Wirkung\u00a0trat\u00a0in\u00a0den\u00a0kontrollierten \u00a0Untersuchungen \u00a0am\u00a0h\u00e4ufigsten \u00a0Schwindel \u00a0auf.\u00a0\nAuch\u00a0Kopfschmerzen \u00a0und\u00a0\u00c4nderungen \u00a0der\u00a0Lipidspiegel \u00a0wurden\u00a0verzeichnet. \u00a0Gesamtinzidenz \u00a0\nunerw\u00fcnschter \u00a0Wirkungen \u00a0und\u00a0Auspr\u00e4gung \u00a0waren\u00a0innerhalb \u00a0klinischer \u00a0Studien\u00a0aber\u00a0mit\u00a0denen\u00a0der\u00a0\nKontroll\u2010Gruppen\u00a0\u2013\u00a0einschlie\u00dflich \u00a0der\u00a0Placebo\u2010Gruppe\u00a0\u2013\u00a0vergleichbar. \u00a0Auch\u00a0wurde\u00a0die\u00a0\nStudienbehandlung \u00a0in\u00a0den\u00a0Verum\u2010Gruppen\u00a0nicht\u00a0h\u00e4ufiger\u00a0als\u00a0in\u00a0der\u00a0Placebo\u2010Gruppe\u00a0wegen\u00a0\nunerw\u00fcnschter \u00a0Wirkungen \u00a0vorzeitig\u00a0beendet\u00a0(Matthes, \u00a02014).\u00a0\u00a0\n\u00a0\nLeitlinienempfehlungen \u00a0\nDie\u00a0nationalen \u00a0Leitlinien\u00a0wurden\u00a0in\u00a0Zusammenhang \u00a0mit\u00a0den\u00a0Empfehlungen \u00a0der\u00a0europ\u00e4ischen \u00a0\nFachgesellschaften \u00a0ESH/ESC\u00a0zur\u00a0Behandlung \u00a0der\u00a0arteriellen \u00a0Hypertonie \u00a0aktualisiert \u00a0(ESH/ESC, \u00a02013).\u00a0\nAls\u00a0auff\u00e4llige \u00a0\u00c4nderung \u00a0gegen\u00fcber \u00a0den\u00a0vorangegangenen \u00a0Empfehlungen \u00a0der\u00a0europ\u00e4ischen \u00a0\nFachgesellschaften \u00a0ist\u00a0die\u00a0Vereinheitlichung \u00a0der\u00a0systolischen \u00a0Zielblutdruckwerte \u00a0bei\u00a0Personen \u00a0mit\u00a0\nhohem\u00a0und\u00a0solchen\u00a0mit\u00a0niedrigem \u00a0kardiovaskul\u00e4ren \u00a0Risiko\u00a0auf\u00a0unter\u00a0140\u00a0mm\u00a0Hg\u00a0zu\u00a0nennen.\u00a0Die\u00a0\nNotwendigkeit \u00a0einer\u00a0antihypertensiven \u00a0Behandlung \u00a0soll\u00a0nach\u00a0Empfehlung \u00a0der\u00a0Leitlinienautoren \u00a0nicht\u00a0\nallein\u00a0anhand\u00a0der\u00a0Blutdruckwerte \u00a0festgestellt \u00a0werden.\u00a0Vielmehr\u00a0ist\u00a0das\u00a0individuelle \u00a0kardiovaskul\u00e4re \u00a0\nRisikoprofil \u00a0zu\u00a0ber\u00fccksichtigen, \u00a0das\u00a0sich\u00a0neben\u00a0dem\u00a0erh\u00f6hten \u00a0Blutdruck \u00a0durch\u00a0das\u00a0Vorhandensein \u00a0\nweiterer\u00a0Risikofaktoren \u00a0wie\u00a0beispielsweise \u00a0Geschlecht, \u00a0Raucherstatus, \u00a0Fettstoffwechselst\u00f6rungen, \u00a0\n\u00dcbergewicht, \u00a0Diabetes\u00a0oder\u00a0Nierenerkrankungen \u00a0etc.\u00a0sowie\u00a0manifeste \u00a0endokrinologische \u00a0oder\u00a0\nkardiovaskul\u00e4re \u00a0Zusatzerkrankungen \u00a0absch\u00e4tzen \u00a0l\u00e4sst.\u00a0Eine\u00a0blutdrucksenkende \u00a0Behandlung \u00a0kann\u00a0\nsowohl\u00a0mit\u00a0Mono\u2010\u00a0wie\u00a0auch\u00a0mit\u00a0Kombinationspr\u00e4paraten \u00a0initiiert\u00a0werden.\u00a0Neben\u00a0medikament\u00f6sen \u00a0\nMa\u00dfnahmen \u00a0werden\u00a0nicht\u2010pharmakologische \u00a0Ma\u00dfnahmen \u00a0zur\u00a0\u00c4nderung \u00a0des\u00a0Lebensstils \u00a0als\u00a0wichtige\u00a0\ntherapeutische \u00a0Ma\u00dfnahme \u00a0empfohlen. \u00a0Hierzu\u00a0geh\u00f6rt\u00a0die\u00a0Kochsalzrestriktion \u00a0auf\u00a05\u20106\u00a0g/Tag,\u00a0\nRauchverzicht, \u00a0eingeschr\u00e4nkter \u00a0Alkoholkonsum, \u00a0Gewichtsreduktion \u00a0auf\u00a0einen\u00a0BMI\u00a0von\u00a0\u2264\u00a025\u00a0kg/m2\u00a0\nund\u00a0regelm\u00e4\u00dfige \u00a0Bewegung. \u00a0F\u00fcr\u00a0die\u00a0pharmakologische \u00a0Intervention \u00a0steht\u00a0eine\u00a0Vielzahl\u00a0von\u00a0\u00a0\n178\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Wirkstoffgruppen \u00a0zur\u00a0Verf\u00fcgung. \u00a0F\u00fcr\u00a0keine\u00a0dieser\u00a0Wirkstoffgruppen \u00a0\u2013\u00a0Diuretika, \u00a0Betablocker, \u00a0\nCalcium\u2010Antagonisten, \u00a0ACE\u2010Hemmer, \u00a0Sartane\u00a0\u2013\u00a0ist\u00a0ein\u00a0klinisch\u00a0relevanter \u00a0Vorteil\u00a0gegen\u00fcber \u00a0den\u00a0\nanderen\u00a0Blutdrucksenkern \u00a0bewiesen. \u00a0Die\u00a0Auswahl\u00a0der\u00a0Wirkstoffe \u00a0erfolgt\u00a0daher\u00a0vor\u00a0dem\u00a0Hintergrund \u00a0\nindividueller \u00a0Gegebenheiten. \u00a0\u00a0\n\u00a0\nNutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nNach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0ist\u00a0f\u00fcr\u00a0Arzneimittel, \u00a0die\u00a0pharmakologisch \u2010therapeutisch \u00a0mit\u00a0Festbetragsarznei \u2010\nmitteln\u00a0vergleichbar \u00a0sind,\u00a0der\u00a0medizinische \u00a0Zusatznutzen \u00a0als\u00a0therapeutische \u00a0Verbesserung \u00a0anhand\u00a0\npatientenrelevanter \u00a0Endpunkte \u00a0nachzuweisen. \u00a0Legt\u00a0der\u00a0pharmazeutische \u00a0Unternehmer \u00a0die\u00a0\nerforderlichen \u00a0Nachweise \u00a0auch\u00a0nach\u00a0Aufforderung \u00a0durch\u00a0die\u00a0zust\u00e4ndigen \u00a0Beh\u00f6rden \u00a0nicht\u00a0vor,\u00a0gilt\u00a0ein\u00a0\nZusatznutzen \u00a0als\u00a0nicht\u00a0belegt.\u00a0\nDie\u00a0Markteinf\u00fchrung \u00a0von\u00a0Azilsartanmedoxomil \u00a0war\u00a0am\u00a015.\u00a0Januar\u00a02012.\u00a0Bis\u00a0zu\u00a0diesem\u00a0sp\u00e4test\u2010\nm\u00f6glichen \u00a0Zeitpunkt \u00a0wurde\u00a0vom\u00a0pharmazeutischen \u00a0Unternehmer \u00a0trotz\u00a0entsprechender \u00a0\nAufforderung \u00a0kein\u00a0Nutzendossier \u00a0beim\u00a0Gemeinsamen \u00a0Bundesausschuss \u00a0zur\u00a0Begutachtung \u00a0\neingereicht. \u00a0Aus\u00a0diesem\u00a0Grund\u00a0gilt\u00a0ein\u00a0Zusatznutzen \u00a0f\u00fcr\u00a0Azilsartanmedoxomil \u00a0gegen\u00fcber \u00a0einer\u00a0\nzweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0wie\u00a0etwa\u00a0andere\u00a0Vertreter \u00a0aus\u00a0der\u00a0Gruppe\u00a0der\u00a0Sartane\u00a0oder\u00a0ACE\u2010\nHemmer\u00a0als\u00a0nicht\u00a0belegt\u00a0und\u00a0der\u00a0Wirkstoff \u00a0wird\u00a0in\u00a0\u00dcbereinstimmung \u00a0mit\u00a0den\u00a0rechtlichen \u00a0\nFestlegungen \u00a0in\u00a0die\u00a0Festbetragsgruppe \u00a0\u201eAngiotensin \u2010II\u2010Antagonisten, \u00a0Gruppe\u00a01\u201c\u00a0eingeordnet \u00a0(G\u2010BA,\u00a0\n2012a).\u00a0\u00a0\n\u00a0Kosten\u00a0\nWirkstof f\u00a0 Behandlungsmodus Behandlungstage Jahrestherapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nAzilsartanmedoxomil  1\u00a0x\u00a0t\u00e4glich\u00a040\u00a0mg 360 344,68\u00a0\u20ac\nVergleichstherapie  \u00a0\nCandesartan  1\u00a0x\u00a0t\u00e4glich\u00a08\u00a0mg 360 73,18\u00a0\u20ac\nValsartan  1\u00a0x\u00a0t\u00e4glich\u00a080\u00a0mg 360 77,69\u00a0\u20ac\nOlmesartan  1\u00a0x\u00a0t\u00e4glich\u00a020\u00a0mg 360 344,68\u00a0\u20ac\nTabelle\u00a030:\u00a0Jahrestherapiekosten \u00a0von\u00a0Azilsartanmedoxomil \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0\nKosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0\n\u00a0\n\u00a0\u00a0 \n179\u00a0\n\u00a0\nHintergrundinformationen \u00a011.5 Brentuximabvedotin \u00a0\nHandelsname: \u00a0Adcetris\u00ae \u00a0 \u00a0\u00a0\u00a0 Hersteller: \u00a0Takeda\u00a0\nIndikation: \u00a0CD30+\u00a0Hodgkin\u2010Lymphom \u00a0\u00a0 \u00a0 Markteinf\u00fchrung: \u00a0Dezember \u00a02012\u00a0\nATC\u2010Code:\u00a0L01XC12\u00a0 \u00a0\u00a0\u00a0\u00a0 DDD:\u00a06\u00a0mg\u00a0\nDarreichungsform: \u00a0Pulver\u00a0zur\u00a0Herstellung \u00a0einer\u00a0Infusionsl\u00f6sung \u00a0\nBewertung: \u00a0siehe\u00a0Seite\u00a047\u00a0\nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nBrentuximabvedotin \u00a0ist\u00a0ein\u00a0Konjugat\u00a0(sog.\u00a0Antibody\u2010drug\u00a0conjugate ,\u00a0ADC)\u00a0aus\u00a0einem\u00a0monoklonalen \u00a0\nAntik\u00f6rper \u00a0und\u00a0einem\u00a0Zytostatikum \u00a0(Monomethylauristatin \u00a0E).\u00a0Das\u00a0Antik\u00f6rpermolek\u00fcl, \u00a0das\u00a0selektiv\u00a0\nan\u00a0CD30\u2010Oberfl\u00e4chenmolek\u00fcle \u00a0bindet,\u00a0ist\u00a0mit\u00a0vier\u00a0Molek\u00fclen \u00a0Monomethyl \u2010auristatin \u00a0E\u00a0konjugiert, \u00a0\nwelches\u00a0das\u00a0Mikrotubuli \u2010Netzwerk \u00a0der\u00a0Zelle\u00a0st\u00f6rt\u00a0und\u00a0so\u00a0den\u00a0Zellzyklus \u00a0unterbricht. \u00a0\nBei\u00a0den\u00a0beiden\u00a0Indikationen \u00a0klassisches \u00a0Hodgkin\u2010Lymphom \u00a0(HL)\u00a0und\u00a0systemisches \u00a0anaplastisches \u00a0\ngro\u00dfzelliges \u00a0Lymphom \u00a0(sALCL)\u00a0weisen\u00a0die\u00a0malignen \u00a0Zellen\u00a0unabh\u00e4ngig \u00a0vom\u00a0Krankheitsstadium, \u00a0von\u00a0\nden\u00a0Vortherapien \u00a0und\u00a0vom\u00a0Transplantationsstatus \u00a0eine\u00a0hohe\u00a0Expression \u00a0des\u00a0CD30\u2010Antigens\u00a0auf.\u00a0\nNach\u00a0spezifischer \u00a0Bindung\u00a0an\u00a0die\u00a0CD30\u2010positive\u00a0Lymphomzelle \u00a0wird\u00a0das\u00a0Antik\u00f6rperkonjugat \u00a0in\u00a0die\u00a0\nZelle\u00a0aufgenommen \u00a0und\u00a0das\u00a0Zytostatikum \u00a0abgespalten, \u00a0so\u00a0dass\u00a0es\u00a0seine\u00a0Apoptose \u2010induzierende \u00a0\nWirkung\u00a0entfalten\u00a0kann\u00a0(Takeda,\u00a02014b;\u00a0EMA,\u00a02012a).\u00a0\n\u00a0Zulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nAdcetris\u00ae \u00a0wurde\u00a0im\u00a0Oktober\u00a02012\u00a0von\u00a0der\u00a0europ\u00e4ischen \u00a0Arzneimittel \u2010Agentur\u00a0EMA\u00a0zugelassen \u00a0und\u00a0\nist\u00a0seit\u00a0dem\u00a001.12.2012 \u00a0auf\u00a0dem\u00a0deutschen \u00a0Markt.\u00a0Das\u00a0Mittel\u00a0kann\u00a0bei\u00a0Erwachsenen \u00a0mit\u00a0\nrezidiviertem \u00a0oder\u00a0\ntherapierefrakt\u00e4rem \u00a0CD30\u2010positivem \u00a0Hodgkin\u2010Lymphom, \u00a0die\u00a0bereits\u00a0eine\u00a0\nautologe\u00a0Stammzelltransplantation \u00a0oder\u00a0mindestens \u00a0zwei\u00a0andere\u00a0Therapien \u00a0bekommen \u00a0haben,\u00a0\neingesetzt \u00a0werden.\u00a0Au\u00dferdem \u00a0stellt\u00a0es\u00a0eine\u00a0Therapieoption \u00a0zur\u00a0Behandlung \u00a0von\u00a0Erwachsenen \u00a0mit\u00a0\nrezidiviertem \u00a0oder\u00a0refrakt\u00e4rem \u00a0systemischem \u00a0anaplastischem \u00a0gro\u00dfzelligem \u00a0Lymphom \u00a0(sALCL)\u00a0dar.\u00a0\nBis\u00a0dato\u00a0gab\u00a0es\u00a0in\u00a0Deutschland \u00a0keine\u00a0f\u00fcr\u00a0diese\u00a0Indikationen \u00a0zugelassenen \u00a0Medikamente. \u00a0Da\u00a0diese\u00a0\nLymphome \u00a0seltene\u00a0Erkrankungen \u00a0sind,\u00a0wurde\u00a0der\u00a0Wirkstoff \u00a0von\u00a0der\u00a0EMA\u00a0am\u00a015.01.2009 \u00a0als\u00a0Orphan\u00a0\nDrug\u00a0ausgewiesen. \u00a0Die\u00a0Verabreichung \u00a0erfolgt\u00a0als\u00a0intraven\u00f6se \u00a0Infusion\u00a0\u00fcber\u00a030\u00a0Minuten\u00a0alle\u00a0drei\u00a0\nWochen\u00a0(Takeda,\u00a02014b;\u00a0EMA,\u00a02012a).\u00a0\n\u00a0\nInformationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nDas\u00a0Hodgkin\u2010Lymphom \u00a0(Morbus\u00a0Hodgkin,\u00a0Lymphogranulomatose) \u00a0ist\u00a0eine\u00a0maligne\u00a0Erkrankung \u00a0des\u00a0\nlymphatischen \u00a0Systems,\u00a0die\u00a0sich\u00a0durch\u00a0das\u00a0Vorkommen \u00a0typischer\u00a0Hodgkin\u2010\u00a0und\u00a0Reed\u2010Sternberg \u2010\nZellen\u00a0von\u00a0der\u00a0Gruppe\u00a0der\u00a0Non\u2010Hodgkin\u2010Lymphome \u00a0und\u00a0von\u00a0Lymphknotenschwellungen \u00a0anderer\u00a0\nUrsache\u00a0abgrenzen \u00a0l\u00e4sst.\u00a0In\u00a0Deutschland \u00a0erkrankten \u00a0im\u00a0Jahr\u00a02010\u00a0etwa\u00a02.200\u00a0Patienten, \u00a0M\u00e4nner\u00a0sind\u00a0\nim\u00a0Verh\u00e4ltnis \u00a03:2\u00a0h\u00e4ufiger\u00a0als\u00a0Frauen\u00a0betroffen. \u00a0Die\u00a0Krankheit \u00a0kann\u00a0in\u00a0jedem\u00a0Alter\u00a0auftreten. \u00a0\u00a0\n180\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Erste\u00a0Anzeichen \u00a0eines\u00a0Hodgkin\u2010Lymphoms \u00a0sind\u00a0meistens\u00a0regionale \u00a0Lymphknotenschwellungen, \u00a0die\u00a0\nvon\u00a0Symptomen \u00a0wie\u00a0starker\u00a0Nachtschwei\u00df, \u00a0Juckreiz\u00a0am\u00a0ganzen\u00a0K\u00f6rper,\u00a0Fieber\u00a0mit\u00a0wechselndem \u00a0\nVerlauf\u00a0und\u00a0auff\u00e4lligem \u00a0Gewichtsverlust \u00a0begleitet\u00a0sein\u00a0k\u00f6nnen.\u00a0\nDie\u00a0Prognose \u00a0ist\u00a0g\u00fcnstig,\u00a0heutzutage \u00a0k\u00f6nnen\u00a0\u00fcber\u00a080\u00a0Prozent\u00a0aller\u00a0Patienten \u00a0geheilt\u00a0werden.\u00a0Zumeist\u00a0\nwerden\u00a0Polychemotherapie \u00a0und\u00a0Strahlentherapie \u00a0miteinander \u00a0kombiniert, \u00a0bei\u00a0einem\u00a0Rezidiv\u00a0ist\u00a0die\u00a0\nStammzelltransplantation \u00a0eine\u00a0weitere\u00a0Therapieoption \u00a0(GHSG,2015; \u00a0RKI\u00a0&\u00a0ZfKD,\u00a02013b).\u00a0\nAnaplastische \u00a0gro\u00dfzellige \u00a0Lymphome \u00a0(ALCL)\u00a0sind\u00a0T\u2010Zell\u2010Lymphome \u00a0und\u00a0machen\u00a0zwei\u00a0bis\u00a0drei\u00a0Prozent\u00a0\naller\u00a0Non\u2010Hodgkin\u2010Lymphome \u00a0bei\u00a0Erwachsenen \u00a0aus.\u00a0Wesentliche \u00a0Merkmale \u00a0sind\u00a0die\u00a0Proliferation \u00a0\ngro\u00dfer\u00a0lymphatischer \u00a0Zellen\u00a0mit\u00a0starker\u00a0Expression \u00a0von\u00a0CD30\u00a0und\u00a0ein\u00a0charakteristisches \u00a0\nAusbreitungsmuster. \u00a0Man\u00a0unterscheidet \u00a0eine\u00a0prim\u00e4r\u00a0kutane\u00a0von\u00a0einer\u00a0prim\u00e4r\u00a0systemischen \u00a0Form\u00a0\nund\u00a0hier\u00a0wiederum \u00a0Subgruppen \u00a0mit\u00a0oder\u00a0ohne\u00a0Ver\u00e4nderung \u00a0des\u00a0ALK\u2010Gens\u00a0(Pro\u00a0et\u00a0al.,\u00a02012).\u00a0\n\u00a0Evidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nWirksamkeit \u00a0und\u00a0Sicherheit \u00a0von\u00a0Brentuximabvedotin \u00a0als\u00a0Monotherapie \u00a0wurden\u00a0im\u00a0Wesentlichen \u00a0in\u00a0\nzwei\u00a0Phase\u2010II\u2010Studien\u00a0an\u00a0Patienten \u00a0mit\u00a0rezidivierendem \u00a0oder\u00a0therapierefrakt\u00e4rem\n\u00a0Hodgkin\u00a0Lymphom \u00a0\noder\u00a0anaplastischem \u00a0gro\u00dfzelligem \u00a0Lymphom \u00a0untersucht. \u00a0\nIn\u00a0einer\u00a0offenen\u00a0einarmigen \u00a0Phase\u2010II\u2010Studie\u00a0an\u00a0102\u00a0Patienten \u00a0mit\u00a0rezidiviertem \u00a0oder\u00a0therapie\u2010\nrefrakt\u00e4rem \u00a0Hodgkin\u2010Lymphom \u00a0nach\u00a0autologer \u00a0Stammzelltransplantation \u00a0(ASCT)\u00a0wurde\u00a0\nBrentuximabvedotin \u00a0in\u00a0einer\u00a0Dosis\u00a0von\u00a01,8\u00a0mg/kg\u00a0K\u00f6rpergewicht \u00a0als\u00a0Kurzinfusion \u00a0alle\u00a0drei\u00a0Wochen\u00a0\nbis\u00a0zu\u00a016\u00a0Zyklen\u00a0lang\u00a0eingesetzt. \u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0zur\u00a0Ermittlung \u00a0der\u00a0Wirksamkeit \u00a0war\u00a0die\u00a0objektive \u00a0\nAnsprechrate \u00a0ORR,\u00a0definiert\u00a0als\u00a0Anteil\u00a0der\u00a0Patienten \u00a0mit\u00a0kompletter \u00a0oder\u00a0partieller\u00a0Remission \u00a0im\u00a0\nBeobachtungszeitraum. \u00a0Die\u00a0ORR\u00a0betrug\u00a075\u00a0Prozent,\u00a034\u00a0Prozent\u00a0der\u00a0Patienten \u00a0erreichten \u00a0eine\u00a0\nkomplette \u00a0Remission. \u00a0Das\u00a0mediane\u00a0progressionsfreie \u00a0\u00dcberleben \u00a0aller\u00a0Patienten \u00a0betrug\u00a05,6\u00a0Monate,\u00a0\ndas\u00a0der\u00a0Patienten \u00a0mit\u00a0kompletter \u00a0Remission \u00a020,5\u00a0Monate.\u00a0Nach\u00a0einer\u00a0Beobachtungsdauer \u00a0von\u00a0mehr\u00a0\nals\u00a018\u00a0Monaten\u00a0waren\u00a031\u00a0Patienten \u00a0noch\u00a0ohne\u00a0Progress. \u00a0H\u00e4ufigste \u00a0Nebenwirkungen \u00a0waren\u00a0\nperiphere \u00a0sensorische \u00a0Neuropathie, \u00a0\u00dcbelkeit,\u00a0Fatigue,\u00a0Neutropenie \u00a0und\u00a0Diarrhoe\u00a0(Younes\u00a0et\u00a0al.,\u00a0\n2012).\u00a0\nDa\u00a0in\u00a0dieser\u00a0Studie\u00a0Patienten \u00a0ohne\u00a0vorausgehende \u00a0ASCT\u00a0nicht\u00a0untersucht \u00a0wurden\u00a0und\u00a0es\u00a0keine\u00a0\nrelevante \u00a0Einzelstudie \u00a0gibt,\u00a0in\u00a0der\u00a0ASCT\u2010naive\u00a0Patienten \u00a0mit\u00a0Brentuximabvedotin \u00a0behandelt \u00a0wurden,\u00a0\nzog\u00a0man\u00a0im\u00a0Rahmen\u00a0des\u00a0europ\u00e4ischen \u00a0Zulassungsverfahrens \u00a0Daten\u00a0von\u00a0einzelnen \u00a0ASCT\u2010naiven\u00a0\nPatienten \u00a0aus\u00a0verschiedenen \u00a0(Phase\u2010I\u2010)Studien\u00a0und\u00a0Fallserien \u00a0heran.\u00a0Diese\u00a0aggregierte \u00a0Fallserie\u00a0\numfasste\u00a0insgesamt \u00a059\u00a0Patienten, \u00a0die\u00a0ORR\u00a0betrug\u00a054\u00a0Prozent,\u00a022\u00a0Prozent\u00a0der\u00a0Patienten \u00a0hatten\u00a0eine\u00a0\nkomplette \u00a0Remission \u00a0(G\u2010BA,\u00a02013d).\u00a0\nIn\u00a0der\u00a0zweiten\u00a0offenen\u00a0einarmigen \u00a0Studie\u00a0erhielten\u00a058\u00a0Patienten \u00a0mit\u00a0rezidivierendem \u00a0oder\u00a0\ntherapierefrakt\u00e4rem \u00a0sALCL\u00a0dreimal\u00a0w\u00f6chentlich \u00a0eine\u00a0Kurzinfusion \u00a0mit\u00a01,8\u00a0mg/kg\u00a0K\u00f6rpergewicht \u00a0\nBrentuximabvedotin \u00a0\u00fcber\u00a0bis\u00a0zu\u00a016\u00a0geplante\u00a0Zyklen.\u00a0Im\u00a0Durchschnitt \u00a0lag\u00a0die\u00a0Behandlungsdauer \u00a0bei\u00a0\nsieben\u00a0Zyklen.\u00a059\u00a0Prozent\u00a0der\u00a0Patienten \u00a0zeigten\u00a0eine\u00a0komplette, \u00a027\u00a0Prozent\u00a0eine\u00a0partielle\u00a0Remission. \u00a0\nDie\u00a0mediane\u00a0Dauer\u00a0des\u00a0objektiven \u00a0Ansprechens \u00a0betrug\u00a012,6\u00a0Monate\u00a0und\u00a0bei\u00a0den\u00a0Patienten, \u00a0die\u00a0eine\u00a0\nkomplette \u00a0Remission \u00a0erreicht\u00a0hatten,\u00a013,2\u00a0Monate.\u00a0Das\u00a0mediane\u00a0progressionsfreie \u00a0\u00dcberleben \u00a0der\u00a0\nGesamtgruppe \u00a0betrug\u00a013,3\u00a0Monate.\u00a0Als\u00a0h\u00e4ufigste \u00a0Nebenwirkungen \u00a0der\u00a0Schweregrade \u00a03\u00a0und\u00a04\u00a0traten\u00a0\nNeutropenie, \u00a0Thrombozytopenie \u00a0und\u00a0periphere \u00a0sensorische \u00a0Neuropathie \u00a0auf\u00a0(Pro\u00a0et\u00a0al.,\u00a02012).\u00a0 \n181\u00a0\n\u00a0\nHintergrundinformationen \u00a0Eine\u00a0Phase\u2010I\u2010Studie\u00a0gibt\u00a0Hinweise\u00a0darauf,\u00a0dass\u00a0Brentuximabvedotin \u00a0auch\u00a0in\u00a0der\u00a0Erstlinien \u2010Therapie\u00a0\nvon\u00a0Patienten \u00a0mit\u00a0neu\u00a0diagnostizierten \u00a0CD30(+)\u00a0T\u2010Zell\u2010Lymphom \u00a0eine\u00a0Option\u00a0darstellen \u00a0k\u00f6nnte\u00a0(Fa\u2010\nnale\u00a0et\u00a0al.,\u00a02014).\u00a0Weitere\u00a0Studien\u00a0mit\u00a0gr\u00f6\u00dferer\u00a0Fallzahl\u00a0werden\u00a0allerdings \u00a0ben\u00f6tigt,\u00a0um\u00a0diese\u00a0Ergeb\u2010\nnisse\u00a0zu\u00a0erh\u00e4rten. \u00a0In\u00a0einer\u00a0aktuellen \u00a0placebokontrollierten \u00a0Phase\u2010III\u2010Studie\u00a0wurde\u00a0untersucht, \u00a0wel\u2010\nchen\u00a0Einfluss\u00a0als\u00a0fr\u00fche\u00a0Konsolidierungstherapie \u00a0nach\u00a0autologer \u00a0Stammzelltherapie \u00a0eingesetztes \u00a0\nBrentuximabvedotin \u00a0auf\u00a0das\u00a0progressionsfreie \u00a0\u00dcberleben \u00a0der\u00a0Patienten \u00a0hat\u00a0(Moskowitz \u00a0et\u00a0al.,\u00a02015).\u00a0\nDer\u00a0prim\u00e4re\u00a0Endpunkt \u00a0war\u00a0die\u00a0Dauer\u00a0des\u00a0progressionsfreien \u00a0\u00dcberlebens, \u00a0definiert\u00a0als\u00a0die\u00a0Zeit\u00a0begin\u2010\nnend\u00a0von\u00a0der\u00a0Randomisierung \u00a0bis\u00a0zur\u00a0ersten\u00a0Dokumentation \u00a0eines\u00a0Tumors\u00a0oder\u00a0Tod.\u00a0Gegen\u00fcber \u00a0\nPlacebo\u00a0verl\u00e4ngerte \u00a0Brentuximabvedotin \u00a0signifikant \u00a0das\u00a0progressionsfreie \u00a0\u00dcberleben \u00a0(medianes \u00a0pro\u2010\ngressionsfreies \u00a0\u00dcberleben: \u00a042,9\u00a0vs.\u00a024,1\u00a0Monate;\u00a0p\u00a0=0,0013). \u00a0H\u00e4ufigste \u00a0Nebenwirkungen \u00a0in\u00a0der\u00a0Ve\u2010\nrum\u2010Gruppe\u00a0waren\u00a0periphere \u00a0sensorische \u00a0Neuropathien. \u00a0\u00a0\n\u00a0\nLeitlinienempfehlungen \u00a0\nBei\u00a0den\u00a0meisten\u00a0Patienten \u00a0mit\u00a0Hodgkin\u2010Lymphom \u00a0und\u00a0Rezidiv\u00a0nach\u00a0der\u00a0Initialtherapie \u00a0ist\u00a0eine\u00a0Re\u2010\nInduktionstherapie, \u00a0gefolgt\u00a0von\u00a0einer\u00a0Hochdosis \u2010Chemotherapie \u00a0mit\u00a0anschlie\u00dfender \u00a0autologer \u00a0\nStammzelltransplantation \u00a0die\u00a0Therapie\u00a0der\u00a0Wahl.\u00a0Sowohl\u00a0f\u00fcr\u00a0Patienten, \u00a0f\u00fcr\u00a0die\u00a0eine\u00a0\nHochdosistherapie \u00a0nicht\u00a0geeignet\u00a0ist,\u00a0als\u00a0auch\u00a0f\u00fcr\u00a0solche\u00a0mit\u00a0erneutem \u00a0Rezidiv\u00a0nach\u00a0autologer \u00a0\nStammzelltransplantation \u00a0gibt\u00a0es\u00a0keine\u00a0Standardtherapie. \u00a0Hier\u00a0erfolgt\u00a0die\u00a0Auswahl\u00a0der\u00a0Behand\u2010\nlungsma\u00dfnahmen \u00a0unter\u00a0Ber\u00fccksichtigung \u00a0von\u00a0Allgemeinzustand, \u00a0Begleiterkrankungen \u00a0und\u00a0\nbisherigen \u00a0Therapien \u00a0des\u00a0Patienten. \u00a0\u00a0\nIn\u00a0der\u00a0Onkopedia \u2010Leitlinie\u00a0mit\u00a0Stand\u00a0Juli\u00a02012\u00a0wird\u00a0Brentuximabvedotin \u00a0erw\u00e4hnt\u00a0als\u00a0in\u00a0den\u00a0USA\u00a02011\u00a0\nf\u00fcr\u00a0die\u00a0Rezidivtherapie \u00a0nach\u00a0autologer \u00a0Stammzelltransplantation \u00a0zugelassenes \u00a0Arzneimittel, \u00a0dessen\u00a0\nZulassung \u00a0in\u00a0Europa\u00a0f\u00fcr\u00a02012\u00a0erwartet\u00a0wird\u00a0(DGHO,\u00a02012).\u00a0F\u00fcr\u00a0die\u00a0Behandlung \u00a0anaplastischer \u00a0\ngro\u00dfzelliger \u00a0Lymphome \u00a0(ALCL)\u00a0bei\u00a0Erwachsenen \u00a0gibt\u00a0es\u00a0weder\u00a0in\u00a0der\u00a0Erstlinien \u2010\u00a0noch\u00a0in\u00a0der\u00a0\nRezidivtherapie \u00a0einen\u00a0durch\u00a0kontrollierte \u00a0Studien\u00a0abgesicherten \u00a0Standard. \u00a0\n\u00a0Nutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nBrentuximabvedotin \u00a0ist\u00a0ein\u00a0Orphan\u00a0Drug ,\u00a0f\u00fcr\u00a0das\u00a0der\u00a0medizinische \u00a0Zusatznutzen \u00a0durch\u00a0die\u00a0Zulassung \u00a0\nals\u00a0belegt\u00a0gilt.\u00a0Das\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens \u00a0wird\u00a0vom\u00a0G\u2010BA\u00a0auf\u00a0der\u00a0Grundlage \u00a0der\u00a0Zulassung \u00a0und\u00a0\nder\u00a0ihr\u00a0zugrunde \u00a0liegenden \u00a0\nStudien\u00a0bestimmt, \u00a0eine\u00a0zweckm\u00e4\u00dfige \u00a0Vergleichstherapie \u00a0wird\u00a0zur\u00a0\nBewertung \u00a0nicht\u00a0herangezogen. \u00a0\nDie\u00a0beiden\u00a0Zulassungsstudien \u00a0f\u00fcr\u00a0Brentuximabvedotin \u00a0sind\u00a0offene,\u00a0einarmige \u00a0Phase\u2010II\u2010Studien,\u00a0bei\u00a0\nderen\u00a0Ergebnissen \u00a0von\u00a0einem\u00a0hohen\u00a0Verzerrungspotential \u00a0ausgegangen \u00a0werden\u00a0muss.\u00a0Gleiches\u00a0gilt\u00a0\nf\u00fcr\u00a0die\u00a0aggregierte \u00a0Fallserie\u00a0von\u00a0ASCT\u2010naiven\u00a0Patienten. \u00a0\nDer\u00a0G\u2010BA\u00a0konstatiert, \u00a0dass\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens \u00a0bei\u00a0allen\u00a0drei\u00a0bewerteten \u00a0Indikationen \u00a0\nnicht\u00a0quantifizierbar \u00a0ist.\u00a0\n \u00a0\u00a0\n182\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Kosten\u00a0\nWirkstof f\u00a0 Behandlungsmodus Behandlungstage Jahrestherapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nBrentuximabvedotin  1\u00a0x\u00a01,8\u00a0mg/kg\u00a0alle\u00a0drei\u00a0\nWochen\u00a0als\u00a0intraven\u00f6se \u00a0\nInfusion\u00a0\u00a016 188.077,44 \u00a0\u20ac\nDosis\u2010Berechnung \u00a0mit\u00a0einem\u00a0K\u00f6rpergewicht \u00a0von\u00a072\u00a0kg \nTabelle\u00a031:\u00a0Jahrestherapiekosten \u00a0von\u00a0Brentuximabvedotin \u00a0(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0\u00a0\n\u00a0\u00a0 \n183\u00a0\n\u00a0\nHintergrundinformationen \u00a011.6 Ceftarolinfosamil \u00a0\nHandelsname: \u00a0Zinforo\u00ae\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0 \u00a0 Hersteller: \u00a0AstraZeneca \u00a0\nIndikation: \u00a0Haut\u2010\u00a0und\u00a0Weichgewebeinfektionen, \u00a0Pneumonie \u00a0\u00a0 \u00a0Markteinf\u00fchrung: \u00a0Oktober\u00a02012\u00a0\nATC\u2010Code:\u00a0J01DI02\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 DDD:\u00a01,2\u00a0g\u00a0\nDarreichungsform: \u00a0Pulver\u00a0zur\u00a0Herstellung \u00a0eine\u00a0Infusionsl\u00f6sung \u00a0\nBewertung: \u00a0siehe\u00a0Seite\u00a051 \nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nCeftarolinfosamil \u00a0ist\u00a0ein\u00a0neues\u00a0Cephalosporin \u00a0mit\u00a0einem\u00a0erweiterten \u00a0Wirkspektrum \u00a0bei\u00a0resistenten \u00a0\ngrampositiven \u00a0Erregern\u00a0einschlie\u00dflich \u00a0MRSA.\u00a0Chemisch \u00a0\u00e4hnelt\u00a0Ceftarolinfosamil \u00a0einem\u00a0\u00e4lteren\u00a0\nAbk\u00f6mmling \u00a0der\u00a0Cephalosporine, \u00a0Cefozopran, \u00a0der\u00a0nur\u00a0noch\u00a0in\u00a0China\u00a0eingesetzt \u00a0wird\u00a0(Brodt,\u00a02013).\u00a0\nGegen\u00fcber \u00a0gram\u2010negativen \u00a0Erregern\u00a0ist\u00a0Ceftarolinfosamil \u00a0\u00e4hnlich\u00a0effektiv\u00a0wie\u00a0andere\u00a0\nCephalosporine. \u00a0Das\u00a0schwer\u00a0wasserl\u00f6sliche \u00a0Ceftarolin \u00a0wird\u00a0als\u00a0N\u2010Phosphono \u2010Prodrug\u00a0\n(Ceftarolinfosamil) \u00a0intraven\u00f6s \u00a0verabreicht \u00a0im\u00a0Blut\u00a0durch\u00a0Plasmaphosphatasen \u00a0in\u00a0die\u00a0aktive\u00a0Form\u00a0\n(Ceftarolin) \u00a0\u00fcberf\u00fchrt. \u00a0Das\u00a0Mittel\u00a0hat\u00a0mit\u00a0ca.\u00a020\u00a0Prozent\u00a0eine\u00a0geringe\u00a0Plasmaproteinbindung. \u00a0Seine\u00a0\nElimination \u00a0erfolgt\u00a0haupts\u00e4chlich \u00a0\u00fcber\u00a0die\u00a0Niere,\u00a0was\u00a0eine\u00a0Dosisanpassung \u00a0bei\u00a0moderat\u00a0\neingeschr\u00e4nkter \u00a0Nierenfunktion \u00a0erforderlich \u00a0macht\u00a0(AstraZeneca, \u00a02014a).\u00a0\u00a0\n\u00c4hnlich\u00a0wie\u00a0andere\u00a0Cephalosporine \u00a0wirkt\u00a0Ceftarolinfosamil \u00a0durch\u00a0Bindung\u00a0an\u00a0membranst\u00e4ndige \u00a0\nEnzyme,\u00a0sogenannte \u00a0Penicillin\u2010bindende \u00a0Proteine\u00a0(PBP),\u00a0was\u00a0zu\u00a0einer\u00a0Hemmung \u00a0der\u00a0Synthese\u00a0der\u00a0\nbakteriellen \u00a0Zellwand\u00a0und\u00a0in\u00a0Folge\u00a0zu\u00a0Zelllyse\u00a0und\u00a0Zelltod\u00a0f\u00fchrt.\u00a0Im\u00a0Gegensatz \u00a0zu\u00a0anderen\u00a0Vertretern \u00a0\nder\u00a0Wirkstoffgruppe \u00a0besitzt\u00a0Ceftarolinfosamil \u00a0aber\u00a0eine\u00a0hohe\u00a0Bindungsaffinit\u00e4t \u00a0an\u00a0modifizierte \u00a0PBPs,\u00a0\nderen\u00a0Ausbildung \u00a0an\u00a0der\u00a0bakteriellen \u00a0Zellwand\u00a0Resistenzen \u00a0vermitteln: \u00a0So\u00a0werden\u00a0PBP2a\u00a0von\u00a0\nMethicillin \u2010resistentem \u00a0Staphylococcus \u00a0aureus\u00a0(MRSA)\u00a0und\u00a0PBP2b,\u00a02x\u00a0sowie\u00a01a\u00a0von\u00a0Penicillin\u2010\nresistentem \u00a0Streptococcus \u00a0pneumoniae \u00a0exprimiert \u00a0(Shirley\u00a0et\u00a0al.,\u00a02013).\u00a0Gegen\u00fcber \u00a0Enterococcus \u00a0\nfaecium\u00a0und\u00a0Enterococcus \u00a0faecalis\u00a0ist\u00a0Ceftarolinfosamil \u00a0dagegen\u00a0nur\u00a0begrenzt\u00a0wirksam.\u00a0\u00a0\nDie\u00a0hohe\u00a0Wirksamkeit \u00a0gegen\u00fcber \u00a0MRSA\u00a0ist\u00a0weltweit\u00a0gegeben\u00a0(USA,\u00a0Europa,\u00a0S\u00fcdafrika, \u00a0Asien\u00a0und\u00a0\nPazifik)\u00a0und\u00a0unabh\u00e4ngig \u00a0vom\u00a0Alter\u00a0der\u00a0Patienten. \u00a0Regionale \u00a0Unterschiede \u00a0bzgl.\u00a0der\u00a0bakteriziden \u00a0\nWirksamkeit \u00a0von\u00a0Ceftarolinfosamil \u00a0auf\u00a0Staphylococcen, \u00a0Streptokokken, \u00a0Haemophilus \u2010Arten\u00a0und\u00a0\nMoraxella \u00a0catarrhalis \u00a0sind\u00a0minimal\u00a0(Shirley\u00a0et\u00a0al.,\u00a02013).\u00a0\n\u00a0Zulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nCeftarolinfosamil \u00a0ist\u00a0zugelassen \u00a0zur\u00a0Behandlung \u00a0komplizierter \u00a0Haut\u2010\u00a0und\u00a0Weichgewebeinfektionen \u00a0\n(Complicated \u00a0skin\u00a0and\u00a0soft\u00a0tissue\u00a0infections ,\u00a0cSST)\u00a0sowie\n\u00a0zur\u00a0Behandlung \u00a0ambulant \u00a0erworbener \u00a0\nPneumonien \u00a0(CAP).\u00a0Es\u00a0stellt\u00a0das\u00a0erste\u00a0\u03b2\u2010Lactam\u2010Antibiotikum \u00a0dar,\u00a0das\u00a0bei\u00a0MRSA\u2010verursachten \u00a0Haut\u2010\u00a0\nund\u00a0Weichteilinfektionen \u00a0zugelassen \u00a0wurde.\u00a0Ceftarolinfosamil \u00a0kann\u00a0bei\u00a0Erwachsenen \u00a0eingesetzt \u00a0\nwerden\u00a0und\u00a0ist\u00a0aufgrund\u00a0unzureichender \u00a0Daten\u00a0nicht\u00a0f\u00fcr\u00a0die\u00a0Anwendung \u00a0bei\u00a0Kindern\u00a0gedacht\u00a0\n(AstraZeneca, \u00a02014a).\u00a0\u00a0\n \u00a0\u00a0\n184\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Informationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nStaphylococcus \u00a0aureus\u00a0ist\u00a0ein\u00a0besonders \u00a0anpassungsf\u00e4higer \u00a0Erreger.\u00a0Anfang\u00a0der\u00a01960er\u00a0Jahre\u00a0\nkonnten\u00a0Staphylococcus \u00a0aureus\u2010St\u00e4mme\u00a0isoliert\u00a0werden,\u00a0die\u00a0gegen\u00fcber \u00a0Methicillin, \u00a0einem\u00a0erst\u00a0ein\u00a0\nJahr\u00a0zuvor\u00a0eingef\u00fchrten \u00a0Penicillinase \u2010festen\u00a0\u03b2\u2010Lactam\u2010Antibiotikum, \u00a0bereits\u00a0Resistenzen \u00a0entwickelt \u00a0\nhatten.\u00a0In\u00a0den\u00a0Folgejahren \u00a0kamen\u00a0Resistenzen \u00a0gegen\u00a0Chinolone, \u00a0gegen\u00a0Glykopeptid \u00a0wie\u00a0Vancomycin \u00a0\nsowie\u00a0gegen\u00a0Linezolid\u00a0hinzu\u00a0(Sch\u00f6fer\u00a0et\u00a0al.,\u00a02011).\u00a0Derartige \u00a0Staphylococcen \u00a0sind\u00a0vor\u00a0allem\u00a0im\u00a0\nstation\u00e4ren \u00a0Bereich\u00a0von\u00a0Bedeutung, \u00a0da\u00a0Patienten \u00a0mit\u00a0MRSA\u2010Infektionen \u00a0aufgrund\u00a0der\u00a0Gef\u00e4hrdung \u00a0\nimmunsupprimierter \u00a0Patienten \u00a0isoliert\u00a0behandelt \u00a0werden\u00a0m\u00fcssen.\u00a0Derzeit\u00a0sch\u00e4tzt\u00a0man\u00a0die\u00a0\nGesamtrate \u00a0an\u00a0MRSA\u2010bedingten \u00a0Infektionen \u00a0im\u00a0Krankenhaus \u00a0auf\u00a020\u00a0Prozent.\u00a0Bei\u00a0Risikopatienten \u00a0auf\u00a0\nIntensivstationen \u00a0liegt\u00a0der\u00a0Anteil\u00a0deutlich\u00a0h\u00f6her,\u00a0bisweilen \u00a0doppelt\u00a0so\u00a0hoch.\u00a02008\u00a0lag\u00a0die\u00a0Gesamtzahl \u00a0\nvon\u00a0nosokomialen \u00a0MRSA\u2010Infektionen \u00a0Untersuchungen \u00a0zufolge\u00a0bei\u00a0ca.\u00a0130.000\u00a0pro\u00a0Jahr\u00a0(K\u00f6ck\u00a0et\u00a0al.,\u00a0\n2011),\u00a0in\u00a0den\u00a0vergangenen \u00a0Jahren\u00a0scheint\u00a0sie\u00a0aber\u00a0zu\u00a0sinken\u00a0(Meyer\u00a0et\u00a0al.,\u00a02014).\u00a0Dies\u00a0wird\u00a0auch\u00a0\ndurch\u00a0das\u00a0Krankenhaus \u2010Infektions \u2010Surveillance \u2010System\u00a0(KISS)\u00a0f\u00fcr\u00a0die\u00a0Jahre\u00a02007\u00a0bis\u00a02012\u00a0best\u00e4tigt. \u00a0Im\u00a0\nDurchschnitt \u00a0betrug\u00a02012\u00a0der\u00a0Anteil\u00a0von\u00a0im\u00a0Krankenhaus \u00a0erworbenem \u00a0MRSA\u00a0bei\u00a0Intensivpatienten \u00a0\nund\u00a0bei\u00a0operierten \u00a0Patienten \u00a027\u00a0Prozent.\u00a0Innerhalb \u00a0von\u00a0sechs\u00a0Jahren\u00a0sank\u00a0auf\u00a0den\u00a0Intensivstationen \u00a0\nder\u00a0absolute\u00a0Anteil\u00a0von\u00a0MRSA\u2010Infektionen \u00a0der\u00a0unteren\u00a0Atemwege \u00a0von\u00a036\u00a0Prozent\u00a0auf\u00a030\u00a0Prozent,\u00a0der\u00a0\nvon\u00a0postoperativen \u00a0MRSA\u2010bedingten \u00a0Wundinfektionen \u00a0von\u00a020\u00a0Prozent\u00a0auf\u00a015\u00a0Prozent.\u00a0Die\u00a0Ursachen \u00a0\nhierf\u00fcr\u00a0sind\u00a0unklar.\u00a0Die\u00a0Autoren\u00a0f\u00fchren\u00a0die\u00a0g\u00fcnstige\u00a0Entwicklung \u00a0einerseits \u00a0auf\u00a0interventionelle \u00a0\nMa\u00dfnahmen \u00a0zur\u00a0Eind\u00e4mmung \u00a0der\u00a0Ausbreitung \u00a0von\u00a0MRSA\u00a0im\u00a0station\u00e4ren \u00a0Bereich\u00a0zur\u00fcck,\u00a0erw\u00e4gen\u00a0\nandererseits \u00a0aber\u00a0auch\u00a0biologische \u00a0Ver\u00e4nderungen \u00a0des\u00a0Erregers.\u00a0\n\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nCeftarolinfosamil \u00a0wurde\u00a0vor\u00a0der\u00a0Zulassung \u00a0durch\u00a0ein\u00a0klinisches \u00a0Studienprogramm \u00a0bestehend \u00a0aus\u00a0vier\u00a0\nPhase\u2010III\u2010Studien\u00a0an\u00a0Patienten \u00a0mit\u00a0komplizierten \u00a0Haut\u2010\u00a0und\u00a0Weichgewebeinfektionen \u00a0sowie\u00a0an\u00a0\nPatienten \u00a0mit\u00a0ambulant \u00a0erworbenen \u00a0Pneumonien \u00a0auf\u00a0Wirksamkeit \u00a0und\u00a0Vertr\u00e4glichkeit \u00a0gepr\u00fcft\u00a0\n(Corey\u00a0et\u00a0al.,\u00a02010;\u00a0File\u00a0et\u00a0al.,\u00a02010).\u00a0\u00a0\nStudien\u00a0gegen\u00fcber \u00a0der\u00a0derzeitigen \u00a0Standardtherapie \u00a0bei\u00a0MRSA\u2010Infektionen \u00a0von\u00a0Haut\u00a0oder\u00a0\nWeichgeweben \u00a0(z.B.\u00a0Monotherapie \u00a0mit\u00a0Clindamycin, \u00a0Vancomycin \u00a0oder\u00a0Linezolid) \u00a0fehlen\u00a0(N.N.,\u00a02013).\u00a0\nGegen\u00fcber \u00a0einer\u00a0Kombinationstherapie \u00a0aus\u00a0Vancomycin \u00a0plus\u00a0Aztreonam \u00a0(jeweils\u00a01\u00a0g\u00a0i.v.\u00a0alle\u00a0zw\u00f6lf\u00a0\nStunden)\u00a0war\u00a0Ceftarolinfosamil \u00a0(600\u00a0mg\u00a0i.v.\u00a0alle\u00a0zw\u00f6lf\u00a0Stunden)\u00a0bei\u00a0Patienten \u00a0mit\u00a0komplizierten \u00a0Haut\u2010\u00a0\nund\u00a0Weichgewebeinfektionen \u00a0sowohl\u00a0im\u00a0gesamten \u00a0Studienkollektiv \u00a0wie\u00a0auch\u00a0bei\u00a0Patienten \u00a0mit\u00a0\nMRSA\u2010Infektionen \u00a0bzgl.\u00a0klinischer \u00a0Heilungsrate \u00a0nicht\u2010unterlegen. \u00a0Nach\u00a0Intention\u2010to\u2010treat\u2010Analyse\u00a0\nkann\u00a0nach\u00a0einer\u00a0Behandlungsdauer \u00a0von\u00a0f\u00fcnf\u00a0bis\u00a014\u00a0Tagen\u00a0bei\u00a0dieser\u00a0Indikation \u00a0mit\u00a0Heilungsraten \u00a0von\u00a0\n85,9\u00a0Prozent\u00a0unter\u00a0Ceftarolinfosamil \u00a0im\u00a0Vergleich \u00a0zu\u00a085,5\u00a0Prozent\u00a0unter\u00a0Kontrollbehandlung \u00a0\ngerechnet \u00a0werden.\u00a0Werden\u00a0nur\u00a0Patienten \u00a0ausgewertet, \u00a0f\u00fcr\u00a0die\u00a0vollst\u00e4ndige \u00a0Daten\u00a0zur\u00a0\nEndpunkterhebung \u00a0vorhanden \u00a0waren,\u00a0liegen\u00a0die\u00a0Heilungsraten \u00a0bei\u00a091,6\u00a0Prozent\u00a0vs.\u00a092,7\u00a0Prozent.\u00a0Bei\u00a0\nMRSA\u2010Patienten \u00a0lagen\u00a0die\u00a0Heilungsraten \u00a0bei\u00a093,4\u00a0Prozent\u00a0unter\u00a0Ceftarolinfosamil \u00a0versus\u00a094,3\u00a0Prozent\u00a0\nunter\u00a0Kontrollbehandlung \u00a0(Corey\u00a0et\u00a0al.,\u00a02010).\u00a0\u00a0\nAn\u00a0Patienten \u00a0mit\u00a0ambulant \u00a0erworbener \u00a0Pneumonie \u00a0(CAP)\u00a0wurden\u00a0zwei\u00a0Untersuchungen \u00a0im\u00a0Vergleich \u00a0\nzu\u00a0Ceftriaxon \u00a0durchgef\u00fchrt. \u00a0Eingeschlossen \u00a0waren\u00a0CAP\u2010Patienten, \u00a0die\u00a0deswegen \u00a0ein\u00a0Krankenhaus \u00a0\naufsuchen, \u00a0aber\u00a0nicht\u00a0intensivmedizinisch \u00a0versorgt\u00a0werden\u00a0mussten.\u00a0Personen \u00a0mit\u00a0hohem\u00a0Risiko\u00a0f\u00fcr\u00a0\nmultiresistente \u00a0Erreger\u00a0wurden\u00a0nicht\u00a0in\u00a0das\u00a0Studienkollektiv \u00a0aufgenommen. \u00a0In\u00a0den\u00a0Einzelstudien \u00a0 \n185\u00a0\n\u00a0\nHintergrundinformationen \u00a0ergibt\u00a0sich\u00a0f\u00fcr\u00a0Ceftarolinfosamil \u00a0eine\u00a0Nicht\u2010Unterlegenheit \u00a0gegen\u00fcber \u00a0Ceftriaxon. \u00a0In\u00a0der\u00a0\nzusammengefassten \u00a0Datenanalyse \u00a0werden\u00a0im\u00a0modifizierten \u00a0ITT\u2010Kollektiv\u00a0unter\u00a0Ceftarolinfosamil \u00a0\nHeilungsraten \u00a0von\u00a082,6\u00a0Prozent\u00a0vs.\u00a076,6\u00a0Prozent\u00a0unter\u00a0Ceftriaxon \u00a0gesehen.\u00a0Die\u00a0Ratendifferenz \u00a0\nzwischen\u00a0den\u00a0Behandlungsgruppen \u00a0liegt\u00a0bei\u00a0sechs\u00a0Prozent,\u00a0allerdings \u00a0mit\u00a0einem\u00a0breiten\u00a0\nKonfidenzintervall \u00a0(CI\u00a095\u00a0Prozent:\u00a01,4\u00a0Prozent\u00a0bis\u00a010,7\u00a0Prozent)\u00a0und\u00a0k\u00f6nnte\u00a0mit\u00a0einer\u00a0besseren\u00a0\nWirksamkeit \u00a0von\u00a0Ceftarolinfosamil \u00a0auf\u00a0multiresistenten \u00a0Streptococcus \u00a0pneumoniae \u00a0in\u00a0\nZusammenhang \u00a0stehen\u00a0(File\u00a0et\u00a0al.,\u00a02010).\u00a0Dass\u00a0Ceftarolinfosamil \u00a0hier\u00a0tats\u00e4chlich \u00a0einen\u00a0klinisch\u00a0\nrelevanten \u00a0Vorteil\u00a0besitzt,\u00a0muss\u00a0erst\u00a0in\u00a0eigenen\u00a0Untersuchungen \u00a0best\u00e4tigt\u00a0werden.\u00a0\u00a0\nDas\u00a0Vertr\u00e4glichkeitsprofil \u00a0von\u00a0Ceftarolinfosamil \u00a0entspricht \u00a0nach\u00a0den\u00a0derzeit\u00a0vorliegenden \u00a0\nUntersuchungsdaten \u00a0dem\u00a0der\u00a0Wirkstoffgruppe \u00a0(Corrado\u00a0et\u00a0al.,\u00a02010).\u00a0Am\u00a0h\u00e4ufigsten \u00a0treten\u00a0\ngastrointestinale \u00a0Beschwerden \u00a0wie\u00a0\u00dcbelkeit\u00a0und\u00a0Durchfall\u00a0auf\u00a0(ca.\u00a0drei\u00a0Prozent),\u00a0gefolgt\u00a0von\u00a0\nKopfschmerzen \u00a0und\u00a0Hautreaktionen \u00a0wie\u00a0Juckreiz\u00a0(ca.\u00a0zwei\u00a0Prozent)\u00a0(EMA,\u00a02012b;\u00a0Corrado\u00a0et\u00a0al.,\u00a0\n2010).\u00a0Untersuchungen \u00a0an\u00a0gesunden \u00a0Menschen \u00a0ergaben\u00a0auch\u00a0bei\u00a0hoher\u00a0Dosis\u00a0(1.500\u00a0mg\u00a0\nCeftarolinfosamil) \u00a0im\u00a0Vergleich \u00a0zu\u00a0Placebo\u00a0und\u00a0Moxifloxacin \u00a0als\u00a0Positivkontrolle \u00a0keinen\u00a0Hinweis\u00a0auf\u00a0\nproarrhythmogene \u00a0Effekte\u00a0(Riccobene \u00a0et\u00a0al.,\u00a02013).\u00a0\n\u00a0\nLeitlinienempfehlungen \u00a0\nIn\u00a0der\u00a0aktuellen \u00a0S3\u2010Leitlinie\u00a0zur\u00a0Epidemiologie, \u00a0Diagnostik \u00a0und\u00a0Therapie\u00a0erwachsener \u00a0Patienten \u00a0mit\u00a0\nnosokomialer \u00a0Pneumonie \u00a0(AWMF\u2010Registernummer \u00a0020/013)\u00a0werden\u00a0f\u00fcr\u00a0Patienten \u00a0mit\u00a0Pneumonien \u00a0\nohne\u00a0Verdacht\u00a0auf\u00a0Infektion\u00a0mit\u00a0multiresistenten \u00a0Erregern\u00a0Cephalosporine \u00a0der\u00a0Gruppe\u00a03a,\u00a0\nAminopenicilline/ \u03b2\u2010Laktamaseinhibitoren, \u00a0Ertapenem \u00a0oder\u00a0pneumokokkenwirksame \u00a0Fluoro\u2010\nchinolone \u00a0als\u00a0Mittel\u00a0der\u00a0ersten\u00a0Wahl\u00a0empfohlen. \u00a0Zur\u00a0dritten\u00a0Generation \u00a0der\u00a0Cephalosporine \u00a0geh\u00f6ren\u00a0\nbeispielsweise \u00a0Ceftriaxon \u00a0und\u00a0Cefotaxim. \u00a0Diese\u00a0Verbindungen \u00a0besitzen\u00a0eine\u00a0relativ\u00a0geringe\u00a0Aktivit\u00e4t\u00a0\ngegen\u00fcber \u00a0Staphylococceninfektionen \u00a0und\u00a0werden\u00a0daher\u00a0zu\u00a0deren\u00a0Behandlung \u00a0nicht\u00a0empfohlen \u00a0\n(Dalhoff\u00a0et\u00a0al.,\u00a02012).\u00a0Ceftarolinfosamil, \u00a0als\u00a0Cephalosporin \u00a0der\u00a0\u201ef\u00fcnften\u201c \u00a0Generation \u00a0eingruppiert \u00a0\n(http://www.paul \u2010ehrlich\u2010gesellschaft.de/aktuelles/538), \u00a0wird\u00a0namentlich \u00a0in\u00a0der\u00a0bis\u00a02016\u00a0g\u00fcltigen\u00a0\nLeitlinie\u00a0nicht\u00a0erw\u00e4hnt.\u00a0\u00a0\nAmbulant \u00a0erworbene \u00a0Methicillin \u2010resistente \u2010Staphylococcen(MRSA) \u2010Pneumonien \u00a0sind\u00a0in\u00a0Deutschland \u00a0\nselten.\u00a0Bei\u00a0Patienten, \u00a0die\u00a0mit\u00a0Pneumonien \u00a0station\u00e4r\u00a0aufgenommen \u00a0werden,\u00a0k\u00f6nnen\u00a0daher\u00a0\nMethicillin \u2010empfindliche \u00a0Erreger\u00a0(MSSA)\u00a0vermutet \u00a0werden.\u00a0F\u00fcr\u00a0Infektionen \u00a0mit\u00a0MSSA\u00a0werden\u00a0durch\u00a0\ndie\u00a0Leitlinienautoren \u00a0Penicillinase \u2010feste\u00a0\u03b2 \u2010 Laktamantibiotika, \u00a0Makrolide, \u00a0Clindamycin \u00a0und\u00a0\nFluorochinolone \u00a0empfohlen. \u00a0F\u00fcr\u00a0MRSA\u2010resistente \u00a0St\u00e4mme\u00a0werden\u00a0Vancomycin, \u00a0Teicoplanin \u00a0und\u00a0\nLinezolid\u00a0als\u00a0\u201e100\u00a0Prozent\u00a0empfindliche\u201c \u00a0Therapieoptionen \u00a0genannt\u00a0(Dalhoff\u00a0et\u00a0al.,\u00a02012).\u00a0\u00a0\nF\u00fcr\u00a0die\u00a0Behandlung \u00a0von\u00a0durch\u00a0Staphylococcen \u00a0verursachte \u00a0Haut\u2010\u00a0und\u00a0Schleimhautinfektionen \u00a0liegt\u00a0\neine\u00a0S2k\u2010Leitlinie\u00a0der\u00a0Deutschen \u00a0Dermatologischen \u00a0Gesellschaft \u00a0vor\u00a0mit\u00a0G\u00fcltigkeit \u00a0bis\u00a0zum\u00a0M\u00e4rz\u00a02016\u00a0\n(Sch\u00f6fer\u00a0et\u00a0al.,\u00a02011).\u00a0Auch\u00a0hier\u00a0werden\u00a0bei\u00a0den\u00a0Therapieempfehlungen \u00a0MSSA\u2010\u00a0und\u00a0MRSA\u2010\u00a0\nverursachte \u00a0Infektionen \u00a0unterschieden. \u00a0Von\u00a0den\u00a0MSSA\u00a0sind\u00a0bis\u00a0zu\u00a080\u00a0Prozent\u00a0resistent\u00a0gegen\u00a0\nPenicillin, \u00a0Ampicillin, \u00a0Amoxicillin, \u00a0Mezlocillin \u00a0und\u00a0Piperacillin. \u00a0Bei\u00a0den\u00a0MRSA\u00a0sind\u00a0in\u00a0den\u00a0letzten\u00a0Jahren\u00a0\nvermehrt \u00a0Erreger\u00a0mit\u00a0ausgepr\u00e4gter \u00a0Mehrfachresistenz \u00a0zu\u00a0beobachten. \u00a0Gegen\u00a0MSSA\u2010Infektionen \u00a0\nnennen\u00a0die\u00a0Autoren\u00a0Amoxicillin/Clavulans\u00e4ure \u2010Kombinationspr\u00e4parate, \u00a0Flucloxacillin, \u00a0Makrolide \u00a0und\u00a0\nClindamycin \u00a0als\u00a0Mittel\u00a0der\u00a0Wahl.\u00a0Bei\u00a0MRSA\u2010Infektionen \u00a0werden\u00a0in\u00a0Absprache \u00a0mit\u00a0einem\u00a0Infektiologen \u00a0\u00a0\n186\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0u.a.\u00a0Fosfomycin, \u00a0Daptomycin, \u00a0Linezolid\u00a0oder\u00a0auch\u00a0Vancomycin \u00a0als\u00a0Therapieoptionen \u00a0f\u00fcr\u00a0eine\u00a0\nMonotherapie \u00a0empfohlen \u00a0(Sch\u00f6fer\u00a0et\u00a0al.,\u00a02011).\u00a0\n\u00a0\nNutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nCeftarolinfosamil \u00a0wird\u00a0nur\u00a0an\u00a0Krankenhausversorgende \u00a0Apotheken \u00a0ausgeliefert. \u00a0Da\u00a0das\u00a0Mittel\u00a0vor\u00a0\nallem\u00a0im\u00a0station\u00e4ren \u00a0Breich\u00a0eingesetzt \u00a0wird,\u00a0wurde\u00a0der\u00a0Wirkstoff \u00a0vom\u00a0Gemeinsamen \u00a0\nBundesausschuss \u00a0wegen\u00a0\u00f6konomischer \u00a0Geringf\u00fcgigkeit \u00a0gem\u00e4\u00df\u00a0Sozialgesetzbuch \u00a0V,\u00a0\u00a7\u00a035a,\u00a0Abs.\u00a01a\u00a0von\u00a0\nder\u00a0fr\u00fchen\u00a0Nutzenbewertung \u00a0unbefristet \u00a0freigestellt \u00a0(G\u2010BA,\u00a02012b).\u00a0F\u00fcr\u00a0Ceftarolin \u00a0wurde\u00a0daher\u00a0keine\u00a0\nStellungnahme \u00a0zum\u00a0Zusatznutzen \u00a0durch\u00a0das\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit \u00a0im\u00a0\nGesundheitswesen \u00a0(IQWiG)\u00a0erarbeitet. \u00a0\u00a0\n\u00a0\nKosten\u00a0\nCeftarolinfosamil \u00a0wird\u00a0nur\u00a0an\u00a0Krankenhausversorgende \u00a0Apotheken \u00a0ausgeliefert. \u00a0\u00a0\n \u00a0 \n187\u00a0\n\u00a0\nHintergrundinformationen \u00a011.7 Crizotinib \u00a0\nHandelsname: \u00a0Xalkori\u00ae\u00a0\u00a0\u00a0\u00a0 Hersteller: \u00a0Pfizer\u00a0\nIndikation: \u00a0Lungenkarzinom \u00a0 \u00a0 \u00a0\u00a0\u00a0 Markteinf\u00fchrung: \u00a0November \u00a02012\u00a0\nATC\u2010Code:\u00a0L01XE16\u00a0 \u00a0\u00a0\u00a0\u00a0 DDD:\u00a00,5\u00a0g\u00a0\nDarreichungsform: \u00a0Hartkapsel \u00a0\nBewertung: \u00a0siehe\u00a0Seite\u00a053 \nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nCrizotinib \u00a0ist\u00a0ein\u00a0oral\u00a0einzunehmender \u00a0Tyrosinkinaseinhibitor \u00a0der\u00a0Anaplastische \u2010Lymphom \u2010Kinase\u00a0\n(ALK).\u00a0Es\u00a0handelt\u00a0sich\u00a0um\u00a0ein\u00a0neuartiges \u00a0Wirkprinzip. \u00a0Die\u00a0ALK\u00a0geh\u00f6rt\u00a0zu\u00a0den\u00a0Rezeptortyrosinkinasen, \u00a0\nderen\u00a0Aktivierung \u00a0unter\u00a0Beteiligung \u00a0komplexer \u00a0Signaltransduktionswege \u00a0eine\u00a0unkontrollierte \u00a0\nZellproliferation \u00a0f\u00f6rdert.\u00a0Mutationen \u00a0des\u00a0ALK\u2010Gens\u00a0mit\u00a0\u00dcberexpression \u00a0von\u00a0ALK\u00a0kommen\u00a0bei\u00a0etwa\u00a0\nvier\u00a0Prozent\u00a0aller\u00a0Patienten \u00a0mit\u00a0nicht\u2010kleinzelligem \u00a0Lungenkarzinom \u00a0vor.\u00a0Crizotinib \u00a0bindet\u00a0kompetitiv \u00a0\nin\u00a0der\u00a0ATP\u2010Bindungstasche \u00a0des\u00a0ALK\u2010Enzyms\u00a0und\u00a0blockiert\u00a0dadurch\u00a0dessen\u00a0Aktivit\u00e4t.\u00a0Neben\u00a0der\u00a0ALK\u00a0\nhemmt\u00a0Crizotinib \u00a0die\u00a0c\u2010Met/HGFR \u2010,\u00a0ROS\u2010\u00a0und\u00a0RON\u2010Kinasen\u00a0(Pfizer,\u00a02014b;\u00a0EMA,\u00a02014c).\u00a0\n\u00a0Zulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nAm\u00a023.\u00a0Oktober\u00a02012\u00a0erteilte\u00a0die\u00a0Europ\u00e4ische \u00a0Kommission \u00a0die\u00a0\nGenehmigung \u00a0f\u00fcr\u00a0das\u00a0\nInverkehrbringen \u00a0von\u00a0Xalkori\u00ae\u00a0in\u00a0der\u00a0gesamten \u00a0Europ\u00e4ischen \u00a0Union,\u00a0seit\u00a0Mitte\u00a0November \u00a02012\u00a0ist\u00a0es\u00a0\nauf\u00a0dem\u00a0deutschen \u00a0Markt\u00a0verf\u00fcgbar. \u00a0Crizotinib \u00a0hat\u00a0aufgrund\u00a0der\u00a0hohen\u00a0Ansprechraten \u00a0in\u00a0den\u00a0Phase\u2010\nI\u2010Studien\u00a0eine\u00a0beschleunigte, \u00a0aber\u00a0auch\u00a0bedingte\u00a0Zulassung \u00a0(Conditional \u00a0Marketing \u00a0Authorization )\u00a0\nerhalten.\u00a0Der\u00a0pharmazeutische \u00a0Unternehmer \u00a0Pfizer\u00a0ist\u00a0gefordert, \u00a0die\u00a0Daten\u00a0der\u00a0noch\u00a0laufenden \u00a0\nPhase\u2010III\u2010Studien\u00a0nachzureichen \u00a0(EMA,\u00a02014c).\u00a0Xalkori\u00ae\u00a0ist\u00a0zugelassen \u00a0f\u00fcr\u00a0die\u00a0Zweitlinien \u2010Therapie\u00a0\nvon\u00a0Patienten \u00a0mit\u00a0ALK\u2010positivem, \u00a0fortgeschrittenem \u00a0nicht\u2010kleinzelligen \u00a0Lungenkarzinom \u00a0(NSCLC).\u00a0\nVoraussetzung \u00a0f\u00fcr\u00a0seine\u00a0Anwendung \u00a0ist\u00a0ein\u00a0molekularpathologischer \u00a0Test,\u00a0mit\u00a0dem\u00a0das\u00a0Vorliegen \u00a0\neiner\u00a0ALK\u2010Mutation \u00a0nachgewiesen \u00a0wird.\u00a0\n\u00a0Informationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nLungenkrebs \u00a0(Bronchialkarzinom) \u00a0geh\u00f6rt\u00a0\nzu\u00a0den\u00a0h\u00e4ufigsten \u00a0Krebserkrankungen \u00a0in\u00a0Deutschland. \u00a0\nDurch\u00a0seine\u00a0ung\u00fcnstige \u00a0Prognose \u00a0ist\u00a0er\u00a0der\u00a0h\u00e4ufigste \u00a0letale\u00a0Tumor\u00a0in\u00a0Deutschland. \u00a0M\u00e4nner\u00a0sind\u00a0etwa\u00a0\n2,5mal\u00a0h\u00e4ufiger\u00a0als\u00a0Frauen\u00a0betroffen, \u00a0allerdings \u00a0ist\u00a0seit\u00a0Ende\u00a0der\u00a01980er\u00a0Jahre\u00a0durch\u00a0die\u00a0ver\u00e4nderten \u00a0\nRauchgewohnheiten \u00a0bei\u00a0M\u00e4nnern \u00a0ein\u00a0r\u00fcckl\u00e4ufiger \u00a0Trend\u00a0und\u00a0bei\u00a0Frauen\u00a0eine\u00a0Zunahme \u00a0der\u00a0Inzidenz\u00a0\nzu\u00a0beobachten. \u00a0Das\u00a0mittlere\u00a0Erkrankungsalter \u00a0liegt\u00a0bei\u00a0knapp\u00a070\u00a0Jahren.\u00a080\u201085\u00a0Prozent\u00a0der\u00a0\nLungenkrebspatienten \u00a0haben\u00a0ein\u00a0nicht\u2010kleinzelliges \u00a0Bronchialkarzinom \u00a0(NSCLC).\u00a0\nIn\u00a0den\u00a0letzten\u00a0Jahren\u00a0wurden\u00a0beim\u00a0NSCLC\u00a0genetisch \u00a0unterschiedliche \u00a0Subtypen \u00a0mit\u00a0onkogenen \u00a0Mu\u2010\ntationen\u00a0identifiziert. \u00a0Neben\u00a0aktivierenden \u00a0Mutationen \u00a0des\u00a0epidermalen \u00a0Wachstumsfaktor \u2010\nRezeptors \u00a0(EGFR)\u00a0mit\u00a0einer\u00a0Inzidenz\u00a0von\u00a010\u201015\u00a0Prozent\u00a0(h\u00e4ufiger\u00a0bei\u00a0lebenslangen \u00a0Nichtrauchern) \u00a0\nfindet\u00a0man\u00a0bei\u00a0ca.\u00a0vier\u00a0Prozent\u00a0aller\u00a0Patienten \u00a0mit\u00a0NSCLC\u00a0in\u00a0den\u00a0Tumorzellen \u00a0eine\u00a0Mutation \u00a0des\u00a0ALK\u2010\nGens\u00a0(DGHO,\u00a02015;\u00a0Peters\u00a0et\u00a0al.,\u00a02012).\u00a0Durch\u00a0Chromosomenbr\u00fcche \u00a0im\u00a0ALK\u2010Gen\u00a0und\u00a0im\u00a0nahegelege \u2010\nnen\u00a0EML4\u2010Gen\u00a0kommt\u00a0es\u00a0durch\u00a0Gentranslokation \u00a0bzw.\u00a0\u2010inversion\u00a0zur\u00a0Entstehung \u00a0des\u00a0EML4\u2010ALK\u2010\u00a0\n188\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Gens,\u00a0was\u00a0zu\u00a0einer\u00a0\u00dcberexpression \u00a0von\u00a0ALK\u00a0f\u00fchrt,\u00a0die\u00a0im\u00a0normalen \u00a0Lungengewebe \u00a0nicht\u00a0aktiv\u00a0ist.\u00a0\nFolge\u00a0ist\u00a0eine\u00a0gesteigerte \u00a0Tumorzellproliferation. \u00a0\n\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDer\u00a0bedingten \u00a0Zulassung \u00a0von\u00a0Crizotinib \u00a0liegen\u00a0die\u00a0vorl\u00e4ufigen \u00a0Ergebnisse \u00a0dreier\u00a0noch\u00a0nicht\u00a0\nabgeschlossener \u00a0Studien\u00a0zugrunde. \u00a0In\u00a0der\u00a0f\u00fcr\u00a0die\u00a0Zulassung \u00a0relevanten \u00a0Phase\u2010I\u2010Studie\u00a0an\u00a0ALK\u2010\npositiven, \u00a0rezidivierten \u00a0und\u00a0vorbehandelten \u00a0Patienten \u00a0lag\u00a0die\u00a0Ansprechrate \u00a0bei\u00a060\u00a0Prozent,\u00a0das\u00a0\nprogressionsfreie \u00a0\u00dcberleben \u00a0betrug\u00a09,2\u00a0Monate.\u00a0Diese\u00a0im\u00a0Vergleich \u00a0zur\u00a0Zweitlinienbehandlung \u00a0mit\u00a0\nkonventioneller \u00a0Chemotherapie \u00a0hohe\u00a0Ansprechrate \u00a0wurde\u00a0in\u00a0einer\u00a0weiteren\u00a0einarmigen \u00a0Phase\u2010II\u2010\nStudie\u00a0best\u00e4tigt\u00a0und\u00a0f\u00fchrte\u00a0zur\u00a0beschleunigten, \u00a0bedingten \u00a0Zulassung \u00a0bei\u00a0der\u00a0FDA\u00a0im\u00a0August\u00a02011\u00a0\n(EMA,\u00a02014c).\u00a0\nIn\u00a0die\u00a0offene,\u00a0kontrollierte, \u00a0randomisierte \u00a0Phase\u2010III\u2010Studie\u00a0PROFILE\u00a01007\u00a0wurden\u00a0318\u00a0Patienten \u00a0mit\u00a0\nfortgeschrittenem \u00a0ALK\u2010positiven\u00a0NSCLC\u00a0nach\u00a0Vorbehandlung \u00a0mit\u00a0einer\u00a0Platin\u2010haltigen\u00a0\nChemotherapie \u00a0eingeschlossen. \u00a0Sie\u00a0erhielten\u00a0entweder \u00a0zweimal\u00a0t\u00e4glich\u00a0250\u00a0mg\u00a0Crizotinib \u00a0oder\u00a0eine\u00a0\nZweitlinien \u2010Chemotherapie \u00a0mit\u00a0Pemetrexed \u00a0oder\u00a0Docetaxel. \u00a0Prim\u00e4rer\u00a0Studienendpunkt \u00a0war\u00a0das\u00a0\nprogressionsfreie \u00a0\u00dcberleben, \u00a0welches\u00a0im\u00a0Crizotinib \u2010Arm\u00a0bei\u00a07,7\u00a0Monaten\u00a0und\u00a0im\u00a0Chemotherapie \u2010\nArm\u00a0bei\u00a0drei\u00a0Monaten\u00a0lag.\u00a0Das\u00a0objektive \u00a0Ansprechen \u00a0auf\u00a0Crizotinib \u00a0betrug\u00a065,3\u00a0Prozent\u00a0vs.\u00a019,5\u00a0\nProzent\u00a0auf\u00a0die\u00a0Chemotherapie. \u00a0Das\u00a0Gesamt\u00fcberleben \u00a0war\u00a0in\u00a0beiden\u00a0Armen\u00a0vergleichbar \u00a0hoch,\u00a0da\u00a0\nnach\u00a0einer\u00a0Interimsanalyse \u00a0ein\u00a0Crossover \u00a0m\u00f6glich\u00a0war\u00a0und\u00a0die\u00a0meisten\u00a0Patienten \u00a0aus\u00a0der\u00a0\nChemotherapie \u2010Gruppe\u00a0im\u00a0Rezidiv\u00a0Crizotinib \u00a0erhielten\u00a0(Shaw\u00a0et\u00a0al.,\u00a02012).\u00a0Als\u00a0h\u00e4ufigste \u00a0\nunerw\u00fcnschte \u00a0Nebenwirkungen \u00a0traten\u00a0unter\u00a0Crizotinib \u00a0erh\u00f6hte\u00a0Transaminasen, \u00a0Sehst\u00f6rungen, \u00a0\nDiarrhoe, \u00a0Obstipation \u00a0und\u00a0Neutropenie \u00a0auf.\u00a0\n\u00a0Leitlinienempfehlungen \u00a0\nDie\u00a0Behandlung \u00a0nicht\u2010kleinzelliger \u00a0Bronchialkarzinome \u00a0erfolgt\u00a0stadienabh\u00e4ngig \u00a0unter\u00a0\nBer\u00fccksichtigung \u00a0von\u00a0Allgemeinzustand, \u00a0Symptomatik, \u00a0Komorbidit\u00e4ten, \u00a0Vorbehandlung \u00a0und\u00a0\nPatientenpr\u00e4ferenz. \u00a0Bei\u00a0lokaler\u00a0Begrenzung \u00a0des\u00a0Tumors\u00a0ist\u00a0die\u00a0Operation \u00a0das\u00a0Mittel\u00a0\nder\u00a0Wahl\u00a0mit\u00a0\nkurativem \u00a0Anspruch. \u00a0Weil\u00a0die\u00a0Erkrankung \u00a0h\u00e4ufig\u00a0erst\u00a0in\u00a0einem\u00a0fortgeschrittenen \u00a0Stadium\u00a0festgestellt \u00a0\nwird,\u00a0ist\u00a0eine\u00a0vollst\u00e4ndige \u00a0Operation \u00a0allerdings \u00a0nur\u00a0bei\u00a0weniger\u00a0als\u00a0einem\u00a0Drittel\u00a0der\u00a0Patienten \u00a0\ndurchf\u00fchrbar. \u00a035\u201040\u00a0Prozent\u00a0der\u00a0Patienten \u00a0mit\u00a0NSCLC\u00a0werden\u00a0im\u00a0metastasierenden \u00a0Stadium\u00a0IV\u00a0\ndiagnostiziert, \u00a0hier\u00a0gilt\u00a0die\u00a0Krankheit \u00a0als\u00a0unheilbar \u00a0und\u00a0die\u00a0Therapie\u00a0ist\u00a0palliativ.\u00a0Sie\u00a0richtet\u00a0sich\u00a0nach\u00a0\nden\u00a0Beschwerden \u00a0und\u00a0nach\u00a0dem\u00a0Ansprechen \u00a0auf\u00a0die\u00a0jeweiligen \u00a0Ma\u00dfnahmen. \u00a0H\u00e4ufig\u00a0kommen\u00a0\nsowohl\u00a0Bestrahlung \u00a0als\u00a0auch\u00a0systemische \u00a0medikament\u00f6se \u00a0Therapie\u00a0zum\u00a0Einsatz.\u00a0Das\u00a0mediane\u00a0\nGesamt\u00fcberleben \u00a0der\u00a0Patienten \u00a0mit\u00a0einer\u00a0Standard\u2010Chemotherapie \u00a0liegt\u00a0bei\u00a0unter\u00a0einem\u00a0Jahr.\u00a0\u00a0\u00a0\nDie\u00a0derzeit\u00a0g\u00fcltige\u00a0Fassung\u00a0der\u00a0Leitlinie\u00a0der\u00a0DGHO\u00a0von\u00a0Oktober\u00a02012\u00a0empfiehlt \u00a0bei\u00a0allen\u00a0Patienten \u00a0\nmit\u00a0Nicht\u2010Plattenepithelkarzinom \u00a0unabh\u00e4ngig \u00a0vom\u00a0Raucherstatus \u00a0die\u00a0Erhebung \u00a0des\u00a0EGFR\u2010\nMutationsstatus \u00a0und\u00a0des\u00a0ALK\u2010Translokationsstatus \u00a0als\u00a0Grundlage \u00a0f\u00fcr\u00a0die\u00a0Therapiestrategie. \u00a0W\u00e4hrend \u00a0\nf\u00fcr\u00a0Patienten \u00a0mit\u00a0unmutiertem \u00a0EGF\u2010Rezeptor\u00a0initial\u00a0eine\u00a0platinhaltige \u00a0Kombinationschemotherapie \u00a0\nStandard\u00a0ist,\u00a0werden\u00a0bei\u00a0Patienten \u00a0mit\u00a0aktivierenden \u00a0EGFR\u2010Mutationen \u00a0die\u00a0Tyrosinkinaseinhibitoren \u00a0\nGefitinib\u00a0(Iressa\u00ae)\u00a0oder\u00a0Erlotinib\u00a0(Tarceva\u00ae) \u00a0in\u00a0der\u00a0Erstlinien \u2010Therapie\u00a0eingesetzt. \u00a0Im\u00a0Algorithmus \u00a0f\u00fcr\u00a0\ndie\u00a0palliative\u00a0medikament\u00f6se \u00a0Erstlinien \u2010Therapie\u00a0findet\u00a0sich\u00a0auch\u00a0Crizotinib \u00a0als\u00a0m\u00f6gliche\u00a0 \n189\u00a0\n\u00a0\nHintergrundinformationen \u00a0Behandlungsma\u00dfnahme \u00a0bei\u00a0ALK\u2010Translokation. \u00a0In\u00a0der\u00a0Zweitlinien \u2010Therapie\u00a0wird\u00a0bei\u00a0unmutiertem \u00a0\nEGFR\u00a0in\u00a0der\u00a0Regel\u00a0eine\u00a0Monochemotherapie, \u00a0z.B.\u00a0mit\u00a0Docetaxel \u00a0oder\u00a0Pemetrexed, \u00a0durchgef\u00fchrt, \u00a0bei\u00a0\nmit\u00a0Tyrosinkinaseinhibitoren \u00a0vorbehandelten \u00a0Patienten \u00a0mit\u00a0EGF\u2010Mutation \u00a0eine\u00a0Platin\u2010basierte\u00a0\nChemotherapie. \u00a0\n\u00a0\nNutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDer\u00a0G\u2010BA\u00a0legt\u00a0der\u00a0Bewertung \u00a0des\u00a0Ausma\u00dfes \u00a0des\u00a0Zusatznutzens \u00a0lediglich\u00a0die\u00a0Ergebnisse \u00a0einer\u00a0\nInterimsanalyse \u00a0mit\u00a0Datenschnitt \u00a0vom\u00a030.03.2012 \u00a0der\u00a0noch\u00a0laufenden \u00a0PROFILE\u00a01007\u2010Studie\u00a0zugrunde \u00a0\nund\u00a0sch\u00e4tzt\u00a0das\u00a0Verzerrungspotential \u00a0als\u00a0hoch\u00a0ein,\u00a0vor\u00a0allem,\u00a0weil\u00a0das\u00a0Studiendesign \u00a0unverblindet \u00a0\nund\u00a0ein\u00a0hoher\u00a0Anteil\u00a0an\u00a0Patienten \u00a0im\u00a0Studienverlauf \u00a0aus\u00a0der\u00a0Kontrollgruppe \u00a0in\u00a0die\u00a0Crizotinib \u2010\nBehandlungsgruppe \u00a0gewechselt \u00a0ist.\u00a0F\u00fcr\u00a0Patienten \u00a0mit\u00a0vorbehandeltem, \u00a0fortgeschrittenem \u00a0ALK\u2010\npositiven\u00a0NSCLC,\u00a0bei\u00a0denen\u00a0eine\u00a0Chemotherapie \u00a0angezeigt \u00a0ist,\u00a0sieht\u00a0er\u00a0einen\u00a0Anhaltspunkt \u00a0f\u00fcr\u00a0einen\u00a0\nbetr\u00e4chtlichen \u00a0Zusatznutzen \u00a0von\u00a0Crizotinib \u00a0gegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0\naufgrund\u00a0einer\u00a0deutlichen \u00a0Verbesserung \u00a0der\u00a0Lebensqualit\u00e4t \u00a0und\u00a0Krankheitssymptomatik. \u00a0F\u00fcr\u00a0\nPatienten \u00a0ohne\u00a0Indikation \u00a0f\u00fcr\u00a0eine\u00a0Chemotherapie \u00a0ist\u00a0aufgrund\u00a0fehlender \u00a0Daten\u00a0ein\u00a0Zusatznutzen \u00a0\nnicht\u00a0belegt .\u00a0Der\u00a0Beschluss \u00a0des\u00a0G\u2010BA\u00a0ist\u00a0auf\u00a0zwei\u00a0Jahre\u00a0befristet,\u00a0da\u00a0Crizotinib \u00a0von\u00a0der\u00a0EMA\u00a0unter\u00a0\nAuflagen\u00a0zugelassen \u00a0wurde\u00a0und\u00a0vom\u00a0pharmazeutischen \u00a0Unternehmer \u00a0die\u00a0Vorlage\u00a0weiterer\u00a0Daten\u00a0aus\u00a0\nden\u00a0zum\u00a0Zeitpunkt \u00a0der\u00a0Zulassung \u00a0noch\u00a0laufenden \u00a0Studien\u00a0sowie\u00a0ein\u00a0Sicherheitsreview \u00a0zu\u00a0hepatischen \u00a0\nSt\u00f6rungen \u00a0gefordert \u00a0werden.\u00a0\n\u00a0Kosten\u00a0\nWirkstof f\u00a0 Behandlungsmodus Behandlungstage Jahrestherapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nCrizotinib  2\u00a0x\u00a0t\u00e4glich\u00a0250\u00a0mg 360 73.053,24 \u00a0\u20ac\nVergleichstherapie  \u00a0\nDocetaxel  In\u00a0Zyklen:\u00a01\u00a0Zyklus\u00a0=\u00a021\u00a0Tage\n1\u00a0x\u00a075\u00a0mg/m2\u00a0pro\u00a0Zyklus\u00a017 23.170,49 \u00a0\u20ac\nPemetrexed  In\u00a0Zyklen:\u00a01\u00a0Zyklus\u00a0=\u00a021\u00a0Tage\nTag\u00a01:\u00a01\u00a0x\u00a0500mg/m2\u00a0\u00a017 78.545,44 \u00a0\u20ac\nDosis\u2010Berechnung \u00a0mit\u00a0einer\u00a0K\u00f6rperoberfl\u00e4che \u00a0(KOF)\u00a0von\u00a01,73\u00a0m2 \nTabelle\u00a032:\u00a0Jahrestherapiekosten \u00a0von\u00a0Crizotinib \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0Kosten\u00a0\nzus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0\n \u00a0\u00a0\n190\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a011.8 Dapagliflozin \u00a0\nHandelsname: \u00a0Forxiga\u00ae     Hersteller: \u00a0AstraZeneca  \nIndikation: \u00a0Diabetes\u00a0mellitus\u00a0Typ\u00a02\u00a0\u00a0 \u00a0 Markteinf\u00fchrung: \u00a0Dezember \u00a02012 \nATC\u2010Code:\u00a0A10BX09      DDD:\u00a010\u00a0mg \nDarreichungsform: \u00a0Filmtablette  \nBewertung: \u00a0siehe\u00a0Seite\u00a057\u00a0\nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nDapagliflozin \u00a0ist\u00a0der\u00a0erste\u00a0selektive\u00a0Hemmstoff \u00a0des\u00a0Natrium\u2010Glukose\u2010Cotransporter \u2010Typ\u00a02\u00a0(sodium\u2010\u00a0\nglucose\u2010co\u2010transporter \u00a0type\u00a02,\u00a0SGLT2).\u00a0Der\u00a0transmembran\u00e4re \u00a0SLGT2\u00a0ist\u00a0ein\u00a0f\u00fcr\u00a0Glukose\u00a0niedrig\u00a0affiner\u00a0\nTransporter \u00a0mit\u00a0hoher\u00a0Transportkapazit\u00e4t, \u00a0der\u00a0in\u00a0den\u00a0Membranen \u00a0des\u00a0proximalen \u00a0Nierentubulus \u00a0\nlokalisiert \u00a0und\u00a0f\u00fcr\u00a0etwa\u00a090\u00a0Prozent\u00a0der\u00a0aus\u00a0dem\u00a0Prim\u00e4rharn \u00a0r\u00fcckresorbierten \u00a0Glukose\u00a0verantwortlich \u00a0\nist.\u00a0Der\u00a0vor\u00a0allem\u00a0im\u00a0D\u00fcnndarm \u00a0lokalisierte \u00a0SLGT1\u00a0wird\u00a0erst\u00a0in\u00a0\u00fcber\u00a01000\u2010fach\u00a0h\u00f6herer\u00a0Dosierung \u00a0\ngehemmt \u00a0(Fricke\u00a0et\u00a0al.,\u00a02013).\u00a0Strukturell \u00a0handelt\u00a0es\u00a0sich\u00a0bei\u00a0Dapagliflozin \u00a0um\u00a0ein\u00a0C\u2010Glucosid,\u00a0das\u00a0\nnicht\u00a0durch\u00a0enterale\u00a0\u03b2\u2010Glukosidasen \u00a0abgebaut \u00a0wird.\u00a0Die\u00a0selektive\u00a0Hemmung \u00a0des\u00a0renalen\u00a0SLGT2\u00a0f\u00fchrt\u00a0\nzu\u00a0einer\u00a0Verringerung \u00a0der\u00a0Glukosemenge, \u00a0die\u00a0aus\u00a0dem\u00a0Prim\u00e4rharn \u00a0wieder\u00a0in\u00a0den\u00a0Blutkreislauf \u00a0\naufgenommen \u00a0wird.\u00a0Dapagliflozin \u00a0entfaltet\u00a0seine\u00a0blutzuckersenkende \u00a0Wirkung\u00a0unabh\u00e4ngig \u00a0vom\u00a0\nInsulinstoffwechsel \u00a0und\u00a0besitzt\u00a0daher\u00a0auch\u00a0kein\u00a0intrinsisches \u00a0Hypoglyk\u00e4mierisiko. \u00a0Seine\u00a0Wirkung\u00a0ist\u00a0\naber\u00a0abh\u00e4ngig\u00a0von\u00a0der\u00a0Nierenfunktion, \u00a0d.h.\u00a0bei\u00a0nachlassender \u00a0Nierenfunktion \u00a0nimmt\u00a0auch\u00a0die\u00a0\nblutzuckersenkende \u00a0Wirkung\u00a0von\u00a0Dapaglifozin \u00a0ab\u00a0(EMA,\u00a02012c).\u00a0Bei\u00a0Patienten \u00a0mit\u00a0m\u00e4\u00dfiger\u00a0oder\u00a0\nschwerer\u00a0Niereninsuffizienz \u00a0wird\u00a0deshalb\u00a0die\u00a0Anwendung \u00a0nicht\u00a0empfohlen. \u00a0Als\u00a0unerw\u00fcnschte \u00a0\nWirkungen \u00a0werden\u00a0aufgrund\u00a0der\u00a0mit\u00a0dem\u00a0Wirkeffekt \u00a0von\u00a0Dapagliflozin \u00a0einhergehenden \u00a0Glukosurie \u00a0\nam\u00a0h\u00e4ufigsten \u00a0Harnwegsinfektionen, \u00a0Infektionen \u00a0des\u00a0Genitaltrakts, \u00a0eine\u00a0erh\u00f6hte\u00a0Urinausscheidung \u00a0\nund\u00a0Beschwerden \u00a0bei\u00a0der\u00a0Harnentleerung \u00a0beobachtet. \u00a0In\u00a0seltenen\u00a0F\u00e4llen\u00a0wurde\u00a0im\u00a0Zusammenhang \u00a0\nmit\u00a0der\u00a0Einnahme \u00a0\u00fcber\u00a0Blasenkarzinome \u00a0bzw.\u00a0Krebserkrankungen \u00a0an\u00a0Brust\u00a0und\u00a0Prostata\u00a0sowie\u00a0\u00fcber\u00a0\nschwerwiegende \u00a0Leberfunktionsst\u00f6rungen \u00a0berichtet\u00a0(EMA,\u00a02012c).\u00a0\u00a0\n\u00a0Zulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nDapagliflozin \u00a0(Forxiga\u00ae) \u00a0ist\u00a0zur\u00a0Verbesserung \u00a0der\u00a0Blutzuckerkontrolle \u00a0bei\u00a0Erwachsenen \u00a0mit\u00a0Diabetes\u00a0\nmellitus\u00a0Typ\u00a02\u00a0zugelassen. \u00a0Es\u00a0kann\u00a0als\u00a0alleiniges \u00a0orales\u00a0Antidiabetikum \u00a0angewendet \u00a0werden,\u00a0wenn\u00a0\nnur\u00a0mit\u00a0Di\u00e4t\u00a0und\u00a0\nBewegung \u00a0der\u00a0Blutzucker \u00a0nicht\u00a0ausreichend \u00a0kontrolliert \u00a0und\u00a0Metformin \u00a0als\u00a0\nStandardmedikament \u00a0wegen\u00a0Unvertr\u00e4glichkeiten \u00a0oder\u00a0Kontraindikationen \u00a0nicht\u00a0eingesetzt \u00a0werden\u00a0\nkann.\u00a0Dapagliflozin \u00a0kann\u00a0auch\u00a0mit\u00a0anderen\u00a0blutzuckersenkenden \u00a0Arzneimitteln \u00a0(einschlie\u00dflich \u00a0Insulin)\u00a0\nkombiniert \u00a0werden,\u00a0wenn\u00a0diese\u00a0allein\u00a0den\u00a0Blutzucker \u00a0nicht\u00a0ausreichend \u00a0senken\u00a0konnten.\u00a0Forxiga\u00ae\u00a0\nwird\u00a0in\u00a0Einzeldosen \u00a0von\u00a05\u00a0und\u00a010\u00a0mg\u00a0Dapagliflozin \u00a0angeboten. \u00a0Die\u00a0empfohlene \u00a0Tagesdosierung \u00a0von\u00a0\nDapagliflozin \u00a0liegt\u00a0bei\u00a0einmal\u00a0t\u00e4glich\u00a010\u00a0mg.\u00a0Bei\u00a0Patienten \u00a0mit\u00a0einer\u00a0schweren \u00a0Funktionsst\u00f6rung \u00a0der\u00a0\nLeber\u00a0soll\u00a0die\u00a0Dosis\u00a0auf\u00a05\u00a0mg\u00a0t\u00e4glich\u00a0reduziert\u00a0werden\u00a0(AstraZeneca, \u00a02014b).\u00a0\u00a0\nNeben\u00a0dem\u00a0Monotherapeutikum \u00a0Forxiga\u00ae\u00a0steht\u00a0f\u00fcr\u00a0die\u00a0Therapie\u00a0von\u00a0erwachsenen \u00a0Typ\u20102\u2010Diabetikern \u00a0\nmittlerweile \u00a0auch\u00a0eine\u00a0Fixkombination \u00a0bestehend \u00a0aus\u00a0Dapagliflozin \u00a0und\u00a0Metformin \u00a0(Xigduo\u00ae) \u00a0in\u00a0\nverschiedener \u00a0Dosierung \u00a0zur\u00a0Verf\u00fcgung. \u00a0Das\u00a0Mittel\u00a0ist\u00a0f\u00fcr\u00a0die\u00a0antidiabetische \u00a0Therapie\u00a0bei\u00a0Patienten \u00a0\nzugelassen, \u00a0bei\u00a0denen\u00a0der\u00a0Blutzucker \u00a0mit\u00a0der\u00a0maximal\u00a0vertr\u00e4glichen \u00a0Dosis\u00a0von\u00a0Metformin \u00a0allein\u00a0nicht\u00a0\nausreichend \u00a0kontrolliert \u00a0werden\u00a0kann.\u00a0Au\u00dferdem \u00a0kann\u00a0es\u00a0in\u00a0Kombination \u00a0mit\u00a0anderen\u00a0 \n191\u00a0\n\u00a0\nHintergrundinformationen \u00a0blutzuckersenkenden \u00a0Arzneimitteln \u00a0einschlie\u00dflich \u00a0Insulin\u00a0gegeben\u00a0werden,\u00a0wenn\u00a0der\u00a0Blutzucker \u00a0mit\u00a0\nMetformin \u00a0und\u00a0diesen\u00a0Arzneimitteln \u00a0nicht\u00a0ausreichend \u00a0kontrolliert \u00a0wird,\u00a0sowie\u00a0bei\u00a0Patienten \u00a0die\u00a0\nbereits\u00a0mit\u00a0einer\u00a0Kombination \u00a0aus\u00a0Dapagliflozin \u00a0und\u00a0Metformin \u00a0als\u00a0separate\u00a0Tabletten \u00a0behandelt \u00a0\nwerden\u00a0(AstraZeneca, \u00a02014b).\u00a0\u00a0\n\u00a0\nInformationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nVon\u00a0den\u00a0Diabetikern \u00a0in\u00a0Deutschland \u00a0haben\u00a0etwa\u00a0f\u00fcnf\u00a0bis\u00a0zehn\u00a0Prozent\u00a0Typ\u20101\u2010Diabetes, \u00a090\u00a0Prozent\u00a0\nleiden\u00a0an\u00a0Typ\u20102\u2010Diabetes. \u00a0Daneben\u00a0gibt\u00a0es\u00a0noch\u00a0einige\u00a0seltene\u00a0Diabetesformen, \u00a0die\u00a0zahlenm\u00e4\u00dfig \u00a0\nnicht\u00a0ins\u00a0Gewicht\u00a0fallen,\u00a0bei\u00a0der\u00a0Diagnostik \u00a0aber\u00a0ber\u00fccksichtigt \u00a0werden\u00a0m\u00fcssen.\u00a0\u00a0\nBez\u00fcglich \u00a0der\u00a0Erkrankungsh\u00e4ufigkeit \u00a0von\u00a0Typ\u20102\u2010Diabetes\u00a0in\u00a0Deutschland \u00a0gibt\u00a0es\u00a0keine\u00a0eindeutigen \u00a0\nAussagen \u00a0(Hauner,\u00a02013).\u00a0Verschiedene \u00a0Institutionen \u00a0und\u00a0Forschungsunternehmen \u00a0kommen\u00a0\naufgrund\u00a0unterschiedlicher \u00a0Diagnosekriterien \u00a0und\u00a0Erfassungsmethoden \u00a0zu\u00a0abweichenden \u00a0Zahlen.\u00a0\nEine\u00a0repr\u00e4sentative \u00a0Studie\u00a0aus\u00a0dem\u00a0Jahr\u00a02012\u00a0kommt\u00a0nach\u00a0Befragung \u00a0von\u00a08.000\u00a0Teilnehmern \u00a0im\u00a0\nAlter\u00a0zwischen\u00a018\u00a0und\u00a079\u00a0Jahren\u00a0zu\u00a0dem\u00a0Ergebnis,\u00a0dass\u00a0bei\u00a07,2\u00a0Prozent\u00a0ein\u00a0Arzt\u00a0einen\u00a0Diabetes\u00a0\nmellitus\u00a0diagnostiziert \u00a0hatte\u00a0bzw.\u00a0diese\u00a0Personen \u00a0in\u00a0den\u00a0letzten\u00a0sieben\u00a0Tagen\u00a0Antidiabetika \u00a0\neingenommen \u00a0hatten.\u00a0Vergleicht \u00a0man\u00a0diese\u00a0Angaben\u00a0mit\u00a0den\u00a0Ergebnissen \u00a0des\u00a0\nBundesgesundheitssurveys \u00a0aus\u00a0dem\u00a0Jahr\u00a01998,\u00a0ergibt\u00a0sich\u00a0f\u00fcr\u00a0die\u00a0Zwischenzeit \u00a0eine\u00a0absolute\u00a0\nSteigerung \u00a0der\u00a0Pr\u00e4valenz \u00a0um\u00a0zwei\u00a0Prozentpunkte \u00a0(Kurth,\u00a02012).\u00a0Lediglich\u00a0ein\u00a0Drittel\u00a0l\u00e4sst\u00a0sich\u00a0durch\u00a0\ndie\u00a0steigende \u00a0Alterung\u00a0der\u00a0Gesellschaft \u00a0und\u00a0der\u00a0damit\u00a0einhergehenden \u00a0Zunahme \u00a0der\u00a0\nErkrankungsh\u00e4ufigkeit \u00a0erkl\u00e4ren\u00a0(Hauner,\u00a02013.\u00a0Im\u00a0Alter\u00a0zwischen\u00a040\u00a0und\u00a059\u00a0Jahren\u00a0liegt\u00a0die\u00a0Pr\u00e4valenz \u00a0\nzwischen\u00a0vier\u00a0und\u00a0zehn\u00a0Prozent,\u00a0bei\u00a0den\u00a0Menschen \u00a0im\u00a0Alter\u00a0von\u00a060\u00a0Jahren\u00a0und\u00a0dar\u00fcber\u00a0sind\u00a0es\u00a0\nzwischen\u00a018\u00a0und\u00a028\u00a0Prozent\u00a0(Hauner,\u00a02013).\u00a0Neben\u00a0den\u00a0durch\u00a0Diagnosen \u00a0verifizierten \u00a0Typ\u20102\u2010\nDiabetes\u2010Erkrankungen \u00a0muss\u00a0in\u00a0Deutschland \u00a0verschiedenen \u00a0Untersuchungen \u00a0zufolge\u00a0zus\u00e4tzlich \u00a0noch\u00a0\nvon\u00a0einer\u00a0Dunkelziffer \u00a0von\u00a0ein\u00a0bis\u00a0zwei\u00a0Prozent\u00a0nicht\u2010diagnostizierter \u00a0Patientenf\u00e4lle \u00a0ausgegangen \u00a0\nwerden\u00a0(Hauner,\u00a02013).\u00a0\u00a0\nJ\u00e4hrlich\u00a0liegt\u00a0die\u00a0Neuerkrankungsrate \u00a0bei\u00a055\u2010\u00a0bis\u00a074\u2010j\u00e4hrigen\u00a0M\u00e4nnern \u00a0bei\u00a0ca.\u00a0zwei\u00a0Prozent\u00a0pro\u00a0Jahr,\u00a0\nbei\u00a0gleichaltrigen \u00a0Frauen\u00a0bei\u00a0etwas\u00a0h\u00f6her\u00a0als\u00a0ein\u00a0Prozent.\u00a0Dies\u00a0entspricht \u00a0in\u00a0etwa\u00a0270.000\u00a0\nNeuerkrankungen \u00a0pro\u00a0Jahr\u00a0in\u00a0der\u00a0\u00e4lteren\u00a0deutschen \u00a0Bev\u00f6lkerung \u00a0(Hauner,\u00a02013;\u00a0Rathmann, \u00a02009).\u00a0\n\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDapagliflozin \u00a0f\u00fchrt\u00a0in\u00a0Placebo\u2010kontrollierten \u00a0Studien\u00a0zu\u00a0einer\u00a0m\u00e4\u00dfigen\u00a0Senkung\u00a0des\u00a0HbA1c\u2010Wertes\u00a0\nvon\u00a00,55\u00a0bis\u00a00,8\u00a0Prozent\u00a0und\u00a0zeigt\u00a0in\u00a0direkt\u00a0vergleichenden \u00a0Studien\u00a0hierin\u00a0eine\u00a0Nicht\u2010Unterlegenheit \u00a0\ngegen\u00fcber \u00a0dem\u00a0Sulfonylharnstoff \u00a0Glipizid,\u00a0in\u00a0Deutschland \u00a0au\u00dfer\u00a0Handel,\u00a0(Vitaplana, \u00a02015;\u00a0Kleefstra\u00a0\net\u00a0al.,\u00a02013)\u00a0und\u00a0Metformin. \u00a0Dar\u00fcber\u00a0hinaus\u00a0liegen\u00a0placebokontrollierte \u00a0Untersuchungen \u00a0mit\u00a0\nDapagliflozin \u00a0als\u00a0Add\u2010on\u2010Medikation \u00a0zu\u00a0Metformin, \u00a0Sulfonylharnstoffen, \u00a0Pioglitazon, \u00a0Sitagliptin \u00a0und\u00a0\nInsulin\u00a0vor.\u00a0Die\u00a0kombinierte \u00a0Anwendung \u00a0zeigte\u00a0konsistent \u00a0eine\u00a0Verbesserung \u00a0der\u00a0HbA1c\u2010Werte\u00a0im\u00a0\nVergleich \u00a0zur\u00a0Therapie\u00a0mit\u00a0einem\u00a0Antidiabetikum \u00a0allein\u00a0(Scheen,\u00a02015).\u00a0Die\u00a0bisher\u00a0vorliegenden \u00a0\nStudien\u00a0zu\u00a0Dapagliflozin \u00a0zeigen\u00a0aber\u00a0weder\u00a0f\u00fcr\u00a0den\u00a0Einsatz\u00a0als\u00a0Monotherapeutikum \u00a0noch\u00a0in\u00a0der\u00a0\nKombinationsbehandlung \u00a0mit\u00a0anderen\u00a0antidiabetischen \u00a0Wirkstoffen \u00a0eine\u00a0Auswirkung \u00a0auf\u00a0\nFolgeerkrankungen \u00a0des\u00a0Diabetes\u00a0oder\u00a0Mortalit\u00e4t. \u00a0Auf\u00a0diese\u00a0Endpunkte \u00a0hatte\u00a0der\u00a0pharmazeutische \u00a0\nHersteller \u00a0die\u00a0Bem\u00fchungen \u00a0zum\u00a0Nachweis \u00a0eines\u00a0Zusatznutzens \u00a0auch\u00a0nicht\u00a0ausgerichtet. \u00a0AstraZeneca \u00a0\u00a0\n192\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0f\u00fchrt\u00a0als\u00a0Vorteile\u00a0f\u00fcr\u00a0Dapagliflozin \u00a0vielmehr\u00a0ein\u00a0geringeres \u00a0Risiko\u00a0f\u00fcr\u00a0Hypoglyk\u00e4mien \u00a0sowie\u00a0\nGewichtsverlust \u00a0und\u00a0Blutdrucksenkung \u00a0an.\u00a0Diese\u00a0Behauptungen \u00a0werden\u00a0aber\u00a0nicht\u00a0durch\u00a0geeignete \u00a0\nStudien\u00a0unterst\u00fctzt: \u00a0Entweder \u00a0wird\u00a0in\u00a0den\u00a0verf\u00fcgbaren \u00a0Studien\u00a0nicht\u00a0das\u00a0Patientenkollektiv \u00a0getestet,\u00a0\nf\u00fcr\u00a0das\u00a0eine\u00a0Zulassung \u00a0besteht,\u00a0oder\u00a0Dapagliflozin \u00a0wird\u00a0nicht\u00a0gegen\u00a0die\u00a0festgelegte \u00a0zweckm\u00e4\u00dfige \u00a0\nVergleichstherapie \u00a0verglichen \u00a0(IQWiG,\u00a02013c;\u00a0G\u2010BA,\u00a02013e).\u00a0Systematische \u00a0\u00dcbersichten \u00a0der\u00a0\nvorhandenen \u00a0Untersuchungen \u00a0kommen\u00a0auch\u00a0aktuell\u00a0noch\u00a0zu\u00a0dem\u00a0Ergebnis,\u00a0dass\u00a0das\u00a0Mittel\u00a0\ngegen\u00fcber \u00a0den\u00a0zur\u00a0Verf\u00fcgung \u00a0stehenden \u00a0Antidiabetika \u00a0keinen\u00a0therapeutischen \u00a0Vorteil\u00a0aufweist,\u00a0\nwohl\u00a0aber\u00a0gegen\u00fcber \u00a0diesen\u00a0mit\u00a0deutlich\u00a0h\u00f6heren\u00a0Kosten\u00a0aufwartet \u00a0(Escudero \u2010Vitaplana \u00a0et\u00a0al.,\u00a0\n2015),\u00a0und\u00a0dass\u00a0wichtige\u00a0Informationen \u00a0zu\u00a0den\u00a0therapeutischen \u00a0Auswirkungen \u00a0auf\u00a0das\u00a0\nkardiovaskul\u00e4re \u00a0System\u00a0noch\u00a0fehlen\u00a0(Scheen,\u00a02015).\u00a0\u00a0\nGegen\u00fcber \u00a0einem\u00a0Scheinmedikament, \u00a0dem\u00a0Standardtherapeutikum \u00a0Metformin \u00a0oder\u00a0einem\u00a0Vertreter \u00a0\nder\u00a0DPP\u20104\u2010Inhibitoren \u00a0sinkt\u00a0das\u00a0K\u00f6rpergewicht \u00a0unter\u00a0Dapagliflozin \u00a0zwischen\u00a0einem\u00a0und\u00a02,5\u00a0\nKilogramm \u00a0(Kleefstra \u00a0et\u00a0al.,\u00a02013;\u00a0Goring\u00a0et\u00a0al.,\u00a02014).\u00a0Gegen\u00fcber \u00a0Sulfonylharnstoffen \u00a0sind\u00a0es\u00a0\nzwischen\u00a0zwei\u00a0und\u00a04,5\u00a0Kilogramm \u00a0(Matthei\u00a0et\u00a0al.,\u00a02015;\u00a0Del\u00a0Prato\u00a0et\u00a0al.,\u00a02015).\u00a0Die\u00a0therapeutische \u00a0\nRelevanz\u00a0dieses\u00a0Gewichtsverlustes \u00a0ist\u00a0aber\u00a0nicht\u00a0anhand\u00a0patientenrelevanter \u00a0Endpunkte \u00a0wie\u00a0\nMorbidit\u00e4tssenkung \u00a0oder\u00a0Lebensqualit\u00e4tserh\u00f6hung \u00a0belegt.\u00a0Unter\u00a0Dapagliflozin \u00a0werden\u00a0vermehrt \u00a0\nurogentiale \u00a0Infektionen \u00a0wie\u00a0Harnwegsinfektionen, \u00a0Vulvovaginitis \u00a0und\u00a0Balanitis\u00a0beobachtet, \u00a0die\u00a0bei\u00a0\neinem\u00a0bis\u00a0zehn\u00a0von\u00a0100\u00a0Behandelten \u00a0auftreten. \u00a0Als\u00a0potentielle \u00a0Unvertr\u00e4glichkeiten \u00a0in\u00a0der\u00a0\nLangzeitbehandlung \u00a0m\u00fcssen\u00a0Auswirkungen \u00a0auf\u00a0die\u00a0Nieren\u2010\u00a0und\u00a0Leberfunktion, \u00a0auf\u00a0den\u00a0\nKnochenstoffwechsel \u00a0und\u00a0auf\u00a0verschiedene \u00a0Krebserkrankungen \u00a0(Blase,\u00a0Prostata\u00a0und\u00a0Brust)\u00a0weiter\u00a0\nunter\u00a0Beobachtung \u00a0bleiben\u00a0(DTBn,\u00a02014).\u00a0\u00a0\n\u00a0\nLeitlinienempfehlungen \u00a0\nDie\u00a0aktuelle\u00a0Nationale \u00a0Versorgungsleitlinie \u00a0wurde\u00a0unter\u00a0Beteiligung \u00a0verschiedener \u00a0\nFachgesellschaften \u00a0und\u00a0mit\u00a0Ber\u00fccksichtigung \u00a0der\u00a0Kriterien\u00a0einer\u00a0Evidenz\u2010basierten \u00a0Medizin\u00a0\nerarbeitet. \u00a0Beteiligt\u00a0waren\u00a0unter\u00a0anderem\u00a0die\u00a0Arzneimittelkommission \u00a0der\u00a0deutschen \u00a0\u00c4rzteschaft \u00a0\n(AKD\u00c4),\u00a0die\u00a0Deutsche \u00a0Diabetes\u00a0Gesellschaft \u00a0und\u00a0die\u00a0Deutsche \u00a0Gesellschaft \u00a0f\u00fcr\u00a0Allgemeinmedizin \u00a0und\u00a0\nFamilienmedizin \u00a0(NVL\u00a0Diabetes, \u00a02013).\u00a0Auf\u00a0Grundlage \u00a0der\u00a0vorhandenen \u00a0Evidenz\u00a0wird\u00a0Metformin \u00a0von\u00a0\nallen\u00a0Beteiligten \u00a0als\u00a0Mittel\u00a0der\u00a0ersten\u00a0Wahl\u00a0bei\u00a0der\u00a0antidiabetischen \u00a0Therapie\u00a0bewertet, \u00a0wenn\u00a0Di\u00e4t\u00a0\nund\u00a0Bewegung \u00a0keine\u00a0ausreichenden \u00a0blutzuckersenkenden \u00a0Effekte\u00a0zeigen.\u00a0Bei\u00a0den\u00a0\nSulfonylharnstoffen \u00a0wird\u00a0insbesondere \u00a0f\u00fcr\u00a0Glibenclamid \u00a0und\u00a0Gliclazid\u00a0eine\u00a0Wirksamkeit \u00a0auf\u00a0\nmikrovaskul\u00e4re \u00a0Ereignisse \u00a0als\u00a0nachgewiesen \u00a0angesehen. \u00a0Bei\u00a0den\u00a0oralen\u00a0Antidiabetika \u00a0werden\u00a0sie\u00a0\naufgrund\u00a0der\u00a0vorhandenen \u00a0Nutzenbelege \u00a0als\u00a0Mittel\u00a0der\u00a0zweiten\u00a0Wahl\u00a0empfohlen, \u00a0falls\u00a0Metformin \u00a0\nnicht\u00a0gegeben\u00a0werden\u00a0kann.\u00a0Bez\u00fcglich \u00a0einer\u00a0Kombinationstherapie \u00a0oraler\u00a0Antidiabetika \u00a0gehen\u00a0die\u00a0\nMeinungen \u00a0der\u00a0Fachgesellschaften \u00a0auseinander. \u00a0F\u00fcr\u00a0die\u00a0Kombination \u00a0aus\u00a0Metformin \u00a0und\u00a0\nSulfonylharnstoff \u00a0finden\u00a0sich\u00a0Hinweise\u00a0auf\u00a0eine\u00a0m\u00f6glicherweise \u00a0erh\u00f6hte\u00a0kardiovaskul\u00e4re \u00a0Mortalit\u00e4t. \u00a0\nAKD\u00c4\u00a0und\u00a0DEGAM\u00a0empfehlen \u00a0zur\u00a0Kombinationsbehandlung \u00a0daher\u00a0in\u00a0erster\u00a0Linie\u00a0die\u00a0gemeinsame \u00a0\nVerabreichung \u00a0von\u00a0Metformin \u00a0und\u00a0Insulin,\u00a0w\u00e4hrend\u00a0die\u00a0diabetischen \u00a0Fachgesellschaften \u00a0eine\u00a0\nindividuelle \u00a0Entscheidung \u00a0aufgrund\u00a0von\u00a0Patientenpr\u00e4ferenzen \u00a0und\u00a0Therapiezielen \u00a0bevorzugen. \u00a0So\u00a0\nwerden\u00a0SLGT2\u2010Inhibitoren \u00a0beispielsweise \u00a0als\u00a0empfehlenswerte \u00a0Kombinationspartner \u00a0zus\u00e4tzlich \u00a0zu\u00a0\nMetformin \u00a0bei\u00a0Patienten \u00a0mit\u00a0erheblichen \u00a0Gewichtsproblemen, \u00a0Neigung\u00a0zu\u00a0Hypoglyk\u00e4mien \u00a0und\u00a0\nKomorbidit\u00e4ten \u00a0dargestellt. \u00a0In\u00a0diesen\u00a0F\u00e4llen\u00a0wird\u00a0von\u00a0den\u00a0beurteilenden \u00a0Fachgesellschaften \u00a0der\u00a0\nEinsatz\u00a0von\u00a0z.\u00a0B.\u00a0Sulfonylharnstoffen \u00a0eher\u00a0negativ\u00a0bewertet. \u00a0\u00a0 \n193\u00a0\n\u00a0\nHintergrundinformationen \u00a0Nutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDapagliflozin \u00a0wurde\u00a0im\u00a0Jahr\u00a02013\u00a0bzgl.\u00a0seines\u00a0Zusatznutzens \u00a0in\u00a0der\u00a0antidiabetischen \u00a0Therapie\u00a0\nbewertet. \u00a0F\u00fcr\u00a0die\u00a0Monotherapie, \u00a0wenn\u00a0eine\u00a0Behandlung \u00a0mit\u00a0Metformin \u00a0nicht\u00a0m\u00f6glich\u00a0ist,\u00a0wird\u00a0als\u00a0\nzweckm\u00e4\u00dfige \u00a0Vergleichstherapie \u00a0ein\u00a0Sulfonylharnstoff \u00a0(Glibenclamid \u00a0oder\u00a0Glimepirid) \u00a0herangezogen. \u00a0\nDie\u00a0(fixe)\u00a0Kombination \u00a0aus\u00a0Dapagliflozin \u00a0und\u00a0Metformin \u00a0bzw.\u00a0Dapagliflozin \u00a0und\u00a0Sulfonylharnstoff \u00a0\nsollte\u00a0gegen\u00fcber \u00a0einer\u00a0Kombination \u00a0aus\u00a0Sulfonylharnstoff \u00a0(Glibenclamid \u00a0oder\u00a0Glimepirid) \u00a0und\u00a0\nMetformin \u00a0einen\u00a0zus\u00e4tzlichen \u00a0Nutzen\u00a0besitzen.\u00a0Die\u00a0Kombination \u00a0aus\u00a0Dapagliflozin \u00a0und\u00a0Insulin\u00a0oder\u00a0\neinem\u00a0insulinhaltigen \u00a0Therapieregime \u00a0sollte\u00a0gegen\u00fcber \u00a0Insulin\u00a0alleine\u00a0oder\u00a0einer\u00a0Kombination \u00a0aus\u00a0\nMetformin \u00a0und\u00a0Insulin\u00a0einen\u00a0therapeutischen \u00a0Vorteil\u00a0aufzeigen. \u00a0Da\u00a0der\u00a0pU\u00a0keine\u00a0geeigneten \u00a0Daten\u00a0\nzur\u00a0Beurteilung \u00a0der\u00a0Vor\u2010\u00a0und\u00a0Nachteile \u00a0von\u00a0Dapagliflozin \u00a0vorlegen\u00a0konnte,\u00a0wurde\u00a0durch\u00a0das\u00a0IQWiG\u00a0\nf\u00fcr\u00a0keines\u00a0der\u00a0genannten \u00a0Anwendungsgebiete \u00a0ein\u00a0Zusatznutzen \u00a0festgestellt \u00a0(IQWiG,\u00a02013c).\u00a0Dieser\u00a0\nAnsicht\u00a0folgte\u00a0der\u00a0Gemeinsame \u00a0Bundesausschuss \u00a0in\u00a0seiner\u00a0Beschlussfassung \u00a0vom\u00a06.\u00a0Juni\u00a02013\u00a0und\u00a0\nstellte\u00a0fest,\u00a0dass\u00a0weder\u00a0f\u00fcr\u00a0die\u00a0Monotherapie \u00a0mit\u00a0Dapagliflozin \u00a0noch\u00a0f\u00fcr\u00a0die\u00a0Kombinationstherapie \u00a0\nvon\u00a0Dapagliflozin \u00a0mit\u00a0Metformin, \u00a0mit\u00a0einem\u00a0Sulfonylharnstoff \u00a0oder\u00a0mit\u00a0Insulin\u00a0ein\u00a0Zusatznutzen \u00a0\nbelegt\u00a0ist\u00a0(G\u2010BA,\u00a02013e).\u00a0Der\u00a0G\u2010BA\u00a0akzeptiert \u00a0das\u00a0Abweichen \u00a0von\u00a0der\u00a0vorgeschlagenen \u00a0\nVergleichstherapie \u00a0durch\u00a0den\u00a0pU\u00a0nicht\u00a0und\u00a0nennt\u00a0als\u00a0Begr\u00fcndung, \u00a0dass\u00a0das\u00a0m\u00f6gliche\u00a0Auftreten \u00a0von\u00a0\nEffekten\u00a0wie\u00a0eine\u00a0Gewichtszunahme \u00a0oder\u00a0Hypoglyk\u00e4mien \u00a0nicht\u00a0dazu\u00a0f\u00fchrt,\u00a0dass\u00a0eine\u00a0\nSulfonylharnstofftherapie \u00a0kontraindiziert \u00a0ist\u00a0und\u00a0als\u00a0zweckm\u00e4\u00dfige \u00a0Vergleichstherapie \u00a0nicht\u00a0mehr\u00a0\ninfrage\u00a0kommt\u00a0(G\u2010BA,\u00a02013e).\u00a0All\u00a0diese\u00a0Feststellungen \u00a0gelten\u00a0auch\u00a0f\u00fcr\u00a0die\u00a0Fixkombination \u00a0aus\u00a0\nDapagliflozin \u00a0und\u00a0Metformin \u00a0(Xigduo\u00ae, \u00a0G\u2010BA,\u00a02014b).\u00a0\nZeitweilig \u00a0setzte\u00a0der\u00a0pU\u00a0im\u00a0Anschluss \u00a0an\u00a0die\u00a0beh\u00f6rdliche \u00a0Stellungnahme \u00a0die\u00a0Produkte\u00a0au\u00dfer\u00a0Vertrieb.\u00a0\nErst\u00a0nach\u00a0einer\u00a0Einigung\u00a0in\u00a0den\u00a0Preisverhandlungen \u00a0waren\u00a0die\u00a0Mittel\u00a0wieder\u00a0im\u00a0deutschen \u00a0\nArzneimittelmarkt \u00a0verf\u00fcgbar. \u00a0\u00a0\n\u00a0\nKosten\u00a0\nWirkstof f\u00a0 Behandlungsmodus Behandlungstage Jahrestherapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nDapagliflozin  1\u00a0x\u00a0t\u00e4glich\u00a010\u00a0mg 360 424,80\u00a0\u20ac\nVergleichstherapie  \u00a0\nGlibenclamid  2\u00a0x\u00a0t\u00e4glich\u00a03,5\u00a0mg 360 59,72\u00a0\u20ac\nGlimepirid  1\u00a0x\u00a0t\u00e4glich\u00a02\u00a0mg 360 52,62\u00a0\u20ac\nTabelle\u00a033:\u00a0Jahrestherapiekosten \u00a0(Monotherapie) \u00a0von\u00a0Dapagliflozin \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0\n(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0\n \n \u00a0\u00a0\n194\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a011.9 Decitabin \u00a0\nHandelsname: \u00a0Dacogen\u00ae     Hersteller: \u00a0Janssen\u00a0Cilag \nIndikation: \u00a0Akute\u00a0myeloische \u00a0Leuk\u00e4mie   Markteinf\u00fchrung: \u00a0November \u00a02012 \nATC\u2010Code:\u00a0L01BC08\u00a0    DDD:\u00a06,43\u00a0mg \nDarreichungsform: \u00a0Pulver\u00a0zur\u00a0Herstellung \u00a0einer\u00a0Infusionsl\u00f6sung  \nBewertung: \u00a0siehe\u00a0Seite\u00a061 \nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nDecitabin \u00a0ist\u00a0ein\u00a0Cytidin\u2010Desoxynucleosid \u2010Analogon \u00a0mit\u00a0einem\u00a0dualen\u00a0Wirkungsmechanismus. \u00a0Nach\u00a0\nintrazellul\u00e4rer \u00a0Umwandlung \u00a0zum\u00a0Triphosphat \u00a0wird\u00a0es\u00a0als\u00a0Antimetabolit \u00a0in\u00a0die\u00a0DNA\u00a0eingebaut \u00a0und\u00a0\nst\u00f6rt\u00a0als\u00a0klassisches \u00a0Zytostatikum \u00a0die\u00a0Zellproliferation. \u00a0Zudem\u00a0hemmt\u00a0es\u00a0die\u00a0DNA\u2010Methyltransferase, \u00a0\nein\u00a0Enzym,\u00a0welches\u00a0die\u00a0Promoterregion \u00a0von\u00a0Tumorsuppressorgenen \u00a0methyliert \u00a0und\u00a0das\u00a0Ablesen\u00a0\ndieser\u00a0Gene\u00a0hemmt.\u00a0Der\u00a0biochemische \u00a0Prozess\u00a0der\u00a0DNA\u2010Methylierung \u00a0spielt\u00a0eine\u00a0wichtige\u00a0Rolle\u00a0bei\u00a0\nder\u00a0Regulation \u00a0der\u00a0Gentranskription. \u00a0Bei\u00a0einer\u00a0Hypermethylierung \u00a0als\u00a0epigenetische \u00a0Mutation \u00a0ist\u00a0die\u00a0\nTranskription \u00a0von\u00a0Tumorsuppressorgenen \u00a0reduziert\u00a0und\u00a0somit\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0maligne\u00a0Neoplasien \u00a0\nerh\u00f6ht.\u00a0Decitabin \u00a0f\u00fchrt\u00a0zu\u00a0einer\u00a0Hypomethylierung \u00a0neugebildeter \u00a0DNA,\u00a0wodurch\u00a0die\u00a0\nTumorsuppressorgene \u00a0reaktiviert \u00a0werden\u00a0und\u00a0ihre\u00a0Funktion\u00a0f\u00fcr\u00a0die\u00a0Kontrolle\u00a0von\u00a0Proliferation, \u00a0\nDifferenzierung \u00a0und\u00a0Apoptose \u00a0von\u00a0Knochenmarkzellen \u00a0wiederhergestellt \u00a0wird\u00a0(Janssen\u00a0Cilag,\u00a02014a;\u00a0\nEMA,\u00a02012).\u00a0Decitabin \u00a0ist\u00a0chemisch \u00a0verwandt \u00a0mit\u00a0Azacitidin \u00a0(Vidaza\u00ae), \u00a0das\u00a0im\u00a0Dezember \u00a02008\u00a0\nzugelassen \u00a0wurde\u00a0zur\u00a0Behandlung \u00a0von\u00a0Patienten \u00a0mit\u00a0bestimmten \u00a0Formen\u00a0des\u00a0Myelodysplastischen \u00a0\nSyndroms \u00a0(MDS),\u00a0der\u00a0AML\u00a0bis\u00a030\u00a0Prozent\u00a0Blasten\u00a0und\u00a0der\u00a0chronischen \u00a0myelomonozyt\u00e4ren \u00a0Leuk\u00e4mie. \u00a0\n\u00a0\nZulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nDacogen\u00ae \u00a0wurde\u00a0im\u00a0September \u00a02012\u00a0von\u00a0der\u00a0europ\u00e4ischen \u00a0Arzneimittel \u2010Agentur\u00a0EMA\u00a0zugelassen \u00a0\nund\u00a0ist\u00a0seit\u00a0November \u00a02012\u00a0auf\u00a0dem\u00a0deutschen \u00a0Markt.\u00a0Es\u00a0ist\u00a0indiziert\u00a0zur\u00a0Behandlung \u00a0von\u00a0\nerwachsenen \u00a0Patienten \u00a0ab\u00a0einem\u00a0Alter\u00a0von\u00a065\u00a0Jahren\u00a0mit\u00a0neu\u00a0diagnostizierter \u00a0de\u00a0novo\u00a0oder\u00a0\nsekund\u00e4rer \u00a0akuter\u00a0myeloischer \u00a0Leuk\u00e4mie \u00a0(AML)\u00a0gem\u00e4\u00df\u00a0der\u00a0Klassifikation \u00a0der\u00a0WHO,\u00a0f\u00fcr\u00a0die\u00a0eine\u00a0\nStandard\u2010Induktionstherapie \u00a0nicht\u00a0in\u00a0Frage\u00a0kommt.\u00a0Da\u00a0die\u00a0AML\u00a0als\u00a0seltene\u00a0Erkrankung \u00a0gilt,\u00a0wurde\u00a0\nDecitabin \u00a02006\u00a0von\u00a0der\u00a0EMA\u00a0als\u00a0Orphan\u00a0Drug\u00a0ausgewiesen. \u00a0Der\u00a0Wirkstoff \u00a0wird\u00a0in\u00a0vierw\u00f6chigen \u00a0\nZyklen\u00a0in\u00a0einer\u00a0Tagesdosis \u00a0von\u00a020\u00a0mg/m2\u00a0K\u00f6rperoberfl\u00e4che \u00a0an\u00a0f\u00fcnf\u00a0aufeinander \u00a0folgenden \u00a0Tagen\u00a0als\u00a0\neinst\u00fcndige \u00a0Infusion\u00a0intraven\u00f6s \u00a0verabreicht \u00a0(Janssen\u00a0Cilag,\u00a02014a;\u00a0EMA,\u00a02012d).\u00a0\u00a0\n\u00a0\nInformationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nDie\u00a0akute\u00a0myeloische \u00a0Leuk\u00e4mie \u00a0(AML)\u00a0kann\u00a0in\u00a0jedem\u00a0Lebensalter \u00a0auftreten. \u00a0Die\u00a0Inzidenz\u00a0betr\u00e4gt\u00a0ca.\u00a0\n3,7\u00a0Erkrankungen \u00a0pro\u00a0100.000\u00a0Einwohner \u00a0pro\u00a0Jahr,\u00a0steigt\u00a0aber\u00a0mit\u00a0dem\u00a0Alter\u00a0auf\u00a0mehr\u00a0als\u00a0100\u00a0F\u00e4lle\u00a0\npro\u00a0100.000\u00a0Einwohner \u00a0bei\u00a0\u00fcber\u00a070\u2010J\u00e4hrigen\u00a0an\u00a0(RKI\u00a0&\u00a0ZfKD,\u00a02013c).\u00a0\nEine\u00a0AML\u00a0f\u00fchrt\u00a0zu\u00a0einer\u00a0teils\u00a0massiven \u00a0Vermehrung \u00a0unreifer\u00a0Vorl\u00e4uferzellen \u00a0der\u00a0Myelopoese \u00a0im\u00a0\nKnochenmark \u00a0und\u00a0in\u00a0der\u00a0Mehrzahl \u00a0der\u00a0F\u00e4lle\u00a0auch\u00a0im\u00a0Blut.\u00a0Die\u00a0normale\u00a0H\u00e4matopoese \u00a0wird\u00a0verdr\u00e4ngt, \u00a0\nund\u00a0es\u00a0entsteht\u00a0ein\u00a0Mangel\u00a0an\u00a0Erythrozyten, \u00a0Thrombozyten \u00a0und\u00a0funktionsf\u00e4higen \u00a0Granulozyten. \u00a0Bei\u00a0\nden\u00a0meisten\u00a0Patienten \u00a0tritt\u00a0die\u00a0Erkrankung \u00a0ohne\u00a0eine\u00a0erkennbare \u00a0Ursache\u00a0auf\u00a0(de\u00a0novo\u2010AML).\u00a0Die\u00a0 \n195\u00a0\n\u00a0\nHintergrundinformationen \u00a0wesentlich \u00a0seltenere \u00a0sekund\u00e4re \u00a0AML\u00a0kann\u00a0sich\u00a0aus\u00a0einem\u00a0fr\u00fcheren\u00a0myelodysplastischen \u00a0Syndrom\u00a0\nentwickeln \u00a0oder\u00a0infolge\u00a0Chemotherapie, \u00a0Bestrahlung \u00a0oder\u00a0einer\u00a0Exposition \u00a0mit\u00a0Benzol\u00a0entstehen. \u00a0\nDie\u00a0Symptome \u00a0sind\u00a0vorwiegend \u00a0auf\u00a0die\u00a0Knochenmarkinsuffizienz \u00a0zur\u00fcckzuf\u00fchren \u00a0und\u00a0treten\u00a0\naufgrund\u00a0des\u00a0raschen\u00a0Verlaufs\u00a0erst\u00a0kurz\u00a0vor\u00a0der\u00a0Diagnosestellung \u00a0auf.\u00a0Bei\u00a0ungef\u00e4hr\u00a0der\u00a0H\u00e4lfte\u00a0der\u00a0\nBetroffenen \u00a0ist\u00a0Fatigue\u00a0das\u00a0Leitsymptom, \u00a0andere\u00a0Symptome \u00a0sind\u00a0z.B.\u00a0Bl\u00e4sse,\u00a0Nachtschwei\u00df, \u00a0\nBlutungen, \u00a0Fieber,\u00a0unterschiedliche \u00a0Infektionen, \u00a0Stomatitis \u00a0und\u00a0Mundsoor. \u00a0Die\u00a0AML\u00a0ist\u00a0klinisch\u00a0und\u00a0\nbiologisch \u00a0heterogen. \u00a0Die\u00a0WHO\u2010Klassifikation \u00a0hat\u00a0die\u00a0vorher\u00a0gebr\u00e4uchliche \u00a0French\u2010American \u2010British\u00a0\n(FAB)\u00a0\u2013\u00a0Einteilung \u00a0abgel\u00f6st\u00a0und\u00a0unterscheidet \u00a0zahlreiche \u00a0Subtypen \u00a0anhand\u00a0von\u00a0Morphologie, \u00a0\nImmunph\u00e4notyp \u00a0und\u00a0klinischen \u00a0Merkmalen \u00a0sowie\u00a0zytogenetischen \u00a0und\u00a0molekularen \u00a0Anomalien. \u00a0\nDie\u00a0Behandlung \u00a0sowohl\u00a0einer\u00a0de\u00a0novo\u00a0als\u00a0auch\u00a0einer\u00a0sekund\u00e4ren \u00a0AML\u00a0ist\u00a0\u00fcblicherweise \u00a0in\u00a0zwei\u00a0\nPhasen\u00a0aufgeteilt. \u00a0Zun\u00e4chst\u00a0wird\u00a0eine\u00a0intensive\u00a0Induktions \u2010Chemotherapie \u00a0mit\u00a0dem\u00a0Ziel\u00a0der\u00a0\nRemission \u00a0durchgef\u00fchrt, \u00a0anschlie\u00dfend \u00a0erfolgt\u00a0eine\u00a0Postremissionstherapie. \u00a0Bei\u00a0Patienten \u00a0unter\u00a060\u00a0\nJahren\u00a0liegen\u00a0die\u00a0Raten\u00a0kompletter \u00a0Remissionen \u00a0inzwischen \u00a0bei\u00a0\u00fcber\u00a070\u00a0Prozent,\u00a0die\u00a0Rate\u00a0\nanhaltender \u00a0Remissionen \u00a0nach\u00a0f\u00fcnf\u00a0Jahren\u00a0\u00fcber\u00a030\u00a0Prozent\u00a0(DGHO,\u00a02013b).\u00a0Die\u00a0Prognose \u00a0f\u00fcr\u00a0\u00e4ltere\u00a0\nPatienten, \u00a0bei\u00a0denen\u00a0h\u00e4ufiger\u00a0eine\u00a0Chemotherapie \u2010Resistenz \u00a0und\u00a0zudem\u00a0eine\u00a0erh\u00f6hte\u00a0Therapie\u2010\nassoziierte \u00a0Mortalit\u00e4t \u00a0unter\u00a0der\u00a0intensiven \u00a0zytostatischen \u00a0Therapie\u00a0auftritt,\u00a0ist\u00a0weitaus\u00a0schlechter. \u00a0\n\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDie\u00a0Zulassungsstudie \u00a0ist\u00a0eine\u00a0offen\u00a0randomisierte \u00a0Phase\u2010III\u2010Studie\u00a0an\u00a0485\u00a0Patienten \u00a0\u2265\u00a065\u00a0Jahre\u00a0mit\u00a0\nneu\u00a0diagnostizierter \u00a0de\u00a0novo\u00a0oder\u00a0sekund\u00e4rer \u00a0AML,\u00a0die\u00a0eine\u00a0Zytogenetik \u00a0mit\u00a0schlechtem \u00a0oder\u00a0\nmittelm\u00e4\u00dfigem \u00a0Risikoprofil \u00a0aufwiesen. \u00a0242\u00a0Patienten \u00a0erhielten\u00a0Decitabin \u00a0(20mg/m2\u00a0t\u00e4glich\u00a0als\u00a0\neinst\u00fcndige \u00a0i.v.\u2010Infusion\u00a0an\u00a0f\u00fcnf\u00a0Tagen\u00a0alle\u00a0vier\u00a0Wochen), \u00a0die\u00a0243\u00a0Patienten \u00a0der\u00a0Vergleichsgruppe \u00a0\nbekamen \u00a0\u00fcberwiegend \u00a0niedrig\u00a0dosiertes \u00a0Cytarabin \u00a0(20mg/m2\u00a0t\u00e4glich\u00a0subkutan \u00a0an\u00a0zehn\u00a0Tagen\u00a0alle\u00a0\nvier\u00a0Wochen), \u00a0knapp\u00a0zw\u00f6lf\u00a0Prozent\u00a0alleinige\u00a0supportive \u00a0Ma\u00dfnahmen. \u00a0Zum\u00a0prim\u00e4ren \u00a0\nErhebungszeitpunkt \u00a0konnte\u00a0mit\u00a0Decitabin \u00a0eine\u00a0statistisch \u00a0nicht\u00a0signifikante \u00a0Verl\u00e4ngerung \u00a0der\u00a0\nGesamt\u00fcberlebenszeit \u00a0um\u00a02,7\u00a0Monate\u00a0beobachtet \u00a0werden,\u00a0die\u00a0zum\u00a0ungeplanten \u00a0Analysezeitpunkt \u00a0\nein\u00a0Jahr\u00a0sp\u00e4ter\u00a0Signifikanz \u00a0erreichte. \u00a0Den\u00a0sekund\u00e4ren \u00a0Endpunkt \u00a0einer\u00a0kompletten \u00a0Remission \u00a0\nerreichten \u00a017,8\u00a0Prozent\u00a0der\u00a0Patienten \u00a0mit\u00a0Decitabin \u00a0vs.\u00a07,8\u00a0Prozent\u00a0der\u00a0Vergleichsgruppe, \u00a0das\u00a0\nprogressionsfreie \u00a0\u00dcberleben \u00a0war\u00a0mit\u00a03,7\u00a0Monaten\u00a0vs.\u00a02,1\u00a0Monaten\u00a0unter\u00a0Decitabin \u00a0l\u00e4nger\u00a0(Kantarjian \u00a0\net\u00a0al.,\u00a02012).\u00a0In\u00a0einer\u00a0ersten\u00a0einarmigen \u00a0Phase\u2010II\u2010Studie\u00a0mit\u00a0Decitabin \u00a0als\u00a0Initialtherapie \u00a0an\u00a055\u00a0\nPatienten \u00a0\u2265 \u00a0 60\u00a0Jahre\u00a0mit\u00a0AML\u00a0erreichte\u00a0fast\u00a0ein\u00a0Viertel\u00a0eine\u00a0komplette \u00a0Remission, \u00a0die\u00a0\ndurchschnittlich \u00a018,2\u00a0Monate\u00a0anhielt.\u00a0Das\u00a0Gesamt\u00fcberleben \u00a0lag\u00a0bei\u00a07,6\u00a0Monaten. \u00a0Als\u00a0sehr\u00a0h\u00e4ufige\u00a0\nNebenwirkungen \u00a0traten\u00a0vor\u00a0allem\u00a0Myelosuppression \u00a0und\u00a0damit\u00a0verbunden \u00a0Thrombozytopenie, \u00a0\nNeutropenie \u00a0mit\u00a0und\u00a0ohne\u00a0Fieber\u00a0und\u00a0An\u00e4mie\u00a0sowie\u00a0Pneumonie \u00a0auf.\u00a0Das\u00a0Sicherheitsprofil \u00a0von\u00a0\nDecitabin \u00a0\u00e4hnelt\u00a0dem\u00a0von\u00a0niedrig\u00a0dosiertem \u00a0Cytarabin, \u00a0allerdings \u00a0traten\u00a0Infektionen \u00a0und\u00a0\nNeutropenie \u00a0unter\u00a0dem\u00a0neueren\u00a0Wirkstoff \u00a0h\u00e4ufiger\u00a0auf\u00a0(EMA,\u00a02012d).\u00a0\nAktuelle\u00a0Untersuchungen \u00a0geben\u00a0Hinweise\u00a0auf\u00a0eine\u00a0m\u00f6gliche\u00a0Unterlegenheit \u00a0des\u00a0neuen\u00a0Wirkstoffes \u00a0\ngegen\u00fcber \u00a0Azacitidin \u00a0bzw.\u00a0niedrig\u00a0dosiertem \u00a0Cytarabin. \u00a0Xie\u00a0et\u00a0al.\u00a0(2015)\u00a0untersuchten \u00a0in\u00a0ihrer\u00a0\nMetaanalyse \u00a0Wirksamkeit, \u00a0Sicherheit \u00a0und\u00a0\u00dcberlebensvorteil \u00a0von\u00a0Decitabin \u00a0im\u00a0Vergleich \u00a0zu\u00a0Azacitidin \u00a0\nzur\u00a0Behandlung \u00a0des\u00a0Myelodysplastischen \u00a0Syndroms. \u00a0Die\u00a0gepoolten \u00a0Sch\u00e4tzungen \u00a0ergaben\u00a0eine\u00a0h\u00f6here\u00a0\nSignifikanz \u00a0f\u00fcr\u00a0Azacitidin \u00a0im\u00a0Vergleich \u00a0zu\u00a0Decitabin \u00a0hinsichtlich \u00a0partieller\u00a0Remission, \u00a0h\u00e4matologischer \u00a0\nVerbesserung \u00a0und\u00a0der\u00a0allgemeinen \u00a0Ansprechrate. \u00a0Aus\u00a0diesem\u00a0Grund\u00a0empfehlen \u00a0die\u00a0Autoren\u00a0\u00a0\n196\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Azacitidin \u00a0als\u00a0First\u2010Line\u2010Agent\u00a0insbesondere \u00a0bei\u00a0\u00e4lteren\u00a0Patienten \u00a0oder\u00a0solchen\u00a0mit\u00a0einem\u00a0erh\u00f6hten \u00a0\nRisiko.\u00a0Eine\u00a0weitere\u00a0Untersuchung \u00a0konnte\u00a0ebenfalls\u00a0keine\u00a0statistisch \u00a0signifikanten \u00a0Unterschiede \u00a0\nzwischen\u00a0niedrig\u00a0dosiertem \u00a0Cytarabin \u00a0und\u00a0Decitabin \u00a0feststellen. \u00a0Auch\u00a0hier\u00a0traten\u00a0in\u00a0beiden\u00a0\nBehandlungsgruppen \u00a0schwerwiegende \u00a0Ereignisse \u00a0wie\u00a0Neutropenie, \u00a0Thrombozytopenie, \u00a0An\u00e4mie,\u00a0\nInfektionen \u00a0(Lungenentz\u00fcndung) \u00a0und\u00a0Magen\u2010Darm\u2010St\u00f6rungen \u00a0auf\u00a0(Prescrire, \u00a02014a).\u00a0\u00a0\n\u00a0\nLeitlinienempfehlungen \u00a0\nWie\u00a0bei\u00a0j\u00fcngeren\u00a0Patienten, \u00a0wird\u00a0auch\u00a0bei\u00a0Patienten \u00a0\u00fcber\u00a060\u00a0Jahre\u00a0die\u00a0Standard\u2010Induktionstherapie, \u00a0\nbestehend \u00a0aus\u00a0der\u00a0dreit\u00e4gigen \u00a0Gabe\u00a0eines\u00a0Anthrazyklins, \u00a0z.B.\u00a0Daunorubicin, \u00a0und\u00a0der\u00a0siebent\u00e4gigen \u00a0\nkontinuierlichen \u00a0Infusion\u00a0von\u00a0Cytarabin \u00a0(3+7\u2010Schema)\u00a0durchgef\u00fchrt. \u00a0Bei\u00a0Nicht\u2010Erreichen \u00a0des\u00a0Ziels\u00a0\neiner\u00a0kompletten \u00a0Remission \u00a0mit\u00a0weniger\u00a0als\u00a0f\u00fcnf\u00a0Prozent\u00a0Blasten\u00a0im\u00a0Knochenmark \u00a0kann\u00a0sich\u00a0ein\u00a0\nzweiter\u00a0Zyklus\u00a0anschlie\u00dfen. \u00a0Auch\u00a0die\u00a0Konsolidierungstherapie \u00a0erfolgt\u00a0wie\u00a0bei\u00a0J\u00fcngeren\u00a0mit\u00a0\nhochdosiertem \u00a0Cytarabin, \u00a0unter\u00a0Ber\u00fccksichtigung \u00a0von\u00a0Komorbidit\u00e4ten \u00a0und\u00a0insbesondere \u00a0der\u00a0ZNS\u2010\nToxizit\u00e4t\u00a0des\u00a0Zytostatikums \u00a0jedoch\u00a0oft\u00a0mit\u00a0geringeren \u00a0Dosierungen \u00a0und\u00a0weniger\u00a0Zyklen.\u00a0F\u00fcr\u00a0geeignete \u00a0\nPatienten \u00a0ist\u00a0alternativ \u00a0ebenso\u00a0die\u00a0dosisreduzierte \u00a0allogene\u00a0Stammzelltransplantation \u00a0eine\u00a0Option.\u00a0\nBei\u00a0nicht\u2010intensiv\u00a0behandelbaren \u00a0\u00e4lteren\u00a0Patienten \u00a0mit\u00a0niedrigproliferierender \u00a0AML\u00a0mit\u00a0bis\u00a0zu\u00a030\u00a0\nProzent\u00a0Knochenmarkblasten \u00a0gilt\u00a0die\u00a0ambulant \u00a0durchf\u00fchrbare \u00a0Therapie\u00a0mit\u00a0dem\u00a0\nhypomethylierenden \u00a0Antimetaboliten \u00a05\u2010Azacitidin \u00a0(75mg/m\u00b2 \u00a0s.c.\u00a0einmal\u00a0t\u00e4glich\u00a0\u00fcber\u00a0sieben\u00a0Tage\u00a0alle\u00a0\nvier\u00a0Wochen)\u00a0als\u00a0momentaner \u00a0Standard. \u00a0Patienten, \u00a0f\u00fcr\u00a0die\u00a0weder\u00a0eine\u00a0intensive\u00a0Induktionstherapie \u00a0\nnoch\u00a0eine\u00a0hypomethylierende \u00a0Therapie\u00a0infrage\u00a0kommt,\u00a0wird\u00a0niedrigdosiertes \u00a0Cytarabin \u00a0(10mg/m\u00b2 \u00a0\ns.c.\u00a0zweimal\u00a0t\u00e4glich\u00a0\u00fcber\u00a0zehn\u00a0Tage\u00a0alle\u00a0vier\u00a0Wochen)\u00a0empfohlen. \u00a0\nF\u00fcr\u00a0nicht\u2010intensiv\u00a0behandelbare \u00a0Patienten \u00a0mit\u00a0mehr\u00a0als\u00a030\u00a0Prozent\u00a0Knochenmarkblasten \u00a0und\u00a0\nzytogenetischen \u00a0Hochrisiko \u2010Ver\u00e4nderungen \u00a0existiert\u00a0keine\u00a0Standard\u2010Therapie\u00a0(Krug\u00a0et\u00a0al.,\u00a02011).\u00a0\n\u00a0\nNutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nF\u00fcr\u00a0Decitabin \u00a0als\u00a0Orphan\u2010Arzneimittel \u00a0gilt\u00a0der\u00a0Zusatznutzen \u00a0durch\u00a0die\u00a0Zulassung \u00a0als\u00a0belegt.\u00a0Trotz\u00a0der\u00a0\nSchwere\u00a0der\u00a0Erkrankung \u00a0AML\u00a0und\u00a0der\u00a0mangelnden \u00a0Therapieoptionen \u00a0f\u00fcr\u00a0\u00e4ltere\u00a0Patienten \u00a0konstatiert \u00a0\nder\u00a0G\u2010BA\u00a0nur\u00a0einen\u00a0geringen\u00a0Zusatznutzen \u00a0f\u00fcr\u00a0Decitabin. \u00a0Dieser\u00a0ergibt\u00a0sich\u00a0aus\u00a0der\u00a0Verl\u00e4ngerung \u00a0der\u00a0\nmedianen \u00a0\u00dcberlebensdauer \u00a0um\u00a02,7\u00a0Monate\u00a0gegen\u00fcber \u00a0der\u00a0Vergleichsgruppe \u00a0in\u00a0der\u00a0\nZulassungsstudie, \u00a0was\u00a0vor\u00a0dem\u00a0Hintergrund \u00a0der\u00a0Aggressivit\u00e4t \u00a0und\u00a0des\u00a0Schweregrades \u00a0der\u00a0Erkrankung \u00a0\nals\u00a0moderate \u00a0Verbesserung \u00a0des\u00a0therapierelevanten \u00a0Nutzens\u00a0gesehen\u00a0wird.\u00a0Unsicherheiten \u00a0in\u00a0der\u00a0\nstatistischen \u00a0Analyse,\u00a0die\u00a0fragliche\u00a0\u00dcbertragbarkeit \u00a0der\u00a0Studiendaten \u00a0auf\u00a0die\u00a0deutsche\u00a0\nVersorgungssituation \u00a0sowie\u00a0fehlende\u00a0valide\u00a0Aussagen \u00a0bez\u00fcglich \u00a0Morbidit\u00e4t \u00a0und\u00a0Lebensqualit\u00e4t \u00a0\nverhindern \u00a0die\u00a0Einstufung \u00a0als\u00a0betr\u00e4chtlichen \u00a0Zusatznutzen \u00a0(G\u2010BA,\u00a02013f).\u00a0\n\u00a0\u00a0 \n197\u00a0\n\u00a0\nHintergrundinformationen \u00a0Kosten\u00a0\nWirkstof f\u00a0 Behandlungsmodus Behandlungstage Jahrestherapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nDecitabin  In\u00a0Zyklen:\u00a01\u00a0Zyklus\u00a0=\u00a05\u00a0Tage\u00a0\n1\u00a0x\u00a0t\u00e4glich\u00a020\u00a0mg/m2\u00a0pro\u00a0\nZyklus.\u00a0Insgesamt \u00a012\u00a0Zyklen.\u00a060 89.899,20 \u00a0\u20ac\nVergleichstherapie  \u00a0\nAzacitidin  In\u00a0Zyklen:\u00a01\u00a0Zyklus\u00a0=\u00a07\u00a0Tage\u00a0\n1\u00a0x\u00a0t\u00e4glich\u00a075\u00a0mg/m2\u00a0pro\u00a0\nZyklus.\u00a0Insgesamt \u00a012\u00a0Zyklen.\u00a084 78.309,84 \u00a0\u20ac\nDosis\u2010Berechnung \u00a0mit\u00a0einer\u00a0K\u00f6rperoberfl\u00e4che \u00a0(KOF)\u00a0von\u00a01,73\u00a0m2 \nTabelle\u00a034:\u00a0Jahrestherapiekosten \u00a0von\u00a0Decitabin \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0Kosten\u00a0\nzus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0\n \u00a0\u00a0\n198\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a011.10  Ivacaftor\u00a0\nHandelsname: \u00a0Kalydeco\u00ae     Hersteller: \u00a0Vertex  \nIndikation: \u00a0Zystische\u00a0Fibrose\u00a0(Mukoviszidose) \u00a0 Markteinf\u00fchrung: \u00a0August\u00a02012 \nATC\u2010Code:\u00a0R07AX02\u00a0    DDD:\u00a00,3\u00a0g \nDarreichungsform: \u00a0Filmtablette  \nBewertung: \u00a0siehe\u00a0Seite\u00a065\u00a0\nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nIvacaftor\u00a0ist\u00a0der\u00a0erste\u00a0Vertreter \u00a0einer\u00a0neuen\u00a0Wirkstoffgruppe \u00a0und\u00a0wirkt\u00a0als\u00a0Potentiator \u00a0des\u00a0Cystic\u00a0\nFibrosis\u00a0Transmembrane \u00a0Conductance \u00a0Regulators \u00a0(CFTR).\u00a0CFTR\u00a0ist\u00a0ein\u00a0integrales \u00a0Protein\u00a0in\u00a0den\u00a0\nMembranen \u00a0sekretorischer \u00a0Epithelzellen, \u00a0das\u00a0zu\u00a0den\u00a0cAMP\u2010regulierten \u00a0Ionenkan\u00e4len \u00a0geh\u00f6rt.\u00a0CFTR\u2010\nKan\u00e4le\u00a0werden\u00a0vor\u00a0allem\u00a0in\u00a0Lunge,\u00a0Nieren,\u00a0Schwei\u00dfdr\u00fcsen \u00a0und\u00a0in\u00a0der\u00a0Bauchspeicheldr\u00fcse \u00a0exprimiert. \u00a0\nFunktionelle \u00a0Einschr\u00e4nkungen \u00a0des\u00a0Kanals\u00a0f\u00fchren\u00a0zu\u00a0ver\u00e4nderten \u00a0Ionenstr\u00f6men, \u00a0insbesondere \u00a0der\u00a0\nChloridausstrom \u00a0bzw.\u00a0der\u00a0Chlorid\u2010Bikarbonat \u2010Cotransport \u00a0aus\u00a0der\u00a0Epithelzelle \u00a0ist\u00a0beeintr\u00e4chtigt. \u00a0\nStrukturelle \u00a0Ver\u00e4nderungen \u00a0im\u00a0CFTR\u2010Protein\u00a0treten\u00a0in\u00a0Folge\u00a0von\u00a0Genmutationen \u00a0auf.\u00a0F\u00fcr\u00a0das\u00a0CFTR\u2010\nGen\u00a0sind\u00a0bereits\u00a0vielf\u00e4ltige \u00a0Genmutationen \u00a0bekannt,\u00a0von\u00a0denen\u00a0aber\u00a0nur\u00a0wenigen\u00a0eine\u00a0funktionelle \u00a0\nBedeutung \u00a0zugeordnet \u00a0werden\u00a0kann.\u00a0Man\u00a0unterscheidet \u00a0insgesamt \u00a0sechs\u00a0verschiedene \u00a0\nMutationsklassen. \u00a0CFTR\u2010Gen\u2010Mutationen \u00a0von\u00a0Klasse\u00a0I\u00a0bis\u00a0III\u00a0werden\u00a0als\u00a0schwere\u00a0Ver\u00e4nderungen \u00a0\nangesehen, \u00a0bei\u00a0denen\u00a0die\u00a0Funktion\u00a0des\u00a0CFTR\u2010Kanals\u00a0nahezu\u00a0vollst\u00e4ndig \u00a0gehemmt \u00a0ist.\u00a0Bei\u00a0an\u00a0\nMukoviszidose \u00a0Erkrankten \u00a0aus\u00a0der\u00a0nordamerikanischen \u00a0oder\u00a0nordeurop\u00e4ischen \u00a0Bev\u00f6lkerung \u00a0treten\u00a0\nbei\u00a0etwa\u00a070\u00a0von\u00a0100\u00a0Klasse\u00a0II\u2010Mutationen \u00a0auf\u00a0(Fricke\u00a0&\u00a0Schwabe, \u00a02013).\u00a0Hierbei\u00a0wird\u00a0das\u00a0Protein\u00a0\nzwar\u00a0gebildet,\u00a0besitzt\u00a0aber\u00a0eine\u00a0fehlerhafte \u00a0Terti\u00e4rstruktur. \u00a0Es\u00a0wird\u00a0nicht\u00a0zur\u00a0Zellmembran \u00a0\ntransportiert \u00a0und\u00a0stattdessen \u00a0direkt\u00a0im\u00a0endoplasmatischen \u00a0Retikulum \u00a0abgebaut. \u00a0Bei\u00a0einer\u00a0deutlich\u00a0\ngeringeren \u00a0Anzahl,\u00a0n\u00e4mlich\u00a0bei\u00a0vier\u00a0bis\u00a0f\u00fcnf\u00a0von\u00a0100\u00a0Erkrankten, \u00a0spielen\u00a0Klasse\u00a0III\u2010Mutationen \u00a0eine\u00a0\nRolle,\u00a0bei\u00a0denen\u00a0das\u00a0fertige\u00a0Protein\u00a0zwar\u00a0in\u00a0die\u00a0Membran \u00a0eingebaut \u00a0wird,\u00a0aber\u00a0nicht\u00a0durch\u00a0cAMP\u00a0\noder\u00a0ATP\u00a0aktiviert\u00a0werden\u00a0kann\u00a0(App,\u00a02013).\u00a0Dadurch\u00a0wird\u00a0die\u00a0Regulation \u00a0der\u00a0Wasser\u00a0und\u00a0\nElektrolytstr\u00f6me \u00a0intra\u2010\u00a0und\u00a0extrazellul\u00e4r \u00a0behindert. \u00a0Geringe\u00a0extrazellul\u00e4re \u00a0Chlorid\u00a0und\u00a0Bikarbonat \u2010\nKonzentrationen \u00a0f\u00fchren\u00a0in\u00a0der\u00a0Lunge\u00a0\u00fcber\u00a0Dehydratation \u00a0und\u00a0Ver\u00e4nderung \u00a0der\u00a0L\u00f6slichkeit \u00a0luminaler \u00a0\nMucine\u00a0im\u00a0Extrazellularraum \u00a0zu\u00a0z\u00e4hfl\u00fcssigem \u00a0Bronchialsekret \u00a0und\u00a0einer\u00a0Verminderung \u00a0der\u00a0\nmukozili\u00e4ren \u00a0Clearance \u00a0(App,\u00a02013;\u00a0Fricke\u00a0&\u00a0Schwabe, \u00a02013).\u00a0\u00a0\nIvacaftor\u00a0besitzt\u00a0eine\u00a0einfache\u00a0chemische \u00a0Struktur.\u00a0Das\u00a0Molek\u00fcl\u00a0besteht\u00a0aus\u00a0einem\u00a0substituierten \u00a0\nPhenol,\u00a0das\u00a0\u00fcber\u00a0eine\u00a0Amidbr\u00fccke \u00a0mit\u00a0einer\u00a01,4\u2010Dihydrochinolin \u2010Struktur\u00a0verbunden \u00a0ist.\u00a0Bei\u00a0Einsatz\u00a0\nvon\u00a0Ivacaftor\u00a0ist\u00a0die\u00a0\u00d6ffnungswahrscheinlichkeit \u00a0mutationsbedingt \u00a0ver\u00e4nderter \u00a0CFTR\u2010Kan\u00e4le\u00a0erh\u00f6ht,\u00a0\nwodurch\u00a0sich\u00a0Elektrolyt \u2010\u00a0und\u00a0Wasserstr\u00f6me \u00a0normalisieren. \u00a0Der\u00a0zugrunde \u00a0liegende\u00a0Wirkmechanismus \u00a0\nist\u00a0allerdings \u00a0noch\u00a0nicht\u00a0vollst\u00e4ndig \u00a0gekl\u00e4rt\u00a0(Vertex,\u00a02015).\u00a0\u00a0\n\u00a0\nZulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nIvacaftor\u00a0ist\u00a0zugelassen \u00a0zur\u00a0Behandlung \u00a0der\u00a0zystischen \u00a0Fibrose\u00a0(CF,\u00a0Mukoviszidose), \u00a0wenn\u00a0gleichzeitig \u00a0\nGating\u2010Mutationen \u00a0der\u00a0Klasse\u00a0III\u00a0im\u00a0CFTR\u2010Gen\u00a0vorliegen. \u00a0Zu\u00a0diesen\u00a0z\u00e4hlen\u00a0G551D,\u00a0G1244E,\u00a0G1349D,\u00a0\nG178R,\u00a0G551S,\u00a0S1251N,\u00a0S1255P,\u00a0S549N\u00a0oder\u00a0S549R.\u00a0Das\u00a0Mittel\u00a0kann\u00a0bei\u00a0Kindern\u00a0und\u00a0Jugendlichen \u00a0ab\u00a0\neinem\u00a0Alter\u00a0von\u00a0sechs\u00a0Jahren\u00a0und\u00a0bei\u00a0Erwachsenen \u00a0eingesetzt \u00a0werden.\u00a0Bevor\u00a0mit\u00a0einer\u00a0Behandlung \u00a0\nmit\u00a0Ivacaftor\u00a0begonnen \u00a0wird,\u00a0ist\u00a0zur\u00a0Sicherung \u00a0des\u00a0sachgerechten \u00a0Einsatzes\u00a0der\u00a0Nachweis \u00a0mindestens \u00a0 \n199\u00a0\n\u00a0\nHintergrundinformationen \u00a0einer\u00a0Genmutation \u00a0mit\u00a0Hilfe\u00a0eines\u00a0validierten \u00a0Genotypisierungsprogramm \u00a0erforderlich \u00a0(Vertex,\u00a0\n2015).\u00a0\u00a0\nKalydeco\u00ae \u00a0ist\u00a0als\u00a0Orphan\u00a0Drug\u00a0durch\u00a0die\u00a0Europ\u00e4ische \u00a0Zulassungsbeh\u00f6rde \u00a0zugelassen \u00a0(EMA,\u00a02012e).\u00a0\nDas\u00a0Mittel\u00a0wird\u00a0zweimal\u00a0t\u00e4glich\u00a0zu\u00a0je\u00a0150\u00a0mg\u00a0oral\u00a0verabreicht. \u00a0Die\u00a0Einnahme \u00a0mit\u00a0Nahrung\u00a0kann\u00a0die\u00a0\nBioverf\u00fcgbarkeit \u00a0von\u00a0Ivacaftor\u00a0erh\u00f6hen,\u00a0daher\u00a0sollte\u00a0Kalydeco\u00ae \u00a0zu\u00a0den\u00a0Mahlzeiten \u00a0eingenommen \u00a0\nwerden.\u00a0Bei\u00a0Patienten \u00a0mit\u00a0moderater \u00a0und\u00a0schwerer \u00a0Leberfunktionsst\u00f6rung \u00a0wird\u00a0eine\u00a0Reduktion \u00a0der\u00a0\nTagesmaximaldosis \u00a0empfohlen. \u00a0Grapefruitsaft \u00a0und\u00a0CYP3A4\u2010\u00a0sowie\u00a0CYP3A5\u2010Inhibitoren \u00a0k\u00f6nnen\u00a0Abbau\u00a0\nund\u00a0Ausscheidung \u00a0von\u00a0Ivacaftor\u00a0hemmen, \u00a0wohingegen \u00a0Induktoren \u00a0die\u00a0Wirksamkeit \u00a0von\u00a0Ivacaftor\u00a0\nbeeintr\u00e4chtigen \u00a0k\u00f6nnen\u00a0(Vertex,\u00a02015).\u00a0\n\u00a0\nInformationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nMukoviszidose \u00a0geh\u00f6rt\u00a0zu\u00a0den\u00a0autosomal \u2010rezessiv\u00a0vererbten \u00a0Erkrankungen. \u00a0Sie\u00a0verl\u00e4uft\u00a0progredient \u00a0\nund\u00a0betrifft\u00a0als\u00a0Multiorganerkrankung \u00a0alle\u00a0exokrinen \u00a0Dr\u00fcsen.\u00a0Die\u00a0Erkrankung \u00a0wird\u00a0durch\u00a0Mutationen \u00a0\nam\u00a0Cystic\u00a0Fibrosis\u00a0Transmembrane \u00a0Conductance \u00a0Regulators \u00a0(CFTR)\u2010Gen\u00a0hervorgerufen. \u00a0Das\u00a0CFTR\u2010Gen\u00a0\nkodiert\u00a0ein\u00a0Protein,\u00a0das\u00a0als\u00a0transmembran\u00e4rer \u00a0Chloridkanal \u00a0in\u00a0Epithelzellen \u00a0zahlreicher \u00a0Dr\u00fcsen\u00a0und\u00a0\nSchleimh\u00e4ute \u00a0wie\u00a0Lunge,\u00a0Nieren\u00a0und\u00a0Pankreas\u00a0exprimiert \u00a0wird.\u00a0Fehlfunktionen \u00a0des\u00a0Proteins\u00a0f\u00fchren\u00a0\nzu\u00a0den\u00a0typischen \u00a0Krankheitszeichen \u00a0der\u00a0Mukoviszidose, \u00a0Kardinalsymptome \u00a0sind\u00a0chronisch \u2010\nobstruktive \u00a0Lungenerkrankung, \u00a0exokrine\u00a0Pankreasinsuffizienz \u00a0mit\u00a0Mangel\u2013\u00a0und\u00a0Unterern\u00e4hrung \u00a0\nsowie\u00a0erh\u00f6hter\u00a0Salzverlust \u00a0\u00fcber\u00a0die\u00a0Schwei\u00dfdr\u00fcsen. \u00a0Vordergr\u00fcndig \u00a0und\u00a0prognosebestimmend \u00a0sind\u00a0\nvor\u00a0allem\u00a0die\u00a0Funktionseinschr\u00e4nkungen \u00a0in\u00a0der\u00a0Lunge\u00a0(App,\u00a02013).\u00a0\u00a0\nIn\u00a0Deutschland \u00a0wird\u00a0die\u00a0Inzidenz\u00a0an\u00a0Mukoviszidose \u00a0Erkrankten \u00a0auf\u00a01:\u00a03.300\u00a0gesch\u00e4tzt \u00a0(Naehrlich \u00a0et\u00a0\nal.,\u00a02013),\u00a0ihre\u00a0absolute\u00a0Zahl\u00a0liegt\u00a0hierzulande \u00a0bei\u00a0etwa\u00a08.500.\u00a0Der\u00a0Anteil\u00a0an\u00a0Personen \u00a0mit\u00a0einer\u00a0\nKlasse\u00a0III\u2010Gating\u2010Mutation \u00a0des\u00a0CFTR\u2010Gens\u00a0liegt\u00a0bei\u00a0vier\u00a0bis\u00a0f\u00fcnf\u00a0Prozent.\u00a0Man\u00a0sch\u00e4tzt,\u00a0dass\u00a0etwa\u00a0170\u00a0\nPersonen \u00a0in\u00a0Deutschland \u00a0von\u00a0dem\u00a0f\u00fcr\u00a0Ivacaftor\u00a0zugelassenen \u00a0Indikationsgebiet \u00a0erfasst\u00a0werden.\u00a0\nDavon\u00a0sind\u00a027\u00a0Patienten \u00a0im\u00a0Alter\u00a0von\u00a0sechs\u00a0bis\u00a0elf\u00a0Jahren\u00a0(G\u2010BA,\u00a02013).\u00a0Mukoviszidose \u00a0geht\u00a0mit\u00a0einer\u00a0\ndeutlich\u00a0verk\u00fcrzten \u00a0Lebensdauer \u00a0einher.\u00a0Fr\u00fcher\u00a0verstarben \u00a0die\u00a0Betroffenen \u00a0h\u00e4ufig\u00a0schon\u00a0im\u00a0\nKindesalter. \u00a0Durch\u00a0die\u00a0therapeutischen \u00a0Fortschritte \u00a0liegt\u00a0der\u00a0Median\u00a0der\u00a0Lebenserwartung \u00a0bei\u00a0\nMukoviszidose \u2010Erkrankten \u00a0mittlerweile \u00a0bei\u00a0knapp\u00a040\u00a0Jahren\u00a0(Naehrlich \u00a0et\u00a0al.,\u00a02013).\u00a0\n\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nF\u00fcr\u00a0Kinder\u00a0unter\u00a0sechs\u00a0Jahren\u00a0liegen\u00a0keine\u00a0Daten\u00a0zu\u00a0Wirksamkeit \u00a0und\u00a0Vertr\u00e4glichkeit \u00a0vor.\u00a0Zum\u00a0\nNutzenbeleg \u00a0von\u00a0Ivacaftor\u00a0bei\u00a0Patienten \u00a0mit\u00a0Gating\u2010Mutation \u00a0G551D\u00a0wurden\u00a0drei\u00a0randomisierte \u00a0\nPhase\u2010III\u2010\u00a0sowie\u00a0eine\u00a0offene\u00a0Extensions \u2010Studie\u00a0durchgef\u00fchrt \u00a0(McKone\u00a0et\u00a0al.,\u00a02014;\u00a0Davies\u00a0et\u00a0al.,\u00a02013;\u00a0\nFlume\u00a0et\u00a0al.,\u00a02012;\u00a0Ramsey\u00a0et\u00a0al.,\u00a02011).\u00a0Die\u00a0Studienergebnisse \u00a0lassen\u00a0sich\u00a0auf\u00a0Patienten \u00a0\u00fcbertragen, \u00a0\ndie\u00a0auf\u00a0mindestens \u00a0einem\u00a0Allel\u00a0eine\u00a0G551D\u2010Mutation \u00a0aufweisen \u00a0und\u00a0an\u00a0einer\u00a0milden\u00a0bis\u00a0moderaten \u00a0\nLungenfunktionseinschr\u00e4nkung \u00a0leiden.\u00a0Patienten \u00a0mit\u00a0schwerer\u00a0Lungenerkrankung \u00a0(z.B.\u00a0FEV1%\u00a0<\u00a040\u00a0\nProzent)\u00a0waren\u00a0in\u00a0den\u00a0kontrollierten \u00a0Untersuchungen \u00a0ausgeschlossen. \u00a0Zu\u00a0diesem\u00a0Patientenkollektiv \u00a0\nliegt\u00a0lediglich\u00a0eine\u00a0Anwendungsbeobachtung \u00a0aus\u00a0den\u00a0Vereinigten \u00a0Staaten\u00a0vor:\u00a0Danach\u00a0ergibt\u00a0sich\u00a0im\u00a0\nVergleich \u00a0zur\u00a0Baseline\u00a0auch\u00a0bei\u00a0diesen\u00a0Patienten \u00a0eine\u00a0mittlere\u00a0Besserung \u00a0der\u00a0forcierten \u00a0\nEinsekundenkapazit\u00e4t \u00a0(FEV1%)\u00a0um\u00a05,5\u00a0Prozent\u00a0und\u00a0eine\u00a0durchschnittliche \u00a0Gewichtszunahme \u00a0von\u00a03,3\u00a0\nKilogramm \u00a0(Taylor\u2010Cousar\u00a0et\u00a0al.,\u00a02015).\u00a0Bei\u00a0Ramsey\u00a0et\u00a0al.\u00a0wurden\u00a0167\u00a0Patienten \u00a0mit\u00a0Genmutation \u00a0in\u00a0\u00a0\n200\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0mindestens \u00a0einem\u00a0CFTR\u2010Allel\u00a0und\u00a0einem\u00a0Alter\u00a0von\u00a012\u00a0Jahren\u00a0und\u00a0\u00e4lter\u00a0\u00fcber\u00a024\u00a0bzw.\u00a048\u00a0Wochen\u00a0mit\u00a0\nIvacaftor\u00a0im\u00a0randomisierten \u00a0Vergleich \u00a0zu\u00a0Placebo\u00a0behandelt. \u00a0Davon\u00a0wurden\u00a0161\u00a0Patienten \u00a0\nausgewertet. \u00a0Die\u00a0Patienten \u00a0erhielten\u00a0\u2013\u00a0mit\u00a0Ausnahme \u00a0von\u00a0Inhalationen \u00a0mit\u00a0hypertoner \u00a0\nKochsalzl\u00f6sung \u00a0\u2013\u00a0die\u00a0derzeitige \u00a0Standardtherapie \u00a0bei\u00a0Mukoviszidose, \u00a0bestehend \u00a0aus\u00a0Dornase\u00a0alfa\u2010\nInhalationen \u00a0und\u00a0Abdeckung \u00a0mit\u00a0Antibiotika. \u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0waren\u00a0Verbesserungen \u00a0der\u00a0\nLungenfunktion \u00a0(FEV1%)\u00a0nach\u00a024\u00a0Wochen.\u00a0Die\u00a0forcierte\u00a0Einsekundenkapazit\u00e4t \u00a0verbesserte \u00a0sich\u00a0unter\u00a0\nIvacaftor\u00a0im\u00a0Vergleich \u00a0zu\u00a0Placebo\u00a0innerhalb \u00a0von\u00a024\u00a0Wochen\u00a0um\u00a010,6\u00a0Prozentpunkte. \u00a0Eine\u00a0statistisch \u00a0\nsignifikante \u00a0Verbesserung \u00a0der\u00a0Lungenfunktion \u00a0war\u00a0auch\u00a0nach\u00a048\u00a0Wochen\u00a0zu\u00a0erkennen. \u00a0Zudem\u00a0hatten\u00a0\nnach\u00a048\u00a0Behandlungswochen \u00a067\u00a0Prozent\u00a0der\u00a0Patienten \u00a0unter\u00a0Ivacaftor\u00a0keine\u00a0Exazerbation \u00a0im\u00a0\nVergleich \u00a0zu\u00a041\u00a0Prozent\u00a0unter\u00a0Placebo.\u00a0Diese\u00a0Verbesserungen \u00a0schlagen\u00a0sich\u00a0in\u00a0der\u00a0Beurteilung \u00a0der\u00a0\nLebensqualit\u00e4t \u00a0nieder:\u00a0Nach\u00a048\u00a0Behandlungswochen \u00a0zeigt\u00a0sich\u00a0zwischen\u00a0Placebo\u00a0und\u00a0Ivacaftor\u00a0bei\u00a0\neinem\u00a0validierten \u00a0Erhebungsinstrument \u00a0zur\u00a0Lebensqualit\u00e4t \u00a0(CFQ\u2010R)\u00a0eine\u00a0klinisch\u00a0relevante \u00a0\nScoredifferenz \u00a0von\u00a08,6\u00a0Punkten\u00a0zugunsten \u00a0von\u00a0Ivacaftor. \u00a0Die\u00a0Rate\u00a0exazerbationsbedingter \u00a0\nKrankenhauseinweisungen \u00a0bzw.\u00a0der\u00a0Gebrauch \u00a0parenteral \u00a0verabreichter \u00a0Antibiotika \u00a0sank\u00a0dagegen\u00a0\nnicht\u00a0durch\u00a0die\u00a0Ivacaftor\u2010Behandlung. \u00a0Bei\u00a0Davies\u00a0et\u00a0al.\u00a0waren\u00a052\u00a0Mukoviszidose \u2010Patienten \u00a0im\u00a0Alter\u00a0\nzwischen\u00a06\u00a0und\u00a011\u00a0Jahren\u00a0eingeschlossen. \u00a0Auch\u00a0bei\u00a0diesem\u00a0Kollektiv\u00a0verbesserte \u00a0sich\u00a0\u2013\u00a0zus\u00e4tzlich \u00a0zur\u00a0\nbisherigen \u00a0Behandlung \u00a0mit\u00a0Dornase\u00a0alfa\u00a0oder\u00a0inhalativen \u00a0Antibiotika \u00a0\u2013\u00a0unter\u00a0Ivacaftor\u00a0im\u00a0Vergleich \u00a0\nzur\u00a0Placebo\u2010Behandlung \u00a0die\u00a0Lungenfunktion \u00a0(FEV1%)\u00a0um\u00a012,5\u00a0Prozentpunkte \u00a0nach\u00a024\u00a0Wochen\u00a0und\u00a0\num\u00a010,0\u00a0Prozentpunkte \u00a0nach\u00a048\u00a0Wochen.\u00a0Auch\u00a0das\u00a0Gewicht\u00a0nahm\u00a0in\u00a0der\u00a0Ivacaftor\u2010Gruppe\u00a0deutlicher \u00a0\nzu\u00a0als\u00a0unter\u00a0Placebo.\u00a0Eine\u00a0unbalancierte \u00a0Verteilung \u00a0von\u00a0Patienten \u00a0mit\u00a0eingeschr\u00e4nkter \u00a0\nLungenfunktion \u00a0(FEV1\u00a0<\u00a070\u00a0Prozent)\u00a0auf\u00a0die\u00a0Behandlungsgruppen \u00a0weckt\u00a0Zweifel\u00a0an\u00a0der\u00a0\nErgebnissicherheit \u00a0dieser\u00a0Studie\u00a0(Prescrire \u00a0Int.,\u00a02013a).\u00a0In\u00a0beiden\u00a0Studien\u00a0traten\u00a0Nebenwirkungen \u00a0in\u00a0\nden\u00a0Behandlungsgruppen \u00a0h\u00e4ufig\u00a0auf,\u00a0insbesondere \u00a0Kopfschmerzen, \u00a0obere\u00a0Atemwegserkrankungen, \u00a0\nDurchfall\u00a0und\u00a0Schwindel. \u00a0Schwere\u00a0unerw\u00fcnschte \u00a0Wirkungen \u00a0wurden\u00a0aber\u00a0unter\u00a0Placebo\u00a0h\u00e4ufiger\u00a0\nbeobachtet, \u00a0auch\u00a0wurde\u00a0die\u00a0Studienbehandlung \u00a0unter\u00a0Placebo\u00a0h\u00e4ufiger\u00a0wegen\u00a0unerw\u00fcnschter \u00a0\nWirkungen \u00a0abgebrochen. \u00a0In\u00a0der\u00a0offenen\u00a0Extensions \u2010Studie\u00a0\u00fcber\u00a096\u00a0Wochen\u00a0wurden\u00a0Patienten \u00a0\neingeschlossen, \u00a0die\u00a0die\u00a0beiden\u00a0Phase\u2010III\u2010Zulassungsstudien \u00a0\u00fcber\u00a048\u00a0Wochen\u00a0komplett\u00a0durchlaufen \u00a0\nhatten.\u00a0Es\u00a0konnten\u00a0192\u00a0Personen \u00a0unter\u00a0Ivacaftor\u00a0weiterbeobachtet \u00a0werden.\u00a0Die\u00a0Extensionsphase \u00a0\nbest\u00e4tigt\u00a0die\u00a0Ergebnisse \u00a0der\u00a0kontrollierten \u00a0Studien:\u00a0Ivacaftor\u00a0besserte\u00a0die\u00a0Lungenfunktion \u00a0(FEV1%)\u00a0\nbei\u00a0den\u00a0zuvor\u00a0mit\u00a0Placebo\u00a0behandelten \u00a0Personen \u00a0in\u00a0vergleichbarem \u00a0Ausma\u00df\u00a0wie\u00a0unter\u00a0kontrollierten \u00a0\nBedingungen \u00a0(9,4\u00a0Prozent\u00a0bei\u00a0Jugendlichen \u00a0ab\u00a0zw\u00f6lf\u00a0Jahren\u00a0und\u00a0Erwachsenen \u00a0und\u00a010,3\u00a0Prozent\u00a0bei\u00a0\nKindern).\u00a0Auch\u00a0bei\u00a0diesen\u00a0Patienten \u00a0kam\u00a0es\u00a0zu\u00a0einer\u00a0Gewichtszunahme. \u00a0Bei\u00a0zuvor\u00a0mit\u00a0Ivacaftor\u00a0\nbehandelten \u00a0Personen \u00a0blieben\u00a0die\u00a0Besserung \u00a0der\u00a0Lungenfunktion \u00a0und\u00a0eine\u00a0niedrige\u00a0\nExazerbationsrate \u00a0bis\u00a0zum\u00a0Ende\u00a0der\u00a0Beobachtung \u00a0in\u00a0Woche\u00a0144\u00a0erhalten.\u00a0H\u00e4ufigste \u00a0Nebenwirkungen \u00a0\nwaren\u00a0Exazerbationen, \u00a0Husten\u00a0und\u00a0Infektionen \u00a0der\u00a0oberen\u00a0Atemwege \u00a0(McKone\u00a0et\u00a0al.,\u00a02014).\u00a0In\u00a0einer\u00a0\naktuellen \u00a0systematischen \u00a0\u00dcbersichtsarbeit \u00a0zu\u00a0Ivacaftor\u00a0werden\u00a0diese\u00a0Ergebnisse \u00a0best\u00e4tigt\u00a0(Patel\u00a0et\u00a0\nal.,\u00a02015).\u00a0Infektionen \u00a0der\u00a0oberen\u00a0Atemwege \u00a0\u2013\u00a0auch\u00a0bakteriell \u00a0infizierte\u00a0\u2013\u00a0kommen\u00a0dabei\u00a0unter\u00a0\nIvacaftor\u00a0numerisch \u00a0h\u00e4ufiger\u00a0vor\u00a0als\u00a0unter\u00a0Scheinbehandlung. \u00a0Daneben\u00a0treten\u00a0Kopf\u2010\u00a0und\u00a0\nOhrschmerzen \u00a0sowie\u00a0erh\u00f6hte\u00a0Leberwerte \u00a0unter\u00a0Verum\u00a0h\u00e4ufiger\u00a0auf.\u00a0Die\u00a0Vertr\u00e4glichkeit \u00a0von\u00a0Ivacaftor\u00a0\nbei\u00a0Daueranwendung \u00a0ist\u00a0aufgrund\u00a0fehlender \u00a0Daten\u00a0unklar\u00a0(Prescrire \u00a0Int.,\u00a02013a).\u00a0Zu\u00a0Non\u2010G551D\u2010\nMutationen \u00a0der\u00a0Klasse\u00a0III\u00a0wurde\u00a0Ivacaftor\u00a0an\u00a0insgesamt \u00a039\u00a0Patienten \u00a0mit\u00a0einer\u00a0Non\u2010G551D\u2010CFTR\u2010\nGating\u2010Mutation \u00a0auf\u00a0mindestens \u00a0einem\u00a0Allel\u00a0gegen\u00fcber \u00a0Scheinmedikament \u00a0in\u00a0einem\u00a0Cross\u2010Over\u2010\nDesign\u00a0gepr\u00fcft\u00a0(De\u00a0Boeck\u00a0et\u00a0al.,\u00a02014).\u00a0Die\u00a0Studiendauer \u00a0lag\u00a0bei\u00a024\u00a0Wochen\u00a0mit\u00a0jeweils\u00a0zwei\u00a0\nachtw\u00f6chigen \u00a0Behandlungsphasen \u00a0mit\u00a0Ivacaftor\u00a0und\u00a0einer\u00a0Wash\u2010Out\u2010Phase\u00a0von\u00a0vier\u00a0bis\u00a0acht\u00a0\nWochen.\u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0war\u00a0die\u00a0Verbesserung \u00a0der\u00a0Lungenfunktion \u00a0anhand\u00a0FEV1%.\u00a0Als\u00a0\nsekund\u00e4re \u00a0Endpunkte \u00a0wurden\u00a0BMI,\u00a0Chloridgehalt \u00a0des\u00a0Schwei\u00dfes \u00a0und\u00a0Lebensqualit\u00e4t \u00a0(respiratorische \u00a0\nDom\u00e4ne\u00a0des\u00a0CFQ\u2010R\u2010Scores )\u00a0bestimmt. \u00a0Die\u00a0achtw\u00f6chige \u00a0Behandlung \u00a0mit\u00a0Ivacaftor\u00a0f\u00fchrte\u00a0bei\u00a0den\u00a0 \n201\u00a0\n\u00a0\nHintergrundinformationen \u00a0Patienten \u00a0zu\u00a0einer\u00a0signifikanten \u00a0Verbesserung \u00a0der\u00a0Lungenfunktion \u00a0mit\u00a0einer\u00a0Steigerung \u00a0von\u00a0FEV1%\u00a0\num\u00a0mehr\u00a0als\u00a0zehn\u00a0Prozent\u00a0gegen\u00fcber \u00a0Scheinmedikament, \u00a0die\u00a0auch\u00a0mit\u00a0einer\u00a0Gewichtszunahme \u00a0im\u00a0\nVergleich \u00a0zur\u00a0Baseline\u00a0und\u00a0einer\u00a0Lebensqualit\u00e4tserh\u00f6hung \u00a0einhergingen. \u00a0\u00a0\nNach\u00a0Flume\u00a0et\u00a0al.\u00a0zeigt\u00a0eine\u00a0Anwendung \u00a0von\u00a0Ivacaftor\u00a0bei\u00a0Mukoviszidose \u2010Patienten \u00a0mit\u00a0Gating\u2010\nMutationen \u00a0der\u00a0Klasse\u00a0II,\u00a0die\u00a0die\u00a0\u00fcberwiegende \u00a0Mehrheit \u00a0der\u00a0Erkrankten \u00a0stellen,\u00a0keine\u00a0\ntherapeutischen \u00a0Effekte.\u00a0Neuen\u00a0Erkenntnissen \u00a0aus\u00a0zwei\u00a0Phase\u2010III\u2010Studien\u00a0zufolge\u00a0f\u00fchrt\u00a0eine\u00a0\nKombination \u00a0von\u00a0CFTR\u2010Potentiatoren \u00a0und\u00a0\u2010Korrektoren \u00a0zu\u00a0einer\u00a0signifikanten \u00a0Verbesserung \u00a0der\u00a0\nLungenfunktion, \u00a0obgleich\u00a0das\u00a0Ausmass\u00a0der\u00a0Verbesserung \u00a0hinter\u00a0den\u00a0Erwartungen \u00a0zur\u00fcck\u00a0blieb\u00a0\n(Wainwright \u00a0et\u00a0al,\u00a02015).\u00a0\u00a0\n\u00a0\nLeitlinienempfehlungen \u00a0\nEine\u00a0aktuelle\u00a0Leitlinie\u00a0zur\u00a0Standardtherapie \u00a0der\u00a0Mukoviszidose \u00a0in\u00a0Deutschland \u00a0fehlt.\u00a0Vorhanden \u00a0ist\u00a0\neine\u00a0fachgesellschafts\u00fcbergreifende \u00a0Leitlinie,\u00a0die\u00a0sich\u00a0in\u00a0erster\u00a0Linie\u00a0mit\u00a0der\u00a0Lungenerkrankung \u00a0bei\u00a0\nMukoviszidose \u00a0nach\u00a0dem\u00a0ersten\u00a0Nachweis \u00a0von\u00a0Pseudomonas \u00a0aeruginosa \u00a0befasst\u00a0(M\u00fcller\u00a0et\u00a0al.,\u00a02013).\u00a0\nIn\u00a0dieser\u00a0Leitlinie\u00a0werden\u00a0nicht\u2010medikament\u00f6se \u00a0Ma\u00dfnahmen \u00a0wie\u00a0Physiotherapie, \u00a0Sport\u00a0und\u00a0\nErn\u00e4hrungstherapie \u00a0sowie\u00a0die\u00a0medikament\u00f6se \u00a0Behandlung \u00a0mit\u00a0Inhalationen \u00a0von\u00a0hypertoner \u00a0\nKochsalzl\u00f6sung \u00a0oder\u00a0Dornase\u00a0alfa\u00a0bzw.\u00a0einer\u00a0Einnahme \u00a0von\u00a0Ivacaftor\u00a0nicht\u00a0behandelt. \u00a0Bei\u00a0\npersistierender \u00a0Pseudomonas \u00a0aeruginosa \u2010Infektion\u00a0empfehlen \u00a0die\u00a0deutschen \u00a0Leitlinienautoren \u00a0die\u00a0\ninhalative \u00a0Anwendung \u00a0von\u00a0Tobramycin \u00a0\u00fcber\u00a0vier\u00a0Wochen.\u00a0Als\u00a0Alternative \u00a0nennen\u00a0sie\u00a0Ciprofloxacin \u00a0\nperoral\u00a0in\u00a0Kombination \u00a0mit\u00a0inhalativem \u00a0Colistin\u00a0\u00fcber\u00a0drei\u00a0Wochen.\u00a0\nInternational \u00a0findet\u00a0sich\u00a0eine\u00a0aktuelle\u00a0US\u2010amerikanische \u00a0Therapieempfehlung \u00a0zur\u00a0medikament\u00f6sen \u00a0\nBehandlung \u00a0von\u00a0Mukoviszidose \u2010Patienten \u00a0(Mogayzel \u00a0et\u00a0al.,\u00a02013).\u00a0Auf\u00a0Basis\u00a0der\u00a0vorhandenen \u00a0\nLiteratur\u00a0wird\u00a0mit\u00a0hoher\u00a0Evidenz\u00a0Dornase\u00a0alfa\u00a0als\u00a0Standardtherapeutikum \u00a0bei\u00a0Kindern\u00a0ab\u00a0sechs\u00a0\nJahren\u00a0und\u00a0Erwachsenen \u00a0mit\u00a0mittelschwerer \u00a0bis\u00a0schwerer\u00a0Lungenerkrankung \u00a0empfohlen. \u00a0\nLungenfunktion \u00a0und\u00a0Lebensqualit\u00e4t \u00a0lassen\u00a0sich\u00a0substantiell \u00a0steigern,\u00a0Exazerbationen \u00a0treten\u00a0seltener\u00a0\nauf.\u00a0Bei\u00a0milden\u00a0Formen\u00a0der\u00a0Lungenerkrankung \u00a0ist\u00a0der\u00a0Effekt\u00a0von\u00a0Dornase\u00a0alfa\u00a0weniger\u00a0stark\u00a0\nausgepr\u00e4gt. \u00a0Wenn\u00a0gleichzeitig \u00a0CFTR\u2010Genmutationen \u00a0der\u00a0Klasse\u00a0III\u00a0vorliegen, \u00a0wird\u00a0mit\u00a0gleichem\u00a0\nEmpfehlungsgrad \u00a0Ivacaftor\u00a0zur\u00a0routinem\u00e4\u00dfigen \u00a0Anwendung \u00a0empfohlen. \u00a0Eine\u00a0subgruppenspezifische \u00a0\nEmpfehlung \u00a0nach\u00a0Alter\u00a0und\u00a0Schweregrad \u00a0der\u00a0Erkrankung \u00a0fehlt.\u00a0F\u00fcr\u00a0die\u00a0Inhalation \u00a0von\u00a0hypertoner \u00a0\nKochsalzl\u00f6sung \u00a0liegt\u00a0moderate \u00a0Evidenz\u00a0f\u00fcr\u00a0eine\u00a0Verbesserung \u00a0von\u00a0Lungenfunktion \u00a0und\u00a0\nLebensqualit\u00e4t \u00a0sowie\u00a0f\u00fcr\u00a0eine\u00a0Verringerung \u00a0von\u00a0Exazerbationen \u00a0vor.\u00a0Die\u00a0Leitlinienersteller \u00a0sehen\u00a0\neinen\u00a0moderaten \u00a0Therapieeffekt \u00a0und\u00a0empfehlen \u00a0auch\u00a0diese\u00a0Ma\u00dfnahme \u00a0als\u00a0Standardtherapie \u00a0\nunabh\u00e4ngig \u00a0vom\u00a0Schweregrad \u00a0der\u00a0Erkrankung. \u00a0Bei\u00a0mittelschwerer \u00a0bis\u00a0schwerer \u00a0Lungenerkrankung \u00a0\nund\u00a0Pseudomonas \u00a0aeruginosa \u2010Nachweis \u00a0k\u00f6nnen\u00a0durch\u00a0Tobramycin \u2010Inhalationen \u00a0Lungenfunktion \u00a0und\u00a0\nLebensqualit\u00e4t \u00a0gesteigert \u00a0und\u00a0Exazerbationen \u00a0vermieden \u00a0werden.\u00a0Das\u00a0gilt\u00a0den\u00a0Empfehlungen \u00a0zufolge\u00a0\nauch\u00a0f\u00fcr\u00a0die\u00a0Anwendung \u00a0von\u00a0Azithromycin \u00a0oral\u00a0und\u00a0Aztreonam \u00a0inhalativ.\u00a0\n\u00a0\nNutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDas\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens \u00a0von\u00a0Ivacaftor\u00a0wurde\u00a0durch\u00a0den\u00a0Gemeinsamen \u00a0Bundesausschuss \u00a0nach\u00a0\n\u00a7\u00a035a\u00a0auf\u00a0Grundlage \u00a0der\u00a0Zulassungsstudien \u00a0bewertet \u00a0(G\u2010BA,\u00a02012c).\u00a0Auf\u00a0Basis\u00a0der\u00a0zwei\u00a0randomisiert \u2010\nkontrollierten \u00a0Phase\u2010III\u2010Studien\u00a0wird\u00a0dem\u00a0Mittel\u00a0\u2013\u00a0subgruppenspezifisch \u00a0\u2013\u00a0ein\u00a0Zusatznutzen \u00a0bei\u00a0\u00a0\n202\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Patienten \u00a0mit\u00a0einer\u00a0G551D\u2010Mutation \u00a0im\u00a0CFTR\u2010Gen\u00a0attestiert: \u00a0F\u00fcr\u00a0Kinder\u00a0zwischen\u00a0sechs\u00a0und\u00a0elf\u00a0\nJahren\u00a0besitzt\u00a0Ivacaftor\u00a0danach\u00a0aufgrund\u00a0der\u00a0Verbesserung \u00a0der\u00a0Lungenfunktion \u00a0und\u00a0gegebenenfalls \u00a0\nauch\u00a0einer\u00a0Gewichtszunahme \u00a0einen\u00a0geringen\u00a0Zusatznutzen .\u00a0Die\u00a0Surrogatmarker \u00a0Lungenfunktion \u00a0\n(FEV1%)\u00a0wie\u00a0auch\u00a0K\u00f6rpergewicht \u00a0(BMI,\u00a0Kilogramm) \u00a0werden\u00a0im\u00a0Hinblick\u00a0auf\u00a0ihre\u00a0Aussagekraft \u00a0in\u00a0\nBezug\u00a0auf\u00a0Mortalit\u00e4t \u00a0als\u00a0noch\u00a0nicht\u00a0ausreichend \u00a0validiert\u00a0beschrieben. \u00a0Aussagen \u00a0zu\u00a0klinisch\u00a0\nrelevanten \u00a0Endpunkten \u00a0wie\u00a0Verringerung \u00a0von\u00a0Exazerbationen \u00a0oder\u00a0Verbesserung \u00a0der\u00a0Lebensqualit\u00e4t \u00a0\nk\u00f6nnen\u00a0f\u00fcr\u00a0dieses\u00a0Patientenkollektiv \u00a0nicht\u00a0gemacht\u00a0werden.\u00a0F\u00fcr\u00a0Jugendliche \u00a0(ab\u00a0zw\u00f6lf\u00a0Jahre)\u00a0und\u00a0\nErwachsene \u00a0wird\u00a0dagegen\u00a0ein\u00a0betr\u00e4chtlicher \u00a0Zusatznutzen \u00a0gesehen.\u00a0Ivacaftor\u00a0f\u00fchrt\u00a0bei\u00a0diesem\u00a0\nKollektiv\u00a0zu\u00a0einer\u00a0Verbesserung \u00a0der\u00a0Lungenfunktion \u00a0(FEV1%)\u00a0und\u00a0zu\u00a0einer\u00a0Gewichtszunahme, \u00a0zeigt\u00a0\naber\u00a0auch\u00a0eine\u00a0Verringerung \u00a0der\u00a0Exazerbationsrate. \u00a0So\u00a0sank\u00a0die\u00a0Anzahl\u00a0der\u00a0Exazerbationen \u00a0\nallgemein, \u00a0genauso\u00a0wie\u00a0die\u00a0Rate\u00a0an\u00a0akuten\u00a0Verschlimmerungen, \u00a0die\u00a0zu\u00a0einer\u00a0Krankenhauseinweisung \u00a0\nf\u00fchrten\u00a0oder\u00a0eine\u00a0parenterale \u00a0Antibiotikagabe \u00a0erforderlich \u00a0machten. \u00a0Im\u00a0Zusammenhang \u00a0mit\u00a0diesen\u00a0\nEffekten\u00a0zeigen\u00a0sich\u00a0bei\u00a0diesem\u00a0Patientenkollektiv \u00a0auch\u00a0konsistente \u00a0Verbesserungen \u00a0in\u00a0der\u00a0\nLebensqualit\u00e4t \u00a0(G\u2010BA,\u00a02013g).\u00a0Im\u00a0Februar\u00a02015\u00a0wurde\u00a0f\u00fcr\u00a0die\u00a0Erweiterung \u00a0der\u00a0Zulassungsgebiete \u00a0auf\u00a0\nMukoviszidose \u2010Patienten \u00a0mit\u00a0Gating\u2010Mutationen \u00a0G1244E,\u00a0G1349D,\u00a0G178R,\u00a0G551S,\u00a0S1251N,\u00a0S1255P,\u00a0\nS549N\u00a0und\u00a0S549R\u00a0ebenfalls\u00a0ein\u00a0geringer\u00a0Zusatznutzen \u00a0festgestellt \u00a0(G\u2010BA,\u00a02015c).\u00a0In\u00a0den\u00a0vorhandenen \u00a0\nStudien\u00a0waren\u00a0nur\u00a0wenige\u00a0Patienten \u00a0mit\u00a0Non\u2010G551D\u2010Mutationen \u00a0vertreten. \u00a0Die\u00a0Daten\u00a0zeigen\u00a0f\u00fcr\u00a0\nPatienten \u00a0mit\u00a0milder\u00a0bis\u00a0moderater \u00a0Lungenerkrankung \u00a0eine\u00a0signifikante \u00a0Verbesserung \u00a0der\u00a0\nLungenfunktion \u00a0(FEV1%)\u00a0sowie\u00a0eine\u00a0leichte\u00a0Verbesserung \u00a0des\u00a0BMI\u00a0und\u00a0lassen\u00a0eine\u00a0Verbesserung \u00a0der\u00a0\nLebensqualit\u00e4t \u00a0erkennen. \u00a0Valide\u00a0Aussagen \u00a0zur\u00a0Verminderung \u00a0von\u00a0Exazerbationen \u00a0des\u00a0\nKrankheitsbildes \u00a0lassen\u00a0sich\u00a0dagegen\u00a0nicht\u00a0ableiten.\u00a0\u00a0\n\u00a0\nKosten\u00a0\nWirkstof f\u00a0 Behandlungsmodus Behandlungstage Jahrestherapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nIvacaftor  2\u00a0x\u00a0t\u00e4glich\u00a0150\u00a0mg 360 283.997,19 \u00a0\u20ac\u00a0\nTabelle\u00a035:\u00a0Jahrestherapiekosten \u00a0von Ivacaftor\u00a0(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0\n\u00a0\n   \n203\u00a0\n\u00a0\nHintergrundinformationen \u00a011.11  Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0\u00a0\nHandelsname: \u00a0Zoely\u00ae      Hersteller: \u00a0MSD \nIndikation: \u00a0Orale\u00a0Kontrazeption \u00a0\u00a0 \u00a0 Markteinf\u00fchrung: \u00a0Januar\u00a02012 \nATC\u2010Code:\u00a0G03AA14      DDD:\u00a01\u00a0Zykluspackung \u00a0mit\u00a028\u00a0Tabletten  \nDarreichungsform: \u00a0Filmtablette  \nBewertung: \u00a0siehe\u00a0Seite\u00a069 \nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nOrale\u00a0Kontrazeptiva \u00a0beinhalten \u00a0in\u00a0aller\u00a0Regel\u00a0eine\u00a0Estrogen\u2010\u00a0und\u00a0eine\u00a0Gestagenkomponente. \u00a0Die\u00a0\nGestagenkomponente \u00a0verhindert \u00a0die\u00a0Ovulation, \u00a0hemmt\u00a0die\u00a0Follikelreifung, \u00a0hat\u00a0Auswirkungen \u00a0auf\u00a0die\u00a0\nEndometriumdicke \u00a0und\u00a0den\u00a0Zervixschleim. \u00a0Diese\u00a0Teilwirkungen \u00a0tragen\u00a0allesamt\u00a0zur\u00a0kontrazeptiven \u00a0\nWirkung\u00a0der\u00a0Mittel\u00a0bei.\u00a0Die\u00a0Estrogenkomponente \u00a0hat\u00a0ebenfalls\u00a0einen\u00a0Anteil\u00a0an\u00a0der\u00a0kontrazeptiven \u00a0\nWirkung\u00a0der\u00a0Kombination, \u00a0wird\u00a0aber\u00a0in\u00a0der\u00a0Hauptsache \u00a0zugesetzt, \u00a0um\u00a0den\u00a0stabilen\u00a0Aufbau\u00a0der\u00a0\nGeb\u00e4rmutter \u00a0zu\u00a0gew\u00e4hrleisten \u00a0und\u00a0die\u00a0\u2013\u00a0aufgrund\u00a0der\u00a0antiestrogenen \u00a0Wirkung\u00a0der\u00a0Gestagene \u00a0\u2013\u00a0\nsinkenden \u00a0endogenen \u00a0Estradiolplasmakonzentrationen \u00a0zu\u00a0kompensieren \u00a0(EMA,\u00a02011).\u00a0\u00a0\nMit\u00a0dem\u00a0nat\u00fcrlich\u00a0vorkommenden \u00a0Estradiol\u00a0enth\u00e4lt\u00a0Zoely\u00ae\u00a0eine\u00a0schwach\u00a0wirkende \u00a0\nEstrogenkomponente. \u00a0Das\u00a0\u00fcblicherweise \u00a0kombinierten \u00a0oralen\u00a0Kontrazeptiva \u00a0zugesetzte \u00a0\nEthinylestradiol \u00a0hat\u00a0eine\u00a0deutlich\u00a0h\u00f6here\u00a0estrogene \u00a0Wirkpotenz \u00a0und\u00a0besitzt\u00a0deswegen \u00a0auch\u00a0ein\u00a0\nh\u00f6heres\u00a0Nebenwirkungsrisiko \u00a0\u2013\u00a0einschlie\u00dflich \u00a0eines\u00a0dosisabh\u00e4ngigen \u00a0Risikos\u00a0f\u00fcr\u00a0thromboembolische \u00a0\nEreignisse. \u00a0Auch\u00a0Estradiol\u00a0unterst\u00fctzt \u00a0in\u00a0Kombination \u00a0mit\u00a0Gestagenen \u00a0deren\u00a0kontrazeptive \u00a0\nWirksamkeit \u00a0und\u00a0kann\u00a0deswegen \u00a0in\u00a0hormonellen \u00a0Kontrazeptiva \u00a0zum\u00a0Einsatz\u00a0kommen. \u00a0Um\u00a0einen\u00a0\nstabilen\u00a0Zyklus\u00a0zu\u00a0erreichen, \u00a0m\u00fcssen\u00a0Estradiol\u2010haltige\u00a0Kontrazeptiva \u00a0aber\u00a0an\u00a0mehr\u00a0Tagen\u00a0eines\u00a0Zyklus\u00a0\neingenommen \u00a0werden\u00a0als\u00a0Mittel\u00a0mit\u00a0Ethinylestradiol. \u00a0Das\u00a0\u201ejunge\u201c\u00a0Gestagen \u00a0Nomegestrol \u00a0ist\u00a0ein\u00a0\nHydroxyprogesteronderivat \u00a0und\u00a0zeigt\u00a0enge\u00a0strukturelle \u00a0Verwandtschaft \u00a0zu\u00a0Medroxyprogesteron. \u00a0Im\u00a0\nVergleich \u00a0zu\u00a0diesem\u00a0zeichnet\u00a0sich\u00a0Nomegestrol \u00a0durch\u00a0eine\u00a0ausgepr\u00e4gtere \u00a0progestagene \u00a0Aktivit\u00e4t\u00a0aus\u00a0\n(Sitruk\u2010Ware,\u00a02004).\u00a0Es\u00a0bindet\u00a0mit\u00a0hoher\u00a0Affinit\u00e4t\u00a0an\u00a0den\u00a0Progesteron \u2010Rezeptor, \u00a0hat\u00a0nur\u00a0eine\u00a0geringe\u00a0\nAffinit\u00e4t\u00a0am\u00a0Androgen \u2010\u00a0und\u00a0Glucocorticoidrezeptor \u00a0und\u00a0besitzt\u00a0keine\u00a0Bindungsaktivit\u00e4t \u00a0am\u00a0Estrogen\u2010\u00a0\nbzw.\u00a0Mineralcorticoidrezeptor \u00a0(Sitruk\u2010Ware,\u00a02004).\u00a0\n\u00a0\nZulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nZoely\u00ae\u00a0wurde\u00a0im\u00a0Juli\u00a02011\u00a0durch\u00a0die\u00a0Europ\u00e4ische \u00a0Zulassungsbeh\u00f6rde \u00a0zugelassen \u00a0und\u00a0im\u00a0Januar\u00a02012\u00a0\nin\u00a0den\u00a0deutschen \u00a0Arzneimittelmarkt \u00a0eingef\u00fchrt. \u00a0Das\u00a0Mittel\u00a0ist\u00a0seither\u00a0zugelassen \u00a0zur\u00a0oralen\u00a0\nKontrazeption \u00a0(EMA,\u00a02011;\u00a0MSD;\u00a02015).\u00a0In\u00a0der\u00a0Zulassung \u00a0wird\u00a0darauf\u00a0hingewiesen, \u00a0dass\u00a0bei\u00a0\nVerschreibung \u00a0individuelle \u00a0Risikofaktoren, \u00a0insbesondere \u00a0im\u00a0Hinblick\u00a0auf\u00a0ven\u00f6se\u00a0Thromboembolien, \u00a0\nzu\u00a0ber\u00fccksichtigen \u00a0sind\u00a0und\u00a0das\u00a0Nebenwirkungsrisiko \u00a0von\u00a0Zoely\u00ae\u00a0mit\u00a0dem\u00a0anderer\u00a0kombinierten \u00a0\nhormonellen \u00a0Kontrazeptiva \u00a0zu\u00a0vergleichen \u00a0ist.\u00a0Das\u00a0Mittel\u00a0unterliegt \u00a0als\u00a0neuartige \u00a0Kombination \u00a0noch\u00a0\neiner\u00a0zus\u00e4tzlichen \u00a0\u00dcberwachung \u00a0und\u00a0tr\u00e4gt\u00a0das\u00a0schwarze \u00a0Dreieck\u00a0auf\u00a0seiner\u00a0Verpackung. \u00a0\u00a0\n\u00a0\u00a0\u00a0\n204\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Informationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nMit\u00a0dem\u00a0Einsetzen \u00a0der\u00a0ersten\u00a0Regelblutung \u00a0beginnt\u00a0f\u00fcr\u00a0jede\u00a0Frau\u00a0eine\u00a0etwa\u00a035\u00a0bis\u00a040\u00a0Jahre\u00a0\nandauernde \u00a0Zeit\u00a0der\u00a0Fruchtbarkeit. \u00a0Damit\u00a0stellt\u00a0sich\u00a0auch\u00a0f\u00fcr\u00a0jede\u00a0Frau\u00a0die\u00a0Frage\u00a0nach\u00a0einer\u00a0auf\u00a0ihre\u00a0\nindividuellen \u00a0Bed\u00fcrfnisse \u00a0abgestimmten \u00a0Kontrazeptionsmethode. \u00a0Am\u00a01.\u00a0Juni\u00a01961,\u00a0vor\u00a0nunmehr \u00a0\nmehr\u00a0als\u00a050\u00a0Jahren,\u00a0wurde\u00a0das\u00a0erste\u00a0orale\u00a0Kombinationskontrazeptivum \u00a0in\u00a0den\u00a0deutschen \u00a0Handel\u00a0\neingef\u00fchrt. \u00a0Seit\u00a0dieser\u00a0Zeit\u00a0prosperiert \u00a0der\u00a0Markt\u00a0der\u00a0Verh\u00fctungsmittel. \u00a0Mittlerweile \u00a0stehen\u00a0\nunterschiedliche \u00a0Applikationsformen \u00a0wie\u00a0Implantat, \u00a0Pflaster,\u00a0Vaginalring \u00a0oder\u00a0Intrauterinpessar \u00a0\n(IUP),\u00a0unterschiedliche \u00a0St\u00e4rken,\u00a0Zusammensetzungen \u00a0und\u00a0auch\u00a0hormonfreie \u00a0Kontrazeptiva \u00a0zur\u00a0\nVerf\u00fcgung, \u00a0so\u00a0dass\u00a0individuelle \u00a0Erfordernisse \u00a0bei\u00a0der\u00a0Auswahl\u00a0ber\u00fccksichtigt \u00a0werden\u00a0k\u00f6nnen.\u00a0Von\u00a0\nden\u00a0sch\u00e4tzungsweise \u00a020\u00a0Millionen \u00a0Frauen\u00a0im\u00a0geb\u00e4rf\u00e4higen \u00a0Alter\u00a0nimmt\u00a0rund\u00a0ein\u00a0Drittel\u00a0in\u00a0\nDeutschland \u00a0ein\u00a0hormonelles \u00a0Kombinationskontrazeptivum \u00a0ein\u00a0(Wiegratz \u00a0et\u00a0al.,\u00a02011).\u00a0Mehr\u00a0als\u00a090\u00a0\nProzent\u00a0der\u00a0Anwenderinnen \u00a0sind\u00a0damit\u00a0sehr\u00a0zufrieden \u00a0(Skouby,\u00a02010).\u00a0\u00dcberwiegend \u00a0handelt\u00a0es\u00a0sich\u00a0\ndabei\u00a0um\u00a0Mittel\u00a0mit\u00a0niedrigerem \u00a0Estrogenanteil \u00a0(<\u00a050\u00a0\u03bcg\u00a0Ethinylestradiol) \u00a0(DGGG,\u00a02010).\u00a0\nDie\u00a0kontrazeptive \u00a0Wirksamkeit \u00a0von\u00a0Verh\u00fctungsmitteln \u00a0wird\u00a0mit\u00a0Hilfe\u00a0des\u00a0Pearl\u00a0Index\u00a0beziffert.\u00a0Dieser\u00a0\ngibt\u00a0die\u00a0Anzahl\u00a0an\u00a0Schwangerschaften \u00a0pro\u00a0100\u00a0Frauenjahre \u00a0an.\u00a0Bei\u00a0Frauen,\u00a0die\u00a0nicht\u00a0verh\u00fcten, \u00a0liegt\u00a0\nder\u00a0Pearl\u00a0Index\u00a0bei\u00a060\u00a0bis\u00a080\u00a0Schwangerschaften \u00a0pro\u00a0100\u00a0Frauenjahre. \u00a0Der\u00a0Pearl\u00a0Index\u00a0nach\u00a0\nSterilisation \u00a0einer\u00a0Frau\u00a0liegt\u00a0im\u00a0Vergleich \u00a0dazu\u00a0bei\u00a00,2\u00a0bis\u00a00,3\u00a0Schwangerschaften \u00a0pro\u00a0100\u00a0\nFrauenjahre. \u00a0Bei\u00a0der\u00a0Pille\u00a0wird\u00a0der\u00a0Pearl\u00a0Index\u00a0\u2013\u00a0vorausgesetzt \u00a0sie\u00a0wird\u00a0regelm\u00e4\u00dfig \u00a0und\u00a0entsprechend \u00a0\nder\u00a0Einnahmeempfehlungen \u00a0angewendet \u00a0\u2013\u00a0mit\u00a00,1\u00a0bis\u00a00,9\u00a0angegeben \u00a0(Pro\u00a0Familia,\u00a02013).\u00a0\u00a0\nDa\u00a0es\u00a0sich\u00a0bei\u00a0der\u00a0Anwendung \u00a0der\u00a0\u201ePille\u201c\u00a0um\u00a0eine\u00a0unter\u00a0Umst\u00e4nden \u00a0jahrelang \u00a0bestehende \u00a0\nMedikation \u00a0des\u00a0gesunden \u00a0weiblichen \u00a0Organismus \u00a0handelt,\u00a0ist\u00a0die\u00a0Frage\u00a0nach\u00a0einer\u00a0vertr\u00e4glichen \u00a0\nAnwendungsform \u00a0zentral.\u00a0Im\u00a0Vordergrund \u00a0stehen\u00a0hier\u00a0thromboembolische \u00a0Ereignisse \u00a0wie\u00a0tiefe\u00a0\nBeinvenenthrombosen \u00a0und\u00a0Lungenembolien \u00a0sowie\u00a0kardiovaskul\u00e4re \u00a0Ereignisse. \u00a0Das\u00a0Risiko\u00a0steigt\u00a0mit\u00a0\ndem\u00a0Alter\u00a0der\u00a0Frauen\u00a0und\u00a0nimmt\u00a0bei\u00a0Raucherinnen \u00a0und\u00a0Frauen\u00a0mit\u00a0kardiovaskul\u00e4ren \u00a0Risikofaktoren \u00a0\nwie\u00a0\u00dcbergewicht \u00a0und\u00a0Diabetes\u00a0mellitus\u00a0noch\u00a0weiter\u00a0zu.\u00a0Nach\u00a0heutigem \u00a0Wissen\u00a0l\u00e4sst\u00a0sich\u00a0das\u00a0\nThromboembolierisiko \u00a0durch\u00a0Dosisreduktion \u00a0der\u00a0Estrogenkomponente \u00a0und\u00a0durch\u00a0die\u00a0Auswahl\u00a0eines\u00a0\nvertr\u00e4glichen \u00a0Gestagens \u00a0reduzieren. \u00a0\u00a0\n\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nZoely\u00ae\u00a0wurde\u00a0aufgrund\u00a0von\u00a0zwei\u00a0randomisierten \u00a0Studien\u00a0mit\u00a0insgesamt \u00a0mehr\u00a0als\u00a04.400\u00a0Frauen\u00a0\nzugelassen \u00a0(Mansour \u00a0et\u00a0al.,\u00a02011;\u00a0Westhoff \u00a0et\u00a0al.,\u00a02012).\u00a0Die\u00a0kontrazeptive \u00a0Wirksamkeit \u00a0des\u00a0Mittels\u00a0\nwurde\u00a0in\u00a0diesen\u00a0Studien\u00a0als\u00a0prim\u00e4re\u00a0Zielgr\u00f6\u00dfe \u00a0im\u00a0Vergleich \u00a0zu\u00a0Drospirenon \u00a0(3\u00a0mg)/Ethinylestradiol \u00a0\n(30\u00a0\u03bcg)\u00a0untersucht. \u00a0Da\u00a0sich\u00a0die\u00a0Therapieregime \u00a0(24\u00a0vs.\u00a021\u00a0wirkstoffhaltige \u00a0Tabletten) \u00a0unterschieden, \u00a0\nwaren\u00a0beide\u00a0Studien\u00a0unverblindet. \u00a0Danach\u00a0kann\u00a0Zoely\u00ae\u00a0mindestens \u00a0ebenso\u00a0gut\u00a0Schwangerschaften \u00a0\nverhindern \u00a0wie\u00a0eine\u00a0Fixkombination \u00a0aus\u00a0Drospirenon \u00a0und\u00a0Ethinylestradiol. \u00a0Zwar\u00a0lagen\u00a0die\u00a0Pearl\u00a0\nIndices\u00a0f\u00fcr\u00a0Zoely\u00ae\u00a0etwas\u00a0niedriger\u00a0als\u00a0unter\u00a0der\u00a0Vergleichstherapie, \u00a0der\u00a0Unterschied \u00a0zwischen\u00a0den\u00a0\nBehandlungsregimen \u00a0war\u00a0aber\u00a0statistisch \u00a0nicht\u00a0abzusichern. \u00a0\u00a0\nDemgegen\u00fcber \u00a0ergaben\u00a0sich\u00a0jedoch\u00a0deutliche \u00a0Unterschiede \u00a0bei\u00a0der\u00a0Zykluskontrolle: \u00a0Unter\u00a0Zoely\u00ae\u00a0\nkommt\u00a0es\u00a0in\u00a0Abh\u00e4ngigkeit \u00a0der\u00a0Anwendungsdauer \u00a0zu\u00a0einer\u00a0Abnahme \u00a0der\u00a0Blutungsintensit\u00e4t \u00a0bis\u00a0hin\u00a0\nzum\u00a0v\u00f6lligen\u00a0Ausbleiben \u00a0der\u00a0Blutung.\u00a0In\u00a0den\u00a0kontrollierten \u00a0Studien\u00a0lag\u00a0die\u00a0kumulative \u00a0\nAmenorrhoerate \u00a0nach\u00a0einem\u00a0Jahr\u00a0bei\u00a0rund\u00a026\u00a0Prozent\u00a0im\u00a0Vergleich \u00a0zu\u00a0einem\u00a0Prozent\u00a0in\u00a0der\u00a0Ver\u2010 \n205\u00a0\n\u00a0\nHintergrundinformationen \u00a0gleichsgruppe. \u00a0Dieser\u00a0Unterschied \u00a0war\u00a0signifikant. \u00a0Das\u00a0Ausbleiben \u00a0der\u00a0Blutungen \u00a0erschwert \u00a0die\u00a0\nBeurteilung \u00a0des\u00a0Konzeptionsschutzes, \u00a0auch\u00a0wenn\u00a0das\u00a0Pr\u00e4parat\u00a0regelm\u00e4\u00dfig \u00a0und\u00a0den\u00a0Empfehlungen \u00a0\nentsprechend \u00a0angewendet \u00a0wurde.\u00a0Betroffene \u00a0Frauen\u00a0werden\u00a0in\u00a0diesem\u00a0Fall\u00a0wohl\u00a0eine\u00a0Abkl\u00e4rung \u00a0\nw\u00fcnschen. \u00a0Bleibt\u00a0die\u00a0Regelblutung \u00a0zweimal\u00a0hintereinander \u00a0aus,\u00a0wird\u00a0vom\u00a0pU\u00a0generell\u00a0empfohlen, \u00a0vor\u00a0\nder\u00a0weiteren\u00a0Einnahme \u00a0eine\u00a0Schwangerschaft \u00a0auszuschlie\u00dfen. \u00a0Abgesehen \u00a0von\u00a0den\u00a0\u00c4nderungen \u00a0des\u00a0\nBlutungsmusters \u00a0entspricht \u00a0das\u00a0Nebenwirkungsprofil \u00a0von\u00a0Zoely\u00ae\u00a0den\u00a0allgemein \u00a0bekannten \u00a0\nunerw\u00fcnschten \u00a0Wirkungen \u00a0hormoneller \u00a0Kombinationskontrazeptiva. \u00a0Im\u00a0Vergleich \u00a0zu\u00a0\nDrospirenon/Ethinylestradiol \u00a0scheint\u00a0lediglich\u00a0Akne\u00a0h\u00e4ufiger\u00a0aufzutreten \u00a0(15,4\u00a0Prozent\u00a0unter\u00a0Zoely\u00ae\u00a0\nvs.\u00a07,9\u00a0Prozent\u00a0unter\u00a0Vergleich). \u00a0Insgesamt \u00a0werden\u00a0unter\u00a0Zoely\u00ae\u00a0h\u00e4ufiger\u00a0Nebenwirkungen \u00a0beklagt\u00a0\n(ca.\u00a075\u00a0Prozent\u00a0unter\u00a0Zoely\u00ae\u00a0vs.\u00a069\u00a0Prozent\u00a0unter\u00a0Vergleich). \u00a0Die\u00a0Therapie\u00a0wird\u00a0deswegen \u00a0auch\u00a0\nh\u00e4ufiger\u00a0abgebrochen \u00a0(MSD,\u00a02015).\u00a0Daten\u00a0zur\u00a0Langzeitvertr\u00e4glichkeit \u00a0der\u00a0Fixkombination \u00a0fehlen,\u00a0\nweswegen \u00a0eine\u00a0Beurteilung \u00a0des\u00a0Thromboembolierisikos \u00a0im\u00a0Vergleich \u00a0zu\u00a0gut\u00a0und\u00a0lange\u00a0erprobten \u00a0\nhormonellen \u00a0Kombinationspr\u00e4paraten \u00a0zur\u00a0oralen\u00a0Anwendung \u00a0nicht\u00a0m\u00f6glich\u00a0ist.\u00a0\n\u00a0\nLeitlinienempfehlungen \u00a0\nEine\u00a0aktuell\u00a0g\u00fcltige\u00a0Leitlinie\u00a0steht\u00a0derzeit\u00a0in\u00a0Deutschland \u00a0nicht\u00a0zur\u00a0Verf\u00fcgung. \u00a0Laut\u00a0Angaben\u00a0auf\u00a0der\u00a0\nWebsite\u00a0der\u00a0AWMF\u00a0ist\u00a0ein\u00a0Leitlinienvorhaben \u00a0angemeldet, \u00a0das\u00a0unter\u00a0Federf\u00fchrung \u00a0der\u00a0Deutschen \u00a0\nGesellschaft \u00a0f\u00fcr\u00a0Gyn\u00e4kologie \u00a0und\u00a0Geburtshilfe \u00a0(DGGG)\u00a0in\u00a0Kooperation \u00a0mit\u00a0verschiedenen \u00a0anderen\u00a0\u00a0\nFachgesellschaften \u00a0eine\u00a0Erstellung \u00a0einer\u00a0evidenzbasierten \u00a0Handlungsempfehlung \u00a0f\u00fcr\u00a0\u00c4rzte\u00a0zur\u00a0\nBeratung\u00a0von\u00a0Frauen\u00a0(S3)\u00a0bis\u00a0Ende\u00a02016\u00a0fertigstellen \u00a0will.\u00a0\nIn\u00a0der\u00a0mittlerweile \u00a0abgelaufenen \u00a0Vorl\u00e4uferversion \u00a0dieser\u00a0Leitlinie\u00a0werden\u00a0alle\u00a0oralen\u00a0\nOvulationshemmer \u00a0ohne\u00a0Unterscheidung \u00a0der\u00a0Zusammensetzung \u00a0als\u00a0Mittel\u00a0mit\u00a0sicherer\u00a0aber\u00a0auch\u00a0\nreversibler \u00a0kontrazeptiver \u00a0Wirksamkeit \u00a0mit\u00a0guter\u00a0Zykluskontrolle \u00a0beschrieben. \u00a0Als\u00a0nachteilig \u00a0werden\u00a0\nm\u00f6gliche\u00a0Wechselwirkungen \u00a0und\u00a0die\u00a0typischen \u00a0Nebenwirkungen \u00a0einer\u00a0Therapie\u00a0mit\u00a0Estrogenen \u00a0und\u00a0\nGestagenen \u00a0angegeben. \u00a0Die\u00a0kontrazeptive \u00a0Sicherheit \u00a0der\u00a0Gruppe\u00a0wird\u00a0mit\u00a0einem\u00a0Pearl\u00a0Index\u00a0von\u00a00,1\u00a0\nbis\u00a00,9\u00a0angegeben, \u00a0die\u00a0durch\u00a0die\u00a0gleichzeitige \u00a0Einnahme \u00a0interagierender \u00a0Arzneimittel \u00a0oder\u00a0bei\u00a0\nschwerer\u00a0Adipositas \u00a0beeintr\u00e4chtigt \u00a0sein\u00a0kann.\u00a0Monophasische \u00a0orale\u00a0Kontrazeptiva \u00a0werden\u00a0vor\u00a0\ndiesem\u00a0Hintergrund \u00a0unterschiedslos \u00a0als\u00a0geeignet\u00a0angesehen. \u00a0M\u00f6gliche \u00a0Vertr\u00e4glichkeitsunterschiede \u00a0\nzwischen\u00a0den\u00a0verf\u00fcgbaren \u00a0hormonellen \u00a0Kontrazeptiva \u00a0sind\u00a0nicht\u00a0angesprochen \u00a0(DGGG,\u00a02010).\u00a0\nMit\u00a0m\u00f6glichen \u00a0Vertr\u00e4glichkeitsunterschieden \u00a0befasste\u00a0sich\u00a0auf\u00a0Antrag\u00a0von\u00a0Frankreich \u00a0aber\u00a0der\u00a0\nAusschuss \u00a0f\u00fcr\u00a0Risikobewertung \u00a0in\u00a0der\u00a0Pharmakovigilanz \u00a0(PRAC)\u00a0der\u00a0Europ\u00e4ischen \u00a0\nArzneimittelbeh\u00f6rde \u00a0(European \u00a0Medicines \u00a0Agency,\u00a0EMA):\u00a0Er\u00a0beurteilte \u00a0im\u00a0Jahr\u00a02013\u00a0das\u00a0\nThromboembolierisiko \u00a0der\u00a0oralen\u00a0Kontrazeptiva \u00a0vor\u00a0dem\u00a0Hintergrund \u00a0der\u00a0verschiedenen \u00a0darin\u00a0\nenthaltenen \u00a0Gestagene \u00a0(EMA,\u00a02013b).\u00a0Danach\u00a0sind\u00a0deutliche \u00a0Unterschiede \u00a0zwischen\u00a0den\u00a0\nverschiedenen \u00a0Gestagenkomponenten \u00a0erkennbar: \u00a0Drospirenon, \u00a0Gestoden \u00a0und\u00a0Desogestrel \u00a0f\u00fchren\u00a0\npro\u00a0Jahr\u00a0bei\u00a0neun\u00a0bis\u00a0zw\u00f6lf\u00a0von\u00a010.000\u00a0Frauen\u00a0zu\u00a0einer\u00a0ven\u00f6sen\u00a0Thromboembolie. \u00a0Bei\u00a0\nLevonorgestrel, \u00a0Norgestimat \u00a0und\u00a0Norethisteron \u00a0liegt\u00a0diese\u00a0Anzahl\u00a0sch\u00e4tzungsweise \u00a0bei\u00a0f\u00fcnf\u00a0bis\u00a0\nsieben\u00a0von\u00a010.000,\u00a0bei\u00a0Etonogestrel \u00a0und\u00a0Norelgestromin \u00a0wird\u00a0die\u00a0Thromboembolierate \u00a0auf\u00a0sechs\u00a0bis\u00a0\nzw\u00f6lf\u00a0von\u00a010.000\u00a0gesch\u00e4tzt. \u00a0F\u00fcr\u00a0Chlormadinon, \u00a0Dienogest \u00a0und\u00a0Nomegestrol \u00a0liegen\u00a0f\u00fcr\u00a0die\u00a0\nRisikoeinsch\u00e4tzung \u00a0keine\u00a0geeigneten \u00a0Daten\u00a0vor,\u00a0um\u00a0das\u00a0Risiko\u00a0einzusch\u00e4tzen. \u00a0Das\u00a0\nThromboembolierisiko \u00a0ist\u00a0vor\u00a0allem\u00a0im\u00a0ersten\u00a0Jahr\u00a0der\u00a0Anwendung \u00a0erh\u00f6ht\u00a0oder\u00a0wenn\u00a0nach\u00a0einer\u00a0\nPause\u00a0von\u00a0mehr\u00a0als\u00a0vier\u00a0Wochen\u00a0erneut\u00a0mit\u00a0der\u00a0Einnahme \u00a0begonnen \u00a0wird\u00a0und\u00a0sinkt\u00a0danach\u00a0auf\u00a0ein\u00a0\nkontinuierlich \u00a0niedrigeres \u00a0Niveau.\u00a0Immobilisation, \u00a0Rauchen, \u00a0\u00dcbergewicht \u00a0und\u00a0eine\u00a0famili\u00e4re\u00a0\u00a0\n206\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Disposition \u00a0(Thrombophilie) \u00a0k\u00f6nnen\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0thromboembolische \u00a0Ereignisse \u00a0weiter\u00a0erh\u00f6hen.\u00a0Im\u00a0\nGegensatz \u00a0zur\u00a0Vertr\u00e4glichkeit \u00a0konnte\u00a0der\u00a0PRAC\u00a0keine\u00a0Unterschiede \u00a0im\u00a0Hinblick\u00a0auf\u00a0die\u00a0kontrazeptive \u00a0\nWirksamkeit \u00a0der\u00a0Mittel\u00a0erkennen. \u00a0\u00a0\nDa\u00a0sich\u00a0aufgrund\u00a0der\u00a0breiten\u00a0Anwendung \u00a0von\u00a0Kontrazeptiva \u00a0trotz\u00a0der\u00a0gering\u00a0erscheinenden \u00a0\nUnterschiede \u00a0zwischen\u00a0den\u00a0verschiedenen \u00a0Produkten \u00a0erhebliche \u00a0Abweichungen \u00a0in\u00a0den\u00a0absoluten \u00a0\nThromboembolieraten \u00a0ergeben,\u00a0formuliert \u00a0die\u00a0Arzneimittelkommission \u00a0der\u00a0deutschen \u00a0\u00c4rzteschaft \u00a0\u2013\u00a0\nim\u00a0Gegensatz \u00a0zum\u00a0PRAC\u00a0und\u00a0derzeit\u00a0auch\u00a0den\u00a0nationalen \u00a0Fachgesellschaften \u00a0\u2013\u00a0\u00a0eine\u00a0Empfehlung. \u00a0\nNach\u00a0ihrer\u00a0Ansicht\u00a0sollen\u00a0Erstanwenderinnen \u00a0vorzugsweise \u00a0kombinierte \u00a0hormonale \u00a0Kontrazeptiva \u00a0\nmit\u00a0einem\u00a0niedrigeren \u00a0Risiko\u00a0f\u00fcr\u00a0ven\u00f6se\u00a0Thromboembolien \u00a0erhalten\u00a0(Pr\u00e4parate \u00a0mit\u00a0Levonorgestrel, \u00a0\nNoresthisteron \u00a0oder\u00a0Norgestimat \u00a0als\u00a0Gestagenanteil). \u00a0Dies\u00a0gilt\u00a0auch\u00a0f\u00fcr\u00a0Frauen\u00a0mit\u00a0einem\u00a0aus\u00a0\nanderen\u00a0Gr\u00fcnden\u00a0erh\u00f6hten \u00a0Risiko\u00a0f\u00fcr\u00a0ven\u00f6se\u00a0Thromboembolien \u00a0(wie\u00a0z.\u00a0B.\u00a0Rauchen, \u00a0\u00dcbergewicht), \u00a0\nwenn\u00a0nach\u00a0individueller \u00a0Nutzen\u2010Risiko\u2010Abw\u00e4gung \u00a0ein\u00a0Kontrazeptivum \u00a0verordnet \u00a0wird\u00a0(AKd\u00c4,\u00a02014).\u00a0\u00a0\n\u00a0\nNutzenbewertung \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nNach\u00a0der\u00a0Richtlinie \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0der\u00a0Krankenkassen \u00a0und\u00a0\u00c4rzte\u00a0zur\u00a0\nEmpf\u00e4ngnisregelung \u00a0und\u00a0zum\u00a0Schwangerschaftsabbruch \u00a0fallen\u00a0die\u00a0Kosten\u00a0f\u00fcr\u00a0Mittel\u00a0zur\u00a0\nEmpf\u00e4ngnisverh\u00fctung \u00a0nicht\u00a0unter\u00a0die\u00a0Leistungspflicht \u00a0der\u00a0GKV.\u00a0Ausgenommen \u00a0hiervon\u00a0sind\u00a0\nverordnungspflichtige \u00a0Kontrazeptiva \u00a0bei\u00a0Frauen\u00a0bis\u00a0zum\u00a0vollendeten \u00a020.\u00a0Lebensjahr, \u00a0d.h.\u00a0bis\u00a0einen\u00a0\nTag\u00a0vor\u00a0ihrem\u00a020.\u00a0Geburtstag \u00a0(GBA,\u00a02011).\u00a0Da\u00a0Zoely\u00ae\u00a0als\u00a0Kontrazeptivum \u00a0nur\u00a0in\u00a0bestimmten \u00a0F\u00e4llen\u00a0\nder\u00a0Erstattungspflicht \u00a0der\u00a0gesetzlichen \u00a0Krankenversicherungen \u00a0(GKV)\u00a0unterliegt, \u00a0wurde\u00a0keine\u00a0\nNutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a735a\u00a0SGBV\u00a0durchgef\u00fchrt. \u00a0\u00a0\n\u00a0\nKosten\u00a0\nWirkstof f\u00a0 Behandlungsmodus Behandlungstage Jahrestherapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nNomegestrolacetat \u00a0+\u00a0Estradiol  1\u00a0Zyklus\u00a0(24\u00a0Wirkstoff \u2010haltige\u00a0\nTabletten \u00a0+\u00a04\u00a0Placebo\u2010\nTabletten) \u00a0288 137,96\u00a0\u20ac\nTabelle\u00a036:\u00a0Jahrestherapiekosten \u00a0von Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0(orales\u00a0Kontrazeptivum) \u00a0(ohne\u00a0Kosten\u00a0\nzus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0\n \u00a0 \n207\u00a0\n\u00a0\nHintergrundinformationen \u00a011.12  Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0\nHandelsname: \u00a0Naemis\u00ae     Hersteller: \u00a0Teva \nIndikation: \u00a0Hormontherapie \u00a0\u00a0   Markteinf\u00fchrung: \u00a0November \u00a02012 \nATC\u2010Code:\u00a0G03FB12\u00a0    DDD:\u00a01\u00a0Zykluspackung \u00a0mit\u00a024\u00a0Tabletten \u00a0\u00a0\nDarreichungsform: \u00a0Tablette  \nBewertung: \u00a0siehe\u00a0Seite\u00a073 \nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nAufgrund \u00a0der\u00a0hormonellen \u00a0\u00c4nderungen \u00a0in\u00a0der\u00a0Postmenopause \u00a0und\u00a0dem\u00a0damit\u00a0verbundenen \u00a0Abfall\u00a0\nder\u00a0endogenen \u00a0Estrogen\u2010Plasmakonzentration \u00a0entwickeln \u00a0manche\u00a0Frauen\u00a0in\u00a0dieser\u00a0Phase\u00a0typische\u00a0\nBeschwerden \u00a0wie\u00a0Hitzewallungen, \u00a0Schwei\u00dfausbr\u00fcche \u00a0und\u00a0vaginale\u00a0Trockenheit. \u00a0Zur\u00a0Verbesserung \u00a0\nder\u00a0Symptomatik \u00a0werden\u00a0daher\u00a0Estrogen\u2010haltige\u00a0Produkte\u00a0in\u00a0Form\u00a0von\u00a0Tabletten \u00a0zum\u00a0Einnehmen, \u00a0\nPflaster\u00a0oder\u00a0Gele\u00a0oder\u00a0auch\u00a0intramuskul\u00e4re \u00a0Injektionen \u00a0als\u00a0Substitution \u00a0angeboten. \u00a0Das\u00a0\n\u00fcblicherweise \u00a0enthaltene \u00a0Estradiol\u00a0oder\u00a0Estradiolvalerat \u00a0verbessert \u00a0aber\u00a0nicht\u00a0nur\u00a0die\u00a0Symptomatik, \u00a0\nsondern\u00a0f\u00fchrt\u00a0auch\u00a0zur\u00a0Proliferation \u00a0des\u00a0Endometriums \u00a0in\u00a0der\u00a0Geb\u00e4rmutter. \u00a0Eine\u00a0Monotherapie \u00a0mit\u00a0\nEstrogenen \u00a0kommt\u00a0daher\u00a0nur\u00a0bei\u00a0hysterektomierten \u00a0Frauen\u00a0in\u00a0Frage.\u00a0Bei\u00a0Frauen\u00a0mit\u00a0intakter\u00a0\nGeb\u00e4rmutter \u00a0ist\u00a0der\u00a0Zusatz\u00a0eines\u00a0Gestagens \u00a0erforderlich, \u00a0um\u00a0eine\u00a0Endometriumhyperplasie \u00a0und\u00a0in\u00a0\nderen\u00a0Folge\u00a0auch\u00a0\u2010krebs\u00a0zu\u00a0verhindern \u00a0(Furness\u00a0et\u00a0al.,\u00a02012).\u00a0Das\u00a0Gestagen \u00a0sorgt\u00a0f\u00fcr\u00a0die\u00a0sekretorische \u00a0\nUmwandlung \u00a0des\u00a0Endometriums. \u00a0In\u00a0der\u00a0mehrt\u00e4tigen \u00a0Einnahmepause \u00a0nach\u00a0Beendigung \u00a0einer\u00a0\nZykluspackung \u00a0tritt\u00a0eine\u00a0Entzugsblutung \u00a0unter\u00a0Absto\u00dfung \u00a0der\u00a0Geb\u00e4rmutterschleimhaut \u00a0ein.\u00a0\u00a0\nNaemis\u00ae\u00a0enth\u00e4lt\u00a0als\u00a0Sequenzpr\u00e4parat \u00a0nur\u00a0in\u00a0der\u00a0zweiten\u00a0Zyklush\u00e4lfte \u00a0mit\u00a0Nomegestrol \u00a0einen\u00a0\nGestagenzusatz. \u00a0Gestagene \u00a0k\u00f6nnen\u00a0grunds\u00e4tzlich \u00a0in\u00a0zwei\u00a0Klassen\u00a0unterteilt \u00a0werden:\u00a0C21\u2010Steroide,\u00a0\ndie\u00a0sich\u00a0vom\u00a0Progesteron \u00a0ableiten,\u00a0und\u00a0C19\u2010Steroide,\u00a0die\u00a0sich\u00a0von\u00a019\u2010Nortestosteron \u00a0ableiten.\u00a0Die\u00a0\njeweiligen \u00a0Vertreter \u00a0besitzen\u00a0unterschiedliche \u00a0pharmakologische \u00a0Eigenschaften, \u00a0so\u00a0haben\u00a0\nProgesteronderivate \u00a0\u00fcberwiegend \u00a0neutrale\u00a0Eigenschaften \u00a0im\u00a0Hinblick\u00a0auf\u00a0metabolische \u00a0Parameter \u00a0\noder\u00a0nur\u00a0gering\u00a0ausgepr\u00e4gte \u00a0androgene \u00a0Effekte.\u00a0Nomegestrol \u00a0ist\u00a0ein\u00a0Hydroxyprogesteronderivat \u00a0und\u00a0\nzeigt\u00a0enge\u00a0strukturelle \u00a0Verwandtschaft \u00a0zu\u00a0Medroxyprogesteron. \u00a0Im\u00a0Vergleich \u00a0zu\u00a0diesem\u00a0besitzt\u00a0\nNomegestrol \u00a0ausgepr\u00e4gtere \u00a0progestagene \u00a0Aktivit\u00e4t\u00a0(Sitruk\u2010Ware,\u00a02004).\u00a0Es\u00a0wirkt\u00a0als\u00a0ein\u00a0relativ\u00a0\nselektiver \u00a0Progesteronagonist, \u00a0mit\u00a0nur\u00a0geringen\u00a0Auswirkungen \u00a0am\u00a0Androgen \u2010\u00a0und\u00a0Glucocorticoid \u2010\nRezeptor\u00a0und\u00a0ohne\u00a0Bindung\u00a0am\u00a0Estrogen\u2010\u00a0bzw.\u00a0Mineralcorticoidrezeptor \u00a0(Sitruk\u2010Ware,\u00a02004).\u00a0\u00a0\n\u00a0\nZulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nNaemis\u00ae\u00a0ist\u00a0als\u00a0Hormontherapeutikum \u00a0zur\u00a0Behandlung \u00a0von\u00a0Estrogenmangelsymptomen \u00a0bei\u00a0\npostmenopausalen \u00a0Frauen\u00a0zugelassen \u00a0(Teva,\u00a02013).\u00a0Es\u00a0handelt\u00a0sich\u00a0um\u00a0ein\u00a0typisches \u00a0\nZweiphasenpr\u00e4parat. \u00a0Die\u00a0Monatspackung \u00a0besteht\u00a0aus\u00a024\u00a0Tabletten, \u00a0von\u00a0denen\u00a0die\u00a0ersten\u00a0zehn\u00a0\nTabletten \u00a0der\u00a0ersten\u00a0Phase\u00a0lediglich\u00a0Estradiol\u00a0als\u00a0Estrogenkomponente \u00a0enthalten. \u00a0In\u00a0den\u00a0restlichen \u00a0\n14\u00a0Tabletten \u00a0der\u00a0zweiten\u00a0Phase\u00a0ist\u00a0dem\u00a0nat\u00fcrlich\u00a0vorkommenden \u00a0Estradiol\u00a0Nomegestrol \u00a0ein\u00a0\nneuartiges \u00a0Gestagen \u00a0beigemischt. \u00a0\n\u00a0\u00a0\u00a0\n208\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Informationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nAls\u00a0Wechseljahre \u00a0oder\u00a0Klimakterium \u00a0wird\u00a0im\u00a0Leben\u00a0einer\u00a0Frau\u00a0die\u00a0\u00dcbergangsphase \u00a0zwischen\u00a0dem\u00a0\nBeginn\u00a0unregelm\u00e4\u00dfiger \u00a0Blutungen \u00a0bis\u00a0zum\u00a0Erl\u00f6schen \u00a0der\u00a0zyklischen \u00a0Ovarialfunktion \u00a0bezeichnet. \u00a0\nInnerhalb \u00a0dieser\u00a0Zeit\u00a0findet\u00a0auch\u00a0die\u00a0letzte\u00a0Regelblutung \u00a0statt.\u00a0Das\u00a0mittlere\u00a0Alter,\u00a0in\u00a0dem\u00a0die\u00a0\nweiblichen \u00a0Keimdr\u00fcsen \u00a0ihre\u00a0Funktion\u00a0einstellen \u00a0liegt\u00a0bei\u00a051\u00a0\u00b1\u00a03\u00a0Jahre.\u00a0Aufgrund \u00a0der\u00a0nachlassenden \u00a0\nFunktion\u00a0der\u00a0Ovarien\u00a0sinken\u00a0Estrogen\u2010\u00a0und\u00a0Gestagen \u2010Plasmaspiegel, \u00a0die\u00a0Feedback \u2010Funktion\u00a0an\u00a0die\u00a0\nHypophyse \u00a0geht\u00a0verloren\u00a0und\u00a0die\u00a0von\u00a0ihr\u00a0ausgesch\u00fctteten \u00a0Gonadotropine \u00a0steigen\u00a0stark\u00a0an.\u00a0Etwa\u00a0ein\u00a0\nDrittel\u00a0der\u00a0Frauen\u00a0in\u00a0der\u00a0Postmenopause \u00a0weist\u00a0trotz\u00a0sinkender \u00a0Estrogen\u2010Plasmakonzentrationen \u00a0\nkeine\u00a0klimakterischen \u00a0Beschwerden \u00a0auf.\u00a0Bei\u00a0zwei\u00a0Dritteln\u00a0der\u00a0Frauen\u00a0stellen\u00a0sich\u00a0aber\u00a0aufgrund\u00a0der\u00a0\nhormonellen \u00a0Ver\u00e4nderungen \u00a0typische,\u00a0in\u00a0erster\u00a0Linie\u00a0vasomotorische \u00a0Beschwerden \u00a0ein.\u00a0Hierzu\u00a0\nz\u00e4hlen\u00a0Hitzewallungen, \u00a0Schwei\u00dfausbr\u00fcche, \u00a0vaginale\u00a0Trockenheit, \u00a0Schwindel, \u00a0Tachykardien. \u00a0Nicht\u00a0\nselten\u00a0sind\u00a0diese\u00a0Beschwerden \u00a0auch\u00a0begleitet\u00a0von\u00a0Schlafst\u00f6rungen, \u00a0M\u00fcdigkeit, \u00a0Antriebshemmung \u00a0\nund\u00a0depressiver \u00a0Verstimmung. \u00a0Behandlungsbed\u00fcrftige \u00a0klimakterische \u00a0Beschwerden \u00a0k\u00f6nnen\u00a0durch\u00a0\nHormongabe, \u00a0in\u00a0erster\u00a0Linie\u00a0Estrogensubstitution, \u00a0gelindert\u00a0werden.\u00a0Aber:\u00a0Eine\u00a0derartige\u00a0\nHormonanwendung \u00a0muss\u00a0unter\u00a0Umst\u00e4nden \u00a0\u00fcber\u00a0einen\u00a0l\u00e4ngeren\u00a0Zeitraum\u00a0durchgef\u00fchrt \u00a0werden.\u00a0In\u00a0\njedem\u00a0Fall\u00a0sind\u00a0damit\u00a0verbundene \u00a0Risiken\u00a0bei\u00a0der\u00a0Indikationsstellung \u00a0zu\u00a0ber\u00fccksichtigen. \u00a0\nSystematischen \u00a0\u00dcbersichtsarbeiten \u00a0zufolge\u00a0bessern\u00a0sich\u00a0bereits\u00a0nach\u00a0kurzer\u00a0Einnahmezeit \u00a0typische\u00a0\nWechseljahrsbeschwerden \u00a0und\u00a0bei\u00a0Langzeitanwendung \u00a0k\u00f6nnen\u00a0auch\u00a0Knochenfrakturen \u00a0verhindert \u00a0\nwerden\u00a0(MacLennan \u00a0et\u00a0al.,\u00a02004;\u00a0Marjoribanks \u00a0et\u00a0al.,\u00a02012,\u00a0Nelson,\u00a02002).\u00a0Positive\u00a0Auswirkungen \u00a0auf\u00a0\nHerzerkrankungen \u00a0sind\u00a0in\u00a0der\u00a0prim\u00e4r\u2010\u00a0wie\u00a0auch\u00a0in\u00a0der\u00a0sekund\u00e4rpr\u00e4ventiven \u00a0Anwendung \u00a0jedoch\u00a0nicht\u00a0\nvorhanden \u00a0oder\u00a0nur\u00a0gering\u00a0ausgepr\u00e4gt \u00a0(Boardman \u00a0et\u00a0al.,\u00a02015).\u00a0Auch\u00a0bieten\u00a0Hormone \u00a0keinen\u00a0Schutz\u00a0\ngegen\u00a0dementielle \u00a0Erkrankungen \u00a0im\u00a0Alter\u00a0oder\u00a0andere\u00a0Alterserscheinungen \u00a0wie\u00a0Inkontinenz \u00a0(Lethaby\u00a0\net\u00a0al.,\u00a02008;\u00a0Marjoribanks \u00a0et\u00a0al.,\u00a02012).\u00a0Daf\u00fcr\u00a0steigt\u00a0mit\u00a0einer\u00a0langfristigen \u00a0Anwendung \u00a0weiblicher \u00a0\nHormone \u00a0bei\u00a0einem\u00a0Durchschnittsalter \u00a0der\u00a0Anwenderinnen \u00a0von\u00a060\u00a0Jahren\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0Schlaganf\u00e4lle \u00a0\nund\u00a0ven\u00f6se\u00a0Thromboembolien \u00a0(Boardman \u00a0et\u00a0al.,\u00a02015).\u00a0Auch\u00a0das\u00a0Brustkrebsrisiko \u00a0kann\u00a0durch\u00a0die\u00a0\nHormonanwendung \u00a0\u2013\u00a0zus\u00e4tzlich \u00a0zum\u00a0altersbedingten \u00a0Risiko\u00a0\u2013\u00a0weiter\u00a0ansteigen \u00a0(Marjoribanks \u00a0et\u00a0al.,\u00a0\n2012).\u00a0Aufgrund \u00a0dieser\u00a0Ergebnisse \u00a0wird\u00a0inzwischen \u00a0f\u00fcr\u00a0jeden\u00a0Einzelfall\u00a0eine\u00a0Risiko\u2010Nutzen\u2010Abw\u00e4gung \u00a0\nvor\u00a0Beginn\u00a0einer\u00a0Hormontherapie \u00a0gefordert. \u00a0Dieser\u00a0Forderung \u00a0scheinen\u00a0die\u00a0verordnenden \u00a0\u00c4rzte\u00a0auch\u00a0\nnachzukommen. \u00a0Nach\u00a0den\u00a0Angaben\u00a0des\u00a0Arzneiverordnungs \u2010Reports\u00a02014\u00a0sind\u00a0seit\u00a01999\u00a0die\u00a0\nVerordnungszahlen \u00a0f\u00fcr\u00a0Estrogenpr\u00e4parate \u00a0bei\u00a0postmenopausaler \u00a0Symptomatik \u00a0um\u00a076\u00a0Prozent\u00a0\nzur\u00fcckgegangen \u00a0(Schwabe, \u00a02014).\u00a0\u00a0\n\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nZu\u00a0Naemis\u00ae\u00a0und\u00a0seiner\u00a0spezifischen \u00a0Zusammensetzung \u00a0liegen\u00a0nur\u00a0wenige\u00a0randomisiert \u00a0kontrollierte \u00a0\nStudien\u00a0vor,\u00a0sie\u00a0untersuchen \u00a0\u00fcberwiegend \u00a0lediglich\u00a0kleine\u00a0Patientenkollektive \u00a0und\u00a0wurden\u00a0nicht\u00a0alle\u00a0\nverblindet \u00a0durchgef\u00fchrt. \u00a0Danach\u00a0sind\u00a0mit\u00a0dem\u00a0Sequenzpr\u00e4parat \u00a0offenbar\u00a0Verbesserungen \u00a0eines\u00a0\npostmenopausalen \u00a0Beschwerdebildes \u00a0zu\u00a0erreichen, \u00a0wie\u00a0sie\u00a0auch\u00a0f\u00fcr\u00a0andere\u00a0Kombinationspr\u00e4parate \u00a0\nmit\u00a0anderen\u00a0Gestagenen \u00a0gefunden \u00a0werden\u00a0(Stomati\u00a0et\u00a0al.,\u00a01997).\u00a0Untersuchungen \u00a0an\u00a0Frauen\u00a0mit\u00a0\nkombiniertem \u00a0Einsatz\u00a0von\u00a0topischen \u00a0Estradiolzubereitungen \u00a0und\u00a0sequentieller \u00a0Gabe\u00a0von\u00a0\nNomegestrol \u00a0an\u00a014\u00a0Tagen\u00a0best\u00e4tigen \u00a0dieses\u00a0Ergebnis\u00a0(Foidart\u00a0et\u00a0al.,\u00a01997).\u00a0Nomegestrol \u00a0f\u00fchrt\u00a0im\u00a0\nVergleich \u00a0zu\u00a0anderen\u00a0Gestagenen \u00a0(Progesteron, \u00a0Medroxyprogesteron) \u00a0zu\u00a0regelm\u00e4\u00dfigen \u00a0\nAbbruchblutungen \u00a0(DiCarlo\u00a0et\u00a0al.,\u00a02005).\u00a0In\u00a0Surrogatmarkerstudien \u00a0\u00fcber\u00a0maximal\u00a0sechs\u00a0\nBehandlungsmonate \u00a0konnte\u00a0gezeigt\u00a0werden,\u00a0dass\u00a0Estradiol\u00a0in\u00a0sequentieller \u00a0Kombination \u00a0mit\u00a0 \n209\u00a0\n\u00a0\nHintergrundinformationen \u00a0Nomegestrol \u00a0keine\u00a0negativen \u00a0Eigenschaften \u00a0auf\u00a0den\u00a0Knochenstoffwechsel \u00a0besitzt,\u00a0sondern\u00a0den\u00a0\nKnochenabbau \u00a0zu\u00a0reduzieren \u00a0vermag\u00a0(Colette\u00a0et\u00a0al.,\u00a02003;\u00a0Nguy\u00ean\u2010Pascal\u00a0et\u00a0al,.\u00a02005).\u00a0\nLangzeituntersuchungen \u00a0zur\u00a0besseren\u00a0Einsch\u00e4tzung \u00a0der\u00a0Risiko\u2010Nutzen\u2010Bilanz\u00a0einer\u00a0l\u00e4ngerfristigen \u00a0\nAnwendung \u00a0von\u00a0Naemis\u00ae\u00a0fehlen.\u00a0\u00a0\n\u00a0\nLeitlinienempfehlungen \u00a0\nDie\u00a0auf\u00a0der\u00a0Website\u00a0der\u00a0Arbeitsgemeinschaft \u00a0wissenschaftlicher \u00a0medizinischer \u00a0Fachgesellschaften \u00a0\n(AWMF)\u00a0gelistete\u00a0Leitlinie\u00a0zur\u00a0Behandlung \u00a0in\u00a0der\u00a0Peri\u2010\u00a0und\u00a0Postmenopause \u00a0besitzt\u00a0derzeit\u00a0keine\u00a0\nG\u00fcltigkeit \u00a0und\u00a0wird\u00a0aktuell\u00a0\u00fcberpr\u00fcft. \u00a0Das\u00a0G\u00fcltigkeitsdatum \u00a0war\u00a0am\u00a001.\u00a0September \u00a02014\u00a0abgelaufen. \u00a0\nDie\u00a0Leitlinienautoren \u00a0konstatieren \u00a0in\u00a0der\u00a0alten\u00a0Leitlinienversion, \u00a0dass\u00a0die\u00a0Wirksamkeit \u00a0der\u00a0oralen\u00a0\nEstrogenbehandlung \u00a0bei\u00a0Hitzewallungen \u00a0belegt\u00a0ist\u00a0und\u00a0die\u00a0vorhandenen \u00a0Derivate\u00a0und\u00a0\nApplikationsformen \u00a0sich\u00a0in\u00a0dieser\u00a0Hinsicht\u00a0nicht\u00a0voneinander \u00a0unterscheiden. \u00a0Die\u00a0publizierten \u00a0Studien\u00a0\nbeschreiben \u00a0in\u00a0der\u00a0Regel\u00a0kurze\u00a0Behandlungszeitr\u00e4ume \u00a0(ca.\u00a0drei\u00a0Monate). \u00a0Stehen\u00a0vor\u00a0allem\u00a0vaginale\u00a0\nBeschwerden \u00a0im\u00a0Vordergrund, \u00a0wird\u00a0die\u00a0Anwendung \u00a0topischer \u00a0Mittel\u00a0pr\u00e4feriert. \u00a0Lokal\u00a0wirkende \u00a0\nMittel\u00a0werden\u00a0\u2013\u00a0im\u00a0Gegensatz \u00a0zu\u00a0oralen\u00a0Zubereitungsformen \u00a0\u2013\u00a0bei\u00a0rezidivierenden \u00a0\nHarnweginfektionen \u00a0als\u00a0Behandlungsoption \u00a0genannt.\u00a0Orale\u00a0Hormontherapeutika \u00a0k\u00f6nnen\u00a0den\u00a0\nLeitlinienautoren \u00a0zufolge\u00a0zudem\u00a0zur\u00a0Frakturprophylaxe \u00a0bei\u00a0Frauen\u00a0mit\u00a0hohem\u00a0Risiko\u00a0f\u00fcr\u00a0\nKnochenbr\u00fcche \u00a0und\u00a0Unvertr\u00e4glichkeiten \u00a0bzw.\u00a0Kontraindikationen \u00a0f\u00fcr\u00a0andere\u00a0empfohlene \u00a0\nOsteoporosemittel \u00a0eingesetzt \u00a0werden.\u00a0Demgegen\u00fcber \u00a0wird\u00a0ihr\u00a0Einsatz\u00a0zur\u00a0Prim\u00e4r\u2010\u00a0bzw.\u00a0\nSekund\u00e4rpr\u00e4vention \u00a0der\u00a0koronaren \u00a0Herzkrankheit \u00a0abgelehnt, \u00a0da\u00a0auf\u00a0Basis\u00a0der\u00a0vorliegenden \u00a0\nUntersuchungen \u00a0keine\u00a0sichere\u00a0Aussage\u00a0m\u00f6glich\u00a0ist.\u00a0Da\u00a0bei\u00a0l\u00e4nger\u00a0andauernder \u00a0Estrogenbehandlung \u00a0\ndas\u00a0Risiko\u00a0f\u00fcr\u00a0Endometriumhyperplasie \u00a0und\u00a0gegebenenfalls \u00a0auch\u00a0\u2010krebs\u00a0bei\u00a0Frauen\u00a0mit\u00a0intakter\u00a0\nGeb\u00e4rmutter \u00a0ansteigt,\u00a0wird\u00a0eine\u00a0Beimischung \u00a0von\u00a0Gestagenen \u00a0an\u00a0mindestens \u00a0zehn\u00a0Zyklustagen \u00a0\ngefordert. \u00a0Bei\u00a0Langzeitanwendung \u00a0der\u00a0Hormone \u00a0werden\u00a0\u2013\u00a0mit\u00a0dem\u00a0Ziel\u00a0der\u00a0Endometriumatrophie \u00a0\u2013\u00a0\nsogar\u00a0kontinuierlich \u00a0kombinierte \u00a0Hormontherapeutika \u00a0bevorzugt. \u00a0F\u00fcr\u00a0orale\u00a0Hormonpr\u00e4parate \u00a0wird\u00a0\ndar\u00fcber\u00a0hinaus\u00a0eine\u00a0Risikoerh\u00f6hung \u00a0f\u00fcr\u00a0Schlaganfall \u00a0sowie\u00a0f\u00fcr\u00a0ven\u00f6se\u00a0Thrombosen \u00a0und\u00a0\nLungenembolien \u00a0beschrieben. \u00a0Insbesondere \u00a0f\u00fcr\u00a0die\u00a0letztgenannten \u00a0unerw\u00fcnschten \u00a0Wirkungen \u00a0ist\u00a0\ndas\u00a0Risiko\u00a0in\u00a0erster\u00a0Linie\u00a0w\u00e4hrend\u00a0des\u00a0ersten\u00a0Behandlungsjahres \u00a0erh\u00f6ht.\u00a0Das\u00a0Risiko\u00a0f\u00fcr\u00a0diese\u00a0\nEreignisse \u00a0nimmt\u00a0mit\u00a0dem\u00a0Alter\u00a0und\u00a0steigendem \u00a0K\u00f6rpergewicht \u00a0sowie\u00a0famili\u00e4rer \u00a0Disposition \u00a0zu.\u00a0Es\u00a0\ngibt\u00a0Hinweise, \u00a0dass\u00a0transdermale \u00a0Applikationsformen \u00a0eine\u00a0geringere \u00a0Risikoerh\u00f6hung \u00a0mit\u00a0sich\u00a0bringen\u00a0\nals\u00a0orale\u00a0Zubereitungen \u00a0(DGGG,\u00a02009).\u00a0Aus\u00a0diesen\u00a0Hinweisen \u00a0lassen\u00a0sich\u00a0aber\u00a0noch\u00a0keine\u00a0definitiven \u00a0\nEmpfehlungen \u00a0ableiten.\u00a0Bei\u00a0der\u00a0Entscheidung \u00a0f\u00fcr\u00a0oder\u00a0gegen\u00a0eine\u00a0Hormontherapie \u00a0muss\u00a0au\u00dferdem \u00a0\ndas\u00a0erh\u00f6hte\u00a0Brustkrebsrisiko \u00a0bedacht\u00a0werden.\u00a0\nSowohl\u00a0in\u00a0einer\u00a0aktuellen \u00a0evidenzbasierten \u00a0kanadischen \u00a0Leitlinie\u00a0(Reid\u00a0et\u00a0al.,\u00a02014)\u00a0wie\u00a0auch\u00a0in\u00a0\naktuellen \u00a0Reviews\u00a0der\u00a0Cochrane \u00a0Collaboration \u00a0werden\u00a0diese\u00a0Empfehlungen \u00a0best\u00e4tigt. \u00a0In\u00a0Bezug\u00a0auf\u00a0\nkardiovaskul\u00e4re \u00a0Effekte\u00a0einer\u00a0Hormontherapie \u00a0bei\u00a0Frauen,\u00a0deren\u00a0Menopause \u00a0bei\u00a0Behandlungsbeginn \u00a0\nnoch\u00a0weniger\u00a0als\u00a0zehn\u00a0Jahre\u00a0zur\u00fcckliegt, \u00a0findet\u00a0sich\u00a0im\u00a0systematischen \u00a0Review\u00a0der\u00a0Cochrane \u00a0\nCollaboration \u00a0eine\u00a0Post\u2010Protokoll\u2010Subgruppenanalyse \u00a0aus\u00a0f\u00fcnf\u00a0prim\u00e4rpr\u00e4ventiven \u00a0Studien.\u00a0Danach\u00a0\nk\u00f6nnte\u00a0ein\u00a0fr\u00fcher,\u00a0mindestens \u00a0drei\u00a0bis\u00a0zehn\u00a0Jahre\u00a0andauernder \u00a0Einsatz\u00a0von\u00a0Hormonpr\u00e4paraten \u00a0die\u00a0\nGesamtsterblichkeit, \u00a0die\u00a0kardiovaskul\u00e4re \u00a0Sterblichkeit \u00a0und\u00a0die\u00a0Rate\u00a0an\u00a0koronarer \u00a0Herzkrankheit \u00a0\nsenken.\u00a0Ob\u00a0damit\u00a0auch\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0hormonabh\u00e4ngige \u00a0Krebserkrankungen \u00a0steigt,\u00a0wird\u00a0nicht\u00a0\ndargestellt. \u00a0Diese\u00a0Art\u00a0der\u00a0Behandlung \u00a0geht\u00a0aber\u00a0ebenfalls\u00a0mit\u00a0einer\u00a0erh\u00f6hten \u00a0Rate\u00a0ven\u00f6ser\u00a0\nThromboembolien \u00a0einher\u00a0(Boardman \u00a0et\u00a0al.,\u00a02015).\u00a0F\u00fcr\u00a0diese\u00a0so\u00a0genannte \u00a0\u201eTiming\u2010Hypothese\u201c \u00a0liegen\u00a0\u00a0\n210\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0allerdings \u00a0noch\u00a0keine\u00a0Studien\u00a0vor,\u00a0die\u00a0im\u00a0beschriebenen \u00a0Kollektiv\u00a0einen\u00a0Nutzen\u00a0anhand\u00a0harter\u00a0\nklinischer \u00a0Endpunkte \u00a0aufzeigten. \u00a0\n\u00a0\nNutzenbewertung \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nNaemis\u00ae\u00a0wurde\u00a0im\u00a0Jahr\u00a02012\u00a0als\u00a0zweites\u00a0Mittel\u00a0mit\u00a0der\u00a0Kombination \u00a0Estradiol\u00a0und\u00a0Nomegestrol \u00a0\n(allerdings \u00a0mit\u00a0unterschiedlicher \u00a0Dosierung \u00a0der\u00a0Einzelwirkstoffe \u00a0in\u00a0der\u00a0jeweiligen \u00a0Applikationsform \u00a0\nund\u00a0anderslautender \u00a0Indikation) \u00a0in\u00a0den\u00a0deutschen \u00a0Arzneimittelmarkt \u00a0eingef\u00fchrt. \u00a0Eine\u00a0fr\u00fche\u00a0\nNutzenbewertung \u00a0f\u00fcr\u00a0dieses\u00a0Mittel\u00a0wurde\u00a0nicht\u00a0vorgenommen. \u00a0\u00a0\n\u00a0Kosten\u00a0\nWirkstof f\u00a0 Behandlungsmodus Behandlungstage Jahrestherapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nNomegestrolacetat \u00a0+\u00a0Estradiol  1\u00a0Zyklus\u00a0(24\u00a0Wirkstoff \u2010haltige\u00a0\nTabletten \u00a0+\u00a04\u00a0Placebo\u2010\nTabletten) \u00a0288 193,08\u00a0\u20ac\nTabelle\u00a037:\u00a0Jahrestherapiekosten \u00a0von\u00a0Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0(Hormontherapie) \u00a0(ohne\u00a0Kosten\u00a0\nzus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0\n\u00a0\n   \n211\u00a0\n\u00a0\nHintergrundinformationen \u00a011.13  Pasireotid \u00a0\n\u00a0\u00a0\u00a0Handelsname: \u00a0Signifor\u00ae     Hersteller: \u00a0Novartis\u00a0Pharma  \nIndikation: \u00a0Morbus\u00a0Cushing\u00a0\u00a0   Zulassung: \u00a0Juni\u00a02012 \nATC\u2010Code:\u00a0H01CB05\u00a0    DDD:\u00a01,2\u00a0mg\u00a0\nDarreichungsform: \u00a0Injektionsl\u00f6sung \u00a0\nBewertung: \u00a0siehe\u00a0Seite\u00a077 \nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nPasireotid \u00a0z\u00e4hlt\u00a0zur\u00a0pharmakotherapeutischen \u00a0Gruppe\u00a0der\u00a0Somatostatin \u2010Analoga.\u00a0Wie\u00a0die\u00a0nat\u00fcrlich\u00a0\nvorkommenden \u00a0Peptidhormone \u00a0Somatostatin \u201014\u00a0und\u00a0Somatostatin \u201028\u00a0und\u00a0andere\u00a0Somatostatin \u2010\nAnaloga\u00a0entfaltet\u00a0Pasireotid \u00a0seine\u00a0pharmakologische \u00a0Wirkung\u00a0\u00fcber\u00a0die\u00a0Bindung\u00a0an\u00a0Somatostatin \u2010\nRezeptoren \u00a0(Novartis, \u00a02015a).\u00a0Unter\u00a0normalen \u00a0physiologischen \u00a0Bedingungen \u00a0werden\u00a0beim\u00a0\nMenschen \u00a0Somatostatin \u2010Rezeptor\u2010Subtypen \u00a0(hsst1,\u00a02,\u00a03,\u00a04\u00a0und\u00a05)\u00a0in\u00a0verschiedenen \u00a0Geweben \u00a0\nexprimiert, \u00a0besonders \u00a0aber\u00a0in\u00a0neuroendokrinen \u00a0Tumoren. \u00a0Diese\u00a0Tumoren\u00a0sezernieren \u00a0\u00fcberm\u00e4\u00dfig \u00a0\nHormone, \u00a0einschlie\u00dflich \u00a0dem\u00a0Wachstumshormon \u00a0GH\u00a0(growth\u00a0hormone ).\u00a0Andere\u00a0Bezeichnungen \u00a0f\u00fcr\u00a0\ndas\u00a0Wachstumshormon \u00a0sind\u00a0somatotropes \u00a0Hormon\u00a0(STH)\u00a0oder\u00a0Somatotropin. \u00a0Somatotropin \u00a0als\u00a0\neffektorisches \u00a0Hormon\u00a0f\u00f6rdert\u00a0das\u00a0K\u00f6rperwachstum \u00a0und\u00a0seine\u00a0Reifung,\u00a0zus\u00e4tzlich \u00a0steigert\u00a0es\u00a0die\u00a0\nProteinbiosynthese, \u00a0die\u00a0Lipolyse\u00a0und\u00a0Ketogenese \u00a0(Insulin\u2010antagonistische \u00a0Wirkung) \u00a0und\u00a0unterst\u00fctzt \u00a0\ndie\u00a0Mineralisation \u00a0der\u00a0Knochen. \u00a0Bei\u00a0einer\u00a0\u00fcberm\u00e4\u00dfigen \u00a0Produktion \u00a0des\u00a0Wachstumshormons \u00a0kommt\u00a0\nes\u00a0bei\u00a0Kindern\u00a0zu\u00a0Riesenwuchs \u00a0und\u00a0bei\u00a0Erwachsenen \u00a0zu\u00a0unproportioniertem \u00a0Knochenwuchs \u00a0(gro\u00dfe\u00a0\nH\u00e4nde\u00a0und\u00a0F\u00fc\u00dfe\u00a0sowie\u00a0grobe\u00a0Gesichtsz\u00fcge) \u00a0(Mutschler \u00a0et\u00a0al.,\u00a02008).\u00a0Pasireotid \u00a0bindet\u00a0mit\u00a0hoher\u00a0\nAffinit\u00e4t\u00a0an\u00a0vier\u00a0der\u00a0f\u00fcnf\u00a0hsst\u2010Rezeptoren \u00a0(Novartis, \u00a02015a).\u00a0\u00a0\n\u00a0\nZulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nPasireotid \u00a0(Signifor\u00ae) \u00a0wurde\u00a0im\u00a0Juni\u00a02012\u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0von\u00a0erwachsenen \u00a0Patienten \u00a0mit\u00a0Morbus\u00a0\nCushing,\u00a0f\u00fcr\u00a0die\u00a0ein\u00a0chirurgischer \u00a0Eingriff\u00a0keine\u00a0Option\u00a0ist\u00a0oder\u00a0bei\u00a0denen\u00a0ein\u00a0chirurgischer \u00a0Eingriff\u00a0\nfehlgeschlagen \u00a0ist\u00a0(Novartis, \u00a02015a),\u00a0zugelassen. \u00a0Da\u00a0es\u00a0sich\u00a0beim\u00a0Morbus\u00a0Cushing\u00a0um\u00a0eine\u00a0seltene\u00a0\nErkrankung \u00a0handelt,\u00a0wurde\u00a0Pasireotid \u00a0als\u00a0Arzneimittel \u00a0f\u00fcr\u00a0seltene\u00a0Leiden\u00a0(Orphan\u00a0Drug )\u00a0\nausgewiesen. \u00a0\u00a0\nDie\u00a0empfohlene \u00a0Anfangsdosierung \u00a0betr\u00e4gt\u00a00,6\u00a0mg\u00a0als\u00a0subkutane \u00a0Injektion\u00a0zweimal\u00a0t\u00e4glich.\u00a0Zwei\u00a0\nMonate\u00a0nach\u00a0Beginn\u00a0der\u00a0Behandlung \u00a0sollte\u00a0bei\u00a0den\u00a0Patienten \u00a0der\u00a0klinische\u00a0Nutzen\u00a0beurteilt\u00a0werden.\u00a0\nPatienten \u00a0mit\u00a0einer\u00a0signifikanten \u00a0Abnahme \u00a0des\u00a0freien\u00a0Cortisols\u00a0im\u00a0Urin\u00a0sollten\u00a0so\u00a0lange\u00a0behandelt \u00a0\nwerden,\u00a0wie\u00a0der\u00a0Nutzen\u00a0anh\u00e4lt.\u00a0Abh\u00e4ngig \u00a0vom\u00a0Ansprechen \u00a0auf\u00a0die\u00a0Behandlung \u00a0kann\u00a0eine\u00a0\nDosiserh\u00f6hung \u00a0auf\u00a00,9\u00a0mg\u00a0in\u00a0Betracht\u00a0gezogen\u00a0werden,\u00a0soweit\u00a0die\u00a0Dosis\u00a0von\u00a00,6\u00a0mg\u00a0vom\u00a0Patienten \u00a0\ngut\u00a0vertragen \u00a0wurde.\u00a0Sollte\u00a0nach\u00a0einer\u00a0zweimonatigen \u00a0Therapie\u00a0der\u00a0Patient\u00a0nicht\u00a0ausreichend \u00a0auf\u00a0\nden\u00a0Wirkstoff \u00a0angesprochen \u00a0haben,\u00a0ist\u00a0eine\u00a0Beendigung \u00a0der\u00a0Behandlung \u00a0in\u00a0Erw\u00e4gung \u00a0zu\u00a0ziehen\u00a0\n(Novartis, \u00a02015a).\u00a0\nEnde\u00a02014\u00a0erteilte\u00a0die\u00a0Europ\u00e4ische \u00a0Kommission \u00a0die\u00a0europaweite \u00a0Zulassung \u00a0f\u00fcr\u00a0Signifor\u00ae\u00a0zur\u00a0\nBehandlung \u00a0von\u00a0erwachsenen \u00a0Patienten \u00a0mit\u00a0Akromegalie, \u00a0f\u00fcr\u00a0die\u00a0ein\u00a0chirurgischer \u00a0Eingriff\u00a0keine\u00a0\nOption\u00a0ist\u00a0oder\u00a0nicht\u00a0kurativ\u00a0erfolgreich \u00a0war,\u00a0und\u00a0die\u00a0unter\u00a0der\u00a0Behandlung \u00a0mit\u00a0einem\u00a0anderen\u00a0\nSomatostatin \u2010Analogon \u00a0unzureichend \u00a0kontrolliert \u00a0sind\u00a0(EMA,\u00a02014d;\u00a0Novartis,\u00a02015b).\u00a0Hier\u00a0betr\u00e4gt\u00a0\u00a0\n212\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0die\u00a0empfohlene \u00a0Anfangsdosierung \u00a040\u00a0mg\u00a0Pasireotid \u00a0alle\u00a0vier\u00a0Wochen.\u00a0Bei\u00a0Patienten, \u00a0bei\u00a0denen\u00a0nach\u00a0\ndreimonatiger \u00a0Behandlung \u00a0mit\u00a040\u00a0mg\u00a0Signifor\u00ae\u00a0der\u00a0GH\u00a0und\u00a0der\u00a0IGF\u20101\u2010Plasmaspiegel \u00a0nicht\u00a0vollst\u00e4ndig \u00a0\nkontrolliert \u00a0sind,\u00a0kann\u00a0die\u00a0Dosis\u00a0auf\u00a0maximal\u00a060\u00a0mg\u00a0erh\u00f6ht\u00a0werden\u00a0(Novartis, \u00a02015b).\u00a0\u00a0\n\u00a0Informationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nBeim\u00a0Morbus\u00a0Cushing\u00a0handelt\u00a0es\u00a0sich\n\u00a0um\u00a0eine\u00a0Sonderform \u00a0des\u00a0Cushing\u2010Syndroms. \u00a0Die\u00a0Ursache\u00a0der\u00a0\nErkrankung \u00a0liegt\u00a0in\u00a0einem\u00a0Adrenocorticotropes \u2010Hormon(ACTH) \u2010produzierenden \u00a0Mikro\u2010\u00a0(unter\u00a0einem\u00a0\nZentimeter \u00a0Gr\u00f6\u00dfe)\u00a0oder\u00a0Makroadenom \u00a0(\u00fcber\u00a0einem\u00a0Zentimeter \u00a0Gr\u00f6\u00dfe)\u00a0des\u00a0\nHypophysenvorderlappens. \u00a0Durch\u00a0die\u00a0ACTH\u2010stimulierende \u00a0Aussch\u00fcttung \u00a0von\u00a0Cortisol\u00a0aus\u00a0den\u00a0\nNebennieren \u00a0kann\u00a0es\u00a0zu\u00a0einer\u00a0\u00fcberm\u00e4\u00dfigen \u00a0und\u00a0unkontrollierten \u00a0Hormonproduktion \u00a0kommen, \u00a0\nsodass\u00a0ein\u00a0andauernder \u00a0Hypercortisolismus \u00a0vorliegt\u00a0(Netzwerk \u00a0Hypophysen \u2010\u00a0und\u00a0\nNebennierenerkrankungen \u00a0e.V.,\u00a02014).\u00a0\u00a0\nDie\u00a0Diagnostik \u00a0dieser\u00a0seltenen\u00a0Erkrankung \u00a0erfolgt\u00a0\u00fcber\u00a0die\u00a0Messung\u00a0von\u00a0Cortisol\u00a0und\u00a0ACTH\u00a0im\u00a0Blut.\u00a0\nW\u00e4hrend \u00a0bei\u00a0einem\u00a0ACTH\u2010abh\u00e4ngigen \u00a0Cushing\u2010Syndrom\u00a0erh\u00f6hte\u00a0Cortisol\u2010\u00a0und\u00a0ACTH\u2010Spiegel\u00a0\nvorliegen, \u00a0ist\u00a0bei\u00a0einem\u00a0Cushing\u2010Syndrom\u00a0aufgrund\u00a0eines\u00a0Nebennierenrinden \u2010Prozesses \u00a0der\u00a0Cortisol\u2010\nSpiegel\u00a0im\u00a0Serum\u00a0erh\u00f6ht\u00a0und\u00a0ACTH\u00a0supprimiert \u00a0(Scherbaum, \u00a02015).\u00a0\u00a0\nTypische\u00a0Symptome \u00a0eines\u00a0Morbus\u00a0Cushing\u00a0sind\u00a0u.a.\u00a0neben\u00a0einem\u00a0runden\u00a0Gesicht\u00a0mit\u00a0ger\u00f6teter \u00a0Haut\u00a0\nauch\u00a0ein\u00a0sogenannter \u00a0\u201eStiernacken\u201c, \u00a0Hypertonie, \u00a0Adipositas, \u00a0Hirsutismus \u00a0und\u00a0Diabetes\u00a0mellitus.\u00a0\u00a0\nAuf\u00a0eine\u00a0Millionen \u00a0Einwohner \u00a0werden\u00a0f\u00fcnf\u00a0bis\u00a0zehn\u00a0Patienten \u00a0mit\u00a0einem\u00a0Morbus\u00a0Cushing\u00a0pro\u00a0Jahr\u00a0\nbeobachtet. \u00a0Meist\u00a0erkranken \u00a0die\u00a0Menschen \u00a0zwischen\u00a0dem\u00a020.\u00a0und\u00a050.\u00a0Lebensjahr. \u00a0Aber\u00a0auch\u00a0Kinder\u00a0\nund\u00a0Patienten \u00a0im\u00a0h\u00f6heren\u00a0Lebensalter \u00a0k\u00f6nnen\u00a0betroffen \u00a0sein\u00a0(Netzwerk \u00a0Hypophysen \u2010\u00a0und\u00a0\nNebennierenerkrankungen \u00a0e.V.,\u00a02014).\u00a0\nDer\u00a0Erkrankung \u00a0der\u00a0Akromegalie \u00a0liegt\u00a0ebenfalls\u00a0eine\u00a0chronische \u00a0\u00dcberproduktion \u00a0des\u00a0\nWachstumshormons \u00a0zugrunde, \u00a0die\u00a0von\u00a0einem\u00a0in\u00a0der\u00a0Regel\u00a0oft\u00a0gutartigen \u00a0Tumor\u00a0der\u00a0Hypophyse \u00a0\nverursacht \u00a0wird.\u00a0Letztendlich \u00a0f\u00fchrt\u00a0die\u00a0andauernde \u00a0\u00dcberproduktion \u00a0bei\u00a0Erwachsenen \u00a0zu\u00a0einem\u00a0\nWachstum \u00a0von\u00a0Weichteilen, \u00a0inneren\u00a0Organen\u00a0und\u00a0des\u00a0Skeletts\u00a0im\u00a0Bereich\u00a0von\u00a0H\u00e4nden,\u00a0F\u00fc\u00dfen,\u00a0Kinn\u00a0\nund\u00a0Nase.\u00a0Weitere\u00a0Symptome \u00a0dieser\u00a0Erkrankung \u00a0sind\u00a0Gelenkbeschwerden, \u00a0Zahnfehlstellungen, \u00a0die\u00a0\nVergr\u00f6\u00dferung \u00a0der\u00a0Zunge\u00a0und\u00a0den\u00a0daraus\u00a0folgenden \u00a0Sprechst\u00f6rungen. \u00a0Diabetes\u00a0mellitus,\u00a0\nBluthochdruck \u00a0sowie\u00a0kardiale\u00a0Erkrankungen \u00a0sind\u00a0m\u00f6gliche\u00a0Folgeerkrankungen \u00a0der\u00a0Akromegalie. \u00a0Die\u00a0\ndurchschnittliche \u00a0Lebenserwartung \u00a0erkrankter \u00a0Personen \u00a0liegt\u00a0ungef\u00e4hr\u00a0zehn\u00a0Jahre\u00a0unter\u00a0der\u00a0der\u00a0\nNormalbev\u00f6lkerung \u00a0(IQWiG,\u00a02015).\u00a0\u00a0\n\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDas\u00a0Somatostatin \u2010Analogon \u00a0wurde\u00a0zun\u00e4chst\u00a0in\u00a0einer\u00a0offenen,\u00a0einarmigen \u00a0Phase\u2010II\u2010Studie\u00a0an\u00a029\u00a0\nPatienten \u00a0mit\u00a0Morbus\u00a0Cushing\u00a0(Boscaro\u00a0et\u00a0al.,\u00a02009)\u00a0untersucht. \u00a0Untersuchungsgegenstand \u00a0war\u00a0die\u00a0\nEntwicklung \u00a0des\u00a0Cortisol\u2010Gehalts\u00a0im\u00a0Urin\u00a0nach\u00a0einer\u00a015t\u00e4gigen \u00a0Behandlung \u00a0mit\u00a0Pasireotid. \u00a0Bei\u00a076\u00a0\nProzent\u00a0der\u00a0Patienten \u00a0hatte\u00a0sich\u00a0nach\u00a0dieser\u00a0Behandlungsdauer \u00a0die\u00a0Cortisolausscheidung \u00a0im\u00a0Urin\u00a0\nabgesenkt, \u00a0von\u00a0diesen\u00a0hatten\u00a017\u00a0Prozent\u00a0Cortisol\u2010freien\u00a0Urin\u00a0nach\u00a0einer\u00a015t\u00e4gigen \u00a0Behandlung. \u00a0\nZulassungsrelevante \u00a0Daten\u00a0lieferte\u00a0schlie\u00dflich \u00a0eine\u00a0randomisierte \u00a0Doppelblindstudie \u00a0mit\u00a0insgesamt \u00a0 \n213\u00a0\n\u00a0\nHintergrundinformationen \u00a0162\u00a0Morbus\u00a0Cushing\u2010Patienten, \u00a0bei\u00a0denen\u00a0entweder \u00a0ein\u00a0rezidivierender \u00a0oder\u00a0nicht\u00a0operabler \u00a0Morbus\u00a0\nCushing\u00a0diagnostiziert \u00a0worden\u00a0war\u00a0(Colao\u00a0et\u00a0al.,\u00a02012).\u00a0Die\u00a0Studienteilnehmer \u00a0erhielten\u00a0entweder \u00a0\n600\u00a0oder\u00a0900\u00a0\u00b5g\u00a0Pasireotid \u00a0zweimal\u00a0t\u00e4glich\u00a0subkutan. \u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0dieser\u00a0Studie\u00a0war\u00a0der\u00a0Anteil\u00a0\nder\u00a0Patienten, \u00a0die\u00a0nach\u00a0sechsmonatiger \u00a0Therapie\u00a0einen\u00a0normalisierten \u00a0Cortisol\u2010Spiegel\u00a0im\u00a0Urin\u00a0\naufwiesen. \u00a0Die\u00a0Behandlung \u00a0wurde\u00a0im\u00a0Anschluss \u00a0als\u00a0open\u2010label\u00a0f\u00fcr\u00a0die\u00a0n\u00e4chsten\u00a0sechs\u00a0Monate\u00a0\nweitergef\u00fchrt \u00a0(Colao\u00a0et\u00a0al.,\u00a02012).\u00a012\u00a0der\u00a082\u00a0Patienten \u00a0(15\u00a0Prozent)\u00a0aus\u00a0dem\u00a0Behandlungsarm \u00a0mit\u00a0\n600\u00a0\u00b5g\u00a0Pasireotid \u00a0und\u00a021\u00a0der\u00a080\u00a0Patienten \u00a0(26\u00a0Prozent)\u00a0aus\u00a0dem\u00a0Behandlungsarm \u00a0mit\u00a0900\u00a0\u00b5g\u00a0\nPasireotid \u00a0erreichten \u00a0den\u00a0prim\u00e4ren \u00a0Endpunkt. \u00a0Die\u00a0mediane\u00a0urin\u00e4re\u00a0Cortisolausscheidung \u00a0hatte\u00a0\nbereits\u00a0nach\u00a0einer\u00a0zweimonatigen \u00a0Behandlung \u00a0um\u00a0die\u00a0H\u00e4lfte\u00a0abgenommen. \u00a0Das\u00a0Niveau\u00a0konnte\u00a0in\u00a0\nbeiden\u00a0Behandlungsarmen \u00a0bis\u00a0zum\u00a0Studienende \u00a0nach\u00a0zw\u00f6lf\u00a0Monaten\u00a0gehalten\u00a0werden.\u00a0Mittlerweile \u00a0\nliegen\u00a0Daten\u00a0einer\u00a0Langzeitstudie \u00a0vor,\u00a0die\u00a0die\u00a0Wirksamkeit \u00a0und\u00a0Sicherheit \u00a0von\u00a0Pasireotid \u00a0\u00fcber\u00a024\u00a0\nMonate\u00a0untersuchte \u00a0(Boscaro\u00a0et\u00a0al.,\u00a02014)\u00a0und\u00a0aufgrund\u00a0der\u00a0Ergebnisse \u00a0den\u00a0Wirkstoff \u00a0auch\u00a0als\u00a0\nm\u00f6gliche\u00a0Option\u00a0in\u00a0der\u00a0Langzeittherapie \u00a0sieht.\u00a0Zu\u00a0beachten \u00a0ist\u00a0allerdings \u00a0die\u00a0geringe\u00a0Fallzahl\u00a0(n\u00a0=\u00a019).\u00a0\nDen\u00a0positiven\u00a0Effekten\u00a0von\u00a0Pasireotid \u00a0stehen\u00a0unerw\u00fcnschte \u00a0Ereignisse \u00a0gegen\u00fcber. \u00a0In\u00a0der\u00a0Studie\u00a0\nB2305\u00a0(Colao\u00a0et\u00a0al.,\u00a02012)\u00a0kam\u00a0es\u00a0bei\u00a0der\u00a0H\u00e4lfte\u00a0der\u00a0Patienten \u00a0zu\u00a0Nebenwirkungen \u00a03.\u00a0oder\u00a04.\u00a0Grades.\u00a0\nUnter\u00a0dem\u00a0neuen\u00a0Wirkstoff \u00a0wurden\u00a0h\u00e4ufiger\u00a0Hyperglyk\u00e4mien \u00a0diagnostiziert, \u00a0weswegen \u00a0der\u00a0\nBlutzucker \u00a0bei\u00a0den\u00a0behandelten \u00a0Patienten \u00a0regelm\u00e4\u00dfig \u00a0kontrolliert \u00a0werden\u00a0sollte\u00a0(Ceccato\u00a0et\u00a0al.,\u00a0\n2015).\u00a0Auch\u00a0wird\u00a0eine\u00a0klinische\u00a0\u00dcberwachung \u00a0der\u00a0Herzfrequenz \u00a0vor\u00a0allem\u00a0zu\u00a0Behandlungsbeginn \u00a0bei\u00a0\nden\u00a0Patienten \u00a0empfohlen, \u00a0die\u00a0Pasireotid \u00a0zusammen \u00a0mit\u00a0Bradykardie \u2010ausl\u00f6senden \u00a0Arzneimitteln \u00a0\nbekommen \u00a0(Betablocker, \u00a0Anticholinergika, \u00a0Calciumkanalblocker, \u00a0Antiarrhythmika). \u00a0Gleiches\u00a0gilt\u00a0f\u00fcr\u00a0\nPatienten, \u00a0die\u00a0zus\u00e4tzlich \u00a0Arzneimittel \u00a0erhalten,\u00a0die\u00a0das\u00a0QT\u2010Intervall\u00a0verl\u00e4ngern \u00a0(Novartis, \u00a02015a).\u00a0\u00a0\nDie\u00a0Zulassung \u00a0des\u00a0Wirkstoffes \u00a0zur\u00a0Behandlung \u00a0der\u00a0Akromegalie \u00a0beruht\u00a0auf\u00a0einer\u00a0Pivotalstudie \u00a0\n(C2402).\u00a0In\u00a0dieser\u00a0klinischen \u00a0Untersuchung \u00a0wurden\u00a0die\u00a0Patienten \u00a0auf\u00a0zwei\u00a0Pasireotid \u2010\nInterventionsgruppen \u00a0(doppelblind, \u00a040\u00a0oder\u00a060\u00a0mg)\u00a0und\u00a0eine\u00a0Kontrollgruppe, \u00a0in\u00a0der\u00a0die\u00a0bisherige\u00a0\nBehandlung \u00a0mit\u00a0einem\u00a0Somatostatin \u2010Analogon \u00a0fortgesetzt \u00a0wurde,\u00a0aufgeteilt \u00a0(Gadelha\u00a0et\u00a0al.,\u00a02014).\u00a0\nInsgesamt \u00a0betrug\u00a0die\u00a0Behandlungsdauer \u00a024\u00a0Wochen.\u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0dieser\u00a0Studie\u00a0war\u00a0der\u00a0Anteil\u00a0\nder\u00a0Patienten \u00a0mit\u00a0biochemischer \u00a0Kontrolle\u00a0\u2013\u00a0definiert\u00a0als\u00a0ein\u00a0Wachstumshormon \u2010(GH)Wert \u00a0<\u00a02,5\u00a0\u03bcg/l\u00a0\nund\u00a0Normalisierung \u00a0des\u00a0f\u00fcr\u00a0Geschlecht \u00a0und\u00a0Alter\u00a0adjustierten \u00a0Insulin\u2010\u00e4hnlichen \u00a0Wachstumsfaktor \u00a0\n(IGF)\u20101\u2010Wertes\u00a0im\u00a0Serum\u00a0nach\u00a024\u00a0Wochen.\u00a0Zu\u00a0den\u00a0sekund\u00e4ren \u00a0Endpunkten \u00a0z\u00e4hlten\u00a0der\u00a0Anteil\u00a0der\u00a0\nPatienten \u00a0mit\u00a0einer\u00a0Reduktion \u00a0des\u00a0Tumorvolumens, \u00a0Ver\u00e4nderungen \u00a0in\u00a0der\u00a0Akromegalie \u2010\nSymptomatik, \u00a0Lebensqualit\u00e4t, \u00a0Sicherheit \u00a0und\u00a0Vertr\u00e4glichkeit. \u00a0Den\u00a0prim\u00e4ren \u00a0Endpunkt \u00a0erreichten \u00a015\u00a0\nProzent\u00a0aus\u00a0der\u00a040\u00a0mg\u2010Verum\u2010Gruppe\u00a0und\u00a020\u00a0Prozent\u00a0aus\u00a0der\u00a060\u00a0mg\u2010Verum\u2010Gruppe\u00a0(vs.\u00a0null\u00a0Prozent\u00a0\naus\u00a0der\u00a0aktiven\u00a0Kontrollgruppe). \u00a0Auch\u00a0hinsichtlich \u00a0der\u00a0Ver\u00e4nderung \u00a0der\u00a0Kopfschmerzsymptomatik \u00a0\ngab\u00a0es\u00a0einen\u00a0statistisch \u00a0signifikanten \u00a0Effekt\u00a0zugunsten \u00a0der\u00a0Interventionsgruppen. \u00a0Bei\u00a0den\u00a0anderen\u00a0\nAkromegalie \u2010Symptomen \u00a0wie\u00a0beispielsweise \u00a0Fatigue,\u00a0Par\u00e4sthesie, \u00a0Osteoarthralgie \u00a0oder\u00a0Ringgr\u00f6\u00dfe \u00a0\ngab\u00a0es\u00a0allerdings \u00a0keinen\u00a0signifikanten \u00a0Unterschied \u00a0im\u00a0Vergleich \u00a0zur\u00a0aktiven\u00a0Kontrollgruppe \u00a0(Gadelha\u00a0\net\u00a0al.,\u00a02014).\u00a0Die\u00a0supportive \u00a0Studie\u00a0C2305\u00a0(Colao\u00a0et\u00a0al.,\u00a02014)\u00a0schloss\u00a0therapienaive \u00a0erwachsene \u00a0\nPatienten \u00a0mit\u00a0Akromegalie \u00a0ein\u00a0und\u00a0teilte\u00a0sie\u00a0auf\u00a0eine\u00a0Pasireotid \u2010Interventionsgruppe \u00a0(40\u00a0mg,\u00a0\nlangwirkend) \u00a0oder\u00a0eine\u00a0Octreotid \u2010Kontrollgruppe \u00a0(20\u00a0mg,\u00a0langwirkend) \u00a0zu.\u00a0Der\u00a0prim\u00e4re\u00a0Endpunkt \u00a0\nentsprach \u00a0dem\u00a0der\u00a0C2402\u2010Studie.\u00a0Dieser\u00a0wurde\u00a0im\u00a0Vergleich \u00a0zu\u00a0Octreotid \u00a0von\u00a0signifikant \u00a0mehr\u00a0\nPasireotid \u2010behandelten \u00a0Patienten \u00a0erreicht\u00a0(31,3\u00a0Prozent\u00a0vs.\u00a019,2\u00a0Prozent,\u00a0p\u00a0=\u00a00,007).\u00a0\u00a0\n \u00a0\u00a0\n214\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Leitlinienempfehlungen \u00a0\nIn\u00a0der\u00a0einzigen\u00a0deutschsprachigen \u00a0Leitlinie\u00a0zum\u00a0Cushing\u00a0Syndrom, \u00a0die\u00a0Leitlinie\u00a0der\u00a0Deutschen \u00a0\nGesellschaft \u00a0f\u00fcr\u00a0Kinderheilkunde \u00a0und\u00a0Jugendmedizin, \u00a0wird\u00a0keine\u00a0medikament\u00f6se \u00a0Therapieoption \u00a0f\u00fcr\u00a0\nMorbus\u00a0Cushing\u00a0(DGKJ,\u00a02010)\u00a0empfohlen. \u00a0Bis\u00a0zum\u00a0Zeitpunkt \u00a0der\u00a0Zulassung \u00a0von\u00a0Pasireotid \u00a0bestand\u00a0\ndie\u00a0erfolgreiche \u00a0Therapie\u00a0des\u00a0Morbus\u00a0Cushing\u00a0aus\u00a0der\u00a0chirurgischen \u00a0Entfernung \u00a0des\u00a0Tumors\u00a0oder\u00a0der\u00a0\nNebennieren \u00a0oder\u00a0alternativ \u00a0aus\u00a0der\u00a0Radiotherapie \u00a0bei\u00a0Relapse .\u00a0Die\u00a0bis\u00a0dato\u00a0in\u00a0dieser\u00a0Indikation \u00a0\u00a0\nunternommenen \u00a0pharmakotherapeutischen \u00a0Behandlungsversuche \u00a0mit\u00a0beispielsweise \u00a0Ketoconazol, \u00a0\nCabergolin \u00a0oder\u00a0Mifepriston \u00a0waren\u00a0ausschlie\u00dflich \u00a0Off\u2010Label\u2010Anwendungen \u00a0(Mancini\u00a0et\u00a0al.,\u00a02010).\u00a0\u00a0\nWie\u00a0bei\u00a0Morbus\u00a0Cushing\u00a0ist\u00a0auch\u00a0bei\u00a0der\u00a0Akromegalie \u00a0eine\u00a0vollst\u00e4ndige \u00a0chirurgische \u00a0Entfernung \u00a0des\u00a0\nTumors\u00a0und\u00a0damit\u00a0die\u00a0Heilung\u00a0der\u00a0Erkrankung \u00a0die\u00a0Therapie\u00a0der\u00a0Wahl.\u00a0Ist\u00a0ein\u00a0solches\u00a0Vorgehen \u00a0\nkontraindiziert \u00a0oder\u00a0war\u00a0eine\u00a0Operation \u00a0nicht\u00a0erfolgreich, \u00a0wird\u00a0in\u00a0der\u00a0Regel\u00a0versucht, \u00a0die\u00a0Erkrankung \u00a0\nmedikament\u00f6s \u00a0oder\u00a0mittels\u00a0Radiotherapie \u00a0zu\u00a0behandeln. \u00a0Bei\u00a0der\u00a0medikament\u00f6sen \u00a0Therapie\u00a0kommen\u00a0\nvor\u00a0allem\u00a0Somatostatin \u2010Analoga\u00a0wie\u00a0Lanreotid \u00a0oder\u00a0Octreotid \u00a0im\u00a0In\u2010Label\u00a0Use\u00a0zum\u00a0Einsatz.\u00a0\nSogenannte \u00a0Dopamin\u2010Agonisten \u00a0(Cabergolin) \u00a0waren\u00a0die\u00a0ersten\u00a0Medikamente, \u00a0die\u00a0zur\u00a0Hemmung \u00a0der\u00a0\nSekretion \u00a0des\u00a0Wachstumshormons \u00a0bei\u00a0der\u00a0Akromegalie \u00a0eingesetzt \u00a0wurden\u00a0(Deutsches \u00a0Akromegalie \u2010\nRegister,\u00a02015).\u00a0Seit\u00a02003\u00a0steht\u00a0au\u00dferdem \u00a0ein\u00a0synthetischer \u00a0Wachstumshormon \u2010Rezeptor\u2010Antagonist \u00a0\nzur\u00a0Verf\u00fcgung \u00a0(Pegvisomant), \u00a0der\u00a0an\u00a0die\u00a0auf\u00a0der\u00a0Zelloberfl\u00e4che \u00a0vorhandenen \u00a0Wachstumhorm \u2010\nRezeptoren \u00a0bindet\u00a0und\u00a0so\u00a0kompetitiv \u00a0die\u00a0Bindung\u00a0des\u00a0k\u00f6rpereigenen \u00a0Hormons \u00a0hemmt.\u00a0Die\u00a0\nKonzentration \u00a0des\u00a0Wachstumshormons \u00a0im\u00a0Blut\u00a0bleibt\u00a0unter\u00a0der\u00a0Behandlung \u00a0mit\u00a0Pegvisomant \u00a0\nunver\u00e4ndert \u00a0hoch\u00a0oder\u00a0steigt\u00a0sogar\u00a0an,\u00a0es\u00a0kann\u00a0aber\u00a0keine\u00a0Wirkung\u00a0mehr\u00a0entfaltet\u00a0werden\u00a0\n(Deutsches \u00a0Akromegalie \u2010Register,\u00a02015).\u00a0\n\u00a0\nNutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nNach\u00a0den\u00a0Vorgaben \u00a0des\u00a0Arzneimittelmarktneuordnungsgesetzes \u00a0(AMNOG) \u00a0gilt\u00a0bei\u00a0einem\u00a0Orphan\u00a0\nDrug\u00a0wie\u00a0Pasireotid \u00a0der\u00a0Zusatznutzen \u00a0mit\u00a0der\u00a0Zulassung \u00a0als\u00a0belegt,\u00a0solange\u00a0sich\u00a0das\u00a0Arzneimittel \u00a0nicht\u00a0\nzu\u00a0einem\u00a0umsatzstarken \u00a0Arzneimittel \u00a0entwickelt. \u00a0Daher\u00a0bewertet \u00a0der\u00a0G\u2010BA\u00a0nur\u00a0noch\u00a0das\u00a0Ausma\u00df\u00a0\neines\u00a0Zusatznutzens. \u00a0\nF\u00fcr\u00a0Patienten, \u00a0bei\u00a0denen\u00a0die\u00a0Behandlung \u00a0mit\u00a0Pasireotid \u00a0angezeigt \u00a0ist,\u00a0da\u00a0ein\u00a0chirurgischer \u00a0Eingriff\u00a0\nkeine\u00a0Option\u00a0darstellt\u00a0oder\u00a0bei\u00a0denen\u00a0ein\u00a0chirurgischer \u00a0Eingriff\u00a0fehlgeschlagen \u00a0ist,\u00a0konstatierte \u00a0der\u00a0\nGemeinsame \u00a0Bundesausschuss \u00a0in\u00a0seinem\u00a0Beschluss \u00a0vom\u00a06.\u00a0Dezember \u00a02012\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0\nZusatznutzens \u00a0als\u00a0gering\u00a0(G\u2010BA,\u00a02012d).\u00a0Begr\u00fcndet \u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0seine\u00a0Entscheidung \u00a0darin,\u00a0dass\u00a0\nderzeit\u00a0noch\u00a0keine\u00a0Aussage\u00a0zum\u00a0Endpunkt \u00a0Gesamt\u00fcberleben \u00a0getroffen \u00a0werden\u00a0kann.\u00a0Eine\u00a0dauerhafte \u00a0\nSenkung\u00a0des\u00a0pathologisch \u00a0erh\u00f6hten \u00a0Serum\u2010Cortisolspiegels \u00a0sei\u00a0nach\u00a0Auffassung \u00a0des\u00a0G\u2010BA\u00a0zwar\u00a0\npatientenrelevant, \u00a0aufgrund\u00a0der\u00a0begrenzten \u00a0Studiendauer \u00a0liegen\u00a0jedoch\u00a0keine\u00a0Daten\u00a0vor,\u00a0die\u00a0eine\u00a0\nNachhaltigkeit \u00a0des\u00a0Effektes\u00a0zeigen\u00a0und\u00a0eine\u00a0Bewertung \u00a0von\u00a0Pasireotid \u00a0f\u00fcr\u00a0die\u00a0Langzeitanwendung \u00a0\nzulassen.\u00a0Ferner\u00a0f\u00fchrt\u00a0der\u00a0G\u2010BA\u00a0an,\u00a0dass\u00a0ein\u00a0hoher\u00a0Anteil\u00a0an\u00a0Patienten \u00a0nicht\u00a0oder\u00a0nicht\u00a0ausreichend \u00a0\nauf\u00a0die\u00a0Therapie\u00a0mit\u00a0Pasireotid \u00a0anspricht \u00a0(Non\u2010Responder ).\u00a0So\u00a0war\u00a0neben\u00a0dem\u00a0Auftreten \u00a0\nunerw\u00fcnschter \u00a0Ereignisse \u00a0ein\u00a0nicht\u00a0befriedigendes \u00a0Therapieansprechen \u00a0der\u00a0h\u00e4ufigste \u00a0Grund\u00a0f\u00fcr\u00a0\neinen\u00a0Studienabbruch \u00a0gem\u00e4\u00df\u00a0Intention\u2010To\u2010Treat\u2010Prinzip.\u00a0\nZu\u00a0der\u00a0gleichen\u00a0Bewertung \u00a0kam\u00a0der\u00a0Ausschuss \u00a0bei\u00a0dem\u00a0Indikationsgebiet \u00a0\u201eAkromegalie\u201c. \u00a0Auch\u00a0hier\u00a0\nkonstatierte \u00a0der\u00a0G\u2010BA\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens \u00a0als\u00a0gering\u00a0f\u00fcr\u00a0Patienten, \u00a0bei\u00a0denen\u00a0eine\u00a0 \n215\u00a0\n\u00a0\nHintergrundinformationen \u00a0chirurgische \u00a0Behandlung \u00a0nicht\u00a0erfolgreich \u00a0war\u00a0oder\u00a0nicht\u00a0in\u00a0Frage\u00a0kommt,\u00a0und\u00a0die\u00a0auf\u00a0eine\u00a0\nBehandlung \u00a0mit\u00a0einem\u00a0anderen\u00a0Somatostatin \u2010Analogon \u00a0nicht\u00a0ausreichend \u00a0angesprochen \u00a0haben.\u00a0In\u00a0\nder\u00a0Gesamtbetrachtung \u00a0der\u00a0Ergebnisse \u00a0zur\u00a0Morbidit\u00e4t, \u00a0zur\u00a0Lebensqualit\u00e4t \u00a0und\u00a0zu\u00a0den\u00a0\nNebenwikungen \u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0keine\u00a0nachhaltige \u00a0bisher\u00a0nicht\u00a0erreichte\u00a0deutliche \u00a0Verbesserung \u00a0des\u00a0\ntherapierelevanten \u00a0Nutzens,\u00a0insbesondere \u00a0keine\u00a0Abschw\u00e4chung \u00a0schwerwiegender \u00a0Symptome \u00a0oder\u00a0\neine\u00a0f\u00fcr\u00a0die\u00a0Patientinnen \u00a0und\u00a0Patienten \u00a0sp\u00fcrbare\u00a0Linderung \u00a0der\u00a0Erkrankung. \u00a0Au\u00dferdem \u00a0m\u00fcssen\u00a0die\u00a0\npositiven\u00a0Effekte\u00a0bei\u00a0der\u00a0biochemischen \u00a0Kontrolle\u00a0und\u00a0der\u00a0Verbesserung \u00a0der\u00a0Kopfschmerzen \u00a0\nabgewogen \u00a0werden\u00a0gegen\u00fcber \u00a0den\u00a0negativen \u00a0Effekten\u00a0der\u00a0erh\u00f6hten \u00a0Nebenwirkungen. \u00a0\n\u00a0Kosten\u00a0\nWirkstof f\u00a0 Behandlungsmodus Behandlungstage Jahrestherapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nPasireotid  2\u00a0x\u00a0t\u00e4glich\u00a00,9\u00a0mg 360 46.626,48 \u00a0\u20ac\nTabelle\u00a038:\u00a0Jahrestherapiekosten \u00a0von\u00a0Pasireotid \u00a0f\u00fcr\u00a0(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen). \u00a0Zugelassenes \u00a0\nAnwendungsgebiet: \u00a0Morbus\u00a0Cushing\u00a0\u00a0\n\u00a0\nWirkstof f\u00a0 Behandlungsmodus Behandlungstage Jahrestherapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nPasireotid  1\u00a0x\u00a0alle\u00a04\u00a0Wochen\u00a040\u00a0mg 13 44.749,25 \u00a0\u20ac\nTabelle\u00a039:\u00a0Jahrestherapiekosten \u00a0von\u00a0Pasireotid \u00a0f\u00fcr\u00a0(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen). \u00a0Zugelassenes \u00a0\nAnwendungsgebiet: \u00a0Akromegalie \u00a0\n\u00a0\u00a0\u00a0\n216\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a011.14  Perampanel \u00a0\nHandelsname: \u00a0Fycompa\u00ae     Hersteller: \u00a0Eisai \nIndikation: \u00a0Epilepsie\u00a0(Zusatztherapie \u00a0fokale\u00a0Anf\u00e4lle)\u00a0Markteinf\u00fchrung: \u00a0September \u00a02012 \nATC\u2010Code:\u00a0N03AX22      DDD:\u00a08\u00a0mg \nDarreichungsform: \u00a0Filmtablette  \nBewertung: \u00a0siehe\u00a0Seite\u00a082 \nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nDer\u00a0Wirkstoff \u00a0Perampanel \u00a0geh\u00f6rt\u00a0zur\u00a0pharmakotherapeutischen \u00a0Gruppe\u00a0der\u00a0Antiepileptika \u00a0und\u00a0ist\u00a0\nder\u00a0erste\u00a0Vertreter \u00a0der\u00a0Wirkstoffklasse \u00a0der\u00a0selektiven, \u00a0nicht\u2010kompetitiven \u00a0Antagonisten \u00a0des\u00a0\nGlutamat \u2010Rezeptors \u00a0vom\u00a0Typ\u00a0AMPA\u00a0(\u03b1\u2010Amino\u20103\u2010hydroxy\u20105\u2010methyl\u20104\u2010isoxazolproprions\u00e4ure) \u00a0(Eisai,\u00a0\n2014).\u00a0\u00a0\nAMPA\u00a0ist\u00a0ein\u00a0synthetischer \u00a0Agonist,\u00a0der\u00a0den\u00a0Rezeptor\u00a0spezifisch \u00a0aktiviert\u00a0und\u00a0daher\u00a0namensgebend \u00a0\nwar.\u00a0Durch\u00a0Rezeptoraktivierung \u00a0wird\u00a0die\u00a0Leitf\u00e4higkeit \u00a0postsynaptischer \u00a0Membranen \u00a0ver\u00e4ndert. \u00a0\nAls\u00a0prim\u00e4rer\u00a0exzitatorischer \u00a0Neurotransmitter \u00a0im\u00a0zentralen \u00a0Nervensystem \u00a0soll\u00a0Glutamat \u00a0bei\u00a0einer\u00a0\nReihe\u00a0neurologischer \u00a0Erkrankungen, \u00a0die\u00a0ihren\u00a0Ursprung \u00a0in\u00a0einer\u00a0\u00fcberm\u00e4\u00dfigen \u00a0neuronalen \u00a0Erregung\u00a0\nfinden,\u00a0eine\u00a0entscheidende \u00a0Rolle\u00a0einnehmen. \u00a0Durch\u00a0Aktivierung \u00a0der\u00a0AMPA\u2010Rezeptoren, \u00a0die\u00a0in\u00a0fast\u00a0\nallen\u00a0exzitatorischen \u00a0Neuronen \u00a0vorhanden \u00a0sind,\u00a0finden\u00a0m\u00f6glicherweise \u00a0schnelle\u00a0exzitatorische \u00a0\nsynaptische \u00a0Signal\u00fcbertragungen \u00a0im\u00a0Gehirn\u00a0statt\u00a0(Eisai,\u00a02014).\u00a0Der\u00a0genaue\u00a0Wirkmechanismus \u00a0von\u00a0\nPerampanel \u00a0ist\u00a0nicht\u00a0gekl\u00e4rt.\u00a0In\u2010vitro\u2010Studien\u00a0legen\u00a0jedoch\u00a0den\u00a0Verdacht\u00a0nahe,\u00a0dass\u00a0er\u00a0auf\u00a0dem\u00a0nicht\u2010\nkompetitiven \u00a0Antagonismus \u00a0des\u00a0Neurotransmitters \u00a0Glutamat \u00a0am\u00a0AMPA\u2010Rezeptor\u00a0beruht.\u00a0Durch\u00a0\nAbschw\u00e4chung \u00a0der\u00a0Glutamat \u2010Wirkung\u00a0und\u00a0der\u00a0daraus\u00a0resultierenden \u00a0Hemmung \u00a0der\u00a0durch\u00a0AMPA\u2010\nRezeptoren \u00a0vermittelten \u00a0postsynaptischen \u00a0\u00dcbererregung \u00a0k\u00f6nnen\u00a0letztendlich \u00a0epileptische \u00a0Anf\u00e4lle\u00a0\nreduziert\u00a0werden.\u00a0\u00a0\n\u00a0\nZulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nIm\u00a0Juli\u00a02012\u00a0erfolgte\u00a0die\u00a0europaweite \u00a0Zulassung \u00a0von\u00a0Perampanel \u00a0als\u00a0Zusatztherapie \u00a0fokaler\u00a0Anf\u00e4lle\u00a0\nmit\u00a0oder\u00a0ohne\u00a0sekund\u00e4re \u00a0Generalisierung \u00a0bei\u00a0Epilepsie\u2010Patienten \u00a0ab\u00a0zw\u00f6lf\u00a0Jahren.\u00a0In\u00a0Abh\u00e4ngigkeit \u00a0\nvom\u00a0individuellen \u00a0Ansprechen \u00a0muss\u00a0der\u00a0Wirkstoff \u00a0bis\u00a0zur\u00a0gew\u00fcnschten \u00a0Erhaltungsdosis \u00a0auftitriert \u00a0\nwerden.\u00a0Die\u00a0Einnahme \u00a0erfolgt\u00a0einmal\u00a0t\u00e4glich\u00a0abends\u00a0vor\u00a0dem\u00a0Schlafengehen \u00a0(Eisai,\u00a02014).\u00a0\u00a0\nAufgrund \u00a0des\u00a0negativen \u00a0Votums\u00a0des\u00a0G\u2010BA\u00a0bei\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung \u00a0und\u00a0der\u00a0daraus\u00a0\nresultierenden \u00a0Einstufung \u00a0in\u00a0eine\u00a0Festbetragsgruppe \u00a0nahm\u00a0der\u00a0pU\u00a0das\u00a0Fertigarzneimittel \u00a0Fycompa\u00ae \u00a0\nnach\u00a0einer\u00a0neunmonatigen \u00a0Vermarktungszeit \u00a0aus\u00a0dem\u00a0Handel\u00a0(Eisai,\u00a02013).\u00a0Ziel\u00a0war\u00a0dabei,\u00a0durch\u00a0\neine\u00a0erneute\u00a0G\u2010BA\u2010Nutzenbewertung \u00a0eine\u00a0bessere\u00a0Basis\u00a0f\u00fcr\u00a0die\u00a0Preisverhandlung \u00a0zu\u00a0erzielen.\u00a0Auch\u00a0\ndieses\u00a0Ziel\u00a0wurde\u00a0nicht\u00a0erreicht\u00a0(siehe\u00a0unten).\u00a0\u00a0\n \u00a0 \n217\u00a0\n\u00a0\nHintergrundinformationen \u00a0Informationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nUnter\u00a0einem\u00a0epileptischen \u00a0Anfall\u00a0versteht\u00a0man\u00a0eine\u00a0vor\u00fcbergehende, \u00a0pl\u00f6tzliche \u00a0Dysfunktion \u00a0des\u00a0\nZentralen \u00a0Nervensystems \u00a0(ZN),\u00a0die\u00a0auf\u00a0eine\u00a0gesteigerte \u00a0Erregbarkeit \u00a0(\u00dcbererregbarkeit) \u00a0zentraler\u00a0\nNeurone\u00a0und\u00a0damit\u00a0einer\u00a0Senkung\u00a0der\u00a0Krampfschwelle \u00a0beruht\u00a0und\u00a0mit\u00a0abnormen \u00a0motorischen \u00a0\nReaktionen, \u00a0Bewusstseinsst\u00f6rungen \u00a0bzw.\u00a0Bewusstseinsverlust \u00a0sowie\u00a0teilweise\u00a0auch\u00a0verst\u00e4rkten \u00a0\nvegetativen \u00a0Reaktionen \u00a0einhergeht \u00a0(Mutschler \u00a0et\u00a0al.,\u00a02008).\u00a0In\u00a0Abh\u00e4ngigkeit \u00a0vom\u00a0Ursprungsort \u00a0\nwerden\u00a0nur\u00a0wenige\u00a0Sekunden \u00a0dauernde \u00a0Aussetzer \u00a0(Absencen ),\u00a0Abl\u00e4ufe\u00a0mit\u00a0Zuckungen \u00a0einer\u00a0\nExtremit\u00e4t \u00a0bis\u00a0hin\u00a0zu\u00a0komplexeren \u00a0Bewegungs \u2010\u00a0und\u00a0Bewusstseinsph\u00e4nomenen \u00a0und\u00a0klassische \u00a0\ntonisch\u2010klonische \u00a0Anf\u00e4llen\u00a0unterschieden \u00a0(DGN,\u00a02012).\u00a0Epilepsien \u00a0und\u00a0die\u00a0damit\u00a0verbundenen \u00a0Anf\u00e4lle\u00a0\nhaben\u00a0eine\u00a0Vielzahl\u00a0von\u00a0Ursachen, \u00a0welche\u00a0von\u00a0genetischen \u00a0Dispositionen \u00a0(z.B.\u00a0Ionenkanal \u2010\u00a0oder\u00a0\nTransmitter \u2010Rezeptormutation) \u00a0\u00fcber\u00a0verschiedene \u00a0Stoffwechseldefekte, \u00a0angeborene \u00a0und\u00a0perinatal\u00a0\nerworbene \u00a0Hirnmissbildungen \u00a0bzw.\u00a0\u2010sch\u00e4den,\u00a0\u00fcber\u00a0Entz\u00fcndungs \u2010\u00a0und\u00a0Traumafolgen \u00a0bis\u00a0hin\u00a0zu\u00a0\nHirntumoren, \u00a0vaskul\u00e4ren \u00a0L\u00e4sionen\u00a0und\u00a0tuber\u00f6ser \u00a0Sklerose\u00a0etc.\u00a0reichen\u00a0(DGN,\u00a02012).\u00a0Je\u00a0nach\u00a0\nAusbreitung \u00a0unterscheidet \u00a0man\u00a0fokale\u00a0von\u00a0generalisierten \u00a0epileptischen \u00a0Anf\u00e4llen.\u00a0Letztere\u00a0betreffen \u00a0\nden\u00a0ganzen\u00a0K\u00f6rper,\u00a0w\u00e4hrend\u00a0fokale\u00a0Anf\u00e4lle\u00a0auf\u00a0einen\u00a0kleinen\u00a0Teil\u00a0des\u00a0Gehirns\u00a0begrenzt\u00a0bleiben\u00a0und\u00a0\nsomit\u00a0nur\u00a0einzelne\u00a0K\u00f6rperstellen \u00a0betroffen \u00a0sind.\u00a0Allerdings \u00a0kann\u00a0sich\u00a0ein\u00a0fokaler\u00a0Anfall\u00a0auch\u00a0\u00fcber\u00a0den\u00a0\ngesamten \u00a0K\u00f6rper\u00a0ausbreiten; \u00a0in\u00a0diesem\u00a0Fall\u00a0spricht\u00a0man\u00a0von\u00a0einer\u00a0sekund\u00e4ren \u00a0Generalisierung. \u00a0\u00a0\nF\u00fcr\u00a0den\u00a0therapeutischen \u00a0Erfolg\u00a0ist\u00a0die\u00a0Einteilung \u00a0in\u00a0fokale\u00a0und\u00a0idiopathische, \u00a0generalisierte \u00a0Epilepsien \u00a0\nvon\u00a0enormer\u00a0Bedeutung, \u00a0da\u00a0in\u00a0der\u00a0Gruppe\u00a0der\u00a0generalisierten \u00a0Epilepsiesyndrome \u00a0nicht\u00a0nur\u00a0wenige\u00a0\nMedikamente \u00a0gut\u00a0wirksam\u00a0sind,\u00a0sondern\u00a0bestimmte \u00a0Antikonvulsiva \u00a0auch\u00a0Anf\u00e4lle\u00a0provozieren \u00a0k\u00f6nnen\u00a0\n(Carbamazepin, \u00a0Gabapentin, \u00a0Oxcarbazepin, \u00a0Phenytoin, \u00a0Vigabatrin) \u00a0(DGN,\u00a02012).\u00a0So\u00a0erfolgt\u00a0die\u00a0Wahl\u00a0\nder\u00a0Antiepileptika \u00a0grunds\u00e4tzlich \u00a0auf\u00a0der\u00a0Ebene\u00a0der\u00a0Unterteilung \u00a0fokal\u00a0versus\u00a0generalisiert .\u00a0In\u00a0dieser\u00a0\nKonstellation \u00a0k\u00f6nnen\u00a0Fehldiagnosen \u00a0nicht\u00a0immer\u00a0ausgeschlossen \u00a0werden\u00a0(DGN,\u00a02012).\u00a0\u00a0\nAnf\u00e4lle\u00a0k\u00f6nnen\u00a0auch\u00a0in\u00a0ihrer\u00a0H\u00e4ufigkeit \u00a0variieren. \u00a0Diese\u00a0reichen\u00a0von\u00a0weniger\u00a0als\u00a0einem\u00a0pro\u00a0Jahr\u00a0bis\u00a0\nhin\u00a0zu\u00a0mehreren \u00a0Anf\u00e4llen\u00a0pro\u00a0Tag.\u00a0Auch\u00a0wenn\u00a0Epilepsien \u00a0in\u00a0jedem\u00a0Alter\u00a0auftreten \u00a0k\u00f6nnen,\u00a0werden\u00a0\nbereits\u00a0vor\u00a0dem\u00a010.\u00a0Lebensjahr \u00a0etwa\u00a050\u00a0Prozent\u00a0und\u00a0bis\u00a0zum\u00a020.\u00a0Lebensjahr \u00a0etwa\u00a0zwei\u00a0Drittel\u00a0davon\u00a0\nmanifest\u00a0(Mutschler \u00a0et\u00a0al.,\u00a02008).\u00a0\nDie\u00a0Epilepsie\u00a0ist\u00a0eine\u00a0der\u00a0weltweit\u00a0h\u00e4ufigsten \u00a0neurologischen \u00a0Erkrankungen, \u00a0deren\u00a0Zahl\u00a0auf\u00a0ca.\u00a050\u00a0\nMillionen \u00a0Menschen \u00a0gesch\u00e4tzt \u00a0wird\u00a0(WHO,\u00a02015a).\u00a0\u00a0\n\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nWirksamkeit \u00a0und\u00a0Sicherheit \u00a0von\u00a0Perampanel \u00a0wurden\u00a0in\u00a0drei\u00a0multizentrischen \u00a0randomisierten \u00a0\nklinischen \u00a0Studien\u00a0der\u00a0Phase\u00a0III\u00a0durchgef\u00fchrt. \u00a0Alle\u00a0drei\u00a0Studien\u00a0wiesen\u00a0ein\u00a0\u00e4hnliches \u00a0Studiendesign \u00a0\nauf\u00a0(nach\u00a0einer\u00a0sechsw\u00f6chigen \u00a0Pr\u00e4\u2010Randomisierungsphase \u00a0\u2013\u00a0dreiw\u00f6chige \u00a0Ausgangs \u2010\u00a0und\u00a0daran\u00a0\nanschlie\u00dfende \u00a0dreiw\u00f6chige \u00a0Titrationsphase \u00a0\u2013\u00a0folgte\u00a0eine\u00a0Erhaltungstherapie \u00a0\u00fcber\u00a013\u00a0Wochen). \u00a0In\u00a0die\u00a0\nStudien\u00a0aufgenommen \u00a0wurden\u00a0solche\u00a0Patienten \u00a0mit\u00a0therapieresistenter \u00a0partieller\u00a0Epilepsie\u00a0ab\u00a0zw\u00f6lf\u00a0\nJahren,\u00a0die\u00a0unter\u00a0stabiler\u00a0antiepileptischer \u00a0Therapie\u00a0eine\u00a0definierte \u00a0Anzahl\u00a0Anf\u00e4lle\u00a0in\u00a0der\u00a0Pr\u00e4\u2010\nRandomisierungsphase \u00a0hatten.\u00a0Patienten \u00a0mit\u00a0Abh\u00e4ngigkeitserkrankung \u00a0oder\u00a0einem\u00a0Status\u00a0epilepticus \u00a0\nwurden\u00a0ausgeschlossen. \u00a0\u00a0\nIn\u00a0der\u00a0ersten\u00a0Studie\u00a0(304)\u00a0mit\u00a0insgesamt \u00a0388\u00a0Patienten \u00a0sollte\u00a0die\u00a0Sicherheit \u00a0und\u00a0Wirksamkeit \u00a0einer\u00a0\neinmal\u00a0t\u00e4glichen\u00a0Gabe\u00a0von\u00a0Perampanel \u00a0(8\u00a0oder\u00a012\u00a0mg)\u00a0\u00fcberpr\u00fcft \u00a0werden.\u00a0In\u00a0dieser\u00a0Studie\u00a0war\u00a0eine\u00a0\u00a0\n218\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a050prozentige \u00a0Responder \u2010Rate\u00a0(Anteil\u00a0der\u00a0Patienten \u00a0mit\u00a0mindestens \u00a050prozentiger \u00a0Reduktion \u00a0der\u00a0\nAnfallsfrequenz) \u00a0der\u00a0prim\u00e4re\u00a0Endpunkt \u00a0und\u00a0ausschlaggebend \u00a0f\u00fcr\u00a0die\u00a0EU\u2010Zulassung \u00a0(French\u00a0et\u00a0al.,\u00a0\n2012).\u00a0Erst\u00a0nach\u00a0Ausschluss \u00a0der\u00a0zentral\u2010\u00a0und\u00a0s\u00fcdamerikanischen \u00a0Studienzentren, \u00a0die\u00a0immerhin \u00a0gut\u00a0\nein\u00a0F\u00fcnftel\u00a0der\u00a0Studienpopulation \u00a0ausmachten, \u00a0konnte\u00a0eine\u00a0statistisch \u00a0signifikante \u00a0\u00dcberlegenheit \u00a0\ngegen\u00fcber \u00a0Placebo\u00a0hinsichtlich \u00a0der\u00a0Ansprechrate \u00a0aufgezeigt \u00a0werden.\u00a0Zwischen \u00a0der\u00a08\u2010mg\u2010\u00a0und\u00a0der\u00a012\u2010\nmg\u2010Dosierung \u00a0fanden\u00a0sich\u00a0keine\u00a0relevanten \u00a0Unterschiede \u00a0hinsichtlich \u00a0der\u00a0Ansprechraten. \u00a0In\u00a0einer\u00a0\nweiteren\u00a0Studie\u00a0(305)\u00a0lag\u00a0die\u00a050prozentige \u00a0Responder \u2010Rate\u00a0bei\u00a014,7\u00a0Prozent\u00a0(Placebo), \u00a033,3\u00a0Prozent\u00a0\n(8\u00a0mg\u00a0Perampanel) \u00a0und\u00a033,9\u00a0Prozent\u00a0(12\u00a0mg\u00a0Perampanel). \u00a0Perampanel \u00a0erwies\u00a0sich\u00a0in\u00a0beiden\u00a0\nDosierungen \u00a0signifikant \u00a0gegen\u00fcber \u00a0Placebo\u00a0(p\u00a0=\u00a00,002\u00a0bzw.\u00a0p\u00a0<\u00a00,001)\u00a0(French\u00a0et\u00a0al.,\u00a02013).\u00a0Diese\u00a0\nStudie\u00a0best\u00e4tigte \u00a0die\u00a0vorangegangen \u00a0Ergebnisse \u00a0von\u00a0Krauss\u00a0et\u00a0al.\u00a0(2012,\u00a0Studie\u00a0306).\u00a0\u00a0\nUm\u00a0die\u00a0Langzeitvertr\u00e4glichkeit \u00a0von\u00a0Perampanel \u00a0zu\u00a0demonstrieren, \u00a0wurden\u00a0die\u00a0Patienten, \u00a0die\u00a0die\u00a0o.g.\u00a0\nrandomisierten \u00a0Studien\u00a0abgeschlossen \u00a0hatten\u00a0(n\u00a0=\u00a01.186)\u00a0in\u00a0eine\u00a0offene\u00a0Verl\u00e4ngerungsstudie \u00a0\neingeschlossen \u00a0(Studie\u00a0307,\u00a0Krauss\u00a0et\u00a0al.,\u00a02013).\u00a0Die\u00a0zuvor\u00a0mit\u00a0Placebo\u00a0behandelten \u00a0Patienten \u00a0\nwurden\u00a0\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von\u00a016\u00a0Wochen\u00a0auf\u00a0Perampanel \u00a0umgestellt \u00a0und\u00a0erhielten\u00a0im\u00a0Anschluss \u00a0\ndaran\u00a0den\u00a0neuen\u00a0Wirkstoff \u00a0\u00fcber\u00a0ein\u00a0Jahr\u00a0und\u00a0l\u00e4nger.\u00a0In\u00a0\u00dcbereinstimmung \u00a0mit\u00a0den\u00a0\nzulassungsrelevanten \u00a0Phase\u2010III\u2010Studien\u00a0zeigten\u00a0die\u00a0Zwischenergebnisse \u00a0dieser\u00a0Studie\u00a0ein\u00a0g\u00fcnstiges \u00a0\nVertr\u00e4glichkeitsprofil \u00a0f\u00fcr\u00a0Patienten \u00a0mit\u00a0refrakt\u00e4ren \u00a0fokalen\u00a0Anf\u00e4llen\u00a0bei\u00a0der\u00a0Einnahme \u00a0\u00fcber\u00a0einen\u00a0\nl\u00e4ngeren\u00a0Zeitraum. \u00a0\u00a0\nPerampanel \u00a0wurde\u00a0als\u00a0Add\u2010on\u00a0zugelassen, \u00a0Interaktionen \u00a0gerade\u00a0auch\u00a0mit\u00a0anderen\u00a0Antikonvulsiva \u00a0gilt\u00a0\nes\u00a0dabei\u00a0unbedingt \u00a0zu\u00a0beachten \u00a0(Zaccara\u00a0&\u00a0Perucca,\u00a02014;\u00a0Patsalos,\u00a02015).\u00a0\nH\u00e4ufigste \u00a0Nebenwirkungen \u00a0in\u00a0den\u00a0klinischen \u00a0Studien\u00a0waren\u00a0neben\u00a0Schwindel \u00a0(20\u00a0Prozent)\u00a0und\u00a0\nSomnolenz \u00a0(15\u00a0Prozent)\u00a0auch\u00a0ver\u00e4ndertes \u00a0Essverhalten \u00a0(erh\u00f6hter \u00a0oder\u00a0verminderter \u00a0Appetit),\u00a0\nVerwirrtheit, \u00a0Angst,\u00a0Aggressivit\u00e4t \u00a0und\u00a0Reizbarkeit. \u00a0Insbesondere \u00a0Schwindel, \u00a0Somnolenz \u00a0und\u00a0\nAggressivit\u00e4t \u00a0f\u00fchrten\u00a0in\u00a0der\u00a0Extensionsphase \u00a0zu\u00a0Dosisver\u00e4nderungen \u00a0oder\u00a0Abbrechen \u00a0der\u00a0\nBehandlung \u00a0(Rosenfeld \u00a0et\u00a0al.,\u00a02015).\u00a0\nErgebnisse \u00a0einer\u00a0Meta\u2010Analyse\u00a0lassen\u00a0keine\u00a0Unterschiede \u00a0zwischen\u00a0den\u00a0einzelnen \u00a0Add\u2010on\u2010\nAntikonvulsiva \u00a0in\u00a0Bezug\u00a0auf\u00a0die\u00a0Pr\u00e4vention \u00a0von\u00a0generalisierten \u00a0tonisch\u2010klonischen \u00a0Anf\u00e4llen\u00a0bei\u00a0\nrefrakt\u00e4rer \u00a0fokaler\u00a0Epilepsie\u00a0erkennen \u00a0(Hemery\u00a0et\u00a0al.,\u00a02014).\u00a0\u00a0\n\u00a0\nLeitlinienempfehlungen \u00a0\nW\u00e4hrend \u00a0nach\u00a0einem\u00a0ersten\u00a0Anfall\u00a0eine\u00a0medikament\u00f6se \u00a0Therapie\u00a0in\u00a0Betracht\u00a0gezogen\u00a0werden\u00a0kann,\u00a0\nsollte\u00a0sie\u00a0nach\u00a0mehreren \u00a0Anf\u00e4llen\u00a0definitiv\u00a0begonnen \u00a0werden,\u00a0da\u00a0von\u00a0einer\u00a0chronischen \u00a0\nAnfallsdiposition \u00a0ausgegangen \u00a0werden\u00a0muss\u00a0und\u00a0das\u00a0Unterlassen \u00a0einer\u00a0Therapie\u00a0das\u00a0\nGef\u00e4hrdungsrisiko \u00a0steigert\u00a0(DGN,\u00a02012).\u00a0Eine\u00a0Pharmakotherapie \u00a0ist\u00a0nicht\u00a0kurativ ,\u00a0da\u00a0Antiepileptika \u00a0\nnicht\u00a0antiepileptisch \u00a0im\u00a0eigentlichen \u00a0Sinn\u00a0wirken,\u00a0sondern\u00a0vielmehr\u00a0\u201eAnfallsblocker\u201c \u00a0sind.\u00a0Sie\u00a0\nerh\u00f6hen\u00a0damit\u00a0die\u00a0\u201eSchwelle\u201c \u00a0des\u00a0Gehirns\u00a0f\u00fcr\u00a0das\u00a0Auftreten \u00a0von\u00a0Anf\u00e4llen\u00a0bei\u00a0einem\u00a0gegebenen \u00a0\nchronischen \u00a0Zustand\u00a0mit\u00a0erniedrigter \u00a0\u201eSchwelle\u201c \u00a0(DGN,\u00a02012).\u00a0Die\u00a0Bezeichnung \u00a0der\u00a0Antiepileptika \u00a0als\u00a0\nAntikonvulsiva \u00a0ist\u00a0dementsprechend \u00a0treffender. \u00a0\u00a0\nGenerell\u00a0erfolgt\u00a0die\u00a0Auswahl\u00a0eines\u00a0geeigneten \u00a0Medikaments \u00a0\u2013\u00a0was\u00a0bei\u00a0etwa\u00a060\u00a0Prozent\u00a0aller\u00a0\nPatienten \u00a0dauerhaft \u00a0eingenommen \u00a0werden\u00a0muss\u00a0\u2013\u00a0individuell, \u00a0da\u00a0neben\u00a0der\u00a0Wirksamkeit \u00a0weitere\u00a0\nKriterien\u00a0wie\u00a0Vertr\u00e4glichkeit, \u00a0Sicherheit, \u00a0Pharmakokinetik, \u00a0Preis\u00a0und\u00a0spezifische \u00a0Patientenbed\u00fcrfnisse \u00a0 \n219\u00a0\n\u00a0\nHintergrundinformationen \u00a0(Komedikation, \u00a0\u00dcbergewicht \u00a0etc.)\u00a0mit\u00a0eingehen. \u00a0Prinzipiell \u00a0gilt\u00a0nach\u00a0Auffassung \u00a0der\u00a0Deutschen \u00a0\nGesellschaft \u00a0f\u00fcr\u00a0Neurologie, \u00a0dass\u00a0bei\u00a0fokalen\u00a0Epilepsien \u00a0Medikamente \u00a0wie\u00a0Carbamazepin, \u00a0Lamotrigin, \u00a0\nLevetiracetam \u00a0oder\u00a0Phenobarbital \u00a0in\u00a0der\u00a0Ersttherapie \u00a0vergleichbar \u00a0wirksam\u00a0sind.\u00a0Mittel\u00a0der\u00a0ersten\u00a0\nWahl\u00a0sind\u00a0jedoch\u00a0Lamotrigin \u00a0und\u00a0Levetiracetam. \u00a0Nach\u00a0Angaben\u00a0der\u00a0Leitlinie\u00a0provozieren \u00a0beide\u00a0\nSubstanzen \u00a0in\u00a0der\u00a0Regel\u00a0bei\u00a0idiopathischen \u00a0generalisierten \u00a0Epilepsien \u00a0keine\u00a0Anf\u00e4lle.\u00a0Des\u00a0Weiteren \u00a0\nwird\u00a0Levetiracetam \u00a0\u2013\u00a0mit\u00a0Ausnahme \u00a0einer\u00a0nicht\u2010hepatischen \u00a0Hydrolyse \u00a0\u2013\u00a0nicht\u00a0metabolisiert \u00a0und\u00a0\nmuss\u00a0nicht\u00a0langwierig \u00a0aufdosiert \u00a0werden\u00a0(DGN,\u00a02012).\u00a0\nGrunds\u00e4tzlich \u00a0ist\u00a0eine\u00a0Monotherapie \u00a0der\u00a0Add\u2010on\u2010Therapie\u00a0vorzuziehen. \u00a0Die\u00a0Zulassung \u00a0von\u00a0\nPerampanel \u00a0wird\u00a0in\u00a0der\u00a0Leitlinie\u00a0erw\u00e4hnt,\u00a0ohne\u00a0eine\u00a0therapeutische \u00a0Empfehlung \u00a0auszusprechen. \u00a0\n\u00a0\nNutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nIn\u00a0seinem\u00a0ersten\u00a0Beschluss \u00a0vom\u00a07.\u00a0M\u00e4rz\u00a02013\u00a0konstatierte \u00a0der\u00a0G\u2010BA\u00a0dem\u00a0neuen\u00a0Wirkstoff \u00a0einen\u00a0nicht\u00a0\nbelegten\u00a0Zusatznutzen \u00a0im\u00a0Verh\u00e4ltnis \u00a0zur\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie. \u00a0Bei\u00a0der\u00a0Festlegung \u00a0der\u00a0\nzweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0ging\u00a0der\u00a0G\u2010BA\u00a0von\u00a0zwei\u00a0unterschiedlichen \u00a0therapeutischen \u00a0\nAusgangssituationen \u00a0aus:\u00a0entweder \u00a0Perampanel \u00a0vs.\u00a0Lamotrigin \u00a0als\u00a0Add\u2010on\u00a0zu\u00a0einer\u00a0Basistherapie \u00a0\noder\u00a0Perampanel \u00a0vs.\u00a0Topiramat \u00a0als\u00a0Add\u2010on,\u00a0f\u00fcr\u00a0den\u00a0Fall,\u00a0dass\u00a0Lamotrigin \u00a0die\u00a0Basistherapie \u00a0darstellt\u00a0\n(G\u2010BA,\u00a02013h).\u00a0Der\u00a0pU\u00a0wich\u00a0in\u00a0seinem\u00a0Dossier\u00a0von\u00a0dieser\u00a0Festlegung \u00a0ab\u00a0mit\u00a0der\u00a0Begr\u00fcndung, \u00a0dass\u00a0ein\u00a0\nVergleich \u00a0mit\u00a0Topiramat \u00a0als\u00a0Add\u2010on\u00a0zur\u00a0Lamotrigin \u2010Basistherapie \u00a0nicht\u00a0zielf\u00fchrend \u00a0sei.\u00a0Seine\u00a0\nEntscheidung \u00a0zum\u00a0Zusatznutzen \u00a0von\u00a0Perampanel \u00a0begr\u00fcndete \u00a0der\u00a0G\u2010BA\u00a0damit,\u00a0dass\u00a0sich\u00a0aus\u00a0dem\u00a0\nHersteller \u2010Dossier\u00a0mangels\u00a0Daten\u00a0keine\u00a0Bewertung \u00a0gegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0\nableiten\u00a0lasse.\u00a0Alle\u00a0vorgelegten \u00a0Untersuchungen \u00a0waren\u00a0placebokontrolliert \u00a0und\u00a0allein\u00a0nicht\u00a0\nausreichend \u00a0f\u00fcr\u00a0den\u00a0geforderten \u00a0Nachweis. \u00a0Auch\u00a0seien\u00a0weder\u00a0die\u00a0direkten\u00a0noch\u00a0die\u00a0indirekten \u00a0\nVergleichsanalysen \u00a0vom\u00a0pU\u00a0ad\u00e4quat\u00a0durchgef\u00fchrt \u00a0worden,\u00a0um\u00a0einen\u00a0Zusatznutzen \u00a0erkennen \u00a0zu\u00a0\nlassen.\u00a0Als\u00a0Konsequenz \u00a0nahm\u00a0der\u00a0pU\u00a0das\u00a0Arzneimittel \u00a0aus\u00a0dem\u00a0Handel\u00a0und\u00a0beantragte \u00a0eine\u00a0erneute\u00a0\nNutzenbewertung. \u00a0\nAuch\u00a0in\u00a0der\u00a0zweiten\u00a0Nutzenbewertung \u00a0vom\u00a06.\u00a0November \u00a02014\u00a0fiel\u00a0das\u00a0Urteil\u00a0des\u00a0Gemeinsamen \u00a0\nBundesausschusses \u00a0zu\u00a0Ungunsten \u00a0des\u00a0neuen\u00a0Wirkstoffes \u00a0aus\u00a0(G\u2010BA,\u00a02014c).\u00a0Nach\u00a0dem\u00a0Wegfall\u00a0des\u00a0\nWirtschaftlichkeitskriteriums \u00a0f\u00fcr\u00a0die\u00a0Vergleichstherapie \u00a0bestimmte \u00a0der\u00a0G\u2010BA\u00a0eine\u00a0neue,\u00a0umfassende \u00a0\nzweckm\u00e4\u00dfige \u00a0Vergleichstherapie \u00a0mit\u00a0insgesamt \u00a0zehn\u00a0\u2013\u00a0sowohl\u00a0patentierten \u00a0als\u00a0auch\u00a0generischen \u00a0\u2013\u00a0\nWirkstoffen, \u00a0bestehend \u00a0aus\u00a0Eslicarbazepin, \u00a0Gabapentin, \u00a0Lacosamid, \u00a0Lamotrigin, \u00a0Levetiracetam, \u00a0\nOxcarbazepin, \u00a0Pregabalin, \u00a0Topiramat, \u00a0Valproins\u00e4ure \u00a0oder\u00a0Zonisamid. \u00a0Auch\u00a0bei\u00a0dieser\u00a0erneuten \u00a0\nmodifizierten \u00a0Bewertung \u00a0sah\u00a0der\u00a0G\u2010BA\u00a0den\u00a0Zusatznutzen \u00a0von\u00a0Perampanel \u00a0gegen\u00fcber \u00a0einer\u00a0\nindividuellen \u00a0antiepileptischen \u00a0Zusatztherapie \u00a0mit\u00a0einem\u00a0der\u00a0oben\u00a0benannten \u00a0Wirkstoffe \u00a0als\u00a0nicht\u00a0\nbelegt\u00a0an.\u00a0\u00a0\n\u00a0\nKosten\u00a0\nAufgrund \u00a0der\u00a0Marktr\u00fccknahme \u00a0im\u00a0Jahr\u00a02013\u00a0erfolgt\u00a0keine\u00a0Kostenanalyse. \u00a0\n  \u00a0\n220\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a011.15  Pixantron \u00a0\u00a0\nHandelsname: \u00a0Pixuvri\u00ae     Hersteller: \u00a0CTI\u00a0Life\u00a0Sciences\u00a0Ltd. \nIndikation: \u00a0Non\u2010Hodgkin\u2010B\u2010Zell\u2010Lymphome \u00a0  Markteinf\u00fchrung: \u00a0Dezember \u00a02012 \nATC\u2010Code:\u00a0L01DB11      DDD:\u00a09,64\u00a0mg \nDarreichungsform: \u00a0Pulver\u00a0zur\u00a0Herstellung \u00a0einer\u00a0Infusionsl\u00f6sung  \nBewertung: \u00a0siehe\u00a0Seite\u00a086 \nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nDas\u00a0Zytostatikum \u00a0Pixantron \u00a0wurde\u00a0vor\u00a0mehr\u00a0als\u00a020\u00a0Jahren\u00a0entwickelt \u00a0und\u00a0z\u00e4hlt\u00a0zur\u00a0erweiterten \u00a0\nGruppe\u00a0der\u00a0Anthrazykline. \u00a0Chemisch \u00a0\u00e4hnelt\u00a0es\u00a0dem\u00a0Anthracendion \u00a0Mitoxantron. \u00a0Anders\u00a0als\u00a0\nAnthrazykline \u00a0und\u00a0Mitoxantron \u00a0ist\u00a0es\u00a0nur\u00a0ein\u00a0schwacher \u00a0Topoisomerase \u2010II\u2010Hemmstoff, \u00a0alkyliert\u00a0aber\u00a0\ndirekt\u00a0die\u00a0DNA,\u00a0bildet\u00a0stabile\u00a0DNA\u2010Addukte\u00a0und\u00a0induziert\u00a0Doppelstrangbr\u00fcche. \u00a0\u00a0\n\u00a0Zulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nPixantron \u00a0ist\u00a0als\u00a0Monotherapie \u00a0bei\u00a0erwachsenen \u00a0Patienten \u00a0mit\u00a0mehrfach \u00a0rezidivierten \u00a0oder\u00a0\ntherapierefrakt\u00e4ren \u00a0aggressiven \u00a0Non\u2010Hodgkin\u2010B\u2010Zell\u2010Lymphomen \u00a0mit\u00a0Beschr\u00e4nkung \u00a0auf\u00a0die\u00a0Dritt\u2010\u00a0\nund\u00a0Viertlinientherapie \u00a0zugelassen. \u00a0Die\u00a0Zulassung \u00a0durch\u00a0die\u00a0Europ\u00e4ische \u00a0Arzneimittel \u2010Agentur\u00a0EMA\u00a0\nerfolgte\u00a0\u201ebedingt\u201c \u00a0bzw.\u00a0unter\u00a0den\u00a0\u201ebesonderen \u00a0Bedingungen\u201c, \u00a0dass\u00a0weitere\u00a0Nachweise \u00a0f\u00fcr\u00a0den\u00a0\nNutzen\u00a0\nvon\u00a0Pixantron \u00a0nachgeliefert \u00a0werden\u00a0m\u00fcssen.\u00a0Die\u00a0EMA\u00a0wird\u00a0j\u00e4hrlich\u00a0alle\u00a0neuen\u00a0Informationen \u00a0\npr\u00fcfen\u00a0und\u00a0bewerten. \u00a0Die\u00a0empfohlene \u00a0Dosis\u00a0betr\u00e4gt\u00a050\u00a0mg/m2\u00a0Pixantron \u00a0als\u00a0Base\u00a0an\u00a0Tag\u00a0eins,\u00a0acht\u00a0\nund\u00a015\u00a0von\u00a0bis\u00a0zu\u00a0sechs\u00a028\u2010Tage\u2010Zyklen.\u00a0Die\u00a0Anwendung \u00a0erfolgt\u00a0als\u00a0intraven\u00f6se \u00a0Infusion\u00a0unter\u00a0\nVerwendung \u00a0eines\u00a0In\u2010Line\u2010Filters\u00a0\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von\u00a0mindestens \u00a060\u00a0Minuten. \u00a0\n\u00a0\nInformationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nNon\u2010Hodgkin\u2010Lymphome \u00a0bilden\u00a0eine\u00a0biologisch \u00a0und\u00a0klinisch\u00a0heterogene \u00a0Gruppe\u00a0lymphatischer \u00a0\nNeoplasien. \u00a0Im\u00a0Gegensatz \u00a0zu\u00a0den\u00a0Hodgkin\u2010Lymphomen \u00a0k\u00f6nnen\u00a0bei\u00a0ihnen\u00a0keine\u00a0die\u00a0f\u00fcr\u00a0diese\u00a0\ntypischen \u00a0Reed\u2010Sternberg \u2010Riesenzellen \u00a0nachgewiesen \u00a0werden.\u00a0Non\u2010Hodgkin\u2010Lymphome \u00a0gehen\u00a0zu\u00a090\u00a0\nProzent\u00a0von\u00a0B\u2010Lymphozyten \u00a0aus.\u00a0Je\u00a0nach\u00a0Malignit\u00e4t, \u00a0Wachstumsgeschwindigkeit \u00a0und\u00a0Ausbreitungsart \u00a0\nunterscheidet \u00a0man\u00a0niedrigmaligne \u00a0(indolente) \u00a0und\u00a0hochmaligne \u00a0(aggressive) \u00a0Non\u2010Hodgkin\u2010\nLymphome. \u00a0Das\u00a0diffuse\u00a0gro\u00dfzellige \u00a0B\u2010Zell\u2010Lymphom \u00a0ist\u00a0mit\u00a0ca.\u00a0einem\u00a0Drittel\u00a0aller\u00a0F\u00e4lle\u00a0und\u00a0sieben\u00a0\nF\u00e4llen\u00a0pro\u00a0100.000\u00a0Einwohner \u00a0pro\u00a0Jahr\u00a0(DGHO,\u00a02014a)\u00a0die\u00a0h\u00e4ufigste \u00a0Entit\u00e4t.\u00a0Es\u00a0ist\u00a0durch\u00a0einen\u00a0\naggressiven \u00a0klinischen \u00a0Verlauf\u00a0charakterisiert \u00a0und\u00a0entsteht\u00a0meistens\u00a0de\u00a0novo\u00a0und\u00a0nur\u00a0relativ\u00a0selten\u00a0\nsekund\u00e4r\u00a0im\u00a0Verlauf\u00a0eines\u00a0weniger\u00a0aggressiven \u00a0(kleinzelligen) \u00a0Lymphoms. \u00a0Seltener\u00a0vorkommende \u00a0\nNon\u2010Hodgkin\u2010Lymphome \u00a0sind\u00a0die\u00a0follikul\u00e4ren \u00a0Lymphome, \u00a0T\u2010Zelllymphome, \u00a0Marginalzelllymphome \u00a0\nund\u00a0Mantelzelllymphome. \u00a0\nDie\u00a0anf\u00e4nglichen \u00a0Symptome \u00a0sind\u00a0fast\u00a0immer\u00a0schmerzlose \u00a0Lymphknotenvergr\u00f6\u00dferungen \u00a0an\u00a0den\u00a0\nSeiten\u00a0des\u00a0Halses.\u00a0Zu\u00a0den\u00a0unspezifischen \u00a0und\u00a0manchmal \u00a0nur\u00a0geringen\u00a0Beschwerden \u00a0z\u00e4hlen\u00a0\nM\u00fcdigkeit, \u00a0Appetitlosigkeit, \u00a0\u00dcbelkeit\u00a0und\u00a0eine\u00a0erh\u00f6hte\u00a0Infektanf\u00e4lligkeit. \u00a0Wesentlich \u00a0seltener\u00a0als\u00a0\nbeim\u00a0Hodgkin\u2010Lymphom \u00a0treten\u00a0sogenannte \u00a0B\u2010Symptome \u00a0wie\u00a0Fieber,\u00a0Nachtschwei\u00df \u00a0oder\u00a0\nGewichtsabnahme \u00a0auf.\u00a0In\u00a0etwa\u00a0der\u00a0H\u00e4lfte\u00a0der\u00a0F\u00e4lle\u00a0wird\u00a0eine\u00a0Infiltration \u00a0des\u00a0Knochenmarks \u00a0 \n221\u00a0\n\u00a0\nHintergrundinformationen \u00a0beobachtet \u00a0mit\u00a0daraus\u00a0folgender \u00a0gest\u00f6rter \u00a0Blutbildung, \u00a0die\u00a0sich\u00a0z.B.\u00a0als\u00a0An\u00e4mie\u00a0oder\u00a0Thrombopenie \u00a0\nmanifestiert \u00a0(Kompetenznetz \u00a0Maligne\u00a0Lymphome, \u00a02008).\u00a0\u00a0\nIm\u00a0Jahr\u00a02010\u00a0erkrankten \u00a0in\u00a0Deutschland \u00a0etwa\u00a016.000\u00a0Personen \u00a0an\u00a0einem\u00a0Non\u2010Hodgkin\u2010Lymphom, \u00a0\netwa\u00a06.000\u00a0Personen \u00a0starben\u00a0daran.\u00a0Auch\u00a0wenn\u00a0die\u00a0Erkrankung \u00a0schon\u00a0im\u00a0Kindesalter \u00a0vorkommen \u00a0\nkann,\u00a0liegt\u00a0das\u00a0mittlere\u00a0Erkrankungsalter \u00a0bei\u00a0Diagnosestellung \u00a0bei\u00a0M\u00e4nnern \u00a0und\u00a0Frauen\u00a0um\u00a0die\u00a070\u00a0\nJahre.\u00a0Die\u00a0Prognose \u00a0der\u00a0Non\u2010Hodgkin\u2010Lymphome \u00a0ist\u00a0vom\u00a0Alter\u00a0sowie\u00a0von\u00a0Typ\u00a0und\u00a0Ausbreitung \u00a0der\u00a0\nErkrankung \u00a0abh\u00e4ngig\u00a0und\u00a0mit\u00a0relativen\u00a05\u2010Jahres\u2010\u00dcberlebensraten \u00a0von\u00a067\u00a0Prozent\u00a0sowohl\u00a0bei\u00a0\nM\u00e4nnern \u00a0als\u00a0auch\u00a0bei\u00a0Frauen\u00a0generell\u00a0eher\u00a0gut.\u00a0Einige,\u00a0auch\u00a0hoch\u00a0maligne\u00a0Erkrankungsformen, \u00a0\nk\u00f6nnen\u00a0inzwischen \u00a0mit\u00a0Aussicht\u00a0auf\u00a0Heilung\u00a0behandelt \u00a0werden\u00a0(RKI\u00a0&\u00a0GEKID,\u00a02013a).\u00a0\n\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nGrundlage \u00a0der\u00a0bedingten \u00a0Zulassung \u00a0ist\u00a0eine\u00a0randomisierte, \u00a0kontrollierte \u00a0Studie,\u00a0in\u00a0der\u00a0Pixantron \u00a0zur\u00a0\nMonotherapie \u00a0von\u00a0Non\u2010Hodgkin\u2010B\u2010Zell\u2010Lymphomen \u00a0(NHL)\u00a0bei\u00a0insgesamt \u00a0140\u00a0Patienten \u00a0mit\u00a0\nrezidiviertem \u00a0oder\u00a0refrakt\u00e4rem \u00a0aggressivem \u00a0NHL\u00a0nach\u00a0mindestens \u00a0zwei\u00a0vorherigen \u00a0Chemotherapien \u00a0\nbewertet \u00a0wurde.\u00a0Sie\u00a0erhielten\u00a0entweder \u00a0Pixantron \u00a0oder\u00a0eine\u00a0patientenindividuell \u00a0vom\u00a0Arzt\u00a0\nbestimmte \u00a0Monotherapie \u00a0mit\u00a0einer\u00a0von\u00a0sieben\u00a0festgelegten \u00a0Substanzen \u00a0(Mitoxantron, \u00a0Etoposid, \u00a0\nIfosfamid, \u00a0Gemcitabin, \u00a0Oxaliplatin, \u00a0Vinorelbin \u00a0oder\u00a0Rituximab) \u00a0(Pettengell \u00a0et\u00a0al.,\u00a02012).\u00a0Mit\u00a0Pixantron \u00a0\nerreichten \u00a020\u00a0Prozent\u00a0der\u00a0Patienten \u00a0eine\u00a0komplette \u00a0Remission \u00a0im\u00a0Vergleich \u00a0zu\u00a05,7\u00a0Prozent\u00a0im\u00a0\nVergleichsarm. \u00a0Das\u00a0mediane\u00a0progressionsfreie \u00a0\u00dcberleben \u00a0verl\u00e4ngerte \u00a0sich\u00a0durch\u00a0Pixantron \u00a0signifikant \u00a0\num\u00a02,7\u00a0Monate.\u00a0Die\u00a0h\u00e4ufigsten \u00a0Nebenwirkungen \u00a0unter\u00a0Pixantron \u00a0waren\u00a0febrile\u00a0und\u00a0nicht\u2010febrile\u00a0\nNeutropenien \u00a0sowie\u00a0Thrombozytopenien. \u00a0\nIn\u00a0einer\u00a0weiteren\u00a0Studie\u00a0sollte\u00a0die\u00a0Nicht\u2010Unterlegenheit \u00a0eines\u00a0Pixantron \u2010basierten \u00a0Regimes\u00a0im\u00a0\nVergleich \u00a0zu\u00a0einem\u00a0Doxorubicin \u2010basierten \u00a0Regime\u00a0aufgezeigt \u00a0werden\u00a0(Herbrecht \u00a0et\u00a0al.,\u00a02013).\u00a0\nVerglichen \u00a0wurde\u00a0die\u00a0Behandlung \u00a0mit\u00a0Cylophosphamid, \u00a0Pixantron, \u00a0Vincristin, \u00a0Predniden \u00a0und\u00a0\nRituximab \u00a0(CPOP\u2010R\u00a0Protokoll) \u00a0mit\u00a0der\u00a0Kombination \u00a0aus\u00a0Cyclophsphamid, \u00a0Hydroxydoxorubicin, \u00a0\nVincristin, \u00a0Predniden \u00a0und\u00a0Rituximab \u00a0(CHOP\u2010R\u2010Protokoll\u00a0).\u00a0Die\u00a0Antwortrate \u00a0des\u00a0Pixantron \u2010basierenden \u00a0\nRegimes\u00a0erwies\u00a0sich\u00a0dabei\u00a0als\u00a0niedriger, \u00a0ebenso\u00a0schlechter \u00a0schnitt\u00a0der\u00a0neue\u00a0Wirkstoff \u00a0bei\u00a0den\u00a0harten\u00a0\npatientenrelevanten \u00a0Endpunkten \u00a0(Gesamt\u00fcberlebenszeit, \u00a0progressionsfreies \u00a0\u00dcberleben) \u00a0ab.\u00a0In\u00a0\npuncto\u00a0Kardiotoxizit\u00e4t \u00a0scheint\u00a0Pixantron \u00a0aber\u00a0besser\u00a0vertr\u00e4glich \u00a0zu\u00a0sein\u00a0als\u00a0Doxorubicin \u00a0(Herbrecht \u00a0et\u00a0\nal.,\u00a02013).\u00a0\u00a0\nDie\u00a0Zulassung \u00a0des\u00a0Wirkstoffes \u00a0ist\u00a0mit\u00a0der\u00a0Bedingung \u00a0verkn\u00fcpft \u00a0worden,\u00a0dass\u00a0bis\u00a0Juni\u00a02015\u00a0eine\u00a0\nrandomisierte, \u00a0kontrollierte \u00a0Phase\u2010III\u2010Studie\u00a0mit\u00a0Pixantron \u2010Rituximab \u00a0versus\u00a0Gemcitabin \u2010Rituximab \u00a0\nbei\u00a0Patienten \u00a0mit\u00a0aggressivem \u00a0B\u2010Zell\u2010Non\u2010Hodgkin\u2010Lymphom \u00a0durchgef\u00fchrt \u00a0wird,\u00a0bei\u00a0denen\u00a0die\u00a0\nErstlinien \u2010Therapie\u00a0mit\u00a0CHOP\u2010R\u00a0versagt\u00a0hat\u00a0und\u00a0die\u00a0nicht\u00a0geeignet\u00a0sind\u00a0f\u00fcr\u00a0eine\u00a0autologe\u00a0\nStammzelltransplantation \u00a0(Zweitlinie) \u00a0oder\u00a0bei\u00a0denen\u00a0die\u00a0autologe\u00a0Stammzelltransplantation \u00a0versagt\u00a0\nhat\u00a0(Dritt\u2010\u00a0oder\u00a0Viertlinie). \u00a0\n \u00a0\u00a0\n222\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Leitlinienempfehlungen \u00a0\nDas\u00a0diffuse\u00a0gro\u00dfzellige \u00a0B\u2010Zell\u2010Lymphom \u00a0als\u00a0gr\u00f6\u00dfte\u00a0Gruppe\u00a0der\u00a0Non\u2010Hodgkin\u2010Lymphome \u00a0und\u00a0die\u00a0ihm\u00a0\nverwandten \u00a0Entit\u00e4ten \u00a0werden\u00a0mit\u00a0kurativem \u00a0Anspruch \u00a0behandelt \u00a0(DGHO,\u00a02014a).\u00a0In\u00a0der\u00a0Erstlinien \u2010\nTherapie\u00a0ist\u00a0das\u00a0CHOP\u2010R\u2010Protokoll\u00a0Goldstandard. \u00a0F\u00fcr\u00a0Personen \u00a0mit\u00a0bereits\u00a0vorgesch\u00e4digtem \u00a0Herzen\u00a0\nkann\u00a0hier\u00a0das\u00a0Doxorubicin \u00a0durch\u00a0liposomales \u00a0Doxorubicin \u00a0oder\u00a0durch\u00a0Etoposid\u00a0ersetzt\u00a0werden\u00a0\n(NCCN,\u00a02014).\u00a0\nBei\u00a0Rezidiven \u00a0erhalten\u00a0Patienten \u00a0unter\u00a060\u201370\u00a0Jahren\u00a0ohne\u00a0Kontraindikationen \u00a0eine\u00a0autologe\u00a0oder\u00a0\nallogene\u00a0Blutstammzelltransplantation. \u00a0Patienten, \u00a0die\u00a0aufgrund\u00a0ihrer\u00a0Komorbidit\u00e4t \u00a0oder\u00a0ihres\u00a0Alters\u00a0\nf\u00fcr\u00a0eine\u00a0Stammzelltransplantation \u00a0nicht\u00a0geeignet\u00a0sind,\u00a0werden\u00a0mit\u00a0Regimen\u00a0behandelt, \u00a0in\u00a0denen\u00a0\nRituximab \u00a0mit\u00a0anderen\u00a0Zytostatika \u00a0als\u00a0in\u00a0CHOP\u00a0kombiniert \u00a0wird,\u00a0z.B.\u00a0mit\u00a0Cisplatin\u00a0und\u00a0Cytarabin \u00a0in\u00a0R\u2010\nDHAP\u00a0oder\u00a0mit\u00a0Ifosfamid, \u00a0Carboplatin \u00a0und\u00a0Etoposid\u00a0in\u00a0R\u2010ICE.\u00a0\nIm\u00a0Falle\u00a0eines\u00a0erneuten \u00a0Rezidivs\u00a0k\u00f6nnen\u00a0in\u00a0den\u00a0meisten\u00a0F\u00e4llen\u00a0die\u00a0in\u00a0der\u00a0Erst\u2010\u00a0und\u00a0Zweitlinie \u00a0\nverwendeten \u00a0Substanzen \u00a0nicht\u00a0mehr\u00a0verwendet \u00a0werden,\u00a0z.B.\u00a0Anthrazykline \u00a0bei\u00a0Erreichen \u00a0der\u00a0\nkumulativen \u00a0H\u00f6chstdosis \u00a0oder\u00a0Rituximab \u00a0bei\u00a0einem\u00a0Fr\u00fchrezidiv. \u00a0F\u00fcr\u00a0die\u00a0Dritt\u2010\u00a0und\u00a0Viertlinientherapie \u00a0\nexistieren \u00a0keine\u00a0eindeutigen \u00a0Empfehlungen \u00a0f\u00fcr\u00a0Wirkstoffe \u00a0oder\u00a0Wirkstoffkombinationen. \u00a0Hier\u00a0ist\u00a0\nvielmehr\u00a0ein\u00a0individuelles \u00a0Behandlungsregime \u00a0vorgesehen, \u00a0was\u00a0sowohl\u00a0die\u00a0Teilnahme \u00a0an\u00a0einer\u00a0\nklinischen \u00a0Studie,\u00a0eine\u00a0palliative\u00a0Versorgung \u00a0oder\u00a0eine\u00a0Monotherapie \u00a0nach\u00a0Ma\u00dfgabe \u00a0des\u00a0\nbehandelnden \u00a0Arztes\u00a0bedeuten \u00a0kann.\u00a0Eine\u00a0Stammzelltransplantation \u00a0wird\u00a0nicht\u00a0empfohlen. \u00a0\n\u00a0\nNutzenbewertung \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDer\u00a0Gemeinsame \u00a0Bundesausschuss \u00a0(G\u2010BA)\u00a0wertet\u00a0den\u00a0Zusatznutzen \u00a0von\u00a0Pixantron \u00a0gegen\u00fcber \u00a0der\u00a0\nzweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0als\u00a0nicht\u00a0belegt\u00a0(G\u2010BA,\u00a02013i).\u00a0\nDerzeit\u00a0stehen\u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0der\u00a0Non\u2010Hodgkin\u2010B\u2010Zell\u2010Lymphome \u00a0zahlreiche \u00a0Wirkstoffe \u00a0bzw.\u00a0\nWirkstoffkombinationen \u00a0zur\u00a0Verf\u00fcgung. \u00a0F\u00fcr\u00a0die\u00a0Monotherapie \u00a0sind\u00a0die\u00a0Wirkstoffe \u00a0Trofosfamid, \u00a0\nVinblastin, \u00a0Vincristin, \u00a0Vindesin, \u00a0Mitoxantron \u00a0sowie,\u00a0unter\u00a0Ber\u00fccksichtigung \u00a0des\u00a0Krankheitsstadiums, \u00a0\nauch\u00a0Cyclophosphamid \u00a0im\u00a0Einsatz.\u00a0F\u00fcr\u00a0die\u00a0Behandlung \u00a0follikul\u00e4rer \u00a0Lymphome \u00a0Grad\u00a0III\u00a0und\u00a0IV\u00a0ist\u00a0der\u00a0\nWirkstoff \u00a0Rituximab \u00a0zugelassen. \u00a0F\u00fcr\u00a0die\u00a0Kombinationstherapie \u00a0weisen\u00a0u.a.\u00a0die\u00a0Wirkstoffe \u00a0Etoposid, \u00a0\nMethotrexat, \u00a0Bleomycin \u00a0sowie\u00a0Ifosfamid \u00a0eine\u00a0Zulassung \u00a0auf.\u00a0Nach\u00a0Angabe\u00a0des\u00a0G\u2010BA\u00a0wird\u00a0f\u00fcr\u00a0die\u00a0\nBehandlung \u00a0des\u00a0mehrfach \u00a0rezidivierten \u00a0oder\u00a0therapierefrakt\u00e4ren \u00a0aggressiven \u00a0Non\u2010Hodgkin\u2010B\u2010Zell\u2010\nLymphoms \u00a0auf\u00a0Basis\u00a0relevanter \u00a0Leitlinien\u00a0f\u00fcr\u00a0die\u00a0Dritt\u2010\u00a0oder\u00a0Viertlinientherapie \u00a0keine\u00a0eindeutige \u00a0\nEmpfehlung \u00a0f\u00fcr\u00a0einen\u00a0der\u00a0infrage\u00a0kommenden \u00a0Wirkstoffe \u00a0oder\u00a0Behandlungsregime \u00a0gegeben.\u00a0Der\u00a0G\u2010\nBA\u00a0trifft\u00a0die\u00a0Auswahl\u00a0einer\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0nach\u00a0dem\u00a0Stand\u00a0der\u00a0medizinischen \u00a0\nErkenntnisse. \u00a0Dieser\u00a0sieht\u00a0f\u00fcr\u00a0die\u00a0Dritt\u2010\u00a0und\u00a0Viertlinienbehandlung \u00a0die\u00a0patientenindividuelle \u00a0Therapie\u00a0\nnach\u00a0Ma\u00dfgabe \u00a0des\u00a0behandelnden \u00a0Arztes\u00a0vor,\u00a0vorausgesetzt, \u00a0die\u00a0entsprechenden \u00a0Wirkstoffe \u00a0kommen\u00a0\nf\u00fcr\u00a0eine\u00a0erneute\u00a0Therapie\u00a0infrage.\u00a0Hierbei\u00a0k\u00f6nnen\u00a0sowohl\u00a0Mono\u2010\u00a0als\u00a0auch\u00a0die\u00a0Kombinationstherapien \u00a0\neingesetzt \u00a0werden.\u00a0\u00a0\nDie\u00a0Begr\u00fcndung \u00a0seiner\u00a0fr\u00fchen\u00a0Nutzenbewertung \u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0in\u00a0erster\u00a0Linie\u00a0darin,\u00a0dass\u00a0die\u00a0f\u00fcr\u00a0den\u00a0\nNachweis \u00a0eines\u00a0Zusatznutzens \u00a0vom\u00a0pharmazeutischen \u00a0Unternehmer \u00a0herangezogene \u00a0PIX301\u2010Studie\u00a0\ndie\u00a0zweckm\u00e4\u00dfige \u00a0Vergleichstherapie \u00a0und\u00a0den\u00a0Versorgungsstand \u00a0hinsichtlich \u00a0der\u00a0Vortherapien \u00a0in\u00a0\nDeutschland \u00a0nicht\u00a0abbildet.\u00a0Gemessen \u00a0an\u00a0der\u00a0Zulassung \u00a0f\u00fcr\u00a0die\u00a0Anwendung \u00a0in\u00a0der\u00a0Dritt\u2010\u00a0und\u00a0\nViertlinientherapie \u00a0von\u00a0rezidivierten \u00a0oder\u00a0therapierefrakt\u00e4ren \u00a0aggressiven \u00a0Non\u2010Hodgkin\u2010B\u2010Zell\u2010 \n223\u00a0\n\u00a0\nHintergrundinformationen \u00a0Lymphomen \u00a0ist\u00a0die\u00a0Einschr\u00e4nkung \u00a0auf\u00a0eine\u00a0Monotherapie \u00a0vor\u00a0dem\u00a0Hintergrund \u00a0zu\u00a0hinterfragen, \u00a0dass\u00a0\nes\u00a0keine\u00a0Standardtherapie \u00a0gibt\u00a0und\u00a0patientenindividuell \u00a0auch\u00a0die\u00a0Kombinationstherapie \u00a0eine\u00a0Option\u00a0\nsein\u00a0kann.\u00a0Zudem\u00a0sind\u00a0einige\u00a0der\u00a0sieben\u00a0in\u00a0der\u00a0Vergleichsgruppe \u00a0verwendeten \u00a0Wirkstoffe \u00a0explizit\u00a0nur\u00a0\nf\u00fcr\u00a0die\u00a0Kombinationstherapie \u00a0zugelassen \u00a0und\u00a0nur\u00a0zwei\u00a0von\u00a0den\u00a0sieben\u00a0Wirkstoffen \u00a0besitzen\u00a0\n\u00fcberhaupt \u00a0in\u00a0Deutschland \u00a0f\u00fcr\u00a0die\u00a0in\u00a0der\u00a0Studie\u00a0praktizierte \u00a0Anwendung \u00a0eine\u00a0Zulassung. \u00a0Die\u00a0\nVorbehandlung \u00a0der\u00a0Studienpopulation \u00a0entspricht \u00a0nicht\u00a0dem\u00a0Versorgungsstandard \u00a0in\u00a0Deutschland, \u00a0da\u00a0\nnur\u00a055\u00a0Prozent\u00a0der\u00a0eingeschlossenen \u00a0Patienten \u00a0vorher\u00a0mit\u00a0Rituximab \u00a0behandelt \u00a0wurden,\u00a0was\u00a0in\u00a0\nDeutschland \u00a0Standard\u00a0in\u00a0der\u00a0Erstlinien \u2010Therapie\u00a0ist.\u00a0Auch\u00a0gab\u00a0es\u00a0weniger\u00a0Patienten \u00a0mit\u00a0\nStammzelltransplantation \u00a0in\u00a0der\u00a0Vorgeschichte \u00a0als\u00a0in\u00a0Deutschland \u00a0\u00fcblich.\u00a0\nDieses\u00a0spiegelt\u00a0sich\u00a0wieder\u00a0in\u00a0den\u00a0Auflagen, \u00a0mit\u00a0denen\u00a0die\u00a0Europ\u00e4ische \u00a0Arzneimittelagentur \u00a0ihre\u00a0\nZulassung \u00a0verkn\u00fcpft \u00a0hat:\u00a0dass\u00a0n\u00e4mlich\u00a0weitere\u00a0Nutzenbelege \u00a0f\u00fcr\u00a0Pixantron \u00a0bei\u00a0Patienten \u00a0vorgelegt \u00a0\nwerden\u00a0m\u00fcssen,\u00a0die\u00a0eine\u00a0vorherige \u00a0Behandlung \u00a0mit\u00a0Rituximab \u00a0erhalten\u00a0haben.\u00a0\n\u00a0\nKosten\u00a0\nWirkstof f\u00a0 Behandlungsmodus Behandlungstage (Jahres)Therapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nPixantron  In\u00a0Zyklen:\u00a01\u00a0Zyklus\u00a0=\u00a028\u00a0Tage\u00a0\nTag\u00a01,\u00a08,\u00a015:\u00a01\u00a0x\u00a0t\u00e4glich\u00a050\u00a0\nmg/m2\u00a018 56.756,70 \u00a0\u20ac\nVergleichstherapie  \u00a0\nMitoxantron \u00a0(Monotherapie)  In\u00a0Zyklen:\u00a01\u00a0Zyklus\u00a0=\u00a021\u00a0Tage\u00a0\nTag\u00a01:\u00a01\u00a0x\u00a0t\u00e4glich\u00a014\u00a0mg/m2\u00a01415.011,16\u00a0\u20ac\nCHOP\u2010Schema\u00a0\n(Kombinationstherapie)  In\u00a0Zyklen:\u00a01\u00a0Zyklus\u00a0=\u00a021\u00a0Tage\u00a0\nCyclophosphamid  Tag\u00a01:\u00a01\u00a0x\u00a0t\u00e4glich\u00a0750\u00a0mg/m2\u00a0 8 539,60\u00a0\u20ac\nDoxorubicin  Tag\u00a01:\u00a01\u00a0x\u00a0t\u00e4glich\u00a050\u00a0mg/m2\u00a0 8 1.944,48\u00a0\u20ac\nVincristin  Tag\u00a01:\u00a01\u00a0x\u00a0t\u00e4glich\u00a01,4\u00a0mg/m2\u00a0 8 199,44\u00a0\u20ac\nPrednison  Tag\u00a01\u20105:\u00a01\u00a0x\u00a0t\u00e4glich\u00a040\u00a0mg/m2\u00a0 40 361,55\u00a0\u20ac\n3.045,07\u00a0\u20ac\u00a0\nCHOP\u2010R\u2010Schema  \n(Kombinationstherapie) \u00a0In\u00a0Zyklen:\u00a01\u00a0Zyklus\u00a0=\u00a021\u00a0Tage\u00a0\nCyclophosphamid  Tag\u00a01:\u00a01\u00a0x\u00a0t\u00e4glich\u00a0750\u00a0mg/m2\u00a0 8 539,60\u00a0\u20ac\nDoxorubicin  Tag\u00a01:\u00a01\u00a0x\u00a0t\u00e4glich\u00a050\u00a0mg/m2\u00a0 8 1.944,48\u00a0\u20ac\nVincristin  Tag\u00a01:\u00a01\u00a0x\u00a0t\u00e4glich\u00a01,4\u00a0mg/m2\u00a0 8 199,44\u00a0\u20ac\nPrednison  Tag\u00a01\u20105:\u00a01\u00a0x\u00a0t\u00e4glich\u00a040\u00a0mg/m2\u00a0 40 361,55\u00a0\u20ac\nRituximab  Tag\u00a01:\u00a01\u00a0x\u00a0t\u00e4glich\u00a0375\u00a0mg/m2\u00a0 8 23.077,44 \u00a0\u20ac\n26.122,51 \u00a0\u20ac\u00a0\nDosis\u2010Berechnung \u00a0mit\u00a0einer\u00a0K\u00f6rperoberfl\u00e4che \u00a0(KOF)\u00a0von\u00a01,73\u00a0m2 \n1\u00a0Ausgehend \u00a0von\u00a0einer\u00a0kumulativen \u00a0Gesamtdosis \u00a0von\u00a0maximal\u00a0200\u00a0mg\u00a0Mitoxantron. \u00a0\nTabelle\u00a040:\u00a0Jahrestherapiekosten \u00a0von\u00a0Pixantron \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0Kosten\u00a0\nzus\u00e4tzlicher \u00a0GKV\u2010Leistungen). \u00a0\n\u00a0 \u00a0\u00a0\n224\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a011.16  Rilpivirin\u00a0\u00a0\nHandelsname: \u00a0Edurant\u00ae\u00a0 \u00a0\u00a0\u00a0 Hersteller: \u00a0Janssen\u00a0Cilag\u00a0\nIndikation: \u00a0Humanes \u00a0Immundefizienz \u2010Virus\u00a0\u00a0Typ\u00a01\u00a0Markteinf\u00fchrung: \u00a0Januar\u00a02012\u00a0\u00a0\nATC\u2010Code:\u00a0J05AG05\u00a0 \u00a0\u00a0\u00a0\u00a0 DDD:\u00a025\u00a0mg\u00a0\nDarreichungsform: \u00a0Filmtablette \u00a0\nBewertung: \u00a0siehe\u00a0Seite\u00a090 \nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nDie\u00a0Humanen \u00a0Immundefizienz \u2010Viren\u00a0(HIV)\u00a0geh\u00f6ren\u00a0zu\u00a0den\u00a0lymphotropen \u00a0Primaten\u2010Lentiviren \u00a0aus\u00a0der\u00a0\nFamilie\u00a0der\u00a0Retroviren. \u00a0Dabei\u00a0enthalten \u00a0die\u00a0einzelnen \u00a0Viruspartikel \u00a0je\u00a0zwei\u00a0RNA\u2010Str\u00e4nge,\u00a0umschlossen \u00a0\nvon\u00a0einem\u00a0Capsid\u2010Protein\u00a0(p24)\u00a0und\u00a0einer\u00a0Lipidmembran \u00a0mit\u00a0H\u00fcllproteinen \u00a0(gp120,\u00a0gp41)\u00a0(RKI,\u00a0\n2013).\u00a0Eine\u00a0infizierte\u00a0Zelle\u00a0ist\u00a0grunds\u00e4tzlich \u00a0w\u00e4hrend\u00a0ihrer\u00a0gesamten \u00a0Lebenszeit \u00a0in\u00a0der\u00a0Lage,\u00a0neues\u00a0\nVirus\u00a0zu\u00a0produzieren, \u00a0da\u00a0die\u00a0virale\u00a0RNA\u00a0durch\u00a0eine\u00a0viruseigene \u00a0Reverse\u00a0Transkriptase \u00a0in\u00a0provirale\u00a0\nDNA\u00a0umgeschrieben \u00a0und\u00a0nach\u00a0dem\u00a0Transport \u00a0in\u00a0den\u00a0Zellkern\u00a0durch\u00a0eine\u00a0virale\u00a0Integrase \u00a0in\u00a0das\u00a0\nZellgenom \u00a0integriert \u00a0wird\u00a0(RKI,\u00a02013).\u00a0\nDer\u00a0Wirkstoff \u00a0Rilpivirin\u00a0ist\u00a0ein\u00a0Diarylpyrimidin \u00a0aus\u00a0der\u00a0pharmakotherapeutischen \u00a0Gruppe\u00a0der\u00a0nicht\u2010\nnukleosidalen \u00a0Reverse\u2010Transkriptase \u2010Inhibitoren \u00a0(NNRTI).\u00a0Die\u00a0Wirkung\u00a0beruht\u00a0dabei\u00a0auf\u00a0der\u00a0nicht\u2010\nkompetitiven \u00a0Hemmung \u00a0von\u00a0viruseigener \u00a0Reverse\u00a0Transkriptase. \u00a0\n\u00a0Zulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nEdurant\u00ae\u00a0wurde\u00a0im\u00a0November \u00a02011\u00a0europaweit \u00a0zugelassen \u00a0und\u00a0kann\u00a0seither\u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0von\u00a0\nInfektionen \u00a0mit\u00a0dem\u00a0humanen \u00a0Immundefizienz \u2010Virus\u00a0Typ\u00a01\u00a0(HIV\u20101)\u00a0bei\u00a0antiretroviral \u00a0nicht\u00a0\nvorbehandelten \u00a0erwachsenen\n\u00a0Patienten \u00a0mit\u00a0einer\u00a0Viruslast\u00a0von\u00a0\u2264\u00a0100.000\u00a0HIV\u20101\u2010RNA\u2010Kopien/ml \u00a0\neingesetzt \u00a0werden.\u00a0Die\u00a0Gabe\u00a0erfolgt\u00a0grunds\u00e4tzlich \u00a0als\u00a0Kombinationstherapie \u00a0mit\u00a0anderen\u00a0\nantiretroviralen \u00a0Arzneimitteln \u00a0(beispielsweise \u00a0mit\u00a0Emtricitabin \u00a0und\u00a0Tenofovir \u00a0oder\u00a0Zidovudin \u00a0und\u00a0\nLamivudin). \u00a0Vor\u00a0der\u00a0Anwendung \u00a0sind\u00a0die\u00a0Ergebnisse \u00a0eines\u00a0genotypischen \u00a0Resistenztests \u00a0zu\u00a0\nber\u00fccksichtigen \u00a0(Janssen\u00a0Cilag,\u00a02014b).\u00a0Die\u00a0empfohlene \u00a0Dosierung \u00a0von\u00a0Edurant\u00ae\u00a0ist\u00a0eine\u00a0Filmtablette \u00a0\n(25\u00a0mg)\u00a0einmal\u00a0t\u00e4glich\u00a0zu\u00a0einer\u00a0Mahlzeit. \u00a0\nIm\u00a0selben\u00a0Monat\u00a0erfolgte\u00a0die\u00a0Zulassung \u00a0f\u00fcr\u00a0das\u00a0fixe\u00a0Kombinationspr\u00e4parat \u00a0Eviplera\u00ae, \u00a0bestehend \u00a0aus\u00a0\n200\u00a0mg\u00a0Emtricitabin, \u00a025\u00a0mg\u00a0Rilpivirin\u00a0und\u00a0245\u00a0mg\u00a0Tenofovirdisoproxil \u00a0(Gilead,\u00a02014).\u00a0Eviplera\u00ae \u00a0ist\u00a0\nsowohl\u00a0f\u00fcr\u00a0antiretroviral \u2010therapienaive \u00a0wie\u00a0auch\u00a0f\u00fcr\u00a0antiretroviral \u2010therapieerfahrene \u00a0Patienten \u00a0\nzugelassen. \u00a0Bei\u00a0der\u00a0letztgenannten \u00a0Patientengruppe \u00a0m\u00fcssen\u00a0neben\u00a0den\u00a0Ergebnissen \u00a0des\u00a0\ngenotypischen \u00a0Resistenztests \u00a0auch\u00a0historische \u00a0Resistenzdaten \u00a0ber\u00fccksichtigt \u00a0werden.\u00a0Auch\u00a0hier\u00a0\nerfolgt\u00a0die\u00a0einmal\u00a0t\u00e4gliche\u00a0Einnahme \u00a0von\u00a0Eviplera\u00ae \u00a0zu\u00a0einer\u00a0Mahlzeit. \u00a0\u00a0\n\u00a0\u00a0 \n225\u00a0\n\u00a0\nHintergrundinformationen \u00a0Informationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nBei\u00a0den\u00a0HI\u2010Viren\u00a0werden\u00a0in\u00a0die\u00a0Klassen\u00a0HIV\u20101\u00a0und\u00a0HIV\u20102\u00a0unterschieden, \u00a0die\u00a0wiederum \u00a0in\u00a0verschiedene \u00a0\nUntergruppen \u00a0(M,\u00a0N,\u00a0O\u00a0und\u00a0P)1\u00a0sowie\u00a0Subtypen \u00a0(A\u00a0bis\u00a0K)\u00a0unterteilt \u00a0werden\u00a0k\u00f6nnen.\u00a0Eine\u00a0Koinfektion \u00a0\nmit\u00a0verschiedenen \u00a0HIV\u2010Subtypen \u00a0kann\u00a0dazu\u00a0f\u00fchren,\u00a0dass\u00a0rekombinante \u00a0Formen\u00a0entstehen, \u00a0die\u00a0\ncirculating \u00a0recombinant \u00a0forms\u00a0(CRFs)\u00a0genannt\u00a0werden.\u00a0Mittlerweile \u00a0lassen\u00a0sich\u00a0beim\u00a0Menschen \u00a0von\u00a0\nHIV\u20101\u00a0neun\u00a0Subtypen \u00a0in\u00a0der\u00a0Gruppe\u00a0M\u00a0und\u00a0mindestens \u00a015\u00a0CRF\u00a0identifizieren. \u00a0In\u00a0die\u00a0Gruppe\u00a0M\u00a0von\u00a0\nHIV\u20101\u00a0fallen\u00a0mehr\u00a0als\u00a090\u00a0Prozent\u00a0aller\u00a0HIV\u2010Infektionen, \u00a0in\u00a0Europa\u00a0ist\u00a0Subtyp\u00a0B\u00a0der\u00a0vorherrschende \u00a0\nSubtyp.\u00a0HIV\u20102\u00a0findet\u00a0sich\u00a0\u00fcberwiegend \u00a0in\u00a0Westafrika \u00a0(RKI,\u00a02013).\u00a0Das\u00a0Virus\u00a0wird\u00a0entweder \u00a0durch\u00a0Blut\u00a0\noder\u00a0andere\u00a0infekti\u00f6se \u00a0K\u00f6rperfl\u00fcssigkeiten \u00a0(Sperma,\u00a0Vaginalsekret, \u00a0Fl\u00fcssigkeitsfilm \u00a0auf\u00a0der\u00a0\nDarmschleimhaut) \u00a0\u00fcbertragen. \u00a0Neben\u00a0dem\u00a0ungesch\u00fctzten \u00a0Sexualkontakt \u00a0sind\u00a0die\u00a0parenterale \u00a0\n\u00dcbertragung \u00a0sowie\u00a0die\u00a0\u00dcbertragung \u00a0von\u00a0der\u00a0Schwangeren \u00a0auf\u00a0ihr\u00a0Kind\u00a0(in\u00a0der\u00a0Regel\u00a0w\u00e4hrend\u00a0der\u00a0\nGeburt\u00a0und\u00a0durch\u00a0das\u00a0Stillen)\u00a0die\u00a0h\u00e4ufigsten \u00a0Infektionswege \u00a0(RKI,\u00a02013).\u00a0Hat\u00a0eine\u00a0Infektion\u00a0\nstattgefunden, \u00a0k\u00f6nnen\u00a0spezifische \u00a0Antik\u00f6rper \u00a0gegen\u00a0HIV\u00a0in\u00a0der\u00a0Regel\u00a0zwei\u00a0bis\u00a0zehn\u00a0Wochen\u00a0nach\u00a0\nerfolgter\u00a0Infektion\u00a0nachgewiesen \u00a0werden.\u00a0Ein\u00a0Teil\u00a0der\u00a0Infizierten \u00a0weist\u00a0ein\u00a0unspezifisches \u00a0akutes\u00a0\ngrippe\u00e4hnliches \u00a0Krankheitsbild \u00a0auf.\u00a0Nach\u00a0der\u00a0Akutphase \u00a0kann\u00a0der\u00a0infizierte\u00a0Patient\u00a0\u00fcber\u00a0Monate\u00a0oder\u00a0\nJahre\u00a0ein\u00a0symptomfreies \u00a0oder\u00a0symptomarmes \u00a0Stadium\u00a0durchlaufen, \u00a0wobei\u00a0sich\u00a0die\u00a0Symptome \u00a0einer\u00a0\nchronischen \u00a0HIV\u2010Infektion\u00a0in\u00a0der\u00a0Regel\u00a0als\u00a0unspezifische \u00a0St\u00f6rungen \u00a0des\u00a0Allgemeinbefindens \u00a0(Haut\u2010\u00a0\nund\u00a0Schleimhautver\u00e4nderungen, \u00a0gastrointestinale \u00a0Beschwerden) \u00a0manifestieren \u00a0(RKI,\u00a02013).\u00a0\u00a0\nAIDS\u00a0(Acquired\u00a0Immuno\u2010Deficiency \u00a0Syndrome )\u00a0als\u00a0Endstadium \u00a0einer\u00a0HIV\u2010Erkrankung \u00a0ist\u00a0durch\u00a0erh\u00f6hte\u00a0\nAnf\u00e4lligkeit \u00a0gegen\u00a0opportunistische \u00a0Erreger,\u00a0d.h.\u00a0Mikroorganismen, \u00a0die\u00a0nur\u00a0bei\u00a0einer\u00a0\nAbwehrschw\u00e4che \u00a0pathogen \u00a0sind,\u00a0sowie\u00a0ein\u00a0vermehrtes \u00a0Auftreten \u00a0maligner\u00a0Tumoren\u00a0(Kaposi\u2010\nSarkomen) \u00a0und\u00a0St\u00f6rungen \u00a0des\u00a0Nervensystems \u00a0charakterisiert \u00a0(Mutschler \u00a0et\u00a0al.,\u00a02008).\u00a0\u00a0\nNach\u00a0Angaben\u00a0der\u00a0WHO\u00a0waren\u00a0Ende\u00a02013\u00a0weltweit\u00a035\u00a0Mio.\u00a0Menschen \u00a0mit\u00a0dem\u00a0HI\u2010Virus\u00a0infiziert\u00a0\n(WHO,\u00a02015).\u00a0Die\u00a0Zahl\u00a0der\u00a0derzeit\u00a0in\u00a0Deutschland \u00a0mit\u00a0einer\u00a0HIV\u2010Infektion\u00a0lebenden \u00a0Menschen \u00a0liegt\u00a0\nbei\u00a0etwa\u00a080.000\u00a0und\u00a0stellt\u00a0im\u00a0europ\u00e4ischen \u00a0Vergleich \u00a0eine\u00a0eher\u00a0niedrige\u00a0Pr\u00e4valenz \u00a0dar.\u00a0Hierzulande \u00a0\nsind\u00a0HIV\u2010Infektionen \u00a0bislang\u00a0auf\u00a0bestimmte \u00a0Hochrisiko \u2010Bev\u00f6lkerungsgruppen \u00a0beschr\u00e4nkt \u00a0geblieben \u00a0\n(M\u00e4nner\u00a0mit\u00a0gleichgeschlechtlichen \u00a0Sexualkontakten, \u00a0Personen \u00a0mit\u00a0Herkunft\u00a0aus\u00a0L\u00e4ndern\u00a0mit\u00a0hoher\u00a0\nVerbreitung \u00a0von\u00a0HIV\u00a0in\u00a0der\u00a0Allgemeinbev\u00f6lkerung, \u00a0den\u00a0sogenannten \u00a0Hochpr\u00e4valenzregionen \u00a0sowie\u00a0\ni.v.\u2010Drogen\u2010Konsumenten) \u00a0(RKI,\u00a02014b).\u00a0\u00a0\n\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nEvidenz\u00a0zur\u00a0Sicherheit \u00a0und\u00a0Wirksamkeit \u00a0liefern\u00a0die\u00a048\u2010Wochen\u2010Daten\u00a0von\u00a0zwei\u00a0randomisierten, \u00a0\ndoppelblinden \u00a0Studien\u00a0der\u00a0Phase\u00a0III.\u00a0In\u00a0der\u00a0ersten\u00a0Studie\u00a0um\u00a0Cohen\u00a0et\u00a0al.\u00a0(2011,\u00a0THRIVE)\u00a0wurde\u00a0an\u00a0\ninsgesamt \u00a0680\u00a0antiretroviral \u2010therapienaiven \u00a0Patienten \u00a0die\u00a0Nicht\u2010Unterlegenheit \u00a0von\u00a0Rilpivirin\u00a0(25\u00a0mg\u00a0\neinmal\u00a0t\u00e4glich)\u00a0im\u00a0Vergleich \u00a0zu\u00a0Efavirenz\u00a0(600\u00a0mg\u00a0einmal\u00a0t\u00e4glich)\u00a0untersucht. \u00a0Das\u00a0Basisregime \u00a0wurde\u00a0\npatientenindividuell \u00a0zusammengestellt \u00a0und\u00a0enthielt\u00a0Tenofovirdisoproxil \u00a0+\u00a0Emtricitabin, \u00a0Zidovudin \u00a0+\u00a0\n                                        \n1\u00a0\u201eSowohl\u00a0HIV\u20101\u2010\u00a0als\u00a0auch\u00a0HIV\u20102\u2010Isolate\u00a0werden\u00a0je\u00a0nach\u00a0ihrer\u00a0phylogenetischen \u00a0Verwandtschaft \u00a0in\u00a0Gruppen\u00a0eingeteilt, \u00a0die\u00a0nach\u00a0heutigem \u00a0\nWissensstand \u00a0jeweils\u00a0aus\u00a0einer\u00a0separaten \u00a0cross\u2010species\u00a0\u00dcbertragung \u00a0vom\u00a0Affen\u00a0auf\u00a0den\u00a0Menschen \u00a0entstanden \u00a0sind.\u00a0F\u00fcr\u00a0HIV\u20102\u00a0handelt\u00a0es\u00a0\nsich\u00a0dabei\u00a0um\u00a0die\u00a0sieben\u00a0Gruppen\u00a0A,\u00a0B,\u00a0C,\u00a0D,\u00a0E,\u00a0F\u00a0und\u00a0G,\u00a0von\u00a0denen\u00a0aber\u00a0nur\u00a0A\u00a0und\u00a0B\u00a0zu\u00a0einer\u00a0nennenswerten \u00a0Anzahl\u00a0an\u00a0Infektionen \u00a0f\u00fchren.\u00a0\nHIV\u20101\u00a0wird\u00a0in\u00a0die\u00a0drei\u00a0Gruppen\u00a0M,\u00a0N\u00a0und\u00a0O\u00a0eingeteilt. \u00a0Die\u00a0genetische \u00a0Heterogenit\u00e4t \u00a0zwischen\u00a0den\u00a0jeweiligen \u00a0Gruppen\u00a0beider\u00a0HIV\u2010Typen\u00a0\nliegt\u00a0bei\u00a0ca.\u00a030\u00a0bis\u00a035%.\u201c\u00a0(Gerhardt, \u00a02006,\u00a0S.\u00a018/19).\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n226\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Lamivudin \u00a0oder\u00a0Abacavir\u00a0+\u00a0Lamivudin. \u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0dieser\u00a0Studie\u00a0war\u00a0die\u00a0Anzahl\u00a0der\u00a0Patienten \u00a0\nmit\u00a0einer\u00a0Viruslast\u00a0unter\u00a050\u00a0Kopien/ml \u00a0nach\u00a048\u00a0Wochen.\u00a0In\u00a0dieser\u00a0Studie\u00a0erwies\u00a0sich\u00a0Rilpivirin\u00a0\ngegen\u00fcber \u00a0Efavirenz\u00a0im\u00a0prim\u00e4ren \u00a0Endpunkt \u00a0als\u00a0nicht\u00a0unterlegen \u00a0(86\u00a0Prozent\u00a0vs.\u00a082\u00a0Prozent).\u00a0Der\u00a0\nAnstieg\u00a0der\u00a0CD4\u2010Zellzahlen \u00a0\u2013\u00a0ein\u00a0Indiz\u00a0f\u00fcr\u00a0den\u00a0Status\u00a0im\u00a0Immunsystem \u00a0\u2013\u00a0war\u00a0ebenfalls\u00a0in\u00a0beiden\u00a0\nBehandlungsarmen \u00a0vergleichbar. \u00a0Zwar\u00a0waren\u00a0behandlungsbedingte \u00a0Nebenwirkungen \u00a0wie\u00a0\nHauterscheinungen, \u00a0Schwindel \u00a0und\u00a0erh\u00f6hten \u00a0Lipidwerte \u00a0unter\u00a0dem\u00a0neuen\u00a0NNRTI\u00a0seltener\u00a0als\u00a0unter\u00a0\nder\u00a0etablierten \u00a0Therapie\u00a0(16\u00a0Prozent\u00a0vs.\u00a031\u00a0Prozent),\u00a0der\u00a0besseren\u00a0Vertr\u00e4glichkeit \u00a0steht\u00a0allerdings \u00a0\nauch\u00a0eine\u00a0h\u00f6here\u00a0virologische \u00a0Versagerrate \u00a0(Non\u2010Response )\u00a0als\u00a0unter\u00a0Efavirenz\u00a0gegen\u00fcber \u00a0(7\u00a0Prozent\u00a0\nvs.\u00a05\u00a0Prozent).\u00a0Auch\u00a0traten\u00a0unter\u00a0Rilpivirin\u00a0mehr\u00a0Resistenzen \u00a0und\u00a0Kreuzresistenzen \u00a0gegen\u00fcber \u00a0den\u00a0im\u00a0\nBehandlungsregime \u00a0enthaltenen \u00a0antiviralen \u00a0Substanzen \u00a0(Tenofovirdisoproxilfumarat \u00a0plus\u00a0\nEmtricitabin, \u00a0Zidovudin \u00a0plus\u00a0Lamivudin \u00a0oder\u00a0Abacavir\u00a0plus\u00a0Lamivudin) \u00a0auf\u00a0als\u00a0unter\u00a0Efavirenz. \u00a0Diese\u00a0\nErgebnisse \u00a0werden\u00a0durch\u00a0die\u00a0Studie\u00a0von\u00a0Porter\u00a0et\u00a0al.\u00a0(2015)\u00a0erh\u00e4rtet,\u00a0die\u00a0die\u00a0Resistenzentwicklung \u00a0\nder\u00a0fixen\u00a0Kombination \u00a0(Emtricitabin, \u00a0Rilpivirin\u00a0und\u00a0Tenofovirdisoproxil) \u00a0untersuchten. \u00a0Die\u00a0zweite\u00a0\nStudie\u00a0wies\u00a0ein\u00a0anderes\u00a0Basisregime \u00a0(Rilpivirin \u00a0und\u00a0Efavirenz, \u00a0jeweils\u00a0in\u00a0Kombination \u00a0mit\u00a0den\u00a0beiden\u00a0\nNukleosid \u2010Reverse\u2010Transkriptase \u2010Inhibitoren \u00a0Tenofovir \u00a0und\u00a0Emtricitabin) \u00a0auf,\u00a0war\u00a0jedoch\u00a0vom\u00a0\nStudiendesign \u00a0mit\u00a0der\u00a0THRIVE\u2010Studie\u00a0identisch\u00a0und\u00a0lieferte\u00a0nahezu\u00a0vergleichbare \u00a0Ergebnisse \u00a0(Molina\u00a0\net\u00a0al.,\u00a02011).\u00a0Die\u00a0gepoolte\u00a0Analyse\u00a0der\u00a0beiden\u00a0Studien\u00a0ergab,\u00a0dass\u00a0nach\u00a096\u00a0Wochen\u00a0die\u00a0Viruslast\u00a0bei\u00a0\n84\u00a0Prozent\u00a0der\u00a0mit\u00a0Rilpivirin\u00a0und\u00a0bei\u00a080\u00a0Prozent\u00a0der\u00a0mit\u00a0Efavirenz\u00a0behandelten \u00a0Patienten \u00a0unter\u00a0der\u00a0\nNachweisgrenze \u00a0von\u00a050\u00a0Viruskopien/ml \u00a0lagen\u00a0(Molina\u00a0et\u00a0al.,\u00a02014).\u00a0Ergebnisse \u00a0zur\u00a0Sicherheit \u00a0und\u00a0\nWirksamkeit \u00a0von\u00a0Rilpivirin\u00a0waren\u00a0sowohl\u00a0f\u00fcr\u00a0\u00e4ltere\u00a0als\u00a0auch\u00a0f\u00fcr\u00a0j\u00fcngere\u00a0Patienten \u00a0gleich\u00a0(Ryan\u00a0et\u00a0al.,\u00a0\n2013).\u00a0\nDie\u00a0zugelassene \u00a0Fixkombination \u00a0bietet\u00a0eine\u00a0bessere\u00a0Therapiesicherheit \u00a0durch\u00a0eine\u00a0h\u00f6here\u00a0\nPatientenzufriedenheit \u00a0und\u00a0einer\u00a0daraus\u00a0resultierenden \u00a0h\u00f6heren\u00a0Adh\u00e4renz \u00a0(Brunetta \u00a0et\u00a0al.,\u00a02015).\u00a0\nDaten\u00a0zur\u00a0Sicherheit, \u00a0Wirksamkeit \u00a0und\u00a0Vertr\u00e4glichkeit \u00a0der\u00a0Fixkombination \u00a0gegen\u00fcber \u00a0eines\u00a0weiteren\u00a0\nSingle\u2010Tablet\u2010Regimes,\u00a0bestehend \u00a0aus\u00a0Efavirenz\u00a0+\u00a0Emtricitabin \u00a0+\u00a0Tenofovir, \u00a0in\u00a0antiretroviral \u2010\ntherapienaiven \u00a0Patienten \u00a0lieferte\u00a0u.a.\u00a0die\u00a0Studie\u00a0um\u00a0Cohen\u00a0et\u00a0al.\u00a0(2014).\u00a0In\u00a0Behandlungswoche \u00a048\u00a0\nbewiesen \u00a0beide\u00a0Regime\u00a0\u00fcber\u00a0die\u00a0Gesamtpopulation \u00a0vergleichbare \u00a0(nicht\u2010unterlegene) \u00a0\nTherapieeffekte; \u00a0statistisch \u00a0relevante \u00a0Unterschiede \u00a0zugunsten \u00a0des\u00a0Rilpivirin\u2010Regimes\u00a0fanden\u00a0sich\u00a0\nlediglich\u00a0f\u00fcr\u00a0Patienten \u00a0mit\u00a0einer\u00a0Ausgangsviruslast \u00a0von\u00a0weniger\u00a0als\u00a0100.000\u00a0Viruskopien/ml \u00a0(88,8\u00a0\nProzent\u00a0vs.\u00a081,6\u00a0Prozent).\u00a0\u00a0\nAls\u00a0sehr\u00a0h\u00e4ufige\u00a0Nebenwirkungen \u00a0von\u00a0Rilpivirin\u00a0wurden\u00a0in\u00a0den\u00a0o.g.\u00a0Studien\u00a0erh\u00f6hte\u00a0Werte\u00a0des\u00a0\nGesamtcholesterols \u00a0und\u00a0des\u00a0LDL\u2010Cholesterols \u00a0sowie\u00a0Kopfschmerzen \u00a0und\u00a0\u00dcbelkeit\u00a0beschrieben. \u00a0\u00a0\n\u00a0\nLeitlinienempfehlungen \u00a0\nDas\u00a0Ziel\u00a0der\u00a0antiretroviralen \u00a0Therapie\u00a0(ART)\u00a0ist\u00a0es,\u00a0durch\u00a0Hemmung \u00a0der\u00a0HIV\u2010Replikation \u00a0nicht\u00a0nur\u00a0\ninfektionsbedingte \u00a0Symptome \u00a0zu\u00a0unterdr\u00fccken, \u00a0sondern\u00a0auch\u00a0die\u00a0Krankheitsprogression \u00a0zu\u00a0\nvermindern, \u00a0eine\u00a0Rekonstitution \u00a0der\u00a0zellul\u00e4ren \u00a0Immunit\u00e4t \u00a0zu\u00a0erreichen \u00a0und\u00a0die\u00a0chronische \u00a0\nImmunaktivierung \u00a0mit\u00a0ihren\u00a0resultierenden \u00a0Entz\u00fcndungsprozessen \u00a0zu\u00a0reduzieren \u00a0(DAIG,\u00a02014).\u00a0Da\u00a0\neine\u00a0ART\u00a0in\u00a0der\u00a0Regel\u00a0lebenslang \u00a0eingenommen \u00a0werden\u00a0muss,\u00a0richtet\u00a0sich\u00a0die\u00a0Auswahl\u00a0der\u00a0\nMedikamentenkombination \u00a0nach\u00a0der\u00a0Lebenssituation, \u00a0den\u00a0Ko\u2010Infektionen \u00a0und\u00a0Morbidit\u00e4ten \u00a0der\u00a0\nbetroffenen \u00a0Person\u00a0sowie\u00a0dem\u00a0Nebenwirkungsprofil. \u00a0Nur\u00a0eine\u00a0dauerhafte \u00a0Reduktion \u00a0der\u00a0Viruslast\u00a0\nauf\u00a0unter\u00a050\u00a0RNA\u2010Kopien/ml \u00a0k\u00f6nnen\u00a0Resistenzentwicklung \u00a0und\u00a0konsekutives \u00a0Therapieversagen \u00a0\nnachhaltig \u00a0verhindern \u00a0(DAIG,\u00a02014).\u00a0Die\u00a0Frage\u00a0nach\u00a0einer\u00a0Behandlungsindikation \u00a0richtet\u00a0sich\u00a0nach\u00a0 \n227\u00a0\n\u00a0\nHintergrundinformationen \u00a0verschiedenen \u00a0Kriterien\u00a0(symptomatisch, \u00a0asymptomatisch, \u00a0CD4+\u2010Zellzahl,\u00a0CD8+\u2010Zellzahl,\u00a0\nPlasmavir\u00e4mie, \u00a0Wunsch\u00a0des\u00a0Patienten \u00a0nach\u00a0Senkung\u00a0der\u00a0Infektiosit\u00e4t, \u00a0chronische \u00a0Hepatitis\u00a0B\u2010\u00a0\nund/oder \u00a0C\u2010Ko\u2010Infektion, \u00a0h\u00f6heres\u00a0Lebensalter, \u00a0rasches\u00a0Absinken\u00a0der\u00a0CD4\u2010Zellen)\u00a0(DAIG,\u00a02014).\u00a0\nF\u00fcr\u00a0die\u00a0Therapie\u00a0der\u00a0HIV\u2010Infektion\u00a0stehen\u00a0eine\u00a0Reihe\u00a0von\u00a0Wirkstoffen \u00a0zur\u00a0Verf\u00fcgung, \u00a0deren\u00a0\nWirksamkeit \u00a0auf\u00a0der\u00a0Interaktion \u00a0mit\u00a0unterschiedlichen \u00a0drug\u00a0targets\u00a0beruht.\u00a0Die\u00a0Substanzen \u00a0lassen\u00a0\nsich\u00a0dabei\u00a0in\u00a0folgende\u00a0Gruppen\u00a0einteilen: \u00a0Nukleosid \u2010/Nukleotidanaloga \u00a0(NRTI\u00a0bzw.\u00a0NtRTI),\u00a0nicht\u2010\nnukleosidische \u00a0Reverse\u2010Transkriptase \u2010Inhibitoren \u00a0(NNRTI),\u00a0Ritonavir\u2010\u00a0oder\u00a0Cobicistat \u2010geboosterte \u00a0\nProtease\u2010Inhibitoren \u00a0(\u201ePI/r\u201c\u00a0bzw.\u00a0\u201ePI/c\u201c)\u00a0und\u00a0Integrase \u2010inhibitoren \u00a0(INI).\u00a0\u00a0\n\u00a0Tabelle\u00a041\u00a0gibt\u00a0einen\u00a0\u00dcberblick \u00a0der\u00a0von\u00a0der\u00a0DAIG\u2010Leitlinie\u00a0empfohlenen \u00a0Wirkstoffkombinationen, \u00a0in\u00a0\ndenen\u00a0auch\u00a0Ritonavir\u00a0empfohlen \u00a0wird.\u00a0\u00a0\nKombinationspartner \u00a01\u00a0 Kombinationspartner \u00a02\u00a0\nNukleosid \u2010/\u00a0Nukleotidkombinationen \u00a0\u00a0\nempfohlen: \u00a0\n\u2010 Tenofovir/Emtricitabin \u00a0\n\u2010 Abacavir/Lamivudin1\u00a0\nAlternative: \u00a0\n\u2010 Tenofovir/Lamivudin \u00a0\n\u00a0NNRTI\nempfohlen: \u00a0\n\u2010 Efavirenz2\u00a0\n\u2010 Nevirapin3\u00a0\n\u2010 Rilpivirin4\u00a0\nPI\u00a0\nempfohlen: \u00a0\n\u2010 Atazanavir/r \u00a0\n\u2010 Darunavir/r \u00a0\n\u2010 Lopinavir/r \u00a0\nAlternative \u00a0\n\u2010 Fosamprenavir/r \u00a0\nINI\u00a0\nEmpfohlen: \u00a0\n\u2010 Dolutegravir \u00a0\n\u2010 Raltegravir \u00a0\n\u2010 Elvitegravir/c \u00a0\u00a0\n(+\u00a0Tenofovir \u00a0DF/Emtricitabin) \u00a0\u00a0\n1Einsatz\u00a0nach\u00a0negativem \u00a0Screening \u00a0auf\u00a0HLA\u2010B*5701,\u00a0Einsatz\u00a0mit\u00a0Vorsicht\u00a0bei\u00a0Plasmavir\u00e4mie \u00a0>100.000 \u00a0Kopien/mL \u00a0und\u00a0hohem\u00a0kardiovaskul\u00e4 \u2010\nrem\u00a0Risiko\u00a0(Framingham \u2010Score\u00a0>20%/10\u00a0Jahre).\u00a0\n2Kein\u00a0Einsatz\u00a0bei\u00a0Schwangerschaft \u00a0und\u00a0bei\u00a0Frauen\u00a0mit\u00a0Schwangerschaftswunsch. \u00a0\n3Einsatz\u00a0mit\u00a0Vorsicht\u00a0bei\u00a0bestehender \u00a0Lebererkrankung, \u00a0M\u00e4nnern \u00a0mit\u00a0mehr\u00a0als\u00a0400\u00a0CD4+\u00a0T\u2010Zellen/\u00a0\n\u03bcl\u00a0bzw.\u00a0bei\u00a0Frauen\u00a0mit\u00a0mehr\u00a0als\u00a0250\u00a0CD4+\u00a0T\u2010Zellen/\u03bcl.\u00a0\n4Cave:\u00a0Nicht\u00a0bei\u00a0HIV\u2010RNA\u00a0>100.000 \u00a0K/mL\u00a0(keine\u00a0Zulassung). \u00a0\n\u00a0\nQuelle:\u00a0DAIG\u00a0(2014),\u00a0S.\u00a018\u00a0\nTabelle\u00a041:\u00a0Bevorzugte \u00a0Kombinationen \u00a0in\u00a0der\u00a0Therapie\u00a0der\u00a0HIV\u2010Infektion \u00a0\n\u00a0\u00a0\u00a0\n228\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Neben\u00a0antiretroviralen \u00a0Stoffen\u00a0ist\u00a0auch\u00a0eine\u00a0medikament\u00f6se \u00a0Therapie\u00a0der\u00a0bei\u00a0diesen\u00a0Patienten \u00a0\nh\u00e4ufig\u00a0zus\u00e4tzlich \u00a0auftretenden, \u00a0schweren \u00a0Infektionskrankheiten \u00a0(opportunistischen \u00a0Infektionen) \u00a0\nnotwendig. \u00a0Diese\u00a0beruhen\u00a0auf\u00a0dem\u00a0HIV\u2010bedingten \u00a0Defekt\u00a0der\u00a0zellul\u00e4ren \u00a0Immunfunktion, \u00a0\ninsbesondere \u00a0einer\u00a0Zerst\u00f6rung \u00a0der\u00a0T\u2010Helfer\u2010Zellen\u00a0(Mutschler \u00a0et\u00a0al.,\u00a02008).\u00a0\u00a0\n\u00a0\nNutzenbewertung \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nRilpivirin\u00a0bzw.\u00a0seine\u00a0fixe\u00a0Kombination, \u00a0bestehend \u00a0aus\u00a0Emtricitabin, \u00a0Rilpivirin\u00a0und\u00a0Tenofovirdisoproxil \u00a0\ndurchliefen \u00a0als\u00a0erste\u00a0antiretrovirale \u00a0Wirkstoffe \u00a0zur\u00a0Behandlung \u00a0der\u00a0HIV\u2010Infektion\u00a0die\u00a0fr\u00fche\u00a0\nNutzenbewertung1.\u00a0Der\u00a0G\u2010BA\u00a0sah\u00a0f\u00fcr\u00a0den\u00a0Wirkstoff \u00a0Rilpivirin\u00a0(als\u00a0Einzelsubstanz) \u00a0in\u00a0Kombination \u00a0mit\u00a0\nanderen\u00a0antiretroviralen \u00a0Arzneimitteln \u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0von\u00a0Infektionen \u00a0mit\u00a0dem\u00a0HIV\u2010Virus\u00a0Typ\u00a01\u00a0\nbei\u00a0antiretroviral \u00a0nicht\u00a0vorbehandelten \u00a0erwachsenen \u00a0Patienten \u00a0mit\u00a0einer\u00a0Viruslast\u00a0von\u00a0\u2264\u00a0100.000\u00a0HIV\u2010\n1\u2010RNA\u2010Kopien/ml \u00a0einen\u00a0Beleg\u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0Zusatznutzen \u00a0gegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0\nVergleichstherapie \u00a0(hier:\u00a0Efavirenz\u00a0in\u00a0Kombination \u00a0mit\u00a0zwei\u00a0Nukleosid \u2010/Nukleotidanaloga \u00a0(Tenofovir \u00a0\nplus\u00a0Emtricitabin \u00a0oder\u00a0Abacavir\u00a0plus\u00a0Lamivudin)) \u00a0(G\u2010BA,\u00a02012e).\u00a0\u00a0\nZur\u00a0Beantwortung \u00a0der\u00a0Fragestellung \u00a0hatte\u00a0der\u00a0pU\u00a0in\u00a0seinem\u00a0Dossier\u00a0die\u00a0Metaanalyse \u00a0der\u00a0Ergebnisse \u00a0\nvon\u00a0drei\u00a0randomisierten \u00a0kontrollierten \u00a0Studien\u00a0vorgelegt \u00a0(Studie\u00a0C204,\u00a0ECHO,\u00a0THRIVE).\u00a0Bei\u00a0nach\u00a0\nGeschlecht \u00a0getrennter \u00a0Betrachtung \u00a0ergab\u00a0sich\u00a0aus\u00a0den\u00a0Woche\u201048\u2010Daten\u00a0f\u00fcr\u00a0M\u00e4nner\u00a0ein\u00a0statistisch \u00a0\nsignifikantes \u00a0Ergebnis\u00a0zugunsten \u00a0von\u00a0Rilpivirin, \u00a0nicht\u00a0jedoch\u00a0f\u00fcr\u00a0Frauen.\u00a0Die\u00a0Woche\u201096\u2010Daten\u00a0zeigten\u00a0\nbereits\u00a0eine\u00a0Abschw\u00e4chung \u00a0des\u00a0Subgruppenunterschieds \u00a0f\u00fcr\u00a0das\u00a0Merkmal\u00a0\u201eGeschlecht\u201c \u00a0in\u00a0Bezug\u00a0auf\u00a0\ndie\u00a0Effektgr\u00f6\u00dfe \u00a0und\u00a0den\u00a0Effektunterschied \u00a0zwischen\u00a0der\u00a0Rilpivirin\u2010\u00a0und\u00a0Efavirenz\u2010Gruppe.\u00a0Nach\u00a0dieser\u00a0\nZeit\u00a0konnte\u00a0in\u00a0der\u00a0Gesamtgruppe \u00a0(M\u00e4nner\u00a0und\u00a0Frauen)\u00a0kein\u00a0statistisch \u00a0signifikanter \u00a0Unterschied \u00a0\nzwischen\u00a0den\u00a0Behandlungsgruppen \u00a0festgestellt \u00a0werden.\u00a0Aus\u00a0diesem\u00a0Grund\u00a0lag\u00a0nach\u00a0Auffassung \u00a0des\u00a0\nG\u2010BA\u00a0f\u00fcr\u00a0den\u00a0Endpunkt \u00a0\"Virologisches \u00a0Ansprechen \u00a0(Viruslast)\" \u00a0f\u00fcr\u00a0Rilpivirin\u00a0kein\u00a0Zusatznutzen \u00a0\ngegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0vor.\u00a0Zwar\u00a0konnten\u00a0Nebenwirkungen \u00a0unter\u00a0der\u00a0\nTherapie\u00a0mit\u00a0Rilpivirin\u00a0\u2013\u00a0teils\u00a0statistisch \u00a0nicht\u00a0signifikant \u00a0\u2013\u00a0verringert \u00a0werden\u00a0(Erkrankungen \u00a0des\u00a0\nNervensystems, \u00a0psychiatrische \u00a0Ereignisse), \u00a0dies\u00a0f\u00fchrte\u00a0jedoch\u00a0nicht\u00a0zu\u00a0einer\u00a0relevanten \u00a0Verbesserung \u00a0\nder\u00a0Lebensqualit\u00e4t \u00a0(G\u2010BA,\u00a02012e).\u00a0\u00a0\nIn\u00a0der\u00a0Gesamtbetrachtung \u00a0gelangte\u00a0der\u00a0G\u2010BA\u00a0zu\u00a0dem\u00a0Entschluss, \u00a0dass\u00a0der\u00a0Zusatznutzen \u00a0des\u00a0\nArzneimittels \u00a0als\u00a0gering\u00a0einzustufen \u00a0sei,\u00a0da\u00a0\u201eauf\u00a0Basis\u00a0der\u00a0Angaben\u00a0im\u00a0Dossier\u00a0und\u00a0der\u00a0Ergebnisse \u00a0der\u00a0\nNutzenbewertung \u00a0gegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0keine\u00a0bisher\u00a0nicht\u00a0erreichte\u00a0\ndeutliche \u00a0Verbesserung \u00a0des\u00a0therapierelevanten \u00a0Nutzens\u00a0und\u00a0keine\u00a0bedeutsame \u00a0Vermeidung \u00a0nicht\u2010\nschwerwiegender \u00a0Nebenwirkungen\u201c \u00a0vorlag.\u00a0Eine\u00a0Einstufung \u00a0als\u00a0betr\u00e4chtlicher \u00a0Zusatznutzen \u00a0sei\u00a0daher\u00a0\nnicht\u00a0gerechtfertigt \u00a0(G\u2010BA,\u00a02012e).\u00a0\u00a0\nBei\u00a0der\u00a0Bewertung \u00a0der\u00a0Fixkombination, \u00a0bestehend \u00a0aus\u00a0Emtricitabin, \u00a0Rilpivirin\u00a0und\u00a0\nTenofovirdisoproxil, \u00a0kam\u00a0der\u00a0G\u2010BA\u00a0bei\u00a0der\u00a0Gesamtschau \u00a0der\u00a0Ergebnisse \u00a0zu\u00a0gleichen\u00a0Urteilen.\u00a0Auch\u00a0\nhier\u00a0konstatierte \u00a0der\u00a0Ausschuss \u00a0f\u00fcr\u00a0die\u00a0neue\u00a0Fixkombination \u00a0gegen\u00fcber \u00a0Efavirenz\u00a0in\u00a0Kombination \u00a0mit\u00a0\nTenofovir \u00a0plus\u00a0Emtricitabin \u00a0einen\u00a0Beleg\u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0Zusatznutzen \u00a0(G\u2010BA,\u00a02012f).\u00a0\n                                        \n1\u00a0Weitere\u00a0Wirkstoffe \u00a0folgten,\u00a0darunter\u00a0die\u00a0fixe\u00a0Kombination, \u00a0bestehend \u00a0aus\u00a0Elvitegravir \u00a0+\u00a0Cobicistat \u00a0+\u00a0Emtricitabin \u00a0und\u00a0Tenofovirdisoproxil \u00a0\n(2013),\u00a0Cobicistat \u00a0als\u00a0Monotherapie \u00a0(2014),\u00a0Dolutegravir \u00a0als\u00a0Monotherapeutikum \u00a0(2014)\u00a0und\u00a0seine\u00a0fixe\u00a0Kombination, \u00a0bestehend \u00a0aus\u00a0Dolut\u2010\negravir\u00a0+\u00a0Abacavir\u00a0+\u00a0Lamivudin \u00a0(2014).\u00a0 \n229\u00a0\n\u00a0\nHintergrundinformationen \u00a0Im\u00a0Jahr\u00a02014\u00a0durchlief\u00a0die\u00a0Fixkombination \u00a0eine\u00a0erneute\u00a0Nutzenbewertung \u00a0f\u00fcr\u00a0die\u00a0Erweiterung \u00a0des\u00a0\nIndikationsgebiets \u00a0um\u00a0antiretroviral \u00a0vorbehandelte \u00a0Patienten \u00a0ohne\u00a0HIV\u20101\u00a0Mutationen, \u00a0die\u00a0\nbekannterma\u00dfen \u00a0mit\u00a0Resistenzen \u00a0assoziiert \u00a0sind.\u00a0F\u00fcr\u00a0diese\u00a0Indikation \u00a0sah\u00a0der\u00a0G\u2010BA\u00a0den\u00a0Zusatznutzen \u00a0\ngegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0(individuelle \u00a0antiretrovirale \u00a0Therapie) \u00a0als\u00a0nicht\u00a0\nbelegt\u00a0an.\u00a0Da\u00a0der\u00a0pU\u00a0die\u00a0durch\u00a0den\u00a0G\u2010BA\u00a0festgelegte \u00a0zweckm\u00e4\u00dfige \u00a0Vergleichstherapie \u00a0in\u00a0seinem\u00a0\nArzneimitteldossier \u00a0nicht\u00a0ber\u00fccksichtigte, \u00a0fehlen\u00a0die\u00a0entsprechenden \u00a0Daten,\u00a0um\u00a0den\u00a0Zusatznutzen \u00a0\nbewerten \u00a0zu\u00a0k\u00f6nnen\u00a0(G\u2010BA,\u00a02014d).\u00a0\n\u00a0\nKosten\u00a0\nWirkstof f\u00a0 Behandlungsmodus Behandlungstage Jahrestherapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nRilpivirin  1\u00a0x\u00a0t\u00e4glich\u00a025\u00a0mg 360 5.068,20\u00a0\u20ac\nVergleichstherapie  \u00a0\nEfavirenz  1\u00a0x\u00a0t\u00e4glich\u00a0600\u00a0mg 360 5.057,80\u00a0\u20ac\nTabelle\u00a042:\u00a0Jahrestherapiekosten \u00a0von\u00a0Rilpivirin\u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0Kosten\u00a0\nzus\u00e4tzlicher \u00a0GKV\u2010Leistungen).  \n\u00a0\n  \u00a0\n230\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a011.17  Ruxolitinib \u00a0\nHandelsname: \u00a0Jakavi\u00ae\u00a0\u00a0\u00a0\u00a0\u00a0 Hersteller: \u00a0Novartis\u00a0Pharma\u00a0\nIndikation: \u00a0Splenomegalie/ \u00a0Symptome \u00a0der\u00a0Myelofibrose \u00a0\u00a0 Markteinf\u00fchrung: \u00a0September \u00a02012\u00a0\nATC\u2010Code:\u00a0L01XE18\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0 DDD:\u00a030\u00a0mg\u00a0\nDarreichungsform: \u00a0Tablette\u00a0\nBewertung: \u00a0siehe\u00a0Seite\u00a094\u00a0\nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nRuxolitinib \u00a0geh\u00f6rt\u00a0zur\u00a0Wirkstoffgruppe \u00a0der\u00a0Proteinkinase \u2010Inhibitoren. \u00a0Bei\u00a0Myelofibrose \u2010Patienten \u00a0\nsind\u00a0eine\u00a0Dysregulation \u00a0bzw.\u00a0\u00dcberaktivierung \u00a0der\u00a0JAK\u2010STAT\u2010Signalweiterleitung1\u00a0und\u00a0damit\u00a0einherge\u2010\nhend\u00a0eine\u00a0Dysregulation \u00a0der\u00a0H\u00e4matopoese \u00a0sowie\u00a0der\u00a0Funktion\u00a0des\u00a0Immunsystems \u00a0urs\u00e4chlich \u00a0(G\u2010BA,\u00a0\n2013j).\u00a0Die\u00a0Blutbildung \u00a0findet\u00a0mit\u00a0Fortschreiten \u00a0der\u00a0Erkrankung \u00a0immer\u00a0mehr\u00a0in\u00a0Leber\u00a0und\u00a0Milz\u00a0statt.\u00a0\u00a0\nDurch\u00a0selektive\u00a0Hemmung \u00a0der\u00a0Janus\u2010assoziierten \u00a0Kinasen\u00a0JAK1\u00a0und\u00a0JAK2,\u00a0die\u00a0bei\u00a0der\u00a0H\u00e4matopoese \u00a0\nund\u00a0im\u00a0Immunsystem \u00a0eine\u00a0wichtige\u00a0Rolle\u00a0spielen,\u00a0wird\u00a0mit\u00a0Ruxolitinib \u00a0der\u00a0JAK\u2010STAT\u2010Signalweg \u00a0unter\u2010\nbrochen\u00a0bzw.\u00a0deaktiviert. \u00a0Als\u00a0Folge\u00a0der\u00a0Hemmung \u00a0wird\u00a0die\u00a0Aktivit\u00e4t\u00a0der\u00a0ektopen\u00a0Blutbildung \u00a0in\u00a0Leber\u00a0\nund\u00a0Milz\u00a0herabgesetzt, \u00a0wodurch\u00a0beide\u00a0Organe\u00a0an\u00a0Gr\u00f6\u00dfe\u00a0verlieren\u00a0(Tefferi\u00a0et\u00a0al.,\u00a02011;\u00a0Novartis,\u00a0\n2015c).\u00a0\u00a0\n\u00a0\nZulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nIm\u00a0August\u00a02012\u00a0erteilte\u00a0die\u00a0EMA\u00a0die\u00a0Zulassung \u00a0f\u00fcr\u00a0Ruxolitinib \u00a0als\u00a0Orphan\u00a0Drug\u00a0zur\u00a0Therapie\u00a0der\u00a0sel\u2010\ntenen\u00a0Leuk\u00e4mie \u2010Form\u00a0Myelofibrose. \u00a0Anwendungsgebiete \u00a0des\u00a0Wirkstoffes \u00a0sind\u00a0die\u00a0krankheitsbeding \u2010\nte\u00a0Splenomegalie \u00a0(Vergr\u00f6\u00dferung \u00a0der\u00a0Milz)\u00a0oder\u00a0Symptome \u00a0bei\u00a0Erwachsenen \u00a0mit\u00a0prim\u00e4rer\u00a0Myelo\u2010\nfibrose\u00a0(auch:\u00a0chronische \u00a0idiopathische \u00a0Myelofibrose) \u00a0(PMF),\u00a0Post\u2010Polycythaemia \u2010vera\u2010Myelofibrose \u00a0\n(PPV\u2010MF)\u00a0oder\u00a0Post\u2010Essentieller \u2010Thrombozyth\u00e4mie \u2010Myelofibrose \u00a0(PET\u2010MF)\u00a0sowie\u00a0die\u00a0Polycythaemia \u00a0\nvera,\u00a0die\u00a0resistent\u00a0gegen\u00fcber \u00a0Hydroxycarbamid \u00a0sind\u00a0oder\u00a0dieses\u00a0Mittel\u00a0nicht\u00a0vertragen \u00a0(Novartis, \u00a0\n2015c).\u00a0Die\u00a0Anfangsdosis \u00a0von\u00a0Ruxolitinib \u00a0ist\u00a0abh\u00e4ngig\u00a0vom\u00a0Krankheitsbild \u00a0und\u00a0der\u00a0Thrombozytenzahl \u00a0\nim\u00a0Plasma\u00a0zu\u00a0Behandlungsbeginn. \u00a0Die\u00a0maximale \u00a0Dosis\u00a0liegt\u00a0bei\u00a025\u00a0mg\u00a0zweimal\u00a0t\u00e4glich\u00a0(Novartis, \u00a0\n2015c).\u00a0\n\u00a0\nInformationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nMyelofibrose \u00a0z\u00e4hlt\u00a0zu\u00a0den\u00a0Bluterkrankungen. \u00a0Sie\u00a0beruht\u00a0auf\u00a0einer\u00a0Fehlfunktion \u00a0der\u00a0h\u00e4matopoeti \u2010\nschen\u00a0Stammzellen \u00a0im\u00a0Knochenmark. \u00a0Die\u00a0Myelofibrose \u00a0kann\u00a0prim\u00e4r\u00a0oder\u00a0sekund\u00e4r \u00a0als\u00a0Folge\u00a0einer\u00a0\nessentiellen \u00a0Thrombozytopenie \u00a0oder\u00a0Polyzyth\u00e4mia \u00a0vera\u00a0auftreten. \u00a0Da\u00a0die\u00a0Differenzierung \u00a0nur\u00a0hin\u2010\nsichtlich\u00a0ihrer\u00a0unterschiedlichen \u00a0Entstehung \u00a0relevant\u00a0ist,\u00a0wird\u00a0im\u00a0Folgenden \u00a0ausschlie\u00dflich \u00a0von\u00a0einer\u00a0\nMyelofibrose \u00a0(MF)\u00a0gesprochen. \u00a0\u00a0\nDas\u00a0blutbildende \u00a0Knochenmark \u00a0wird\u00a0zunehmend \u00a0durch\u00a0Bindegewebe \u00a0ersetzt\u00a0(Verfaserung \u00a0oder\u00a0Fib\u2010\nrosierung). \u00a0Die\u00a0Stammzellver\u00e4nderung \u00a0im\u00a0Knochenmark \u00a0f\u00fchrt\u00a0zur\u00a0Bildung\u00a0von\u00a0zu\u00a0vielen\u00a0Leukozyten \u00a0\nund\u00a0Thrombozyten \u00a0(Leukozytose \u00a0und\u00a0Thrombozytose), \u00a0so\u00a0dass\u00a0sich\u00a0im\u00a0weiteren\u00a0Verlauf\u00a0einer\u00a0Myelo\u2010\nfibrose\u00a0vermehrt \u00a0unreife\u00a0Vorl\u00e4uferzellen \u00a0sowie\u00a0krankhaft \u00a0geformte \u00a0Blutzellen \u00a0finden.\u00a0Es\u00a0kommt\u00a0zu\u00a0\neiner\u00a0Auslagerung \u00a0der\u00a0H\u00e4matopoese \u00a0(in\u00a0erster\u00a0Linie\u00a0in\u00a0Milz\u00a0und\u00a0Leber).\u00a0Diese\u00a0ist\u00a0urs\u00e4chlich \u00a0f\u00fcr\u00a0die\u00a0\n                                        \n1\u00a0JAK\u00a0steht\u00a0f\u00fcr\u00a0Janusinkinase \u00a0und\u00a0STAT\u00a0f\u00fcr\u00a0signal\u00a0transducers \u00a0and\u00a0activators \u00a0of\u00a0transcribtion. \u00a0 \n231\u00a0\n\u00a0\nHintergrundinformationen \u00a0Vergr\u00f6\u00dferung \u00a0der\u00a0entsprechenden \u00a0Organe\u00a0(Splenomegalie \u00a0und\u00a0Hepatomegalie) \u00a0und\u00a0kann\u00a0bei\u00a0pro\u2010\ngressivem \u00a0Krankheitsverlauf \u00a0zu\u00a0einem\u00a0Milzinfarkt \u00a0f\u00fchren\u00a0(G\u2010BA,\u00a02013j).\u00a0\u00a0\nIm\u00a0initialen\u00a0Stadium\u00a0ist\u00a0die\u00a0Myelofibrose \u00a0meist\u00a0asymptomatisch, \u00a0wobei\u00a0Ver\u00e4nderungen \u00a0des\u00a0\nBlutbildes \u00a0(hierbei\u00a0am\u00a0h\u00e4ufigsten \u00a0eine\u00a0Thrombozytose \u00a0und\u00a0bzw.\u00a0oder\u00a0An\u00e4mie)\u00a0erste\u00a0Hinweise\u00a0gibt.\u00a0\nSchreitet\u00a0die\u00a0Erkrankung \u00a0weiter\u00a0voran,\u00a0entwickeln \u00a0sich\u00a0durch\u00a0die\u00a0zunehmende \u00a0Fibrose\u00a0und\u00a0\nVerdr\u00e4ngung \u00a0der\u00a0normalen \u00a0Blutbildung \u00a0Zeichen\u00a0der\u00a0ineffektiven \u00a0H\u00e4matopoese \u00a0(An\u00e4mie,\u00a0\nThrombozytopenie, \u00a0Leukozytopenie, \u00a0LDH\u2010Erh\u00f6hung) \u00a0und\u00a0Allgemeinsymptome \u00a0(Leistungsminderung, \u00a0\nFieber,\u00a0Nachtschwei\u00df, \u00a0Appetitlosigkeit \u00a0und\u00a0Gewichtsverlust) \u00a0sowie\u00a0andere\u00a0k\u00f6rperliche \u00a0\nBeeintr\u00e4chtigungen \u00a0durch\u00a0die\u00a0extramedull\u00e4re \u00a0H\u00e4matopoese \u00a0(Splenomegalie, \u00a0Hepatomegalie, \u00a0\nKnochenschmerzen) \u00a0(DGHO,\u00a02014).\u00a0Der\u00a0klinische\u00a0Verlauf\u00a0von\u00a0Patienten \u00a0mit\u00a0MF\u00a0ist\u00a0heterogen \u00a0und\u00a0\nAussagen \u00a0bez\u00fcglich \u00a0einer\u00a0mittleren \u00a0\u00dcberlebensdauer \u00a0\u2013\u00a0in\u00a0der\u00a0Literatur\u00a0werden\u00a03,5\u00a0bis\u00a0zehn\u00a0Jahre\u00a0\nangegeben \u00a0\u2013\u00a0sind\u00a0nur\u00a0unter\u00a0Vorbehalt \u00a0m\u00f6glich\u00a0(DGHO,\u00a02014).\u00a0Die\u00a0Unterscheidung \u00a0zwischen\u00a0einer\u00a0\nchronischen \u00a0MF,\u00a0einer\u00a0akuten\u00a0Myelofibrose \u00a0und\u00a0einer\u00a0Myelodysplasie \u00a0mit\u00a0Myelofibrose \u00a0ist\u00a0klinisch\u00a0\nrelevant,\u00a0da\u00a0die\u00a0akute\u00a0Myelofibrose \u00a0und\u00a0die\u00a0Myelodysplasie \u00a0mit\u00a0Myelofibrose \u00a0mit\u00a0einer\u00a0deutlich\u00a0\nschlechteren \u00a0Prognose \u00a0assoziiert \u00a0sind\u00a0(DGHO,\u00a02014).\u00a0\nWie\u00a0die\u00a0Myelofibrose \u00a0z\u00e4hlt\u00a0auch\u00a0die\u00a0Polycythaemia \u00a0vera\u00a0als\u00a0seltene\u00a0Krankheit \u00a0zu\u00a0den\u00a0\nMyeloproliferativen \u00a0Neoplasien .\u00a0Unter\u00a0diesem\u00a0Begriff\u00a0wird\u00a0eine\u00a0Reihe\u00a0von\u00a0Krankheiten \u00a0\nzusammengefasst, \u00a0die\u00a0mit\u00a0einer\u00a0gesteigerten \u00a0Neubildung \u00a0von\u00a0Blutzellen \u00a0im\u00a0Knochenmark \u00a0\neinhergehen. \u00a0In\u00a0der\u00a0Regel\u00a0werden\u00a0bei\u00a0dieser\u00a0Erkrankung \u00a0alle\u00a0drei\u00a0Blutzellarten \u00a0\u00fcberm\u00e4\u00dfig \u00a0produziert, \u00a0\nwobei\u00a0die\u00a0\u00dcberproduktion \u00a0in\u00a0erster\u00a0Linie\u00a0die\u00a0roten\u00a0Blutk\u00f6rperchen \u00a0betrifft.\u00a0Die\u00a0Krankheit \u00a0ist\u00a0zu\u00a0\nBeginn\u00a0meist\u00a0symptomlos \u00a0und\u00a0verursacht \u00a0erst\u00a0im\u00a0weiteren\u00a0Verlauf\u00a0Beschwerden \u00a0wie\u00a0\nDurchblutungsst\u00f6rungen \u00a0an\u00a0den\u00a0H\u00e4nden\u00a0und\u00a0F\u00fc\u00dfen,\u00a0Kopfschmerzen, \u00a0Schwindel, \u00a0Sehst\u00f6rungen, \u00a0\nJuckreiz,\u00a0insbesondere \u00a0nach\u00a0hei\u00dfem\u00a0Duschen\u00a0oder\u00a0Baden\u00a0(aquagener \u00a0Pruritus), \u00a0R\u00f6tung\u00a0von\u00a0Gesicht,\u00a0\nArmen\u00a0und\u00a0Beinen\u00a0und\u00a0bzw.\u00a0oder\u00a0Schmerzen \u00a0in\u00a0Armen\u00a0und\u00a0Beinen.\u00a0H\u00e4ufig\u00a0vergr\u00f6\u00dfert \u00a0sich\u00a0die\u00a0Milz\u00a0\nund\u00a0l\u00f6st\u00a0schmerzhafte \u00a0Beschwerden \u00a0im\u00a0Oberbauch \u00a0aus.\u00a0\u00a0\n\u00a0Evidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nBasis\u00a0f\u00fcr\u00a0die\u00a0Zulassung \u00a0von\u00a0Ruxolitinib \u00a0sind\u00a0die\u00a0Ergebnisse \u00a0zweier\u00a0Phase\u2010III\u2010Studien\u00a0(COMFORT \u2010I\u00a0und\u00a0\nCOMFORT \u2010II),\u00a0in\u00a0denen\u00a0der\u00a0Wirkstoff \u00a0an\u00a0insgesamt \u00a0528\n\u00a0Myelofibrose \u2010Patienten \u00a0mit\u00a0intermedi\u00e4rem \u00a0\noder\u00a0hohem\u00a0Risiko\u00a0untersucht \u00a0wurde.\u00a0In\u00a0der\u00a0ersten\u00a0placebokontrollierten \u00a0Studie\u00a0COMFORT \u2010I\u00a0wurden\u00a0\n309\u00a0Patienten \u00a0im\u00a0Verh\u00e4ltnis \u00a01:1\u00a0randomisiert \u00a0und\u00a0erhielten\u00a0\u00fcber\u00a024\u00a0Wochen\u00a0zweimal\u00a0t\u00e4glich\u00a0oral\u00a0\nRuxolitinib \u00a0(15\u00a0oder\u00a020\u00a0mg)\u00a0oder\u00a0Placebo\u00a0(Verstovsek \u00a0et\u00a0al.,\u00a02012).\u00a0Das\u00a0mediane\u00a0Milzvolumen \u00a0der\u00a0in\u00a0\ndiese\u00a0Studie\u00a0eingeschlossenen \u00a0Patienten \u00a0lag\u00a0zu\u00a0Studienbeginn \u00a0bei\u00a0\u00fcber\u00a02.500\u00a0cm3\u00a0und\u00a0war\u00a0somit\u00a0um\u00a0\ndas\u00a0Zehnfache \u00a0gr\u00f6\u00dfer\u00a0als\u00a0das\u00a0normale\u00a0Milzvolumen \u00a0von\u00a0200\u00a0cm3.\u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0dieser\u00a0Studie\u00a0\nwar\u00a0das\u00a0Ansprechen, \u00a0definiert\u00a0als\u00a0Anteil\u00a0der\u00a0Patienten, \u00a0die\u00a0nach\u00a0Woche\u00a024\u00a0eine\u00a0Reduktion \u00a0des\u00a0\nMilzvolumens \u00a0um\u00a0mindestens \u00a035\u00a0Prozent\u00a0im\u00a0Vergleich \u00a0zum\u00a0Ausgangswert \u00a0erreicht\u00a0hatten.\u00a0Den\u00a0\nprim\u00e4ren \u00a0Endpunkt \u00a0erreichten \u00a041,9\u00a0Prozent\u00a0der\u00a0Patienten \u00a0aus\u00a0dem\u00a0Verum\u2010Arm\u00a0im\u00a0Vergleich \u00a0zu\u00a00,7\u00a0\nProzent\u00a0unter\u00a0Placebo.\u00a0Dar\u00fcber\u00a0hinaus\u00a0konnte\u00a0unter\u00a0dem\u00a0Wirkstoff \u00a0im\u00a0Vergleich \u00a0zur\u00a0\nScheinmedikation \u00a0eine\u00a0signifikante \u00a0Senkung\u00a0des\u00a0Symptomen \u2010Scores\u00a0(beispielsweise \u00a0im\u00a0Hinblick\u00a0auf\u00a0\nM\u00fcdigkeit, \u00a0Schw\u00e4che, \u00a0Bauchschmerzen, \u00a0Kachexie, \u00a0Gewichtsverlust, \u00a0Juckreiz,\u00a0n\u00e4chtliche \u00a0\nSchwei\u00dfausbr\u00fcche \u00a0und\u00a0Knochenschmerzen) \u00a0erzielt\u00a0werden\u00a0(45,9\u00a0Prozent\u00a0vs.\u00a05,3\u00a0Prozent).\u00a0Unter\u00a0den\u00a0\nPatienten, \u00a0die\u00a0Ruxolitinib \u00a0erhielten, \u00a0waren\u00a0An\u00e4mie\u00a0(45,2\u00a0Prozent),\u00a0Thrombozytopenie \u00a0(12,9\u00a0Prozent)\u00a0\nund\u00a0Neutropenie \u00a0(7,1\u00a0Prozent)\u00a0die\u00a0h\u00e4ufigsten \u00a0diagnostizierten \u00a0schweren \u00a0Nebenwirkungen \u00a0der\u00a0\u00a0\n232\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Behandlung. \u00a0Eine\u00a0Subgruppen \u2010Analyse\u00a0aus\u00a0COMFORT \u2010I\u00a0demonstrierte \u00a0die\u00a0Effektivit\u00e4t \u00a0(Reduzierung \u00a0\ndes\u00a0Milzvolumens) \u00a0des\u00a0Wirkstoffes \u00a0\u2013\u00a0unabh\u00e4ngig \u00a0vom\u00a0Krankheitsbild \u00a0bzw.\u00a0der\u00a0Ausgangssituation \u00a0\n(u.a.\u00a0PMF,\u00a0PPV\u2010MF\u00a0oder\u00a0PET\u2010MF,\u00a0Alter,\u00a0IPSS\u00a0(International \u00a0Prognostic \u00a0Scoring\u00a0System )\u2010Risiko,\u00a0JAK2\u00a0\nV617F\u2010Mutation) \u00a0(Verstovsek \u00a0et\u00a0al.,\u00a02013).\u00a0\u00a0\nIn\u00a0der\u00a0zweiten\u00a0Studie\u00a0(COMFORT \u2010II)\u00a0wurde\u00a0die\u00a0Wirksamkeit \u00a0und\u00a0Sicherheit \u00a0von\u00a0Ruxolitinib \u00a0mit\u00a0der\u00a0\nbesten\u00a0verf\u00fcgbaren \u00a0Therapie\u00a0(BAT),\u00a0bestehend \u00a0aus\u00a0Hydroxycarbamid \u00a0und\u00a0Glucocorticoide \u00a0(als\u00a0Mono\u2010\u00a0\noder\u00a0Kombinationstherapie) \u00a0oder\u00a0Nicht\u2010Behandlung, \u00a0verglichen. \u00a0In\u00a0die\u00a0Studie\u00a0eingeschlossen \u00a0wurden\u00a0\n219\u00a0Patienten, \u00a0von\u00a0denen\u00a0146\u00a0Patienten \u00a0zweimal\u00a0t\u00e4glich\u00a0Ruxolitinib \u00a0(15\u00a0oder\u00a020\u00a0mg\u00a0p.o.)\u00a0erhielten. \u00a0\nPrim\u00e4rer\u00a0Endpunkt \u00a0dieser\u00a0Studie\u00a0war\u00a0das\u00a0Ansprechen, \u00a0definiert\u00a0als\u00a0Anteil\u00a0der\u00a0Patienten, \u00a0die\u00a0nach\u00a0\nWoche\u00a048\u00a0eine\u00a0Reduktion \u00a0des\u00a0Milzvolumens \u00a0um\u00a0mindestens \u00a035\u00a0Prozent\u00a0im\u00a0Vergleich \u00a0zum\u00a0\nAusgangswert \u00a0erreicht\u00a0hatten\u00a0(Harrison \u00a0et\u00a0al.,\u00a02012).\u00a028\u00a0Prozent\u00a0der\u00a0Patienten \u00a0aus\u00a0der\u00a0Verum\u2010\nGruppe\u00a0erreichten \u00a0den\u00a0prim\u00e4ren \u00a0Endpunkt, \u00a0aus\u00a0der\u00a0BAT\u2010Gruppe\u00a0hingegen\u00a0keiner.\u00a0Die\u00a0mediane\u00a0Dauer\u00a0\nbis\u00a0zu\u00a0einer\u00a0Reduktion \u00a0der\u00a0Milzgr\u00f6\u00dfe \u00a0um\u00a0mindestens \u00a035\u00a0Prozent\u00a0betrug\u00a0in\u00a0der\u00a0COMFORT \u2010II\u2010Studie\u00a0\n12,3\u00a0Wochen.\u00a0Um\u00a0ein\u00a0Ansprechen \u00a0definitiv\u00a0beurteilen \u00a0zu\u00a0k\u00f6nnen,\u00a0sollte\u00a0die\u00a0Therapie\u00a0\u00fcber\u00a0sechs\u00a0\nMonate\u00a0fortgesetzt \u00a0werden.\u00a0Sicherheit, \u00a0Effektivit\u00e4t \u00a0und\u00a0Wirksamkeit \u00a0des\u00a0Orphan\u00a0Drug\u00a0werden\u00a0auch\u00a0\ndurch\u00a0Follow\u2010Ups\u00a0erh\u00e4rtet\u00a0(Verstovsek \u00a0\u00a0et\u00a0al.,\u00a02013;\u00a0Verstovsek \u00a0et\u00a0al.,\u00a02015;\u00a0Cervantes \u00a0et\u00a0al.,\u00a02013,\u00a0\nPassamonti \u00a0et\u00a0al.,\u00a02014).\u00a0\nNeuere\u00a0Untersuchungen \u00a0zeigen,\u00a0dass\u00a0die\u00a0Therapie\u00a0mit\u00a0Ruxolitinib \u00a0den\u00a0Stoffwechsel \u2010\u00a0und\u00a0\nErn\u00e4hrungszustand \u00a0(Mesa\u00a0et\u00a0al.,\u00a02015)\u00a0sowie\u00a0die\u00a0gesundheitsbezogene \u00a0Lebensqualit\u00e4t \u00a0(Harrison \u00a0et\u00a0\nal.,\u00a02013)\u00a0der\u00a0betroffenen \u00a0Patienten \u00a0verbessern \u00a0kann.\u00a0Auch\u00a0spielt\u00a0der\u00a0MF\u2010Mutationstyp \u00a0eine\u00a0Rolle,\u00a0\nwenn\u00a0es\u00a0um\u00a0die\u00a0klinische\u00a0Wirksamkeit \u00a0von\u00a0Ruxolitinib \u00a0geht\u00a0(Guglielmelli \u00a0et\u00a0al.,\u00a02014).\u00a0\u00a0\nIn\u00a0einer\u00a0offenen\u00a0Phase\u2010III\u2010Studie\u00a0wurden\u00a0Wirksamkeit \u00a0und\u00a0Sicherheit \u00a0von\u00a0Ruxolitinib \u00a0im\u00a0Vergleich \u00a0zu\u00a0\nHydroxycarbamid \u00a0bei\u00a0Patienten \u00a0(n\u00a0=\u00a0222)\u00a0mit\u00a0Polycythaemia \u00a0vera\u00a0untersucht, \u00a0die\u00a0nicht\u00a0ausreichend \u00a0\nauf\u00a0Hydroxycarbamid \u00a0angesprochen \u00a0haben\u00a0oder\u00a0dieses\u00a0Mittel\u00a0nicht\u00a0vertragen \u00a0(Vannucchi \u00a0et\u00a0al.,\u00a0\n2015).\u00a0Der\u00a0prim\u00e4re\u00a0Endpunkt \u00a0dieser\u00a0Studie\u00a0war\u00a0sowohl\u00a0die\u00a0Anzahl\u00a0der\u00a0Patienten \u00a0mit\u00a0kontrolliertem \u00a0\nH\u00e4matokrit \u2010Wert\u00a0bis\u00a0Woche\u00a032\u00a0als\u00a0auch\u00a0die\u00a0Anzahl\u00a0der\u00a0Patienten \u00a0mit\u00a0einer\u00a035prozentigen \u00a0\nVerringerung \u00a0des\u00a0Milzvolumens \u00a0in\u00a0Woche\u00a032.\u00a0Den\u00a0prim\u00e4ren \u00a0Endpunkt \u00a0erreichten \u00a021\u00a0Prozent\u00a0aus\u00a0dem\u00a0\nVerum\u2010Arm\u00a0im\u00a0Vergleich \u00a0zu\u00a0einem\u00a0Prozent\u00a0aus\u00a0dem\u00a0Kontroll\u2010Arm\u00a0(p\u00a0<\u00a00,001)\u00a0(kontrollierter \u00a0\nH\u00e4matokrit \u2010Wert:\u00a060\u00a0Prozent\u00a0(Verum)\u00a0vs.\u00a020\u00a0Prozent\u00a0(Kontrolle); \u00a0Verkleinerung \u00a0der\u00a0Milz\u00a0um\u00a035\u00a0\nProzent:\u00a038\u00a0Prozent\u00a0(Verum)\u00a0vs.\u00a01\u00a0Prozent\u00a0(Kontrolle); \u00a0komplette \u00a0Remission: \u00a024\u00a0Prozent\u00a0(Verum)\u00a0vs.\u00a09\u00a0\nProzent\u00a0(Kontrolle)). \u00a0Insgesamt \u00a0erwies\u00a0sich\u00a0Ruxolitinib \u00a0signifikant \u00a0\u00fcberlegen \u00a0gegen\u00fcber \u00a0der\u00a0\nStandardtherapie, \u00a0verbunden \u00a0mit\u00a0h\u00e4ufiger\u00a0auftretenden \u00a0Nebenwirkungen \u00a0wie\u00a0An\u00e4mien\u00a03.\u00a0Und\u00a04.\u00a0\nGrades\u00a0(2\u00a0Prozent\u00a0vs.\u00a00\u00a0Prozent),\u00a0Thrombozytop\u00e4nie \u00a0(5\u00a0Prozent\u00a0vs.\u00a04\u00a0Prozent)\u00a0sowie\u00a0Herpes\u00a0zoster\u2010\nInfektionen \u00a0(6\u00a0Prozent\u00a0vs.\u00a00\u00a0Prozent).\u00a0Thromboembolische \u00a0Ereignisse \u00a0wurden\u00a0hingegen\u00a0im\u00a0Kontroll\u2010\nArm\u00a0h\u00e4ufiger\u00a0registriert \u00a0(sechs\u00a0Patienten \u00a0vs.\u00a0einem\u00a0Patient\u00a0im\u00a0Verum\u2010Arm).\u00a0Die\u00a0Ergebnisse \u00a0der\u00a0\nPhase\u2010III\u2010Studie\u00a0erh\u00e4rteten \u00a0somit\u00a0die\u00a0Daten\u00a0aus\u00a0einer\u00a0Phase\u2010II\u2010Studie\u00a0um\u00a0Verstovsek \u00a0et\u00a0al.\u00a0(2014).\u00a0\u00a0\n\u00a0\u00a0 \n233\u00a0\n\u00a0\nHintergrundinformationen \u00a0Leitlinienempfehlungen1\u00a0\nGrunds\u00e4tzlich \u00a0richtet\u00a0sich\u00a0die\u00a0Therapie\u00a0der\u00a0Myelofibrose \u00a0nach\u00a0dem\u00a0Risiko\u00a0und\u00a0dem\u00a0Alter\u00a0des\u00a0\nPatienten. \u00a0Die\u00a0Beobachtungsstrategie \u00a0(Watch\u00a0&\u00a0Wait )\u00a0gilt\u00a0dabei\u00a0f\u00fcr\u00a0Patienten \u00a0mit\u00a0niedrigem \u00a0Risiko\u00a0\nf\u00fcr\u00a0ein\u00a0schnelles\u00a0Fortschreiten \u00a0der\u00a0Erkrankung \u00a0und\u00a0ohne\u00a0klinische\u00a0Probleme. \u00a0Die\u00a0allogene\u00a0\nStammzelltransplantation \u00a0(alloSZT)\u00a0\u2013\u00a0entweder \u00a0mit\u00a0einem\u00a0Familien\u2010\u00a0oder\u00a0einem\u00a0Fremdspender \u00a0\ndurchgef\u00fchrt \u00a0\u2013\u00a0ist\u00a0nach\u00a0wie\u00a0vor\u00a0die\u00a0einzige\u00a0Therapie\u00a0mit\u00a0kurativem \u00a0Charakter, \u00a0die\u00a0jedoch\u00a0mit\u00a0einer\u00a0\nnicht\u00a0unerheblichen \u00a0Morbidit\u00e4t \u00a0und\u00a0einer\u00a0transplantationsassoziierten \u00a0Mortalit\u00e4t \u00a0von\u00a020\u00a0bis\u00a0zu\u00a030\u00a0\nProzent\u00a0belastet\u00a0ist\u00a0(DGHO,\u00a02014).\u00a0Aufgrund \u00a0der\u00a0schlechten \u00a0Prognose \u00a0sollte\u00a0die\u00a0alloSZT\u00a0insbesondere \u00a0\nRisikopatienten \u00a0vorbehalten \u00a0bleiben,\u00a0wenn\u00a0diese\u00a0in\u00a0einem\u00a0transplantationsf\u00e4higen \u00a0Zustand\u00a0und\u00a0nicht\u00a0\n\u00e4lter\u00a0als\u00a070\u00a0Jahre\u00a0sind.\u00a0Bei\u00a0den\u00a0Patienten, \u00a0bei\u00a0denen\u00a0eine\u00a0Stammzelltransplantation \u00a0nicht\u00a0m\u00f6glich\u00a0ist,\u00a0\nkann\u00a0aktuell\u00a0nur\u00a0eine\u00a0problemorientiert \u2010palliative\u00a0Therapie\u00a0mit\u00a0dem\u00a0Ziel\u00a0einer\u00a0Besserung \u00a0einzelner \u00a0\nSymptome \u00a0angeboten \u00a0werden.\u00a0Die\u00a0DGHO\u00a0erw\u00e4hnt\u00a0den\u00a0oralen\u00a0JAK1/2\u2010Inhibitor\u00a0Ruxolitinib \u00a0als\u00a0erste\u00a0\nzugelassene, \u00a0effektive\u00a0und\u00a0gut\u00a0vertr\u00e4gliche \u00a0medikament\u00f6se \u00a0Therapie\u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0der\u00a0prim\u00e4ren\u00a0\nMyelofibrose \u00a0(PMF)\u00a0bzw.\u00a0der\u00a0post\u2010PV\u2010/post\u2010ET\u2010Myelofibrose \u00a0in\u00a0ihrer\u00a0Leitlinie.\u00a0So\u00a0werden\u00a0durch\u00a0\nRuxolitinib \u00a0insbesondere \u00a0die\u00a0krankheitsassoziierten \u00a0Symptome \u00a0und\u00a0die\u00a0Splenomegalie \u00a0positiv\u00a0\nadressiert. \u00a0(DGHO,\u00a02014).\u00a0\nVor\u00a0der\u00a0Zulassung \u00a0von\u00a0Ruxolitinib \u00a0war\u00a0die\u00a0Gabe\u00a0von\u00a0Hydroxycarbamid \u00a0(Hydroxyurea) \u00a0die\u00a0\nmedikament\u00f6se \u00a0Standardtherapie \u00a0zur\u00a0Behandlung \u00a0einer\u00a0MF\u2010bedingten \u00a0Splenomegalie. \u00a0Fallberichten \u00a0\nzufolge\u00a0kann\u00a0insbesondere \u00a0bei\u00a0den\u00a0betroffenen \u00a0MF\u2010Personen \u00a0mit\u00a0ausgepr\u00e4gter \u00a0Leukozytose \u00a0aber\u00a0\nnoch\u00a0hinreichender \u00a0oder\u00a0erh\u00f6hter\u00a0Thrombozytenzahl \u00a0mit\u00a0einer\u00a0Wirkstoff \u2010Kombination, \u00a0bestehend \u00a0\naus\u00a0Hydroxycarbamid \u00a0+\u00a0Ruxolotinib, \u00a0die\u00a0Leukozytenzahl \u00a0gut\u00a0kontrolliert \u00a0werden.\u00a0\u00dcber\u00a0eine\u00a0\nmedikament\u00f6se \u00a0Therapie\u00a0hinaus\u00a0kommt\u00a0au\u00dferdem \u00a0eine\u00a0Splenektomie \u00a0bzw.\u00a0eine\u00a0Milzbestrahlung \u00a0\ninfrage.\u00a0Gerade\u00a0das\u00a0operative \u00a0Verfahren \u00a0hat\u00a0zwar\u00a0die\u00a0h\u00f6chste\u00a0Morbidit\u00e4ts \u2010\u00a0und\u00a0Mortalit\u00e4tsrate, \u00a0\ndennoch\u00a0konnte\u00a0nach\u00a0einem\u00a0Jahr\u00a0f\u00fcr\u00a076\u00a0Prozent\u00a0der\u00a0Patienten \u00a0ein\u00a0palliativer \u00a0Nutzen\u00a0der\u00a0\nSplenektomie, \u00a0d.h.\u00a0Besserung \u00a0des\u00a0Allgemeinbefindens \u00a0und\u00a0fehlende\u00a0Beschwerden \u00a0aufgrund\u00a0der\u00a0\nMilzvergr\u00f6\u00dferung, \u00a0belegt\u00a0werden\u00a0(DGHO,\u00a02014).\u00a0Zur\u00a0Behandlung \u00a0einer\u00a0therapiebed\u00fcrftigen \u00a0An\u00e4mie\u00a0\nwerden\u00a0Glucocorticoide \u00a0eingesetzt, \u00a0die\u00a0bei\u00a0ca.\u00a0einem\u00a0Drittel\u00a0der\u00a0Patienten \u00a0ein\u00a0Ansprechen \u00a0erzielen,\u00a0\nh\u00e4ufig\u00a0handelt\u00a0es\u00a0sich\u00a0allerdings \u00a0dabei\u00a0um\u00a0einen\u00a0kurzfristigen \u00a0Effekt.\u00a0Als\u00a0Alternative \u00a0steht\u00a0eine\u00a0\nErythropoetin \u2010Behandlung \u00a0zur\u00a0Diskussion \u00a0unter\u00a0der\u00a020\u201025\u00a0Prozent\u00a0der\u00a0F\u00e4lle\u00a0eine\u00a0komplette \u00a0\nRemission \u00a0erfahren\u00a0oder\u00a0aber\u00a0die\u00a0Gabe\u00a0von\u00a0Androgenen \u00a0wie\u00a0Danazol\u00a0(ein\u00a0Ansprechen \u00a0der\u00a0An\u00e4mie\u00a0\nkann\u00a0in\u00a0ca.\u00a050\u00a0Prozent\u00a0der\u00a0behandelten \u00a0F\u00e4lle\u00a0erwartet\u00a0werden)\u00a0(DGHO,\u00a02014).\u00a0\u00a0\nNeben\u00a0den\u00a0aufgef\u00fchrten \u00a0Wirkstoffen \u00a0werden\u00a0derzeit\u00a0weitere\u00a0Substanzen \u00a0zur\u00a0Behandlung \u00a0der\u00a0\nMyelofibrose \u00a0im\u00a0Off\u2010Label\u00a0Use\u00a0eingesetzt. \u00a0Hierzu\u00a0geh\u00f6ren\u00a0neben\u00a0immunmodulatorischen \u00a0Substanzen \u00a0\nwie\u00a0(PEG\u2010)Interferon \u00a0\u03b1,\u00a0Thalidomid, \u00a0Lenalidomid \u00a0und\u00a0Pomalidomid \u00a0auch\u00a0Everolimus \u00a0und\u00a0Histon\u2010\nDeacetylase \u2010Inhibitoren \u00a0wie\u00a0Givinostat \u00a0und\u00a0Panobinostat. \u00a0\u00a0\n  \n                                        \n1\u00a0Da\u00a0sich\u00a0die\u00a0Therapie\u00a0der\u00a0beiden\u00a0Erkrankungen \u00a0gleicht,\u00a0soll\u00a0im\u00a0hier\u00a0nur\u00a0auf\u00a0die\u00a0Therapie\u00a0der\u00a0Erstindikation \u00a0eingegangen \u00a0werden.\u00a0\n\u00a0\u00a0\n234\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Nutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nIn\u00a0der\u00a0Indikation \u00a0der\u00a0chronisch \u00a0myeloproliferativen \u00a0Erkrankungen \u00a0durchlief\u00a0der\u00a0Wirkstoff \u00a0Ruxolitinib \u00a0\ngleich\u00a0zweimal\u00a0hintereinander \u00a0eine\u00a0fr\u00fche\u00a0Nutzenbewertung. \u00a0In\u00a0seinem\u00a0ersten\u00a0Beschluss \u00a0vom\u00a07.\u00a0M\u00e4rz\u00a0\n2013\u00a0betrachtete \u00a0der\u00a0G\u2010BA\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens \u00a0als\u00a0gering .\u00a0Laut\u00a0Aussage\u00a0des\u00a0Ausschusses \u00a0\nhandele\u00a0es\u00a0sich\u00a0um\u00a0eine\u00a0bisher\u00a0nicht\u00a0erreichte\u00a0moderate \u00a0und\u00a0nicht\u00a0nur\u00a0geringf\u00fcgige \u00a0Verbesserung \u00a0\ndes\u00a0therapierelevanten \u00a0Nutzens,\u00a0da\u00a0eine\u00a0Verringerung \u00a0von\u00a0nicht\u00a0schwerwiegenden \u00a0Symptomen \u00a0der\u00a0\nErkrankung \u00a0(Endpunkt \u00a0\u201eMorbidit\u00e4t\u201c) \u00a0erreicht\u00a0wird\u00a0(G\u2010BA,\u00a02013j).\u00a0\u00a0\nZwischenzeitlich \u00a0hatte\u00a0der\u00a0Umsatz\u00a0des\u00a0Medikaments \u00a0die\u00a0im\u00a0AMNOG\u00a0festgelegte \u00a0Umsatzgrenze \u00a0von\u00a0\n50\u00a0Mio.\u00a0Euro\u00a0\u00fcberschritten, \u00a0so\u00a0dass\u00a0ein\u00a0erneutes\u00a0Verfahren \u00a0eingeleitet \u00a0werden\u00a0musste.\u00a0Als\u00a0\nzweckm\u00e4\u00dfige \u00a0Vergleichstherapie \u00a0zur\u00a0Behandlung \u00a0von\u00a0krankheitsbedingter \u00a0Splenomegalie \u00a0oder\u00a0\nSymptomen \u00a0bei\u00a0Erwachsenen \u00a0mit\u00a0prim\u00e4rer\u00a0Myelofibrose, \u00a0Post\u2010Polycythaemia \u2010vera\u2010Myelofibrose \u00a0\noder\u00a0Post\u2010Essentieller \u2010Thrombozyth\u00e4mie \u2010Myelofibrose \u00a0diente\u00a0in\u00a0diesem\u00a0Verfahren \u00a0eine\u00a0Best\u00a0\nSupportive \u00a0Care\u00a0(BSC).\u00a0Darunter\u00a0wird\u00a0eine\u00a0Therapie\u00a0verstanden, \u00a0die\u00a0eine\u00a0bestm\u00f6gliche, \u00a0\npatientenindividuell \u00a0optimierte, \u00a0unterst\u00fctzende \u00a0Behandlung \u00a0zur\u00a0Linderung \u00a0von\u00a0Symptomen \u00a0und\u00a0\nVerbesserung \u00a0der\u00a0Lebensqualit\u00e4t \u00a0gew\u00e4hrleistet. \u00a0Der\u00a0G\u2010BA\u00a0konstatierte \u00a0in\u00a0seinem\u00a0zweiten\u00a0Beschluss \u00a0\nvom\u00a06.\u00a0November \u00a02014\u00a0bzgl.\u00a0Ausma\u00df\u00a0und\u00a0die\u00a0Wahrscheinlichkeit \u00a0des\u00a0Zusatznutzens \u00a0gegen\u00fcber \u00a0BSC\u00a0\neinen\u00a0Anhaltspunkt \u00a0f\u00fcr\u00a0einen\u00a0betr\u00e4chtlichen \u00a0Zusatznutzen .\u00a0F\u00fcr\u00a0den\u00a0Endpunkt \u00a0Gesamt\u00fcberleben \u00a0\nergab\u00a0sich\u00a0zwar\u00a0weder\u00a0in\u00a0der\u00a0Prim\u00e4ranalyse \u00a0noch\u00a0in\u00a0der\u00a0geplanten \u00a03\u2010Jahres\u2010Auswertung \u00a0ein\u00a0\nstatistisch \u00a0signifikanter \u00a0Effekt\u00a0zugunsten \u00a0von\u00a0Ruxolitinib. \u00a0Die\u00a0Ergebnisse \u00a0aus\u00a0erg\u00e4nzenden \u00a0post\u2010hoc\u2010\nAnalysen\u00a0der\u00a0Datenschnitte \u00a0vom\u00a001.03.2011 \u00a0und\u00a0vom\u00a005.04.2013 \u00a0zeigten\u00a0allerdings \u00a0signifikante \u00a0\nErgebnisse \u00a0zugunsten \u00a0von\u00a0Ruxolitinib \u00a0(G\u2010BA,\u00a02014e).\u00a0M\u00f6glicherweise \u00a0wird\u00a0der\u00a0wahre\u00a0Effekt\u00a0von\u00a0\nRuxolitinib \u00a0noch\u00a0untersch\u00e4tzt, \u00a0da\u00a0die\u00a0Auswirkungen \u00a0des\u00a0Verum\u00a0aufgrund\u00a0der\u00a0Intention\u2010to\u2010treat\u2010\nAuswertungsmethode \u00a0auch\u00a0im\u00a0Kontroll\u2010Arm\u00a0der\u00a0Studie\u00a0ber\u00fccksichtigt \u00a0wurden.\u00a0Auch\u00a0ist\u00a0nach\u00a0\nAuffassung \u00a0des\u00a0G\u2010BA\u00a0eine\u00a0lang\u00a0anhaltende \u00a0Verringerung \u00a0des\u00a0pathologisch \u00a0erh\u00f6hten \u00a0Milzvolumens \u00a0\nverbunden \u00a0mit\u00a0einer\u00a0f\u00fcr\u00a0den\u00a0Patienten \u00a0sp\u00fcrbaren \u00a0Abnahme \u00a0beeintr\u00e4chtigender \u00a0Krankheitssymptome \u00a0\npatientenrelevant. \u00a0Die\u00a0unter\u00a0der\u00a0Behandlung \u00a0mit\u00a0Ruxolitinib \u00a0auftretenden \u00a0Nebenwirkungen \u00a0werden\u00a0\nzwar\u00a0als\u00a0f\u00fcr\u00a0die\u00a0Patienten \u00a0bedeutend, \u00a0aber\u00a0\u00fcberwiegend \u00a0als\u00a0kontrollierbar \u00a0und\u00a0behandelbar \u00a0\neingestuft \u00a0(G\u2010BA,\u00a02014e).\u00a0\u00a0\nDie\u00a0Nutzenbewertung \u00a0in\u00a0der\u00a0Indikation \u00a0Polycythaemia \u00a0vera\u00a0steht\u00a0derzeit\u00a0noch\u00a0aus,\u00a0die\u00a0\nBeschlussfassung \u00a0wird\u00a0Mitte\u00a0Oktober\u00a0erwartet. \u00a0\u00a0\n\u00a0Kosten\u00a0\nWirkstof f\u00a0 Behandlungsmodus Behandlungstage Jahrestherapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nRuxolitinib  2\u00a0x\u00a0t\u00e4glich\u00a020\u00a0mg 360 55.005,43 \u00a0\u20ac\nTabelle\u00a043:\u00a0Jahrestherapiekosten \u00a0von\u00a0Ruxolitinib \u00a0(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0f\u00fcr\u00a0alle\u00a0\nIndikationsbereiche \u00a0\u00a0 \n235\u00a0\n\u00a0\nHintergrundinformationen \u00a011.18  Tegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0Oteracil\u00a0\nHandelsname: \u00a0Teysuno\u00ae \u00a0\u00a0\u00a0\u00a0 Hersteller: \u00a0Nordic\u00a0Pharma\u00a0\nIndikation: \u00a0Magenkarzinom \u00a0\u00a0 \u00a0 \u00a0 \u00a0 Markteinf\u00fchrung: \u00a0Juli\u00a02012\u00a0\nATC\u2010Code:\u00a0L01BC73\u00a0 \u00a0\u00a0\u00a0\u00a0 DDD:\u00a067,5\u00a0mg\u00a0bezogen\u00a0auf\u00a0Tegafur\u00a0\nDarreichungsform: \u00a0Hartkapsel \u00a0\nBewertung: \u00a0siehe\u00a0Seite\u00a098 \nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nBei\u00a0dem\u00a0Fertigarzneimittel \u00a0Teysuno\u00ae \u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0ein\u00a0Kombinationspr\u00e4parat \u00a0mit\u00a0festgelegter \u00a0\nDosis\u00a0aus\u00a0drei\u00a0Wirkstoffen: \u00a0Tegafur,\u00a0das\u00a0nach\u00a0Absorption \u00a0in\u00a0den\u00a0Antikrebswirkstoff \u00a05\u2010FU\u00a0\numgewandelt \u00a0wird,\u00a0Gimeracil, \u00a0ein\u00a0Dihydropyrimidindehydrogenase \u2010(DPD)\u2010Hemmer, \u00a0um\u00a0den\u00a0Abbau\u00a0\nvon\u00a05\u2010FU\u00a0im\u00a0K\u00f6rper\u00a0zu\u00a0verhindern, \u00a0und\u00a0Oteracil,\u00a0ein\u00a0Orotatphosphoribosyltransferase \u2010(OPRT)\u2010\nHemmer, \u00a0der\u00a0die\u00a0Aktivit\u00e4t\u00a0von\u00a05\u2010FU\u00a0in\u00a0der\u00a0normalen \u00a0Magen\u2010Darm\u2010Mukosa\u00a0herabsetzt \u00a0(Nordic\u00a0\nPharma,\u00a02013).\u00a0\nNach\u00a0Capecitabin \u00a0steht\u00a0mit\u00a0Tegafur\u00a0nun\u00a0ein\u00a0zweites\u00a0oral\u00a0einsetzbares \u00a05\u2010Fluorouracil \u2010Prodrug\u00a0zur\u00a0\nVerf\u00fcgung. \u00a0Die\u00a0zytostatische \u00a0Wirkung\u00a0des\u00a0Antimetaboliten \u00a05\u2010FU\u00a0beruht\u00a0neben\u00a0seiner\u00a0strukturellen \u00a0\n\u00c4hnlichkeit \u00a0mit\u00a0der\u00a0Pyrimidinbase \u00a0Uracil\u00a0und\u00a0dem\u00a0damit\u00a0verbundenen \u00a0Einbau\u00a0als\u00a0falscher\u00a0Baustein\u00a0in\u00a0\ndie\u00a0RNA\u00a0auch\u00a0auf\u00a0der\u00a0Hemmung \u00a0des\u00a0Schl\u00fcsselenzyms \u00a0Thymidilat \u2010Synthase\u00a0in\u00a0der\u00a0Pyrimidin \u2010\nBiosynthese. \u00a0Dadurch\u00a0wird\u00a0die\u00a0Methylierung \u00a0von\u00a0Desoxyuridyls\u00e4ure \u00a0zu\u00a0Thymidyls\u00e4ure \u00a0effektiv\u00a0\nblockiert, \u00a0was\u00a0zu\u00a0einer\u00a0Hemmung \u00a0der\u00a0DNA\u2010Synthese\u00a0und\u00a0des\u00a0Zellwachstums \u00a0f\u00fchrt\u00a0(Mutschler \u00a0et\u00a0al.,\u00a0\n2008).\u00a0\n\u00a0\nZulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nDie\u00a0fixe\u00a0Kombination \u00a0der\u00a0drei\u00a0Wirkstoffe \u00a0wurde\u00a0bereits\u00a0vor\u00a020\u00a0Jahren\u00a0in\u00a0Japan\u00a0entwickelt \u00a0und\u00a0dort\u00a0im\u00a0\nJahr\u00a01999\u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0des\u00a0fortgeschrittenen \u00a0Magenkarzinoms \u00a0zugelassen \u00a0(Schwabe \u00a0&\u00a0\nPaffrath,\u00a02013).\u00a0Im\u00a0M\u00e4rz\u00a02011\u00a0erfolgte\u00a0schlie\u00dflich \u00a0die\u00a0europaweite \u00a0Zulassung \u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0von\u00a0\nfortgeschrittenem \u00a0Magenkrebs \u00a0bei\u00a0Erwachsenen \u00a0in\u00a0Kombination \u00a0mit\u00a0Cisplatin\u00a0(Nordic\u00a0Pharma,\u00a02013).\u00a0\nDie\u00a0empfohlene \u00a0Standarddosis \u00a0der\u00a0fixen\u00a0Dreifachkombination \u00a0in\u00a0Verbindung \u00a0mit\u00a0Cisplatin\u00a0ist\u00a025\u00a0\nmg/m2,\u00a0zweimal\u00a0t\u00e4glich\u00a0(morgens \u00a0und\u00a0abends)\u00a0f\u00fcr\u00a021\u00a0aufeinander \u00a0folgende\u00a0Tage\u00a0gefolgt\u00a0von\u00a0einer\u00a0\nsiebent\u00e4gigen \u00a0Pause.\u00a0Ein\u00a0solcher\u00a0Behandlungszyklus \u00a0wird\u00a0alle\u00a0vier\u00a0Wochen\u00a0wiederholt. \u00a0\u00a0\nSollte\u00a0der\u00a0Patient\u00a0w\u00e4hrend\u00a0der\u00a0Behandlung \u00a0mehr\u00a0als\u00a0zehn\u00a0Prozent\u00a0an\u00a0Gewicht\u00a0zu\u2010\u00a0oder\u00a0abnehmen, \u00a0\nmuss\u00a0die\u00a0K\u00f6rperoberfl\u00e4che \u00a0neu\u00a0berechnet \u00a0und\u00a0die\u00a0Teysuno\u00ae \u2010Dosis\u00a0entsprechend \u00a0angepasst \u00a0werden,\u00a0\ninsbesondere \u00a0dann,\u00a0wenn\u00a0die\u00a0Gewichtszunahme \u00a0nicht\u00a0auf\u00a0eine\u00a0Wassereinlagerung \u00a0zur\u00fcckzuf\u00fchren \u00a0ist\u00a0\n(Nordic\u00a0Pharma,\u00a02013).\u00a0\n\u00a0\u00a0\u00a0\n236\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Informationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nDie\u00a0genaue\u00a0Ursache\u00a0f\u00fcr\u00a0die\u00a0Entwicklung \u00a0eines\u00a0Magenkarzinoms \u00a0ist\u00a0bislang\u00a0unbekannt. \u00a0Sicher\u00a0ist,\u00a0dass\u00a0\nbestimmte \u00a0Risikofaktoren \u00a0diesen\u00a0Krebs\u00a0beg\u00fcnstigen. \u00a0Dazu\u00a0z\u00e4hlen\u00a0neben\u00a0einer\u00a0bakteriellen \u00a0Infektion\u00a0\ndes\u00a0Magens\u00a0mit\u00a0Helicobacter \u00a0pylori\u00a0auch\u00a0Ern\u00e4hrungsfaktoren \u00a0(beispielsweise \u00a0eine\u00a0an\u00a0pflanzlichen \u00a0\nBestandteilen \u00a0arme\u00a0oder\u00a0an\u00a0tierischen \u00a0Bestandteilen \u00a0reiche\u00a0Ern\u00e4hrung \u00a0sowie\u00a0\u00dcbergewicht), \u00a0eine\u00a0\ngenetische \u00a0Disposition \u00a0(Verwandte \u00a0ersten\u00a0Grades\u00a0von\u00a0Erkrankten \u00a0haben\u00a0ein\u00a0zwei\u2010\u00a0bis\u00a0dreifach\u00a0\nh\u00f6heres\u00a0Risiko\u00a0als\u00a0die\u00a0allgemeine \u00a0Bev\u00f6lkerung) \u00a0sowie\u00a0Rauchen\u00a0und\u00a0\u00fcberm\u00e4\u00dfiger \u00a0Alkoholkonsum. \u00a0\nChronisches \u00a0Sodbrennen \u00a0bzw.\u00a0eine\u00a0gastro\u00f6sophageale \u00a0Refluxkrankheit \u00a0erh\u00f6hen\u00a0ebenfalls\u00a0das\u00a0Risiko\u00a0\nf\u00fcr\u00a0bestimmte \u00a0Tumorformen \u00a0im\u00a0\u00dcbergang \u00a0vom\u00a0Magen\u00a0zur\u00a0Speiser\u00f6hre \u00a0(RKI\u00a0&\u00a0GEKID,\u00a02013b).\u00a0In\u00a0\neinem\u00a0fr\u00fchen\u00a0Stadium\u00a0entwickelt \u00a0sich\u00a0der\u00a0Magenkrebs \u00a0bei\u00a0den\u00a0meisten\u00a0Betroffenen \u00a0symptomlos. \u00a0\nTreten\u00a0die\u00a0ersten\u00a0Anzeichen \u00a0auf,\u00a0sind\u00a0diese\u00a0meist\u00a0nicht\u00a0spezifisch. \u00a0So\u00a0leiden\u00a0Betroffene \u00a0unter\u00a0\nBauchschmerzen \u00a0oder\u00a0\u00dcbelkeit.\u00a0Auch\u00a0der\u00a0Eindruck, \u00a0bestimmte \u00a0Nahrungsmittel \u00a0nicht\u00a0mehr\u00a0so\u00a0gut\u00a0zu\u00a0\nvertragen \u00a0oder\u00a0eine\u00a0Abneigung \u00a0gegen\u00a0(fleischhaltige) \u00a0Speisen\u00a0zu\u00a0entwickeln, \u00a0kann\u00a0ein\u00a0unspezifisches \u00a0\nSymptom \u00a0sein.\u00a0\u00a0\nDas\u00a0mittlere\u00a0Erkrankungsalter \u00a0liegt\u00a0mit\u00a071\u00a0Jahren\u00a0bei\u00a0M\u00e4nnern \u00a0und\u00a075\u00a0Jahren\u00a0bei\u00a0Frauen\u00a0\nvergleichsweise \u00a0hoch,\u00a0die\u00a05\u2010Jahres\u2010\u00dcberlebensraten \u00a0(33\u00a0Prozent)\u00a0sind\u00a0hingegen\u00a0im\u00a0Vergleich \u00a0zu\u00a0\nanderen\u00a0Krebserkrankungen \u00a0nach\u00a0wie\u00a0vor\u00a0ung\u00fcnstig \u00a0(RKI\u00a0&\u00a0GEKID,\u00a02013b).\u00a0Trotz\u00a0der\u00a0\ndemographischen \u00a0Entwicklung \u00a0ist\u00a0seit\u00a0mehr\u00a0als\u00a030\u00a0Jahren\u00a0ein\u00a0stetiger\u00a0R\u00fcckgang \u00a0der\u00a0Erkrankungs \u2010\u00a0und\u00a0\nSterberaten \u00a0an\u00a0Magenkrebs \u00a0zu\u00a0beobachten. \u00a0\u00a0\nNach\u00a0den\u00a0aktuellen \u00a0Zahlen\u00a0des\u00a0Robert\u00a0Koch\u2010Instituts\u00a0und\u00a0der\u00a0Gesellschaft \u00a0der\u00a0epidemiologischen \u00a0\nKrebsregister \u00a0in\u00a0Deutschland \u00a0liegt\u00a0die\u00a0Inzidenz\u00a0des\u00a0Magenkarzinoms \u00a0j\u00e4hrlich\u00a0insgesamt \u00a0bei\u00a0etwa\u00a0\n16.000\u00a0Neuerkrankungen. \u00a0M\u00e4nner\u00a0sind\u00a0dabei\u00a0etwas\u00a0h\u00e4ufiger\u00a0betroffen \u00a0als\u00a0Frauen.\u00a0Die\u00a0\nstandardisierte \u00a0Erkrankungsrate \u00a0pro\u00a0100.000\u00a0Personen \u00a0und\u00a0Jahr\u00a0betr\u00e4gt\u00a014,3\u00a0bei\u00a0M\u00e4nnern \u00a0und\u00a07,7\u00a0\nbei\u00a0Frauen\u00a0(Prognose \u00a0f\u00fcr\u00a02014)\u00a0(RKI\u00a0&\u00a0ZfKD,\u00a02015).\u00a0\u00a0\n\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nF\u00fcr\u00a0die\u00a0europ\u00e4ische \u00a0Zulassung \u00a0relevante \u00a0Daten\u00a0lieferte\u00a0die\u00a0FLAGS\u2010Studie\u00a0von\u00a0Ajani\u00a0et\u00a0al.\u00a0(2010).\u00a0In\u00a0\ndieser\u00a0offenen,\u00a0randomisierten \u00a0und\u00a0aktiv\u2010kontrollierten \u00a0Phase\u2010III\u2010Studie\u00a0wurden\u00a0Wirksamkeit \u00a0und\u00a0\nSicherheit \u00a0von\u00a0Teysuno\u00ae \u00a0im\u00a0Vergleich \u00a0zu\u00a05\u2010FU,\u00a0jeweils\u00a0in\u00a0Kombination \u00a0mit\u00a0Cisplatin,\u00a0untersucht. \u00a0\nPatienten, \u00a0die\u00a0in\u00a0diese\u00a0Studie\u00a0aufgenommen \u00a0wurden,\u00a0wiesen\u00a0ein\u00a0fortgeschrittenes \u00a0Magen\u2010\u00a0oder\u00a0\ngastro\u00f6sophagealen \u00a0Adenokarzinom \u00a0auf\u00a0und\u00a0waren\u00a0in\u00a0diesen\u00a0Indikationen \u00a0noch\u00a0nicht\u00a0mit\u00a0einer\u00a0\nChemotherapie \u00a0behandelt \u00a0worden.\u00a0521\u00a0Patienten \u00a0der\u00a0Verum\u2010Gruppe\u00a0erhielten\u00a025\u00a0mg/m2\u00a0Teysuno\u00ae, \u00a0\n\u00fcber\u00a021\u00a0Tage\u00a0gefolgt\u00a0von\u00a0einer\u00a0siebent\u00e4gigen \u00a0Pause,\u00a0in\u00a0Kombination \u00a0mit\u00a0Cisplatin\u00a0(75\u00a0mg/m2,\u00a0alle\u00a028\u00a0\nTage).\u00a0Die\u00a0Patienten \u00a0im\u00a0Kontroll\u2010Arm\u00a0(n\u00a0=\u00a0508)\u00a0wurden\u00a0mit\u00a05\u2010FU\u00a0(1.000\u00a0mg/m2/24 \u00a0Stunden\u00a0\u00fcber\u00a0120\u00a0\nStunden)\u00a0in\u00a0Kombination \u00a0mit\u00a01.000\u00a0mg/m2\u00a0Cisplatin\u00a0behandelt. \u00a0Beide\u00a0Therapieregime \u00a0wurden\u00a0alle\u00a028\u00a0\nTage\u00a0wiederholt). \u00a0Die\u00a0Behandlung \u00a0mit\u00a0Cisplatin\u00a0wurde\u00a0auf\u00a0sechs\u00a0Zyklen\u00a0begrenzt. \u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0\ndieser\u00a0Studie\u00a0war\u00a0die\u00a0\u00dcberlegenheit \u00a0im\u00a0Gesamt\u00fcberleben \u00a0der\u00a0Dreifachkombination \u00a0+\u00a0Cisplatin\u00a0im\u00a0\nVergleich \u00a0zu\u00a05\u2010FU\u00a0+\u00a0Cisplatin\u00a0bei\u00a0Patienten \u00a0mit\u00a0fortgeschrittenem \u00a0Magen\u2010\u00a0oder\u00a0gastro\u00f6sophagealen \u00a0\nAdenokarzinom. \u00a0Das\u00a0\u00dcberleben \u00a0wurde\u00a0definiert\u00a0als\u00a0die\u00a0Zeit\u00a0vom\u00a0Tag\u00a0der\u00a0Randomisierung \u00a0bis\u00a0zum\u00a0\nTodestag. \u00a0Bei\u00a0vergleichbarer \u00a0Wirksamkeit \u00a0in\u00a0Bezug\u00a0auf\u00a0das\u00a0mediane\u00a0Gesamt\u00fcberleben \u00a0(8,6\u00a0Monate\u00a0in\u00a0\nder\u00a0Verum\u2010Gruppe\u00a0vs.\u00a07,9\u00a0Monate\u00a0im\u00a0Kontroll\u2010Arm)\u00a0zeigten\u00a0sich\u00a0signifikante \u00a0Sicherheitsvorteile \u00a0unter\u00a0\nder\u00a0Dreifachkombination \u00a0+\u00a0Cisplatin\u00a0gegen\u00fcber \u00a05\u2010FU\u00a0+\u00a0Cisplatin\u00a0(Neutropenie \u00a032,3\u00a0Prozent\u00a0vs.\u00a063,3\u00a0 \n237\u00a0\n\u00a0\nHintergrundinformationen \u00a0Prozent,\u00a0Stomatitis \u00a01,3\u00a0Prozent\u00a0vs.\u00a013,6\u00a0Prozent,\u00a0Hypokali\u00e4mie \u00a03,6\u00a0Prozent\u00a0vs.\u00a010,8\u00a0Prozent,\u00a0\ntherapiebedingte \u00a0Todesf\u00e4lle \u00a02,5\u00a0Prozent\u00a0vs.\u00a04,9\u00a0Prozent).\u00a0\u00a0\nZus\u00e4tzlich \u00a0zur\u00a0Pivotalstudie \u00a0wurden\u00a0vom\u00a0pU\u00a0Daten\u00a0aus\u00a0den\u00a0japanischen \u00a0Zulassungsstudien \u00a0\neingereicht \u00a0(EMA,\u00a02010).\u00a0Aufgrund \u00a0unterschiedlicher \u00a0Genetik\u00a0und\u00a0einem\u00a0anderen\u00a0Dosierungsschema \u00a0\nist\u00a0die\u00a0\u00dcbertragung \u00a0der\u00a0daraus\u00a0gewonnen \u00a0Informationen \u00a0auf\u00a0die\u00a0westliche \u00a0Bev\u00f6lkerung \u00a0aber\u00a0limitiert\u00a0\n(EMA,\u00a02010).\u00a0Derzeit\u00a0fehlen\u00a0direkte\u00a0Vergleichsstudien \u00a0mit\u00a0Capecitabin \u00a0(Kobayakawa \u00a0&\u00a0Kojima,\u00a02011).\u00a0\nAufgrund \u00a0der\u00a0Nicht\u2010\u00dcberlegenheit \u00a0von\u00a0Tegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0Oteracil\u00a0gegen\u00fcber \u00a0Capecitabin \u00a0wird\u00a0\nvon\u00a0den\u00a0Autoren\u00a0des\u00a0Prescrire\u00a0Int.\u00a0(2013b)\u00a0Capecitabin \u00a0weiterhin \u00a0als\u00a0Mittel\u00a0der\u00a0ersten\u00a0Wahl\u00a0zur\u00a0\nTherapie\u00a0des\u00a0fortgeschrittenen \u00a0Magenkarzinoms \u00a0empfohlen. \u00a0Unter\u00a0der\u00a0Tegafur\u2010Kombination \u00a0\nscheinen\u00a0wohl\u00a0weniger\u00a0Dysaethesien \u00a0an\u00a0den\u00a0Gliedma\u00dfen \u00a0aufzutreten, \u00a0daf\u00fcr\u00a0aber\u00a0ein\u00a0geringeres \u00a0\nRisiko\u00a0f\u00fcr\u00a0schwerwiegende \u00a0unerw\u00fcnschte \u00a0gastrointestinale \u00a0Arzneimittelwirkungen \u00a0zu\u00a0bestehen \u00a0\n(Prescrire \u00a0Int.,\u00a02013b).\u00a0\n\u00a0\nLeitlinienempfehlungen \u00a0\nF\u00fcr\u00a0die\u00a0chemotherapeutische \u00a0Behandlung \u00a0des\u00a0Magenkarzinoms \u00a0stehen\u00a0mehrere\u00a0Substanzen \u00a0zur\u00a0\nVerf\u00fcgung, \u00a0die\u00a0auf\u00a0unterschiedliche \u00a0Art\u00a0die\u00a0Zellteilung \u00a0verhindern \u00a0sollen.\u00a0In\u00a0der\u00a0Regel\u00a0werden\u00a0\nmehrere\u00a0Wirkstoffe \u00a0mit\u00a0unterschiedlichen \u00a0drug\u00a0targets\u00a0kombiniert. \u00a0In\u00a0Studien\u00a0konnte\u00a0gezeigt\u00a0\nwerden,\u00a0dass\u00a0Patienten, \u00a0die\u00a0mit\u00a0einer\u00a0Wirkstoffkombination \u00a0behandelt \u00a0wurden,\u00a0einen\u00a0\n\u00dcberlebensvorteil \u00a0von\u00a0durchschnittlich \u00a0eineinhalb \u00a0Monaten\u00a0gegen\u00fcber \u00a0Patienten \u00a0hatten,\u00a0die\u00a0nur\u00a0\neinen\u00a0Wirkstoff \u00a0erhalten\u00a0hatten\u00a0(DGVS,\u00a02012).\u00a0\u00a0\nNeben\u00a05\u2010FU\u00a0werden\u00a0u.a.\u00a0Cisplatin\u00a0und\u00a0Oxaliplatin \u00a0eingesetzt. \u00a0Sie\u00a0st\u00f6ren\u00a0den\u00a0Aufbau\u00a0der\u00a0\nErbinformation \u00a0und\u00a0verhindern \u00a0so\u00a0die\u00a0Zellproliferation. \u00a0W\u00e4hrend \u00a0Cisplatin\u00a0beim\u00a0Magenkarzinom \u00a0als\u00a0\nwesentlicher \u00a0Bestandteil \u00a0einer\u00a0kombinierten \u00a0Chemotherapie \u00a0verabreicht \u00a0wird,\u00a0ist\u00a0der\u00a0Wirkstoff \u00a0\nOxaliplatin \u00a0in\u00a0Deutschland \u00a0nur\u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0von\u00a0Darmkrebs \u00a0zugelassen \u00a0(Lauer\u2010Taxe,\u00a0Stand\u00a0Juni\u00a0\n2015).\u00a0Nach\u00a0Aussage\u00a0der\u00a0DGVS\u2010Leitlinie\u00a0kann\u00a0Oxaliplatin \u00a0auch\u00a0bei\u00a0Magenkarzinom \u00a0vor\u00a0allem\u00a0bei\u00a0\nPatienten \u00a0eingesetzt \u00a0werden,\u00a0die\u00a0Cisplatin\u00a0nicht\u00a0vertragen \u00a0(beispielsweise \u00a0\u00e4ltere\u00a0Patienten) \u00a0(DGVS,\u00a0\n2012).\u00a0\nWie\u00a0Oxaliplatin \u00a0wird\u00a0auch\u00a0Irinotecan, \u00a0ein\u00a0spezifischer \u00a0Inhibitor\u00a0der\u00a0DNA\u2010Topoisomerase, \u00a0bei\u00a0der\u00a0\nTherapie\u00a0des\u00a0Magenkarzinoms \u00a0off\u2010label\u00a0eingesetzt \u00a0(Lauer\u2010Taxe,\u00a0Stand\u00a0Juni\u00a02015)\u00a0und\u00a0kann\u00a0bei\u00a0\nPatienten \u00a0angewendet \u00a0werden,\u00a0die\u00a0f\u00fcr\u00a0eine\u00a0Cisplatin\u2010Therapie\u00a0nicht\u00a0in\u00a0Frage\u00a0kommen\u00a0(DGVS,\u00a02012).\u00a0\u00a0\nDocetaxel, \u00a0zur\u00a0pharmakotherapeutischen \u00a0Gruppe\u00a0der\u00a0Taxane\u00a0geh\u00f6rend, \u00a0ist\u00a0bei\u00a0Magenkrebs \u00a0in\u00a0\nVerbindung \u00a0mit\u00a0Cisplatin\u00a0und\u00a05\u2010FU\u00a0in\u00a0einer\u00a0Dreifach\u2010Kombination \u00a0zugelassen. \u00a0\u00a0\nEbenfalls\u00a0zur\u00a0Behandlung \u00a0von\u00a0Patienten \u00a0mit\u00a0gastrointestinalen \u00a0Tumoren, \u00a0speziell\u00a0kolorektalen \u00a0\nKarzinomen, \u00a0aber\u00a0auch\u00a0Magen\u2010\u00a0und\u00a0Pankreaskarzinomen, \u00a0wird\u00a0das\u00a0orale\u00a0Fluoropyrimidin \u00a0Capecitabin \u00a0\neingesetzt. \u00a0Das\u00a0Mittel\u00a0hat\u00a0sich\u00a0als\u00a0effektive\u00a0Therapiealternative \u00a0zur\u00a0Infusion\u00a0von\u00a05\u2010\nFluorouracil/Folins\u00e4ure \u00a0(5\u2010FU/FS)\u00a0etabliert\u00a0\u2013\u00a0unabh\u00e4ngig \u00a0vom\u00a0Krankheitsstadium \u00a0und\u00a0Lebensalter \u00a0der\u00a0\nPatienten. \u00a0Es\u00a0wird\u00a0sowohl\u00a0in\u00a0der\u00a0Mono\u2010\u00a0wie\u00a0auch\u00a0in\u00a0der\u00a0Polychemotherapie \u00a0verabreicht \u00a0(DGVS,\u00a0\n2012).\u00a0\n \u00a0\u00a0\n238\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Nutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nTeysuno\u00ae \u00a0ist\u00a0in\u00a0Kombination \u00a0mit\u00a0Cisplatin\u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0von\u00a0fortgeschrittenem \u00a0Magenkrebs \u00a0bei\u00a0\nErwachsenen \u00a0indiziert.\u00a0In\u00a0seinem\u00a0Beschluss \u00a0vom\u00a020.\u00a0Dezember \u00a02012\u00a0konstatierte \u00a0der\u00a0Gemeinsame \u00a0\nBundesausschuss, \u00a0dass\u00a0der\u00a0Zusatznutzen \u00a0im\u00a0Verh\u00e4ltnis \u00a0zur\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0(Zwei\u2010\nfachkombination \u00a0von\u00a0Cisplatin\u00a0mit\u00a05\u2010Fluorouracil \u00a0oder\u00a0Capecitabin) \u00a0nicht\u00a0belegt\u00a0sei\u00a0(G\u2010BA,\u00a02012g).\u00a0\u00a0\nDer\u00a0pharmazeutische \u00a0Unternehmer \u00a0hatte\u00a0nach\u00a0Angaben\u00a0des\u00a0G\u2010BA\u00a0die\u00a0erforderlichen \u00a0Nachweise \u00a0f\u00fcr\u00a0\ndie\u00a0Nutzenbewertung \u00a0trotz\u00a0Aufforderung \u00a0nicht\u00a0vollst\u00e4ndig \u00a0vorgelegt. \u00a0\u00a0\n\u00a0\nKosten\u00a0\nWirkstof f\u00a0 Behandlungsmodus Behandlungstage Jahrestherapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0in\u00a0\nKombination \u00a0mit\u00a0Cisplatin  \u00a0\nTegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0Oteracil  In\u00a0Zyklen:\u00a01\u00a0Zyklus\u00a0=\u00a028\u00a0Tage.\nTag\u00a01\u201021:\u00a02\u00a0x\u00a0t\u00e4glich\u00a025\u00a0mg/m2273 6.704,30\u00a0\u20ac\nCisplatin  In\u00a0Zyklen:\u00a01\u00a0Zyklus\u00a0=\u00a028\u00a0Tage.\u00a0\n1\u00a0x\u00a075\u00a0mg/m2\u00a0pro\u00a0Zyklus\u00a013 1.902,42\u00a0\u20ac\n8.606,72\u00a0\u20ac\u00a0\nVergleichstherapie \u00a0in\u00a0\nKombination \u00a0mit\u00a0Cisplatin  \u00a0\n5\u2010Fluorouracil  In\u00a0Zyklen:\u00a01\u00a0Zyklus\u00a0=\u00a028\u00a0Tage.\u00a0\nTag\u00a01\u20105:\u00a01\u00a0x\u00a01.000\u00a0mg/m2\u00a0\nt\u00e4glich\u00a065 1.992,90\u00a0\u20ac\nCisplatin  In\u00a0Zyklen:\u00a01\u00a0Zyklus\u00a0=\u00a028\u00a0Tage.\u00a0\n1\u00a0x\u00a0100\u00a0mg/m2\u00a0pro\u00a0Zyklus\u00a013 2.294,63\u00a0\u20ac\n4.287,53\u00a0\u20ac\u00a0\nCapecitabin  In\u00a0Zyklen:\u00a01\u00a0Zyklus\u00a0=\u00a021\u00a0Tage.\u00a0\nTag\u00a01\u201014:\u00a02\u00a0x\u00a01.000\u00a0mg/m2\u00a0\nt\u00e4glich\u00a0238 2374,33\u00a0\u20ac\nCisplatin  In\u00a0Zyklen:\u00a01\u00a0Zyklus\u00a0=\u00a021\u00a0Tage.\u00a0\n1\u00a0x\u00a080\u00a0mg/m2\u00a0pro\u00a0Zyklus\u00a017 2.780,18\u00a0\u20ac\n5.154,51\u00a0\u20ac\u00a0\nTabelle\u00a044:\u00a0Jahrestherapiekosten \u00a0von\u00a0Tegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0Oteracil\u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0\n(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen).  \n \u00a0 \n239\u00a0\n\u00a0\nHintergrundinformationen \u00a011.19  Vandetanib \u00a0\u00a0\nHandelsname: \u00a0Caprelsa\u00ae \u00a0 \u00a0\u00a0\u00a0 Hersteller: \u00a0AstraZeneca \u00a0\nIndikation: \u00a0Schilddr\u00fcsenkarzinom \u00a0\u00a0\u00a0 Markteinf\u00fchrung: \u00a0M\u00e4rz\u00a02012\u00a0\nATC\u2010Code:\u00a0L01XE12\u00a0 \u00a0\u00a0\u00a0\u00a0 DDD:\u00a00,3\u00a0g\u00a0\nDarreichungsform: \u00a0Filmtablette \u00a0\nBewertung: \u00a0siehe\u00a0Seite\u00a0102\u00a0\u00a0\nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nVandetanib \u00a0ist\u00a0ein\u00a0Multi\u2010Kinaseinhibitor. \u00a0Der\u00a0Wirkstoff \u00a0bindet\u00a0kompetitiv \u00a0in\u00a0der\u00a0ATP\u2010Bindungstasche \u00a0\ndes\u00a0epidermalen \u00a0Wachstumsfaktor \u2010Rezeptors \u00a0(EGFR)\u00a0und\u00a0des\u00a0vaskul\u00e4ren \u00a0endothelialen \u00a0\nWachstumsfaktor \u2010Rezeptors \u00a02\u00a0(VEGFR\u20102)\u00a0und\u00a0hemmt\u00a0so\u00a0deren\u00a0stimulierenden \u00a0Effekte\u00a0auf\u00a0\nZellproliferation \u00a0und\u00a0Angiogenese. \u00a0Dar\u00fcber\u00a0hinaus\u00a0wird\u00a0die\u00a0RET\u2010Kinase\u00a0blockiert, \u00a0eine\u00a0Tyrosinkinase, \u00a0\nderen\u00a0Aktivit\u00e4t\u00a0eine\u00a0wichtige\u00a0Rolle\u00a0bei\u00a0der\u00a0Progression \u00a0und\u00a0Metastasierung \u00a0des\u00a0medull\u00e4ren \u00a0\nSchilddr\u00fcsenkarzinoms \u00a0spielt\u00a0(AstraZeneca, \u00a02014d).\u00a0Der\u00a0Wirkstoff \u00a0hemmt\u00a0neben\u00a0dem\u00a0Wildtyp\u00a0der\u00a0\nRET\u2010Kinase\u00a0auch\u00a0die\u00a0meisten\u00a0aktiven\u00a0Mutationen \u00a0dieses\u00a0Enzyms.\u00a0\n\u00a0Zulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nCaprelsa\u00ae \u00a0wurde\u00a0im\u00a0Februar\u00a02012\u00a0von\u00a0der\u00a0EMA\u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0des\u00a0aggressiven\n\u00a0und\u00a0\nsymptomatischen \u00a0medull\u00e4ren \u00a0Schilddr\u00fcsenkarzinoms \u00a0(Medullary \u00a0Thyroid\u00a0Cancer\u00a0=\u00a0MTC)\u00a0bei\u00a0\nPatienten \u00a0mit\u00a0nicht\u2010resektabler, \u00a0lokal\u00a0fortgeschrittener \u00a0oder\u00a0metastasierter \u00a0Erkrankung \u00a0zugelassen. \u00a0\nVandetanib \u00a0ist\u00a0die\u00a0erste\u00a0zugelassene \u00a0Arzneimitteltherapie \u00a0in\u00a0dieser\u00a0Indikation. \u00a0Die\u00a0Beschr\u00e4nkung \u00a0der\u00a0\nZulassung \u00a0auf\u00a0Patienten \u00a0mit\u00a0symptomatischem \u00a0und\u00a0gleichzeitig \u00a0aggressivem \u00a0Verlauf\u00a0des\u00a0MTC\u00a0erfolgte\u00a0\naufgrund\u00a0der\u00a0h\u00e4ufigen\u00a0und\u00a0teilweise\u00a0schwerwiegenden \u00a0Nebenwirkungen \u00a0von\u00a0Vandetanib. \u00a0In\u00a0erster\u00a0\nLinie\u00a0betrifft\u00a0dies\u00a0Herzrhythmusst\u00f6rungen \u00a0und\u00a0potentiell \u00a0t\u00f6dliche\u00a0Komplikationen \u00a0durch\u00a0eine\u00a0\nerhebliche \u00a0QTc\u2010Zeit\u2010Verl\u00e4ngerung, \u00a0die\u00a0im\u00a0Zusammenhang \u00a0mit\u00a0der\u00a0langen\u00a0Halbwertszeit \u00a0der\u00a0Substanz\u00a0\nvon\u00a019\u00a0Tagen\u00a0besonders \u00a0problematisch \u00a0ist.\u00a0Aus\u00a0Sicherheitsgr\u00fcnden \u00a0muss\u00a0den\u00a0Patienten \u00a0mit\u00a0der\u00a0\nVerschreibung \u00a0von\u00a0Caprelsa\u00ae \u00a0ein\u00a0Patientenpass \u00a0ausgeh\u00e4ndigt \u00a0werden.\u00a0Mit\u00a0der\u00a0Zulassung \u00a0wurde\u00a0die\u00a0\nAuflage\u00a0verkn\u00fcpft, \u00a0weitere\u00a0Studienergebnisse \u00a0vorzulegen, \u00a0insbesondere \u00a0\u00fcber\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0\nNutzens\u00a0bei\u00a0Patienten \u00a0mit\u00a0negativem \u00a0RET\u2010Mutationsstatus \u00a0(EMA,\u00a02011a).\u00a0In\u00a0der\u00a0Fachinformation \u00a0\nwird\u00a0darauf\u00a0hingewiesen, \u00a0dass\u00a0bei\u00a0Patienten \u00a0ohne\u00a0Mutation \u00a0im\u00a0RET\u2010Gen\u00a0der\u00a0Nutzen\u00a0von\u00a0Vandetanib \u00a0\ngeringer\u00a0sein\u00a0kann,\u00a0und\u00a0empfohlen, \u00a0vor\u00a0dem\u00a0Beginn\u00a0einer\u00a0Therapie\u00a0mit\u00a0Vandetanib \u00a0den\u00a0RET\u2010\nMutationsstatus \u00a0zu\u00a0bestimmen \u00a0(AstraZeneca, \u00a02014d).\u00a0Vandetanib \u00a0wird\u00a0einmal\u00a0t\u00e4glich\u00a0als\u00a0Tablette\u00a0in\u00a0\neiner\u00a0Dosis\u00a0von\u00a0300\u00a0mg\u00a0eingenommen. \u00a0\nIm\u00a0M\u00e4rz\u00a02014\u00a0wurde\u00a0der\u00a0orale\u00a0Multikinase \u2010Inhibitor\u00a0Capozantinib \u00a0(Cometriq\u00ae) \u00a0mit\u00a0sehr\u00a0\u00e4hnlichem \u00a0\nWirkungsmechanismus \u00a0f\u00fcr\u00a0die\u00a0gleiche\u00a0Indikation \u00a0zugelassen. \u00a0\n\u00a0\u00a0\u00a0\n240\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Informationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nSchilddr\u00fcsenkrebs \u00a0ist\u00a0ein\u00a0relativ\u00a0seltener\u00a0maligner\u00a0Tumor,\u00a0stellt\u00a0aber\u00a0den\u00a0h\u00e4ufigsten \u00a0malignen \u00a0\nendokrinen \u00a0Tumor.\u00a0Pro\u00a0Jahr\u00a0erkranken \u00a0in\u00a0Deutschland \u00a0zwischen\u00a06.000\u00a0und\u00a06.500\u00a0Menschen. \u00a0Das\u00a0\nmittlere\u00a0Erkrankungsalter \u00a0betr\u00e4gt\u00a0bei\u00a0Frauen\u00a052\u00a0und\u00a0bei\u00a0M\u00e4nnern \u00a056\u00a0Jahre,\u00a0Frauen\u00a0sind\u00a0deutlich\u00a0\nh\u00e4ufiger\u00a0betroffen. \u00a0Histologisch \u00a0unterscheidet \u00a0man\u00a0verschiedene \u00a0Typen.\u00a0Die\u00a0von\u00a0den\u00a0Thyreozyten \u00a0\nausgehenden \u00a0papill\u00e4ren \u00a0und\u00a0follikul\u00e4ren \u00a0\u00a0Karzinome, \u00a0die\u00a0auch\u00a0als\u00a0differenzierte \u00a0Karzinome \u00a0\nbezeichnet \u00a0werden,\u00a0machen\u00a080\u201090\u00a0Prozent\u00a0aller\u00a0malignen \u00a0Schilddr\u00fcsentumoren \u00a0aus\u00a0(Das\u00a0Rote\u00a0Buch,\u00a0\n2014).\u00a0Die\u00a0medull\u00e4ren \u00a0Karzinome \u00a0mit\u00a0einer\u00a0H\u00e4ufigkeit \u00a0von\u00a05\u201010\u00a0Prozent\u00a0gehen\u00a0von\u00a0den\u00a0\nparafollikul\u00e4ren \u00a0C\u2010Zellen\u00a0aus,\u00a0die\u00a0nicht\u00a0an\u00a0der\u00a0Schilddr\u00fcsenhormonsynthese \u00a0beteiligt\u00a0sind,\u00a0sondern\u00a0\nCalcitonin \u00a0produzieren. \u00a0Etwa\u00a020\u201025\u00a0Prozent\u00a0der\u00a0medull\u00e4ren \u00a0Karzinome \u00a0werden\u00a0autosomal \u2010dominant \u00a0\nvererbt\u00a0und\u00a0treten\u00a0famili\u00e4r\u00a0geh\u00e4uft\u00a0auf\u00a0im\u00a0Rahmen\u00a0der\u00a0sogenannten \u00a0Multiplen \u00a0endokrinen \u00a0Neoplasie \u00a0\nTyp\u00a02A/2B\u00a0(MEN\u20102\u2010Syndrom) \u00a0bzw.\u00a0des\u00a0famili\u00e4ren \u00a0medull\u00e4ren \u00a0Schilddr\u00fcsenkarzinoms \u00a0(FMTC).\u00a0\nMolekulargenetisch \u00a0finden\u00a0sich\u00a0hier\u00a0Keimbahnmutationen \u00a0des\u00a0RET\u2010Protoonkogens, \u00a0die\u00a0zu\u00a0einer\u00a0\n\u00dcberexpression \u00a0des\u00a0RET\u2010Rezeptors \u00a0f\u00fchren.\u00a0Die\u00a0nicht\u2010heredit\u00e4ren \u00a0medull\u00e4ren \u00a0Schilddr\u00fcsenkarzinome \u00a0\nbezeichnet \u00a0man\u00a0auch\u00a0als\u00a0sporadische \u00a0MTC.\u00a0Hier\u00a0lassen\u00a0sich\u00a0in\u00a0ungef\u00e4hr\u00a0der\u00a0H\u00e4lfte\u00a0der\u00a0F\u00e4lle\u00a0\nsomatische \u00a0RET\u2010Mutationen \u00a0nachweisen, \u00a0au\u00dferdem \u00a0sind\u00a0beim\u00a0MTC\u00a0h\u00e4ufig\u00a0VEGF\u2010Rezeptoren \u00a0\n\u00fcberexprimiert. \u00a0\nDie\u00a0Prognose \u00a0der\u00a0differenzierten \u00a0Schilddr\u00fcsenkarzinome \u00a0ist\u00a0gut\u00a0und\u00a0wesentlich \u00a0g\u00fcnstiger \u00a0als\u00a0die\u00a0der\u00a0\nseltenen\u00a0medull\u00e4ren \u00a0Schilddr\u00fcsenkarzinome. \u00a0Das\u00a0medull\u00e4re \u00a0Karzinom \u00a0w\u00e4chst\u00a0meist\u00a0langsam,\u00a0\nmetastasiert \u00a0aber\u00a0fr\u00fch\u00a0in\u00a0die\u00a0regionalen \u00a0Lymphknoten \u00a0und\u00a0sp\u00e4ter\u00a0auch\u00a0h\u00e4matogen \u00a0mit\u00a0\nFernmetastasen \u00a0vor\u00a0allem\u00a0in\u00a0Leber,\u00a0Lunge\u00a0und\u00a0Knochen. \u00a0Nach\u00a0Diagnose\u00a0von\u00a0Fernmetastasen \u00a0liegt\u00a0die\u00a0\u00a0\nabsolute\u00a05\u2010Jahres\u00fcberlebensrate \u00a0bei\u00a0ca.\u00a085\u00a0Prozent\u00a0mit\u00a0einer\u00a0Schwankungsbreite \u00a0zwischen\u00a070\u201092\u00a0\nProzent\u00a0je\u00a0nach\u00a0Bundesland \u00a0und\u00a0Geschlecht. \u00a0\u00a0\nDer\u00a0zytotoxischen \u00a0Chemotherapie \u00a0kommt\u00a0auch\u00a0in\u00a0der\u00a0palliativen \u00a0Situation\u00a0nur\u00a0eine\u00a0untergeordnete \u00a0\nRolle\u00a0zu,\u00a0sie\u00a0erfolgt\u00a0bei\u00a0rascher\u00a0Progredienz \u00a0mit\u00a0tumorbedingter \u00a0Symptomatik, \u00a0Funktionseinbu\u00dfen \u00a0\noder\u00a0Komplikationen. \u00a0Der\u00a0Einsatz\u00a0der\u00a0neuen\u00a0Multi\u2010Kinaseinhibitoren \u00a0erweitert \u00a0hier\u00a0die\u00a0\ntherapeutischen \u00a0M\u00f6glichkeiten. \u00a0\n\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nIn\u00a0die\u00a0zulassungsrelevante \u00a0randomisierte \u00a0(2:1),\u00a0doppelblinde, \u00a0placebo\u2010kontrollierte \u00a0Phase\u2010III\u2010Studie\u00a0\nwurden\u00a0insgesamt \u00a0331\u00a0Patienten \u00a0mit\u00a0nicht\u2010resektablem \u00a0und\u00a0lokal\u00a0fortgeschrittenem \u00a0oder\u00a0\nmetastasiertem \u00a0medull\u00e4ren \u00a0Schilddr\u00fcsenkarzinom \u00a0eingeschlossen \u00a0(Wells\u00a0et\u00a0al.,\u00a02012).\u00a0Deren\u00a0\nKrankheitsverlauf \u00a0war\u00a0jedoch\u00a0nicht\u00a0zwangsl\u00e4ufig \u00a0aggressiv\u00a0und\u00a0symptomatisch, \u00a0nur\u00a0bis\u00a0zu\u00a056\u00a0Prozent\u00a0\nder\u00a0Gesamtstudienpopulation \u00a0entsprach \u00a0laut\u00a0European \u00a0Public\u00a0Assessment \u00a0Report\u00a0(EPAR)\u00a0der\u00a0\nZielpopulation \u00a0gem\u00e4\u00df\u00a0Zulassung. \u00a0Die\u00a0231\u00a0Patienten \u00a0der\u00a0Verumgruppe \u00a0erhielten\u00a0300\u00a0mg\u00a0Vandetanib, \u00a0\ndie\u00a0100\u00a0Patienten \u00a0der\u00a0Kontrollgruppe \u00a0Placebo.\u00a0In\u00a0beiden\u00a0Gruppen\u00a0bekamen \u00a0die\u00a0Patienten \u00a0eine\u00a0als\u00a0\nBSC\u00a0eingestufte \u00a0Begleittherapie, \u00a0also\u00a0eine\u00a0bestm\u00f6gliche, \u00a0patientenindividuell \u00a0optimierte, \u00a0\nunterst\u00fctzende \u00a0Behandlung \u00a0zur\u00a0Linderung \u00a0von\u00a0Symptomen \u00a0und\u00a0zur\u00a0Verbesserung \u00a0der\u00a0Lebensqualit\u00e4t. \u00a0\nProtokollgem\u00e4\u00df \u00a0wurde\u00a0die\u00a0Studienmedikation \u00a0bis\u00a0zum\u00a0Krankheitsprogress \u00a0fortgef\u00fchrt, \u00a0danach\u00a0folgte\u00a0\ndie\u00a0Entblindung \u00a0mit\u00a0der\u00a0M\u00f6glichkeit \u00a0einer\u00a0Open\u2010label\u2010Behandlung \u00a0mit\u00a0Vandetanib. \u00a0Der\u00a0prim\u00e4re\u00a0\nEndpunkt \u00a0war\u00a0das\u00a0progressionsfreie \u00a0\u00dcberleben \u00a0(PFS).\u00a0Das\u00a0mediane\u00a0PFS\u00a0lag\u00a0unter\u00a0Placebo\u00a0bei\u00a019,3\u00a0\nMonaten\u00a0und\u00a0unter\u00a0Vandetanib \u00a0bei\u00a030,5\u00a0Monaten. \u00a0Die\u00a0objektive \u00a0Ansprechrate \u00a0(ORR)\u00a0als\u00a0sekund\u00e4rer \u00a0 \n241\u00a0\n\u00a0\nHintergrundinformationen \u00a0Endpunkt \u00a0lag\u00a0bei\u00a045\u00a0Prozent\u00a0unter\u00a0Vandetanib \u00a0und\u00a013\u00a0Prozent\u00a0unter\u00a0Placebo.\u00a0In\u00a0Bezug\u00a0auf\u00a0das\u00a0\nGesamt\u00fcberleben \u00a0ergab\u00a0sich\u00a0in\u00a0dieser\u00a0Untersuchung \u00a0kein\u00a0signifikanter \u00a0Unterschied \u00a0zwischen\u00a0den\u00a0\nBehandlungsgruppen. \u00a0Obwohl\u00a0bei\u00a0allen\u00a0Patienten \u00a0ein\u00a0Test\u00a0auf\u00a0RET\u2010Mutation \u00a0vorgesehen \u00a0war,\u00a0konnte\u00a0\nder\u00a0RET\u2010Status\u00a0bei\u00a0einem\u00a0gro\u00dfen\u00a0Teil\u00a0der\u00a0Patienten \u00a0nicht\u00a0festgestellt \u00a0werden.\u00a0Subgruppenanalysen \u00a0\nergaben\u00a0Hinweise\u00a0darauf,\u00a0dass\u00a0in\u00a0der\u00a0Gruppe\u00a0mit\u00a0bei\u00a0Studieneinschluss \u00a0bekanntem \u00a0positivem \u00a0RET\u2010\nStatus\u00a0die\u00a0\u00dcberlegenheit \u00a0von\u00a0Vandetanib \u00a0gegen\u00fcber \u00a0Placebo\u00a0ausgepr\u00e4gter \u00a0war\u00a0als\u00a0in\u00a0der\u00a0Gruppe\u00a0mit\u00a0\nunbekanntem \u00a0RET\u2010Status.\u00a0Schwere\u00a0unerw\u00fcnschte \u00a0Nebenwirkungen, \u00a0vor\u00a0allem\u00a0Diarrhoe, \u00a0\nHautausschl\u00e4ge \u00a0und\u00a0QTc\u2010Verl\u00e4ngerung \u00a0traten\u00a0insgesamt \u00a0unter\u00a0Vandetanib \u00a0signifikant \u00a0h\u00e4ufiger\u00a0auf\u00a0als\u00a0\nunter\u00a0Placebo.\u00a0Zudem\u00a0ist\u00a0in\u00a0seltenen\u00a0F\u00e4llen\u00a0unter\u00a0Vandetanib \u00a0ein\u00a0posteriores \u00a0reversibles \u00a0\nEnzephalopathiesyndrom \u00a0beschrieben, \u00a0das\u00a0sich\u00a0bei\u00a0den\u00a0Betroffenen \u00a0durch\u00a0Krampfanf\u00e4lle, \u00a0\nKopfschmerzen \u00a0und\u00a0Verwirrtheit \u00a0bemerkbar \u00a0macht\u00a0(Astra\u00a0Zeneca,2014d). \u00a0Personen \u00a0mit\u00a0geringer\u00a0\nMuskelmasse \u00a0besitzen\u00a0dabei\u00a0ein\u00a0h\u00f6heres\u00a0Risiko\u00a0f\u00fcr\u00a0schwere\u00a0Nebenwirkungen \u00a0(Massicotte \u00a0et\u00a0al.,\u00a0\n2013).\u00a0Das\u00a0Interaktionspotential \u00a0mit\u00a0anderen\u00a0Arzneimitteln \u00a0und\u00a0eine\u00a0m\u00f6glicherweise \u00a0daraus\u00a0\nresultierende \u00a0Dosisanpassung \u00a0oder\u00a0Kontraindikation \u00a0muss\u00a0ebenfalls\u00a0beachtet\u00a0werden\u00a0(AstraZeneca, \u00a0\n2014d;\u00a0Johansson \u00a0et\u00a0al.,\u00a02014).\u00a0\u00a0\nIn\u00a0ihrem\u00a0systematischen \u00a0Review\u00a0kamen\u00a0Klein\u00a0Hesselink \u00a0et\u00a0al.\u00a0(2015)\u00a0zu\u00a0dem\u00a0Schluss,\u00a0dass\u00a0Tyrosin\u2010\nKinaseinhibitor \u00a0nach\u00a0sorgf\u00e4ltiger \u00a0Nutzen\u2010Risiko\u2010Abw\u00e4gung \u00a0nur\u00a0an\u00a0Patienten \u00a0mit\u00a0rasch\u00a0\nfortschreitender \u00a0Erkrankung \u00a0verabreicht \u00a0werden\u00a0sollte.\u00a0\u00a0\nAnwendungsbeobachtungen \u00a0bei\u00a0Kindern\u00a0und\u00a0Jugendlichen \u00a0lieferten\u00a0erste\u00a0positive\u00a0Ergebnisse \u00a0(Fox.\u00a0t\u00a0\nal.,\u00a02013).\u00a0\u00a0\n\u00a0\nLeitlinienempfehlungen \u00a0\nDie\u00a0Behandlung \u00a0der\u00a0medull\u00e4ren \u00a0Schilddr\u00fcsenkarzinome \u00a0ist\u00a0symptomorientiert \u00a0und\u00a0besteht\u00a0prim\u00e4r\u00a0in\u00a0\nder\u00a0chirurgischen \u00a0Resektion \u00a0des\u00a0Tumors\u00a0und\u00a0der\u00a0Metastasen. \u00a0W\u00e4hrend \u00a0bei\u00a0der\u00a0multimodalen \u00a0\nTherapie\u00a0der\u00a0differenzierten \u00a0Schilddr\u00fcsenkarzinome \u00a0die\u00a0Radiojodtherapie \u00a0eine\u00a0wichtige\u00a0Rolle\u00a0spielt,\u00a0\nist\u00a0sie\u00a0beim\u00a0MTC\u00a0nicht\u00a0sinnvoll,\u00a0da\u00a0die\u00a0C\u2010Zellen\u00a0kein\u00a0radioaktives \u00a0Jod\u00a0speichern. \u00a0Bei\u00a0Patienten \u00a0mit\u00a0\nmedull\u00e4rem \u00a0Schilddr\u00fcsenkarzinom \u00a0ohne\u00a0nachweisbare \u00a0Lymphknotenmetastasen \u00a0erfolgt\u00a0\nstandardm\u00e4\u00dfig \u00a0die\u00a0totale\u00a0Thyreoidektomie \u00a0mit\u00a0prophylaktischer \u00a0beidseitiger \u00a0zentraler\u00a0\nLymphknotendissektion \u00a0(Pacini\u00a0et\u00a0al.,\u00a02012).\u00a0Auch\u00a0bei\u00a0Lymphknotenbefall, \u00a0Lokalrezidiven \u00a0und\u00a0\nFernmetastasen \u00a0ist\u00a0die\u00a0chirurgische \u00a0Resektion \u00a0Hauptbehandlungsma\u00dfnahme. \u00a0Eine\u00a0perkutane \u00a0\nStrahlentherapie \u00a0wird\u00a0in\u00a0Einzelf\u00e4llen \u00a0palliativ\u00a0zur\u00a0Reduzierung \u00a0des\u00a0Risikos\u00a0f\u00fcr\u00a0Lokalrezidive \u00a0\ndurchgef\u00fchrt, \u00a0bei\u00a0Lebermetastasen \u00a0kann\u00a0die\u00a0Chemoembolisation \u00a0hilfreich\u00a0sein.\u00a0Die\u00a0systemische \u00a0\nMono\u2010\u00a0oder\u00a0Polychemotherapie \u00a0ist\u00a0dem\u00a0fortgeschrittenen \u00a0Krankheitsstadium \u00a0mit\u00a0hoher\u00a0Tumorlast, \u00a0\nausgepr\u00e4gter \u00a0Symptomatik \u00a0und\u00a0bzw.\u00a0oder\u00a0drohenden \u00a0Komplikationen \u00a0vorbehalten \u00a0und\u00a0zeigt\u00a0nur\u00a0\nbegrenzte \u00a0Effektivit\u00e4t \u00a0(<\u00a020\u00a0Prozent\u00a0Response \u2010Rate).\u00a0Bisherige\u00a0Studien\u00a0mit\u00a0Multi\u2010Kinaseinhibitoren \u00a0\nwie\u00a0Sunitinib, \u00a0Sorafenib, \u00a0Vandetanib \u00a0und\u00a0Cabozantinib \u00a0werden\u00a0als\u00a0vielversprechend \u00a0f\u00fcr\u00a0die\u00a0\nVerbesserung \u00a0der\u00a0therapeutischen \u00a0M\u00f6glichkeiten \u00a0angesehen. \u00a0In\u00a0der\u00a0ESMO\u2010Leitlinie\u00a02012\u00a0f\u00fcr\u00a0\nSchilddr\u00fcsenkarzinome \u00a0wird\u00a0Vandetanib \u00a0als\u00a0ein\u00a0k\u00fcrzlich\u00a0von\u00a0FDA\u00a0und\u00a0EMA\u00a0zugelassenes \u00a0Medikament \u00a0\nzur\u00a0palliativen \u00a0Behandlung \u00a0des\u00a0fortgeschrittenen \u00a0medull\u00e4ren \u00a0Schilddr\u00fcsenkarzinoms \u00a0erw\u00e4hnt.\u00a0In\u00a0der\u00a0\naktuell\u00a0\u00fcberarbeiteten \u00a0Fassung\u00a0der\u00a0US\u2010amerikanischen \u00a0Thyreoid\u00a0Association \u00a0(ATA)\u2010Guidelines \u00a0zur\u00a0\nBehandlung \u00a0von\u00a0medull\u00e4ren \u00a0Schilddr\u00fcsenkarzinomen \u00a0werden\u00a0Multi\u2010Kinaseinhibitoren, \u00a0die\u00a0sowohl\u00a0\nRET\u00a0als\u00a0auch\u00a0VEGFR\u00a0hemmen, \u00a0als\u00a0erw\u00e4genswert \u00a0f\u00fcr\u00a0die\u00a0systemische \u00a0Therapie\u00a0von\u00a0symptomatischen \u00a0\noder\u00a0progredienten \u00a0metastasierenden \u00a0medull\u00e4ren \u00a0Schilddr\u00fcsenkarzinomen \u00a0mit\u00a0gro\u00dfer\u00a0Tumorlast \u00a0\u00a0\n242\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0empfohlen \u00a0(Wells\u00a0et\u00a0al.,\u00a02015).\u00a0Hingewiesen \u00a0wird\u00a0hier\u00a0aber\u00a0auch\u00a0auf\u00a0die\u00a0noch\u00a0vielen\u00a0offenen\u00a0Fragen,\u00a0\nz.B.\u00a0hinsichtlich \u00a0des\u00a0Auftretens \u00a0von\u00a0Resistenzen, \u00a0der\u00a0Therapiedauer \u00a0oder\u00a0des\u00a0unklaren\u00a0Benefits\u00a0f\u00fcr\u00a0\ndas\u00a0Gesamt\u00fcberleben. \u00a0\n\u00a0Nutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDie\u00a0einzige\u00a0f\u00fcr\u00a0die\u00a0Nutzenbewertung \u00a0relevante \u00a0Studie\u00a0war\u00a0die\u00a0Zulassungsstudie. \u00a0Deren\u00a0\nVerzerrungspotential \u00a0wird\u00a0als\n\u00a0sehr\u00a0hoch\u00a0eingesch\u00e4tzt, \u00a0vor\u00a0allem,\u00a0weil\u00a0die\u00a0Studienteilnehmer \u00a0die\u00a0\nBehandlung \u00a0bei\u00a0Progression \u00a0wechseln \u00a0konnten\u00a0und\u00a0die\u00a0Daten\u00a0zu\u00a0den\u00a0Krankheitsverl\u00e4ufen \u00a0nach\u00a0dem\u00a0\nTherapiewechsel \u00a0nicht\u00a0mehr\u00a0ber\u00fccksichtigt \u00a0wurden.\u00a0Zudem\u00a0war\u00a0die\u00a0mediane\u00a0Behandlungsdauer \u00a0im\u00a0\nVandetanib \u2010Arm\u00a0mit\u00a0knapp\u00a089\u00a0Wochen\u00a0deutlich\u00a0l\u00e4nger\u00a0als\u00a0die\u00a0im\u00a0Vergleichsarm \u00a0mit\u00a037\u00a0Wochen.\u00a0Im\u00a0\nersten\u00a0Beschluss \u00a0zur\u00a0fr\u00fchen\u00a0Nutzenbewertung \u00a0vom\u00a006.09.2012 \u00a0sah\u00a0der\u00a0G\u2010BA\u00a0zun\u00e4chst\u00a0keinen\u00a0\nZusatznutzen \u00a0f\u00fcr\u00a0Vandetanib \u00a0(G\u2010BA,\u00a02012h).\u00a0Das\u00a0Dossier\u00a0wurde\u00a0als\u00a0inhaltlich\u00a0unvollst\u00e4ndig \u00a0\nangesehen, \u00a0insbesondere \u00a0weil\u00a0in\u00a0die\u00a0Zulassungsstudie \u00a0auch\u00a0Patienten \u00a0mit\u00a0nicht\u2010aggressivem \u00a0und\u00a0\nsymptomatischem \u00a0Krankheitsverlauf \u00a0eingeschlossen \u00a0waren\u00a0und\u00a0eine\u00a0separate\u00a0Auswertung \u00a0f\u00fcr\u00a0die\u00a0\nPatienten \u00a0mit\u00a0der\u00a0Indikation, \u00a0f\u00fcr\u00a0die\u00a0der\u00a0Wirkstoff \u00a0zugelassen \u00a0ist,\u00a0fehlte.\u00a0Nachdem \u00a0der\u00a0pU\u00a0ein\u00a0\n\u00fcberarbeitetes \u00a0Dossier\u00a0mit\u00a0der\u00a0Auswertung \u00a0von\u00a0Daten\u00a0f\u00fcr\u00a0die\u00a0gem\u00e4\u00df\u00a0Zulassung \u00a0behandelten \u00a0\nPatienten \u00a0vorlegte,\u00a0erfolgte\u00a0im\u00a0Fr\u00fchjahr\u00a02013\u00a0eine\u00a0erneute\u00a0Nutzenbewertung \u00a0mit\u00a0dem\u00a0Ergebnis\u00a0des\u00a0\nnicht\u00a0belegten\u00a0Zusatznutzens. \u00a0Zwar\u00a0gab\u00a0es\u00a0einen\u00a0Anhaltspunkt \u00a0f\u00fcr\u00a0einen\u00a0Zusatznutzen \u00a0bei\u00a0unter\u00a065\u2010\nJ\u00e4hrigen\u00a0bez\u00fcglich \u00a0sp\u00e4ter\u00a0auftretender \u00a0oder\u00a0sich\u00a0sp\u00e4ter\u00a0verschlimmernder \u00a0Schmerzen, \u00a0jedoch\u00a0\nmachte\u00a0die\u00a0insgesamt \u00a0schlechte \u00a0Datenlage \u00a0zu\u00a0den\u00a0Nebenwirkungen \u00a0ein\u00a0Abw\u00e4gen \u00a0zwischen\u00a0den\u00a0\npositiven\u00a0und\u00a0negativen \u00a0Effekten\u00a0unm\u00f6glich. \u00a0Im\u00a0Stellungnahmeverfahren \u00a0beim\u00a0G\u2010BA\u00a0reichte\u00a0der\u00a0pU\u00a0\nnochmals \u00a0zus\u00e4tzliche \u00a0Studiendaten, \u00a0diesmal\u00a0zu\u00a0den\u00a0Nebenwirkungen \u00a0und\u00a0zur\u00a0Auspr\u00e4gung \u00a0der\u00a0\nSchmerzen \u00a0nach,\u00a0aufgrund\u00a0derer\u00a0das\u00a0IQWIG\u00a0im\u00a0August\u00a02013\u00a0in\u00a0einem\u00a0Addendum \u00a0Vandetanib \u00a0einen\u00a0\nAnhaltspunkt \u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0Zusatznutzen \u00a0f\u00fcr\u00a0unter\u00a065\u2010J\u00e4hrige\u00a0im\u00a0Hinblick\u00a0auf\u00a0eine\u00a0verz\u00f6gerte \u00a0\nSchmerzprogression \u00a0bescheinigt. \u00a0Der\u00a0G\u2010BA\u00a0stellt\u00a0in\u00a0seinem\u00a0anschlie\u00dfenden \u00a0Beschluss \u00a0vom\u00a0September \u00a0\n2013\u00a0f\u00fcr\u00a0Vandetanib \u00a0ebenfalls\u00a0einen\u00a0Anhaltspunkt \u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0Zusatznutzen \u00a0fest,\u00a0allerdings \u00a0\nohne\u00a0altersspezifische \u00a0Einschr\u00e4nkungen \u00a0(G\u2010BA,\u00a02013k).\u00a0Ein\u00a0altersspezifischer \u00a0Wirkunterschied \u00a0von\u00a0\nVandetanib \u00a0wird\u00a0vor\u00a0dem\u00a0Hintergrund \u00a0der\u00a0bisherigen \u00a0klinischen \u00a0Erfahrungen \u00a0mit\u00a0MTC\u2010Patienten \u00a0als\u00a0\nbiologisch \u00a0nicht\u00a0plausibel\u00a0und\u00a0als\u00a0medizinisch \u00a0nicht\u00a0begr\u00fcndet \u00a0angesehen. \u00a0\n\u00a0\nKosten\u00a0\u00a0\nWirkstof f\u00a0 Behandlungsmodus Behandlungstage Jahrestherapiekosten\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nVandetanib  1\u00a0x\u00a0t\u00e4glich\u00a0300\u00a0mg 360 57.103,56 \u00a0\u20ac\nTabelle\u00a045:\u00a0Jahrestherapiekosten \u00a0von\u00a0Vandetanib \u00a0(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen)  \n \u00a0 \n243\u00a0\n\u00a0\nHintergrundinformationen \u00a011.20  Vemurafenib \u00a0\nHandelsname: \u00a0Zelboraf\u00ae \u00a0 \u00a0\u00a0\u00a0 Hersteller: \u00a0Roche\u00a0\nIndikation: \u00a0Melanom \u00a0(metastasiert, \u00a0nicht\u00a0operabel) \u00a0Markteinf\u00fchrung: \u00a0M\u00e4rz\u00a02012\u00a0\u00a0\nATC\u2010Code:\u00a0L01XE15\u00a0 \u00a0\u00a0\u00a0\u00a0 DDD:\u00a0\u00a01.920\u00a0mg\u00a0\nDarreichungsform: \u00a0Filmtablette \u00a0\nBewertung: \u00a0siehe\u00a0Seite\u00a0106\u00a0\nWirkstoff \u00a0und\u00a0Pharmakologie \u00a0\nVemurafenib \u00a0ist\u00a0ein\u00a0oral\u00a0verf\u00fcgbarer, \u00a0selektiver \u00a0Inhibitor\u00a0der\u00a0BRAF\u2010Serin\u2010Threonin\u2010Kinase\u00a0und\u00a0z\u00e4hlt\u00a0\ndamit\u00a0zu\u00a0den\u00a0Kinaseinhibitoren, \u00a0die\u00a0im\u00a0K\u00f6rper\u00a0in\u00a0wichtige\u00a0Signal\u00fcbertragungswege \u00a0eingreifen. \u00a0\nBRAF\u00a0stellt\u00a0ein\u00a0zentrales\u00a0Protein\u00a0im\u00a0MAPK\u2010Signaltransduktionsweg \u00a0dar\u00a0(MAPK\u00a0=\u00a0Mitogen\u00a0aktivierte \u00a0\nProtein\u2010Kinase).\u00a0V600\u2010Mutationen \u00a0des\u00a0BRAF\u2010Gens\u00a0f\u00fchren\u00a0zu\u00a0verst\u00e4rkter \u00a0Zellproliferation \u00a0und\u00a0verhin\u2010\ndern\u00a0die\u00a0Apoptose \u00a0(Roche,\u00a02013).\u00a0\n\u00a0\nZulassung \u00a0und\u00a0Pr\u00e4parat\u00a0\nZelboraf\u00ae \u00a0mit\u00a0dem\u00a0Wirkstoff \u00a0Vemurafenib \u00a0ist\u00a0zugelassen \u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0von\u00a0erwachsenen \u00a0Pati\u2010\nenten,\u00a0die\u00a0an\u00a0schwarzem \u00a0Hautkrebs \u00a0(malignes \u00a0Melanom) \u00a0erkrankt\u00a0sind\u00a0und\u00a0deren\u00a0Melanom \u00a0nicht\u00a0\nmehr\u00a0durch\u00a0eine\u00a0Operation \u00a0entfernbar \u00a0ist\u00a0oder\u00a0bei\u00a0denen\u00a0sich\u00a0bereits\u00a0Metastasen \u00a0gebildet\u00a0haben.\u00a0\nVor\u00a0dem\u00a0Einsatz\u00a0muss\u00a0durch\u00a0einen\u00a0validierten \u00a0Test\u00a0nachgewiesen \u00a0werden,\u00a0ob\u00a0im\u00a0Tumorgewebe \u00a0ein\u00a0\nbestimmter \u00a0diagnostischer \u00a0Marker\u00a0(BRAF\u2010V600E\u2010Mutation) \u00a0vorhanden \u00a0ist.\u00a0Nur\u00a0bei\u00a0einem\u00a0positiven\u00a0\nTestergebnis \u00a0kann\u00a0von\u00a0einer\u00a0Wirkung\u00a0des\u00a0Wirkstoffes \u00a0ausgegangen \u00a0werden.\u00a0\n\u00a0\nInformationen \u00a0zum\u00a0Indikationsgebiet \u00a0\nUnter\u00a0einem\u00a0Melanom \u00a0versteht\u00a0man\u00a0eine\u00a0an\u00a0der\u00a0Haut\u00a0(seltener\u00a0an\u00a0der\u00a0Schleimhaut) \u00a0vorkommende \u00a0\nGeschwulst. \u00a0Im\u00a0Jahr\u00a02008\u00a0rangierte\u00a0das\u00a0maligne\u00a0Melanom \u00a0(schwarzer \u00a0Hautkrebs) \u00a0bei\u00a0Frauen\u00a0auf\u00a0Platz\u00a0\n5\u00a0und\u00a0bei\u00a0M\u00e4nnern \u00a0auf\u00a0Platz\u00a0acht\u00a0der\u00a0h\u00e4ufigsten \u00a0soliden\u00a0Tumorentit\u00e4ten \u00a0in\u00a0Deutschland \u00a0(DKG,\u00a02013).\u00a0\nEs\u00a0z\u00e4hlt\u00a0au\u00dferdem \u00a0zu\u00a0den\u00a0Hauttumoren \u00a0mit\u00a0der\u00a0h\u00f6chsten \u00a0Metastasierungsrate. \u00a0B\u00f6sartige \u00a0Melanome \u00a0\ngehen\u00a0in\u00a0der\u00a0Regel\u00a0von\u00a0den\u00a0pigmentbildenden \u00a0Zellen\u00a0der\u00a0Haut\u00a0aus,\u00a0sie\u00a0entstehen \u00a0h\u00e4ufig\u00a0spontan\u00a0auf\u00a0\nzuvor\u00a0v\u00f6llig\u00a0normaler \u00a0Haut.\u00a0Die\u00a0Inzidenz\u00a0ist\u00a0steigend,\u00a0vermutlich \u00a0durch\u00a0eine\u00a0h\u00f6here\u00a0Sonnenbelastung \u00a0\nder\u00a0Haut,\u00a0insbesondere \u00a0bei\u00a0h\u00e4ufigen\u00a0Sonnenbr\u00e4nden. \u00a0Der\u00a0Anstieg\u00a0der\u00a0Mortalit\u00e4tsrate \u00a0f\u00e4llt\u00a0hingegen\u00a0\ndeutlich\u00a0geringer\u00a0aus\u00a0als\u00a0der\u00a0der\u00a0Inzidenzrate, \u00a0m\u00f6glicherweise \u00a0bedingt\u00a0durch\u00a0eine\u00a0bessere\u00a0Fr\u00fcher\u2010\nkennung\u00a0sowie\u00a0verbesserte \u00a0Therapiem\u00f6glichkeiten. \u00a0Insofern\u00a0kann\u00a0von\u00a0einer\u00a0Stabilisierung \u00a0der\u00a0Morta\u2010\nlit\u00e4tsrate\u00a0ausgegangen \u00a0werden\u00a0(DKG,\u00a02013).\u00a0\n\u00a0\u00a0\u00a0\n244\u00a0\u00a0\n\u00a0\nHintergrundinformationen \u00a0Evidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nZulassungsrelevant \u00a0war\u00a0eine\u00a0offene,\u00a0randomisierte \u00a0Phase\u2010III\u2010Studie\u00a0mit\u00a0675\u00a0therapienaiven \u00a0Patienten \u00a0\nund\u00a0vorliegendem \u00a0BRAF\u2010V600E\u2010Mutation \u2010positivem, \u00a0nicht\u2010resezierbarem \u00a0oder\u00a0metastasierten \u00a0\nMelanom \u00a0(Chapman \u00a0et\u00a0al.,\u00a02011).\u00a0337\u00a0Patienten \u00a0erhielten\u00a0Vemurafenib \u00a0960\u00a0mg\u00a0zweimal\u00a0t\u00e4glich,\u00a0die\u00a0\n\u00fcbrigen\u00a0338\u00a0bekamen \u00a0alle\u00a0drei\u00a0Wochen\u00a01.000\u00a0mg/m2\u00a0Dacarbazin. \u00a0Bei\u00a0der\u00a0zuvor\u00a0festgelegten \u00a0\nInterimsanalyse \u00a0wurden\u00a0signifikante \u00a0Verbesserungen \u00a0in\u00a0den\u00a0beiden\u00a0co\u2010prim\u00e4ren \u00a0Endpunkten \u00a0\nGesamt\u00fcberleben \u00a0und\u00a0progressionsfreies \u00a0\u00dcberleben \u00a0beobachtet. \u00a0So\u00a0lag\u00a0nach\u00a0sechs\u00a0Monaten\u00a0das\u00a0\nGesamt\u00fcberleben \u00a0in\u00a0der\u00a0Vemurafenib \u2010Gruppe\u00a0bei\u00a084\u00a0Prozent\u00a0und\u00a0in\u00a0der\u00a0Dacarbazin \u2010Gruppe\u00a0bei\u00a064\u00a0\nProzent,\u00a0das\u00a0progressionsfreie \u00a0\u00dcberleben \u00a0wurde\u00a0durchschnittlich \u00a0von\u00a01,6\u00a0auf\u00a05,3\u00a0Monate\u00a0verl\u00e4ngert. \u00a0\nDie\u00a0Ansprechrate \u00a0bei\u00a0Vemurafenib \u00a0war\u00a0mit\u00a048\u00a0Prozent\u00a0fast\u00a09\u2010mal\u00a0so\u00a0hoch\u00a0wie\u00a0unter\u00a0der\u00a0\nChemotherapie. \u00a0Auf\u00a0Empfehlung \u00a0des\u00a0Data\u00a0Safety\u00a0Monitoring \u00a0Boards\u00a0(DSMB)\u00a0wurden\u00a0die\u00a0Ergebnisse \u00a0\nder\u00a0Analyse\u00a0im\u00a0Januar\u00a02011\u00a0ver\u00f6ffentlicht \u00a0und\u00a0die\u00a0Studie\u00a0wurde\u00a0so\u00a0angepasst, \u00a0dass\u00a0Dacarbazin \u2010\nPatienten \u00a0in\u00a0den\u00a0Vemurafenib \u2010Arm\u00a0wechseln \u00a0konnten.\u00a0\nH\u00e4ufigste \u00a0Nebenwirkungen \u00a0waren\u00a0Gelenkschmerzen, \u00a0Hautausschlag, \u00a0M\u00fcdigkeit, \u00a0Haarausfall, \u00a0\nPlattenepithelkarzinom, \u00a0Lichtempfindlichkeit, \u00a0\u00dcbelkeit\u00a0und\u00a0Durchfall. \u00a0Bei\u00a038\u00a0Prozent\u00a0der\u00a0Patienten \u00a0\nerfolgte\u00a0eine\u00a0Dosisanpassung \u00a0aufgrund\u00a0toxischer\u00a0Effekte.\u00a0\u00a0\nDie\u00a0Studie\u00a0um\u00a0Sosman\u00a0et\u00a0al.\u00a0(2012)\u00a0untersuchte \u00a0als\u00a0prim\u00e4ren \u00a0Endpunkt \u00a0die\u00a0Anzahl\u00a0der\u00a0Patienten, \u00a0die\u00a0\nauf\u00a0eine\u00a0Therapie\u00a0mit\u00a0Vemurafenib \u00a0ansprachen. \u00a0Insgesamt \u00a0erreichten \u00a0gut\u00a053\u00a0Prozent\u00a0der\u00a0\nStudienteilnehmer \u00a0eine\u00a0(mediane) \u00a0Ansprechrate, \u00a0das\u00a0mediane\u00a0Gesamt\u00fcberleben \u00a0in\u00a0dieser\u00a0\nStudienpopulation \u00a0lag\u00a0bei\u00a016\u00a0Monaten. \u00a0\u00a0\nIm\u00a0August\u00a02013\u00a0informierte \u00a0der\u00a0pharmazeutische \u00a0Unternehmer \u00a0in\u00a0einem\u00a0Rote\u2010Hand\u2010Brief\u00a0\u00fcber\u00a0das\u00a0\nRisiko\u00a0f\u00fcr\u00a0eine\u00a0Progression \u00a0maligner\u00a0Erkrankungen \u00a0und\u00a0Arzneimittelausschlag \u00a0mit\u00a0Eosinophilie \u00a0und\u00a0\nsystemischen \u00a0Symptomen \u00a0(DRESS\u2010Syndrom) \u00a0in\u00a0Verbindung \u00a0mit\u00a0Zelboraf\u00ae \u00a0(Roche,\u00a02013a).\u00a0\nDie\u00a0Ergebnisse \u00a0des\u00a0erweiterten \u00a0Follow\u2010Ups\u00a0einer\u00a0randomisierten, \u00a0offenen\u00a0Phase\u2010III\u2010Studie\u00a0(BRIM\u20103)\u00a0\ndemonstrieren \u00a0die\u00a0Sicherheit \u00a0und\u00a0Wirksamkeit \u00a0von\u00a0Vemurafenib \u00a0(960\u00a0mg\u00a0p.o.\u00a0zweimal\u00a0t\u00e4glich)\u00a0im\u00a0\nVergleich \u00a0zu\u00a0Dacarbazin \u00a0(1.000\u00a0mg/m2\u00a0K\u00f6rperoberfl\u00e4che \u00a0i.v.\u00a0alle\u00a0drei\u00a0Wochen)\u00a0bei\u00a0Patienten, \u00a0die\u00a0\nverschiedene \u00a0Mutationen \u00a0(V600E,\u00a0V600K)\u00a0aufweisen \u00a0(McArthur \u00a0et\u00a0al.,\u00a02014).\u00a0Vemurafenib \u00a0war\u00a0in\u00a0\nbeiden\u00a0Gruppen\u00a0signifikant \u00a0\u00fcberlegen \u00a0gegen\u00fcber \u00a0Dacarbazin. \u00a0In\u00a0der\u00a0Gesamtschau \u00a0verl\u00e4ngerte \u00a0\nVemurafenib \u00a0das\u00a0mediane\u00a0Gesamt\u00fcberleben \u00a0(13,6\u00a0Monate\u00a0vs.\u00a09,7\u00a0Monate;\u00a0p\u00a0=\u00a00,0008),\u00a0sondern\u00a0\nebenso\u00a0das\u00a0mediane\u00a0progressionsfreie \u00a0\u00dcberleben \u00a0(6.9\u00a0Monate\u00a0vs.\u00a01,6\u00a0Monate;\u00a0p\u00a0<\u00a00,0001).\u00a0So\u00a0\nverbessert \u00a0die\u00a0BRAF\u2010Inhibition \u00a0mit\u00a0Vemurafenib \u00a0das\u00a0\u00dcberleben \u00a0bei\u00a0Patienten \u00a0mit\u00a0h\u00e4ufig\u00a0\nvorkommender \u00a0V600E\u2010\u00a0sowie\u00a0bei\u00a0Patienten \u00a0mit\u00a0selten\u00a0vorkommender \u00a0V600K\u2010Mutation. \u00a0\nLarkin\u00a0et\u00a0al.\u00a0ver\u00f6ffentlichten \u00a0im\u00a0Jahr\u00a02014\u00a0die\u00a0Ergebnisse \u00a0ihrer\u00a0Sicherheitsstudie \u00a0und\u00a0best\u00e4tigten \u00a0\ndamit\u00a0das\u00a0Sicherheitsprofil \u00a0der\u00a0Pivotalstudie. \u00a0Weitere\u00a0Daten\u00a0im\u00a0Hinblick\u00a0auf\u00a0eine\u00a0m\u00f6gliche\u00a0Nieren\u2010\u00a0\nund\u00a0Pankreastoxizit\u00e4t \u00a0sowie\u00a0ein\u00a0Risiko\u00a0weiterer\u00a0extrakutaner \u00a0Krebserkrankungen \u00a0sind\u00a0erforderlich \u00a0\n(Prescrire \u00a0Int,\u00a02015).\u00a0\u00a0\n\u00a0\u00a0 \n245\u00a0\n\u00a0\nHintergrundinformationen \u00a0Leitlinienempfehlungen \u00a0\nMutationen \u00a0in\u00a0BRAF\u00a0werden\u00a0bei\u00a040\u00a0bis\u00a060\u00a0Prozent\u00a0der\u00a0Melanome \u00a0detektiert, \u00a0wobei\u00a090\u00a0Prozent\u00a0dieser\u00a0\nMutationen \u00a0zu\u00a0einem\u00a0Aminos\u00e4ureaustausch \u00a0von\u00a0Valin\u00a0(V)\u00a0durch\u00a0Glutamat \u00a0(E)\u00a0(BRAF\u00a0V600E)\u00a0f\u00fchren.\u00a0\nDiese\u00a0Ver\u00e4nderung \u00a0f\u00fchrt\u00a0zu\u00a0einer\u00a0Aktivierung \u00a0des\u00a0Signaltransduktionsweges, \u00a0der\u00a0relevant\u00a0ist\u00a0f\u00fcr\u00a0die\u00a0\nTumorentwicklung \u00a0und\u00a0\u2010progression \u00a0des\u00a0Melanoms \u00a0(DKG,\u00a02013).\u00a0Vemurafenib \u00a0wird\u00a0in\u00a0der\u00a0S3\u2010Leitlinie\u00a0\n\u201eDiagnostik, \u00a0Therapie\u00a0und\u00a0Nachsorge \u00a0des\u00a0Melanoms\u201c \u00a0neben\u00a0dem\u00a0BRAF\u2010Inhibitor\u00a0Dabrafenib \u00a0er\u2010\nw\u00e4hnt.\u00a0Insbesondere \u00a0Melanom \u2010Patienten \u00a0mit\u00a0hoher\u00a0Tumorlast \u00a0profitieren \u00a0dabei\u00a0von\u00a0der\u00a0Behandlung \u00a0\nmit\u00a0einem\u00a0BRAF\u2010Inhibitor. \u00a0Allerdings \u00a0ist\u00a0die\u00a0Dauer\u00a0des\u00a0Ansprechens \u00a0aufgrund\u00a0der\u00a0Ausbildung \u00a0von\u00a0\nResistenzmechanismen \u00a0begrenzt\u00a0und\u00a0betr\u00e4gt\u00a0f\u00fcnf\u00a0bis\u00a0sieben\u00a0Monate.\u00a0Auch\u00a0sind\u00a0BRAF\u2010Inhibitoren \u00a0\nkontraindiziert \u00a0bei\u00a0Melanom \u2010Patienten \u00a0mit\u00a0BRAF\u2010Wildtyp\u00a0(DKG,\u00a02013).\u00a0\nBei\u00a0niedriger\u00a0Tumorlast, \u00a0geringer\u00a0Dynamik\u00a0und\u00a0wenig\u00a0klinischen \u00a0Beschwerden \u00a0kann\u00a0eine\u00a0Chemothe \u2010\nrapie\u00a0oder\u00a0alternativ \u00a0Ipilimumab \u00a0als\u00a0Behandlungsoption \u00a0in\u00a0Betracht\u00a0gezogen\u00a0werden\u00a0(DKG,\u00a02013).  \n\u00a0\nNutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nVemurafenib \u00a0wurde\u00a0im\u00a0Rahmen\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung \u00a0durch\u00a0den\u00a0G\u2010BA\u00a0mit\u00a0Dacarbazin \u00a0vergli\u2010\nchen.\u00a0In\u00a0der\u00a0Gesamtschau \u00a0der\u00a0Vor\u2010\u00a0und\u00a0Nachteile \u00a0konnte\u00a0ein\u00a0Hinweis\u00a0auf\u00a0einen\u00a0betr\u00e4chtlichen \u00a0Zu\u2010\nsatznutzen \u00a0von\u00a0Vemurafenib \u00a0gegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen \u00a0Vergleichstherapie \u00a0Dacarbazin \u00a0festge\u2010\nstellt\u00a0werden.\u00a0Die\u00a0Bewertung \u00a0erfolgte\u00a0im\u00a0Wesentlichen \u00a0auf\u00a0Basis\u00a0einer\u00a0randomisierten \u00a0kontrollierten \u00a0\nStudie\u00a0(Chapman \u00a0et\u00a0al.,\u00a02011).\u00a0In\u00a0Bezug\u00a0auf\u00a0das\u00a0Gesamt\u00fcberleben \u00a0zeigte\u00a0sich\u00a0hier\u00a0ein\u00a0signifikanter \u00a0\nVorteil\u00a0f\u00fcr\u00a0Vemurafenib, \u00a0das\u00a0mediane\u00a0Gesamt\u00fcberleben \u00a0verl\u00e4ngerte \u00a0sich\u00a0gegen\u00fcber \u00a0Dacarbazin \u00a0von\u00a0\n9,6\u00a0auf\u00a013,2\u00a0Monate.\u00a0F\u00fcr\u00a0die\u00a0Endpunkte \u00a0\u201eMorbidit\u00e4t\u201c \u00a0und\u00a0\u201eLebensqualit\u00e4t\u201c \u00a0konnten\u00a0hingegen\u00a0keine\u00a0\nrelevanten \u00a0Vorteile\u00a0gefunden \u00a0werden.\u00a0In\u00a0der\u00a0Vemurafenib \u2010Gruppe\u00a0kam\u00a0es\u00a0im\u00a0Vergleich \u00a0zur\u00a0Kontroll\u2010\ngruppe\u00a0h\u00e4ufiger\u00a0zu\u00a0schweren \u00a0und\u00a0schwerwiegenden \u00a0unerw\u00fcnschten \u00a0Ereignissen, \u00a0so\u00a0traten\u00a0unter\u00a0der\u00a0\nTherapie\u00a0bei\u00a0etwa\u00a0einem\u00a0von\u00a0f\u00fcnf\u00a0Patienten \u00a0(im\u00a0Normalfall \u00a0gut\u00a0behandelbare) \u00a0kutane\u00a0Plattenepithel \u2010\nkarzinome \u00a0auf\u00a0(G\u2010BA,\u00a02012i).\u00a0Die\u00a0Neubewertung \u00a0nach\u00a0Fristablauf \u00a0(Beschlussfassung \u00a0vom\u00a06.\u00a0M\u00e4rz\u00a0\n2014f)\u00a0best\u00e4tigte \u00a0erneut\u00a0den\u00a0Hinweis\u00a0auf\u00a0einen\u00a0betr\u00e4chtlichen \u00a0Zusatznutzen \u00a0von\u00a0Vemurafenib \u00a0ge\u2010\ngen\u00fcber\u00a0Dacarbazin. \u00a0\n\u00a0\nKosten\u00a0\nWirkstof f\u00a0 Behandlungsmodus Behandlungstage* Jahrestherapiekosten**\nzu\u00a0bewertendes \u00a0Arzneimittel \u00a0\nVemurafenib  2\u00a0x\u00a0t\u00e4glich\u00a0960\u00a0mg 360 97.313,14 \u00a0\u20ac\nVergleichstherapie  \u00a0\nDacarbazin  1\u00a0x\u00a0850\u00a0mg/m2\u00a0alle\u00a0drei\u00a0\nWochen\u00a0\u00a017 5.531,80\u00a0\u20ac\nTabelle\u00a046:\u00a0Jahrestherapiekosten \u00a0von\u00a0Vemurafenib \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0Kosten\u00a0\nzus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0\n  \u00a0\n246\u00a0Literaturverzeichnis \u00a0\n1. ABM\u00a0(2012).\u00a0Neues\u00a0onkologisches \u00a0Arzneimittel: \u00a0Vemurafenib \u00a0(Zelboraf\u00ae). \u00a0AMB\u00a046,34.\u00a0\u00a0\n2. Ajani\u00a0JA,\u00a0Rodriguez \u00a0W,\u00a0Bodoky\u00a0G,\u00a0Moiseyenko \u00a0V,\u00a0Lichinitser \u00a0M,\u00a0Gorbunova \u00a0V,\u00a0Vynnychenko \u00a0I,\u00a0Garin\u00a0A,\u00a0Lang\u00a0I,\u00a0\nFalcon\u00a0S\u00a0(2010).\u00a0Multicenter \u00a0phase\u00a0III\u00a0comparison \u00a0of\u00a0cisplatin/S \u20101\u00a0with\u00a0cisplatin/infusional \u00a0fluorouracil \u00a0in\u00a0\nadvanced \u00a0gastric\u00a0or\u00a0gastroesophageal \u00a0adenocarcinoma \u00a0study:\u00a0the\u00a0FLAGS\u00a0trial.\u00a0J\u00a0Clin\u00a0Oncol.\u00a028(9):1547 \u201053.\u00a0\n3. Akd\u00c4\u00a0\u2013\u00a0Arzneimittelkommission \u00a0der\u00a0deutschen \u00a0\u00c4rzteschaft \u00a0(2012).\u00a0Neue\u00a0Arzneimittel \u00a0Zelboraf\u00a0(Vemurafenib). \u00a0\nhttp://www.akdae.de/Arzneim itteltherapie/NA/Archiv/2012034 \u2010Zelboraf.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a012.\u00a0Juni\u00a0\n2012.\u00a0Letzter\u00a0Zugriff:\u00a028.05.2015. \u00a0\n4. AKd\u00c4\u00a0\u2013\u00a0Arzneimittelkommission \u00a0der\u00a0deutschen \u00a0\u00c4rzteschaft \u00a0(2014).\u00a0UAW\u2010News\u00a0International. \u00a0Bei\u00a0der\u00a0\nVerschreibung \u00a0von\u00a0kombinierten \u00a0hormonalen \u00a0Kontrazeptiva \u00a0sollte\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0thromboembolische \u00a0Ereignisse \u00a0\nber\u00fccksichtigt \u00a0werden.\u00a0Dtsch\u00a0\u00c4rzteblatt. \u00a0111:\u00a0A1533\u2010A1534.\u00a0\n5. Almirall\u00a0(2014).\u00a0Fachinformation \u00a0\u2013\u00a0Zusammenfassung \u00a0der\u00a0Merkmale \u00a0des\u00a0Arzneimittels \u00a0\u2010\u00a0Eklira\uf0d2\u00a0Genuair\uf0d2\u00a0322\u00a0\nMikrogramm \u00a0Pulver\u00a0zur\u00a0Inhalation. \u00a0Stand\u00a0der\u00a0Information: \u00a0Mai\u00a02014.\u00a0\n6. Anderson \u00a0GL,\u00a0Limacher\u00a0M,\u00a0Assaf\u00a0AR,\u00a0Bassford\u00a0T,\u00a0Beresford \u00a0SA,\u00a0Black\u00a0H,\u00a0Bonds\u00a0D,\u00a0Brunner\u00a0R,\u00a0Brzyski\u00a0R,\u00a0Caan\u00a0B,\u00a0\nChlebowski \u00a0R,\u00a0Curb\u00a0D,\u00a0Gass\u00a0M,\u00a0Hays\u00a0J,\u00a0Heiss\u00a0G,\u00a0Hendrix\u00a0S,\u00a0Howard\u00a0BV,\u00a0Hsia\u00a0J,\u00a0Hubbell\u00a0A,\u00a0Jackson\u00a0R,\u00a0Johnson\u00a0KC,\u00a0\nJudd\u00a0H,\u00a0Kotchen\u00a0JM,\u00a0Kuller\u00a0L,\u00a0LaCroix\u00a0AZ,\u00a0Lane\u00a0D,\u00a0Langer\u00a0RD,\u00a0Lasser\u00a0N,\u00a0Lewis\u00a0CE,\u00a0Manson\u00a0J,\u00a0Margolis\u00a0K,\u00a0Ockene\u00a0J,\u00a0\nO'Sullivan \u00a0MJ,\u00a0Phillips\u00a0L,\u00a0Prentice\u00a0RL,\u00a0Ritenbaugh \u00a0C,\u00a0Robbins\u00a0J,\u00a0Rossouw\u00a0JE,\u00a0Sarto\u00a0G,\u00a0Stefanick\u00a0ML,\u00a0Van\u00a0Horn\u00a0L,\u00a0\nWactawski \u2010Wende\u00a0J,\u00a0Wallace\u00a0R,\u00a0Wassertheil \u2010Smoller\u00a0S;\u00a0Women's \u00a0Health\u00a0Initiative\u00a0Steering\u00a0Committee \u00a0(2004).\u00a0\nEffects\u00a0of\u00a0conjugated \u00a0equine\u00a0estrogen\u00a0in\u00a0postmenopausal \u00a0women\u00a0with\u00a0hysterectomy: \u00a0the\u00a0Women's \u00a0Health\u00a0\nInitiative\u00a0randomized \u00a0controlled \u00a0trial.\u00a0JAMA.\u00a0291\u00a0(14):\u00a01701\u201012.\u00a0\n7. App\u00a0EM\u00a0(2013).\u00a0Mukoviszidose. \u00a0In:\u00a0Matthys\u00a0M,\u00a0Seeger\u00a0W:\u00a0Klinische\u00a0Pneumologie. \u00a0Berlin:\u00a0Springer\u00a0Verlag.\u00a0\n8. AstraZeneca \u00a0(2014a).\u00a0Fachinformation \u00a0Zinforo\u00ae\u00a0600mg\u00a0Pulver\u00a0zur\u00a0Herstellung \u00a0eines\u00a0Konzentrats \u00a0f\u00fcr\u00a0eine\u00a0\nInfusionsl\u00f6sung. \u00a0Stand\u00a0der\u00a0Information: \u00a0Oktober\u00a02014.\u00a0\n9. AstraZeneca \u00a0(2014b).\u00a0Fachinformation \u00a0Forxiga\u00ae.\u00a0Stand\u00a0der\u00a0Information: \u00a0Oktober\u00a02014.\u00a0\n10. AstraZeneca \u00a0(2014c).\u00a0Fachinformation \u00a0Xigduo\u00ae.\u00a0Stand\u00a0der\u00a0Information: \u00a0Oktober\u00a02014.\u00a0\n11. AstraZeneca \u00a0(2014d).\u00a0Fachinformation \u00a0Caprelsa\u00ae. \u00a0Stand\u00a0der\u00a0Information: \u00a0Oktober\u00a02014.\u00a0\n12. Bayer\u00a0(2015).\u00a0Fachinformation \u00a0Eylea\u00ae\u00a040mg/ml\u00a0Injektionsl\u00f6sung \u00a0in\u00a0einer\u00a0Durchstechflasche. \u00a0Stand\u00a0der\u00a0\nInformation: \u00a0Februar\u00a02015.\u00a0\n13. Beckett\u00a0N,\u00a0Peters\u00a0R,\u00a0Tuomilehto \u00a0J,\u00a0Swift\u00a0C,\u00a0Sever\u00a0P,\u00a0Potter\u00a0J,\u00a0McCormack \u00a0T,\u00a0Forette\u00a0F,\u00a0Gil\u2010Extremera \u00a0B,\u00a0Dumitrascu \u00a0\nD,\u00a0Staessen\u00a0JA,\u00a0Thijs\u00a0L,\u00a0Fletcher\u00a0A,\u00a0Bulpitt\u00a0C;\u00a0HYVTE\u00a0Study\u00a0Group\u00a0(2011).\u00a0Immediate \u00a0and\u00a0late\u00a0benefits\u00a0of\u00a0treating\u00a0\nvery\u00a0elderly\u00a0people\u00a0with\u00a0hypertension: \u00a0results\u00a0from\u00a0active\u00a0treatment \u00a0extension \u00a0to\u00a0Hypertension \u00a0in\u00a0the\u00a0Very\u00a0\nElderly\u00a0randomised \u00a0controlled \u00a0trial.\u00a0BMJ.\u00a0344:\u00a0d7541.\u00a0\u00a0\n14. Beral\u00a0V,\u00a0Banks\u00a0E,\u00a0Reeves\u00a0G\u00a0(2002).\u00a0Evidence\u00a0from\u00a0randomised \u00a0trials\u00a0on\u00a0the\u00a0long\u2010term\u00a0effects\u00a0of\u00a0hormone \u00a0\nreplacement \u00a0therapy.\u00a0Lancet.\u00a0360\u00a0(9337):\u00a0942\u20104.\u00a0\n15. Beral\u00a0V\u00a0(2003).\u00a0Million\u00a0Women\u00a0Study\u00a0Collaborators. \u00a0Breast\u00a0cancer\u00a0and\u00a0hormone\u2010replacement \u00a0therapy\u00a0in\u00a0the\u00a0Mil\u2010\nlion\u00a0Women\u00a0Study.\u00a0Lancet.\u00a0362\u00a0(9382):\u00a0419\u201027.\u00a0\u00a0\n16. BMS\u00a0(2013).\u00a0Bristol\u2010Myers\u00a0Squibb.\u00a0Wichtige\u00a0Information \u00a0\u2013\u00a0Vermehrtes \u00a0Auftreten \u00a0von\u00a0akuten\u00a0Transplantat \u2010\nAbsto\u00dfungsreaktionen \u00a0unter\u00a0der\u00a0Behandlung \u00a0mit\u00a0NULOJIX\u00a0(Belatacept) \u00a0im\u00a0Zusammenhang \u00a0mit\u00a0einer\u00a0schnellen \u00a0\nDosis\u2010Reduktion \u00a0von\u00a0Corticosteroiden \u00a0bei\u00a0Patienten \u00a0mit\u00a0einem\u00a0hohen\u00a0immunologischen \u00a0Risiko\u00a0f\u00fcr\u00a0akute\u00a0\nAbsto\u00dfungsreaktionen. \u00a0Stand\u00a0der\u00a0Information: \u00a022.03.2013. \u00a0 \n247\u00a017. Boardman \u00a0HMP,\u00a0Hartley\u00a0L,\u00a0Eisinga\u00a0A,\u00a0Main\u00a0C,\u00a0Roqu\u00e9\u00a0i\u00a0Figuls\u00a0M,\u00a0Bonfill\u00a0Cosp\u00a0X,\u00a0Gabriel\u00a0Sanchez\u00a0R,\u00a0Knight\u00a0B\u00a0(2015).\u00a0\nHormone \u00a0therapy\u00a0for\u00a0preventing \u00a0cardiovascular \u00a0disease\u00a0in\u00a0post\u2010menopausal \u00a0women.\u00a0Cochrane \u00a0Database \u00a0of\u00a0\nSystematic \u00a0Reviews,\u00a0Issue\u00a03.\u00a0Art.\u00a0No.:\u00a0CD002229. \u00a0DOI:\u00a010.1002/14651858.CD002229.pub4. \u00a0\u00a0\n18. Boscaro\u00a0M,\u00a0Ludlam\u00a0WH,\u00a0Atkinson\u00a0B,\u00a0Glusman\u00a0JE,\u00a0Petersenn \u00a0S,\u00a0Reincke\u00a0M,\u00a0Snyder,\u00a0P,\u00a0Tabarin\u00a0A,\u00a0Biller\u00a0BM,\u00a0Findling\u00a0\nJ,\u00a0Melmed\u00a0S,\u00a0Darby\u00a0CH,\u00a0Hu\u00a0K,\u00a0Wang\u00a0Y,\u00a0Freda\u00a0PU,\u00a0Grossman \u00a0AB,\u00a0Frohman\u00a0LA,\u00a0Bertherat \u00a0J\u00a0(2009).\u00a0Treatment \u00a0of\u00a0\npituitary\u2010dependent \u00a0Cushing's \u00a0disease\u00a0with\u00a0the\u00a0multireceptor \u00a0ligand\u00a0somatostatin \u00a0analog\u00a0pasireotide \u00a0(SOM230): \u00a0a\u00a0\nmulticenter, \u00a0phase\u00a0II\u00a0trial.\u00a0J\u00a0Clin\u00a0Endocrinol \u00a0Metab.\u00a094(1):115 \u201022.\u00a0\n19. Boyer\u00a0D,\u00a0Heier\u00a0J,\u00a0Brown\u00a0DM,\u00a0Clark\u00a0WL,\u00a0Vitti\u00a0R,\u00a0Berliner\u00a0AJ,\u00a0Groetzbach \u00a0G,\u00a0Zeitz\u00a0O,\u00a0Sandbrink \u00a0R,\u00a0Zhu\u00a0X,\u00a0Beckmann \u00a0K,\u00a0\nHaller\u00a0JA\u00a0(2012).\u00a0Vascular\u00a0endothelial \u00a0growth\u00a0factor\u00a0Trap\u2010Eye\u00a0for\u00a0macular\u00a0edema\u00a0secondary \u00a0to\u00a0central\u00a0retinal\u00a0vein\u00a0\nocclusion: \u00a0six\u2010month\u00a0results\u00a0of\u00a0the\u00a0phase\u00a03\u00a0COPERNICUS \u00a0study.\u00a0Ophthalmology. \u00a0119(5):024 \u201032.\u00a0Erratum\u00a0in:\u00a0\nOphthalmology. \u00a0119(11):\u00a02204.\u00a0\n20. Boyle\u00a0MP,\u00a0Bell\u00a0SC,\u00a0Konstan\u00a0MW,\u00a0McColley\u00a0SA,\u00a0Rowe\u00a0SM,\u00a0Rietschel\u00a0E,\u00a0Huang\u00a0X,\u00a0Waltz\u00a0D,\u00a0Patel\u00a0NR,\u00a0Rodman\u00a0D;\u00a0\nVX09\u2010809\u2010102\u00a0study\u00a0group\u00a0(2014).\u00a0A\u00a0CFTR\u00a0corrector \u00a0(lumacaftor) \u00a0and\u00a0a\u00a0CFTR\u00a0potentiator \u00a0(ivacaftor) \u00a0for\u00a0treatment \u00a0\nof\u00a0patients\u00a0with\u00a0cystic\u00a0fibrosis\u00a0who\u00a0have\u00a0a\u00a0phe508del \u00a0CFTR\u00a0mutation: \u00a0a\u00a0phase\u00a02\u00a0randomised \u00a0controlled \u00a0trial.\u00a0\nLancet\u00a0Respir\u00a0Med.\u00a02:\u00a0527\u2010538.\u00a0\n21. Braendle\u00a0W\u00a0(2005).\u00a0Endokrinologie \u00a0des\u00a0Klimakteriums \u00a0und\u00a0der\u00a0Postmenopause. \u00a0In:\u00a0Braendle\u00a0W\u00a0(2005).\u00a0Das\u00a0\nKlimakterium. \u00a0Stuttgart: \u00a0Wissenschaftliche \u00a0Verlagsgesellschaft \u00a0mbg.\u00a0\u00a0\n22. Briasoulis \u00a0A,\u00a0Agarwal\u00a0V,\u00a0Tousoulis \u00a0D,\u00a0Stefanadis \u00a0C\u00a0(2014).\u00a0Effects\u00a0of\u00a0antihypertensive \u00a0treatment \u00a0in\u00a0patients\u00a0over\u00a065\u00a0\nyears\u00a0of\u00a0age:\u00a0a\u00a0meta\u2010analysis\u00a0of\u00a0randomised \u00a0controlled \u00a0studies.\u00a0Heart.\u00a0100(4):317 \u201023.\u00a0\u00a0\n23. Brodt\u00a0HR\u00a0(2013).\u00a0Stille\u00a0\u2013\u00a0Antibiotika \u2010Therapie. \u00a0Klinik\u00a0und\u00a0Praxis\u00a0der\u00a0antiinfekti\u00f6sen \u00a0Behandlung. \u00a012.\u00a0Auflage\u00a02013.\u00a0\nStuttgart: \u00a0Schattauer \u00a0Verlag.\u00a0\n24. Brunetta\u00a0J,\u00a0Moreno\u00a0Guill\u00e9n\u00a0S,\u00a0Antinori\u00a0A,\u00a0Yeni\u00a0P,\u00a0Wade\u00a0B,\u00a0Johnson\u00a0M,\u00a0Shalit\u00a0P,\u00a0Ebrahimi\u00a0R,\u00a0Johnson\u00a0B,\u00a0Walker\u00a0I,\u00a0\nDe\u2010Oertel\u00a0S\u00a0(2015).\u00a0Patient\u2010Reported \u00a0Outcomes \u00a0After\u00a0a\u00a0Switch\u00a0to\u00a0a\u00a0Single\u2010Tablet\u00a0Regimen\u00a0of\u00a0Rilpivirine, \u00a0\nEmtricitabine, \u00a0and\u00a0Tenofovir \u00a0DF\u00a0in\u00a0HIV\u20101\u2010Positive,\u00a0Virologically \u00a0Suppressed \u00a0Individuals: \u00a0Additional \u00a0Findings\u00a0From\u00a0a\u00a0\nRandomized, \u00a0Open\u2010Label,\u00a048\u2010Week\u00a0Trial.\u00a0Patient.\u00a08\u00a0(3):\u00a0257\u201067.\u00a0\n25. Bundesministerium \u00a0der\u00a0Justiz\u00a0und\u00a0f\u00fcr\u00a0Verbraucherschutz \u00a0(2012).\u00a0Verordnung \u00a0\u00fcber\u00a0die\u00a0Anwendung \u00a0der\u00a0Guten\u00a0\nKlinischen \u00a0Praxis\u00a0bei\u00a0der\u00a0Durchf\u00fchrung \u00a0von\u00a0klinischen \u00a0Pr\u00fcfungen \u00a0mit\u00a0Arzneimitteln \u00a0zur\u00a0Anwendung \u00a0am\u00a0Menschen \u00a0\n(GCP\u2010Verordnung \u00a0\u2013\u00a0GCP\u2010V).\u00a0GCP\u2010Verordnung \u00a0vom\u00a09.\u00a0August\u00a02004\u00a0(BGBl.\u00a0I\u00a0S.\u00a02081),\u00a0die\u00a0zuletzt\u00a0durch\u00a0Artikel\u00a08\u00a0des\u00a0\nGesetzes\u00a0vom\u00a019.\u00a0Oktober\u00a02012\u00a0(BGBl.\u00a0I\u00a0S.\u00a02192)\u00a0ge\u00e4ndert\u00a0worden\u00a0ist.\u00a0http://www.gesetze \u2010im\u2010internet.de/gcp \u2010\nv/BJNR208100004.html, \u00a0letzter\u00a0Zugriff:\u00a007.02.2014. \u00a0\n26. Canonico \u00a0M,\u00a0Plu\u2010Bureau\u00a0G,\u00a0Lowe\u00a0GD,\u00a0Scarabin\u00a0PY\u00a0(2008).\u00a0Hormone \u00a0replacement \u00a0therapy\u00a0and\u00a0risk\u00a0of\u00a0venous\u00a0\nthromboembolism \u00a0in\u00a0postmenopausal \u00a0women:\u00a0systematic \u00a0review\u00a0and\u00a0meta\u2010analysis.\u00a0BMJ.\u00a0336(7655): \u00a01227\u201031.\u00a0\n27. Casetta\u00a0I,\u00a0Iuliano\u00a0G,\u00a0Filippini\u00a0G\u00a0(2009).\u00a0Azathioprine \u00a0for\u00a0multiple\u00a0sclerosis.\u00a0J\u00a0Neurol\u00a0Neurosurg \u00a0Psychiatry. \u00a080\u00a0\n(2):131\u20102;\u00a0discussion \u00a0132.\u00a0\n28. Cazzola\u00a0M,\u00a0MacNee\u00a0W,\u00a0Martinez\u00a0FJ,\u00a0Rabe\u00a0KF,\u00a0Franciosi\u00a0LG,\u00a0Barnes\u00a0PJ,\u00a0Brusasco\u00a0V,\u00a0Burge\u00a0PS,\u00a0Calverley\u00a0PM,\u00a0Celli\u00a0BR,\u00a0\nJones\u00a0PW,\u00a0Mahler\u00a0DA,\u00a0Make\u00a0B,\u00a0Miravitlles \u00a0M,\u00a0Page\u00a0CP,\u00a0Palange\u00a0P,\u00a0Parr\u00a0D,\u00a0Pistolesi\u00a0M,\u00a0Rennard\u00a0SI,\u00a0Rutten\u2010van\u00a0\nM\u00f6lken\u00a0MP,\u00a0Stockley\u00a0R,\u00a0Sullivan\u00a0SD,\u00a0Wedzicha \u00a0JA,\u00a0Wouters\u00a0EF;\u00a0American \u00a0Thoracic\u00a0Society;\u00a0European \u00a0Respiratory \u00a0\nSociety\u00a0Task\u00a0Force\u00a0on\u00a0outcomes \u00a0of\u00a0COPD\u00a0(2008).\u00a0Outcomes \u00a0for\u00a0COPD\u00a0pharmacological \u00a0trials:\u00a0from\u00a0lung\u00a0function\u00a0to\u00a0\nbiomarkers. \u00a0Eur\u00a0Respir\u00a0J.\u00a031(2):\u00a0416\u201069.\u00a0\u00a0\n29. Ceccato\u00a0F,\u00a0Scaroni\u00a0C,\u00a0Boscaro\u00a0M\u00a0(2015).\u00a0Clinical\u00a0use\u00a0of\u00a0pasireotide \u00a0for\u00a0Cushing's \u00a0disease\u00a0in\u00a0adults.\u00a0Ther\u00a0Clin\u00a0Risk\u00a0\nManag.11: \u00a0425\u201034.\u00a0\n30. Cervantes \u00a0F,\u00a0Vannucchi \u00a0AM,\u00a0Kiladjian\u00a0JJ,\u00a0Al\u2010Ali\u00a0HK,\u00a0Sirulnik\u00a0A,\u00a0Stalbovskaya \u00a0V,\u00a0McQuitty \u00a0M,\u00a0Hunter\u00a0DS,\u00a0Levy\u00a0RS,\u00a0\nPassamonti \u00a0F,\u00a0Barbui\u00a0T,\u00a0Barosi\u00a0G,\u00a0Harrison\u00a0CN,\u00a0Knoops\u00a0L,\u00a0Gisslinger \u00a0H;\u00a0COMFORT \u2010II\u00a0investigators \u00a0(2013).\u00a0Three\u2010\nyear\u00a0efficacy,\u00a0safety,\u00a0and\u00a0survival\u00a0findings\u00a0from\u00a0COMFORT \u2010II,\u00a0a\u00a0phase\u00a03\u00a0study\u00a0comparing \u00a0ruxolitinib \u00a0with\u00a0best\u00a0\navailable\u00a0therapy\u00a0for\u00a0myelofibrosis. \u00a0Blood.\u00a0122\u00a0(25):\u00a04047\u201053.\u00a0\u00a0\n248\u00a031. Chapman \u00a0PB,\u00a0Hauschild \u00a0A,\u00a0Robert\u00a0C,\u00a0Haanen\u00a0JB,\u00a0Ascierto\u00a0P,\u00a0Larkin\u00a0J,\u00a0Dummer\u00a0R,\u00a0Garbe\u00a0C,\u00a0Testori\u00a0A,\u00a0Maio\u00a0M,\u00a0Hogg\u00a0\nD,\u00a0Lorigan\u00a0P,\u00a0Lebbe\u00a0C,\u00a0Jouary\u00a0T,\u00a0Schadendorf \u00a0D,\u00a0Ribas\u00a0A,\u00a0O'Day\u00a0SJ,\u00a0Sosman\u00a0JA,\u00a0Kirkwood \u00a0JM,\u00a0Eggermont \u00a0AM,\u00a0Dreno\u00a0\nB,\u00a0Nolop\u00a0K,\u00a0Li\u00a0J,\u00a0Nelson\u00a0B,\u00a0Hou\u00a0J,\u00a0Lee\u00a0RJ,\u00a0Flaherty\u00a0KT,\u00a0McArthur \u00a0GA;\u00a0BRIM\u20103\u00a0Study\u00a0Group\u00a0(2011):\u00a0Improved \u00a0survival\u00a0\nwith\u00a0vemurafenib \u00a0in\u00a0melanoma \u00a0with\u00a0BRAF\u00a0V600E\u00a0mutation. \u00a0N\u00a0Engl\u00a0J\u00a0Med.\u00a0364\u00a0(26):\u00a02507\u201016.\u00a0\n32. Chen\u00a0E,\u00a0Looman\u00a0M,\u00a0Laouri\u00a0M,\u00a0Gallagher \u00a0M,\u00a0Van\u00a0Nuys\u00a0K,\u00a0Lakdawalla \u00a0D,\u00a0Fortuny\u00a0J\u00a0(2010).\u00a0Burden\u00a0of\u00a0illness\u00a0of\u00a0\ndiabetic\u00a0macular\u00a0edema:\u00a0literature \u00a0review.\u00a0Curr\u00a0Med\u00a0Res\u00a0Opin.\u00a026(7):1587 \u201097.\u00a0\u00a0\n33. Chlebowski \u00a0RT,\u00a0Anderson \u00a0GL,\u00a0Gass\u00a0M,\u00a0Lane\u00a0DS,\u00a0Aragaki\u00a0AK,\u00a0Kuller\u00a0LH,\u00a0Manson\u00a0JE,\u00a0Stefanick\u00a0ML,\u00a0Ockene\u00a0J,\u00a0Sarto\u00a0\nGE,\u00a0Johnson\u00a0KC,\u00a0Wactawski \u2010Wende\u00a0J,\u00a0Ravdin\u00a0PM,\u00a0Schenken \u00a0R,\u00a0Hendrix\u00a0SL,\u00a0Rajkovic\u00a0A,\u00a0Rohan\u00a0TE,\u00a0Yasmeen\u00a0S,\u00a0\nPrentice\u00a0RL;\u00a0WHI\u00a0Investigators \u00a0(2010).\u00a0Estrogen\u00a0plus\u00a0progestin \u00a0and\u00a0breast\u00a0cancer\u00a0incidence \u00a0and\u00a0mortality\u00a0in\u00a0\npostmenopausal \u00a0women.\u00a0JAMA.\u00a0304\u00a0(15):\u00a01684\u201092.\u00a0\n34. Cohen\u00a0CJ,\u00a0Andrade\u2010Villanueva \u00a0J,\u00a0Clotet\u00a0B,\u00a0Fourie\u00a0J,\u00a0Johnson\u00a0MA,\u00a0Ruxrungtham \u00a0K,\u00a0Wu\u00a0H,\u00a0Zorrilla\u00a0C,\u00a0Crauwels\u00a0H,\u00a0\nRimsky\u00a0LT,\u00a0Vanveggel \u00a0S,\u00a0Boven\u00a0K;\u00a0THRIVE\u00a0study\u00a0group\u00a0(2011).\u00a0Rilpivirine \u00a0versus\u00a0efavirenz\u00a0with\u00a0two\u00a0background \u00a0\nnucleoside \u00a0or\u00a0nucleotide \u00a0reverse\u00a0transcriptase \u00a0inhibitors \u00a0in\u00a0treatment \u2010naive\u00a0adults\u00a0infected\u00a0with\u00a0HIV\u20101\u00a0(THRIVE): \u00a0a\u00a0\nphase\u00a03,\u00a0randomised, \u00a0non\u2010inferiority \u00a0trial.\u00a0Lancet.\u00a0378\u00a0(9787):\u00a0229\u201037.\u00a0\n35. Cohen\u00a0C,\u00a0Wohl\u00a0D,\u00a0Arribas\u00a0JR,\u00a0Henry\u00a0K,\u00a0Van\u00a0Lunzen\u00a0J,\u00a0Bloch\u00a0M,\u00a0Towner\u00a0W,\u00a0Wilkins\u00a0E,\u00a0Ebrahimi\u00a0R,\u00a0Porter\u00a0D,\u00a0White\u00a0K,\u00a0\nWalker\u00a0I,\u00a0Chuck\u00a0S,\u00a0De\u2010Oertel\u00a0S,\u00a0Fralich\u00a0T\u00a0(2014).\u00a0Week\u00a048\u00a0results\u00a0from\u00a0a\u00a0randomized \u00a0clinical\u00a0trial\u00a0of\u00a0\nrilpivirine/emtricitabine/tenofovir \u00a0disoproxil \u00a0fumarate \u00a0vs.\u00a0efavirenz/emtricitabine/tenofovir \u00a0disoproxil \u00a0fumarate \u00a0\nin\u00a0treatment \u2010na\u00efve\u00a0HIV\u20101\u2010infected\u00a0adults.\u00a0AIDS.\u00a028\u00a0(7):\u00a0989\u201097.\u00a0\n36. Colao\u00a0A,\u00a0Petersenn \u00a0S,\u00a0Newell\u2010Price\u00a0J,\u00a0Findling\u00a0JW,\u00a0Gu\u00a0F,\u00a0Maldonado \u00a0M,\u00a0Schoenherr \u00a0U,\u00a0Mills\u00a0D,\u00a0Salgado\u00a0LR,\u00a0Biller\u00a0\nBM;\u00a0Pasireotide \u00a0B2305\u00a0Study\u00a0Group\u00a0(2012).\u00a0A\u00a012\u2010month\u00a0phase\u00a03\u00a0study\u00a0of\u00a0pasireotide \u00a0in\u00a0Cushing's \u00a0disease.\u00a0N\u00a0Engl\u00a0J\u00a0\nMed.\u00a0366(10):\u00a0914\u201024.\u00a0\n37. Colao\u00a0A,\u00a0Bronstein \u00a0MD,\u00a0Freda\u00a0P,\u00a0Gu\u00a0F,\u00a0Shen\u00a0CC,\u00a0Gadelha\u00a0M,\u00a0Fleseriu\u00a0M,\u00a0van\u00a0der\u00a0Lely\u00a0AJ,\u00a0Farrall\u00a0AJ,\u00a0Hermosillo \u00a0\nRes\u00e9ndiz\u00a0K,\u00a0Ruffin\u00a0M,\u00a0Chen\u00a0Y,\u00a0Sheppard \u00a0M;\u00a0Pasireotide \u00a0C2305\u00a0Study\u00a0Group\u00a0(2014).\u00a0Pasireotide \u00a0versus\u00a0octreotide \u00a0\nin\u00a0acromegaly: \u00a0a\u00a0head\u2010to\u2010head\u00a0superiority \u00a0study.\u00a0J\u00a0Clin\u00a0Endocrinol \u00a0Metab.\u00a099\u00a0(3):\u00a0791\u20109.\u00a0\n38. Collaborative \u00a0Group\u00a0On\u00a0Epidemiological \u00a0Studies\u00a0Of\u00a0Ovarian\u00a0Cancer,\u00a0Beral\u00a0V,\u00a0Gaitskell\u00a0K,\u00a0Hermon\u00a0C,\u00a0Moser\u00a0K,\u00a0\nReeves\u00a0G,\u00a0Peto\u00a0R\u00a0(2015).\u00a0Menopausal \u00a0hormone\u00a0use\u00a0and\u00a0ovarian\u00a0cancer\u00a0risk:\u00a0individual \u00a0participant \u00a0meta\u2010analysis\u00a0\nof\u00a052\u00a0epidemiological \u00a0studies.\u00a0Lancet.\u00a0385\u00a0(9980):\u00a01835\u201042.\u00a0\n39. Collette\u00a0J,\u00a0Viethel\u00a0P,\u00a0Dethor\u00a0M,\u00a0Chevallier \u00a0T,\u00a0Micheletti \u00a0MC,\u00a0Foidart\u00a0JM,\u00a0Reginster \u00a0JY\u00a0(2003).\u00a0[Comparison \u00a0of\u00a0\nchanges\u00a0in\u00a0biochemical \u00a0markers\u00a0of\u00a0bone\u00a0turnover\u00a0after\u00a06\u00a0months\u00a0of\u00a0hormone \u00a0replacement \u00a0therapy\u00a0with\u00a0either\u00a0\ntransdermal \u00a017\u00a0beta\u2010estradiol\u00a0or\u00a0equine\u00a0conjugated \u00a0estrogen\u00a0plus\u00a0nomegestrol \u00a0acetate].\u00a0Gynecol\u00a0Obstet\u00a0Fertil.\u00a0\n31:\u00a0434\u2010441.\u00a0\u00a0\n40. Corey\u00a0GR,\u00a0Wilcox\u00a0M,\u00a0Talbot\u00a0GH,\u00a0Friedland \u00a0HD,\u00a0Baculik\u00a0T,\u00a0Witherell \u00a0GW,\u00a0Critchley\u00a0I,\u00a0Das\u00a0AF,\u00a0Thye\u00a0D\u00a0(2010).\u00a0\nIntegrated \u00a0analysis\u00a0of\u00a0CANVAS\u00a01\u00a0and\u00a02:\u00a0phase\u00a03,\u00a0multicenter, \u00a0randomized, \u00a0double\u2010blind\u00a0studies\u00a0to\u00a0evaluate\u00a0the\u00a0\nsafety\u00a0and\u00a0efficacy\u00a0of\u00a0ceftaroline \u00a0versus\u00a0vancomycin \u00a0plus\u00a0aztreonam \u00a0in\u00a0complicated \u00a0skin\u00a0and\u00a0skin\u2010structure\u00a0\ninfection. \u00a0Clin\u00a0Infect\u00a0Dis.\u00a051:\u00a0641\u2010650.\u00a0\u00a0\n41. Corrado\u00a0ML\u00a0(2010).\u00a0Integrated \u00a0safety\u00a0summary \u00a0of\u00a0CANVAS\u00a01\u00a0and\u00a02\u00a0trials:\u00a0Phase\u00a0III,\u00a0randomized, \u00a0double\u2010blind\u00a0\nstudies\u00a0evaluating \u00a0ceftaroline \u00a0fosamil\u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0patients\u00a0with\u00a0complicated \u00a0skin\u00a0and\u00a0skin\u00a0structure\u00a0\ninfections. \u00a0J\u00a0Antimicrob \u00a0Chemother. \u00a065\u00a0Suppl\u00a04:\u00a0iv67\u2010iv71.\u00a0\n42. CTI\u00a0Life\u00a0Sciences\u00a0Ltd.\u00a0(2014).\u00a0Fachinformation \u00a0Pixuvri\u00ae\u00a029\u00a0mg\u00a0Pulver\u00a0f\u00fcr\u00a0ein\u00a0Konzentrat \u00a0zur\u00a0Herstellung \u00a0einer\u00a0\nInfusionsl\u00f6sung. \u00a0Stand\u00a0der\u00a0Information: \u00a0M\u00e4rz\u00a02014.\u00a0\n43. DAIG\u00a0(2015).\u00a0Deutsche \u00a0AIDS\u2010Gesellschaft \u00a0e.V.\u00a0und\u00a0\u00d6sterreichische \u00a0AIDS\u00a0Gesellschaft. \u00a0Deutsch\u2010\u00d6sterreichische \u00a0\nLeitlinie\u00a0zur\u00a0antiretroviralen \u00a0Therapie\u00a0der\u00a0HIV\u2010Infektion. \u00a0AWMF\u2010Register\u2010Nr.:\u00a0055\u2010001.\u00a0Version\u00a01.0.\u00a0Stand\u00a0der\u00a0\nInformation: \u00a013.05.2014. \u00a0\u00a0\n44. Dalhoff\u00a0K,\u00a0Abele\u2010Horn\u00a0M,\u00a0Andreas\u00a0S,\u00a0Bauer\u00a0T,\u00a0von\u00a0Baum\u00a0H,\u00a0Deja\u00a0M,\u00a0Ewig\u00a0S,\u00a0Gastmeier \u00a0R,\u00a0Gatermann \u00a0S,\u00a0Gerlach\u00a0H,\u00a0\nGrabein\u00a0B,\u00a0H\u00f6ffken\u00a0G,\u00a0Kern\u00a0WV,\u00a0Kramme\u00a0E,\u00a0Lange\u00a0C,\u00a0Lorenz\u00a0J,\u00a0Mayer\u00a0K,\u00a0Nachtigall \u00a0I,\u00a0Pletz\u00a0M,\u00a0Rohde\u00a0G,\u00a0Rossenau \u00a0S,\u00a0 \n249\u00a0Schaaf\u00a0B,\u00a0Schaumann \u00a0R,\u00a0Schreiter\u00a0D,\u00a0Sch\u00fctte\u00a0H,\u00a0Seifert\u00a0H,\u00a0Sitter\u00a0H,\u00a0Spies\u00a0C,\u00a0Welte\u00a0T\u00a0(2012).\u00a0S3\u2010Leitlinie\u00a0\nEpidemiologie, \u00a0Diagnostik \u00a0und\u00a0Therapie\u00a0erwachsener \u00a0Patienten \u00a0mit\u00a0nosokomialer \u00a0Pneumonie. \u00a0S\u20103\u00a0Leitlinie\u00a0der\u00a0\nDeutschen \u00a0Gesellschaft \u00a0f\u00fcr\u00a0An\u00e4sthesiologie \u00a0und\u00a0Intensivmedizin \u00a0e.V.,\u00a0der\u00a0Deutschen \u00a0Gesellschaft \u00a0f\u00fcr\u00a0Infektiologie \u00a0\ne.V.,\u00a0der\u00a0Deutschen \u00a0Gesellschaft \u00a0f\u00fcr\u00a0Hygiene\u00a0und\u00a0Mikrobiologie \u00a0e.V.,\u00a0der\u00a0Deutschen \u00a0Gesellschaft \u00a0f\u00fcr\u00a0Pneumologie \u00a0\nund\u00a0Beatmungsmedizin \u00a0e.V.\u00a0und\u00a0der\u00a0Paul\u2010Ehrlich\u00a0Gesellschaft \u00a0f\u00fcr\u00a0Chemotherapie \u00a0e.V.;\u00a0AWMF\u2010Registernummer \u00a0\n020/013,\u00a0www.awmf.org. \u00a0Letzter\u00a0Zugriff\u00a017.03.2015. \u00a0\n45. Davies\u00a0JC,\u00a0Wainwright \u00a0CE,\u00a0Canny\u00a0GJ,\u00a0Chilvers\u00a0MA,\u00a0Howenstine \u00a0MS,\u00a0Munck\u00a0A,\u00a0Mainz\u00a0JG,\u00a0Rodriguez \u00a0S,\u00a0Li\u00a0H,\u00a0Yen\u00a0K,\u00a0\nOrdo\u00f1ez\u00a0CL,\u00a0Ahrens\u00a0R;\u00a0VX08\u2010770\u2010103\u00a0(ENVISION) \u00a0Study\u00a0Group\u00a0(2013).\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0ivacaftor\u00a0in\u00a0patients\u00a0\naged\u00a06\u00a0to\u00a011\u00a0years\u00a0with\u00a0cystic\u00a0fibrosis\u00a0with\u00a0a\u00a0G551D\u00a0mutation. \u00a0Am\u00a0J\u00a0Respir\u00a0Crit\u00a0Care\u00a0Med.\u00a0187:\u00a01219\u20101225.\u00a0\u00a0\n46. De\u00a0Boeck\u00a0K,\u00a0Munck\u00a0A,\u00a0Walker\u00a0S,\u00a0Faro\u00a0A,\u00a0Hiatt\u00a0P,\u00a0Gilmartin \u00a0G,\u00a0Higgins\u00a0M\u00a0(2014).\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0ivacaftor\u00a0in\u00a0\npatients\u00a0with\u00a0cystic\u00a0fibrosis\u00a0and\u00a0a\u00a0non\u2010G551D\u00a0gating\u00a0mutation. \u00a0J\u00a0Cyst\u00a0Fibros.\u00a013:\u00a0674\u2010680.\u00a0\u00a0\n47. Del\u00a0Prato\u00a0S,\u00a0Nauck\u00a0M,\u00a0Dur\u00e1n\u2010Garcia\u00a0S,\u00a0Maffei\u00a0L,\u00a0Rohwedder \u00a0K,\u00a0Theuerkauf \u00a0A,\u00a0Parikh\u00a0S\u00a0(2015).\u00a0Long\u2010term\u00a0glycaemic \u00a0\nresponse\u00a0and\u00a0tolerability \u00a0of\u00a0dapagliflozin \u00a0versus\u00a0a\u00a0sulphonylurea \u00a0as\u00a0add\u2010on\u00a0therapy\u00a0to\u00a0metformin \u00a0in\u00a0type\u00a02\u00a0\ndiabetes\u00a0patients:\u00a04\u2010year\u00a0data.\u00a0Diabetes\u00a0Obes\u00a0Metab.\u00a017\u00a0(6):\u00a0581\u2013590. \u00a0\n48. Deutsche \u00a0Hochdruckliga \u00a0e.V.\u00a0(2013).\u00a0ESC\u00a0Pocket\u00a0Guidelines. \u00a0Leitlinien\u00a0f\u00fcr\u00a0das\u00a0Management \u00a0der\u00a0arteriellen \u00a0\nHypertonie. \u00a0 http://www.hochdruckliga.de/tl_file s/content/dhl/downloads/2014_Pocket \u2010\nLeitlinien_Arterielle_Hypertonie.pdf, \u00a0letzter\u00a0Zugriff\u00a023.06.2015. \u00a0\n49. Deutsches \u00a0Akromegalie \u2010Register\u00a0(2015).\u00a0http://www.akromegalie \u2010register.de/wDeutsch/akromegalie/therapiemo \u00a0\neglichkeiten/medikamentoese _therapie.php?navanchor=1110021. \u00a0Letzter\u00a0Zugriff:\u00a030.05.2015. \u00a0\n50. DGGG\u00a0\u2013\u00a0Deutsche \u00a0Gesellschaft \u00a0f\u00fcr\u00a0Gyn\u00e4kologie \u00a0und\u00a0Geburtshilfe \u00a0(2010).\u00a0Empf\u00e4ngnisverh\u00fctung: \u00a0Familienplanung \u00a0\nin\u00a0Deutschland. \u00a0Stand\u00a0September \u00a02010,\u00a0ehemals\u00a0S1\u2010Leitlinie;\u00a0AWMF\u00a0015/015;\u00a0seit\u00a001.09.2010 \u00a0eingestuft \u00a0als\u00a0\n\u201cSonstiger \u00a0Text\u201c\u00a0der\u00a0DGGG.\u00a0\n51. DGGG\u00a0\u2013\u00a0Deutsche \u00a0Gesellschaft \u00a0f\u00fcr\u00a0Gyn\u00e4kologie \u00a0und\u00a0Geburtshilfe \u00a0(2009).\u00a0Hormontherapie \u00a0in\u00a0der\u00a0Peri\u2010\u00a0und\u00a0\nPostmenopause \u00a0(HAT).\u00a0AWMF\u00a0Register\u00a0N5.\u00a0015/062.\u00a0Entwicklungsstufe \u00a03\u00a0+\u00a0IDA.\u00a0Stand\u00a02009;\u00a0G\u00fcltig\u00a0bis\u00a0\n01.09.2014; \u00a0http://www.awmf.org/l eitlinien/detail/ll/015 \u2010062.html. \u00a0Letzter\u00a0Zugriff\u00a013.04.2015. \u00a0\n52. DGHO\u00a0\u2013\u00a0Deutsche \u00a0Gesellschaft \u00a0f\u00fcr\u00a0H\u00e4matologie \u00a0und\u00a0Medizinische \u00a0Onkologie \u00a0(2012).\u00a0onkopedia: \u00a0Leitlinie\u00a0Hodgkin\u2010\nLymphome. \u00a0 https://www.onkopedia.com/de/o nkopedia/guidelines/hodgkin \u2010\nlymphome/@@view/html/index.html. \u00a0Stand\u00a0der\u00a0Information: \u00a0Juli\u00a02012.\u00a0Letzter\u00a0Zugriff:\u00a023.07.2015. \u00a0\n53. DGHO\u00a0\u2013\u00a0Deutsche \u00a0Gesellschaft \u00a0f\u00fcr\u00a0H\u00e4matologie \u00a0und\u00a0Medizinische \u00a0Onkologie \u00a0(2013a).\u00a0onkopedia: \u00a0Leitlinie\u00a0Nieren\u2010\nzellkarzinom \u00a0(Hypernephrom). \u00a0https://www.onkopedia.com/de/onkoped ia/guidelines/nierenzellkarzinom \u2010\nhypernephrom/@@view/html/index.html. \u00a0Stand\u00a0der\u00a0Information: \u00a0Februar\u00a02013.\u00a0Letzter\u00a0Zugriff:\u00a020.02.2015. \u00a0\n54. DGHO\u00a0\u2013\u00a0Deutsche \u00a0Gesellschaft \u00a0f\u00fcr\u00a0H\u00e4matologie \u00a0und\u00a0Medizinische \u00a0Onkologie \u00a0(2013b).\u00a0Fr\u00fche\u00a0Nutzenbewertung. \u00a0\nStellungnahme \u00a0Decitabin \u00a0http://www.dgho.de/informationen/stellung \u00a0nahmen/fruehe \u2010nutzenbewertung. \u00a0Letzter\u00a0\nZugriff:\u00a001.05.2015. \u00a0\n55. DGHO\u00a0\u2013\u00a0Deutsche \u00a0Gesellschaft \u00a0f\u00fcr\u00a0H\u00e4matologie \u00a0und\u00a0Medizinische \u00a0Onkologie \u00a0(2014a):\u00a0onkopedia: \u00a0Leitlinie\u00a0Diffuses\u00a0\ngro\u00dfzelliges \u00a0B\u2010Zell\u2010Lymphom. \u00a0https://www.onkopedia.com/de/o nkopedia/guidelines/diffuses \u2010grosszelliges \u2010b\u2010zell\u2010\nlymphom/@@view/html/index.html. \u00a0Stand\u00a0der\u00a0Information: \u00a0November \u00a02014.\u00a0Letzter\u00a0Zugriff:\u00a024.07.2015. \u00a0\n56. DGHO\u00a0\u2013\u00a0Deutsche \u00a0Gesellschaft \u00a0f\u00fcr\u00a0H\u00e4matologie \u00a0und\u00a0Medizinische \u00a0Onkologie \u00a0(2015).\u00a0onkopedia: \u00a0Leitlinie\u00a0\nLungenkarzinom, \u00a0 nicht\u2010kleinzellig \u00a0 (NSCLC).\u00a0\nhttps://www.onkopedia.com/de/onk opedia/guidelines/lungenkarzinom \u2010nicht\u2010kleinzellig \u2010\nnsclc/@@view/html/index.html. \u00a0Stand\u00a0der\u00a0Information: \u00a0April\u00a02015.\u00a0Letzter\u00a0Zugriff:\u00a023.07.2015. \u00a0\n57. DGHO\u00a0\u2013\u00a0Deutsche \u00a0Gesellschaft \u00a0f\u00fcr\u00a0H\u00e4matologie \u00a0und\u00a0Medizinische \u00a0Onkologie \u00a0(2014).\u00a0Prim\u00e4re\u00a0Myelofibrose. \u00a0Stand\u00a0\nder\u00a0Information: \u00a0Juni\u00a02014.\u00a0\u00a0\n250\u00a058. DGKJ\u00a0\u2013\u00a0Deutsche \u00a0Gesellschaft \u00a0f\u00fcr\u00a0Kinderheilkunde \u00a0und\u00a0Jugendmedizin \u00a0(2010).\u00a0Cushing\u2010Syndrom. \u00a0\nhttp://www.awmf.org/upl oads/tx_szleitlinien/027 \u2010033_S1_Cushing \u2010Syndrom_2010_abgelaufen.pdf. \u00a0Stand\u00a0der\u00a0\nInformation: \u00a001.01.2010 \u00a0\u2013\u00a0derzeit\u00a0in\u00a0\u00dcberarbeitung. \u00a0Letzter\u00a0Zugriff:\u00a024.07.2015. \u00a0\n59. DGN\u00a0\u2013\u00a0Deutsche \u00a0Gesellschaft \u00a0f\u00fcr\u00a0Neurologie \u00a0(2012).\u00a0Erster\u00a0epileptischer \u00a0Anfall\u00a0und\u00a0Epilepsien \u00a0im\u00a0\nErwachsenenalter. \u00a0 http://www.awmf.org/upl oads/tx_szleitlinien/030 \u2010\n041l_S1_Erster_epileptischer_Anfall_ und_Epilepsien_im_Erw achsenenalter_2013 \u201008_1.pdf. \u00a0 Stand\u00a0 der\u00a0\nInformation: \u00a0September \u00a02012.\u00a0Letzter\u00a0Zugriff:\u00a024.07.2015. \u00a0\n60. DGN\u00a0\u2013\u00a0Deutsche \u00a0Gesellschaft \u00a0f\u00fcr\u00a0Neurologie \u00a0(2014).\u00a0Diagnose\u00a0und\u00a0Therapie\u00a0der\u00a0Multiplen \u00a0Sklerose.\u00a0\nhttp://www.awmf.org/upl oads/tx_szleitlinien/030 \u2010050l_S2e_Multiple_Sklerose _Diagnostik_Therapie_2014 \u2010\n08.pdf.\u00a0Stand\u00a0der\u00a0Information: \u00a02012,\u00a0Erg\u00e4nzung \u00a02014.\u00a0Letzter\u00a0Zugriff:\u00a031.05.2015. \u00a0\n61. DGVS\u00a0\u2013\u00a0Deutsche \u00a0Gesellschaft \u00a0f\u00fcr\u00a0H\u00e4matologie \u00a0und\u00a0Medizinische \u00a0Onkologie \u00a0(2012).\u00a0Magenkarzinom \u00a0\u201eDiagnostik \u00a0\nund\u00a0Therapie\u00a0der\u00a0Adenokarzinome \u00a0des\u00a0Magens\u00a0und\u00a0\u00f6sophagogastralen \u00a0\u00dcbergangs\u201c. \u00a0Langversion. \u00a0\nhttp://www.awmf.org/upl oads/tx_szleitlinien/032 \u2010\n009l_S3_Magenkarzinon_Diagnostik_T herapie_Adenokarzinome_Magen_%C3 %B6sophagogastralen_%C3%9Cber\ngang_2012 \u201002_01.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a0Februar\u00a02012.\u00a0G\u00fcltigkeit \u00a0der\u00a0Leitlinie\u00a0nach\u00a0Pr\u00fcfung\u00a0durch\u00a0das\u00a0\nLeitliniensekretariat \u00a0bis\u00a0zum\u00a031.12.2015 \u00a0verl\u00e4ngert. \u00a0Letzter\u00a0Zugriff:\u00a024.07.2015. \u00a0\n62. Di\u00a0Carlo\u00a0C,\u00a0Sammartino \u00a0A,\u00a0Di\u00a0Spiezio\u00a0Sardo\u00a0A,\u00a0Tommaselli \u00a0GA,\u00a0Guida\u00a0M,\u00a0Mandato\u00a0VD,\u00a0D'Elia\u00a0A,\u00a0Nappi\u00a0C\u00a0(2005).\u00a0\nBleeding\u00a0patterns\u00a0during\u00a0continuous \u00a0estradiol\u00a0with\u00a0\u00a0different\u00a0sequential \u00a0progestogens \u00a0therapy.\u00a0Menopause. \u00a012:\u00a0\n520\u2010525.\u00a0\u00a0\n63. Dietzel\u00a0M,\u00a0Farwick\u00a0A,\u00a0Hense\u00a0HW\u00a0(2010).\u00a0[Genetic\u00a0and\u00a0risk\u00a0factors\u00a0for\u00a0exudative \u00a0AMD].\u00a0Ophthalmologe. \u00a0107(12):\u00a0\n1103\u20108.\u00a0\u00a0\n64. DKG\u00a0\u2013\u00a0Deutsche \u00a0Krebsgesellschaft \u00a0e.V.\u00a0(2013):\u00a0Leitlinienprogramm \u00a0Onkologie \u00a0der\u00a0AWMF,\u00a0Deutschen \u00a0\nKrebsgesellschaft \u00a0e.V.\u00a0und\u00a0Deutschen \u00a0Krebshilfe \u00a0e.V.\u00a0\u2013Malignes \u00a0Melanom. \u00a0S3\u2010Leitlinie\u00a0\u201eDiagnostik, \u00a0Therapie\u00a0und\u00a0\nNachsorge \u00a0 des\u00a0 Melanoms\u201c. \u00a0 http://www.awmf.org/uploads/tx_szleitlinien/032 \u2010\n024l_S3_Melanom_Diagnostik _Therapie_Nachsorge_2013 \u201002.pdf.\u00a0Stand\u00a0der\u00a0Information: \u00a0Februar\u00a02013.\u00a0Letzter\u00a0\nZugriff:\u00a025.07.2015. \u00a0\n65. DOG\u00a0\u2013\u00a0Deutsche \u00a0Ophthalmologische \u00a0Gesellschaft \u00a0(2010)\u00a0Stellungnahme \u00a0der\u00a0Deutschen \u00a0Ophthalmologischen \u00a0\nGesellschaft, \u00a0der\u00a0Retinologischen \u00a0Gesellschaft \u00a0und\u00a0des\u00a0Berufsverbandes \u00a0der\u00a0Augen\u00e4rzte \u00a0Deutschlands \u00a0Therapie\u00a0\nder\u00a0diabetischen \u00a0Makulopathie. \u00a0http://www.dog.org/wp \u2010content/uploads/2009/09/Stellungnahme \u2010zur\u2010Therapie\u2010\nder\u2010diabetischen \u2010Makulopathie \u20104.pdf.\u00a0Stand\u00a0der\u00a0Information: \u00a0Dezember \u00a02010.\u00a0Letzter\u00a0Zugriff:\u00a015.05.2015. \u00a0\n66. DOG\u00a0\u2013\u00a0Deutsche \u00a0Ophthalmologische \u00a0Gesellschaft \u00a0(2013)\u00a0Stellungnahme \u00a0der\u00a0Deutschen \u00a0Ophthalmologischen \u00a0\nGesellschaft, \u00a0der\u00a0Retinologischen \u00a0Gesellschaft \u00a0und\u00a0des\u00a0Berufsverbandes \u00a0der\u00a0Augen\u00e4rzte \u00a0Deutschlands \u00a0Therapie\u00a0\nder\u00a0 diabetischen \u00a0 Makulopathie. \u00a0\nhttp://cms.augeninfo.de/fileadmin/stellungnahmen/Ste llungnahme_zur_Therapie_der_diabetischen_Makulopat\nhie_5.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a0April\u00a02013.\u00a0Letzter\u00a0Zugriff:\u00a015.05.2015. \u00a0\n67. DOG\u00a0\u2013\u00a0Deutsche \u00a0Ophthalmologische \u00a0Gesellschaft \u00a0(2014)\u00a0Aktuelle\u00a0Stellungnahme \u00a0der\u00a0Retinologischen \u00a0\nGesellschaft, \u00a0der\u00a0Deutschen \u00a0Ophthalmologischen \u00a0Gesellschaft \u00a0und\u00a0des\u00a0Berufsverbandes \u00a0der\u00a0Augen\u00e4rzte \u00a0\nDeutschlands \u00a0e.V.\u00a0Die\u00a0Anti\u2010VEGF\u2010Therapie\u00a0bei\u00a0der\u00a0neovaskul\u00e4ren \u00a0altersabh\u00e4ngigen \u00a0Makuladegeneration: \u00a0\nTherapeutische \u00a0 Strategien. \u00a0 http://cms.augeninfo.de/fileadmin/stellungnahmen/Anti \u2010VEGF\u2010\nTherapie_bei_der_neovask_T herapeut_Strategie.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a0November \u00a02014.\u00a0Letzter\u00a0Zugriff:\u00a0\n15.05.2015. \u00a0\n68. Donohue\u00a0JF\u00a0(2005).\u00a0Minimal\u00a0clinically\u00a0important \u00a0differences \u00a0in\u00a0COPD\u00a0lung\u00a0function.\u00a0COPD.\u00a02(1):\u00a0111\u201024.\u00a0\n69. Dtbn\u00a0(2014)\u00a0Drug\u00a0Assessment \u00a0Report\u00a0Dapagliflozin. \u00a0Drug\u00a0therapeutic \u00a0bulletin\u00a0Navarra\u00a005/2014.\u00a0www.navarra.es. \u00a0\nLetzter\u00a0Zugriff:\u00a028.03.2015. \u00a0 \n251\u00a070. Eisai\u00a0(2013).\u00a0Presseportal \u00a0\u2013\u00a0Eisai\u00a0setzt\u00a0vor\u00fcbergehend \u00a0den\u00a0Vertrieb\u00a0des\u00a0innovativen \u00a0Antiepileptikums \u00a0Fycompa\u00ae \u00a0\n(Perampanel) \u00a0 in\u00a0 Deutschland \u00a0 aus.\u00a0 Stand\u00a0 der\u00a0 Information: \u00a0 25.06.2013. \u00a0\nhttp://www.presseportal.de/pm/64962/2500257, \u00a0letzter\u00a0Zugriff:\u00a030.05.2015. \u00a0\n71. Eisai\u00a0(2014).\u00a0Fachinformation \u00a0Fycompa\u00ae \u00a0Filmtabletten. \u00a0Stand\u00a0der\u00a0Information: \u00a0September \u00a02014.\u00a0\n72. Ellis\u00a0LM,\u00a0Bernstein \u00a0DS,\u00a0Voest\u00a0EE,\u00a0Berlin\u00a0JD,\u00a0Sargent\u00a0D,\u00a0Cortazar\u00a0P,\u00a0Garrett\u2010Mayer\u00a0E,\u00a0Herbst\u00a0RS,\u00a0Lilenbaum \u00a0RC,\u00a0Sima\u00a0\nC,\u00a0Venook\u00a0AP,\u00a0Gonen\u00a0M,\u00a0Schilsky\u00a0RL,\u00a0Meropol\u00a0NJ,\u00a0Schnipper \u00a0LE.\u00a0American \u00a0Society\u00a0of\u00a0Clinical\u00a0Oncology \u00a0perspective: \u00a0\u00a0\nRaising\u00a0the\u00a0bar\u00a0for\u00a0clinical\u00a0trials\u00a0by\u00a0defining\u00a0clinically\u00a0meaningful \u00a0outcomes. \u00a0J\u00a0Clin\u00a0Oncol.\u00a02014\u00a0Apr\u00a020;32(12):1277 \u2010\n80.\u00a0\n73. EMA\u00a0\u2013\u00a0European \u00a0Medicines \u00a0Agency\u00a0(2010).\u00a0CHMP\u00a0Assessment \u00a0Report\u00a0for\u00a0Teysuno\u00a0(tegafur/gimeracil/oteracil). \u00a0\nEMA/CHMP/831565/2010. \u00a0 http://www.ema.europa.eu/docs /en_GB/document_library/EPAR_ \u2010\n_Public_assessment_report/human/001242/WC500104417.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a016.12.2010. \u00a0Letzter\u00a0\nZugriff:\u00a024.07.2015. \u00a0\n74. EMA\u00a0\u2013\u00a0European \u00a0Medicines \u00a0Agency\u00a0(2011).CHMP \u00a0Assessment \u00a0report\u00a0for\u00a0Zoely.\u00a0International \u00a0nonproprietary \u00a0\nName:\u00a0nomegestrol/estradiol. \u00a0Procedure \u00a0No.\u00a0EMEA/H/C/001213. \u00a0Doc.Nr.:\u00a0EMA/CHMP/906891/2011. \u00a0\nhttp://www.ema.europa.eu/docs /en_GB/document_library/EPAR_ \u2010\n_Public_assessment_report/human/001213/WC500115833.pdf. \u00a0Letzter\u00a0Zugriff:\u00a031.05.2015. \u00a0\n75. EMA\u00a0\u2010\u00a0European \u00a0Medicines \u00a0Agency\u00a0(2011a).\u00a0CHMP\u00a0Assessment \u00a0report\u00a0for\u00a0Caprelsa.\u00a0International \u00a0nonproprietary \u00a0\nName:\u00a0 Vandetanib. \u00a0 Procedure \u00a0 No.\u00a0 EMEA/H/C/002315//0000. \u00a0 EMA/128076/2012. \u00a0\u00a0\nhttp://www.ema.europa.eu/docs /en_GB/document_library/EPAR_ \u2010\n_Public_assessment_report/human/002315/WC500123603.pdf. \u00a0Stand\u00a0der\u00a0Inforamtion: \u00a017.11.2011. \u00a0Letzter\u00a0\nZugriff:\u00a024.07.2015. \u00a0\n76. EMA\u00a0\u2013\u00a0European \u00a0Medicines \u00a0Agency\u00a0(2012a).\u00a0Zusammenfassung \u00a0der\u00a0Merkmale \u00a0des\u00a0Arzneimittels \u00a0Adcetris\u00ae. \u00a0Stand\u00a0\nder\u00a0 Information: \u00a0 16.01.2015. \u00a0 http://www.ema.europa.eu/docs /en_GB/document_library/EPAR_ \u2010\n_Product_Information/human/002455/WC500135055.pdf. \u00a0Letzter\u00a0Zugriff:\u00a031.05.2015. \u00a0\n77. EMA\u00a0\u2013\u00a0European \u00a0Medicine \u00a0Agency\u00a0(2012b).\u00a0Committee \u00a0for\u00a0Medicinal \u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(CHMP)\u00a0\nAssessment \u00a0report\u00a0Zinforo\u00a0ceftaroline \u00a0fosamil\u00a0Procedure \u00a0No.:\u00a0EMEA/H/C/002252. \u00a0Stand\u00a0der\u00a0Information: \u00a021.\u00a0Juni\u00a0\n2012.\u00a0 EMA/472628/2012. \u00a0 http://www.ema.europa.eu/docs /en_GB/document_library/EPAR_ \u2010\n_Public_assessment_report/human/002252/WC500132587.pdf. \u00a0Letzter\u00a0Zugriff:\u00a031.05.2015. \u00a0\n78. EMA\u00a0\u2013\u00a0European \u00a0Medicines \u00a0Agency\u00a0(2012c).\u00a0Committee \u00a0for\u00a0Medicinal \u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(CHMP)\u00a0\nAssessment \u00a0report:\u00a0Forxiga\u00a0dapagliflozin \u00a0Procedure \u00a0No.:\u00a0EMEA/H/C/002322. \u00a0EMA/689976/2012. \u00a0\nhttp://www.ema.europa.eu/docs /en_GB/document_library/EPAR_ \u2010\n_Public_assessment_report/human/002322/WC500136024.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a018\u00a0September \u00a02012.\u00a0\nLetzter\u00a0Zugriff:\u00a019.03.2015. \u00a0\n79. EMA\u00a0 \u2013\u00a0 European \u00a0 Medicines \u00a0 Agency\u00a0 (2012d).\u00a0 EPAR\u00a0 f\u00fcr\u00a0 Dacogen\u00ae. \u00a0\nhttp://www.ema.europa.eu/docs /en_GB/document_library/EPAR_ \u2010\n_Summary_for_the_public/human/002221/WC500133572.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a029.07.2014. \u00a0Letzter\u00a0\nZugriff:\u00a031.05.2015. \u00a0\n80. EMA\u00a0\u2013\u00a0European \u00a0Medicines \u00a0Agency\u00a0(2012e).\u00a0Committee \u00a0for\u00a0Medicinal \u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(CHMP)\u00a0\nAssessment \u00a0report\u00a0Kalydeco\u00a0Ivacaftor\u00a0Procedure \u00a0No.:\u00a0EMEA/H/C/002494//0000. \u00a0EMA/473279/2012. \u00a0\nhttp://www.ema.europa.eu/docs /en_GB/document_library/EPAR_ \u2010\n_Public_assessment_report/human/002494/WC500130766.pdf. \u00a0Letzter\u00a0Zugriff:\u00a028.04.2015. \u00a0\n81. EMA\u00a0\u2013\u00a0European \u00a0Medicines \u00a0Agency\u00a0(2013b).\u00a0Benefits\u00a0of\u00a0Diane\u00a035\u00a0and\u00a0its\u00a0generics\u00a0outweigh \u00a0risks\u00a0in\u00a0certain\u00a0patient\u00a0\ngroups\u00a0\u2013\u00a0PRAC\u00a0recommendation \u00a0endorsed \u00a0by\u00a0CMDh.\u00a0Stand\u00a0der\u00a0Information: \u00a030.05.2013. \u00a0\nhttp://www.ema.europa.eu/docs/en_GB/docum ent_library/Press_release/2013/05/WC500143774.pdf. \u00a0,\u00a0letzter\u00a0\nZugriff:\u00a005.06.2015. \u00a0\u00a0\n252\u00a082. EMA\u00a0\u2013\u00a0European \u00a0Medicines \u00a0Agency\u00a0(2014a).\u00a0Zusammenfassung \u00a0der\u00a0Merkmale \u00a0des\u00a0Arzneimittels \u00a0Bretaris\u00ae\u00a0\nGenuair\u00ae. \u00a0 http://www.ema.europa.eu/docs /de_DE/document_library/EPAR_ \u2010_Product_Infor \u00a0\nmation/human/002706/WC500132732.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a018.12.2014. \u00a0Letzter\u00a0Zugriff:\u00a029.12.2014. \u00a0\n83. EMA\u00a0\u2013\u00a0European \u00a0Medicines \u00a0Agency\u00a0(2014b).\u00a0Zusammenfassung \u00a0der\u00a0Merkmale \u00a0des\u00a0Arzneimittels \u00a0Inlyta\u00ae.\u00a0\nhttp://www.ema.europa.eu/docs /de_DE/document_library/EPAR_ \u2010\n_Product_Information/human/002406/WC500132188.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a014.08.2014. \u00a0Letzter\u00a0Zugriff:\u00a0\n31.05.2015. \u00a0\n84. EMA\u00a0\u2013\u00a0European \u00a0Medicines \u00a0Agency\u00a0(2014c).\u00a0Zusammenfassung \u00a0der\u00a0Merkmale \u00a0des\u00a0Arzneimittels \u00a0Xalkori\u00ae.\u00a0\nhttp://www.ema.europa.eu/docs /de_DE/document_library/EPAR_ \u2010\n_Summary_for_the_public/human/002489/WC500134762.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a0M\u00e4rz\u00a02014.\u00a0Letzter\u00a0Zugriff:\u00a0\n31.05.2015. \u00a0\n85. EMA\u00a0\u2013\u00a0European \u00a0Medicines \u00a0Agency\u00a0(2014d).\u00a0CHMP\u00a0Assessment \u00a0Report\u00a0Signifor\u00a0(Pasireotid). \u00a0\nEMA/CHMP/524716/2014.. \u00a0 http://www.ema.europa.eu/docs /en_GB/document_library/EPAR_ \u2010\n_Assessment_Report_ \u2010_Variation/human/002052/WC500179070.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a025.09.2014. \u00a0Letzter\u00a0\nZugriff:\u00a031.05.2015. \u00a0\n86. Escudero\u00a0Vilaplana\u00a0B,\u00a0Almod\u00f3var \u00a0Carret\u00f3n\u00a0MJ,\u00a0Herrero\u00a0Hern\u00e1ndez \u00a0S\u00a0(2014).\u00a0[Dapagliflozin, \u00a0a\u00a0novel\u00a0oral\u00a0\nantidiabetic \u00a0with\u00a0an\u00a0uncertain \u00a0future].\u00a0Farm\u00a0Hosp.\u00a038:\u00a0468\u2010474.\u00a0\u00a0\n87. ESH/ECH\u00a0\u2013\u00a0European \u00a0Society\u00a0of\u00a0Hypertension/European \u00a0Society\u00a0of\u00a0Cardiology \u00a0(2013).\u00a0ESH/ESC\u00a0guidelines \u00a0for\u00a0the\u00a0\nmanagement \u00a0of\u00a0arterial\u00a0hypertension: \u00a0the\u00a0Task\u00a0Force\u00a0for\u00a0the\u00a0Management \u00a0of\u00a0Arterial\u00a0Hypertension \u00a0of\u00a0the\u00a0\nEuropean \u00a0Society\u00a0of\u00a0Hypertension \u00a0(ESH)\u00a0and\u00a0of\u00a0the\u00a0European \u00a0Society\u00a0of\u00a0Cardiology \u00a0(ESC).\u00a0Eur\u00a0Heart\u00a0J.\u00a034(28):\u00a0\n2159\u2010219.\u00a0\n88. Fabbri\u00a0LM,\u00a0Rabe\u00a0KF\u00a0(2007).\u00a0From\u00a0COPD\u00a0to\u00a0chronic\u00a0systemic\u00a0inflammatory \u00a0syndrome? \u00a0Lancet.\u00a0370(9589): \u00a0797\u20109.\u00a0\n89. Fanale\u00a0MA,\u00a0Horwitz\u00a0SM,\u00a0Forero\u2010Torres\u00a0A,\u00a0Bartlett\u00a0NL,\u00a0Advani\u00a0RH,\u00a0Pro\u00a0B,\u00a0Chen\u00a0RW,\u00a0Davies\u00a0A,\u00a0Illidge\u00a0T,\u00a0Huebner\u00a0D,\u00a0\nKennedy\u00a0DA,\u00a0Shustov\u00a0AR\u00a0(2014).\u00a0Brentuximab \u00a0vedotin\u00a0in\u00a0the\u00a0front\u2010line\u00a0treatment \u00a0of\u00a0patients\u00a0with\u00a0CD30+\u00a0\nperipheral \u00a0T\u2010cell\u00a0lymphomas: \u00a0results\u00a0of\u00a0a\u00a0phase\u00a0I\u00a0study.\u00a0J\u00a0Clin\u00a0Oncol.\u00a032\u00a0(28):\u00a03137\u201043.\u00a0\n90. File\u00a0TM\u00a0Jr,\u00a0Low\u00a0DE,\u00a0Eckburg\u00a0PB,\u00a0Talbot\u00a0GH,\u00a0Friedland \u00a0HD,\u00a0Lee\u00a0J,\u00a0Llorens\u00a0L,\u00a0Critchley\u00a0I,\u00a0Thye\u00a0D\u00a0(2010).\u00a0Integrated \u00a0\nanalysis\u00a0of\u00a0FOCUS\u00a01\u00a0and\u00a0FOCUS\u00a02:\u00a0randomized, \u00a0doubled\u2010blinded,\u00a0multicenter \u00a0phase\u00a03\u00a0trials\u00a0of\u00a0the\u00a0efficacy\u00a0and\u00a0\nsafety\u00a0of\u00a0ceftaroline \u00a0fosamil\u00a0versus\u00a0ceftriaxone \u00a0in\u00a0patients\u00a0with\u00a0community \u2010acquired\u00a0pneumonia. \u00a0Clin\u00a0Infect\u00a0Dis.\u00a0\n51:\u00a01395\u2010405.\u00a0\u00a0\n91. Flume\u00a0PA,\u00a0Liou\u00a0TG,\u00a0Borowitz\u00a0DS,\u00a0Li\u00a0H,\u00a0Yen\u00a0K,\u00a0Ordo\u00f1ez\u00a0CL,\u00a0Geller\u00a0DE;\u00a0VX\u00a008\u2010770\u2010104\u00a0Study\u00a0Group\u00a0(2012).\u00a0Ivacaftor\u00a0\nin\u00a0subjects\u00a0with\u00a0cystic\u00a0fibrosis\u00a0who\u00a0are\u00a0homozygous \u00a0for\u00a0the\u00a0F508del\u2010CFTR\u00a0mutation. \u00a0Chest.\u00a0142:\u00a0718\u2010724.\u00a0\u00a0\n92. Foidart\u00a0JM,\u00a0B\u00e9liard\u00a0A,\u00a0Hedon\u00a0B,\u00a0Ochsenbein \u00a0E,\u00a0Bernard\u00a0AM,\u00a0Bergeron \u00a0C,\u00a0Thomas\u00a0JL\u00a0(1997).\u00a0Impact\u00a0of\u00a0\npercutaneous \u00a0oestradiol \u00a0gels\u00a0in\u00a0postmenopausal \u00a0hormone \u00a0replacement \u00a0therapy\u00a0on\u00a0clinical\u00a0symptoms \u00a0and\u00a0\nendometrium. \u00a0Br\u00a0J\u00a0Obstet\u00a0Gynaecol. \u00a0104:\u00a0305\u2010310.\u00a0\n93. Fojo\u00a0T,\u00a0Mailankody \u00a0S,\u00a0Lo\u00a0A\u00a0(2014).\u00a0Unintended \u00a0consequences \u00a0of\u00a0expensive \u00a0cancer\u00a0therapeutics\u2014the \u00a0pursuit\u00a0of\u00a0\nmarginal\u00a0indications \u00a0and\u00a0a\u00a0me\u2010too\u00a0mentality \u00a0that\u00a0stifles\u00a0innovation \u00a0and\u00a0creativity: \u00a0the\u00a0John\u00a0Conley\u00a0Lecture.\u00a0JAMA\u00a0\nOtolaryngol \u00a0Head\u00a0Neck\u00a0Surg.\u00a0140\u00a0(12):\u00a01225\u201036.\u00a0\n94. F\u00f6rstermann \u00a0U\u00a0(2013).\u00a0Pharmakologie \u00a0des\u00a0cardiovaskul\u00e4ren \u00a0Systems\u00a0\u2013\u00a0die\u00a0Blutgef\u00e4\u00dfe; \u00a0\u2010Behandlung \u00a0von\u00a0\nHypertonie \u00a0und\u00a0Hypotonie. \u00a0In:\u00a0Aktories\u00a0K,\u00a0F\u00f6rstermann \u00a0U,\u00a0Hofmann \u00a0F,\u00a0Starke\u00a0K.\u00a0Allgemeine \u00a0und\u00a0spezielle\u00a0\nPharmakologie \u00a0und\u00a0Toxikologie. \u00a011.\u00a0Auflage.\u00a0M\u00fcnchen: \u00a0Urban\u00a0Fischer.\u00a0\n95. Fox\u00a0E,\u00a0Widemann \u00a0BC,\u00a0Chuk\u00a0MK,\u00a0Marcus\u00a0L,\u00a0Aikin\u00a0A,\u00a0Whitcomb \u00a0PO,\u00a0Merino\u00a0MJ,\u00a0Lodish\u00a0M,\u00a0Dombi\u00a0E,\u00a0Steinberg \u00a0SM,\u00a0\nWells\u00a0SA,\u00a0Balis\u00a0FM\u00a0(2013).\u00a0Vandetanib \u00a0in\u00a0children\u00a0and\u00a0adolescents \u00a0with\u00a0multiple\u00a0endocrine \u00a0neoplasia \u00a0type\u00a02B\u00a0\nassociated \u00a0medullary \u00a0thyroid\u00a0carcinoma. \u00a0Clin\u00a0Cancer\u00a0Res.\u00a019\u00a0(15):\u00a04239\u201048.\u00a0\u00a0 \n253\u00a096. French\u00a0JA,\u00a0Krauss\u00a0GL,\u00a0Biton\u00a0V,\u00a0Squillacote \u00a0D,\u00a0Yang\u00a0H,\u00a0Laurenza\u00a0A,\u00a0Kumar\u00a0D,\u00a0Rogawski \u00a0MA\u00a0(2012).\u00a0Adjunctive \u00a0\nperampanel \u00a0for\u00a0refractory \u00a0partial\u2010onset\u00a0seizures:\u00a0randomized \u00a0phase\u00a0III\u00a0study\u00a0304.\u00a0Neurology. \u00a079\u00a0(6):\u00a0589\u201096.\u00a0\n97. French\u00a0JA,\u00a0Krauss\u00a0GL,\u00a0Steinhoff\u00a0BJ,\u00a0Squillacote \u00a0D,\u00a0Yang\u00a0H,\u00a0Kumar\u00a0D,\u00a0Laurenza\u00a0A\u00a0(2013).\u00a0Evaluation \u00a0of\u00a0adjunctive \u00a0\nperampanel \u00a0in\u00a0patients\u00a0with\u00a0refractory \u00a0partial\u2010onset\u00a0seizures:\u00a0results\u00a0of\u00a0randomized \u00a0global\u00a0phase\u00a0III\u00a0study\u00a0305.\u00a0\nEpilepsia. \u00a054\u00a0(1):\u00a0117\u201025.\u00a0\n98. Fricke\u00a0U,\u00a0G\u00fcnther\u00a0J\u00a0(2001).\u00a0Methodik \u00a0der\u00a0ATC\u2010Klassifikation \u00a0und\u00a0DDD\u2010Festlegung \u00a0f\u00fcr\u00a0den\u00a0deutschen \u00a0\nArzneimittelmarkt. \u00a0Bonn:\u00a0WIdO.\u00a0\n99. Fricke\u00a0U,\u00a0Zawinell\u00a0A\u00a0(2009).\u00a0Anatomisch \u2010therapeutisch \u2010chemische \u00a0Klassifikation \u00a0mit\u00a0Tagesdosen \u00a0f\u00fcr\u00a0den\u00a0\ndeutschen \u00a0Arzneimittelmarkt \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a073\u00a0Abs.\u00a08\u00a0Satz\u00a05\u00a0SGB\u00a0V.\u00a0Beschlussfassung \u00a0der\u00a0Arbeitsgruppe \u00a0ATC/DDD \u00a0des\u00a0\nKuratoriums \u00a0f\u00fcr\u00a0Fragen\u00a0der\u00a0Klassifikation \u00a0im\u00a0Gesundheitswesen. \u00a0Stand\u00a0der\u00a0Information: \u00a027.11.2009. \u00a0\n100. Fricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2013).\u00a0Neue\u00a0Arzneimittel \u00a02012.\u00a0In:\u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg).\u00a0Arzneiverordnungs \u2010Report\u00a0\n2013.\u00a0Berlin,\u00a0Heidelberg: \u00a0Springer\u00a0Verlag.\u00a0\n101. Furness\u00a0S,\u00a0Roberts\u00a0H,\u00a0Marjoribanks \u00a0J,\u00a0Lethaby\u00a0A.\u00a0Hormone \u00a0therapy\u00a0in\u00a0postmenopausal \u00a0women\u00a0and\u00a0risk\u00a0of\u00a0\nendometrial \u00a0hyperplasia. \u00a0Cochrane \u00a0Database \u00a0of\u00a0Systematic \u00a0Reviews\u00a02012,\u00a0Issue\u00a08.\u00a0Art.\u00a0No.:\u00a0CD000402. \u00a0DOI:\u00a0\n10.1002/14651858.CD000402.pub4. \u00a0\n102. Gadelha\u00a0MR,\u00a0Bronstein \u00a0MD,\u00a0Brue\u00a0T,\u00a0Coculescu \u00a0M,\u00a0Fleseriu\u00a0M,\u00a0Guitelman \u00a0M,\u00a0Pronin\u00a0V,\u00a0Raverot\u00a0G,\u00a0Shimon\u00a0I,\u00a0Lievre\u00a0\nKK,\u00a0Fleck\u00a0J,\u00a0Aout\u00a0M,\u00a0Pedroncelli \u00a0AM,\u00a0Colao\u00a0A;\u00a0Pasireotide \u00a0C2402\u00a0Study\u00a0Group\u00a0(2014).\u00a0Pasireotide \u00a0versus\u00a0continued \u00a0\ntreatment \u00a0with\u00a0octreotide \u00a0or\u00a0lanreotide \u00a0in\u00a0patients\u00a0with\u00a0inadequately \u00a0controlled \u00a0acromegaly \u00a0(PAOLA):\u00a0a\u00a0\nrandomised, \u00a0phase\u00a03\u00a0trial.\u00a0Lancet\u00a0Diabetes\u00a0Endocrinol. \u00a02\u00a0(11):\u00a0875\u201084.\u00a0\n103. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2011).\u00a0Richtlinie \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0zur\u00a0\nEmpf\u00e4ngnisregelung \u00a0und\u00a0zum\u00a0Schwangerschaftsabbruch \u00a0[vormals: \u00a0Sonstige\u00a0Hilfen\u2010Richtlinien] \u00a0in\u00a0der\u00a0Fassung\u00a0vom\u00a0\n10.\u00a0Dezember \u00a01985\u00a0(Bundesanzeiger \u00a0Nr.\u00a060a\u00a0vom\u00a027.\u00a0M\u00e4rz\u00a01986),\u00a0zuletzt\u00a0ge\u00e4ndert\u00a0am\u00a021.\u00a0Juli\u00a02011\u00a0ver\u00f6ffentlicht \u00a0\nim\u00a0Bundesanzeiger \u00a0Nr.\u00a0139,\u00a0Seite\u00a03251,\u00a0in\u00a0Kraft\u00a0getreten\u00a0am\u00a015.\u00a0September \u00a02011.\u00a0https://www.g \u2010\nba.de/downloads/62 \u2010492\u2010557/ESA\u2010RL_2011\u201007\u201021.pdf.\u00a0Letzter\u00a0Zugriff:\u00a031.05.2015. \u00a0\n104. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2012a).\u00a0Tragende \u00a0Gr\u00fcnde\u00a0zum\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0\nBundesausschusses \u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie: \u00a0Anlage\u00a0XII\u2010\u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0\nNutzenbewertung \u00a0von\u00a0Arzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0des\u00a0F\u00fcnften\u00a0Buches\u00a0Sozialgesetzbuch \u00a0(SGB\u00a0\nV)\u00a0und\u00a0Anlage\u00a0IX\u2010\u00a0Festbetragsgruppenbildung \u00a0Angiotensin \u2010II\u2010Antagonisten, \u00a0Gruppe\u00a01,\u00a0in\u00a0Stufe\u00a02\u00a0nach\u00a0\u00a7\u00a035a\u00a0Absatz\u00a0\n3\u00a0in\u00a0Verbindung \u00a0mit\u00a0Absatz\u00a04\u00a0Satz\u00a01\u00a0SGB\u00a0V.\u00a0Stand\u00a0der\u00a0Information: \u00a015.03.2012. \u00a0\n105. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2012b).\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0\u00fcber\u00a0einen\u00a0\nAntrag\u00a0auf\u00a0Freistellung \u00a0von\u00a0der\u00a0Nutzenbewertung \u00a0wegen\u00a0Geringf\u00fcgigkeit \u00a0nach\u00a0\u00a7\u00a035a\u00a0Abs.\u00a01a\u00a0SGB\u00a0V\u00a0\u201eAndere\u00a0Beta\u2010\nLactam\u2010Antibiotika\u201c. \u00a0www.g\u2010ba.de.\u00a0Stand\u00a0der\u00a0Information: \u00a003.05.2012. \u00a0Letzter\u00a0Zugriff:\u00a017.03.2015. \u00a0\n106. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2012c).\u00a0Nutzenbewertung \u00a0von\u00a0Arzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\n\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0Bewertung \u00a0von\u00a0Arzneimitteln \u00a0f\u00fcr\u00a0seltene\u00a0Leiden\u00a0nach\u00a0\u00a7\u00a035a\u00a0Absatz\u00a01\u00a0Satz\u00a010\u00a0i.V.\u00a0m.\u00a05.\u00a0Kapitel\u00a0\u00a7\u00a012\u00a0Nr.\u00a0\n1\u00a0Satz\u00a02\u00a0VerfO\u00a0Wirkstoff: \u00a0Ivacaftor. \u00a0https://www.g \u2010ba.de/downloads/92 \u2010975\u2010130/Nutzenbewertung%20G \u2010BA.pdf.\u00a0\nStand\u00a0der\u00a0Information: \u00a015.11.2012. \u00a0Letzter\u00a0Zugriff\u00a027.04.2015. \u00a0\n107. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2012d).\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0Bundesauschusses \u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0\nArzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a735a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Pasireotid. \u00a0https://www.g \u2010ba.de/downloads/39 \u2010261\u2010\n1611/2012 \u201012\u201006_AM\u2010RL\u2010XII_Pasireotid_BAnz.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a006.12.2012. \u00a0Letzter\u00a0Zugriff:\u00a024.07.2015. \u00a0\n108. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2012e).\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0Bundesauschusses \u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0\nArzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a735a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Rilpivirin. \u00a0https://www.g \u2010ba.de/downloads/39 \u2010261\u2010\n1523/2012 \u201007\u201005_AM\u2010RL\u2010XII_Rilpivirin_BAnz.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a005.07.2012. \u00a0Letzter\u00a0Zugriff:\u00a024.07.2015. \u00a0\u00a0\n254\u00a0109. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2012f).\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0Bundesauschusses \u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0\nArzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a735a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Emtricitabin, \u00a0Rilpivirin\u00a0und\u00a0Tenofovirdisoproxil. \u00a0\nhttps://www.g \u2010ba.de/downloads/39 \u2010261\u20101522/2012 \u201007\u201005_AM\u2010RL\u2010XII_Emtricitabin \u2010Rilpivirin\u2010\nTenofovir_BAnz.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a005.07.2012. \u00a0Letzter\u00a0Zugriff:\u00a024.07.2015. \u00a0\n110. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2012g).\u00a0Beschluss \u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010\nRL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0Arzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\n\u2013\u00a0Tegafur/Gimeracil/Oteracil. \u00a0https://www.g \u2010ba.de/downloads/39 \u2010261\u20101620/2012 \u201012\u201020_Tegafur \u2010Gimeracil \u2010\nOteracil_BAnz.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a020.12.2012. \u00a0Letzter\u00a0Zugriff:\u00a024.07.2015. \u00a0\n111. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2012h).\u00a0Beschluss \u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010\nRL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0Arzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\n\u2013\u00a0Vandetanib. \u00a0https://www.g \u2010ba.de/downloads/39 \u2010261\u20101561/2012 \u201009\u201006_AM\u2010RL\u2010XII_Vandetanib_BAnz.pdf. \u00a0\nStand\u00a0der\u00a0Information: \u00a006.09.2012. \u00a0Letzter\u00a0Zugriff:\u00a018.06.2015. \u00a0\n112. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2012i).\u00a0Beschluss \u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010\nRL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0Arzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\n\u2013\u00a0Vemurafenib. \u00a0https://www.g \u2010ba.de/downloads/39 \u2010261\u20101560/2012 \u201009\u201006_AM\u2010RL\u2010XII_Vemurafenib_BAnz.pdf. \u00a0\nStand\u00a0der\u00a0Information: \u00a006.09.2012. \u00a0Letzter\u00a0Zugriff:\u00a025.07.2015. \u00a0\n113. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2012j).\u00a0Beschluss \u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010\nRL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0Arzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\n\u2013\u00a0Fingolimod. \u00a0https://www.g \u2010ba.de/downloads/39 \u2010261\u20101468/2012 \u201003\u201029_AM\u2010RL\u2010XII_Fingolimod_BAnz.pdf. \u00a0Stand\u00a0\nder\u00a0Information: \u00a029.03.2012. \u00a0Letzter\u00a0Zugriff:\u00a005.08.2015. \u00a0\n114. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2013a).\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010 \u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0\nArzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Aclidiniumbromid. \u00a0https://www.g \u2010ba.de/downloads/39 \u2010\n261\u20101674/2013 \u201003\u201021_AM\u2010RL\u2010XII_Aclidiniumbromid_BAnz.pdf. \u00a0Beschlussfassung: \u00a021.03.2013. \u00a0Letzter\u00a0Zugriff:\u00a0\n01.04.2015. \u00a0\n115. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2013b).\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010 \u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0\nArzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Aflibercept. \u00a0https://www.g \u2010ba.de/downloads/39 \u2010261\u2010\n1731/2013 \u201006\u201006_AM\u2010RL\u2010XII_Aflibercept_BAnz.pdf. \u00a0Beschlussfassung: \u00a006.06.2013. \u00a0Letzter\u00a0Zugriff:\u00a002.05.2015. \u00a0\n116. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2013c).\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010 \u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0\nArzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Axitinib.\u00a0https://www.g \u2010ba.de/downloads/39 \u2010261\u2010\n1675/2013 \u201003\u201021_AM\u2010RL\u2010XII_Axitinib.pdf. \u00a0Beschlussfassung: \u00a021.03.2013. \u00a0Letzter\u00a0Zugriff:\u00a001.02.2015. \u00a0\n117. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2013d).\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010 \u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0\nArzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Brentuximab \u00a0Vedotin.\u00a0https://www.g \u2010\nba.de/downloads/39 \u2010261\u20101711/2013 \u201005\u201016_AM\u2010RL\u2010XII_Brentuximab.pdf. \u00a0Beschlussfassung: \u00a016.05.2013. \u00a0Letzter\u00a0\nZugriff:\u00a015.05.2015. \u00a0\n118. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2013e).\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie(AM \u2010RL):\u00a0Anlage\u00a0XII\u2010\u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0Nutzenbewertung \u00a0von\u00a0Arzneimitteln \u00a0\nmit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a735a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Dapagliflozin. \u00a0https://www.g \u2010ba.de/downloads/39 \u2010261\u20101730/2013 \u201006\u2010\n06_AM\u2010RL\u2010XII_Dapagliflozin_BAnz.pdf. \u00a0Beschlussfassung: \u00a06.\u00a0Juni\u00a02013.\u00a0Letzter\u00a0Zugriff:\u00a016.05.2013. \u00a0\u00a0\n119. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2013f).\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie(AM \u2010RL):\u00a0Anlage\u00a0XII\u2010\u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0Nutzenbewertung \u00a0von\u00a0Arzneimitteln \u00a0\nmit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a735a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Decitabin. \u00a0https://www.g \u2010ba.de/downloads/39 \u2010261\u20101703/2013 \u201005\u2010\n02_AM\u2010RL\u2010XII_Decitabin_BAnz.pdf. \u00a0Beschlussfassung: \u00a002.05.2013. \u00a0Letzter\u00a0Zugriff:\u00a015.05.2015. \u00a0 \n255\u00a0120. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2013g).\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0\u00fcber\u00a0eine\u00a0\u00c4n\u2010\nderung\u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0Arzneimitteln \u00a0\nmit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Ivacaftor. \u00a07.\u00a0Februar\u00a02013.\u00a0https://www.g \u2010ba.de/downloads/39 \u2010261\u2010\n1648/2013 \u201002\u201007_AM\u2010RL\u2010XII_Ivacaftor_BAnz.pdf. \u00a0Letzter\u00a0Zugriff\u00a027.04.2015. \u00a0\n121. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2013h).\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010 \u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0\nArzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Perampanel. \u00a0https://www.g \u2010\nba.de/informationen/nutzenbewertung/39/#tab/beschluesse. \u00a0Stand\u00a0der\u00a0Information: \u00a07.\u00a0M\u00e4rz\u00a02013.\u00a0Letzter\u00a0\nZugriff:\u00a024.07.2015. \u00a0\n122. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2013i).\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010 \u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0\nArzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Pixantron. \u00a0https://www.g \u2010ba.de/downloads/39 \u2010261\u2010\n1712/2013 \u201005\u201016_AM\u2010RL\u2010XII_Pixantron_BAnz.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a016.05.2013. \u00a0Letzter\u00a0Zugriff:\u00a024.07.2015. \u00a0\n123. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2013j).\u00a0Nutzenbewertung \u00a0von\u00a0Arzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\n\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0Bewertung \u00a0von\u00a0Arzneimitteln \u00a0f\u00fcr\u00a0seltene\u00a0Leiden\u00a0nach\u00a0\u00a7\u00a035a\u00a0Absatz\u00a01\u00a0Satz\u00a010\u00a0i.V.m.\u00a05.\u00a0Kapitel\u00a0\u00a7\u00a012\u00a0Nr.\u00a0\n1\u00a0Satz\u00a02\u00a0VerfO\u00a0Wirkstoff \u00a0\u2010 \u00a0Ruxolitinib. \u00a0https://www.g \u2010ba.de/downloads/39 \u2010261\u20101665/2013 \u201003\u201007_AM\u2010RL\u2010\nXII_Ruxolitinib_BAnz.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a007.03.2013. \u00a0Letzter\u00a0Zugriff:\u00a024.07.2015. \u00a0\n124. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2013k).\u00a0Nutzenbewertung \u00a0von\u00a0Arzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\n\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0Bewertung \u00a0von\u00a0Arzneimitteln \u00a0f\u00fcr\u00a0seltene\u00a0Leiden\u00a0nach\u00a0\u00a7\u00a035a\u00a0Absatz\u00a01\u00a0Satz\u00a010\u00a0i.V.m.\u00a05.\u00a0Kapitel\u00a0\u00a7\u00a012\u00a0Nr.\u00a0\n1\u00a0Satz\u00a02\u00a0VerfO\u00a0Wirkstoff \u00a0\u2013\u00a0Vandetanib. \u00a0https://www.g \u2010ba.de/downloads/39 \u2010261\u20101807/2013 \u201009\u201005_AM\u2010RL\u2010\nXII_Vandetanib_BAnz.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a005.09.2013. \u00a0Letzter\u00a0Zugriff:\u00a018.06.2015. \u00a0\n125. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2014a).\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010 \u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0\nArzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u2013\u00a0Aflibercept \u00a0(Makula\u00f6dem \u00a0infolge\u00a0eines\u00a0retinalen\u00a0\nZentralvenenverschlusses). \u00a0https://www.g \u2010ba.de/downloads/39 \u2010261\u20101946/2014 \u201003\u201020_AM\u2010RL\u2010XII_Aflibercept \u2010\nnAWG_2013 \u201010\u201001\u2010D\u2010080_BAnz.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a020.03.2014. \u00a0Letzter\u00a0Zugriff:\u00a003.05.2015. \u00a0\n126. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2014b).\u00a0Tragende \u00a0Gr\u00fcnde\u00a0zum\u00a0Beschluss \u00a0d\u00a0es\u00a0Gemeinsamen \u00a0\nBundesausschusses \u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie(AM \u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0\nNutzenbewertung \u00a0von\u00a0Arzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013Dapagliflozin/Metformin. \u00a0\nhttps://www.g \u2010ba.de/downloads/39 \u2010261\u20102043/2014 \u201008\u201007_AM\u2010RL\u2010XII_Dapagliflozin_Metformin_2014 \u201002\u201015\u2010D\u2010\n097_BAnz.pdf. \u00a0Beschlussfassung: \u00a007.08.2014. \u00a0Letzter\u00a0Zugriff:\u00a023.07.2015. \u00a0\n127. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2014c).\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010 \u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0\nArzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u2013\u00a0Perampanel. \u00a0https://www.g \u2010ba.de/downloads/39 \u2010261\u2010\n2091/2014 \u201011\u201006_AM\u2010RL\u2010XII_Perampanel_2014 \u201005\u201015\u2010D\u2010106_BAnz.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a06.\u00a0November \u00a0\n2014.\u00a0Letzter\u00a0Zugriff:\u00a024.07.2015. \u00a0\n128. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2014d).\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0\u00fcber\u00a0eine\u00a0\u00c4n\u2010\nderung\u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0Arzneimitteln \u00a0\nmit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Emtricitabin/Rilpivirin/Tenofovirdisoproxil \u00a0(neues\u00a0Anwendungsgebiet) \u00a0\nhttps://www.g \u2010ba.de/downloads/39 \u2010261\u20102006/2014 \u201006\u201019_AM\u2010RL\u2010XII_Rilpivirin \u2010Kombi_2014 \u201001\u201001\u2010D\u2010\n089_BAnz.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a019.06.2014. \u00a0Letzter\u00a0Zugriff:\u00a024.07.2015. \u00a0\n129. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2014e).\u00a0Beschluss \u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010\nRL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0Arzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGBV\u00a0\n\u2013\u00a0Ruxolitinib. \u00a0https://www.g \u2010ba.de/downloads/39 \u2010261\u20102090/2014 \u201011\u201006_AM\u2010RL\u2010XII_Ruxolitinib_2014 \u201005\u201015\u2010D\u2010\n108_BAnz.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a006.11.2014. \u00a0Letzter\u00a0Zugriff:\u00a024.07.2015. \u00a0\n130. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2014f).\u00a0Beschluss \u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010\nRL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0Arzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGBV\u00a0\u00a0\n256\u00a0\u2013\u00a0Vemurafenib. \u00a0https://www.g \u2010ba.de/downloads/39 \u2010261\u20101943/2014 \u201003\u201006_AM\u2010RL\u2010XII_Vemurafenib_2013 \u201009\u201015\u2010\nD\u2010074_BAnz.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a006.03.2014. \u00a0Letzter\u00a0Zugriff:\u00a025.07.2015. \u00a0\n131. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2014g).\u00a0Beschluss \u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010\nRL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0Arzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGBV\u00a0\n\u2013\u00a0Dabrafenib. \u00a0https://www.g \u2010ba.de/downloads/39 \u2010261\u20101968/2014 \u201004\u201003_AM\u2010RL\u2010XII_Dabrafenib_2013 \u201010\u201001\u2010D\u2010\n076_BAnz.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a003.04.2014. \u00a0Letzter\u00a0Zugriff:\u00a025.07.2015. \u00a0\n132. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2015a)\u00a0Anlage\u00a0IV\u00a0zum\u00a0Abschnitt \u00a0H\u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0\nVerordnungseinschr\u00e4nkungen \u00a0und\u00a0\u2013ausschl\u00fcsse \u00a0in\u00a0der\u00a0Arzneimittelversorgung \u00a0\u2013\u00a0Therapiehinweise \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a092\u00a0\nAbs.\u00a02\u00a0Satz\u00a07\u00a0SGB\u00a0V\u00a0i.V.\u00a0m.\u00a0\u00a7\u00a017\u00a0AM\u2010RL\u00a0zur\u00a0wirtschaftlichen \u00a0Verordnungsweise \u00a0von\u00a0Arzneimitteln. \u00a0Verf\u00fcgbar \u00a0unter:\u00a0\nhttps://www.g \u2010ba.de/downloads/83 \u2010691\u2010370/AM\u2010RL\u2010IV\u2010Therapiehinweise_2015 \u201002\u201005.pdf.\u00a0Letzter\u00a0Zugriff:\u00a0\n22.05.2015. \u00a0\n133. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2015b).\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010 \u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0\nArzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2010 \u00a0Aflibercept \u00a0(Visusbeeintr\u00e4chtigung \u00a0infolge\u00a0eines\u00a0\ndiabetischen \u00a0 Makula\u00f6dems). \u00a0 https://www.g \u2010ba.de/downloads/39 \u2010261\u20102202/2015 \u201003\u201005_AM\u2010RL\u2010\nXII_Aflibercept_nAWG_2014 \u201009\u201015\u2010D\u2010137_BAnz.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a005.03.2015. \u00a0Letzter\u00a0Zugriff:\u00a0\n02.05.2015. \u00a0\n134. G\u2010BA\u00a0\u2013\u00a0Gemeinsamer \u00a0Bundesausschuss \u00a0(2015c).\u00a0Beschluss \u00a0des\u00a0Gemeinsamen \u00a0Bundesausschusses \u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung \u00a0der\u00a0Arzneimittel \u2010Richtlinie \u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010 \u00a0Beschl\u00fcsse \u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung \u00a0von\u00a0\nArzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Ivacaftor\u00a0neues\u00a0Anwendungsgebiet \u00a0Vom\u00a019.\u00a0Februar\u00a0\n2015.\u00a0 https://www.g \u2010ba.de/downloads/39 \u2010261\u20102178/2015 \u201002\u201019_AM\u2010RL\u2010XII_Ivacaftor \u2010nAWG_2014 \u201009\u201001\u2010D\u2010\n133_BAnz.pdf, \u00a0letzter\u00a0Zugriff\u00a007.05.2015. \u00a0\n135. Gerhardt\u00a0M\u00a0(2006).\u00a0HIV\u00a0(Human\u00a0Immunodeficiency \u00a0Virus)\u00a0Typ\u00a01:\u00a0Subtypenverteilung, \u00a0Mehrfachinfektionen \u00a0und\u00a0\nCharakterisierung \u00a0der\u00a0Viruspopulationen \u00a0in\u00a0einer\u00a0Hochrisikokohorte \u00a0in\u00a0Tansania. \u00a0Dissertation \u00a0zum\u00a0Erwerb\u00a0des\u00a0\nDoktorgrades \u00a0der\u00a0Humanbiologie \u00a0an\u00a0der\u00a0Medizinischen \u00a0Fakult\u00e4t\u00a0der\u00a0Ludwig\u2010Maximilians \u2010Universit\u00e4t \u00a0zu\u00a0M\u00fcnchen. \u00a0\u00a0\n136. GHSG\u00a0\u2013\u00a0German\u00a0Hodgkin\u00a0Study\u00a0Group\u00a0(2015).\u00a0Das\u00a0Hodgkin\u00a0Lymphom. \u00a0http://www.ghsg.org/. \u00a0Letzter\u00a0Zugriff:\u00a0\n27.02.2015. \u00a0\n137. Gilead\u00a0(2014).\u00a0Fachinformation \u00a0Eviplera\u00ae \u00a0200\u00a0mg/25\u00a0mg/245\u00a0mg\u00a0Filmtabletten. \u00a0Stand\u00a0der\u00a0Information: \u00a0September \u00a0\n2014.\u00a0\n138. GOLD\u00a0\u2013\u00a0Global\u00a0Initiative\u00a0For\u00a0Chronic\u00a0Obstructive \u00a0Lung\u00a0Disease\u00a0(2015).\u00a0Global\u00a0Strategy\u00a0For\u00a0The\u00a0Diagnosis, \u00a0\nManagement \u00a0And\u00a0Prevention \u00a0Of\u00a0Chronic\u00a0Obstructive \u00a0Pulmonary \u00a0Disease.\u00a0Updated\u00a02015.\u00a0\nhttp://www.goldcopd.org/uploads/users /files/GOLD_Report_2015_Feb18.pdf, \u00a0letzter\u00a0Zugriff:\u00a016.03.2015. \u00a0\n139. Goring\u00a0S,\u00a0Hawkins\u00a0N,\u00a0Wygant\u00a0G,\u00a0Roudaut\u00a0M,\u00a0Townsend \u00a0R,\u00a0Wood\u00a0I,\u00a0Barnett\u00a0AH\u00a0(2014).\u00a0Dapagliflozin \u00a0compared \u00a0\nwith\u00a0other\u00a0oral\u00a0anti\u2010diabetes\u00a0treatments \u00a0when\u00a0added\u00a0to\u00a0metformin \u00a0monotherapy: \u00a0a\u00a0systematic \u00a0review\u00a0and\u00a0\nnetwork\u00a0meta\u2010analysis.\u00a0Diabetes\u00a0Obes\u00a0Metab.\u00a016(5):\u00a0433\u201042.\u00a0\n140. Guglielmelli \u00a0P,\u00a0Biamonte \u00a0F,\u00a0Rotunno\u00a0G,\u00a0Artusi\u00a0V,\u00a0Artuso\u00a0L,\u00a0Bernardis \u00a0I,\u00a0Tenedini\u00a0E,\u00a0Pieri\u00a0L,\u00a0Paoli\u00a0C,\u00a0Mannarelli \u00a0C,\u00a0\nFjerza\u00a0R,\u00a0Rumi\u00a0E,\u00a0Stalbovskaya \u00a0V,\u00a0Squires\u00a0M,\u00a0Cazzola\u00a0M,\u00a0Manfredini \u00a0R,\u00a0Harrison\u00a0C,\u00a0Tagliafico \u00a0E,\u00a0Vannucchi \u00a0AM;\u00a0\nCOMFORT \u2010II\u00a0Investigators; \u00a0Associazione \u00a0Italiana\u00a0per\u00a0la\u00a0Ricerca\u00a0sul\u00a0Cancro\u00a0Gruppo\u00a0Italiano\u00a0Malattie\u00a0\nMieloproliferative \u00a0(AGIMM) \u00a0Investigators \u00a0(2014).\u00a0Impact\u00a0of\u00a0mutational \u00a0status\u00a0on\u00a0outcomes \u00a0in\u00a0myelofibrosis \u00a0\npatients\u00a0treated\u00a0with\u00a0ruxolitinib \u00a0in\u00a0the\u00a0COMFORT \u2010II\u00a0study.\u00a0Blood.\u00a0123\u00a0(14):\u00a02157\u201060.\u00a0\n141. Haimov\u2010Kochman \u00a0R,\u00a0Barak\u2010Glantz\u00a0E,\u00a0Arbel\u00a0R,\u00a0Leefsma\u00a0M,\u00a0Brzezinski \u00a0A,\u00a0Milwidsky \u00a0A,\u00a0Hochner\u2010Celnikier\u00a0D\u00a0(2006).\u00a0\nGradual\u00a0discontinuation \u00a0of\u00a0hormone \u00a0therapy\u00a0does\u00a0not\u00a0prevent\u00a0the\u00a0reappearance \u00a0of\u00a0climacteric \u00a0symptoms: \u00a0a\u00a0\nrandomized \u00a0prospective \u00a0study.\u00a0Menopause. \u00a013\u00a0(3):\u00a0370\u20106.\u00a0\n142. Harrison\u00a0C,\u00a0Kiladjian\u00a0JJ,\u00a0Al\u2010Ali\u00a0HK,\u00a0Gisslinger \u00a0H,\u00a0Waltzman \u00a0R,\u00a0Stalbovskaya \u00a0V,\u00a0McQuitty \u00a0M,\u00a0Hunter\u00a0DS,\u00a0Levy\u00a0R,\u00a0\nKnoops\u00a0L,\u00a0Cervantes \u00a0F,\u00a0Vannucchi \u00a0AM,\u00a0Barbui\u00a0T,\u00a0Barosi\u00a0G\u00a0(2012).\u00a0JAK\u00a0inhibition \u00a0with\u00a0ruxolitinib \u00a0versus\u00a0best\u00a0\navailable\u00a0therapy\u00a0for\u00a0myelofibrosis. \u00a0N\u00a0Engl\u00a0J\u00a0Med.\u00a0366\u00a0(9):\u00a0787\u201098.\u00a0\u00a0 \n257\u00a0143. Harrison\u00a0CN,\u00a0Mesa\u00a0RA,\u00a0Kiladjian\u00a0JJ,\u00a0Al\u2010Ali\u00a0HK,\u00a0Gisslinger \u00a0H,\u00a0Knoops\u00a0L,\u00a0Squier\u00a0M,\u00a0Sirulnik\u00a0A,\u00a0Mendelson \u00a0E,\u00a0Zhou\u00a0X,\u00a0\nCopley\u2010Merriman \u00a0C,\u00a0Hunter\u00a0DS,\u00a0Levy\u00a0RS,\u00a0Cervantes \u00a0F,\u00a0Passamonti \u00a0F,\u00a0Barbui\u00a0T,\u00a0Barosi\u00a0G,\u00a0Vannucchi \u00a0AM\u00a0(2013).\u00a0\nHealth\u2010related\u00a0quality\u00a0of\u00a0life\u00a0and\u00a0symptoms \u00a0in\u00a0patients\u00a0with\u00a0myelofibrosis \u00a0treated\u00a0with\u00a0ruxolitinib \u00a0versus\u00a0best\u00a0\navailable\u00a0therapy.\u00a0Br\u00a0J\u00a0Haematol. \u00a0162\u00a0(2):\u00a0229\u201039.\u00a0\n144. Hauner\u00a0H\u00a0(2013).\u00a0Diabetesepidemie \u00a0und\u00a0Dunkelziffer. \u00a0In:\u00a0Deutscher \u00a0Gesundheitsbericht: \u00a0Diabetes\u00a02013.\u00a0Von\u00a0der\u00a0\nDeutschen \u00a0Diabetes\u00a0Hilfe.\u00a0http://www.diabetesde.org. \u00a0Letzter\u00a0Zugriff:\u00a028.03.2015. \u00a0\n145. Hauschild \u00a0A,\u00a0Grob\u00a0JJ,\u00a0Demidov\u00a0LV,\u00a0Jouary\u00a0T,\u00a0Gutzmer\u00a0R,\u00a0Millward\u00a0M,\u00a0Rutkowski \u00a0P,\u00a0Blank\u00a0CU,\u00a0Miller\u00a0WH\u00a0Jr,\u00a0\nKaempgen \u00a0E,\u00a0Mart\u00edn\u2010Algarra\u00a0S,\u00a0Karaszewska \u00a0B,\u00a0Mauch\u00a0C,\u00a0Chiarion\u2010Sileni\u00a0V,\u00a0Martin\u00a0AM,\u00a0Swann\u00a0S,\u00a0Haney\u00a0P,\u00a0\nMirakhur \u00a0B,\u00a0Guckert\u00a0ME,\u00a0Goodman \u00a0V,\u00a0Chapman \u00a0PB\u00a0(2012).\u00a0Dabrafenib \u00a0in\u00a0BRAF\u2010mutated\u00a0metastatic \u00a0melanoma: \u00a0a\u00a0\nmulticentre, \u00a0open\u2010label,\u00a0phase\u00a03\u00a0randomised \u00a0controlled \u00a0trial.\u00a0Lancet.\u00a0380\u00a0(9839):\u00a0358\u201065.\u00a0\n146. H\u00e4ussler\u00a0B,\u00a0H\u00f6er\u00a0A,\u00a0Hempel\u00a0E\u00a0(2013):\u00a0Arzneimittel \u2010Atlas\u00a02012.\u00a0Der\u00a0Arzneimittelverbrauch \u00a0in\u00a0der\u00a0GKV.\u00a0Berlin,\u00a0\nHeidelberg: \u00a0Springer\u2010Verlag.\u00a0\n147. Heier\u00a0JS,\u00a0Brown\u00a0DM,\u00a0Chong\u00a0V,\u00a0Korobelnik \u00a0JF,\u00a0Kaiser\u00a0PK,\u00a0Nguyen\u00a0QD,\u00a0Kirchhof\u00a0B,\u00a0Ho\u00a0A,\u00a0Ogura\u00a0Y,\u00a0Yancopoulos \u00a0GD,\u00a0\nStahl\u00a0N,\u00a0Vitti\u00a0R,\u00a0Berliner\u00a0AJ,\u00a0Soo\u00a0Y,\u00a0Anderesi\u00a0M,\u00a0Groetzbach \u00a0G,\u00a0Sommerauer \u00a0B,\u00a0Sandbrink \u00a0R,\u00a0Simader\u00a0C,\u00a0Schmidt\u2010\nErfurth\u00a0U;\u00a0VIEW\u00a01\u00a0and\u00a0VIEW\u00a02\u00a0Study\u00a0Groups\u00a0(2012).\u00a0Intravitreal \u00a0aflibercept \u00a0(VEGF\u00a0trap\u2010eye)\u00a0in\u00a0wet\u00a0age\u2010related\u00a0\u00a0\nmacular\u00a0degeneration. \u00a0Ophthalmology. \u00a0119(12):\u00a02537\u201048.\u00a0\u00a0\n148. Hemery\u00a0C,\u00a0Ryvlin\u00a0P,\u00a0Rheims\u00a0S\u00a0(2014).\u00a0Prevention \u00a0of\u00a0generalized \u00a0tonic\u2010clonic\u00a0seizures\u00a0\u00a0in\u00a0refractory \u00a0focal\u00a0epilepsy:\u00a0a\u00a0\nmeta\u2010analysis.\u00a0Epilepsia. \u00a055(11):1789 \u201099.\u00a0\n149. Herbrecht \u00a0R,\u00a0Cernohous \u00a0P,\u00a0Engert\u00a0A,\u00a0Le\u00a0Gouill\u00a0S,\u00a0Macdonald \u00a0D,\u00a0Machida\u00a0C,\u00a0Myint\u00a0H,\u00a0Saleh\u00a0A,\u00a0Singer\u00a0J,\u00a0Wilhelm\u00a0M,\u00a0\nvan\u00a0der\u00a0Jagt\u00a0R\u00a0(2013).\u00a0Comparison \u00a0of\u00a0pixantrone \u2010based\u00a0regimen\u00a0(CPOP\u2010R)\u00a0with\u00a0doxorubicin \u2010based\u00a0therapy\u00a0(CHOP\u2010\nR)\u00a0for\u00a0treatment \u00a0of\u00a0diffuse\u00a0large\u00a0B\u2010cell\u00a0lymphoma. \u00a0Ann\u00a0Oncol.\u00a024\u00a0(10):\u00a02618\u201023.\u00a0\n150. Hodi\u00a0FS,\u00a0O'Day\u00a0SJ,\u00a0McDermott \u00a0DF,\u00a0Weber\u00a0RW,\u00a0Sosman\u00a0JA,\u00a0Haanen\u00a0JB,\u00a0Gonzalez\u00a0R,\u00a0Robert\u00a0C,\u00a0Schadendorf \u00a0D,\u00a0Hassel\u00a0\nJC,\u00a0Akerley\u00a0W,\u00a0van\u00a0den\u00a0Eertwegh \u00a0AJ,\u00a0Lutzky\u00a0J,\u00a0Lorigan\u00a0P,\u00a0Vaubel\u00a0JM,\u00a0Linette\u00a0GP,\u00a0Hogg\u00a0D,\u00a0Ottensmeier \u00a0CH,\u00a0Lebb\u00e9\u00a0C,\u00a0\nPeschel\u00a0C,\u00a0Quirt\u00a0I,\u00a0Clark\u00a0JI,\u00a0Wolchok\u00a0JD,\u00a0Weber\u00a0JS,\u00a0Tian\u00a0J,\u00a0Yellin\u00a0MJ,\u00a0Nichol\u00a0GM,\u00a0Hoos\u00a0A,\u00a0Urba\u00a0WJ\u00a0(2010).\u00a0Improved \u00a0\nsurvival\u00a0with\u00a0ipilimumab \u00a0in\u00a0patients\u00a0with\u00a0metastatic \u00a0melanoma. \u00a0N\u00a0Engl\u00a0J\u00a0Med.\u00a0363\u00a0(8):\u00a0711\u201023.\u00a0\n151. Hoffmann \u00a0S,\u00a0Vitzthum\u00a0K,\u00a0Mache\u00a0S,\u00a0Spallek\u00a0M,\u00a0Quarcoo\u00a0D,\u00a0Groneberg \u00a0DA,\u00a0Uibel\u00a0S\u00a0(2009).\u00a0Multiple\u00a0Sklerose:\u00a0\nEpidemiologie, \u00a0\u00a0Pathophysiologie, \u00a0Diagnostik \u00a0und\u00a0Therapie. \u00a0Prakt\u00a0Arb\u00a0med.\u00a017:\u00a012\u201018.\u00a0\n152. Hogg\u00a0JC,\u00a0Chu\u00a0F,\u00a0Utokaparch \u00a0S,\u00a0Woods\u00a0R,\u00a0Elliott\u00a0WM,\u00a0Buzatu\u00a0L,\u00a0Cherniack \u00a0RM,\u00a0Rogers\u00a0RM,\u00a0Sciurba\u00a0FC,\u00a0Coxson\u00a0HO,\u00a0\nPar\u00e9\u00a0PD\u00a0(2004).\u00a0The\u00a0nature\u00a0of\u00a0small\u2010airway\u00a0obstruction \u00a0in\u00a0chronic\u00a0obstructive \u00a0pulmonary \u00a0disease.\u00a0N\u00a0Engl\u00a0J\u00a0Med.\u00a0\n350(26):\u00a02645\u201053.\u00a0\n153. Holz\u00a0FG,\u00a0Roider\u00a0J,\u00a0Ogura\u00a0Y,\u00a0Korobelnik \u00a0JF,\u00a0Simader\u00a0C,\u00a0Groetzbach \u00a0G,\u00a0Vitti\u00a0R,\u00a0Berliner\u00a0AJ,\u00a0Hiemeyer \u00a0F,\u00a0Beckmann \u00a0K,\u00a0\nZeitz\u00a0O,\u00a0Sandbrink \u00a0R\u00a0(2013).\u00a0VEGF\u00a0Trap\u2010Eye\u00a0for\u00a0macular\u00a0oedema\u00a0secondary \u00a0to\u00a0central\u00a0retinal\u00a0vein\u00a0occlusion: \u00a06\u2010\nmonth\u00a0results\u00a0of\u00a0the\u00a0phase\u00a0III\u00a0GALILEO\u00a0study.\u00a0Br\u00a0J\u00a0Ophthalmol. \u00a097(3):\u00a0278\u201084.\u00a0\u00a0\n154. IMS\u00a0Health\u00a0(2013).\u00a0Der\u00a0pharmazeutische \u00a0Markt\u00a0(DPM)\u00a02012.\u00a0\n155. IMS\u00a0Health\u00a0(2014).\u00a0Der\u00a0pharmazeutische \u00a0Markt\u00a0(DPM)\u00a02013.\u00a0\n156. IQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit \u00a0im\u00a0Gesundheitswesen \u00a0(2012).\u00a0IQWiG\u2010Berichte\u00a0\u2013\u00a0Nr.\u00a0133\u00a0\nVemurafenib \u00a0\u2013\u00a0Nutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V.\u00a0Auftrag\u00a0A12\u201008\u00a0Stand\u00a013.06.2012. \u00a0\nhttps://www.iqwig.de/download/A12 \u201008_Vemurafenib_Nutzenbewertung_35a_SGB_V.pdf, \u00a0letzter\u00a0Zugriff\u00a0\n23.06.2015. \u00a0\n157. IQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit \u00a0im\u00a0Gesundheitswesen \u00a0(2013a).\u00a0IQWiG\u2010Berichte\u00a0\u2013\u00a0Nr.\u00a0203\u00a0\nDabrafenib \u00a0\u2013Nutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V.\u00a0Auftrag\u00a0A13\u201035.\u00a0Stand\u00a023.12.2013. \u00a0https://www.g \u2010\nba.de/downloads/92 \u2010975\u2010393/2013 \u201012\u201023_A13\u201035_Dabrafenib_Nutzenbewertung \u201035a\u2010SGB\u2010V.pdf,\u00a0letzter\u00a0Zugriff\u00a0\n23.06.2015. \u00a0\u00a0\n258\u00a0158. IQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit \u00a0im\u00a0Gesundheitswesen \u00a0(2013b)\u00a0.\u00a0IQWiG\u2010Berichte\u00a0Nr.\u00a0201\u00a0\u2013\u00a0\nAflibercept \u00a0(Eylea\u00a0\u2013\u00a0neues\u00a0Anwendungsgebiet) \u00a0\u2013\u00a0Nutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V.\u00a0Stand\u00a019.12.2013. \u00a0\nhttps://www.g \u2010ba.de/downloads/92 \u2010975\u2010380/2013 \u201012\u201019_A13\u201036_Aflibercept \u2010Eylea_Nutzenbewertung \u201035a\u2010SGB\u2010\nV.pdf,\u00a0letzter\u00a0Zugriff\u00a023.06.2015. \u00a0\n159. IQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit \u00a0im\u00a0Gesundheitswesen \u00a0(2013c).\u00a0IQWiG\u2010Berichte\u00a0\u2013\u00a0Nr.\u00a0155.\u00a0\nDapagliflozin \u00a0\u2013\u00a0Nutzenbewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0.\u00a0Auftrag\u00a0A12\u201018.\u00a0Stand\u00a012.03.2013. \u00a0https://www.g \u2010\nba.de/downloads/92 \u2010975\u2010207/Dapagliflozin_Nutzenbewertung_IQWiG \u201035a.pdf,\u00a0letzter\u00a0Zugriff\u00a023.06.2015. \u00a0\n160. IQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit \u00a0im\u00a0Gesundheitswesen \u00a0(2014a).\u00a0IQWiG\u2010Berichte\u00a0\u2013\u00a0Nr.\u00a0210\u00a0\nAddendum \u00a0zum\u00a0Auftrag\u00a0A13\u201035\u00a0Dabrafenib \u00a0\u2013\u00a0Addendum. \u00a0Auftrag\u00a0A14\u201010.\u00a0Stand\u00a014.03.2014. \u00a0\nhttps://www.iqwig.de/download/A14 \u201010_Addendum \u2010zum\u2010Auftrag\u2010A13\u201035_Dabrafenib.pdf, \u00a0 letzter\u00a0 Zugriff\u00a0\n23.06.2015. \u00a0\n161. IQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit \u00a0im\u00a0Gesundheitswesen \u00a0(2015).\u00a0IQWiG\u2010Berichte\u00a0Nr.\u00a0268\u00a0\u2013\u00a0\nPasireotid \u00a0(neues\u00a0Anwendungsgebiet) \u00a0\u2013\u00a0Bewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0Abs.\u00a01\u00a0Satz\u00a010\u00a0SGB\u00a0V.\u00a0Bewertung \u00a0von\u00a0\nArzneimitteln \u00a0f\u00fcr\u00a0seltene\u00a0Leiden\u00a0nach\u00a0\u00a7\u00a035a\u00a0Absatz\u00a01\u00a0Satz\u00a010\u00a0i.V.m.\u00a05.\u00a0Kapitel\u00a0\u00a7\u00a012\u00a0Nr.\u00a01\u00a0Satz\u00a02\u00a0VerfO.\u00a0Stand\u00a0\n12.03.2015. \u00a0https://www.iqwig.de/download/G14 \u201014_Pasireotid_Bewertung \u201035a\u2010Abs1\u2010Satz10\u2010SGB\u2010V.pdf,\u00a0letzter\u00a0\nZugriff\u00a023.06.2015. \u00a0\n162. IQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit \u00a0im\u00a0Gesundheitswesen \u00a0(2015a).\u00a0IQWiG\u2010Berichte\u00a0Nr.\u00a0313\u00a0\u2013\u00a0\nFingolimod \u00a0(Ablauf\u00a0Befristung) \u00a0\u2013\u00a0Bewertung \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0Abs.\u00a01\u00a0Satz\u00a010\u00a0SGB\u00a0V.\u00a0Auftrag\u00a0A15\u201012\u00a0Stand\u00a029.06.2015. \u00a0\nhttps://www.g \u2010ba.de/downloads/92 \u2010975\u2010822/2015 \u201006\u201029_Nutzenbewertung \u2010IQWiG_Fingolimod.pdf, \u00a0 letzter\u00a0\nZugriff\u00a023.06.2015. \u00a0\n163. Janssen\u00a0Cilag\u00a0(2013):\u00a0Rote\u00a0Hand\u2010Brief:\u00a0Vorgehensweise \u00a0bei\u00a0Auftreten \u00a0schwerer\u00a0Hautreaktionen \u00a0in\u00a0Verbindung \u00a0mit\u00a0\neine\u00a0INVICO\u00ae\u2010Therapie\u00a0(Telaprevir). \u00a0Stand:\u00a008.04.2013. \u00a0\n164. Janssen\u00a0Cilag\u00a0(2014a).\u00a0Fachinformation \u00a0Dacogen\u00ae \u00a050mg\u00a0Pulver\u00a0f\u00fcr\u00a0ein\u00a0Konzentrat \u00a0zur\u00a0Herstellung \u00a0einer\u00a0\nInfusionsl\u00f6sung. \u00a0Stand\u00a0der\u00a0Information: \u00a0Juli\u00a02014.\u00a0\n165. Janssen\u00a0Cilag\u00a0(2014b).\u00a0Fachinformation \u00a0Edurant\u00ae\u00a025\u00a0mg\u00a0Filmtabletten. \u00a0Stand\u00a0der\u00a0Information: \u00a0M\u00e4rz\u00a02014.\u00a0\n166. Johansson \u00a0S,\u00a0Read\u00a0J,\u00a0Oliver\u00a0S,\u00a0Steinberg \u00a0M,\u00a0Li\u00a0Y,\u00a0Lisbon\u00a0E,\u00a0Mathews \u00a0D,\u00a0Leese\u00a0PT,\u00a0Martin\u00a0P\u00a0(2014).\u00a0Pharmacokinetic \u00a0\nevaluations \u00a0of\u00a0the\u00a0co\u2010administrations \u00a0of\u00a0Vandetanib \u00a0and\u00a0metformin, \u00a0digoxin,\u00a0midazolam, \u00a0omeprazole \u00a0or\u00a0\nranitidine. \u00a0Clin\u00a0Pharmacokinet. \u00a053(9):\u00a0837\u201047.\u00a0\n167. Jones\u00a0PW,\u00a0Rennard\u00a0SI,\u00a0Agusti\u00a0A,\u00a0Chanez\u00a0P,\u00a0Magnussen \u00a0H,\u00a0Fabbri\u00a0L,\u00a0Donohue\u00a0JF,\u00a0Bateman\u00a0ED,\u00a0Gross\u00a0NJ,\u00a0Lamarca\u00a0R,\u00a0\nCaracta\u00a0C,\u00a0Gil\u00a0EGD\u00a0(2011).\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0once\u2010daily\u00a0aclidinium \u00a0in\u00a0chronic\u00a0obstructive \u00a0pulmonary \u00a0disease.\u00a0\nRespir\u00a0Res.\u00a026(12):\u00a055.\u00a0\u00a0\n168. Jones\u00a0PW,\u00a0Singh\u00a0D,\u00a0Bateman\u00a0ED,\u00a0Agusti\u00a0A,\u00a0Lamarca\u00a0R,\u00a0de\u00a0Miquel\u00a0G,\u00a0Segarra\u00a0R,\u00a0Caracta\u00a0C,\u00a0Garcia\u00a0Gil\u00a0E\u00a0(2012).\u00a0\nEfficacy\u00a0and\u00a0safety\u00a0of\u00a0twice\u2010daily\u00a0aclidinium \u00a0bromide\u00a0in\u00a0COPD\u00a0patients:\u00a0the\u00a0ATTAIN\u00a0study.\u00a0Eur\u00a0Respir\u00a0J.\u00a040(4):\u00a0830\u2010\n6.\u00a0\u00a0\n169. Kantarjian \u00a0HM,\u00a0Thomas\u00a0XG,\u00a0Dmoszynska \u00a0A,\u00a0Wierzbowska \u00a0A,\u00a0Mazur\u00a0G,\u00a0Mayer\u00a0J,\u00a0Gau\u00a0JP,\u00a0Chou\u00a0WC,\u00a0Buckstein \u00a0R,\u00a0\nCermak\u00a0J,\u00a0Kuo\u00a0CY,\u00a0Oriol\u00a0A,\u00a0Ravandi\u00a0F,\u00a0Faderl\u00a0S,\u00a0Delaunay \u00a0J,\u00a0Lys\u00e1k\u00a0D,\u00a0Minden\u00a0M,\u00a0Arthur\u00a0C\u00a0(2012).\u00a0Multicenter, \u00a0\nrandomized, \u00a0open\u2010label,\u00a0phase\u00a0III\u00a0trial\u00a0of\u00a0decitabine \u00a0versus\u00a0patient\u00a0choice,\u00a0with\u00a0physician \u00a0advice,\u00a0of\u00a0either\u00a0\nsupportive \u00a0care\u00a0or\u00a0low\u2010dose\u00a0cytarabine \u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0older\u00a0patients\u00a0with\u00a0newly\u00a0diagnosed \u00a0acute\u00a0myeloid\u00a0\nleukemia. \u00a0J\u00a0Clin\u00a0Oncol\u00a030\u00a0(21):\u00a02670\u20107.\u00a0\u00a0\n170. Kerwin\u00a0EM,\u00a0D'Urzo\u00a0AD,\u00a0Gelb\u00a0AF,\u00a0Lakkis\u00a0H,\u00a0Garcia\u00a0Gil\u00a0E,\u00a0Caracta\u00a0CF;\u00a0ACCORD\u00a0I\u00a0study\u00a0investigators \u00a0(2012).\u00a0Efficacy\u00a0\nand\u00a0safety\u00a0of\u00a0a\u00a012\u2010week\u00a0treatment \u00a0with\u00a0twice\u2010daily\u00a0aclidinium \u00a0bromide\u00a0in\u00a0COPD\u00a0patients\u00a0(ACCORD \u00a0COPD\u00a0I).\u00a0COPD.\u00a0\n9(2):\u00a090\u2010101.\u00a0\u00a0\n171. Kleefstra\u00a0N,\u00a0Drion\u00a0I,\u00a0van\u00a0Hateren\u00a0KJ,\u00a0Holleman \u00a0F,\u00a0Goudswaard \u00a0AN,\u00a0Bilo\u00a0HJ\u00a0(2013).\u00a0[SGLT\u20102\u00a0inhibitors: \u00a0diabetes\u00a0\ntreatment \u00a0by\u00a0glycosuria; \u00a0literature \u00a0review\u00a0on\u00a0the\u00a0effect\u00a0of\u00a0dapagliflozin]. \u00a0Ned\u00a0Tijdschr\u00a0Geneeskd. \u00a0157:\u00a0A5969.\u00a0\u00a0 \n259\u00a0172. Klein\u00a0Hesselink \u00a0EN,\u00a0Steenvoorden \u00a0D,\u00a0Kapiteijn\u00a0E,\u00a0Corssmit\u00a0EP,\u00a0van\u00a0der\u00a0Horst\u2010Schrivers\u00a0AN,\u00a0Lefrandt\u00a0JD,\u00a0Links\u00a0TP,\u00a0\nDekkers\u00a0OM\u00a0(2015).\u00a0Therapy\u00a0of\u00a0endocrine \u00a0disease:\u00a0response\u00a0and\u00a0toxicity\u00a0of\u00a0small\u2010molecule\u00a0tyrosine\u00a0kinase\u00a0\ninhibitors \u00a0in\u00a0patients\u00a0with\u00a0thyroid\u00a0carcinoma: \u00a0a\u00a0systematic \u00a0review\u00a0and\u00a0meta\u2010analysis.\u00a0Eur\u00a0J\u00a0Endocrinol. \u00a0\n172(5):R215 \u201025.\u00a0\n173. Kobayakawa \u00a0M,\u00a0Kojima\u00a0Y\u00a0(2011).\u00a0Tegafur/gimeracil/oteracil \u00a0(S\u20101)\u00a0approved \u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0advanced \u00a0gastric\u00a0\ncancer\u00a0in\u00a0adults\u00a0when\u00a0given\u00a0in\u00a0combination \u00a0with\u00a0cisplatin:\u00a0a\u00a0review\u00a0comparing \u00a0it\u00a0with\u00a0other\u00a0fluoropyrimidine \u2010\nbased\u00a0therapies. \u00a0Onco\u00a0Targets\u00a0Ther.\u00a04:\u00a0193\u2010201.\u00a0\n174. K\u00f6ck\u00a0R,\u00a0Mellmann \u00a0A,\u00a0Schaumburg \u00a0F,\u00a0Friedrich\u00a0AW,\u00a0Kipp\u00a0F,\u00a0Becker\u00a0K\u00a0(2011).\u00a0The\u00a0epidemiology \u00a0of\u00a0methicillin \u2010\nresistant\u00a0Staphylococcus \u00a0aureus\u00a0(MRSA)\u00a0in\u00a0Germany. \u00a0Dtsch\u00a0Arztebl\u00a0Int.\u00a0108:\u00a0761\u2010767.\u00a0\u00a0\n175. Kompetenznetz \u00a0 Maligne\u00a0 Lymphome \u00a0 (2008).\u00a0 Anaplastisches \u00a0 gro\u00dfzelliges \u00a0 Lymphom. \u00a0\nhttp://www.lymphome.de/InfoLymphome/Pathologi eUndKlassifikation/KlassNHL/AnaplaGrossLymph.jsp. \u00a0Letzter\u00a0\nZugriff\u00a023.06.2015. \u00a0\n176. Korobelnik \u00a0JF,\u00a0Do\u00a0DV,\u00a0Schmidt\u2010Erfurth\u00a0U,\u00a0Boyer\u00a0DS,\u00a0Holz\u00a0FG,\u00a0Heier\u00a0JS,\u00a0Midena\u00a0E,\u00a0Kaiser\u00a0PK,\u00a0Terasaki\u00a0H,\u00a0Marcus\u00a0DM,\u00a0\nNguyen\u00a0QD,\u00a0Jaffe\u00a0GJ,\u00a0Slakter\u00a0JS,\u00a0Simader\u00a0C,\u00a0Soo\u00a0Y,\u00a0Schmelter \u00a0T,\u00a0Yancopoulos \u00a0GD,\u00a0Stahl\u00a0N,\u00a0Vitti\u00a0R,\u00a0Berliner\u00a0AJ,\u00a0Zeitz\u00a0\nO,\u00a0Metzig\u00a0C,\u00a0Brown\u00a0DM\u00a0(2014).\u00a0Intravitreal \u00a0aflibercept \u00a0for\u00a0diabetic\u00a0macular\u00a0edema.\u00a0Ophthalmology. \u00a0121(11):\u00a0\n2247\u201054.\u00a0\n177. Krauss\u00a0GL,\u00a0Serratosa \u00a0JM,\u00a0Villanueva \u00a0V,\u00a0Endziniene \u00a0M,\u00a0Hong\u00a0Z,\u00a0French\u00a0J,\u00a0Yang\u00a0H,\u00a0Squillacote \u00a0D,\u00a0Edwards\u00a0HB,\u00a0Zhu\u00a0J,\u00a0\nLaurenza\u00a0A\u00a0(2012).\u00a0Randomized \u00a0phase\u00a0III\u00a0study\u00a0306:\u00a0adjunctive \u00a0perampanel \u00a0for\u00a0refractory \u00a0partial\u2010onset\u00a0seizures.\u00a0\nNeurology. \u00a078\u00a0(18):\u00a01408\u201015.\u00a0\u00a0\n178. Krauss\u00a0GL,\u00a0Perucca\u00a0E,\u00a0Ben\u2010Menachem \u00a0E,\u00a0Kwan\u00a0P,\u00a0Shih\u00a0JJ,\u00a0Squillacote \u00a0D,\u00a0Yang\u00a0H,\u00a0Gee\u00a0M,\u00a0Zhu\u00a0J,\u00a0Laurenza\u00a0A\u00a0(2013).\u00a0\nPerampanel, \u00a0a\u00a0selective, \u00a0noncompetitive \u00a0\u03b1 \u2010amino\u20103\u2010hydroxy\u20105\u2010methyl\u20104\u2010isoxazolepropionic \u00a0acid\u00a0receptor\u00a0\nantagonist, \u00a0as\u00a0adjunctive \u00a0therapy\u00a0for\u00a0refractory \u00a0partial\u2010onset\u00a0seizures:\u00a0interim\u00a0results\u00a0from\u00a0phase\u00a0III,\u00a0extension \u00a0\nstudy\u00a0307.\u00a0Epilepsia. \u00a054\u00a0(1):\u00a0126\u201034.\u00a0\n179. Krug,\u00a0Utz;\u00a0B\u00fcchner,\u00a0Thomas;\u00a0Berdel,\u00a0Wolfgang; \u00a0M\u00fcller\u2010Tidow,\u00a0Carsten\u00a0(2011).\u00a0Behandlung \u00a0\u00e4lterer\u00a0Patienten \u00a0mit\u00a0\nAML.\u00a0Dtsch\u00a0Arztebl.\u00a0Int\u00a0108\u00a0(51\u201052):\u00a0863\u201070.\u00a0\n180. Kurth\u00a0BM\u00a0(2012).\u00a0Erste\u00a0Ergebnisse \u00a0aus\u00a0der\u00a0\u201eStudie\u00a0zur\u00a0Gesundheit \u00a0Erwachsener \u00a0in\u00a0Deutschland\u201c \u00a0(DEGS).\u00a0\nBundesgesundheitsbl \u00a055:\u00a0980\u2010999.\u00a0\n181. Larkin\u00a0J,\u00a0Del\u00a0Vecchio\u00a0M,\u00a0Ascierto\u00a0PA,\u00a0Krajsova\u00a0I,\u00a0Schachter \u00a0J,\u00a0Neyns\u00a0B,\u00a0Espinosa\u00a0E,\u00a0Garbe\u00a0C,\u00a0Sileni\u00a0VC,\u00a0Gogas\u00a0H,\u00a0\nMiller\u00a0WH\u00a0Jr,\u00a0Mandal\u00e0\u00a0M,\u00a0Hospers\u00a0GA,\u00a0Arance\u00a0A,\u00a0Queirolo\u00a0P,\u00a0Hauschild \u00a0A,\u00a0Brown\u00a0MP,\u00a0Mitchell\u00a0L,\u00a0Veronese \u00a0L,\u00a0Blank\u00a0\nCU\u00a0(2014).\u00a0Vemurafenib \u00a0in\u00a0patients\u00a0with\u00a0BRAF(V600) \u00a0mutated\u00a0metastatic \u00a0melanoma: \u00a0an\u00a0open\u2010label,\u00a0multicentre, \u00a0\nsafety\u00a0study.\u00a0Lancet\u00a0Oncol.\u00a015\u00a0(4):\u00a0436\u201044.\u00a0\n182. Lethaby\u00a0A,\u00a0Hogervorst \u00a0E,\u00a0Richards\u00a0M,\u00a0Yesufu\u00a0A,\u00a0Yaffe\u00a0K\u00a0(2008).\u00a0Hormone \u00a0replacement \u00a0therapy\u00a0for\u00a0cognitive\u00a0\nfunction\u00a0in\u00a0postmenopausal \u00a0women.\u00a0Cochrane \u00a0Database \u00a0of\u00a0Systematic \u00a0Reviews.\u00a0Issue\u00a01.\u00a0Art.\u00a0No.:\u00a0CD003122. \u00a0DOI:\u00a0\n10.1002/14651858.CD003122.pub2. \u00a0\n183. Lindh\u2010Astrand\u00a0L,\u00a0Bixo\u00a0M,\u00a0Hirschberg \u00a0AL,\u00a0Sundstr\u00f6m \u2010Poromaa\u00a0I,\u00a0Hammar\u00a0M\u00a0(2010).\u00a0A\u00a0randomized \u00a0controlled \u00a0study\u00a0\nof\u00a0taper\u2010down\u00a0or\u00a0abrupt\u00a0discontinuation \u00a0of\u00a0hormone\u00a0therapy\u00a0in\u00a0women\u00a0treated\u00a0for\u00a0vasomotor \u00a0symptoms. \u00a0\nMenopause. \u00a017\u00a0(1):\u00a072\u20109.\u00a0\n184. Long\u00a0SW,\u00a0Olsen\u00a0RJ,\u00a0Mehta\u00a0SC,\u00a0Palzkill\u00a0T,\u00a0Cernoch\u00a0PL,\u00a0Perez\u00a0KK,\u00a0Musick\u00a0WL,\u00a0Rosato\u00a0AE,\u00a0Musser\u00a0JM\u00a0(2014).\u00a0PBP2a\u00a0\nmutations \u00a0causing\u00a0high\u2010level\u00a0Ceftaroline \u00a0resistance \u00a0in\u00a0clinical\u00a0methicillin \u2010resistant\u00a0Staphylococcus \u00a0aureus\u00a0isolates.\u00a0\nAntimicrob \u00a0Agents\u00a0Chemother. \u00a058:\u00a06668\u20106674.\u00a0\u00a0\n185. Ludwig\u00a0WD\u00a0(2015).\u00a0Anforderungen \u00a0an\u00a0die\u00a0Arzneimittelentwicklung \u00a0in\u00a0der\u00a0Onkologie, \u00a0in\u00a0Trittin\u00a0C\u00a0(Hg),\u00a0Sammelband \u00a0\nVersorgungsforschung. \u00a0St.\u00a0Augustin; \u00a0Asgard.\u00a0\u00a0\u00a0\n260\u00a0186. Ludwig\u00a0WD,\u00a0Schildmann \u00a0J\u00a0(2015).\u00a0Kostenexplosion \u00a0in\u00a0der\u00a0medikament\u00f6sen \u00a0Therapie\u00a0onkologischer \u00a0Erkrankungen. \u00a0\nUrsachen, \u00a0L\u00f6sungsans\u00e4tze \u00a0und\u00a0medizinethische \u00a0Voraussetzungen. \u00a0Der\u00a0Onkologe \u00a008/15.\u00a0DOI\u00a010.1007/s00761 \u2010015\u2010\n2958\u20105.\u00a0\n187. MacLennan \u00a0AH,\u00a0Broadbent \u00a0JL,\u00a0Lester\u00a0S,\u00a0Moore\u00a0V\u00a0(2004).\u00a0Oral\u00a0oestrogen \u00a0and\u00a0combined \u00a0oestrogen/progestogen \u00a0\ntherapy\u00a0versus\u00a0placebo\u00a0for\u00a0hot\u00a0flushes.\u00a0Cochrane \u00a0Database \u00a0of\u00a0Systematic \u00a0Reviews.\u00a0Issue\u00a04.\u00a0Art.\u00a0No.:\u00a0CD002978. \u00a0\nDOI:\u00a010.1002/14651858.CD002978.pub2. \u00a0\u00a0\n188. Mancini\u00a0T,\u00a0Porcelli\u00a0T,\u00a0Giustina\u00a0A\u00a0(2010).\u00a0Treatment \u00a0of\u00a0Cushing\u00a0disease:\u00a0overview\u00a0and\u00a0recent\u00a0findings.\u00a0Ther\u00a0Clin\u00a0Risk\u00a0\nManag.\u00a06:\u00a0505\u201016.\u00a0\n189. Mansour\u00a0D,\u00a0Verhoeven \u00a0C,\u00a0Sommer\u00a0W,\u00a0Weisberg \u00a0E,\u00a0Taneepanichskul \u00a0S,\u00a0Melis\u00a0GB,\u00a0Sundstr\u00f6m \u2010Poromaa\u00a0I,\u00a0Korver\u00a0T\u00a0\n(2011).\u00a0Efficacy\u00a0and\u00a0tolerability \u00a0of\u00a0a\u00a0monophasic \u00a0combined \u00a0oral\u00a0contraceptive \u00a0containing \u00a0nomegestrol \u00a0acetate\u00a0and\u00a0\n17\u03b2\u2010oestradiol \u00a0in\u00a0a\u00a024/4\u00a0regimen,\u00a0in\u00a0comparison \u00a0to\u00a0an\u00a0oral\u00a0contraceptive \u00a0containing \u00a0ethinylestradiol \u00a0and\u00a0\ndrospirenone \u00a0in\u00a0a\u00a021/7\u00a0regimen.\u00a0Eur\u00a0J\u00a0Contracept \u00a0Reprod\u00a0Health\u00a0Care.\u00a016:\u00a0430\u2010443.\u00a0\u00a0\n190. Marjoribanks \u00a0J,\u00a0Farquhar\u00a0C,\u00a0Roberts\u00a0H,\u00a0Lethaby\u00a0A\u00a0(2012).\u00a0Long\u00a0term\u00a0hormone \u00a0therapy\u00a0for\u00a0perimenopausal \u00a0and\u00a0\npostmenopausal \u00a0women.\u00a0Cochrane \u00a0Database \u00a0of\u00a0Systematic \u00a0Reviews.\u00a0Issue\u00a07.\u00a0Art.\u00a0No.:\u00a0CD004143. \u00a0DOI:\u00a0\n10.1002/14651858.CD004143.pub4. \u00a0\n191. Massicotte \u00a0MH,\u00a0Borget\u00a0I,\u00a0Broutin\u00a0S,\u00a0Baracos\u00a0VE,\u00a0Leboulleux \u00a0S,\u00a0Baudin\u00a0E,\u00a0Paci\u00a0A,\u00a0Deroussent \u00a0A,\u00a0Schlumberger \u00a0M,\u00a0\nAntoun\u00a0S\u00a0(2013).\u00a0Body\u00a0composition \u00a0variation\u00a0and\u00a0impact\u00a0of\u00a0low\u00a0skeletal\u00a0muscle\u00a0mass\u00a0in\u00a0patients\u00a0with\u00a0advanced \u00a0\nmedullary \u00a0thyroid\u00a0carcinoma \u00a0treated\u00a0with\u00a0vandetanib: \u00a0results\u00a0from\u00a0a\u00a0placebo\u2010controlled \u00a0study.\u00a0J\u00a0Clin\u00a0Endocrinol \u00a0\nMetab.\u00a098(6):\u00a02401\u20108.\u00a0\n192. Matthaei\u00a0S,\u00a0Bowering \u00a0K,\u00a0Rohwedder \u00a0K,\u00a0Grohl\u00a0A,\u00a0Parikh\u00a0S;\u00a0Study\u00a005\u00a0Group\u00a0(2015).\u00a0Dapagliflozin \u00a0Improves \u00a0Glycemic\u00a0\nControl\u00a0and\u00a0Reduces\u00a0Body\u00a0Weight\u00a0as\u00a0Add\u2010on\u00a0Therapy\u00a0to\u00a0Metformin \u00a0Plus\u00a0Sulfonylurea: \u00a0A\u00a024\u2010Week\u00a0Randomized, \u00a0\nDouble\u2010Blind\u00a0Clinical\u00a0Trial.\u00a0Diabetes\u00a0Care.\u00a0383:\u00a0365\u2010372.\u00a0\n193. Matthes\u00a0J\u00a0(2014).\u00a0Mittel\u00a0mit\u00a0Wirkung\u00a0auf\u00a0das\u00a0Renin\u2010Angiotensin \u2010System.\u00a0In:\u00a0Fricke\u00a0U,\u00a0Beck\u00a0T\u00a0(Hrsg.).\u00a0Neue\u00a0\nArzneimittel. \u00a0Fakten\u00a0und\u00a0Bewertungen. \u00a0Stuttgart: \u00a0Wissenschaftliche \u00a0Verlagsgesellschaft. \u00a0Band\u00a021:\u00a0157\u2010180.\u00a0\n194. McArthur \u00a0GA,\u00a0Chapman \u00a0PB,\u00a0Robert\u00a0C,\u00a0Larkin\u00a0J,\u00a0Haanen\u00a0JB,\u00a0Dummer\u00a0R,\u00a0Ribas\u00a0A,\u00a0Hogg\u00a0D,\u00a0Hamid\u00a0O,\u00a0Ascierto\u00a0PA,\u00a0\nGarbe\u00a0C,\u00a0Testori\u00a0A,\u00a0Maio\u00a0M,\u00a0Lorigan\u00a0P,\u00a0Lebb\u00e9\u00a0C,\u00a0Jouary\u00a0T,\u00a0Schadendorf \u00a0D,\u00a0O'Day\u00a0SJ,\u00a0Kirkwood \u00a0JM,\u00a0Eggermont \u00a0AM,\u00a0\nDr\u00e9no\u00a0B,\u00a0Sosman\u00a0JA,\u00a0Flaherty\u00a0KT,\u00a0Yin\u00a0M,\u00a0Caro\u00a0I,\u00a0Cheng\u00a0S,\u00a0Trunzer\u00a0K,\u00a0Hauschild \u00a0A\u00a0(2014).\u00a0Safety\u00a0and\u00a0efficacy\u00a0of\u00a0\nvemurafenib \u00a0in\u00a0BRAF(V600E) \u00a0and\u00a0BRAF(V600K) \u00a0mutation \u2010positive\u00a0melanoma \u00a0(BRIM\u20103):\u00a0extended \u00a0follow\u2010up\u00a0of\u00a0a\u00a0\nphase\u00a03,\u00a0randomised, \u00a0open\u2010label\u00a0study.\u00a0Lancet\u00a0Oncol.\u00a015\u00a0(3):\u00a0323\u201032.\u00a0\n195. McKone\u00a0EF,\u00a0Borowitz\u00a0D,\u00a0Drevinek\u00a0P,\u00a0Griese\u00a0M,\u00a0Konstan\u00a0MW,\u00a0Wainwright \u00a0C,\u00a0Ratjen\u00a0F,\u00a0Sermet\u2010Gaudelus \u00a0I,\u00a0Plant\u00a0B,\u00a0\nMunck\u00a0A,\u00a0Jiang\u00a0Y,\u00a0Gilmartin \u00a0G,\u00a0Davies\u00a0JC;\u00a0VX08\u2010770\u2010105\u00a0(PERSIST) \u00a0Study\u00a0Group\u00a0(2014).\u00a0Long\u2010term\u00a0safety\u00a0and\u00a0\nefficacy\u00a0of\u00a0ivacaftor\u00a0in\u00a0patients\u00a0with\u00a0cystic\u00a0fibrosis\u00a0who\u00a0have\u00a0the\u00a0Gly551Asp \u2010CFTR\u00a0mutation: \u00a0a\u00a0phase\u00a03,\u00a0open\u2010label\u00a0\nextension \u00a0study\u00a0(PERSIST). \u00a0Lancet\u00a0Respir\u00a0Med.\u00a02:\u00a0902\u2010910.\u00a0\n196. Mendes\u00a0RE,\u00a0Tsakris\u00a0A,\u00a0Sader\u00a0HS,\u00a0Jones\u00a0RN,\u00a0Biek\u00a0D,\u00a0McGhee\u00a0P,\u00a0Appelbaum \u00a0PC,\u00a0Kosowska \u2010Shick\u00a0K\u00a0(2012).\u00a0\nCharacterization \u00a0of\u00a0methicillin \u2010resistant\u00a0Staphylococcus \u00a0aureus\u00a0displaying \u00a0increased \u00a0MICs\u00a0of\u00a0ceftaroline. \u00a0J\u00a0\nAntimicrob \u00a0Chemother. \u00a067:\u00a01321\u20101324.\u00a0\u00a0\n197. Mesa\u00a0RA,\u00a0Verstovsek \u00a0S,\u00a0Gupta\u00a0V,\u00a0Mascarenhas \u00a0JO,\u00a0Atallah\u00a0E,\u00a0Burn\u00a0T,\u00a0Sun\u00a0W,\u00a0Sandor\u00a0V,\u00a0Gotlib\u00a0J\u00a0(2015).\u00a0Effects\u00a0of\u00a0\nruxolitinib \u00a0treatment \u00a0on\u00a0metabolic \u00a0and\u00a0nutritional \u00a0parameters \u00a0in\u00a0patients\u00a0with\u00a0myelofibrosis \u00a0from\u00a0COMFORT \u2010I.\u00a0\nClin\u00a0Lymphoma \u00a0Myeloma \u00a0Leuk.\u00a015\u00a0(4):\u00a0214\u2010221.e1.\u00a0\n198. Meyer\u00a0E,\u00a0Schr\u00f6der\u00a0C,\u00a0Gastmeier \u00a0P,\u00a0Geffers\u00a0C\u00a0(2014).\u00a0The\u00a0reduction \u00a0of\u00a0nosocomial \u00a0MRSA\u00a0infection\u00a0in\u00a0Germany: \u00a0an\u00a0\nanalysis\u00a0of\u00a0data\u00a0from\u00a0the\u00a0Hospital\u00a0Infection\u00a0Surveillance \u00a0System\u00a0(KISS)\u00a0between\u00a02007\u00a0and\u00a02012.\u00a0Dtsch\u00a0Arztebl\u00a0Int.\u00a0\n111:\u00a0331\u2010336.\u00a0\n199. Mogayzel \u00a0PJ\u00a0Jr,\u00a0Naureckas \u00a0ET,\u00a0Robinson \u00a0KA,\u00a0Mueller\u00a0G,\u00a0Hadjiliadis \u00a0D,\u00a0Hoag\u00a0JB,\u00a0Lubsch\u00a0L,\u00a0Hazle\u00a0L,\u00a0Sabadosa \u00a0K,\u00a0\nMarshall\u00a0B,\u00a0Pulmonary \u00a0Clinical\u00a0Practice\u00a0Guidelines \u00a0Committee \u00a0(2013).\u00a0Cystic\u00a0fibrosis\u00a0pulmonary \u00a0guidelines. \u00a0\nChronic\u00a0medications \u00a0for\u00a0maintenance \u00a0of\u00a0lung\u00a0health.\u00a0Am\u00a0J\u00a0Respir\u00a0Crit\u00a0Care\u00a0Med.\u00a0187:\u00a0680\u2010689.\u00a0 \n261\u00a0200. Molina\u00a0JM,\u00a0Cahn\u00a0P,\u00a0Grinsztejn \u00a0B,\u00a0Lazzarin\u00a0A,\u00a0Mills\u00a0A,\u00a0Saag\u00a0M,\u00a0Supparatpinyo \u00a0K,\u00a0Walmsley \u00a0S,\u00a0Crauwels\u00a0H,\u00a0Rimsky\u00a0LT,\u00a0\nVanveggel \u00a0S,\u00a0Boven\u00a0K;\u00a0ECHO\u00a0study\u00a0group\u00a0(2011).\u00a0Rilpivirine \u00a0versus\u00a0efavirenz\u00a0with\u00a0tenofovir\u00a0and\u00a0emtricitabine \u00a0in\u00a0\ntreatment \u2010naive\u00a0adults\u00a0infected\u00a0with\u00a0HIV\u20101\u00a0(ECHO):\u00a0a\u00a0phase\u00a03\u00a0randomised \u00a0double\u2010blind\u00a0active\u2010controlled \u00a0trial.\u00a0\nLancet.\u00a0378\u00a0(9787):\u00a0238\u201046.\u00a0\n201. Molina\u00a0JM,\u00a0Clumeck\u00a0N,\u00a0Orkin\u00a0C,\u00a0Rimsky\u00a0LT,\u00a0Vanveggel \u00a0S,\u00a0Stevens\u00a0M;\u00a0ECHO\u00a0and\u00a0THRIVE\u00a0Study\u00a0Groups\u00a0(2014).\u00a0Week\u00a0\n96\u00a0analysis\u00a0of\u00a0rilpivirine \u00a0or\u00a0efavirenz\u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0with\u00a0baseline\u00a0viral\u00a0load\u00a0\u2264\u00a0100\u00a0000\u00a0copies/mL \u00a0in\u00a0the\u00a0\npooled\u00a0ECHO\u00a0and\u00a0THRIVE\u00a0phase\u00a03,\u00a0randomized, \u00a0double\u2010blind\u00a0trials.\u00a0HIV\u00a0Med.\u00a015\u00a0(1):\u00a057\u201062.\u00a0\n202. Moskowitz \u00a0AJ,\u00a0Sch\u00f6der\u00a0H,\u00a0Yahalom\u00a0J,\u00a0McCall\u00a0SJ,\u00a0Fox\u00a0SY,\u00a0Gerecitano \u00a0J,\u00a0Grewal\u00a0R,\u00a0Hamlin\u00a0PA,\u00a0Horwitz\u00a0S,\u00a0Kobos\u00a0R,\u00a0\nKumar\u00a0A,\u00a0Matasar\u00a0M,\u00a0Noy\u00a0A,\u00a0Palomba\u00a0ML,\u00a0Perales\u00a0MA,\u00a0Portlock\u00a0CS,\u00a0Sauter\u00a0C,\u00a0Shukla\u00a0N,\u00a0Steinherz \u00a0P,\u00a0Straus\u00a0D,\u00a0\nTrippett\u00a0T,\u00a0Younes\u00a0A,\u00a0Zelenetz\u00a0A,\u00a0Moskowitz \u00a0CH\u00a0(2015).\u00a0PET\u2010adapted\u00a0sequential \u00a0salvage\u00a0therapy\u00a0with\u00a0\nbrentuximabvedotin \u00a0followed\u00a0by\u00a0augmented \u00a0ifosamide, \u00a0carboplatin, \u00a0and\u00a0etoposide \u00a0for\u00a0patients\u00a0with\u00a0relapsed\u00a0and\u00a0\nrefractory \u00a0Hodgkin's \u00a0lymphoma: \u00a0a\u00a0non\u2010randomised, \u00a0open\u2010label,\u00a0single\u2010centre,\u00a0phase\u00a02\u00a0study.\u00a0Lancet\u00a0Oncol.\u00a016\u00a0(3):\u00a0\n284\u201092.\u00a0\n203. Motzer\u00a0RJ,\u00a0Escudier\u00a0B,\u00a0Tomczak\u00a0P,\u00a0Hutson\u00a0TE,\u00a0Michaelson \u00a0MD,\u00a0Negrier\u00a0S,\u00a0Oudard\u00a0S,\u00a0Gore\u00a0ME,\u00a0Tarazi\u00a0J,\u00a0Hariharan \u00a0S,\u00a0\nChen\u00a0C,\u00a0Rosbrook \u00a0B,\u00a0Kim\u00a0S,\u00a0Rini\u00a0B\u00a0(2013).\u00a0Axitinib\u00a0versus\u00a0sorafenib \u00a0as\u00a0second\u2010line\u00a0treatment \u00a0for\u00a0advanced \u00a0renal\u00a0\ncell\u00a0carcinoma: \u00a0overall\u00a0survival\u00a0analysis\u00a0and\u00a0updated\u00a0results\u00a0from\u00a0a\u00a0randomised \u00a0phase\u00a03\u00a0trial.\u00a0Lancet\u00a0Oncol.\u00a014\u00a0(6):\u00a0\n552\u201062.\u00a0\n204. MSD\u00a0(2015).\u00a0Zoely\u00a02,5\u00a0mg/1,5\u00a0mg\u00a0Filmtabletten. \u00a0Stand\u00a0der\u00a0Information: \u00a0Januar\u00a02015.\u00a0\n205. MSD\u00a0(2012):\u00a0Rote\u2010Hand\u2010Brief\u00a0\u2013\u00a0Information \u00a0f\u00fcr\u00a0Angeh\u00f6rige \u00a0der\u00a0medizinischen \u00a0Fachkreise \u00a0\u00fcber\u00a0\nArzneimittelinteraktionen \u00a0zwischen\u00a0Victrelis\u00ae\u00a0(Boceprevir) \u00a0und\u00a0Ritonavir\u2010geboosterten \u00a0HIV\u2010Proteaseinhibitoren. \u00a0\nStand:\u00a023.02.2012. \u00a0\n206. M\u00fcller\u00a0FM,\u00a0Bend\u00a0J,\u00a0Rietschel\u00a0E\u00a0(2013).\u00a0S3\u00a0\u2010\u00a0Leitlinie\u00a0\u201eLungenerkrankung \u00a0bei\u00a0Mukoviszidose\u201c, \u00a0Modul\u00a01:\u00a0Diagnostik \u00a0\nund\u00a0Therapie\u00a0nach\u00a0dem\u00a0ersten\u00a0Nachweis \u00a0von\u00a0Pseudomonas \u00a0aeruginosa. \u00a0AWMF\u2010Register\u00a0Nr.\u00a0026/022,\u00a0Klasse:\u00a0S3.\u00a0\nAktueller\u00a0 Stand\u00a0 06/2013.\u00a0 http://www.awmf.org/uploads/tx_szleitlinien/026 \u2010\n022l_S3_Lungenerkrankung_bei _Mukoviszidose_Modul_1_2013 \u201006_01.pdf. \u00a0Letzter\u00a0Zugriff\u00a023.06.2015. \u00a0\n207. Mutschler \u00a0E,\u00a0Geisslinger \u00a0G,\u00a0Kroemer\u00a0HK,\u00a0Ruth\u00a0P,\u00a0Sch\u00e4fer\u2010Korting\u00a0M\u00a0(2008).\u00a0Arzneimittelwirkungen \u00a0\u2013\u00a0Lehrbuch \u00a0der\u00a0\nPharmakologie \u00a0und\u00a0Toxikologie. \u00a09.,\u00a0vollst\u00e4ndig \u00a0neu\u00a0bearbeitete \u00a0und\u00a0erweitere \u00a0Auflage.\u00a0Stuttgart: \u00a0\nWissenschaftliche \u00a0Verlagsgesellschaft. \u00a0\n208. N.N\u00a0(2013).\u00a0Ceftaroline \u00a0fosamil:\u00a0just\u00a0another\u00a0intravenous \u00a0antibiotic. \u00a0Prescrire\u00a0Int.\u00a022:\u00a0291.\u00a0\n209. Naehrlich \u00a0L,\u00a0Stuhrmann \u2010Spangenberg \u00a0M,\u00a0Barben\u00a0J,\u00a0Bargon\u00a0J,\u00a0Blankenstein \u00a0O,\u00a0Bremer\u00a0W,\u00a0Brunsmannn \u00a0F,\u00a0Buchholz\u00a0\nT,\u00a0Ellemunter \u00a0H,\u00a0Fusch\u00a0C,\u00a0Gembruch \u00a0U,\u00a0Hammermann \u00a0J,\u00a0Jacobeit\u00a0J,\u00a0Jung\u00a0A,\u00a0Keim\u00a0V,\u00a0Loff\u00a0S,\u00a0Mayr\u00a0S,\u00a0Pfeiffer\u2010Auler\u00a0S,\u00a0\nRossi\u00a0R,\u00a0Sitter\u00a0H,\u00a0Stern\u00a0M,\u00a0Stra\u00dfburg \u00a0C,\u00a0Derichs\u00a0N\u00a0(2013).\u00a0S2\u2010Konsensus \u2010Leitlinie\u00a0\u201eDiagnose \u00a0der\u00a0Mukoviszidose\u201c \u00a0\nunter\u00a0Federf\u00fchrung \u00a0der\u00a0Gesellschaft \u00a0f\u00fcr\u00a0P\u00e4diatrischen \u00a0Pneumologie. \u00a0AWMF\u2010Register\u00a0Nr.\u00a0026/023\u00a0Klasse:\u00a0S2k.\u00a0\u00a0\nhttp://www.awmf.org/upl oads/tx_szleitlinien/026 \u2010023lS_2k_Diagnose_der_Mukoviszidose_2013 \u201007.pdf.\u00a0Letzter\u00a0\nZugriff\u00a027.04.2015. \u00a0\n210. NVL\u00a0\u2013\u00a0Nationale \u00a0VersorgungsLeitlinie \u00a0(2013).\u00a0Therapie\u00a0des\u00a0Typ\u20102\u2010Diabetes\u00a0Langfassung. \u00a01.\u00a0Auflage,\u00a0Version\u00a04:\u00a0\nAugust\u00a02013.\u00a0Zuletzt\u00a0ge\u00e4ndert: \u00a0November \u00a02014.\u00a0G\u00fcltigkeit \u00a02018.\u00a0AWMF\u00a0\u2013\u00a0RegisterNr.: \u00a0nvl\u2010001g.\u00a0www.awmf.org, \u00a0\nletzter\u00a0Zugriff:\u00a028.03.2015. \u00a0\n211. NCCN\u00a0\u2013\u00a0National\u00a0Comprehensive \u00a0Cancer\u00a0Network\u00a0(2014).\u00a0\u00a0Non\u2010Hodgkin\u2019s \u00a0Lymphomas \u00a0\u2013\u00a0Clinical\u00a0Practice\u00a0\nGuidelines \u00a0in\u00a0Oncology. \u00a0http://www.nccn.org/about/nhl.pdf. \u00a0Stand\u00a0der\u00a0Information: \u00a0April\u00a02014.\u00a0Letzter\u00a0Zugriff:\u00a0\n24.07.2015. \u00a0\n212. Nelson\u00a0HD\u00a0(2002).\u00a0Hormone \u00a0Replacement \u00a0Therapy\u00a0and\u00a0Osteoporosis. \u00a0Rockville: \u00a0Agency\u00a0for\u00a0Healthcare \u00a0Research\u00a0\nand\u00a0Quality.\u00a0http://www.ncbi.nlm.nih.gov/books/NBK42693/. \u00a0Letzter\u00a0Zugriff\u00a023.06.2015. \u00a0\n213. Ness\u00a0J,\u00a0Aronow\u00a0WS,\u00a0Beck\u00a0G\u00a0(2006).\u00a0Menopausal \u00a0symptoms \u00a0after\u00a0cessation \u00a0of\u00a0hormone \u00a0replacement \u00a0therapy.\u00a0\nMaturitas. \u00a053\u00a0(3):\u00a0356\u201061.\u00a0\u00a0\n262\u00a0214. Netzwerk \u00a0Hypophysen \u2010\u00a0und\u00a0Nebennierenerkrankungen \u00a0e.V.\u00a0(2014).\u00a0Informationsbrosch\u00fcre \u00a0Cushing\u2010Syndrom\u00a0f\u00fcr\u00a0\nPatientinnen \u00a0 und\u00a0 Patienten. \u00a0 http://www.glandula \u2010\nonline.de/fileadmin/krankheitsb ilder_broschueren/Cushing.pdf. \u00a0Letzter\u00a0Zugriff:\u00a015.05.2015. \u00a0\n215. Nguy\u00ean\u2010Pascal\u00a0ML,\u00a0Thomas\u00a0JL,\u00a0Bergougnoux \u00a0L,\u00a0Garnero\u00a0P,\u00a0Drapier\u2010Faure\u00a0E,\u00a0Delmas\u00a0PD\u00a0(2005).\u00a0Nomegestrol \u00a0\nacetate\u00a0may\u00a0enhance\u00a0the\u00a0skeletal\u00a0effects\u00a0of\u00a0estradiol\u00a0on\u00a0biochemical \u00a0markers\u00a0of\u00a0bone\u00a0turnover\u00a0in\u00a0menopausal \u00a0\nwomen\u00a0after\u00a0a\u00a012\u2010week\u00a0treatment \u00a0period.\u00a0Climacteric. \u00a08:\u00a0136\u2010145.\u00a0\u00a0\n216. Ni\u00a0H,\u00a0Soe\u00a0Z,\u00a0Moe\u00a0S\u00a0(2014).\u00a0Aclidinium \u00a0bromide\u00a0for\u00a0stable\u00a0chronic\u00a0obstructive \u00a0pulmonary \u00a0disease.\u00a0Cochrane \u00a0\nDatabase \u00a0Syst\u00a0Rev.\u00a09:CD010509. \u00a0doi:\u00a010.1002/14651858.CD010509.pub2. \u00a0\n217. Nordic\u00a0Pharma\u00a0(2013).\u00a0Zusammenfassung \u00a0der\u00a0Merkmale \u00a0des\u00a0Arzneimittels \u00a0Teysuno\u00a015\u00a0mg/4,35\u00a0mg/11,8\u00a0mg\u00a0\nHartkapseln \u00a0bzw.\u00a0Teysuno\u00a020\u00a0mg/5,8\u00a0mg/15,8\u00a0mg\u00a0Hartkapseln. \u00a0Stand\u00a0der\u00a0Information: \u00a0September \u00a02013.\u00a0\n218. Novartis\u00a0Pharma\u00a0(2014).\u00a0Fachinformation \u00a0Lucentis\u00ae \u00a0Injektionsl\u00f6sung. \u00a0Stand\u00a0der\u00a0Information: \u00a0September \u00a02014.\u00a0\n219. Novartis\u00a0Pharma\u00a0(2015a).\u00a0Fachinformation \u00a0Signifor\u00ae\u00a0Injektionsl\u00f6sung. \u00a0Stand\u00a0der\u00a0Information: \u00a0M\u00e4rz\u00a02015.\u00a0\n220. Novartis\u00a0Pharma\u00a0(2015b).\u00a0Fachinformation \u00a0Signifor\u00ae\u00a0Pulver\u00a0und\u00a0L\u00f6sungsmittel \u00a0zur\u00a0Herstellung \u00a0einer\u00a0\nInjektionssuspension. \u00a0Stand\u00a0der\u00a0Information: \u00a0M\u00e4rz\u00a02015.\u00a0\n221. Novartis\u00a0Pharma\u00a0(2015c).\u00a0Fachinformation \u00a0Jakavi\u00ae\u00a0Tabletten. \u00a0Stand\u00a0der\u00a0Information: \u00a0April\u00a02015.\u00a0\n222. NVL\u00a0\u2013\u00a0Nationale \u00a0VersorgungsLeitlinie \u00a0(2012).\u00a0Nationale \u00a0VersorgungsLeitlinie \u00a0COPD.\u00a0Langfassung. \u00a0Version\u00a01.9.\u00a0\nStand:\u00a0Januar\u00a02012.\u00a0G\u00fcltigkeit \u00a0abgelaufen \u00a0\u2013\u00a0Leitlinie\u00a0in\u00a0\u00dcberarbeitung. \u00a0http://www.leitlinien.de/mdb/downloads/ \u00a0\nnvl/copd/copd \u2010vers1.9\u2010lang.pdf,\u00a0letzter\u00a0Zugriff:\u00a028.12.2014. \u00a0\u00a0\n223. Oba\u00a0Y,\u00a0Lone\u00a0NA\u00a0(2015).\u00a0Comparative \u00a0efficacy\u00a0of\u00a0long\u2010acting\u00a0muscarinic \u00a0antagonists \u00a0in\u00a0preventing \u00a0COPD\u00a0\nexacerbations: \u00a0a\u00a0network\u00a0meta\u2010analysis\u00a0and\u00a0meta\u2010regression. \u00a0Ther\u00a0Adv\u00a0Respir\u00a0Dis.\u00a09\u00a0(1):\u00a03\u201015.\u00a0\n224. Pacini\u00a0F,\u00a0Castagna\u00a0MG,\u00a0Brilli\u00a0L,\u00a0Pentheroudakis \u00a0G;\u00a0ESMO\u00a0Guidelines \u00a0Working\u00a0Group\u00a0(2012).\u00a0Thyroid\u00a0cancer:\u00a0ESMO\u00a0\nClinical\u00a0Practice\u00a0Guidelines \u00a0for\u00a0diagnosis, \u00a0treatment \u00a0and\u00a0follow\u2010up.\u00a0Ann\u00a0Oncol.\u00a02012\u00a0Oct;23\u00a0Suppl\u00a07:vii110\u20109.\u00a0\u00a0\n225. Parry\u00a0BL\u00a0(2008).\u00a0Perimenopausal \u00a0depression. \u00a0Am\u00a0J\u00a0Psychiatry. \u00a0165\u00a0(1):\u00a023\u20107.\u00a0\n226. Passamonti \u00a0F,\u00a0Maffioli\u00a0M,\u00a0Cervantes \u00a0F,\u00a0Vannucchi \u00a0AM,\u00a0Morra\u00a0E,\u00a0Barbui\u00a0T,\u00a0Caramazza \u00a0D,\u00a0Pieri\u00a0L,\u00a0Rumi\u00a0E,\u00a0Gisslinger \u00a0\nH,\u00a0Knoops\u00a0L,\u00a0Kiladjian\u00a0JJ,\u00a0Mora\u00a0B,\u00a0Hollaender \u00a0N,\u00a0Pascutto\u00a0C,\u00a0Harrison\u00a0C,\u00a0Cazzola\u00a0M\u00a0(2014).\u00a0Impact\u00a0of\u00a0ruxolitinib \u00a0on\u00a0\nthe\u00a0natural\u00a0history\u00a0of\u00a0primary\u00a0myelofibrosis: \u00a0a\u00a0comparison \u00a0of\u00a0the\u00a0DIPSS\u00a0and\u00a0the\u00a0COMFORT \u20102\u00a0cohorts.\u00a0Blood.\u00a0123\u00a0\n(12):\u00a01833\u20105.\u00a0\n227. Patel\u00a0S,\u00a0Sinha\u00a0IP,\u00a0Dwan\u00a0K,\u00a0Echevarria \u00a0C,\u00a0Schechter \u00a0M,\u00a0Southern\u00a0KW\u00a0(2015).\u00a0Potentiators \u00a0(specific\u00a0therapies \u00a0for\u00a0\nclass\u00a0III\u00a0and\u00a0IV\u00a0mutations) \u00a0for\u00a0cystic\u00a0fibrosis.\u00a0Cochrane \u00a0Database \u00a0of\u00a0Systematic \u00a0Reviews.\u00a0Issue\u00a03.\u00a0Art.\u00a0No.:\u00a0\nCD009841. \u00a0DOI:\u00a010.1002/14651858.CD009841.pub2. \u00a0\n228. Patsalos\u00a0PN\u00a0(2015).\u00a0The\u00a0clinical\u00a0pharmacology \u00a0profile\u00a0of\u00a0the\u00a0new\u00a0antiepileptic \u00a0drug\u00a0perampanel: \u00a0A\u00a0novel\u00a0\nnoncompetitive \u00a0AMPA\u00a0receptor\u00a0antagonist. \u00a0Epilepsia. \u00a056(1):\u00a012\u201027.\u00a0\n229. Peters\u00a0S,\u00a0Adjei\u00a0AA,\u00a0Gridelli\u00a0C,\u00a0Reck\u00a0M,\u00a0Kerr\u00a0K,\u00a0Felip\u00a0E\u00a0(2012).\u00a0ESMO\u00a0Guideline \u00a0Working\u00a0Group.\u00a0Metastatic \u00a0non\u2010\nsmall\u2010cell\u00a0lung\u00a0cancer\u00a0(NSCLC):\u00a0ESMO\u00a0Clinical\u00a0Practice\u00a0Guidelines \u00a0for\u00a0diagnosis, \u00a0treatment \u00a0and\u00a0follow\u2010up.\u00a0Ann\u00a0\nOncol.;\u00a023\u00a0Suppl\u00a07:vii56\u201064.\u00a0\n230. Pettengell \u00a0R,\u00a0Coiffier\u00a0B,\u00a0Narayanan \u00a0G,\u00a0de\u00a0Mendoza \u00a0FH,\u00a0Digumarti \u00a0R,\u00a0Gomez\u00a0H,\u00a0Zinzani\u00a0PL,\u00a0Schiller\u00a0G,\u00a0Rizzieri\u00a0D,\u00a0\nBoland\u00a0G,\u00a0Cernohous \u00a0P,\u00a0Wang\u00a0L,\u00a0Kuepfer\u00a0C,\u00a0Gorbatchevsky \u00a0I,\u00a0Singer\u00a0JW\u00a0(2012).\u00a0Pixantrone \u00a0dimaleate \u00a0versus\u00a0other\u00a0\nchemotherapeutic \u00a0agents\u00a0as\u00a0a\u00a0single\u2010agent\u00a0salvage\u00a0treatment \u00a0in\u00a0patients\u00a0with\u00a0relapsed\u00a0or\u00a0refractory \u00a0aggressive \u00a0\nnon\u2010Hodgkin\u00a0lymphoma: \u00a0a\u00a0phase\u00a03,\u00a0multicentre, \u00a0open\u2010label,\u00a0randomised \u00a0trial.\u00a0Lancet\u00a0Oncol.\u00a013(7):\u00a0696\u2010706.\u00a0\u00a0\n231. Pfannkuche \u00a0M,\u00a0Glaeske\u00a0G,\u00a0Neye\u00a0H,\u00a0Sch\u00f6ffski\u00a0O,\u00a0Hoffmann \u00a0F\u00a0(2009).\u00a0Kostenvergleiche \u00a0f\u00fcr\u00a0Arzneimittel \u00a0auf\u00a0der\u00a0Basis\u00a0\nvon\u00a0DDD\u00a0im\u00a0Rahmen\u00a0der\u00a0Vertrags\u00e4rztlichen \u00a0Versorgung. \u00a0Gesundh\u00a0\u00f6kon\u00a0Qual\u00a0manag.\u00a014\u00a0(1):\u00a017\u201023.\u00a0 \n263\u00a0232. Pfizer\u00a0(2014a).\u00a0Fachinformation \u00a0Inlyta\u00ae\u00a01/3/5/7\u00a0mg\u00a0Filmtabletten. \u00a0Stand\u00a0der\u00a0Information: \u00a0Mai\u00a02014.\u00a0\n233. Pfizer\u00a0(2014b).\u00a0Fachinformation \u00a0Xalkori\u00ae\u00a0200/250\u00a0mg\u00a0Hartkapseln. \u00a0Stand\u00a0der\u00a0Information: \u00a0August\u00a02014.\u00a0\n234. Porter\u00a0DP,\u00a0Kulkarni\u00a0R,\u00a0Fralich\u00a0T,\u00a0Miller\u00a0MD,\u00a0White\u00a0KL\u00a0(2015).\u00a096\u2010week\u00a0resistance \u00a0analyses\u00a0of\u00a0the\u00a0STaR\u00a0study:\u00a0\nrilpivirine/emtricitabine/tenofovir \u00a0DF\u00a0versus\u00a0efavirenz/emtricitabine/tenofovir \u00a0DF\u00a0in\u00a0antiretroviral \u2010naive,\u00a0HIV\u20101\u2010\ninfected\u00a0subjects.\u00a0HIV\u00a0Clin\u00a0Trials.\u00a016\u00a0(1):\u00a030\u20108.\u00a0\n235. Prescrire\u00a0Int.\u00a0(2012).\u00a0Vemurafenib. \u00a0Value\u00a0unclear\u00a0in\u00a0metastatic \u00a0melanoma. \u00a0Prescrire\u00a0Int.\u00a032\u00a0(344):\u00a0414\u2010416.\u00a0\n236. Prescrire\u00a0Int.\u00a0(2012a).\u00a0Estradiol\u00a0+\u00a0Nomegestrol \u00a0+\u00a0Nomegestrol. \u00a0Prescrire\u00a0Int.\u00a021\u00a0(133):\u00a0292.\u00a0\n237. Prescrire\u00a0Int.\u00a0(2013a).\u00a0Ivacaftor\u00a0\u2013\u00a0Uncertain \u00a0harm\u2010benefit\u00a0balance.\u00a0Prescrire\u00a0Int.\u00a022\u00a0(142):\u00a0229.\u00a0\n238. Prescrire\u00a0Int.\u00a0(2013b).\u00a0Tegafur\u00a0+\u00a0gimeracil\u00a0+\u00a0oteracil.\u00a0Just\u00a0another\u00a0fluorouracil \u00a0precursor. \u00a0Prescrire\u00a0Int.\u00a022\u00a0(138):\u00a0\n122.\u00a0\n239. Prescrire\u00a0Int.\u00a0(2014a).\u00a0Decitabine. \u00a0Acute\u00a0myeloid\u00a0leukaemia: \u00a0no\u00a0progress. \u00a0Prescrire\u00a0Int.\u00a023\u00a0(148):\u00a092\u20104.\u00a0Review.\u00a0\n240. Prescrire\u00a0Int.\u00a0(2014b).\u00a0Vemurafenib \u00a0(Zelboraf) \u00a0with\u00a0longer\u00a0follow\u00a0up.\u00a0Prescrire\u00a0Int.\u00a034\u00a0(374):\u00a0893\u2010894.\u00a0\n241. Prescrire\u00a0Int.\u00a0(2015).\u00a0Vemurafenib \u00a0(Zelboraf) \u00a0with\u00a0longer\u00a0follow\u2010up.\u00a0Metastatic \u00a0melanoma: \u00a0a\u00a0few\u00a0extra\u00a0months\u00a0of\u00a0\nlife,\u00a0but\u00a0many\u00a0adverse\u00a0effects.\u00a0Prescrire\u00a0Int.\u00a024\u00a0(159):\u00a089\u201090.\u00a0\u00a0\n242. Pro\u00a0B,\u00a0Advani\u00a0R,\u00a0Brice\u00a0P,\u00a0Bartlett\u00a0NL,\u00a0Rosenblatt \u00a0JD,\u00a0Illidge\u00a0T,\u00a0Matous\u00a0J,\u00a0Ramchandren \u00a0R,\u00a0Fanale\u00a0M,\u00a0Connors\u00a0JM,\u00a0\nYang\u00a0Y,\u00a0Sievers\u00a0EL,\u00a0Kennedy\u00a0DA,\u00a0Shustov\u00a0A\u00a0(2012).\u00a0Brentuximab \u00a0vedotin\u00a0(SGN\u201035)\u00a0in\u00a0patients\u00a0with\u00a0relapsed\u00a0or\u00a0\nrefractory \u00a0systemic\u00a0anaplastic \u00a0large\u2010cell\u00a0lymphoma: \u00a0results\u00a0of\u00a0a\u00a0phase\u00a0II\u00a0study.\u00a0J\u00a0Clin\u00a0Oncol.;\u00a030\u00a0(18):\u00a02190\u20106.\u00a0\n243. Pro\u00a0Familia\u00a0(2013).\u00a0Pearl\u00a0Index.\u00a0http://www.profamilia.de/er wachsene/verhuetung/pearl \u2010index.html. \u00a0Stand\u00a0der\u00a0\nInformation: \u00a020.09.2013. \u00a0Letzter\u00a0Zugriff:\u00a024.07.2015. \u00a0\n244. Ramsey\u00a0BW,\u00a0Davies\u00a0J,\u00a0McElvaney \u00a0NG,\u00a0Tullis\u00a0E,\u00a0Bell\u00a0SC,\u00a0D\u0159ev\u00ednek\u00a0P,\u00a0Griese\u00a0M,\u00a0McKone\u00a0EF,\u00a0Wainwright \u00a0CE,\u00a0Konstan\u00a0\nMW,\u00a0Moss\u00a0R,\u00a0Ratjen\u00a0F,\u00a0Sermet\u2010Gaudelus \u00a0I,\u00a0Rowe\u00a0SM,\u00a0Dong\u00a0Q,\u00a0Rodriguez \u00a0S,\u00a0Yen\u00a0K,\u00a0Ordo\u00f1ez\u00a0C,\u00a0Elborn\u00a0JS;\u00a0VX08\u2010770\u2010\n102\u00a0Study\u00a0Group\u00a0(2011).\u00a0A\u00a0CFTR\u00a0potentiator \u00a0in\u00a0patients\u00a0with\u00a0cystic\u00a0fibrosis\u00a0and\u00a0the\u00a0G551D\u00a0mutation. \u00a0N\u00a0Engl\u00a0J\u00a0Med.\u00a0\n365:\u00a01663\u20101672.\u00a0\u00a0\n245. Rathmann \u00a0W,\u00a0Strassburger \u00a0K,\u00a0Heier\u00a0M,\u00a0Holle\u00a0R,\u00a0Thorand\u00a0B,\u00a0Giani\u00a0G,\u00a0Meisinger \u00a0C\u00a0(2009).\u00a0Incidence \u00a0of\u00a0Type\u00a02\u00a0\ndiabetes\u00a0in\u00a0the\u00a0elderly\u00a0German\u00a0population \u00a0and\u00a0the\u00a0effect\u00a0of\u00a0clinical\u00a0and\u00a0lifestyle\u00a0risk\u00a0factors.\u00a0KORA\u00a0S4/F4\u00a0Cohort\u00a0\nstudy,\u00a0Diab\u00a0Med\u00a026:\u00a01212\u20101219.\u00a0\n246. Reid\u00a0R,\u00a0Abramson \u00a0BL,\u00a0Blake\u00a0J,\u00a0Desindes\u00a0S,\u00a0Dodin\u00a0S,\u00a0Johnston\u00a0S,\u00a0Rowe\u00a0T,\u00a0Sodhi\u00a0N,\u00a0Wilks\u00a0P,\u00a0Wolfman \u00a0W;\u00a0Menopause \u00a0\nand\u00a0Osteoporosis \u00a0Working\u00a0Group,\u00a0Fortier\u00a0M,\u00a0Reid\u00a0\u00a0R,\u00a0Abramson \u00a0BL,\u00a0Blake\u00a0J,\u00a0Desindes\u00a0S,\u00a0Dodin\u00a0S,\u00a0Graves\u00a0L,\u00a0Guthrie\u00a0\nB,\u00a0Khan\u00a0A,\u00a0Johnston\u00a0S,\u00a0Rowe\u00a0T,\u00a0Sodhi\u00a0N,\u00a0Wilks\u00a0P,\u00a0Wolfman \u00a0W\u00a0(2014).\u00a0Menopause \u00a0and\u00a0Osteoporosis \u00a0Working\u00a0\nGroup;\u00a0Society\u00a0of\u00a0Obstetricians \u00a0and\u00a0Gynaecologists \u00a0of\u00a0Canada.\u00a0Managing \u00a0menopause. \u00a0J\u00a0Obstet\u00a0Gynaecol \u00a0Can.\u00a036:\u00a0\n830\u2010838.\u00a0\n247. Renoux\u00a0C,\u00a0Dell'aniello \u00a0S,\u00a0Garbe\u00a0E,\u00a0Suissa\u00a0S.\u00a0(2010).\u00a0Transdermal \u00a0and\u00a0oral\u00a0hormone\u00a0replacement \u00a0therapy\u00a0and\u00a0the\u00a0\nrisk\u00a0of\u00a0stroke:\u00a0a\u00a0nested\u00a0case\u2010control\u00a0study.\u00a0BMJ\u00a0340:\u00a0c2519.\u00a0\n248. Riccobene \u00a0TA,\u00a0Rekeda\u00a0L,\u00a0Rank\u00a0D,\u00a0Llorens\u00a0L\u00a0(2013).\u00a0Evaluation \u00a0of\u00a0the\u00a0effect\u00a0of\u00a0a\u00a0supratherapeutic \u00a0dose\u00a0of\u00a0\nintravenous \u00a0ceftaroline \u00a0fosamil\u00a0on\u00a0the\u00a0corrected \u00a0QT\u00a0interval.\u00a0Antimicrob \u00a0Agents\u00a0Chemother. \u00a057:\u00a01777\u20101783.\u00a0\n249. Rini\u00a0BI,\u00a0Escudier\u00a0B,\u00a0Tomczak\u00a0P,\u00a0Kaprin\u00a0A,\u00a0Szczylik\u00a0C,\u00a0Hutson\u00a0TE,\u00a0Michaelson \u00a0MD,\u00a0Gorbunova \u00a0VA,\u00a0Gore\u00a0ME,\u00a0Rusakov\u00a0\nIG,\u00a0Negrier\u00a0S,\u00a0Ou\u00a0YC,\u00a0Castellano \u00a0D,\u00a0Lim\u00a0HY,\u00a0Uemura\u00a0H,\u00a0Tarazi\u00a0J,\u00a0Cella\u00a0D,\u00a0Chen\u00a0C,\u00a0Rosbrook \u00a0B,\u00a0Kim\u00a0S,\u00a0Motzer\u00a0RJ\u00a0\n(2011).\u00a0Comparative \u00a0effectiveness \u00a0of\u00a0axitinib\u00a0versus\u00a0sorafenib \u00a0in\u00a0advanced \u00a0renal\u00a0cell\u00a0carcinoma \u00a0(AXIS):\u00a0a\u00a0\nrandomised \u00a0phase\u00a03\u00a0trial.\u00a0Lancet.\u00a0378(9807): \u00a01931\u20101939.\u00a0\u00a0\n264\u00a0250. Rini\u00a0BI,\u00a0Melichar\u00a0B,\u00a0Ueda\u00a0T,\u00a0Gr\u00fcnwald \u00a0V,\u00a0Fishman\u00a0MN,\u00a0Arranz\u00a0JA,\u00a0Bair\u00a0AH,\u00a0Pithavala\u00a0YK,\u00a0Andrews\u00a0GI,\u00a0Pavlov\u00a0D,\u00a0Kim\u00a0\nS,\u00a0Jonasch\u00a0E\u00a0(2013).\u00a0Axitinib\u00a0with\u00a0or\u00a0without\u00a0dose\u00a0titration\u00a0for\u00a0first\u2010line\u00a0metastatic \u00a0renal\u2010cell\u00a0carcinoma: \u00a0a\u00a0\nrandomised \u00a0double\u2010blind\u00a0phase\u00a02\u00a0trial.\u00a0Lancet\u00a0Oncol.\u00a014\u00a0(12):\u00a01233\u201042.\u00a0\n251. RKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2013).\u00a0HIV/Aids. \u00a0RKI\u2010Ratgeber\u00a0f\u00fcr\u00a0\u00c4rzte.\u00a0Stand\u00a0der\u00a0Information: \u00a020.12.2013. \u00a0\nhttp://www.rki.de/DE/Content/Infekt/EpidB ull/Merkblaetter/Ratgeber_HIV_AIDS.html, \u00a0 letzter\u00a0 Zugriff\u00a0\n22.06.2015. \u00a0\n252. RKI\u00a0 \u2013\u00a0 Robert\u00a0 Koch\u2010Institut\u00a0 (2014a).\u00a0 Chronische \u00a0 Lungenerkrankungen. \u00a0\nhttp://www.rki.de/DE/Content/Gesundheitsmonitoring/ Themen/Chronische_Erkrank ungen/lungene rkrankungen\n/lungenerkrankungen_tab.html;jsession id=0F3A062733A30AB39DC93A14CF095465.2_cid363, \u00a0letzter\u00a0Zugriff\u00a0\n22.06.2015. \u00a0\n253. RKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2014b).\u00a0Epidemiologisches \u00a0Bulletin.\u00a0Sch\u00e4tzung \u00a0der\u00a0Pr\u00e4valenz \u00a0und\u00a0Inzidenz\u00a0von\u00a0HIV\u2010\nInfektionen \u00a0 in\u00a0 Deutschland \u00a0 (Stand:\u00a0 Ende\u00a0 2013)\u00a0\nhttp://www.rki.de/DE/Content/Infe kt/EpidBull/Archiv/2014/Ausgaben/ 44_14.pdf?__blob=publicationFile, \u00a0letzter\u00a0\nZugriff\u00a022.06.2015. \u00a0\n254. RKI\u00a0&\u00a0GEKID\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0&\u00a0Gesellschaft \u00a0der\u00a0epidemiologischen \u00a0Krebsregister \u00a0in\u00a0Deutschland \u00a0(2012).\u00a0\nBeitr\u00e4ge\u00a0zur\u00a0Gesundheitsberichterstattung \u00a0des\u00a0Bundes.\u00a0Krebs\u00a0in\u00a0Deutschland \u00a02007/2008. \u00a0\nhttp://www.rki.de/DE/Content/Gesundheitsmonitoring/ Gesundheitsberichterstatt ung/GBEDownloadsB/KID2012.\npdf?__blob=publicationFile. \u00a0Letzter\u00a0Zugriff:\u00a028.05.2015. \u00a0\n255. RKI\u00a0&\u00a0GEKID\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0&\u00a0Gesellschaft \u00a0der\u00a0epidemiologischen \u00a0Krebsregister \u00a0in\u00a0Deutschland \u00a0(2013a).\u00a0\nBeitr\u00e4ge\u00a0zur\u00a0Gesundheitsberichterstattung \u00a0des\u00a0Bundes.\u00a0Krebs\u00a0in\u00a0Deutschland \u00a02009/2010. \u00a0Non\u2010Hodgkin\u2010\nLymphome. \u00a0\nhttp://www.krebsdaten.de/Krebs/DE/Content/Publik ationen/Krebs_in_Deutschland/kid_2013/kid_2013_c82 \u2010\n85_non_hodgkin.pdf?__blob=publicationFile, \u00a0letzter\u00a0Zugriff\u00a022.06.2015. \u00a0\n256. RKI\u00a0&\u00a0GEKID\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0&\u00a0Gesellschaft \u00a0der\u00a0epidemiologischen \u00a0Krebsregister \u00a0in\u00a0Deutschland \u00a0e.\u00a0V.\u00a0\n(2013b).\u00a0Beitr\u00e4ge\u00a0zur\u00a0Gesundheitsberichterstattung \u00a0des\u00a0Bundes.\u00a0Krebs\u00a0in\u00a0Deutschland \u00a02009/2010. \u00a0Magen.\u00a0\nhttp://www.krebsdaten.de/Krebs/DE/Content/Publik ationen/Krebs_in_Deutschland/kid_2013/kid_2013_c16_ma\ngen.pdf?__blob=publicationFile, \u00a0letzter\u00a0Zugriff\u00a022.06.2015. \u00a0\n257. RKI\u00a0&\u00a0ZfKD\u00a0(2013a).\u00a0Robert\u2010Koch\u2010Institut\u00a0&\u00a0Zentrum\u00a0f\u00fcr\u00a0Krebsregisterdaten \u00a0\u2013\u00a0Krebsarten \u00a0\u2013\u00a0Nierenkrebs. \u00a0\nhttp://www.rki.de/Krebs/DE/Content/Krebsa rten/Nierenkrebs/nie renkrebs_node.html. \u00a0Stand\u00a0der\u00a0Information: \u00a0\n13.12.2013. \u00a0Letzter\u00a0Zugriff:\u00a026.02.2015. \u00a0\n258. RKI\u00a0&\u00a0ZfKD\u00a0(2013b).\u00a0Robert\u00a0Koch\u00a0Institut\u00a0&\u00a0Zentrum\u00a0f\u00fcr\u00a0Krebsregisterdaten \u00a0(2013b):\u00a0Krebs\u00a0in\u00a0Deutschland \u00a0\n2009/2010 \u00a0 \u2013\u00a0 Morbus\u00a0 Hodgkin\u00a0\nhttp://www.rki.de/Krebs/DE/Content/ Publikationen/Krebs_in_Deutschla nd/kid_2013/krebs_in_deutschland_201\n3.pdf?__blob=publicationFile. \u00a0Stand\u00a0der\u00a0Information: \u00a009.08.2013. \u00a0Letzter\u00a0Zugriff:\u00a028.05.2015. \u00a0\n259. RKI\u00a0&\u00a0ZfKD\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0&\u00a0Zentrum\u00a0f\u00fcr\u00a0Krebsregisterdaten \u00a0(2013c).\u00a0Krebsarten. \u00a0Leuk\u00e4mien. \u00a0\nhttp://www.krebsdaten.de/Krebs/DE/Content/K rebsarten/Leukaemien/l eukaemien_node.html, \u00a0letzter\u00a0Zugriff\u00a0\n22.06.2015. \u00a0\n260. RKI\u00a0&\u00a0ZfKD\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0&\u00a0Zentrum\u00a0f\u00fcr\u00a0Krebsregisterdaten \u00a0(2015).\u00a0Magenkrebs \u00a0(Magenkarzinom) \u00a0ICD\u201010\u00a0\nC16.\u00a0 Stand\u00a0 der\u00a0 Information: \u00a0 25.03.2015. \u00a0\nhttp://www.rki.de/Krebs/DE/Content/Krebsa rten/Magenkrebs/mage nkrebs_node.html, \u00a0 letzter\u00a0 Zugriff\u00a0\n22.06.2015. \u00a0\n261. Robert\u00a0C,\u00a0Thomas\u00a0L,\u00a0Bondarenko \u00a0I,\u00a0O\u2019Day\u00a0S,\u00a0M\u00a0D\u00a0JW,\u00a0Garbe\u00a0C,\u00a0Lebbe\u00a0C,\u00a0Baurain\u00a0JF,\u00a0Testori\u00a0A,\u00a0Grob\u00a0JJ,\u00a0Davidson\u00a0N,\u00a0\nRichards\u00a0J,\u00a0Maio\u00a0M,\u00a0Hauschild \u00a0A,\u00a0Miller\u00a0WH\u00a0Jr,\u00a0Gascon\u00a0P,\u00a0Lotem\u00a0M,\u00a0Harmankaya \u00a0K,\u00a0Ibrahim\u00a0R,\u00a0Francis\u00a0S,\u00a0Chen\u00a0TT,\u00a0\nHumphrey \u00a0R,\u00a0Hoos\u00a0A,\u00a0Wolchok\u00a0JD\u00a0(2011a).\u00a0Ipilimumab \u00a0plus\u00a0dacarbazine \u00a0for\u00a0previously \u00a0untreated \u00a0metastatic \u00a0\nmelanoma. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a0364:\u00a02517\u20132526. \u00a0 \n265\u00a0262. Robert\u00a0C,\u00a0Arnault\u00a0JP,\u00a0Mateus\u00a0C\u00a0(2011b).\u00a0RAF\u00a0inhibition \u00a0and\u00a0induction \u00a0of\u00a0cutaneous \u00a0squamous \u00a0cell\u00a0carcinoma. \u00a0Curr\u00a0\nOpin\u00a0Oncol.\u00a023\u00a0(2):\u00a0177\u201082.\u00a0\n263. Roche\u00a0(2013).\u00a0Fachinformation \u00a0Zelboraf\u00ae \u00a0240\u00a0mg\u00a0Filmtabletten. \u00a0Stand\u00a0der\u00a0Information: \u00a0Dezember \u00a02013.\u00a0\n264. Roche\u00a0(2013a).\u00a0Rote\u2010Hand\u2010Brief:\u00a0Zelboraf\u00ae \u00a0(Vemurafenib) \u00a0Wichtige\u00a0Arzneimittelwarnung: \u00a0Risiko\u00a0f\u00fcr\u00a0eine\u00a0\nProgression \u00a0maligner\u00a0Erkrankungen \u00a0und\u00a0\u00a0Arzneimittelausschlag \u00a0mit\u00a0Eosinophilie \u00a0und\u00a0systemischen \u00a0Symptomen \u00a0\n(DRESS\u2010Syndrom) \u00a0in\u00a0Verbindung \u00a0mit\u00a0Zelboraf\u00ae \u00a0(Vemurafenib). \u00a0Stand:\u00a030.08.2013. \u00a0\n265. Rosenfeld \u00a0W,\u00a0Conry\u00a0J,\u00a0Lagae\u00a0L,\u00a0Rozentals \u00a0G,\u00a0Yang\u00a0H,\u00a0Fain\u00a0R,\u00a0Williams\u00a0B,\u00a0Kumar\u00a0\u00a0D,\u00a0Zhu\u00a0J,\u00a0Laurenza\u00a0A\u00a0(2015).\u00a0Efficacy\u00a0\nand\u00a0safety\u00a0of\u00a0perampanel \u00a0in\u00a0adolescent \u00a0patients\u00a0with\u00a0drug\u2010resistant\u00a0partial\u00a0seizures\u00a0in\u00a0three\u00a0double\u2010blind,\u00a0\nplacebo\u2010controlled, \u00a0phase\u00a0III\u00a0randomized \u00a0clinical\u00a0studies\u00a0and\u00a0a\u00a0combined \u00a0extension \u00a0study.\u00a0Eur\u00a0J\u00a0Paediatr\u00a0Neurol.\u00a0\npii:\u00a0S1090\u20103798(15)00042 \u20102.\u00a0\n266. Rossouw\u00a0JE,\u00a0Anderson \u00a0GL,\u00a0Prentice\u00a0RL,\u00a0LaCroix\u00a0AZ,\u00a0Kooperberg \u00a0C,\u00a0Stefanick\u00a0ML,\u00a0Jackson\u00a0RD,\u00a0Beresford \u00a0SA,\u00a0Howard\u00a0\nBV,\u00a0Johnson\u00a0KC,\u00a0Kotchen\u00a0JM,\u00a0Ockene\u00a0J;\u00a0Writing\u00a0Group\u00a0for\u00a0the\u00a0Women's \u00a0Health\u00a0Initiative\u00a0Investigators \u00a0(2002).\u00a0\nRisks\u00a0and\u00a0benefits\u00a0of\u00a0estrogen\u00a0plus\u00a0progestin \u00a0in\u00a0healthy\u00a0postmenopausal \u00a0women:\u00a0principal\u00a0results\u00a0From\u00a0the\u00a0\nWomen's \u00a0Health\u00a0Initiative\u00a0randomized \u00a0controlled \u00a0trial.\u00a0JAMA.\u00a0288\u00a0(3):\u00a0321\u201033.\u00a0\n267. Ryan\u00a0R,\u00a0Dayaram\u00a0YK,\u00a0Schaible\u00a0D,\u00a0Coate\u00a0B,\u00a0Anderson \u00a0D\u00a0(2013).\u00a0Outcomes \u00a0in\u00a0older\u00a0versus\u00a0younger\u00a0patients\u00a0over\u00a096\u00a0\nweeks\u00a0in\u00a0HIV\u20101\u2010\u00a0infected\u00a0patients\u00a0treated\u00a0with\u00a0rilpivirine \u00a0or\u00a0efavirenz\u00a0in\u00a0ECHO\u00a0and\u00a0THRIVE.\u00a0Curr\u00a0HIV\u00a0Res.\u00a011\u00a0(7):\u00a0\n570\u20105.\u00a0\u00a0\n268. Scheen\u00a0AJ\u00a0(2015).\u00a0Pharmacodynamics, \u00a0efficacy\u00a0and\u00a0safety\u00a0of\u00a0sodium\u2010glucose\u00a0co\u2010transporter \u00a0type\u00a02\u00a0(SGLT2)\u00a0\ninhibitors \u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0type\u00a02\u00a0diabetes\u00a0mellitus.\u00a0Drugs.\u00a075:\u00a033\u201059.\u00a0\n269. Scherbaum \u00a0WA\u00a0(2015).\u00a0Informationen \u00a0f\u00fcr\u00a0Patienten \u00a0und\u00a0Fachleute \u00a0aus\u00a0erster\u00a0Hand.\u00a0Schwerpunkt: \u00a0\nEndokrinologie/Diabetologie. \u00a0Morbus\u00a0Cushing.\u00a0http://www.diabetes \u2010deutschland.de/morbuscushing/, \u00a0letzter\u00a0\nZugriff:\u00a015.05.2014. \u00a0\n270. Schierbeck \u00a0LL,\u00a0Rejnmark \u00a0L,\u00a0Tofteng\u00a0CL,\u00a0Stilgren\u00a0L,\u00a0Eiken\u00a0P,\u00a0Mosekilde \u00a0L,\u00a0K\u00f8ber\u00a0L,\u00a0Jensen\u00a0JE\u00a0(2012).\u00a0Effect\u00a0of\u00a0\nhormone \u00a0replacement \u00a0therapy\u00a0on\u00a0cardiovascular \u00a0events\u00a0in\u00a0recently\u00a0postmenopausal \u00a0women:\u00a0randomised \u00a0trial.\u00a0\nBMJ.\u00a0345:\u00a0e6409.\u00a0\n271. Sch\u00f6fer\u00a0H,\u00a0Bruns\u00a0R,\u00a0Effendy\u00a0I,\u00a0Hartmann \u00a0M,\u00a0Jappe\u00a0U,\u00a0Plettenberg \u00a0A,\u00a0Reimann\u00a0H,\u00a0Seifert\u00a0H,\u00a0Shah\u00a0P,\u00a0Sunderk\u00f6tter \u00a0\nC1,\u00a0Weberschock \u00a0T,\u00a0Wichelhaus \u00a0TA,\u00a0Nast\u00a0A\u00a0(2011).\u00a0Diagnostik \u00a0und\u00a0Therapie\u00a0Staphylococcus \u00a0aureus\u00a0bedingter \u00a0\nInfektionen \u00a0der\u00a0Haut\u00a0und\u00a0Schleimh\u00e4ute. \u00a0S2k\u00a0\u2013\u00a0IDA\u00a0Leitlinie\u00a0der\u00a0Deutschen \u00a0Dermatologischen \u00a0Gesellschaft \u00a0u.a.\u00a0\nAWMF\u2010Register\u00a0Nr.:\u00a0013/038.\u00a0\n272. Schrader\u00a0WF\u00a0(2006).\u00a0[Age\u2010related\u00a0macular\u00a0degeneration: \u00a0a\u00a0socioeconomic \u00a0time\u00a0bomb\u00a0in\u00a0our\u00a0aging\u00a0society].\u00a0\nOphthalmologe. \u00a0103\u00a0(9):\u00a0742\u20108.\u00a0\u00a0\n273. Schwabe\u00a0U\u00a0&\u00a0Paffrath\u00a0D\u00a0(2011).\u00a0Arzneiverordnungs \u2010Report\u00a02011.\u00a0Berlin,\u00a0Heidelberg: \u00a0Springer\u2010Verlag.\u00a0\n274. Schwabe\u00a0U\u00a0&\u00a0Paffrath\u00a0D\u00a0(2013).\u00a0Arzneiverordnungs \u2010Report\u00a02013.\u00a0Berlin,\u00a0Heidelberg: \u00a0Springer\u2010Verlag.\u00a0\n275. Schwabe\u00a0U\u00a0&\u00a0Paffrath\u00a0D\u00a0(2014).\u00a0Arzneiverordnungs \u2010Report\u00a02014.\u00a0Berlin,\u00a0Heidelberg: \u00a0Springer\u2010Verlag.\u00a0\n276. Schwabe\u00a0U\u00a0(2014).\u00a0Sexualhormone. \u00a0In:\u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs \u2010Report\u00a02014.\u00a0Berlin,\u00a0\nHeidelberg: \u00a0Springer\u2010Verlag.\u00a0\n277. Shaw\u00a0AT,\u00a0Kim\u00a0DW,\u00a0Nakagawa \u00a0K,\u00a0Seto\u00a0T,\u00a0Crin\u00f2\u00a0L,\u00a0Ahn\u00a0M,\u00a0De\u00a0Pas\u00a0T,\u00a0Besse\u00a0B,\u00a0Solomon\u00a0B,\u00a0Blackhall\u00a0FH,\u00a0Wu\u00a0Y,\u00a0Thomas\u00a0\nM,\u00a0O'Byrne\u00a0KJ,\u00a0Moro\u2010Sibilot\u00a0D,\u00a0Camidge\u00a0R,\u00a0Hirsh\u00a0V,\u00a0Mok\u00a0TSK,\u00a0Tassell\u00a0V,\u00a0Polli\u00a0A,\u00a0Janne\u00a0PA\u00a0(2012).\u00a0Phase\u00a0III\u00a0study\u00a0of\u00a0\ncrizotinib \u00a0versus.\u00a0pemetrexed \u00a0or\u00a0docetaxel \u00a0chemotherapy \u00a0in\u00a0patients\u00a0with\u00a0advanced \u00a0ALK\u2010positive\u00a0NSCLC\u00a0(PROFILE\u00a0\n1007).\u00a0Presented \u00a0at\u00a0the\u00a037th\u00a0ESMO\u00a0Congress\u00a0(abstract\u00a02862),\u00a0Wien.\u00a0http://oncologypro.esmo.org/Meeting \u2010\nResources/ESMO \u20102012/Phase \u2010III\u2010study\u2010of\u2010crizotinib \u2010versus\u2010pemetrexed \u2010or\u2010docetaxel \u2010chemotherapy \u2010in\u2010patients\u2010\nwith\u2010advanced \u2010ALK\u2010positive\u2010non\u2010small\u2010cell\u2010lung\u2010cancer\u2010NSCLC\u2010PROFILE\u20101007.\u00a0Letzter\u00a0Zugriff:\u00a022.06.2015. \u00a0\u00a0\n266\u00a0278. Shirley\u00a0DA,\u00a0Heil\u00a0EL,\u00a0Johnson\u00a0JK\u00a0(2013).\u00a0Ceftaroline \u00a0fosamil:\u00a0a\u00a0brief\u00a0clinical\u00a0review.\u00a0Infect\u00a0Dis\u00a0Ther.\u00a02:\u00a095\u2010110.\u00a0\n279. Sitruk\u2010Ware\u00a0R\u00a0(2004).\u00a0New\u00a0progestogens: \u00a0a\u00a0review\u00a0of\u00a0their\u00a0effects\u00a0in\u00a0perimenopausal \u00a0and\u00a0postmenopausal \u00a0\nwomen.\u00a0Drugs\u00a0Aging.\u00a021:\u00a0865\u2010883.\u00a0\n280. Skouby\u00a0SO\u00a0(2010).\u00a0Contraceptive \u00a0use\u00a0and\u00a0behavior\u00a0in\u00a0the\u00a021st\u00a0century:\u00a0a\u00a0comprehensive \u00a0study\u00a0across\u00a0five\u00a0\nEuropean \u00a0countries. \u00a0Eur\u00a0J\u00a0Contracept \u00a0Reprod\u00a0Health\u00a0Care.\u00a0Suppl\u00a02:\u00a0S42\u201053.\u00a0\n281. Sosman\u00a0JA,\u00a0Kim\u00a0KB,\u00a0Schuchter \u00a0L,\u00a0Gonzalez\u00a0R,\u00a0Pavlick\u00a0AC,\u00a0Weber\u00a0JS,\u00a0McArthur \u00a0GA,\u00a0Hutson\u00a0TE,\u00a0Moschos\u00a0SJ,\u00a0Flaherty\u00a0\nKT,\u00a0Hersey\u00a0P,\u00a0Kefford\u00a0R,\u00a0Lawrence \u00a0D,\u00a0Puzanov\u00a0I,\u00a0Lewis\u00a0KD,\u00a0Amaravadi \u00a0RK,\u00a0Chmielowski \u00a0B,\u00a0Lawrence \u00a0HJ,\u00a0Shyr\u00a0Y,\u00a0Ye\u00a0\nF,\u00a0Li\u00a0J,\u00a0Nolop\u00a0KB,\u00a0Lee\u00a0RJ,\u00a0Joe\u00a0AK,\u00a0Ribas\u00a0A\u00a0(2012).\u00a0Survival\u00a0in\u00a0BRAF\u00a0V600\u2010mutant\u00a0advanced \u00a0melanoma \u00a0treated\u00a0with\u00a0\nvemurafenib. \u00a0N\u00a0Engl\u00a0J\u00a0Med.\u00a0366(8):\u00a0707\u201014.\u00a0\n282. Stomati\u00a0M,\u00a0Bersi\u00a0C,\u00a0Rubino\u00a0S,\u00a0Palumbo\u00a0M,\u00a0Comitini\u00a0G,\u00a0Genazzani \u00a0AD,\u00a0Santuz\u00a0M,\u00a0Petraglia\u00a0F,\u00a0Genazzani \u00a0AR\u00a0(1997).\u00a0\nNeuroendocrine \u00a0effects\u00a0of\u00a0different\u00a0estradiol\u2010progestin \u00a0regimens \u00a0in\u00a0postmenopausal \u00a0women.\u00a0Maturitas. \u00a028:\u00a0127\u2010\n135.\u00a0\u00a0\n283. Takagi\u00a0H,\u00a0Mizuno\u00a0Y,\u00a0Niwa\u00a0M,\u00a0Goto\u00a0SN,\u00a0Umemoto \u00a0T\u00a0(2014).\u00a0A\u00a0meta\u2010analysis\u00a0of\u00a0randomized \u00a0\u00a0controlled \u00a0trials\u00a0of\u00a0\nazilsartan \u00a0therapy\u00a0for\u00a0blood\u00a0pressure\u00a0reduction. \u00a0Hypertens \u00a0Res.\u00a037(5):\u00a0432\u20107.\u00a0\n284. Takeda\u00a0(2014a).\u00a0Fachinformation \u00a0Edarbi\u00a020m,\u00a040,\u00a080\u00a0mg\u00a0Tabletten. \u00a0Stand\u00a0der\u00a0Information: \u00a0September \u00a02014.\u00a0\n285. Taylor\u2010Cousar\u00a0J,\u00a0Niknian\u00a0M,\u00a0Gilmartin \u00a0G,\u00a0Pilewski\u00a0JM;\u00a0for\u00a0the\u00a0VX11\u2010770\u2010901\u00a0investigators \u00a0(2015).\u00a0Effect\u00a0of\u00a0ivacaftor\u00a0\nin\u00a0patients\u00a0with\u00a0advanced \u00a0cystic\u00a0fibrosis\u00a0and\u00a0a\u00a0G551D\u2010CFTR\u00a0mutation: \u00a0Safety\u00a0and\u00a0efficacy\u00a0in\u00a0an\u00a0expanded \u00a0access\u00a0\nprogram\u00a0in\u00a0the\u00a0United\u00a0States.\u00a0J\u00a0Cyst\u00a0Fibros.\u00a0Feb\u00a011.\u00a0pii:\u00a0S1569\u20101993(15)00010 \u20107.\u00a0\u00a0\n286. Teva\u00a0(2013).\u00a0Fachinformation \u00a0Naemis\u00ae. \u00a0Stand\u00a0der\u00a0Information: \u00a0April\u00a02013.\u00a0\n287. Tefferi\u00a0A,\u00a0Litzow\u00a0MR,\u00a0Pardanani \u00a0(2011).\u00a0A.\u00a0Long\u2010term\u00a0outcome\u00a0of\u00a0treatment \u00a0with\u00a0ruxolitinib \u00a0in\u00a0myelofibrosis. \u00a0N\u00a0\nEngl\u00a0J\u00a0Med.\u00a0365\u00a0(15):\u00a01455\u20107.\u00a0\n288. The\u00a0Diabetic\u00a0Retinopathy \u00a0Clinical\u00a0Research\u00a0Network\u00a0(2015).\u00a0Aflibercept, \u00a0Bevacizumab, \u00a0or\u00a0Ranibizumab \u00a0for\u00a0\nDiabetic\u00a0Macular\u00a0Edema.\u00a0N\u00a0Engl\u00a0J\u00a0Med.\u00a0Feb\u00a018.\u00a0[Epub\u00a0ahead\u00a0of\u00a0print].\u00a0\n289. van\u00a0Leeuwen\u00a0R,\u00a0Klaver\u00a0CC,\u00a0Vingerling \u00a0JR,\u00a0Hofman\u00a0A,\u00a0de\u00a0Jong\u00a0PT\u00a0(2003).\u00a0Epidemiology \u00a0of\u00a0age\u2010related\u00a0maculopathy: \u00a0\na\u00a0review.\u00a0Eur\u00a0J\u00a0Epidemiol. \u00a018(9):\u00a0845\u201054.\u00a0\n290. Vannucchi \u00a0AM,\u00a0Kiladjian\u00a0JJ,\u00a0Griesshammer \u00a0M,\u00a0Masszi\u00a0T,\u00a0Durrant\u00a0S,\u00a0Passamonti \u00a0F,\u00a0Harrison\u00a0CN,\u00a0Pane\u00a0F,\u00a0Zachee\u00a0P,\u00a0\nMesa\u00a0R,\u00a0He\u00a0S,\u00a0Jones\u00a0MM,\u00a0Garrett\u00a0W,\u00a0Li\u00a0J,\u00a0Pirron\u00a0U,\u00a0Habr\u00a0D,\u00a0Verstovsek \u00a0S\u00a0(2015).\u00a0Ruxolitinib \u00a0versus\u00a0standard\u00a0\ntherapy\u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0polycythemia \u00a0vera.\u00a0N\u00a0Engl\u00a0J\u00a0Med.\u00a0372\u00a0(5):\u00a0426\u201035.\u00a0\n291. Verstovsek \u00a0S,\u00a0Mesa\u00a0RA,\u00a0Gotlib\u00a0J,\u00a0Levy\u00a0RS,\u00a0Gupta\u00a0V,\u00a0DiPersio\u00a0JF,\u00a0Catalano\u00a0JV,\u00a0Deininger \u00a0M,\u00a0Miller\u00a0C,\u00a0Silver\u00a0RT,\u00a0Talpaz\u00a0\nM,\u00a0Winton\u00a0EF,\u00a0Harvey\u00a0JH\u00a0Jr,\u00a0Arcasoy\u00a0MO,\u00a0Hexner\u00a0E,\u00a0Lyons\u00a0RM,\u00a0Paquette\u00a0R,\u00a0Raza\u00a0A,\u00a0Vaddi\u00a0K,\u00a0Erickson\u2010Viitanen\u00a0S,\u00a0\nKoumenis \u00a0IL,\u00a0Sun\u00a0W,\u00a0Sandor\u00a0V,\u00a0Kantarjian \u00a0HM\u00a0(2012).\u00a0A\u00a0double\u2010blind,\u00a0placebo\u2010controlled \u00a0trial\u00a0of\u00a0ruxolitinib \u00a0for\u00a0\nmyelofibrosis. \u00a0N\u00a0Engl\u00a0J\u00a0Med.\u00a0366\u00a0(9):\u00a0799\u2010807.\u00a0\n292. Verstovsek \u00a0S,\u00a0Mesa\u00a0RA,\u00a0Gotlib\u00a0J,\u00a0Levy\u00a0RS,\u00a0Gupta\u00a0V,\u00a0DiPersio\u00a0JF,\u00a0Catalano\u00a0JV,\u00a0Deininger \u00a0M,\u00a0Miller\u00a0C,\u00a0Silver\u00a0RT,\u00a0Talpaz\u00a0\nM,\u00a0Winton\u00a0EF,\u00a0Harvey\u00a0JH\u00a0Jr,\u00a0Arcasoy\u00a0MO,\u00a0Hexner\u00a0E,\u00a0Lyons\u00a0RM,\u00a0Paquette\u00a0R,\u00a0Raza\u00a0A,\u00a0Vaddi\u00a0K,\u00a0Erickson\u2010Viitanen\u00a0S,\u00a0\nSun\u00a0W,\u00a0Sandor\u00a0V,\u00a0Kantarjian \u00a0HM\u00a0(2013).\u00a0The\u00a0clinical\u00a0benefit\u00a0of\u00a0ruxolitinib \u00a0across\u00a0patient\u00a0subgroups: \u00a0analysis\u00a0of\u00a0a\u00a0\nplacebo\u2010controlled, \u00a0Phase\u00a0III\u00a0study\u00a0in\u00a0patients\u00a0with\u00a0myelofibrosis. \u00a0Br\u00a0J\u00a0Haematol. \u00a0161\u00a0(4):\u00a0508\u201016.\u00a0\n293. Verstovsek \u00a0S,\u00a0Mesa\u00a0RA,\u00a0Gotlib\u00a0J,\u00a0Levy\u00a0RS,\u00a0Gupta\u00a0V,\u00a0DiPersio\u00a0JF,\u00a0Catalano\u00a0JV,\u00a0Deininger \u00a0MW,\u00a0Miller\u00a0CB,\u00a0Silver\u00a0RT,\u00a0\nTalpaz\u00a0M,\u00a0Winton\u00a0EF,\u00a0Harvey\u00a0JH\u00a0Jr,\u00a0Arcasoy\u00a0MO,\u00a0Hexner\u00a0EO,\u00a0Lyons\u00a0RM,\u00a0Raza\u00a0A,\u00a0Vaddi\u00a0K,\u00a0Sun\u00a0W,\u00a0Peng\u00a0W,\u00a0Sandor\u00a0V,\u00a0\nKantarjian \u00a0H;\u00a0COMFORT \u2010I\u00a0investigators \u00a0(2015).\u00a0Efficacy,\u00a0safety,\u00a0and\u00a0survival\u00a0with\u00a0ruxolitinib \u00a0in\u00a0patients\u00a0with\u00a0\nmyelofibrosis: \u00a0results\u00a0of\u00a0a\u00a0median\u00a03\u2010year\u00a0follow\u2010up\u00a0of\u00a0COMFORT \u2010I.\u00a0Haematologica. \u00a0100\u00a0(4):\u00a0479\u201088.\u00a0\n294. Vertex\u00a0Pharmaceuticals \u00a0(2015).\u00a0Fachinformation \u00a0Kalydeco\u2122 \u00a0150\u00a0mg\u00a0Filmtabletten. \u00a0Stand\u00a0der\u00a0Information: \u00a0Januar\u00a0\n2015.\u00a0 \n267\u00a0295. Vinogradova \u00a0Y,\u00a0Coupland \u00a0C,\u00a0Hippisley\u2010Cox\u00a0J\u00a0(2015).\u00a0Use\u00a0of\u00a0combined \u00a0oral\u00a0contraceptives \u00a0and\u00a0risk\u00a0of\u00a0venous\u00a0\nthromboembolism: \u00a0nested\u00a0case\u2010control\u00a0studies\u00a0using\u00a0the\u00a0QResearch \u00a0and\u00a0CPRD\u00a0databases. \u00a0BMJ.\u00a0350:\u00a0h2135.\u00a0\u00a0\n296. Vitiello\u00a0D,\u00a0Naftolin\u00a0F,\u00a0Taylor\u00a0HS\u00a0(2007).\u00a0Menopause: \u00a0developing \u00a0a\u00a0rational\u00a0treatment \u00a0plan.\u00a0Gynecol\u00a0Endocrinol. \u00a023\u00a0\n(12):\u00a0682\u201091.\u00a0\u00a0\n297. Vogelmeier \u00a0C,\u00a0Buhl\u00a0R,\u00a0Criee\u00a0CP,\u00a0Gillissen\u00a0A,\u00a0Kardos\u00a0P,\u00a0K\u00f6hler\u00a0D,\u00a0Magnussen \u00a0H,\u00a0Morr\u00a0H,\u00a0Nowak\u00a0D,\u00a0Pfeiffer\u2010Kascha\u00a0D,\u00a0\nPetro\u00a0W,\u00a0Rabe\u00a0K,\u00a0Schultz\u00a0K,\u00a0Sitter\u00a0H,\u00a0Teschler\u00a0H,\u00a0Welte\u00a0T,\u00a0Wettengel \u00a0R,\u00a0Worth\u00a0H\u00a0(2007).\u00a0Leitlinie\u00a0der\u00a0Deutschen \u00a0\nAtemwegsliga \u00a0und\u00a0der\u00a0Deutschen \u00a0Gesellschaft \u00a0f\u00fcr\u00a0Pneumologie \u00a0und\u00a0Beatmungsmedizin \u00a0zur\u00a0Diagnostik \u00a0und\u00a0\nTherapie\u00a0von\u00a0Patienten \u00a0mit\u00a0chronisch \u00a0obstruktiver \u00a0Bronchitis \u00a0und\u00a0Lungenemphysem \u00a0(COPD).\u00a0Pneumologie. \u00a061\u00a0(5):\u00a0\ne1\u00a040.\u00a0\n298. Weeraratna \u00a0AT\u00a0(2012).\u00a0RAF\u00a0around\u00a0the\u00a0edges\u2010\u2010the\u00a0paradox\u00a0of\u00a0BRAF\u00a0inhibitors. \u00a0N\u00a0Engl\u00a0J\u00a0Med.\u00a0366\u00a0(3):\u00a0271\u20103.\u00a0\n299. Wells\u00a0SA\u00a0Jr,\u00a0Robinson \u00a0BG,\u00a0Gagel\u00a0RF,\u00a0Dralle\u00a0H,\u00a0Fagin\u00a0JA,\u00a0Santoro\u00a0M,\u00a0Baudin\u00a0E,\u00a0Elisei\u00a0R,\u00a0Jarzab\u00a0B,\u00a0Vasselli\u00a0JR,\u00a0Read\u00a0J,\u00a0\nLangmuir \u00a0P,\u00a0Ryan\u00a0AJ,\u00a0Schlumberger \u00a0MJ\u00a0(2012).\u00a0Vandetanib \u00a0in\u00a0patients\u00a0with\u00a0locally\u00a0advanced \u00a0or\u00a0metastatic \u00a0\nmedullary \u00a0thyroid\u00a0cancer:\u00a0a\u00a0randomized, \u00a0double\u2010blind\u00a0phase\u00a0III\u00a0trial.\u00a0J\u00a0Clin\u00a0Oncol.\u00a030\u00a0(2):\u00a0134\u201041.\u00a0\n300. Wells\u00a0SA\u00a0Jr.,\u00a0Asa\u00a0SL,\u00a0Dralle\u00a0H,\u00a0Elisei\u00a0R,\u00a0Evans\u00a0DB,\u00a0Gagel\u00a0RF,\u00a0Lee\u00a0N,\u00a0Machens\u00a0A,\u00a0Moley\u00a0JF,\u00a0Pacini\u00a0F,\u00a0Raue\u00a0F,\u00a0Frank\u2010\nRaue\u00a0K,\u00a0Robinson \u00a0B,\u00a0Rosenthal \u00a0MS,\u00a0Santoro\u00a0M,\u00a0Schlumberger \u00a0M,\u00a0Shah\u00a0M,\u00a0Waguespack \u00a0SG\u00a0(2015).\u00a0Revised\u00a0\nAmerican \u00a0Thyroid\u00a0Association \u00a0Guidelines \u00a0for\u00a0the\u00a0Management \u00a0of\u00a0Medullary \u00a0Thyroid\u00a0Carcinoma. \u00a0ATA\u00a0Guideline \u00a0\nmedullary \u00a0cancer\u00a0TKIs.pdf.\u00a0Letzter\u00a0Zugriff:\u00a018.06.2015. \u00a0\n301. Westhoff \u00a0C,\u00a0Kaunitz\u00a0AM,\u00a0Korver\u00a0T,\u00a0Sommer\u00a0W,\u00a0Bahamondes \u00a0L,\u00a0Darney\u00a0P,\u00a0Verhoeven \u00a0C\u00a0(2012).\u00a0Efficacy,\u00a0safety,\u00a0and\u00a0\ntolerability \u00a0of\u00a0a\u00a0monophasic \u00a0oral\u00a0contraceptive \u00a0containing \u00a0nomegestrol \u00a0acetate\u00a0and\u00a017\u03b2\u2010estradiol: \u00a0a\u00a0randomized \u00a0\ncontrolled \u00a0trial.\u00a0Obstet\u00a0Gynecol.\u00a0119:\u00a0989\u2010099.\u00a0\u00a0\n302. WHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization \u00a0(2004).\u00a0Guidelines \u00a0for\u00a0ATC\u00a0classification \u00a0and\u00a0DDD\u00a0assignment \u00a0\u2013\u00a0World\u00a0Health\u00a0\nOrganization \u00a0Collaborating \u00a0Centre\u00a0for\u00a0Drug\u00a0Statistics\u00a0Methodology. \u00a0New\u00a0York:\u00a0World\u00a0Health\u00a0Organization. \u00a0\n303. WHO\u00a0 \u2013\u00a0 World\u00a0 Health\u00a0 Organization \u00a0 (2015a).\u00a0 Epilepsy.\u00a0 Fact\u00a0 Sheet\u00a0 No\u00a0 999.\u00a0\nhttp://www.who.int/mediacentre/factsheets/fs999/en/. \u00a0Stand\u00a0der\u00a0Information: \u00a0Mai\u00a02015.\u00a0Letzter\u00a0Zugriff:\u00a0\n31.05.2015. \u00a0\n304. WHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization \u00a0(2015b).\u00a0\u2013\u00a0HIV/AIDS. \u00a0http://www.who.int/hiv/en/. \u00a0Letzter\u00a0Zugriff:\u00a025.05.2015. \u00a0\n305. Wick\u2010Urban\u00a0B\u00a0(2008).\u00a0Nierenzellkarzinom. \u00a0Deutlich\u00a0bessere\u00a0Prognose \u00a0dank\u00a0neuer\u00a0Arzneistoffe. \u00a0Pharmazeutische \u00a0\nZeitung\u00a0153\u00a033:\u00a014\u201021.\u00a0\n306. Wiegratz\u00a0I,\u00a0Thaler\u00a0CJ\u00a0(2011).\u00a0Hormonal \u00a0contraception \u2010\u2010what\u00a0kind,\u00a0when,\u00a0and\u00a0for\u00a0whom?\u00a0Dtsch\u00a0Arztebl\u00a0Int.\u00a0108:\u00a0\n495\u2010505.\u00a0\n307. Windt\u00a0R\u00a0(2010).\u00a0Analyse\u00a0der\u00a0medikament\u00f6sen \u00a0Versorgung \u00a0von\u00a0Asthmapatienten \u00a0im\u00a0Erwachsenenalter \u00a0mit\u00a0\nRoutinedaten. \u00a0Dissertation. \u00a0Saarbr\u00fccken: \u00a0S\u00fcdwestdeutscher \u00a0Verlag\u00a0f\u00fcr\u00a0Hochschulschriften. \u00a0\n308. Windt\u00a0R,\u00a0Boeschen \u00a0D,\u00a0Glaeske\u00a0G\u00a0(2014).\u00a0Innovationsreport \u00a02014\u00a0\u2013\u00a0Wissenschaftliche \u00a0Studie\u00a0zur\u00a0Versorgung \u00a0mit\u00a0\ninnovativen \u00a0Arzneimitteln \u00a0\u2013\u00a0Eine\u00a0Analyse\u00a0von\u00a0Evidenz\u00a0und\u00a0Effizienz\u00a0(Langfassung). \u00a0Bremen:\u00a0ZeS.\u00a0\u00a0\n309. Wainwright \u00a0CE,\u00a0Elborn\u00a0JS,\u00a0Ramsey\u00a0BW,\u00a0Marigowda \u00a0G,\u00a0Huang\u00a0X,\u00a0Cipolli\u00a0M,\u00a0Colombo\u00a0C,\u00a0Davies\u00a0JC,\u00a0De\u00a0Boeck\u00a0K,\u00a0\nFlume\u00a0PA,\u00a0Konstan\u00a0MW,\u00a0McColley \u00a0SA,\u00a0McCoy\u00a0K,\u00a0McKone\u00a0EF,\u00a0Munck\u00a0A,\u00a0Ratjen\u00a0F,\u00a0Rowe\u00a0SM,\u00a0Waltz\u00a0D,\u00a0Boyle\u00a0MP;\u00a0\nTRAFFIC\u00a0Study\u00a0Group;\u00a0TRANSPORT \u00a0Study\u00a0Group\u00a0(2015).\u00a0Lumacaftor \u2010Ivacaftor\u00a0in\u00a0Patients\u00a0with\u00a0Cystic\u00a0Fibrosis\u00a0\nHomozygous \u00a0for\u00a0Phe508del \u00a0CFTR.\u00a0N\u00a0Engl\u00a0J\u00a0Med.;\u00a0373(3):\u00a0220\u201031.\u00a0\n310. Xie\u00a0M,\u00a0Jiang\u00a0Q,\u00a0Xie\u00a0Y\u00a0(2015).\u00a0Comparison \u00a0between\u00a0decitabine \u00a0and\u00a0azacitidine \u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0myelodysplastic \u00a0\nsyndrome: \u00a0a\u00a0meta\u2010analysis\u00a0with\u00a01,392\u00a0participants. \u00a0Clin\u00a0Lymphoma \u00a0Myeloma \u00a0Leuk.\u00a015\u00a0(1):\u00a022\u20108.\u00a0\u00a0\n268\u00a0311. Xue\u00a0H,\u00a0Lu\u00a0Z,\u00a0Tang\u00a0WL,\u00a0Pang\u00a0LW,\u00a0Wang\u00a0GM,\u00a0Wong\u00a0GW,\u00a0Wright\u00a0JM\u00a0(2015).\u00a0First\u2010line\u00a0drugs\u00a0inhibiting \u00a0the\u00a0renin\u00a0\nangiotensin \u00a0system\u00a0versus\u00a0other\u00a0first\u2010line\u00a0antihypertensive \u00a0\u00a0drug\u00a0classes\u00a0for\u00a0hypertension. \u00a0Cochrane \u00a0Database \u00a0\nSyst\u00a0Rev.\u00a0Jan\u00a011;1:CD008170. \u00a0doi:\u00a010.1002/14651858.CD008170.pub2. \u00a0\u00a0\n312. Younes\u00a0A,\u00a0Gopal\u00a0AK,\u00a0Smith\u00a0SE,\u00a0Ansell\u00a0SM,\u00a0Rosenblatt \u00a0JD,\u00a0Savage\u00a0KJ,\u00a0Ramchandren \u00a0R,\u00a0Bartlett\u00a0NL,\u00a0Cheson\u00a0BD,\u00a0de\u00a0\nVos\u00a0S,\u00a0Forero\u2010Torres\u00a0A,\u00a0Moskowitz \u00a0CH,\u00a0Connors\u00a0JM,\u00a0Engert\u00a0A,\u00a0Larsen\u00a0EK,\u00a0Kennedy\u00a0DA,\u00a0Sievers\u00a0EL,\u00a0Chen\u00a0R\u00a0(2012).\u00a0\nResults\u00a0of\u00a0a\u00a0pivotal\u00a0phase\u00a0II\u00a0study\u00a0of\u00a0Brentuximab \u00a0Vedotin\u00a0for\u00a0patients\u00a0with\u00a0relapsed\u00a0or\u00a0refractory \u00a0Hodgkin\u00b4s \u00a0\nlymphoma. \u00a0J\u00a0Clin\u00a0Oncol\u00a030\u00a0(18),\u00a02183\u20102189.\u00a0\n313. Zaccara\u00a0G,\u00a0Perucca\u00a0E\u00a0(2014).\u00a0Interactions \u00a0between\u00a0antiepileptic \u00a0drugs,\u00a0and\u00a0between\u00a0antiepileptic \u00a0drugs\u00a0and\u00a0other\u00a0\ndrugs.\u00a0Epileptic\u00a0Disord.\u00a016\u00a0(4):\u00a0409\u201031.\u00a0\n \u00a0 \n269\u00a0Abk\u00fcrzungsverzeichnis \u00a0\nAbs.\u00a0\u00a0 \u00a0 \u00a0 Absatz\u00a0\nAKB\u00a0\u00a0 \u00a0 \u00a0 Arzneimittelkursbuch \u00a0\nAkd\u00c4\u00a0\u00a0 \u00a0 \u00a0 Arzneimittelkommission \u00a0der\u00a0deutschen \u00a0\u00c4rzteschaft \u00a0\nAMNOG\u00a0\u00a0 \u00a0 \u00a0 Arzneimittelmarktneuordnungsgesetz \u00a0\na\u2010t\u00a0\u00a0 \u00a0 \u00a0 arznei\u2010telegramm \u00a0\nATC\u2010Code\u00a0\u00a0 \u00a0 \u00a0 Anatomisch \u2010Therapeutisch \u2010Chemischer \u00a0Code\u00a0\nAWMF\u00a0\u00a0 \u00a0 \u00a0 Arbeitsgemeinschaft \u00a0der\u00a0Wissenschaftlichen \u00a0Medizinischen \u00a0Fachgesellschaften \u00a0e.V.\u00a0\u00a0\nBfArM\u00a0\u00a0 \u00a0 \u00a0 Bundesinstitut \u00a0f\u00fcr\u00a0Arzneimittel \u00a0und\u00a0Medizinprodukte \u00a0\nBSC\u00a0\u00a0 \u00a0 \u00a0 Best\u00a0Supportive \u00a0Care\u00a0\nbzgl.\u00a0\u00a0 \u00a0 \u00a0 bez\u00fcglich \u00a0\nbzw.\u00a0\u00a0 \u00a0 \u00a0 beziehungsweise \u00a0\nca.\u00a0\u00a0 \u00a0 \u00a0 circa\u00a0\nCHMP\u00a0\u00a0 \u00a0 \u00a0 Committee \u00a0for\u00a0Medicinal \u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0\nDDD\u00a0\u00a0 \u00a0 \u00a0 Defined\u00a0Daily\u00a0Dose\u00a0\u2013\u00a0definierte \u00a0Tagesdosis \u00a0\nDGN\u00a0\u00a0 \u00a0 \u00a0 Deutsche \u00a0Gesellschaft \u00a0f\u00fcr\u00a0Neurologie \u00a0\nd.h.\u00a0\u00a0 \u00a0 \u00a0 das\u00a0hei\u00dft\u00a0\nDKG\u00a0\u00a0 \u00a0 \u00a0 Deutsche \u00a0Krebsgesellschaft \u00a0\nDPhG\u00a0\u00a0 \u00a0 \u00a0 Deutsche \u00a0Pharmazeutische \u00a0Gesellschaft \u00a0\nDSM\u00a0\u00a0 \u00a0 \u00a0 Diagnostic \u00a0and\u00a0Statistical \u00a0Manual\u00a0of\u00a0Mental\u00a0Disorders \u00a0\nd.V.\u00a0\u00a0 \u00a0 \u00a0 der\u00a0Verfasser \u00a0\nEKG\u00a0\u00a0 \u00a0 \u00a0 Elektrokardiogramm \u00a0\nEMA\u00a0\u00a0 \u00a0 \u00a0 European \u00a0Medicines \u00a0Agency\u00a0\u2013\u00a0Europ\u00e4ische \u00a0Zulassungsbeh\u00f6rde \u00a0\nengl.\u00a0\u00a0 \u00a0 \u00a0 englisch\u00a0\nFDA\u00a0\u00a0 \u00a0 \u00a0 Food\u00a0and\u00a0Drug\u00a0Administration \u00a0\u2013\u00a0US\u2010Amerikanische \u00a0Zulassungsbeh\u00f6rde \u00a0\nFI\u00a0\u00a0 \u00a0 \u00a0 Fachinformation \u00a0\nFVC\u00a0\u00a0 \u00a0 \u00a0 Forcierte\u00a0Vitalkapazit\u00e4t \u00a0\nG\u2010BA\u00a0\u00a0 \u00a0 \u00a0 Gemeinsamer \u00a0Bundesausschuss \u00a0\nGI\u00a0\u00a0 \u00a0 \u00a0 gastrointestinal \u00a0(Magen\u2010Darm)\u00a0\nggf.\u00a0\u00a0 \u00a0 \u00a0 gegebenenfalls \u00a0\nGKV\u00a0\u00a0 \u00a0 \u00a0 Gesetzliche \u00a0Krankenversicherung \u00a0\nI.E.\u00a0\u00a0 \u00a0 \u00a0 Internationale \u00a0Einheiten \u00a0\u00a0\n270\u00a0IFN\u00a0\u00a0 \u00a0 \u00a0 Interferon \u00a0\ni.m.\u00a0\u00a0 \u00a0 \u00a0 intramuskul\u00e4r \u00a0\nIQWiG\u00a0\u00a0 \u00a0 \u00a0 Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit \u00a0im\u00a0Gesundheitswesen \u00a0\ni.v.\u00a0\u00a0 \u00a0 \u00a0 intraven\u00f6s \u00a0\nkg\u00a0\u00a0 \u00a0 \u00a0 Kilogramm \u00a0\nKG\u00a0\u00a0 \u00a0 \u00a0 K\u00f6rpergewicht \u00a0\nLL\u00a0\u00a0 \u00a0 \u00a0 Leitlinie\u00a0\nm2\u00a0\u00a0 \u00a0 \u00a0Quadratmeter \u00a0\nmg\u00a0\u00a0 \u00a0 \u00a0 Milligramm \u00a0\nml\u00a0\u00a0 \u00a0 \u00a0 Milliliter\u00a0\nMS\u00a0\u00a0 \u00a0 \u00a0 Multiple\u00a0Sklerose\u00a0\n\u00b5g\u00a0\u00a0 \u00a0 \u00a0 \u00a0 Mikrogramm \u00a0\nNVL\u00a0\u00a0 \u00a0 \u00a0 Nationale \u00a0Versorgungsleitlinie \u00a0\npU\u00a0\u00a0 \u00a0 \u00a0 Pharmazeutischer \u00a0Unternehmer \u00a0\nPZ\u00a0\u00a0 \u00a0 \u00a0 Pharmazeutische \u00a0Zeitung\u00a0\nRKI\u00a0\u00a0 \u00a0 \u00a0 Robert\u00a0Koch\u2010Institut\u00a0\nRRMS\u00a0\u00a0 \u00a0 \u00a0 Relapsing \u00a0Remitting \u00a0MS\u00a0\nSGB\u00a0V\u00a0\u00a0 \u00a0 \u00a0 Sozialgesetzbuch \u00a05\u00a0\nTK\u00a0\u00a0 \u00a0 \u00a0 Techniker \u00a0Krankenkasse \u00a0\nTsd.\u00a0\u00a0 \u00a0 \u00a0 Tausend\u00a0\nu.a.\u00a0\u00a0 \u00a0 \u00a0 unter\u00a0anderem\u00a0\nUAW\u00a0\u00a0 \u00a0 \u00a0 Unerw\u00fcnschte \u00a0Arzneimittelwirkung(en) \u00a0\nvs.\u00a0\u00a0 \u00a0 \u00a0 versus\u00a0\nWHO\u00a0\u00a0 \u00a0 \u00a0 World\u00a0Health\u00a0Organization \u00a0\u2010\u00a0Weltgesundheitsorganisation \u00a0\nWIdO\u00a0\u00a0 \u00a0 \u00a0 Wissenschaftliches \u00a0Institut\u00a0der\u00a0Ortskrankenkassen \u00a0\nz.B.\u00a0\u00a0 \u00a0 \u00a0 zum\u00a0Beispiel\u00a0\nZNS\u00a0\u00a0 \u00a0 \u00a0 Zentrales \u00a0Nervensystem \u00a0\n \u00a0 \n271\u00a0Abbildungsverzeichnis \u00a0\nAbbildung \u00a01:\u00a0Markteinf\u00fchrung \u00a0von\u00a0Arzneimitteln \u00a0mit\u00a0neuen\u00a0Wirkstoffen \u00a0mit\u00a0der\u00a0Anzahl\u00a0innovativer \u00a0und\u00a0verbesserter \u00a0\nWirkstoffe \u00a0im\u00a0Zeitraum\u00a01995\u20102012\u00a0(eigene\u00a0Darstellung \u00a0nach\u00a0Schwabe\u00a0&\u00a0Paffrath,\u00a02013)\u00a0....................................... \u00a021\u00a0\nAbbildung \u00a02:\u00a0Verordnungspr\u00e4valenz \u00a0der\u00a0neuen\u00a0Wirkstoffe \u00a0in\u00a0Promille\u00a0nach\u00a0Bundesl\u00e4ndern \u00a0(nur\u00a0Verordnungen \u00a0im\u00a0Jahr\u00a0\n2013)\u00a0bezogen\u00a0auf\u00a0die\u00a0Versicherten \u00a0der\u00a0TK\u00a0............................................................................................................... \u00a028\u00a0\nAbbildung \u00a03:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Aclidiniumbromid \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0....................... \u00a032\u00a0\nAbbildung \u00a04:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Aclidiniumbromid \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0................ \u00a032\u00a0\nAbbildung \u00a05:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Aclidiniumbromid \u00a0nach\u00a0Monaten\u00a0(2012\u20102013)............ \u00a033\u00a0\nAbbildung \u00a06:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Aflibercept \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0................................. \u00a037\u00a0\nAbbildung \u00a07:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Aflibercept \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0........................... \u00a037\u00a0\nAbbildung \u00a08:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Aflibercept \u00a0nach\u00a0Monaten\u00a0(2012\u20102013)\u00a0...................... \u00a038\u00a0\nAbbildung \u00a09:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Axitinib\u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0....................................... \u00a041\u00a0\nAbbildung \u00a010:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Axitinib\u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0.............................. \u00a041\u00a0\nAbbildung \u00a011:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Axitinib\u00a0nach\u00a0Monaten\u00a0(2012\u20102013)\u00a0.......................... \u00a042\u00a0\nAbbildung \u00a012:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Azilsartanmedoxomil \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0............... \u00a045\u00a0\nAbbildung \u00a013:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Azilsartanmedoxomil \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0.........\u00a045\u00a0\nAbbildung \u00a014:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Azilsartanmedoxomil \u00a0nach\u00a0Monaten\u00a0(2012\u2010\n2013)\u00a0............................................................................................................................... ........................................... \u00a046\u00a0\nAbbildung \u00a015:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Brentuximabvedotin \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0................ \u00a049\u00a0\nAbbildung \u00a016:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Brentuximabvedotin \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0..........\u00a049\u00a0\nAbbildung \u00a017:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Brentuximabvedotin \u00a0nach\u00a0Monaten\u00a0(2012\u20102013)\u00a0.....\u00a050\u00a0\nAbbildung \u00a018:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Crizotinib \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0.................................. \u00a055\u00a0\nAbbildung \u00a019:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Crizotinib \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0........................... \u00a055\u00a0\nAbbildung \u00a020:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Crizotinib \u00a0nach\u00a0Monaten\u00a0(2012\u20102013)\u00a0....................... \u00a056\u00a0\nAbbildung \u00a021:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Dapagliflozin \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0............................ \u00a059\u00a0\nAbbildung \u00a022:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Dapagliflozin \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0...................... \u00a059\u00a0\nAbbildung \u00a023:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Dapagliflozin \u00a0nach\u00a0Monaten\u00a0(2012\u20102013)\u00a0................. \u00a060\u00a0\nAbbildung \u00a024:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Decitabin \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0.................................. \u00a063\u00a0\nAbbildung \u00a025:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Decitabin \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0........................... \u00a063\u00a0\nAbbildung \u00a026:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Decitabin \u00a0nach\u00a0Monaten\u00a0(2012\u20102013)\u00a0....................... \u00a064\u00a0\nAbbildung \u00a027:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Ivacaftor\u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0................................... \u00a067\u00a0\nAbbildung \u00a028:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Ivacaftor\u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0............................ \u00a067\u00a0\nAbbildung \u00a029:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Ivacaftor\u00a0nach\u00a0Monaten\u00a0(2012\u20102013)\u00a0........................ \u00a068\u00a0\nAbbildung \u00a030:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0(orales\u00a0Kontrazeptivum) \u00a0je\u00a0Monat\u00a0nach\u00a0\nPackungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0............................................................................................................................... .....\u00a071\u00a0\nAbbildung \u00a031:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0(orales\u00a0Kontrazeptivum) \u00a0\nnach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0............................................................................................................................. \u00a071\u00a0\nAbbildung \u00a032:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0(orales\u00a0\nKontrazeptivum) \u00a0nach\u00a0Monaten\u00a0(2012\u20102013)\u00a0........................................................................................................... \u00a072\u00a0\nAbbildung \u00a033:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0(Hormontherapie) \u00a0je\u00a0Monat\u00a0nach\u00a0\nPackungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0............................................................................................................................... .....\u00a075\u00a0\nAbbildung \u00a034:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0(Hormontherapie) \u00a0nach\u00a0\nAlter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0............................................................................................................................... .......\u00a075\u00a0\nAbbildung \u00a035:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0\n(Hormontherapie) \u00a0nach\u00a0Monaten\u00a0(2012\u20102013)\u00a0......................................................................................................... \u00a076\u00a0\nAbbildung \u00a036:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Pasireotid \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0................................. \u00a080\u00a0\nAbbildung \u00a037:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Pasireotid \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)........................... \u00a080\u00a0\nAbbildung \u00a038:Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Pasireotid \u00a0nach\u00a0Monaten\u00a0(2012\u20102013)\u00a0....................... \u00a081\u00a0\nAbbildung \u00a039:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Perampanel \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0.............................. \u00a084\u00a0\nAbbildung \u00a040:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Perampanel \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0....................... \u00a084\u00a0\nAbbildung \u00a041:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Perampanel \u00a0nach\u00a0Monaten\u00a0(2012\u20102013)\u00a0................... \u00a085\u00a0\nAbbildung \u00a042:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Pixantron \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0.................................. \u00a088\u00a0\nAbbildung \u00a043:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Pixantron \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0........................... \u00a088\u00a0\u00a0\n272\u00a0Abbildung \u00a044:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Pixantron \u00a0nach\u00a0Monaten\u00a0(2012\u20102013)\u00a0....................... \u00a089\u00a0\nAbbildung \u00a045:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Rilpivirin\u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0................................... \u00a092\u00a0\nAbbildung \u00a046:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Rilpivirin\u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0............................. \u00a092\u00a0\nAbbildung \u00a047:Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Rilpivirin\u00a0nach\u00a0Monaten\u00a0(2012\u20102013)\u00a0......................... \u00a093\u00a0\nAbbildung \u00a048:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Ruxolitinib \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0................................ \u00a096\u00a0\nAbbildung \u00a049:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Ruxolitinib \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013).......................... \u00a096\u00a0\nAbbildung \u00a050:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Ruxolitinib \u00a0nach\u00a0Monaten\u00a0(2012\u20102013)\u00a0..................... \u00a097\u00a0\nAbbildung \u00a051:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Tegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0Oteracil\u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u2010\n2013)\u00a0............................................................................................................................... ......................................... \u00a0100\u00a0\nAbbildung \u00a052:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Tegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0Oteracil\u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0\n(2013)\u00a0............................................................................................................................... ....................................... \u00a0100\u00a0\nAbbildung \u00a053:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Tegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0Oteracil\u00a0nach\u00a0Monaten \u00a0\n(2012\u20102013)\u00a0............................................................................................................................... .............................. \u00a0101\u00a0\nAbbildung \u00a054:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Vandetanib \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0............................. \u00a0104\u00a0\nAbbildung \u00a055:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Vandetanib \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0...................... \u00a0104\u00a0\nAbbildung \u00a056:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Vandetanib \u00a0nach\u00a0Monaten\u00a0(2012\u20102013)\u00a0.................. \u00a0105\u00a0\nAbbildung \u00a057:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Vemurafenib \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0.......................... \u00a0108\u00a0\nAbbildung \u00a058:\u00a0Versicherte \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0Vemurafenib \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0(2013)\u00a0.................... \u00a0108\u00a0\nAbbildung \u00a059:\u00a0Verordnete \u00a0Tagesdosen \u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze \u00a0von\u00a0Vemurafenib \u00a0nach\u00a0Monaten\u00a0(2012\u20102013)\u00a0............... \u00a0109\u00a0\nAbbildung \u00a060:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Apixaban \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0................................ \u00a0113\u00a0\nAbbildung \u00a061:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Boceprevir \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0.............................. \u00a0113\u00a0\nAbbildung \u00a062:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Telaprevir \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0............................... \u00a0114\u00a0\nAbbildung \u00a063:\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0Ticagrelor \u00a0je\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen \u00a0(2012\u20102013)\u00a0............................... \u00a0114\u00a0\nAbbildung \u00a064:\u00a0Verordnungspr\u00e4valenz \u00a0der\u00a0neuen\u00a0Wirkstoffe \u00a0aus\u00a0dem\u00a0Jahr\u00a02012\u00a0ohne\u00a0Zusatznutzen \u00a0(\u201erote\u00a0Ampel\u201c)\u00a0f\u00fcr\u00a0\nTK\u2010Versicherte \u00a0in\u00a0Promille\u00a0nach\u00a0Bundesl\u00e4ndern \u00a0(nur\u00a0Verordnungen \u00a0im\u00a0Jahr\u00a02013)\u00a0............................................... \u00a0119\u00a0\nAbbildung \u00a065:\u00a0Ausgaben \u00a0und\u00a0verordnete \u00a0Packungen \u00a0von\u00a0Fingolimod \u00a0nach\u00a0Alter\u00a0der\u00a0TK\u2010Versicherten \u00a0mit\u00a0einer\u00a0MS\u2010\nDiagnose\u00a0im\u00a0Jahr\u00a02013\u00a0............................................................................................................................... ..............\u00a0123\u00a0\nAbbildung \u00a066:\u00a0Verteilung \u00a0der\u00a0Patienten \u00a0mit\u00a0Fingolimod \u2010Verordnungen \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0im\u00a0Jahr\u00a02013\u00a0................ \u00a0124\u00a0\nAbbildung \u00a067:\u00a0Verordnete \u00a0Packungen \u00a0Fingolimod \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0im\u00a0Jahr\u00a02013\u00a0................................................. \u00a0124\u00a0\nAbbildung \u00a068:\u00a0Anzahl\u00a0der\u00a0mit\u00a0Fingolimod \u00a0behandelten \u00a0Versicherten \u00a0nach\u00a0Arztgruppen \u00a0in\u00a0den\u00a0Jahren\u00a02012\u00a0und\u00a02013\u00a0........\u00a0125\u00a0\nAbbildung \u00a069:\u00a0Verordnete \u00a0Packungen \u00a0von\u00a0Fingolimod \u00a0nach\u00a0Arztgruppen \u00a0in\u00a0den\u00a0Jahren\u00a02012\u00a0und\u00a02013\u00a0.............................. \u00a0126\u00a0\nAbbildung \u00a070:\u00a0Umsatz\u00a0von\u00a0Fingolimod \u00a0nach\u00a0Arztgruppen \u00a0in\u00a0den\u00a0Jahren\u00a02012\u00a0und\u00a02013\u00a0....................................................... \u00a0126\u00a0\nAbbildung \u00a071:\u00a0Stufentherapie \u00a0der\u00a0Multiplen \u00a0Sklerose\u00a0............................................................................................................ \u00a0128\u00a0\nAbbildung \u00a072:\u00a0Ausgaben \u00a0und\u00a0verordnete \u00a0Packungen \u00a0von\u00a0Azathioprin \u00a0nach\u00a0Alter\u00a0der\u00a0TK\u2010Versicherten \u00a0mit\u00a0einer\u00a0MS\u2010\nDiagnose\u00a0im\u00a0Jahr\u00a02013\u00a0............................................................................................................................... ..............\u00a0129\u00a0\nAbbildung \u00a073:\u00a0Verordnete \u00a0Packungen \u00a0von\u00a0Azathioprin \u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0im\u00a0Jahr\u00a02013\u00a0.......................................... \u00a0130\u00a0\nAbbildung \u00a074:\u00a0Anzahl\u00a0der\u00a0MS\u2010Patientinnen \u00a0und\u00a0Patienten \u00a0mit\u00a0Verordnung \u00a0von\u00a0Azathioprin \u00a0nach\u00a0Arztgruppen................... \u00a0131\u00a0\nAbbildung \u00a075:\u00a0Packungsverordnung \u00a0von\u00a0Azathioprin \u00a0nach\u00a0Arztgruppen \u00a0bei\u00a0der\u00a0Diagnose\u00a0MS\u00a0in\u00a0den\u00a0Jahren\u00a02012\u00a0und\u00a0\n2013\u00a0............................................................................................................................... .......................................... \u00a0131\u00a0\nAbbildung \u00a076:\u00a0Ums\u00e4tze\u00a0von\u00a0Azathioprin \u00a0nach\u00a0Arztgruppen \u00a0in\u00a0den\u00a0Jahren\u00a02012\u00a0und\u00a02013\u00a0.................................................... \u00a0132\u00a0\nAbbildung \u00a077:\u00a0\u00dcbersicht \u00a0der\u00a0Anzahl\u00a0TK\u2010versicherter \u00a0Frauen\u00a0je\u00a0Alterscluster \u00a0mit\u00a0und\u00a0ohne\u00a0Hormontherapie* \u00a0in\u00a0den\u00a0\nJahren\u00a02011\u00a0bis\u00a02013\u00a0............................................................................................................................... ................ \u00a0148\u00a0 \n273\u00a0Tabellenverzeichnis \u00a0\nTabelle\u00a01:\u00a0Indikationen \u00a0der\u00a0neuen\u00a0Arzneimittel \u00a0des\u00a0Jahres\u00a02012\u00a0............................................................................................. \u00a013\u00a0\nTabelle\u00a02:\u00a0Quantitative \u00a0Charakteristika \u00a0der\u00a0Anteile\u00a0von\u00a0neuen\u00a0Arzneimitteln \u00a0des\u00a0Jahres\u00a02012\u00a0in\u00a0den\u00a0Jahren\u00a02012\u00a0und\u00a0\n2013\u00a0auf\u00a0Basis\u00a0der\u00a0TK\u2010Routinedaten \u00a0.......................................................................................................................... \u00a014\u00a0\nTabelle\u00a03:\u00a0Im\u00a0Report\u00a0bewertete \u00a0neue\u00a0Wirkstoffe \u00a0des\u00a0Jahres\u00a02012\u00a0und\u00a0die\u00a0entsprechenden \u00a0ATC\u2010Codes\u00a0................................. \u00a020\u00a0\nTabelle\u00a04:\u00a0\u00dcbersicht \u00a0der\u00a0neuen\u00a0Wirkstoffe/Wirkstoffkombinationen \u00a0des\u00a0Jahres\u00a02012\u00a0und\u00a0deren\u00a0Bewertungen \u00a0in\u00a0\nStandardwerken \u00a0............................................................................................................................... ......................... \u00a024\u00a0\nTabelle\u00a05:\u00a0Top\u2010Liste\u00a0der\u00a0neuen\u00a0Arzneimittel \u00a0des\u00a0Jahres\u00a02012\u00a0\u2013\u00a0nach\u00a0Umsatz\u00a0im\u00a0Jahr\u00a02013\u00a0(TK\u00a0und\u00a0gesamter \u00a0\nApothekenmarkt \u00a0Deutschlands) \u00a0............................................................................................................................... .\u00a025\u00a0\nTabelle\u00a06:\u00a0Top\u2010Liste\u00a0der\u00a0neuen\u00a0Arzneimittel \u00a0des\u00a0Jahres\u00a02012\u00a0\u2013\u00a0nach\u00a0Anzahl\u00a0verordneter \u00a0Packungen \u00a0im\u00a0Jahr\u00a02013\u00a0(TK\u00a0\nund\u00a0gesamter \u00a0Apothekenmarkt \u00a0Deutschlands) \u00a0......................................................................................................... \u00a026\u00a0\nTabelle\u00a07:\u00a0Anzahl,\u00a0Alter\u00a0und\u00a0Geschlecht \u00a0der\u00a0Versicherten \u00a0mit\u00a0mindestens \u00a0einer\u00a0Verordnung \u00a0der\u00a0neuen\u00a0Wirkstoffe \u00a0\n(Daten\u00a0aus\u00a0dem\u00a0Jahr\u00a02013)\u00a0............................................................................................................................... .........\u00a029\u00a0\nTabelle\u00a08:\u00a0Umsatzzahlen \u00a0der\u00a0Arzneimittel \u00a0des\u00a0letzten\u00a0Innovationsreportes \u00a0im\u00a0Jahr\u00a02013\u00a0und\u00a0\u00c4nderungen \u00a0zum\u00a0Vorjahr\u00a0\n(TK\u2010Daten)\u00a0............................................................................................................................... ................................. \u00a0111\u00a0\nTabelle\u00a09:\u00a0Verordnungszahlen \u00a0der\u00a0Arzneimittel \u00a0des\u00a0letzten\u00a0Innovationsreportes \u00a0im\u00a0Jahr\u00a02013\u00a0und\u00a0\u00c4nderungen \u00a0zum\u00a0\nVorjahr\u00a0(TK\u2010Daten)\u00a0............................................................................................................................... .................... \u00a0112\u00a0\nTabelle\u00a010:\u00a0Zusammenfassung \u00a0der\u00a0Wirkstoffbewertungen \u00a0(neue\u00a0Wirkstoffe \u00a0des\u00a0Jahres\u00a02012)\u00a0nach\u00a0dem\u00a0im\u00a0Report\u00a0\ngenutzten \u00a0Ampelschema \u00a0............................................................................................................................... ..........\u00a0115\u00a0\nTabelle\u00a011:\u00a0Gesamt\u2010Score\u00a0Innovationsbewertung \u00a0.................................................................................................................. \u00a0117\u00a0\nTabelle\u00a012:\u00a0Gesamt\u2010Score\u00a0Innovationsbewertung \u00a0Orphan\u00a0Drugs\u00a0........................................................................................... \u00a0118\u00a0\nTabelle\u00a013:\u00a0\u00dcbersicht \u00a0der\u00a0Verordnungen \u00a0von\u00a0Fingolimod \u00a0und\u00a0weiterer\u00a0medikament\u00f6ser \u00a0Therapien \u00a0bei\u00a0TK\u2010Versicherten \u00a0\nmit\u00a0MS\u2010Erkrankung \u00a0(ICD\u00a0G35)\u00a0............................................................................................................................... ...\u00a0122\u00a0\nTabelle\u00a014:\u00a0Verteilung \u00a0und\u00a0Anzahl\u00a0der\u00a0MS\u2010Patientinnen \u00a0und\u00a0Patienten \u00a0auf\u00a0die\u00a0Wirkstoffe \u00a0Azathioprin \u00a0und\u00a0Fingolimod \u00a0\nauf\u00a0Basis\u00a0von\u00a0TK\u2010Routinedaten \u00a0............................................................................................................................... .\u00a0129\u00a0\nTabelle\u00a015:\u00a0Verordnungen \u00a0und\u00a0Ums\u00e4tze\u00a0von\u00a0MS\u2010Arzneimitteln \u00a0in\u00a0der\u00a0GKV\u00a0im\u00a0Jahr\u00a02013\u00a0...................................................... \u00a0133\u00a0\nTabelle\u00a016:\u00a0Industrieums\u00e4tze \u00a0und\u00a0Packungsverk\u00e4ufe \u00a0in\u00a0der\u00a0ambulanten \u00a0Arzneimittelversorgung \u00a0in\u00a0Deutschland \u00a0im\u00a0\nJahre\u00a02014\u00a0............................................................................................................................... ................................ \u00a0134\u00a0\nTabelle\u00a017:\u00a0Die\u00a0im\u00a0Jahre\u00a02012\u00a0neu\u00a0zugelassenen \u00a0Arzneimittel \u00a0zur\u00a0Behandlung \u00a0von\u00a0onkologischen \u00a0Erkrankungen \u00a0............... \u00a0135\u00a0\nTabelle\u00a018:\u00a0Untersuchte \u00a0Wirkstoffe \u00a0und\u00a0Wirkstoffgruppen \u00a0sowie\u00a0Pharmazentralnummern \u00a0(PZN)\u00a0zur\u00a0Hormontherapie \u00a0......\u00a0146\u00a0\nTabelle\u00a019:\u00a0Anteil\u00a0der\u00a0Hormon\u2010Anwenderinnen \u00a0unter\u00a0den\u00a0weiblichen \u00a0TK\u2010Versicherten \u00a0nach\u00a0Alter\u00a0in\u00a0den\u00a0Jahren\u00a02011\u00a0\nbis\u00a02013\u00a0............................................................................................................................... .................................... \u00a0147\u00a0\nTabelle\u00a020:\u00a0Anteil\u00a0der\u00a0weiblichen \u00a0TK\u2010Versicherten \u00a0ab\u00a040\u00a0Jahre\u00a0an\u00a0der\u00a0durchschnittlichen \u00a0weiblichen \u00a0Bev\u00f6lkerung \u00a0ab\u00a040\u00a0\nJahre\u00a0in\u00a0Deutschland \u00a0im\u00a0Jahr\u00a02013\u00a0.......................................................................................................................... \u00a0149\u00a0\nTabelle\u00a021:\u00a0Anteil\u00a0der\u00a0Hormon\u2010Anwenderinnen \u00a0der\u00a0weiblichen \u00a0TK\u2010Versicherten \u00a0\u00fcber\u00a040\u00a0Jahre\u00a0nach\u00a0Bundesland \u00a0in\u00a0den\u00a0\nJahren\u00a02011\u00a0bis\u00a02013\u00a0............................................................................................................................... ................ \u00a0150\u00a0\nTabelle\u00a022:\u00a0Anzahl\u00a0der\u00a0verordneten \u00a0Packungen \u00a0und\u00a0DDD\u00a0(Estrogen \u00a0und\u00a0Gestagen) \u00a0sowie\u00a0Ausgaben \u00a0in\u00a0Euro\u00a0f\u00fcr\u00a0die\u00a0\nHormontherapie \u00a0in\u00a0den\u00a0Jahren\u00a02011\u00a0bis\u00a02013\u00a0auf\u00a0Basis\u00a0von\u00a0TK\u2010Routinedaten \u00a0....................................................... \u00a0151\u00a0\nTabelle\u00a023:\u00a0Die\u00a0verordnungsst\u00e4rksten \u00a0Pr\u00e4parate \u00a0in\u00a0der\u00a0Wirkstoffgruppe \u00a0der\u00a0estrogenhaltigen \u00a0Kombinationen \u00a0mit\u00a0\nsequentieller \u00a0Gestagenzugabe \u00a0in\u00a02011\u00a0bis\u00a02013,\u00a0absteigend \u00a0nach\u00a0verordneten \u00a0DDD\u00a0in\u00a02013\u00a0............................... \u00a0152\u00a0\nTabelle\u00a024:\u00a0Die\u00a0verordnungsst\u00e4rksten \u00a0Pr\u00e4parate \u00a0in\u00a0der\u00a0Wirkstoffgruppe \u00a0der\u00a0estrogenhaltigen \u00a0Kombinationen \u00a0mit\u00a0\nkontinuierlicher \u00a0Gestagenzugabe \u00a0in\u00a02011\u00a0bis\u00a02013,\u00a0absteigend \u00a0nach\u00a0verordneten \u00a0DDD\u00a0in\u00a02013\u00a0........................... \u00a0153\u00a0\nTabelle\u00a025:\u00a0Jahrestherapiekosten \u00a0von\u00a0Aclidiniumbromid \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0Kosten\u00a0\nzus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0............................................................................................................................... ...\u00a0162\u00a0\nTabelle\u00a026:\u00a0Jahrestherapiekosten \u00a0(erstes\u00a0Jahr)\u00a0von\u00a0Aflibercept \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0Kosten\u00a0\nzus\u00e4tzlicher \u00a0GKV\u2010Leistungen). \u00a0Zugelassenes \u00a0Anwendungsgebiet: \u00a0AMD\u00a0.................................................................. \u00a0169\u00a0\nTabelle\u00a027:\u00a0Jahrestherapiekosten \u00a0(erstes\u00a0Jahr)\u00a0von\u00a0Aflibercept \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0Kosten\u00a0\nzus\u00e4tzlicher \u00a0GKV\u2010Leistungen). \u00a0Zugelassenes \u00a0Anwendungsgebiet: \u00a0Makula\u00f6dem \u00a0infolge\u00a0eines\u00a0retinalen\u00a0\nZentralvenenverschlusses \u00a0............................................................................................................................... .........\u00a0170\u00a0\nTabelle\u00a028:\u00a0Jahrestherapiekosten \u00a0(erstes\u00a0Jahr)\u00a0von\u00a0Aflibercept \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0Kosten\u00a0\nzus\u00e4tzlicher \u00a0GKV\u2010Leistungen). \u00a0Zugelassenes \u00a0Anwendungsgebiet: \u00a0Visusbeeintr\u00e4chtigung \u00a0infolge\u00a0eines\u00a0\ndiabetischen \u00a0Makula\u00f6dems \u00a0............................................................................................................................... ......\u00a0171\u00a0\nTabelle\u00a029:\u00a0Jahrestherapiekosten \u00a0von\u00a0Axitinib\u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010\nLeistungen) \u00a0............................................................................................................................... ............................... \u00a0175\u00a0\nTabelle\u00a030:\u00a0Jahrestherapiekosten \u00a0von\u00a0Azilsartanmedoxomil \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0Kosten\u00a0\nzus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0............................................................................................................................... ...\u00a0178\u00a0\u00a0\n274\u00a0Tabelle\u00a031:\u00a0Jahrestherapiekosten \u00a0von\u00a0Brentuximabvedotin \u00a0(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0............................. \u00a0182\u00a0\nTabelle\u00a032:\u00a0Jahrestherapiekosten \u00a0von\u00a0Crizotinib \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010\nLeistungen) \u00a0............................................................................................................................... ............................... \u00a0189\u00a0\nTabelle\u00a033:\u00a0Jahrestherapiekosten \u00a0(Monotherapie) \u00a0von\u00a0Dapagliflozin \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0\nKosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0....................................................................................................................... \u00a0193\u00a0\nTabelle\u00a034:\u00a0Jahrestherapiekosten \u00a0von\u00a0Decitabin \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010\nLeistungen) \u00a0............................................................................................................................... ............................... \u00a0197\u00a0\nTabelle\u00a035:\u00a0Jahrestherapiekosten \u00a0von Ivacaftor\u00a0(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0................................................ \u00a0202\u00a0\nTabelle\u00a036:\u00a0Jahrestherapiekosten \u00a0von Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0(orales\u00a0Kontrazeptivum) \u00a0(ohne\u00a0Kosten\u00a0\nzus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0............................................................................................................................... ...\u00a0206\u00a0\nTabelle\u00a037:\u00a0Jahrestherapiekosten \u00a0von\u00a0Nomegestrolacetat \u00a0+\u00a0Estradiol\u00a0(Hormontherapie) \u00a0(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0\nGKV\u2010Leistungen) \u00a0............................................................................................................................... ....................... \u00a0210\u00a0\nTabelle\u00a038:\u00a0Jahrestherapiekosten \u00a0von\u00a0Pasireotid \u00a0f\u00fcr\u00a0(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen). \u00a0Zugelassenes \u00a0\nAnwendungsgebiet: \u00a0Morbus\u00a0Cushing\u00a0...................................................................................................................... \u00a0215\u00a0\nTabelle\u00a039:\u00a0Jahrestherapiekosten \u00a0von\u00a0Pasireotid \u00a0f\u00fcr\u00a0(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen). \u00a0Zugelassenes \u00a0\nAnwendungsgebiet: \u00a0Akromegalie \u00a0............................................................................................................................ \u00a0215\u00a0\nTabelle\u00a040:\u00a0Jahrestherapiekosten \u00a0von\u00a0Pixantron \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010\nLeistungen). \u00a0............................................................................................................................... .............................. \u00a0223\u00a0\nTabelle\u00a041:\u00a0Bevorzugte \u00a0Kombinationen \u00a0in\u00a0der\u00a0Therapie\u00a0der\u00a0HIV\u2010Infektion............................................................................. \u00a0227\u00a0\nTabelle\u00a042:\u00a0Jahrestherapiekosten \u00a0von\u00a0Rilpivirin\u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010\nLeistungen). \u00a0............................................................................................................................... .............................. \u00a0229\u00a0\nTabelle\u00a043:\u00a0Jahrestherapiekosten \u00a0von\u00a0Ruxolitinib \u00a0(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0f\u00fcr\u00a0alle\u00a0\nIndikationsbereiche \u00a0............................................................................................................................... .................. \u00a0234\u00a0\nTabelle\u00a044:\u00a0Jahrestherapiekosten \u00a0von\u00a0Tegafur\u00a0+\u00a0Gimeracil \u00a0+\u00a0Oteracil\u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0\nKosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen). \u00a0...................................................................................................................... \u00a0238\u00a0\nTabelle\u00a045:\u00a0Jahrestherapiekosten \u00a0von\u00a0Vandetanib \u00a0(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0GKV\u2010Leistungen) \u00a0............................................ \u00a0242\u00a0\nTabelle\u00a046:\u00a0Jahrestherapiekosten \u00a0von\u00a0Vemurafenib \u00a0und\u00a0zweckm\u00e4\u00dfiger \u00a0Vergleichstherapie \u00a0(ohne\u00a0Kosten\u00a0zus\u00e4tzlicher \u00a0\nGKV\u2010Leistungen) \u00a0............................................................................................................................... ....................... \u00a0245\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0 \n275\u00a0Herausgeber \u00a0und\u00a0wissenschaftliche \u00a0Beratung/Autoren \u00a0\n\u00a0\nProf.\u00a0Dr.\u00a0Gerd\u00a0Glaeske\u00a0\nStudium\u00a0der\u00a0Pharmazie \u00a0in\u00a0Aachen\u00a0und\u00a0Hamburg, \u00a0dort\u00a0auch\u00a0Promotion. \u00a0Ab\u00a01981\u00a0Wissenschaftlicher \u00a0Mitarbeiter \u00a0im\u00a0Bremer\u00a0Institut\u00a0f\u00fcr\u00a0\nPr\u00e4ventionsforschung \u00a0und\u00a0Sozialmedizin \u00a0(BIPS),\u00a0dort\u00a0ab\u00a01985\u00a0Leiter\u00a0der\u00a0Abteilung \u00a0Arzneimittelepidemiologie, \u00a0Projektleitung \u00a0einer\u00a0Arznei\u2010\nmittelbewertungsstudie \u00a0(Bewertender \u00a0Arzneimittelindex, \u00a0hrsg.\u00a0von\u00a0E.\u00a0Greiser).\u00a0Ab\u00a01988\u00a0Leiter\u00a0von\u00a0Pharmakologischen \u00a0Beratungsdiensten \u00a0\nin\u00a0Krankenkassen, \u00a0Leiter\u00a0der\u00a0Abteilung \u00a0Verbandspolitik \u00a0beim\u00a0Verband\u00a0der\u00a0Angestellten \u00a0Krankenkassen \u00a0(VdAK),\u00a0sp\u00e4ter\u00a0der\u00a0Abteilung \u00a0f\u00fcr\u00a0\nmedizinisch \u2010wissenschaftliche \u00a0Grundsatzfragen, \u00a0zuletzt\u00a0bei\u00a0der\u00a0BARMER\u00a0Ersatzkasse. \u00a0\nSeit\u00a01999\u00a0Professor \u00a0f\u00fcr\u00a0Arzneimittelversorgungsforschung \u00a0am\u00a0Zentrum\u00a0f\u00fcr\u00a0Sozialpolitik \u00a0(ZeS),\u00a0ab\u00a02015\u00a0im\u00a0SOCIUM\u00a0der\u00a0Universit\u00e4t \u00a0Bremen,\u00a0\nForschungszentrum \u00a0Ungleichheit \u00a0und\u00a0Sozialpolitik. \u00a0Ab\u00a02007\u00a0Co\u2010Leiter\u00a0der\u00a0Abteilung \u00a0Gesundheits\u00f6konomie, \u00a0Gesundheitspolitik \u00a0und\u00a0Versor\u2010\ngungsforschung, \u00a0ab\u00a02015\u00a0umbenannt \u00a0in\u00a0Abteilung \u00a0soziale\u00a0Ungleichheit \u00a0und\u00a0Sozialpolitik: \u00a0Gesundheit, \u00a0Pflege\u00a0und\u00a0Alterssicherung. \u00a0\nVon\u00a02003\u00a0bis\u00a02009\u00a0vom\u00a0Gesundheitsminister \u00a0berufenes \u00a0Mitglied\u00a0im\u00a0Sachverst\u00e4ndigenrat \u00a0zur\u00a0Begutachtung \u00a0der\u00a0Entwicklung \u00a0im\u00a0Gesund\u2010\nheitswesen \u00a0(www.svr \u2010gesundheit.de), \u00a0seit\u00a02003\u00a0Mitglied\u00a0im\u00a0wissenschaftlichen \u00a0Beirat\u00a0der\u00a0Bundeszentrale \u00a0f\u00fcr\u00a0gesundheitliche \u00a0Aufkl\u00e4rung \u00a0\n(BZgA),\u00a0Bis\u00a02013\u00a0Mitglied\u00a0in\u00a0der\u00a0BTM\u2010Kommission \u00a0des\u00a0Bundesinstitutes \u00a0f\u00fcr\u00a0Arzneimittel \u00a0und\u00a0Medizinprodukte \u00a0(BfArM).\u00a0Von\u00a02007\u00a0bis\u00a0zum\u00a0\nR\u00fccktritt\u00a0am\u00a025.\u00a0M\u00e4rz\u00a02008\u00a0von\u00a0der\u00a0Gesundheitsministerin \u00a0berufenes \u00a0Mitglied\u00a0und\u00a0gew\u00e4hlter \u00a0Vorsitzender \u00a0im\u00a0wissenschaftlichen \u00a0Beirat\u00a0\ndes\u00a0BVA\u00a0zur\u00a0Erstellung \u00a0eines\u00a0Gutachtens \u00a0zum\u00a0morbidit\u00e4tsorientierten \u00a0Risikostrukturausgleichs. \u00a0\nMitglied\u00a0der\u00a0Drug\u2010Utilization \u2010Research\u2010Group\u00a0der\u00a0WHO,\u00a0seit\u00a02005\u00a0nach\u00a0vierj\u00e4hriger \u00a0T\u00e4tigkeit\u00a0als\u00a01.\u00a0Vorsitzender \u00a0der\u00a0Gesellschaft \u00a0f\u00fcr\u00a0Arz\u2010\nneimittelanwendungsforschung \u00a0und\u00a0Arzneimittelepidemiologie \u00a0(GAA)\u00a0nun\u00a0Berater\u00a0des\u00a0Vorstands, \u00a02006\u00a0bis\u00a02014\u00a0Mitglied\u00a0im\u00a0gesch\u00e4ftsf\u00fch \u2010\nrenden\u00a0Vorstand\u00a0des\u00a0Deutschen \u00a0Netzwerkes \u00a0Versorgungsforschung \u00a0(DNVF).\u00a0Mitglied\u00a0in\u00a0diversen\u00a0medizinischen \u00a0und\u00a0epidemiologischen \u00a0\nFachgesellschaften. \u00a0Ab\u00a02009\u00a0vom\u00a0\u00f6sterreichischen \u00a0Bundesminister \u00a0f\u00fcr\u00a0Gesundheit \u00a0berufenes \u00a0Mitglied\u00a0des\u00a0Kommission \u00a0f\u00fcr\u00a0rationale\u00a0Arz\u2010\nneimitteltherapie. \u00a0\n\u00a0\nProf.\u00a0Dr.\u00a0Wolf\u2010Dieter\u00a0Ludwig\u00a0\nStudium\u00a0der\u00a0Humanmedizin \u00a0in\u00a0Louvain\u00a0(Belgien), \u00a0Frankfurt \u00a0am\u00a0Main\u00a0und\u00a0Berlin\u00a0bis\u00a01979.\u00a0Von\u00a01979\u00a0bis\u00a01981\u00a0Wissenschaftlicher \u00a0Mitarbeiter \u00a0\nam\u00a0Pharmakologischen \u00a0Institut\u00a0der\u00a0Freien\u00a0Universit\u00e4t \u00a0(FU)\u00a0Berlin.\u00a0Von\u00a01981\u00a0bis\u00a01993\u00a0Fort\u2010\u00a0und\u00a0Weiterbildung \u00a0zum\u00a0Facharzt\u00a0f\u00fcr\u00a0Innere\u00a0\nMedizin\u00a0mit\u00a0Zusatzbezeichnung \u00a0H\u00e4matologie/internistische \u00a0Onkologie \u00a0in\u00a0der\u00a0Abteilung \u00a0f\u00fcr\u00a0Innere\u00a0Medizin\u00a0mit\u00a0Schwerpunkt \u00a0H\u00e4matologie \u00a0\nund\u00a0Onkologie \u00a0des\u00a0Universit\u00e4tsklinikums \u00a0Steglitz\u00a0der\u00a0FU\u00a0Berlin.\u00a01982\u00a0Promotion \u00a0und\u00a01991\u00a0Habilitation. \u00a0Im\u00a0Jahr\u00a01994\u00a0Berufung \u00a0auf\u00a0C3\u2010\nProfessur \u00a0f\u00fcr\u00a0Innere\u00a0Medizin\u00a0f\u00fcr\u00a0H\u00e4matologie. \u00a0Onkologie \u00a0und\u00a0Angewandte \u00a0Molekularbiologie \u00a0im\u00a0Fachbereich \u00a0Universit\u00e4tsklinikum \u00a0Rudolf\u2010\nVirchow\u00a0(Bereich\u00a0Berlin\u2010Buch).\u00a0Seit\u00a02001\u00a0Chefarzt\u00a0der\u00a0Klinik\u00a0f\u00fcr\u00a0H\u00e4matologie, \u00a0Onkologie, \u00a0Tumorimmunologie \u00a0und\u00a0Palliativmedizin, \u00a0Robert\u2010\nR\u00f6ssle\u2010Klinik,\u00a0HELIOS\u00a0Klinikum\u00a0Berlin\u2010Buch.\u00a0\nUnter\u00a0anderem\u00a0seit\u00a02006\u00a0Vorsitzender \u00a0der\u00a0Arzneimittelkommission \u00a0der\u00a0deutschen \u00a0\u00c4rzteschaft \u00a0und\u00a0Mit\u2010Herausgeber \u00a0des\u00a0unabh\u00e4ngigen \u00a0\nInformationsblatts \u00a0DER\u00a0ARZNEIMITTELBRIEF. \u00a0Fachredakteur \u00a0f\u00fcr\u00a0das\u00a0Gebiet\u00a0\u201eArzneimitteltherapie \u00a0und\u00a0H\u00e4matologie\u201c \u00a0der\u00a0medizinisch \u2010\nwissenschaftlichen \u00a0Redaktion \u00a0des\u00a0Deutschen \u00a0\u00c4rzteblattes. \u00a0Seit\u00a0M\u00e4rz\u00a02013\u00a0Mitglied\u00a0des\u00a0Management \u00a0Board\u00a0der\u00a0European \u00a0Medicines \u00a0\nAgency\u00a0(EMA)\u00a0als\u00a0Vertreter \u00a0der\u00a0europ\u00e4ischen \u00a0\u00c4rzteschaft. \u00a0\n\u00a0\nProf.\u00a0Dr.\u00a0Petra\u00a0Th\u00fcrmann \u00a0\nNach\u00a0dem\u00a0Studium\u00a0der\u00a0Humanmedizin \u00a0bis\u00a01985\u00a0an\u00a0der\u00a0Johann\u00a0Wolfgang \u00a0Goethe\u2010Universit\u00e4t \u00a0in\u00a0Frankfurt \u00a0am\u00a0Main\u00a0Weiterbildung \u00a0zur\u00a0\u00c4rztin\u00a0\nf\u00fcr\u00a0Klinische\u00a0Pharmakologie \u00a0am\u00a0gleichnamigen \u00a0Institut\u00a0in\u00a0Frankfurt. \u00a0Habilitation \u00a01997\u00a0und\u00a0im\u00a0selben\u00a0Jahr\u00a0Direktorin \u00a0des\u00a0Philipp\u00a0Klee\u2010\nInstituts\u00a0f\u00fcr\u00a0Klinische\u00a0Pharmakologie \u00a0am\u00a0HELIOS\u00a0Klinikum\u00a0Wuppertal. \u00a0Im\u00a0Jahr\u00a01998\u00a0Berufung \u00a0auf\u00a0den\u00a0Lehrstuhl \u00a0f\u00fcr\u00a0Klinische\u00a0Pharmakologie \u00a0\nan\u00a0die\u00a0Universit\u00e4t \u00a0Witten/Herdecke. \u00a0\nUnter\u00a0anderem\u00a0Mitglied\u00a0im\u00a0Sachverst\u00e4ndigenrat \u00a0zur\u00a0Begutachtung \u00a0der\u00a0Entwicklung \u00a0im\u00a0Gesundheitswesen, \u00a0in\u00a0der\u00a0Arzneimittelkommission \u00a0\nder\u00a0deutschen \u00a0\u00c4rzteschaft \u00a0sowie\u00a0Schatzmeisterin \u00a0der\u00a0International \u00a0Union\u00a0of\u00a0Basic\u00a0and\u00a0Clinical\u00a0Pharmacology \u00a0(IUPHAR). \u00a0Forschungsschwer \u2010\npunkte:\u00a0Arzneimitteltherapiesicherheit, \u00a0geriatrische \u00a0Pharmakotherapie \u00a0(PRISCUS\u2010Liste)\u00a0und\u00a0Geschlechterunterschiede \u00a0in\u00a0der\u00a0Pharmakothe \u2010\nrapie.\u00a0\n\u00a0\nDaniela\u00a0Boeschen, \u00a0MSc,\u00a0Apothekerin \u00a0\nStudium\u00a0der\u00a0Pharmazie \u00a0an\u00a0der\u00a0Westf\u00e4lischen \u00a0Wilhelms \u2010Universit\u00e4t \u00a0M\u00fcnster\u00a0und\u00a0anschlie\u00dfende \u00a0Approbation \u00a0zur\u00a0Apothekerin. \u00a0Im\u00a0Anschluss \u00a0\ndaran\u00a0mehrere\u00a0Jahre\u00a0t\u00e4tig\u00a0sowohl\u00a0in\u00a0\u00f6ffentlichen \u00a0Apotheken \u00a0als\u00a0auch\u00a0in\u00a0der\u00a0pharmazeutischen \u00a0Industrie\u00a0im\u00a0Bereich\u00a0Research\u00a0&\u00a0Develop\u2010\nment\u00a0in\u00a0M\u00fcnchen, \u00a0Stuttgart, \u00a0Berlin\u00a0und\u00a0Bremen.\u00a02009\u00a0Erlangung \u00a0des\u00a0MSc\u00a0in\u00a0Consumer \u00a0Health\u00a0Care\u00a0an\u00a0der\u00a0Charit\u00e9\u2010Universit\u00e4tsmedizin \u00a0\nBerlin\u00a0mit\u00a0den\u00a0Schwerpunkten \u00a0rechtliche \u00a0Grundlagen, \u00a0Pharmakoepidemiologie, \u00a0Pharmako\u00f6konomie, \u00a0Qualit\u00e4tssicherung \u00a0und\u00a0Gesundheits \u2010\nmanagement. \u00a0Seit\u00a0September \u00a02011\u00a0Wissenschaftliche \u00a0Mitarbeiterin \u00a0am\u00a0Zentrum\u00a0f\u00fcr\u00a0Sozialpolitik \u00a0(ZeS),\u00a0ab\u00a02015\u00a0SOCIUM,\u00a0Forschungszent \u2010\nrum\u00a0Ungleichheit \u00a0und\u00a0Sozialpolitik, \u00a0Abteilung: \u00a0Gesundheit, \u00a0Pflege\u00a0und\u00a0Alterssicherung \u00a0an\u00a0der\u00a0Universit\u00e4t \u00a0Bremen.\u00a0\n\u00a0\nD\u00f6rte\u00a0Fuchs,\u00a0Apothekerin \u00a0\nStudium\u00a0der\u00a0Pharmazie. \u00a0Seit\u00a01990\u00a0hauptberuflich \u00a0in\u00a0einer\u00a0Krankenhausapotheke \u00a0t\u00e4tig.\u00a0Im\u00a0Jahr\u00a01994\u00a0Abschluss \u00a0der\u00a0Weiterbildung \u00a0zur\u00a0Fach\u2010\napothekerin \u00a0f\u00fcr\u00a0Klinische\u00a0Pharmazie, \u00a0im\u00a0Jahr\u00a02008\u00a0Abschluss \u00a0der\u00a0Weiterbildung \u00a0im\u00a0Bereich\u00a0\u201eNaturheilkunde \u00a0und\u00a0Hom\u00f6opathie\u201c. \u00a0Dozentin\u00a0\nf\u00fcr\u00a0Pflegekr\u00e4fte. \u00a0Seit\u00a0Juni\u00a02010\u00a0Wissenschaftliche \u00a0Mitarbeiterin \u00a0am\u00a0Zentrum\u00a0f\u00fcr\u00a0Sozialpolitik \u00a0(ZeS),\u00a0ab\u00a02015\u00a0SOCIUM,\u00a0Forschungszentrum \u00a0\nUngleichheit \u00a0und\u00a0Sozialpolitik, \u00a0Abteilung: \u00a0Gesundheit, \u00a0Pflege\u00a0und\u00a0Alterssicherung \u00a0an\u00a0der\u00a0Universit\u00e4t \u00a0Bremen.\u00a0\n\u00a0\nDr.\u00a0Judith\u00a0G\u00fcnther,\u00a0Apothekerin \u00a0\nStudium\u00a0der\u00a0Pharmazie \u00a0an\u00a0der\u00a0Universit\u00e4t \u00a0des\u00a0Saarlandes, \u00a0Saarbr\u00fccken, \u00a0und\u00a0Approbation \u00a0zur\u00a0Apothekerin. \u00a0Zwischen \u00a01989\u00a0und\u00a01993\u00a0Anfer\u2010\ntigung\u00a0einer\u00a0Promotion \u00a0zum\u00a0Dr.\u00a0rer.\u00a0nat.\u00a0am\u00a0Institut\u00a0f\u00fcr\u00a0Pharmakologie \u00a0der\u00a0Universit\u00e4t \u00a0zu\u00a0K\u00f6ln\u00a0unter\u00a0der\u00a0Leitung\u00a0von\u00a0Prof.\u00a0Dr.\u00a0U.\u00a0Fricke.\u00a0\nAnschlie\u00dfend \u00a0bis\u00a01999\u00a0Leiterin\u00a0des\u00a0Pharmakologischen \u00a0Beratungsdienstes \u00a0der\u00a0AOK\u2010Regionaldirektion \u00a0Essen\u00a0und\u00a0Elternzeit. \u00a0Freie\u00a0Mitarbeit \u00a0\nin\u00a0diversen\u00a0gesundheitspolitisch \u00a0relevanten \u00a0Projekten, \u00a0u.a.\u00a0GEK\u2010Arzneimittelindex. \u00a0Zwischen \u00a01999\u00a0und\u00a02002\u00a0wissenschaftliche \u00a0Mitarbeite \u2010\u00a0\n276\u00a0rin\u00a0des\u00a0Wissenschaftlichen \u00a0Instituts\u00a0der\u00a0AOK\u00a0(WIdO).\u00a0Seit\u00a02002\u00a0wissenschaftliche \u00a0Mitarbeiterin \u00a0bei\u00a0Pharma Facts\u00a0GmbH,\u00a0B\u00fcroleitung \u00a0Frei\u2010\nburg.\u00a0Fachapothekerin \u00a0f\u00fcr\u00a0Arzneimittelinformation. \u00a0Bis\u00a02015\u00a0Mitarbeiterin \u00a0am\u00a0Zentrum\u00a0f\u00fcr\u00a0Sozialpolitik \u00a0(ZeS),\u00a0jetzt\u00a0SOCIUM,\u00a0Forschungs \u2010\nzentrum\u00a0Ungleichheit \u00a0und\u00a0Sozialpolitik, \u00a0Abteilung: \u00a0Gesundheit, \u00a0Pflege\u00a0und\u00a0Alterssicherung \u00a0an\u00a0der\u00a0Universit\u00e4t \u00a0Bremen.\u00a0\nAutorin\u00a0und\u00a0Coautorin \u00a0bzw.\u00a0pharmazeutisch \u2010pharmakologische \u00a0Beraterin \u00a0diverser\u00a0Arzneimittel \u2010Publikationen \u00a0f\u00fcr\u00a0Fachpersonal \u00a0und\u00a0Laien\u00a0\n(\u201eNeue\u00a0Arzneimittel\u201c; \u00a0\u201eArzneistoff \u2010Profile\u201c;\u00a0\u201eArzneiverordnungsReport\u201c; \u00a0\u201eHandbuch \u00a0Medikamente\u201c; \u00a0\u201eHandbuch \u00a0Selbstmedikation; \u00a0\u201eHand\u2010\nbuch\u00a0Rezeptfreie \u00a0Medikamente\u201c; \u00a0\u201eNebenwirkung \u00a0Sucht\u201c).\u00a0Mitglied\u00a0des\u00a0Deutschen \u00a0Netzwerk \u00a0f\u00fcr\u00a0Evidenzbasierte \u00a0Medizin\u00a0(DNEbM), \u00a0Spre\u2010\ncherin\u00a0des\u00a0Fachbereiches \u00a0Evidenzbasierte \u00a0Pharmazie. \u00a0Mitglied\u00a0bei\u00a0der\u00a0Deutschen \u00a0Gesellschaft \u00a0f\u00fcr\u00a0Pharmakologie \u00a0und\u00a0Toxikologie \u00a0(DGPT)\u00a0\nsowie\u00a0in\u00a0der\u00a0Gesellschaft \u00a0f\u00fcr\u00a0Arzneimittelanwendungsforschung \u00a0und\u00a0Arzneimittelepidemiologie \u00a0(GAA).\u00a0\u00a0\n\u00a0\nProjektmitarbeiterinnen \u00a0\u00a0\n\u00a0\nAngela\u00a0Fritsch\u00a0\nStudium\u00a0der\u00a0Geographie \u00a0an\u00a0der\u00a0Universit\u00e4t \u00a0Bonn\u00a0(Abschluss: \u00a0Dipl.\u00a0Geographin). \u00a0Anschlie\u00dfend \u00a0Ausbildung \u00a0zur\u00a0Organisationsprogrammiere \u2010\nrin\u00a0am\u00a0Control\u00a0Data\u00a0Institut\u00a0in\u00a0Dortmund \u00a0(Abschluss: \u00a0Organisationsprogrammiererin). \u00a0Danach\u00a0Anstellung \u00a0in\u00a0verschiedenen \u00a0Softwareh\u00e4u \u2010\nsern.\u00a0Seit\u00a0M\u00e4rz\u00a02005\u00a0Mitarbeiterin \u00a0am\u00a0Zentrum\u00a0f\u00fcr\u00a0Sozialpolitik \u00a0(ZeS),\u00a0ab\u00a02015\u00a0SOCIUM,\u00a0Forschungszentrum \u00a0Ungleichheit \u00a0und\u00a0Sozialpolitik, \u00a0\nAbteilung: \u00a0Gesundheit, \u00a0Pflege\u00a0und\u00a0Alterssicherung \u00a0an\u00a0der\u00a0Universit\u00e4t \u00a0Bremen.\u00a0\n\u00a0\nDipl.\u00a0Soz.\u00a0Friederike \u00a0H\u00f6fel\u00a0\nStudium\u00a0der\u00a0Anglistik,\u00a0Kunst\u00a0und\u00a0Philosophie \u00a0in\u00a0Berlin\u00a0und\u00a0Bremen.\u00a0Ausbildung \u00a0zur\u00a0Wirtschaftsassistentin, \u00a0Schwerpunkt \u00a0Fremdsprachen \u00a0in\u00a0\nBremen.\u00a0Studium\u00a0der\u00a0Soziologie \u00a0an\u00a0der\u00a0Universit\u00e4t \u00a0Bremen.\u00a0Bis\u00a02015\u00a0Mitarbeiterin \u00a0am\u00a0Zentrum\u00a0f\u00fcr\u00a0Sozialpolitik \u00a0(ZeS),\u00a0jetzt\u00a0SOCIUM,\u00a0For\u2010\nschungszentrum \u00a0Ungleichheit \u00a0und\u00a0Sozialpolitik, \u00a0Abteilung: \u00a0Gesundheit, \u00a0Pflege\u00a0und\u00a0Alterssicherung \u00a0an\u00a0der\u00a0Universit\u00e4t \u00a0Bremen.\u00a0\n\u00a0\nSarah\u00a0Volz\u00a0\nStudium\u00a0des\u00a0Integrierten \u00a0Designs\u00a0an\u00a0der\u00a0Hochschule \u00a0f\u00fcr\u00a0K\u00fcnste\u00a0Bremen\u00a0im\u00a0Master.\u00a0Bis\u00a02015\u00a0Mitarbeiterin \u00a0am\u00a0Zentrum\u00a0f\u00fcr\u00a0Sozialpolitik \u00a0\n(ZeS),\u00a0jetzt\u00a0SOCIUM,\u00a0Forschungszentrum \u00a0Ungleichheit \u00a0und\u00a0Sozialpolitik, \u00a0Abteilung: \u00a0Gesundheit, \u00a0Pflege\u00a0und\u00a0Alterssicherung \u00a0an\u00a0der\u00a0Universi\u2010\nt\u00e4t\u00a0Bremen.\u00a0\n\u00a0\n\u00a0", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}